0001564590-22-005228.txt : 20220215 0001564590-22-005228.hdr.sgml : 20220215 20220215163138 ACCESSION NUMBER: 0001564590-22-005228 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 116 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220215 DATE AS OF CHANGE: 20220215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 22639627 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 10-K 1 adpt-10k_20211231.htm 10-K adpt-10k_20211231.htm
false FY 0001478320 --12-31 true 2032-10 true 2029-10 true true P5Y P4Y P7Y http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member P10Y6M18D P11Y3M29D P5Y3M7D P5Y3M7D P5Y3M7D 0.005 0.004 0.014 0.671 0.705 0.643 30.86 17.68 7.80 66.50 55.23 47.81 P6Y29D P6Y29D P6Y29D 0.014 0.017 0.025 0.700 0.733 0.729 0001478320 2021-01-01 2021-12-31 iso4217:USD 0001478320 2021-06-30 xbrli:shares 0001478320 2022-02-10 0001478320 2021-12-31 0001478320 2020-12-31 iso4217:USD xbrli:shares 0001478320 adpt:SequencingRevenueMember 2021-01-01 2021-12-31 0001478320 adpt:SequencingRevenueMember 2020-01-01 2020-12-31 0001478320 adpt:SequencingRevenueMember 2019-01-01 2019-12-31 0001478320 adpt:DevelopmentRevenueMember 2021-01-01 2021-12-31 0001478320 adpt:DevelopmentRevenueMember 2020-01-01 2020-12-31 0001478320 adpt:DevelopmentRevenueMember 2019-01-01 2019-12-31 0001478320 2020-01-01 2020-12-31 0001478320 2019-01-01 2019-12-31 0001478320 us-gaap:ConvertiblePreferredStockMember 2018-12-31 0001478320 us-gaap:CommonStockMember 2018-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001478320 us-gaap:RetainedEarningsMember 2018-12-31 0001478320 2018-12-31 0001478320 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001478320 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001478320 us-gaap:CommonStockMember 2019-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001478320 us-gaap:RetainedEarningsMember 2019-12-31 0001478320 2019-12-31 0001478320 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001478320 us-gaap:RetainedEarningsMember srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2019-12-31 0001478320 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2019-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001478320 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001478320 us-gaap:CommonStockMember 2020-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001478320 us-gaap:RetainedEarningsMember 2020-12-31 0001478320 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001478320 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001478320 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001478320 us-gaap:CommonStockMember 2021-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001478320 us-gaap:RetainedEarningsMember 2021-12-31 0001478320 us-gaap:NoncontrollingInterestMember 2021-12-31 xbrli:pure 0001478320 adpt:DigitalBiotechnologiesIncMember 2021-12-31 0001478320 adpt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001478320 adpt:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001478320 adpt:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001478320 adpt:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001478320 adpt:GenentechIncAndRocheGroupMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001478320 adpt:GenentechIncAndRocheGroupMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001478320 adpt:GenentechIncAndRocheGroupMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001478320 adpt:LaboratoryEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001478320 adpt:LaboratoryEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001478320 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001478320 adpt:ComputerEquipmentAndSoftwareMember srt:MinimumMember 2021-01-01 2021-12-31 0001478320 adpt:ComputerEquipmentAndSoftwareMember srt:MaximumMember 2021-01-01 2021-12-31 0001478320 adpt:FurnitureAndOfficeEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001478320 adpt:FurnitureAndOfficeEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2014-12-31 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2021-12-31 adpt:Performance_Obligation adpt:Segment 0001478320 adpt:DevelopmentSupportRevenueMember 2021-01-01 2021-12-31 0001478320 adpt:DevelopmentSupportRevenueMember 2020-01-01 2020-12-31 0001478320 adpt:DevelopmentSupportRevenueMember 2019-01-01 2019-12-31 0001478320 adpt:DevelopmentRevenueRegulatoryMilestonesMember 2021-01-01 2021-12-31 0001478320 adpt:DevelopmentRevenueRegulatoryMilestonesMember 2020-01-01 2020-12-31 0001478320 adpt:DevelopmentRevenueRegulatoryMilestonesMember 2019-01-01 2019-12-31 0001478320 adpt:MRDDevelopmentAgreementsMember 2021-01-01 2021-12-31 0001478320 adpt:MRDDevelopmentAgreementsMember adpt:DevelopmentRevenueMember 2021-01-01 2021-12-31 0001478320 adpt:MRDDevelopmentAgreementsMember 2020-01-01 2020-12-31 0001478320 adpt:MRDDevelopmentAgreementsMember 2019-01-01 2019-12-31 0001478320 adpt:MRDDevelopmentAgreementsMember srt:MaximumMember 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember 2019-02-01 2019-02-28 0001478320 adpt:GenentechCollaborationAgreementMember srt:MinimumMember 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember adpt:RegulatoryMilestonesMember srt:MaximumMember 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember adpt:DevelopmentMilestonesMember srt:MaximumMember 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember adpt:CommercialMilestonesMember srt:MaximumMember 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember 2021-01-01 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember srt:MinimumMember 2021-01-01 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember srt:MaximumMember 2021-01-01 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember 2020-01-01 2020-12-31 0001478320 adpt:GenentechCollaborationAgreementMember 2019-01-01 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2021-12-31 0001478320 us-gaap:CorporateBondSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2021-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2021-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2021-12-31 0001478320 us-gaap:CorporateBondSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2021-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2021-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2020-12-31 0001478320 us-gaap:CorporateBondSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2020-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2020-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2020-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2020-12-31 0001478320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-12-31 0001478320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001478320 us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001478320 adpt:LaboratoryEquipmentMember 2021-12-31 0001478320 adpt:LaboratoryEquipmentMember 2020-12-31 0001478320 us-gaap:ComputerEquipmentMember 2021-12-31 0001478320 us-gaap:ComputerEquipmentMember 2020-12-31 0001478320 adpt:FurnitureAndOfficeEquipmentMember 2021-12-31 0001478320 adpt:FurnitureAndOfficeEquipmentMember 2020-12-31 0001478320 adpt:ComputerSoftwareMember 2021-12-31 0001478320 adpt:ComputerSoftwareMember 2020-12-31 0001478320 us-gaap:ConstructionInProgressMember 2021-12-31 0001478320 us-gaap:ConstructionInProgressMember 2020-12-31 0001478320 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001478320 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001478320 2015-12-31 0001478320 us-gaap:IntellectualPropertyMember 2021-01-01 2021-12-31 0001478320 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0001478320 us-gaap:IntellectualPropertyMember 2021-12-31 0001478320 us-gaap:DevelopedTechnologyRightsMember 2020-12-31 0001478320 us-gaap:IntellectualPropertyMember 2020-12-31 0001478320 adpt:SequencingRevenueMember 2021-12-31 0001478320 adpt:SequencingRevenueMember 2020-12-31 0001478320 adpt:DevelopmentRevenueMember 2021-12-31 0001478320 adpt:DevelopmentRevenueMember 2020-12-31 0001478320 adpt:DevelopmentRevenueMember adpt:GenentechIncMember 2021-12-31 0001478320 adpt:DevelopmentRevenueMember adpt:GenentechIncMember 2020-12-31 0001478320 adpt:GenentechIncMember 2022-01-01 2021-12-31 0001478320 adpt:GenentechIncMember 2022-01-01 srt:MinimumMember 2021-12-31 0001478320 adpt:GenentechIncMember 2022-01-01 srt:MaximumMember 2021-12-31 0001478320 adpt:SpecificPatientsMember adpt:MedicareRevenueMember 2021-01-01 2021-12-31 0001478320 2021-12-30 2021-12-31 utr:sqft 0001478320 stpr:WA 2019-08-31 0001478320 stpr:WA 2019-08-01 2019-08-31 0001478320 2019-08-31 0001478320 2019-08-01 2019-08-31 0001478320 2019-10-31 0001478320 2019-10-01 2019-10-31 0001478320 srt:MaximumMember 2019-10-31 0001478320 2018-04-30 0001478320 2021-03-31 0001478320 2018-04-01 2018-04-30 0001478320 2020-02-29 0001478320 2020-02-01 2020-02-29 0001478320 2019-12-01 2019-12-31 0001478320 srt:MinimumMember 2021-12-31 0001478320 srt:MaximumMember 2021-12-31 adpt:Lease 0001478320 us-gaap:AccountingStandardsUpdate201602Member 2020-12-31 adpt:Vote 0001478320 adpt:CommonStockOptionsAndRestrictedStockUnitsGrantedMember 2021-12-31 0001478320 us-gaap:EmployeeStockOptionMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-12-31 0001478320 us-gaap:EmployeeStockOptionMember us-gaap:EmployeeStockMember 2021-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember srt:MaximumMember 2020-01-01 2020-01-01 0001478320 us-gaap:EmployeeStockMember srt:MaximumMember 2020-01-01 2020-01-01 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-01-01 2021-01-01 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2014-01-01 2014-12-31 0001478320 adpt:SequentaTwoThousandAndEightStockPlanMember 2021-12-31 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-12-31 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember 2021-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember adpt:NonEmployeeDirectorsMember 2021-01-01 2021-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001478320 srt:MinimumMember 2021-01-01 2021-12-31 0001478320 srt:MinimumMember 2020-01-01 2020-12-31 0001478320 srt:MinimumMember 2019-01-01 2019-12-31 0001478320 srt:MaximumMember 2021-01-01 2021-12-31 0001478320 srt:MaximumMember 2020-01-01 2020-12-31 0001478320 srt:MaximumMember 2019-01-01 2019-12-31 0001478320 us-gaap:ValuationTechniqueOptionPricingModelMember 2021-01-01 2021-12-31 0001478320 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001478320 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001478320 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001478320 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001478320 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001478320 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001478320 adpt:MicrosoftCollaborationAgreementMember 2017-12-01 2017-12-31 0001478320 adpt:SeriesFOneConvertiblePreferredStockMember adpt:MicrosoftCollaborationAgreementMember 2017-12-31 0001478320 us-gaap:DomesticCountryMember 2021-12-31 0001478320 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001478320 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001478320 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001478320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2019-01-01 2019-12-31 0001478320 adpt:CommonStockWarrantsMember 2021-01-01 2021-12-31 0001478320 adpt:CommonStockWarrantsMember 2020-01-01 2020-12-31 0001478320 adpt:CommonStockWarrantsMember 2019-01-01 2019-12-31 0001478320 adpt:ConvertiblePreferredStockWarrantsMember 2019-01-01 2019-12-31

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-K

 

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

OR

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____to _____

Commission File Number: 001-38957

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

 

Washington

27-0907024

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

1165 Eastlake Avenue East

Seattle, Washington

98109

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (206) 659-0067

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The NASDAQ Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes ☐ No ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

Large accelerated filer

 

☒

  

Accelerated filer

 

☐

 

 

 

 

Non-accelerated filer

 

☐

  

Smaller reporting company

 

☐

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒ 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Global Select Market on June 30, 2021 (the last business day of the Registrant’s most recently completed second fiscal quarter), was approximately $3,951,000,000.

As of February 10, 2022, the Registrant had 141,583,720 shares of common stock, $0.0001 par value per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the registrant’s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2022.

 

 

 

 

Table of Contents

 

 

 

Page

PART I

 

3

Item 1.

Business

3

Item 1A.

Risk Factors

43

Item 1B.

Unresolved Staff Comments

88

Item 2.

Properties

88

Item 3.

Legal Proceedings

89

Item 4.

Mine Safety Disclosures

89

 

 

 

PART II

 

90

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

90

Item 6.

[Reserved]

90

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

91

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

101

Item 8.

Financial Statements and Supplementary Data

102

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

132

Item 9A.

Controls and Procedures

132

Item 9B.

Other Information

134

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

134

 

 

 

PART III

 

135

Item 10.

Directors, Executive Officers and Corporate Governance

135

Item 11.

Executive Compensation

135

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

135

Item 13.

Certain Relationships and Related Transactions, and Director Independence

135

Item 14.

Principal Accounting Fees and Services

135

 

 

 

PART IV

 

136

Item 15.

Exhibits, Financial Statement Schedules

136

Item 16.

Form 10-K Summary

138

SIGNATURES

139

 

 

 

 

FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. Some of the statements in the “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections and elsewhere in this Annual Report on Form 10-K contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements expressed or implied in this Annual Report on Form 10-K include, but are not limited to, statements about:

 

•

the success of our significant investments in our continued research and development of new products and services;

 

•

the success of developing, commercializing and achieving commercial market acceptance of clonoSEQ, T-Detect, immunoSEQ, our TCR-Antigen Map, T cell receptor (“TCR”)-based cellular therapies, neutralizing antibody products or processes, such as TruAB, and additional products and services beyond our current portfolio;

 

•

the potential for our identified research priorities to advance our proprietary immune medicine platform or our future products and services;

 

•

the success, cost and timing of our research development activities, preclinical and clinical studies and, in certain instances, clinical trials and clinical validations;

 

•

the potential benefits of collaborations, our ability to enter into collaborations or arrangements and our ability to attract collaborators with development, manufacturing, regulatory and commercialization expertise;

 

•

the ability and willingness of our collaborators to continue development, manufacturing, distribution and commercialization activities relating to our jointly developed products and services;

 

•

our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop products and services;

 

•

our ability to obtain and maintain regulatory approval of our products and services;

 

•

the pricing and reimbursement of our products and services following approval where required;

 

•

our ability, and that of our collaborators, to commercialize our products and services, including products related to COVID-19;

 

•

our ability to obtain equipment and materials (including reagents or other materials that may also require additional internal validation) from our suppliers, and in some cases single suppliers;

 

•

our ability to generate revenue and obtain funding for our operations, including funding necessary to complete further development of our current and future products and services, and if successful, commercialization;

 

•

the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in combination with others;

 

•

the rate and degree of market acceptance of our products and services;

 

•

the potential adverse effect on our business, operations and plans or timelines (including those plans and timelines related to expansion initiatives and clinical development) resulting from a health epidemic or pandemic, including the COVID-19 pandemic and future variants of the SARS-CoV-2 virus;

 

•

our financial performance;

 

•

our expectations regarding our ability to obtain and maintain intellectual property protection for our immune medicine platform, products, services and related technologies and the direction of such protection;

 

•

regulatory developments in the United States (“U.S.”) and foreign countries;

 

•

the success of competing products or services that are or may become available;

1

 

 

•

developments relating to our competitors and our industry;

 

•

our ability to attract and retain key scientific or management personnel;

 

•

the impact of laws and regulations; and

 

•

our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

In addition, you should refer to the “Risk Factors” section of this Annual Report on Form 10-K for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements herein represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.

In this Annual Report on Form 10-K, unless the context requires otherwise, all references to “we,” “our,” “us,” “Adaptive” and the “Company” refer to Adaptive Biotechnologies Corporation.

2

PART I

Item 1. Business

Overview

We are advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use these insights to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have three commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune disorders and infectious diseases. Since our inception in 2009, we have characterized over 58 billion immune receptors, established partnerships and commercial relationships with 175 biopharmaceutical companies and launched three product lines. Our goal is to understand the adaptive immune system and translate it into new products with unprecedented scale, precision and speed.

Our immune medicine platform is the foundation for our expanding suite of products and services. The cornerstone of our platform and core immunosequencing product, immunoSEQ, serves as our underlying research and development engine and generates revenue from academic and biopharmaceutical customers. Our first clinical diagnostic product, clonoSEQ, is the first test authorized by the Food and Drug Administration (“FDA”) for the detection and monitoring of minimal residual disease (“MRD”) in patients with multiple myeloma (“MM”), B cell acute lymphoblastic leukemia (“ALL”) and chronic lymphocytic leukemia (“CLL”) and is also available as a CLIA-validated laboratory developed test (“LDT”) for patients with other lymphoid cancers. Leveraging our collaboration with Microsoft Corporation (“Microsoft”), we are creating a map of the interaction between the immune system and disease (our “TCR-Antigen Map”). We are using this map to develop research solutions by disease called immunoSEQ T-MAP and a diagnostic product for many diseases from a single blood test called T-Detect.

T-Detect COVID, the first indication for the T-Detect product line, received Emergency Use Authorization (“EUA”) for confirmation of recent or prior SARS-CoV-2 infection, the virus that causes COVID-19, in March 2021. We confirmed signals in Crohn’s disease, celiac disease, and multiple sclerosis, identified new signals in ulcerative colitis, and rheumatoid arthritis, and are focusing on generating additional signals in autoimmune disease states. In addition, we have completed our clinical validation of the immuneSense Lyme study, which represents another technical proof point in our ability to map T cells to disease specific antigens. Our therapeutic product candidates, being developed under our collaboration agreement with Genentech, Inc. (“Genentech”), leverage our platform to identify specific receptors on immune cells to develop into cellular therapies in oncology. We believe this approach has the potential to be applicable to patients across a wide range of cancers. In addition, we extended our platform to inform vaccine design and development through our licensing agreement with Vaccibody AS, now known as Nykode Therapeutics AS (“Nykode”). We believe there is potential to apply our platform to vaccine development and design across multiple disease states.

Immune medicine is one of the largest global addressable markets in healthcare. We estimate the potential global market opportunity for our portfolio to be approximately $54 billion, including approximately $6 billion for products and services related to the detection of MRD and approximately $48 billion for diagnostic and drug discovery applications driven by mapping immune receptors to disease-specific antigens. This currently includes T-Detect and cellular therapy in oncology and is expected to grow with additional opportunities stemming from our platform. We use multiple sources and assumptions to estimate the total addressable market for immune medicine. While we believe them to be reasonable, these sources and assumptions may be incorrect or subject to change due to any number of factors. In particular, the indications we choose to commercialize for T-Detect may vary depending on ongoing signal validation and market considerations. In addition, our drug discovery initiatives are still in the early stages of development and the market opportunity excludes neutralizing antibodies, which may make our assumptions and estimates more uncertain. Despite the novelty of this area, we believe we are uniquely positioned to develop and commercialize a pipeline of immune-driven diagnostic and therapeutic products across multiple disease states by leveraging the cumulative learning from our immune medicine platform.

We were able to achieve and progress towards many key milestones in 2021 in each business area:

 

•

In March 2021, T-Detect COVID was granted EUA by the Food and Drug Administration, becoming the first-in-class test to confirm recent or prior COVID-19 infection. Data demonstrates that T-Detect COVID can detect prior infection nearly 12 months after diagnosis in some patients. T-Detect COVID was ordered by over 30,000 consumers and providers on behalf of their patients. In addition, we received a positive technical assessment from Palmetto GBA’s Molecular Diagnostics Program (“MolDX”), followed by a coverage decision from Noridian Mutual Insurance Company providing a path to reimbursement in 2022 for immunocompromised patients.

3

 

•

immunoSEQ T-MAP COVID, another byproduct of leveraging the TCR-Antigen Map collaboration, continues to be a source of valuable insight as we advance towards an understanding of the T cell response to SarS-CoV-2 at scale and with precision, including with respect to emerging variants of concern. For new variants of concern, such as Delta or Omicron, we have demonstrated the ability to identify mutations and connect them to our large-scale antigen-specific datasets in order to measure T-cell response to vaccination and determine the role of cellular immunity.

 

•

The T-Detect product continued to make significant advances in the autoimmune space. With respect to autoimmune diseases, we confirmed signals in Crohn’s disease and multiple sclerosis and identified new signals in ulcerative colitis and rheumatoid arthritis. These clinical signals were identified in a series of well-characterized case-control sample sets from collaborating institutions, including over 5,000 samples in inflammatory bowel disease (“IBD”), and we plan to advance some of these signals to blinded clinical validation studies in the near future.

 

•

Our clinical diagnostics business continued to grow year over year. For our clonoSEQ product, we grew our test volume by 48% to 22,516 tests delivered. We increased the all-time number of unique patients tested by more than 46% to over 22,000 patients by the end of 2021. We have filed to expand our existing label for ALL in bone marrow to include blood, and we enhanced the clinical report for CLL patients to include immunoglobulin heavy chain – V (“IGHV”) mutation status, which has been well received by our clinical customers.

 

•

In drug discovery, we continue to make good progress with our shared and private product programs under our Genentech collaboration. Regarding the shared product, we delivered to Genentech efficacy and safety data for our TCR candidate that targets a shared cancer neoantigen. Following review of data generated by both us and Genentech using this TCR candidate, Genentech recently selected this TCR candidate to progress as a potential therapeutic product candidate. Also, in 2022, we’re on track to deliver to Genentech up to two additional TCR data packages for consideration by Genentech. Regarding our private program, we conducted initial proof of concept screens by successfully processing blood from approximately 60 cancer patients. We continue to work closely with Genentech to establish the private product specifications and to build our private product data package. The personalized data that we generate in 2022 with Genentech will help start to define steps toward early product development by Genentech.

 

•

We also extended our drug discovery efforts by establishing a new worldwide licensing agreement in July 2021 with Nykode, whereby virus-specific T cell epitopes identified by our platform will be used to inform the design and development of novel SARS-CoV-2 vaccine candidates. The Nykode 2-arm Phase I/II trial started in the fourth quarter of 2021 and is currently enrolling individuals in Norway who are already vaccinated. This T cell-based vaccine is intended to address SARS-CoV-2 variants of concern and may be used as a potential universal booster to available vaccines. The Nykode collaboration represents a significant extension of the platform into vaccine design and development.

 

•

Key financial highlights for 2021 include full year revenue up 57% to $154.3 million, cash, cash equivalents and marketable securities of $570.2 million and clinical sequencing volume up 48% to 22,516 tests, excluding T-Detect COVID volume.

 

•

In addition, we moved into our new corporate headquarters in Seattle, Washington in September 2021, increased warehouse space in the Seattle area, and opened a new office in New York City in 2021. These facilities are designed to allow for continued scaling and growth, as well as laboratory and operational optimization in the Seattle area.

Our Immune Medicine Platform

The adaptive immune system is comprised of specialized cells, called T cells and B cells, which hold the instructions for diagnosing and treating most diseases. These instructions enable these cells to identify, bind and destroy pathogens or human cells presenting foreign signals of disease (“antigens”) using receptors on their cell surface. Unlike all other genes in the human genome, the genetic sequences of TCRs and B cell receptors (“BCRs”) rearrange over time creating massive genetic diversity. The resulting diversity of the adaptive immune repertoire, which consists of over 100 million different genes in a healthy adult compared to approximately 30,000 genes in the static human genome, gives the immune system the ability to detect and respond to millions of different antigens associated with human disease.

Our immune medicine platform combines a suite of proprietary chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. It extracts and interprets insights from the adaptive immune system with the scale, precision and speed required to enable the design of clinical products tailored to the specific genetics of each patient’s immune system.

4

Our immune medicine platform performs the following key functions related to immune receptors:

 

•

Sequence. immunoSEQ sequences single chains of “Y-shaped” TCRs or BCRs using next generation sequencing (“NGS”), enabling us to understand the quantity and diversity of T and B cells in a biological sample. This provides deep insights into individual and collective immune responses at a scale that is thousands of times greater than was previously possible.

 

•

Map. MIRA (Multiplexed Identification of T cell Receptor Antigen Specificity) maps millions of TCRs to thousands of clinically relevant antigens. Combined with immunoSEQ, MIRA elucidates what potential diseases a patient’s immune system has been exposed to or is actively fighting.

 

•

Pair. pairSEQ builds on immunoSEQ by using a combinatorial strategy to accurately pair both chains of Y-shaped immune cell receptors at high-throughput, which is challenging to do at scale using other methods because the two chains of the Y-shaped receptors are located on different chromosomes. The ability to accurately pair both chains of the receptors in a sample enables us to reconstruct receptors for therapeutic purposes.

 

•

Characterize. TruTCR characterizes binding, cytotoxicity and safety properties of antigen-specific, paired TCRs to identify a subset that is therapeutic-grade, enabling the discovery and development of optimal clinical candidates to be engineered into TCR-mediated cellular therapies. TruAB is our high-throughput antibody discovery process that enables the selection of potent, naturally occurring, full length antibodies for therapeutic or prophylactic development.

The massive amount of data generated by our immune medicine platform is stored in our dynamic clinical immunomics database. We believe the application of machine learning, supported by our collaboration with Microsoft, has the potential to exponentially accelerate our ability to derive novel insights from this database and use them to inform our robust product development efforts.

The current coronavirus pandemic is highlighting the critical importance of understanding the immune response to disease broadly, making our technology more relevant than ever. In 2020, together with Microsoft, we created the ImmuneCODE program to map the T cell response to SARS-CoV-2 across the global population. Our goal was to leverage the existing capabilities of our high throughput platform to generate an unprecedented amount of T cell data from over 9,000 samples to understand the adaptive immune response to COVID-19. From these samples, we have mapped over 160,000 high-confidence TCRs to all parts of the virus which we have shown to be most immunogenic. We have published several papers over the past year that demonstrate the correlation between the T cell response and real world efficacy of vaccination as the virus has mutated. This mapping effort has enabled us to develop and commercialize multiple products that have supported the fight against COVID-19. In our research business, we offered a product called immunoSEQ T-MAP COVID to provide a better way for vaccine developers and researchers to include the T-cell response in their studies. We are pleased to see top-tier vaccine developers such as Johnson & Johnson, Moderna, and AstraZeneca continue to recognize the power of this product. Leveraging the same data, we launched a clinical diagnostic called T-Detect COVID to confirm recent or prior infection. T-Detect is the only T cell-based test for COVID authorized by the FDA pursuant to the EUA pathway. Additionally, we signed a drug discovery agreement with NyKode of the design and development of a next-generation DNA-based T cell mediated vaccine for COVID and the first patient was dosed in December 2021. Importantly, we believe we can leverage what we accomplished for COVID-19 using disease-specific immune receptor data across other disease states going forward.

5

In addition to the opportunities driven from understanding the T cell response to SARS-CoV-2, we also extended our platform to identify highly potent neutralizing antibodies against the virus. We currently have a portfolio of highly potent neutralizing antibodies against SARS-CoV-2 and continue to explore potential partnerships. We are exploring the potential of leveraging this differentiated antibody discovery capability across multiple disease states.

We believe COVID-19 brought the role of the immune system to the forefront of society and has created the opportunity for us to be positioned as the “go to” company to rapidly and reproducibly assess the T-cell response to any pathogen, including future pandemics.

Our Current Products and Pipeline

Our current portfolio includes commercial products and services in clinical diagnostics and life sciences research, and we are developing products and services in both clinical diagnostics and drug discovery. We plan to continue to invest in our immune medicine platform to develop additional clinical products, which we prioritize based on clinical actionability, unmet medical need and commercial viability.

Clinical Diagnostics – clonoSEQ and T-Detect

Our clonoSEQ diagnostic test detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as MRD. In September 2018, clonoSEQ was granted marketing authorization from the FDA, under the de novo process, for patients with MM and ALL to monitor their MRD from bone marrow samples. In August 2020, the clonoSEQ label was expanded to include patients with CLL from bone marrow and blood samples. clonoSEQ is also available for use in other lymphoid cancers as an LDT. In January 2019, clonoSEQ received Medicare coverage aligned with the FDA label and National Comprehensive Cancer Network (“NCCN”) guidelines for longitudinal monitoring in MM and ALL. We secured additional payor coverage for clonoSEQ aligned with our FDA label with Medicare, national private payors and large regional plans for a total of over 240 million covered lives for ALL and MM and over 150 million covered lives for CLL. In November 2021, MolDX published its LCD for MRD testing. This LCD not only affirms the importance of MRD and clonoSEQ coverage in ALL, MM and CLL in bone marrow and blood, but also provides a clear and efficient pathway for seeking expanded clonoSEQ coverage through technical assessments in Non-Hodgkin’s Lymphoma (“NHL”).

clonoSEQ testing has been ordered by clinicians for over 22,000 unique patients and used by more than 60 biopharmaceutical companies in over 150 clinical trials. We continue to deepen our commercial investments to expand clinical adoption of clonoSEQ and have increased the strength of our specialized sales and customer support organization and supporting infrastructure in the United States, and we have successfully transferred the technology to seven labs in other parts of the world. We believe clonoSEQ has broad applicability across all lymphoid malignancies. We submitted a 510(k) premarket notification for ALL from blood samples in February 2021 and are actively advancing validation studies in certain NHL sub-types. We are also awaiting results from a clinical study using clonoSEQ to assess MRD in blood for multiple myeloma.

6

In addition, we continue to develop product improvements for clonoSEQ. In the third quarter of 2021, we launched an enhanced version of our clonoSEQ B-cell Clonality (ID) reports, which now includes IGHV mutation status for patients with CLL. The presence of IGHV mutations have been proven prognostic of better outcomes in CLL patients. We believe that this improvement strengthens the clonoSEQ product by aiding clinicians in evaluating prognosis, simplifying diagnosis, and improving overall patient management by providing additional clinically valuable CLL information, and preliminary feedback indicates these improvements have been well received.

With respect to T-Detect, we developed this diagnostic product by leveraging Microsoft’s machine learning capabilities to create the TCR-Antigen Map, which may enable early or accurate detection of many diseases from a single blood test. Initially, we are validating detection of a set of discrete diseases for which there is a significant unmet medical need for better diagnostic testing and early intervention, and where antigen specificity is well-known. These include infectious diseases, autoimmune disorders and certain prevalent cancer types. We launched the first indication, T-Detect COVID, to confirm recent or prior SARS-CoV-2 infection, which represents a stepping-stone to the long-term vision of T-Detect where a single blood sample can provide information about what diseases a person’s immune system has seen or is currently fighting.

We launched T-Detect COVID in the fourth quarter of 2020 and the product received EUA in March 2021. We are in the process of working with the FDA to extend the label to include a semi-quantitative measure to enable the test to monitor T cell response over time. We are concurrently working with select biopharmaceutical collaborators to try to establish a correlate of protection. Leveraging the infrastructure built to support this initial indication, we are on track to make T-Detect Lyme available in our CLIA lab during the 2022 Lyme season. Additionally, we confirmed signals in Crohn’s disease, celiac disease, and multiple sclerosis, identified new signals in ulcerative colitis and rheumatoid arthritis, and are focusing on generating additional signals in autoimmune disease states. Our immune medicine platform enables parallel development because it can work with retrospective sample sets and uses machine learning and computational statistics to continuously improve our detection and accuracy which is applied to all of the diagnostic algorithms.

For T-Detect COVID, our T-cell based test shows higher sensitivity than multiple antibody serology tests to confirm recent or prior infection. Data demonstrates that T-Detect COVID can detect prior infection nearly 12 months after diagnosis in some patients. Additionally, T-cell testing can be used to distinguish natural SARS-CoV-2 infection from COVID-19 vaccine response, an important advantage over antibody tests. The sensitivity of T-Detect COVID is equivalent to or greater than serology testing in RT-PCR-confirmed SARS-CoV-2 cases, and the product has demonstrated a percent positive agreement (“PPA”) of 100% in individuals with RT-PCR–confirmed SARS-CoV-2.

With T-Detect COVID, we initially targeted groups and individuals for whom knowledge of past infection or exposure is valuable, including self-pay consumers, employers and concierge medicine physician groups. Our market research showed that there are many people who were unable to access testing in spring of 2020 or had unexpected results from antibody or PCR testing, and are still curious or skeptical about a previous infection. This is particularly true for individuals who were asymptomatic or had mild symptoms, in whom antibody testing may be less reliable. Additionally, our research indicates high interest among consumers in understanding immunity to COVID-19.We believe there is a significant need to for clinicians to manage patient care, including vaccine or booster regimens, by assessing the immune responses of immunocompromised patients.  We also believe we are uniquely suited to assess and provide insights to clinicians as to the immune responses of those patient whose immunocompromised status is the result of prior cancer infection, a market that is complementary to our oncology expertise. We continue to offer the ability to contribute to on-market research to quantitatively assess the duration of immunity as defined by the persistence of SARS-CoV-2 specific T cells.

In addition, we have completed our clinical validation for our immuneSense Lyme study, which represents another technical proof point in our ability to map T cells to disease specific antigens We expect to leverage the infrastructure built for T-Detect COVID with an anticipated market availability during the 2022 Lyme season. There are approximately 3.4 million Lyme diagnostic tests performed annually. Initially, we are focused on market entry for early and more accurate diagnosis of Lyme disease for patients with non-descript symptoms that are suspected to be caused by Lyme. This population is over 600,000 patients in the United States each year.

7

Learnings from T-Detect COVID and Lyme efforts have helped us accelerate our assessment of various diseases in parallel across the different stages of our research and development pipeline. We begin the process with diseases that meet key market attractiveness criteria such as high unmet medical need, understanding of the antigenic space, and our access to samples with metadata. We then seek early clinical signals in prioritized disease states and continue to refine our modeling for those that appear promising. For each signal, we generate data in several ways: run naïve blood to map receptors to antigens, collaborate on studies with control groups, and leverage a database of unlabeled samples. Once a signal is confirmed in additional independent cohorts and the product profile is deemed attractive, we proceed with a full commercial validation and generation of a locked-down algorithm to take into clinical validation and regulatory submission.

There are many economic advantages of T-Detect both in the research and development stage and as a commercial product. For the research and development pipeline, we leverage the same capital expenditures and workflow for signal generation across all diseases allowing us to study multiple diseases in parallel without requiring substantial workflow adjustments or significant new capital expenditures for specific new disease states. Once commercialized, again, we use the same blood sample and the same underlying chemistry for all diseases with a small incremental investment in software for each individual disease, enabling a long-term high margin profile.

Life Sciences Research

Our immunoSEQ research service and kits are used to answer translational research questions and discover new prognostic and diagnostic signals. Our technology has been used for research purposes by over 2,400 academic researchers and 175 biopharmaceutical companies and incorporated into over 650 clinical trials since our inception in 2009. Importantly, immunoSEQ is analytically validated so that all research data generated using immunoSEQ can be used for clinical validation of potential diagnostic applications.

We launched immunoSEQ T-MAP COVID in August 2020 for vaccine developers and researchers to accurately and reproducibly measure the T-cell immune response to vaccines and track the persistence of that response over time, including with respect to emerging variants of concern. immunoSEQ T-MAP COVID combines the sequencing and mapping capabilities of Adaptive’s immune medicine platform to show how T cells respond to different parts of the virus, including the various parts of the spike protein. A key objective with T-MAP COVID is to answer many outstanding questions about durability of COVID-19 vaccines, especially in light of new variants of the virus. For new variants of concern, such as Delta or Omicron, we have demonstrated the ability to identify mutations and connect them to our large-scale antigen-specific datasets in order to measure T-cell response to vaccination and determine the role of cellular immunity. Our T-MAP product offers significant advantages over other technologies to detect and monitor T cells at scale using a small amount of blood without the need for live cells that require special sample handling.

To date, we have sequenced a subset of patient samples (pre- and post-vaccination) from clinical trials sponsored by several top-tier vaccine developers, including Moderna, Johnson & Johnson, AstraZeneca, University of Oxford, and the Bill and Melinda Gates Foundation among others. Using our immunoSEQ T-MAP COVID product, we can identify and track expanded T cells induced by a vaccine, which can be distinguished from a natural infection, in order to monitor vaccine efficacy. With some partners, we are working towards understanding how T cell activation may provide a correlate of protection. This has become increasingly critical in the wake of variants since the antibody response is increasingly off-target and T cells are correlating more closely with real-world vaccine efficacy.

In an effort to understand immunity for immunocompromised patients, we have also collaborated with the Leukemia and Lymphoma Society and other prestigious academic labs in order to study the T cell response of this subset of patients who do not always have the ability to mount an antibody response to vaccination.

Drug Discovery

Our drug discovery efforts to date are focused on identifying therapeutic-grade TCRs and antibody-secreting BCRs to enable our partners to engineer, manufacture and commercialize therapeutic candidates, as well as to design and develop vaccines.

Our TruTCR process characterizes TCRs against shared antigens for use in the development of therapeutics. In December 2018, we entered into an exclusive collaboration with Genentech to leverage this capability for the development of cellular therapies in oncology. We are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines:

 

•

Shared Products. The shared products will use “off-the-shelf” TCRs identified against cancer antigens shared among patients (“Shared Products”). We completed an assessment of efficacy and safety data to enable a decision to select our lead TCR candidate. Following review of this data by both us and Genentech, Genentech recently selected this TCR candidate to progress as a potential therapeutic product candidate. Meanwhile, we continue to screen and characterize TCRs against clinically relevant targets in solid tumors. We are on track to deliver to Genentech up to two additional TCR data packages for consideration by Genentech.

8

 

•

Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (“Personalized Product”). In the second half of 2020, we started screening blood from cancer patients to identify TCRs specific to a patient’s tumor mutations. We conducted initial proof of concept screens by successfully processing blood from approximately 60 cancer patients, demonstrating that in certain of these patients we were able to identify naturally-occurring TCRs from the cancer patient’s own blood that are specific to that patient’s unique tumor mutations. To support our near-term and long-term objectives for the Personalized Product, we opened our dedicated prototype lab in South San Francisco in 2021, which will have capacity to perform first-in-human clinical trials. We believe the lab positions us to potentially pursue additional opportunities outside of this collaboration, including cellular therapy in other disease states and cancer vaccines.

We also extended our drug discovery efforts by establishing a new worldwide licensing agreement in July 2021 with Nykode, whereby virus-specific T cell epitopes identified by our platform will be used to inform the design and development of novel SARS-CoV-2 vaccine candidates. The Nykode 2-arm Phase I/II trial is currently in progress with individuals in Norway who are already vaccinated. This T cell-based vaccine is intended to address SARS-CoV-2 variants of concern and may be used as a potential universal booster to available vaccines. The Nykode collaboration represents a significant extension of the platform into vaccine design and development. The platform is being deployed to both design and develop the vaccine, potentially creating opportunity for a new commercial product. Although this is the first licensing agreement we have entered into with vaccine design and development as the primary goal, we believe it may provide a useful proof of concept for extending the platform’s ability to design vaccines that may be applicable to other disease states as well.

Our TruAB process, similar to our TruTCR process, leverages our high-throughput capabilities to screen millions of BCRs to identify unique antibodies from the blood of COVID-19 patients. In several months, we used blood from over 300 patients to identify hundreds of thousands of antibodies, of which we synthesized and characterized over 3,300 antibodies that bind to various parts of the SARS-CoV-2 virus. Our lead TruAB candidates that neutralize live virus at very low concentrations, which means that a very small amount of each of these antibodies is able to block the virus from infecting cells. Importantly, our drug discovery approach is differentiated from other groups because of the scale and throughput of our TruAB approach that allows us to identify a much broader set of naturally-occurring, fully human antibody candidates to select the best ones for clinical development. The first potential clinical application of our antibodies is to treat patients who are actively fighting or have recently recovered from COVID-19.

Our Clinical Portfolio and Pipeline

Our clonoSEQ pipeline

 

 

9

 

Our T-Detect pipeline

Our Drug Discovery Pipeline

Our Competitive Strengths

We aim to harness the inherent biology of the adaptive immune system to develop clinical products and services that improve human health by leveraging our core competitive strengths.

 

•

Our immune medicine platform is uniquely capable of supporting clinical products. We have developed a platform that is capable of reading and translating the massive genetic diversity of the adaptive immune system and its selective response to disease. Specifically, our platform sequences immune receptors and maps them to antigens for diagnostic applications, pairs receptor chains and characterizes antigen-specific, paired receptors to identify optimal clinical targets for therapeutic use. We are the only company that can perform all of these functions—and we do so at an unprecedented scale to develop novel clinical diagnostic and therapeutic products.

10

 

•

Our clinical immunomics database provides a robust product development engine. Using the adaptive immune system as our product source-code, we are building a dynamic clinical immunomics database, now being annotated with antigens using machine learning, that drives our ability to rapidly discover and develop potential diagnostic and therapeutic applications. Our aim is to translate the natural capabilities of the immune system into the clinic by capturing the millions of diverse unique receptors present in a patient’s blood, then leveraging the resultant data set into multiple products and services.

 

•

Clinical applicability spans diagnostic and therapeutic product potential. Our ability to accumulate, synthesize and process billions of immunomic datapoints to generate multiple clinical diagnostic and therapeutic applications across disease areas provides optionality to our commercial pipeline. Each of our products also has broad applicability, enabling robust product lifecycle extensions.

 

•

Expanding regulatory and reimbursement expertise will help inform future clinical product development. Having successfully obtained EUA for T-Detect COVID, FDA marketing authorization and expanded coverage for multiple indications of clonoSEQ from Medicare and several national private payors, we believe we have developed valuable core capabilities that will facilitate future product development through to regulatory approval and reimbursement. We believe this capability will inform future development of other clinical products, including early detection tests.

 

•

Transformational collaborations with industry leaders validate our platform. Our collaborations with industry-defining leaders such as Genentech and Microsoft validate our unique approach to advancing the promise of immune medicine. We will continue to seek opportunities to optimize our ever-growing clinical immunomics database to drive product development and commercial success and facilitate efficient use of capital.

 

•

Strong intellectual property protects our immune medicine platform and its applications. As of December 31, 2021, we had filed 471 patent applications, 420 of which had issued as of that date, covering improvements in sequencing methods and new ways to leverage adaptive immune receptors for life sciences research, clinical diagnostic and drug discovery applications.

Our Strategy

Our focus is to leverage our immune medicine platform and competitive strengths to develop transformative clinical solutions accessible to patients around the world.

 

•

Powering the age of immune medicine. We facilitate the development of the immune medicine field by providing a platform to encourage generation of immunomics data to facilitate a deeper understanding of, and biological discovery from, the adaptive immune system. We leverage the unique capability of our platform to translate the genetics of a patient’s immune system with the scale, precision and speed required to enable the development of personalized products, including clinical diagnostic tests for disease monitoring and early detection, as well as immune-based therapeutics.

 

•

Entrench our products and services in clinical drug development with biopharmaceutical collaborators. Position our platform as the gold standard for the validation of potential immune-driven clinical discoveries in late-stage clinical trials. Since inception, our products and services have been used by 175 biopharmaceutical companies and incorporated into hundreds of clinical trials, and clonoSEQ has proven to be the MRD test of choice for select registrational trials. To deepen our established position as a partner of choice, we provide end-to-end support, including hypothesis-driven trial design, extensive data analyses, parallel regulatory support, compliant data transfers and novel target screening. These synergistic relationships advance the development and adoption of our own clinical products and inform drug development for our partners.

 

•

Rapidly identify and advance new products, leveraging foundational technology to generate revenue and address clinical diagnostic challenges in key disease states, such as autoimmune, cancer, and COVID-19. We integrate proven chemistry into our clinical products in development, avoiding the need to re-engineer new products for every clinical application. We do this by serially identifying new applications of T-Detect for early detection of disease using retrospective datasets without requiring live cells from large cohorts of patients, and by characterizing TCRs for therapeutic use. As our platform focuses on cancer, autoimmune disorders and infectious diseases, we believe we will benefit from economies of scale and drive margin improvement over time.

 

•

Drive the commercial adoption of distributed, reimbursed and regulated clinical products. Expand distribution and drive usage of our products and services. Leverage the commercial infrastructure built for clonoSEQ and T-Detect COVID to submit clinical data for regulatory clearance of our products and services, expand current payor coverage and provide robust billing and patient access infrastructure for multiple clinical applications.

11

 

•

Maintain an entrepreneurial, scientifically rigorous, data-driven and inclusive corporate culture. Fuel the promise and potential that our platform offers to help patients better manage their disease by translating insights from our world-class team, which includes 180 people with medical or doctoral degrees with expertise in biology, chemistry, bioinformatics, software, drug discovery, development and commercialization, into clinical products and services. We plan to continue to expand our team to advance the promise of immune medicine.

A Primer: The Adaptive Immune System

Over millions of years, the adaptive immune system has evolved an elegant solution to keeping people healthy. It recognizes and responds to most antigens, whether they come from outside the body, such as a virus, or inside the body, such as mutations that drive cancer.

The innate and adaptive immune systems both play a role in human immunity, but only the adaptive immune system provides a specific response to signals of disease, or antigens. These disease specific antigens are primarily fragments of proteins that are recognized as foreign, such as proteins from a virus. However, antigens can be recognized as foreign even if they are not from a pathogen. In cancer cells, antigens are generated from neoantigens, which are derived from mutations specific only to the cancer, or tumor associated antigens (“TAAs”), which are from aberrantly expressed normal proteins. For autoimmune disorders, the immune system mistakenly recognizes normal protein fragments as foreign antigens and attacks otherwise healthy tissue.

The Adaptive Immune Response

The key cells of the adaptive immune system that enable our bodies to mount responses against antigens are called T cells and B cells. T cells can destroy target cells directly, and B cells secrete antibodies, activating other parts of the immune system to destroy targets.

Each T and B cell has a unique Y-shaped receptor, which can recognize one or a small number of the millions of antigens to which our bodies are continuously exposed. When an adaptive immune response is initiated against a particular disease, the T cells and B cells encoding the disease-specific targeting receptors rapidly multiply through clonal expansion, allowing for a powerful immune response. Some of these expanded cells directly attack the disease, and others form long-term memory to allow rapid recognition of the same antigens in the future and protect against reinfection. Unlike all other genes in the human genome, the genetic sequences of TCRs and BCRs rearrange over time through a complex biological process resulting in massive diversity. The diversity of these receptors is made possible by a unique reshuffling of their genetic code known as V(D)J recombination (V=Variable, D=Diversity, J=Joining). This recombination process only occurs in T cells and B cells, and it results in each cell clone having a unique receptor-associated deoxyribonucleic acid (“DNA”) sequence. This unique DNA sequence acts like a barcode that can be used to identify and track an individual receptor over time, as shown in the figure below:

 

12

 

The adaptive immune response requires millions of these unique receptors to be widely distributed and present in the blood at all times in order to have the ability to rapidly respond to many different diseases simultaneously. Even after a specific TCR binds to an antigen and clonally expands, the frequency of these expanded T-cell clones containing the TCR remains relatively low in relation to the estimated trillions of other T cells that are circulating. We have demonstrated this by sequencing thousands of healthy individuals for control cohorts for our research and development efforts. We now know that disease-specific TCRs that are clonally expanded in a patient’s blood are present, on average, at less than 1 cell out of 100,000 cells. Despite their relatively low abundance, disease-specific TCRs can mount a systemic, persistent response to most perturbations because of the highly specialized properties of the immune response summarized in the table below:

In order to fully leverage these inherent properties of the immune system to develop clinical products, this enormous diversity and scale must be taken into consideration to be able to reliably and repeatedly measure the relative frequency of each disease-specific T cell in the blood. For example, cancer-specific TCRs circulating in the blood of a cancer patient are only present at 1 out of 100,000 cells. Auto-reactive T cells specific to any given autoimmune disorder circulating in the blood are only present at 1 out of 1,000,000 cells. Accordingly, the ability to detect disease-specific T cells requires a technology that can quantitatively probe a minimum of hundreds of thousands to millions of blood cells from each sample.

Our Immune Medicine Platform

We built a platform that can reveal and translate these properties of the adaptive immune system with the scale, precision and speed required to enable the development of personalized products, including disease monitoring, clinical diagnostic tests for early detection and immune-based therapeutics. Our immune medicine platform combines a suite of proprietary chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system and transform the diagnosis and treatment of disease.

The massive amount of data generated by our immune medicine platform is stored in our dynamic clinical immunomics database. We believe the application of machine learning with Microsoft has the potential to exponentially accelerate the growth of novel insights from this database, which we expect will further inform our product development efforts, as demonstrated by the growing number of clinical signals we are generating, including signals for SarS-CoV-2 and Lyme disease for our current products. We have also confirmed signals in Crohn’s disease, celiac disease, and multiple sclerosis and identified new signals in ulcerative colitis and rheumatoid arthritis.

13

Sequence with immunoSEQ

immunoSEQ sequences single chains of Y-shaped TCRs and BCRs using NGS. NGS generally describes several modern sequencing technologies that enable more efficient DNA and ribonucleic acid (“RNA”) sequencing than prior technologies. The key innovation in the development of immunoSEQ, pioneered by Dr. Harlan Robins and a team of leading immunologists at the Fred Hutchinson Cancer Research Center (“Fred Hutch”), was a novel approach utilizing PCR, hybridization and sequencing of rearranged TCRs to determine the sequences in millions of rearranged TCR genes, as shown in the figure below. We apply a similar approach for BCR sequencing. All of the data generated by immunoSEQ is uploaded to our clinical immunomics database and accessed through our proprietary cloud-based visualization and analytic tool called the immunoSEQ Analyzer.

 

One of the biggest challenges of any multiplex PCR technique is controlling for PCR amplification bias, which is critical for accuracy. We solved for this problem by creating a synthetic immune repertoire that mimics rearranged immune receptor loci for all V and J genes. By identifying specific primers that are either under or over amplified, titrating the primer concentrations and computationally adjusting residual bias, we optimize quantitation. The accuracy and reproducibility of our bias control methodology was demonstrated in our lab and independently in a multi-center, lab-to-lab concordance study using our immunoSEQ RUO kit. The ability to generate an unbiased TCR or BCR sequencing read-out is paramount for any clinical product and will be required for the utility and reliability of clinical kits.

immunoSEQ enables us to observe the majority of receptors involved in a real human immune response, providing deep insights into a complex biological system that was previously challenging to understand.

Map with MIRA

Our proprietary MIRA technology enables the identification of TCRs specific to thousands of antigens simultaneously. The MIRA technology leverages a multiplexed, combinatorial approach to mapping TCRs to antigens in four steps:

 

1.

Identify and query antigens of interest which can include neoantigens, tumor-associated, viral, infectious, autoimmune or other antigens.

 

2.

Pool the antigens of interest and incubate them with immune cells from multiple donors whereby antigen specificities are determined based on the antigen pool design.

 

3.

Sort T cells by marker of interest.

 

4.

Match T cell clones to specific antigens based on the presence of specific sequences in designated pools.

14

 

Combined with immunoSEQ, MIRA elucidates what diseases a patient’s immune system has been exposed to or is actively fighting at a scale that is one thousand times more sensitive than standard immunological techniques such as ELISPOT, or enzyme-linked immunospot.

Pair with pairSEQ

Our proprietary pairSEQ technology builds on immunosequencing by using a combinatorial strategy to accurately pair the two chains of Y-shaped immune cell receptors at higher throughput than can be achieved with single cell sequencing. Pairing is difficult because the two chains of the Y-shaped receptor are located on different chromosomes, which get separated when DNA is extracted from a cell for sequencing. By pairing TCRs or BCRs, we rapidly detect thousands of complete chain sequences to develop new TCR-mediated cellular therapies or to develop differentiated antibodies.

Characterize with TruTCR

TruTCR characterizes binding, cytotoxicity and safety properties of antigen-specific, paired TCRs to identify a select subset that are therapeutic-grade, enabling the development of optimal clinical candidates to be engineered into TCR-mediated cellular therapies. Our comprehensive TCR characterization process utilizes advanced cellular immunology to measure TCRs against a variety of metrics to determine the optimal clinical candidates. Antigen-specific, paired TCRs undergo evaluation for avidity, cytokine release, cytotoxicity and safety. Those TCRs that pass the first safety filter are then evaluated for TCR reactivity against T cell lines and primary cells. To date, we have identified and characterized to different stages more than 5,000 unique antigen-specific TCRs against 600 different clinically relevant targets, constituting our pipeline of possible clinical candidates. TCR characterization using TruTCR is summarized in the figure below:

 

In collaboration with Genentech, we plan to apply a similar process to screen, identify and characterize in real-time what we believe are the most promising patient-specific TCRs targeting the patient’s specific cancer antigens, advancing the next generation of cellular therapy in oncology.

Discover with TruAB

TruAB enables the discovery and characterization of BCRs for use as therapeutic antibodies. Our key differentiator is the ability to tap into the massive diversity of the B-cell repertoire to identify naturally-occurring, fully human antibodies at unprecedented scale.

In April 2020, we deployed our platform to identify neutralizing antibodies to the SARS-CoV-2 virus that causes COVID-19. We processed blood from more than 300 recovered and symptomatic COVID-19 patients. We then applied our high-throughput BCR pairing technology and paired more than 490,000 antibody heavy and light chains. We evaluated these BCR sequences in silico and selected more than 3,300 likely attractive antibody candidates for downstream functional characterization, including affinity binding and live virus neutralization.

15

Beyond COVID-19, we believe these efforts represent a differentiated platform extension that will position us to pursue additional potential antibody discovery opportunities in a variety of disease states, including in autoimmunity where there is an unmet need.

Clinical Immunomics Database

We are developing a large, dynamic clinical immunomics database. We use our proprietary software and core competency in computational biology to structure and store immune receptor data and to create tools for rapid analysis and easy visualization. All immunosequencing data is processed and uploaded to a secure cloud-based database.

The record of diseases a person has encountered, both past and present, is recorded in their TCR repertoire. This comprehensive disease information is contained in the immunosequencing data that we generate from each sample, which we believe will be revealed over time by our TCR-Antigen Map. We plan to map, both directly and through machine learning, an estimated 1015 TCRs to thousands of clinically relevant antigens, which we believe will allow us to annotate this immunosequencing data with information about disease states, increasing the value of the data over time.

We leverage our database to fuel our pipeline of immune medicine products. With over 58 billion immune receptors, our platform enables us to work with retrospective samples which serve as training sets to which our Microsoft collaborators apply machine learning and computational statistics to improve the accuracy of certain of our clinical products and services.

Our Products and Services

Our current portfolio includes commercial products and services in clinical diagnostics and life sciences research, and we are developing products and services in both clinical diagnostics and drug discovery. Our commercial research product, immunoSEQ, primarily serves as our underlying research and development engine to develop and validate our clinical pipeline. Our first commercial diagnostic product, clonoSEQ, is our FDA-cleared test to monitor MRD in patients with select blood cancers. In 2020 we launched T-Detect COVID, for the confirmation of recent or prior COVID-19 infection. Our commercial research and clinical products leverage the sequencing and mapping capabilities of our immune medicine platform and the revenue generated by these products largely contributes to sequencing revenues. Our pipeline of clinical diagnostics for the early and accurate detection of many diseases will be commercialized under the expanding T-Detect product line and will continue to grow our sequencing revenues over time. Our drug discovery efforts to date are focused on identifying therapeutic-grade TCRs (TruTCR) and antibody-secreting BCRs (TruAB) to enable our partners to engineer, manufacture and commercialize therapeutic candidates. With Genentech, we are advancing our pipeline of both shared and personalized TCR-mediated cellular therapies for cancer patients. We also extended our platform to identify highly potent neutralizing antibodies against SARS-CoV-2 and this differentiated approach can be leveraged across other disease states. Our drug discovery pipeline leverages the sequencing, mapping, pairing and characterization components of our platform and generates most of our development revenue. We further extended our platform in drug discovery by establishing a new worldwide licensing agreement with Nykode, whereby virus-specific T cell epitopes identified by our platform will be used to inform the design and development of novel SARS-CoV-2 vaccine candidates. We plan to continue to invest in our platform to develop additional clinical applications, which we prioritize based on rigorous data requirements for clinically actionability, unmet medical need and commercial viability.

16

Clinical Diagnostics

We aim to be a global leader in immune-driven diagnostics for early detection, prognosis and monitoring of disease. To achieve this long-term goal, we are focused on leveraging the sequencing and mapping functions of our immune medicine platform to develop diagnostic tests that meet regulatory standards, are widely reimbursed and are accessible to patients all around the world.

Monitoring MRD with clonoSEQ

Our first diagnostic product, clonoSEQ, is an FDA-authorized NGS test for the detection and monitoring of MRD in bone marrow or blood samples in patients with select lymphoid malignancies in which the malignant cell is derived from a T cell or a B cell. MRD refers to the presence and number of these malignant T or B cells that may remain in a patient’s body during and following treatment. Because our technology quantifies the frequency of every T cell or B cell in a sample, we can monitor MRD accurately at a sensitivity of 1 out of 1,000,000 cells, given sufficient sample input. By taking a baseline measurement prior to starting therapy and then tracking the number of cells at several time points following therapy initiation, hematologists can improve their ability to assess treatment response, predict long-term patient outcomes, monitor disease burden over time and detect potential relapse. clonoSEQ is FDA-authorized for patients with MM and ALL from bone marrow samples and for patients with CLL from bone marrow and blood samples. clonoSEQ is also currently available as an LDT for use across lymphoid malignancies and sample types, including those which have not been authorized by the FDA.

NCCN Guidelines recommend using a validated test to measure MRD to define the burden of disease and assess response to therapy in MM and ALL after each treatment stage. NGS MRD testing has been added to these guidelines and we plan to seek expansion of the recommendations to include additional time points in each disease state and to incorporate clonoSEQ specific data. To that end, in 2021, NCCN updated the adult ALL guidelines to emphasize the importance of achieving MRD negativity and incorporate recommendations on MRD actionability post-induction.

MRD monitoring is becoming increasingly important in the hematologic oncology field because highly effective new therapies are extending survival. This has created a need for more sensitive tools to monitor the disease status of patients over longer periods of time and has introduced the potential for MRD to be included as a surrogate or primary endpoint in registrational clinical trials. We believe we are uniquely positioned to benefit from these industry dynamics with both our clinical and biopharmaceutical customers.

In the clinic, clonoSEQ testing has been ordered by clinicians at centers all around the country, including all 31 NCCN centers, for over 22,000 unique patients. We believe increased adoption of clonoSEQ will now be possible due to the extensive coverage policies granted by Medicare to assess MRD at multiple time points throughout therapy in MM, ALL and CLL, and several national private payors and large regional payors, together representing over 240 million total covered lives in ALL and MM and over 150 million covered lives in CLL. We are in active discussions with other large private national and regional payors. To further develop the mounting real-world evidence demonstrating the actionability of MRD monitoring, we launched a clinical registry in 2020. This prospective, multicenter, observational study will include approximately 500 adult patients with lymphoid malignancies in the United States.

Among biopharmaceutical companies, we believe clonoSEQ remains the preferred commercial test for MRD monitoring in their registrational trials. To that end, clonoSEQ is now being used by more than 60 biopharmaceutical companies in over 150 clinical trials. To continue demonstrating clinical utility across disease settings and lines of therapy, clonoSEQ is also being used in 95 ongoing prospective investigator-led clinical trials, and our MRD data have been included in over 110 peer-reviewed publications.

We believe clonoSEQ has broad applicability across all lymphoid malignancies. Specifically, we submitted a 510(k) premarket notification for ALL from blood samples in February 2021 and are actively validating the test for patients with NHL disease types.

We continue to deepen our commercial investments to expand clinical adoption of clonoSEQ and have increased the size of our specialized sales and customer support organization and supporting infrastructure. We have continued to expand our team of demand generation representatives who are hematology specialists and are focusing their efforts on expanding access to clonoSEQ in community oncology settings. Outside of the United States, we have successfully transferred the technology to seven labs across France, Germany, Italy, UK, Spain, Australia and Japan which provide local testing options, primarily in support of collaborative group and investigator-sponsored studies.

17

The Technology

clonoSEQ is our FDA-authorized, NGS MRD technology that is designed to sequence all rearranged receptor sequences in a tumor in parallel to ensure accurate, sensitive and robust MRD monitoring.

A summary of the steps for FDA-authorized usage is as follows:

 

1.

gDNA is extracted from bone marrow.

 

2.

Extracted DNA quality is assessed, and rearranged immune receptors are amplified using a multiplex PCR.

 

3.

Reaction-specific index barcode sequences for sample identification are added to the amplified receptor sequences by PCR.

 

4.

Sequencing libraries are prepared from barcoded amplified DNA which are then sequenced by synthesis using NGS.

 

5.

Raw sequence data are uploaded from the sequencing instrument to our analysis pipeline.

 

6.

Sequence data is analyzed in a multi-step process, where a sample’s sequence data is first identified using the sample index sequences and the data is then processed using a proprietary algorithm with in-line controls to remove amplification bias.

 

7.

Following completion of these data processing steps, a report is issued.

Adaptive Assist: Patient support program

Adaptive Assist is our patient support program to facilitate access to clonoSEQ testing services for patients who could benefit from the clinical insights provided by NGS MRD testing. Patients can call to discuss their individual circumstances with one of our dedicated patient support representatives in order to better understand their coverage prior to clonoSEQ testing and to navigate the insurance process, including appeals for denied claims. We also offer financial assistance for qualified uninsured and under-insured patients who cannot afford their patient financial responsibility for clonoSEQ.

Clinical Validation in FDA Filing for MM, ALL and CLL

Our clonoSEQ test has been shown to help better predict patient outcomes and add insight to the evaluation of disease response to therapy because we have clinically validated clonoSEQ’s ability to detect MRD at a sensitivity greater than the current clinical standard for all lymphoid malignancies. clonoSEQ has demonstrated sensitivity of 1 out of 1,000,000 cells (10-6), given sufficient sample input, which is a deeper resolution than the current accepted standard of 1 out of 100,000 cells (10-5), 1 out of 10,000 cells (10-4) or 1 out of 10,000 cells (10-4) for MM, ALL and CLL, respectively. Based on these results, as further illustrated below, we believe clinical standards for MRD sensitivity may be increased to 10-6 to better predict patient outcomes.

Clinical validation in MM was demonstrated in two studies. The first study, a 720 patient, randomized phase III trial conducted at the Dana Farber Cancer Institute (DFCI 10-106), evaluated the ability to predict progression-free survival (“PFS”) and disease-free survival in patients who achieved complete response (“CR”) and the ability to predict PFS in all evaluable patients. This study demonstrates that MRD negativity for patients in CR significantly predicts PFS.

The second study, a 706 patient, randomized phase III trial sponsored by Janssen Biotech, Inc. (“ALCYONE”), evaluated Darzalex in patients with newly diagnosed MM who were transplant ineligible and served as the basis of the approval of Darzalex in combination with Bortezomib, Melphalan and Prednisone (“VMP”) in this patient population. This study provides evidence that our clonoSEQ diagnostic test is predictive of PFS, regardless of treatment received. Patients who were MRD negative at less than or equal to 10-5 had longer PFS and the group with persistent MRD negativity had the longest PFS overall.

18

Patients who were MRD negative by the clonoSEQ Assay had longer PFS

compared to MRD positive patients regardless of treatment.

 

Clinical validation in ALL was demonstrated in two Children’s Oncology Group studies, AALL0232 (high risk) and AALL0331 (standard risk) by evaluating the ability of clonoSEQ to predict event-free survival (“EFS”) at a primary cutoff of 10-4 and across a continuous MRD measure. Results demonstrate that patients with the lowest levels of MRD have better outcomes than patients with higher disease burden regardless of risk stratification.

Patients with lower levels of MRD (less than 1/100,000 cells), using the increased

sensitivity of clonoSEQ, have a higher probability of EFS.

 

Clinical validation in CLL was demonstrated in two studies. The first, a 337 patient randomized phase III registrational study in previously untreated CLL patients sponsored by Roche (CLL14), evaluated the ability of clonoSEQ to predict PFS at a primary cutoff of 10-5 and across continuous MRD measures from blood. The study demonstrates that MRD negative patients had significantly better PFS, independent of treatment regimen.

19

The second was a prospective, phase 2 clinical trial in previously untreated CLL patients in which MRD was assessed from both blood and bone marrow. MRD negativity at multiple cutoffs (10-4, 10-5, and 10-6) was significantly associated with better PFS. MRD was also prognostic of PFS when disease burden was assessed as a continuous measure (no MRD threshold). This study demonstrates that MRD is predictive of better PFS and can be assessed from either bone marrow or blood.

CLL Patients with lower levels of MRD in blood have a higher probability of EFS

 

Evolution of MRD into Clinical Decision Making Tool

While clinical utility has been a barrier to adoption in the past, this is changing quickly as we see multiple studies reading out that clearly demonstrate the value of MRD testing for patients.

 

•

For example, the MASTER trial presented at ASH 2021 and published in the Journal of Clinical Oncology (JCO) showed 98% of standard and high-risk patients who discontinued treatment after two negative clonoSEQ MRD tests did not progress after 12 months of treatment discontinuation. This data supports the goal of adapting treatment regimens to give relief to patients from side effects and saving substantial costs for the health care system.

 

•

Martinez-Lopez published a retrospective cohort analysis of 400 newly diagnosed myeloma patients in which MRD was used interventionaly to escalate, change, or stop therapy for 67 of those patients. Data showed that for MRD negative patients who stopped therapy, progression-free survival (PFS) was not negatively impacted. Also, for MRD positive patients in whom therapy was changed or intensified, PFS was significantly better than in patients who remained on the same course of therapy. This analysis supports the potential for use of MRD to modify treatment.

Strategy to Achieve Market Leadership

We aim to drive adoption and achieve market leadership for MRD monitoring with clonoSEQ for all lymphoid malignancies. To do so, we are executing upon the following strategic initiatives:

 

•

Invest in commercial initiatives to increase awareness and usage in the clinic. We are expanding our sales organization to target key customer segments, including academic centers, integrated health networks and community clinicians, in a tiered manner based on patient volume. Importantly, clonoSEQ is now being used clinically at all 31 NCCN institutions. In 2021, we also drove significant uptake in Tier 2-3 community accounts. We will continue to increase the strength of our specialized sales organization and supporting infrastructure, including building out our teams focused on community oncology centers and integrated delivery networks. We are also focusing on deeper penetration of the patient opportunity within academic institutions currently using clonoSEQ. We also continue to build advocacy on an educational basis through a variety of patient educational initiatives and peer to peer programming about the impact of MRD status on clinical decision-making.

20

 

•

Expand reimbursement with public and private payors. We are working with new payors to develop appropriate coverage policies, generate healthcare economic information and provide robust billing and patient access infrastructure. As of December 31, 2021, we secured Medicare and private payor coverage for clonoSEQ for over 240 million covered lives for MM and ALL and over 150 million covered lives for CLL. In November 2021, MolDX published its LCD for MRD testing. This LCD not only affirms the importance of MRD and clonoSEQ coverage in ALL, MM and CLL in bone marrow and blood, but also provides a clear and efficient pathway for seeking expanded clonoSEQ coverage through technical assessments in NHL.

 

•

Entrench clonoSEQ in biopharmaceutical clinical trials. As the industry pursues the inclusion of MRD as a potential surrogate or primary endpoint in clinical trials for lymphoid malignancies, having a standardized and highly accurate and sensitive method for MRD testing to guide clinical decisions in late-stage trials, including registrational trials, is valuable. Our goal is to position clonoSEQ for use by our biopharmaceutical collaborators as the MRD test of choice for these clinical trials.

 

•

Validate clonoSEQ in additional indications for use. With the end goal of clonoSEQ becoming a universal MRD test for all lymphoid malignancies, we have developed a robust lifecycle development plan to generate sufficient clinical evidence to support the extension of the FDA label across lymphoid malignancies. We are already cleared in ALL and MM from bone marrow and CLL from bone marrow and blood. At the same time, we are increasing marketing support for clonoSEQ usage as a CLIA-validated lab-developed testing service, where samples for any lymphoid cancer indication and a range of sample types (including blood) are acceptable, and payer coverage is already in place for blood-based testing in ALL, MM and CLL. Going forward, we will continue to evaluate the optimal commercial path (FDA or CLIA) for each additional indication, with an increasing focus on NHL.

 

•

Validate clonoSEQ in blood to offer a minimally invasive alternative. Testing with blood is less invasive for patients and less expensive as compared to MRD testing from bone marrow samples, and it may only be possible because of the deep sensitivity of our clonoSEQ diagnostic test. Therefore, blood-based MRD testing may enable more frequent monitoring of patients over longer periods of time. We have already received FDA clearance for clonoSEQ from blood samples for patients with CLL, we submitted for FDA clearance for ALL from blood samples and are evaluating the path forward, and we will continue to expand testing with blood to other indications over time.

 

•

Invest in product and customer experience improvements. For 2022, we are making significant investments to support our field force, including providing enhanced selling direction, data and training.  We are also making significant investments in improving our assay’s performance for evaluation of ctDNA in plasma, and, with respect to the process of ordering malignancies clonoSEQ testing and obtaining test results, aiming to continue to enhance our customer-facing software interface and user experience.

Early or Accurate Detection with T-Detect

By learning to read the antigen specificity of a patient’s immune system, we are developing the T-Detect test for early or accurate detection across a broad range of diseases, including infectious diseases, autoimmune disorders, and certain prevalent cancer types. We believe the adaptive immune system presents an ideal model for diagnostic tools for early or accurate detection of disease. In many cases, treatment is typically most effective early in the course of a disease, when there is a minimal amount of disease-specific antigen present. TCRs recognize this very small amount of antigen before it is detectable by conventional methods and then they expand exponentially. Given this large response in proportion to the amount of antigen present, we believe we will be able to see this signal of disease much sooner than is possible with other methods of early disease detection. Additionally, in some disease states, knowledge of prior infection from certain pathogens, e.g., COVID-19 and Lyme, may inform the basis of clinical decision-making or ongoing patient care. Finally, the ability to rapidly and accurately identify the cause of non-descript symptoms may increase efficiency and compress the timeline between symptom and diagnosis, thus reducing the diagnostic odyssey that patients often endure in the current diagnostic paradigm.

We are leveraging our existing immunoSEQ technology to develop T-Detect for the early or accurate detection of many diseases simultaneously. This is possible because our platform works with retrospective sample sets and uses machine learning and computational statistics to continuously improve accuracy without requiring large cohorts of prospective patients. We began by developing T-Detect for the early detection of specific disease states that meet the following criteria:

 

•

Clinically relevant antigens are known and understood.

 

•

High unmet medical need for diagnosis.

 

•

Potential to improve patient outcomes with early intervention.

 

•

Availability of sample sets with patient outcomes.

21

 

Using these data, we aim to simulate the natural diagnostic capability of the immune system into the clinic where we will use the map for the early or accurate detection of many diseases. The potential economic model for T-Detect of becoming "one test with many results" is very compelling. When multiple tests are ordered at the same time, the marginal cost for each additional test result is negligible.

Through iterative data generation efforts, we continue to improve the accuracy of the TCR signatures of each disease by running blood samples from healthy donors, collaborating on retrospective studies with control groups in select disease states, and leveraging our database for additional sequences to include in the TCR signatures.

We see the evolution of T-Detect in three phases over time:

 

•

Phase I: Launch T-Detect disease by disease with a more accurate test versus the current standard of care.

 

•

Phase II: Introduce T-Detect panel(s) for the differentiated diagnosis of disease when the symptoms are shared among several diseases.

 

•

Phase III: Enable T-Detect for population immunomics, where anything we map, we will be able to diagnose from a single blood sample. 

First Commercial Indication: T-Detect COVID

In response to the COVID-19 pandemic, we collaborated with Microsoft to create the ImmuneCODE program to map the T cell response to SARS-CoV-2 across the global population. Our goal was to leverage the existing capabilities of our high throughput platform to generate an unprecedented amount of T cell data from over 9,000 samples to understand the adaptive immune response to COVID. From these samples, we have mapped over 160,000 high-confidence TCRs to all parts of the virus which we have shown to be most immunogenic.  T-Detect COVID received EUA for confirmation of recent or prior SARS-CoV-2 infection in March 2021.  

This represents a stepping-stone to the long-term vision of T-Detect where a single blood sample can provide information about what diseases a person’s immune system has seen or is currently fighting. Data demonstrates that the T-cell response is more persistent than the antibody response to the virus, persisting to at least twelve months following initial infection, and performance of T-Detect COVID is equivalent to or better than antibody testing at all timepoints evaluated.   

Clinical Validation of Detection of Recent or Prior SARS-CoV-2 Infection

Our T-Detect COVID test is a novel T-cell based assay that has demonstrated high percent positive and percent negative agreement (PPA and NPA) to identify or exclude prior SARS-CoV-2 infection in PCR-confirmed SARS-CoV-2 cases and lack of cross-reactivity to several viral and/or respiratory pathogens.

PPA was demonstrated in two studies: 1) a primary PPA study evaluating residual blood samples (N=205) from subjects diagnosed with SARS-CoV-2 infection based on the EUA Abbott RealTime SARS-CoV-2 RT-PCR test from a single U.S. reference lab (Discovery Life Sciences, New York); and 2) a secondary PPA study using both retrospectively and prospectively collected samples from multiple cohorts (N=77; ImmuneRACE and ImmuneSense™ COVID-19) and identified as positive based on a variety of EUA testing methods performed by a number of different labs. T-Detect COVID demonstrated high PPA particularly in the timeframe of ≥15 days since diagnosis (97.1%) as well as ≥15 days since symptom onset (94.5%), as shown in Table 1.

Table 1. Positive Percent Agreement (PPA) of T-Detect COVID Assay with SARS-CoV-2 RT-PCR according to days since symptom onset or days since diagnosis.

 

Days Since 

Diagnosis 

RT-PCR+ Samples (N)

T-Detect Positive (N)

T-Detect PPA (95% CI)

0-7 days 

35 

25 

71.4 (53.7 - 85.4)

8-14 days 

33 

31 

93.9 (92.7 - 99.3) 

≥15 days 

137 

133 

97.1 (92.7 - 99.2)

All (range 0-91 days)

205 

N/A 

N/A 

Days Since 

Symptom Onset 

 

 

 

0-7 days 

13 

7 

53.8 (25.1 - 80.8)

8-14 days 

9 

7 

77.8 (40.0 - 97.2)

≥15 days 

55 

52 

94.5 (84.9 - 98.9)

All (range 0-106 days)

77 

N/A 

N/A 

22

 

NPA was demonstrated in two studies: 1) a primary NPA including 124 retrospective frozen clinical remnant blood samples collected prior to December 2019 and thus presumed negative for SARS-CoV-2 infection; and 2) a secondary NPA study using blood samples from subjects enrolled prospectively (ImmuneSense COVID-19) from October through November 2020 who presented with SARS-CoV-2 symptoms but tested negative for SARS-CoV-2 using RT-PCR EUA, BioFire RP V2.1, and EUA antibody tests.

T-Detect COVID demonstrated NPA of approximately 100% in individuals who had compatible symptoms of infection but were either presumed or confirmed negative for SARS-CoV-2 by PCR and antibody testing, as shown in Table 2.

 

Table 2. Negative Percent Agreement (NPA) of T-Detect COVID Assay with pre-pandemic samples sourced retrospectively (DLS) and prospectively enrolled subjects (ImmuneSense COVID-19) negative for SARS-CoV-2 by EUA RT-PCR and antibody testing.

 

Cohort 

Samples (N)

T-Detect Negative Results (N)

NPA (95% CI) 

 

DLS 

87 

87 

100 (95.8 – 100) 

 

ImmuneSense COVID-19 

79 

78 

98.7 (93.1 – 99.97) 

 

Second Indication: T-Detect Lyme

We previously established proof of concept in acute Lyme disease from two independent, retrospective cohorts of over 200 patients with early Lyme disease.  The TCR repertoire sequencing demonstrated a near doubling in sensitivity for identifying disease compared to STTT (56% vs. 30%) in patients tested within 30 days of symptom onset (2/3 of patients were tested within 8 days of symptom onset), with the sensitivity over STTT being most significant in the four days following the onset of symptoms (44% vs 14%). TCR repertoire sequencing was approximately 99% specific in an independent set of control samples that had all tested STTT-negative. 37% of early Lyme cases that initially tested STTT negative were identified. Additionally, the relative abundance of T-cell signatures was found to correlate with disease severity markers, such as abnormal liver function tests, disseminated rashes, and several other Lyme disease-associated symptoms. The signal in Lyme further demonstrates that machine learning can be leveraged to develop diagnostic signals, even without the large cohorts of prospective patient data often required for diagnostics development.  We completed the ImmuneSENSE Lyme study and expect to launch as a CLIA-service offering during the 2022 Lyme season, leveraging the infrastructure built for T-Detect COVID.  

T-Detect Pipeline

To achieve our goal of developing a diagnostic test for early detection across a broad range of diseases, we are pursuing the following strategic plan:

 

•

Apply machine learning to high-throughput mapping to generate the TCR-Antigen Map.

 

•

Demonstrate clinical signals for early detection using mapped TCRs in select indications.

 

•

Launch one TCR sequencing technology, T-Detect, for initial indications.

 

•

Broaden utility to a wide range of diseases without requiring large prospective trials.

We have optimized our research and development funnel and expanded our lab capacity to expedite our ability to move many diseases through the funnel in parallel. We start by prioritizing diseases that meet key market attractiveness criteria such as high unmet medical need, understanding of the antigenic space, and our access to samples with metadata. Once an early signal is identified, we refine our modeling with additional case control studies and by leveraging our clinical immunomics dataset. Once we confirm a signal, we proceed with a full commercial validation and generation of a locked-down algorithm to take into clinical validation and regulatory submission.

23

In terms of other T-Detect indications in the pipeline, we continue to advance T-Detect in multiple autoimmune indications in parallel. In 2021, we confirmed signals in Crohn’s disease and multiple sclerosis and identified new signals in ulcerative colitis and rheumatoid arthritis. These clinical signals were identified in a series of well-characterized case-control sample sets from collaborating institutions, including over 5,000 samples in IBD, and we plan to advance some of these signals to blinded clinical validation studies in the near future.

For new indications, there are many economic advantages of T-Detect both in the research and development stage and as a commercial product. For the research and development pipeline, we use the same capital expenditures and workflow for signal generation across all diseases allowing us to study multiple diseases in parallel. Once commercialized, again, we use the same blood sample and the same underlying chemistry for all diseases with a small incremental investment in software for each individual disease, enabling a long-term high margin profile.

Life Sciences Research

immunoSEQ for Research Use Only

Our immunoSEQ technology, which we offer to customers as a service and a kit, is the core of our immune medicine platform. immunoSEQ utilizes multiplex, bias-controlled PCR to accurately and quantitatively sequence millions of immune receptors at high-throughput directly from DNA. We believe immunoSEQ is positioned to become the global standard for immunosequencing due to the quality and reliability of our data and the analytics and data visualization tools that are easily accessible to customers in the immunoSEQ Analyzer, whether sequenced as a service or a kit.

Since inception, immunoSEQ has been used for research purposes by over 2,400 academic researchers and 175 biopharmaceutical companies and incorporated into over 650 clinical trials to answer translational research questions relating to the adaptive immune system, monitor response to therapies and discover new prognostic and diagnostic signals. These research questions are answered by using the data generated by immunoSEQ and uploaded to the immunoSEQ Analyzer to study different properties and dynamics of all of the sequences in an immune repertoire, such as frequency or abundance, and by tracking specific sequences over time in clinical trials. Graphical representations of the Analyzer output are shown in the figure below:

 

immunoSEQ provides a growing revenue stream. However, we also use immunoSEQ as the foundational technology for our clinical diagnostic and therapeutic products. To fuel innovation, we also provide immunoSEQ to select research and development collaborators who gain access to immunoSEQ and significant computational and analytical support, co-share and co-publish the data with us, and contribute to the validation of potential clinical diagnostic discoveries. For example, we work closely with our collaborators to conduct translational research to explore the use of immunosequencing to predict responders to novel immunotherapies such as checkpoint inhibitors.

Our immunoSEQ Analyzer is housed on a secure cloud-based database and is the visualization gateway to our clinical immunomics database that currently has billions of TCR and BCR sequences which are often annotated and accompanied by samples with associated metadata. We offer computational services to assist our customers in realizing the power of their data and to compare their data to other publicly available datasets in our clinical immunomics database. We contribute some of our own research and development sequences into the publicly available datasets and customers are offered the option to make their data public using one of our tools on our immunoSEQ Analyzer, called immuneACCESS, through which researchers can expedite and streamline the peer-review process by sharing their data with reviewers prior to manuscript submission.  The ongoing analysis of immune receptor data from an expanding database tagged with clinical metadata, when possible, has led to over 650 peer-reviewed publications referencing immunoSEQ and potential clinical signals to explore.

immunoSEQ T-MAP

In 2020, we identified some key opportunities to expand our research product offering to include mapping data generated by our platform. Sequences mapped to clinically relevant antigens have many benefits beyond just repertoire sequencing dynamics and we plan to offer immunoSEQ T-MAP across many disease states in the future.

24

We launched immunoSEQ T-MAP COVID in August 2020 for vaccine developers and researchers to accurately and reproducibly measure the T-cell immune response to vaccines and track the persistence of that response over time, including with respect to emerging variants of concern. immunoSEQ T-MAP COVID combines the sequencing and mapping capabilities of Adaptive’s immune medicine platform to show how T cells respond to different parts of the virus, including the various parts of the spike protein. A key objective with T-MAP COVID is to answer many outstanding questions about durability of COVID-19 vaccines, especially in light of new variants of the virus. For new variants of concern, such as Delta or Omicron, we have demonstrated the ability to identify mutations and connect them to our large-scale antigen-specific datasets in order to measure T-cell response to vaccination and determine the role of cellular immunity. Our T-MAP product offers significant advantages over other technologies to detect and monitor T cells at scale using a small amount of blood without the need for live cells that require special sample handling.

To date, we have sequenced a subset of patient samples (pre- and post-vaccination) from clinical trials sponsored by several top-tier vaccine developers, including Moderna, Johnson & Johnson, AstraZeneca, University of Oxford, Bill and Melinda Gates Foundation among others. Using our immunoSEQ T-MAP COVID product, we can identify and track expanded T cells induced by a vaccine, which can be distinguished from a natural infection, in order to monitor vaccine efficacy. With some partners, we are working towards understanding how T cell activation may provide a correlate of protection. This has become increasingly critical in the wake of variants since the antibody response is increasingly off-target and T cells are correlating more closely with real-world vaccine efficacy.

In an effort to understand immunity for immunocompromised patients, we have also collaborated with the Leukemia and Lymphoma Society and other prestigious academic labs in order to study the T cell response of this subset of patients who do not always have the ability to mount an antibody response to vaccination.

Drug Discovery

Our aim is to develop immune-mediated therapies in oncology and other disease areas by using the full functionality of our immune medicine platform, including TruTCR and TruAB for TCR and antibody characterization, respectively. We are currently working to leverage our immune receptor discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our own end-to-end capabilities for the further development of our own portfolio of therapeutic candidates.

25

 

TCR Discovery for Cellular Therapy using TruTCR

We have developed a high-throughput TCR screening process that allows for the discovery of antigen-specific TCRs that occur in low frequencies in healthy individuals. We believe this provides a set of naturally-occurring TCRs with a more favorable safety profile in comparison to engineered TCRs. We then further characterize these naturally-occurring TCRs for binding avidity and cytotoxic potency. To date, we have identified and characterized to different stages more than 5,000 unique antigen-specific, paired TCRs against 600 different clinically relevant targets, constituting our pipeline of possible clinical candidates. We complete a data package for each characterized TCR that we believe meets the thresholds for therapeutic evaluation. These thresholds are divided into a series of seven key steps covering antigen specificity, functional avidity, cytolysis and safety assessment. A package is considered complete when the TCR meets the rigorous criteria for all seven steps and the data are compiled to support an IND package. As a proof of concept, we compared our fully characterized TCR against WT-1, a TAA often overexpressed in various cancers, to a benchmark WT-1 TCR. A gold standard for testing TCR efficacy is killing of cells that naturally express the target antigen at low levels. Using a cancer cell line that is known to express low levels of WT-1, our candidate WT-1 TCR was over four times more effective at killing cancer cells than the benchmark TCR. The complete data package for our lead WT-1 TCR candidate demonstrates improved avidity, cytolysis and a promising safety profile.

Our high-throughput screening technologies enable us to discover TCRs against any type of antigen which opens up the potential to develop novel TCR-mediated cellular therapies for any type of cancer. As compared to cellular therapies that target T cell surface antigens that are not specific to cancer, we believe our approach to TCR cellular therapies may mitigate the risk of off-target side effects. Therefore, we believe our approach may be applicable to the vast majority of solid tumors, even those where the tissue of origin is vital to survival such as lung or renal.

In December 2018, Genentech selected our platform to develop, manufacture and commercialize novel neoantigen directed T cell therapies for the treatment of a broad range of cancers. Our ultimate goal is to harness the vast majority of therapeutically relevant, patient-specific TCRs against neoantigens and advance the next generation of cellular therapies in oncology. We believe our TCR discovery capabilities may also facilitate the development of cellular therapies in disease areas beyond cancer, which we can commercialize outside of the Genentech collaboration.

In addition to cellular therapy applications, we believe our TCR screening capabilities can guide the design and development of next generation vaccines by characterizing the immunogenicity of hundreds of antigens at a time. Our platform can also be used to then monitor early signs of antigen-specific immune response in patients treated with novel vaccines.

Strategic Collaboration with Genentech

Through our worldwide collaboration and license agreement with Genentech, we plan to develop, manufacture and commercialize novel neoantigen directed T cell therapies for the treatment of a broad range of cancers to advance the next generation of cellular therapies in oncology. We are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines:

 

•

Shared Products. The Shared Products will use “off-the-shelf” TCRs identified against cancer antigens shared among patients. We completed an assessment of efficacy and safety data to enable a decision to select our lead TCR candidate. Following review of this data by both us and Genentech, Genentech recently selected this TCR candidate to progress as a potential therapeutic product candidate. Meanwhile, we continue to screen and characterize TCRs against clinically relevant targets in solid tumors. We are on track to deliver to Genentech up to two additional TCR data packages for consideration by Genentech.

 

•

Personalized Product. The Personalized Product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient.  In the second half of 2020, we started screening blood from cancer patients to identify TCRs specific to a patient’s tumor mutations. We conducted initial proof of concept screens by successfully processing blood from approximately 60 cancer patients, demonstrating that in certain of these patients we were able to identify naturally-occurring TCRs from the cancer patient’s own blood that are specific to that patient’s unique tumor mutations. To support our near-term and long-term objectives for the Personalized Product, we opened our dedicated prototype lab in South San Francisco in 2021, which will have capacity to perform first-in-human clinical trials. We believe the lab positions us to potentially pursue additional opportunities outside of this collaboration, including cellular therapy in other disease states and cancer vaccines.

26

 

Under the terms of the agreement, we received a $300.0 million initial upfront payment in February 2019, and we may be eligible to receive approximately $1.8 billion in aggregate milestone payments upon achievement of specified development, regulatory and commercial milestones. Additionally, we may receive royalties on sales of products commercialized under that agreement. Genentech will be responsible for clinical, regulatory and commercialization efforts. We will be responsible for the screening and identification of TCRs that can most effectively recognize and directly target specific cancer antigens, including neoantigens.

In parallel, we plan to evaluate an investment in additional facilities that would allow us to scale our end-to-end screening of patient-specific TCRs for potential future late-stage clinical trials and commercialization of the Personalized Product. We believe this investment would position us to potentially pursue additional opportunities outside of this collaboration, including developing and commercializing vaccines and cellular therapies in other disease states.

Vaccine Development with Nykode

We also extended our drug discovery efforts by establishing a new worldwide licensing agreement in July 2021 with Nykode, whereby virus-specific T cell epitopes identified by our platform will be used to inform the design and development of novel SARS-CoV-2 vaccine candidates. The Nykode 2-arm Phase I/II trial is currently enrolling individuals in Norway who are already vaccinated. This T cell-based vaccine is intended to address SARS-CoV-2 variants of concern and may be used as a potential universal booster to available vaccines. The Nykode collaboration represents a significant extension of the platform into vaccine design and development. The platform is being deployed to both design and develop the vaccine as opposed to an evaluative use of our data following infection, as well as in direct support of a new commercial product. Although this is the first licensing agreement we have entered into with vaccine design and development as a primary goal, we believe it may provide a useful proof of concept for extending the platform’s ability to design vaccines for other disease states.

Developing neutralizing antibodies using TruAB

Our TruAB process, similar to our TruTCR process, leverages our high-throughput capabilities to screen millions of BCRs to identify unique antibodies from human blood. Our first proof of concept is for patients who are actively fighting or have recently recovered from COVID-19. In just several months, we collected blood from over 300 patients and hundreds of thousands of antibodies, of which we synthesized and characterized over 3,300 antibodies to various parts of the SARS-CoV-2 virus. To date, we identified several candidates that neutralize live virus at very low concentrations, which means that a very small amount of each of these antibodies is able to block the virus from infecting cells. Using our TruAB antibody discovery approach, we identified several lead antibody candidates that strongly bind to different parts of the virus. Our growing portfolio of novel antibodies includes candidates that don’t bind the classic RBD region and instead bind to S1, Trimer or S2. We believe we are one of the only groups that has identified S2-specific antibodies that neutralize the virus. This could have important advantages in a cocktail strategy that targets different mechanisms of action to inhibit the virus and potentially virus variants.

 

27

 

Importantly, our drug discovery approach is differentiated from other groups because of the scale and throughput of our TruAB approach that allows us to identify a much broader set of naturally-occurring, fully human antibody candidates to select the best ones for clinical development. Beyond COVID-19, we are exploring applications of TruAB discovery in other diseases, including autoimmunity.

Our People and Culture

Our employees, internally referred to as “Adapters,” are passionate about immune medicine, empowered by scientific discipline and fueled by our foresight and curiosity about the adaptive immune system.

As of December 31, 2021, we had 858 full-time employees of which 180 hold medical or doctoral degrees. None of our employees are subject to a collective bargaining agreement and we have not experienced any work stoppages. We believe relations with our employees are good.

Our talented employees drive our mission and share core values that both stem from and define our culture. This plays an invaluable role in our ability to execute at all levels in our organization. Our core values are used in candidate screening, rewards and recognition criteria, and in employee evaluations to help reinforce their importance in our organization:

 

•

Make it happen. Individual ownership and accountability keep us moving forward.

 

•

Innovate fearlessly. Push against boundaries and think boldly to achieve world-changing results.

 

•

Debate openly. Value discussions inspired by different points of view.

 

•

Work together. Demonstrate you care about the success of others. The same goes for our partners and customers—together we can achieve more.

 

•

Follow True North. Show up with integrity and do the right thing.

 

•

Have fun. Fun makes everything better.

We believe our employees are highly engaged, and we were recognized consecutively from 2018 to 2021 by the Puget Sound Business Journal as one of Washington State’s Best Places to Work. We were also nationally certified as a 2021 Great Place to Work.

28

Diversity and Inclusion

We pride ourselves on inclusive team building, product design and gender diversity at all levels of management. We are committed to creating and maintaining a culture of belonging. In 2021, we expanded and implemented several diversity and inclusion initiatives. We continued to provide quality DEI programming through Employee Resource Groups (“ERGs”) including Women@Adaptive, Adaptive PRIDE, Black Adapter Network and Working Life and Wellness, and in 2021 launched two new ERGs: Asian Pacific@Adaptive and Sustainability@Adaptive. We continued to explore diversity sourcing programs and partnerships, and we expanded our diversity training to a growing population of hiring managers. We also integrated hidden bias training into our Leader of People Program. Our Equity Advisory Council of senior leaders maintained a strategic focus on clinical studies, commercial engagement, recruiting, and retention through a diversity and inclusion lens. In November 2021, we received a Corporate Equality Index (CEI) score of 95/100 from the Human Rights Commission. Our score of 95 is an increase of 20 points from last year’s previous CEI score. We successfully executed a second year of our STEM minority mentoring partnership with University of Washington. During the grand opening of our new Seattle headquarters building, and with the help of Governor Jay Inslee, we also announced our partnership with SPIN Girls, a transformative local program that builds leadership and provides immersive STEM experiences, while pairing students with female-identifying mentors of color from across King County.

Compensation and Benefits

We strive to provide compensation and benefits that are competitive to market and create incentives to attract and retain employees. Our compensation package includes market-competitive base pay, performance-based short-term incentives, health care, retirement benefits, paid time off and family leave. In addition, we offer employees the benefit of equity ownership in the Company through restricted stock unit awards. We also provide access to a variety of health and wellness resources, with special attention paid to mental health in 2021. This year also saw the inaugural winners of our Adaptive Leadership Awards announced, recognizing and celebrating those who best embody our Adaptive Leadership Principles.

Employee Development & Training

We prioritize employee development and training and have established programs to support a culture of employee development. Specifically, in 2021, we offered multiple learning solutions, including our Leader Orientation Program, our Leader of People Program, and our L-re:combinator Fellowship Program. We launched Leader of Leaders for employees at or above Director level. We also completely reworked and relaunched our employee onboarding program, DayOne. All of our leadership development programs are multi-week, blended learning courses that feature self-paced online learning and live virtual training. DayOne focuses not just on HR and compliance orientation, but cultural onboarding with small group interactions among our Chief Executive Officer, cultural ambassadors and fellow new Adapters.

In 2021, over 130 Adapters attended leadership development programs and consumed approximately 2,400 hours of training. Over 200 Adapters completed DayOne. In our annual employee survey, Adaptive Listens, Adapters generally judged our managerial corps as one of Adaptive’s strengths, a sign that investing in their development is translating into real-world results.

COVID-19 Preparedness

Since the emergence of COVID-19, our cross-functional COVID-19 preparedness committee has been meeting at least weekly to monitor the progress of the disease, stay apprised of expert external guidance, discuss and implement preparedness plans as needed, and provide clear communication to all Adapters. We implemented measures to reduce the risk of exposure of COVID-19 to the employees who continue to work on site, including the implementation of work-from-home policies for certain employees, as well as the implementation of shifts and zones to physically distance employees who remain on site, including extra sanitation measures. For those employees working remotely, we provided additional equipment to support their ergonomic and technology needs. Beginning in 2022, our offices and infrastructure are now set up to support and enable a hybrid workforce, with safety and other factors related to on site work continually evaluated by our Covid-19 preparedness committee. 

Strategic Collaborations and Other Agreements

Genentech Agreement

In December 2018, we entered into an agreement with Genentech (“Genentech Agreement”) to develop, manufacture and commercialize novel neoantigen directed T cell therapies for the treatment of a broad range of cancers. Pursuant to the Genentech Agreement, we are responsible for the screening and identification of TCRs that can most effectively recognize and directly target specific neoantigens, while Genentech is responsible for clinical, regulatory and commercialization efforts. During the term of the Genentech Agreement, we have agreed to certain defined exclusivity obligations or restrictions with respect to the development and commercialization of certain cell therapies.

29

In February 2019, we received a $300.0 million upfront payment from Genentech. We also may be eligible to receive approximately $1.8 billion over time, including payments of up to $75.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones, and up to $1.4 billion upon the achievement of specified commercial milestones. Genentech will also pay us tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of the Shared Products and the Personalized Product arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. For the year ended December 31, 2021, 2020 and 2019, the Genentech Agreement accounted for 40.2%, 53.7% and 41.3% of our revenue, respectively.

The Genentech Agreement will continue until the expiration of all royalty payments, but may be terminated by mutual agreement, upon an uncured material breach by either party, upon insolvency of either party, or by Genentech for convenience upon prior written notice.

Microsoft Agreement

In December 2017, we entered into a strategic collaboration agreement with Microsoft (“Microsoft Agreement”) to map TCR sequences to the antigens they bind with the goal of developing diagnostic tests for early detection of many diseases from a single blood test.

Pursuant to the Microsoft Agreement, Microsoft applies machine learning and computational statistics to our clinical immunomics data in order to produce predictive models that allow us to map TCR sequences to the antigens they bind. Under the Microsoft Agreement, we retain all rights to these predictive models and the data underlying our TCR-Antigen Map, including the right to commercialize clinical products using our TCR-Antigen Map. We and Microsoft have granted each other certain licenses to one another’s intellectual property rights and have agreed to certain defined exclusivity obligations with respect to collaborations and projects that are substantially similar to the Microsoft Agreement.

During the term of the Microsoft Agreement, we have agreed to exclusively use Microsoft’s Azure cloud services at standard volume pricing with a minimum Azure consumption requirement. We have also agreed to host each diagnostic product developed as a direct result of the Microsoft Agreement on Azure throughout the term of the Microsoft Agreement and for a period of five years thereafter. In addition, we have agreed to exclusively use Microsoft’s immunomics artificial intelligence services for TCR-antigen mapping in connection with all of our technology, products and services developed as a direct result of our collaboration with Microsoft throughout the term of the Microsoft Agreement.

The Microsoft Agreement has a seven-year term and may be terminated by mutual agreement or by either party upon an uncured material breach. Concurrently with entry into the Microsoft Agreement, Microsoft purchased shares of our Series F-1 convertible preferred stock which were converted into common stock upon the closing of our initial public offering in July 2019.

Processing and Manufacturing

We process both clinical and research use samples in our laboratory in Seattle, Washington. Our Seattle laboratory is CLIA-certified, CAP-accredited and ISO 13485-certified. After we intake samples sent to us from healthcare providers or research and biopharmaceutical customers, we extract DNA from the sample if required, amplify it and otherwise prepare it for our sequencing and data analysis. Throughout our processes, we apply a rigorous quality management system, which is designed to comply with the Quality System Regulation (“QSR”) and the requirements of CLIA, CAP and other applicable state licensing and accreditation requirements.

In order to process samples submitted to us using immunoSEQ or clonoSEQ, we utilize a combination of proprietary primer mixes and commercial materials, including a multiplex PCR master mix, enzymes, high throughput multi-cycle sequencing reagents and other materials, which we obtain and assemble as needed from various third-party vendors on customary terms. A number of our processing steps utilize automated equipment to help ensure consistency and efficiency. Sequencing is performed using the Illumina NextSeq System, which we have appropriately qualified for the intended uses of our products and services. We also work with a third-party vendor to manufacture our immunoSEQ RUO kit using our proprietary primer mix and other materials. We also use Illumina to develop IVD kits and provide related support for clonoSEQ and T-Detect, pursuant to a September 2019 development and supply agreement with a six-year term and payments to Illumina based on Illumina achieving milestones and revenue share payments ranging from a low to mid-single digit percentage of future net sales, subject to customary reductions.

For our TCR-Antigen Map and drug discovery initiatives, we conduct our current operations at our laboratories in Seattle, Washington and South San Francisco, California. These laboratories have cell sorting, tissue culture and other processing equipment.

30

We use a limited number of suppliers, or in some cases single suppliers, for our laboratory equipment and materials. We manage this concentration risk by targeting or building to levels of surplus stock that, we believe, would allow us to locate alternative suppliers if needed. However, if one of our suppliers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers and may face delays in processing samples or developing and commercializing our products and services. We have occasionally faced delays in the form of longer lead times for equipment that is subject to increased demand due to public health measures taken to combat the COVID-19 pandemic. In particular, we have purchased the Illumina NextSeq System, and Illumina also supplies us with reagents that have been designed for use solely with this sequencer. While we acquire these reagents from Illumina on customary terms, if we had to replace the reagents we use we may also need to acquire and qualify a replacement sequencer, validate the reagents and potentially revalidate aspects of our existing assays.

Distribution

We processed our first immunoSEQ samples in 2011 and issued our first clonoSEQ report in 2013. Since then, we have focused on expanding our customer base. We sell our products and services primarily through our own internal sales force. Our sales and marketing efforts are targeted at department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors and research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. We seek to increase awareness of our products and services among our target customers through direct sales calls, trade shows, seminars, academic conferences, web presence and other forms of internet marketing. Our drug discovery efforts are focused on large biopharmaceutical companies.

Intellectual Property

We have an extensive global portfolio of intellectual property rights to protect our immune medicine platform, the products and services that draw on it and our reputation in the industry.

As of December 31, 2021, we owned or controlled 471 active patents and patent applications whose claims are intended to cover what we do, what we plan to do and what others might do to compete with us. From our earliest patent filings in 2009, our portfolio has been tailored to reflect our efforts to harness the adaptive immune system for research, diagnostic and therapeutic applications. Our patent claims extend to not only adaptive immune receptor molecules, but also to uniquely powerful techniques for sequencing immune cell receptors, determining clonality and immune competency, diagnosing disease, predicting responses to immunotherapy and identifying new drug candidates. Our patent protection generally expires in years ranging from 2029 to 2040.

Critical know-how we develop is protected by a trade secrecy program to ensure against inappropriate disclosure or use. Encompassed in our know-how is our proprietary database of coding sequences, antigen reactivities and safety profiles for immune receptors, which is vast and growing. Even with collaborators, access to our immune medicine platform technology is limited and tightly controlled through contracts and careful communication. We own our immune medicine platform, including improvements we or collaborators make to it, and retain rights in data resulting from its use.

We also pursue trademark registration for our product and service names and promotional slogans in our existing and projected markets.

Intellectual Property Portfolio by the Numbers

As of December 31, 2021, our intellectual property portfolio consisted of the following:

 

•

471 patent applications filed worldwide directly or in conjunction with a co-owner or licensor since 2009;

 

•

51 pending patent applications;

 

•

420 issued patents across our immune medicine platform;

 

•

24 patent families directed to methods and tools useful in our immune medicine platform for non-target specific immunosequencing and research, including immunoSEQ;

 

•

17 patent families directed to methods and tools useful in diagnosis, prognosis and disease monitoring, including clonoSEQ, T-Detect and the TCR-Antigen Map;

 

•

12 patent families directed to methods and tools useful in drug discovery, including TruTCR, MIRA and pairSEQ;

 

•

1 patent family directed to therapeutic antibodies;

 

•

1 patent family directed to gene sequencing technology; and

 

•

28 trademarks registered and pending registration worldwide.

31

 

Patent Portfolio

We have developed an expansive patent portfolio in commercially important markets with claims to critical aspects of our technology, beginning with our first patent applications exclusively licensed from Fred Hutch in 2009. Our ongoing patent strategy is to generate a return on our patenting investments, which values substantive quality over volume to build a defensible moat around technology we use as well as what others might develop to design around our position.

We prioritize pursuing patent claims with a reasonable likelihood of being granted. Where patentability for a particular invention is questionable, we often choose to protect it as a trade secret instead. In some instances, however, we may seek to push the patentability envelope when the state of the applicable patent laws are in flux, such as patent eligibility for naturally occurring molecules, including TCRs, in the United States.

Methods of Measuring Adaptive Immunity

In 2009, a U.S. provisional patent application was filed to pursue protection for immunosequencing by our co-founder, Dr. Harlan Robins. The invention broadly relates to methods for assessing the adaptive immune system status of individuals. Rearranged V and J segment genes of TCRs or BCRs are targeted as biomarkers for assessing the status of the immune system at one or more points in time. Granted claims extend to the use of particular sets of amplification primers, while pending claims are being pursued to capture additional assessment techniques. Licensed exclusively to us by Fred Hutch, the application has since spawned more than 31 additional patent applications, many of which have been granted as of December 31, 2021, including U.S. Patent No. 9,809,813.

Optimizing Nucleic Acid Amplification Reactions

Amplification of nucleic acids can result in over- or under-representation of the amplified molecules, misrepresenting the number present in the source material, such as a blood sample. Dr. Robins invented a method to correct for such bias, thereby improving the precision of PCR-based quantification of TCR and BCR coding sequences in a sample. The claimed approach utilizes synthetic templates, reflecting nucleic acid sequences for rearranged V and J receptor segments in the sampled cells. More than twenty-eight related patent applications have since been filed, many of which have been granted as of December 31, 2021, including U.S. Patent Nos. 9,371,558 and 10,214,770.

Diagnosing and Monitoring Disease

In connection with our acquisition (“Sequenta Acquisition”) of Sequenta, Inc (“Sequenta”) in 2015, we purchased Sequenta’s extensive patent portfolio. The portfolio includes 124 patent applications which disclose and claim methods to identify and quantify T cell-based immune responses to antigen exposure using NGS. TCR and BCR DNA, RNA or cell-free DNA from samples, including blood and bone marrow, are used to detect, prognose and monitor disease, including autoimmune disease, infection and cancer. More than one hundred twelve patents have been granted in the portfolio as of December 31, 2021, including U.S. Patent Nos. 8,628,927 and 8,236,503.

Our diagnostic methods also apply to the detection of MRD (the target of our B cell-based clonoSEQ diagnostic test for assessing how disease burden changes in response to treatment or during remission) and T-Detect (our T cell-based diagnostic tests). Multiple patents have been granted from additional applications relating to diagnostic methods and diagnostically significant TCRs filed by us, including U.S. Patent No. 9,824,179.

TCR-Antigen Map

In connection with our Microsoft collaboration, we are developing a diagnostic product to detect cancer and other diseases at their earliest stage by learning the signals and responses of the activated immune receptors in a patient’s blood. Pre-collaboration, we filed 10 related patent applications for methods to produce antigen-exposed enriched T cell populations and identify their antigen specificities by comparison to a pre-exposure population of cells or by use of an algorithm. We have filed additional patent applications relating to algorithmic-based methods to characterize antigen specificities and will continue to do so as our work proceeds with Microsoft.

32

MIRA

We developed and are pursuing patent protection for bioinformatic-based methods to determine the antigen specificity of TCRs by exposing T cells to a panel of multiple antigens. Antigen exposure can be performed by incubation or presentation; for example, it can be performed via recombinant expression in another cell. These methods may also be used to pair the two TCR chains as well as to identify high avidity TCRs. Several patents have been granted as of December 31, 2021, including U.S. Patent No. 10,066,265.

pairSEQ

In nature, TCRs and BCRs exist as a heterodimer of paired chains, each of which is encoded on a different chromosome. Immunosequencing reveals the nucleotide structure of each individual chain, but not which chains match as cognate pairs. We developed and are pursuing patent protection for multiple bioinformatic-based approaches to pairing the two chains of TCRs and BCRs, including one deployed in our pairSEQ technique. Our methods also allow for identification of receptor chain pairs which are specific to particular antigen targets. Over fifty related patent applications have been filed, nearly half of which have matured into granted patents as of December 31, 2021, including U.S. Patent No. 10,077,478.

Assessing Responsiveness to Immunotherapy

Leveraging our immunosequencing technologies, we developed methods for predicting responses to immunotherapy, vaccines and infection. To those ends, rearranged TCR or BCR sequences are quantified and their levels or frequencies compared at different points in time. More than 20 related patent applications have been filed, most of which have been granted as of December 31, 2021, including U.S. Patent No. 10,221,461.

Therapeutic Antibodies

We developed a therapeutic antibody discovery process called TruAB from which neutralizing antibodies to SARS-CoV-2 have been produced. A patent application to these antibodies was filed in 2020 and is pending.

In-Licensed and Acquired Intellectual Property Rights

While we have developed the majority of our immune medicine platform, products and services, we occasionally license or acquire third-party owned inventions to bolster the strength of our patent estate and ensure freedom to operate.

Early work by Dr. Robins with Fred Hutch led to discoveries around immunosequencing methods and tools covered by 128 patents and patent applications in the United States and abroad which we exclusively licensed. Our rights are for all fields of use worldwide and are sublicensable. To the extent any licensed granted patent rights extend to products or services sold by us, we pay Fred Hutch a royalty rate of 0.75% of net sales on licensed products.

Through our Sequenta Acquisition, we also obtained an exclusive paid-up license, with rights to sublicense, to patents filed in the United States, Europe, Australia and China owned by iRepertoire, Inc. The license is for worldwide use in diagnosis, prognosis, treatment and monitoring of any proliferative disorder for which rearranged nucleic acids capable of encoding an immune receptor, whether productive or unproductive, or functional or nonfunctional, of a cell, excluding tumor infiltrating lymphocytes, of the proliferative disorder can be used as markers for the disorder, including, but not limited to, lymphoid and myeloid proliferative disorders, such as ALL, CLL, acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin’s and NHL, plasma cell neoplasms, such as MM, monoclonal gammopathy of undetermined significance, monoclonal B cell lymphocytosis and myelodysplastic syndromes.

In addition to the patent estate acquired from Sequenta, we also acquired ownership of immunosequencing-related patent portfolios from Imdaptive, Inc. and ImmunID S.A.S.

Trademarks

We own various trademarks, applications and unregistered trademarks in the United States and other commercially important markets, including our company name, product and service names and other trade or service marks. Our trademark portfolio is designed to protect the brands for our products and services, both current and in the pipeline.

33

Trade Secrecy Program

We have a trade secrecy program to prevent disclosure of our trade secrets to others, except under stringent conditions of confidentiality when disclosure is critical to our business. Our trade secrets include the composition of certain reagents, assay protocols and immunosequencing-related data, such as immune receptor sequences. We protect trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements provide that all confidential information developed or made known during the course of an individual or entities’ relationship with us must be kept confidential during and after the relationship. These agreements also provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties.

Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Accordingly, we may not be able to meaningfully protect our trade secrets. For more information regarding the risks related to our intellectual property, see “Risk Factors—Risks Related to Our Intellectual Property.”

Competition

The biotechnology and pharmaceutical industries, including the fields of life sciences research, clinical diagnostics and drug discovery, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. Given the breadth and promise of immune medicine, we face substantial competition from many different sources, including life sciences tools, diagnostics, pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions across various components of our platform and product and service offerings. Due to the significant interest and growth in immune medicine more broadly, we expect the intensity of the competition to increase. However, we believe our scale, precision and speed, and the resulting clinical applicability, distinguish us from our competitors. In life sciences research, immunoSEQ faces competition from a number of companies.

In clinical diagnostics, clonoSEQ faces competition primarily from institutions performing flow cytometry in-house, particularly outside of the United States. We may also face competition from companies developing early cancer detection testing products for indications that do not currently compete with clonoSEQ.

In drug discovery, clinical trials in the field of immune medicine are being pursued by a number of industry and academic players.

Immune medicine is being pursued by several biotechnology companies as well as by large-cap biopharmaceutical companies. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, regulatory approval and compliance, and sales and distribution than we do. Mergers and acquisitions involving life sciences research, clinical diagnostics or drug discovery companies in the immune medicine space may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and in acquiring technologies complementary to, or necessary for, our programs.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize research or diagnostic products or services that are more accurate, more convenient to use or more cost-effective than our products or services. Competitor therapeutic products could also prove safer, more effective, more convenient to administer or more cost-effective than any therapeutic products we may develop with our collaborators. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the relevant market.

Government Regulation

Life Sciences Research Use Only Technologies

Our core research product, immunoSEQ, is a RUO tool in the United States that provides data to third parties such as biopharmaceutical companies that are themselves engaged in the research and development of potential diagnostic and therapeutic products and services for which they may later pursue investigation and clearance, authorization or approval from regulatory authorities, such as the FDA.

34

RUO products belong to a separate regulatory classification under a long-standing FDA regulation. From an FDA perspective, products that are intended for research use only and are labeled as RUO are exempt from most regulatory controls, and are therefore not subject to the regulatory requirements discussed below for clinical diagnostic products. Thus, RUO products may be used or distributed for research use without first obtaining FDA clearance, authorization or approval. The products must bear the statement: “For Research Use Only. Not for use in diagnostic procedures.” RUO products cannot make any claims related to safety, effectiveness or diagnostic utility, and they cannot be intended for human clinical diagnostic use. Accordingly, a product labeled RUO but intended or promoted for clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act (“FDCA”) and subject to FDA enforcement action. The FDA will consider the totality of the circumstances surrounding distribution and use of an RUO product, including how the product is marketed and to whom, when determining its intended use. If the FDA disagrees with a company’s RUO status for its product, the company may be subject to FDA enforcement activities, including, without limitation, requiring the company to seek clearance, authorization or approval for the products. If the FDA determines an RUO product is adulterated and misbranded, enforcement may also include a warning letter, seizure, an injunction and/or criminal fines for FDCA violations.

Clinical Diagnostics in the United States

Our first diagnostic product, clonoSEQ, was granted marketing authorization by the FDA for the detection and monitoring of MRD in bone marrow samples in patients with MM and ALL under the de novo process in September 2018, which classified clonoSEQ and future DNA-based tests to measure MRD in hematological malignancies as Class II devices, as explained further below. In August 2020, we received our third FDA clearance for clonoSEQ, following a 510(k) submission, for CLL in bone marrow as well as blood samples.  We submitted a 510(k) premarket notification for ALL from blood samples in February 2021 and are actively advancing validation studies in certain NHL sub-types.

In the United States, medical devices are subject to extensive regulation by the FDA under the FDCA and its implementing regulations, and other federal and state statutes and regulations. The FDA regulates the design, development, preclinical, analytical and clinical testing, manufacture, safety, effectiveness, clearance, authorization or approval, record-keeping, packaging, labeling, storage, adverse event reporting, advertising, promotion, marketing, sales, distribution and import and export of medical devices. IVDs are a type of medical device and include reagents and instruments used in the diagnosis or detection of diseases, conditions or infections, including, without limitation, the presence of certain chemicals, genetic information or other biomarkers. Predictive, prognostic and screening tests can also be IVDs.

After a medical device is placed on the market, numerous regulatory requirements apply. These include:

 

•

compliance with the FDA’s QSR, which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance of complaint and related investigation files, and other quality assurance controls during the manufacturing process;

 

•

labeling regulations, which prohibit the promotion of products for uncleared, or unapproved uses, or “off-label” uses, and impose other restrictions on labeling; and

 

•

obligations to investigate and report to the FDA adverse events, including deaths, or serious injuries that may have been or were caused by a medical device and malfunctions in the device that would likely cause or contribute to a death or serious injury if it were to recur.

Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions, including but not limited to, warning letters; fines, injunctions, and civil penalties; recall or seizure of the device; operating restrictions, partial suspension or total shutdown of production; refusal to grant 510(k) clearance or premarket approvals (“PMAs”) of new devices; withdrawal of clearance or approval; and civil or criminal prosecution.

Position in the European Union

In the EU, IVDs can be placed on the market by obtaining a “CE mark,” which demonstrates conformity via a self-certification with the In vitro Diagnostic Medical Device Directive (“IVDD”). clonoSEQ obtained a CE mark in May 2019 for all B-cell malignancies with blood and bone marrow. The requirements under the Directive include:

 

•

Essential Requirements. The IVDD specifies “essential requirements” that all medical devices must meet to demonstrate the product is safe and effective under normal conditions of use. The requirements are similar to those adopted by the FDA relating to quality systems and product labeling.

 

•

Conformity Assessment. The requirements to obtain a CE mark are risk-based, and follow a similar classification system as in the United States. However, unlike the United States, which requires virtually all devices to undergo some level of premarket review by the FDA, the IVDD currently allows manufacturers to bring many devices to market using a process in which the manufacturer self-certifies that the device conforms to the applicable essential requirements.

35

 

•

Vigilance. The IVDD specifies requirements for post market reporting similar to those adopted by the FDA.

On May 26, 2017, the EU released a new regulatory framework, the In vitro Diagnostic Medical Device Regulation (“IVDR”), which will replace the IVDD. Our products in the EU will have to comply with the IVDR requirements by May 2026, subject to the applicable transitional provisions before full compliance is required. The IVDR is considerably stricter in regulatory oversight than the IVDD and will require more IVD devices to be reviewed by a notified body before being placed on the market. Until that time, our products must continue to meet the requirements of IVDD for commercialization in the EU.

U.S. Federal and State Regulation of Laboratories

Given that aspects of our business at certain facilities involve acting as a clinical laboratory, we are required to hold certain federal and state licenses, certifications and permits to conduct our business.

As to federal certifications, CLIA establishes rigorous quality standards for all laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of, or assessment of health. As a clinical laboratory, we must obtain a CLIA certificate based on the complexity of testing performed at the laboratory, such as a Certificate of Compliance for high-complexity testing. CLIA also mandates compliance with various operational, personnel, facilities administration, quality and proficiency requirements, intended to ensure that their clinical laboratory testing services are accurate, reliable and timely. CLIA compliance and certification is also a prerequisite to be eligible to bill for services provided to government payors and for many private payors. Furthermore, we are subject to survey and inspection every two years to assess compliance with program standards, and may be subject to additional unannounced inspections. Laboratories performing high-complexity testing are required to meet more stringent requirements than laboratories performing less complex tests.

In addition to CLIA requirements, we elect to participate in the accreditation program of the CAP. The U.S. Centers for Medicare & Medicaid Services (“CMS”), the agency that oversees CLIA, has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of CMS inspections for accredited laboratories. Therefore, because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA.

CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. Select states, including Washington, have laboratory regulations that have been deemed by the federal government to be at least as stringent as CLIA, and thus laboratories licensed under those state regimes are exempt from CLIA and the state Department of Health is permitted to issue a CLIA number, along with a state Medical Test Site license, rather than a certificate being issued by CMS. Our laboratory holds the required Washington license. State laws may require that laboratory personnel meet certain qualifications, specify certain quality control procedures, facility requirements or prescribe record maintenance requirements.

Several states additionally require the licensure of out-of-state laboratories that accept specimens from those states. For example, New York requires a laboratory to hold a permit which is issued after an on-site inspection and approval of each LDT offered by a laboratory, and has various, more stringent requirements than CLIA and CAP, including those for personnel qualifications, proficiency testing, physical facility and equipment and quality control standards. Our laboratory holds the required licenses for Maryland, Rhode Island, Pennsylvania, New York and California.

From time to time, other states may require out-of-state laboratories to obtain licensure in order to accept specimens from the state. If we identify any other state with such requirements, or if we are contacted by any other state advising us of such requirements, we intend to follow instructions from the state regulators as to how we should comply with such requirements.

If a clinical laboratory is found to be out of compliance with CLIA certification, CAP accreditation or a state license or permit, the applicable regulatory agency may, among other things, suspend, restrict or revoke the certification, accreditation, license or permit to operate the clinical laboratory, assess civil monetary penalties and impose specific corrective action plans, among other sanctions.

Laboratory Developed Tests in the United States

The FDA has historically exercised enforcement discretion to not regulate most LDTs. As such, LDTs have not been subject to FDA’s marketing clearance and approval processes, or post-marketing controls, for medical devices. LDTs are generally considered to be tests that are designed, developed, validated and used within a single laboratory. Laboratories certified as “high complexity” under CLIA may develop, manufacture, validate and run LDTs. clonoSEQ is available as an LDT for use in assessing MRD for other lymphoid malignancies, including  NHL and use in other specimen types, at our Seattle, Washington laboratory.

36

In that respect, Congress introduced legislation to establish a framework for FDA to oversee marketing of in vitro clinical tests (“IVCTs”), such as test kits and LDTs (the Verifying Accurate Leading-edge IVCT Development Act, or “VALID Act”). Under the VALID Act, FDA would oversee IVCTs, requiring pre-market review for high-risk IVCTs which expose patients to serious or irreversible harm and novel IVCTs. As currently drafted, existing LDTs at the time of VALID Act passage would be grandfathered as approved. For new low risk IVCTs, developers would submit a representative IVCT to FDA for review and issuance of a technology certification for the specific IVCT reviewed and later developed test within the scope of the certification. It is not certain whether or in what form the VALID Act bill will pass Congress, but passage could increase the stringency of regulatory review required for our LDT products.

If the VALID Act does not pass, the FDA may decide to exercise enforcement discretion for LDTs, especially if it perceives a LDT as posing a risk to patients. Therefore, the regulatory path for marketing of LDTs is subject to uncertainty given the FDA’s latitude in interpreting and applying its laws and policies.

In November 2020, the U.S. Department of Health and Human Services advised that the FDA did not have authority to require LDTs related to COVID to obtain an EUA prior to marketing. HHS also instructed the FDA to review voluntary EUA submissions of LDTs for COVID-19 in order to extend certain statutory immunities to liability for those laboratories under the federal Public Readiness and Emergency Preparedness Act (“PREP Act”). In March 2021, the FDA issued an EUA for T-Detect COVID to confirm recent or prior SARS-CoV-2 infection. In November 2021, HHS rescinded its previous statement that the FDA did not have authority over LDTs. The FDA modified its policy and has required all COVID related LDTs on the market to submit an EUA request within 60 days of the policy, and has also made clear that no additional COVID related LDTs may come onto the market prior to issuance of an EUA.

Federal and State Privacy, Security and Breach Notification Laws

Many state and federal laws govern the processing of personal information or individually identifiable health information. At the federal level, under the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and the Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”), the U.S. Department of Health and Human Services (“HHS”) issued regulations that establish standards for protecting the privacy and security of “protected health information” used or disclosed by certain healthcare providers and other “covered entities” and their “business associates.” Three principal data protection-related regulations with which we are required to comply have been issued in final form under HIPAA and HITECH: privacy regulations, security regulations and security breach notification regulations.

The privacy regulations govern the use and disclosure of “protected” health information by covered healthcare providers, as well as health insurance plans. They also set forth certain rights that an individual has with respect to his or her protected health information maintained by a covered health care provider, including the right to access or amend certain records containing protected health information or to request restrictions on the use or disclosure of protected health information. The security regulations establish requirements for safeguarding the confidentiality, integrity and availability of protected health information that is electronically transmitted or electronically stored. HITECH, among other things, established certain health information security breach notification requirements. A covered entity must notify HHS and each affected individual of a breach of unsecured protected health information as well as the media if the breach involves more than 500 individuals.

HIPAA violations are subject to civil and criminal penalties. Additionally, to the extent that we submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied.

Section 5(a) of the Federal Trade Commission Act (“FTCA”) has also been used to regulate data privacy and security at the federal level. According to the U.S. Federal Trade Commission (“FTC”), failing to take appropriate steps to keep consumers’ personal information secure or using or disclosing personal information in violation of a company’s privacy notice may constitute unfair or deceptive acts or practices in or affecting commerce in violation of the FTCA. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Although we have and maintain a system for compliance with privacy laws and regulations, failure to comply with them could expose us to potential FTC enforcement action and fines.

In addition, certain state laws govern the privacy and security of health information and personal information. Some of the state laws governing health information privacy and security are more stringent than HIPAA (including providing for patient enforcement of these state laws) and often differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. There has also recently been an influx of state privacy and security laws that introduce similar compliance complexities, including the California Consumer Privacy Act (“CCPA”), the Colorado Privacy Act (“CPA”) and the Virginia Consumer Data Protection Act (“VCDPA”). In addition, there are state breach notification laws in every state, as well as D.C., Guam and Puerto Rico. Failure to comply with these laws, where applicable, can result in the imposition of significant civil or criminal penalties and private litigation.

37

General Data Protection Regulation in the EU and Internationally

The General Data Protection Regulation (“GDPR”) is a legal framework that sets requirements for the collection and processing of personal information of individuals within the European Economic Area (“EEA”). The GDPR sets out the principles for data management and the rights of the individual, while also imposing very significant fines that can be revenue-based. It applies to U.S. companies that process personal information of persons in the EEA in connection with the offer of products or services to those persons, or the monitoring of such persons’ behavior. It may also apply when a U.S. company processes personal information in the context of the activities of an entity established in the EEA. The GDPR became enforceable on May 25, 2018. The regulation is a comprehensive privacy law, meaning that it applies to all types of personal information, including the human resources record of employees and even the Internet Protocol addresses of people using online services. The GDPR builds upon data rights that the EU had previously advocated, such as the right of an individual to be forgotten and the right to data portability.

Many other countries and regions also have privacy and data protection laws, some of which are modeled after the European framework. This includes countries within Europe that are not part of the EEA, such as the United Kingdom and Switzerland, and therefore operate under different privacy and data protection frameworks.

In addition to laws that directly impose privacy and data protection obligations on companies, there is also a growing interest in laws and regulations that govern data areas that are related to, but not completely related to data privacy. One area of these laws relates to use and testing of genetic and genomic data. In addition to the federal Genetic Information Nondiscrimination Act , there are a number of state laws that have recently passed (e.g., the California Genetic Information Privacy Act) and that continue to make appearances on states’ legislative schedules. There have been similar draft bills at the state level that would regulate machine learning, artificial intelligence, the Internet of Things, and human specimen use. There have been similar trends internationally, such as ongoing public consultations in the European Union on the Digital Governance Act and an Artificial Intelligence Regulation.

Federal, State and Foreign Fraud and Abuse Laws

In the United States, there are various fraud and abuse laws with which we must comply and we are subject to regulation by various federal, state and local authorities, including CMS, other divisions of HHS, such as the Office of Inspector General (“OIG”), the U.S. Department of Justice (“DOJ”) and individual U.S. Attorney offices within the DOJ, and state and local governments. We also may be subject to foreign fraud and abuse laws.

In the United States, the Anti-Kickback Statute (“AKS”) prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for patient referrals for, or purchasing, leasing, ordering or arranging for the purchase, lease or order of, any healthcare item or service reimbursable under a governmental payor program. Courts have stated that a financial arrangement may violate the AKS if any one purpose of the arrangement is to encourage patient referrals or other federal healthcare program business, regardless of whether there are other legitimate purposes for the arrangement. The definition of “remuneration” has been broadly interpreted to include anything of value, including gifts, discounts, meals, travel, credit arrangements, payments of cash, consulting fees, waivers of co-payments, ownership interests and providing anything at less than its fair market value. Recognizing that the AKS is broad and may technically prohibit many innocuous or beneficial arrangements within the healthcare industry, the OIG issued a series of regulatory “safe harbors.” These safe harbor regulations set forth certain provisions, which, if met, will assure healthcare providers and other parties that they will not be prosecuted under the AKS. The failure of a transaction or arrangement to fit within a specific safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the AKS will be pursued. In those instances, arrangements will be evaluated on a case-by-case basis to determine whether enforcement will be pursued. Penalties for AKS violations are severe and can include imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs. The regulations establishing safe harbor protection are subject to change and could affect future operations. Many states also have anti-kickback statutes, some of which may apply to items or services reimbursed by any third-party payor, including commercial insurers as well as patient self-pay. A violation of the AKS may be grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.

The civil monetary penalties statute is another potential statute under which a clinical laboratory may be subject to enforcement. Among other things, the civil monetary penalties statute imposes fines against any person who is determined to have presented, or caused to be presented, claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent. The civil monetary penalties statute also prohibits a person from offering or providing remuneration to any Medicare or Medicaid beneficiary that is likely to influence the individual to order or receive its items or services from a particular provider or supplier.

38

The exclusion statute requires the exclusion of entities and individuals who have been convicted of federal-program related crimes or healthcare felony fraud or controlled substance charges. The statute also permits the exclusion of those that have been convicted of any form of fraud, the AKS, for obstructing an investigation or audit, certain controlled substance offenses, those whose healthcare license has been revoked or suspended and those who have filed claims for excessive charges or unnecessary services. If we were to be excluded, our products and services would be ineligible for reimbursement from any federal programs, including Medicare and Medicaid, and no other entity participating in those programs would be permitted to enter into contracts with us. In order to preserve access to beneficial healthcare items and services, the government may elect to exclude officers and key employees of manufacturers, rather than excluding the organization. Such enforcement actions would prohibit us from engaging those individuals, which could adversely affect operations and result in significant reputational harm.

Congress has also enacted statutes that impose criminal liability for healthcare fraud and abuse. The Health Care Fraud Statute prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from governmental payor programs such as the Medicare and Medicaid programs. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefit programs, items or services-public or private. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from governmental payor programs.

The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal governmental payor program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has defrauded the federal government by submitting a false claim to the federal government and permit such individuals to share in any amounts paid by the entity to the government in fines or settlement. Qui tam complaints are filed under seal, and the cases may progress for a number of years before a complaint is unsealed and a healthcare provider or supplier becomes aware of its existence. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties ranging from $11,803 to $23,607 for each false claim. The False Claims Act is the federal government’s primary civil tool in healthcare fraud cases. False Claims Act liability is not limited to direct providers of health items or services. The government has asserted liability under the False Claims Act against manufacturers and other third parties who caused another party to file a false claim.

In addition, various states have enacted false claim laws analogous to the federal False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely a governmental payor program.

On October 25, 2018, the Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act of 2018 (“SUPPORT Act”) was enacted. The SUPPORT Act included the Eliminating Kickbacks in Recovery Act of 2018 (“EKRA”), which establishes an all-payor anti-kickback prohibition that extends to arrangements with recovery homes, clinical laboratories and clinical treatment facilities. EKRA includes a number of statutory exceptions, and directs agencies to develop further exceptions. Current exceptions in some cases reference and in others differ from the AKS safe harbors. Significantly, the prohibitions apply with respect to the soliciting or receipt of remuneration for any referrals to recovery homes, clinical treatment facilities, or clinical laboratories, whether or not related to treating substance use disorders. Further, the prohibitions cover the payment or offer of remuneration to induce a referral to, or in exchange for, an individual using the services of, such providers. This law creates additional risk that relationships with referral sources could be problematic.

For anti-corruption legislation, the U.S. Foreign Corrupt Practices Act (“FCPA”) is the most widely enforced law. It is the first to introduce corporate liability, responsibility for third parties and extraterritoriality for corruption offences, meaning companies and persons can be held criminally and civilly responsible for corruption offences committed abroad. It was enacted for the purpose of making it unlawful for certain classes of persons and entities to make payments to foreign government officials to assist in obtaining or retaining business. With the enactment of certain amendments in 1998, the anti-bribery provisions of the FCPA now also apply to foreign firms and persons who cause, directly or through agents, an act in furtherance of such a corrupt payment to take place within the territory of the United States. The FCPA also requires companies whose securities are listed in the United States to meet its accounting provisions, which were designed to operate in tandem with the anti-bribery provisions, require corporations covered by the provisions to (a) make and keep books and records that accurately and fairly reflect the transactions of the corporation and (b) devise and maintain an adequate system of internal accounting controls.

39

In Europe, various countries have adopted anti-bribery laws providing for severe consequences, in the form of criminal penalties or significant fines, for individuals or companies committing a bribery offence. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation. For instance, in the United Kingdom, under the Bribery Act 2010, which came into effect in July 2011, a bribery offense occurs when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities, including any function of a public nature. Bribery of foreign public officials also falls within the scope of the Bribery Act 2010. Under this regime, an individual found in breach of the Bribery Act 2010 faces imprisonment of up to 10 years. In addition, the individual can be subject to an unlimited fine, if found to have committed an offense, as can commercial organizations that are found to have failed to prevent bribery. In 2016, France passed an anti-bribery and compliance law (“Sapin II”), and the French anti-corruption agency (“AFA”) was established. The Sapin II law makes it compulsory for companies within the scope of the law to implement internal procedures to fight corruption. One of the items that must be prepared is a corruption risk map, as well as an anti-corruption code of conduct. These documents are subject to investigation by the AFA and failure to comply with the requirements can lead to a fine of up to €1.0 million for a company and €200,000 for executives.

In 2021, Adaptive expanded its European presence and hired employees within the UK and as such, has a potential for the UK Bribery Act to apply as it can be triggered by any act committed within the UK. Currently, we are not subject to the jurisdictional requirements of Sapin II as we do not have offices in France. If we were to have future growth in the European market, this law could potentially become applicable to us.

U.S. Physician Referral Prohibitions

The Physician Self-Referral Law (“Stark Law”) prohibits physicians from referring patients to entities with which the physician or an immediate family member has a financial relationship, such as ownership, investment or compensation, for designed health services (“DHS”) payable by Medicare and Medicaid, unless the financial arrangement meets an applicable exception. DHS includes clinical laboratory tests. Penalties for violating the Stark Law include the return of funds received for all prohibited referrals, fines, civil monetary penalties and possible exclusion from federal health care programs. In addition to the Stark Law, many states have their own self-referral bans, which may extend to all self-referrals, regardless of the payor. See “Risk Factors—Risks Relating to Government Regulation—We are subject to various laws and regulations, such as healthcare fraud and abuse laws, false claim laws and health information privacy and security laws, among others, and failure to comply with these laws and regulations may have an adverse effect on our business.”

Corporate Practice of Medicine in the United States

Numerous states have enacted laws prohibiting business corporations, such as us, from practicing medicine and employing or engaging physicians to practice medicine, generally referred to as the prohibition against the corporate practice of medicine. These laws are designed to prevent interference in the medical decision-making process by anyone who is not a licensed physician. For example, California’s Medical Board has indicated that determining what diagnostic tests are appropriate for a particular condition and taking responsibility for the ultimate overall care of the patient, including providing treatment options available to the patient, would constitute the unlicensed practice of medicine if performed by an unlicensed person. Violation of these corporate practice of medicine laws may result in civil or criminal fines, as well as sanctions imposed against us or the professional through licensure proceedings. Typically such laws are only applicable to entities that have a physical presence in the state.

Other Regulatory Requirements

Our laboratory is subject to federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including chemical, biological agents and compounds, blood and bone marrow samples and other human tissue. Typically, we use outside vendors who are contractually obligated to comply with applicable laws and regulations to dispose of such waste. These vendors are licensed or otherwise qualified to handle and dispose of such waste.

Our partners in the development of therapeutic agents are responsible for developing and manufacturing those products. In so doing, they are subject to FDA and Medicare regulatory requirements related to, among other things, manufacture, promotion, price reporting and fraud and abuse laws.

Our laboratories are subject to extensive requirements related to workplace safety established by the U.S. Occupational Safety and Health Administration. These include requirements to develop and implement programs to protect workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.

40

U.S. Healthcare Reform

In the United States, a number of recent legislative and regulatory changes at the federal and state levels have sought to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Affordable Care Act (“ACA”) became law. This law substantially changed the way healthcare is financed by both commercial and government payors, and it has significantly impacted our industry. Since 2016 there have been efforts to repeal all or part of the ACA. For example, the Tax Cuts and Jobs Act (“TCJA”), among other things, removes penalties for not complying with the ACA’s individual mandate to carry health insurance. The U.S. Congress may take further action regarding the ACA, including, but not limited to, repeal or replacement. Additionally, all or a portion of the ACA and related subsequent legislation may be modified, repealed or otherwise invalidated through judicial challenge, which could result in lower numbers of insured individuals, or reduced coverage for insured individuals, and which could adversely affect our business. However, it remains to be seen whether or when new legislation modifying the ACA will be enacted, what any such the new legislation might provide and what impact it might have on the size and coverage of the insured population or on efforts to contain or lower the cost of healthcare. We cannot predict the implications, if any, of such legislation on our and our collaborators’ businesses and financial conditions.

We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial payors to reduce costs while trying to expand individual healthcare benefits. If enacted, some such proposals could expand or contract the insured population, increasing or decreasing demand for our products and services. On the other hand, some proposals could impose additional limitations on the prices we will be able to charge for our tests or on the coverage of or the amounts of reimbursement available for our tests from payors, including commercial payors and government payors.

The federal physician payment transparency requirements (“Physician Payments Sunshine Act”) and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children’s Health Insurance Program, with certain exceptions, to annually report to HHS information related to certain payments or other transfers of value made or distributed to covered recipients, defined to include doctors, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, certified nurse-midwives, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.

There are also state transparency and gift ban laws that require manufacturers to provide reports to state governments on pricing and marketing information. Several states have enacted legislation requiring medical device manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales and marketing activities, and such laws may also prohibit or limit certain other sales and marketing practices. These laws may adversely affect our sales, marketing, and other activities by imposing administrative and compliance burdens on us. Although we have a system for tracking and reporting “sunshine” law required information, if we fail to do so as required, we could be subject to government enforcement action and potential penalties.

Coverage and Reimbursement Generally

Reimbursement and billing requirements of applicable laws and payors for diagnostic services are highly complex. Laboratories must bill various payors, such as private third-party payors, including managed care organizations (“MCO”), and state and federal health care programs, such as Medicare and Medicaid, and each may have different billing requirements. Depending on the reimbursement arrangement and applicable law, the party that reimburses us for our services may be a third party who provides coverage to the patient, such as an insurance company or MCO; a state or federal healthcare program; or the patient. Additionally, the audit requirements we must meet to ensure compliance with applicable laws and regulations, as well as our internal compliance policies and procedures, add further complexity to the billing process. As such, we are at risk of being paid less or no part of our price for our products for reasons including:

 

•

variability in coverage and information requirements among various payors;

 

•

patient financial assistance programs;

 

•

missing, incomplete or inaccurate billing information provided by ordering physicians;

 

•

billings to payors with whom we do not have contracts;

 

•

disputes with payors as to which party is responsible for payment; and

 

•

disputes with payors as to the appropriate level of reimbursement.

41

 

In addition, we may not be free to determine the price charged for our products. For instance, the No Surprises Act (“NSA”) was enacted on December 27, 2020 and took effect on January 1, 2022. One of the goals of the NSA is to protect patients from “surprise” medical bills resulting from gaps in coverage for services provided by out-of-network providers, such as laboratories, related to patient visits at in-network facilities. The NSA limits the amount out-of-network laboratories may charge a patient for laboratory services ordered during an in-network facility visit. In addition, the NSA establishes an independent dispute resolution process for determining the amount of reimbursement for the laboratory service in the event that the laboratory and insurer cannot agree on a rate.

Certain countries, including a number of member states of the EU, set prices and make reimbursement decisions for diagnostics and pharmaceutical products. Additionally, some countries require approval of the maximum sale price of a product before it can be marketed, and this price may be reviewed during the product lifecycle, or mandatory discounts or profit caps may be applied. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. We may therefore be constrained in our pricing strategies in markets outside of the United States.

For additional information on coverage and reimbursement in the United States, see “Risk Factors—Risks Relating to Government Regulation—Future Medicare payment rates are uncertain.”

Our Compliance Program

Our compliance program is intended to prevent and detect violations of law or our policies. It was developed in view of both adopting the principles of the AdvaMed Code of Ethics and addressing the HHS OIG’s elements of a compliance program. We have designed our compliance program to fit the size, resources, market position and other unique aspects of our company. Our code of conduct is our statement of ethical and compliance principles that guide our daily operations. In addition, we have developed policies and procedures, and corresponding education and training, to effectively communicate our standards to employees as it relates to job functions and legal obligations under applicable state and federal healthcare program requirements, as well as those outside the United States. We regularly perform live and process monitoring activities on a risk-based approach, and audit capabilities are built into our transparency procedures. We maintain a hotline available via multiple channels to report any known or suspected compliance violations, and we have a strict non-retaliation policy for all claims brought forward in good faith.

Corporate Information

We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. In January 2015, we acquired Sequenta, Inc. (“Sequenta”), a San Francisco, California-based company that was also developing an NGS test for MRD (“Sequenta Acquisition”). Our principal executive offices are located at 1165 Eastlake Avenue East, Seattle, Washington 98109, and our telephone number is (206) 659-0067.

Available Information

We maintain a website at www.adaptivebiotech.com. The contents of our website are not incorporated in, or otherwise to be regarded as part of, this Annual Report on Form 10-K. We make available, free of charge on our website, access to our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as soon as reasonably practicable after we file or furnish them electronically with the Securities and Exchange Commission (“SEC”). Investors and others should note that we announce material financial information to our investors using our investor relations website (http://investors.adaptivebiotech.com), SEC filings, press releases, public conference calls and webcasts. We use these channels as well as social media to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on social media channels.

42

Item 1A. Risk Factors

Investing in our Company involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section, before investing in our Company. Any of the risk factors we describe below could adversely affect our business, financial condition, results of operations, prospects or the trading price of our securities. The risks described below are not the only ones we face and additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business, financial condition, operating results, prospects and the trading price of our securities.

Summary of Risk Factors

Generally, the risks described below relate to the following:

 

•

the effects of health epidemics, including the COVID-19 pandemic or future variants of the SARS-CoV-2 virus, in regions where we or third parties on which we rely have significant laboratory operations, manufacturing facilities, concentrations of clinical trial sites or other business operations;

 

•

our significant net losses since inception, expected net losses in the future and need for significant investments in products and services;

 

•

our ability to leverage our immune medicine platform to discover, develop, commercialize and obtain regulatory clearance, authorization and approval for our products and services, particularly in light of the novelty of immune medicine and our methods;

 

•

our ability to develop our TCR-Antigen Map and yield additional insights from it that are commercially viable;

 

•

our collaboration with Genentech and ability to develop and commercialize cellular therapeutics, including our ability to achieve milestones and realize the intended benefits of the collaboration;

 

•

our ability to leverage our immune medicine platform to discover, develop and commercialize additional products and services, including those related to COVID-19, may not be successful;

 

•

our laboratory operations, including errors or defects in our products or services and our reliance on a limited number of suppliers, and in some cases single suppliers, for our equipment and materials, some of which include reagents or other materials that may also require additional internal validation prior to use;

 

•

our limited experience with the development and commercialization of cellular therapeutics;

 

•

market acceptance of our products and services, and our limited sales and marketing experience;

 

•

our expected reliance on collaborators for development and clinical testing of therapeutic product candidates, which may fail at any time due to a number of possible unforeseen events;

 

•

our ability to increase our capacity, manage the evolution of our products and services, stay current in our rapidly changing industry, expand our workforce and otherwise manage our growth;

 

•

the loss of any member of our senior management team, or of the support of key opinion leaders;

 

•

the extensive regulation of our industry, including reimbursement coverage decisions; and

 

•

the validity of our patents, protection of our trade secrets and related intellectual property matters.

43

 

Risks Relating to Our Business

We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.

We have incurred significant losses since our inception. For the year ended December 31, 2021, 2020 and 2019, we incurred a net loss of $207.3 million, $146.2 million and $68.6 million, respectively. As of December 31, 2021, we had an accumulated deficit of $718.9 million. We have funded our operations to date principally from the sale of convertible preferred stock and common stock, including the sale of common stock in our initial public offering, and, to a lesser extent, sequencing and development revenue. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue to invest in the development of products and services utilizing our immune medicine platform to support the validation of additional clinical diagnostic and therapeutic products and services. We will need to generate significant additional revenue to achieve and sustain profitability.

We expect to make significant investments in our continued research and development of new products and services, which may not be successful.

We are seeking to leverage our immune medicine platform to develop a pipeline of future disease-specific research, diagnostic and therapeutic products and services. For example, we are developing our TCR-Antigen Map with a view toward continually advancing the development of T-Detect, a diagnostic test that may enable early and accurate detection of multiple diseases from a single blood test, into further indications. In addition, we are developing certain therapeutic product candidates under our collaboration agreement with Genentech by leveraging our platform to identify TCRs that can be engineered into personalized cellular immunotherapies. We expect to incur significant expenses to advance these development efforts, but they may not be successful.

Developing new products and services is a speculative and risky endeavor. Products or services that initially show promise may fail to achieve the desired results or may not achieve acceptable levels of analytical accuracy or clinical utility. We may need to alter our products in development and repeat clinical studies before we identify a potentially successful product or service. Product development is expensive, may take years to complete and can have uncertain outcomes. Failure can occur at any stage of the development. If, after development, a product or service appears successful, we or our collaborators may, depending on the nature of the product or service, still need to obtain FDA and other regulatory clearances, authorizations or approvals before we can market it. The FDA’s clearance, authorization or approval pathways, including seeking EUA for new indications of T-Detect or other products, are likely to involve significant time, as well as additional research, development and clinical study expenditures. The FDA may not clear, authorize or approve any future product or service we develop. Even if we develop a product or service that receives regulatory clearance, authorization or approval, we or our collaborators would need to commit substantial resources to commercialize, sell and market it before it could be profitable, and the product or service may never be commercially successful. Additionally, development of any product or service may be disrupted or made less viable by the development of competing products or services.

New potential products and services may fail at any stage of development or commercialization and if we determine that any of our current or future products or services are unlikely to succeed, we may abandon them without any return on our investment. If we are unsuccessful in developing additional products or services, our potential for growth may be impaired.

If we are not successful in leveraging our immune medicine platform to discover, develop and commercialize additional products and services, our ability to expand our business and achieve our strategic objectives would be impaired.

A key element of our strategy is to leverage our immune medicine platform to discover, develop and potentially commercialize additional products and services beyond our current portfolio to diagnose and treat various disease states. In particular, for clonoSEQ we are attempting to generate sufficient clinical evidence to support the utility of MRD in additional lymphoid cancers beyond ALL, MM and CLL, while also demonstrating the clinical utility of blood as a sample type for all lymphoid cancers. If we are unable to generate compelling evidence supporting clonoSEQ use in other indications or sample types, our platform may face a broader obstacle to using our immunosequencing data for commercially viable products and services.

Identifying new products and services requires substantial technical, financial and human resources, whether or not any products or services are ultimately developed or commercialized. We may pursue what we believe is a promising opportunity to leverage our platform only to discover that certain of our risk or resource allocation decisions were incorrect or insufficient, or that individual products, services or our science in general has technology or biology risks that were previously unknown or underappreciated. Our strategy of pursuing the value of our immune medicine platform over a long time horizon and across a broad array of human diseases may not be effective. In the event material decisions in any of these areas turn out to be incorrect or sub-optimal, we may experience a material adverse impact on our business and ability to fund our operations and we may never realize what we believe is the potential of our immune medicine platform.

44

Our efforts to develop our TCR-Antigen Map may not be successful, and it may not yield the insights we expect at all or on a timetable that allows us to develop or commercialize any new diagnostic products.

We are leveraging our collaboration with Microsoft to develop our TCR-Antigen Map. Together we are using immunosequencing, proprietary computational modeling and machine learning to map TCR sequences to the antigens they bind. However, we may not be successful in developing a comprehensive TCR-Antigen Map for any number of reasons including difficulty accessing required sample sets to validate signals and complications in advancing algorithmic-based methods that accurately define TCR signatures to be validated. As a result, it may require significantly more time and resources for us to determine how to use machine learning to accelerate our mapping process, which could adversely impact our ability to develop or commercialize new diagnostic products or services. In addition, even with the aid of machine learning, we expect the TCR-Antigen Map to take us several years to develop.

The TCR-Antigen Map we are developing may not yield clinically actionable insights on a timetable that is commercially viable, or at all. Our goal is to leverage the TCR-Antigen Map in connection with the development of T-Detect to enable early or accurate detection across a broad range of diseases. We have confirmed signals for SARS-CoV-2, acute Lyme disease, Crohn’s disease, celiac disease and multiple sclerosis. We have also identified early signals in ulcerative colitis and rheumatoid arthritis and we will seek to confirm those signals in ongoing validation work. We will also seek to identify new signals in other select autoimmune disorders or other diseases. If our computational modeling and machine learning efforts do not accelerate the pace at which we can validate association of TCR sequences to the antigens they bind, the timetable for our business model may not be commercially viable. Even if we can accelerate this timeline, our products and services derived from our novel technologies may have product or service level errors. If we are unable to make meaningful progress in our TCR-Antigen Map and successfully use it to develop and commercialize new diagnostic products or services, our business and results of operations will suffer.

We are exposed to risks associated with our agreement with Genentech, and we may not realize the advantages we expect from it.

In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (“Genentech Agreement”), with the goal of accelerating the development and commercialization of novel cancer-specific antigen and neoantigen directed T cell therapies for the treatment of a broad range of tumor types. Under the terms of the Genentech Agreement, we received $300.0 million in an initial upfront payment in February 2019 and may be eligible to receive approximately $1.8 billion in additional payments over time upon achievement of specified development, regulatory and commercial milestones. In addition, Genentech will pay us royalties on sales of products commercialized under the agreement. We may not be successful in achieving these milestones, and products developed under the Genentech Agreement may not be commercialized in the timeframe we expect, achieve significant sales, or be commercialized at all.

We are exposed to numerous risks associated with the Genentech Agreement, including sharing a measure of control over the operations of our research and development portions of the collaboration with Genentech and Genentech having sole control over the commercialization of any products developed via the collaboration. For instance, in 2021, Genentech suspended development of a drug against our first shared antigen target candidate in response to published data. The Genentech Agreement also prevents us from, among other things, developing or commercializing TCR-based cellular therapies outside the scope of the collaboration in the field of oncology on our own or with any third party. Our collaboration involves risks that are different from the risks involved in independently conducting operations, including that Genentech may:

 

•

have or develop economic or business interests that are inconsistent with ours;

 

•

take actions contrary to our instructions, requests, policies or objectives;

 

•

take actions that reduce our return on investment for this collaboration;

 

•

fail to distinguish itself from biosimilar competition; or

 

•

take actions that harm our reputation or restrict our ability to run our business.

Genentech’s degree of control over collaboration development and commercialization efforts may impact the amounts we receive under the Genentech Agreement. For example, Genentech may suspend development of product candidates or decide not to pursue commercialization of product candidates at all, or it may agree to pay royalties to third parties or adopt a pricing model that reduces the amount of royalties we might otherwise expect. It is also possible that effective cell therapies will not be developed under the Genentech Agreement or, if developed, approved by the FDA or comparable regulatory authorities outside of the United States. Genentech may also terminate the Genentech Agreement at its convenience, at any time and without cause.

45

We may not be able to perform our product research, development and commercialization related obligations under the Genentech Agreement, including performing TCR screening activities for product candidates being developed and commercialized under that agreement. For example, in the event a product is commercialized under the Genentech Agreement, as the volume of product sales grows, we will likely need to continue to increase our workflow capacity for sample intake, customer service and general process improvements, and expand our internal quality assurance program to support TCR screening on a larger scale within expected turnaround times. We will likely need additional certified laboratory scientists and other scientific and technical personnel for the Personalized Product to identify and target therapeutically relevant, patient-specific neoantigens. We will likely also need to acquire additional laboratory space and equipment, which can take several months or more to procure, set up and validate. These process enhancements and increases in scale, expansion of personnel, laboratory space and equipment may not be successfully implemented, and we may not have adequate laboratory facilities or resources to accommodate all the requirements that we currently anticipate needing to be successful. If we cannot satisfy our obligations, Genentech is entitled to trigger a technology transfer of our TCR screening process (specific to the Personalized Product) or terminate the Genentech Agreement. In addition, due to our significant obligations under the Genentech Agreement, we may face challenges in meeting the needs of existing customers, collaborators and suppliers and securing new customers, including any biopharmaceutical customers that are actual or potential competitors with Genentech.

If we support the commercialization of one or more products under the Genentech Agreement, we may need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business, both under the Genentech Agreement and otherwise. As a result, our relationship with Genentech may not result in the realization of its anticipated benefits.

We have limited experience with the development and commercialization of cellular therapeutics, and future TCR-based cellular therapies may never be successfully developed and commercialized as part of our Genentech collaboration.

We have limited experience with the development of cellular therapeutics, and no experience with the commercialization, marketing and distribution of cellular therapeutics. Our therapeutic product candidates are at an early stage of discovery and development under our Genentech collaboration, and we are continuing to develop our TruTCR process being used under that collaboration to develop TCR-based cellular therapies for the treatment of cancer. Under our Genentech collaboration, Genentech has invested significant financial resources to develop future TCR-based cellular therapies, including conducting preclinical studies and other early research and development activities, and providing general and administrative support for these operations. Our future success is dependent on our and Genentech’s ability to successfully develop therapeutic product candidates and advance those product candidates into the clinic, and Genentech’s ability, where applicable, to obtain regulatory and marketing approval for, and then successfully commercialize, cellular therapeutics. We and Genentech have not yet developed and commercialized any cellular therapeutics, and we may not be able to do so.

We currently use, and in the future expect to increase our use of, collaborators for several aspects of our operations, and if we cannot maintain current and enter new relationships with collaborators, our business will suffer.

We have limited resources to conduct our life sciences research, clinical diagnostics and drug discovery operations and have not yet fully established infrastructure for sales, marketing or distribution in connection with our products and services. Accordingly, we have entered into collaboration agreements under which our collaborators have provided, and may in the future provide, funding and other resources for developing and potentially commercializing our products and services. In particular, we have entered into the Genentech Agreement, with the goal of accelerating the development and commercialization of T cell therapies for the treatment of a broad range of tumor types, and a strategic collaboration agreement with Microsoft (“Microsoft Agreement”), which provides us with access to Microsoft’s research and machine learning technologies that we are using to develop our TCR-Antigen Map. We are pursuing several additional industry and academic collaborations to access patient cohorts that could accelerate our TCR-Antigen Map signal generation and validation for our immune-based diagnostics or drug discovery product or services pipeline. These collaborations may result in our incurring significant expenses in pursuit of potential products and services, and we may not be successful in identifying, developing or commercializing any potential products or services.

46

Our future success depends in part on our ability to maintain these relationships and to establish new relationships. Many factors may impact the success of such collaborations, including our ability to perform our obligations, our collaborators’ satisfaction with our products and services, our collaborators’ performance of their obligations to us, our collaborators’ internal priorities, resource allocation decisions and competitive opportunities, the ability to obtain regulatory approvals, disagreements with collaborators, the costs required of either party to the collaboration and related financing needs, and operating, legal and other risks in any relevant jurisdiction. In addition to reducing our revenue or delaying the development of our future products and services, the loss of one or more of these relationships may reduce our exposure to research, data, clinical trials or computing technologies that facilitate the collection and incorporation of new information into our clinical immunomics database. All of the risks relating to product and service development, regulatory clearance, authorization or approval and commercialization described herein apply to us derivatively through the activities of our collaborators.

We engage in conversations with companies regarding potential collaborations on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, and any products and services developed as part of the collaboration may not produce successful outcomes. Speculation in the industry about our existing or potential collaborations can be a catalyst for adverse speculation about us, or our products or services, which can adversely affect our reputation and our business.

Significant additional research and development and, in certain instances, clinical trials or validation will be required before we can potentially seek regulatory clearance, authorization or approval for, or commercialize any of our products or services in development.

We are developing a pipeline of immune-driven diagnostics and therapeutics, including T-Detect and cellular therapies in oncology, but significant additional research and development activities and clinical trials or validations could be required before we and our collaborators will have a chance to achieve additional commercially viable products. Our research and development efforts remain subject to all of the risks associated with the development of new products and services based on immune-driven diagnostics and immune-mediated therapies. Development of the underlying technology may be affected by unanticipated technical or other problems, among other research and development issues, and the possible insufficiency of funds needed to complete development of these products and services. Safety, regulatory and efficacy issues, clinical hurdles or other challenges may result in delays and cause us to incur additional expenses that would increase our losses. If we and our collaborators cannot complete, or if we experience significant delays in developing, our clinical diagnostics or therapeutics, including cellular therapies, T-cell based vaccines or antibody discoveries, particularly after incurring significant expenditures, our business may fail and investors may lose the entirety of their investment.

Prior to obtaining regulatory clearances, authorizations or approvals for the commercial sale of any new products or services, we must demonstrate that our products and services are both safe and effective for use in each target disease indication. Clinical studies may be necessary to demonstrate that a product or service is safe and effective. Clinical testing or validation is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time. For therapeutics, the results of preclinical studies and early clinical trials of products and services in development may not be predictive of the results of later-stage clinical trials, and initial success in clinical trials may not be indicative of results obtained when clinical trials are completed. There is typically an extremely high rate of failure as therapeutic products in development proceed through clinical trials. Products in later stages of clinical trials or validation also may fail to show the desired safety and efficacy profile despite having progressed through non-clinical studies and initial clinical trials or validations. Any delays in the development of our products and services may harm our business, financial condition and prospects significantly.

Errors or defects in our products or services could harm our reputation, decrease market acceptance of our products or services or expose us to product liability claims.

We are creating new products and services, many of which are initially based on largely untested technologies. As all of our products and services progress, we or others may determine that we made product or service level scientific or technological mistakes or omissions. The testing processes utilize a number of complex and sophisticated biochemical, informatics, optical and mechanical processes, many of which are highly sensitive to external factors and variation between testing runs. Refinements to our processes may initially result in unanticipated issues that reduce the efficiency or increase variability. In particular, sequencing, which is a key component of these processes, could be inefficient with higher than expected variability thereby increasing total sequencing costs and reducing the number of samples we can process in a given time period, which may negatively impact customer turnaround time. Therefore, inefficient or variable processes can cause variability in our operating results and damage our reputation.

47

In addition, our laboratory operations could result in any number of errors or defects. Our quality assurance system or product development processes may fail to prevent us from inadvertent problems with samples, sample quality, lab processes including sequencing, software, data upload or analysis, raw materials, reagent manufacturing, assay quality or design, or other components or processes. In addition, our assays may have quality or design errors, and we may have inadequate procedures or instrumentation to process samples, assemble our proprietary primer mixes and commercial materials, upload and analyze data, or otherwise conduct our laboratory operations. If we provide products or services with undiscovered errors to our customers, our clinical diagnostics may falsely indicate a patient has a disease or fail to detect disease in a patient who requires treatment. We believe our customers are likely to be particularly sensitive to product and service defects, errors and delays, including if our products and services fail to indicate the presence of residual disease with high accuracy from clinical specimens or if we fail to list or inaccurately indicate the presence or absence of disease in our test report. In drug discovery, such errors may interfere with our collaborators’ clinical studies or result in adverse safety or efficacy profiles for their products in development. This may harm our customers’ businesses and may cause us to incur significant costs, divert the attention of key personnel, encourage regulatory enforcement action against us, create a significant customer relations problem for us and cause our reputation to suffer. We may also be subject to warranty and liability claims for damages related to errors or defects in our products or services. Any of these developments could harm our business and operating results.

Our current and future products and services may never achieve significant commercial market acceptance.

Our success depends on the market’s confidence that we can provide immune-driven research, diagnostic and therapeutic products and services that improve clinical outcomes, lower healthcare costs and enable better biopharmaceutical development. Failure of our products and services, or those jointly developed with our collaborators, to perform as expected could significantly impair our operating results and our reputation. We believe patients, clinicians, academic institutions and biopharmaceutical companies are likely to be particularly sensitive to defects, errors, inaccuracies, delays and toxicities in or associated with our products and services. Furthermore, inadequate performance of these products or services may result in lower confidence in our immune medicine platform in general.

We and our collaborators may not succeed in achieving significant commercial market acceptance for our current or future products and services due to a number of factors, including:

 

•

our ability to demonstrate the clinical utility of our immune medicine platform and related products and services and their potential advantages over existing life sciences research, clinical diagnostic and drug discovery technologies to academic institutions, biopharmaceutical companies and the medical community;

 

•

our ability, and that of our collaborators, to secure and maintain FDA and other regulatory clearance, authorization or approval for our products;

 

•

the agreement by third-party payors to reimburse our diagnostics, the scope and extent of which will affect patients’ willingness or ability to pay for our diagnostics, even in markets that we expect to be primarily self-pay, and will likely heavily influence physicians’ decisions to recommend our tests;

 

•

the rate of adoption of our immune medicine platform and related products and services by academic institutions, clinicians, key opinion leaders, advocacy groups and biopharmaceutical companies; and

 

•

the impact of our investments in product innovation and commercial growth.

Additionally, our customers and collaborators may decide to decrease or discontinue their use of our products and services due to changes in their research and development plans, failures in their clinical trials, financial constraints, the regulatory environment, negative publicity about our products and services, competing products or the reimbursement landscape, all of which are circumstances outside of our control. We may not be successful in addressing these or other factors that might affect the market acceptance of our products, services and technologies. Failure to achieve widespread market acceptance of our immune medicine platform and related products and services would materially harm our business, financial condition and results of operations.

48

We rely on a limited number of suppliers or, in many cases, single suppliers, for laboratory equipment and materials and may not be able to find replacements or immediately transition to alternative suppliers.

We rely on a limited number of suppliers, or in many cases single suppliers, to provide certain sequencers and equipment that we use in our laboratory operations, as well as reagents and other laboratory materials for our products and services. An interruption in our laboratory operations, kit distribution or technology transfer could occur if we encounter delays, quality issues or other difficulties in securing these sequencers, equipment, reagents or other materials, and if we cannot then obtain an acceptable substitute. In addition, we would likely be required to incur significant costs and devote significant efforts to find new suppliers, acquire and qualify new equipment, validate new reagents and revalidate aspects of our existing assays, which may cause delays in our processing of samples or development and commercialization of products and services. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. Internal changes in processes or compositions of our reagents or other materials may also require validation efforts by us and supply of new materials from our suppliers which could impact timing of production and levels of inventory while such changes are being implemented. Further, as a result of the COVID-19 pandemic, the overall demand for supplies and equipment used in vaccine development and distribution or other public health or disease prevention initiatives may continue to increase lead times for purchased supplies and equipment, thus potentially lowering our production capacity. Combined with lowered production capacity, any significantly increased demand for existing or new products or services, such as T-Detect COVID, may affect our ability to fulfill orders, resulting in a material adverse effect on volume or revenue.

In particular, we have purchased and rely on the Illumina NextSeq System. Illumina supplies us with reagents that have been designed for use solely with this sequencer and Illumina is the sole provider of maintenance and repair services for the Illumina NextSeq System. We also license our laboratory information management software from Illumina and receive services from Illumina related to that software. We believe there are only a few other equipment manufacturers that are currently capable of supplying the equipment necessary for our laboratory operations, including sequencers and various associated reagents. The use of sequencers manufactured by a company other than Illumina would require us to alter our laboratory operations. Transitioning to and qualifying a new sequencer would be time-consuming and expensive, may result in interruptions in our laboratory operations, could affect the performance specifications of our laboratory operations or could require that we revalidate the reagents of our immunoSEQ kits, immunoSEQ services, T-Detect or clonoSEQ diagnostic testing services, and could require us to obtain additional clearance, authorization, approval, accreditation, or licensure for the changes. We may not be able to secure and implement alternative sequencers, associated reagents and other materials without experiencing interruptions in our workflow. In the case of an alternative supplier to Illumina, any replacement sequencers and various associated reagents may not be available or may not meet our quality control and performance requirements for our laboratory operations. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment and reagents we require for our products and services, our business, financial condition, results of operations and reputation could be adversely affected. In addition, Illumina is not obligated to meet all of our requirements for reagent supply. In the event Illumina ceases or slows its production of, or is otherwise unwilling or unable to continue to supply the sequencer reagents necessary for and currently used in our business at or near current pricing, we may be required to purchase different reagents from Illumina or to purchase from a different reagent vendor under terms and conditions which could be less favorable to us. Any disruption in Illumina’s operations or the suppliers of our reagents, materials or other equipment could impact our supply chain and laboratory operations of our immune medicine platform and our ability to conduct our business and generate revenue.

We have limited experience in marketing and selling products and services, and if we are unable to expand our direct sales and marketing force or partner with collaborators in certain product areas and markets to adequately address our customers’ needs, our business may be adversely affected.

We have limited experience in marketing and selling our research and diagnostic products and services and no experience marketing and selling therapeutic products and services. Accordingly, we or our collaborators may not be able to market and sell our current or future products and services effectively enough to support our planned growth.

Our research and diagnostic sales and marketing efforts are targeted at a large and diverse market with highly specialized segments, including department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors and research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. As a result, we believe it is necessary for our sales representatives to have relevant, specialized market experience. Competition for experienced sales and marketing personnel is intense, and new members of our sales organization may require intense training to apply their experience and expertise to our products and services. We may not be able to attract and retain personnel or be able to build or adequately train an efficient and effective sales organization, which could negatively impact sales and market acceptance of our clinical diagnostics and limit our revenue growth and potential profitability.

49

We established a collaboration with Genentech for the research, development, marketing, promotion, distribution and sale of TCR-based cellular therapies for the treatment of cancer. Under the Genentech Agreement, Genentech has the sole right and authority to commercialize products developed under that agreement. It will be Genentech’s responsibility to locate, qualify and engage distribution partners, clinicians and local hospitals with industry experience and knowledge to effectively market and sell products developed under that agreement. Genentech may not be able to engage distribution partners, clinicians or hospitals on favorable terms, or at all. If Genentech’s sales and marketing efforts with respect to products developed under the Genentech Agreement are not successful, we may not achieve significant market acceptance for our drug discovery services and platform, which would materially and adversely impact our business operations.

If we or our collaborators experience any of a number of possible unforeseen events in connection with clinical trials, our or their ability to conduct further clinical trials of, obtain regulatory clearance, authorization or approval of or commercialize future products and services or improvements to current products and services, could be delayed or prevented.

We or our collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our or their ability to conduct further clinical trials or obtain regulatory clearance, authorization or approval of or commercialize future products and services or improvements to current products and services, including:

Evolving Regulatory Requirements and Policies

 

•

the area of “precision medicine” or “personalized medicine” and its regulation may be subject to ongoing changes in terms of regulatory requirements and governmental policies, in ways we cannot predict;

Trial Design

 

•

regulatory authorities or ethical review boards, including IRBs, may not authorize commencement of a clinical trial or conduct a clinical trial at a prospective trial site;

 

•

there may be delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;

 

•

the FDA or other regulatory authorities may disagree with a clinical trial design or a sponsor’s interpretation of data and may change the requirements for product clearance, authorization or approval even after they have reviewed and commented on the clinical trial design;

 

•

differences in trial design between early stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials;

 

•

the FDA or other regulatory authorities may disagree about whether study endpoints are clinically meaningful;

 

•

the number of patients, or amount of data, required for clinical trials, or improvements to current products, may be larger than anticipated, patient enrollment in these clinical trials may be slower than anticipated or patients may drop out of clinical trials at a higher rate than anticipated;

Testing

 

•

changes may be made to product candidates after commencing clinical trials, which may require that previously completed stages of clinical testing be repeated or delay later stages of testing, for example, we, or our collaborators, may pursue one or more different product development pathways for our T cell immunotherapies;

 

•

clinical trials may fail to satisfy the applicable regulatory requirements of the FDA or other regulatory authorities responsible for oversight of the conduct of clinical trials in other countries;

 

•

regulators may elect to impose a clinical hold, or governing IRBs, data safety monitoring board or ethics committees may elect to suspend or terminate our clinical research or trials for various reasons, including non-compliance with regulatory requirements or a finding that the participants are being exposed to unacceptable risks to their health or the privacy of their health information being disclosed;

 

•

the cost of clinical trials of future products and services, or improvements to current products and services, may be greater than we anticipate;

 

•

we may not have sufficient capacity in our laboratories to perform testing as requested or volumes requested or with the requested turnaround times necessary for clinical trials;

50

 

•

the supply or quality of materials or data necessary to conduct clinical trials of future products and services, or improvements to current products and services, may be insufficient or inadequate;

Trial Outcomes

 

•

the outcome of our collaborators’ preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results;

 

•

product candidates may be associated with negative or inconclusive results in clinical trials, and we or our collaborators may decide to deprioritize or abandon these product candidates, or regulatory authorities may require us to abandon them or impose onerous changes or requirements, which could lead to deprioritization or abandonment;

 

•

product candidates may have undesirable side effects which could lead to serious adverse events, or other unexpected characteristics. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us, our collaborators or their investigators, IRBs or ethics committees to suspend or terminate the trial of that product candidate;

 

•

clinical trials may suggest or demonstrate that products or services are not as efficacious or safe as other similar diagnostics or therapies; and

 

•

preclinical and clinical data are often susceptible to varying interpretations and analyses, and our products and services in development may fail to obtain regulatory clearance, authorization or approval, even if they perform satisfactorily in preclinical studies and clinical trials.

Delays of this nature could also allow competitors to bring products to market before we or our collaborators do, potentially impairing our ability to successfully commercialize our products and services in development and harming our business and results of operations. Any delays in the development of our products and services or those jointly developed with our collaborators may significantly harm our business, financial condition and prospects. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory clearance, authorization or approval of products and services in development.

We will need to develop and expand our workforce, commercial infrastructure and laboratory operations to support anticipated growth in demand for our products and services. We may encounter difficulties in managing this and in meeting fluctuations in this demand.

We will need to expand our workforce, commercial infrastructure and laboratory operations to support anticipated growth in demand for our products and services. If we are unable to support fluctuations in the demand for our products and services, including ensuring that we have adequate capacity to meet increased demand as well as other customer requirements (such as turnaround time and service level), our business could suffer. As of December 31, 2021, we had 858 full-time employees and we expect to increase the number of employees, including potential contingent employees as needed to address demand fluctuations, and the scope of our operations as we continue to develop our clinical diagnostic products and services. As we and our collaborators commercialize additional products and services, we will need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher service costs, declining service quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and services and could damage our reputation and the prospects for our business.

To manage our anticipated expansion, we must continue to implement and improve our managerial, operational and financial systems, continue to expand our facilities and continue to recruit and train additional qualified personnel. Also, our management and operations teams may need to divert a disproportionate amount of their attention away from their day-to-day activities and devote a substantial amount of time to managing these development and improvement activities.

Due to our limited resources and early stage of growth, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit, train, and retain additional qualified personnel. This may result in weaknesses in our infrastructure, operational mistakes, slower development of our products and services, missed or delayed milestone achievement, significant cost overruns, loss of business opportunities, loss of employees and contingent workers, inability to execute on hiring plans and reduced productivity among remaining employees and contingent workers.

If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, and our ability to develop and commercialize our products and services and compete effectively, will depend, in part, on our ability to effectively manage our future development and expansion.

51

Our business could be adversely affected by the effects of health epidemics, including the recent COVID‑19 pandemic, in regions where we or third parties on which we rely have significant laboratory operations, manufacturing facilities, concentrations of clinical trial sites or other business operations. The COVID-19 pandemic could materially affect our operations, including at our headquarters in Seattle and at our offices in South San Francisco, each subject to COVID-19 related government restrictions, as well as the business or operations of our manufacturers, contract research organizations or other third parties with whom we conduct business.

Our business could be adversely affected by global pandemics or health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and such pandemics or epidemics could cause significant disruption in the operations of third-party manufacturers, suppliers, general contractors and sub-contractors related to capital projects and CROs upon whom we rely. The global pandemic of COVID-19 continues to rapidly evolve. We do not yet know the full extent of potential delays or impacts on our business, clinical trials, sales force expansion plans and other initiatives, or the impacts to healthcare systems or the global economy as a whole.

Most of our facilities and employees are based in Seattle, Washington at our corporate headquarters, where the state government has imposed “stay at home” restrictions designed to slow the spread of COVID-19, which have disrupted our normal operations. Similarly, San Mateo County, California had a “shelter-in-place” order with restrictions that have disrupted our normal operations in our South San Francisco office.

With respect to our laboratory operations, we intend to rely on the measures implemented in early 2020 to reduce the risk of exposure of COVID-19 to the employees who continue to work on site as part of government-defined essential services, including the implementation of work-from-home policies for certain employees, as well as physical distancing and contact tracing those employees who remain on site. We have also required all on-site employees to be vaccinated, subject to applicable religious and medical exemptions. We work with a variety of materials and samples from COVID-19 patients that could be hazardous to human health. We intend to continue to adhere to the safety measures implemented to reduce the risk of exposure to our on-site staff.

We have experienced a number of staffing and supply chain disruptions due to COVID-19 and anticipate these will continue into the future. The effects of the stay-at-home orders or similar government orders and internal protective measures may negatively impact productivity, disrupt our business and delay our clinical programs and corporate expansion initiatives, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations regarding our ability to conduct our business in the ordinary course. Confirmed positive cases, close contacts, and other identified risks have resulted in disruptions to regular on-site staffing, and these disruptions may continue to negatively impact our research and production.

The effects of government restrictions such as the stay at home orders and our other operational safety measures may negatively impact productivity, disrupt our business and delay our clinical programs and corporate expansion initiatives, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations regarding our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.

Quarantines, stay at home orders and similar government orders, or the perception that such orders, shutdowns or other restrictions on business operations could occur, whether related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing or supplier facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In addition, public health measures undertaken to combat the COVID-19 pandemic or vaccine development and distribution efforts may increase demand for equipment or supplies, which we use in the ordinary course of our business. This increased demand has resulted in longer lead times for equipment purchases and may result in internal conservation of supplies, which may slow production.

 While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.

The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.

52

The COVID-19 pandemic could adversely impact portions of our business that rely on research and development activities or clinical trials and delay or disrupt our pipeline, which may adversely impact revenue.

The extent to which the COVID-19 pandemic may impact our business with respect to research and development and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, vaccine distribution, variants of the virus, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. As the COVID-19 pandemic continues to spread around the globe, we will likely experience disruptions that could severely impact our business with respect to research and development and clinical trials, including:

 

•

delays or difficulties in enrolling patients or maintaining scheduled study visits in our clinical trials;

 

•

delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;

 

•

negative impact on interactions necessary for commercial testing, due to restricted access for industry employees;

 

•

patient and clinician avoidance of “elective” procedures that may encompass our products and services, and general reluctance of patients to seek in-person care;

 

•

challenges in providing clinical education with respect to our novel products and services in a virtual setting, and restrictions on clinician and provider travel;

 

•

diversion of healthcare resources, clinical staff, physicians and advanced practice providers in oncology, including hospitals serving as our clinical trial sites, away from the conduct of clinical trials related to our non-COVID-19 related products and services;

 

•

interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;

 

•

limitations in employee resources that would otherwise be focused on the conduct of our business with respect to research and development or clinical trials, including due to illness of our employees or their families, an increase in childcare responsibilities for certain employees, the desire of our employees to avoid close contact or contact with large groups of people or as a result of the governmental imposition of stay at home orders or similar working restrictions;

 

•

delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;

 

•

delays in clinical sites receiving the supplies and materials needed to conduct clinical trials;

 

•

interruption in global shipping that may affect the transport of clinical trial materials;

 

•

changes in regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or discontinuing clinical trials altogether;

 

•

delays in necessary interactions and anticipated timelines with local and federal regulators (including the FDA), ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and

 

•

refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.

In addition, regulatory milestones represent a substantial part of our business strategy and are a key component of development revenue. The disruptions set forth above may materially affect our ability to achieve regulatory milestones, resulting in delays in our clinical pipeline and a material adverse effect on revenues.

Our efforts to discover and develop products and services related to COVID-19 may not be successful from either a platform extension or commercialization perspective.

We are attempting to leverage our immune medicine platform to discover and develop potential antibody therapies and We are attempting to leverage our immune medicine platform to discover and develop potential antibody therapies and diagnostics for COVID-19. Our efforts in this area are early and continue to evolve and mature continuously as we augment our databases and pool of knowledge.

53

While we believe quantifying virus-specific T cells may provide important research and diagnostic advantages because T cells appear to persist longer and protect against severity of disease, the data upon which such belief is based is limited and our analyses are preliminary. As we continue to collect and analyze additional data, we may find that our initial hypotheses are not applicable to new variants of the SARS-CoV-2 virus or are not supported by a larger data set or further analysis. If our beliefs regarding the effectiveness of our current products and services related to COVID-19 are incorrect, or if we are unable to establish a correlate of protection between the T cell response and immunity to COVID-19, that could have a material adverse effect on the market for our products and services related to COVID-19 as well as collaborations for which a correlate of protection is a vital element. Accordingly, our revenue, reputation, financial condition, and our stock price would be adversely impacted.

Our efforts to further develop and commercialize T-Detect COVID, neutralizing antibodies for COVID-19 or other products related to COVID-19, including efforts by our partners or collaborators, involve a high degree of risk, and our efforts may fail for many reasons, including:

 

•

failure of our products to be effective against new variants of COVID-19;

 

•

failure of T-Detect COVID or TruAB neutralizing antibodies to perform as expected against current strains of COVID-19 or new variants, as well as the possibility of defects and errors;

 

•

failure to obtain a suitable partner for neutralizing antibody therapeutics or failure of our collaborators in vaccine development to bring products to market;

 

•

lack of validation data, particularly as new variants of COVID-19 arise;

 

•

failure to demonstrate the analytical accuracy or clinical utility of existing antibody therapies and diagnostic tests;

 

•

failure to obtain the necessary regulatory approvals or clearances; or

 

•

commercial disruption caused by the development of competing products or services.

Additionally, there can be no assurances as to the commercial success of either T-Detect COVID, neutralizing antibodies, vaccines or diagnostic tests. Our investments in the discovery and development of products and services related to COVID-19 may not be accretive to our future financial results and if we determine that any product or service is unlikely to succeed, we may abandon them without any return on our investment.

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.

Our financial condition and operating results have varied in the past and will continue to fluctuate from quarter-to-quarter and year-to-year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this Annual Report on Form 10-K:

 

•

the timing of upfront payments from our collaborators;

 

•

our ability and that of our collaborators to develop and successfully commercialize our products and services;

 

•

our ability to achieve collaboration-based milestones on currently contemplated timelines, or at all;

 

•

availability and extent of reimbursement by governmental and private payors for our products and services;

 

•

the ability of our clinical sales teams to convert physicians from using incumbent products in the market to clonoSEQ and new diagnostic products and services we may develop, such as T-Detect COVID and other T-Detect products;

 

•

our ability to drive repeat usage of the clonoSEQ diagnostic test by physicians and get reimbursed for that repeat usage by commercial and government payors for monitoring of MRD;

 

•

our ability to drive repeat usage of T-Detect COVID by physicians serving immunocompromised patients and get reimbursed for that usage by commercial and government payors for determination of recent or prior infection;

 

•

the outcomes of research initiatives, clinical trials or other product development or approval processes conducted by us or our collaborators;

 

•

the level of demand for our products and services, which may vary significantly or be unknown for our newest products and services, such as T-Detect or immunoSEQ T-MAP COVID;

 

•

our relationships, and any associated exclusivity terms, with collaborators;

 

•

our ability to manage our growth;

54

 

 

•

our contractual or other obligations to provide resources to fund our products and services and to provide resources to our collaborations;

 

•

delays or failures in advancement of future products in clinical trials by us or our collaborators;

 

•

risks associated with the future international expansion of our business, including the potential to conduct clinical trials and commercialize our products and services in multiple international locations;

 

•

our ability and that of our collaborators to consistently manufacture our products;

 

•

our dependence on, and the need to attract and retain, key management and other personnel;

 

•

our ability to obtain, protect and enforce our intellectual property rights;

 

•

our ability to prevent the theft or misappropriation of our intellectual property, know-how or technologies;

 

•

our ability to obtain additional capital that may be necessary to expand our business;

 

•

our ability to accurately report our financial results in a timely manner;

 

•

business interruptions such as power outages, strikes, acts of terrorism or natural disasters; and

 

•

our ability to use our net operating loss (“NOL”) carryforwards to offset future taxable income.

The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.

While as a general matter we intend to periodically report on the status of our development initiatives, including anticipated next steps, we may not provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosure of any such milestones related to any of our products and services that are managed by our collaborators. Any disclosure by us or our collaborators of data that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may decline as a result of unexpected clinical trial results in one or more of our products and services, including adverse safety events reported for any of our products or services.

We have estimated the sizes of the markets for our current and future products and services, and these markets may be smaller than we estimate.

Our estimates of the annual addressable markets for our current products and services and those under development are based on a number of internal and third-party estimates, including, without limitation, the number of patients who have developed one or more of a broad range of cancers, the number of individuals who are at a higher risk for developing one or more of a broad range of cancers, the number of individuals who have developed or are at a higher risk of developing certain autoimmune disorders, the number of individuals with certain infectious diseases we or our collaborators are able to treat through our products and services, the proportion of patients in each market whose needs can be addressed by our or our collaborators’ products and services, the number of potential tests utilized per treatment course per patient and the assumed prices at which we can sell our current and future products and services for markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual addressable market for our current or future products and services may prove to be incorrect. If the actual number of patients who would benefit from our products or services, the price at which we can sell future products and services or the annual addressable market for our products or services is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.

If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully commercialize our products and services.

The biotechnology and pharmaceutical industries, including the fields of life sciences research, clinical diagnostics and drug discovery are intense and highly competitive. These fields are characterized by rapidly advancing technologies and a strong emphasis on intellectual property. Given the breadth and promise of immune medicine, we face substantial competition from many different sources, including life sciences tools, diagnostics, pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions across various components of our platform and product and service offerings. Due to the significant interest and growth in immune medicine more broadly, we expect the intensity of the competition to increase.

55

For instance, in life sciences research, immunoSEQ faces competition from a number of companies, including Thermo Fisher Scientific Inc. and 10X Genomics, Inc., among others. In clinical diagnostics, our clonoSEQ MRD test faces competition from both conventional and next-generation flow cytometry performed either in-house by our target customers or by reference labs, as well as from labs and institutions advancing research-use-only MRD technologies for clinical applications and commercial-stage oncology diagnostics companies extending the application of their solid tumor (ctDNA) MRD products into the hematology MRD space. In addition, our T-cell based diagnostic, T-Detect COVID, may face competition from other manufacturers such as Qiagen, who are seeking to commercialize T-cell testing to consumers. In drug discovery, clinical trials of immune medicines are being undertaken by a number of industry and academic players.

Our competitors may have or obtain the knowledge necessary to generate and characterize similar data to our known data for the purpose of identifying and developing products or services that could compete with any of our products or services. Further, immune medicine is being pursued by several biotechnology companies as well as by large-cap biopharmaceutical companies. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, regulatory approval and compliance, and sales and distribution than we do.

We could be adversely affected if we do not develop our life sciences research, clinical diagnostic and drug discovery products and services, obtain required regulatory and other clearances, authorizations or approvals, obtain or enforce patents covering our discoveries and launch our products and services before our competitors. Moreover, our competitors may succeed in developing immunosequencing-based life sciences research, clinical diagnostics and drug discoveries that circumvent our technologies, products or services. Our competitors may succeed in developing and commercializing research or diagnostic products or services that are more accurate, more convenient to use or more cost-effective than our products or services or therapeutic products that prove to be safer, more effective, more convenient to administer or more cost-effective than any therapeutic products we may develop with our collaborators or that would render our technologies, products and services less competitive or obsolete. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur and become more widely known. For additional information regarding our competition, see the “Business—Competition” section of this Annual Report on Form 10-K.

The life sciences industry is subject to rapid change, which could make our immune medicine platform and related products and services that we develop obsolete.

Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product and service introductions and enhancements and evolving industry standards, all of which could make our current and future products and services obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to life sciences research and the diagnosis and treatment of cancer, infectious disease such as COVID-19, and autoimmune disorders. There have also been advances in technologies used to computationally analyze very large amounts of biologic information. If we do not update our products and services to reflect new scientific knowledge about immunosequencing, immunology, computational biology, software development, new disease diagnostics and therapies or the diseases we seek to treat, our products and services could become obsolete and sales of our current products and services and any future products and services we develop based on our immune medicine platform could decline or fail to grow as expected.

The loss of any member of our senior management team or our inability to attract and retain highly skilled scientists, clinicians and salespeople could adversely affect our business.

Our success depends on the skills, experience and performance of key members of our senior management team, including our co-founders and executive officers. The individual and collective efforts of these employees will be important as we continue to develop products and services based on our immune medicine platform. The loss or incapacity of existing members of our executive management team could adversely affect our operations if we experience difficulties in hiring qualified successors. Our executive officers have signed employment agreements with us, but their service is at-will and may end at any point in time.

Our research and development initiatives and laboratory operations depend on our ability to attract and retain highly skilled scientists, technicians and software engineers. We may not be able to attract or retain qualified scientists, technicians or software engineers in the future due to the competition for qualified personnel among life sciences and technology businesses, particularly near our headquarters located in Seattle, Washington and our laboratory facilities located in South San Francisco, California. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting, training and retention difficulties can limit our ability to support our research and development and commercialization efforts. We also employ a number of workers on work authorization visas. We may have difficulty recruiting and retaining these workers as immigration regulations continue to change and as a result of the backlog of processing of immigration applications at the federal level. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.

56

In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory and commercialization strategy. Our consultants and advisors may provide services to other organizations and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current consultants or advisors might impede the achievement of our research, development, regulatory and commercialization objectives. We have also have flexibly grown our workforce through the use of contingent workers, temporary employees, and part-time workers. We may not be able to retain the services of such personnel which might result in delays in the operation of our business.

If we lose the support of key thought leaders, it may be difficult to establish products and services enabled by our immune medicine platform as industry standards, which may limit our revenue growth and ability to achieve profitability.

We have established relationships with leading oncology, hematology, immunology, autoimmunity or inflammatory disease, transplantation and solid tumor thought leaders at premier academic and research institutions. If these key thought leaders determine that our immune medicine platform or our current or future products or services are not clinically effective, determine that alternative technologies are more effective or elect to use internally developed services, we could encounter significant difficulty validating our products or services, driving adoption or establishing our immune medicine platform as an industry standard, which would limit our revenue growth and our ability to achieve profitability. In addition, negative publications or reviews by clinicians, industry groups or other important stakeholders may negatively impact our revenue growth and ability to achieve profitability.

We depend on our information technology systems and any failure of these systems could harm our business.

We depend on information technology and telecommunications systems, including third-party cloud computing infrastructure, operating systems and artificial intelligence platforms, for significant elements of our operations, including our laboratory information management system, clinical immunomics database, immunoSEQ Analyzer, TCR-Antigen Map, laboratory workflow tools, customer and collaborator reporting and related functions. We also depend on our proprietary workflow software to support new product and service launches and regulatory compliance.

We use complex software processes and pipelines to manage samples and evaluate sequencing result data. These are subject to initial design or ongoing modifications which may result in unanticipated issues that could cause variability in patient results, leading to service disruptions or errors, resulting in liability.

We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. In addition to these business systems, we have installed, and intend to extend, the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including laboratory operations, test validation, sample tracking, quality control, customer service support, billing and reimbursement, research and development activities, scientific and medical curation and general administrative activities. In addition, our third-party billing and collections provider depends upon technology and telecommunications systems provided by outside vendors.

In addition to the risks directly relevant to our vendors, systems, and information technology, there are risks associated with the outside vendors and third parties with whom they subcontract. For example, our third-party billing and collections provider depends upon technology and telecommunications systems provided by outside vendors. Subcontractors can be a vector of vulnerability, as any weaknesses in their organization’s technical and organizational controls could affect vendor operations as well as data management, in turn impacting our own operations and ability to safeguard critical data.

Information technology and telecommunications systems are vulnerable to attack in a variety of forms and from a variety of sources, including telecommunications or network failures, malicious human acts (such as ransomware) and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of these systems or those used by our collaborators or subcontractors could prevent us from conducting our comprehensive immunosequencing analysis, clinical diagnostics and drug discovery, preparing and providing reports to researchers, clinicians and our collaborators, billing payors, handling physician inquiries, conducting research and development activities and managing the administrative aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation in the future.

57

International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.

Because we and our collaborators currently market our products and services outside of the United States and may market future products and services outside of the United States, if cleared, authorized or approved, our business is subject to risks associated with doing business outside of the United States, including an increase in our expenses and diversion of our management’s attention from the development of future products and services. Accordingly, our business and financial results in the future could be adversely affected due to a variety of factors, including:

 

•

multiple, conflicting and changing laws and regulations such as privacy, security and data use regulations, tax laws, export and import restrictions, economic sanctions and embargoes, employment laws, anticorruption laws, regulatory requirements, reimbursement or payor regimes and other governmental approvals, permits and licenses;

 

•

failure by us, our collaborators or our distributors to obtain regulatory clearance, authorization or approval for the use of our products and services in various countries;

 

•

additional potentially relevant third-party patent rights;

 

•

complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property;

 

•

difficulties in staffing and managing foreign operations;

 

•

complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;

 

•

difficulties in negotiating favorable reimbursement negotiations with governmental authorities;

 

•

logistics and regulations associated with shipping samples, including infrastructure conditions and transportation delays;

 

•

limits in our ability to penetrate international markets if we are not able to conduct our immunosequencing or clinical diagnostic services locally;

 

•

financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and services and exposure to foreign currency exchange rate fluctuations;

 

•

natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;

 

•

regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ activities that may fall within the purview of the FCPA, its books and records provisions, or its anti-bribery provisions, or laws similar to the FCPA in other jurisdictions in which we may now or in the future operate, such as the United Kingdom’s Bribery Act of 2010; and

 

•

anti-bribery requirements of several member states in the European Union (“EU”) and other countries, such as the United Kingdom’s Bribery Act of 2010, that are constantly changing and require disclosure of information to which U.S. legal privilege may not extend.

Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.

We may never obtain approval in the EU or in any other foreign country for any of our products or services and, even if we do, we or our collaborators may never be able to commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential.

In order to eventually market any of our current or future products and services in any particular foreign jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding quality, safety, performance and efficacy. In addition, clinical trials or clinical investigations conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory clearance, authorization or approval in one country does not guarantee regulatory clearance, authorization or approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods.

58

Seeking foreign regulatory clearance, authorization or approval could result in difficulties and costs for us and our collaborators and require additional preclinical studies, clinical trials or clinical investigations which could be costly and time-consuming. Regulatory requirements and ethical approval obligations can vary widely from country to country and could delay or prevent the introduction of our products and services in those countries. The foreign regulatory clearance, authorization or approval process involves all of the risks and uncertainties associated with FDA clearance, authorization or approval. We currently sell our RUO kits outside of the United States and have completed a technology transfer process for research use to sites in France, Germany, Italy, the United Kingdom, Spain, and Australia, but have no experience in obtaining regulatory clearance, authorization or approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required regulatory clearances, authorizations or approvals in international markets, or if those approvals are delayed, our target market will be reduced and our ability to realize the full market potential of our products and services will be unrealized.

If our laboratory facilities become damaged or inoperable or we are required to vacate our existing facilities, our ability to conduct our laboratory processes and analysis and pursue our research and development efforts may be jeopardized.

We operate laboratory facilities located in Seattle, Washington and South San Francisco, California. Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure or terrorism, which may render it difficult or impossible for us to operate our immune medicine platform for some period of time. The inability to perform our laboratory processes or to reduce the backlog of sequences that could develop if our facilities are inoperable, for even a short period of time, or to replace or repair inventory such as reagents or customer samples may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. In addition, the expansion of our corporate headquarters, laboratory space and warehousing facilities in the Seattle, Washington area has increased the volume of material and sample transfers between and among local facilities, increasing risk to materials and customer samples.

Furthermore, our facilities and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify new facilities or license or transfer our proprietary technologies to a third party, particularly in light of licensure and accreditation requirements. Even in the unlikely event we are able to find a third party with such qualifications to enable us to conduct our laboratory processes, we may be unable to negotiate commercially reasonable terms.

We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.

We may need to raise additional capital to fund our existing operations, develop additional products and services, commercialize new products and services or expand our operations.

Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flow from operations, will be sufficient to meet our anticipated cash requirements over at least the next 12 months. If our available cash and investment balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, including because of lower demand for our products and services as a result of risks described herein, we may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing.

We may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:

 

•

increase our sales and marketing efforts to drive market adoption of our life sciences research, clinical diagnostics and therapeutics;

 

•

fund development efforts for our current and future products and services;

 

•

expand our products and services into other disease indications and clinical applications;

 

•

acquire, license or invest in technologies;

 

•

acquire or invest in complementary businesses or assets; and

 

•

finance capital expenditures, such as our corporate headquarters expansion, and general and administrative expenses.

Our present and future funding requirements will depend on many factors, including:

 

•

our ability to achieve revenue growth;

 

•

our rate of progress in establishing payor coverage and reimbursement arrangements with domestic and international commercial third-party payors and government payors;

59

 

•

the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts;

 

•

our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of our immunoSEQ research services and kits, and reimbursement for our clonoSEQ diagnostic test, T-Detect COVID and cellular therapies developed under the Genentech Agreement;

 

•

our rate of progress in, and research and development expenses associated with, products and services in research and early development;

 

•

the effect of competing technological, product and market developments;

 

•

costs related to international expansion; and

 

•

the potential cost of and delays in product development as a result of any regulatory oversight applicable to our products and services.

The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our shareholders could result. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products and services or grant licenses on terms that are not favorable to us.

Our ability to use our NOL carryforwards and certain other tax attributes may be limited.

We have incurred net losses since our inception and we may never achieve or sustain profitability. Generally, losses incurred will carry forward until such losses expire (for losses generated prior to January 1, 2018) or are used to offset future taxable income, if any. Utilization of our NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986 (“Section 382”) and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. If there should be an ownership change, our ability to utilize our NOL carryforwards and credits could be limited. We have completed a Section 382 analysis for changes in ownership through December 31, 2020 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the TCJA, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years. Based on the available objective evidence, management determined that it was more likely than not that the net deferred tax assets would not be realizable as of December 31, 2021. Accordingly, management applied a full valuation allowance against net deferred tax assets as of December 31, 2021.

We may experience ownership changes in the future as a result of shifts in our stock ownership, which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change NOL carryforwards to offset such taxable income will be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we attain profitability, we may be unable to use a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows.

We could be adversely affected by violations of the FCPA and other worldwide anti-bribery laws.

As we expand geographically, commercialize our products and services, and attempt to obtain required clearances, authorizations or approvals required to offer products and services for sale, we or our collaborators may be deemed to do business outside the United States, including because international customers may be able to order our products and services. As a result, we or our collaborators would be subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. In addition, our collaborators or any third-party distributors could be deemed to be our agents and we could be held responsible for their actions, including violations of the FCPA. Other U.S. companies in the life sciences industry have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with non-U.S. government officials. We may also become subject to similar anti-bribery laws in the jurisdictions in which we may operate, including the United Kingdom’s Bribery Act of 2010, which also prohibits commercial bribery and makes it a crime for companies to fail to prevent bribery. These laws are complex and far-reaching in nature, and we may be required in the future to alter one or more of our practices to be in compliance with these laws. Accordingly, our expansion internationally will demand a high degree of vigilance, and any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, prospects, financial condition or results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.

60

We may acquire other businesses or form joint ventures or make investments in other companies or technologies that could negatively affect our operating results, dilute our shareholders’ ownership, increase our debt or cause us to incur significant expense.

We may pursue acquisitions of businesses and assets. We also may pursue joint ventures or investments that leverage our immune medicine platform and industry experience to expand our offerings or distribution. We have no experience forming joint ventures and limited experience investing in or acquiring other companies. We may not be able to find suitable joint ventures, investment or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate the acquired company successfully into our existing business, and we could assume unknown or contingent liabilities, including regulatory violations such as the FCPA or similar laws. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our financial condition, results of operations and cash flows. Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may experience losses related to investments in other companies, which could have a material negative effect on our results of operations and financial condition. We may not realize the anticipated benefits of any acquisition, technology license, collaboration or joint venture.

To finance any acquisitions or joint ventures, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our shareholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration.

Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and financial markets. A severe or prolonged economic downturn, as result of a global pandemic or otherwise, could result in a variety of risks to our business, including weakened demand for our products and services and our ability to raise additional capital when needed on favorable terms, if at all. A weak or declining economy could strain our collaborators, possibly resulting in supply disruption, or cause delays in their payments to us. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.

We work with materials, including chemicals, biological agents and compounds and samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties.

In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which increase with the volume of material and sample transfers and could cause an interruption of our commercialization efforts, research and development programs, and business operations, as well as environmental damage resulting in costly cleanup and liabilities under applicable laws and regulations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. While our property insurance policy provides limited coverage in the event of contamination from hazardous and biological products and the resulting cleanup costs, we do not currently have any additional insurance coverage for legal liability for claims arising from the handling, storage or disposal of hazardous materials. Accordingly, in the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected.

61

If we were to be sued for product liability or professional liability, we could face substantial liabilities that exceed our resources.

The marketing, sale and use of our products and services could lead to the filing of product or professional liability claims were someone to allege that our products or services identified inaccurate, incomplete or untimely information regarding the sequence or antigen specificities of TCRs, BCRs or antigens analyzed or the clonality characterized, or MRD or malignancy detected, or that our products or services otherwise failed to perform as designed or intended. We could also be potentially exposed to claims relating to therapeutic failures of products commercialized under our collaborations, such as a cellular therapy marketed by Genentech that is manufactured based on TCR-related sequences and data we provide. We may also be subject to liability for errors in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. Regardless of merit or eventual outcome, product liability and professional liability claims may result in:

 

•

decreased demand for any products, services or clinical solutions that we have developed or may develop;

 

•

loss of revenue;

 

•

substantial monetary awards to patients or their families;

 

•

significant time and costs to defend related litigation;

 

•

withdrawal of clinical trial participants;

 

•

the inability to commercialize any products, services or clinical solutions that we have developed or may develop; and

 

•

injury to our reputation and significant negative media attention.

We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause current collaborators to terminate existing agreements or potential collaborators to seek other companies, any of which could impact our results of operations.

We or our collaborators may be adversely affected by natural or man-made disasters or other business interruptions, such as cybersecurity attacks, and our business continuity and disaster recovery plans, or those of our collaborators, may not adequately protect us from the effects of a serious disaster.

Natural and man-made disasters and other events beyond our control could severely disrupt our operations, or those of our collaborators, and have a material adverse impact on our business, results of operations, financial condition and prospects. If a natural disaster, power outage, cybersecurity attack or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our laboratory facilities or those of our collaborators, limited our or our collaborators’ ability to access or use our respective digital information systems or that otherwise disrupted our respective operations, it may be difficult or, in certain cases, impossible for us or our collaborators to continue our respective businesses for a substantial period of time. The disaster recovery and business continuity plans we and our collaborators currently have in place are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. Our cybersecurity liability insurance may not cover any or all damages, depending on the severity and extent, we or our collaborators could sustain based on any breach of our respective computer security protocols or other cybersecurity attack, including potential liability arising out of third parties’ negatively impacted data privacy rights. We may incur substantial expenses as a result of the limited nature of our respective disaster recovery and business continuity plans, which could have a material adverse impact on our business.

Risks Relating to Government Regulation

We conduct our business in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our results of operations and financial condition and harm our business.

The life sciences industry is highly regulated, and the regulatory environment in which we and our collaborators operate may change significantly and adversely to us in the future. Areas of the regulatory environment that may affect our ability to conduct business include, without limitation, federal and state laws relating to:

 

•

laboratory testing, including CLIA and state laboratory licensing laws;

 

•

the development, testing, use, distribution, promotion and advertising of research services, kits, clinical diagnostics and cellular therapies, including certain LDTs, which are regulated by the FDA under the FDCA and the FTC;

 

•

test ordering, documentation of tests ordered, billing practices and claims payment under CMS and the HHS OIG enforcing those laws and regulations;

62

 

•

cellular therapies, medical device and in vitro diagnostic clearance, marketing authorization or approval;

 

•

laboratory anti-mark-up laws;

 

•

the handling and disposal of medical and hazardous waste;

 

•

fraud and abuse laws such as the False Claims Act, the AKS, EKRA, and the Stark Law;

 

•

Occupational Safety and Health Administration rules and regulations;

 

•

HIPAA and other federal and state medical data privacy and security laws;

 

•

the Genetic Information Nondiscrimination Act (“GINA”) and similar state laws; and

 

•

coverage and restrictions on coverage and reimbursement for research services, kits, clinical diagnostics and cellular therapies and Medicare, Medicaid, other governmental payors and private insurers reimbursement levels.

In particular, the laws, regulations and policies governing the marketing of RUO products, LDTs and clinical diagnostic tests and services are extremely complex and are subject to interpretation by the courts and governmental agencies. Our failure to comply could lead to civil or criminal penalties, exclusion from participation in state and federal health care programs, or prohibitions or restrictions on our laboratories’ ability to provide or receive payment for our services. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payors.

The insurance coverage and reimbursement status of newly approved products and services, in a new category of diagnostics and therapeutics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future products and services could limit our ability, and that of our collaborators, to fully commercialize our products and services and decrease our ability to generate revenue.

The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford the clinical diagnostic tests and cellular therapeutics that we and our collaborators currently or plan to develop and sell. In addition, because our clinical diagnostics and therapeutic products and services represent new approaches to the research, diagnosis, detection and treatment of diseases, we cannot accurately estimate how our products and services, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of our products and services will depend substantially, both domestically and internationally, on the extent to which the costs of our products and services are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize some of our products or services. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment in any of our products or services. If we adopt a self-pay strategy with respect to any products or services, we may experience similar difficulties in the establishment or maintenance of sufficiently high pricing. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our products and services.

There is significant uncertainty related to the insurance coverage and reimbursement of newly cleared, authorized or approved products and services. In the United States, many significant decisions about reimbursement for new diagnostics and medicines are typically made by CMS, an agency within the HHS, and its contractors. CMS and its contractors decide whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS policies to a substantial degree. It is difficult to predict what CMS and its contractors will decide with respect to reimbursement for novel products and services such as ours. Additionally, reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement, or have been approved under restricted conditions, in certain European countries.

63

Outside the United States, the reimbursement process and timelines vary significantly. Certain countries, including a number of member states of the EU, set prices and make reimbursement decisions for diagnostics and pharmaceutical products, or medicinal products, as they are commonly referred to in the EU, with limited participation from the marketing authorization or Conformité Européene (“CE”) mark holders, or may take decisions that are unfavorable to the authorization or CE mark holder where they have participated in the process. We cannot be sure that such prices and reimbursement decisions will be acceptable to us or our collaborators. If the regulatory authorities in these foreign jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products and services in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to control the healthcare budget by focusing cost-cutting efforts on medicinal products, and to a lesser extent, medical devices, provided under their state-run healthcare systems. These international price control efforts have impacted all regions of the world, but have been most prominent in the EU. Additionally, some countries require approval of the sale price of a product before it can be marketed or mandatory discounts or profit caps may be applied. Further, after the sale price is approved, it remains subject to review during the product lifecycle. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. As a result, we or our collaborators might obtain marketing approval for a product or service in a particular country, but then may experience delays in the reimbursement approval or be subject to price regulations that would delay the commercial launch of our product or service, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of that product or service in that particular country.

Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for newly cleared, authorized or approved devices and medicines and, as a result, they may not cover or provide adequate payment for our clinical diagnostics or the cellular therapies to be sold by us or our collaborators. For example, the U.S. government introduced the Lower Drug Costs Now Act of 2019 to reduce the cost of drugs. This blueprint contains certain measures that HHS is already working to implement. In addition, the No Surprises Act (“NSA”) took effect in January 2022. One of the goals of the NSA is to protect patients from “surprise” medical bills resulting from gaps in coverage for services provided by out-of-network providers, such as laboratories, related to patient visits at in-network facilities. The NSA limits the amount out-of-network laboratories may charge a patient for laboratory services ordered during an in-network facility visit and establishes an independent dispute resolution process for determining the amount of reimbursement for the laboratory service in the event that the laboratory and insurer cannot agree on a rate. To the extent the NSA limits the price charged for our diagnostic products or cellular therapeutics, the commercial viability of those products may be adversely affected.

At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological program pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, which are, in some cases, designed to encourage importation from other countries and bulk purchasing.

We expect to experience pricing pressures on our clinical diagnostics and cellular therapies sold by us and our collaborators due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

Our business could be harmed by the loss, suspension or other restriction on a license, certification or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations or other state, federal and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.

Federal law requires virtually all clinical laboratories to comply with CLIA, which generally involves becoming certified by the federal and state government for the testing that will be performed and complying with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate and reliable. CLIA certification is also a prerequisite to be eligible to bill state and federal healthcare programs, as well as many private third-party payors, for laboratory research and clinical diagnostic testing services. As a condition of our CLIA certification, our Seattle, Washington laboratory is subject to survey and inspection every other year, additional random inspections and surprise inspections based on complaints received by state or federal regulators. The biennial survey and inspection is conducted by CMS, a CMS agent or, if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization, such as CAP. Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation or limitation of a laboratory’s CLIA certificate, which is necessary to conduct business, as well as the imposition of significant civil, administrative or criminal sanctions against the lab, its owners and other individuals. In addition, we are subject to regulation under certain state laws and regulations governing laboratory licensure. Some states, including Washington, have enacted laboratory licensure and compliance laws that are more stringent than CLIA. Changes in state licensure laws that affect our ability to offer and provide research and diagnostic products and services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.

64

Any sanction imposed under CLIA, its implementing regulations or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business.

Changes in law relating to health insurance coverage and payment may adversely affect our business.

In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. clinical diagnostic and biopharmaceutical industries. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and medical devices, including laboratory kits, and promoted a new Medicare Part D coverage gap discount program.

Some of the provisions of the ACA have been subject to judicial and Congressional challenges. It is also unclear how regulatory provisions and sub-regulatory guidance, both of which fluctuate continually, may affect interpretation and implementation of the ACA and its practical effects on our business. In addition, changes in the number of patients that can look to third-party payment to help afford our products and services may affect the demand for these products and services.

We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase downward pressure on drug and device pricing. Such reforms could have an adverse effect on anticipated revenues from our products and services, including those that we jointly develop with our collaborators, and may affect our overall financial condition and ability to develop or obtain regulatory clearance, authorization or approval for our products and services.

Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and clear, authorize or approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory and policy changes. In addition, government funding of agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and devices to be reviewed and cleared, authorized or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

We must maintain compliance with FDA requirements for our products and services and failure to maintain compliance with FDA requirements may prevent or delay the marketing of our products and services.

Even after we have obtained marketing authorization, as we have for clonoSEQ and T-Detect COVID under an EUA, we must comply with the scope of that clearance, authorization or approval. Failure to comply with those limitations or the additional, extensive and ongoing post-marketing obligations imposed by the FDA or other regulatory requirements of other regulatory agencies could result in unanticipated compliance expenditures, a range of administrative enforcement actions, injunctions and criminal prosecution. FDA post-market obligations include, among other things, compliance with the FDA QSR, establishing registration and device listings, labeling requirements, reporting of certain adverse events and malfunctions, and reporting of certain recalls. In addition, circumstances may arise that cause us to recall equipment used in connection with our products and services. Such recalls could have an adverse effect on our ability to provide those products and services, which in turn would adversely affect our financial condition. Our collaborators will also be required to maintain FDA clearance, authorization or approval for the products and services that we jointly develop. Any failure by us or our collaborators to maintain such clearance, authorization or approval could impair or cause a delay in our ability to profit from these collaborations.

65

Products and services offered RUO may be subject to regulatory scrutiny.

Certain of our products are currently labeled and sold for RUO and not for the diagnosis or treatment of disease. Because such products are not intended for diagnostic use, and the products do not include clinical or diagnostic claims or provide directions for use as diagnostic products, they are not subject to the same level of regulation by the FDA as medical devices. In particular, while the FDA regulations require that RUO products be appropriately labeled, “For Research Use Only,” the regulations do not subject such products to the FDA’s pre- and post-market controls for medical devices. Pursuant to FDA guidance on RUO products, a company may not make clinical or diagnostic claims about an RUO product or provide clinical directions or clinical support services to customers of RUO products. A product labeled RUO but deemed by the FDA to be intended for clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the FDCA and subject to FDA enforcement action. The FDA considers the totality of the circumstances surrounding distribution and use of a product labeled as RUO, including how the product is marketed and to whom, when determining its intended use. If the FDA were to disagree with our RUO classification or modify its approach to regulating products labeled for RUO, we could experience reduced revenue or increased compliance and other costs, which could adversely affect our business, prospects, results of operations and financial condition. In the event that the FDA requires marketing authorization of our RUO products in the future, the FDA may not ultimately grant any clearance, authorization or approval requested by us in a timely manner, or at all.

Future changes in FDA enforcement discretion for LDTs could subject our operations to much more significant regulatory requirements.

In addition to offering the cleared version of clonoSEQ as a test for MRD in certain blood cancers, we also currently offer an LDT version of this test. Further, we offer our T-Detect COVID test as an LDT. The FDA has a policy of enforcement discretion with respect to LDTs whereby the FDA does not actively enforce its medical device regulatory requirements for such tests. However, in October 2014, the FDA issued two draft guidance documents stating that the FDA intended to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the existing classification of medical devices. Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give Congressional authorizing committees the opportunity to develop a legislative solution, it is unclear if Congress or the FDA will modify the current approach to the regulation of LDTs in a way that would subject our current or future services marketed as LDTs to the enforcement of FDA regulatory requirements. The FDA Commissioner and the Director of the Center for Devices and Radiological Health (“CDRH”) have expressed significant concerns regarding disparities between some LDTs and in vitro diagnostics that have been reviewed, cleared, authorized or approved by the FDA. If the FDA were to determine that T-Detect COVID and NGS MRD tests offered as LDTs are not within the policy for LDTs for any reason, including new rules, policies or guidance, or due to changes in statute, our tests may become subject to extensive FDA requirements or our business may otherwise be adversely affected. If the FDA were to disagree with our LDT status or modify its approach to regulating LDTs, we could experience reduced revenue or increased costs, which could adversely affect our business, prospects, results of operations and financial condition. If required, the regulatory marketing authorization process required to bring our current or future LDTs into compliance may involve, among other things, successfully completing additional clinical validations and submitting to and obtaining clearance from the FDA for a premarket clearance (510(k)) submission or authorization for a de novo or approval of a PMA. Furthermore, recently introduced legislation, if passed, such as the VALID Act, could create new or different regulatory and compliance burdens on us and could have a negative effect on our ability to develop new products, which could have a material effect on our business. In the event that the FDA requires marketing authorization of our LDTs in the future, the FDA may not ultimately grant any clearance, authorization or approval requested by us in a timely manner, or at all. In addition, if the FDA inspects our laboratory in relation to the marketing of our FDA-cleared clonoSEQ test, any enforcement action the FDA takes might not be limited to the FDA-cleared clonoSEQ test and could encompass our LDT testing service.

For each product and service we are developing that requires FDA premarket review, the FDA may not grant clearance, authorization or premarket approval and failure to obtain necessary approvals for our future products and services would adversely affect our ability to grow our business.

Before we begin to manufacture, label and market additional clinical diagnostic products for commercial diagnostic use in the United States, we may be required to obtain either clearance, marketing authorization or approval from the FDA, unless an exemption applies or the FDA exercises its enforcement discretion and refrains from enforcing its requirements. For example, the FDA currently has a policy of refraining from enforcing its medical device requirements with respect to LDTs, which the FDA considers to be a type of in vitro diagnostic test that is designed, manufactured and used within a single properly licensed laboratory.

66

The process of obtaining PMA is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process. In the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. Conversely, in the 510(k) clearance process, the FDA must determine that a proposed device is “substantially equivalent” to a legally marketed “predicate” device in order for the product to be cleared for marketing. To be “substantially equivalent,” the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics or if it has different technological characteristics as the predicate device, the proposed device must be as safe and effective as, and not raise different questions of safety or effectiveness than, the predicate device. Clinical data is sometimes required to support substantial equivalence. For lower-risk devices that would otherwise automatically be placed into Class III, which require a PMA because no predicate device is available and the devices do not fall within an existing 510(k)-exempt classification, an applicant may submit a de novo request to down classify the device into Class II or Class I, which would not require a PMA. In the de novo process, the FDA must determine that general and special controls are sufficient to provide reasonable assurance of the safety and effectiveness of a device, which is low to moderate risk and has no predicate. In other words, the applicant must justify the “down-classification” to Class I or II for a new product type that would otherwise automatically be placed into Class III, but is lower risk. Clinical data may be required. For laboratory tests for which FDA clearance, authorization or approval is required, the FDA may also require data to support analytical and clinical validity.

The 510(k), de novo and PMA processes can be expensive and lengthy and require the payment of significant fees, unless an exemption applies. The FDA’s 510(k) clearance pathway usually takes from three to nine months from submission, but it can take longer for a novel type of product. The FDA’s de novo classification pathway usually takes from six to 12 months, but for many applicants can take up to 18 months or more.

The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained. Any delay or failure to obtain necessary regulatory clearances, authorizations or approvals would have a material adverse effect on our business, financial condition and prospects.

The FDA can delay, limit or deny clearance, authorization or approval of a device for many reasons, including:

 

•

the inability to demonstrate to the satisfaction of the FDA that the products are safe or effective for their intended uses;

 

•

the disagreement of the FDA with the design, conduct or implementation of the clinical trials or the analysis or interpretation of data from preclinical studies, analytical studies or clinical trials;

 

•

serious and unexpected adverse device effects experienced by participants in clinical trials;

 

•

the data from preclinical studies, analytical studies and clinical trials may be insufficient to support clearance, authorization or approval, where required;

 

•

the inability to demonstrate that the clinical and other benefits of the device outweigh the risks;

 

•

an advisory committee, if convened by the FDA, may recommend against approval of a PMA or other application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee makes a favorable recommendation, the FDA may still not approve the product;

 

•

the FDA may identify deficiencies in our marketing application;

 

•

the FDA may identify deficiencies in our or our collaborators’ manufacturing processes, facilities or analytical methods;

 

•

the potential for policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering clinical data or regulatory filings insufficient for clearance, authorization or approval; and

 

•

the FDA or foreign regulatory authorities may audit clinical trial data and conclude that the data is not sufficiently reliable to support a PMA.

There are numerous FDA personnel assigned to review different aspects of marketing submissions, which can present uncertainties based on their ability to exercise judgment and discretion during the review process. During the course of review, the FDA may request or require additional data and information, and the development and provision of these data and information may be time-consuming and expensive. The process of obtaining regulatory clearances, authorizations or approvals to market a medical device can be costly and time-consuming, and we may not be able to obtain these clearances, authorizations or approvals on a timely basis, or at all for our products in development. If we are unable to obtain clearance, authorization or approval for any products for which we plan to seek clearance, authorization or approval, our business may be harmed.

67

Modifications to our products with FDA clearance may require new FDA clearances, authorizations or approvals, or may require us to cease marketing or recall the modified clinical diagnostic products or future clinical products until clearances are obtained.

Any modification to a 510(k)-cleared device that significantly affects its safety or effectiveness, or that constitutes a major change in its intended use, could require a new 510(k) clearance, a new de novo authorization or approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. The FDA may not agree with our decisions regarding whether new clearances, authorizations or approvals are necessary.

For any product approved pursuant to a PMA, we would be required to seek supplemental approval for many types of modifications to the approved product. The FDA requires manufacturers in the first instance to determine whether a PMA supplement or other regulatory filing is needed or whether the change may be reported via the PMA Annual Report, but may disagree with a company’s assessment.

If the FDA disagrees with our determination, which it may not review until we submit an annual report or the FDA conducts an inspection or other inquiry, and requires us to seek new clearances, authorizations or approvals for modifications to our previously cleared, authorized or approved clinical diagnostic products for which we have concluded new clearances, authorizations or approvals are unnecessary, we may be required to cease marketing or distribution of these clinical diagnostic products or to recall the modified products until we obtain clearance, authorization or approval. We may also be subject to enforcement action, including, among other things, significant regulatory fines or penalties.

Our employees, principal investigators, consultants and collaborators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of fraud or other misconduct by our employees, consultants and those of our collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent improper marketing, fraud, misconduct, kickbacks, bribery, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct. In addition, our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such investigations or actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, which could have a significant impact on our business. We currently have a compliance program in accordance with the elements of an effective program outlined by the HHS OIG, which could help mitigate damages, but cannot prevent all misconduct. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees, suffer adverse publicity and reputational harm, and have the attention of management diverted in defending ourselves against any of these claims or investigations.

If third-party payors, including private payors and government healthcare programs, do not provide coverage of, or adequate reimbursement for, our clinical diagnostic products, our commercial success will be negatively affected.

Our revenue depends in part on achieving broad coverage and reimbursement for our diagnostic tests from payors, including both private and government payors. Certain large private payors have issued policies that decline to cover testing methods that they regard as experimental or investigational. Other payors may issue similar non-coverage policies. If payors do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of the price of our diagnostic tests, we may need to seek payment from the patient where this is not precluded by law or contract, which may adversely affect demand for our tests. Coverage determinations by a payor may depend on a number of factors, including, but not limited to, a payor’s determination that a certain diagnostic test is appropriate, medically necessary or cost-effective. If we are unable to provide payors with sufficient evidence of the clinical utility and validity of our diagnostic tests, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenues and our ability to succeed. To the extent that more competitors enter our markets, the availability of coverage and the reimbursement rate for our tests and new diagnostic products may decrease as we encounter pricing pressure from our competitors.

68

Each payor makes its own decision regarding coverage of our tests and the applicable payment rates, and payors may not provide adequate coverage or reimbursement for our current or future products. Although we may contract with certain payors, working with payors through contract or otherwise to assure reimbursement is time-consuming and costly and outcomes are uncertain. In addition, the determinations by a payor whether to cover our clinical diagnostic product and the amount it will reimburse for them are often made on an indication-by-indication basis. In cases where there is no coverage policy or we do not have a contracted rate for reimbursement as a participating provider, the patient is typically responsible for a greater share of the cost of the test, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection. Through our Adaptive Assist patient support program, we provide clonoSEQ diagnostic tests for reduced rates or without charge to eligible low-income patients that may result in payors requiring us to provide evidence of eligibility of such patients to pay reduced out-of-pocket amounts.

Our claims for reimbursement from payors may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming, expensive and may not result in payment. Payors may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the payors believe the funds were paid in error or determine that our clonoSEQ diagnostic tests or other clinical diagnostic products were medically unnecessary. In addition, similar to federal payors, state and federal laws permit commercial payors to seek civil and criminal penalties against a manufacturer if they feel they have been defrauded. If a payor audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial payors for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was too much. In these situations, the payor will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We do not have a mechanism to dispute these retroactive adjustments and we cannot predict when, or how often, a payor might engage in these reviews.

Future Medicare payment rates are uncertain.

In January 2020, CMS revised the National Coverage Determination (“NCD”) for molecular diagnostic laboratory testing services utilizing a NGS methodology, which includes our clinical diagnostic products, for Medicare beneficiaries with advanced cancer. CMS revised the NCD to extend specific coverage for germline (inherited) testing. CMS stated that it is continuing to make other technical, clarifying and conforming changes in the NCD manual and they are also clarifying the existing policy related to diagnostic tests for Somatic (Acquired) Cancer. If CMS were to make material revisions to policy, this could potentially impact the scope of clonoSEQ coverage.

Under Medicare Part B, payment for most diagnostic laboratory tests is made under the Clinical Laboratory Fee Schedule (“CLFS”), which assigns payment amounts to tests based on billing codes. Under the Protecting Access to Medicare Act of 2014 (“PAMA”), certain laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or Medicare’s Physician Fee Schedule are required to report to CMS every three years, or annually for “advanced diagnostic laboratory tests,” commercial payor payment rates and volumes for tests they perform and that are assigned specific billing codes. PAMA has special provisions relating to “advanced diagnostic laboratory tests,” as defined by the statute, and these provisions affect the rate-setting at the time of launch and the periodicity of rate reporting and revision. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. If, in the future, clonoSEQ or any of our tests are assigned a specific code we would be required to report commercial payor payment data on those tests. Payments for tests billed under miscellaneous codes are determined by the MACs, which also have discretion to change those payment rates.

CMS uses the data reported by laboratories to calculate a payment rate for each CLFS test, other than those coded with miscellaneous codes and certain others, based on the volume-weighted median of the private payor rates. These rates apply for three years, except that payment rates for advanced diagnostic laboratory tests apply for one year. If we offer tests with specific codes, this apparatus would apply. Under these circumstances, Medicare’s payment rates would be determined by the rates we and other laboratories, if any, with tests that share the specific codes we use, obtain from commercial payors. In that case, if we are unable to obtain and maintain adequate reimbursement rates from commercial payors, this may adversely affect our Medicare rates.

In some circumstances, our tests may be furnished to hospital inpatients and paid by Medicare under different rules. For example, when a specimen is obtained from a patient who is at the time classified by Medicare as a hospital inpatient, Medicare would not make a separate payment for the test and we would have to look to the hospital for payment. We do not know how often this will occur or whether hospitals will resist paying us for our tests. In this situation, Medicare coverage would be determined by the MAC for the jurisdiction where the hospital is located, which may not cover our tests.

69

Our RUO, clinical diagnostic and therapeutic products or services, and those jointly developed with our collaborators, may in the future be subject to product or service recalls. A recall of products or services, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our or our collaborators’ products or services, could have a significant adverse impact on us.

The FDA has the authority to require the recall of commercialized products or services that are subject to FDA regulation. Manufacturers may, under their own initiative, recall a product or service if any deficiency is found. The FDA requires that certain corrections and removals, including recalls intended to reduce a health risk, be reported to the FDA within ten working days of initiating such correction or removal. For reportable corrections and removals, companies are required to make additional periodic submissions to the FDA after initiating the recall, and often engage with the FDA on their recall strategy prior to initiating the recall. A government-mandated or voluntary recall by us, one of our distributors or our collaborators could occur as a result of an unacceptable health risk, component failures, failures in laboratory processes, malfunctions, manufacturing errors, design or labeling defects, or other deficiencies and issues. Recalls of any of our commercialized products or services or those jointly developed with our collaborators would divert managerial and financial resources and adversely affect our reputation, results of operations and financial condition. We may also be subject to liability claims, be required to bear other costs or take other actions that may negatively impact our future sales and our ability to generate profits. Companies are also required to maintain certain records of corrections and removals, even if these do not require reporting to the FDA. We or our collaborators may initiate voluntary recalls involving our commercialized products or services in the future that we determine do not require FDA notification. If the FDA disagrees with our determinations, they may require us to report those actions as recalls. A future recall announcement by us or our collaborators could harm our reputation with customers and negatively affect our results of operations and financial condition. In addition, the FDA or other agency could take enforcement action for failing to report the recalls when they were conducted.

If we or our collaborators initiate a recall, including a correction or removal, for one of our commercialized products or services, issue a safety alert, or undertake a field action or recall to reduce a health risk, this could lead to increased scrutiny by the FDA, other governmental and regulatory enforcement bodies, and our or our collaborators’ customers regarding the quality and safety of our products and services, and to negative publicity, including FDA alerts, press releases, or administrative or judicial actions. Furthermore, the submission of these reports could be used against us by competitors and cause customers to delay purchase decisions or cancel orders, which would harm our reputation.

Any additional commercialized products and services or any future products and services that obtain regulatory clearance, authorization, approval, accreditation or licensure will remain subject to regulatory scrutiny and our failure to maintain our regulatory clearances, authorizations, approvals, accreditations or licensures could adversely affect our reputation, business and results of operations.

Even if we or our collaborators obtain regulatory clearance, authorization, approval, accreditation or licensure in a jurisdiction for our products and services, the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our products and services, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance of our or our collaborators’ manufacturing and distribution. Advertising for certain devices and labeling, including promotional labeling, for all devices must comply with FDA requirements. In addition, device advertising and promotion may also be subject to other federal and state laws. For example, the FDA shares jurisdiction over the regulation of device advertising with the FTC. Advertising for devices characterized as restricted by the FDA is subject to specified FDA requirements, while advertising for non-restricted devices is regulated by the FTC.

If we or our collaborators fail to comply with applicable regulatory requirements following clearance, authorization, approval, accreditation or licensure of any of our products and services, a regulatory agency may:

 

•

initiate an inspection of our or our collaborators’ facilities;

 

•

issue an untitled or warning letter asserting that we or our collaborators are in violation of law;

 

•

seek an injunction or impose civil or criminal penalties or monetary fines;

 

•

suspend or withdraw regulatory clearance, authorization or approval, or revoke a license or accreditation;

 

•

suspend any ongoing clinical studies;

 

•

delay or refuse clearance, authorization or approval of a pending regulatory submission or supplement submitted by us or our collaborators;

 

•

impose restrictions on our or our collaborators’ cleared, authorized, approved, accredited or licensed products or services;

 

•

seize or recall the product or service;

 

•

partially suspend or entirely shut down our or our collaborators’ manufacturing or laboratory operations;

70

 

 

•

issue advisories or other field actions;

 

•

impose operating restrictions;

 

•

refuse to allow us or our collaborators to enter into supply contracts, including government contracts; or

 

•

refer matters to the DOJ or other enforcement or regulatory bodies.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our and our collaborators’ ability to commercialize any cleared, authorized or approved products and services and generate revenues.

If any of our diagnostic products or services cause or contribute to a death or serious injury, or malfunction in certain ways, we will be required to report such death, serious injury or malfunction under applicable medical device reporting regulations, and such events can result in voluntary corrective actions or agency enforcement actions.

Under FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or one of our similar devices were to recur. If such a death, serious injury or malfunction were to occur, and we or our collaborators are unable to demonstrate that the adverse events were caused by factors other than our or our collaborator’s products and services, regulatory authorities could order us to cease further development of, or deny clearance, authorization or approval of, any of our or our collaborators’ products and services for any or all targeted indications. Even if we and our collaborators are able to demonstrate that any serious adverse events are not related to our products and services, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we or our collaborators elect, or are required, to delay, suspend or terminate any clinical trial of any product in development, the commercial prospects of such product in development may be harmed and our ability to generate product revenues may be delayed or eliminated. Any of these occurrences may harm our and our collaborators’ ability to identify and develop future products and services, and may significantly harm our business, financial condition, result of operations and prospects.

71

We are subject to various laws and regulations, such as healthcare fraud and abuse laws, false claim laws and health information privacy and security laws, among others, and failure to comply with these laws and regulations may have an adverse effect on our business.

Healthcare providers, physicians, hospitals and third-party payors often play a primary role in the recommendation and prescription of any currently marketed products and services for which we may obtain clearance, authorization or approval. Our current and future arrangements with healthcare providers, physicians, hospitals and third-party payors, and our sales, marketing and educational activities related to our products and services, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations at the federal and state level that may constrain our business or financial arrangements, and the relationships through which we market, sell and distribute our products and services. In addition, our operations are also subject to various federal and state fraud and abuse, physician payment transparency, and privacy and security laws, including, without limitation:

 

•

The AKS, which prohibits, among other things, persons and entities, including clinical laboratories, from knowingly and willfully soliciting, receiving, offering or paying remuneration, whether directly or indirectly, overtly or covertly, in case or in kind, to induce or reward or in return for either the referral of an individual or the purchase, lease, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program such as Medicare or Medicaid. The AKS has been interpreted broadly to apply to, among other things, arrangements between clinical laboratories and prescribers and purchasers of our tests. The term “remuneration” expressly includes kickbacks, bribes or rebates and has been broadly interpreted to include anything of value, including gifts, discounts, waivers of payment, ownership interests and any goods or services provided at less than their fair market value. There are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, these exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. The failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of the facts and circumstances to determine whether one purpose of the remuneration in the arrangement was to induce referrals or generate business that is payable by a federal healthcare program. A violation of the AKS may be grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the False Claims Act. Moreover, certain AKS safe harbors currently protecting rebates paid by device manufacturers to third parties and other arrangements between device manufacturers and third parties may later be modified or repealed pursuant to a pending regulatory proposal, which could require us to revisit or modify our business practices. Our practices may not meet all of the criteria for safe harbor protection from AKS liability in all cases. A person or entity does not need to have actual knowledge of the AKS or specific intent to violate any AKS provisions to have committed a violation. In addition, renumeration may not be offered or provided to beneficiaries under the vili monetary penalty law provision prohibiting inducements to beneficiaries.

 

•

Section 8122 of the SUPPORT Act, EKRA, which establishes an all-payor anti-kickback prohibition that extends to arrangements with recovery homes, clinical laboratories and clinical treatment facilities. EKRA includes a number of statutory exceptions, and directs agencies to develop further exceptions. Current EKRA exceptions in some cases reference, and in others differ from, the AKS safe harbors. Significantly, the EKRA prohibitions apply to the soliciting or receipt of remuneration for any referrals to recovery homes, clinical treatment facilities or clinical laboratories, whether or not related to the treatment of substance use disorders. Further, the EKRA prohibitions cover the payment or offer of remuneration to induce a referral to, or in exchange for, an individual using the services of such providers. EKRA creates additional risk that relationships with referral sources could be problematic.

 

•

Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment to, or approval by, the federal government that are false, fictitious or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes “any request or demand” for money or property presented to the federal government. The False Claims Act also permits a private individual acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery. In addition, AKS violations implicate the False Claims Act. Conduct that results in a False Claims Act violation may also implicate various federal criminal statutes.

72

 

•

The Criminal Health Care Fraud Statute, which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the AKS, a person or entity does not need to have actual knowledge or specific intent to violate the Criminal Health Care Fraud Statute.

 

•

The Stark Law, which is directed at “self-referral,” prohibits, with certain exceptions, referrals for certain DHS, including laboratory services, that are covered by Medicare and Medicaid by physicians who personally, or through a family member, have an investment or ownership interest in, or a compensation arrangement with, an entity performing the tests. The prohibition also extends to payment for any testing referred in violation of the Stark Law. Because the Stark Law is a strict liability statute, proof of specific intent to violate the law is not a required element of a violation. Any person who engages in a scheme to circumvent the Stark Law’s referral prohibition may be fined up to $100,000 for each such arrangement or scheme. In addition, any person who presents or causes to be presented a claim to Medicare or Medicaid in violation of the Stark Law is subject to civil monetary penalties of up to $15,000 per bill submission, an assessment of up to three times the amount claimed and possible exclusion from participation in federal governmental payor programs, and those claims are considered false claims for which the parties to the arrangement may be liable under the False Claims Act. Bills submitted in violation of the Stark Law may not be paid by Medicare or Medicaid, and any person collecting any amounts with respect to any such prohibited bill is obligated to refund such amounts. Many states have comparable laws that are not limited to Medicare and Medicaid referrals. The Stark Law also places an annual cap on the amount of non-monetary compensation, which consists of meal spend and educational items, that a company can spend on a physician in the aggregate. This annual cap requires careful tracking and coordination and if it is exceeded, as long as the amount exceeded is less than 50% of the total annual cap and is recouped from the physician within 180 calendar days or before the end of the calendar year, it is not a violation. This “return” option may only be used once every three years with respect to the same referring physician. We occasionally enter into financial relationships, usually compensation relationships, such as a consulting arrangement, with physicians who refer patients for testing. If these arrangements do not meet the Stark Law’s requirements, any claims submitted to Medicare or Medicaid could violate the law and put both the physician referral source and us at risk.

 

•

The administrative simplification provisions of HIPAA, as amended and supplemented by HITECH, impose, among other things, obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of protected health information (“PHI”) held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and their respective business associates. Among other things, HITECH made certain aspects of HIPAA’s rules, notably the “HIPAA Security Rule,” directly applicable to business associates, independent contractors or agents of covered entities that create, receive, maintain or transmit PHI in connection with providing a function on behalf of, or a service to, a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA regulation and seek attorneys’ fees and costs associated with pursuing federal civil actions. The HHS Office for Civil Rights (“OCR”) has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. The OCR has recently increased both its efforts to audit HIPAA compliance and its level of enforcement, with one recent penalty exceeding $16 million.

 

•

GINA, which restricts employers and health insurance companies from requiring or using the results of genetic tests in specific contexts and does not provide a private right of action. A number of states have also adopted laws regarding genetic tests, some aligned with GINA and some with broader applicability, including granting broader rights to individuals and imposing strict obligations on organizations to safeguard genetic data and the results of any such testing.

 

•

The Physician Payments Sunshine Act created under the ACA, and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children’s Health Insurance Program, with certain exceptions, to annually report to HHS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The Physician Payments Sunshine Act has been extended to payments and transfers of value to physician assistants, nurse practitioners and other mid-level healthcare providers, with reporting requirements going into effect in 2022 for payments and transfers of value made to these practitioners in 2021. In addition, certain state and local laws may impose additional transparency and healthcare compliance requirements on medical device manufacturers, as well as certain restrictions or limits on interactions with healthcare professionals.

73

 

•

The FTCA, which the FTC interprets to require taking appropriate steps to secure consumers’ personal information and considers the failures to do so to constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTCA. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards, and the FTC’s guidance for appropriately securing consumers’ personal information is consistent with what is required by the HIPAA Security Rule. Some states, most notably Massachusetts and Nevada, also have adopted laws requiring the implementation of security measures to protect personal information, and all 50 states and the District of Columbia, Puerto Rico and Guam, have adopted breach notification laws.

 

•

Analogous state laws and regulations, such as state anti-kickback, self-referral and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and in some cases even in self-pay scenarios. In addition, some state laws require life sciences companies to comply with the industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to impose transparency requirements or restrictions on marketing activities.

 

•

Various state, federal and foreign laws and regulations govern our ability to communicate, prospect, advertise and market our products and services through email, phone, text messages, facsimile and online methods.

Because of the breadth of these laws and the narrowness of the exceptions and safe harbors available under them, it is possible that certain of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of the ongoing interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that business arrangements with third parties comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert management’s attention from our business.

If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private qui tam actions brought by individual whistleblowers in the name of the government and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.

Our collection, use and disclosure of personal information, including health and employee information, is subject to state, federal and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm.

The privacy and security of personal information stored, maintained, received or transmitted, including electronically, is a major issue in the United States and abroad. While we strive to comply with all applicable privacy and security laws and regulations, including, in our case, our own posted privacy policies, legal standards for privacy, including but not limited to “unfairness” and “deception,” as enforced by the FTC and state attorneys general, these laws and regulations continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause us to lose customers, which could have a material adverse effect on our business. Recently, there has been an increase in public awareness of privacy issues in the wake of revelations about the data-collection activities of various government agencies and in the number of private privacy-related lawsuits filed against companies (including a private right of action under the CCPA and other similar state laws, as described below). Concerns about our practices with regard to the collection, use, retention, disclosure or security of personal information or other privacy-related matters, even if unfounded and even if we are in compliance with applicable laws, could damage our reputation and harm our business. Additionally, we receive personal information, including PHI from third parties, and if such third parties breach their representations to us regarding their compliance with applicable privacy and security laws, we could be exposed to proceedings or actions by government agencies or others.

Numerous foreign, federal and state laws and regulations govern the collection, dissemination, use and confidentiality of personal information, including genetic, biometric and health information, including state privacy, data security and breach notification laws, federal and state consumer protection and employment laws, HIPAA, GINA, the GDPR and other foreign data protection laws. These laws and regulations are increasing in complexity and number, may change frequently and sometimes conflict.

74

The HIPAA privacy, security and breach notification regulations, including the expanded requirements under HITECH, establish comprehensive federal standards with respect to the uses and disclosures of PHI by health plans, healthcare providers, including laboratories, and healthcare clearinghouses, in addition to setting standards to protect the confidentiality, integrity and security of PHI. The regulations establish a complex regulatory framework on a variety of subjects, including:

 

•

the circumstances under which uses and disclosures of PHI are permitted or required without a specific authorization by the patient;

 

•

a patient’s rights to access, amend and receive an accounting of certain disclosures of PHI;

 

•

requirements to notify individuals if there is a breach of their unsecured PHI;

 

•

the contents of notices that must be provided to patients regarding our privacy practices for PHI;

 

•

administrative, technical and physical safeguards required of entities that use or receive PHI; and

 

•

the safeguarding of PHI.

Penalties for violations of these laws vary. For instance, penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include civil monetary penalties of up to $58,490 per violation, which cap has been increased to account for inflation, not to exceed approximately $1.75 million per calendar year, for each provision of HIPAA that is violated and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and imprisonment. However, a single breach can result in findings of violations of multiple provisions, leading to possible penalties in excess of $1.75 million for violations in a calendar year. Any person who knowingly obtains or discloses PHI in violation of HIPAA may face a criminal penalty of up to $50,000 and up to one year of imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious harm. In addition, responding to government investigations or related third-party private rights of action regarding alleged violations of these and other laws and regulations, even if they ultimately result in no findings of violations or no penalties imposed, can consume our resources and impact our business and, if public, harm our reputation.

Computer networks are vulnerable to breach and unauthorized persons may in the future be able to exploit weaknesses in the security systems of our computer networks and gain access to PHI. Additionally, we share PHI with third-party contractors, and while they are contractually obligated under business associate agreements to safeguard and maintain the confidentiality of PHI, their indemnification of us would not insulate us from reputational harm. Unauthorized persons may be able to gain access to PHI stored in such third-party contractors’ computer networks. Any wrongful use or disclosure of PHI by us or our third-party contractors, including disclosure due to data theft or unauthorized access to our or our third-party contractors’ computer networks, could subject us to fines or penalties that could adversely affect our business and results of operations. Although HIPAA and the regulations promulgated thereunder do not provide for a private right of action, we could incur damages under state laws to private parties for the wrongful use or disclosure of confidential health information or other private personal information.

Further, various states, such as California, New York and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personal information. These laws and regulations are not necessarily preempted by HIPAA, but they have a wider scope and afford greater protection to individuals than HIPAA. Where state laws are more protective, we and our collaborators must comply with the stricter provisions where they apply. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our customers and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy, security and data use issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our immune medicine platform and related products and services could intensify. Changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as PHI, along with increased customer demand for enhanced data security infrastructure, could greatly increase the cost of providing our products and services, decrease demand for our products and services, reduce our revenue and subject us to additional liabilities.

We currently operate in some and may eventually operate in additional countries outside of the United States whose laws may in some cases be more stringent than the requirements in the United States. For example, the EU has specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the United States. In addition, some countries have stricter consumer notice or consent requirements relating to personal data collection, use or sharing, have more stringent requirements relating to organizations’ privacy programs and provide stronger individual rights.

75

Moreover, international privacy and data security regulations may become more complex and result in greater penalties. For instance, the GDPR governs the collection and use of personal data of data subjects in the EU and the EEA. The GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to obtain consent or other legal bases from individuals to process their personal data, provide robust disclosures to individuals, accommodate a set of individual data rights, provide data security breach notifications within 72 hours after becoming aware of the breach, limit retention of personal information and apply enhanced protections to health data and other special categories of personal data. The GDPR also applies to pseudonymized data, which is defined as “the processing of personal data in such a way that the data can no longer be attributed to a specific data subject without the use of additional information,” and imposes additional obligations when we contract with third-party processors in connection with the processing of any personal data. The GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data, could cause our costs to increase and could harm our financial condition. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to €20 million or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. Compliance with the GDPR requires us to put in place and maintain additional policies, procedures and documentation that may not have been required under the preceding framework, which may result in other substantial expenditures. This may be onerous and adversely affect our business, financial condition, results of operations and the profitability of our platform of products and services. Failure to comply with the GDPR and other countries’ privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with contracts entered into with our collaborators and other third-party payors, and have an adverse effect on our business and financial condition. Currently, the GDPR is only applicable to us as a processor, but as we continue to expand into the European market, the GDPR will have direct applicability to us as a controller.

The GDPR also imposes strict rules on the transfer of personal data out of the EU to the United States. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. In addition, these rules are consistently under scrutiny. In July 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-US Privacy Shield, effective immediately, one of the methods for transfers of personal data into the US. The CJEU found that under US surveillance laws, the US government has access to personal data that does not provide Europeans with privacy protections equivalent with the level of protection required under EU law and required companies based outside of the EU/EEA to implement additional protective measures to safeguard data from the EU/EEA. Furthering these requirements, the European Commission published a revised set of Standard Contractual Clauses in June 2021, which replace the former Standard Contractual Clauses on all existing transfers by December 2022 and impose additional technical and organizational measures on companies. Despite these recent changes, there is continued uncertainty in this area given that EU supervisory authorities are increasingly fining companies based in the United States for data transfers. In addition, given the CJEU’s findings on US surveillance laws, a future case might deem transfers to the United States based on Standard Contractual Clauses invalid because they fail to meet that "essentially equivalent to that guaranteed within the EU" standard.

In addition to the GDPR, we continue to expand our business into several jurisdictions that have data privacy laws or begin to develop new data privacy laws. Organizations operating in Canada and covered by the Personal Information Protection and Electronic Documents Act (“PIPEDA”), or equivalent Canadian provincial laws, must obtain an individual’s consent when they collect, use or disclose that individual’s personal information. Individuals have the right to access and challenge the accuracy of their personal information held by an organization, and personal information may only be used for the purposes for which it was collected. If an organization intends to use personal information for another purpose, it must again obtain that individual’s consent.

Because of the breadth of these data protection laws and the narrowness of their exceptions and safe harbors, it is possible that our business or data protection policies could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of heightened regulatory focus on data privacy and security issues. If our operations are found to be in violation of any of the data protection laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private qui tam actions brought by individual whistleblowers in the name of the government, class action litigation and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corrective action plan or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.

76

In addition, the interpretation and application of consumer, health-related and data protection laws, especially with respect to genetic samples and data, in the United States, the EU and elsewhere, are changing and are also often uncertain, contradictory and in flux. Within the United States, an increasing number of states have been and continue to add privacy bills to their legislative calendars each year. While not all of these bills become law, they add significant uncertainty about additional obligations or potential penalties. There are parallel activities at the federal level, with proposed rulemaking related to the FTC Act and HIPAA underway, as well as the potential of a federal privacy law similar to the GDPR. There are similar trends at the international level, with potential new laws, as well as interpretation of existing laws (e.g., GDPR) that may impact Adaptive’s operations. These uncertainties are confounded by parallel changes in laws adjacent to privacy, such as those impacting machine learning and artificial intelligence or data use, and we may incur substantial expense or experience disruption as related to compliance with these laws, which would adversely affect our ability to conduct our business.

Security breaches, loss of data and other disruptions could compromise confidential, personal and sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.

In the ordinary course of our business, we and our collaborators collect and store sensitive data, including PHI, personal information, credit card and other financial information, intellectual property and proprietary business information owned or controlled by ourselves or our customers, third-party payors, our collaborators, government entities, insurance companies and other parties. We manage and maintain our applications and data through a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage components of our data centers. We also transmit sensitive data, including patient data, telephonically, through our website and pursuant to arrangements with multiple third-party vendors and their subcontractors. These applications and data encompass a wide variety of critical business information, including research and development information, patient data, commercial information and financial information. We face a number of risks related to protecting this critical information, including loss-of-access risk, unauthorized access, use, disclosure or modification, and the risk of our inability to adequately monitor, audit and modify our respective control over our critical information. This risk extends to the data we entrust to the third-party vendors and subcontractors that help us manage this sensitive data or otherwise process it on our behalf.

The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive and proprietary data from unauthorized access, use or disclosure, no security measures can be perfect and our respective information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, liability under federal or state laws that protect the privacy of personal information, such as HIPAA or HITECH, and regulatory penalties. Notice of breaches may be required to be provided to affected individuals, the Secretary of HHS or other federal, state and foreign regulators, the media or state attorneys general. Such a notice could harm our reputation and ability to compete. Although we have implemented security measures and formal, dedicated enterprise security programs to prevent unauthorized access to patient and other personal data, such data is currently accessible through multiple channels and we may experience one or more data breaches. Unauthorized access, loss or dissemination could also disrupt our operations and damage our reputation, which could adversely affect our results of operations and financial condition.

No TCR-based cellular therapies have been approved in this new potential category of medicines and may never be approved as a result of efforts by others or us. TCR-based cellular therapy drug discovery has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of immune medicines.

As a potential new category of medicines, no TCR-based cellular therapies have been approved to date by the FDA or other regulatory agency. Successful discovery and development of TCR-based cellular therapies by us and our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our and their control. We and our collaborators have made and will continue to make a series of business decisions and take calculated risks to advance our development efforts and pipeline of immune-driven therapeutic product candidates, including those related to TCR-based cellular therapies, delivery technology and manufacturing processes, which may be shown to be incorrect based on further work by us, our collaborators or others. Our cellular therapeutics product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic, experience clinical holds or fail to reach the market for many reasons, including:

 

•

discovery efforts identifying potential TCR-based cellular therapies may not be successful;

 

•

nonclinical or preclinical study results may show potential TCR-based cellular therapies to be less effective than desired or to have harmful or problematic side effects;

 

•

clinical trials may fail to meet one or more endpoints, or results may show the TCR-based cellular therapies to be less effective than expected or to have unacceptable side effects or toxicities;

77

 

•

adverse effects relating to any one of our therapeutic product candidates or adverse effects relating to our TruTCR process may lead to delays in or termination of one or more of our products or services;

 

•

the inability of our translational models to reduce risk or predict outcomes in humans, given that each component of our therapeutic product candidates may have a dependent or independent effect on safety, tolerability and efficacy, and that such effects may, among other things, be species-dependent;

 

•

manufacturing failures or insufficient supply of current good manufacturing practices (“cGMP”) materials for future clinical trials, or higher than expected cost, could delay or set back clinical trials or make TCR-based cellular therapies commercially unattractive;

 

•

our collaborators’ improvements in the manufacturing processes for this new class of potential immune medicines may not be sufficient to satisfy the clinical or commercial demand of our jointly developed TCR-based cellular therapies or regulatory requirements for clinical trials;

 

•

changes that we or our collaborators make to optimize manufacturing, testing or formulating of cGMP materials could impact the safety, tolerability and efficacy of our therapeutic products in development;

 

•

pricing or reimbursement issues or other factors that delay clinical trials or make any TCR-based cellular therapies uneconomical or noncompetitive with other immunotherapies;

 

•

failure to timely advance our or our collaborators’ therapeutic products or receive the necessary regulatory clearances, authorizations or approvals or a delay in receiving such clearances, authorizations or approvals due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, Biologics License Application or the equivalent application, discussions with the FDA or the European Medicines Agency, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding; and

 

•

the proprietary rights of others and their competing products and services that may prevent our TCR-based cellular therapies from being commercialized or threaten future commercialization activities.

Risks Relating to our Intellectual Property

We may not be successful in obtaining or maintaining sufficient intellectual property protection for our products, services and technologies and uses thereof, and the scope of the intellectual property protection obtained may not be sufficiently broad.

As is the case with other companies engaged in the life sciences industry, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or license from third parties, particularly patents, in the United States and other countries with respect to our products, services and technologies. We rely on patent protection in addition to trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or enable us to gain or maintain any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.

To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate barriers to competition, our competitive position could be adversely affected, as could our business.

We apply for or in-license patents covering our products and technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing patents is costly, time-consuming and complex, and we may fail to apply for patents on important products, services and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications or to maintain the rights to patents licensed from third parties. Consequently, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

As of December 31, 2021, we own or have rights to 471 active patents and patent applications filed in the United States, Europe and elsewhere. Of these, there are 51 pending patent applications and 420 granted patents. Our pending patent applications may not result in issued patents in a timely fashion or at all. Even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is also possible that others will design around our current or future patented technologies.

78

Some of our patents, licensed patents or patent applications may be challenged in the future, and we may not be successful in defending any such challenges. For example, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (“USPTO”), or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights. Any successful third-party challenge to our patents could result in patent claims being narrowed, or patents being invalidated or held unenforceable, in whole or in part, which could lead to increased competition to our business. Conversely, we may have to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products or services. The patent positions of biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Inconsistent policies regarding the eligibility for patent protection and the breadth of patentable claims in such companies’ patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of methods and compositions of matter useful in relation to immunosequencing.

The patent position of companies engaged in the development and commercialization of clinical diagnostic tests, like our clonoSEQ diagnostic test and T-Detect products, are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the eligibility and scope of patentability of certain inventions or discoveries relating to certain diagnostic tests and related technology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular immune receptors and cancer) may not be patentable. Precisely what constitutes a law of nature is uncertain, and it is possible that certain aspects of our clinical diagnostics would be considered natural laws. The evolving case law in the United States may adversely affect our ability to obtain patents or defend patents we have obtained or have licensed and may facilitate third-party challenges to any owned or licensed patents. The laws of some foreign countries do not protect intellectual property rights to the same extent or for the same subject matter as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on our products and services in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

79

Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products and services.

Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, a third party that files a patent application before us could be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either file any patent application related to our products or services or invent any of the inventions claimed in our or our licensor’s patents or patent applications.

Third parties may also submit prior art to the USPTO during patent prosecution to attack the validity of a patent and it is also possible in the United States and other countries for third parties to challenge granted patents through Patent Office proceedings such as, in the United States, post-grant review, inter partes review and derivation proceedings. In the United States, a lower evidentiary standard is imposed in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim. As such, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents could have a material adverse effect on our business.

Recent U.S. Supreme Court rulings have also narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including with respect to naturally occurring biological molecules such as the immune cell receptors which are a focus of our immune medicine platform. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

Issued patents covering our products and services could be found invalid or unenforceable if challenged.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in the United States and abroad, in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Additionally, if we and our licensing partners initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our products or technologies, the defendant could counterclaim that the patent covering our product is invalid or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. In addition, the United States now awards patent priority to the first party to file a patent application, and others may submit patent claims covering our inventions prior to us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. A successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, which could have a material adverse impact on our business. Furthermore, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products and services.

We may not be aware of all third-party intellectual property rights potentially relating to our immune medicine platform, products and services. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management’s attention and resources.

80

We rely on licenses from third parties in relation to certain products and services and if we lose these licenses then we may be subjected to future litigation.

We are a party to license agreements that grant us rights to use certain intellectual property, including patents and patent applications, typically in certain specified fields of use. Some of those licensed rights could provide us with freedom to operate for aspects of our products and services. We may need to obtain additional licenses from others to advance our research, development and commercialization activities.

Our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.

Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

Moreover, disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:

 

•

the scope of rights granted under the license agreement and other interpretation-related issues;

 

•

whether, and the extent to which, our products, services, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

 

•

our right to sublicense patent and other rights to third parties under collaborative development relationships;

 

•

our diligence obligations under the license agreement and what activities satisfy those diligence obligations;

 

•

the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and

 

•

the priority of invention of patented technology.

If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements.

In addition, the agreements under which we currently license intellectual property or technology from third parties are complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize any affected products or services, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.

Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs to us and distract our management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys’ fees, costs and expenses and royalties or be enjoined from selling our products or services, which could adversely affect our ability to offer products or services, our ability to continue operations and our financial condition.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to patent protection, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, collaborators, academic institutions, life sciences research partners and, when needed, our advisers as well as other third parties. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.

81

For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.

We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems. Besides the possibility that these security measures could be breached, such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may also not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.

Certain former employees have obtained employment with companies or academic institutions that could be considered competitive with us. This competition may be limited by contractual provisions which may or may not be enforceable by us in certain jurisdictions. In addition, we may not be aware of such competitive employment arrangements until after our trade secrets have been disclosed to potentially competitive companies.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We employ, and expect to employ in the future, individuals who were previously employed at universities or other companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential products and services, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.

We may not be able to protect and enforce our trademarks.

We have not yet registered certain of our trademarks in all of our potential markets, although we have registered Adaptive Biotechnologies, clonoSEQ, immunoSEQ, pairSEQ and TruTCR in the United States, the EU and a number of other countries and are seeking to register additional trademarks, including our new corporate logos, certain slogans, T-Detect and TruAB for our antibody development program. As we apply to register our unregistered trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In certain countries outside of the United States, trademark registration is required to enforce trademark rights. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Ownership disputes may arise, for example, from conflicting obligations of employees, consultants or others who are involved in developing our future products and services. Our co-founder, Dr. Harlan Robins, had dual employment with Fred Hutch and us until June of 2019, and accordingly has had obligations to assign his rights to inventions to either Fred Hutch or us depending on how and where the inventions were conceived, reduced to practice, developed or created. Disputes may arise in the future between Fred Hutch and us regarding ownership of intellectual property generated by Dr. Robins’ work. Fred Hutch may claim to have ownership rights to our intellectual property.

82

Litigation may be necessary to defend against these and other claims by a third party challenging inventorship of our or our licensors’ ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product or services. Alternatively, we may need to obtain one or more additional licenses from the third party which will be time-consuming and expensive and could result in substantial costs and diversion of resources and could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our development and commercialization efforts of our products and services.

There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the life sciences, clinical diagnostics and drug discovery industries, including patent infringement lawsuits, declaratory judgment litigation and adversarial proceedings before the USPTO, including interferences, derivation proceedings, ex parte reexaminations, post-grant review and inter partes review, as well as corresponding proceedings in foreign courts and foreign patent offices.

We are currently involved in appeals from Opposition Proceedings at the European Patent Office related to three of our patents: EP2364368, EP2387627, and EP3059337. We may, in the future, become involved with litigation or actions at the USPTO or foreign patent offices with various third parties. We expect that the number of such claims may increase as our industry expands, more patents are issued, the number of products or services increases and the level of competition in our industry increases. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management’s time and attention from the development of our business, requiring the payment of monetary damages (including treble damages, attorneys’ fees, costs and expenses) or royalty payments.

It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any such litigation might not be favorable to us, and even if we were to prevail, such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.

As we move into new markets and expand our products or services offerings, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection.

Third parties may assert that we are employing their proprietary technology without authorization. Given that clinical diagnostics and drug discovery fields are intense and highly competitive areas, there may be third-party intellectual property rights that others believe could relate to our immune medicine platform, products and services. We have been approached on four occasions with an offer from a third-party patent owner or licensee to license rights to us under patents relating to immune medicine. We have been contacted by Invivoscribe, Inc. regarding U.S. Pat. No. 7,785,783 on March 24, 2012; by Keygene NV regarding U.S. Pat. No. 9,453,256 on October 10, 2016; by MorphoSys AG regarding EP Patent 2243030 and U.S. Pat. No. 9,404,929 on October 10, 2018; and by DName-iT NV regarding EP Patent 2201143 and U.S. Pat. No. 8,318,434 in December 2018. In each instance, we have declined to pursue licenses to the patents and the matters have not been pursued further. One or more of these or other third-party patent owners or licensees may pursue or threaten to pursue litigation against us to enforce one or more patents. It would be costly and time-consuming to defend such claims.

83

Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future products, technologies and services may infringe. We cannot be certain that we have identified or addressed all potentially significant third-party patents in advance of an infringement claim being made against us. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our products or services infringes these patents. Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services and could result in the award of substantial damages against us, including treble damages, attorneys’ fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our products or services could materially affect our business and our ability to gain market acceptance for our products or services.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.

In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.

Patent terms may be inadequate to protect our competitive position on our products and services for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products and services are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new products and services, patents protecting such products and services might expire before or shortly after such products and services are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

Risks Relating to our Common Stock

The market price of our common stock is volatile and is likely to continue to fluctuate substantially.

The market price of our common stock has been and is likely to continue to be highly volatile and may fluctuate substantially due to many factors, many of which are beyond our control. These factors include:

 

•

the commencement or termination of our collaborations;

 

•

the timing of achievement of specified milestones in the development of our products and services;

 

•

introductions of new or expanded products or services or new pricing policies by us or by our competitors;

 

•

changes in the status of our regulatory clearances, authorizations, approvals or applications, or those jointly developed with our collaborators;

 

•

where required, the results of clinical trials of our future products and services, those jointly developed with our collaborators or those of our competitors;

 

•

the success of competitive products or technologies;

 

•

announcements by us or our competitors of significant acquisitions, collaborators or divestitures;

84

 

 

•

changes in governmental regulations and regulatory or legal developments in the United States and other countries;

 

•

developments or disputes concerning patent applications, issued patents or other proprietary rights;

 

•

the recruitment or departure of key personnel;

 

•

actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

 

•

variations in our financial results or those of companies that are perceived to be similar to us;

 

•

changes in the structure of healthcare payment systems;

 

•

market conditions in the life sciences, clinical diagnostics or drug discovery industry;

 

•

general economic, industry and market conditions;

 

•

sales of our securities, including sales by our directors, officers or significant shareholders;

 

•

speculation about our business in the media or the investment community; and

 

•

other factors, including factors unrelated to our operating performance or the operating performance of our competitors.

In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. If the market for stock in our industry or the stock market in general experiences uneven investor confidence, the market price of our common stock could decline for reasons unrelated to our business, operating results or financial condition. The market price of our common stock might also decline in reaction to events that affect other companies within, or outside, our industry even if these events do not directly affect us. Any decline in the market price of our common stock may impair our ability to raise capital through the sale of equity securities.

In the past, securities class action litigation has often been instituted against companies following periods of volatility in their stock price. This type of litigation, if instituted against us, could result in substantial costs to us and divert our management’s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.

If securities analysts do not publish research or reports about our business, or we are the subject of negative publicity, the price of our stock could decline.

The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not control these analysts. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable evaluations of our company or our stock, the price of our stock could decline. If one or more of these analysts cease coverage of our company or fail to publish reports covering our company regularly, our stock may lose visibility in the market, which in turn could cause our stock price to decline. In addition, if we are the subject of negative publicity, whether from an analyst, academic, industry group or the general or financial press, our stock price may decline.

If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock and potentially impair our ability to raise capital through the sale of equity securities.

85

Substantial future sales or perceived potential sales of our common stock or other equity securities in the public market could cause the price of our common stock to decline significantly.

Sales of substantial amounts of our common stock or other equity securities in the public market, particularly by our directors, executive officers and significant shareholders, including upon the expiration of any lock-up periods entered into in connection with offerings of our common stock or other equity securities, or the perception that these sales could occur, could materially and adversely affect the price of our common stock and impair our ability to raise capital through the sale of equity securities.

We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared.

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”), we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Our compliance with Section 404 necessitates that we incur substantial accounting expense and expend significant management efforts. We will continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.

We are also required to maintain disclosure controls and procedures. Disclosure controls and procedures means our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. We do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. We believe a control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

Provisions in our charter documents and Washington law could make an acquisition of our company more difficult and limit attempts by our shareholders to replace or remove our current management.

Our amended and restated articles of incorporation (“Articles of Incorporation”) and our amended and restated bylaws (“Bylaws”), as well as Washington law, contain provisions that may have the effect of deterring takeovers or delaying or preventing a change in control of us or changes in our management that a shareholder might deem to be in his or her best interest. Our Articles of Incorporation and Bylaws contain provisions that:

 

•

authorize “blank check” preferred stock, which could be issued by our board of directors without shareholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;

 

•

create a classified board of directors whose members serve staggered three-year terms, with one class being elected each year by our shareholders;

 

•

specify that special meetings of our shareholders can be called only by our board of directors, the Chairperson of our board of directors, our chief executive officer or our president;

 

•

provide that a director may only be removed from the board of directors for cause and then only by the affirmative vote of our shareholders;

 

•

provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even if less than a quorum;

 

•

specify that only our board of directors may change the size of our board of directors;

 

•

establish an advance notice procedure for shareholder proposals to be brought before an annual meeting of our shareholders, including proposed nominations of persons for election to our board of directors;

 

•

specify that no shareholder is permitted to cumulate votes at any election of directors;

86

 

 

•

expressly authorize our board of directors to modify, alter or repeal our Bylaws; and

 

•

require supermajority votes of the holders of our common stock to amend specified provisions of our Articles of Incorporation and Bylaws.

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management or our board of directors.

In addition, because we are incorporated in the State of Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act (“WBCA”), which prohibits certain business combinations between us and certain significant shareholders unless specified conditions are met. These provisions may also have the effect of delaying or preventing a change in control of our company.

Any provision of our Articles of Incorporation or Bylaws or Washington law that has the effect of delaying or deterring a change in control could limit the opportunity for our shareholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.

Our Articles of Incorporation provide that the state courts located in King County, Washington and, to the extent enforceable, the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our shareholders, which could limit our shareholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

Our Articles of Incorporation provide that, unless we consent in writing to the selection of an alternative forum, the state courts located in King County, Washington (or, if the state courts located within King County, Washington do not have jurisdiction, the federal district court for the Western District of Washington) shall be the sole and exclusive forum for commencing and maintaining any proceeding (1) asserting a claim based on a violation of a duty under the laws of the State of Washington by any of our current or former directors, officers or shareholders in such capacity, (2) commenced or maintained in the right of our corporation, (3) asserting a claim arising pursuant to any provision of the WBCA, our Articles of Incorporation or our Bylaws (as either may be amended from time to time) or (4) asserting a claim concerning our internal affairs that is not included in clauses (1) through (3) above, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.

Our Articles of Incorporation provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (“Securities Act”), subject to applicable law.

Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our shareholders will not be deemed to have waived our compliance with these laws, rules and regulations. These exclusive-forum provisions may limit a shareholder’s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees or cause shareholders to incur additional costs to bring claims in the forums designated in our Articles of Incorporation.

If a court were to find these exclusive-forum provisions in our Articles of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a jurisdiction other than those designated in the exclusive forum provision, and the provision may not be enforced by a court in that jurisdiction. It is unclear whether Washington courts would reach a similar conclusion under Washington law. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.

87

Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

Our Articles of Incorporation provide that we will indemnify our directors and officers to the fullest extent permitted by Washington law.

In addition, as permitted by Section 23B.08.510 through Section 23B.08.570 of the WBCA, our Articles of Incorporation and our indemnification agreements that we have entered into with most of our directors and officers provide that:

 

•

We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Washington law. Washington law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful;

 

•

We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;

 

•

We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;

 

•

The rights conferred in our Articles of Incorporation are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and

 

•

We may not retroactively amend our Articles of Incorporation provisions to reduce our indemnification obligations to directors, officers, employees and agents.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business, and do not anticipate paying any cash dividends on our common stock for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

Item 1B. Unresolved Staff Comments

Not applicable.

Item 2. Properties

Our newly occupied corporate headquarters is located in Seattle, Washington, where we lease approximately 100,000 square feet. The lease expires in August 2033, subject to our option to twice extend the lease for five years. Additionally, in two separate Seattle, Washington locations, we lease approximately 65,500 square feet pursuant to a lease that expires October 2032, subject to two options to extend the lease for five years, and approximately 14,750 square feet, pursuant to a lease expiring in October 2029, subject to our ability to exercise an early termination right in 2022. All of our Seattle, Washington locations contain office and laboratory space.

In 2021, we executed a lease to rent approximately 27,000 square feet of a warehouse in Bothell, Washington. The lease expires in October 2031, subject to an early termination option in 2028 and an option to twice extend the lease for five years.

We also lease approximately 33,300 square feet of laboratory and office space in South San Francisco, California, pursuant to an amended lease that expires March 2026, subject to our option to extend the lease for five years, and approximately 3,100 square feet of office space in New York City, New York, pursuant to a lease that expires November 2025, subject to our ability to exercise an early termination right in 2023.

We may add new facilities or expand existing facilities as we add employees and scale our operations, and we believe suitable additional or substitute space will be available as needed.

88

From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 4. Mine Safety Disclosures

Not applicable.

89

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information for Common Stock

Our common stock began trading on The Nasdaq Global Select Market under the symbol “ADPT” on June 27, 2019. Prior to that date, there was no public trading market for our common stock.

Holders of Record

As of February 10, 2022, there were approximately 100 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.

Dividend Policy

We currently intend to retain all available funds and any future earnings to fund the growth and development of our business. We do not intend to pay cash dividends to our shareholders in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. Our future ability to pay cash dividends on our common stock may also be limited by the terms of any future debt securities, preferred stock or credit facility.

Stock Performance Graph

The graph below compares the cumulative total shareholder return on our common stock with the cumulative total return on the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph assumes $100 was invested in our common stock at the market close on June 27, 2019, which was our initial trading day. Data for the NASDAQ Composite Index and the NASDAQ Biotechnology Index assume reinvestment of dividends. Our offering price of our common stock in our initial public offering, which had a closing stock price of $40.30 on June 27, 2019, was $20.00 per share. The stock price performance below is based upon historical data and is not necessarily indicative of, nor intended to forecast, future performance of our common stock.

 

This graph shall not be deemed to be “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Exchange Act or incorporated by reference into any filing of Adaptive Biotechnologies Corporation under the Securities Act or the Exchange Act.

Item 6. [Reserved]

Not applicable.

90

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes and the other financial information appearing elsewhere in this Annual Report on Form 10-K, as well as the other financial information we file with the SEC from time to time. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties relating to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

This section generally discusses 2021 and 2020 items and year-to-year comparisons between 2021 and 2020. Discussions of 2019 items and year-to-year comparisons between 2020 and 2019 may be found in Part II, Item 7 under the caption "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 24, 2021.

Overview

We are advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune disorders and infectious diseases.

Our immune medicine platform is the foundation for our expanding suite of products and services. The cornerstone of our platform and core immunosequencing product, immunoSEQ, serves as our underlying research and development engine and generates revenue from biopharmaceutical and academic customers. Our first clinical diagnostic product, clonoSEQ, is the first test authorized by the FDA for the detection and monitoring of MRD in patients with MM, ALL and CLL and is also available as a CLIA-validated LDT for patients with other lymphoid cancers. Leveraging our collaboration with Microsoft, we are creating the TCR-Antigen Map. We are using this map to develop research solutions by disease called immunoSEQ T-MAP and a diagnostic product for many diseases from a single blood test called T-Detect.

T-Detect COVID, for which we have received EUA, is designed to confirm past SARS-CoV-2 infection, the virus that causes COVID-19, and is also the first indication for the T-Detect product line. We expect to launch a second indication, T-Detect Lyme, during the 2022 Lyme season. In addition, we have confirmed signals in Crohn’s disease, celiac disease, and multiple sclerosis, as well as identified new signals in ulcerative colitis and rheumatoid arthritis.

Our therapeutic product candidates, being developed under the Genentech Agreement, leverage our platform to identify specific receptors on immune cells to develop into cellular therapies in oncology. We also extended our platform to identify highly potent neutralizing antibodies against SARS-CoV-2 and we believe this differentiated approach may be leveraged across multiple disease states.

For our life sciences research customers, we provide two categories of products and services using immunoSEQ. First, we provide immunosequencing services, the revenue from which we record as sequencing revenue. Second, we provide certain research customers professional support, for which we receive nonrefundable upfront or recurring payments. We may receive additional payments upon those customers achieving specified milestones. Revenue related to these activities are recorded as development revenue.

For our clinical diagnostics customers, we sell our clonoSEQ diagnostic test and T-Detect COVID test, which include our immunosequencing services and are thus recorded as sequencing revenue. In the future, we intend to sell other diagnostic products and services, including other indications for T-Detect, which we also expect to record as sequencing revenue.

For our current drug discovery collaborator, Genentech, we screen, identify and characterize TCRs in support of our collaboration. We record revenue from this collaboration as development revenue.

91

Historically, we have sold immunoSEQ as a fee-for-service offering. These research offerings have comprised the majority of our revenue to date, although our business is pursuing broader opportunities. As we continue to expand the use of our clonoSEQ diagnostic tests, develop and commercialize T-Detect and develop and commercialize therapeutic product candidates with our drug discovery collaborator, we expect our mix of revenue to shift to clinical products and services, which we believe will become our largest sources of revenue.

We are actively pursuing opportunities to deepen our relationships with current customers and initiate relationships with new customers. We have an experienced, specialty salesforce that is targeting department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors, research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. As MRD assessment becomes standard practice for patient management across a range of blood cancers, we believe it will be essential for clinicians and patients to have access to a highly accurate, sensitive and standardized MRD assessment tool. We are focused on establishing and maintaining collaborative relationships with payors, developing health economic evidence and building billing and patient access infrastructure to expand reimbursement coverage for our clinical diagnostics. We continue to seek expanded coverage of our clonoSEQ diagnostic test and have successfully expanded coverage through contractual agreements or positive medical policies with Medicare and several of the largest national private health insurers in the United States.

We recognized revenue of $154.3 million and $98.4 million for the year ended December 31, 2021 and 2020, respectively. Net loss attributable to Adaptive Biotechnologies Corporation was $207.3 million and $146.2 million for the year ended December 31, 2021 and 2020, respectively. We have funded our operations to date principally from the sale of convertible preferred stock and common stock and, to a lesser extent, sequencing and development revenue. As of December 31, 2021 and 2020, we had cash, cash equivalents and marketable securities of $570.2 million and $806.8 million, respectively.

Follow-On Offering

In July 2020, we completed an underwritten public offering of our common stock in which we issued and sold 7,200,000 shares of common stock at a public offering price of $40.00 per share. We received $271.8 million in net proceeds, after deducting underwriting discounts and net offering expenses paid by us.

Components of Results of Operations

Revenue

We derive our revenue from two sources: (1) sequencing revenue and (2) development revenue.

Sequencing revenue. Sequencing revenue reflects the amounts generated from providing testing services through clonoSEQ to clinical and research customers, from providing our T-Detect COVID test to clinical customers and from providing sequencing services through immunoSEQ to research customers.

For our clinical customers, we primarily derive revenue from providing our clonoSEQ report to ordering physicians. We bill medical institutions and commercial and government payors based on tests delivered to ordering physicians. Amounts paid for clonoSEQ diagnostic tests by medical institutions and commercial and government payors vary based on respective reimbursement rates and patient responsibilities, which may differ from our targeted list price. We recognize clinical revenue by evaluating customer payment history, contracted reimbursement rates, if applicable, and other adjustments to estimate the amount of revenue that is collectible.

For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and recognized either as we deliver our estimate of the remaining tests in a patient’s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.

For our research customers, which include biopharmaceutical customers and academic institutions, delivery of the sequencing results may include some level of professional support and analysis. Terms with biopharmaceutical customers generally include non-refundable upfront payments, which we record as deferred revenue. For all research customers, we recognize revenue as we deliver sequencing results. From time to time, we offer discounts in order to gain rights and access to certain datasets. Revenue is recognized net of these discounts and costs associated with these services are reflected in cost of revenue. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered.

92

Development revenue. Development revenue primarily represents regulatory or development support services that we provide to biopharmaceutical customers who seek access to our platform to support their therapeutic development activities. We enter into collaboration and similar agreements with these customers. These agreements may include substantial non-refundable upfront payments, which we recognize as development revenue over time as we perform the respective services. When the agreements include sequencing activities, we separately classify those activities as sequencing revenue. Additionally, we generate development revenue from the achievement of regulatory milestones.

During the year ended December 31, 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as development revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).

We expect revenue to increase over the long term, particularly as the mix of revenue migrates to clinical diagnostics and drug discovery. The pace by which this mix migrates will be determined by the level of customer adoption and frequency of use of our products and services. Our revenue may fluctuate from period to period due to the uncertain nature of delivery of our products and services, the achievement of milestones by us or our customers, timing of expenses incurred, changes in estimates of total anticipated costs related to our Genentech Agreement and other events not within our control, such as the delivery of customer samples or customer decisions to no longer pursue their development initiatives.

Due to the ongoing uncertainties related to the COVID-19 pandemic, we may experience variability in revenue in the near term as our customers’ abilities to procure samples for their research initiatives change, as customer initiatives evolve and as clinical testing is impacted by the pandemic.

Cost of Revenue

Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs and allocated facility costs associated with processing samples and professional support for our sequencing revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition. As such, cost of revenue and related volume does not always trend in the same direction as revenue recognition and related volume. Additionally, costs to support our Genentech Agreement are a component of our research and development expenses.

We expect cost of revenue to increase in absolute dollars as we grow our sequencing volume and make increased investments in laboratory automation and facilities, but the cost per sample to decrease over the long term due to the efficiencies we may gain as sequencing volume increases from improved utilization of our laboratory capacity, automation and other value engineering initiatives. If our sample volume throughput is reduced as a result of the COVID-19 pandemic or otherwise, cost of revenue as a percentage of total revenue may be adversely impacted due to fixed overhead costs.

Research and Development Expenses

Research and development expenses consist of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. We are currently conducting research and development activities for several products and services and we typically use our laboratory materials, personnel, facilities, information technology and other development resources across multiple development programs. Additionally, certain of these research and development activities benefit more than one of our product opportunities. We do not track research and development expenses by specific product candidates.

A component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. Additionally, the costs to support our Genentech Agreement are a component of our research and development expenses. Some of these activities have generated and may in the future generate development revenue.

We expect our research and development expenses to continue to increase in absolute dollars as we innovate and expand the application of our platform. However, we expect research and development expenses to decrease as a percentage of revenue in the long term, although the percentage may fluctuate from period to period due to the timing and extent of our development and commercialization efforts.

93

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs, such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.

We expect our sales and marketing expenses to increase in absolute dollars as we expand our commercial sales, marketing and business development teams and increase marketing activities to drive awareness and adoption of our products and services. However, we expect sales and marketing expenses to decrease as a percentage of revenue in the long term, subject to fluctuations from period to period due to the timing and magnitude of these expenses.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel-related expenses (including salaries, benefits and share-based compensation) for our personnel in executive, legal, finance and accounting, human resources and other administrative functions, including third-party billing services. In addition, these expenses include insurance costs, external legal costs, accounting and tax service expenses, consulting fees and allocated facility costs.

We expect our general and administrative expenses to continue to increase in absolute dollars as we increase headcount. Though expected to increase in absolute dollars, we expect these expenses to decrease as a percentage of revenue in the long term as revenue increases.

94

Statements of Operations Data and Other Financial and Operating Data

The following table sets forth our statements of operations data and other financial and operating data for the periods presented:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

 

(in thousands, except share and per share amounts)

 

Statements of Operations Data:

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Sequencing revenue

 

$

78,896

 

 

$

41,439

 

 

$

43,519

 

Development revenue

 

 

75,448

 

 

 

56,943

 

 

 

41,552

 

Total revenue

 

 

154,344

 

 

 

98,382

 

 

 

85,071

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

49,301

 

 

 

22,530

 

 

 

22,274

 

Research and development

 

 

142,343

 

 

 

116,072

 

 

 

70,705

 

Sales and marketing

 

 

95,465

 

 

 

61,358

 

 

 

38,453

 

General and administrative

 

 

74,502

 

 

 

49,536

 

 

 

30,332

 

Amortization of intangible assets

 

 

1,699

 

 

 

1,703

 

 

 

1,698

 

Total operating expenses

 

 

363,310

 

 

 

251,199

 

 

 

163,462

 

Loss from operations

 

 

(208,966

)

 

 

(152,817

)

 

 

(78,391

)

Interest and other income, net

 

 

1,668

 

 

 

6,590

 

 

 

9,785

 

Net loss

 

 

(207,298

)

 

 

(146,227

)

 

 

(68,606

)

Add: Net loss attributable to noncontrolling interest

 

 

19

 

 

 

—

 

 

 

—

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

 

(207,279

)

 

 

(146,227

)

 

 

(68,606

)

Fair value adjustment to Series E-1 convertible preferred stock options

 

 

—

 

 

 

—

 

 

 

(964

)

Net loss attributable to Adaptive Biotechnologies Corporation common shareholders

 

$

(207,279

)

 

$

(146,227

)

 

$

(69,570

)

Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(1.48

)

 

$

(1.11

)

 

$

(1.01

)

Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

 

140,354,915

 

 

 

131,216,468

 

 

 

69,165,315

 

Other Financial and Operating Data:

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA(1)

 

$

(151,743

)

 

$

(119,584

)

 

$

(57,476

)

 

(1) Adjusted EBITDA is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, income tax (expense) benefit, depreciation and amortization and share-based compensation expenses. Please refer to “Adjusted EBITDA” below for a reconciliation between Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, and a discussion about the limitations of Adjusted EBITDA.

Comparison of the Years Ended December 31, 2021 and 2020

Revenue

 

 

 

Year Ended December 31,

 

 

Change

 

 

Percent of Revenue

 

(in thousands, except percentages)

 

2021

 

 

2020

 

 

$

 

 

%

 

 

2021

 

 

2020

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sequencing revenue

 

$

78,896

 

 

$

41,439

 

 

$

37,457

 

 

 

90

%

 

 

51

%

 

 

42

%

Development revenue

 

 

75,448

 

 

 

56,943

 

 

 

18,505

 

 

 

32

 

 

 

49

 

 

 

58

 

Total revenue

 

$

154,344

 

 

$

98,382

 

 

$

55,962

 

 

 

57

 

 

 

100

%

 

 

100

%

The $37.5 million increase in sequencing revenue was primarily attributable to a $24.3 million increase in revenue generated from biopharmaceutical and academic customers, inclusive of a $2.9 million increase due to changes in estimates of total samples to be provided under certain of our MRD development agreements. Additionally, there was a $13.2 million increase in revenue generated from clinical customers, inclusive of a $1.9 million increase related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and a change in our estimate of expected cumulative tests per patient for one of our covered indications.

95

Research sequencing volume increased by 42% to 32,146 sequences delivered in the year ended December 31, 2021 from 22,663 sequences delivered in the year ended December 31, 2020. Clinical sequencing volume, excluding T-Detect COVID volume, increased by 48% to 22,516 clinical tests delivered in the year ended December 31, 2021 from 15,186 clinical tests delivered in the year ended December 31, 2020.

The $18.5 million increase in development revenue was primarily attributable to a $9.2 million increase in revenue generated from the Genentech Agreement and an $8.4 million increase in revenue recognized from MRD development agreements, inclusive of a $7.5 million increase in revenue recognized upon the achievement of certain regulatory milestones by us and our customers' therapeutics.

Cost of Revenue

 

 

 

Year Ended December 31,

 

 

Change

 

 

Percent of Revenue

 

(in thousands, except percentages)

 

2021

 

 

2020

 

 

$

 

 

%

 

 

2021

 

 

2020

 

Cost of revenue

 

$

49,301

 

 

$

22,530

 

 

$

26,771

 

 

 

119

%

 

 

32

%

 

 

23

%

The $26.8 million increase in cost of revenue was primarily attributable to a $13.5 million increase in labor, overhead and facility costs and a $9.7 million increase in materials costs resulting from increased revenue sample volume. Additionally, there was a $1.6 million increase in sample collection costs and a $1.5 million increase in shipping costs. These increases were partially offset by a $0.9 million decrease related to higher usage of our production laboratory to process research and development samples versus revenue samples.

Research and Development

 

 

 

Year Ended December 31,

 

 

Change

 

 

Percent of Revenue

 

(in thousands, except percentages)

 

2021

 

 

2020

 

 

$

 

 

%

 

 

2021

 

 

2020

 

Research and development

 

$

142,343

 

 

$

116,072

 

 

$

26,271

 

 

 

23

%

 

 

92

%

 

 

118

%

 

The following table presents disaggregated research and development expenses by cost classification for the periods presented:

 

 

 

Year Ended December 31,

 

 

 

 

 

(in thousands)

 

2021

 

 

2020

 

 

Change

 

Research and development materials and allocated production laboratory expenses

 

$

51,625

 

 

$

50,561

 

 

$

1,064

 

Personnel expenses

 

 

62,874

 

 

 

44,969

 

 

 

17,905

 

Allocable facilities and information technology expenses

 

 

6,363

 

 

 

5,277

 

 

 

1,086

 

Software and cloud services expenses

 

 

3,344

 

 

 

3,521

 

 

 

(177

)

Depreciation and other expenses

 

 

18,137

 

 

 

11,744

 

 

 

6,393

 

Total

 

$

142,343

 

 

$

116,072

 

 

$

26,271

 

The $26.3 million increase in research and development expenses was primarily attributable to a $17.9 million increase in personnel costs and a $6.4 million increase in depreciation and other expenses, which included a $2.3 million increase in consultant costs.

Sales and Marketing

 

 

 

Year Ended December 31,

 

 

Change

 

 

Percent of Revenue

 

(in thousands, except percentages)

 

2021

 

 

2020

 

 

$

 

 

%

 

 

2021

 

 

2020

 

Sales and marketing

 

$

95,465

 

 

$

61,358

 

 

$

34,107

 

 

 

56

%

 

 

62

%

 

 

62

%

The $34.1 million increase in sales and marketing expenses was primarily attributable to $23.7 million in additional personnel costs, $6.0 million in additional marketing expenses, a $2.2 million increase in travel and customer event related expenses and a $1.2 million increase in consultant costs. Our clonoSEQ and T-Detect marketing efforts were the largest drivers of the $6.0 million increase in marketing expenses.

 

96

 

General and Administrative

 

 

 

Year Ended December 31,

 

 

Change

 

 

Percent of Revenue

 

(in thousands, except percentages)

 

2021

 

 

2020

 

 

$

 

 

%

 

 

2021

 

 

2020

 

General and administrative

 

$

74,502

 

 

$

49,536

 

 

$

24,966

 

 

 

50

%

 

 

48

%

 

 

50

%

The $25.0 million increase in general and administrative expenses was primarily attributable to a $13.3 million increase in personnel costs, as well as a $7.8 million increase in building, facility and depreciation related expenses. Additionally, there was a $2.3 million increase in consultant costs and a $2.2 million increase in computer and software expenses, which were partially offset by a $2.1 million decrease in legal, accounting and tax fees.

Interest and Other Income, Net

 

 

 

Year Ended December 31,

 

 

Change

(in thousands, except percentages)

 

2021

 

 

2020

 

 

$

 

 

%

Interest and other income, net

 

$

1,668

 

 

$

6,590

 

 

$

(4,922

)

 

(75)%

The $4.9 million decrease in interest and other income, net was primarily attributable to a $4.8 million decrease in net interest income and investment amortization resulting from reductions in interest rates and related yields of a smaller portfolio.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, income tax (expense) benefit, depreciation and amortization and share-based compensation expenses.

Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.

Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:

 

•

all expenditures or future requirements for capital expenditures or contractual commitments;

 

•

changes in our working capital needs;

 

•

income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;

 

•

the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;

 

•

the non-cash component of employee compensation expense; and

 

•

the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.

In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

97

The following is a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation to Adjusted EBITDA for the periods presented (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

$

(207,279

)

 

$

(146,227

)

 

$

(68,606

)

Interest and other income, net

 

 

(1,668

)

 

 

(6,590

)

 

 

(9,785

)

Depreciation and amortization expense

 

 

13,953

 

 

 

8,472

 

 

 

7,791

 

Share-based compensation expense (1)

 

 

43,251

 

 

 

24,761

 

 

 

13,124

 

Adjusted EBITDA

 

$

(151,743

)

 

$

(119,584

)

 

$

(57,476

)

 

(1) Represents share-based compensation expense related to option and restricted stock unit awards. See Note 13 of the accompanying notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our share-based compensation expense.

Liquidity and Capital Resources

We have incurred losses since inception and have incurred negative cash flows from operations since inception through December 31, 2018, and again in the years ended December 31, 2020 and 2021. As of December 31, 2021, we had an accumulated deficit of $718.9 million.

We have funded our operations to date principally from the sale of convertible preferred stock and common stock and, to a lesser extent, sequencing and development revenue. As of December 31, 2021, we had cash, cash equivalents and marketable securities of $570.2 million.

We believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. If our available cash, cash equivalents and marketable securities balances and anticipated cash flows from operations are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our shareholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. This additional capital may not be available on reasonable terms, or at all.

We plan to utilize the existing cash, cash equivalents and marketable securities on hand primarily to fund our commercial and marketing activities associated with our clinical products and services, continued research and development initiatives for our pipeline candidates and drug discovery initiatives and ongoing investments in our immune medicine platform. We also expect to make capital expenditures in the near term related to the expansion of our laboratory space and expect to continue investing in laboratory equipment and operations to support our anticipated growth. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to capital preservation and liquidity. Currently, our funds are held in money market funds and marketable securities consisting of U.S. government debt securities and corporate bonds.

Our contractual obligations as of December 31, 2021 include operating lease obligations of $149.5 million, reflecting the minimum commitments for our office and laboratory spaces in Seattle, Washington and South San Francisco, California, our warehouse lease in Bothell, Washington and our office lease in New York City, New York, as well as a commitment for server space in Seattle, Washington. See Note 10 of the accompanying notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information, including the timing of cash payments related to these lease obligations. Additionally, we have minimum commitments for laboratory material suppliers, which are generally fulfilled within one year, software and service license commitments, which are generally fulfilled within one to three years, purchase commitments for cloud data storage through our collaboration with Microsoft and royalty commitments. Furthermore, in connection with one of our lease agreements, we have an existing letter of credit of $2.1 million with one of our existing financial institutions.

While we may experience variability in revenue in the near term, as long-term revenue from sales of our current and future products and services is expected to grow, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.

98

Cash Flows

The following table summarizes our uses and sources of cash for the years ended December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Net cash used in operating activities

 

$

(192,727

)

 

$

(149,683

)

Net cash provided by (used in) investing activities

 

 

181,210

 

 

 

(117,044

)

Net cash provided by financing activities

 

 

27,146

 

 

 

293,587

 

 

Operating Activities

Cash used in operating activities during the year ended December 31, 2021 was $192.7 million, which was primarily attributable to a net loss of $207.3 million and a net change in operating assets and liabilities of $56.8 million, partially offset by noncash share-based compensation of $43.3 million, noncash depreciation and amortization of $21.2 million and noncash lease expense of $7.0 million. The net change in operating assets and liabilities was primarily due to a $57.7 million reduction in deferred revenue primarily related to revenue recognized from the Genentech Agreement, a $7.4 million increase in accounts receivable, net and a $5.2 million increase in inventory, which were partially offset by an $8.5 million increase in operating lease liabilities, a $3.9 million increase in accounts payable and accrued liabilities primarily related to our corporate bonus to be paid in 2022, and a $1.3 million decrease in prepaid expenses and other assets.

Cash used in operating activities during the year ended December 31, 2020 was $149.7 million, which was primarily attributable to a net loss of $146.2 million and a net change in our operating assets and liabilities of $40.8 million, partially offset by noncash share-based compensation of $24.8 million, noncash depreciation and amortization of $9.2 million and noncash lease expense of $3.3 million. The net change in our operating assets and liabilities was primarily due to a $43.4 million reduction in deferred revenue primarily related to revenue recognized from the Genentech Agreement, a $5.0 million increase in inventory, a $1.4 million increase in prepaid expenses and other current assets and a $0.9 million decrease in operating lease liabilities. These changes were partially offset by an increase in accounts payable and accrued liabilities of $7.5 million and a reduction in accounts receivable, net of $2.6 million.

Investing Activities

Cash provided by investing activities during the year ended December 31, 2021 was $181.2 million, which was primarily attributable to proceeds from maturities of marketable securities of $559.5 million, partially offset by purchases of marketable securities of $316.5 million and purchases of property and equipment of $61.7 million.

Cash used in investing activities during the year ended December 31, 2020 was $117.0 million, which was primarily attributable to purchases of marketable securities of $695.0 million and purchases of property and equipment of $18.8 million, partially offset by proceeds from sales and maturities of marketable securities of $596.7 million.

Financing Activities

Cash provided by financing activities during the year ended December 31, 2021 was $27.1 million, which was primarily attributable to proceeds from the exercise of stock options.

Cash provided by financing activities during the year ended December 31, 2020 was $293.6 million, which was primarily attributable to $271.8 million in proceeds, after deducting underwriting discounts and net offering expenses paid by us, received from our underwritten public offering completed in July 2020, as well as $21.7 million in proceeds from the exercise of stock options.

Net Operating Loss Carryforwards

Utilization of our NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986 (“Section 382”) and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. If there should be an ownership change, our ability to utilize our NOL carryforwards and credits could be limited. We have completed a Section 382 analysis for changes in ownership through December 31, 2020 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the TCJA, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years. Based on the available objective evidence, management determined that it was more likely than not that the net deferred tax assets would not be realizable as of December 31, 2021. Accordingly, management applied a full valuation allowance against net deferred tax assets as of December 31, 2021.

99

Critical Accounting Policies and Estimates

 

We have prepared our consolidated financial statements in accordance with GAAP. Our preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities and related disclosures at the date of the consolidated financial statements, as well as revenue and expense recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and or other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas, including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.

While our significant accounting policies are described in more detail in Note 2 of the accompanying notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies are critical to the judgments and estimates used in the preparation of our consolidated financial statements.

Revenue Recognition

Our development and sequencing revenue arrangements may include upfront payments for the performance of services in the future, which have both fixed and variable consideration. Non-refundable upfront fees and funding for related development services are generally considered fixed consideration, while milestone payments are identified as variable consideration.

In determining the appropriate amount of revenue to recognize as we fulfill our obligations under these agreements, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers. Our performance obligations include sequencing services and services associated with regulatory submission and approval processes. Significant management judgment is applied to determine (1) the measurement of the transaction price, including the constraint on variable consideration, (2) the allocation of the transaction price to the performance obligations and (3) the appropriate input or output based method to recognize revenue and the extent of progress to date.

We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjust our estimate of the overall transaction price.

To determine the allocation of the transaction price to the performance obligations, we apply the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell the services and estimate the price that a customer in that market would be willing to pay for those services.

To select the measure of progress, we consider the expectations of the performance period which may be based on customer-dependent estimates of samples or internal estimates of the performance period based on both the customer and our expected development timeframes. For our collaboration with Genentech, we estimate the extent of progress using a proportional performance model that uses an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. These estimates are based on our internal estimates and development timeframes, which are subject to revision based on the potential outcomes for both product pathways, decisions made by Genentech, regulatory feedback or other factors not currently known. We regularly review our expectations of the extent of progress, including whether any variable consideration is no longer constrained, and, if any changes in estimates are made, we recognize revenue using the cumulative catch-up method.

100

Goodwill

Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1 and upon any occurrence of triggering events or substantive changes in circumstances that could indicate a potential impairment.

We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. We evaluate certain qualitative factors such as macroeconomic conditions, the market and industry in which we operate, cost factors, overall financial performance and other relevant entity-specific events to determine if there are any negative trends or events that could indicate impairment. Key assumptions in this analysis include anticipated demand for our products and services, including industry and regulatory changes, future revenue growth and cash flow trends. These assumptions are determined based on our historical performance and management’s forecasted results. Management’s estimates of forecasted results are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. If we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying amount, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our consolidated statements of operations. To date, we have not recognized any impairment of goodwill.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents and marketable securities. As of December 31, 2021 and 2020, we had cash and cash equivalents of $139.1 million and $123.4 million, respectively, held primarily in cash deposits and money market funds. As of December 31, 2021, we had short-term and long-term marketable securities of $431.1 million, held in U.S. government debt securities and corporate bonds. As of December 31, 2020, we had short-term and long-term marketable securities of $683.4 million, held in U.S. government debt securities and corporate bonds. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the United States. As of December 31, 2021, a hypothetical 100 basis point increase in interest rates would have resulted in a $4.0 million decline of the fair value of our available-for-sale securities, as compared to a $4.3 million decline as of December 31, 2020. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur. Such losses would only be realized if we sold the investments prior to maturity. We do not enter into investments for trading purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.

101

Item 8. Financial Statements and Supplementary Data

Adaptive Biotechnologies Corporation

Index to Consolidated Financial Statements

As of December 31, 2021 and 2020 and

For the Years Ended December 31, 2021, 2020 and 2019

 

 

 

 

 

 

102

 

 

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Adaptive Biotechnologies Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Adaptive Biotechnologies Corporation (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and shareholders’ (deficit) equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 15, 2022 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

103

 

 

 

Genentech Agreement

Description of the Matter

As more fully described in Note 3 of the financial statements, Genentech Agreement revenue is estimated to be recognized over a period of seven to eight years from the effective date. The non-refundable upfront consideration of $300.0 million is recognized using a proportional performance model through an input method based on costs incurred relative to the total estimated costs of research and development efforts. For the year ended December 31, 2021, total revenue recognized was $62.0 million and the related deferred revenue at December 31, 2021 totaled $150.1 million.

Auditing management’s estimate of the total expected research and development costs at completion is complex and requires judgment as a result of the uncertainties of the ultimate progression of the customized product paths, timing and path of development and commercialization decisions, which are controlled by Genentech.

How We Addressed the Matter in Our Audit

We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company’s process to evaluate the progress of the collaboration and the likely path of future development based on significant decisions made by Genentech communicated through the joint committees and any resulting impacts on the total costs of research and development efforts for the collaboration.

To test the estimate of total expected research and development costs, we performed audit procedures that included, among others, observing the quarterly meetings with accounting and the Company collaboration managers discussing the status of the collaboration and the future development for the customized product paths, investigating any changes to the development path. We reviewed supporting documentation to corroborate progress and status of the overall timeline, including meeting minutes from the joint committees.  

 

 

 

 

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2015

Seattle, Washington

February 15, 2022

 

 

 

104

Adaptive Biotechnologies Corporation

 

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

139,065

 

 

$

123,436

 

Short-term marketable securities (amortized cost of $214,115 and $564,036, respectively)

 

 

213,996

 

 

 

564,833

 

Accounts receivable, net

 

 

17,409

 

 

 

10,047

 

Inventory

 

 

19,263

 

 

 

14,063

 

Prepaid expenses and other current assets

 

 

13,015

 

 

 

14,535

 

Total current assets

 

 

402,748

 

 

 

726,914

 

Long-term assets

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

85,262

 

 

 

39,692

 

Operating lease right-of-use assets

 

 

87,678

 

 

 

99,350

 

Long-term marketable securities (amortized cost of $218,163 and $118,429, respectively)

 

 

217,145

 

 

 

118,525

 

Restricted cash

 

 

2,138

 

 

 

2,138

 

Intangible assets, net

 

 

8,526

 

 

 

10,225

 

Goodwill

 

 

118,972

 

 

 

118,972

 

Other assets

 

 

875

 

 

 

598

 

Total assets

 

$

923,344

 

 

$

1,116,414

 

Liabilities and shareholders’ equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,307

 

 

$

3,237

 

Accrued liabilities

 

 

9,343

 

 

 

13,162

 

Accrued compensation and benefits

 

 

15,642

 

 

 

11,950

 

Current portion of operating lease liabilities

 

 

5,055

 

 

 

3,529

 

Current portion of deferred revenue

 

 

80,460

 

 

 

73,319

 

Total current liabilities

 

 

113,807

 

 

 

105,197

 

Long-term liabilities

 

 

 

 

 

 

 

 

Operating lease liabilities, less current portion

 

 

106,685

 

 

 

104,333

 

Deferred revenue, less current portion

 

 

98,750

 

 

 

163,618

 

Total liabilities

 

 

319,242

 

 

 

373,148

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

 

 

Shareholders’ equity

 

 

 

 

 

 

 

 

Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020

 

 

—

 

 

 

—

 

Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2021 and 2020; 141,393,865 and 137,646,896 shares issued and outstanding at December 31, 2021 and 2020, respectively

 

 

14

 

 

 

14

 

Additional paid-in capital

 

 

1,324,006

 

 

 

1,253,971

 

Accumulated other comprehensive (loss) gain

 

 

(1,137

)

 

 

893

 

Accumulated deficit

 

 

(718,891

)

 

 

(511,612

)

Total Adaptive Biotechnologies Corporation shareholders’ equity

 

 

603,992

 

 

 

743,266

 

Noncontrolling interest

 

 

110

 

 

 

—

 

Total shareholders’ equity

 

 

604,102

 

 

 

743,266

 

Total liabilities and shareholders’ equity

 

$

923,344

 

 

$

1,116,414

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

105

Adaptive Biotechnologies Corporation

 

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Sequencing revenue

 

$

78,896

 

 

$

41,439

 

 

$

43,519

 

Development revenue

 

 

75,448

 

 

 

56,943

 

 

 

41,552

 

Total revenue

 

 

154,344

 

 

 

98,382

 

 

 

85,071

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

49,301

 

 

 

22,530

 

 

 

22,274

 

Research and development

 

 

142,343

 

 

 

116,072

 

 

 

70,705

 

Sales and marketing

 

 

95,465

 

 

 

61,358

 

 

 

38,453

 

General and administrative

 

 

74,502

 

 

 

49,536

 

 

 

30,332

 

Amortization of intangible assets

 

 

1,699

 

 

 

1,703

 

 

 

1,698

 

Total operating expenses

 

 

363,310

 

 

 

251,199

 

 

 

163,462

 

Loss from operations

 

 

(208,966

)

 

 

(152,817

)

 

 

(78,391

)

Interest and other income, net

 

 

1,668

 

 

 

6,590

 

 

 

9,785

 

Net loss

 

 

(207,298

)

 

 

(146,227

)

 

 

(68,606

)

Add: Net loss attributable to noncontrolling interest

 

 

19

 

 

 

—

 

 

 

—

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

 

(207,279

)

 

 

(146,227

)

 

 

(68,606

)

Fair value adjustment to Series E-1 convertible preferred stock options

 

 

—

 

 

 

—

 

 

 

(964

)

Net loss attributable to Adaptive Biotechnologies Corporation common shareholders

 

$

(207,279

)

 

$

(146,227

)

 

$

(69,570

)

Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(1.48

)

 

$

(1.11

)

 

$

(1.01

)

Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

 

140,354,915

 

 

 

131,216,468

 

 

 

69,165,315

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

106

Adaptive Biotechnologies Corporation

 

 

Consolidated Statements of Comprehensive Loss

(in thousands)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net loss

 

$

(207,298

)

 

$

(146,227

)

 

$

(68,606

)

Other comprehensive (loss) income:

 

 

 

 

 

 

 

 

 

 

 

 

Change in unrealized gains and losses on investments

 

 

(2,030

)

 

 

222

 

 

 

778

 

Comprehensive loss

 

 

(209,328

)

 

 

(146,005

)

 

 

(67,828

)

Add: Comprehensive loss attributable to noncontrolling interest

 

 

19

 

 

 

—

 

 

 

—

 

Comprehensive loss attributable to Adaptive Biotechnologies Corporation

 

$

(209,309

)

 

$

(146,005

)

 

$

(67,828

)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

107

Adaptive Biotechnologies Corporation

 

Consolidated Statements of Convertible Preferred Stock and Shareholders’ (Deficit) Equity

(in thousands, except share amounts)

 

 

 

Convertible Preferred Stock

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Noncontrolling

 

 

Total

Shareholders’

(Deficit)

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

(Loss) Gain

 

 

Deficit

 

 

Interest

 

 

Equity

 

Balance at December 31, 2018

 

 

92,790,094

 

 

$

560,858

 

 

 

 

12,841,536

 

 

$

1

 

 

$

37,902

 

 

$

(107

)

 

$

(295,908

)

 

$

—

 

 

$

(258,112

)

Proceeds from initial public offering, net of underwriters' discounts and commissions

 

 

—

 

 

 

—

 

 

 

 

17,250,000

 

 

 

2

 

 

 

320,848

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

320,850

 

Initial public offering costs

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

(4,986

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(4,986

)

Conversion of convertible preferred stock to common stock

 

 

(93,039,737

)

 

 

(561,931

)

 

 

 

93,039,737

 

 

 

9

 

 

 

561,922

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

561,931

 

Conversion of convertible preferred stock warrant to common stock warrant

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

2,602

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

2,602

 

Issuance of common stock upon exercise of common stock warrants

 

 

—

 

 

 

—

 

 

 

 

54,792

 

 

 

—

 

 

 

9

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

9

 

Issuance of common stock for cash upon exercise of stock options

 

 

—

 

 

 

—

 

 

 

 

2,043,767

 

 

 

—

 

 

 

4,413

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,413

 

Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value

 

 

249,643

 

 

 

109

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Vesting of restricted stock units

 

 

—

 

 

 

—

 

 

 

 

8,310

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Change in redemption value for vested Series E-1 convertible preferred stock options

 

 

—

 

 

 

964

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(964

)

 

 

—

 

 

 

(964

)

Common stock option and restricted stock unit share-based compensation

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

13,124

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

13,124

 

Other comprehensive income

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

778

 

 

 

—

 

 

 

—

 

 

 

778

 

Net loss

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(68,606

)

 

 

—

 

 

 

(68,606

)

Balance at December 31, 2019

 

 

—

 

 

$

—

 

 

 

 

125,238,142

 

 

$

12

 

 

$

935,834

 

 

$

671

 

 

$

(365,478

)

 

$

—

 

 

$

571,039

 

Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us

 

 

—

 

 

 

—

 

 

 

 

7,200,000

 

 

 

1

 

 

 

271,838

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

271,839

 

Adjustments to accumulated deficit for adoption of guidance on accounting for leases

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

93

 

 

 

—

 

 

 

93

 

Issuance of common stock for cash upon exercise of stock options

 

 

—

 

 

 

—

 

 

 

 

5,204,254

 

 

 

1

 

 

 

21,538

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

21,539

 

Vesting of restricted stock units

 

 

—

 

 

 

—

 

 

 

 

4,500

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Common stock option and restricted stock unit share-based compensation

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

24,761

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

24,761

 

Other comprehensive income

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

222

 

 

 

—

 

 

 

—

 

 

 

222

 

Net loss

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(146,227

)

 

 

—

 

 

 

(146,227

)

Balance at December 31, 2020

 

 

—

 

 

$

—

 

 

 

 

137,646,896

 

 

$

14

 

 

$

1,253,971

 

 

$

893

 

 

$

(511,612

)

 

$

—

 

 

$

743,266

 

Issuance of common stock upon exercise of common stock warrant

 

 

—

 

 

 

—

 

 

 

 

54,162

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock for cash upon exercise of stock options

 

 

—

 

 

 

—

 

 

 

 

3,674,057

 

 

 

—

 

 

 

26,484

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

26,484

 

Vesting of restricted stock units

 

 

—

 

 

 

—

 

 

 

 

18,750

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Common stock option and restricted stock unit share-based compensation

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

43,251

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

43,251

 

Capital contributions for Digital Biotechnologies, Inc.

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

300

 

 

 

—

 

 

 

—

 

 

 

129

 

 

 

429

 

Other comprehensive loss

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2,030

)

 

 

—

 

 

 

—

 

 

 

(2,030

)

Net loss

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(207,279

)

 

 

(19

)

 

 

(207,298

)

Balance at December 31, 2021

 

 

—

 

 

$

—

 

 

 

 

141,393,865

 

 

$

14

 

 

$

1,324,006

 

 

$

(1,137

)

 

$

(718,891

)

 

$

110

 

 

$

604,102

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

108

Adaptive Biotechnologies Corporation

 

Consolidated Statements of Cash Flows

(in thousands)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating activities

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(207,298

)

 

$

(146,227

)

 

$

(68,606

)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation expense

 

 

12,254

 

 

 

6,769

 

 

 

6,093

 

Noncash lease expense

 

 

7,028

 

 

 

3,266

 

 

 

—

 

Share-based compensation expense

 

 

43,251

 

 

 

24,761

 

 

 

13,124

 

Intangible assets amortization

 

 

1,699

 

 

 

1,703

 

 

 

1,698

 

Investment amortization

 

 

7,233

 

 

 

773

 

 

 

(4,463

)

Fair value adjustment of convertible preferred stock warrant

 

 

—

 

 

 

—

 

 

 

2,266

 

Other

 

 

(78

)

 

 

71

 

 

 

359

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

 

 

(7,362

)

 

 

2,613

 

 

 

(7,817

)

Inventory

 

 

(5,200

)

 

 

(4,994

)

 

 

(1,231

)

Prepaid expenses and other current assets

 

 

1,286

 

 

 

(1,362

)

 

 

(8,576

)

Accounts payable and accrued liabilities

 

 

3,940

 

 

 

7,495

 

 

 

6,149

 

Deferred rent

 

 

—

 

 

 

—

 

 

 

78

 

Operating lease right-of-use assets and liabilities

 

 

8,522

 

 

 

(886

)

 

 

—

 

Deferred revenue

 

 

(57,727

)

 

 

(43,389

)

 

 

266,927

 

Other

 

 

(275

)

 

 

(276

)

 

 

(597

)

Net cash (used in) provided by operating activities

 

 

(192,727

)

 

 

(149,683

)

 

 

205,404

 

Investing activities

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(61,746

)

 

 

(18,803

)

 

 

(11,200

)

Purchases of marketable securities

 

 

(316,544

)

 

 

(694,965

)

 

 

(884,217

)

Proceeds from sales and maturities of marketable securities

 

 

559,500

 

 

 

596,724

 

 

 

413,720

 

Net cash provided by (used in) investing activities

 

 

181,210

 

 

 

(117,044

)

 

 

(481,697

)

Financing activities

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from exercise of stock options

 

 

26,717

 

 

 

21,748

 

 

 

4,055

 

Proceeds from public offering of common stock, net of underwriting discounts and commissions

 

 

—

 

 

 

272,160

 

 

 

320,850

 

Payment of public offering costs, net

 

 

—

 

 

 

(321

)

 

 

(4,986

)

Proceeds from issuance of common stock upon the exercise of a common stock warrant

 

 

—

 

 

 

—

 

 

 

9

 

Proceeds from initial capital contributions for Digital Biotechnologies, Inc.

 

 

429

 

 

 

—

 

 

 

—

 

Other

 

 

—

 

 

 

—

 

 

 

(12

)

Net cash provided by financing activities

 

 

27,146

 

 

 

293,587

 

 

 

319,916

 

Net increase in cash, cash equivalents and restricted cash

 

 

15,629

 

 

 

26,860

 

 

 

43,623

 

Cash, cash equivalents and restricted cash at beginning of year

 

 

125,574

 

 

 

98,714

 

 

 

55,091

 

Cash, cash equivalents and restricted cash at end of year

 

$

141,203

 

 

$

125,574

 

 

$

98,714

 

Noncash investing and financing activities

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of equipment included in accounts payable and accrued liabilities

 

$

682

 

 

$

4,679

 

 

$

773

 

Noncash additions to property through lease financing arrangements

 

$

—

 

 

$

—

 

 

$

36,607

 

Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases

 

$

—

 

 

$

36,607

 

 

$

—

 

Conversion of convertible preferred stock to common stock upon closing of initial public offering

 

$

—

 

 

$

—

 

 

$

561,931

 

Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering

 

$

—

 

 

$

—

 

 

$

2,602

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

109

Adaptive Biotechnologies Corporation

 

Notes to Consolidated Financial Statements

1.

Organization and Description of Business

Adaptive Biotechnologies Corporation (“we,” “us” or “our”) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune disorders and infectious diseases.

We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.

Digital Biotechnologies, Inc.

In 2021, we formed a subsidiary, Spin Technologies, Inc., to facilitate the development of a potential new early-stage sequencing technology that is ancillary to our core business. In February 2022, the subsidiary’s name was changed to Digital Biotechnologies, Inc. We have a 70% ownership interest in Digital Biotechnologies, Inc. All intercompany transactions and balances between us and Digital Biotechnologies, Inc. have been eliminated in consolidation. The remaining interest, held by certain of our related parties and related family trusts, was reported as noncontrolling interest in our consolidated financial statements.

2.

Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, its wholly-owned subsidiary and Digital Biotechnologies, Inc. Other shareholders’ interests in Digital Biotechnologies, Inc. are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.

Cash and Cash Equivalents

Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.

Restricted Cash

We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of $2.1 million as of December 31, 2021 and 2020.

110

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

Investments in Marketable Securities

Marketable securities are classified as available-for-sale, consist of U.S. government debt securities and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders’ equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.

Concentrations of Risk

We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.

Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions.

Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.

For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:

 

 

 

Revenue

 

Accounts Receivable, Net

 

 

 

Year Ended December 31,

 

December 31,

 

 

 

2021

 

2020

 

2019

 

2021

 

2020

 

Customer A

 

*%

 

*%

 

13.9%

 

*%

 

 

19.1

%

Customer B

 

*

 

*

 

*

 

11.3

 

12.2

 

Genentech, Inc. and Roche Group

 

41.9

 

55.8

 

42.1

 

*

 

*

 

* less than 10%

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts Receivable

Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.

Additionally, we had $0.2 million and $0.9 million of unbilled receivables as of December 31, 2021 and 2020, respectively. These contract assets are amounts that will become due for which we have an unconditional right to consideration.

Inventory

Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.

Property and Equipment

Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.

Useful lives assigned to property and equipment are as follows:

Laboratory equipment

 

3 years to 7 years

Leasehold improvements

 

Shorter of estimated useful life or remaining lease term

Computer equipment and software

 

3 years to 5 years

Furniture and office equipment

 

3 years to 10 years

 

111

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

 

We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our consolidated statements of operations in accordance with the use of the asset.

Goodwill

Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our consolidated statements of operations. To date, we have not recognized any impairment of goodwill.

Intangible Assets

Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.

Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have not recognized any impairment losses on intangible assets.

Leases

We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy, as well as server space. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of Accounting Standards Update No. 2016-02, Leases (Topic 842) (“ASC 842”).

Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.

We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on our consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.

Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.

Fair Value of Financial Instruments

The Financial Accounting Standards Board (“FASB”) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:

 

•

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

•

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

•

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

112

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level 3 within the valuation hierarchy.

Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2021 and 2020.

Convertible Preferred Stock Warrant

We had issued a freestanding warrant to a venture capital firm to purchase 56,875 shares of Series C convertible preferred stock with an exercise price of $2.64 in connection with a $5.0 million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant.

Prior to the conversion, the fair value of this warrant was classified as a non-current liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders’ deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $2.3 million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our consolidated statements of operations.

When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $2.6 million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.

Revenue Recognition

We recognize revenue in accordance with ASC Topic 606 (“ASC 606”), Revenue from Contracts with Customers. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications.

Overview

Our revenue is generated from immunosequencing (“sequencing”) products and services (“sequencing revenue”) and from regulatory or development support services leveraging our immune medicine platform (“development revenue”). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price.

Sequencing Revenue

Sequencing revenue reflects the amounts generated from providing testing services through clonoSEQ to clinical and research customers, from providing our T-Detect COVID test to clinical customers and from providing sequencing services through immunoSEQ to research customers.

For clinical customers, we primarily derive revenue from providing our clonoSEQ report to ordering physicians. In these transactions, we have identified one performance obligation, the delivery of a clonoSEQ report, and we bill and receive payments from medical institutions and commercial and government third-party payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience.

113

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient’s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.

For research customers, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered.

Development Revenue

We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers’ initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements include single or multiple performance obligations, depending on the contract. For certain contracts, we perform services to support the biopharmaceutical customers’ regulatory submissions as part of their registrational trials. These services may include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. If agreements include sequencing activities, we separately classify those activities as sequencing revenue.

When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers’ control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.

The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.

During the year ended December 31, 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as development revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).

114

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

Contract Balances

In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer’s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.

Share-Based Compensation

Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model.

Advertising

Advertising costs are expensed as incurred. Advertising expenses were $22.4 million, $14.5 million and $6.6 million for the year ended December 31, 2021, 2020 and 2019, respectively.

Cost of Revenue

Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs and allocated facility costs associated with processing samples and professional support for our sequencing revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.

Research and Development Expenses

Research and development expenses consist of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our Genentech Agreement are also a component of our research and development expenses.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.

Income Taxes

Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.

115

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

We calculate basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders by dividing net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect is anti-dilutive.

Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders in conformity with the two-class method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is calculated by dividing the net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to Adaptive Biotechnologies Corporation common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to Adaptive Biotechnologies Corporation common shareholders was not allocated to the convertible preferred stock under the two-class method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect was anti-dilutive.

Segment Information

We have determined that our chief executive officer is the chief operating decision maker (“CODM”). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning at levels or components below the consolidated entity. As such, the consolidated entity operates as one operating segment and represents one reportable segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3, Revenue.

3.

Revenue

We disaggregate our revenue from contracts with customers by type of service, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Sequencing revenue

 

$

78,896

 

 

$

41,439

 

 

$

43,519

 

Development revenue

 

 

 

 

 

 

 

 

 

 

 

 

Development support

 

 

65,448

 

 

 

54,443

 

 

 

39,552

 

Regulatory milestones

 

 

10,000

 

 

 

2,500

 

 

 

2,000

 

Total development revenue

 

 

75,448

 

 

 

56,943

 

 

 

41,552

 

Total revenue

 

$

154,344

 

 

$

98,382

 

 

$

85,071

 

 

116

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

 

MRD Development Agreements

We have entered into agreements with biopharmaceutical customers to further develop and commercialize our MRD product and the biopharmaceutical customers’ therapeutics. Under each of the agreements, we received or will receive non-refundable upfront payments and could receive substantial additional payments upon reaching certain progress-based milestones or achieving certain regulatory milestones pertaining to the customers’ therapeutics and our MRD product.

 

Under the contracts, we identify performance obligations, which may include: (1) obligations to provide services supporting the customer’s regulatory submission activities as they relate to our MRD product; and (2) sequencing services related to customer-provided samples for their regulatory submissions. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated immunosequencing services. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers’ own submission decision-making. We recognize revenue related to the sequencing services as sequencing revenue over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed.

We recognized $3.2 million in revenue during the year ended December 31, 2021 due to changes in estimates of total samples to be provided under certain of our MRD development agreements for which we had previously received upfront consideration, of which $0.3 million was recognized as development revenue in the respective period.

We earned $10.0 million, $2.5 million and $2.0 million during the year ended December 31, 2021, 2020 and 2019, respectively, upon the achievement of certain regulatory milestones by us and our respective customers’ therapeutics. We recognized these earnings as development revenue within the respective periods, as we determined that the amounts were consistent with our estimated standalone selling prices and the respective performance obligations were complete.

In total, we recognized $11.8 million, $3.4 million and $3.7 million in development revenue related to our MRD development agreements during the year ended December 31, 2021, 2020 and 2019, respectively.

As of December 31, 2021, in future periods we could receive up to an additional $333.5 million in milestone payments if certain regulatory approvals are obtained by our customers’ therapeutics in connection with MRD data generated from our MRD product.

Genentech Collaboration Agreement

In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (“Genentech Agreement”) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $300.0 million in February 2019 and may be eligible to receive more than $1.8 billion over time, including payments of up to $75.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones and up to $1,430.0 million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines:

 

•

Shared Products. The shared products will use “off-the-shelf” TCRs identified against cancer antigens shared among patients (“Shared Products”).

 

•

Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (“Personalized Product”).

Under the terms of the agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in ASC Topic 808, Collaborative Arrangements (“ASC 808”), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity’s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC 606 to account for the activities related to the Genentech Agreement.

117

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

In applying ASC 606, we identified the following performance obligations at the inception of the agreement:

 

1.

License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology.

 

2.

License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology.

 

3.

License to utilize all private antigen TCR product data in connection with research and development activities in the field of use.

 

4.

License to existing shared antigen data packages.

 

5.

Research and development services for shared product development, including expansion of shared antigen data packages.

 

6.

Research and development services for private product development.

 

7.

Obligations to participate on various joint research, development and project committees.

 

We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech’s control of product commercialization. Specifically, under the agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other, as opposed to both. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.

Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.

We determined the initial transaction price shall be made up of only the $300.0 million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the transaction price as of December 31, 2021. We excluded the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.

As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize the revenue over a period of approximately seven to eight years from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and the Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.

We recognized revenue of $62.0 million, $52.8 million and $35.1 million during the year ended December 31, 2021, 2020 and 2019, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.

 

118

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

 

4.

Fair Value Measurements

The following tables set forth the fair value of financial assets as of December 31, 2021 and 2020 that were measured at fair value on a recurring basis (in thousands):

 

 

December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

131,946

 

 

$

—

 

 

$

—

 

 

$

131,946

 

U.S. government debt securities

 

 

—

 

 

 

391,145

 

 

 

—

 

 

 

391,145

 

Corporate bonds

 

 

—

 

 

 

39,996

 

 

 

—

 

 

 

39,996

 

Total financial assets

 

$

131,946

 

 

$

431,141

 

 

$

—

 

 

$

563,087

 

 

 

 

December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

103,283

 

 

$

—

 

 

$

—

 

 

$

103,283

 

U.S. government debt securities

 

 

—

 

 

 

671,777

 

 

 

—

 

 

 

671,777

 

Corporate bonds

 

 

—

 

 

 

11,581

 

 

 

—

 

 

 

11,581

 

Total financial assets

 

$

103,283

 

 

$

683,358

 

 

$

—

 

 

$

786,641

 

 

Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government debt securities and corporate bonds, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.

5.

Investments

Available-for-sale investments consisted of the following as of December 31, 2021 and 2020 (in thousands):

 

 

 

December 31, 2021

 

 

 

Amortized Cost

 

 

Unrealized Gain

 

 

Unrealized Loss

 

 

Estimated Fair Value

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

186,752

 

 

$

4

 

 

$

(109

)

 

$

186,647

 

Corporate bonds

 

 

27,363

 

 

 

—

 

 

 

(14

)

 

 

27,349

 

Total short-term marketable securities

 

$

214,115

 

 

$

4

 

 

$

(123

)

 

$

213,996

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

205,472

 

 

$

—

 

 

$

(974

)

 

$

204,498

 

Corporate bonds

 

 

12,691

 

 

 

—

 

 

 

(44

)

 

 

12,647

 

Total long-term marketable securities

 

$

218,163

 

 

$

—

 

 

$

(1,018

)

 

$

217,145

 

 

 

 

December 31, 2020

 

 

 

Amortized Cost

 

 

Unrealized Gain

 

 

Unrealized Loss

 

 

Estimated Fair Value

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

552,539

 

 

$

723

 

 

$

(10

)

 

$

553,252

 

Corporate bonds

 

 

11,497

 

 

 

86

 

 

 

(2

)

 

 

11,581

 

Total short-term marketable securities

 

$

564,036

 

 

$

809

 

 

$

(12

)

 

$

564,833

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

118,429

 

 

$

98

 

 

$

(2

)

 

$

118,525

 

Total long-term marketable securities

 

$

118,429

 

 

$

98

 

 

$

(2

)

 

$

118,525

 

 

All the U.S. government debt securities and corporate bonds designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective consolidated balance sheet date.

119

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of $1.4 million and $2.5 million were presented separately within the prepaid expenses and other current assets line item on our consolidated balance sheet as of December 31, 2021 and 2020, respectively.

The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2021 (in thousands):

 

 

 

Less Than 12 Months

 

 

12 Months Or Greater

 

 

 

Fair Value

 

 

Unrealized Loss

 

 

Fair Value

 

 

Unrealized Loss

 

U.S. government debt securities

 

$

345,014

 

 

$

(1,083

)

 

$

—

 

 

$

—

 

Corporate bonds

 

 

32,886

 

 

 

(58

)

 

 

—

 

 

 

—

 

Total available-for-sale securities

 

$

377,900

 

 

$

(1,141

)

 

$

—

 

 

$

—

 

 

We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.

As of December 31, 2021, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2021 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.

6.

Property and Equipment, Net

Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Laboratory equipment

 

$

36,312

 

 

$

27,767

 

Computer equipment

 

 

6,988

 

 

 

3,600

 

Furniture and office equipment

 

 

5,579

 

 

 

2,717

 

Computer software

 

 

992

 

 

 

860

 

Construction in progress

 

 

5,658

 

 

 

7,185

 

Leasehold improvements

 

 

65,959

 

 

 

21,945

 

Property and equipment, at cost

 

 

121,488

 

 

 

64,074

 

Less: Accumulated depreciation

 

 

(36,226

)

 

 

(24,382

)

Property and equipment, net

 

$

85,262

 

 

$

39,692

 

 

Depreciation expense was $12.3 million, $6.8 million and $6.1 million for the year ended December 31, 2021, 2020 and 2019, respectively.

120

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

7.

Goodwill and Intangible Assets

There have been no changes in the carrying amount of goodwill since its recognition in 2015.

Intangible assets subject to amortization as of December 31, 2021 and 2020 consisted of the following (in thousands):

 

 

 

December 31, 2021

 

 

 

Gross Carrying Amount

 

 

Accumulated Amortization

 

 

Net Carrying Amount

 

Acquired developed technology

 

$

20,000

 

 

$

(11,638

)

 

$

8,362

 

Purchased intellectual property

 

 

325

 

 

 

(161

)

 

 

164

 

Balance at December 31, 2021

 

$

20,325

 

 

$

(11,799

)

 

$

8,526

 

 

 

 

December 31, 2020

 

 

 

Gross Carrying Amount

 

 

Accumulated Amortization

 

 

Net Carrying Amount

 

Acquired developed technology

 

$

20,000

 

 

$

(9,972

)

 

$

10,028

 

Purchased intellectual property

 

 

325

 

 

 

(128

)

 

 

197

 

Balance at December 31, 2020

 

$

20,325

 

 

$

(10,100

)

 

$

10,225

 

 

The developed technology was acquired in connection with our acquisition of Sequenta in 2015. The remaining balance of the acquired technology and the purchased intellectual property is expected to be amortized over the next 5.0 years.

 

As of December 31, 2021, expected future amortization expense for intangible assets was as follows (in thousands):

 

 

2022

 

$

1,699

 

2023

 

 

1,699

 

2024

 

 

1,703

 

2025

 

 

1,699

 

2026

 

 

1,699

 

Thereafter

 

 

27

 

Total future amortization expense

 

$

8,526

 

 

8.

Accrued Liabilities

Accrued liabilities as of December 31, 2021 and 2020 consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Professional fees

 

$

3,687

 

 

$

3,219

 

Clinical and contract research organization costs

 

 

1,646

 

 

 

1,781

 

Travel and entertainment

 

 

184

 

 

 

91

 

Tax liabilities

 

 

391

 

 

 

1,767

 

Purchases of property and equipment

 

 

615

 

 

 

4,423

 

Other

 

 

2,820

 

 

 

1,881

 

Total accrued liabilities

 

$

9,343

 

 

$

13,162

 

The accrued tax liabilities balance as of December 31, 2020 includes a $1.4 million tax withholding liability related to unsettled option exercises as of December 31, 2020.

121

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

9.

Deferred Revenue

Deferred revenue by revenue classification as of December 31, 2021 and 2020 was as follows (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Current deferred revenue

 

 

 

 

 

 

 

 

Sequencing

 

$

21,915

 

 

$

15,463

 

Development

 

 

58,545

 

 

 

57,856

 

Total current deferred revenue

 

 

80,460

 

 

 

73,319

 

Non-current deferred revenue

 

 

 

 

 

 

 

 

Sequencing

 

 

174

 

 

 

724

 

Development

 

 

98,576

 

 

 

162,894

 

Total non-current deferred revenue

 

 

98,750

 

 

 

163,618

 

Total current and non-current deferred revenue

 

$

179,210

 

 

$

236,937

 

Deferred revenue from our Genentech Agreement represents $56.1 million and $94.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2021 and $55.1 million and $157.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2020. In general, we expect that the current amounts will be recognized as revenue within 12 months and the non-current amounts will be recognized as revenue over a period of approximately five to six years from December 31, 2021. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various development activities.

During the year ended December 31, 2021, we recognized $3.6 million in revenue as a result of changes in estimates of total samples to be provided under certain of our agreements and cancelled biopharmaceutical customer sequencing contracts for which we had received upfront consideration. Additionally, we recognized $2.5 million of sequencing revenue during the year ended December 31, 2021 related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and a change in our estimate of expected cumulative tests per patient for one of our covered indications.

Changes in deferred revenue during the year ended December 31, 2021 were as follows (in thousands):

 

Deferred revenue balance at December 31, 2020

 

$

236,937

 

Additions to deferred revenue during the period

 

 

38,062

 

Revenue recognized during the period

 

 

(95,789

)

Deferred revenue balance at December 31, 2021

 

$

179,210

 

122

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

As of December 31, 2021, $75.7 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2020.

10.

Leases

We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy in various locations, as well as server space.

In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately 65,500 square feet. Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years. The amended lease also requires us to pay additional amounts for operating and maintenance expenses.

In August 2019, we entered into an agreement to rent approximately 100,000 square feet in what was a to-be-constructed, new headquarters building in Seattle, Washington. In connection with the lease, we entered into a $2.1 million letter of credit with one of our existing financial institutions. Due to our significant involvement during the construction process of the leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance that proceeded ASC 842. The resulting asset and long-term financing obligation recorded on our balance sheet as of December 31, 2019 for the cost of the building was derecognized effective January 1, 2020 upon adoption of ASC 842. The lease commenced in December 2020, when the landlord delivered the premises to us for construction of certain tenant improvements. We occupied the new building in 2021, cash payment for rent began in October 2021 and the lease term ends in August 2033, subject to our option to twice extend the lease for five years. In connection with this lease, the landlord agreed to fund $20.0 million in improvements, which was subsequently reduced to $14.8 million as a result of our change requests made during landlord construction of the building, net of an administration fee. As of December 31, 2021, we have incurred $14.9 million in certain tenant improvement costs, of which $10.9 million has been reimbursed by the landlord. The remaining $4.0 million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on our consolidated balance sheet as of December 31, 2021 and will be reimbursed by the landlord. As of December 31, 2020, we incurred $5.2 million in certain tenant improvement costs, of which $0.7 million had been reimbursed by the landlord. The remaining $4.5 million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on our consolidated balance sheet as of December 31, 2020. The lease also requires us to pay additional amounts for operating and maintenance expenses.

In October 2019, we entered into an agreement to lease approximately 14,750 square feet in a separate Seattle, Washington location, pursuant to a lease expiring in October 2029, which is subject to our ability to exercise an early termination right after the third year. In connection with the lease, the landlord agreed to provide a tenant improvement allowance in the maximum amount of $0.7 million. The lease also requires us to pay additional amounts for operating expenses.

In April 2018, we entered into a lease agreement to lease approximately 13,400 square feet in South San Francisco, California. The lease term is through March 2026 and provides for one five-year extension option. We are responsible for our share of allocable operating expenses, tax expenses and utilities cost during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $2.4 million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately 19,900 additional square feet and provides for a $0.6 million tenant improvement allowance.

In December 2019, we entered into an agreement to lease approximately 3,100 square feet of office space in New York City, New York, pursuant to a lease that expires November 2025, subject to our ability to exercise an early termination right in 2023. The lease requires us to pay certain operating expenses.

In March 2021, we executed a lease to rent approximately 27,000 square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the year ended December 31, 2021. Rent obligations commenced in October 2021 and the lease expires October 2031, subject to an early termination option after the seventh year and an option to twice extend the lease for five years. The lease requires us to pay certain operating expenses. Furthermore, the landlord agreed to fund $1.2 million in improvements in connection with this lease.

As of December 31, 2021, we were not party to any finance leases. Our leases have remaining terms of 0.3 years to 11.7 years and include options to extend certain of the leases up to 10.0 years and terminate certain of the leases after 3.0 years. We adjust lease terms for these options only when it is reasonably certain we will exercise these options. As of December 31, 2021, it was reasonably certain that we would exercise our option to terminate two of our leases after 3.0 years.

123

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

Other information related to our operating leases as of December 31, 2021 and 2020 was as follows:

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Weighted-average remaining lease term (in years)

 

 

10.55

 

 

 

11.33

 

Weighted-average discount rate

 

 

4.6

%

 

 

4.6

%

 

The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of December 31, 2021 (in thousands):

 

2022

 

$

14,184

 

2023

 

 

13,964

 

2024

 

 

13,692

 

2025

 

 

14,098

 

2026

 

 

12,330

 

Thereafter

 

 

81,188

 

Total undiscounted lease payments

 

 

149,456

 

Less:

 

 

 

 

   Imputed interest rate

 

 

(32,410

)

   Tenant improvement receivables

 

 

(5,306

)

Total operating lease liabilities

 

$

111,740

 

Less: Current portion

 

 

(5,055

)

Operating lease liabilities, less current portion

 

$

106,685

 

 

Operating lease expense was $12.4 million and $5.5 million for the year ended December 31, 2021 and 2020, respectively. Variable lease expense for operating leases was $3.5 million and $2.6 million for the year ended December 31, 2021 and 2020, respectively. Rent expense recognized under ASC 840, Leases, inclusive of operating and maintenance costs, was $5.3 million for the year ended December 31, 2019.

Cash paid for amounts included in the measurement of lease liabilities was $8.3 million and cash received for tenant improvement allowances was $11.5 million during the year ended December 31, 2021. Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2020 was $3.2 million, net of $2.5 million of cash received for tenant improvement allowances. For the year ended December 31, 2021, ROU assets obtained in exchange for operating lease liabilities was $5.4 million. For the year ended December 31, 2020, ROU assets obtained in exchange for operating lease liabilities was $109.1 million, inclusive of the $33.0 million recognized from the adoption of ASC 842.

11.

Commitments and Contingencies

Legal Proceedings

We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2021.

Indemnification Agreements

In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.

124

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

 

12.

Shareholders’ Equity

Common Stock

Our common stock has no preferences or privileges and is not redeemable. Holders of our common stock are entitled to one vote for each share of common stock held. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time.

As of December 31, 2021, we have reserved shares of common stock for the following:

 

Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted

 

 

13,990,175

 

Shares available for future grant under the 2019 Equity Incentive Plan

 

 

22,299,923

 

Shares available for future grant under the Employee Stock Purchase Plan

 

 

2,804,298

 

Total shares of common stock reserved for future issuance

 

 

39,094,396

 

Our 2019 Equity Incentive Plan (“2019 Plan”) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.

Furthermore, our Employee Stock Purchase Plan (“ESPP”) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.

Effective January 1, 2021, our 2019 Plan reserve increased by 6,882,344 shares. Our board of directors determined not to increase the ESPP reserve in 2021. Furthermore, our board of directors determined not to increase the 2019 Plan and ESPP reserves in 2022.

Common Stock Warrant

In 2014, we issued a warrant to purchase 56,875 shares of Series C convertible preferred stock at an exercise price of $2.64. The warrant was exercisable for a period of seven years from the date of issuance. Immediately prior to and in connection with the completion of our initial public offering on July 1, 2019, this convertible preferred stock warrant was converted to a warrant to purchase the same number of shares of common stock. The warrant was exercised on February 25, 2021 through a cashless exercise, resulting in the issuance of 54,162 shares of our common stock. The impact of this cashless exercise was immaterial to our consolidated financial statements. As of December 31, 2021, there were no outstanding warrants to purchase common stock.

13.

Equity Incentive Plans

Sequenta 2008 Stock Plan, as amended

In connection with our acquisition of Sequenta in January 2015, we assumed Sequenta’s Equity Incentive Plan (“2008 Plan”), including all outstanding options and shares available for future issuance under the 2008 Plan, which, prior to the completion of our initial public offering, were all exercisable for Series E-1 convertible preferred stock. Upon completion of our initial public offering in July 2019, the outstanding options were exercisable for common stock. No shares are available for future issuance under this plan and no equity awards are outstanding under this plan as of December 31, 2021.

Adaptive 2009 Equity Incentive Plan

We adopted an equity incentive plan in 2009 (“2009 Plan”) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the option exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Options granted under this plan expire no later than ten years from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While no shares are available for future issuance under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.

125

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

2019 Equity Incentive Plan

The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, options granted under this plan expire no later than ten years from the grant date and vesting is established at the time of grant. Except for certain option and restricted stock unit grants made to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a four-year period, subject to continuous service through each applicable vesting date. As of December 31, 2021, we have authorized 29,131,628 shares of common stock for issuance under the 2019 Plan.

Changes in shares available for grant during the year ended December 31, 2021 were as follows:

 

 

 

Shares Available for Grant

 

Shares available for grant at December 31, 2020

 

 

18,617,001

 

2019 Equity Incentive Plan reserve increase effective January 1, 2021

 

 

6,882,344

 

Options and restricted stock units granted

 

 

(4,306,265

)

Options and restricted stock units forfeited, cancelled or expired

 

 

1,106,843

 

Shares available for grant at December 31, 2021

 

 

22,299,923

 

 

Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2021 was as follows:

 

 

 

Shares Subject to

Outstanding Options

 

 

Weighted-Average Exercise

Price per Share

 

 

Aggregate Intrinsic Value

(in thousands)

 

Options outstanding at December 31, 2020

 

 

14,433,560

 

 

$

12.82

 

 

 

 

 

Options granted

 

 

3,052,025

 

 

 

39.39

 

 

 

 

 

Options forfeited or cancelled

 

 

(992,428

)

 

 

25.90

 

 

 

 

 

Options expired

 

 

(40,116

)

 

 

26.56

 

 

 

 

 

Options exercised

 

 

(3,674,057

)

 

 

7.21

 

 

 

 

 

Options outstanding at December 31, 2021

 

 

12,778,984

 

 

$

19.72

 

 

$

156,105

 

Options vested and exercisable at December 31, 2021

 

7,281,600

 

 

$

10.99

 

 

$

132,537

 

 

The weighted-average remaining contractual life for options outstanding as of December 31, 2021 was 7.0 years. The weighted-average remaining contractual life for vested and exercisable options as of December 31, 2021 was 5.7 years.

The weighted-average grant date fair value per share of options granted during the year ended December 31, 2021, 2020 and 2019 was $24.22, $21.11 and $6.87, respectively. The total intrinsic value of options exercised during the year ended December 31, 2021, 2020 and 2019 was $156.5 million, $190.4 million and $39.1 million, respectively.

Of the $26.7 million proceeds from exercise of stock options included on our consolidated statements of cash flows for the year ended December 31, 2021, $0.3 million related to options exercised during the year ended December 31, 2020 but settled during the year ended December 31, 2021. Of the $21.7 million proceeds from exercise of stock options included on our consolidated statements of cash flows for the year ended December 31, 2020, $0.5 million related to options exercised during the year ended December 31, 2019 but settled during the year ended December 31, 2020.

Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2021 was as follows:

 

 

 

Restricted Stock Units

Outstanding

 

 

Weighted-Average Grant Date

Fair Value per Share

 

Nonvested outstanding restricted stock units at December 31, 2020

 

 

50,000

 

 

$

28.10

 

Restricted stock units granted

 

 

1,254,240

 

 

 

37.98

 

Restricted stock units forfeited or cancelled

 

 

(74,299

)

 

 

43.20

 

Restricted stock units vested

 

 

(18,750

)

 

 

28.10

 

Nonvested outstanding restricted stock units at December 31, 2021

 

 

1,211,191

 

 

$

37.41

 

126

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

 

The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2020 and 2019 was $28.10 and $41.63, respectively.

Grant Date Fair Value of Options and Restricted Stock Units Granted

The estimated grant date fair values of options granted during the years ended December 31, 2021, 2020 and 2019 were estimated using the Black-Scholes option-pricing model with the following assumptions:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Fair value of common stock

 

$30.86 - $66.50

 

 

$17.68 - $55.23

 

 

$7.80 - $47.81

 

Expected term (in years)

 

5.27 - 6.08

 

 

5.27 - 6.08

 

 

5.27 - 6.08

 

Risk-free interest rate

 

0.5% - 1.4%

 

 

0.4% - 1.7%

 

 

1.4% - 2.5%

 

Expected volatility

 

67.1% - 70.0%

 

 

70.5% - 73.3%

 

 

64.3% - 72.9%

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 

The determination of the grant date fair value of stock options using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:

Fair value of common stock—Prior to the closing of our initial public offering, the fair value of our common stock was determined with input from management using valuation methodologies which utilized certain assumptions, including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of our common stock, the methodologies, approaches and assumptions used to estimate the enterprise value were consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. For option grants made after the closing of our initial public offering, the fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.

Expected term—The expected term of options granted to employees and non-employee directors is determined using the “simplified” method, as illustrated in ASC Topic 718, Compensation—Stock Compensation, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is based on the midpoint between the vesting date and the end of the contractual term of the option.

Risk-free interest rate—We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the options.

Expected volatility—As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term.

Expected dividend yield—We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of zero in the option valuation model.

The grant date fair value of restricted stock units granted is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.

The compensation costs related to stock options and restricted stock units for the years ended December 31, 2021, 2020 and 2019 are included on our consolidated statements of operations as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of revenue

 

$

2,100

 

 

$

817

 

 

$

555

 

Research and development

 

 

14,061

 

 

 

8,519

 

 

 

3,934

 

Sales and marketing

 

 

12,312

 

 

 

6,627

 

 

 

3,480

 

General and administrative

 

 

14,778

 

 

 

8,798

 

 

 

5,155

 

Total share-based compensation expense

 

$

43,251

 

 

$

24,761

 

 

$

13,124

 

 

As of December 31, 2021, unrecognized share-based compensation expense related to unvested stock options was $96.8 million, which is expected to be recognized over a remaining weighted-average period of 2.9 years. Additionally, as of December 31, 2021, unrecognized share-based compensation expense related to unvested restricted stock units was $38.3 million, which is expected to be recognized over a remaining weighted-average period of 3.4 years.

127

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

 

14.

Microsoft Collaboration Agreement

Summary of Agreement

In December 2017, we entered into a collaboration agreement with Microsoft (“Microsoft Agreement”) to computationally derive a comprehensive TCR antigen map for purposes of developing a universal diagnostic based on a single blood test.

Contemporaneously with the Microsoft Agreement, we entered into a separate agreement to use Microsoft’s Azure cloud services at standard volume pricing with a minimum Azure purchase requirement of $12.0 million over the seven-year term of the Microsoft Agreement, which we expect to meet in the ordinary course of business.

In addition, contemporaneously with entering into the Microsoft Agreement, Microsoft made a preferred stock investment of $45.0 million as a part of our Series F-1 convertible preferred stock issuance.

Summary of Accounting

The terms of the Microsoft Agreement meet the criteria under ASC Topic 808, Collaborative Arrangements (“ASC 808”), as both parties are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity. ASC 808 does not provide guidance on how to account for the activities under the collaboration and we determined that Microsoft did not meet the definition of a customer under ASC 606. Accordingly, we looked to other guidance to determine the accounting for the respective elements.

We determined that the preferred stock issuance and commitment to use Microsoft’s Azure cloud services were made at terms consistent with market rates. All consideration received as part of the Series F-1 convertible preferred stock issuance was accounted for as part of the Series F-1 preferred stock issuance. Since the commitment to purchase Microsoft’s Azure cloud services was at market terms and we expect to meet the commitment in the ordinary course of business during the seven-year term, we record the expenses in the period in which the services are consumed. These costs are recorded in our consolidated statements of operations based on the underlying activities for which they support.

The remaining elements of the agreement were highly interrelated, so we evaluated them in the aggregate to determine the appropriate accounting application. Specifically, we determined that the transfer of license rights between the parties, our commitment to provide data and immunomics, diagnostic and bioinformatics expertise to Microsoft and Microsoft’s commitment to provide machine learning software and related development services to us were highly interrelated because they were necessary for the parties to perform the activities under the Microsoft Agreement and, therefore, should be evaluated as one unit of account.

We accounted for these collaboration activities by analogy to ASC Topic 845, Nonmonetary Transactions, and determined that major uncertainties exist about the realizability of the value that would be assigned to an asset received from or provided to Microsoft under the collaboration and, therefore, fair value could not be reliably measured. As a result, we did not recognize any non-monetary assets or corresponding non-monetary income or expenses pertaining to the rights provided to us or to be received by us under the Microsoft Agreement.

15.

Income Taxes

The components of loss before provision for income taxes for the periods presented are as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Domestic

 

$

(207,314

)

 

$

(146,227

)

 

$

(68,606

)

Foreign

 

 

16

 

 

 

—

 

 

 

—

 

Total loss before provision for income taxes

 

$

(207,298

)

 

$

(146,227

)

 

$

(68,606

)

128

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of our deferred tax assets and liabilities as of the dates presented are as follows (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets

 

 

 

 

 

 

 

 

Net operating losses

 

$

200,363

 

 

$

105,433

 

Tax credit carryforward

 

 

31,200

 

 

 

18,981

 

Nonqualifying stock options

 

 

18,072

 

 

 

12,096

 

Deferred rent

 

 

—

 

 

 

—

 

Operating lease liabilities

 

 

30,401

 

 

 

31,052

 

Deferred revenue

 

 

42,481

 

 

 

59,713

 

Other

 

 

4,345

 

 

 

2,983

 

Total deferred tax assets

 

 

326,862

 

 

 

230,258

 

Less: Valuation allowance

 

 

(297,020

)

 

 

(197,527

)

Deferred tax assets, net of valuation allowance

 

 

29,842

 

 

 

32,731

 

Deferred tax liabilities

 

 

 

 

 

 

 

 

Tangible and intangible assets

 

 

(7,310

)

 

 

(5,760

)

ROU assets

 

 

(22,532

)

 

 

(26,971

)

Net deferred taxes

 

$

—

 

 

$

—

 

 

ASC Topic 740, Income Taxes, requires that the tax benefit of NOLs, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $99.5 million and $96.6 million during the year ended December 31, 2021 and 2020, respectively.

Federal tax laws impose substantial restrictions on the utilization of NOL and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through December 31, 2020 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the TCJA federal income tax law, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years. As of December 31, 2021, we had U.S. federal NOLs of $192.5 million and U.S. federal tax credits of $33.6 million that will begin to expire in 2028. We also had $576.2 million of NOLs as of December 31, 2021 that do not expire.

The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:

 

 

 

Year Ended December 31,

 

 

2021

 

2020

 

2019

Statutory rate

 

21.0%

 

21.0%

 

21.0%

State tax, net of federal tax benefit

 

8.3

 

13.8

 

8.1

Stock compensation

 

14.1

 

25.2

 

9.8

Permanent items

 

(0.1)

 

(0.1)

 

(1.0)

Credits

 

4.7

 

5.7

 

6.1

Other

 

(0.3)

 

0.5

 

0.3

Change in valuation allowance

 

(47.7)

 

(66.1)

 

(44.3)

Total

 

0.0%

 

0.0%

 

0.0%

 

129

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

 

We account for Global Intangible Low-Taxed Income as period costs when incurred.

We recognize, in our consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $6.9 million as of December 31, 2021. A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):

 

Balance at December 31, 2018

 

$

1,260

 

Additions in 2019

 

 

792

 

Balance at December 31, 2019

 

 

2,052

 

Additions in 2020

 

 

1,437

 

Balance at December 31, 2020

 

 

3,489

 

Additions in 2021

 

 

3,426

 

Balance at December 31, 2021

 

$

6,915

 

 

During the year ended December 31, 2021, 2020 and 2019, we recognized uncertain tax positions of $3.4 million, $1.4 million and $0.8 million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.

We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had no accrued interest or penalties related to uncertain tax positions as of December 31, 2021 and 2020.

We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.

16.

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019 (in thousands, except share and per share amounts):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

$

(207,279

)

 

$

(146,227

)

 

$

(68,606

)

Fair value adjustment to redemption value for Series E-1 convertible preferred stock options

 

 

—

 

 

 

—

 

 

 

(964

)

Net loss attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(207,279

)

 

$

(146,227

)

 

$

(69,570

)

Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

 

140,354,915

 

 

 

131,216,468

 

 

 

69,165,315

 

Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(1.48

)

 

$

(1.11

)

 

$

(1.01

)

 

130

Adaptive Biotechnologies Corporation

Notes to Consolidated Financial Statements (Continued)

 

 

Since we were in a loss position for all periods presented, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is the same as diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019, as they had an anti-dilutive effect:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock (on as if converted basis)

 

 

—

 

 

 

—

 

 

 

46,104,469

 

Stock options issued and outstanding

 

 

13,097,374

 

 

 

16,125,548

 

 

 

17,183,546

 

Nonvested restricted stock units

 

 

693,173

 

 

 

38,125

 

 

 

4,952

 

Common stock warrants

 

 

8,570

 

 

 

56,875

 

 

 

55,961

 

Convertible preferred stock warrant

 

 

—

 

 

 

—

 

 

 

28,204

 

Total

 

 

13,799,117

 

 

 

16,220,548

 

 

 

63,377,132

 

 

 

17.

Retirement Plan

We maintain a salary deferral 401(k) plan (“401(k) Plan”) covering employees who have met certain eligibility requirements. Employees may defer up to 100% of their compensation to the 401(k) Plan, subject to federal limits. We made $2.5 million and $1.6 million in discretionary contributions during the year ended December 31, 2021 and 2020, respectively, which are fully vested after one year of employee service. We did not make any discretionary contributions during the year ended December 31, 2019.

131

 

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of December 31, 2021. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective as of December 31, 2021.

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on that assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2021 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with GAAP.

The effectiveness of our internal control over financial reporting as of December 31, 2021 has been audited by an independent registered public accounting firm, as stated in their report, which is included below.

Changes in Internal Control

There was not any change in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) under the Exchange Act, during the three months ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

132

 

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Adaptive Biotechnologies Corporation

Opinion on Internal Control Over Financial Reporting

We have audited Adaptive Biotechnologies Corporation’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Adaptive Biotechnologies Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (the PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and shareholders’ (deficit) equity and cash flows for each of the three years in the period ended December 31, 2021, and related notes and our report dated February 15, 2022 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Inherent Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP

 

Seattle, Washington

February 15, 2022

133

 

Item 9B. Other Information

Not applicable.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

134

 

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The information required by this Item 10 of Form 10-K will be included in our definitive proxy statement to be filed with the SEC in connection with the solicitation of proxies for our 2022 Annual Meeting of Shareholders (“2022 Proxy Statement”) and is incorporated herein by reference.

Item 11. Executive Compensation

The information required by this Item 11 of Form 10-K will be included in our 2022 Proxy Statement and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this Item 12 of Form 10-K, including with respect to our equity compensation plans, will be included in our 2022 Proxy Statement and is incorporated herein by reference.

The information required by this Item 13 of Form 10-K will be included in our 2022 Proxy Statement and is incorporated herein by reference.

Item 14. Principal Accounting Fees and Services

The information required by this Item 14 of Form 10-K will be included in our 2022 Proxy Statement and is incorporated herein by reference.

 

135

 

 

PART IV

Item 15. Exhibits, Financial Statement Schedules

 

(a)

  The following documents are filed as part of this Annual Report on Form 10-K:

 

(1)

   Financial Statements

See Index to Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K.

 

(2)

   Financial Statement Schedules

All financial statement schedules have been omitted since the required information was not applicable or was not present in amounts sufficient to require submission of the schedules, or because the information required is included in the consolidated financial statements or the accompanying notes.

 

(3)

   Exhibits

The exhibits listed in the following Index to Exhibits are filed, furnished or incorporated by reference as part of this Annual Report on Form 10-K.

Index to Exhibits

 

 

 

 

Incorporated by Reference

Exhibit

Number

Exhibit Title

Filed/Furnished

With This

Report

Form

File No.

Exhibit

Filing Date

3.1

Amended and Restated Articles of Incorporation

 

8-K

001-38957

3.1

7/1/2019

3.2

Amended and Restated Bylaws

 

8-K

001-38957

3.2

7/1/2019

4.1

Seventh Amended and Restated Investors' Rights Agreement among the Registrant and certain of its shareholders, dated May 30, 2019

 

S-1

333-231838

4.1

5/30/2019

4.2

Description of Securities

 

10-K

001-38957

4.3

2/26/2020

10.1†

Strategic Collaboration and License Agreement between Genentech, Inc. and the Registrant, dated December 19, 2018

 

S-1

333-231838

10.1

5/30/2019

10.2†

Strategic Collaboration Agreement between Microsoft Corporation and the Registrant, dated December 11, 2017

 

S-1

333-231838

10.2

5/30/2019

10.3†

Master Terms & Conditions of Sale between Illumina, Inc. and the Registrant, dated May 28, 2019

 

S-1/A

333-231838

10.3

6/17/2019

10.4

Amended and Restated Side Letter Agreement among Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Long Fund Master Ltd. and the Registrant, dated May 8, 2019

 

S-1

333-231838

10.5

5/30/2019

10.5*

Form of Amended and Restated Employment Agreement between the Registrant and certain of its executive officers

 

S-1

333-231838

10.7

5/30/2019

10.6*

Form of Amended and Restated Employment Agreement between the Registrant and each of Lance Baldo, MD and Francis T. Lo

 

S-1

333-231838

10.8

5/30/2019

10.7*

Form of Restated Non-Employee Director Change in Control Agreement between the Registrant and each of its non-employee directors

 

S-1

333-231838

10.9

5/30/2019

10.8*

Executive Severance Agreement between the Registrant and Lance Baldo, MD, dated April 22, 2019

 

S-1

333-231838

10.11

5/30/2019

136

 

 

 

 

Incorporated by Reference

Exhibit

Number

Exhibit Title

Filed/Furnished

With This

Report

Form

File No.

Exhibit

Filing Date

10.9*

Form of Executive Severance Agreement between the Registrant and certain of its executive officers

 

10-Q

001-38957

10.1

8/10/2020

10.10*

Form of Indemnification Agreement between the Registrant and its directors and executive officers

 

S-1

333-231838

10.13

5/30/2019

10.11*

Adaptive Biotechnologies Corporation Non-Employee Director Compensation Policy

 

10-K

001-38957

10.12

2/24/2021

10.12*

Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan and form of award agreement thereunder

 

S-1

333-231838

10.15

5/30/2019

10.13*

Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and form of award agreement thereunder

 

10-Q

001-38957

10.12

8/13/2019

10.14*

Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan

 

S-1/A

333-231838

10.17

6/17/2019

10.15*

Form of Stock Option Agreement for Non-U.S Participants

 

10-K

001-38957

10.16

2/24/2021

10.16*

Form of Restricted Stock Unit Agreement for Non-U.S Participants

 

10-K

001-38957

10.17

2/24/2021

10.17

Lease Agreement between ARE-Seattle No. 11, LLC and Adaptive TCR Corporation, dated July 21, 2011, as amended by Amendment No. 1, dated August 26, 2011, Amendment No. 2, dated June 30, 2014, Amendment No. 3, dated November 5, 2015, Amendment No. 4, dated December 23, 2015, and Amendment No. 5, dated June 6, 2016

 

S-1

333-231838

10.18

5/30/2019

10.18†

Sixth Amendment to Lease Agreement between Adaptive Biotechnologies Corporation and ARE-Seattle No. 11, LLC, dated August 2, 2019

 

8-K

001-38957

10.1

8/7/2019

10.19†

Lease Agreement between Adaptive Biotechnologies Corporation and ARE-Seattle No. 12, LLC, dated August 2, 2019

 

8-K

001-38957

10.2

8/7/2019

21.1

List of Subsidiaries

X

 

 

 

 

23.1

Consent of Independent Registered Public Accounting Firm

X

 

 

 

 

24.1

Power of Attorney (included on the signature page)

X

 

 

 

 

31.1

Certification of Principal Executive Officer pursuant to Rule 13a‑14(a) or Rule 15d‑14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

X

 

 

 

 

31.2

Certification of Principal Financial Officer pursuant to Rule 13a‑14(a) or Rule 15d‑14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

X

 

 

 

 

137

 

 

 

 

Incorporated by Reference

Exhibit

Number

Exhibit Title

Filed/Furnished

With This

Report

Form

File No.

Exhibit

Filing Date

32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

X

 

 

 

 

32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

X

 

 

 

 

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

X

 

 

 

 

101.SCH

Inline XBRL Taxonomy Extension Schema Document

X

 

 

 

 

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

X

 

 

 

 

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

X

 

 

 

 

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

X

 

 

 

 

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

X

 

 

 

 

104

Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)

X

 

 

 

 

 

*

Management contract or compensation plan or arrangement.

†

Portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K promulgated under the Securities Act because the information is not material and would be competitively harmful if publicly disclosed.

Item 16. Form 10-K Summary

Not applicable.

138

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Seattle, State of Washington, on February 15, 2022.

 

Adaptive Biotechnologies Corporation

 

 

 

 

By:    

 

/s/ Chad Robins

 

 

Chad Robins

Chief Executive Officer

 

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Chad Robins, his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

/s/ Chad Robins

Chad Robins

 

Chief Executive Officer and Director

(Principal Executive Officer)

 

 

 

February 15, 2022

 

 

 

/s/ Chad Cohen

Chad Cohen

 

Chief Financial Officer

(Principal Financial Officer)

 

 

 

February 15, 2022

 

 

 

/s/ Kyle Piskel

Kyle Piskel

 

VP, Principal Accounting Officer

(Principal Accounting Officer)

 

 

 

February 15, 2022

 

 

 

/s/ Kevin Conroy

Kevin Conroy

 

Director

 

 

 

 

February 15, 2022

 

 

 

/s/ Michelle Griffin

Michelle Griffin

 

Director

 

 

 

 

February 15, 2022

 

 

 

/s/ Robert Hershberg

Robert Hershberg, PhD, MD

 

Director

 

 

 

 

February 15, 2022

 

 

 

/s/ Peter Neupert

Peter Neupert

 

Director

 

 

 

 

February 15, 2022

 

 

 

/s/ Katey Owen

Katey Owen, PhD

 

Director

 

 

 

 

February 15, 2022

 

 

 

/s/ Michael Pellini

Michael Pellini, MD

 

Director

 

 

 

 

February 15, 2022

 

 

 

/s/ Leslie Trigg

Leslie Trigg

 

Director

 

 

 

 

February 15, 2022

 

 

 

 

139

 EX-21.1 2 adpt-ex211_7.htm EX-21.1 adpt-ex211_7.htm

Exhibit 21.1

List of Subsidiaries of Adaptive Biotechnologies Corporation

Subsidiary

Jurisdiction of Organization

Digital Biotechnologies, Inc.

Delaware

Adaptive Biotechnologies B.V.

Netherlands

 

 EX-23.1 3 adpt-ex231_14.htm EX-23.1 adpt-ex231_14.htm

Exhibit 23.1

 

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements:

 

(1)

Registration Statement (Form S-8 No. 333-232495) pertaining to the Sequenta Inc., 2008 Stock Plan, the Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan, the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and the Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan and

 

(2)

Registration Statement (Form S-3ASR No. 333-239854) of Adaptive Biotechnologies Corporation;

 

of our reports dated February 15, 2022, with respect to the consolidated financial statements of Adaptive Biotechnologies Corporation, and the effectiveness of internal control over financial reporting of Adaptive Biotechnologies Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2021.

 

/s/ Ernst & Young LLP

 

Seattle, Washington

February 15, 2022

 

 EX-31.1 4 adpt-ex311_6.htm EX-31.1 adpt-ex311_6.htm

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Chad Robins, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of Adaptive Biotechnologies Corporation;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

c)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: February 15, 2022

 

By:

/s/ Chad Robins

 

 

 

Chad Robins

 

 

 

Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 EX-31.2 5 adpt-ex312_8.htm EX-31.2 adpt-ex312_8.htm

Exhibit 31.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Chad Cohen, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of Adaptive Biotechnologies Corporation;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

c)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: February 15, 2022

 

By:

/s/ Chad Cohen

 

 

 

Chad Cohen

 

 

 

Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

 

 

 

 

 

 EX-32.1 6 adpt-ex321_11.htm EX-32.1 adpt-ex321_11.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Adaptive Biotechnologies Corporation (the “Company”) on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: February 15, 2022

 

By:

/s/ Chad Robins

 

 

 

Chad Robins

 

 

 

Chief Executive Officer

 

 

 

(Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 EX-32.2 7 adpt-ex322_13.htm EX-32.2 adpt-ex322_13.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Adaptive Biotechnologies Corporation (the “Company”) on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: February 15, 2022

 

By:

/s/ Chad Cohen

 

 

 

Chad Cohen

 

 

 

Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

 

 

 

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 GRAPHIC 8 g4bdklltl5z5000003.jpg GRAPHIC begin 644 g4bdklltl5z5000003.jpg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g4bdklltl5z5000011.jpg GRAPHIC begin 644 g4bdklltl5z5000011.jpg M_]C_X 02D9)1@ ! 0$!+ $L #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" 0#!JH# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_"BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **8[ M8^8#(52,C@EVP%0#HS XY/\ ^K/U+5+#2K*^U'5+ZSTO3=-MWNK_ %&]N%MK M2QAA3?)+>7$[)##&J_>8N!GKVR :=%?D=^Q+_P %=/@C^W=^V1^U5^RO\%M/ MEU?2?V8M!T;5;WXEV]T9](\6W=_K0T&]M=+PHC\JROA,IE1F$GE\$C-?KC0 M45&^\8V[<,26W-CY%7#<_P !ZD'IQR:_G+_;K_X.,OV>?V6/C?<_LU?!/X<^ M,_VJOC1X>O'M/&/A[X>6ES?6?AR:-9#-I\M]86\Z/?VAC=+I)F4(_ SC- '] M'%%?B'_P3:_X+G_LP?\ !0WQC#T(H6K\M6WVL*4HPBY2DE:VG5^B\B[14"OD,-V63& M<=@><'NQ'BXOM\2^]+T"S\OO7^8M)D>HH)QSVIIR1E5! M^N/U_P W*[K:]_R[/N%I6NXZ;_$EV_S:]4.R#T(I:C7<#@J">O& M!Q_^NG\_3I_]?_"DY):W=M.CZ_Y=?0-EJTOFG<6BBCOFB]U>*NNKNM-O\P2= MM;)Z:-K_ #^844F>GX_3CUI:=UT:?>VMGU7JNPDI-VY7T[>7W]?N^XHIC!B> M,_G@?S_I2H3@Y]>]2IIRY4I7UWBUMZZ_@)NSU7SNK=/\_P"KCJ***%.#?*I7 ME_*D[]/\_P "GHKW3^:^0F1ZBEI,#T'Y4 =!6B2?5^G*P2DU>WXI]$^XM&< M=>**0CCIGZ\_J:ARBM&_>OI&SN]M5T[_ '">B3TOII>_Y:?YBYSTYHJ+=@], M>P'I[@4_YOY]^OX=O7].^:4IQAR\[Y>:UM&^U]EJ#4DDTN9O97MU[O3\1U)D M'H12 L?X\7Y;=]'?Y"3;TMZ^\O+S]?N^Y:*3G'OZC^G^-!.T=SC M ]SVH4HOK;U32^]_U^-J2;[?^!+R^_K_ %LM%-SD=<<9..W?_/K368X&,X]? M6FY>XYKWDG:T=7T[7[^NPNKO906\[Z7T5OQ\OF244T$[E("_.1G\ MA_\ KIO3I+9/X7UMIMTO;U$VD[77WK;N/HIN6_N_K_\ 6HW-_=/Y_P#UJ/E+ M_P !E_EYK[PYEW7WH=13AU%-RW]W]?_K4;F_NG\_\ ZU/Y/[GY>7F@ MYEW7WH=13:^\.9=U]XZBFY;^[^O_ -:C M9EB$=MW][.!CM2NO3U37YH-.C3?97\O+S_+N3T5DW6J6&G0275Y M>VMG J;CM>'P]:M&+?PING"2UU^:L>JT5Y=_PN/X:.857QOX;_?(/*)UFQ3S M6;Y0V!/G82<*1DEAFN]L-0L[^(7EC>6U_!*JF.:VF2XA8D<$21%TQC.<9Y!/ MTNG7H54W2JPJ-.SC"2G+=*_+%MV\[$XO+,PP$/:8_ XO!P?P2Q&&K4E-II22 MQJ$X&3THJ)R?NYP?ER,;@3WVGTR?PZ&I:V2^2>SMOMI;?3S6^ MAP_93NM6TE?72VO3>X444UB0,BEUM9W]'_D#T2;W?V5JWMM;U'44S!/SY./[ MO7Z_GV_2C# \M\O7.?T]?UQ^-&MH-)OFW6B<=$[._P#7R%=6;>EO)Z_@/HI M?R[?3_/%+3::=@332:U3V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** (7PSHA+!N2O==S8"G)(VE<9P.GKZ?SM_\%6? MV4O^"H'[=W[1'A']FGX'?$^R^ O[!^K^#$NOC#\1]%N#'XTUG7//<:AX9B2/ M;-Y=U:JBP3(Q,Y\9;E\KG) M7')'/7V/44 ?PJ?\&O\ \$]"_9K_ ."J_P#P56^ ?AJ_O-4T7X7_ _\'^&K M74=1F>XU"^>T\>*MS?:A<29::XNYP\YD8L3YC5_=?7\7'_! T*G_ 7/_P"" MU"AVQ_9&@':3QC_A8C9?=VZA0#TP?2O[1@0>A!Q@?F,C\QS0!\U_MB_%9O@? M^RO^T+\6XED6Y\"?"7QKK-E)N\LKJ":)=PZ=+$_/^HOI;:7&!ED(R,Y'\U__ M :@?LO^ ]=_8D\:?MP?$31=)\%_B7;:#;II5IXM@&HZ7!IPU+1XKC MRE0-(=KW=N7(4A0<]C7]BOA"W:#PKX7A<%)(?#NA1NAZHT6E6D;*<\Y#+B@# M>FE\KYCA4&-\CE4C0=V+L0!CONPH'6HQJ%@QP+ZR8@9GIST_QK MA/BYX(O/B3\,_'G@"PUV_P#"][XU\):WX:MO$FDR-!J6@SZI926L.JV=?^"!?QC48?\ X*1?M(DC^&[<2<']W_ .![8H M _I5^VV?_/Y:?^!,'_QROYS_ -O?]K?7OV=O^"S'['MQK?CC5=*_9XM?V3_B MCKOQ"T73[@/H]]XM@\3ZG'H$=U&CF-M2GB%M';B0;O+*D<5S?_#@[XO\?\;( M?VD><@$>*+[G SQ^[STK\2_^"A?[++_LH?&G1_A9JW[0WB[]H#7H/"XU35O$ M'C>\DU/5_#UT*6>0[X[>>%A>K ."3NQGI%3"Y]BX^SX>RJOG./C*$OJ M5",G.I24XJ?PVM'WES-M)7NS] \-%@N>Z;E45K)& M&W6H3O\ *0LPC &2>" .YX'O_GJ^&/#%AKVOZ+H=SK\6A1ZMJ-K:2ZI(9([: MR-]*L2SW#JPVVZNX9\\1KD] :T_'/@NV\&^+M?\ ""^*8M?7P_>O9'5]/NIY M+2^>/[TUI()0K1C&(V&1(OYCAQ.4>+SQM:G0\-LQIQA",J<)QJ3C9I.24H-Q M76W,].I_35/PF^B+.DJT?I'99'GDN:G[;"-N>GN!NX M#YS]SU8C P>*_A]\/? .7Q'\#?'/QQA\=:+8Z9X%U*TTF^\-W%QMUF]OM0!: MS6WMBPDD2XC21B5R%*\U]L_!/_@D9\<_CU\+?"7Q<^'_ (J\/7_ASQ98QWD* MQS&>:R)R)=*NU#9AOK4C]_$_S)N7/6O!S7&<<9-2E/,^!LPP;A:-1U:=32JX MIJ[YM'UMNUJNQ])EW@A]$_,TEA?'W+IR:YN6.)HS?+>*NDJ;=KV7-HNG1G]? M-M^WC^RE>5ZCVKE?$G_!2']D'PI=P MV6H_&#PU<33QB5/[/O4NU"DXY92 /SXK^83_ (<6_M5J'$>NZ6"R,P033[50 MC@*/,XYR1Z9/ IX_X(6?M4MM*ZUI1.W:[S/*[8QG"%F) YQQQ_3Y:CQQQ;*3 M4N%,1*-[*48U$NC2LY73LKO1/3S.^'T;/Z53_ ,%2?V+^A^+&E?FO_P 576>&/^"B_P"R%XK^U-I_QD\+6HLR M!*NHW\=H2"NN1UXK^7P_\ !"G]JN#6T^-.(VER\*8GO?W[2LHW2=[/6 M][>78J7T;#_@J7^QF25_X6MI.[ .W<,J# MT+C/'YU_-0/^"%G[5FTQOK6EM#N&Z,339;'&23(>_8\=^PJ0?\$*/VJVRKZU MHJQ%OG1"Q:5,$ &3.5[<8]>:>'XUXE;M+A/$)65TU+5Z:WYMO33YA3^CG]%R MFK5O'S"5FW[LHNC'2T?=M&BDTNC>NK7I_2W9_P#!4/\ 8SO;B&U3XLZ-%+/< M);IY\HC4,QQYA;)_>G7K M7\J7_#BG]JH,2VMZ."J+'$4\PLL?]PX;(QTW]C[GA3_P0L_:L!VMK>EI&" P M2>XWE.SJWF?>7M]>_:9\9<4J?[K@W$.DG=WE)::?]/-;^CZ=634^CE]&*IRN M'C]@J2[A_PXJ_:KX)UC1SZ_,V/T85H^,\_BO=X2Q4)M M*T$JDDF[+=2UU\K]RU]'7Z+^S\>L'=))R=:FKNRU25)=;.R5DS^I'0/^"@_[ M)7B/3DU.Q^,W@V&"1B@COM3CMIT(;'SQMDJ."?<=Z9XA_P""A7[)7AFP;4K[ MXS>#;FW601;=/U..YE+GGA!@E<=6Z=J_ER/_ 0K_:K(P=G?#ZZ+3G]CS?/1^9_2HO\ P5+_ &,6 MW@?%;2\QIO/(VL.VUMW)/^?2M'1?^"G'['.NZE9:5:?%K0H+F^9TA>]G6"!& M0$DSRDD1*V,(3]X\>Y_F9?\ X(4_M52==7T7 ''SNO..H .>O.,C\.:4?\$* M_P!JH !M7T@_=\P([JTF%PH\P,"@3@\>F#6G^NO$"_A\)8KVFS]V=FVU>]I- MZVU?F7_Q+I]%UWC_ ,1ZP:TT?M:3LVDDTG3LTF[JZ:/ZJ?\ AN?]EC#N/C9X M#PJE]AUN'<0O+ #@$CG@&O,)O^"H?[&EO<7%L_Q:T9VMY6A9X9%>-G4X;8Q8 M;E![CM7\TI_X(5?M7%6SKVF,=J^6WVBX#*X^]SYG((.#DW+[]&'+:VB]G25[Z;]3^EC_ (>D_L88)_X6QI6,]2Z@ M#MSSG'J:]'T[]O?]E#4[.VOH/C1X)CANHO.C6?5XHY0G7YHCR&(['!_2OY7Q M_P $)_VJ#PVL:/M[CB?[RE&[NND:% MH^=E;3S/Z=?#'_!2;]C_ ,67D]EI_P 8/#5O);VOVMY-1NTM8GC$@CQ&[<-) MD[M@QE3FNSN_V\/V4;2UGNV^-?@66.WB>9Q%K,3%DCR650.3+Z(.IP/6OY5_ M^'%7[562/[9TA,@;O+>6-4(Z"-E8%E XVGC.3S3Q_P $+/VK-NTZSI91BV5% MQ. K\^7)MW_-R,L,XYZ8K&IQKQ8YP5/A/$^R=NDMM.SO9.R^_P!#.I]'#Z,; ME3G'Z06!4/=_<_N)-;?;G1;5]KK:]MS^E'_AZ;^Q@02/BMI>,GJRYZD=-V>W MY4]/^"I/[&+NB+\5]*R\B)DLH5=[;0Q.X\ D9]!DU_-2/^"%/[5)P7UK2&;^ M)LLN6[D#/0GZ=SSFE'_!"K]JA#E=9TC.",DN>",=C]!ZCM6W^N?$6T>%L6ZB MMHXSMS77-:[6G]:6=]/^)=?HON__ !OG!+R]O3?:^GL[/IKUW:Z']5 _;I_9 M6*HX^-O@,+)M8;M;AR%<^O4=UUT6MWMK_ $K_ /#TK]C'C/Q7TP [ MLY(&PJ,D/\W''3KFNQ\,?\%$/V1_%EK/?:=\8_"EO#;W'V9DU'4([21B5!$J MQN26BYQO'&X8(XK^7=O^"%'[5)+(-9TC8X DG77\=7 MK9WZZ3^CC]&*4&J?C[@8R:2C+VE&75='2L[ZKOV=[-_U(>(/^"@W[)?A[3YM M3NOC+X.FMX9!&RV>J1SW$C,0/W4:C+J.N1@8%<"?^"I/[&:@AOBOI7 :3AU/ M"YZF>]?S8'_@A5^U6V?^)UI+ A?)+S3N8AT*[&?!)'<_AZ5^?W[6W[ M'WCS]C?Q9I/@SXG:G:S:GKNB3^(+9[0NQCL[:7RV8KNY)YR.F!FO2R;/^.,X MKO#83@C$5*C@YQAA^>=R?+&[>C22OI8Y<9X"?14RK#1JXSQ^P+H* M456K3JX>E&,Y.,5%OV2AK)K?5MV6MK?W/Z7^WG^RGJ5C:Z@GQK\#10WD$=S" MD^L1),L"_B+X?US31H?CGPWI?BG24:>;*Z?J]NMS:@J),!_*9=RCD'(%=H? M^"%W[5JC)UO2P..?/F[]/^6M>3B.,>,,/7JT*G".)52E-PG'WI^J'#Z.?T9*\8U:7TA,'"G4]Z$>3#-J+<;+^#JK/?JM?,_JN_P"&Y?V5 M/^BW^ ?_ =1?X4#]N7]E0X_XO=X"'_<9BS^6*_E.'_!#']JH]-=TKCK^^GX M_P#(G\JD/_!"_P#:JP-NN:83TR)I^2,9ZR9_*L5QQQ;I;A+$_P#@,NG*_P"? MIIM^B*_XEN^C1U^D+@^F]/#:;?\ 3GS?W>:/ZK?^&Y?V5/\ HM_@'_P=1?X? MX4?\-R_LJ?\ 1;_ /_@YB_PK^5$?\$+OVK3R-;TSCG_73CCU_P!8/_K4G_#C M+]JL_P#,X.#QC_EJ>N>HH_UWXMTOPEB;/O&7]W^_MY]+>@?\2W?1 MH>WTA<'T^QAO+?\ _OK5=>W7R%]&_Z,][?\3#8+H_@PVFW_3G MSU^?D?U7_P##9GFE_X<7_M4_P#0>TL\XXEGX/O^\_\ U]J/]=^++\JX M2Q%]'HI];?W^OWZ>@?\ $MWT:/\ I(;!_P#@&%_N_P#3K?7R^ZUOZKO^&Y?V M5/\ HM_@'_P/]_T M^[1[!_Q+=]&?1?\ $PV#\_E<#/^OF_K(*/]=N+K*7^J6*Y='?EG;[-M>?O^7H@_XEO^C/U^D- M@E>W_+O#=;?].O/7TMU/ZKO^&Y?V4_\ HM_@+_P<1=?R_7\*/^&Y?V4_^BW^ M O\ PGPZ?'Z?=Z!_Q+?\ 1HT_XZ'P?3[&%_N_].M]5]WW?U7? M\-R_LI_]%O\ 7XZQ$/Z?YZ4?\-R_LI_]%O\!_\ @XB_S]?3O7\J/_#BW]J[ M_H-Z7_W_ )O_ ([1_P .+?VKO^@WI?\ W_F_^.T_]=N+O^B2Q/\ X#+R_O\ ME^'H'_$M_P!&?_I(?!]/L87^Y_TY\_ZTM_53_K/O8/R#US42XVXNE'3A&O+2]I M\\8NS3LVIWZ6LK/IV&OHW_1HNFOI#X-WMI;"+?E[T7Z6?EY'KO\ P48_X*"^ M,OV@?BQ\1?A/\)_B-:>"?@[\,--NI]3UO2-0,5]X]U&&V$L-OI%PA!>WE8^6 M@C.%8%N2<5^1=U8^,K+X2^$O']S\8]3EU_X@>(;G2M(\*P>([E[O2-.BCWKJ MOB$;P;7>Y\M5)8'&<\FJ?Q:_9C\,OA!\0I_[$\1>']-N-8L;B\\R" MR\3VUK"LRR:?=/\ +*96)CB4EBTBE<<"O+CX%#_#^Q\>P^(+>:W?6)='U307 MJN?ZO>#OA'X7<*<+<(8'@;,,IS'):RRRMB,RE MEV$S#^UJD\KFY^TQ-2A6Y5C*]L5.<90Y)0]E%J+Y7V]KJ?C5_!U_XLN?BMXA M:]\)^(HM)U;PZWB&[BOKK1R54ZKHT@DW3$S[HXXQ@*,25^TO["_[>/BC]EOX MX>!/A1\1/BW'\0O@;\3-%L]1TWQ#J5]]HN_ =U0^*?%VO:9#J&J7EFTDNG>&!-;"Z>/4KA"R! MX.;=B&79*-@&:.',ZSC 8^AB%'AGQ/PWG6"XVS+),GR6&!S26*Q<*I8GZI"4)X<Z< ME)N:F^=3LK?W?I^W)^RB %_X7AX#Y.Y6_MJ$$Y!W!1CG ]_>I#^W+^RGT7XX M^ /K_;,7\L>M?RG_ /#B_P#:J9 W]OZ8RR(J1L9;@&V9>T8#_,#RI//4GI3O M^'%_[58'_(=TPG)X\Z? 'M^\^E?M\.->+I)3?"%>FY)-QBYOWE:\GS3;5WLD MUUTZ'^5$OHW?1GC5DJ?TAL)[+FDDY0PJEH[MM>QLF]GLNEF?U7+^W+^RGDEO MC?X#QA<_\3F'.3TP,<@\YQWIH_;F_94D!_XO?X!PN3)C6X3M7C!' W?EZ_6O MY4O^'%_[5I^9=>TP,APN;B?#9QE2/,[<@=<_:__8>^*'[&1\$1_$N_ MAN9/'IU:'2UL9[C]R-%BCEN2^)(/$V#H5<1B>%Z]"A1CS5: MT^;EI17+K)\-C\YQTW2P&!HTJ$Z^(J MJ#ERPC"@YNT8N4FD[)7TM<_T!/AU\4/ _P 5M";Q)\/O$>E^*]!%U)9KJFBW M*W=J9H@"\9D7 $B@C*]O6N];KU(4]..,^_UZ]Z_$?_@@J7'[%=R69G7_ (3S M5_+;.Z[O3%?MFZ.ZC&XS/^V\GRW- M:D?8_P!I8:EB.577(Y/X&GK':UFM=;'\+^*'!L. /$7BO@BEBOK=+AC.L1E< M<;)*/UA8=P]YI+E3E>ZLDU=V70G7@#\_SIU(O"X^A_G_ (T9YQ@_7'%>S:RM M=M;7>[_JY^?ZN^FMW=+I]WR%HHH!![C'KV_2E=;W5MQV=KVT[A11G_ZWO]** M86?;>S^3V"BBF[AN*^G?U/I['ZT=O/;S]!:]AU%%%&O8 HHHHN 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%'\^P]3V'K^5(.@.0-RJ"""O)/!0GC)]#G\NH M%+@^A_*D8'&2=@&=QQSC MU]MO7/3M0 44P,PYX]Z6D(R"#T(P?I0!_)E_P $5?V7_CQ\(?\ @L7_ ,%?%;3M$_P"$"\3ZA"R6'B1HO'#7C_89& #;+8F1E'&T!N<\?T8_MA?% M?XA? O\ 9N^*OQ9^$G@";XH_$+P=H"ZGX9\"0JSS>)M1^V0VWV"%4PV\1RM/ MN'14)KZ76W@0DK#$K-C<4]HT?(=%8'.590R'ZHV5/ MY4 ?!?["OQC^*G[9/[&6B>/?VE_A!-\%O'?Q)L?&_A;QE\-+M7$FFZ6]SJ&@ MQEUF+,?[0TI_. ).1+Q\M?R:_"_X5?\ !5S_ (("_M ?'7P+^S=\!D_:A_8Q M^-/C2_\ &?@?2;*:XF?PK<74\\MM!'I\;++I]W:PR"TNW5EANAAO++#=7]WJ M11QA52.-%3.U4141<]<(HV@GN<9S2R112@+-%%,H.0LL:R*#ZJ'! /TQ0!_& M!^RY^RI_P4;_ ."L/_!2;X$?M\?\%!?AQ9? K]G_ /9.E;5_A!\'Y56X.LZ^ MKI,\=[IMPK^7#>7:07.H2SEG=[6$*RKE6_M"P!PH 48"@# "@ * !P !V MINQ %54547(5$&Q!GKA%PO)YZ=SZTZ@ SV[U'+]W!S@D ]>G?/MZT_ SGO02 M #GH1@^X/:AJ4HR47RV:N^_7K?\ KH%[R48WB[*[Z[K_ #./\8:GK.C^%?$F MJ^'=+77?$>G:#JESH>D>:L$.KZG;VTLFGZ>;AOEB:ZN!'"S$=&S[U_ Y^T7\ M _VM?'O[;.G?"WXJ^$=O[1_[1.G>(?BGX(\)7&L1W"7OA#2]1N+*3_B8E3#9 MIH@C-C%;.A+>2&&!7^@6%!_A]#T_NG@X['OG&?6OYT/VM!G_ (.._P#@FYG@ MK^QI\9C&PZE3XRUG>&Z=>G]*^]X#\1\?P!C<1CLHP6$Q.,KTX4)SQ=-R=."U M7LW9J*;YI2MJUI?:WY_QOX%;3PE#X@OFLM&1=8MK^^OY,;V=[6 M%4D2VA) :Y&%1ODX-?,.PN7< L\+B.YEE&YTN\AMDCC,2JACVR=&&K=W>VB.?Z*_T+*'B[])#A7@3.<3B,/P1CL76Q MOBJ.#H_6'0<74NHU?925OY7ZH_-I-9:ULKO2X#+_ &9<7,5S=6!EE6VGNK96 MCBGE@WA)Y8@[>66!P,XQ7]#O_!!W]LF#P-XN\0_LO>--9-OX6\7RS^(? :>/[6)C\B)3M!A^5TJ8-4J4)4JL6I0G3J\JLH1C&/Q6TV=C_ *3^+_V8'T?< M=PE/!< 9#3X2XFP&"^K8'/J>(KR=6I""A)8BE*3@U.MS2DDG?H[NZ_T]K6:* M;+1R12H_*.NUN,<+D,02.N!U!SQ5P_=P"IYST&2?S_STK^&+]F+_ (+'?M+_ M +/&@W?AK7'C^+&F&WMTT9?$UW)+K@,))&/ YS7Z>_!G M_@X1\&S:;>?\+H^&&J6NM).5L(_"L\2VD\6T')^U*[&53GH=I'&*^XR#Q#R' M/ZF&P7M_J>8XNK"E##3@DO:27-"'M?@=Y#E4'6_M;+*T:D<1AZ4%*I66%J-5XJG%.56+YOAOX?A4J$[1T_(>OTKP']FGX]>'/VG?@GX%^.7@_3[_2_#7Q T^ZU#2['561] M2M$M;^YTZ2.X:,*A)FM9"H4<+C/3->]H3M'0_ISSG/7Z]L5][4HU:-65&5"$ M*E*4H.*DG&#C-*:DEIS\>5RL^24-.5QVL]5U) MMW^ROY4A8]@/H /ZTG^?6FYSQANN,X]\=ZEJ22NXQ>FD5N[16WEZ^?K:YUM! MOK=RM;X>E_Q[^FLF[_97\J-W^ROY4F,G(/W0<])2$D#@^&$#.RAOAIJ,(.QF 2 M6]17B3"L"SY+D'//3CBO[&P=Y4,, DCN!SZG\N.M>&_$?]F_X*?%[6+?7_B- M\/\ P_XLU.QA-M;7FL:?;W<\,'5HH7=&9$)P2!C/!Z\U][X9<6X7@?BBCQ!B MZ$\9AZ.'Q=+ZK348W5>"@X\UXV6]W>^J[Z_G_B/PEBN-.&,5P[A,1#!U:N*P MLEB9^_:-.K&HW\,KV_(_FR_8 _X+!_$O4O&/[,G[)Q^'GA]/#;#0/APNN[;C M[>ECI=@UO'>J"XC%P5MTW*4'+,<5_5VN'^0])&W[0. 0 2#GD,V(=*\5^&OA5X6TG7-%N1>Z;?VFE6T5S9W48*I-;2I&'20!B,@Y M.K:6NAMP'D7$7#V5RR_/L[CG-3#N,<-5C&SHX>C2A2A M34G&+?+R+W4W8_FV_;)_X+4?%7]FS]HSXB_!;0/ASX9UG3?!^IK96VH78N?. M974'==F-PN3G' QGKFOF!O\ @X=^-S'_ )))X/P!&VUA=Y?<2&5,S?>P,H>0 M,OA;X7U[Q#JLPFU#5+[2[::ZO)N@>XD,1,A M WD].*YP_L+?LHD-GX,^"][#;\VD68*>@ \K(/Z^E?8Y7Q7X44,KPV'QW!-7 M%9A##TJ=?&K$2@IUXJG[6I&'MTKRU:O%-WV/B,RX3\3\1F.(Q> XXEAL#5K5 M)TL).#DXP?PT_@E9)>>B^5O#?^"8W[:WBS]N7X(^+?B=XK\.Z;X;OM ^(FJ^ M#K:ST]9$BEL[&QL[D32"1F/GN]RR,00NU1@>OL/[=W[1NN_LI?LQ^/\ XX^' M=)L]^E"I-=R)&JAIY$C16<@EE4 GBM?QWX# M\(_$OPW?^#/'&B6/B#PYJ;0M?Z1J4"W%G=?9I!+%YL3@AS'*JNF[.& (Z"OS M+$8G)WQ$\;0PDH9*\=&JL#-V<<$IQFZ*]Z24I03A=2>KO<_3<+@,ZEPY'!XC M,F\Y6$E1>-BG%O$--1JK17LVNC^%K??^45?^#ASXV;>?A-X/P<< 7N2>>N)\ MD>AS^F,]3X)_X. /C/XJ\;^"O"ES\*O"$-KXE\6>'=!EN%6\W6\&KZO::;-* MNZ8_.J7+&/MN S7]!:_L+_LHYQ_PI;P:?0?V-:\?^0NE6K#]B/\ 9'J MQI\!XFG5E0FJ5=XF34*TJ=HS0A*AMI &.Y'_UZ_GV_P"" MAW_!7SXF_L=_M.ZS\#/#'@+P]K^DV'@_POXCBU+4UN/MC7&OVTT\T;F*1%,4 M)CQ&, \\FOZ"5Y157S%7 V9*D\ <#([=/;CO7S-\:OV9?@9\2$\5^/O''PX\ M-^(_%G_")ZI:#6M3TVWN;\1:?I%Z+*/SG3>5M"@W3G[:4J2I5%-2A?D2EIS;OU/TOC3 \0XW))T\@S5Y3CJ, MHU98C=RHQIR=6.S2YY*.GDWZ?DK_ ,$[/^"N7Q._;'_:5L_@CXK^'_ASP[I- MSX/\1^)/[1TPS/=?:M&2!HHI#GG=QP#Z8R<'IUQ M^%?P&X3X;S*.55$'B+0S+AJM5XHS[#5 MB@8Y(_0'T_'VIQP01@8_V _A+\2;3Q5X MHBL9=1?2X+*[M6%G!'OEF#7" /M7!8*WX"OL/(!3C Y+!+=+06VL:>;A"@47"#?-&K?,(WW*#GC) M-?DI_P 0\G@&$74 ^,'BYUFD"X-P5@N,\@R1"/9YJ9Y8CC'Y?TML$"J0IYS@ MC/&>O?\ Q]J0G(R0#@$#@9&.N..N>_7WKYG'<*,'AUE-/)^$^,,PP>50GS8?!S]EB*5"5U)>Q^LPJ MNE'?2'+%7?*DC^:Z/_@WA^',@*\"B(8=2,[P#M/.L>,-8V'7O&FJ_Z7K=^^,(L<\H9X8@?O*NU M=O/7@9^M-9F.YE&]R2K 80,O.Y0#R2BY.1P M<#&3P5EG!G#^65Z.)H8&%+$T7)4I\TM>6UFTY22M9^7K=CXV^D9XP^(>4RR7 MB[C#,,PRY\\ZF#2P^'6(;G%RC6EAX4I5J7-JJ=24HM\ONNRL_E1L;!8%,;AA M8R!G/N#U)[G QZR@@\8 SWQGG'X8_/T%0HA7;@Y "$Y 9",Y?.6W+TRW4\X MZ9F!9L8!(^\K*R_,?[C#M^F>IQ7TLE*T9** H"KA3\XSVZGO^7%?RN?\''_%_P#LP *-OVOX M@\@?].5EW'K_ /6K^IN:0CGY<[E!!/W>N5)Z%ASLYX[U_*__ ,'&IW:A^S 0 M05%Y\0G*/\KNGV&RX /!(/4 9 XKXWC^IR<+9X_9.2E@XQNKJ//[2'-RR6[ MBNJ\OG_47T-91E](WPY@JJ4XYK.4WOR\^#KN-TG:WNM+RZ;,^\/^""PS^Q3* M>>/'NK\=L^5"0>O\_P#]?[;@@X/3'&,^WOS7XB_\$%5?_ABF9B?D;Q[K!0J1 MS$8XB V>C)SD@8..V*_;)F("E1E.278A<8P"K@\[AU!&%Y[YKHX%IQ_U2R*$ M4^5Y=AY4W)R>MVVKZZVW_P G<^/^DY*-+QZ\68RGS8R]U)7O*G]VBM9[ M:7L[EH-DD#MBE_R?_K__ %ZBB.03C&<<^HQP?\#W'-*S *Y8_*#U&?;CCH>@ M]CU[U]9%RJ2F/PJL&/S,0 %"E0&!.&QU4$,2#W& .IXIL@G)X'R *4VNN7R, M'>QR,CJOL.FJ%4E&,'.+]M'1*G"27,Y- M)VUUM=W5KHLLW/(..1G\1T_S^-.R ..@%53N)#-E@H!SD8..> ,'/3>O7TQT M+LEDZ8W*3O!"@=2 >F<0N>IY':G*P(?<&P V%9URI],\#:0../K3M"I+EG%QE% M:N#E9;/32S]=-5W(;Y+3CB/B:Y83M9Z+25TM?M;._D3]L$@Y]/RI0,# JFS2 M!<* LOW2S F('AL?*?F-QP>:F!)YW#A5XSP&]2.=N1QAB>3ZT6MK/G M<4M/BMR].9VW?5/O\BERSFESI2LKQ32;TZ+L^_GY$]%%%'-)V2@E#HUO>RTM MYZOY*XMI: M[NKRZD$5M:6]O$\T]S/(Q4)%#$CN[,0 22,9K^0S]IW_@[8_9_\!?%KQ9\) M_P!ESX#>/OVC+CP1XBU+0M7\3Z-8:C>Z-J_]FS&VEU+0[?2XGOET_P"UI-;Q MS7*KYAA9@%! K^@__@I]HWQ4\0_\$\_VQ]$^"/VX_%C4O@'X\M_ @TUV2^.N MG2I3%]E965A+Y(E P02"1WK^>/\ X-'_ -G?]F[4OV O%GQ2N?!GA'Q/\>]1 M^,OC?P[\3-2US3]/U/Q-HL6F&P.FZ1<13K)<65I+NNY(&P%N'$C(6*24 >%' M_@[N^)7?_@G9\5<_]BSXW_\ D6OT)_X)@_\ !P;XW_X*&_M8^'/V;=8_8^\< M_!W3];\-^*->G\:^(-%\265A;CP]ICZ@EF9M3@2W62[9?*17(+$_(":_HN'P M<^%)S_Q;7P:/3/A[3OU_T;FKVE?#KP)X=OX]4T#P5XGOQ4U !1110 4444 %%%% !1110 4444 %%% M% !1111T:Z/>W7U%;5/9KMIV_K_@A_/M7\Y/[6B$?\''7_!-Q\\']C3XS@#T M \9ZU_/!_2OZ-J_G-_:U_P"5C?\ X)M_]F:_&C_U,];IIVT26UMOE]]M+C>M M[ZWMOKMVOMKJ?T6F-A)G('/) Y.!C'/'/<]Z_+__ (*;?L!:=^VO\+;>#2KN MWTGXF>#'EU+P;K5Q$6621OFFT>\DC'G"PNOONL9!\U4/0$5^HQY(P&,HPJX;$QM5IRBFF[IJ23T4XM*2EO=)G MU?!7&F?\ <391Q;PSC)9?G.2XFGB<'B*>CO#25.=FN:E5@Y4ZD+VE", MS$8 P3G%?,J&-2H!#94[)N%JRJ M\.U:F84Y+F>&JS62R_QEJTN&\XP MDK4\9AL M:;XB^'6MZ[X;L]0>ST[Q;X?M7U"TU& $@7"QQK)/'F,!G4HJJ=P'%?%5S!-9 M7$T%U$UI=VSO!)%*A5U*<,D\3#Y'&,$. 0>",BOS.OA\SR#$X5XO"U,%6IUH MU*4_?A.E7HI2C.,[7=^7:_5.Y_HIP]QMP#XN\/N'#F;Y7G^69M@:T)0HXBE5 MG'#8F@XR5:"YI1M&3BXS6^C/Z*OV-/\ @LOX _9C_9G^%/P(O?A]JFOZC\/= M$NK"[U2&YCBCO#>ZK=W[R09(4^5]K96!RQ"@_7^K/P/XIM/&/@KPAXOM8_+M M?%7AK0_$4<>Y7-O'K>G6^H1Q2$=2@N!&[= P.?;_ #&?NY!S&=X*Q/R4!4,& MZD+YF<#T'TK^N7_@@]^UUXM^+?A;QA\ /'FMS:[K7PQL+75?"]S>R2RSIX-F M=;%+:61RS2_9KPB. ,<)$JHN *_I'@_Q9P_$]7+LHQV6?4\RG#V4<9[:-K)4EA5"G\26 M.N>++?PJEG:2*DD,T]I<7:S;N 1M@(QR #7Y-O\ \'#7PS2-I?\ A5>M':KL M42ZB9U14+%R 20IQMY[D>O'[4_M,?LL_"?\ :S\#:7\/_C#I4^J>'M(UN/7[ M&WM;R6QE34H8)+=)7> @E1%*X SWK^1__@LG^R!\&OV0_'/P5T#X+:/=Z/:> M-/!OB[4-:AN;J2\%U=Z;J%O:V4XFE)9&2.9HS",(X(=N0:_LCPJRK@'B&MA, MBS_ XNOGV*J8KDGAZE14)0A#VE&/NRBERPC-?#=O0_Q0\5\WXXX:]OG.3XZ" MR7"0H?6*+<77C4;IQJ2UWC*4KZ723VV/[!?V(I K;7Q@XX)XS^$G["__!2?]DWX/_LE?"+P1XS^(UII MWBSPQX0ALM3T=X9#+'?VD#NULF%V>9(R[(R#MWL,L!7Y$^!?^"I'BR+_ (*1 MWO[2FJZGJ)^%GBO74\"3>';I_+33_AP]P+/3W>W1O(:^LMPE6=QN"N3D5R/P M>XDQ^9\4QPV6XO"9?E$<=5P$Z].4?K/LJK6&H4IRUJ>TA&4N?;6/1Z]K6%GJ.GW,$BS1S6UY$MS M#+'*A9)$,OQB=.M2E.,XV=-VES>[+F3M-.& MMFM=VM>A^T4*M*O&G*G5C)3@I6C9IW2DI)VV:>EG;\+H[[2/\.OMW]#3P<@$ M=ZB[OJ-.U[*.N^B7Y# O.X]?;ICCL?I_A0 M5)]-PP >1A1VZGG_ .M3Z*JR[*^FMM79IW?=Z)-OH):6LDM6]%:]U;7N1>7Q MC.#GJ"<@>Q)_G^E*R988.%[\G3]*&.N3Z_TXI]%/??7UU7X MBE[Z2:6BM=*SLK/?OION-*YSAF'7'/Y=J8T>23DDD8Y)Y'7VYSC\![U+11;5 M/MRV7V?=32TVV?Y=@5DG[JUZVUU:;UWU:U(]G3@94DC!;J>N>?R^E9^K:8NJ MZ5JNF22-$FIZ9?:=YBC7^9_-/YO)V_:!\7,MU>WU[L.EZ=\K7] MY/=R -MS\AFVJ>X49YZ^6?&3_@@1X"^%'PG^(OQ'M_C=XGU*Y\$^$M9\2VUC MJR[-@*\@GG-?U5UY%\>O VH?$SX-?$[X?Z3+%!J? MC+P5KOAVQGN"?L\=SJ=G);Q/(%R0J,X+$ =!7ZMEGC)Q[AL3@*53/ZOU:.)H M0FIT:$[4>>"G'FG!M0Y(M;^[>ZMNOR?-?!_@2>$Q^)P^11AC/J^(JTW2JU(. M5?D:_P"/?$.F>%M%B\(:[:1:CJ;I M!$TLL+1)&\QP SD9"Y[X%?VG?#WXG^ _BKH\WB#X=^)M-\5Z-%=-92ZAI=PD MUO'NI5'S7=]%9*Q\IX,X7BSA^,^'4%3A[UDKJ$5WU/ MN7XA?%;P!\)]*M=;^(?BC2_"VDWES]CMK[4[A(()KH+N\A9&8*9"OS8],]*\ M;_X;:_9;!*GXR^#=PZJ-3BSTSC[V#T//2OFW_@J%^Q[\1OVS/@KX7^'OPUUG M3-"U71_%\>OW=SJVUM;W[ZG]4G@K] MJ+X"?$3Q!9^%?!OQ+\-Z]X@U#<++2[&^BENKAD5G98XPV20JL3Z8KWEIHU5W M+#9$K-(Q. BH"6)]E )-?S3?L$?\$BOVAOV:/VG? _QC\9^,/#FJ>'/#K73Z MA96=Y?27+^=;S1+Y"2_NBV9 3N(& <=J_I0O(3/;3QHR"2>VN+==P/#S0NBD MX&/O$?KTYKYWB_*,@RC-H87A[-_[:P+H0F\5RJ/+4=2490]U15U!1EM]K7L? M2<'YQGN<94L7G65/+L7[:450=USTURVDK]6W)=;VUM>Z^U?SE?%O\ X(=?M2^./BK\1O&>E^._"T&F^*O%VK:[8PS7E\)X MK6^F\R))EC^17"]0O _EYZ__ 0/_:S=67_A8/A'+HR K?7V5W*0#S@<>WH< M=:_1<'P3X6U\'AJN(XYJT,15PT*E>DZ5%JC5E%-TK.-Y6>ET[]3\XQ?'7B12 MQF*HX;@Y5J-/$U:=&K+G2JTHUG",EJU\"3^^Z5S^OOPIXL\/^.?#ND^*O">K M6FM^'-:@%YIFK6,BS6E];;VC\V"0$K(F]67@_&O-/V+/@SXE_9[_98^"/P6\7W] MM?\ B;X>^$%T/6[ZS+26MU=B_O;C? [_ #[#'<)DMAMP/:OSV_X*L_\ !/3X MN_MKZW\,-4^&'B+1=#C\'6]Y#J(U:XNHA.9RY4H(.I ( /M[FOS3)\JR/&<0 M_P!EX[-/J.21Q6)IK,E92]C2E-4:NKL_:QC%I:_%M8_2LVS//<#PW#,<'EOU MK-GA7(JU10=6DU&]O9-R3UUL?=NO?MU?LL:)HFKZTWQ>\*77]EZ5J M&HO;0ZA";F>.PMY;AK6!&8?OYO+*0!\!G*C.*_)G_@G1_P %6O\ A=W[0_Q[ M\'?%[7H-*\-^();_ ,:_"5[^1(H]/T#PY#,LVA1L, 3/I,#ZM.029'C9$R6% M?@A\=OV%OBE\$OCWX!_9LO?%VB>*?B)X_%O-]DTW53]ATFVN;I8&?6KB[E1+ M;R87^UM#,RE[5-.\#L+82J[6PC;9YL3%MI4U_3N3>#?A]5R_^S*&?5,?&M/,(YE_9<<'A.'*LX9 MK!3E[*I.I%P]E.[]YQDOAL[-7W5U]Q_&?_@L_P#&^X^.?Q)U7X;ZOY?PTN/B M;H$F@);F9TF\)>$PVG74=G$^?(C\16BO>W"L%)N-O7&:_I=^&W_!0/\ 9?\ M'7@'PGXQE^*?AG1Y_$.@Z?J=WI-_?Q07VGW<\"/<6=S&64QSVLS.CX !VY%? MQI_"W]B75?B3^QO\2OVE+#Q!H^GZGX2U@-X<\)S:MIUOJOB;0M-58-=E6SDN M$N(KBWO) \'R+YT2.8]^#7SI\"OA;-\9/$^J>%U\>:7X$.F^'-3\2'4?$=W) M;Z5/_9<;.VG1LK?\?EZ 1;Q("&;&17TN=^#O 7$F >$RO%5,LK\*5I8#,'A< M.G7KU(QI^T==\8.,^'L9+$YDHYFN(7+$X.%6JW3HT M*LN=.,KKD<%[LELGI;1-?U5_\%1_^"IGAOX4?"[PYX?_ &;/'&G:Y\2/%GB2 MQGFU?198KNTTOPUIMPDVKV\[#?BYU6',-K(F!&45L<,)%SSG' MQ;^R1_P3S^*G[7VA^(O&/AOQAX7\+^%_#OB%- @O?&&MPVUQJK0W1BU*73+> M6,*QW5YO^VQ\(?&'[-?Q*D_9TU'Q!!X@\">#]2O/%_@&:UO M;>\M9K;Q/:6RWU[OMI9(4FN)H9%D@0[@JJ67)Q7\Y_2!X)X&X:\-LRR3)\SJ MX[B'*JM:OC95::@Y4JRHRG"LU'E_=J,.1>[;F723;_T._9S\6\3\6?2EX2S' M-<+]3RC%5:;R_D5TZ].$J-/W[WY*OM9-N[:<=;'U5^S!_P %&?%'[*OPW_9Z M^'/A!Y(-,TSXB:AXV^*00C&L>&]66.U;1$'W UL(&F#GJ9.O6O4/C]_P6G^. M?BCXA?&&7X6:E.%/OB,9Y;&T4^.RO[FWU"ZMK:& MYLM-\HW4I*QM"I.PK'",-+@@[BH('?FO@_#CQ+\..#.!N$ZV><$8[.<50RZ< M7BHR@Z=18>4*U2I]7=10E"#4+3:Y^7GC9J31_5/C_P#0A\4_&/QU\5L?PQXH MY'D-+$\41K5,NK1J^UPWUYQC1A.LJ$KU)RC.Z4MVKZQT_M5_X(Z?MS:C^U3\ M(M?\'?$76X[_ .+WP[U&XGU1Y7/VK6_#^IW#7-MJZ(W2*"YG;3U0?=$28&T< M?H1^U;^T+X8_9D^ WC_XP^)+N"*/PYHUR=)MGD19-0UZXB:+2K2*-SF8_:WB MDF2,,XA60XXK_/W^"_Q_^+'[-_BVX\<_"+Q$VC^(;_19M+OC:[E@N=.N49?L M\Z JKO '\^)F!V288?-7TKXF\2?M-?M8ZK#\*K+XK:C\7+6+01X^U*PU/5/L MNAV9I/:WSF??0;\1?#K@:C'B/CG((8_$4JN7 MY9C\0L5.>*S'EE"A[5^QM33J2I^]--.-KV/W6_X)Y_\ !6W0=>^ _P 6K[]H MWQ596?Q'\"ZEXG\6:>U_+Y7_ DNFZHUQJ&GZ7IX)'RV%TT.FQ1+\PB;)'RU M\6?L:_\ !8+XJ:C^UCH-K\9?$07X.^,O$7B[3UM;N4QVWA1/%VJQWFF7[?&_X 7_P&L?A;=ZSXQ\,>*=9^*'@K3O'4&F^%KLW;^%M,U)$ MGL8=:8,R0:E*A#_9R5,94AP&XK^LL3@?!3+^$\9Q1'$RQE#BC#/#9;@_:495 M\+C(T%&-'".34X5W7O*3EUDXW:M$_P \,N\-/I$YMXL4O"E9?5P&:\+UWC,Y MS*KAZ]++W@%:O4QLZL:?+*A]4M4@K6Y4G;FU/Z.]2_X*VO#_ ,%+[#P.NK!O MV;HIH_A1+J2NO]D0^,;XJ&\327@)@:W$XCAMP6)E$IQG%?MAX@_:S_9T\+:Y M?^'/$7Q6\*Z9KNES_9=3TNYU&);FVN'C281RQ[LJ?+D1^F,,,'GC^)?]F_\ M8]\=_M-?!OXB>./AW\1?#$?B/X>ZY!J^K^"/$%W:6%[>7ECF^TN\LI+F2*2> M<);NX=-Z[D"L02,_+WB6[UKX@?\ "QOB1XX\;FT\<:/K.F6%_IESW;GFOR+ 1X'XHX@R[(,RH9CP1.C@*>%IU<4J, MXYC6I1595Y2E-Q4Y4G)S22O+E=TUK_0'%'@MXC<'<(YWQ;PCQ!E/B:LNQ4)Y MO@,LAB'BLK=9PI*/L?8P&O"'B% M-4_9W\'17&@?$"\M61[;4M9UJ(13ZS"\9(N;31XO*DMU^8F;S"H%? OQB_X+ M5?M#7GQZ\;ZY\--?$?P@3QC;77A+P_>1)YDWA_2)D$]K<2Q+E(M4$32%20P2 M4#UK\5&ADB\U&.+@'%[>38EC21@"@@)R9'(899NA)R>E;/ACPYK?B^>_M/#U MA'J%QIVFWVL:A:M+!:J-+TR)I[V\#2M&'FBB4R-#&2[_ '55CQ7WN&SSPOX= MJU,13X6Q6>Y+D6&EEN:9]-TIT*TJ>(4JV*C!3]^HI+ M_$^%RS#9GQUEG"W%_%<<-F^4\&5H8B.,5/%8>+PM!U8T'[&52%2#]G*27-)7 MU5S]U?#O_!:WXFVG[)'Q*\+ZCJEPO[0VI>,KT_#S63Y4EII7A/4KK[?(;O?E MV>QCEFL[3 +;%C.1MK]QOV,_^"COP.^-'P+^&?B#QG\0-$\._$"[T_3_ _X MCT36+N.'49?$=J(]/DN/*S^]&J3H+F' /$^T\\U_"*EQ;O&TR%8K%F5Q,T$; MW;J^U-R ] /NA#C"\XS7NGB?PA=_ CXK>$+/5-?3[Q;#7WMK9\B&2YM;=C:WD:L3'=AD( %?$<4\0>'&9X"OFN3\/9OE^15:F M(S&&?494IT7!15/V<00P((P?ZFI/M$8P"V<\EAC&#WP<' Z<#WK^6;PO\ '']OS_@I1K$]W\"- M:7X)? GPLT.FZ-KTC7$5YK+V:"$S07$)#W$P5?\ 2(7/DI)P.:L>(_B+_P % M"O\ @FUXDT?QK\6?%9^-?P,U;5[*W\3ZE*;NZN]&MVD6&>XO99-[6,(W^9"8 M<(Q4+(037\WU.+\+""QM# YE5RN3?^W>RBZ3I*=O;\O.I*GJDY=.FMT_V!_1 MKSNEB(9!B>+.%Z?'2HROP8L54>;/$**G' N3IJBL9.";5*^]DY6]Y_U)&= 5 MSD*0#N/ &[[N?KZ_G2B>(XQ(OS#(.?\ //L:_G*_:&_X*6?&?]H[Q]X0_9X_ M8-LH+W7_ !1X9T[Q%XH\']'U"-6E1W48B>T)VW+9%Q&Q01 @L:\_\ M1?LX_P#!5GX'Z.?BKX6^.T?Q UO1H3JVH^#;J6ZN8K^*$&>ZMM.AG;RFD"!U MC28;2,CK6T^+Z$E.> R[&YKAZ3<:N*P:C*@G:+W945B,NX?SRK5IYEB*-5N&'G6A"#6&6(G%JGS-Z;VE>*_I MS$PZY4CH<'D'L.IZ^O3WS3O- 7)Y(4N1TPH]R<$^PK\U/^"+_ (J^,;Z.'0_">EW&H3\[?.N8XW-O8Q$D?O;R0"")#P6( MSGM[F'S;"5\M6:J<7A73=9N]O9Q@KSC+71JTD[ZIK0_)\XX"XER7BV7!6+R[ M$2X@684#MX;D)/B)\4M<*&\;B:SS+%*G#GE3A%4TIM6<6X:*<9) M7Y7?^VA9PXRI!7)#$\!><#G.#D\9' SUZX<)@3M&"1]X YP3T /0X'7^5?BO M_P $N_\ @H[JO[3<.K_"+XQVL6E?&+P?IEOJ8E$+VL?B;P]M?M LEM@.60\*00<,>.KJ.A.<\=>IK[W*,TPN;X&EC\/4;HU MG&S25Z;]U2IS3>DF^EWO=7Z_RIQ]X?<1>''$^8<*<38.>$S++:KA/V?[VEB8 M-VIUL/4:2G2K)-PEHUK&24HM*V7PN<$\9P!GZ_E]*;YR;6;(P",9*@$=VR2 M,=P>1Z5%YD+*0)5!;A?FP5>OS2=2K M&AA:,4G5Q%:;2C2HQ7QREK;5?>7P!X>YYXA9M5RS*U2PU/ X2KF6;9EC'.E@ M,LRRA_&QF,KKXD\(? MV7.A@\3"H_K<9*EF,E3P$ZL94DZ.'Q=64:='$U5"G.4M'9:_V>^?C.<<8QDJ MNX9QD$X /KR>W%+]H0L '7MQD'/&3R..._/;/3FOY8+[_@L;^T!\4/ ?A'X M%_"[X=2V/[5NL:S=^$_$:7,$C0:3]A!AN]76VD V.K/() $CB!>,],]I<_L ME?\ !5;2= 'Q)LOVB(;[Q?;0G5Y/"3W5]_9KW*K]I^R6T9;8\CR?N_*D'DD' M:WRFO5I\:X;&U)1R; XS-8TZ4*V(E2BH+"J4%*5";?Q58-NZ7563>K/S_$?1 MJS_((TZ?'/$W#W!F*QM6K3R?#YM7E*KFM&-1TZ6,PZI*T,+6ER>RJU>6\9IS M47[K_IM\Y<@ 9+':OS 9.,CKZ]O7J,CFE$JMN"MAD8!LCC)'0''//' Q7X]_ M\$U/^"@NO_M)R^+?@O\ &S2U\+_'[X7.]OXET^2W>U?5+*VD^R2:U';2HBQ( M+@>2OEC8X97BW+S7Z\A[9RA$JL4P"V[:1DDKN48&<=3V[>E?2Y;F6$S3#QQ. M'K1E"HU%PC9U*%1:3I54[6:::W??:S/QGC#@K/>!<]K\.\082=#%X>G3K*O3 M7/1Q.'KQC/#8NA+W54P^)IM5*,XK5.SBI)HN[^G!Y_S_ #]<>M!< X[\7+RR=TE%/7K;J1PZI 5ZVMPLBY1E8_P!;Y7S"-VWS I4$Y1$7[VWCJ5')/?&": )P M223U5?OG&%7Y*]"^&7P;\ M)Z)\3-2\)Z==W"Z?:^%M"N+6Y\0[DBEV^5-#/'#)\FP+(02N> #_ $>BY4 D M=65>.HW9Y89R ,)=%EV7&@Z-X5EM M-2\2-.L3"X6+4[6\BL$F V*WFL21&< ']*V[#;6&UCG8"1\X Y/!^4=OFQS3 ML/D#8<8R3D<'T SD_45_+]_P;(?M5?M%?M1_L$_M)>-OVB?B%JWQ!\?^"/V@ M?B!X-T_7=8E:>YM-.T?P3X?ODL(9)&9Q:V^H7=R\0R&!+$C<23^'?_!/=?\ M@LM_P5&\7_M9ZO\ "3]N/5_ 7ASX'_'KQAX%33-4O+K]Y;?VO>S:=;VJ)+M6 M*VLS%"G'W8N>E '^B&&.S>R.H ).1R,>HZ\]<@<#D\4T2H20#G #$\8PW3G. M,^U?Q=_$/]A'_@XI_9Q\&^(_C3\/OVWM+^*NN?#[2;_Q/+X'UMKB\AUBPT2& M34[JSMK261XKJX>"WD\N)U*R#Y<E '^@69%!89P4 M(SN]".O&3G)P1U'<8HWDG 4YSM/?#>A YQ[]*_-[_@DA^UE'^VI_P3V_9M^/ M5[KUMXB\::WX&LM'^)DL)5Y;+XC:-&MIXFTV^&2RWMK,L3S*W),PSDG%?*/_ M <$_MI?$C]CO]A*\;X ^(TTC]I#XV?$+PG\+?@YI]L=^N:I=:Y>^7K\NBP9 M$C7>EV+1S^8N/+,L>U@2: /W1=MF-P(R2,]A@9))Z <\]>@R:=\V<%&'H<9 M!Y]1P..>?IUK^/[_ (-5_P!LG]J_]J>/]KO0_P!J;XFZ[\1=9^&>O:+HE@FO M3R7$ND7<5U/::I;+YKR%2EQ"\3KQAT8$<5^2_P"Q+\0_^"P'_!3_ /:[_;@^ M%7P6_;3UOX;:3^S_ /$;QNUM::I>W1MET0?$76_#FEZ;9*)OE%O!;1JG 1 MO % '^C3A^/D/.?3J#QGT!Z@TQG53@Y]"<<@^A'4#T/0\>M?QO:K_P $KO\ M@X&TJQN+_P /?\%$[;6-;M,75C:7][?Q65S<6[B1+2^9)_:V^+7[4/QY_X)K_\%$]*TBP_:5^"^F7.N^&O%-I!;Z:OBO2= M+N[6RN-.6WC(-S//:W$&LVES)^]FLAZ9/IS_/I2?/P M#&V3VX(![?,#C'OT'>OXE_\ @L_^T1^WGXB_X+3_ +-G[!'[*/[0NM?!C3/C MGX4T2S@GMKB=-,T_5Y]&N]4N=2N8XY%W?)92*X"G_6+C.*]0O/\ @E3_ ,' M>GP75WH__!1JUOM4M5=M-M;Z\U!=.N)XF!C2Y*R;U@EP-SJ-V/NY&: /[&A^N<=,>GY4IXY)&WJQR/E'N.N?:OX_/V#?^"R?[:?[,_[+IM/T?X/_ !OT?3CIWA[Q2UVABT!_M>Q;34;;5V5HWOII6N[: M9(UN=K2QH_\ 7_O&,YB?*+(S\$2QG[K#&1T[]#GCUH DY[C'^>/THIN['4Y. M > >AZ=>W;GTIL\B6\,D\\D<$$*/+//.ZQ0PPQ(7DEFEYC\+>+?"WB>2R(%['X=U[2]:DL\MM_TI-.NKAH/F^7] MZ%Y.*Z;(.!D9/0>OTH 6BN1U3X@> =#U2/0]:\=>#='UJ4HL6CZIXGT73]4D M:3'EK'I]W>Q7;E\C8%B.[(VYS75&5 VGZ-I=J USJ6KWEMIVGVZD@ S7EY)#;Q D@ O(N2:JZ# MXG\->*K1K_PMXAT+Q-8I(87O?#VKZ?K-I'*!DQ/F>GTYKC]=^(GP^\+W8T[Q+X\\%^'=1*HXL->\4:)I%YM< HWV6 M_O;>?:P(*G9A@002* .QIN]0K/GY4^\?0\<8ZYY_*JEG?6NHVMO?Z;=VFHV% MW&LMI?6$\5W9W439VR6]S \D,R'!P\;LIP<&OP(OO^"IWQ:US_@NM%_P3'T+ MPKI.B_"_P9\.;'QIXK\1[&NM8\5W^M>%+?Q#;)B4%=-M+*.[@4&W(^T+"S29 M�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�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end GRAPHIC 10 g4bdklltl5z5000005.jpg GRAPHIC begin 644 g4bdklltl5z5000005.jpg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end GRAPHIC 11 g4bdklltl5z5000008.jpg GRAPHIC begin 644 g4bdklltl5z5000008.jpg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ⅅ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
H/<$<>U6<9Y[YSFEHNP*200H?ECC5B&7 M='#''\O!VEPN3O\ 7V_"@0H"K+$K,R^7(XC52R* /4#IN&,5H4F .@'Y4@*JJ7^1AA226#8?AI4AAC^ M[;01KR6CBC3<3W!(4O0TQ8T12- MAVCJJ@ ;B>BJ,"1>YSC'O5[&>HS^%%.[6S8&=YEBAAN!-N>!Y&6&9&0X55 K^AG /4#\J7&.@Q^%',^[ M^\#\(_A#_P $_P#]K/XT?M'^"OVD?^"@7CGPEJUU\,W:?P1\./ ,RMX;L[U9 M/M%O>?NT18&AN%258P#DC[V.G[HL'<[R$D)^1=YS&JG[Q92"&(Z#/6K1 /4 MY]J4*%XQQQT]^31=]V!2,$,8'EP1(O.TK"@D)ZLW RJ[N@SSGM3BF_CE5[9; M^,='V=%[G(Y]N:MD#TX[9%)@>@_*E<"J457!$<1;<@$A17(0$Y/*YW^ISWIH MC0-YA1/E<&,)$%?![5#Y* J8XH]_+!]JH5!X*NX'SYR?O#@<\5=QCH,?A1TZ"@"!5 4 MA QP2NUN5#=3USF//3BF>4HP%@A1F.Z0QJBL<8XR$!/J.]6J/?'- %7R]H// M.?OA=K8[C(SOW<>_&?6FF&')+06[;NC^2C..!][*GT SNXJY10!49@_*G=]V!4"J 0(E01@/$L>U S=PVU1TZ >GYT%%PRLDY7$BJY8;1^[611&3] MW:W"L#SNZCTIZIL&$54P 45%!0<#J!@9W=?8U;P/0?E1@#H!^5 %-H RA&CW M;CN5I%24+)CYBRL#B-NR@^W?AZPH 5$810 -L:+&D@"Y/RJ!LRX'3/7BK5% M#(UVHORA2>2H.<'W-/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH <.A_WH_P#T,44# MH?\ >C_]#%% #>P_W5_]!%%'8?[J_P#H(HH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,XY] M.3GT')_/&*P_$.MVGAS1=7U^_E6*PT?3+O59V@!)STX'4_3K^%?'O[;&NW5K\&IO"6GW1M-5^).KZ;X4M98F(F\J[ MN(?M(B53O*O;[D8 ?=;G@T >X?!_XHZ9\8O!5AX[T6UN;/2M3EN(K5;M=ID2 MWE\L3*#CY)!\P;OVS7J><\]#DJP'0$>GU^IKSSX7>#K#P#X$\)^$M,A%O;:) MH.GV?V?: @N4MT%Q(P &7>0%B>N<9KT/ITZ>GOW_ #- !1110 H)'2DHHH * M*** "BBB@ HHHH 7)QCM2444 %%%% !1110 4444 %%%% !7F_Q-^(^B_"KP MI>>+_$5KK%YI=C-#'<0Z#I<^K:BD.9#XL\$2?8[;4)&&8H]5T;G3989' % MPT-JDY3)5\]?*[3XR_M*?LYV4UA^T#X./Q1\%V$Y2#XK?#Z":>Z.G@C;_:^@ M8DOALB_X^;I56-2&((&* /T=![9!/L12UY-\,OC/\-/BYI-GJ_@/Q3INKQ7* M(QLEN(X]0M6*@F&ZM&;S8IHVRK1,H;*D5ZMO7<4&=P8J.#RPYQGZ\\&VGC*\O;(^.]'WM[1[OS=7N"@B6X\LC[-"QD4>: M^5'/':O6)#@=,GMS^?%?G;_P41CDM/!/P<\6J66+P[\;/ #32*H+QP7VO65K M*XW ESFM=8\$/"+LR$!)HYE)5QZYZYZ<9]J]E' '7\>37YT?"FYDTK]O? MX[^'YCMCU+P;H>L6Z2<-<&6 ,YB]E&0Q[\XK]%E)(Z=.XS@_3/\ C0 ZBBB@ M HHHH **** "BBE&,C)QG(''IU^G44 )3'DQA>,#GGUZ]N:-_)4@AQN^4].. MGS=/F[5S/BKQ3X=\(:)?^)/$VKV>BZ+IMM)=W=]J$R6T,<,:Y<[Y&4%QM8! M-? MC!!\*_AKX>O_ !U::?YQ\9>-=-81^&/#+1%D2TDU)@8+J_=MI>TB;S%YR3BO M IO%7Q5_;1U231/AT^K?#/\ 9SBN)[?7_'4X>U\3^.HQO@DL_#,;*LD.F7$8 M*O?'=&8G/EN&P:^Y_AG\+?!GPA\)Z=X-^'NB6F@Z+IZ!62./,]_<$9N+Z_NC MFXO+RX?+R2SRR(/$%GX9T75/$&JR-#IFCVKWM[,L33-';Q8WN(TPSXSG [9]*WV!/'0=ZR=: MT>WUS1M5T6[59+;5M/N]/F5UW+MNH'A!(YSM9PWX9H SO#'BC1?&.AV'B/0K MTW>CZE$D]I=;=J,#D,KJ.4*GY<$]^:Z<'J,8QCOGZ$'T/4>QKX&_8HU/6O"P M^)OP+\19^V_#;Q=J0TEI69FN]&OIQ+;2 R9S%&I&U5X Z8K[WCQ@')YZD]?Q M^G;VQ0 ^BE..QS^&*2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@!PZ'_ 'H__0Q10.A_WH__ $,44 -[ M#_=7_P!!%%'8?[J_^@BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".3:WR,2%/WL=<>GX]" M/>OS[^)>F:K\6_VQOAWX321CX.^%&C2^)='=->6./:6ZH71<8.* /O"([F+#[O4''4<@58J-/XL=. M,?3FI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH 8ZY7@'(((5<#<>F">P(ZGKTJK<1)+$UM+&CVTBF.6VEC66"XCD'[V- MXV#*8\$AD(*N"001FKM(0#U% 'QI\4?V-/ /C&]'B7X?7]_\'/'EO/\ :K?7 M/!C&QLKN56#@:EID9CLY5<\R,D>\CID]//%^,O[1?P$U:#2OC9X-/C_X=QQK M#%\2?!T"9%D@D#'!$B'.\8X*,"A!Z=: /+_A=\9OAG\7+$WW@;Q-I^J-$Y6;3O-6W MU6UEQDI=V3LLH9?NG/KQ7QU\0OV// /B?4;[Q=X!N[WX5^/)E:> M+6_"\K65I->@EXY+W3HC%!+&7 #C:25ZBO*XOC#^T;^S?8VMI\JDA8X\/*X0Y //0T ?HR#G..<=<=OKZ49KR?X M<_&3X;?%6QBN_!7BC3=4GD5);C2_M"V^KVV1N*SZ?*4GW1\APL90$<''%>J MD9WDYS@9 ' Z<+G!YYSST]* )**** "BBB@ HHHH **** &.1CI]./IGW_*O MA[_@H#I$FL_ (A.6T_QUX'U8%1D)%I^O6T[''5<;"2Q'&,D]*^XR,C^5?.O[ M5MA:7GP"^(DMRH86&AS:C ,8VS68>6'M_P ]4!SR>E 'N/AR=;KP]H%T"#]J MT32KC(.0WFV4+AO3G/4<5J.&+' /^( YQ^&:X7X57+WGPP^'-Z^2]SX'\,S2 M'WDT>T<]?O: MFEE!&6QD[2/7<, #WZYZ5#(Q92A#.V?N\KCRZUS7+KGR;:RL!OGD:5B%WK&RINR<8 M-?)?A;X,?%#]J;7-%^*7[2!N?"W@"SN7O/!WP2LYG$5W:,O++6(?BW\>]5_P"%B_&"XFDN[&2\/FZ%X32<[XK+ M1+ EXU-NN(FG*+)E#\W/'VO&P"[R,.K%7'.-QP"47TP<=.F * *.F:;8:-8V M>F:78VVFZ9I\"6UGI]A!%;V4$" )'!!#&JB% H (154O\QS6H/==OMG( [#Z M@=>G-+TX]..F/THH **** "BBB@ HHHH **** "BBB@ HHHH **** "C)'12 MQ_N@XS^-%(QP"*_0)"F,)P#R 3G[W(PGS3(.3#>)$([F)Q_"Z2QLK X.00: /5J*0 J ,=. MGT//\R:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBCG!P>>G?]?:@ !R<# MD^@ZT YZ1(4EFFD6*&&.2:>5CM2**)2\DC,>BHJEF/8"O MP&^-/_!1#]HW]HKXZ^(OV:?V ?"]KJ/_ B%Y-I_C;XFZI$SZ5IMS;R,DZV] MR!Y8(=" _3\SI&%[7UO:WX?C_5P/Z ]K#M_7^5-)QR>!TY]Z_GNUKX6_P#! M8[X9Z1)X\L/BAX8\=WVF6LFJZCX2F1O)E2%?/GLK:WCEPPA#)E6QC# M#'>IY7VOY]_,#]%7,-M'P?NB2 MY9%/<$*3^M.ANK2YMS<6MU;WEL[8#6<8)QCI2Y6^C_ *M_ MF@+V1G&1DC('<@=3]*7/&>WKVK-DOM/@N5M9M0LDOIEWPVCW4,=TR!>2ELSB M=T'!+(A'<]ZKQ:OI,UP]LFLZ3/?(I46EOJ%K),&7K&;59&FW'DD;,@GVHL^W M6WS_ *8&U_\ K_#UHS^IP/KZ?6JB,Q9F&4(PO\3 [AN?8IR[, ,8P0.M9YUG M11=&Q&M:,+\2%8[3^U+47?F9Y5K4R^=YP'5-AYX/I3Y9=M_Z^7S V\T5#E@X M4G/ .<8+9ZEE[$_G4A.-N59+ M>=E&ERM:H)+R,7UL);-"?FEN(UD)@53D;I%7!%/L]1T[4?,;3]3L+]8@ ZV%Y;W M:HW\,DIMI'89[[P,DYHL^W]:?YH#2R,9R,>O:C(ZY&#TYJJ#_K#(^T*FZ61B MHC4*"0QR=L: Y6WNM9TJU MO3A([>?4+:"Y/;:;6656(;CHF3VYQ3L][=; ;-!XX/'U]O3UKR?XSZ9XSU7X M7^+M,^'FO0>&_%]UIK1:#K][)"EK87O7%?SO?\$^?B!^WC^UAJ=M^T7XG^ M+GAK3/A5J<_C:VA\ 0W, O(Y8M,U&PTF<6AE\Y;6RU&2UO&D>,*JPYW;1Q^M M/['/A7XX>$?A"-&^/WCW3/B9X\?6M0G_ .$DTFXAGLWTV6=FL;3S;2210;=, M1NH;(. P%/D\V_E_FP/K@G!P>#Z'@T9_PK&GU72+.X6TN]6TJWO'(+6=UJ-I M#=N"?D$<4DRR=^..>/45JJ1A5)!X#*1R"I^Z01PWLPR".]9@2>GOT]\^E'^? MRZ_E3)'4*S,RC8N[;):R7L$=TEN> M1++!YGFH@^\)679MZFBS[?TP-4<\#FD) (!(!/0'@G'7 ]J^2/VK-)^+7C[X M;Z=IO[/?Q,\.>#?%UKXMT>[U/6I]4LFMFT6WD_TW3_,$PC$D\7 B=@Q(!"U] M#:!.^D^'/#UMXCUK3Y]572;"VOKR:[A@6_U#R@+BXM'E=?->>4;E$98$$#G( MR@.RS_/'X^GU]J3E &KN'J/SI M:JQRI(LX>-=O(Y4GT'I0!J].M)D<\CCK[?7TK/@GM+N'[397-O=V^T[9[2Y M2[@(W9RKQ,Z,>,XR0"?>HI-0L8;@6TE_8B\D3SHK*>ZABNW4X+2BU,@EDB7D MD[" !D]* -;/&>WKVI,C&\3_8;RWNA M!("#^\6*201'&N.:8YR-H8JQQC@') MZA3GLW3\:6P$F>_8\"C/\\?CZ?6LBYUG1+.46UYK.DV=T?E:UN=2L[>16(QD M12RK)D_[*]:N@JRQS+(IBP-KHX=9%)XD4YVE>>'3.0WK29_P _7I7XY_"S]I'XKZ__ M ,%3_BG\ M3\0-)\.- \ C6=*T,J3'%=LFXL/X0WT]:_7RXN+:SBEN+RZMK& MT '[ZYN$@C63GAYIRD0YP/O?RH T,XHSQGMZ]JRK74;/4HC/8ZA87\:GYFL; MJ&[BP!SNFMW=4/U;G'<5.'PO'U)Y'7Z %C(&.1ST]\=< M>M!(')( Z9-8\&KZ/>7 M;36M)NKJ,.#!!J%K/<(_/!MXY7F!]1MR#QC-?#W M_!0S]KN\_8X^ 5S\1]$T^PUGQ+>:]I'AVPL;BY0&UDU*X2+[?):NPFDBA7=O M*H57H[CK[?7TKRWX-^,V^(/PP\#>+;F]L+S4] M?\+Z1K&IKIUQ%<+#>WUJEQ*N8G8Q*I8JL;E2,$8R#CTTL"H RFX?,Y/!XX') M[GCBGRR[ 2YZ>YP/<^@]Z,XZ\5CW.LZ182B"^UO2;";_ )][K4;*"5&//W)Y MEDY&#T[\5<2:&58Y[62.>.]56=8U9G"1QJ MN6EDD/E1*!]YV)PFW^)G(7CD]Z^/_P!M_P"*6K?#;]D;X_?$3X<:]9#Q?X,\ M":CJNCWNGW]O=26%Y%) JS.L$K%-NYAAL'KQQ32NTNX'V4>#@]>N/8=_I[]* M,\ ]CT/8XZX]<5\-_P#!.?XH>,OC-^QW\&OB5\0]1.J^+/$F@B\UF_9>9KDL M0C*5SE"#\X/<"OMMCM\M4!VL-J./F8>HV=!T]OY4)7=OQ LYZ^W)]AZGTI,C MKD8Z9^G7\JR+S6=)L'"W^KZ982/D(M_J%E:22'D9$V=98FSR#&T1:-V)'//*G) %%GV?W?UW0%W( W$@+Z]OSZ4N?Y9_ M#U^G(K*34-,E:XC74M/>:U'^EQK>VS&U7^]33+/4]/OPSZ M;J>G:DF#&S65Y#>[77.3# #E6P!T-%F^C V/_P!?Y]*3(]1ZUDQZKH\E MR;*/5]-EO"H+V<=_;O?^8N/E^RQR-* O0@1Y'.13KF_L+01?VCJ%E9LSLD;7 M-S#:ARQ)\F-)G0SN.%"H&.>,9.*+/M_7]=-P-7/7VZ^WUH'/3GZJ^*[GQC!!\4]3N=+-#\<_$/P/X9U+57U>'4+<6FL7 M:*WV=+;$Q\]T=D^1-S,-W!P13Y/-[I:+T_S ^^L'&[MZ^U)G_'\/6OY_/V O M&G[=?[1GB'PM^T7X^^,?A/3_ (-ZEJ5[>W/@B.\LTNH=(#R"!+B"28&$#*H9 M'0<\YK]]DNK>Z6.>WF@N(9"OV2:WD26!OE!8>;"6C=6Y*D,PJ91Y;:WO?\+? MY@7<_P"?KT_.C/?MZUE)J&GM=/IZZA8_VCY8E_L];Z![](QUG:U\SSA'TY*; M!GK5J1A@G 8KM=%.Y!L ^9CMP.F"1[_ $I,C.,C)Z#O^76L M:VU?1[N<_&_P"(L'PD M^%'CCX@--917'AGPWJFJV5MJ%U%!]IO;:WDD@AW2NI)9E7Y P#/7:0/4C'_UZ.^._IW_*OYZ?V!?B)^WA^U=XWT'X^^)OBQX+K M^'4?A_:RVIU"32+226-4%JLIF"']W^]$?OFOZ +O4M,TR-'O]3L-,$S[E;4+ MVWL]\?.50W4D9/)Y*9YX[<'*UT8&L>,9XSTSW^E&>_;.,^_I]:I6]Q#- )K> M:*YMI/FCN;:07,7EG[KPS*6CD7CYMC$CJ:K#5-,07(;5M.9K #[7NO;5/LNX M_+]J_>A;:1B<+Y^SVZ4M>P&MUY'3IFDR/4<]/>LRTO+6]B\RRN[._A.W$ME= M)=0AR3G=) [@$#D\X[_6,:WHS3?8DUK2FO1\@M8]1LI+K=G#8M_-\XD-U!7< M#D8XHU[ ;'8'L>A['Z4F1ZCTJI+*L,;F66&/R1OD>:3R41,$^9(TA5$5!\V2 M0.*HG5]&CM5O7UO2!8R QI?/J-HEL\J_?VSF40L0>#M8L.^*->P&T3CKQ]:/ M_P!=9EK,<"@#1_IP?;/2CJ<#KZ=ZSK6[M;Z+S[ M"]M=2@9B/M%G<1W,7F$X9!);N\>Y!DC)SDC.*=-$'T:XF*(IP,XWXZ\=B 7\T=>GTK.M-1T[4$=]+U&PU,+_K!97EM=*G8;GMY M'"9ZX)&>_>K<+$AL@X&<@_?'88VY!&2!N^]QSQ0!-STQR.31GJ>PQGVSTS]> MU,;.0""7!&$5L-LQPSG@<>Y[UDC5=+6[%DNJ:9)J!RJV7]H6QO9%))D"6:RF M5V3&4RF0!BFDWT_IZ ;&1SR..OM]:7KD#J.3[?6LJ'4K*Y::*VO]/OF@;R[F M*WN8I9H#V%Q' S/%(QSQ(% /Y4V\U/3M-"_;]5L--,Y\V%M0O;6S:13P5Q<2 M(S(O/*@@9/>AIK5H#7S1G^>/Q]/K6='+%.L4L$\<]M* T1MW$TE1C4-/DFDM3J%@US"AEFM1>VXN=JYW2/ )/,B1,8+%5Z')I :I M..#P1US1G'7CO6-::MI-](T=AJ^FWTD0_>Q65_:WDH X*E(99)1M/WBR@CMT MK00L1M"[VR7#Y!7;G&Q2.=RC'RN>#G- %GV[CJ/2C/\ GZ=?RK'&MZ*]R;)= M;T@WA_=_8AJ=D;L/TYB$WFYX/&WO@"KP#%?+8."GOCD_I6&^MZ)!="SFUO18KKB-;1]3LTN5=SA8D@:83,Q(X5 ME.X]CR!JQ,4_=EMY !9B,'YCU.< 97'"]0* )Z*** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** '#H?\ >C_]#%% Z'_>C_\ 0Q10 WL/ M]U?_ $$44=A_NK_Z"** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH *0\*2>F0#_P ".*6F29PO]TL M>W/\.?J>!0!\I_MB?$8_#[X):^]@Y?6_%,EOX6T:V4;I);[5)/LN%3JV*^ M7OCG<:9\3?VE?@W\(4>*[@\/37/C7Q-:)\Z68LD5]/>< 8W272(%5NYWI M'MRRJNTAMP/01KC(">N<8(X S0!, .H[\TM&<\^O/YT4 %%%% !1110 4444 M %%%% !1110 4444 %%%% #'8JI;&=O)'J!U'Y=^U>6_%_XP^#O@AX USXF^ M/;BXL?"?AP0OJUY;PM.]K!,VTW4J+G;;0]9)>@SS7J;*& !R!G+8ZLN,;/H> MY]AQ7F'Q=^&VD_%KX7?$'X::W;17.G>-_"FL>'+F&9%ECV7EG+%#A6X!64JP M?JC!6'(H V?A_P#$#PU\3O!?AOX@>"]2CUKPKXMTF#6= U2W*,E[83[MDWRG M:#\K!E!X(/>N ^+W[1OPM^!^H>#-(^(.N?V9JGC[5TT/PQ8HJR7&I:C(0%CB MC'S8^8<]O?-?FE_P1J\9^(-'^%?Q4_91\=7$MOXV_9C^(VL>%TTNY8BYL?"- MQ>RR:)@MEGMI83^Z8$K@D=<5Q%W:VW[:7_!4E;*;_2_A7^R)I!N;V YDM;OQ MY<,J0-&^#&0@V @$D,#D4 ?NM#+YJ1R#.V6))DW##;9%# ,O8@,,CM4M5U5\ MHY& 1\JXP44G(CXXPH&![?C5B@ HHHH **** "F-&K,&(^8< CCCT/J*?10 MTHI()49'3V^GI^'UZU5N;:.>&2">*.>&4%)8YE62.9&&#'*K [T*\%2,5#+[4?A5X]MW,T.O\ A&9[&"8J<@7EI#LBFC)Q MO5@0P)'I7FMI\7?VD_@!J"YL2YM=7L M+J(8EM[K3+H0WBO$V5(O!%]JOPD^(#2?:;3Q?X(NGTJX^V(=ZF[MX,0SP2O@3Q,/G4 M8)YKRV?XR_M*?LX)96'QN\%R_&+P!')';'XD^ +$-KUA;Q817UKPY$=D@VJ' MN;[S-['W7Z<^_7\:*\K^&7QL^%_P 7[ 7OP_\ %VEZY)&B M&\TM)EM]8TURFXP7VEW'E7<,D0RLA$31AE/SG(KU!I%7=NR IP21Q]1W(['C M(/44 244P2*2,'@\!OX2?[H/7/X8SWI] 'SO\>OVH?@_^S1I_AS5?C!XD7PU MIWBG55T?2;IT#Q2W;R1QYF)P8XXVDCWOR '!(/0>Y:-K%CK^EZ?K6D7=MJ&E M:K96M_I]]:2I-!N8_\ A,O SJDEB(#*0D\UM V%,3/)*]+]I2S:_P#@1\4K126C_ +)LCAO;=P.F.PXS7ZL?&" 77PO^($8 #R>%-9PA M'R$_8IN#QUR.!CIVK/[2T_E\][ ?'NK_ +=_[.O[-WPU^#6F?%3Q9)H][KG@ M'0#IT4-M]HDG&G:=:V<^(T.[Y94()'.>O.:P_#W_ 5G_8B\2:S9:''\5(M* MGU&:.WM[S6+22PMO.F<)&AE=2 6) ]J_)*#0?#7Q?_:7_82TSQIH]AXFT"[\ M.^,+&\T[4H%F@F&GZY/;>6RL2"J[#@8X _+]EOC5_P $X_V2_B9\/O%'AP?" M7PSH.H2Z-?OH^MZ18I9WVF7\5M)+;75M+'AU:.<*<\' .#P13E%W=EIY =%\ M>?$6B?\ "Q?VGZA9ZKH5YK+V-A?6%K#5[RZDG0>'VNIEM!-,^2 D:!0#TX'U_IZO'1]&NI8G#B;2)V$B MG@J=/D(<'N3P>1[U/++L_P"O^'_JS \$^"7[67P4_:$U?QAX?^&'BRTUS7? M>I/IGB?2]WEW5C-',T!98^&=&D1ANQA0.<=:[;XR_&_P!\ _"MOXU^)>J-HW MAVZU_2?#5O>[%D5]5UNX%KIT+ ,,">+3XG?LKZCXP_;^^&9 MU+6O"-E^T#XN^'OQR\+0B2ZM8_"$FKF--9%NIXDM][R-/MQ"!DG'%?L-_P % M6OB%X3^*W["'PO\ B+X(U*TUOPQXM^,_P4U?2[VTG%Q;-%=Z]'+)"V, O$Q> M"1&"M$\9;!S1RR[/[@/VFL[R*]M+2]B),%];0WD! SB">-9HBW^]&Z\_6K63 MC) !P3@'/J1S], ^]#]:K7%[#;6UQ>74T-I:VJ-+<7 M-U*D-K#$BLSRF9V4!$4$LSD ?E7+^-O'?A+X=>'K_P 5^-=;LM!T'3(9);F[ MOI5C64JI*P0(3NN)Y3CRHH@[.V%P,U\ _P#%V_VW+P?9?[7^%'[.EM?/$L[F M6Q\5_$6&*3=O,+;9+31;D*%1 ?WD39('8 ZCQQ^T#X^^.FOW7PJ_9;C:33X; MN73_ !O\7KB)UTG18P=MU%X?E:^AO@;^S[X*^"VES/I M<;ZUXLU=OM7B3QCJN;G6M7OG.ZX9[B3+QQ&3.(E;8!P*],\!?#KPK\-/#ECX M6\'Z/9:/I5C"J*EK$J/-* TT[ !I)G8%WE8EF)Y%=GY;A0,@MG)/W1[8'0 M>G/^ 1QX);CNHQ_"#R=OIR>?ZU,J*H Y!)#'ELGOD\Y]/2E P,?YS2T %% M%% !1110 4444 %,8D,.>.,_G3R<125P&YX)Q]T=F;T4GC/K^= 'B?Q' M_:*^%_PJ\;^"?A]XRULZ?XE^(%ZMCX;L]JE;N8L%V[CR/F] >O:O<2V'<'/! MP!CL>00>_%?A1_P4C4']MS]B X\S'BZ(F+T87 VD$'H0,GK7[JR%B[YR0IP. M,8X!(]_7.* ):*0=!]!2T %%%% !1110 4AZ?ITSUXZ4M'X9]OY?K0!DWME# M?VMWIMW&LEO?VUQ9S03 2(89X9(FSNS\IW D?_6KX@_8VUD>%]4^+GP$U)19 MWWPW\9:A)I5NXP;C0-1G,]G=0!L%H'>5U1EX^4U]X;7^7(#9SYC'[P] OKTQ MU%? 7Q8?3_A!^UY\)_B;,WV'1?BSI5S\/_$EU@)9?VOIR^9HB2MPOVJZEE,: ML_+E0,DYH ^_D9C\K9RHVC(ZXYR,=L5)4"LI8YR=K[4_W3AE)QQ@C&#GD5/0 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1R#D<'_/;I110!XE^T5KUWX7^ WQ MFU[3XY);[3/AOXPGMEA+"43C0[X1S+MY'D-B4D(_B2\4-QXN\?\ Q UF?Q#J6%:^F:&ZEA0,_+*DNXR;2V&VAO05^W_BWPW9 M^+O#/B?PKJ'-AXG\/ZQX?O<=5M=6T^XL9F'7E8YV)^E?S&_LQ_'/Q3_P1\^) M_P 2OV5:,$XSS7F_P"QK^VU^Q3\8?'7Q9;X >!= M9\)>-].\-ZKXX\:R:KH;:')?V]I 9Y9;F*4)/YSG&-\0(.<''7?^(G_!4;_@ MG'I7AM/&MUXV\(?$/5KBR66VT/1M"M]<\7M)Y>4LKFS>W:>.8-MC90S[">%R M.?SY_P""=WAKQG^T3^U=^U3^T=IWPLU;X9_"7XJ_#+6O"/A*35-.DTQYKBZM M7@MKB&VE2)D+\,Z[ $R-I.:M)W=V^GI^?]>8'@P^-6A?MZ_%SXC:S\?OVSM/ M_9]^%W@SQ'?Z#X2\ 6^KRZ/J&L16T[P)?MY9!(^0MOZD\YKN?@A^TSH?[$_[ M4WPT^&?@G]K/2?VD/V?_ (L:FNAM:/J\FIZOX6UBZD6&PBEDF.XB25M@SU[= M*^?_ -E_P=^Q+\&/BO\ %OX%_P#!0#X:V^@>)4\7:Q>^$/B+XLTZXCTK4]*- MV\\;_P!I;##&K(_&S<>!QFOJGPB_[ OC[]K+X??";]CK]F'PW\38]*U6RUOQ M)\5H;>[A\.^')=.E2=+FPU+RC!+,G#1C(+.""!6BBVG:_P!VFZW?Y+[P+W_! M3W4_C=KW_!17]G?X=_!CQ]JW@K5/&GA.6S&H074BVEE9WT@2YOOL@=8Y98+: M0O%N'WE%<'^W7^Q/\;/V$O@G_#?]I7X@>)_&/@&_TS4_&4&K:E/)9:TL MUU$',-NTOEI'-.3&Z*,"-^1QS]!?MC&.'_@L9^Q_#YEN)/\ A$+Q(X9 LA6* M+"#:"?FV 87(!( X&:^N_P#@M^RQ_P#!-#]H1BR@#3=(50Q !W:M;!V&XX7 M+$(2 H[GBLW)1LOZ2_JP'B7[^!FN^-/^">O M_!/_ ..6C>%;CQ]X?^#GA7P3)X_\(6=I)>F]\&SVEM9;:Y!$SK9ZHC<[Q7%I;=/.NH89'BC(]2RXV^XYYK\P/^"4D/A?4_@[XH\=>#/V?;3]G_PU MXMUQ9M&T.$317FO6%N9%M-5N[>>..2$M&V4R"6#-D "OT]UBXU"VTS5;C3+> M*[U.*PN9K"QDXBO+R*%FC@DZ[/M#8C)&< ^PK%N[; _D(TOX@^'?VK_V@?C' M9?MA_M3^*O@+J'AOQAJ.@>#/!ZWMSH6FPV<%R8X+I9%99)!L ;>%*]]V*_8O M_@GC\(OV@?A!X_\ $NG)\=M"_:#_ &7-4L4F\!>)7UR/4?$VGWH8[HY;=)I7 MCMO*^3,H1FV[L9-?!/B'XJ_\$\_VD_B)\3? 7[=?POTK]G#XN>&M _X)X:5HO@[_@HE+X*_8Q\>?$'Q M[^S%IVD7#^*M1\07&H7?ATS9(C^P7UR!#=!3D1E #Y0!QGBM[6V27R_RW RM M.\)_M*_M'?\ !2']ICX#?#KXJ:[X'\!7TZW'CO7+>[G>XTWP_%+;VYO\ RX=3NHTGOLRLRH@@9V#EV,MS;>&+MKLR6]YJIB5S#8YPKR2 1C[^<@"O8/^"E MW[7WP^_;BMOAE^QG^R1/ M3'=1Q,\LXV?B]$=9+NTMH)&*PM*NY511MY'(K MM?\ @HI\ ?"_[/?[4_[-?QC^.'P]O_BG^SQ%\//"WP[^(K6VFSW]OH[^'K); M"*9TME=QNW&;<0%98RQ;N.E^-/C'_@B[X-^'EMK_ ,'OA?X1^,?Q"\0QVT'A MGP!H-M=76K/>WS".*VUBU@BDDL@I;#Y#;,$'M2LNR^X#[Y^(G_!2&2+_ ()M MZ7^U%X96W_X37Q%IT'AFV&2Z1^*B/LMU<1;3BOCWX4_\$UOV MA?VC/@G!^T/\0_VF/']A\8_&NE?\)AX2M=-U*>'2=,68-P?M-_LT^(?'O_!+#2-$^'GPH@^&NK:.\'Q"M/A?H0>Z%K%E;N:#RF5) M#$?V3/#EE\0?%A\&?$OX8^$HO#M[\/-6L MYK7Q#JNKZ5 T"QZ9ITD8DN%:= "0%.#D!LT;6LNO]?C^%P+.FZE^UGX7_P"" M=/[0NB_M(R26GC3P+HMWI_A?Q7;SR1ZCJ^F0JZ0W[2!MWFN%4[@^06/J!7SM MI_P*N?VF?^"1WA'QAXJ^(/BRPU7X?^%_$_B43V>IS[]=EM1-_H>I,7#30L,) MLA?V/J-QX>$C MM!=WQDVR3R%5A+,ZJ,'(SGCNOV69HV_X(Q:PRRI@_##QDKRH05(9)\Y.<#&6 M^;.!QSQ1>RUMNEOZ>G0#YJ_X)"?LLV?AW]E?Q)^U1;>.?%3ZO??#;XMZ+!X1 M?4IVT"P>#1=56&^M[3?Y27:-B02 AE!SGIRG[$7[8'B[]GO_@C;XV^-^H:[ M?>)/'2>.O&6A^$[O6+F6]N)=7NM5:&RB8S%B%MD=F5 0,IQTK[;_ ."4CQM_ MP2HU%8V3RU\(_%\*T;A@1_96JY8D$@L#WW#M.TK4[FWTO1X[E6N M=,AFM5E"2++PKJV-HQP :_4K_@G6O[5>A?#'7?!'[5,7VK7?!VI/8>&_$\C% MKK7M(20QP3S#+!MT2JV(Y;?X3VZ:"VC:I?:$9F2.YO7D8RW#F$*P=D4 M.6^E3)+ET2]>NZ_KH!^A7Q+GFB^''CZ:!I(9HO"&O21/&<.A&G3%9(VX.8\% MLD@]*_E-_8,^ 7[2'[;C?%;PMKWQJ\4^#O@CX3\^G5+ M>WNO,W);Q)U53MS[<#^K/XHJ4^&GQ"+ ,#X.\0L&/!3>!="UKQ]KVH>'O'%Y:S#PLQ6^N?,LK^^ M$9BBGR2T08EB2!BB'P_/_(#V/X>W7QZ_X)H_MJ_#/X">)/B;K7Q3^ _QM=[? M17U^5Y[S1;@2%(E$SNS!MV$.<$@$_3A_VW;CXZ^//^"M&E? 'X4?$?5_ ]O\ M5/ NA:!JU_;7,IATC1#8I?ZE>VL08117<\44D,/F]:JZMJE MMU7IZ]O^' \^_;U_9=UO]AG]CQH_"GQB\>>);_QE\??AQ+)J6JZS>27MI:@F M'4+:"?S"R07DN9)(LA2"H(&..Z_X*V^-OB-X:_9W_8UO? 7B/4='\4:IJ_@J MWBEM[N6W-[<7=O;(BW.QAYH1W#R!OO8Y.":^@O\ @O$ZQ_LB^"R\BIN^.O@ MOF145I/M;X!9B,# QL'5B,=J^=?^"L$B?\*,_8-9Y(\OXJ^'>SS"JNI\NP^9 M?%'A#49/#LH\#>&?#5W-IUI ^FVH,6H:@8''GR7)0$[N2V<\5^G?_!1 M5DA_X)T?%DLRQ+)\,=.8D'8J9L+7E3T8GJ,\<_G!_P $RI$_X=^?#/:%5$\' M7B JVY7(M7)<,/XCGD#C*@47C_=W71;77]= /EO_ ()%?'SXDZC\)OV@O!?Q M;UZ]\8W7[//B#5]+@UB]$7QFT#]OCXI M_$3Q+^T/^VEIO[/OPW\+>([W0_"/PYT[5YM)U"^M;6YDC6ZN)8]KJ%"##KK]@3Q[^UG\./A)^QE^R[X=^*5OINJ6FK^*?BW;V]S#X9\'F MRF6:&]L=0\OR9_+\L;6R'\[:NS'->G?M:-;K_P %N_V/$=XD9= B)C^%?Q M;\?>+1\9?%?ASPIXQ\8ZO-=ZK-X+L+HE-6U>QP9&MFF!:43MLCC"XW#->4^ M_P!G?X\'C@=:_:_\ X*7_ !ROO@5\&K+Q'J7P07XX?#C5-;M-)^(^E&![ MW^P/#MU(%FUK[&D!_ =Y?67B%?$LD8,-G<^&X(U/-WF-_G!"C)4'BM5*/+LN:W9 M-=.OW_*^-O^"26H?&C4OV-?!UY\:FU277KG4=1.B2:X9EU23PQ MPNDR7*3@2HSP@-AQD$MVK[@^-_B'Q%X1^%'C?Q)X5\,0>,];T?0[N[M?"]PV M(-76.)VGM6P#N+Q@@#!W-QWKGT4W?\O1_P# N!_)A^SM;_"C]KBQUCQ9^T%^ MW%XI^&WQUU35]2CMO#5[K-QHUAHEXMS+';6HMG=%94<*H60*I (SBOWH_8AT M_P#:,^ _P<^)*_M$>/\ PW\5_!/@FUU'7/AQXTTC4XM3U+5O"^GV4UW'%JKP MR3)%*ZQ*B*6W*K=.*_(_3]7_ ."2'[6WA;7=<_:#TG3?V7_C+I=WJ4?B;0;: MXNO#6JS:A;/*3<:6Z6ZO>2O,I"8"[Y,!3\V:[;_@DWX<\;^-%_:W^&_@3Q)X MW\1_L\7>@ZWX>^%^N^-?MJBXO;JQNK2S:"2\ ^T6Q5XU+(-O.XUKI:R25GK; MKHOZT \7T+XM^%/^"@7C3QW\1_VF_P!MK3/V?O FC>(]0T;P'\)K#6IM*OTT MF":18-3N7C*DL^U,#^(G)Y%>I_L[_M0V_P"QS^V!\+?@;X+_ &H](_:B^ /Q MNO8]%2274WU'6O &H$E;9VEH.>@KYO_ &-?"_["/PF\0^/_ -GG M_@H-\,-/\%?%'P]XLUF[TGQYXSTR>WT#7-$>ZD:+_B9,IA"?=^S&(N60@G%? M6WPMU#]A/QI^V9\,OA=^Q=^R_HWQ'T_0M3@UKQ?\:(+:ZM]!\'M"QEBU'3]1 M:/RKF.%1C (8LR_+SB@#VGX,2QV__!:SXZ7!R$C^%AOMQ.=L26AF$0R?XX^> MIKY<^-'[3-K^VO\ M0_$WX:_$+]JC2_V7_@'\)=7ET$Z<^J3:9J_C/48'$2!UK]!_^"F?[7WQ7ANO@;^S MA^SC>OX>^('[0UM97,GBB!V6YT;2+Z*-I5MMA&"D MO#_V+5M8T35=2N+C1_$EV[1R7-C) TI6*+<6&4&2,]LX\L_X*X_![QYX\_9* M^$'[0'QAO=;\-?%#3KWPSX1\5>"[.\?^P9[^\EMXIM3-L7VO('+R+(5W(5]: M^Y_CY_P6=_9S\/? N/Q)\!_%<7Q!^-GBFPM[7P;\/M-T^;4]3M/$=V(]EKXA MTU%WPQQNYC*MD!R 67'/S?\ \%%O$WQT^(/_ 2S\"?$#X]:);6GQ%N_&7AS MQ-XDTS1-*-I#H>DM-#<)'<646\0S6T09)RY WCD^M1LI:J-K=M?DMF_F@/TT M_P""/-'T/Q-=2:]?S7ATV2:Q#"ST\S,WDVD8F MVB%/E!' P*^GOC[KWC_0/@_XYU/X5:,/$/Q#MO#]Z_@_3&)\BZUEH]EJ)NFU M4):3' )'4=O'/V(?C]\(/CM\ _ $GPJ\R7?[O\P/ROT#_ ()X M?$'XC^ [[XN_M@?M@:IX)^)>MF\UF?2++QE:Z;I_A19'>2WLWACOMTLD6!&8 MPI8*HROIZO\ \$?_ (W_ !"O?BE\G_ (0WQE-/]K>X MLHY'"HMP6;?E#V.#MSG.:_.KX,^'O^"8_B3X+Z9\7_VA_P!I[XG^-OBW>Z4] MSXM^'ESXHU9=5;7) YN-*T[PNBL"BS_*CY##<<)7MW_!#_Q%\.[W]K3]H&U\ M Z-J?A?PU?6,USX4T#7?-36$TB)W,-S>QW02X\V6-=_S)QO(SBK:5GHMGT X M?X:> ?VB?VG_ -OS]JKX->&/C)XF\#?#BV\6W5SXEN[&^F>>&VC=ECTVP)=3 M;[B&_P!6,\Y'I7>>,/AO\9/^"9O[8OP%TCPQ\;O%OCCX#(Q/3I7O/_!->2/\ X>0?MP^7)'N/B.Y5X\IN#^:Q+[020W4$ M$"KO_!8&6./]J#]B$RR(A7QC;8\PKORVI1C"J3G;DY^7)ZU<8*3M9?*/C#\#OV'OV>O$G%?)G[8W_!.+XT_LQ_LI_%GX@?#+X_>,?',*^";J'XJ^$? M$=Y+?6.N:+/L_M&_M$FD86SVTI7;L7)'KR:]9_X*0Z?XD_9B_;)_9K_;MC\/ M:KXN^&VE:=8:!\14TJSGNYM"MU@6")UCMU=_+EAD^TF5@%4H0Q'-=C_P4!_X M*E?LT>._V.OB1X.^"WBD_$GQW\4_A_>6 T#0;2:[E\'Z?7X8SQPK M N3TYR 6/N,5]F_&?6O&_A[X8>,M6^&NBCQ)X[M]$O3X7TD$H+K4?+(B#,,; M=KX.G7XN_P""21C3_@G_ /L];6!8^%P%9#O4DNQ(3'!#'/4@#MD"O3O^ M"A'Q ^)WPT_9.^*OBSX017I\::?H_:F_:E^)NN_&.6"]O/&7P\N/%&K6.H/J!$C2:99>&HD8RL9*/A9=_P#!0+XFGX8^']9\'>#-2\+W4?A+3/$BSPZY?6&Z1(;V]@NU M2@&MX9T/]H?\ :(_X*%?M+?L^^"/BOK_@OP-=:O<7 MOBC4[>\N#?:=ID4[Q_8=*RX$ EY&Z/#8)Q4/QC^'W[4'_!.;]IOX;?"+X+_& M;7_&.C_M-6DFA:&?$]W-?S:'>/-]EU+585F=@)X \LB$XY52,@BOJ+]@MXW_ M ."JG[8*[H]Z3S#;YBM*<7#[L,"24[E"!W'>NT_X*<2(O_!0K_@FE$'0&3Q# MKY0NXQ(/M3!8D0G+$'!&.O /%'7_ ('I_7F!\G_MO_LC?&G]AWX=>$?VM_ _ M[2/C_7/'ND>+_#\?C*PU349Y]-U1]6N5DO$@MGE,4-NZB2,QKP R]Z]'_P"" MNWQI^)U_^SW^PU\0_!&K:KHGC'QGK7AS5OL^EW$L$=[J>JVNG;8;I8F!E@^T MRF65#D$=:^R_^"X\B+^PCK&XH=GC3PDK1LXC5L7&6#%L!67(X'G?LR_M4>.?VF?^">G[0NE?%4@_$OX3Z/ MXC\(>)[W!$FH+8+)8PW+CG;)*T#%CGG?DUZ)JW_!8W]D*#]GQO%2^)=0'Q&? MPLNC+\(&T^['C6+Q&^G+9-8OI31"=;19\-]I7ET(^7')^:/V'OA#X\\%?L!? MM:?%KXC:-<^%]1^.$?BCQ5IFCWL307%OHMR]Q=65[<0R!7@,T0:Q\&[S]H/_@D;I7Q#\2^._%%OJOP[\-ZEK!AAU*?9K3Q';Y.J-OS= MH[.H5)<@L>*OV7OC'X"^(O$&A^(_[7F/\ :D%E MIK2RVGVSS"7P;:W9Q*_\/!Q7I/\ P2%EC;]ASX5%)E=I(9E?@,KQIM&0GW%+ MGKSU)S7XN?\ !0_QGX\_8!_:6^/!X].TI[5)$M[;QEJD\6 MGW-_"8QLCD0W#V^U>3YI^M%T[ZK1I_E_P5VLP/O/_@F/K7C/]I3]KO\ :P_: MLUS7-7NO >F^(;SX=?#?2CMY M31M8*,X:'2]1?<6*@,UK*<#;DC:1GCH>F>*^)_\ @G+\ K/]G;]DKX5^#([; M[)K^J:0GBWQ>\J 3R>)/$ 6]U%I21EFWE2-QR"3CCD_;.LL/[$UG+8QI>I8= MAC ^R2_.QP!?B'J5Y/:Z5J-S'<:E?7.HRQ6MM;W)D$L,-NR$[$&TC@XZ5]>_MR_ M&SQ+^R9X>^!7[#7@/XUGP5JGBE?+\6?&+Q5\">'M4EUMO#]]);V.N:SI$/ESI>"!OWL$S+G8P((?GN:^>/BAXW_X(E^&_ MA3_PG'P[^''@_P"(WCW4[6%O#_PWTBRN;CQ++JA\$:>79-.2]MVD2:[$B M(ZS2HR%X67,9X['$-]4K:K\_E_7<#X*_X)+? 7P]\'/V>M;_ &S]6\<>*)8_ M">B>+3/X1.I3/H3"P9_(D^R%_*#/<",$X!.1WKYW\ >/?!_[=FK>+/B_^U?^ MW58_!/1GU[6]*\'_ GL-=GT:^TFPM+HPV5]=&W;=_I"D2QH,B0 [L5^C7_! M.'X?O\7/^"6WCOX;6%RJ7/B_3O'&FVLD+9*73R23VP4#(S-/$BA2>K#/6OS' M_88T[_@GEX-TSQ9\#?V]_AMHG@'XU^"?$FN>9XL\KNK]/RUUOJ!]5_L5_M4M^S=^VAX0_9,M/VEM+_:8^!7 MQM*>$EP1P/:5X0^/'[2W_!3G]M M/]F31?BKXF\&?"[4_&*KJQO[@7.FVF@PVUQ#I^C[7 LTO)7D1O+VAL=Q MU][_ &7;C]C#XE_MT>&_!_[(7[+NC:[X.^&5Q%XJU'X^SP75KIVDZK9*6+:% M M$F\?Z)_P5-L[CX[6MDNOBZD\4W#:5MD&\HQFYS;E",8'//%?:O_ M 6^^#FL^)-)^"?QD_X0Z_\ 'G@GX:^)_M?C[P[I]I)>R2:'(J1W$QLX@7,2 MHK[MN2>3WKY_B\;_ /!#3_A3P^(O_"#>%CXJ.D)*?AH=/N%\9SZVL 'V)=+" M-*JS72E?7YN5%.+5M5KL[):[:O37;_@; ?5O[-?[97B7]IO_ ()]?'JZ\0:O M;:A\1/A=H&MZ#?>)])N"%UJVM('2VUVUE1BR-+Y1; (_UG%?!?\ P3Z_9"^/ M_P"W%\%+GQ!\3/VAO&GAKX9:;KNL:=X5T'1=2GCOI[R&:0/>74XE\P(KX(3T MXQBON?\ 9ZL/#5W_ ,$]_P!HKQYX3^ %E^S]X>\5>%M=DT31U\V"]U72DMY6 MM]1O()D1X6D0HY1N 6/)KU?_ ((?;9?V+M/D5@<^,-=.8"O[S_3&R^]2=P_O M#NN1WI77*WHFW;T^'_/9?J!\F_\ !//QM\;OV9?V]_B;^PI\2_B!J/Q&\":? MX*U;QMX7UC6)Y;F]L[?3(O-MU21RQS- ',G<%?PKA]"F^.?_ 5A_:Q^.GA2 M+XLZ_P#"_P#9I^!6MOX>>R\*S26ESK5SNDC@:.5'1C-.\4IE< $!<]C7HNA> M7=?\%[?%MJ+B-'O/@'K%CY>Y08/MED;87"\[F+^;DJ5PI'6O'OV*?C=X2_X) MN?MB_M5?!G]I@ZGX#\*?%CQFOB'P/X_U*QN(_#DUO!-<.EQ>:B$:&&&Y6ZD M969U*YV'!!%;EEWT^ZZV_';T8'UC\ ?V:OVR/V,?VKM%\,^$?&NO?%W]E/Q9 M K:O+XCO9;J\\+%UR\T,DCL2;?:69R,G)!R*^7/VG_VHO^&L?VN_B'^SYXD_ M:R^'M5D"0HJ[SY?V:O^"@OQIL?VY?A9<>(/A+\6=7DUGX=_$6;3[BZTC2 MA+-EVN[M%\FUC=B_G"5E9$&5!XJ0-#Q#\4O!?[!7C#P3\1/V:/VX-/\ CUX7 MU#7]/TKQG\+M4UR34[VXL;N>.)[NV:X8 &,,3@'./PK^K'P#XLM?''@GPOXR ML0([3Q1HNGZQ'$K9V?:[:.=E![&-GQM&5..37\ROQ&[>ZN=&T. S(6O+[4(XMD4EN>2LF/F7 )ZU_3+\. MM).B^ _"FD#2(-!>ST.QC.CV[;HM(;R(B^G0G R(.8L^U9SMIIO\GH@/@[_@ MI[^U=XE_97_9[EU;P'"DOQ#\=ZS9^$O##S<*0*_/W MP!_P2]_:/UCX<:=\>;W]J?QS;?M":AHS>+]/C^WS-X=M;Z:W>]CT-[(R%'B* M%K1T\K;M521P0.*Q/AK_P6)_8^MOV;M.\2>(?%L^D?$+P[X57 M1[[X6W%CW4LUG#J&G+.CQVT3 MLVR*:98WVJO1\9Z5X-\+O%'@S]N>'5OCG^UO^WSIWPBN]9U?4H/"7PDT;7Y= M);PYI%K.ZV%Q<>4RN//B"^9$1CC/6NE_X)G67B#]JOPC_P %/K2QL;G2/$'Q M?TK4!I&G31M;SV5SJ:33V=M.' 99&6-4".H.Y@OI7#?L&VW_ 37T7P-J'P6 M_;@^&FC?#+X\_#[6-6T[6-;\?:?RKY<]S,B[O+B#HP=" MLG4%@?8'[#7[6-Q\!OVO]._9&3]HG2/VE_@W\0;":Z\"^,;*_:]O_#&I ?Z) MHEU-(09"[D(7R6//?IY'\:]#_:*^+W_!5OQY\$/A7\6-8\ :7JNC^5KE];7< MTD5AI:8^V16,#NJ)<21;QYBC<&;.37N7[(=]^Q]\4/VSK'0_V0/V7-/O/ 7P MZ26[U?X[W%M'=5\6Z3HOC'1O$6H3W273:A>PQW3HCRD;)!*Y"@8'0#BOT2_X*4? MMP>+/@G\#?A!IWP^UBR\(^+_ ([:?I$"319=E]P'SK-\$_V?;;PA/X^TW_@JA;/\<8;!M;@U!_%%P-'N]8CB-X- M+:PW>4J^(_C?\&+FY\%W_B+ M0P]Y!<:4KFUB\8JJ R2EX5\XX4A20>*\MM?&_P#P0U_X4V?B'/X)\+CQ5;Z1 MYC?#-K&=/&=UKJ1*ILH]'"F17>ZPC,2K;-O ]N[+/K,]C) 96=[5Q*D13=)CH,4679;]OZ_ MKJ!^>/[/GPP^"_[1OP^TGQC?_P#!0CQ-X:_:222 M0:>EF\JP%+:;8@\XH0K8QQQ_2%^PMH?[1OACX'Z;X8_:9UWP_P"+_&6B7]S: M:1XM\/W\6I1Z_P"'8_\ D'7NH7$3R1F]="KL%=L;@.<5^ 6LZ/\ \$9/VCOA M$?BSK'B!?V=_BE#I%]/JW@30;^\T#Q/#XILEDDDL;'28H1)>^9=L$A9C$TWS M8'%?>W_!"C4OBQJ'P0^)+>,K[Q3J/PZ@\:W-M\++WQA'=1ZK=:)!+,L$R+> M3"!K80$ @+O)(SS2:5GI]RU^7]>0'[JT445B 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 X=#_O1_^ABB@=#_ +T?_H8HH ;V'^ZO_H(H MH[#_ '5_]!%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %032PPQRS3NL<,$3RS2$X\N-%+-(_HB! M2V?KZ4^0'.[)&WC X]OQKY]_:?\ &-WX)^"7CO5].9VU6?1Y]*TR*)@DS7>H M(T$31DG+.K-E5 +$YQS2D^6-[7?*FX]K]+Z_?8+KW7?W&X\TNW,[/3JU_P M\,_9>T6S\9_%WX\?'J207EQJ>M#P-X?N#A[?^Q=+D\YKFR?D!GN5:-]O) QQ MTK[TB4^4JG()Y)] ?;Z=>>:^>?V6OAA;_"#X%^ O!JL]S>KI4>M:M?2L6GNM M2UXMJUS)<,V6,D;W?V;D\>6, 9P/HE?NC_/>J<6G:\;:6O+=.VNB?5VWZ W% M-^\[7T:6Z[[Z>@[Z=****5O.'_@7IY>?]70)P?VGK_=_X/\ 7W7****=GWC_ M .!>GEZ_=YCO#^?\/^#_ %;T"BBBBS[Q_P# O3RUW_#S%>'\_P"'IY_U9A11 M119]X_\ @7IY>OW>8[P_F_#T\_/^M HHHHL^\?\ P+T\O7[O,+P_F_#T\_Z^ MX****+/O'_P+T\O-^MA7A_/^'IY_U9A11119]X_^!>GEYO[O,+P_G_#_ (/] M6] HHHHL^\?_ +T\O7[O,=X_P WX>GGY_UIN>!19_W?_ O3R]?N\T*\/YOP]//^K'\]7[9WQ!_X=V?MVVW[5(M)8_AG\?O MAMXA\.^+["T!2SUGX@:)9>=I,]XZ_)%=-++&(G/_ -HGQ/JWQ(UJ6]C(O;/2]2O)Y-(T^.1OGD@M[=HW Z$X/05] MS_&'X"?!K]H7P_;>$/C;\./#?Q+\.V5_#JMAI'B>U>XMH-0MV#Q7=N$DAEAE MC*C+"4!\88,!BO3-$T72="TK3=$T*RMM-T71[.#3M*T^S3R[2QL;6)8+>TMH M^=L4$<:Q@$GA<]3FDD[VO'_P+IIY7OJ%X?S?AZ>?2^IJ1Y!*[BP &21]YCSN M]CS@C\:EI H'2EIV?>/_ (%Z>7K]WF.\/Y_P_P"#_5O0****+/\ N_\ @7IY M>OW>8FX+[7X>GGY_UIGE_5O2ZYH?S/_P'_@A11119]X_^ M!>GEYO[O,=X?S_A_P?ZMZ!11119]X_\ @7IY>OW>8[Q_F_#T\_/^M+E%%%%G MWC_X%Z>7K]WF%X?S_A_P?ZMZ#) < _SXZ]\]A[U5E19$:"XB@D25=KQ2!9H9 MHV'(>-U96SSU'/2KM'X4K/\ N_\ @7IY=+[^0KP_G_#T\_/\&?'GQ+_8V^&W MC+Q.?B'X+FU;X1_%**%A!XZ\"7_!TGQA^'=@Y:V^*_P[L]WB.PTX-C?K_A&+=-GEY_KL-*OB/X.\"_M*_ :+^S/VCOV=I=.\7:)=Z>AM;_Q?X=T MN&"YU/PU!;=7-I9R!E=W9 1\H'V/9I^R[^US9^%O$US:>#/BE<>!-7 M36_#B:C(TNJ>$-?0Y%RU@DT,UM?V\F YD1U5QC' -?3"1H;9;=D+((?LQC"[ MV2)D\LQLG9=@VL'W94@9]=.9):N*M97O?32_3;];>H:O1;MVUT6OF?SY?\$; M?C2G[1'[3W[>GQI&E2:%/X[UGP??:AH:5?P$$9R'M74C)Z\'GC_ .OY?\*OV<_@3\$- M:\6>)/A'\+?"_@#7/B%=F_\ &>H>'K:2TF\07GG23_:=0C:5XY)O/D>5O*2+ M+.2>3Q['>*LEI>P$ ^;;S(B8+$%XF7"IG))^O/3'6H5Y3BVDH.5KWUOIRJUK MZ[:VU%=>^_Y&N:VMEWT>OR/Y+? OQ0\"?"W]J']E+5?BAXPT#P1X8\#^(/BI MIMWXA\27ZV&G64,WBO4IHFFG<,% 3: "O&.*_:WXV_\ !5O]B'X=^!/$6M:) M\>_ ?Q$\0/I6H0Z-X9\"ZM#X@U2]OIK66.T62&S+E(6F9%)SGL +39?%EA=-/96^KF34?*B@6ZB-NK,[/ MA@QER7!P0!]*>%_^"9W[ /@K6K/7_"_[*7PET36M/D22QU"ST>=YH&5@X=EG MNY(CM<=)$D].*N\W?DC=K;71^\DW>U]%KI?73;4K32^BZOK;3H_7^M3\>?V< M?A1XHM/V,?'W[0OC+2M0TS7?BG\<=/\ B%IUG=0O:R1>'Y-1467R2*'C_=RY MY'\)]17]'/AZ\-Y\/='N3\WVKP@D[.3DDMI3G)..20!S7C/[5GAS2Y/V9OB3 MI5M8P6%IH_AV*?3;6UMTM;:S:SO+3R(K6&-5C15' VK_ #-=_P#!6=]7^#_P M_GOO,D:Y\):=!<%V'F3J+!_%-A;:IX:\5?'3XIZ+K%C=*DUO= M6M[>-#(DBD$97>&7H=R@@@@&OQ__ &KO^%B_L8V]W_P3Z\9#4-<^%?BKXY?# MWXF?L\^-+SF=RT< MXF:WM;4.Q!0,.",_UP?#3X/_ S^ M#.FZMHOPK\#Z-X&T;6]7O/$FIVFBQ3)!?ZYJ#F2^OYX)996^U7$A+RR!@KG& M% Q7._%K]G7X%_'IO"G_ N?X8^%OB3-X,U-=9\)3>([-Y[C0=24@K>64L,L M,T;(45MKNZ(5W;,Y-3S=59Q=K-6;;=M-+[?U9#:MK]FT=7W:U7R=T>H^%),> M$_"Q#-N/AG021@'(_LVV.<=O?WZ5Y5\$_ M!FD1_;_$OB35I1B&UT_3(29BC.RH\[A8XU);.5(KR'XV?M.1^!]6L?@]\"_# MR_%#XVSI;:;8^&=(W2Z'X+TT[+>+4/&.H(SPZ99V*;72VE837*Q[%96.:M_ MS]E>+PAXFOOB]\9]:'Q6^.WB!A-<>(KR)Y-"\%Q."3H'@O3YV>#3;&!FV-+Y M;3R/'O60"LW9=7OKIM^/W_/YJ\>LOP[_ #7])^5_./!'P(^)?[07B*P^*W[5 M3FST2POUU7X>? RTD*Z+HEN#YUK>^+5C(74-7"X9H9>(64H0V,U^@UG;6MM; MQ6MG!;VUI;[$LH($6"&*)!A1"$"K\@ 7:%&WIR:M(I))?#'D;P<'KR@0\@#I MD]?RJ7 &.!QTXZ?2BR[_ (>G]?(?N_S+IT]//S_K06BBBG9=W]W_ ?ZMZ!> M'\_X?\'^K>@444467=_=_P '^K>@KP_G_#T\_/\ !A11119=W]W_ ?ZMZ#O M#^;\/^#_ %;T"BBBBR[O[O\ @_U;T"\/YOP]//S_ *TN444467=_=_P?ZMZ" MO#^?\/3S_JS$)P"8\\F] 1M)&:_4/_/ S^G?Z5YE\3_A M#\,?C/X9N?!7Q8\$:!X_\*79+3Z)X@LAS$%69QE9$DQP"CJV"!2T[O[O^ M"%XZ^]MY?\'_ (!^"/[27Q]^#?[5W[?_ .R#H?[/_C?2?BC'X2U--:UW6?"D M\FH:1I=ON\WR;B[CC">>Z_ZQ'P8W^4]J_HTD)9BN< ?+CE,A?O>[8!'3O7S M=\%/V/?V7_V=+VYO?@=\#_ 'PUO+L$75YX;TMH;R8'@[9KJ2XEC'KL=?\ 7W!11119=W]W_!_JWH*\/Y_P]//^K,****++N_N_X/\ M5O0=X?S?A_P?ZMZ!11119=W]W_!_JWH%X?S?AZ>?G_6EUP1U!'X5\G?MD_#R M'X@_ _Q%*D$LNM^ KFR^(?AHVX_TLZQX7D:^2VM2!O N@"DA!P?E!KZPK,O; M>"]CN;*ZBCN+2\ADM)H)!Y@D2=#'*K*/NH0WS#TZX-)N"5Y2:VZ=7;S]?N#3 M?5I6YN57<4^N_P#EMV/._@IXXT_XC_"WP/XRTV^BU"+6-#L'N+B%MR&_@A2W MOHV;/^M@NHI89!U#1MGO7J]?G]^Q7I+?"?6?C+^SE-JDU_:_#OQI?:UX5%R^ M+A?"GB.=]1B80'YEM(;^\GMT<$J2F ?3[]4,V-Y7&?F [J3E"O?N/K4IWVOO MU7]?\'IIJ&G--*[4;6DUR\U[=->_?%] \6Z/?(\%W9Z MQIMO>HUN>'C!F1GC.< +&RD@GFNYI,#K@9SGIWIIV=_^ !\5>&/^"=W[$/A+ MQ%%XK\-_LT?#+3?$,4YNXM0&A%;J.Y+[VF7S9Y(MV[D(8R,]NVNFV.FP M)::7:65C90J(X[.QM8;*W$_45LT?A5\[[=OP^[] / /B M[^S/\ _C[#!:?&3X2>#?'UK:L&MFU[1XI)8GZD"XC,9/+D<[?- [ +/B+X>^+GB;X=:!JOQ)\(Q-!X=\9W%J7UG3893AX;28N!& MK-\VW8<#'I70?%'X4_#KXU^"];^&_P 5?"&E>./ GB!8$UWPMK4#7&F7Z1LL ML2WD0="^R5 _#+@J3[5Z712;;]?Z_0#BO#_@CPGX1\+:3X#\.:!IFG^#]"TZ M#2-+\.0VL;:9I^EVL0@MK*.VF$L;P118C2%@?D&<^OS--_P3\_8MN_&DOQ&N M/V_L)!=_V@CE_M;JLHMP=_/\ J-O^SZ?9U% &3I]C9Z99 MPV5A:V]E:6<:1VEI90QP6T,:#:ACCB145%4848P,=ZO$-RH;Y5Q\X(W$]7;/ M? X(']*GQSGVQ^%(6&<>O'MU[_U_6E>WQ.SW6^OIY]>H)-RY5M:\I=GIIYNS M/FCXN_L@_LR?'N]AU'XP?!+P+X^U"-L0WVNZ,DDX7@%C+"\,C-_M.3G'>O1O MA9\%/A3\%=)3P_\ "CP%X=\#:-&1&+'P_I\-H@0 \3, TKGLNZ0]O6O4Z*U4 MW;WH\M_.]UI?\W_P25*/5M:M;76GG_6NA_.-^R-\,M#^(/\ P4H_;F\-?$;P M+:>)/!>OZ7';WFG^(=&>XTV_MQ?=!+/$D1?KMD@DWX^7-?MC\&_V7/V>?V>A M=_\ "EOA!X+^';7KM)E:=#[@L[>*ZG'7$UQ'<H]G:O@ ?CUSW[?RXI\Z[._8%*/= M_=Z?\$Y7Q-X1\->,-&O/#_BW0M,\2:+>1M#=:;J=K#?6\Z3J5=4AG5@@V$@, M"&V]&S7S=\/_ -@_]CWX5>*T\<_#S]GWX<>&/%D5Q+<1:W8:*@N4GG;=(V)Y M)HMS'GB-=A.5Q7UYCV_2C'MWST[^OUHYG_*_Z^15U_?_ / /3S\_ZTO0:%)( MFB=(GA8B,Q,B&*,)P(?)V[&C .,;=K XQ7RIXM_83_8\\=>,A\0?%G[/GPVU MCQHMS'>?VY<:&@O(KM'WBY/E21P;BXW8,1#'KDYKZZ_#WHQ[=>O%3>71-+M; M_@?U]X77]_\ \!_X/]6]+^>Z[\-O OB3P7=?#C6_"6C7?@+4-/73;SPR]E'# MI&?ALWP>\/^!]#TCX6W.GW&DR^" M[6T:/27TV\#"ZMF@+EO(FWLKC?DY)SZ>N44O>[/[F%U_?_\ ?\ @_U;TOY+ MX!^"WPL^%G@-OA=\.O ^@>$OAT]MJ=C/X5TBW:VTW[)J\07GP^^$'@30/ G@X7=W?GP[H5M]GTY[N^D,MS*(': M0%[IR9)2S')KU_\ #KUI,#T'Y4K2[/[F%U_?Z?9]//S_ *TO\B^-OV%/V/\ MXA^,1\0O&G[/?PX\1>-$:&5M)MT+EH'AAE9&&D:)I=GHVF:;"L%CIUC;Q6UE! BA%58HE55V* ,$$C'7/-;GOCFBK;D MU;E?]?(+K^__ . _\'^K>E^ ^)X=OAKX^CC5WE_X1#Q!''M!)D)TZ?9L7#$M MN;Y0 23@>E?@M_P2?_9Z^%WQJ^"/QH\+_'/X7:3XQT(?%'6I[;3?&>C.T7F? M;KDF:!IDMYR3U!238??-?T0R1+)\KJKJP(*L-R$8&5=2"K*KNL"(';/))R3]_P# ?3S\ M_P 'Z'F?PR^"WPI^"^@Q^%OA1X#\.^!=#C4$6FAV$5H%=1M1#*NZ9QM 'EO( M05[^N1=_L^?!?4?BU9_'6_\ AOX>N/C!I]DNGV/Q"EM6_P"$AM[-(C"MI:7 MD"HHB)B ,9PN1DU[>JA1CK@]J66NVNB>(K1KJTMM4L#OLKX1K(F+RV?YH6 MW87J0:Q/'_[.OP0^*VE^%M"^(GPT\,>+])\#W%C=^%--UBU:>#19M-(-G)9$ M2(8GMBJ&(9.-HZXKW&DP.N!GZ46?9_<%U_?_ / /3S\_ZTOP?C7X=^"OB)X- MU'X=^-?#ECXB\$ZM8)INI>'=1A,NGW.GP*J1V4\(8%H41%50&!P ,\4SP1\/ M/!7PW\+:?X"\#>&=,\+^"-,MC867AW3(_)L;.W9=GDP0EF81N#M<%CN&>PKT M"C'M^E%GV?W!=?W_ /P'_@_U;TOXY\-?@/\ "'X-WGB?4/A=X!\/^";SQIJC MZOXLN-$M6MFU[47)/VN]+22>;,68DD;E_ M$_A'^SQ\$_@'I4NB_!?X:^%/AWI]VYGG@\.Z7%:&XD"[<33L9)C)_#_K-O5L M<4SQ!^S]\&?%/Q-\,_&GQ%\-O#FK_%;PC$(/#/C>\M6N-?TJ/#*UM:W0=5B" M[NIC(QDX['V_\/>C\/>BS6Z?W,+K^_\ ^ >GGY_UI?!U71]+UVPN](UVPL]4 MTZ^AEM[RPOX8[NTNHY5V2(Z2H4V;/6ODC2?^">O[%.B^*3XUTO]F[X M:V?BC[6U_P#VN-' N!=E_,,Z;I&A:7> _$8 )&!7VK^ _$9'Y48SU&?PH]I[ MMN5[6O9^7E_6OD*Z[2MWY7Y>?F9]K;6]I!%;6EO%:VL,:1P00PI!'%&B!$18 MHU5%"JH VJ!C'%.E7>&1E1HG5ED$D?FQE&!#"1#PRG/S?[-7J*%9I:M?+_@_ MU8>FUI_^ /R\_/\ K2_Q_P#$#]@W]COXK>)3XO\ B%^SS\./%/B25TD?5;[1 MA]L9HW\U)',$L*G# 2#*DD_>KZ.\(>"O"?@#0K/PYX+\.Z3X7T"P"PV6E:38 MPV5K;0J J QQ*&9R ,N[L2:[+'M^E%%VMF_^!I;_ "^78+KM-?\ ;OIY_P!= MWI?YV^,?[+/[//[0:VH^-?P@\$?$(Z<&^PRZ[I44UQ&K,'*)-$T4SLY&[+NP M'0"NA^%'P%^#GP&T5M"^#OPX\,_#_2KHAIH= L8[1WQPB&T48]NG3CTZ4GGY_UI?QC3?@%\']"^)^J?&K2O &@ M:=\5=9LETW5O&T5H1KFHZ:!M%I)=>8588&#A!Q5CXK_ WX3?'/1/^$=^+WP] M\+?$+0W<,EEK^F17D<<@Z/O'ESJ^,=)=HYP/7U_KU%'3H*=W_-^'I_7G9]]2 M_E/_ ,!?E_G_ %='SI\'_P!E/]G7]G_SF^"WP?\ !7P[:Y)\]]!TN**1F8Y8 M^;,TLJLW. CJ,U[=J.DZ=K>GW>EZYI]EK&F74H]Z H'052G9=_P_K^O5EUVG_P" /R\_/^M+_(G@_P#8 M4_8^^'_C)_B%X+_9X^'?A_QHTKW URQT5!>Q3RR&1KA5EDDA25W)D)6,$'[N M.,?1/B_P5X3\>^&M4\&^,] TOQ/X4UNS;3M7T'4;2.;3[VWP"(9HFP$7"@;D MV$#C-=G134UJFG9^=^J\O*_X[AJ_AC)OS7+VZM^?]+4\#^"O[-GP(_9WLM;T M[X(_#3PU\-;'Q'=17FOV?AJQ>RBO[B)6%O)=!I9=SQJQ5&&,ACVXKV.]L;;4 MK2:QU&U@O[2^@EM;R"[@2YAFBG&PP/;R!DEMY4W!@1C&",5LT5G97^+3_#U^ M_P#SV?E+)?'EI^S?\,X/%C7S:@^N1Z$ M&N4U -YC3K&9?)C'?B)J= M@-*U#Q3H^GK::K-IXC"+;R&%DB*!1R/*_'@U[K^%&.^.?7%/3N^G3T\^GZ>@ M?*=_\#\O/S_JZ/%/!/[/GP7^''C;Q/\ $;P5\.?#?AOQUXVN&NO%OBC3+5K; M5->N&.2U_*9'65V^\2$7DYI_Q'_9_P#@S\6]=\+>)_B5\.O#WC'Q#X)NEO?" MFJ:S;M/=:)="03)/92!T$3JX5QE6P0/H/:**7,XZ*]M]%Z>O]+SU7-%;N2]8 M_P#!.6U[POH/BK1KSPSXBT33=?G_6AY[\/? MAUX*^%?A#2/ ?P]\.6'A#P=H<9@TOP]HL1BM-.A+%E2)"S>5$3G*9.!787-G M;7EK-;7MO;7%I/$\^_M;^W1H2 MB]-_N\QKG=YWV=F!^8QF#;VQBO5]'_9O^!>@?$=/BSH7PP\*:3\1A8FPC\7: M9ID=MJ,EHB!4MVD@9(EA4* $\KCN:]YI,#I@8^E4IMO>27H^ZTOW7Z/OJ77: M?_@#\O/S_JZ/$O"/[/?P7\#^/?$/Q3\)?#WPWX>^(?BO>_B;Q-IUHT>IZN[L M6=KN8R,&9B22=HQU[5;\:? ?X1?$CQEX*^('COP#H'B;QM\-I99O ?B+5+1I M[_PLUR09Y=%D$B"*64G,DC*V2<@"O8L#T'Y4M/G:\_.U[;?UMK9O4%KTG_X" M_+_/[M>QY9\4_@[\-/C;X2G\"?%GP=I'COPA+>6]Y)H.MP&[M+BZM"'M+AE5 MXR)("N4.>,#(/2OP\_X+0^#(=+TS]B/PUX2\/3Q^'O#_ ,6]'L+/2])L9[RV MTK3;.ZL8X8F$"2"&VAA58\R?*H&TDX-?T+5GW>E:=?F/[=86-[Y+B2'[;9V] MWY#C^.+[1')Y;9YW)M-"J.ZT?3IZ?Y_>GZ#>G\W3[#ZV_*Y\J6O[%7[*6K^+ M='^+VJ? 3X>W?Q)FT[2[J?Q/+H4)U-[S[#;*)2 RVXE 4&60P?,5&?F)-?2. MN^%?#_B?P]?^$-:TBRU+PU?V#Z;>Z'/:JFGW-BR;/LLB1[4$*KD&-0!C\JZE M5"@*H X '0 < =@!VI:KFE_*WM_6WS%=?W_P#P'_@_U;TOX=H?[/OP6\-? M#._^$&B?#GP_I7PUU5)X=2\&6=L5T:_6]8^?$Z&0F178LS?,#SC/'$VE_ +X M-Z-\,KGX+:;\/O#EK\+;^TELKSP2EHS:++;2,#):RV_F9(8XXWC./H:]KQ[? MI2%0>HZ_@?S'-2[MWY7]W_ %=?WO_ ?3S_JWH>'PZ%\.OV9OA!K(\#>"TT;P M-X(TJZU6/PIX7M&^2UMU,D\%C:J7D9PH($*DEC@"OP(NO%6J?\%&4!HYD>%PPRK)(I1T8=U9"5(]": MM@ <#^II>O446EV?W,+K^]_X#_P?ZMZ7\4^&?P%^#?P6U+Q/J?PM^'>@>!K_ M ,97AU/Q3=Z)8M:R:Y>R2F5KB]8R2>9+YK&5B H))X]/1->\/:)XGTN[T3Q' MHNGZYIM\CP7>FZC;0W=EJO/^]]W M]?UZL+K^]_X#Z>?]6/CGPG^P/^QWX'\9)\0O"?[//PVT3QFER]U!K]IHZ"_2 M9F\QY!YLDD!D+DCB(8Z@5].Z]X7T'Q3X>O\ PKXCT:SO_#NK6LVGZEHK0JUG M<62+.ZUS2HI+J'=DG,T!@D]CYK/@8_#Z4 MQ[=>O%'X4)26R?W,+K^__P" >GGY_P!:7\F^%GP9^%_P3\-6_A#X2> _#GP_ M\.V\C2Q:3X=LHK6&'S<;Y%FPTTIEP-RR2,#T&VLCPC^SU\%O _Q'\7_%WPG\ M.?#>@?$SQU*\_C'QI8VK6VM>(G=0C3W\Q=@Y94120@W[0,#%>X48]OTH]_\ MO?E\>\T^SU.TN=/O[6VU&RO$=;FSU"VCN[:="N#$8)0 MR%"N?E(YSN[U\E+_ ,$_?V+8?%8\>1?LW_#)/%WVS^T!KK:*OVI;UY/,-QS+ MY 8-G:/*P#V[5]FX]OTHIQU>"+RU-NR':%7;CBL#X7?"+X:_! M/PVG@[X5>$=(\#^$X;B2XAT/0K5K:SAN;D[YIC&7<[W;YLYZY/7@^H8]OTHQ M[=>O%+WDK)-?)^7^077]_P#\ ]//S_K2_AT/[/?P5MOBW+\>%^'?AR/XP76E MR:#<>/UM6_MVXTDX_P!"ENQ)M2 D#S$\OJ ,T[XO_L]?!+X^Z1#H?QE^&?A3 MXAZ=:RI)%%X@T^&=H)$S^\BG79.0N<']X5.X\=37MVT=<=?Z\T8Z8 QSGC_/ MXTTY1U=[+O\ @*_93>J^SW:6NOF_N\SQ#X1_L\_!#X"Z/-X>^#7PR\)_#O2I M9FGGM/#FDQVOVEVP6E:4F2=P3R%\W:3G@9K:^)WP<^%OQG\.W/A#XK^ O#/C MWP]=/'YNG:]IT-VDS1D,#O(6:(IZ)*HXY':O5 .#C(/J1SQCICMZ=J./;<.. M>"3C]?S[T*H[^_%P71W3NM-^S\NFM]AOF4FN5N,5=R2OVZ7OU_KI\V_"+]D; M]FGX!W4VH?!WX+^"/ 5_,J/M%N5O=4\.S6<=W-KVA0G=>V5G;396:6:,,GE$_M?V4+V5U8V_@:\$>I>*64VYNX[[RFL86FNW\Q5 M,)(Z(Z,59?ZT2,^Q]?;N/H>XZ5AGPWH#7'VMO#VAM=[M_P!J.DZ<;C>#D/YQ MM_,W@C(;=G/-:1JM1Y;-_-_U:W35:+09^/W_ 2$_9G^+/PE\-?&/XS?&GPV MW@7QE\?O%2^);?P// B7OA_0(Y'EL+>_C0*MO<202*K6@^Z #DYK] OC%^Q[ M^R_\?-3M-9^,GP1\!>/-4LHQ#;7FLZ)')=08.8O-DMW@>?:Q;8TI8]N@%?3& MPGDD@^YS^7H/;M3P,>_W2W_ \O(#S/X:_"+X:_!CP]%X5^%?@GP]X% MT"-S*=-\.Z;%9HSE0IE<*#*X*@!=\C>7C<.I!P+']GWX+:7\4+_XTZ;\/M M MOBI?6_V/4/'$5JPUZYMW !ADNM^UE.>FP<"O;/?OTHI/- L;^#4[+2_$%J;N"VO[9UEBOT0/&5E215*G/##..*[F'P] MHEGH,/AN/2[!=!M[!=/MM'^S1RV":;%$+=+58)1(NP1D*%(/YUT5%/FEW?\ M7]?UJ!\6C_@GS^Q4/%S^.S^S=\-1XN:\2^;7O[! N6N6D,HN9@9?(,H<;P?* M SC(Q7UW'I>G6]C'I5O8VD>DPVGV2+3DMH4M1;[/+6 6X01-"ZY5TV $=:UZ M*%)K>[^?I_7],#XNUS_@GI^Q7XE\72>/->_9N^&5_P"+Y+^'46UEM#\F=M0A MD,L,[JDP@RCG>"8L$D[E/2OKC1-'TO0+]$TRQT?2K2,06VGZ9;PVMO L2 MJJ[4@1$P5 7&W. /0ULT57/Y?U]P!11168!1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% #AT/\ O1_^ABB@=#_O1_\ H8HH ;V'^ZO_ *"* M*.P_W5_]!%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4QF(QC%/J)E8GU].>GYT 1R,P!QR5&>1ZDYP!S MVX_I7YT_MC>)+7Q1\6?@#\$[C7+/0='U?Q)_PFGB6]OKV*QA;2O"XCU VCRR M,JM]K(:+RB2&Z $G%?HK)O++@9W ]/4CG\/3&*_FA_X+>64<_QK^ D$T][# M')I'B$2BQO;JPEYP[DM3/\ZP&40?[W,*JI76\; M\L8ONM7;Y.V^GR/''%6$X)X5SKBO'T9U,+DV$J8RI0C%N=3V:$C50TN3A54#'&W' &,6A\6_A M@!@>/?"W'_49L_Y^;7\*(\-VI)SJ7B;=D L/$VM;&7;\I0&]W+C@?AZ&C_A& MK7_H)>)__"GUG_Y-K]]_XEFS]/W,QI)?_"FUG_Y,H_X1V'_ M *"7B7_PIM9_^3*O_B6GB#3_ (4J'2WP].7;7R_$7_%0+@C_ *$>/\_?VVW_ M '?_ _S9_=?_P +;^&'_0^^%?\ P MT>G)OKY+[_O2_:!<#Z?\(6/\O?\ \.G\/\.OS9_==_PMOX8?]#[X5_\ !S9? M_':/^%M_##_H??"O_@YLO_CM?PH?\([#_P!!+Q+_ .%-K/\ \F4?\([#_P!! M+Q+_ .%-K/\ \F4_^):>(=/^%*AT_EV]WSZV_$?_ !4"X(_Z$>/Z?;ZZ:?P] M_P _FS^Z_P#X6W\,/^A]\*_^#FR_^.T?\+;^&'_0^^%?_!S9?_':_A0_X1V' M_H)>)?\ PIM9_P#DRC_A'8?^@EXE_P#"FUG_ .3*/^):>(?^AE0MI_+_ '?/ MR_$/^*@7!'_0CQ_IS^C_ .??]?,_NO\ ^%M_##_H??"O_@YLO_CM'_"V_AA_ MT/OA7_P)?\ PIM9_P#D MRE_Q+3Q!_P!#*A?3I&^\?/R_$/\ BH%P1_T(L>]OMWZK_IWT?]:L_NO_ .%M M_##_ *'WPK_X.;+_ ..T?\+;^&'_ $/OA7_P)?_ M IM9_\ DVC_ (1V'_H)>)?_ IM9_\ DRA?1IX@_P"AE0W2VCJUR^?E^(+] MH%P1_P!"/']+^_Y+7^'JOZZL_NO_ .%M_##_ *'WPK_X.;+_ ..T?\+;^&'_ M $/OA7_P)?_ IM9_\ DRC_ (1V'_H)>)?_ IM M9_\ DRG_ ,2T\0_]#*AT_E_N^?E^/WG_ !4"X(_Z$>/Z?;_P_P#3O_A_F?W7 M_P#"V_AA_P!#[X5_\'-E_P#':/\ A;?PP_Z'WPK_ .#FR_\ CM?PH?\ ".P_ M]!+Q+_X4VL__ ";1_P ([#_T$O$O_A3:S_\ )E'_ !+1Q#I_PI4/+2.J]V_7 MR_$/^*@7!'7(\?TO>>VV_P"[_P"'^;/[K#\6/A>%CGG_D-60P?4$2@Y M_3CO3A\6OA@ /'OA7C_ *C-D/QP)<5_"C_PCL/_ $$O$O\ X4VL_P#R91_P MCL/_ $$O$O\ X4VL_P#R927T:>(-/^%*AWVC_E^T"X'TMD./_P# ME_=_Z=_\/\V?W7_\+;^&'_0^^%?_ /\ _ ^NFG\/?^NK/[KO^%M_##_H??"O_@YLO_CM M'_"V_AA_T/OA7_P/_ / []%_T[_KY MG]U__"W/A@.OC[PK_P"#JR_^.TG_ MWX7_]#]X4_P#!U9?_ !VOX4?^$<@/ M_,3\2G_N9M9_^3?\^U'_ C=O_T$O$O_ (4NL?C_ ,OO^?:C_B6GB#_H94+Z M=(W^SY];?B'_ !4!X&T_X1,?Y>]?:W]S7;^KL_NO_P"%M_##_H??"O\ X.;+ M_P".T?\ "V_AA_T/OA7_ ,'-E_\ ':_A0_X1V'_H)>)?_"FUG_Y-H_X1V'_H M)>)?_"FUG_Y,I+Z-/$'_ $,J'3I'7X7IKY?B+_BH%P1_T(\?Y^__ (=?X>JM M_P '=G]U_P#PMOX8?]#[X5_\'-E_\=H_X6W\,/\ H??"O_@YLO\ X[7\*'_" M.P_]!/Q+_P"%-K/_ ,F4?\([#_T$O$O_ (4VL_\ R93_ .):>(?^AE0_\EZ< MJ[^7X_>?\5 N"/\ H1X__P #_P /_3O^OF?W7_\ "V_AA_T/OA7_ ,'-E_\ M':/^%M_##_H??"O_ (.;+_X[7\*/_".P_P#02\2_^%-K7_R;2?\ ".P_]!+Q M+_X4VL__ "91_P 2T\0Z?\*5#R^'7X;]?+\0_P"*@7!'_0CQ_2_O[;;_ +O_ M (?YL_NO_P"%M_##_H??"O\ X.;+_P".T?\ "V_AA_T/OA7_ ,'-E_\ ':_A M0_X1R'_H)^)?_"FUG_Y,H_X1V'_H)>)?_"FUG_Y,I?\ $M/$&G_"E0];1MIR M^?E^/WK_ (J!<$?]"+,+_P"/_#_<_P"'^;/[K_\ A;?PP_Z'WPK_ .#FR_\ MCM1O\5_A:_#>/?"V#CC^VK(#CM_K?\CBOX5#X<@//]I>)1_W,^LG_P!O,]>: M3_A&[<_>U'Q*?3'B?61SS_T]^M9_\2T<0_\ 0QH?U;I=_P"6]M]3_BH%P1;_ M )$686LMI/\ NZ?P]^W_ 3^ZIOBQ\+B&7_A/_"O.,@ZS9 8[*/WO0=1C\J9 M_P +2^%C)(DOCSPI-#*I26&75K%XI(R"&CDC:0JZL.&#*=PX-?PL?\(U:9YU M#Q-^/B?63_[>9XJ7_A&[+_G_ /$O_A4ZY_\ )HJE]&GB#KF%'HK_ "CNV_G_ M $KO_BH!P1+_ )DF/B^UWK\-_L+R7W]3^N/XD? W]F7Q-K=YX[^'GQ)TGX-? M%"5#Y/B[P)K]EIL5Q.JDQKJFBI(-/NK5I,?:6%LLS*6Q)NKSJQ_:_P#''[.6 MC6]C^T3>>&?BCX;@OA;1?%OX<7T-SG3Y'\N"?6?#2/)J<3PK\UY>$K "&< # M%?RO_P#".V>67[=XD'R'#CQ/K9DRW&T9O,!/[^>3VQS41\,6#1RV\U_K\T,T M8CEB;Q'KCP2JP^>&:&2[,;Q'G._#^G^*/#'Q2\':KH^H11O M!=1ZQ9AHS*!^XE_>Y25"2DT?#QD'=S76CXN?"TNN?'_A167.?^)U8L!G(W*? M-[XXSD<9QZ?P*:_X8TOP_=>";#0CJNC:=J'B[3(+JTT[7-4LX/*EN )D%O;W M,< CFRP<^7O.222:^SY?AGX5#N1!KNUCC9'XHUU2I#=&[>' M4/'NDWEJ\VKVL8F1=%\MWB,DN'!;JR_Q9 ZXK[!3XK_"XH6'C[PHF3M&[6++ M!ZMR?-Y!_GZ\5_G _P#!1#4M:^%.H:9)\.O$/B+PM+J-@LMY)I^OZKFZF654 M26X9KK<\BQY53TV]<'K^68_:$^.X;;_PMOQPP ! 'B#4P% ')P;GTST[G@5^ MN^%&"GXJ\&9?QAE]3ZI0S*#G2I3]UJ*=K:]>NG=::GPGBKF-'PMXOS3A#-83 MKXK+G&$Y13:D[I\R2;O'EL]%YWL?ZO/QM^(7PS\1_"3X@Z+'XY\*S-J'AN]5 M(SK5DV]X]LV%7S&XU:T2 M96@9E!56DW=!GI@CT/7_ "K(_P!H'XX2NBM\5_'+QRO%"\3Z]J#QR0DX<%#< M'AE)!!'/.>M?T)_LG^%],\4?!SP]JVN3ZY>7LD.3.?$6LQLS, 6;RX[L1J6) MZ!0!Z=J^1\=L^P_@9PUA\^SBG4QM"OB(4I*FN9WYE=:=;->=^E]_K/ K)*GC MGGF*R;)ZOU.M0@IIU%9*"2YG*]NMV_2W0_NL;XP_"Y%"3B\*%2#@KW'7IBODKP]I:V6CV::??ZYID=Q!!=30Z M?K>I6<4MW(BL]P\=OMWT6^G<_.OIB\34?H?8WA_!\4PEFU/B!3]A]57.XNFFVVXW_DM? MI?U/[LO@;X7_ &;?@)H=SI7@WQAX:N]^YH[6-EMXLJ$C^75N^VL^)>@SGQ/K?7O MC_3.F>G'2OZ#EX:YG=?OJ;=E?7O:VM[/Y+;Y(_AK_BH-P0O^9#CW?IS>:_Z= MWW:ZG^@0/BW\, /^$]\*D@ 9_MFR[?]M:7_ (6W\,/^A]\*_P#@YLO_ ([7 M^?D8KL_\QKQ+UY_XJ;6__DND\F[_ .@WXE_\*;6_3_K[]>::\-LSM_&IKK:Z M\O/>W?TZL:_:#<#_ /0BQ^MK^]_A?_/O^K_=_H'?\+;^&'_0^^%?_!S9?_': M/^%M_##_ *'WPK_X.;+_ ..U_GX^3=\?\3OQ+V_YF;6_Q_Y>^_Z4>3=\?\3O MQ+V_YF;6_P ?^7OO^E/_ (AMF?\ S_I].OI_>W_/OJ/_ (J#\$?]"+'_ /@; M\O\ IWZ??Z6_T#O^%M_##_H??"O_ (.;+_X[1_PMOX8?]#[X5_\ !S9?_':_ MS\?)N_\ H-^)?_"FUOU_Z^_3BCR;O_H-^)?_ IM;]?^OOTXI?\ $-LS_P"? M]/[UY:O7R^?S%_Q4'X(_Z$>8:M/XWK\.O\/TTTWT6Q_H'?\ "V_AA_T/OA7_ M ,'-E_\ ':/^%M_##_H??"O_ (.;+_X[7^?CY-W_ -!OQ+_X4VM^O_7WZF/^>M?Y^7DW?_ $&_$O\ X4VM^G_7WZ\T>3=_]!OQ+_X4 MVM^G_7WZ\_I1_P 0VS/?V]/[UY:+WO*[O^H?\5!N!]/^$+']%K-^7_3OSZ=_ M0_T#/^%L_"\%6'C[PL"N>?[9LLD'L3YO2G?\+;^%_;QYX5'0_P#(:LO3G_EK MWK_/Q\F[_P"@WXE_\*;6_3_K[]>?TH\F[_Z#?B7_ ,*;6_3_ *^_7FC_ (AK MF7_/ZGWW\T[;Z]]=+KS#_BH-P/\ ]"+'?^!>G_3O^K^EO] [_A;?PP_Z'WPK M_P"#FR_^.T?\+;^&'_0^^%?_ O<7_%0?@C_H18_=?;?3E_Z=^GZ+8_T#O^%M_##_H? M?"O_ (.;+_X[1_PMOX8?]#[X5_\ !S9?_':_S\?)N_\ H-^)?_"FUOU_Z^_3 MC]:/)N_^@WXE_P#"FUOU_P"OOTX_6G_Q#;,_^?\ 3W[^FOQ?Y_B/_BH/P1_T M(L=T^V_+_IWZ??Z6_P! [_A;?PP_Z'WPK_X.;+_X[1_PMOX8?]#[X5_\'-E_ M\=K_ #\?)N_^@WXE_P#"FUOU_P"OOTXH\F[_ .@WXE[_ /,S:W^'_+WV_6E_ MQ#;,_P#G_3^_T\_Z^;#_ (J#<#_]"+'=U[W7W?\ IW_5^FEO] [_ (6W\,/^ MA]\*_P#@YLO_ ([4$GQ:^%S'_D?/"B_*V'&LV1!9N"&Q*3DX]CGG' -?Y_'D MW?/_ !._$O?_ )F;6_P_Y>^WZT>3=\C^W/$H5P0V/$NM_)C!#\W>"QY&1['@ M\TO^(;9KS0Y:U)KF]Z[V5DKK76^VJWU?6Z_XJ"\$2:7]A8_D6LUSO5))I? M MVEMKK9:']C'Q1\9^#O ?[9/P3^+WA?QGHEWIOQ2TR]^$OCVQL-1MY2S6R_;? M"]U<01N"*_T!'0^8?F MY)RI..#U;E<,/>OCL^R:KDF*AAL1*+?(W[K6J]WY;O1Z75WW/ZQ\&O M%W*_&7A:KQ+E.$G@Z-'$?5Y4ZEW)R^:6MHN_FUZ$M%%%>$?KP4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-P <6HOE=UKI=[;7WTN<+ MKWQ%\%>&;O[!XB\5Z#HMVR>GZK? M6D;/C[Q2UFC0]NH)_*OYS8_B?\3TX/Q"\8!L=O$&I'KZ8N@1Q7Z/P]X=YAQ# M@UCJ%>$8244HR>BVZ:=_G^!^)\:^-65<%YG_ &3B\)5JU(:MTVHOI[SYE)6= MK=.O8_U1?^%T?";_ **)X1_\'5G]?^>OI_C2_P#"Z/A,.OQ%\(_AK=D?_:M? MY78^*7Q/)_Y*%XQ'K_Q4.J<;\_G\CXO_B9KA^]GEN)TT^-/LKZ07E>W36ZZ_P"J%_PN MGX2?]%%\)?\ @YLO_CU'_"Z?A)_T47PE_P"#FR_^/5_E>_\ "U/B5_T4'Q?_ M .#_ %3_ .2:/^%J?$K_ **#XO\ _!_JG_R33_X@YG>G^TT_O7E;IYKR%_Q, MQP[_ -"VONK:O^[K\/IZZG^J%_PNGX2?]%%\)?\ @YLO_CU'_"Z?A)_T47PE M_P"#FR_^/5_E>_\ "U/B5_T4'Q?_ .#_ %3_ .2:/^%J?$K_ **#XO\ _!_J MG_R32_X@YG?_ $$T_O\ 3R\U^%A?\3,<._\ 0MKVTZO^Y_=\_P ^Y_JA?\+I M^$G_ $47PE_X.;+_ ./4?\+I^$G_ $47PE_X.;+_ ./5_E>_\+4^)7_10?%_ M_@_U3_Y)H_X6I\2O^B@^+_\ P?ZI_P#)-/\ X@YG?_033^_T\O- OI,<.Z?\ M)M>^G5_W?[OG^+[G^J%_PNGX2?\ 11?"7_@YLO\ X]1_PNGX2?\ 11?"7_@Y MLO\ X]7^5[_PM3XE?]%!\7_^#_5/_DFC_A:GQ*_Z*#XO_P#!_JG_ ,DT?\0< MSO\ Z"J>RZKR_P UK_P1_P#$S'#G_0NK].LO[MOL^GWL_P!4+_A=/PD_Z*+X M2_\ !S9?_'J/^%T_"3_HHOA+_P '-E_\>K_*]_X6I\2O^B@^+_\ P?ZI_P#) M-'_"U/B5_P!%!\7_ /@_U3_Y)H_X@YG?_03#I]KO;R\UY@OI,<.:?\)M?IU? M]W3X?ZNS_5"_X73\)/\ HHOA+_P_Z%M?=?:E_<_N[G^J%_PNGX2?\ 11?"7_@YLO\ MX]1_PNGX2?\ 11?"7_@YLO\ X]7^5[_PM3XE?]%!\7_^#_5/_DFC_A:GQ*_Z M*#XO_P#!_JG_ ,DTUX-9UHUB*>ZZ_P"'OZK??7NQKZ3/#NG_ FU^GVI:/W+ M?9]-?7Y?ZH7_ NGX2?]%%\)?^#FR_\ CU'_ NGX2?]%%\)?^#FR_\ CU?Y M7O\ PM3XE?\ 10?%_P#X/]4_^2:/^%J?$K_HH/B__P '^J?_ "33_P"(-YWI M_M-/[UUM;\UZ?>'_ !,QPYI_PFUWMU?]W^[Z?>S_ %0O^%T_"3_HHOA+_P ' M-E_\>H_X73\)/^BB^$O_ :_"PO^)F.'?^A;7MIU?]S^[Y M_GW/]4+_ (73\)/^BB^$O_!S9?\ QZC_ (73\)/^BB^$O_!S9?\ QZO\KW_A M:GQ+_P"B@>+_ /P?ZI_\DT?\+4^)7_10?%__ (/]4_\ DFD_![.5OBZ2ZZR2 MOMT>OYZ OI,<.Z?\)M>^G5_W?[OG^+[G^J'_ ,+G^$QZ?$7PCC_L,V/_ ,?% M,_X71\)@3_Q<;PB?;^V;+C/(Z3'_ .L.*_RO3\4OB<3E?B!XOQV_XJ#4_IT- MU3C\3_B;MY^(7C 9Z?\ %0ZER1R0N;GD^WI4OP@S9:O%T&K:KGC?[/G^/EY- M%P^DKD%22A3RS$.4K)6;N](V6U_EY[;7_P!4(?&CX3GI\1?"&<_]!FR'_M;/ M?Z?T:?C1\)\_\E&\(C_N,V7Z_O>M?YH'P]^#?[BW.OW=C-<6CK'<5U&J_LT_\ !1'1-/NM6U7X M=?'>STZRB>>[NI#XD$<$48R[MTX4 D]N#S7F2\.7";IRSC 1J1DX2A+$4U*, ME9.+C=--/IZKH>S#QWHSHQJ0X>S.<)1C*-2-*IRRB^5J2:CJGTM?OVM_I,?\ M+I^$W_11?".?^PU98_\ 1OZ4G_"Z?A/_ -%%\(?^#FS_ /CU?Y8>H?$;XO:5 M?3:;J?C?QUIU_;.8Y[.[UG5H+B*520R/$]PC K@[LCC'-1_\+3^)X )^(?C# MYNG_ !/]3/\ *Z[=_3OQ7?3\(LRJ1C..-HRC+5-3BTTW&S73OY?C?RJGTE,E MH2]E6RG%0J)V:FG%WT;5G&][;K?IU9_J@K\:/A,3@_$;PA_X.;/_ ./4P_&? MX29/_%R/"0Y/']M67K_UWK_+ /Q5^)P(!^(GC YP?[?U/''(/AOI_Q@\8:)IJ3S:AJ>CW>OW%G:Q6ZO)/*\T;O&$C1&8G< M!BL\1X39AADI5L?AZ2O'6I4A%:\MM79:NZ\_SZ,-](K*\;S+#Y)C:O(N:7LX M3G9)QNWRQ>VOY[L_TWQ\:/A*.?\ A8WA#GN=:L^?3_EM2CXT_";_ **-X0]O M^)U9_P#QTU_EA7/Q)^*UAO3XA>,.F[_D/:H!_NG_2?O\ ^SUK>/A#F<[Q_J@_P#"Z/A-_P!%&\(? M^#FS_P#CO;_]5)_PNGX3_P#11?"'_@YL_P#X]7^5\?BI\4!M)^(7B_YAD?\ M%0:GD#MN'VKY<]L^HS1_PM3XGG('Q"\894 L/^$@U/C/3_EY_P XIOP?S6-N M;%45?^:4?)/MLV_N$_I,9#&U\KKJ]K7>_P /]W7];>9_JA?\+H^$W?XB^$?_ M =68_\ :II/^%S_ D)!_X6+X1!X_YC=ECKW_>?C7^5_P#\+3^)^ 1\0_%Y MW9Q_Q4&IC..JC-S]\GXJ?%!1D_$'QA MCH,:_J9_E<_D.M,'Q5^)S$;?B)XP+$$[1K^IDX'?_CX..,Y/'3!J/^(09IRI MO%T;-IUMA+Z2_#TXMO+<2HQ:YI1;:B]+7:7YVU5];V?^J,/C M/\)R?^2B>$?_ =68_4RTG_"Y_A1_P!%$\(_^#FS_P#CU?Y7O_"TOBBV /B' MXP8DK_S']1.,@D<_:<=,D^F*#\4OB?S_ ,7%\8'!VG&OZD1GTR+G]:?_ !!W M-4TGBJ2EVYE?[/2_KZZ]P_XF5X:_Z ,8MK:OR\GV7W/Y_P"J$/C/\*,9/Q&\ M'\=?^)S9_P#Q[OV]:/\ A=/PE_Z*-X0/N-:L\=/^NO\ GVZU_E>GXJ?$W[P^ M(/B\#./^0_J>2P]!]IR21T'?'%*/BI\3> I&[.OZF""?\ MY]/\GI0 M_!_-4XIXNBG)JR?Q_>^GM[^U?Y7Y^* M7Q/S@_$+QA@KO!.OZH1M['(N<'GJ!T'7%7-,\<_&C7;^'3- \6_$#6=2N&V0 M6>F:KK-W/*AP*_S2-9^!O[>>@>&U\8:UX,^ M.5AX;D@2<:M.WB);?R73SE?)(ZQ_/@G.,GH,U\Y-\3_BG#.\$WCWQK;SPLRR MPW&N:K%)&P.&#J]PI0@YX//M7/1\+L77FXT,PPM2:ERN-.K"4HR23<;)MWLW M=/\ ):]N(^D)E^#IQGBJZ?]N,_6D_X73\)XUW5./_)GO_0TO_"T_B<,J?B'XOR/^H_J>"/\ 9_TGYAZD< =<&NM^ M$.;QMSXF$=%+5QU5XJ_I=-7[[]3S5])KA^6V65O_ +TU^'IKZV?<_U01\:? MA+CGXB^$2?\ L-67X?\ +6C_ (73\)<_\E%\(X_[#5EG_P!'5_E??\+1^)PQ M_P 7"\8#)P/^)[J>?K_Q\YVCNW3WH_X6E\40Q7_A87B\XQDCQ!J9'/I_I//\ MJF/@_FLK/ZU2UUTDN\?7I?[GYC?TF>'XVOEM=7VN_P##OIO_ ,'>Y_J@_P#" MZ/A,>!\1?"'/_4:L_7_KH*=_PN;X4?\ 11?"'_@ZL_\ X]7^5Z?BE\3P.?B' MXOZ9Q_PD&IYP>,$&YX/L:9_PM/XF@#/Q \8$D9X\0:GP ?07/&3Z]1R,U2\( M,W2NL33:5KM-67PZ=%KKYZ"7TFN'V[?V97;?2[=FN7M'7Y^?<_U1#\9_A../ M^%B^$,^VM69_3S/^:A>+QW M(&OZF2!VSBYX_'%(?BI\3\9_X6%XP(QG']OZGDX]!]IY/MU]J/\ B$.<7Y?K M--2LG:ZNOA\]/G]^K!?29R!OE_LO$7TOJW9NVE^737YVVW/]4,?&GX2]_B+X M1_#6;+_X]2_\+I^$G_11?"7_ (.;+_X]7^5Y_P +0^)__10?&&0%)_XG^J=& MSCI<\GNP/3^+M3S\4OB:.OC_ ,8<_P#4?U3_ .2:?_$'V*I:66DEY=M=? M^#:UB/\ B9CAVZ7]FU[NVCD[V]WR[>?<_P!4#_A=/PD_Z*+X2_\ !S9?_'J/ M^%T_"3_HHOA+_P '-E_\>K_*]_X6I\2_^B@>+_\ P?ZI_P#)-'_"U/B5_P!% M!\7_ /@_U3_Y)JO^(-YVM/K-/>VC]/\ -?D)?28X=ZY;7_\ F_Y-/A[_KW/ M]4+_ (73\)/^BB^$O_!S9?\ QZC_ (73\)/^BB^$O_!S9?\ QZO\KW_A:GQ* M_P"B@^+_ /P?ZI_\DT?\+4^)7_10?%__ (/]4_\ DFC_ (@UG3M?$T]^ZZ\O M^:T?ZL:^DQPYI_PFU^G66_N_W?3[V?ZH7_"Z?A)_T47PE_X.;+_X]1_PNGX2 M?]%%\)?^#FR_^/5_E>_\+4^)7_10?%__ (/]4_\ DFC_ (6I\2O^B@^+_P#P M?ZI_\DU/_$&LYT_VBGK_ 'O3?[U^/'?^A;B-U;WI?W-?A]/ZV_U0O^ M%T_"3_HHOA+_ ,'-E_\ 'J/^%T_"3_HHOA+_ ,'-E_\ 'J_RO?\ A:GQ*_Z* M#XO_ /!_JG_R31_PM3XE?]%!\7_^#_5/_DFC_B#6<_\ 033^]^7EZ??YZB^D MSP]I_P )N(Z?:E_<_NG^J%_PNGX2?]%%\)?^#FR_^/4?\+I^$G_11?"7_@YL MO_CU?Y7O_"U/B5_T4'Q?_P"#_5/_ ))H_P"%J?$K_HH/B_\ \'^J?_)-->#> M==,336S^+O;\=5^H?\3,<._]"VOTMJ]O=_N^FGJ?ZH7_ NGX2?]%%\)?^#F MR_\ CU'_ NGX2?]%%\)?^#FR_\ CU?Y7O\ PM3XE?\ 10?%_P#X/]4_^2:/ M^%J?$K_HH/B__P '^J?_ "33_P"(.9W_ -!-/IU7E_FO-_>'_$S'#G_0MK]. MLO[ME\/I^/R_U0O^%T_"3_HHOA+_ ,'-E_\ 'J/^%T_"3_HHOA+_ ,'-E_\ M'J_RO?\ A:GQ*_Z*#XO_ /!_JG_R31_PM3XE?]%!\7_^#_5/_DFC_B#F=_\ M033Z=?3R\U_D+_B9CAW3_A-K].K_ +G]WL_Q?<_U0O\ A=/PD_Z*+X2_\'-E M_P#'J/\ A=/PD_Z*+X2_\'-E_P#'J_RO?^%J?$K_ **#XO\ _!_JG_R31_PM M3XE?]%!\7_\ @_U3_P"2:7_$&\[_ .@FGV6OIY>:!?28X=_Z%M?IU?\ <_N] MW^?<_P!4+_A=/PD_Z*+X2_\ !S9?_'J/^%T_"3_HHOA+_P '-E_\>K_*]_X6 MI\2O^B@^+_\ P?ZI_P#)-'_"U/B5_P!%!\7_ /@_U3_Y)IKP_=> M7W[K1C7TF>'=/^$VOW^)Z/W?[O737U^7^J%_PNGX2?\ 11?"7_@YLO\ X]0? MC1\)<74%K8^/_ M=WEQ+'##!#JMK M)(\TAPJ*%EQN.<8]?RK_ "OC\4_B>>#\1/& #<<:_J@)_*ZX_P ]Z^HOV)O' MWQ U7]JCX,6FI^-?%-Y8R^--)$]I/K^IO#(?M4*KO4W.R13CD.".NZO,S3PO MS7+L#6S"M6INGATY[]7L?T'%MI-JS:3:72ZOT"BBBD,**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH <.A_WH_\ T,44#H?]Z/\ ]#%% #>P_P!U?_0111V'^ZO_ *"** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ I"<*_FJ_X+:8'QR^ >>VD^(L'C_GR& MOZ3Y/E4=3]W'J5)*+>,HI-NR352.[=N_?Y]_Q3Z1$9R\&N.'34I3 M638OEI*+E.=J3NE%7NW_ )'Y''T_VJEO\ S1\O/1^? M^3#^S\=_T XK_P )ZW]=_P"GHM%)M?U/_?-&U_4_]\T?6\/_ -!=+_P*'EY^ MFFGX"^H8[3_8<5_X3UO+\=7]WW+12;7]3_WS1M?U/_?-'UO#_P#052Z?;AY> M?_#?)C_L_'?] .)_\)ZWEY>OW>8M%)M?U/\ WS1M?U/_ 'S1];P__052_P# MX>7G_7R8?V?CO^@'$_\ A/6\O+U^[S%HI-K^I_[YHVOZG_OFCZWA_P#H*I=/ MMQ\O/T]/DQ?4,=_T XKI_P P];R_X/W?7]?\,Q_P!GX[_H"Q/_ (3UO+R]?N\Q:*3:_J?^^:-K^I_[YH^M MX?3_ &JE_P"!P\O/3^NS#^S\=_T XK_PGK?UW_IZ+12;7]3_ -\T;7]3_P!\ MTOK6'_Z"Z7_@4?+S\EIMWV8OJ&.T_P!AQ7_A/6\OQU?W?<$9& <OW>8M%)M?U/_?-&U_4_]\T?6\/I_M5+_P #AY>>G]=F'U#' M?] .)_\ ">MY?\'^GHOX?Y'2BDVOZG_OFC:_J?\ OFE]:P__ $%4O_ H^7GZ M?C?9B^H8[_H!Q7_A/6\O^#]WW+12;7]3_P!\T;7]3_WS3^MX?_H*I=/MP\OZ M\ODP^H8[_H!Q7_A/6\O^#_6R_P">E'?^N.:3:_J?^^:"KCJ'QQ_"/\]?\.>M M9U<7A^77%TU_V_#RZ?+S[="HX#&+? XGR_<5K7TTVWZ= P QZ^M*6,P]H M:*;VT7KL6L#C+K_ &+$0U7OO#U6H[>7_ \^IYYXXYU+X>$#)_X3 M71Q]0;E#_B,^Q-?=;',C@DYS)C.3CGG]#7PMXX5O[6^'X"/\_C318P!G"N+B M,L2!G& !GID?X_3BO^6$ZD'!_AX],9[U^+PD'(RFY1NR'QVZ!;2R;35TT[6^>I_.OTS'[3QVXG MJ492KQE).4XKF4/=5H\R37SU6UBS:_\ 'Q![RP9QG/4?ES_/DU_4G^QCG_A1 M'AK/:(?R [5_+/:2*UQ9_./^/B(9SU.[HWXYZ_\ Z_ZF_P!C$2/\"O#)5&(^ MSX;:I."0.5P,$'G![?I7X7^T(F9.KR4U4PG]<"SM2?3_ %"$9]/I['O7VA\>8I$^$GC8NC[(]+FEM-[+^4/V[4IYCG/AO\ 4DJZH_68SE!> MT4;^T2^"ZUZ=[FK129_WOR/^'\J,_7\C_A7^G?M*?]W_ ,&+_/7Y'_.I_9V8 M6O\ 4L3JU_S#U;]/+I^GK9P.#FG;L=!^I[<#]./UJ//U_(_X49^OY'_"DZU) M.SY?_!D?+STW%_9F82U^IXE7MI["JNW>/]6];2;O;ITY/;I^7/UHW>W3IR>W M3\N?K4>?K^1_PHS]?R/^%3[:CY;I_P 1>5OM>G]7%_968?\ 0'B?_!%3R_N^ M?X>MI-V.@_4]N1^O/Z4;L=!^I[?TJ//U_(_X49^OY'_"CVU'RZ?\O%Y? MWO3\?,/[*S#_ * \3_X(J>7]WS_#UM)N]N?J?K_Z%S^E)N'7]WS_#UM)NSU'ZG MOR?UY_2C=[=>O)[]?SX^E1Y^OY'_ HS]?R/^%'MJ/E?_&O+^]_PWWA_9>8? M] F)_P#!%3R_N_U;UM)N]NO7D]^OY\?2C=GJ/U/?@_IQ^M1Y^OY'_"C/U_(_ MX4>VHZ;:;?O%Y?WO3\?,/[*S#_H#Q/\ X(J>7]WS_#UM)NSU'ZGOP?TX_6C= M[)_\$5/ M+^[Y_AZVDW>@'Z_3^7'ZT;L=!^I[<#]./UJ//U_(_P"%&?K^1_PH5:CY>7OK MR_O?U]]C^R\P_P"@3$_^"*GE_=_JWK9^X>GZGMT_(?G2[O;ITY/;I^7/UJ// MU_(_X49^OY'_ H]M1\NC^-;Z?WO3^KA_9>8?] F)_\ !%3R_N_U;UM)N]A^ MO;I^1_.C=CH/U/;D?KS^E1Y^OY'_ HS]?R/^%'MJ/ET_P"7B\O[WI^/F']E M9A_T!XG_ ,$5/+^[Y_AZVDW>W/U/U_\ 0N?TI-P[C]3]?Y\_I3,_7\C_ (49 M^OY'_"CVU'RW7_+Q>7][T_7J']EYA_T"8G_P14\O[OG^'K:3=GJ/U/?D_KS^ ME&[V'Z]^OYG\JCS]?R/^%&?K^1_PI^WH^7_@O)[]?SX^E&[.<@9P>?K^1_PIRXY)!(P>Q_3CK2=6@X MRO5C227Q.:^[XOG\AK+,='WI83$65MZ-77;31)_U]WH7P*Q_PT;^SID_\UL\ M!<]\_P!M0=*_T!7QO'X_^@\U_G^_ T?\9&?LY-]U3\:O 0W$-@2?VU;B,'OA MFQG Q@\U_?[*IW;@0I#')W9&!S@J>,D8Z=\U^$>(;C4S>')44U]6BKIWMRN# M_K_AC_:WZ!<*]/PBQGM<-+#3_MA\M.491?SHK MX$_N(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "E&H_.C ]!^5&!Z#\J+OS_K_AE]Q(;A MZC\Z-P]1^=&!Z#\J,#T'Y47?G_7_ R^X W#U'YT;AZC\Z,#T'Y48'H/RHN_ M/^O^&7W &X>H_.C@_*C ]!^5%WY_U_PR^X W#U'YT;AZC\Z,#T'Y M48'H/RHN_/\ K_AE]P!N'J/SHW#U'YT8'H/RHP/0?E1=^?\ 7_#+[@#@_*B[\_Z_X9?< ;AZC\Z-P]1^=&!Z#\J,#T'Y47?G_7_# M+[@#@_*B[\_Z_P"&7W &X>H_.@D=B/S%&!Z#\J,# MT'Y4N:V\>;[]+-?TO\@ 9QR<^XI'&Y&&<$*Q7[O! /1FX4\]>#0QVC@?X>M1 M39DBD1<@LA!X!&W^+/MC/OG!ZUG.2<)+V=O=?2_1?Y?EU9T8=-U(6ER-U*:4 MKVM[RZ[+L?TI:#^TE\??V:/^"+W[._BS]GW5M9T3Q-JGQR\4Z-J=SI&GW&HR MOITM^&EC*6\ MU;PG?M8W]K/<)'+;7,3VA1XI$9@Q8,,$YQFOO?X4?MC^(?V,_P#@C;^S]XZ\ M-^!?!WCR37/C3XNT Z=XRTR+5+2WM7OT+7$4%Q&Z)< @XD #_K7T9^PO_P % M/](_;*L/%_PAC^%_PB^%G[1TFCW=]\,/$:^&M+CTS5KR.(R06$2RPH!>*P B M"-EBPX) -?A3J5:$ M*\.^ 7_!(/XP?%?X>Z7\2O'_ (^\'?!G0O$4 G\,VWB_4+>QU758F3?!)]AN M9HY(XGR/G,8##H3W\U^)6I_&[XF?\%$O#'AG]K+4+O4?&.D_$G3-%U&SO87@ ML5TZUU!1;IIL,F8TL70 J(\(RD =*_=__@H)X,_X)U:]\:;31_CY\??B;X$\ M3:!X5T&TL/!OAR\ET_0=*M(].M?*DL;9&1'=^&)*A26+9YKV99MF>3X3*,HI M-5:E>FZD:]*E/$^Y*SC&\'+X4]-='L?/X?AG*.(\?G^?9C1HTZ>&Q"P^'H3K M4\._:05G5JQE**2EH[I137D?SU?'C_@GM\7?V?OBIX)^'7CF_P!'_P"$7^(U M_#9Z!\3--N$N?"DT=PZHMT;]&>",PJP=HS*K8!XK^H/XO_!WXB?LS?\ !/[X M<>$_@#\=_A[\-6T/P1JFJ>+=;@%G'<_$-FT^47<%I.&0W:S1F5"&=\2,,5^6 MO[9/QF_88M_V Y_@)\%_BKXT^)/B3PSXA&N>$=5\6+-=ZGITC1XF@AU0A_L\ M(7E(EE4 XX].0_X*'7^I77[!W_!/FTDUG48H]4T&UMM5D2\EC2ZL[VZMXKEY MY=P+*D4C%PY(&.>M*G.$,-BYTZD'!TGB'3Y9OFC+6*2T7-:[; M2\N[*\!D/#:XBCA4J\\3@TWQ_-J>C_$GX4ZM>SV=KX^\(W2:EI]O> MHX01:O\ 9I)EL#*<^69_*]<^O]"7[7/@?]A%?A!^R9\//V@/C3X]^%^G:'\& MM"NO#/A_P;.^GZ#KD%S:6\EUJER(&1+N^>;'[\!V))9CFOFZY^+?_!-SX1?L M:_M-? OX:?&;QU\3%^*OAAK7"\3YH\73G2C4>#6*5!TWAJKCR^UC1;]O=4]-W*_?39G%F/A_PWA\+6PD MJ]-5HX*68TL>L1"=2=>I1^L0INFKR46Y>S:Y;=^M_P H/V9O^"97Q<_:H^#% MK\:/!&M:-9:(WC6/PEJ::E(MO;:)&K[;K5[^Y=E5;.W4AV9F"Y/7UY;XT_\ M!/OQ[\/?CKX/^!'PU\6:%\9?%OC*WA>*X\'SQ7UG:29 N(KV2%Y$MX[4Y9YB M54*,EJ_0_P"!GC7Q+X'_ ."%OQAN/#.IW.D7.K_%:_T:ZO+.9[>Z-C<705Q# M-&5D7=&J#(/J.M9__!"+2?!NJ^-_CQXZ^(NN:F+KPW\,=4CAUB%VO=8TVQN; M8I?W^G-*6EAN88\NLD>"&YSU%>K+B'-*4,RQD\3'ZM@:KH0P_L9UG)U5'EG% MQNY.$I/9NZBO,\>APKPU5Q7#^40HU?K6;89XG%XSVL8TH2IIN<(\ZM%2Y6NE M[MG :C_P0]^*]MX>DCL/C1\,-6^)]K9F\N/AS;ZU9MJ*7,<0FET^,K<%FO$/ M[LJN6+C;CBO@/X _L4_$[XX?M(W'[,>H(_@[Q]!+>K=Q:E;M&\3V1=,*' +Q M2L@V-T.X=37[,:)X=_X)->&_B);_ !'MOVM_C9)XMTWQ,^LS32ZM<%FOTOWF MFMICYA9T64/')&V=R#;C%>Q_"WXR?!/XV?\ !8#P9\1?@7>7-[I?_" 26E_J M5W9"RFOKZPM0HOWCV)YC2F,O)(03(Q)Y)KBPW$^>0H8FG4E.I[6@ZM.I6P]6 MG"*BXQAO%-)*6FCO:Z/0Q/ ?#/UG QISIT'#&NA7ITL5#$3Q%!0G)NR&_%GQ?\ ASX0\7Q7USI_A[PSJ&JVJ7VLR(SI M;.\+SB2&2?"[5V\E@,'C'Y-_M _ 'XC_ +,WQ7USX._$G2I+3Q;H5^EOY,*' M&H/?+Y>UF#;U ZU]*_M+_%_XFZA^W[XIU^Y\;>(GOM.^/.G MP6"0ZK=I#!:Q>*8H_*6,/M6/8-GE_=*G;TYK]1_^"EV@:'X]_P""I7[)EGXJ M$+Z?XNTWX3SZ]+($2.=HDL95>X+8#%I5"$/P^VODO&Q?#?">:X;$T/-MNUH?*'P=_P"",/QH\=?#_P /^/?BE\0/!/P4_P"$VL8] M1\&^'_%&HP6FK:O!<)NB+P7$T;VV]F1$9E12K'G')^ ?C_\ LE?&O]G/XNVO MP;\:^&Y[CQ'K4]O'X1OM(B:ZT[Q?;7;A+:XT>:,/%=JX(9C&[@9SG-?='_!: M[XL_$C4_V]O'WA?4->USP]X=\!Z#X5T7P=H>GW5UIVGZ?H\&G_Z/J-G;HT:! MKH*)9'B7:&&+Y/A7\0M9 ML(GEUN>S@=K:P>[F)FU+=AFB'SC,8VY&2%3S?.L%@)YYB\70JT,?1G*&'@U* MK0@K.*BKWYM4I:)MJZ26A;X8X8S#-/\ 5K!X'%X3&8.K153,)2=2EB)2^)5% M%>XG;:ZWUN>(>$O^"(OQ=U#PEI6H^/OB]\./AQXZ\06$.HZ)X"UG6;2/4Y(; MF/S+2"_CEN5>RO&R-R2!&RV/05^7G[0W[/7Q._9F^(M_\-OB?HITS6;5F:UO M8@9-+U:U7#1W=C=?-'<13 JPD1V5@V ?3^B/]HWPG_P2Y\7?'SXC^*/B3^U' M\:-.\?1^,K\ZM8Q:G<6\&B:E!.$%I86WFJ(;&U,02&/:J*@P/0_'7_!6OXZ_ MLL_%WX9? /PQ\!_%6L^.=:^&6GG1K[Q5K\#QZGJ6F+#Y<4MU?;18#*,7B,) M4IX2OETE"G%8BG5JXJ5E\=*#MVE^#9^&D:O+)#;P1O)--,D-NA.5,TK; M40C)R"QZ#(Q7])^F7_PR_P""2_[&WPU\?)X"\.^/_P!J?XZZ:NNZ5J'B6RAO MK+PII5RBF.6W@>.1D=!(""0H^7CIQ_-_H]U#8:UH&H7)5+6QUG3;N;<1Q0,+=YXPR0RC&'#E#C@XR:]7B6I1Q./R7+JTZRPM6KS8J"YXQJN"C+DA55 ME9M/3FN[:Z'S' \'ALJXASG!4U6S/"4<-'#PG!3E1YZK56I!3O'X+;K?5OJ_ MEK1?^"U_[;&B^)[;6O$?BO0?%WAH7OGW/P_UG2;>?P_<6)DPUC%;A'CCA^SE MHHBR C(' KD_^"F_CS]E[XN>(O@_\;/V?;73/#OB/XC>"(]0^,?@;2(XDTWP M[XNA5 8;:&$!(5N"TDC[0 I"\CBL;]B3Q9_P3ST+P;XG_P"&Q-#\6:AXB:]6 M71G\/F+R%T^.,EA(2?G??@;.F#GVKZ;_ ."B'[.'['WAC]G']FC]H/\ 9:T? M6M'\/?%_QO%H]^VN[EN38KK=G9W$C1%0GE>3*^""0RY/0'/FU991D^>T*%#" MU\/4M4]G*DYSHUI.GS+G>L7**:M=I\UEU=_H,)A,ZXFX=S+ZWF>%Q\*;HU*E M"3I1QV!E*O%/E45%M-:6:=E>YX#^RC_P2Q^,7[1_@9/BMXG\3>'O@O\ "_4, MQZ#XE\:7<6GMXBE''_$KAN)(O/MUSAIXE8 8^;FO-OVP/^">_P 7_P!D>QTS MQ;J5UI/Q!^%NMS&QTCQ]X3N(K_20XQF*]FA>46LLA; WLA)!P*_HJ_;@\%?L M%1>$OV9/A?\ M _&SXA?#;3?"7P7\*S^#_#?@VXDT_PYJ=C?Z>LMQJ:- 46Z MOII"QN#@E"!SWKY#^)7Q>_X)X_#C]A/X_P#[/OPE^,7C?XH:CXOTZ#5?"5EX MO675(M#UJUD,EM)IUVXD6T^TLQ5]SQGY17DX;B[-YUH8J*JUJ%;%3PWL94*G M+3A"LZ:O.RAHUSM[+7=MGMYCX?<-83 3PU2M"CB*6$H8F.)J8BDL1.K4I0J> MS=&*4E"3E:W+:W5'P_X$_P""-?QT^(_PG^$/Q?T3Q9X;L_!'Q0TI]9U#5]7N MX[&R\,::@;YKBXN)(@TDFQD6(-EMO"FN+_:L_P""4?Q<_9O^%X^,^A>+O#7Q M7^&MI(+?5M;\(W<=X-/F( _T@122&%8SU9PJG;P$= \0ZGH6E^)- ADUC^S+F6SN+AK19'6&1H64O&6W<,<'//6O.O^"='BCQ' MXI_X)Z?\%!?#'B/5[[7](TOPK87VE6^I74ET+&02R!I;?S6;RF)'S^6 6P5/ M%=\,YXAHX=YNJ]"I@UF4L+5HQ6M.DZ_LDHO^9*UWY::M,\VMPYPB\33R6&&K M_79Y/3Q\<9SQ5-8E4(5)1Y;7Y6W\HZ[GY8_LJ_L@_%_]KOQ=-H'PVTV$:=I, M<=QXA\4ZJ_V;0-&M#C=->7K%84<1[F >3DCWP/NGXT?\$;OBW\/O NN^.?AC M\2_!'QJ7PE8R:IXO\.>%M0M[G6=-MX5+2M;V]O,\LT4$>2S!2/EY."OVF/BQK=Q<6=_I^J>']5O;C4M'U M^QO[2>&:SU"R=G-QE)2V-C 8&.E8XSBW-89CB9X.,OJF$G&%*A&C.'8E?\ >0WUQ*T4 M0NA@F.)GR0#A>IK[!^./_!'3XM_#CX:^)?B=\+_B1X-^-VD^!K*35/&>G^$[ MV"\U72;! &DN$M[:61V5 "7-;S4='^(7AFQNK6[\/V:3-':VTUU%$(;3S5;>!+)&0 PQSBOHK0 M/V*OAWXPT'QUK_\ P3*_;UFE MQ#$T9"ADRW3C'18CBC-Z..A7KVP-&3HVA*G*K2E&HX^TYJD+QA+HG)I1=WJD MC' <"\-ULFJT:*^OYAS8C]ZJRIUIRIK]TZ<)-.<;-MJ-W+?<_ET4@CYT974L MLT98Y5E)0KRV0VX%9!U!!I6Z9)X[9/3VY_*KFKZ9J.D:QK&D:K 8]5TS5=0T M_5(G3RS#J-M=S)=18(')E#,".Q'K5$CU'Z?XU^K4*DJT'+^)[2E"I[BM?F6F MJUOZ?YGX%B*/U?%5:5U3=&K.')/WI*S2WUZ+=_\ !#(P.1T]?<_G2;AZC\Z, M#T'Y48'H/RK52H_.C@_*C ]!^5%WY_U_PR^X W#U'YT;AZC\Z,#T'Y48'H M/RHN_/\ K_AE]P!N'J/SHW#U'YT8'H/RHP/0?E1=^?\ 7_#+[@#@_*B[\_Z_X9?< ;AZC\Z-P]1^=&!Z#\J,#T'Y47?G_7_#+[@# M@_*B[\_Z_P"&7W &X>H_.C@_*C ]!^5% MWY_U_P ,ON -P]1^=*"#W'^?I28'H/RI<8Z#'X47:^]?I;] $8C=C'?CCWXK MZT_86Y_:Q^"P[?\ "9Z./Q^U1?XG\NM?)A )SCITZ\5]:?L+C'[6/P6'_4[Z M1^(^TPG'X9_"OF.,M>',PO\ \^W?KT1^@^&%O]<\D6NF)I[OKSQM;S[G^H-I MF?[-TST_LZRP/^W>.KU4M,_Y!>F?]@ZR_P#2>.KM?Q<]WZO\S_4:/PQMM9?D M%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 X=#_O1_P#H8HH'0_[T?_H8HH ;V'^ZO_H( MHH[#_=7_ -!%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 5&XZ'\,?UJ2F/DC@=_\ &@"&8'&/3!Y[XZ=O MPS[=Z_,;]NS_ ()V6?[:GB#P/XB;X@ZCX'O_ 9%=P0?V?$'>Z2\3RW#$D;% M0?,&'+8"XQ7Z>2*6R.><=LXIB(ZOQC!!!)'(_P YX]ZZ,)BJ^!KT<3AJDJ5? M#R4Z51?%"2U33?5/7U2./,,OP>:8:K@\?AZ>)PU>G*C5HU%S4YTY*THRB]&F MM->[/YW?^'#CCY7_ &C?%#?+@DP+R,Y[MD=?Q]Z3_APV/^CB_$W_ 'Y7_P"* MK^BO"CY0,D=6(Z^U&!Z#\J^F7'7%2;;SK&WR2WCLDTEHGT/@I>$'AO M*3D^$\IN]7;#05WIJ[+R_,_G4_X<-C_HXOQ-_P!^5_\ BJ/^'#8_Z.+\3?\ M?E?_ (JOZ*\#T'Y48'H/RI_Z]\5?]#K&]/\ E[+^[_>\G]_J3_Q![PW_ .B3 MRK_PGCY>7E^+[G\ZG_#AL?\ 1Q?B;_ORO_Q5'_#AL?\ 1Q?B;_ORO_Q5?T5X M'H/RHP/0?E1_KWQ5_P!#K&]/^7LO[O\ >\G]_J'_ !![PW_Z)/*O_">/EY>7 MXON?SJ?\.&Q_T<7XF_[\K_\ %4?\.&Q_T<7XF_[\K_\ %5_17@>@_*C ]!^5 M'^O?%7_0ZQO3_E[+^[_>\G]_J'_$'O#?_HD\J_\ ">/EY>7XON?SJ?\ #AL? M]'%^)O\ ORO_ ,51_P .&Q_T<7XF_P"_*_\ Q5?T5X'H/RHP/0?E1_KWQ5_T M.L;T_P"7LO[O][R?W^H?\0>\-_\ HD\J_P#">/EY>7XON?SJ?\.&Q_T<7XF_ M[\K_ /%4?\.&Q_T<7XF_[\K_ /%5_17@>@_*C ]!^5'^O?%7_0ZQO3_E[+^[ M_>\G]_J'_$'O#?\ Z)/*O_">/EY>7XON?SJ?\.&Q_P!'%^)O^_*__%4?\.&Q M_P!'%^)O^_*__%5_17@>@_*C ]!^5'^O?%7_ $.L;T_Y>R_N_P![R?W^H?\ M$'O#?_HD\J_\)X^7EY?B^Y_.I_PX;'_1Q?B;_ORO_P 51_PX;'_1Q?B;_ORO M_P 57]%>!Z#\J,#T'Y4?Z]\5?]#K&]/^7LO[O][R?W^H?\0>\-_^B3RK_P ) MX^7EY?B^Y_.I_P .&Q_T<7XF_P"_*_\ Q5'_ X;'_1Q?B;_ +\K_P#%5_17 M@>@_*C ]!^5'^O?%7_0ZQO3_ )>R_N_WO)_?ZA_Q![PW_P"B3RK_ ,)X^7EY M?B^Y_.I_PX;'_1Q?B;_ORO\ \51_PX;'_1Q?B;_ORO\ \57]%>!Z#\J,#T'Y M4?Z]\5?]#K&]/^7LO[O][R?W^H?\0>\-_P#HD\J_\)X^7EY?B^Y_.I_PX;'_ M $<7XF_[\K_\51_PX;'_ $<7XF_[\K_\57]%>!Z#\J,#T'Y4?Z]\5?\ 0ZQO M3_E[+^[_ 'O)_?ZA_P 0>\-_^B3RK_PGCY>7E^+[G\ZG_#AL?]'%^)O^_*__ M !5'_#AL?]'%^)O^_*__ !5?T5X'H/RHP/0?E1_KWQ5_T.L;T_Y>R_N_WO)_ M?ZA_Q![PW_Z)/*O_ GCY>7E^+[G\ZG_ X;'_1Q?B;_ +\K_P#%4?\ #AL? M]'%^)O\ ORO_ ,57]%>!Z#\J,#T'Y4?Z]\5?]#K&]/\ E[+^[_>\G]_J'_$' MO#?_ *)/*O\ PGCY>7E^+[G\ZG_#AL?]'%^)O^_*_P#Q5'_#AL?]'%^)O^_* M_P#Q5?T5X'H/RHP/0?E1_KWQ5_T.L;T_Y>R_N_WO)_?ZA_Q![PW_ .B3RK_P MGCY>7E^+[G\ZG_#AL?\ 1Q?B;_ORO_Q5'_#AL?\ 1Q?B;_ORO_Q5?T5X'H/R MHP/0?E1_KWQ5_P!#K&]/^7LO[O\ >\G]_J'_ !![PW_Z)/*O_">/EY>7XON? MSJ?\.&Q_T<7XF_[\K_\ %4?\.&Q_T<7XF_[\K_\ %5_17@>@_*C ]!^5'^O? M%7_0ZQO3_E[+^[_>\G]_J'_$'O#?_HD\J_\ ">/EY>7XON?SJ?\ #AL?]'%^ M)O\ ORO_ ,51_P .&Q_T<7XF_P"_*_\ Q5?T5X'H/RHP/0?E1_KWQ5_T.L;T M_P"7LO[O][R?W^H?\0>\-_\ HD\J_P#">/EY>7XON?SJ?\.&Q_T<7XF_[\K_ M /%4?\.&Q_T<7XF_[\K_ /%5_17@>@_*C ]!^5'^O?%7_0ZQO3_E[+^[_>\G M]_J'_$'O#?\ Z)/*O_">/EY>7XON?SJ?\.&Q_P!'%^)O^_*__%4?\.&Q_P!' M%^)O^_*__%5_17@>@_*C ]!^5'^O?%7_ $.L;T_Y>R_N_P![R?W^H?\ $'O# M?_HD\J_\)X^7EY?B^Y_.I_PX;'_1Q?B;_ORO_P 52?\ #ALGK^T;XF/;FW7^ MC"OZ+,#T'Y4FQ?3^?^-)\=\56M_;.,?>]679>?=/[^X?\0<\-I?\TGE.EM\/ M#R7\ODOF?SK#_@@V^./VC?$QQT_T=>/R;],_TI/^'#Z^96J2TM M;S[(3\&?#:SMPGE+_P"X$'VMO'7IZ]G?7^\6!F[^2,#(QQ\_3^8K^@?:6' M0#MT(S_/-/VX ].1_]:OSSBG),JXUK_6>)\#0SBOHE5Q<%5FE>]HRE=I-] MGZ6/UG@S,,7X?X&66\(XBID&"G/VDL-E_P"YI2G:*;<87C_@UW^!2\+\2K MTDMG<;)"=I'*_>R/8C.,5_55@^B?E1\P(^5>>X'3BO9R:K5X>R_#Y5E$Y8# MX56H8:@W"G3O;X4G]W;\O.SBE3S_ !M;,E0 M*$AM(( (HE7 4(N[@#G@'O7]%0+ ]%(]#G]>*4\Y]ZX\_P +A^*,)2P.?T:> M9X6C5]M3HXJ*J156Z?-[U^RTVZ'9P_BJ_"^*GCIY=S#+;!EE3CY>6X''UKE8_^ M#?G2XUV1_M >(T545(P+<'RPBXPHW=P N>WX5_2%C;GY=P/3V_0T9Z?( 3TS M_P#JJ.'L#A.%(5:?#V'I95"M/VE2.$A&DI2M:[44EJM#RN-\OPGB,\/+C6A3 MXA>%36'>8Q5=TKM7Y7-/7?>^I_. /^#?[3,X_P"&@O$9''2W7U'OFG?\0_NE M_P#1P/B3_P !E^O]X'_ZW'O7]'V#Z)^5.QZ@9^E?1_V_FG_096Z?;?2WGY/\ M#\[_ .(,>&W_ $265?\ A/#^[_=_KW3^;\?\&_NEY'_&0/B3O_R[+W_X$>_3 MT%*/^#?S2L_\G!>).W_+L.PQZ]^OUK^C_ ]!^5&!Z#\JEY[FK?\ OM;9?:^_ M>_4/^(,>&G7A'*>G_+B*TT[)>=OD?S@?\0_FE).,?\NPYQ^/?O1_Q# M^:5Q_P 9!>).,?\ +L.@_*C ]!^5+^W)#T_Y=AV)/][\*_H_P/0?E1@>@_*C^W,U_Z#:W_@0?\07\,_\ HDN?7\/I2'_@W\TO_HX/Q(/^W8>N?[WX M?2OZ0,#T'Y48'H/RH_MS-O\ H-K?^!!_Q!?PST_XQ'*?_!"\O^#^'F?S@'_@ MW\THC_DX+Q(/^W8>N?7\![4?\0_FE<_\9!>).<_\NPXS^/;M7]'^!Z#\J,#T M'Y4?VYFW_0;6_P# @_X@OX9Z?\8CE/\ X(7E?]?P\S^<#_B'\TKG_C(+Q)SG M_EV'&?Q[=J#_ ,&_FE9_Y."\2=_^78=QCU[=?K7]'^!Z#\J,#T'Y4?VYFW_0 M;6_\"#_B"_AG_P!$CE/_ ((7E?\ 7\/,_G /_!OYI1_YN"\2#K_R[#N,?WNW M6C_B'\TK&/\ AH+Q)]?LP],>OX_6OZ/\#T'Y48'H/RH_MS-O^@VM_P"!!_Q! M?PS_ .B1RG_P0O+_ (/X>9_. /\ @W\TK_HX+Q)_X##TQZ_C]:!_P;^:5G_D MX+Q)V_Y=AV&/7OU^M?T?X'H/RHP/0?E1_;F;?]!M;_P(/^(+^&?_ $2.4]+_ M +A>7_!_#S/YO_\ B'\TO_HX/Q)U'_+L.W_ N_>E_P"(?S2N/^,@O$G&/^78 M@_*C^W,V_Z#J__@78/^(+^&?_ $2.4]/^7"\O^#^%^I_.!_Q#^:5G_DX+ MQ)]/LP]<_P![\/I2'_@W\TO_ *.#\2#_ +=AZY_O?A]*_I P/0?E1@>@_*C^ MW,V_Z#:W_@0?\07\,]/^,1RG_P $+R_X/X>9_. ?^#?S2B/^3@O$@_[=AZY] M?P'M1_Q#^Z5_T<%XD[_\NP[_ (]NU?T?X'H/RHP/0?E1_;F;?]!M;_P(/^(+ M^&>G_&(Y3_X(7E?]?P\S^<#_ (A_-*Y_XR"\2W:@_\&_VE<#_A MH'Q&,=/W ^;Z\_GU_*OZ/\#T'Y4UACHJ_ES1_;F:_P#0;6^_N->#'AE9I\(9 M1KI_N\7V?5=U]Q_/G\-O^"&&B_#OXE_#WXB3?&S7-8'@'Q=HWBN/3)H46.]G MT>[2Z@@=MWR*\B!2X&X#D9K^@OD+WN7FVY9I/O;W?\]UY M6/XA?^#D!U'[1WA;)4?\4Z@(!Y V]<8ZX[#//Y5_-;\C*#NQP#D^G],U_HD_ MMX?\$D/ 7[<_Q&T_X@>+/'FJ>';C3].6SCM+2#>C;1CL1G@=^>V#TKX7'_!M M3\#,#/Q3UT\<_P"AGG_Q\?RK]IX.\0*7@QFW&7$4LUP>+A2IRIQ2YTG>[NTO3SU/XH05 QN!]_\_P"?PI">?O\ M7T ^O-?VPC_@VI^!(Z_%+7OPL_\ [.C_ (AJO@7G_DJ>NX_Z\S_\6:^O_P"( MP91_T#5$N]GIMK^%_FS\R?T:.('_ ,S"C?3H_+_@_@?Q/Y'7?^GOC^[^/THR M/[_KV_\ L>_:O[8/^(:KX&?]%2US_P O_LJ/^(:KX&?]%2US_P"_P#LJ?\ MQ%[)=-*G3['^'^YZ^M_-!_Q+1Q!_T,,-_P"3^7]SU_ _B?R/[_KV_P#L>_:@ MD#^/\A_]C7]L'_$-5\#/^BI:Y_X!?_94?\0U7P,_Z*EKG_@%_P#94?\ $7LE MTTJ=/^7?^'^[_P /\T'_ !+1Q!_T,,-Y_%Y?W/7^MOXG\@?Q_P"<9_N_A]:, MC&=_Z<],_P!W\/K7]L'_ !#5? S_ **EKG_@%_\ 94?\0U7P,_Z*EKG_ (!? M_94?\1>R732IT_Y=_P"'^[_P_P T'_$M'$'_ $,,-Y_%Y?W/7\#^)\$'^/\ M,?\ V- (/\?YC_[&O[8/^(:KX&?]%2US_P O_LJ/^(:KX&?]%2US_P"_P#L MJ/\ B+V2=JG3['^#^YKU^_S0?\2T<0_]###?^3^7]WU_#S/XG\C^_P"G;_[' MMWHR/[_IV_\ L>W>O[8/^(:KX&?]%2US_P O_LJ/^(:KX&?]%2US_P"_P#L MJ/\ B+V2Z:5.G_+O_#_=_P"'^:#_ (EHX@_Z&&&_\G\O[GK^!_$_D?W_ -/_ M +&@$'^/TZCU_P" _B:_M@_XAJO@9_T5+7/_ "_^RH_XAJO@9_T5+7/_ +_ M .RH_P"(O9+II4Z?\N_\/]W_ (?YH/\ B6?B#_H88?=?S>5_L>O];?Q/Y&<; M_P!..N/[OX_2C(_O_I[X_N_C]*_M@_XAJO@9_P!%2US_ , O_LJ/^(:KX&?] M%2US_P O_LJ%XO9+II4Z?8_P_W/Z^:#_B6CB#_H88;_ ,G\O[GK^!_$_D?W M_P!/_L:,C^_Z]O3_ (#W[5_;!_Q#5? S_HJ6N?\ @%_]E1_Q#5? S_HJ6N?^ M 7_V5'_$7LETTJ=/L?X?[GKZW\T'_$M'$'_0PPW_ )/Y?W?7\/,_B?R/[_KV M_P#L>_:@D#^/\A_]C7]L'_$-5\#/^BI:Y_X!?_94?\0U7P,_Z*EKG_@%_P#9 M4?\ $7LETTJ=/^7?^'^[_P /\T'_ !+1Q!_T,,-Y_%Y?W/7^MOXGR0/X_P A M_P#8TTMC/S=^P_E[?KGVK^V+_B&J^!G_ $5+7/\ P"_^RI?^(:KX%=_BEKW_ M (!C_P"*'Y5+\7LET]VJ].D+;J/DOO7>_4/^):.(=/\ A0P[_P# O+7X5YZ= M?(_B=)!499#U[CM_C4+E0C@K^V8_P#!M3\"B?\ MDJ6N_C9\_H](?^#:CX%X./BCKF[^%OLA#*>Q4[C@Y]CQFI_XB_DMO@K/2UN5 M:W2^_?UVMN73^C5Q#&<7]?H:23VOK%W6Z_ _G/\ B9^U3\*O%7_!,;X)?LL: M7=:PWQ3\"_%;6_&FO02V(BT=-$OKKS8)8[T2;GG=, P!.N[+'.!^??P\\?\ MB7X7>-_#'Q!\(ZG/I?B#PSJEEJVFW-K*T$H>TF21XT*'*[U# C."#R.:_LT/ M_!M1\#N2?BIK>\E65OLI+JRX#*SY&4(Z#'%!_P"#:?X%,2#\4MH M[&4'"1(E>37XPX?E#"QHO%QEA^?V-2$[2PZF[R4; MIIV5E%232278]ZGX5<[>A_ M.Q^V7^TM^REKOPNTK]GO]D'X2-X=\$Z1>/?:A\0?$:^=XQ\12[#'&MS/+^\A M0 ;BJL0QSGG)K5_;)_:U^#_QL_9(_92^#W@>ZUL^-?A'X??3/%<-Y9"UM()9 M"NTVLJN?. <;@_!"@5_0C_Q#3_ S 8?%376//;LW/L>/?O4@_P"#:CX' M*^Y?BIK:_)AL6>3N( &,D<=<@]/?OUT>.>':"PWNXFK+"59UHJ:NJM2I&,9. M3>[VW[]5H!?V=_\ @H9X'\07=S\+M-;0O GQ>\#[CXHT[0H67R-+)0J? M+7RU!RQ!SZBO.OCY^TY^P%\,?@AXR^ G[%7PEU;Q!=^/XX[;7OBU\2H/M?BK M3[)L.UOIGG[OL[ JJ":-]RJQ.*_=D?\ !M/\#5V;?BCKOR-NR;;(!SABHSR6 M&&^HQ]'_ /$-1\#-[D_%37'*-=5[8OZ MLZOM7@%)^RA+G4Y35];W=U%RY>T;W.NIX5<<5L)3P-6IETY0HO#0QSIM5G3Y M.10GWBX_;LFE:S1_/7X._:U^$.C?\$OO&?[*E_[PQD(X*F/J<9KYQ_8<_:ZUS]C?XP6?CZQTJ+7_#.JZ?<:#XS\*7.3 M::]H-_$(;VWE'/S>6'VM@G)K^IX?\&TWP-#!U^*.L ALY-HQ#KD<-%G&>ISG MKZ8S2_\ $-+\#><_%/6V8_QFU*[1_LIN.!STR?IFNZ'B%PW"CC:#P5>K1QD^ M=-M)P?N^_;HU=/U6B/*?@GQN\3@,4\PPM#$Y9#V="5-J4)0>C@U*Z:E=IMZV MZK9?D[J'Q6_X(A7WB&?X[#X?_%:'XA22R:T_PDC:9/ \^N2N9Y;?'_V^_\ AI#Q=X)B^&GPLLM"O-$T?PUX,TZ.:2PM MO*:*T$T(*"24J%9W/S,<\5^Z8_X-I?@1E0?BCKI1 2/]!VOO/??N/3K_ )%+ M_P 0T_P- 4-\5-:(SEO]#()STW/DYP0.V>*XJ7&.0485:$ZF,Q2KTU#VU1W= M"F^5^QBO=NE9)-IRU^(]?$>%?&V)JX7$0_LO"U<--SE3I126(J6<55D[W3DI M7<4U&_3H_P"1SXP?$;PSXR_:?\5_%31GO#X5U3XJ6OBVUEN(_)N1HR:\FH%Y M8--KEGMC<6VW<<"1>37]#!_X-I_@:X#?\+6UUFW[E9[,\,I( M==V&3;TR/3UH'_!M-\"R23\4-:5,/1\%^-Z<^*/VU?^":/[=&G^$_'7[]U_X=^8] MOXX@TJ (G]L8\L+&^P1>7EEV.>>,'YW_ &D_^"J]SX@^)'[/5^*FNC$;*N+7;AFX)V[L9(%>7A M^+N%Z512J4<74I7?L*,Y-TJ'.FFH4WHKIVY7S)*RCRQT/?Q/AKQ]B*=.%.IE MF#JR]FL1BZ$8O$5W3Y>5SD[O1WN]/.Y^57C+]H;_ (([?M4ZU'\;?C_X!^)G MPY^,%PJ7WB?P]X!,J^'?$VL1QJTUW?%2@ O)U)E4*=H).?7\VOVV_P!I?X2? M'37?"OAWX%_"?1OAA\-OA_8/I>A?98 -6UDX,7V_6)2 \\SI^](;/SDGTS_3 MP?\ @VG^!C_._P 4]=WC 7%IM_[Z&3QGMD]<=>BG_@VG^!N1_P 73UM5ZL%L MRQ+=,C#9QC&/QZUTY=QOPY@,:ZJ>.K0I*V&A*=XTDTKQC%=-OBO9]4K)>=G7 MA%QIG.$E@ZSRJG6FXRJXFC?FJRC;65W:[5MDD]O,_B=X=0AVA=N""(BZ:BZ56#5.4)1:::E!IQ M=]-]5HUL>'D_@3QGDV)=; 9CAJ5224,31JKGIXB"MK*-G3][9.U]GV/R#M]> M_P""%/A]U^(=CX;^-7B#Q*^R_P#^%=ZHTK>%UG/^#:?X'$;E^*>M!L;239 @@<=V!Z=_7Z4'_@VF^!H V?%370 M2WS8M2%(/WB?F[GT./7MGQ^!?PZ^!?\ P4,\#>)(]6^$6@IX=\%?%[P/N_X2>71K=52+ M3[K85/W,+YQD+#T'(KQ;]IC]I7]A;PC\#]7_ &>OV+OA/J5Y9^(;BVFU7XJ? M$"+[5XJ-K$^Z2"#S\E1G(5E?CT)K][?^(:;X&G ;XIZWM#)\IL\@@??^8GC) MZ?G2?\0TOP-_>'_A:FNDE"L(^QG;%VP<$9'3C\>:5'C/ARC6G7A];Y75G6^I M7_%G&^)P\:-=Y9[2-"E06+:]I7E"G"$(J7,Y M)M1BM;7?7R_ /]K[]K[X-_&;]B7]E#X$>";S6G\>?![2A;>+TOK(1:M=/\$16%FM MS9O<12R-*M_,S*;=!NR/E8D\$=Z_H@/_ ;3_ T!2/BGKF]<9 M#Y9!&"0,\ MOGD#/7DGI@?_ (-I_@:3A?BEK15@3\]F25?!PP^88/3CUSGG-=G^OW#CP$KUT>VB>QY/_$%N-?[3GF?U[!3Q+PD,)&ZM&G25 M*-+F4=N;E5VM;-MO6UOYX_V!OV\/!?P \$^,?@!\?/ L7Q)_9_\ B(Z/K&E1 MDG4]"N95\N;4=.;!*S0QLSA%Q\R@^E?50^./_!';]G2#7OB!^S]\-?B%\6/B M1K6GWL.CZ/\ $M7;PYX8N[N%XXKRUB=I%8VK291"H#;0>]?KF?\ @VG^!>-O M_"TM=;E7W-:'(8#:4'S8VG[W/<#CI2G_ (-IO@5G'_"TM9Y48(LL,"#QSNX] M^*X\3QCPQB,;+%Q^NX>-2SGAZ37)5G[K;E=76NON-7VVT._!>$W&N$P$<'/$ M99BH14XT<1B8RE5H\[7NTXI\MEV9"EM'(9/(0JK/&IXP*^R/ G[7?_ M 2[_84NO&/Q/_8L\.?%3QS\9/%OAG6O"]B?'\]Q%H_AV'6;8PRRP1>9)'-Y M0?Y8F4 A1D]Z_4F7_@VH^!S_ #?\+2UO=L"8^RDD;>,[LC(;'H,9ZTP?\&TW MP-"LH^*6NQLY^^EL?ESC!YP%:LL="/-3]KAV[T<0H** M49JS:TTO%QOUN:X'PJX\P>%>$6+RJ=6[E3QBHN&(P\9VZYJVH:U?-(Q:1;J_NY;IPK$#[IDV8Z[5 Z#%9V M[_:Y]2/\._Z5_;!_Q#5_ T*%/Q3UYL+L -GD%CU=B&SV^F?J*4?\&U7P,_Z* MEKG_ (!?_95];3\6D%9*-U'IKYGP>)^C?Q%7K5*CS'#N M56OE?SL?Q/[L]7 Z#A<=3]#^-&1G&_]..N/[OX_2O[8/\ MB&J^!?;XIZ[^-GG_ -GH_P"(:KX&?]%2US_P"_\ LJM>+V2*R2J6Z7@Y/[/7 ME]?R6Z,']&?B!.W]H8?I_-IHK[1];?(_B?R/[_Z>^/[OX_2C(_O_ *?_ &-? MVP?\0U7P,_Z*EKG_ (!?_94?\0U7P,_Z*EKG_@%_]E37B]DFFE3I]C_#_<]? M6_FA?\2T<0?]###?^3^7]WU_#S/XG\C^_P"O;T_X#W[49']_U[?_ &/?M7]L M'_$-5\#/^BI:Y_X!?_94?\0U7P,_Z*EKG_@%_P#94?\ $7LETTJ=/^7?^'^[ M_P /\T'_ !+1Q!_T,,-_Y/Y?W/7\#^)\D#^/\A_]C02!_'^0_P#L:_M@_P"( M:KX&?]%2US_P"_\ LJ/^(:KX&?\ 14M<_P# +_[*C_B+V2Z:5.G_ "[_ ,/] MW_A_F@_XEGX@T_X4,/Y_%Y?W/7^MOXG\C&=_Z<],_P!W\/K1D'^/_.,_W?P^ MM?VP?\0U7P,_Z*EKG_@%_P#94?\ $-5\#/\ HJ6N?^ 7_P!E1_Q%[)=-*G3_ M )=_X?[O_#_-!_Q+1Q!_T,,-_P"3^7]SU_ _B?!!_C_,?_8T9']\]NWK_P ! M[=Z_M@_XAJO@9_T5+7/_ "_^RH_XAJO@9_T5+7/_ +_ .RH_P"(O9)VJ=/L M?X/[FO7[_-!_Q+1Q!_T,,-_Y/Y7^SZ_@?Q/Y']_T[?\ V/;O1D?W_3]?^ ]N M]?VP?\0U7P,_Z*EKG_@%_P#94?\ $-5\#/\ HJ6N?^ 7_P!E1_Q%[)=-*G3_ M )=_X?[O_#_-!_Q+1Q!_T,,-T_F\K_8]?P/XGP0?X_3J/7_@/XFC(SC?^G'7 M']W\?I7]L'_$-5\#/^BI:Y_X!?\ V5'_ !#5? S_ **EKG_@%_\ 94?\1>R7 M32IT_P"7?^'^[_P_S0?\2T<0?]###?\ DWE?['K^!_$]D?W_ ,<9'7_=_'_. M*,_]-!_WS_A_GN..:_MA_P"(:OX&=_BEKG_@%_\ 9&E_XAJO@7_T5+7?_ /_ M .O27B_DJ_Y=U9;:\C[1[6[M[:[[;'_$M'$'_0?A_E?]4O,_B=S_ +8_[Y_S MG\/PI0R@'+YQ[=/Y<_3(Z5_;#_Q#5_ O_HJ6N_\ @'_]>@_\&U'P*88'Q3US MWW6F/RP_7\NW-*7C#DR5XX>I)Z6C*,DF].OS;MY>H+Z,_$4FE',,/%]]?GOY M75OQ/XG 5=P"P49P#GZX(_&OK7]A7YOVL_@H"ZG/C73,\D8QSX0_"GXB>$OB)I/Q2U MN>^\*ZO9ZM;VLMN525[.5)51G#$_,5 S7BY]XGX#,\IKX*G3Y9UXV6DKZVLG MT\M+=.]SZ?@_P!SO(>(\#F5?&8>IA\)4C4>KW33=[:[O[M=D?T.Z5_R"M*]? M[-LUM;4'(MK:&W#=V$,:Q[L>K;=W6K5?@_\ Y+'R\O+^M;E%%%%_3[E_D&O?_P ECY>7 ME_6MRBBBB_I]R_R#7^;HELNEO\OZZE%%%%_3[E_D&O\ -_Y+'R\O+^M;E%%% M'W;WV7^7D&O?JG\,>EO+R_KJ44447]/N7^0+FT][MT7EY>7]:W****+^GW+_ M "#7^;\%Y?Y?UU****+^GW+_ "#7O_Y+'R\O+^M;E%%%%_3[E_D+W]+-?^ I M=O(****+M=ON7^0+VBZK[O3R\OZ8G/''_P!:EHHJ5S)O5-/HXKNM-/GVZ%W? M2,4[Z]GMOIZA0;;:?_;MNGS$DE>WNM]5O&^ZC?]=1HR < MC//3V].*49/<#/8CI[<4M%"C!623[MW=^;2[7W HQ25W-M._/>TF]-[/5:=6 M]0HHHIZ*]EK:UVW=[;V>SM]VVNZ2MM>^S;;;:LO\@).#@#\6_30*,T44[)W4E=.5[7;]W33_/I][!7T;>O-=V2U7?7J&>GO^OTH MS1CIQTZ44M[J2]U6]G9NZTZ_Y[DJ-O:6TYFN5Z77K?2_:W0*.>WZC/Z444N7 M^&[WIW$)XR!F@9([#Z@G^5+15WW6O*W=ZO MFOIMKMIYCWM=6:^TG)RZ::V[=_N$P.V!VSBC!'4Y]\8I:*AQCHH\R6[]YWT[ M;]M;_(&KM-RG=:;W5M%U?9!1115-1E:4E[\;6DKK:SU[_/N"C#S3[JVWIMWZ M=0I.:!R,XP<$>]+1 M1UNHI-VUN]+6V\W_ ):LEW>CC%^]S)[=K:);Z?U:XT+@DYZ_YYI][V\N5>7=>7]:W****=_3[E_D+WM/>V=]E MY?Y?UU****+^GW+_ "#7^;_R6/EY>7]:W****/NTTV7^0:Z:[:?#'R\O+^NI M1111?T^Y?Y!K_-^"\O+R_K6Y1111?T^Y?Y![W\W1+9=+?Y?UU****+^GW+_( M->__ )+'R\O+^M;E%%%%_3[E_D&O?_R6/EY>7]:W****+OR^Y?Y![VGO;.^R M\O\ +^NI1113O?XM5Z+Y=NR^X/>M\7X+R\O+^M;AYS[^U- X()W9]:=14.,7 M+FENMK+T].BL-:+ELFGNVE?I;3;Y/[Q, = /RI:**8;:+9:+T"BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@!PZ'_>C_\ 0Q10.A_WH_\ T,44 -[#_=7_ -!%%'8?[J_^ M@BB@ HHHH **** "BBB@ HHHH ***,T %%&:* "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHIV?9_=_7=?> 4444@"BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%&:* "BBB@ HHHH **** O M_7]>J"BBB@+A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M&:,YZ4 %%%% !1110 4444 %%%% !1110 X=#_O1_P#H8HH'0_[T?_H8HH ; MV'^ZO_H(HH[#_=7_ -!%% !1110 4444 %%%% !2C&#D<]J2D)_F/YB@!<^O M;U_/_([FD.6'!&.OW17*>,=2N]+TJ2\M'"3*ZJ"RAAM('&..>>#7C@^(/B$$ M8G7\JI1;U5A-I;GT<,@8RO\ WR*7+>J_]\C_ !KYU_X6'KX^].,^R@CVYSZ4 M?\+#U[_GO_XX/\:?(_+^OD+G7G_7]?AZ'T5EO5?^^1_C1EO5?^^1_C7SK_PL M/7O^>_\ XX/\:/\ A8>O?\]__'!_C1R/R_KY!SKS_K^OP]#Z*RWJO_?(_P : M,MZK_P!\C_&OG7_A8>O?\]__ !P?XT?\+#U[_GO_ ..#_&CD?E_7R#G7G_7] M?AZ'T5EO5?\ OD?XT9;U7_OD?XU\Z_\ "P]>_P">_P#XX/\ &C_A8>O?\]__ M !P?XTJ_]\C_&C+>J_P#?(_QKYU_X6'KW_/?_ M ,<'^-'_ L/7O\ GO\ ^.#_ !HY'Y?U\@YUY_U_7X>A]%9;U7_OD?XT9;U7 M_OD?XU\Z_P#"P]>_Y[_^.#_&C_A8>O?\]_\ QP?XTJ_]\C_ !KYU_X6'KW_ #W_ /'!_C1_PL/7O^>__C@_QHY' MY?U\@YUY_P!?U^'H?166]5_[Y'^-&6]5_P"^1_C7SK_PL/7O^>__ (X/\:/^ M%AZ]_P ]_P#QP?XTJ_]\C_&OG7_ M (6'KW_/?_QP?XT?\+#U[_GO_P".#_&CD?E_7R#G7G_7]?AZ'T5EO5?^^1_C M1EO5?^^1_C7SK_PL/7O^>_\ XX/\:/\ A8>O?\]__'!_C1R/R_KY!SKS_K^O MP]#Z*RWJO_?(_P :,MZK_P!\C_&OG7_A8>O?\]__ !P?XT?\+#U[_GO_ ..# M_&CD?E_7R#G7G_7]?AZ'T5EO5?\ OD?XT9;U7_OD?XU\Z_\ "P]>_P">_P#X MX/\ &C_A8>O?\]__ !P?XTJ_]\C_&C+>J_P#? M(_QKYU_X6'KW_/?_ ,<'^-'_ L/7O\ GO\ ^.#_ !HY'Y?U\@YUY_U_7X>A M]%9;U7_OD?XT9;U7_OD?XU\Z_P#"P]>_Y[_^.#_&C_A8>O?\]_\ QP?XTJ_]\C_ !KYU_X6'KW_ #W_ /'!_C1_ MPL/7O^>__C@_QHY'Y?U\@YUY_P!?U^'H?166]5_[Y'^-&6]5_P"^1_C7SK_P ML/7O^>__ (X/\:/^%AZ]_P ]_P#QP?XTJ_]\C_&OG7_ (6'KW_/?_QP?XT?\+#U[_GO_P".#_&CD?E_7R#G7G_7 M]?AZ'T5EO5?^^1_C1EO5?^^1_C7SK_PL/7O^>_\ XX/\:/\ A8>O?\]__'!_ MC1R/R_KY!SKS_K^OP]#Z*RWJO_?(_P :,MZK_P!\C_&OG7_A8>O?\]__ !P? MXT?\+#U[_GO_ ..#_&CD?E_7R#G7G_7]?AZ'T7D]\?\ ?('^-&?I^0_PKYS/ MQ#U_M./Q0?XT#XA^(/\ GL#]%'_UZ.1^7]?(7.O,^C,_3\A_A1GZ?D/\*^=/ M^%A>(/\ GK_X[1_PL+Q!_P ]?_':.1^7]?(?.O/^OZ_#T/HO)[8_[Y'_ -:D MRWJO_?(_QKYV_P"%AZ^.LQ'_ ?XTG_ L/7O\ GO\ ^.#_ !HY'Y?U\@YU MY_U_7X>A]%Y^GY#_ I,G_9_[Y%?.O\ PL+Q!_SU_P#':3_A87B#M,,_[H_E MQ35.;T6^FWJO+^MQJ_]\C_ !KYT_X6)K^< M&;\0HQGTZTO_ L/7O\ GO\ ^.#_ !H]E4[]O_;?Z\O^W1\Z\_Z_K\/0^BLM MZK_WR/\ &C+>J_\ ?(_QKYU_X6'KW_/?_P <'^-'_"P]>_Y[_P#C@_QIJ_]\C_&OG7_ (6'KW_/?_QP?XT?\+#U M[_GO_P".#_&CD?E_7R#G7G_7]?AZ'T5EO5?^^1_C1EO5?^^1_C7SK_PL/7O^ M>_\ XX/\:/\ A8>O?\]__'!_C1R/R_KY!SKS_K^OP]#Z*RWJO_?(_P :,MZK M_P!\C_&OG7_A8>O?\]__ !P?XT?\+#U[_GO_ ..#_&CD?E_7R#G7G_7]?AZ' MT5EO5?\ OD?XT9;U7_OD?XU\Z_\ "P]>_P">_P#XX/\ &C_A8>O?\]__ !P? MXTJ_]\C_&C+>J_P#?(_QKYU_X6'KW_/?_ ,<' M^-'_ L/7O\ GO\ ^.#_ !HY'Y?U\@YUY_U_7X>A]%9;U7_OD?XT9;U7_OD? MXU\Z_P#"P]>_Y[_^.#_&C_A8>O?\]_\ QP?XTJ_]\C_ !KYU_X6'KW_ #W_ /'!_C1_PL/7O^>__C@_QHY'Y?U\ M@YUY_P!?U^'H?166]5_[Y'^-&6]5_P"^1_C7SK_PL/7O^>__ (X/\:/^%AZ] M_P ]_P#QP?XTJ_]\C_&OG7_ (6' MKW_/?_QP?XT?\+#U[_GO_P".#_&CD?E_7R#G7G_7]?AZ'T5EO5?^^1_C1EO] MG_O@5\Z_\+#U[_GO_P".#_&C_A8>O?\ /?\ \<'^-'(_+^OD+G7G_7]?AZ'T M4=W3('T4 T#/?GWKYU_X6'KX',H^I7_Z^*8?B'KW_/49/?RP1^>0:2@WNK+3 M?TOYC51+O_5MOZZ>A]&_YZ?XTN?I^0_PKYR_X6'KRC/F@]N(P/UR:5?B)K[9 M_>D?\ '^-/V;6UK?UY"YUZ?U_7W'T7EO5?\ OD?XT9;U7_OD?XU\Z_\ "P]> M_P">_P#XX/\ &@_$37L']_\ ^.#_ !HY'Y?U\@YUY_U_7X>A]#E^/O#\$YI? MX<[CU_NC&/YYS7SA_P +"U[_ )['_OV/_BJE'Q#UXKS,![;!CKZ;J.1^7]?( M.=>?]?U^'H?17)Q\P[8^4?G]:7)^[D9_W>?S_"OG+_A8FOKQ]H7_ +X_^O1_ MPL+7\AO/'/\ L<#COS5NC-6Y7VUMZ?U9VM\KASKS/HP;@1SD?[HQ^-/S]/R' M^%?.?_"P]?Q_KQG_ '!CVYS_ $-)_P +#\0_\]T_+\_Z5')4^TU?3\EY;WW_ M *0^=>?]?U^'H?1F6_V?^^11EO5?^^1_C7SJ/B'KV.9^>^%&/YT?\+#U[_GO M_P".#_&CD?E_7R#G7G_7]?AZ'T5EO5?^^1_C1EO5?^^1_C7SK_PL/7O^>_\ MXX/\:/\ A8>O?\]__'!_C1R/R_KY!SKS_K^OP]#Z*RWJO_?(_P :,MZK_P!\ MC_&OG7_A8>O?\]__ !P?XT?\+#U[_GO_ ..#_&CD?E_7R#G7G_7]?AZ'T5EO M5?\ OD?XT9;U7_OD?XU\Z_\ "P]>_P">_P#XX/\ &C_A8>O?\]__ !P?XTJ_]\C_&C+>J_P#?(_QKYU_X6'KW_/?_ ,<'^-'_ M L/7O\ GO\ ^.#_ !HY'Y?U\@YUY_U_7X>A]%9;U7_OD?XT9;U7_OD?XU\Z M_P#"P]>_Y[_^.#_&C_A8>O?\]_\ QP?XTJ_]\C_ !KYU_X6'KW_ #W_ /'!_C1_PL/7O^>__C@_QHY'Y?U\@YUY M_P!?U^'H?166]5_[Y'^-&6]5_P"^1_C7SK_PL/7O^>__ (X/\:/^%AZ]_P ] M_P#QP?XTJ_]\C_&OG7_ (6'KW_/ M?_QP?XT?\+#U[_GO_P".#_&CD?E_7R#G7G_7]?AZ'T5EO5?^^1_C1EO5?^^1 M_C7SK_PL/7O^>_\ XX/\:/\ A8>O?\]__'!_C1R/R_KY!SKS_K^OP]#Z*RWJ MO_?(_P :,MZK_P!\C_&OG7_A8>O?\]__ !P?XT?\+#U[_GO_ ..#_&CD?E_7 MR#G7G_7]?AZ'T5EO5?\ OD?XT9;U7_OD?XU\Z_\ "P]>_P">_P#XX/\ &C_A M8>O?\]__ !P?XTJ_]\C_&C+>J_P#?(_QKYU_X M6'KW_/?_ ,<'^-'_ L/7O\ GO\ ^.#_ !HY'Y?U\@YUY_U_7X>A]%9;U7_O MD?XT9;U7_OD?XU\Z_P#"P]>_Y[_^.#_&C_A8>O?\]_\ QP?XTJ_]\C_ !KYU_X6'KW_ #W_ /'!_C1_PL/7O^>_ M_C@_QHY'Y?U\@YUY_P!?U^'H?166]5_[Y'^-&6]5_P"^1_C7SK_PL/7O^>__ M (X/\:/^%AZ]_P ]_P#QP?XTJ_] M\C_&OG7_ (6'KW_/?_QP?XT?\+#U[_GO_P".#_&CD?E_7R#G7G_7]?AZ'T5E MO5?^^1_C1EO5?^^1_C7SK_PL/7O^>_\ XX/\:/\ A8>O?\]__'!_C1R/R_KY M!SKS_K^OP]#Z*RWJO_?(_P :,MZK_P!\C_&OG7_A8>O?\]__ !P?XT?\+#U[ M_GO_ ..#_&CD?E_7R#G7G_7]?AZ'T5EO5?\ OD?XT9;U7_OD?XU\Z_\ "P]> M_P">_P#XX/\ &C_A8>O?\]__ !P?XTJ_]\C_& MC+>J_P#?(_QKYU_X6'KW_/?_ ,<'^-'_ L/7O\ GO\ ^.#_ !HY'Y?U\@YU MY_U_7X>A]%9;U7_OD?XT9;U7_OD?XU\Z_P#"P]>_Y[_^.#_&C_A8>O?\]_\ MQP?XTJ_]\C_ !KYU_X6'KW_ #W_ M /'!_C1_PL/7O^>__C@_QHY'Y?U\@YUY_P!?U^'H?166]5_[Y'^-&6]5_P"^ M1_C7SK_PL/7O^>__ (X/\:/^%AZ]_P ]_P#QP?XTJ_]\C_&OG7_ (6'KW_/?_QP?XT?\+#U[_GO_P".#_&CD?E_ M7R#G7G_7]?AZ'T5EO5?^^1_C1EO5?^^1_C7SK_PL/7O^>_\ XX/\:/\ A8>O M?\]__'!_C1R/R_KY!SKS_K^OP]#Z*RWJO_?(_P :,MZK_P!\C_&OG7_A8>O? M\]__ !P?XT?\+#U[_GO_ ..#_&CD?E_7R#G7G_7]?AZ'T5EO5?\ OD?XT9;U M7_OD?XU\Z_\ "P]>_P">_P#XX/\ &C_A8>O?\]__ !P?XTJ_]\C_&C+>J_P#?(_QKYU_X6'KW_/?_ ,<'^-'_ L/7O\ GO\ M^.#_ !HY'Y?U\@YUY_U_7X>A]%9;U7_OD?XT9;U7_OD?XU\Z_P#"P]>_Y[_^ M.#_&C_A8>O?\]_\ QP?XTJ_]\C_ M !KYU_X6'KW_ #W_ /'!_C1_PL/7O^>__C@_QHY'Y?U\@YUY_P!?U^'H?166 M]5_[Y'^-&6]5_P"^1_C7SK_PL/7O^>__ (X/\:/^%AZ]_P ]_P#QP?XTJ_]\C_&OG7_ (6'KW_/?_QP?XT?\+#U M[_GO_P".#_&CD?E_7R#G7G_7]?AZ'T5EO5?^^1_C1EO5?^^1_C7SK_PL/7O^ M>_\ XX/\:/\ A8>O?\]__'!_C1R/R_KY!SKS_K^OP]#Z*RWJO_?(_P :,MZK M_P!\C_&OG7_A8>O?\]__ !P?XT?\+#U[_GO_ ..#_&CD?E_7R#G7G_7]?AZ' MT5EO5?\ OD?XT9;U7_OD?XU\Z_\ "P]>_P">_P#XX/\ &C_A8>O?\]__ !P? MXTJ_]\C_&C+>J_P#?(_QKYU_X6'KW_/?_ ,<' M^-'_ L/7O\ GO\ ^.#_ !HY'Y?U\@YUY_U_7X>A]%9;U7_OD?XT9;U7_OD? MXU\Z_P#"P]>_Y[_^.#_&C_A8>O?\]_\ QP?XTJ_]\C_ !KYU_X6'KW_ #W_ /'!_C1_PL/7O^>__C@_QHY'Y?U\ M@YUY_P!?U^'H?166]5_[Y'^-&6]5_P"^1_C7SK_PL/7O^>__ (X/\:/^%AZ] M_P ]_P#QP?XTJ_]\C_&OG7_ (6' MKW_/?_QP?XT?\+#U[_GO_P".#_&CD?E_7R#G7G_7]?AZ'T5EO5?^^1_C1EO5 M?^^1_C7SK_PL/7O^>_\ XX/\:/\ A8>OGI-G_@(_^O34'U?W!SKS_K^OP]#Z M*RWJO_?(_P :,MZK_P!\C_&OG7_A86O]YO\ QP?XBD/Q$U\*/WN23U"@C'TS M3Y/-_P!?T_Z6JYUYGT5N).,KD?[%+\W/(_[Y'Z5\XCX@Z^Q;$WKC*@>O/7FI M!\0O$'>;Z83_ .O4\C[K^OD'.O,^BLM_L_\ ?(I<_3\A_A7SF?B)KXP#+U_V M1Q[GI0?B)KP'^OR?]P?RW4(#M_?Q_[7RG/\_K1R/NOQ_R!S[?\ M#\/^ ?1?7[K''NHZTHW#^+\U%?.7_"P==PW[\9!.-J]A]3UI4^(6NCDS\_[@ MX_\ 'J.1^7]?(%-65[W/HW+>J_\ ?(_QHRWJO_?(_P :^=?^%AZ]_P ]_P#Q MP?XT?\+#U[_GO_XX/\:.1^7]?(?.O/\ K^OP]#Z*RWJO_?(_QHRWJO\ WR/\ M:^=?^%AZ]_SW_P#'!_C1_P +#U[_ )[_ /C@_P :.1^7]?(.=>?]?U^'H?16 M6]5_[Y'^-&6]5_[Y'^-?.O\ PL/7O^>__C@_QH_X6'KW_/?_ ,<'^-'(_+^O MD'.O/^OZ_#T/HK+>J_\ ?(_QHRWJO_?(_P :^=?^%AZ]_P ]_P#QP?XT?\+# MU[_GO_XX/\:.1^7]?(.=>?\ 7]?AZ'T5EO5?^^1_C1EO5?\ OD?XU\Z_\+#U M[_GO_P".#_&C_A8>O?\ /?\ \<'^-'(_+^OD'.O/^OZ_#T/HK+>J_P#?(_QH MRWJO_?(_QKYU_P"%AZ]_SW_\<'^-'_"P]>_Y[_\ C@_QHY'Y?U\@YUY_U_7X M>A]%9;U7_OD?XT9;U7_OD?XU\Z_\+#U[_GO_ ..#_&C_ (6'KW_/?_QP?XT< MC\OZ^0J_\ ?(_QKYU_X6'KW_/?_P <'^-' M_"P]>_Y[_P#C@_QHY'Y?U\@YUY_U_7X>A]%9;U7_ +Y'^-&6]5_[Y'^-?.O_ M L/7O\ GO\ ^.#_ !H_X6'KW_/?_P <'^-'(_+^OD'.O/\ K^OP]#Z*RWJO M_?(_QHRWJO\ WR/\:^=?^%AZ]_SW_P#'!_C1_P +#U[_ )[_ /C@_P :.1^7 M]?(.=>?]?U^'H?1>3[?]\C_"D.3T('X#_P"M7SK_ ,+#U[_GX'XK_@#_ #H_ MX6%K_P#SW!^B_P"../>CD?E_7R#G7G_7]?AZ'T.<@9+?3Y1^E*'SQD9]T_G7 MSJWC_P 0DY\X?]\J?ZTW_A86OIR92?3Y/_K^]'(_+^OD'.O/^OZ_#T/HT;@. MJ_\ ?(II2CD?E_7R# MG7G_ %_7X>A]%Y;U7_OD?XU'G_;_ /':^=?^%@:\.LX/_ <4+\0]?_YZCCU0 M _GFCD?E_7R%SKS/HX9'4@_@/_KT,< ]/R'_ -;^=?.W_"PO$ ZS?^.C'YYI MK?$'7RI_?#G_ &1CKW/_ -:CD?E_7R'ST^L6^_X>7]6]#Z)SQG=_X[QC\\YS M^%("3T;_ ,=KYW'Q"U_: 9U/MM_^MBFK\0?$&21,._&T>O\ ]:CD?E_7R#FA MT5OZ7E_6OD?1@W#N#]5%+EO5?^^1_C7SK_PL+7QUFQGI\H/]11_PL/7O^>__ M (X/\:.1^7]?(.=>?]?U^'H?166]5_[Y'^-&6]5_[Y'^-?.O_"P]>_Y[_P#C M@_QH_P"%AZ]_SW_\<'^-'(_+^OD'.O/^OZ_#T/HK+>J_]\C_ !HRWJO_ 'R/ M\:^=?^%AZ]_SW_\ '!_C1_PL/7O^>_\ XX/\:.1^7]?(.=>?]?U^'H?166]5 M_P"^1_C1EO5?^^1_C7SK_P +#U[_ )[_ /C@_P :/^%AZ]_SW_\ '!_C1R/R M_KY!SKS_ *_K\/0^BLMZK_WR/\:,MZK_ -\C_&OG7_A8>O?\]_\ QP?XT?\ M"P]>_P">_P#XX/\ &CD?E_7R#G7G_7]?AZ'T5EO5?^^1_C1EO5?^^1_C7SK_ M ,+#U[_GO_XX/\:/^%AZ]_SW_P#'!_C1R/R_KY!SKS_K^OP]#Z*RWJO_ 'R/ M\:,MZK_WR/\ &OG7_A8>O?\ /?\ \<'^-'_"P]>_Y[_^.#_&CD?E_7R#G7G_ M %_7X>A]%9;U7_OD?XT9;U7_ +Y'^-?.O_"P]>_Y[_\ C@_QH_X6'KW_ #W_ M /'!_C1R/R_KY!SKS_K^OP]#Z*RWJO\ WR/\:,MZK_WR/\:^=?\ A8>O?\]_ M_'!_C1_PL/7O^>__ (X/\:.1^7]?(.=>?]?U^'H?166]5_[Y'^-&6]5_[Y'^ M-?.O_"P]>_Y[_P#C@_QH_P"%AZ]_SW_\<'^-'(_+^OD'.O/^OZ_#T/HK+>J_ M]\C_ !HRWJO_ 'R/\:^=?^%AZ]_SW_\ '!_C1_PL/7O^>_\ XX/\:.1^7]?( M.=>?]?U^'H?166]5_P"^1_C1EO5?^^1_C7SK_P +#U[_ )[_ /C@_P :/^%A MZ]_SW_\ '!_C1R/R_KY!SKS_ *_K\/0^BLMZK_WR/\:,MZK_ -\C_&OG7_A8 M>O?\]_\ QP?XT?\ "P]>_P">_P#XX/\ &CD?E_7R#G7G_7]?AZ'T5EO5?^^1 M_C1EO5?^^1_C7SK_ ,+#U[_GO_XX/\:/^%AZ]_SW_P#'!_C1R/R_KY!SKS_K M^OP]#Z*RWJO_ 'R/\:,MZK_WR/\ &OG7_A8>O?\ /?\ \<'^-'_"P]>_Y[_^ M.#_&CD?E_7R#G7G_ %_7X>A]%9;U7_OD?XT9;U7_ +Y'^-?.O_"P]>_Y[_\ MC@_QH_X6'KW_ #W_ /'!_C1R/R_KY!SKS_K^OP]#Z*RWJO\ WR/\:,MZK_WR M/\:^=?\ A8>O?\]__'!_C1_PL/7O^>__ (X/\:.1^7]?(.=>?]?U^'H?166] M5_[Y'^-&6]5_[Y'^-?.O_"P]>_Y[_P#C@_QH_P"%AZ]_SW_\<'^-'(_+^OD' M.O/^OZ_#T/HK+>J_]\C_ !HRWJO_ 'R/\:^=?^%AZ]_SW_\ '!_C1_PL/7O^ M>_\ XX/\:.1^7]?(.=>?]?U^'H?166]5_P"^1_C1EO5?^^1_C7SK_P +#U[_ M )[_ /C@_P :/^%AZ]_SW_\ '!_C1R/R_KY!SKS_ *_K\/0^BOF/3;_WP*0[ M\_P^F,8]^@KYT/Q"U]AQ.N<]QC'O_P#6S5_1_'&N76IVMO/*DB32JC[5R=I. M" >H//%'(_+^OD+G7F>^$]!ZTM1QGY1S_= !&3@CU]?>I*EIKGXC^8I:0]/Q'\Q0!POQ"_Y%^;WE7^@_I7SN/O M8(7CV_SZU]$_$+_D7Y?^NBU\[#[Y^G^%:PV^?Z(SJ=/G^@_Z#'L****LS"BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **87P<8[T[/&>?\ &JCO\#DK-MWLHV5[ MO\EY[CBN9J-TF]F]EWO\KC)&*+O_ (5Y;C)QDB MDGHW3&1UJCK-_;Z7IE[J=W_Q[V-O)>GKBOP3QF\?>%/!K#X*6>1Q.(Q>-N MZ.$PM/VDZD4W>3=_<27D_P!7T4Z'M&E%\[[+UZ+JO._W'W_YK;MI3#XSM+8/ M_H.T_G4J-NX*-GT],#)Y'7_&ODOX;?'#'FZ?XXN@\,:#R=2$9[)$54^F!SV//O4\(?2.\+^*%JQ=E^7G]WKKUUL>JXST7!Z\GG'T-)M;T_E7E1^,O MP[/)UC)_ZYM_^JD_X7)\.QTUC_R&U?4OQJ\+EI_KGD;>[<<93:L[66C>O?7H M]] 6'G_2]/\ /\&>K9&<;#_WU_G^502MM8#;@DC')].YP?6O,?\ A<7P\8_\ MACC/)\MOTY%TFBRDL9(^1>ZT5M+;V M>FO;<]\7AMI7#<#@[@?Z ^U/S_+-?-_A3]H3P[J&;?Q!9R:/=(JAG -U%*W: M3>QP,U[5I/C/PQKBJ-,URPO'< B!+E%F&>S1L%;T^GUKT^$?&+PZXV MH4JN1<3X*O*JK_5Y58?68SNOWOWWZF(44450!1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %&<H4$<=>WYBH MGR,Y4C!&1]?XOH._I69JVOZ'HT9FU?4K*QC R!-=(N,#.3@Y_#^6*\C\3_'O MP/H<<@LKAM:N]N(19MBV"]\3\JXSUX&#WKLPV"Q&*ERPH2M;2W7;K;7M\_(\ M#->)LER>/-F.*I8>4+ODE57-I9_"NOY*[/<58-N5&#",_,Z'*\C/'3(&>?<8 MIX92.&! P"1S^?OZU\N>$/CY:ZOJ-U<^);V+0]-A519V4<.^2;I^\:1F+\;OAJK2&/6FR>D9@;\3WZY^O&>W.T\JQM.7++#5'UNKVL_E\OO\CR ML#X@<*XV+J1S3#PI\SC:I-0G>+2;LWMKIIMJ>LT5Y3_PNWX;?]!W_P @M1_P MNWX;_P#0=_\ (+5E_9^,Z82JWIIJNWEO9[=7=>G;'C/AF3Y5F^#3OO*K&R6F M^O9W5MSU;YCGCGV].YZ=OI4)8[B,\XS@9P?8#N?:O*_^%U_#HL%77CDD!GH?6N0\=?'WPUI^AR'PO>'4M9G?RX-JC; QQ@MG'&3STSS6E+*L94JJ M#I2@F[:[]+].GSNNYABN.N%\/AJ]:.;X2K4I*\*2JI2JM)72Z?U?R7T+D?N^ MC>8I;*H3M )!WC@@Y_"DX)!&&&!D#C&>F1Z]_P#"OS97XS?$B#4#J?\ PD%S M(P-E\<>&H=3$/DWL3""[A /E^;C<6 M4]]PZGWXK7,R['C\*^).3<5XNOE^ M%C5H8JF[P4DI\T4]6HZ7C_>1Z,QW_*!W[_U'_P!>GA<=EX_V<_SIH()4XPW\ M0QT]?R]?YU)7DMSVG%1:2T4N?=*Z;TU3W/T:Z:5E+LVU92?=?\.]>P4444@" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ I01W&?Q(I**J*YI*.UW:_:_]>7J MAQNVO=*W:NKI/HVMGW$?&/NC')/W$7;@ MNR#\Q6V!PF(QU?"82A"-7$XFO##QBI\K=FN98;*<%BLQQL MI8;"X"A4Q6,;CSNG0IQYF]X]$WNGOV.UW[5R8\X Z G((R#G;T]Z<7?('ED, M>=I.&8>JCT^N/PK^:OQ[^W3^T+XN\1W6JZ/XVU'PII:7,DMGI.D,D$4$*R$0 M3S*8W,C,@&[D#'\(QFOO']F#_@H3I6J:'-8M]/U>Q2,6NOP0%FU)"2C M27&#\LVT;FXY)]:_8LU\#>+LKRNGF$::QM2HDWA<-%RJ4T]=;7O;TZVZZ?RW MPQ]+_P ,^(>*\7PW4Q<\LA0G4C1Q^,2I82LJ90$@?Z(WSMC[Q.X8Z6YG]6E:^E[:_?\ F?LD?&CPODN9 M<:9(D]+/%TURM:/6^MWJON]?K7&1]T9S]._KC-1MC[H"@]BS$#/7T[]*^3_^ M&Y?V:,?\CX,_]>C?RW9_SFF']N+]FA@__%=JV1RIM'5".^XEN .N?[V!WYF? M ?%JBVLDS"-E>\L--I;=$]=VOQV!^,WA>U_R6N1=/^8VGW7GYK_ACZSW$ $K ME\@84G')ZYQTI0W#@ ,>^$&8_3>,X'L#-$T*QUWX.>,],\0 M:MI]TLFJ>'M1TY]FJ::6_>QPR%P%O4! 4#GOSQ6I\)O^"CWP<\;VD-MXY2[^ M'VM,$$[W ^U:;*2,8^V)M2-"#7L/PMXQ>7_VA')L4J<5><'2G[:V MGO*E:_*^CO;KZ_.KZ17A.\Z>31XIRZE57+[.M5Q$/85)-[0JMV;\DM--&?HC MUVG*X/&1T![[O3CGN.*DC((;;R%/+#[I[<']/PS7GGA#XK?#7QZH/@WQSX:\ M0LPV^18:C!+.@Q]W82I1ANY3YB,_>/./0US@*0AQT9<<#GC@X;V/(QW/6O@\ M7EV/RZ2CCJ$Z/._=C4BX35MU*+V??M<_9WIRC. MG*Z7O1E%N\?SO\T^BBBN9V6G/&4MVE]G:U_Z_,[K627Q.[]Y;-:65EH%%%%( M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'&#\H)]=I)/\@?2F M#DX*@<9&?E)_(G_Z].)5%.\?*Y/RL0"Q(_A).!Q7 >+OBG\-_A["9_&GCCPY MX9C!P$U/4X()"0,E.K,Q']W QQS2=2E"+<[MJ^SZ]/U]3TSN=X"IQM .3V8\8]+3K.O?&GQ1I/A:%I_+T#PW96IDF@M$SS>W*L%E?H?L]'Z./BO6X>K<0+A;&QHPY/9T'"I]9JJ3BF MX45!RDH_:>RYDVTD?JLK[E#*N5(!'/8].U2M@CA0/KS^E?&P_;T_9>*[_P#A M82=< +9.N!T 5=V< <9XSUQBI3^WM^R[C/\ PL),9X_T)\X[Y&X?Y''I6RQ5 M"[3E:W6]^W9=.U]CYS_B"GB?SR7^IF>NTN6,5@JO,WIH^WGIY)L^OV!QQMSG M^[_B:,#_ &3_ ,"/-?('_#>G[+C#CX@QD>]JW7UY;\^E1#]O+]EW!S\0E! S M_P >;^_^UZCVS[4?6L+_ ,_X].W6WGYH%X)>*;;C_J/GRMU^IU-59?W?4^P] M_!PA.,$@>YQTQST_SBG'<-RF-EPN[. 05X.0!UQWSTK\J?VDO^"C/@O0/!_V M?X%ZW!K?BF^)0W5Q;D0V4++C>B%C^^4_,.OICI7YB>'/V[?VD_#WB2/Q%=?$ M#4]*_ ?XKVGQH^&O MA_XA6D4<#:G;1?;8XP!'!?!%,MO@= K$GO\ =Q7M )')Y#<\=/7CM@]O:N_# M588B+<&Y6LN:.L);:Q=M[WT['\M9_D./X=S;'9+F,80QN7XB="O&/P\T+)\O M>-T[2MU[DGX4445JK)M/IV[W/&:M:SOWM\OS"BBBD(**** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH 0@?W5SZXS_ %K6\/H3K>G_ #8!N(P0HQSG@]:RJV/# M_.LZ>/6X3^= UNK[75SZF0;4 !)QDGTQVIU(.@^@_E2U@W=W-DK;!1112&% M%%% !1110 4444 .'0_[T?\ Z&**!T/^]'_Z&** &]A_NK_Z"**.P_W5_P#0 M110 4444 %%%% !1110 4AZ?B/YBEI#T_$?S% '#?$+_ )%^7_KHM?.P^^?I M_A7T3\0O^1?E_P"NBU\[#[Y^G^%:PV^?Z(SJ=/G^@^BBBK,PHHI3@'[P&/O$ M\_\ ?..O>@!**#@%>H!_O#&<],'IZ]:3('!!#9^[@G@]#D#IGK0 M%!R'"#Y MCU. 0,>Q/?ZT?ACVH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "D(R,4M!^H'NG>N>\2>(M,\-Z3<:MJ\Z110)N5&8*[R*N52,<9).![YK MRL\SW+N&L%B<8NZYI-:16_,K'H8#+<7F&*H8 M6CAZE2==\GL%%JI/VEE!VMI%-WDW9);[&1\0[_2;+PIK<>M7IM+6YL9$#L,D M2LO[L1KP7)/&Q>6Z^M?G3)97J*DOV2Z-O=/_ */+'$^XQ(Q\MTR"#Y@Y('W. M]?2^DZ7K_P ;O$"ZUX@BGL_!MEW\#\=>%.+N?#7PZ^#^K^-GEN-0:71-+3)$DJ%GN#CNH7&2.^ M/;M7K4?[-.G<[=?E10YP!P,$CCIG!]?I7TTL,42K'#%'%!Q^ZB14'XA0 MHX!_^M5H$8X&!Z?Y)_G7ZIP9]#?POR/*,+ALYR_^VL?2@HU\37]I3=5I*\HV MDE&_1:_C=?"5,36YM82UVNM'JMELWZ.[7<^73^S18'('B"4?]L&_GCU_SUH' M[-%@/^9AE_&!C_6OJ.BOL(_19\'DWR\,TH0?2,ZCY7U^T]>]MWV(6+G;73R; MMV[[IV/E=_V9=.Y(UZ09Z?NGZ_YYKE?%GP'@T#29+JQO;O5=0=Q':VUO;R29 MD)P3* ,JO3YFR/3M7VD0",$?SIH10<[0?J!^'/7CMS7F9I]%'PKQV#Q6#P^2 MPP/0$"G'DY'RGITR/R/'^TNGS>[*,79VLN5?(F5>4DVGJK>[]I] M-([N[T=GY]RA9V=II\"06J+ HP(@K/*< +DNS'.!SG)[GFKB9Y!!# _,3_$ MW<]/I4@..F.N0,#@^HXXSWI,#)..2FG8 HHR/<=-Q + G M ! Y!)]>.13B,$<';SN;(^7!].Y(&!C^+'TH ;11C/W2"7Y0'@JGK(O7)&,8 MQ2CYCQDA<[Q@@D_[!/'7USQ32;3?8;35GW$HHSG..F>/4>Q]_6CU^A/_ .OV M]:0@HHXR5R <95CG:2 "5/?+9PK=,T#Z8]J "BBB@ HHHH"^WGL-.TGDC(]_ M\^E,D0/P5W!N&')!''4#U_SWI=N2 M]\,EKK96>^O3?=GEGB7X0^"?% F;4;.;[7*21-#<3HP)R1M1Y'48/3Y>AKP[ MQ#^S L$?F^&=9/W=JV5\OF,>2=N]0%Y)X/Y]:^OR65L$Y4=B,Y^K=<\BG%59 M.% [CU!SG()]/Y5Z>%S/$8:=^9QO:SDN7MYV3_X?S?QV><$\/9W3U.W:SOIIW[+T/1_XA;PE%.4LO4H M1M)I5-UIJTK:=[_Y'RB/V7-+(Y\27"]E(0<,>G&W'7TS^%[ 8#?\"!S^8K6CG^84ZZ_=JN^52]VS;VO97OWTL_2QP8WPHX1Q-"O1 MIX3V52I#FA7YVXT%?K9I?)KIMU/R573=5,OV;^S]1-SN:1@D#>;%A2"LN5(* M*>IZG'-?:O[.%SIL&@7FFF\4:T;LR36DCJKC"D82,X(/L>^>>U?1!T^P6;@H/;=7/H?!WP:X)@Z>68FII"*EJJ,D]G)Z1;?73L? M2,;;T+JCO[_7/2I@,<"O*?A[\2;'QMIT22H+?7;0>7>Z>WR.K M)\K2!3AL\'DY!'6O4T*\8/) S['TZ>]=_!W%^2\9Y)A,YR?$T:L<3!2KTX33 MJ4:^BJ4:D+N4*M.5XSB]4U>Q^BYSDV)R/%SP&)I3I>R;]G.HTU5A)K]Y&223 MC)N]U??>Y)11VY!!]/3Z_P"1]**^LLKM.4;I)VOKK;2W==CR)>Y)1;6JNFM8 MOR3[^04444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH ****:5W;1>NB^\=F_EJ,"X.X^_ M'I^/TH.2?E;I_G\?>C))*G@<_7_.*:PV MG'8'/SMN)L8Y!X!&,YZ<8/TXX].M?/_[3%AI6 MO_!?QOX4U>^%NFNZ)-9:;DXG,X"F&&*-<%P[@#=@GOFO4_&7C/2/!FD2ZIJT MV $*P6RL!-=3_P ,42]?F;:,XZ'\_GWPOX6USXLZ\GC+QH)K?PW:S$Z3I9SL M14/[L&-N'4C:3QENW K\6XO\8L=P[Q%D_#7 -*&9<72Q="LZ4$ZV$RRA2JQE M5KX]QNX6492Y7*#>EG=GUU'P_P -Q1PQG_\ $E>,7:[N?SAZU\/_ !IX8U!]*U;PSK,$D<[);G[%-MNU+$1R0.5( MFA==N,<9) %?;W[,G[ WB#XT:5>^)/'5QJW@;2HYMFG0W$!$UV&.&F$97G>OWW/A[0)DA$VA:/#L?^:6P46]7#VM22@VXZ)J:T>M MM-.^I^3 _P""4G@K//Q)U3_P%/'_ ([WIDG_ 2D\&?=C^)&I,6&T;[5R%[E MU"@$L.O.:_6OJ.,>V1QU[]^OZTPA^#CD=",9&3D]/7'/^-9R\7N-^33,*O3[ M,9::=+=-7Y==B_\ B6#P*/B!XOUF\2RTS3;>R=+6.21L-=:K*(\16J#)W_+@8)) -;'PN_X) M;^*M:AM[SXL^)X/#L[@3DY!R>Y);]3DCZ<5^6YIG&/SJM*KF-5U*SES !T!]:I)O;IK^GZ@%%.PN2,[1@,I8<,O<\<9IISNP%;'&?E/5N!ST& M.2WMBD 44="5/W@<''*_@>AHY[#)[#U]J "BCC/)Z*#M )+-W16&5R.YZ"C@ M'Y@=NW)*D.0QZ(0.C9X;/%.SM?HP"BCIG/RE?O#!;GT!4XZ=>N#1R0<#)'+' MLJGH2/O9-( HHH')V]"1\K$':#WR>_'88/YT %% Y&>Q) [$D=>#SC'2B@ H MHHH **** *]W;1W-O+;3AGAN$*N-QV;6&"A*D,A()Z$$5\??$[]AC]GOXJ?: M[C7] U33]3NV9I-5T[5;PW".<_O%6^N+BW0$DX C'/MP/LGH"HX5OOKP0Q]3 MD9!^A%1[.&4YVG&23G('.T@YXY/:DZ5.I%QF[7OK\_QW?IVVO]%PWQ5GG">. M6/R+'5<#B=+U(:+LM-OQT1^&OQ/\ ^"3>J:?'N"-GV?[ M1I.HP/N8SV-T(]MQ\P^^I*GKC!X_H4(QM X4,N$7A01R",>A'0Y!]*1UW,I* M[F&=4RRE[6$E-BB[VT]WSZNWX[_P##HKP6[;O^%FZIA@"N MRUR AZ$_)]_'WNHSVS2G_@D/X*'_ #4_5NO>T)XSV^3GTK]B0B@\#&>N/7N< M C&3U P/RH*C(()R,X]!GVR:KZC05[N4D[)J,7:VFE];O>Y\Y+Z57C,IRMQ1 M6J0;O&?LZ<96=M)+V=W;<_'@?\$BO!7\/Q-U4GWLS^8_=_YS2M_P2)\$@''Q M-U4<=K1L?CE,U^PC'&,<'OP.?T^M.!+#D#\!_D5/U'"?\^I]/LORV\O\[^1D M_I4^,W-=<2U=.OLH7>W]W;?]3^>W]HS_ ()N:Y\)?"'_ E?PYU6_P#':6;Y MU;2Q;M]L2'&3/#&JARL8R20/;UK\Y+#P-XTU>]_LC3/"VNW5^T@5K58G@ 9)K^R>6..1=KHLBL"KAE5D9",;&4C:RGG*L",=NE9B>'] MMY'FM] T*&:5"LL\.D6$4[QD99?,CMP^6&>=V6$ MG&E[6F_9TZJ3Y9S=US.3M=)W5NUC]TX"^G;Q3PYD5? <2Y4N(<=-.-+'O$TZ M$X*22Y9TN1W4;WZ-Z7>Y\G?L1>'+3P3\#?#_ (6-T%UBW62\UJT5\SVES,P; MRA$W/!R"=HQ^=?8FXL.>G;IZ>U?+_COP-JW@;65\??#X2QP>89=6TU23$\0. MZ4"),<$9^AKV/P%XZTGQKI8OK63RKB)5CN[-N)DN /G"H>0@/3(SBOR7@/Q1 MS!9WB>!>-L-2RGB&A7J/+YJ+IT,VPR:4:E!R=I5.7>*E)Z6U5S^8O$C"?ZTX MW'/Z\?YXH4;N2&4+T(/RL3][MG*X'Z4]B,C_P#0Q10 WL/]U?\ T$44=A_NK_Z" M** "BBB@ HHHH **** "D/3\1_,4M(>GXC^8H X;XA?\B_+_ -=%KYV'WS]/ M\*^B?B%_R+\O_71:^=A]\_3_ K6&WS_ $1G4Z?/]!]1NS+DXX]AD_EU_IZU M)3"KEN%#9P!EBH4MP&^4YR#V_$\"K(6Z]2M-W'Q@\4Z=)(EQJ MUY< R_\ "):3=IA8YR%*:@ZOF'A<_-BOK[P-\/\ PE\-_#MCX3\$:%9:/I6F MH$"6\2>;. ,&[NYF :ZN')9C+*6;<3CUH->:/?\ #8^;]/\ %G[8&IV9O;CX M=>%M"G=/.BTZ]U)IKB,\GRF:*0QAL ]L_6L=/VD?C#X"U%8?C;\&=3TG0YA M\GBGP_*FJ64,:D?O);>U\VXC#%XP#BOKCPSXAT7QWX5T3Q)IDEMJNA>)M, MM=2M&*K/##=9M]6T MM@/,\J13/;RL.89X@?-B=&RI5PI4C! Z5V89@<$''8=>#]W!Z9-(8EY M"YK["\%>+]+\>^%='\5:'*&TW6[*&[A#??A=XPY@;/*O&J[]/D-/EC)ZQA)VDXWT;M[W75+NO^#S M?B;Q)IGA?3+C5-2F2*&",^468 S,!G8HR"3QC@'ZG(KYJTS2]=^-FN-K.L^? M8>#["=7MK-@R+=A#E3M[AL Y(((]J]Y\9> =&\9BR35YKDPV$XD2TC8JDA5@ M=K@<$''0@UUUC86FF6D-E9QK!:Q1QQ)%&H7:$&%5B ,G YS[\5_/O%G 7$WB M'QI0P^=R6&X P#IUL)@NA^B9)Q%E?#>359Y? MSXOB"O%P>+JQNJ%'3W:32LIWT;W^X2RTZWTZS@LK&)(K2)%2")0%$04 $D#& M=Q'/ZUX)\2?VJ_V?O@]JXT'X@?$_POH.N@INTZZU"#[3"9/N^=$)?JOA+P7J^IZ=$V[!NUA\N(MMRR[#)OW]%*C MGH*_SH/B'\0/%GQ2\9Z_XW\<:UJ.OZSKVIWM[<37=U--(CR3R,L<7G.?+BB7 M"HJ_+A1@5_6OAQX<8+,<(\!A%1PF RN,:=.C0C&G>:Y8PC%K9)-7EU?J?RSX MO>+M;@O$8>K+#5,5F&8MU(JO)^QBY:S;J:*5]7\2Y6]]#_2=\$?$7P5\2]#M M_$W@#Q'I7BG19V$8OM)NX;F!789".T3N%;.1@G.1@\].X#*1E3QSST[X/7WS M]:_S]OV&O^"A'QC_ &+/$6LCPJ+[QKX9UVU>*?P;=27=W90W" -#=:;;1^88 MI(2Y/3Z<5[.;>&N9X7&.. M%E2<;_#.K'ROI=>5_P#@'E\/>.W#V8Y71KXU8JCF$K>UITJ%6K06JNHS2DGV MO?;OJ?UF4?@2?\_U]Z_DY_XB!/CB.GP24?\ ;AJ8_P#;?_(YI?\ B(%^.7_1 M$AT_Y\=4_P#D?I[UY_\ J!GR=Y?5]M5"M34;.VNLG[SZO7?H?02\9.#;Q_>8 MV_+'F3PM5VE[M]>7:^JV=DNNI_5^7*\$@?S_ $_PK&U'Q)HNBR6D.KZI8Z;) M?R&.R6]N(K?[0X."D9D==SY.,#/-?RHG_@X#^./?X(C\=/U/_P",5\\?M.?\ M%AOBG^T;\+[[X?ZS\+=0\)W GCU+1O%FCP:G8:EHM_;L'26.^$496%C_ *U) M)%5LXY%:X;P[SBM75*K.E&,ENZD)J[Y;:)]>Z:L_1WXL=XT\*8;"5J]#ZU6J MTH4--;*_:Q_:;%-YJ"2/;)$0I$L;!HG##Y3&ZY5_JI. ?QIY9 M@I8KP.PY;V^7[Q_ <^U?PJ?LZ?\ !8W]K;X'W>CZ3JNMP?%#P];-%;/I&LK+ M+J*V?21;5X?,EEN0@ #'.6PV*YLWX"SC)E_$HN,M;.S[/36^UO77;IT\*>+_#W$D* M/O5L/7G+DC1]F[2U2UDU9>C9^Y>1Z^G7@\^QP:7/)'<'!^O6N&\ ^,;?Q]X7 MT[Q/!IFIZ.+Y5(L-7A>"_5F4';)$X5@%/#< 9!]*[9#][D[L_./X0?13W&,< M^M?$S@Z;Y7:][.VFJT?_ .Y^M4ZL:T;KJN:.^J:3O?;K;S_ "<3@$]QT^O; MKQ7PA^VS^W+X?_8MTCPOJ^O>#=5\8?\ "3W+V\4.GSPQ?9]A_>N0Y&[RQD\# MGH*^[ST/T-?B#_P5S\.V_B[Q9^S3X4OE#6NO^*I--ER,C=>"6*(<]'-?\0^'+[Q9?>(Y;E+70]-E2*ZC@MBOG74IDP/*0 M,IS^7I7S-_P2SUB\\$_\+;_9J\0/(FM_#GQ-<7&FK<-L#Z1?$36IBC?!(CC! M&Y?E&>#C%?*G[=-Q:_M'?%']IK6&5[SP=^S+\'-4T:UCE4O!)XOU"%!5PGE%CST/6O8=^00/O+C.!D#/3!Y!R/3/.:_ ;6?CS\0OV>_ M^"57[(GB[X::FNF:QJ@\)Z'=3["8Y;&^U>YCN8NP)\MBOZ^M?L-X_P#%^LZ- M^S=X@\=V$[1Z_8_"D>)K.Y$:@#51H,-[O*]2HN&9OIQ63W?J_P P.S^*WQ!A M^%7PW\9_$.^L)[^W\'^'K_7I]/@=8Y;V&P@>X,(,A $C;#M;I\V*^=M"_;3\ M 3_LJ^&_VK/$FGWN@^$]?LYIXM+=3<7<,XN!;QPNT89"SR%0/PKY-^%?Q?\ M''QV_P""97Q:^('Q"U&/4?$=WX/\8VTEVL957B@M+Y4CQ@X<;0?RK\[?C'HW MQ:O/^"5'[/6I^%M7MK/P!9V3MJ:+;&,<%MDA0L #T.:T4HV6O1 M=P/Z&[WXUJ/@2_QN\/>'-6\16\GAS_A(].\/6D2'5=30Q":.UA4 C\>:AX2UCP5>ZZA9_#&K)LO=/P>?/& 5]#TKSS MXA_MC?&?PI_P3\^#WQVL=2B/CCQ#K=C::S);Q!([NV^U!#;Q1Q]&F4^5QRG;MZ=/O\ ,VNDE?31?D?NSESYC<,D;$,ZK@8! ^7^]C/49_E7SE^U M9^T5IG[+7P5UWXRZQH=UXCL-$U;1]*ETBS=8KB=M7N/LZE7?Y1Y?WF_+UK\H MK_XA_P#!3[6? ?\ PT;X?M]#M/"%EIUOKUOX EMV.I76@P1"2:=D^^TLD8D= MDQGD'' JU^UW^T=9?M2?\$J/$?Q-AMO[.U5?&?@W1_$UB.18:[8ZLT6I6NSK MN609'7&<=JQ$W&SM^7_#?TO(_;7P3XIB\:^#?#'B^VMI;2W\3Z+I>M16TY#O M:P7]K%=BV)7@R1B4)O'RD_Q=:ZT9V%PC;58)PK'&[[O0$D8ZGI7Y_P#Q*_:0 MTS]E7]BCP%\39[,:KJ\W@KP5HGA71/,VR:IK6HZ;:06,:INR8H9BLDY X4\\ M5\.Q:_\ \%1Y?#2?&I_$?@.VMIK$>(H_AW]OM//_ +&DB^VK;+? MVJOC1\+[0+B73!LU2&(1;B5=8II(SSR0 M*P/B7_P4HO/%GP0^%>D?! QW?Q[^)TMEH4^D>7]HF\-WRO'!J5U=0*&DA>&4 MR%0X4X!R: /VLRRDK(I0@#((.1NY7/U _#OBG-N'3&?J#^N<5Y7\&]'\:Z)\ M-_"]K\0]8.N^,GL8;K7=1P57[;+&KO"$_N)N*=Z]5/&=HQZ =* &#?W'?V_H M:7.>G('7KD#V]>_0&F OSC/7GI_7^E(\WDJ[E?N*6(7DG SA1CECZ54VHQ4I M/EC&+0,=\U\)_$_]O/XBZQ+)I_A/1_^$1M)%*^9J,4BWA)XQ&LB@*>ZX/H>M?B? M&_CAPIP50QGUFM6Q.(HR:C2HX>K.%XVLN:ST^>EO1G[=P%X$\5\>5\)3P5#! M8?#58Q;J5:T8U$K*[47-:_)Z[G[)'5+,726(NH&O'&1;K(IEVXX+("2H]20/ MTYT 3CYN".HR#C'7I_+M^M?@G\)OVJ?&O@76-3U_5;2]\7:U?JRO M#;E'V5+#5)P<(M*$KJ+2VGD?>9]]%+CC+<=/#X2MEF M)I4XT[5:N+HTI\[5Y0Y924O=>B=M?.[/UPS1U_SUK\D#_P %"_&I_P"9#;_O MQWF_*^AX2^C%XC W+#E (;L?/@[/_B/X4E\)PZ5+X8M[^17OKZ&.6WGF3@R10R.$)/&#@]J\G// MI1\%8/*,?B*%+,)YAA*$I8:DL)6ITINUUS57"U_^WEY7/6R+Z+/'&89O@,%C MY9=0P^,J1HXBMAL71J3@FXIWIJ_0_6>'XW_"V[U4Z+%XRT7[87"; M?M<84ONVA5D+[6.[C:.1TZUZG&TM?RUI M-.LJ3033QR@YCG\QC*DRMO$HYR)6(W,2,%CUK]R_V(/B%KOCCX5"WUZ>>]FT M.^^P07<_S2O%Y9;YWR=V,?*23@#IS7S'@Q](VIXF\08CA[,LF5-8BE.48>TY MU5IV:;DI'[3Q2?%5BTEC?R<'<: MX7B/@*I"CP]FV+E+.\BK2Y*,)2E:KB<-&4H\DGLX_P WOI^;\K@H:*2:M*2DFM[7<6TE>[MJ[VL/HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH ***3(SCO0 M%%% !1103CK0 44T,"<#-.H **,]?;K10 44 MS>/?Z_YYIQ8#J?YT +13=Z_7_/O1OST#'\* '44TL <'_P#53L]^U !130P) MP,TY2&. >X_6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBBFE"3Y)NT7\KWZ+[BH_:_PLB(PV2< M=2, _P"'YUR?C/Q=I/@_2IM3U*Y2,K&?L\+GYKB8'*HBCYB2=O0$9_7JB3DY M.<$UP/B_X?:'XRU+1]0UI[ADTC(@M48FVE8R>;NF3HS9 )&0./I\;QVN*WP M[C<)P;[%9MB94J%#$8AKV>'I591A5K.[6M*#YDMVUY'N<.3RJ&.I3SJ4HY?# MWJJAO-QY7"G_ -OOW?GV/#O#'A?7/BSK@\9>,TGM_#]K_BCX8$O_"1^%? MFHSZ4UN"9EN952#SEQR&A\[?D>F:\'PH\*IT/Q"_;;_9?^%?B%/"7CKXQ>$-'U[S1!/I\FJVC7,,Q.-LXCFS% MSC)?&,\U[[X-\;^%/'^AVGB7P1K^G>)= OD$EMJ.F74%W ZD;OOPNXZ8[Y]. M:_RE_$WBWQ)X[UJ_\7^,-;U'7M>UN_N+^\U.]N)9KG?=2O,P82.S)#&&"J!] MW:.E?J)_P3^_X*N?'C]A_3=>\,>'],O_ (E>&M8\J6TT6_?4-1_LN1'/_'G' M")C!$1]Y<*-M?U=C_#9X?!1KX;%2G-1C>$XVBG9)Q4M$U%IQ3OZL_GK >)4, M5BY4\1AE&$9R7-%\TW%/235WK;5Z+R/]% _, ^,X([4O_$21^T%_T0+\M/U? MT_Z]_P#)X]J^6_U(SR:3?U=)O2U1;*RV<][?BD?5?Z[9+=\OUF3T;O2EIHM% M:+^_NS^RG+#C('XK2[FP3@''/')_ DG\!7\:G_$21^T+V^ J@9X!TO521WZ MM;9/U_"E_P"(DC]H3Y-WP(52S@*1I6J [L'"Y%MQGN3CCKCFH7 V=6WP]G_T M]B[;?WM]/\_,7&V3K6U>^_\ #EY*_P -_P"EV9_8;J'B30-+U"RTO5-9T_3M M1U)6;3[6]NHK:2\\OAA;>:ZB5EZ%4RP. 0*W%=F3>!E.HDQ\I!Z%6'RD'MCJ M.:_@3_;+_P""Q_QB_:T\!Z1HNI_#K6/AIXD\)ZK%K/ASQOX>;6=(GTV]@?>( MKB81PJUC,3_I,;MM=@N1Z'[+'_!=_P#;"^#5_IFB^,95^,?A^ 1VMSIMY%-+ MK4D"A4WVHA$C2/L'#<\]>M>B_#K&RPKQ'MJ'M8:\OM8M;1VU_P"&.)>(&40Q M2I/?C'TS3U!YRV< '\# MP.HR3[=N]?A!\ O^"VNE_&*33[:Y_9H^*VE75R8XO,L]%O[B-C)M#.=\!4(K M$YR00.3ZU^W7@[Q+%XP\.:9XBAT^_P!-BU"".X2RU2'[-?6S2H&:*6+ .Y0< M,& (_2OC,PP.-P,E"M"-XNTG%WCI;9]5\WYL^SP6.HXRFZM%25.HN>',K/EL ME9KH[Z'3T445Y\N5NZ^)K5=MCHA>VOJO2R$ +NB*P7%-2\0ZSK%W9V-WK]C=0?8M-N;U M_*:&Y#-O+Q<%D'S 'IUKVCX ?M#V/Q#_ &/_ G\;M0O;>WN+3P \GB.=F 2 MWUO2+*2VN8V8G@^;$@()SN(SSU_GIT7P=J]Q\?/V<_CKXGMY(]9^-?QL\0ZM M9%]PEET2WN$2PF5FP3 1%N7!*X;WJ /ZUE=RF\*?*"Q[6 .P"09 )Z[\G:V3 MQM].:D5G9L1+N8,;E=@,GN#VH ]<_:-_:NT?]G?Q-\*_#.H^&K[7)?BIK MR:+:7-O)''%IDSRB(SR*^&*@L3QZ>XKJ?''[3?@#P)\7OAC\$M1-Q)X\^*A( MT>T@C<+#9")II+R5\;"5=0H7.X]1D5^FE M:8J.62<#.UUC!4=#^%:Q5XJZZ_K_ %_3 _=;X\?M ZS\&/%WPJ\+V/PU\2>/ M8/B-J\FEWVL:!$7M?"*),L7VK5SM.U),[R3@ #FOI=#*R)(W\21.=HPP$JA_ M*)/R%U^[@?AQ7Y'_ +7WQR^-WP.\2_L/^"AK5E)K?Q$UJ'1/B/<) DD>JW,5 MU%%=2QLW,/FJ%05+#ETQ"TWAF?4Y M BX*YQ%$S["Q_N_GZ#_P4GUW3_%&J_LC^(]*E$VF:SXST34[.9#N,MO>?9YE M"-R,[7VD=B">*.5=OZ_I?U=@?LY:SMX(/\ EC64(I'REE#8) M'/6K&9,;MC8X_@;N<9]<>]?EA^UA^UE\3= \;^"_V:?V<=-TV[^*^OZ-87FH MZIK%RD6F:+I[VL)$LDCNJ+("V<,PZ8%?/=Y\>/VXOV2-;\*>+_V@=7\+?$'X M5:]K-KH7B"?1+RW-SH4E_,L0N2MO*[FV@,F3(5QA2ORA_;+^/?QL^!.L_"/\ M:)\ ZH/$_P"S_JTVF)XXT2*%KD6=AJ!B"7ZR(&Q D1NSVQ[GH#Z#J?3I253L(7M;.TM);A[F6"U@@DN)N))IH M8P)I9%7*>9+(-R8/0Y%7* $)X..H['^@X)_"F%F"[B. >0.2?8+U_P YZ9JK MJ5T;&SGO&6:46Z-)MA16E(49\N,=2QP,=R3BOA?XE_MP6/@.:[MX?A?XUNY; M:1X4F;3IDCEDCS^]W^7]QL<$=C6]#"U,3*,87U?3U73R_I Y*"N[6\U?^F?> M#EL;@.F..I'N5ZCZD# ZUG1ZSI\UY+IT-_:S7T";Y[6*:*26)?5U4DJ<>P\+6+>![)@T>TQ2+JF2"HD/G!!\H.< \_2N-^!O[: M/CCX3P:O?2:%J'C;Q%KER9;_ %K4#>7+.1DHML%62")5Y#*K#&.F:^CAPAB9 MTG4:A)V3CSS4;:+17:ZVWVTTTL<^OY>O;^D1'+ 'L>?F^4X_ M'&"?0U)EO3!^H_'TK\.S_P %2/B/GGXD;N,_P#++MTX].*>?^"H MWQ&(&/ATA.1_RZWW'T/E?3'UNFK^9I'&+E M>JTLE;Y;;=-WT/V].3RV*_#W_AZ+\2?^B06.GVL;2W%S0;7R5>&[C;D[!SN&WJ<8QWP. M?F7QSX&UGP3JY\?> ]XM%D:74]%C^ZZ@Y=A&.,,,G(4<>U9G[%OC[7?B-\!? M"^MZ\TT^K6\;::9KC=^\2U(C>Y).2PD PK<\MP:^L7ACDCDA9%9=J[RX#!X7 M!_=8/!&#@GGG/J*_GSQ3\*\#Q9A:D*52."S[*YSQ&79QAG;$4<="*=%*M'_E MRVH*4'>]VC[OA?BK%Y'7C6]E+$8'$I8?$X&I[].I3E92]U[2A%MK5:KN<)X" M\?:7XYTI;JR<1WL(VZC8DXE@N#@,-AP2,CG P,\UW[CYB&[KN7H>/\YXZ@_K MYYH'PYT+PSXCO_$FDF6UN+]766Q!_P!&4.!OD"C R?T/IUKT,K@;@%=/AS1XOP>1X?"\9PHU,VH.=/Z[0_>?6*<%R4ZU2SER3G3MS1: M6KOU9Q<2+**F-G/)YU:>&G*-;EEI*E5J-.=*UDU&[:6SV):*:IR*=7WJNKS'&[DDM'=6?9W/J<=!]!_*EI!T'T'\J6N.>3QWKKZ\B^.WAZ?Q7\'OB1X? MMBR7&H>&-0:-U)4C[$GV]AD<_,ENP]P<=ZLB.Z]4>=_LB^$;/PU\&M!U81@: MO\0);OQQXANG7-S?:MK$SS73^8?F:(!5\I2?E4''!KZ;N9H+>&6>X(2WAB>X M>52/EM(4+L".Q 5C^=>*?L[:G'K/P/\ A;>PJJ@>%+)#'D*R>0'C;;UVMD?Z MKKG->4_MR_'.U^ '[-GQ#\<;F&M7FER:!X:MO,\M[C6-5#6MI@#D'+MA5R6/ M:@W/R?O?A?=?\%%/VI/VC_%DT3R> ?A#X4UCP)X.=8VFBN==@B=8=1@.#&'6 M?Y2R'((%?:/_ 2L^+]UXJ^$&N_!7Q6\EOX^^"?B"]\/WUA=NXNGT:VN)8K- M_+D^9Q(0&! P 1FOA/\ 95_8N_;O\+_"S3?%GPV^-]EX)L?BS"WC35M&DM$- MY#-K$LER(+V5CO./,Y)Y*E>.U87P8TWXN?L$?MSZ OQRUU/$FF_'=9++4O$U MJHMK.34KAP(W8*=CO$S;R6P3T-!-X+LOE_P#^D^\LK:_M+K2;I=UGJ<$T%W& MX#YBN4,;J<@C!#XQ7QK^R+JU[I5]\6_A9?L^WP+XMNY=.#Y/EZ??2R26T<6> M501LN .!VYZ?9]O(K*C)*C1S%721^6N+9\2QSQGIM,>TGGBOB_\ 9KNU\0?& MC]HGQ1:Q9TDZW:Z0DP&$GN+*-HI"K?Q%&C.2,],$T$2:=K>?3T/MP\$#;@!5 M_'CK24#[H/)!)P3G)';]/\\44$!1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !2-T(Z_P#ZQS^F:6@8[\#N?;O3VXU&\)TINT:DE*^J:3LFKK6VE^@W (Z ,<1?$WXE6_A.V&FZ8W]H M>);\&"WLHCYCPE_E1GQRN"C1SWQU\3^&[CP?X@^'VHVL>NR>,M+NM!O-('[PW%K?QF&0.HW%-K%74G'S# M(K^4?XY?\$./VD]*\4S:K\(UTS7_ IKTDNIVUG>2^5=Z"MW*TWV)QP953?M M5CT /7%?U:_#3X:70G;QCXRW7VNWF)H89?G2TW?,@VMD=#STQCFOH,;WY8D M 91B&90HRHC/ $8[IVXKYSP.XL\27FF9\;YQBJF"R[.(JEEG#LX\M.GA?=E3 MQ532ZKRBD[-Z7^'<\GQ@\.^!>)<#A.'\13^NX[+K2Q6:4FERUM.:G3DK;-M2 M25FM7=:+\%O^":W_ 2%T?\ 9Z^T_$_]HFRT7QA\1]1L'M[+PU-!'>:1X[=/XCAAD"OU_7]FKX 8S_PJ3P,2>3_Q([0'YN>0(N.O;.#BO;_E M8J6^9C\Q5<"3=CEBHX7(P-VO?'0^]?N>8\1YUFN)E6 MJ8N=/6]HU)1[=%)7:^1\1D/ _#N0Y;3RW"9?0K0II+VM2A3G.7=NQ_3U%._P"&;/@!_P!$B\"_^"2T^O\ SR_S MTZU[317G_P!I8_KC,0WW5:K_ /)GL/(A68OXM'##S[>T0 <5^A-! P6P<+RQ(#1\X&&&> M3C.#U7T[C>AG6:8:K&K1Q5;FND^:M-Z/?>3L[G/BN%^'<7AZN%K91AI4Z\?9 M3Y,/3BTI)>\FH)[+OMZL_)_]FO\ X(__ +*'P!DMM3U'PZ?B%XEBVO#J/B%% MNHXGP"QCMY 8U7=G+ YP?05^EVA^ ? OA;:?#_@[PYHC?+&/L&E6L31JHVJ8 MW5,@@=QW]\5VA&UMH4>6O"H3\RI_#AL?,6.2W<8P:;A0I3'&25/\0XXY[D?T M^M/'9SF..JQE7QM5QVY75FXW=D]+V??56U(RWA'(7F=K:ZWVU9$". 1]WA#M *CH< <#/? ]?6GIT..FXXI0!QQSZXY^OU MI:\IMO>[]=3Z-67PI)=$NG:P9(YXX]3@>XS[CC'?IWK\9?\ @J04'Q6_9'9F M9#P7\2_AM<:;JJ1;D@NO$-II_P!FMC,R#!E\Z1"I;EST M-4_#WP^N=(_X)L?M/_%C7=\OBCXU:1XH\:WLT@)N5TK4IE>PC:0\[8(DP%)R M < 5^GO[3G[)WPQ_:L\#Z/X%^)(U!+'1+VPO;"_TR/A9X>_8=U7Q-=^-= GL_$?P:BT3PZ;3 M4K6XGUB_G\.0VH@LK:*1Y_,28-',9(T*[3V&:]9T[]DWX21_LX>'OV7=8TZX M\2?#GPUH,.@V UN3[5J!BMGEEM[MKAE#"Z@>9FCE RI%?)_A/_@DA^S?X8.I M6]SJ_CCQ'I5U97UEI>A:WKMW>:/X?6_1D,^EV,9< ?,I>POFV;2 &D ()8].E>6^+59O^"+_P * M'"J4BA1Y&8D!0-5A8D$?ZL!Z1IEQIEM/>W#/J2PW,OG&7SRN?-20_*V,@ ]LT_Y_Y%J;[+IT[6 M_P OOU/FGQ=>Z=??\$O-2EL[RRNH1\(&0M:7,-TR2"P0LLJ1NSQD$8RX4YY[ MYK\S_BS=VVF_\$IOV=-3NQ&+2S\8:+=W2@;@UK#J<+R2$-C9A%8LH!Z?C7Z\ M_##]@#X6_"WX5?$+X0:5XL\<:KX1^(UA/INH+J^LW%Y-I5M.I3R]',HQ:JBG M"J@YP.M?#_\ P4<^"OA3X$?L7_"OX0^')[K4/"N@^/- L($UB7S[^>"[U&%) M//E<*9 R,08_>CFCW_/_ "*C/O9=M/\ AS]'_#_[2'P3TW]EFT^*,GC#PU)X M0TWP"UE/%_:5IN%Z=(:V73I;-G$QE>=@I7RCSBOP;LM&U/3/^"//QQUF^@>U MT_QA^T M+[G4/&D6DWNAZ-JE[X"@UZZ3PA=7CVL4KRS:6O[AMSY+ C'-?:/Q?_94^%OQ M?^ G_#.=Y9S^&OAZLVC3Q6_AQ_L$MO+HO; MJG;^NX.4;/7\'O\ _@\+^#9?"$_C&XLUD^U M6VF:EH^GP6]R(H@P!M9 95D/W3\S$&H_#/["_P -/%?PPL/B99_MG^*9/!]S MH-M=WUPWC&-+?3XWL4DDL9(7NEDCDMES$(DC/*;?2OVHNOA3X-U;X7V?PA\0 M::GB#P;;:!9^'#8ZH!,5^=%Q_P1[_ &$OB!+X^\"SZC?RW]]JQ.=9UIK.:(6,&\;;H7,K[ MB4W%RV:_+?\ 9W.O_L]?'WPI^UC\2_AU:Z5\)_C3XIN;?PZD\+FW\))J-V5M M-44,NRU$_FH._V _@GXX\(^!?AZ6UGPY\/_ M_;:E%X2T.Z>T MTO7+RUD21)-8B0$7+,4^?S,[@2#7M7Q9_9U^&7QA^%'_ IOQ)H\5MX0AL8; M'38]/18)]*%N%$-Q8R*N89DV*P= "&&XYL[J)TFC:WN(A()%924==I !W<$@8%:0((R-V/]KK^->1_!3X4Z=\%O .C M?#S2-;UO7M+T.(P6-[KUX][J"VW\,#W$@W-&@ " ]!BO72<\\?@,#\!0GH_. MWY_U]P$2Y).2>#^?^<4UOO=LC&"1TZ&RF.1VZYP'0G:GM]"*[A1G)7!17P0!G!;.0Q(4]QP,@'-2C( 1MO!S MMQ@$'^(GU^G&:\O)O#;A'(Z"PF&R#!.@JDZL>?#T*C_>24FN:46U9[*[M;0] M+.?$SC'.*T<5C>(LRGB)J$)S5>O3;]G9+W:@_*DVCT'^1Z?Y]:]O_5;AGFIVX?R MRW/%2YL)A[,6WQ#FEG!WY<9B5*WN_P#3RWEH[]3A M/^%9> .G_"':%SP +&'KUZA?\^_;R+XS_LU>!_BAX/G\/V>E:=X>U6,-<:9J M=E;QVYBF0$B)W10<,1\P/!_$5]+=IDGB1QAD^8X+'X7/,TC+ .%>C*MB*TU4DG%I/GD^;5+XKZ/Y'X:P?L'?&B7 M6VL9UL8M->9U&HK(,O#'PLF.<;U / ZG'-?>?[/0M_@K:+\+M>LOL-P;GS4U M)ALBOI,;/,\SH<'U//?-?:A8?*JY(/0*,B/'.<^O;'KWXKS3XA^ -/\ &^FR M*56'4[?_ (\KV$;9XY@-RKQ@X9@">>N0:_FS,/H\U/#C$TN,?"W$UIYOEM=X MO%X"NE[/,,'%QG4P\7IR2Y;J'*XW?*M3]GSGZ0&<>)^%_P!7.-84_P"SZO(J M=>B^6=.M!15.O./,D[2LVFMTWY'I8(95;>K9&\-&1L9#]U@PR"QXXZG -.5- MV#G/X_$#5/#FHGP+X\9H;BVD\C3=0FRD<\>/W>YR2O0>O)K MZ4216C#QD,'4,C Y#JW0@CVZ?YS^^^'OB)EG'F7I*<<%FV"J^QS++JCY<5AJ ML4O:T_8O5Q]/96X&2?K[] MS_GBOTIP_?U&W+DC1BZ7\K=XI^7,[M^GR/DTXQJ5(Q;Y?@LM8YA(3E#VS0!^B^C^._!_B'6M5\ M.:!XITO5],8.307&/->]] M+'N!(!Y//X__ *JIW=Q#!%+-<7,-I;PQM+-265V5410"Q)/: MOSR\ ?\ !4S]CGXD>(K?PUI_C77O#E[=2Q6UO=^,]"N= TVYGFD$<:V]UE>6_\ !6;]IWPK\+/V6O&'P^TO7M;L?B/\5-#TZX^'VK^'K6:? M3I=.BU%#J$L^L0CRK&.XL]Z(SL#)N 4US_@E)^R!JVDZAI^F> 6T+49K M2>*PU'3KN>"[L9]C,MS"X8DNK!64YSP<5KRII/79?DO(#]%=,U*QU6RM]2TJ M_L]2T^[&^._L9HKRTN(0-R-%)$S*K$$9 /XXJ>\O[/3+6YOM3O;+3K*SMFN) MKZ^N(;6W$:Y:1B9F1-J1CD@D[@?EYK\)_P#@F=XX\:?"KX__ !S_ &7?$GBZ M]\3^"OAXU[J>AWE_=O>R66G6SNY1IY#D+'$NT@D8(Z<5Y_K'B/XL?\%.OVHO M&GPW\,>+-=\!?LY_"N\FL-;?1[N6TO-9DMKEK>>V:XB.6>?:[#J0C@8J9145 M=7WZ^@'[36O[5/[-]WK*:!9_&KP-/K4UT+2#31J]O]J>?/SQJI8(PR=JLS 9 M YQS7N<5S%>)YUK=PW5K)LDMKFUECEC,)Y++)"SQRDD\8? R!T-?F9J7_!)3 M]DNY\+2^'K'1-7TK7)+/9;^.+34KF/Q':7(CREW]L!WAGDQYC 989!'>O)_V M"]*_:@_9]^/GQ!_9E^(UIXD\>?!734CU#P5\2-45[F.Q\P9MK 7TCEVC:WV^ M;%MYE^> MIK](+K_@E9^QI=13PK\,8K:26-H$E@FN$F21OE:6!L_*T9PPQSD UKR+S_KY M ?=/A?QGX4\;6*:QX0\1:1XCTF0 M=:-?17B(C#@D1N6 /7)48KJ8M_\3*P1 MALVC_61-T+^I'J?>OYQOA7X=U[]B3_@H9H?P,\ >--7UKX9^.XY)YM!U"^DO MQI*S8*Q%79C!Y1X4$#BOZ/8QS)@!<@G /12!CMVQ^M1)6=D!(>IQTS24@Z#Z M4M2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% $9(8XR0%)Q@-Z+SRW/7&,T.:A%N4E&G:TVVHJ,7HW=Z*RVN7"$YR2A% M2E&4:D8RV#X$\,=L-7C//N*XRE*CEJIM.6& MIR34*E:7*E;W[2DMK'Z5E/#.6Y3E4N(.*:=/V.*C..%RR3?ML0YZ>T=-OW:4 M;W2:5U'6Y_%M\8O^#?/]KSPWXUFB^%L.B>*_"&IS>?:7-Q=B"ZTV&ZE=TLYT M'!%LK89B.=H&. *_>;_@F/\ \$>/ W[*'A&_UKXY:?X=^(OQ'\20QB^M+ZQ@ MN['1LXD%M;)(K NK'8T@^\/O.G7J82C1A5Q=W&K6G3A%3G)J MSO-KF:VUV>A^'+@[AW"YQBL=@\+&53%U:E6G1<6Z-.$Y)QLI:*R:7_ NSP ? MLL_LY_*K_!?X?E,%>- LCM;).1^ZP,]#GGG&?20?LJ_LWGC_ (4O\/\ ZG0+ M/_XW7O>T8 RV1]XY^\?7&./H*-ONWYUY\LRS!NZQ.(5TE95:EM$EHN;2]GZ[ MGK++L##W'A,/"479\M.+3;MU:EL>!_\ #+'[."DJ?@Q\/B!C'_%/V7<9/)B_ M7FFG]EG]G$\+\&/A\#T4GP]8E%.>2^Z/ &#@-V8^M>^,<' R/?)/;TH4;]R9 M#!U*LKCY67KAN>@QG/8@=*G^TGAJ,I MV5DJ=-7U6EG'MU/RG_;;_P""9O@O]ISP7HWPR^'^F>"_A/X:N=42[\::WIGA MZQAUO4=,A<,=-L+F-5DMVE &)4/.*@_9;_X(\?L=_LS):WL/@JU\>^*K<*!K M?BI/MSPMCGRX9$9!T)Z@8-?JZNT )\Y(. YZ#&<*KG>B*VU=N96 MSF8GLH/_ -?IBNO^WLT]E]7^N5N3X>2_O:VOKOVW?;U.5Y+DD\5];GE^'56$ M4G52NKJVBA\-[Z?#?;8Y/P_X'\$>%UC7PUX0\.:&$;Y&TW2;2U8' !*F-.,] MSU/Z#KA]YOJ#@# !(YP!P/PIH'R@JK+SNVM]X^Y]SU'L:J;W_K4]&G"G""C2IJG!+W8I)67R2'4445D:$UON\^(+D%I M$!9?F?&X$@(2 1C.3FOQ&_9WT:S\1_\ !3[]LK0;Z)9[#6OAQ)I4\3C.(+VQ MDMY."-O&\L1T&,^U?M@'>%UD4;F1U921P#R)?@Q MX7^.7_!/K2GN'U;7?B_9Z9X$C!E%S=>$/%&I>?J#6S ;ML42%5"?(!^=?6G[ M8?@RV^'7QB_X)S^!K& 00>%[FRTT1L!'MD6SMVN'&S._=,S^9NY)Y-?HIXA_ M8E^#_B;]IC0OVJ+ZWOF^('AZUMX+2R\W.C-+:AEANY;39L>90YY8DYY%=;\: M/V6? 'QV^(?PN^)'BV\UBTUCX2:G)J?A^'3;IK>VFFEV[ENU52)% 7&#@8P, M<4 ?F9X[\4:+X$_X*ZZ)JGBS5;?0--U[P#9V&F:E?[;:QNKH!,1)/+MB!<': MH+_*W..#5G_@L+\9_ -YX:^#?PHT[Q!8ZCXLN_BOX8UJ:ST^[CO_ +-8#4+4 M1F:6V:6%3*><-(&"GIP*_0;]IW]BOX-?M50:0#TJE*RM9?U;\OZV \&_X*#8/B3]A0*6 M"_\ "0:&'R<(I'V<95\[E'; XZ4?M-7%OI?_ 5&_8WO-0N[;3[:70YXHKB[ MF6WA:002( TLI6)@0=H+N%+$9P3BOT/^,7[*/P]^-E[\*=0\3WFL03?"&[L[ MKPX+&=H1.;+R]BWN WG%C&"S'!KE_P!J3]B3X4?M81^%;CQS=Z_H7B+P5&\/ MA_Q/X8OY-+UFTMWP?)^UP@R%20&)&#D52GWT^_R_X('Q)_P5/*?\+Y_8,EB9 M)8F^(LS*RR!UE4ZE&/W;Q%UD)!#!E)5?X3BO/_BY\3_ OPK_ ."S>AZUX_U" MTTK1M2^"7@_0K+5;_'V6SU._L2MI)),X/D;&!#.< %N37Z+^._V(OAK\1[7] MGNW\4:]XJGN?V<1;GPAJ)U.5KO5);>5)%FUJ8AFNY7*CS'8@L.O-?F[\:OA% MX&^.?_!7?5?AW\0]-CU'0-1_9TT9G4MY4\%Q#:,EM>VTRYDBNX<;T=1G=W%5 MS1[_ )@?0_\ P5>^+'P_D^ EO\.+'6]+U[QGX\UO14\.Z+I=W!J%]=+/5TV*0YX7@\\UX/^V%H&I^%/A_\ L$>&M:W-JVD7_A>*_1U*R><\5LZJ M?25 RJQ)SD8/M]E?![_@F+^SY\(O&L'CS[5XH\?Z[I!?VA]1\ ZCXMO-7LI/A[JT.M:/'I=RUO' M+)[S1->GBATS3)?$<>JMJD\[!;6.VLXKB8LSLZ8;:"#SD5^O?[0'[*/ MPB_:4\-Z?X?^(^B+/+I%M';:3KED3;ZMIWEQ"(2P7:#S%E*JN&!X/:OEKX;? M\$I_V>?A]XKTOQ5J.L^.?B'/HDT=QHVG^-]>NM9TW3989!)$UO;7'R+Y;*NS MT %9S:;T[%*371?->G^1G_M6?$_X>?LX?L3Z#\.9+.+QYJ/C3PIIW@/X>^&M M44S7^KRW,,-G;:E+:;6F#Q-(AWJO##.>#7PM_P $X([[]B?X^?\ "C_COX>M M-%UWXZ^']*\4>!/%UXOSPWMQ SIX16\EX6*,/M$0==I XSC/Z[>,OV-?ACX^ M^.7A;XX^,K[7-=U/P5:0VWA;PE>W;2^%M),(S'<6NFE?(CE! 8-U# 'MFM7] MIC]DCX8?M0Z?X4@\9MJ6A:[X)U6TU;POXN\-W!T_Q#I,MI*LR007L2F1;=V5 M=T7W2!C@=9!R;35EJ?57EME@>!OW-LP1N'W",\8-2UBZ!ISZ)HNC:, M][B@\YYQU]< M'J:R=1T72=5&W5-)L=07!R;FTAGVC&.C*0V>@';BMBC.".H/9AU7_P#7TK2% M6M2DI1NEI9I\NFG6ZV]?\@/E/XL?L??!'XJ64KZEX8@TS4#N U#2HDM)@Q'& M5B P,]QQ^0KB_@)^R+HGP:;6=&U-=&\8>%[^1KC2_P"T=.@EO=+=\GR?/<%I M>".#UY]2:^X .:XQTU!U*NJ5O>?EHKNW3=$\D/Y(_\ @*/-(_A'\,0%4^!/#H8CMI=L!CK_ M '>.G2K0^$7PP;[O@7P[QV;3+?'X<=?\^M>A@# XZ^H]ST/<>A[T\G/8?@*Y M(XS'*5W5K)=;3DM-/[WS^72XZ_P#0,M__ M (FFGX2?#%?^9%\/'_N&6_\ \37I5!YZ@?E6GUW$?\_ZW_@R7EY^7X+Y')#^ M6/W+^NG]79\-_M+?L<>#OC+X0^P^%M.TOPIXDTTFXTJZM;:.!;B7&/(D5!@J M> 23T-?EQHG_ 39^/-_K3:;K,>F66FP.QDU".3>)8U.3Y<9P%9P.@XY!K^B MO"X#8V;>C#LQQSQSV':F%B4VDL3NR N"23[\94]^F.>N*ZWGN80R[&X&ABIX M>IBL-4HT:S;;A*46G4@]_:1?O*V^P4H8=5(XCV;E4H5HOV%N6->S3E&_G'3M M^GR%^SKJ&F_#;0+#X1ZI -+NM! M[=Y%\H:DW =E8@9W,,\'IS7UJ&+LO.W> M6X/*^7@;03GD#@CKCC%>3?$OX;VWBV 7NGF*R\26:F6QOH_D#2)\WDO(,?.3 MD(3U/%MNGI<_6,?D&5 M9[E-/.N&;X>OAZ,5FF4*5ZM)V495Z*UE*[NVHWT7S/HSM@J"!D!^NX'K^'^> ME0L",$G.. 3U ],>G^342LV\*K;@4W @GMZ8!R&Z@]ZL'YN>=H*CGCYFQD?3 M^OTK^D\/6P[A3<)G/VBO%1DFXN\+2NKK72VY^6N*IN<+2BDW= MR?OU)*U^9/5C_ /0Q10 WL/\ =7_T$44=A_NK_P"@BB@ HHHH **** "BBB@ I#T_$?S% M+2'I^(_F* .&^(7_ "+\O_71:^=A]\_3_"OHGXA?\B_+_P!=%KYV'WS]/\*U MAM\_T1G4Z?/]!]5KB"&[AN;2Y3=:W=O/:7"X^_!<1-#,I]=\;LH^M6::ZNP M3&[/"G W9!S\QX&!D\]<8ZFK(6ZZ:K7L?"7P"UO4?@M\4?%W[-7CV^2'3]7U M+4?&OP7U:[?R$O?#]_(9[CPO:ROA);S1W(BAMMP9E=MH)R*I_ML_L?\ BC]K MD_##08_B!!X,\$^#?$T'B3Q?H,NFO?3>*)+.=)K*VBND=5M&!0B1F5A\W3FO MI#XT?!7PG\;/#$6A>(C6C:IK$T4?" M2>)_!UNIU'[;Y843:BKI;S,I=8P*#7E7\TOZM_7W'VOHFE6NA:/I6BZ>@@LM M)TJRT^U@B C\B.SMH[=5!Z,"$WD>K5\1?MO_ +&MW^UMHG@J+P_XOMO OC'P M1KUGK>B^([O3VU *UM*LDELT:,C8F5-A&X#FO7K/]KOX 7=L)KKQ?IZ)=>&O!^GJ3M%W-K]ZK6ES:PAA(Z1[7E3*JP/-!%H?S/\ KY,[#XC_ !"O M_@#\%-&L-;N1XP^(DFDVWA70[/3(Q#-X@UV:W2S2]M++<\L*1.5>0G<% )S7 M3_LW_#J[^'?PVTZUUB(1>)]>N)_$'B/)'FC4=28W3PS/_$UOYAA)Z#!K@OAG M^S]XENO&J?&/X\:S:^+/B(8P/#^A:<9(_"'@F!CO>WT:TD9DENU "37C;]Q! M*[N#M+2&PLYKS6-1!M[%(8R_E.W"N5';)R2>E]R%W2UAFG>1+>TM();NXN)Y%B2*UMXVEG+LV%11&C'<3A5![&O MP]_:!_X+>?"GX8^-M2\&?#/X?W?Q'_L>[DMM1\1K?"STQI()#'<6]D&5A>,& M#+]I4JJD'Y37ZD?M5:9XCU7]G+XT6'A%KAO$5YX#UE--BM3)]KE=849XK01$ M2"X,2R%65N$#YX-?P#74=Q!=:A%=!DO!J-U%MS:.3)#U&"!G@$ M U_G_?LU?#[]HKQ[XYO;+]FJT\12^,8=,DNKZZ\.2S:=%;6'*NU_>#*0B;&R M)7XE8$ 9!K[XC_9I_P""N*83_BX?_A6LW;/7:<^W-=:ITE)OWM>C?IYKK^>Y ME.3<5&G^[2LKI*[M;?[K>A_87M'_ #UM_P#P)M__ ([1M'_/6W_\";?_ ..U M_'L_[-G_ 5R'_111[CQ6Q_0+3/^&;?^"N/][XC?^%2_^%-0I):1=M]'W_/K MKZ"YIZ>\_N7ZK^OS_L-V8ZR0#_MYM_\ X[7A/Q[^/7A?]G?PC%X\\;65_/X5 M2^AL-2O])2/4'TMK@_NKVXMXI-RV\(SYDAXYSCI7\MI_9I_X*X=2?B)^/BQ_ MZCBO)?C/\$/^"CWA+X>:]J_QFN?%L'P]A@QK3ZSXF2:UD'\,'E3*5EDE ^2- M1O., \TTJ?17?G\G?=V?W[^=@;DTUS.S5M$D]E^NOW']>/PB_:)^#'QWTB+6 MOA9\1O#OBBW?F>SAOX(]5MIV5=\5Y8RLKPM'D J":]N;(4MCA>I4AE!Z\N,K M^O2O\_\ _9]^%'[3OCO7+>\_9\\.>/#1,EJ-C? M,[NA 'S'@U_1=^RQ^S]_P5S\*76G7/Q'^.?AK1-!@\N[3PYXNNH?&^FWEN<$ M6]Q'IJV]U$X0 %'FRK<'K7.XTW_R[7WO_AR>6+LI)R2W3D_>?=VM]R_X;]SC M*JG:WRL0"%/4YZ=OI^=/!SD$8(."/2N9\+P>*X-(LE\8WNC7_B+;NO;W0;.2 MPTB3CYE@M+AY)H7[\_P"? M\]:DHH C\O/4_I_]>D\O./F/'IQFI:* (FC'7<1C)^OUI5CWCY M]29QUSCVZ_A7XR?\%/OBW^T3X,^(?[-WP[^ GQ>U?X6W?Q0\33Z-J&J::XLO^"A3:K>Q0R7%G8/X;6T^VS1KYJVK220E4 M24@(7;*\D]J]-_8,_; ^,'Q!^('C_P#9K_:;T[2['XP?#&(,==T^(B'Q-:1J M=][;?$[X/?#KXQZ M18^'_BAX4LO%VCV%Y%J=CI^IPN;:"_MI5EMKF+#(1<1LH8,21G!QP:_*WXN_ MMI_M*?'?XR^)/V;?V&_#^C)<>')'LO&?Q6U^2../1760I/+I,BN(\9Z1_P58_9#T:?XP:S\:],_:<\&:6BWOC+P9J.F+;7.C:8A5KN; M2$2))+HVL98-,AP6P:"^1V36M_\ )?\ !/W'LK&VT^TMM.L85M;"P@AL[.!& MW)#:Q($@B4^BH,=^E:?D/MRL4F#VV'YAT!''3Z_I7RI\%OVB]"_:%_9T?XQ> M"I/L-W/X7U>:[LP^+C0->-ER;B*=/W:8^3N"#7XZ_LQ^'/\ @I5^ MUMX,\5_$[PG^W1J_@C1M.\<>(O#%CH5[HL6H7,,>EWLD:,KQ6RJ5\LI'$""1 MMR<]:!-T^8@%EQDY]2.OXU%P#ASLXW<\<9 _K7X$?%W3? M^"J/[%WA^7XVZ[^T7I'[1O@?P\]M+XO\-:W81V4-M82./,>.S6..>]DV@[G@ M=?)(W/D5^RO[/?Q?T[X^?!SP'\6]+MO[-M?&&B07TFFL0ZZ=>>6HNH(_XC$9 MA((E)+*FW/(H)/9]@Y4CL#SCO@C\^M&Q20,8QT/ '3UQ[4Y3E5/ R.FTJ1]< MYSD8(QQCBEH :%"]*=110 F.2>Y[?Y^E(S8X'4_I3JJW"2LD@CP'*,$)'R!B MI"E@#DJ#U&./!G@/3+K7_ !KXHT#PMHUM$S37FM7\%K!N52V]F9R0RXR%"<^W2OS[_:C^ M%_\ P4;\=17'_"C_ (V> O"5A&)DL]%T+1YM"UFXMB"$BO-9U![BUDE9>"R1 M+@G/'0?SF?M2?L^_\%#O#;W,_P ?M-^('BRQ\UY)]5T[5[CQ+HGEC)+3/IHB MM8@4R3NB( SG.*^QR+AK!9@U]]=PD\A(W+@9:I^[8'%U;OLY #']Z./3.?SK M^%7]E_X7_M?^.K7Q!'^S//K5N+*51K=CH^MII%W 44H8Y;=D$K'&>3PI]Z^M M?^&9?^"M3*I$GQ!"2#:B_P#"7'( Y8-\OJ!G\*]S'<#Y;0J-4\\PL5RQM"'V5TJJA3SW!481A#W924Y-I:RND[\VZOJ^Z9_7QQ_?A M_P# BW_^.TA9>'\?8_[' \^W3_)]JX%PC@$DEGN"YFXK>3^^Z2T6M^F][;^8^ LL MJ.-^), K-:-V32M=-\O;RU^\_KS)!*@/;G+ >*\9^/OQV M^'O[.OPYU7XH?$C5XK/0=+8*(H)H7O[NZ?,5I8V%O'(SW333823&/)3]X+R6],+Q]X_P\8!^@-?.'[37P5_;I\">#+77/VCH M?&,_@5=1BBM[K4-5FUG3K742 $6\1/W=HTG"P2RJ5>;"C#(HMJ\8-7=VO)?UT/0RW@3*:N+ITI\0X7&0C)?NJ3=TKKW=EHK?>_F?L!IW M_!>7X?S^,#9ZC\&=;L?!\ER(!K*:NL]Y!!YNP79MQ&#(OEG>8L@H.,GG/[<_ M"CXI>"?C3X%T7XD> =5CUCP]K=JLUO.C 2VTA"[X;F,$F.:,ML(;KU^G^>D6 MQE2S!F?:X RDH8Y!D'15 .#C&<>]?UO?\$3]-\76/[,FL7VM)=1Z%?>(Y6T" M.[+%);>*-DGDLXW^Y")<#C@XSGO6O''#F19'EE&5"2H8AJ$(TIUHQEBZ;:<_ M9QE/FE))MVBFEL>EQ[P-E^5953S?+5)5,/[.%:RBG5_% 7=AC@9Y('0>VUM#X>,H\D:,(\BH2E>.]TU9/FW;U M3=VQ]%%%!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 FW=D-P'^0,.JH<;LXQ@Y'R_I7/ZEI6 MFPPZIJ2Z=8'4'TZ\B6_6TA&H-&+:0!3=%#(#@D!=W(''2NAJAJN/[,U($'YK M"\&1QC_1I2#D].G7WH _#S_@EN,?M%?M88Y'_"7:AR?X5^TMO&/XG)/MGM7$ M_P#!4_P%\4-&_:"^$?[0MU\-K[XQ_!CP5:0)K'A.T@EN;2TG@?S!+>6T9*HW M!*W+HX0XRIZ#LO\ @ERX/[1'[6 92"OBS4%VD/&@!NFS([.HW^N5(KZ3_;/_ M &M_V@/V6/B#X4UJX^$>A?$?]F'5K58O%][I>B3:AXETFZ8;66>1C-:I'&,N MA> B8?(O.:"HVUNVMMKGQ/JG[7W_ 3/_:NT;1/!/Q=^'.6W@LKQ]" M;3%\.2QA$;.M0Q6PBB##_CX97QUQQFOK3_@H_P"$O 5E_P $Q/B:WA=[#Q-I M'A[PGX-M?!_BN5H=5O4TUM7LUM)[/4F0S 2P;%+1NI=3EAG-?G]^UY^UE^PA M^T_\*]0\ _L__!'7?B)\=O$DD$6DC3_AQ>Z!<^&[RX/[R+'(_D%@ MFUWC. ,U]>_%GX(?%/PS_P $9_$?PCU6SU'6/B)9>"]"N9M'C5[[5D6+6(-2 MFM98US(TFGV8(VX_<^7LQQPT[-/LT_N'[MG[S]-;?U^7R/L;_@G3H'A[3/V1 M_@SJECH^G66JW_A=1?:E;V=O%?ZBVZ(;;RZCC5W0$[L2,V&%?%)KOQ=H&H:'>6> MFVEK:W*6IN+;69U%M=733 "6SC'F1OQV-?K*]TW7POV:.R,3;C&6(4. MR\]^*^Q=9^-7_!7?Q-IUSHUE\%?AKX8NM2CD@AU6WFA6XM8R#&TD4O/E.@8G M>0<=@:YC]FW(_P""KOQYW1D1)H<+B1UEC16\IMC>;@*K 'A2Q)]:_>,,^68D M!F969BX*@9;!BQR 1]\=#CVI\S[O9+?LK ?D#^R7^Q'XU^ WP[^-WQ2^*>MK MXA^.'Q)\+Z]>ZK:2?-%N6'#,=I)AW1D/ Z9K^=?XB^ _C7_P3+_:D\4_'7X5>!==^)G[/?Q*GEO/% MGAG01)+=:<]U<-/*[1*KK UK*TL@G*X*@)R!1=O=L#^B=B!$1'E.6Y'F(%&*2 ^9OCW:?'N]_P""MOCFV_9RO-%L M_B&_@GPQ+%<:_*D5DEDVFOF/8!G@C^5==^TI\9_^"K_[-OA:+Q-XZO/# M%UX4N28-2USPS"FHMH7G$(MY,T2AH%3(9I""!WKU70]W_#[?QB-C?\B)X?\ M*9%=XO+&F2[ED?;M"QGY=^[C/3U_;/QSX-T+X@^&->\'^)].L]7T3Q!87&GW MMM^)'##?'N#J1R2OR$5ORQ_FGTZKR\^OZKYA^.7_!.G]EK2?'. MMC]LCXD_%R/XT?$;Q-"%MWMIA+;^'#C+65Q'DJ+F+.U0JIM([U^V\;;\G/S. M2H /. -OX=^U?S7_![Q#XK_ ."87[9>I?!;Q9J%Q>_ +XL:FTGA:^,%R;#3 M)=0FWVS!?F%O):LQ5_F&X" .HK*2L[*[T6^_]=O*P%VBC]?<=_>BI **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M")E/)Z@D].:\>^+'CS4?"UK9Z'H%G/>>(_$$;KI_DQ&18%W^2TCCID,SVL$UQ:;O)EE16DB!'(C8\J-W)QQFOCN.\CS M;B3AO&Y+DV82RO%XV5&G]=@VIT\.YKZPH-7M*5/F47I9V=UN>YP_F&"RO,Z& M.QN'^MTJ*G)8=KW9UK7I/_"_X7+X:0^(O$C#4_%FJ,;BXFE/ MFM9^8>:^N),"&.TMT+L^\ M\*=H_E5O:NS$C*[AMS,Q(7DC:,C&!G'?K7S7^V+8^(-2_9J^+EEX9-Q+K+^& M;T6\4+>7-))'L+Q(R](Q$');JWSC/$8 MBI*/M:V(Q%2TW.3D^6\K+1[ZG@>)W'&:O),]SSV-;%5<#E6,Q6"P6&I.:4Z5 M*UN==?4%L MK>X6)RDB6\#(V[."$G!^; P,5]R_LW?M1_#W]IGP[/J_A!VTW4]/\O\ M3P] M?3QK=6+OD?([LOGKNS^\& 1CBOY#(@RY1\12J76>.0$!F1F#Q\]&63?N.Z/[!"1\O[R$ GK]H@]>1_K.OK^ M(I6W_[_P '_P 7 M3A;C+*#]X>F>:G_5?!+59]AY;/1M=5UY5Y7\O MP)?2BXS@TX>$/$D&FK2]DVH7LK)CXU?'_P;\!+70M;\?+?0^'M< MOH]*.LZ;&MU'I5Q*=L0O4C9C$SA=P)XP"<\5V/@+XH_#WXG::FJ> _%^B>)- M/E02.UEJ$$ES9MP=MS$S*RL.A !&?I7\Q?QL^%O[9/A+P3=:I\;+W5X_!9GC M@G75==BNXY[D\0PVD#J6DD//EA/WF-WS5YY\"_A;^TSXJO[>Y^!^C>,[3=(J MP:M8R7NFZ*.0 DUTQ%JAS]YID;OUKV'P7E/U3V\'TO/$"AQO+*:OAGFU7 UDHQRV.&J?6H2FU^]E/^'97UM.]_P_KW#;1] MTC/(8G\+I81E WA MSQ+Y?BH1VN%($<^G"W,,S#(_>%MOIG-?ICI4>IQ64*ZS+9SZDR+]KEL(F@M) M) /F:&.0NP5FR0,],9SW^!QN"CA:M2E&M&OR2M[2#O&:TU3[=N_=G]M\!<6Y MAQ?EL<5C,CQF28A0BYT,='EE)NUU%IV^?5FC1117!RR2NTM7;3T1]\URNST= MM4]^G3L-8;N,X_"F^43QNVD]_3^5244A$?ED?=./7M_^OZ4NT'.!M&3D8^]_ MGM3Z* *Y &>, <\C!''/^?2G&-FQM1SD!A\C'OUZ?Y%2[5+ G''S<9'M7X5?$GX6_\%8OV;_"FH_%^+]J_3_CUI?@V ZKK?@?6=+BT^UFTN!M] MU*Z&))+R7:K 1PNIV?/R.*_1G]EO]JS1OV@/V<=-^/'B*VM_#2:98ZBWC*!V M$=II]YH\;/>F,;AFWE:)A;#=E,HA8YQ35NNB ^OXT+<(I8/\R8SD8Z-QG(&. M1CKC/6O+)?@E\,/^%JGXZ2^#M/\ ^%HOHD7AM?&IB;^V&TJ-2B6/F%MAB53@ M+Y?XYK\>=,_::_;J_;]\2^)M/_9#ETGX'? OPUK%]HR?&+4DCE\27UY:S>7+ M)80R*RWL$A7B.),VP^5R20:I^*_BW_P4-_X)]ZAHWB?]H#Q;I'[3'P.UK5+; M3/$'BT6OV37/#C7\R1*4M456AMXR2PN6!7KS5VA_,_Z^7_# ?O(J,-H!8LV" MQ"G.&Z$CJ,GUR,U,L$N"%24\YSL;+<#VS@OQZ\8^'?V/]/\ C!\" M_&VH>$-3\6C0)M#\1:;)"TWV/5F!VP^?'*OR%S&PV9^0U\R^ /V8_P#@J9X[ M\&>%_&4'_!0R\T^'Q+HUGJT%O+X>C:6VBNX%D">>+?9*Z!MA(7!8<8Z4^2/= M_>@/W&VL&PP*COD%<\9&,C^=.PH_BSC![=S@9_'BOPE\$_M#_MJ?L>_M$>!/ M@G^UKXQL/B]\/?BA>?8_#OQ&:&,:N+@NJJK^1'&MO&S,!Y3H6'J:_=J-U:,3 M0NK6[A73/WC%*-Z,.Y RN/I425G9 'EA6PH!)&26Z9[CIUS[_A2") 3@'=W; ML?\ =XXJ7IP#D#OZ^_XT5("8'H/RI:** $R ,GIG&??T^M'[SJ%Q'G#.W"YQ MP,D<'/\ *J>HK?-9W*Z=+#!>F!C:3W,;2VJ3X^7[1&I!DCW8W*I4X!P<]/R< M_:F^#7_!4+QO'?S_ ;^.O@?2=-EWB/PUX8LSX5:2WP=@N-1U0W2&8]"4"_, M=W3BFKR:3;2_JW^7S _2_P"(/Q6^'7PIT:;Q%\1/&GAOPCIT"2$SZUJEO;#" MJQ_=Q[C)))M'RH%&XXQ7B_P$_:V^%_[2FL>)=/\ A0=2U;0_" 6. MD7MS("S)ISS2?Z5T+?+VSTK^/O\ :>^!/[=?A:^N;S]HG1/B'XBC@8F771?7 M?B'PX@4DNXN;0"QQ@%MWE'"Y/-7OV9?A9^VUX]\'75U^S1>:XWA.QOI(]3L- M!\01Z6]K?OG<;^V"B9-X)V2.=I_A !K:S5M7IZ>7EY ?W,HR[V FMRG4'[3 M,@^H\WAN@-6-H_YZV_\ X$V__P =K^.Y?V:O^"N"G:J?$- J@*O_ E3@ #& M,94ELC'S=^U3']FW_@KCC_FHH'3(\5NWX8VTG&_VFEUM;R_/]0/["]H_YZV_ M_@3;_P#QVFMM4'][;DXR!]IM_P#X[7\>O_#-O_!7'^]\1O\ PJ7_ ,*1_P!F MK_@KF<$/\12!UQXJ?C./]G_.*7)'N_P\OZ^[OH'].7[3O[4_PS_94\!3>.OB M)=M(78P:5HEA+')?:K<;2RQQ%';RE8_+YA''O7Y)>#?^"\WP\U?Q@NE>+_@] MJWASPS=726T>N0ZRM]=65O))L6ZN;=(T,F5(++D>6,DYQ7XD_M1?"C]L[P!I M>BZC^TW#XMDTN61HM&GUG5)=3M8IG&&#G'EQ *=RE@#GOR!7QC)''Y>S)8+" MRJV\-O\ ,ZE@,.6!.(^ISC%5)T8TW4JU8*%.W+4:5J4TDVFVK*VC_5Z M1C)V=DG*5J/+JW/17=M;_B?Z*'@CQQX<^(GA/1/&OA.^BU+PYXALX+NPNEP[ MRQRJKQ[@#E)4W*'YR#Q]>6^)OPTM?&,(O;-O[/\ $-@OGVM[$/+:21/G2.1U MQO)QP3G'2OC#_@E)IOBS2?V._ T7B[S//E>:72Q.6>2'2I&'V5B&^[O0KA<< M5^E>TX"9PQ.%+<\KP'Q-'V;J87 M%.*5/$4:T?>C*G)*7N-6:9[.4YWC\AS&GC*4:L)4$GB5.+]G6@VN>$XNW/&4 M;I)IV?GMX;\)/'&M:C>7?@SQ7I\\&MZ/$1]K:,JEU$GW'W=&) Y;@'KQBOS;U->(LQP6%WAJ;?).JU[]11G=13U[)7V[RT445 M]V?.A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6QH'_(8T_\ Z^$_G6/6 MQX?S_;.GX_Y^$_G05'XH_P");^I]3CH/H/Y4M(.@^@_E2USFP4444 %%%% ! M1110 4444 .'0_[T?_H8HH'0_P"]'_Z&** &]A_NK_Z"**.P_P!U?_0110 4 M444 %%%% !1110 4AZ?B/YBEI#T_$?S% '#?$+_D7Y?^NBU\[#[Y^G^%?1/Q M"_Y%^7_KHM?.P^^?I_A6L-OG^B,ZG3Y_H/I02.E)15F8A'&!CCID _ASTJ+Y M\2+\VV; E'.) .@;U'L>,<8Q4U% '/W7ACPS>,)KOPMX9NIU.5FN?#^DSS@K M@@^;+:-(3GN6//)K2M8(;./R[6W@LX\;/+M(8K:/;C&/+MUC0#' '85>I,# MT'Y4 1)D;0!\JY '9<\G&>!].]34G3H!2T %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'H<_Y]/UI:#T/? M@\8ZXST^O;I@TU-1A4GJN1ZR7?336ROJMK_>@O*^JYHV>G:UK]M=[?D0$Y)] MZCF(C5V:18E1-[LQQ%'$!EGW$D;L#H>G3'>FRNL<+32,(HX_FE9SCRP,?>/0 M8Z\?7IBOF;QSXVU;QSJR> O WFM;F1H]8U6$GRT3*GB'RN,W&'O*,+\TN:R:6Y]=POPO6S MRK.MKA=GS.UE;=[,9XY\;:MX^U=_A_\/W81N?)UG6 M&V^6?EE2-U[%-R2 'D'!]ODGXD?\$>_V3OB;JO\ PD^L1>*O"NNW2B369_!] MS8VMOJE^YW2S2VUTK*OF/DOY**6Y/7)'Z->!_ >D^!=&BM[1?,O)\?:;T)NG MD?@ON<_. #G))Z=^:[U'^ZS!4,6Z)=V CC^(AI.I&?O#/H.:^;\)N$\_PN*Q MW&W&^9XB>>YS%36"E-PP^649J,J=&--R4.;EY8R:5[N7H_6XJS3+\53PW#_# MN Y\!@?A&1^/K7[Q!<\>>$HRCW4H^7G MYW/SZ<)TY2C4BX2B[2C+1I^:>I-Y\^?];+CU\Q_Y9H\^?_GM+_W\?_&HN^/Q MHJ4T]OZL2TUNM_\ A_U'-=7+#'F38_WW->3_ !8^#_@+XWZ/IWACXH:2_B3P MQ8W\>J2:'<3W*65U=VSA[:2X6&1/,\LCA)"R$9#*<^W SSBI< _=(/&<9&?IC)YJ6K1C+I+X7W_K_ M #)WOY.SZ?GZ]!N.".Q.2/4TXD_Y_IZ4E%/EEV_(=G>UM=[?=_FO0****D04 M444 ')X !/8$X!]B>V:_!#_@K[XHOO GQF_8_P#%UEX^'O&=QJ]KX6 MT;8VH:RUK%'(NGV(VLOVFX93&B[3R>G6OWM89!&,YX SC)/09R,?F*_$W_@I MK#=-^TW^PU/8PW+K:?$B$M/;1221QE9-]&MY;WEK-\RWMO<6T@ M;,@9+F%HI3(K9+DAR0!D ]>E 'XS?\$9]+TV;X:?&;QA=.DOBO5/BKKRZO*R MJMX':YG;RY&<>:4&2 A.T=AWK]DK^"TO;*[L;V".]LKZVDBN+:[42V\]M.") MXI(\%&AP?WBL"#UQ@5_/Q9ZY\7/^"8WQ^^(6I7WP]U_QO^SO\3='KJ_C\AFN&EMT8_9M['S(SY?&[.<4&J;LN76R5^EOO^9^ MK&I>'_"7A?X8^+M*\':-H6C:3!X:U]XK+1;:UM+07$ME.99Y5LXT5YPQ)8R9 M-+R?5_%^H7-GK!U5; MZ5K^V6-)HPT:J$^S #+,<#DU^NW[)/P3\>?!C]EOQ3!\3M>U?7_'_C#1/$?B M37HM2N[B_;1Y]4LYIWTBU^T/*$C@R$0+MQR*\C_X([I=P?LU>-XI8;FVE;XT M>-W198V1\?;F*.5F 4,N/XVZ?U^1^;^I?M _M]?M_>(_%' M[(_BRT^&/P0FAN;>V\8Z0HO-&UJ]@@N"LSVECJTGVO5(8T_>2M8C;+$5(R#Q M_1#\!OA%I7P+^$G@7X1Z-<-P^VE<+=7ZHIOKM%Y8*TQD:))"2$(! MR:_-C_@J)^S3KMY8Z!^V+\%B^F?&?X+W5K?ZH=.MY%NO%GA^SD66Y2ZDME#R M_9$4O,K;C.A$9R@ K[L_9"_:+TC]ISX(>$?B3:!K+69+2*V\5:8\1BN;7Q!' M L5Q$T;@%4D96F("@X;'7B@R/J+L.6)QRS?Q' Y'IGT_+BBCT)Y)'S-S@D>@ M[8Z&B@ HHHH ***!1>VKV6X?AY^?3\1K$!",9!X[D]/S[=!CVJE*T", D\ >O&<_7']*@./F55P<; MBH)W,H.-P/0?@>?YZ4VH6E3;HNRENU[MUK9/T?1LTI.K"\^=N45&3ES--*RO M;9==->YXKX8_9_\ A+X(\?7WQ/\ !OA&Q\'^+-3A^S:S<:$CV-MJ4);)>:RM MV2R$A;^-8 WS_(..M*I_B9E+J5IWDYU-%9W4KK3=]EYJQI5Q=:LH\U>< M[I-.4G)\NEKMMW3[7[=B3S+C_GK+_P!_&_\ BJ3?/_STD_[^-_\ %4N0.N?R M/^%&1[_D?\*U5[/D?+)*^MNEK_/^NFO,IRB[RJ5)JZ3BM7TU^6GW^8HN900' MFD&3C.YSSV4[3D XQN!!&:X3XC_#_P )_%;P?K/@+Q[I-MXB\+:[#Y.IZ=?I MYT)CQ\K0*^6$J'E)$Q(I^964\UVRY+!P.6Z <\<]*7YLAMJ2!6QNW $, M/F( [X((],YK*EBU2?9!?%Y=^_:I3<+.5"I3 MC.2G%Q2B^=>=GH??9#Q]7J5*F"S^I',SC)7JQ2?NN$5?IMO M?0CT/6-/UVQMM3TNY2>RNHQ)%@@R*2H/EN <+M..O?\ "MGS,C(]<;3C/;TZ M''K^=?(KQ:Y\#]?,L+3W_@G4KC)8;V^PI(2-PR"JJIQZ?A7U%HNLZ9KVG6NI MV%RD]M%WBDN)WBN'^)(?V3Q?EE)4<7@<7"%* M&*=-*/UG".5E-55&Z:^U+9G+Q-PO5RVC'.M.K%7E& M4&VNUK&RR@\]#CIG@9Z9Z^GUZTX!1]TYZ9_+_'/]*B4YY<\\=NI]_P#/Y5(N M.<=\?Y__ %U^VI^UI4O<452C?WTN>^BNFKKTUNDNA\,DFI\RM.*34^D[\NGR M70=1114D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !^'\_P"E03Y*[&6X8G MDM.SDGJ:NW5E9WT365]I]E?V3C$EEJ%K#?6"O!>E72M\MYIGA70].O$4_-A;BSL89P W(P_W MOFZ\UNNB.TBR()$D4AHYHUFAD5P-Z2I(K)(K@D%7#!@3D$_"^A7MPA2YO=#\/:3H]W<(S;V6>YTZTMY M9E=_G=7'$N8Y,[O,2Y73A,KYYW! MP03G.:Z3)P$2-414$:1HFQ(XQ@A$5=H101T4"KE% &(NA:*FHG6$T+1$UEE" M-K::/IZZT\:@JL3ZN+?[>\0!($;3E .,5L*N,Y Y&/ZXZ\8/3&/:GT4 8.J^ M'?#>MRPS:YX:\.ZW-:L6M9M9T/3-4FMV)^]!+?6L\D1X&#&RXQ\N*UH(XX42 M&&&**&-=D<4421QQ(!@)&B*%1 !A5 X %3X!Z@?E1C'0 ?A0 M%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4$XZT4?44TF]%Z@-!)R<]R!_2F'Y=VYMH(P6 &XC^Z!_D_G2C()(&1 MSD=._3'M]*KW5U#;127%PRI;Q([3NY"^5&HW&0,?ERN.YSQ6&+QN&R_"U\;B M:].A1P\)2JSJN,8125VI.32MW?\ DS;#8:KB\11H4Z?/.=2$::5[RFVE%*R; MO=_\%"SW$%O%+/++''#$F]VF*H(U4 M'8)1!J6KQ[OW\9.98MR?P\$=<<\'DU]!^$/!^D>#-&@TO2H$"QJIGF**)))2 M,MYC ;V56Z9YSQ#XU\2+*>&,5B9=7\_YFR_PNX%R7.:G%>4\,8/! MYWCL17JXG&_5X0A)UZCG.4+022#QW[_ .27\R>/KGG'^32-++MP[2G)&TASA3G M.X\].,<\&G$'&1C\?\YIA<@'CK@8!!W9Q\I^O7\*?/5=H^[KWLE;36^MDN_0 M:P]#E'KF. M]TZQOI+@Z?'=H0R3M:HX@GD5AE3-&X'('!.?0-+TW3]#M([#1=.LM'LHE"1V MNF6D%C H 4>7;1Q*Q Y8$D\G)JZ1RRO@$$!%XVN?P.<_7@'Z5)N]1M/''7 MGVQU_+VI1Q>7)'JKZV\]-;+H>;_ &!DM/&5L>LLPKQM10MB M)4*?M>73X:O*Y)IN^][[,;NX(;)8YZCG\3U/YY_(4Y&)!]\=NW''/3Z&?@;X[^.,VK1M"VD>"(A)>Z>%E/[Z;?#* AZ, M< >AXK^F%?\ 6*>?D#= .I7Y0,\\GN/QK\4/V2UO+7_@I3^T;+Y=U;AM/"F9 M1,D;GSRV(W&$9O[W7(- '%?%C]MS]K_]I#P?JWP@^$'[%7Q,^'6I^+K&;2=3 M\2_$B,1:99V=]NA8VL\5O$D4H$C9:X8KY>>.*U_C-\#?&/[)7_!)7XF?#Y[T MR^+Y_#]QJ/BJ[LG?9;SZI=V]Q?VD$\6"?)F9XUD5MKID X-?NB][=R@))=3R MISN261RDF1M_>#<> ORKC(X!KR_XP?#?1OC%\,/''PL\01I-H?C3P_>Z-3-/&WV,KDEZY MX?N4274M+UFWCGL]JL&CWI,K1A48 AB,CC)Z5^!'[.7[3WQ*_P"""?B-IEA<:A8V^AW,^]+>+?VO]('P'_8O\(^-=2_X326'3-=^)L^GWNE6NBZ5)+']J,$\L4?4]3U6XTB.U3[/>265I,65EC DG4*",D\8KZ"_;N^&MY\+/^"?7@KX>7=_ MJ?B+6O#MYX4M-7U.\FN+^_N]56=6NIS(S2R/^\)&XL5&,G .:_27X#VJ7?P% M^&6G7]L)K:\\#:78WEG<@-%Y$NGQHZM&_!,VYEA:__P $X?VR MM+^)/A>VU0?L\_&+5/LOB'3M-AN)M*T75;R9=SM;J&BBR[LV[:!SP:_?K0]; MT_7]*TS7-*G\_2]5L8=1LY>GF0W*+(CE>JC$@4J>0:SFDG9+IY@;'';IVSZ= MOTHHSGGUYXHJ0"BBB@ Y X]G.W/'S8Z ]B::UVM=>:5OQ_IB33?+?WNQF:E96FK6 M\MEJEG9:I9RJT4EGJ5I;WEHZ/\KJT%S')%@KD'Y.E>-_#S]GGX1_"7Q/XB\7 M_#3PG:^#]6\52!M>L]&>:#3;^Z4,!=-9*XM$/)QY4*KSQTKW J#YA+* IP>> MN>WJ.O.13%<^7$_R_,3$I ;8J@XR2O()(ZMTHYG_ #._J_+_ #_K4?6W7M]W M^:)(I;@$*TLW'!S*Y)/.2#GH>,8XQC%6O/F'267_ +[?_&J8PI'.<=2,]<<] M>N#[FIZ$W*Z3;MOJ'];>G^:)?/G_ .>TO_?Q_P#&H7EFZ"67D?\ /1__ (JE MH_"BWI]Z_P P/'OC/\$_AW\?O!UWX!^*GAZ'Q)X>O02JSC_2;.;! FM96.^- MU&"NUL$CGW_.+PY_P15_8XT'7_[?;_A-M:5;DSVNB:S=6QTBV=#F- D(6>2* M,X*98C*_,",U^OISZY)!VJP^4$#[V1R6[ #/TJ%2O+'#J48_.[$@@'(1<[LG MOGIQGH<^&GU#]GK4K+PC-:O_PKS=':Z)Y:?N[" M%<(H)QA55=IP3@8SC-?6NGW=IJ5M#J%C<13V>C=*^:]+U/7?@EKRZ+K/F77@J^ MGVVM\HD=+)V.%61FSPN<94X[#C.?Y8699_X(<1RP^VDT=W;W,0FAFA.5<$95.O#$9Z]QZU?;802ISC (]&[@]>1WZ=17]3 M99F&!S/+\)C,NQ#Q.!Q=-3HUJ;@Z;HM*I"TH2^)NU[]+I]3\GQ.%KX.NZ>(C M*FXRE1=*47&5*4-&XIV5I-/LG>RWUEHI 8_YUC5L>'_ /D,:?\ ]?"?SH''5I/9 MM7]+ZGU..@^@_E2T@Z#Z#^5+7.;A1110 4444 %%%% !1110 X=#_O1_^ABB M@=#_ +T?_H8HH ;V'^ZO_H(HH[#_ '5_]!%% !1110 4444 %%%% !2'I^(_ MF*6D/3\1_,4 <-\0O^1?E_ZZ+7SL/OGZ?X5]$_$+_D7Y?^NBU\[#[Y^G^%:P MV^?Z(SJ=/G^@^BBBK,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *7GG'49(^HY_S^5) M1]>F#_GUJOWCY4XJ<%+F<;VM'2TI7T=M_P"FP<4XNI-V4))+U]UZ^6O]=?*? MB=HWC+Q#I]MI'AB1+>*\?&IW.[:RVY.&VDD'('0#T%:O@3P%I?@G2EM[,*VH M3!7N[T@>9+(V/,W-R3DYR3WZUWI./E Z'.>_T[CO46X D%B,$M(W0J#DA?I_ M+/XU^>Q\-\A?%U3C7&5*F89FH^SPT:T54C@XOK0A4E:,WS-*<;/LCZ:7$^9? MV+3R.#CA\)*495?8^[4Q,?=M&HXV?+&RDTV^J.=\8^)M,\&>%_$/BO5F\G3? M#VDW6HWC%RN8[>,N4'.T&1MJY/KBOYG_ (P_\%"OCKXZ\9:IJ/A7Q!+X5\-6 MMS/;:5I<:!S';P2,D#R,3AVD"EF;OD#I7]$WQWT_1M;^$_CCP]J]ZMC:^(=" MO--BD!3>\TL9,*LI(/S2(O('?KTK^1[QS\,_&G@76;C3M9T#541KN>2RN([& MY>"YM/-<12?)&RG>F#UY^M?COC%QMB\-FF%X>R3-'/$4X2K8O!492E5IQ2O! M572OR33M:+Z-):-'^@OT&>!?#G.Z>?X[CC!X#$XZ/+'+WF+ITJ/(^2ZINI%* M6C:=NMS]?_V-O^"CUS*;[PC\?]4B"Q6XN-%\3,BH9VC_ -=%-MSSMQM#?>/K M7Z#_ /#='[-"'#?$"Q##&?F]>H/;C/Y#O7XB_L@_L&>)OV@;B^U[QW!J?A?P M-;P%K.??\ PH_X;K_9H[_$&P'U/_UJ^13_ ,$A?A-G/_"8ZX3[$<],8PW'Y^O> MD_X=#?"?_H<-=_,?_%5]4\P\596:RW+VG&-M-4FHV7PKIW[KN?D<^%/HF7:? M%'$+]YN+<%HKJR2]M\*V7E?HM/KC_ANK]FL]/B!88![/_7'/^?2O%/CO^WI\ M.M'\%2Z_\)/&^D:GXHTFXBG_ +$O-IMM0L\_OXRP'FF0KP@ //0&O+_^'1/P MF_Z''7/^^O\ Z]>-?'+_ ()B^#_A[X*FU7P->^)/%/BR\D6QT?2(H_,C>XD; MY;F8ALK%!SO. !GJ:X,QS+Q5IX.M-X+"4DH:RHJ\[67PV2OW\_N/I.$^$OHF MU,\RR"X@SK$WQ5-2I8F,5AYQM9QK-UFJ=/\ FERMH^@/@Y_P5/\ A3XPDL]/ M^(5G=>#M3D9$EN26DL)9), >6QRT<>1G#;0._O\ H#X;^.WP@\56\4NA_$#P MU>BZ=3'&NI6T*)K?4_BIJ\'AC2CLE M?3(#F]D!YW,_)53R,<#-?HU\/?\ @G%\"O HAG5M=UAX)E<$W\MK&7&TD@PL M6^]STQQTQ79P=F/B%6A3GF& A6PZDKU*C:J):?"FK^CWTO=)GC^-_"GT9)CP=G^._M%OF2P\88G!<^G[JG)U(Z= M\YX]^.:P=1\,^'M9N]/O]9\/Z+J][IL@FTZ[U/3K:]GL92W$EC).C-:2 8D MA97/QUC3[#5K&1LM9ZI:17=LY)P?-MI4>)NX)(R*Q=)\ >!?#]P;SP]X& M\':'>L-KWFC^'M.T^?;PI+M]\[JZVB@=VMKHK36R2(T4RI+%.-DT,C, MT_M9HI$O()T$D%S;2 JX MFM6!@D5ER'C8'%_#?A>V>T\,>'-%\-VUQ)]HDL]'TVUTVWGG&3] MI=+-$7S'7 )(!K>HH$*3GIG;V/J?X\=\;NE)110 4444"=]+6\_^ ,WCWI#( M "?0$\\#CU(.0/I2;=Q;G&#Z>YJ*6,NC1GHZE3U&0PP<-U!]QR*3;2;2NTFT MN[6R^8[V3=FVD[6[]#F-9\>^#M"1CK'B71K'RSETFOX0Z>H*&39:V6ICQ+J.W;]GTT^9"!]Y4\Z,E1G(SELY^E=CX[_95^%WC MF2ZO=0@U2UNKQB9Y8M1EFC=VYW>6QX_3T]:^.?B5_P $ZXX[:6\^'&NNER@W MBQU#YDG.D::WS74K;N)')^\"G!QGD^]?1B?M8_ S&1XOM65E;.0JD-\DGB762%8ECQ@_7YL?ID<\5\1PYG?B[7P%&?U##5'>46\0W"JW%QT MY>27N?RRO^-CYC(\S\2JF!IRGEV'G+FE&]>34W9K[/*[I=->NJZ+Z0_X:R^! MG/\ Q6%KP/\ GI^O(Z ?CZ4I_:R^!?\ T.%L._E?3<^CQ^UC\"]P(\96V1 MS@-GGID ]2/?Z>U>._&O]M;P'X:\%3S?#S5(-<\379-I81D9CM"<8 YKR/XT_L##PGX-GUSX<7^H:_J M]@3->Z9,JN[V8R6D@&\0S:A_9D&A:E)J4CO!]B6RN0\-\SH<7T,MXAS"K1P^:*M!4,=4J4?:5(Z)0<_=O>UDGKK?<\CP.^"? 'BOP-XGN+>PO1=^$+EWE6"0Y,#')"J"> O& M, =*]T3IN)S\IC.1_%W'7OCIR!QQTJ3(Q]WGUS_G\OSK^B\^\,>'>(.>KQG/&>O/H0,?Y_ M$4FUCC@X[9_S_GBI, 8!]>,@]?Z?Y/O7Z%33E33IJ\*VT5%76]]4V^Y\ MLZC<::NY1E4G)3^TV^DK)62MI?S'44450PHHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB MG'E4E)NTHZI=[?\ !_K0!OW1DYY.>GK_ /JKQSXJ^&?&/BT:7HN@7(L]%N4D M;6KM7*RAMX A&#NP\6>@P3P>*]?;.2?9R'@WPAIG@K2X-,T>W2 K$GVNZ*CS+B;!WL3CEB M>H_AXV\O_RZQL2N/OO@D;A[]!]??F\Q(ZGI^F.YZ=N]>>_$ M7Q!HFA^';_\ M:\2(7B*+8*P\Z1\\(%'S'GCWK\\\07EWA?X3<2?ZO5,)E=; M+LBQTLO@U%>TQT,'+ZLXV5ZE>59)=9-OK<]?+?K?$_$>&Q&+5;%O%8VFJ_-> M7+S0S^2JG]U&I.%4$A5X/3IW[UWWA3Q M^DD'D:U.L4T14K*1_K">""2"<+Z]>M>'PF62WANHH;GR[E!)#^Z8Y0Y"YXSS MUS7I7ACP&^K0&YOVE@C.TQC:5+,QP0<@9 &#^/3O7^!G@)XN_3$S?Q>QD^'7 MG6=XJIBJ]6O@\[ABH97&A4JN=/XU.')R-*%HMM'QEH)D.-0AZ9/3^?'MUIW_"9: /^8A"# MCGYA],]1VX_SBN/_ .%5Z8S<74N/\Y]_T-2#X5:;C(NI/;)!..N,]3S^8YZU M_I\^-?IV.TI<'<*3NKI.M*#@O=T]W"RWZ=+=.A^-_P!F>&,6_99MCFFU>-K< MK5DU\7R7YW9UO_"8Z 1_Q_P'CKN'\BWIQ]*8?&&@*,B_AZ_W@3@D=@3DCZ<_ M6N0/PKTSM=2?F,?4#/Z=A[\T?\*MTM>6NI?;![YXZ9/';GGZ\TO]=OIU12:X M)X4=K:+$3;WBG9?5K:7?9+3YO^S_ U6JS3&MJUKM/T^V_RL7_$'C2SM(UN- M*O8KB2%P[QL/O!LDJ .;8[Y6M9R< DY7@\^V,G/?'3I7 M,ZY\/(=.@8V#3W=U*Z^6<9VYZ\\\#&/;WZ5%HWPSNIE\[5)O)1CCRU.#SCCC MH>F>.G45^$S\1OIX4?%J.&PW#-*>"JJ"QF#?//)4F_?_ 'CII0EKTAIZGU=' M*O#5Y/4J5,5'EY?W;T^L\ZUVT>]NNZ[H]AAUK3+D?N[Z*0M]TB1%Y(Z;0021 M]/;)K44YY5]RGTYS^(].O%<38>!M%L61_P!_(8\88N=H(ZY' [#FNQMXTB3R MXEPBX W,2<=L>O\ 3FO]0?#'-O$3,,MI?\1"R;"Y5F7LZ=E@ZLJM)RLK\MZ< M&TO.*Z^A^*9QA:3MJNCN^W6T]%%%?JCWYKJS5K M**CJK=GKOV1X[:=N7X+>[WOI>]OEZ!1112$%%%% #67*MC[QQP"02 >2#VVC MGM6+:>&/#NG:C<:I9>']&LM7N^;O6K'3;2#5+]<9 NKU$$\B@]0SDUN44 ,V M#WH**RE&!*G!;G!('(56&&7GGT)ZT^B@+M;&'K/AGP[XD@%MXFT/2?$-J@.R M'6M+L]2%M&_)CC6Y1QR<<>F:K:)X.\*>&,#POX4\/^'$?=YJ:#I5EI:2K_$T MJVT<8W'OC.>372T4#YGW?WF+J>@Z1KL#6>MZ/IVMV+L93::I9P:A9N"1L8P7 M2NHE4\J0H(X/:K]O9VUM MM:VZ6]K'&D5I90HD$4$$1PD44: +&D>,JH &W M%6Z*?-+NQ&'K'AGP]XD@CM?$7A_1O$=I$1-'9ZY86^H6BR+RLD4%RCHLH. ' MP"",@YZ7K2QM[&"&VL[>"UL[9/W$5I$L<4" 82VBA 5!''P%4#&..V*O447; MWNP$!R >>@ZC!_$#@'V'2EHHI %%%% ".Z0QO+*1&JC)D^,7PN\-I)_;?CSPYITD)82"34[-""HR5=!-G(_ND4QC888*R_,>IYZ]N]?$/Q-_X)]_ 3XFR7-S=V^NZ?=7;R337 M,6JSR+YT@.[;$2%Y.3U'''3IY.;U5NZW_JZV.#,*F: M0@WE^&HUZG*N5S:36B2T>]G^9YC\9_\ @J!\!/ANUUIOAB:;QMJ\>X.NE[&M MBR@@#S>A&[KM)XZ>E>;_ +.__!1[0/&TWB'Q5\9?$>D^#]-DNC!X=\-6Q)F7 M3XLJ)KW<,F1CM)(Z]J^>?C9_P2%UC3+=M6^#?B,:@$W$Z+JI42RXRP*W )8' MIA/8_$&A_&"#Q-X,\6Z#=-BY"L=+OX'R8_)=CM8#C M."<"OQ6KF_B0LUITEAXQ3(JS-1G2A&ES/V< M(*\;72L[*W;9/3I8_6<]?KUKZEX_Q+]WFP&7\K2;4=7*W+O[GX:_(]]8OQ"M>."P< MX63?,TI=.Z??9_+S^P/^'@G[+?\ T/\ 9_F?\*0_\% ?V6CG_BX=GSG^]Z<= MOP/J*^/C_P $;_A#V\::[[@E<_ENZTW_ (X__ .A;@NE](Z;?W?7\#5_:R_X*7>"/#7@J.V^! M.MV^O>+=3\R%KUMQ@TJW92OVC;P6E!)[=/U_)?PO_P %!/VF_#OB2T\27'CB M?688KH3W>BW4:?8YK#(?%_PBN= M6\7/8/YFKZ=)&9IUMU'S,BIN8JHSVQD'@U^5VD^ _&>O:J-!TOPIK-QJ4DQ1 M[0:?> QN>&5LPA0$;DY(X'3BOR#C3.^-\'FJJXNKB,+]7@J\Z5",GA8TXOWM MG9RLF[6^\_->(,PXXEG6&I*&(I8Q8BFZ=#")JC)7CI)Q2C?I=II/M8_L9_9V M^,-G\>?A1X:^(EM'%#-JMHBW\,>2+.Z1$$L*\'[[]6P"O->I^(/#^F^)M*NM M+U.W\RUN(C&D3@.8'(^62-N3\IY'X=Z^2/V"_"-IX ^ 7AOPBUV1KELC76L6 M9.R>UN;@AC 5)#=20>.W;FOM?(/ &T@ ,.!@D=,=L?E7[MD-;)/$?A"C2Q-3 M#YAA<3@I8?'17).E.IR\KI2I-WC5N]&[.-^Y_3>25<]R>CEU?&*M@,S4*6(] M^+BT_=O*3TYHM+S6OG8\1^&7@KQ?X)UF_P!,O+IKOP<\;2:=-))OFBG3_51A M2Q*I@D$<;J?5G.7M/94G)MJDN;D2LHI*R/1S_ #G&YYCE MB,?3I0E.,%*M127M'#E]ZT4M96U;_P"&E3[OU/\ ];^E/I%)(&?\\TM?7GCA M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !6SX?YUG3QZW,?\ZQJV/#YQK. MGG_IX3^=#OT'&_,K;W5O6^A]3CH/H/Y4M(.@^@_E2USFX4444 %%%% !1110 M 4444 .'0_[T?_H8HH'0_P"]'_Z&** &]A_NK_Z"**.P_P!U?_0110 4444 M%%%% !1110 4AZ?B/YBEI#T_$?S% '#?$+_D7Y?^NBU\[#[Y^G^%?1/Q"_Y% M^7_KHM?.P.7/!Z=_PK6&WS_1&=3I\_T'T4459F%%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !01D<':<'G&<<9_I1020#@^N3[?3U]J?-&$6Y:J&##CW MZ^U?@OBOXH5\FQ5+A#@^@LSXQS*,:&%H0(AK^ MMQRV7A6"8+:Z:VZ)+A%?"-1AMX-1\,:)J26J)' ] MU802N@B&% =E.5_G[<5T6GZ;:Z?8PV=C"L%O"BI'$%";0HQN8>XZ?GQ6G'&$ M3 (!X/3KTS_GZFO0\,?"JCPI0Q&:<0QAF_%&<\N+S;'8J/MG[6I:3IT92UA" MD[045UCTN:9[Q[F5:I"ADN)Q&4Y7@&Z.$H8&I*A-Q5H*K74;.3G>]WIKJ]#, ML]/LM.MH[/3K6VT^U@79;P6<"01VZ],0K& %_(^U:48P@'H>N,?YR>3[T^BO MV:%.G2@J=.$806T(Q48KY+0^$Q&+Q.+K3Q&)KU:]>;;G6JSE.I)O=N4FVPI# MG''6EHJK+LNVQSMWWU]2'([C)^O7_"HG16(D*@R)@H^ 63:#PA(. V?F'>K= M)@>@_*DXQ:LXIKLTK%PJ5*;4J@W=2!AB.RG_9'8=C3 MEXVA<* <\<>YJ1AG ]Z=3BE&SBDN7:R6G]6)G*52SJ-S:?,G)N3YM-;O6^B& M.H96!&[)#\[R2;M;5+;M^ FE*_,D^96=^J[,K;%9E8QHSKR'V#?G&,[@,D@<#M3SO* ME?FP6W$XYSG/6IJ*22C;E2C;LDOR012@E&*44MDEHK6_R7W$7EMZ_P"?R[__ M *J-A]O\_A4M%-Z[Z_+RL5=OK_7]?UN1A6'(QTY'7([@C'(/I4+ID$$?>&U@ M1D,G3RV!ZIVP<\=\T^W)* M78#^:6\L87H"F ._/I7TL_.6Q^ X'MZ^M0LBR1D$ /UW$;LKT,9'0J>YQ7YE MXA^&64<(RS,\)&-*OA,1&,72J1J0L[.7*II;J][O4]_A7 M/9\-8V]'#8>6$J7CCJ#A'V6(A-^\N56N^5Z:^7KYE\.OB)8^,M._>;+;6;8> M3?:>_P DJ2)U94/.:CHVI?\ M)QX%$L&H1-]IU&RARD5RBD;P$'#EE)R,?TKT3X;_ !&T[QGIQB8I::M8 0WE MC-^[D>5.'8*QR<]<@=>E? ^'?B'FF49I1\/O$2:PN;X3]WE>95$XT,XPT+0I M2A4>CKOE2:UO:Z>ME]9Q'PMEV)P4>)^'(N>6UY>TQ6$A9U<%6>LTZ>ZIV.@],\9^I&2*! M_M%C_G_/Y5_1D7S.I--\DDDFURW>EH\J\OM/?T/S5*-.G=4ZD9U)VU];DXX]3]:* <]C^-%(04444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1112TNI-*\ M=4[;#3L0MD,?KFD+_,H(&!DMVPOY'IV^G-/))!Z8SCOGK_.N+\:>,]*\$:1- MJFIR)N"-]DMOY>1Q%Q)EW#F48O.LWQ4,)@L!3]I5K5) M\D4EJJ:WYI57[D8?:DTCORO+L7FF.P^"PE.=6M6FE"G"Z;::?,W9VBEN[=!? M&_C/2O!.D3:GJ$M;^*VN#QAXP$E MKH-M-G2]*;,:3JK?(S(?O ^X'IWI/"?A+7/BUK:^,O&AGAT))_,TK2I,JA"$ M[6\LX&T\'/MWZ5]5V]I%:Q6]O:010PV\8B2!2!&$48## W#KBOY:RK).(?' M?/5Q!Q'0J95X<8'%+^R,KJF!TY[T] !D D],D]^O_ .K\*48RV/;/ MI^%?T_E?!W#>1R4\IR;+<%65*&'>(PV%IT:LZ5.,814IQCS-BW>UNHI&1CU_EWH P,4M%>Y&DJ2Y8J*3;:2 M5CD;D_C7ZZ67Y=NC(L9<@_I^G]*5AA< #!X/')_SWJ2D(SUJT[--:-;:+^NA M-D^G]:?Y+[B-\'#8Y)W<=B.F/IS_ )QAFS=R2?DY R0,]>G?IWJQ16/L*//* M?LJ?/)WE/DCS-K9MVN:>TJ.UYRTT6NB7:Q!DD8/.3T]?;Z'_ /54H&!T&?8= M!TQ_GUI<#K@9^E+6[E)M-O5*R?9+H+FE9QN[/=='ZA1114**C>RM=W?J3Y= MHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F ?O#=S_ !U(5 .X*H 7H!QGU(Z'(ZTZBJ4Y+12:$U>U^FV_\ 70KGD%>BDY*+PI/J M0.II6&XABBY VDA -P'0.0,MCWJ?'M^E%0TF[N*;[V5_O%RQNGRJZT3MK]Y! MT/3'L!C_ #_A^=2!CD97VSSW_P @T[ ]!^5+248QO9)7WT#DCSHR" 64XP>#C)&#Z>_\ ]?BN;$Y9A,?&4<3A<+6I2A*E44X)S2FDDVWOS7L^ MG?L1[.@IPK5HJ/).+C545[2,E9I\VZ5UOY(^8/&_@?6/ >L)XY\$%OLPD,VK M:5'\RLHR7)08P<9P<''O7L7@3QQI/CC3(KNSD*W<)\N^MF.)XY^I3RR=V%(( MW8Y'7&:[F:.&X$RS1+)'.FR:,@%95Z8(/3/<_3WKY@\<>"-9\"ZRWCOP$LGE M1-YNIZ3"Q$3)G+GRAP?EW$MWK^6.(,ASOP4S^KQ3PG2Q.9\&XFO/$<1Y&N:< ML!.:3GC,'25TJ=.-IM12TBVWJ?L>6YGEO&V I9%G-2&#S>A2</\ IY3^=#=M1Q=FF]DUMZGU,.@^@_E2TB_=^F!^8S2USFX4 M444 %%%% !1110 4444 .'0_[T?_ *&**!T/^]'_ .ABB@!O8?[J_P#H(HH[ M#_=7_P!!%% !1110 4444 %%%% !2'I^(_F*6CH"< XZ9Z\\<>Y^AH X7XA? M\B_+_P!=%KYTRV=V.O'^??BOJS6M'MM=L_L-U)JGZ30_ M_$4?\*NT'_G[U7_O]#_\15\R[_U_7];DZ_\ "KM!_P"?O5?^ M_P!#_P#$4?\ "KM!_P"?O5?^_P!#_P#$4Z_ M\*NT'_G[U7_O]#_\11_PJ[0?^?O5?^_T/_Q%',N_]?U_6X>S\_P_X)X517NO M_"KM!_Y^]5_[_0__ !%'_"KM!_Y^]5_[_0__ !%',N_]?U_6X>S\_P /^">% M45[K_P *NT'_ )^]5_[_ $/_ ,11_P *NT'_ )^]5_[_ $/_ ,11S+O_ %_7 M];A[/S_#_@GA5%>Z_P#"KM!_Y^]5_P"_T/\ \11_PJ[0?^?O5?\ O]#_ /$4 MS\_P_P"">%45[K_PJ[0?^?O5?^_T/_Q%'_"KM!_Y^]5_[_0_ M_$4Z_\*NT'_G[U7_O]#_\ $4?\*NT'_G[U7_O] M#_\ $4%45[K_ ,*NT'_G[U7_ +_0 M_P#Q%'_"KM!_Y^]5_P"_T/\ \11S+O\ U_7];A[/S_#_ ()X517NO_"KM!_Y M^]5_[_0__$4?\*NT'_G[U7_O]#_\11S+O_7]?UN'L_/\/^">%45[K_PJ[0?^ M?O5?^_T/_P 11_PJ[0?^?O5?^_T/_P 11S+O_7]?UN'L_/\ #_@GA5%>Z_\ M"KM!_P"?O5?^_P!#_P#$4?\ "KM!_P"?O5?^_P!#_P#$4S\_ MP_X)X517NO\ PJ[0?^?O5?\ O]#_ /$4?\*NT'_G[U7_ +_0_P#Q%',N_P#7 M]?UN'L_/\/\ @GA5%>Z_\*NT'_G[U7_O]#_\11_PJ[0?^?O5?^_T/_Q%',N_ M]?U_6X>S\_P_X)X517NO_"KM!_Y^]5_[_0__ !%'_"KM!_Y^]5_[_0__ !%' M,N_]?U_6X>S\_P /^">%45[K_P *NT'_ )^]5_[_ $/_ ,11_P *NT'_ )^] M5_[_ $/_ ,11S+O_ %_7];A[/S_#_@GA5(Q.#C([9!"D?B0>O0CN#7NW_"KM M!_Y^]5_[_0__ !%!^%VA=KO51_VUA/\ [)2YH73:4G'6/,FTF*5.3C93<6FK M26]M-.OGY:['R1XT\ :3XW-D-7FNEBL)UD2"&79;SD'.V5/XP>_3CC'.*Z_3 M].M--LH].M(!;VD*+&D,*A2"@V@\#IW_ !]*^@S\*M#)S]MU3KG!D@//K]WU MJ3_A5VA]?MFJ9/4^;#D_7Y:^;PW"G#F&SO$\0T\LPRSC%TXTZV-<+UG&,U-* M$I7Y8I]$NG:YZM7-LRJX.EESQ=3ZE3?-[%MM=P!RH_ =QYG)9II^]]J5M9]KZ]+:?\-;PJBO=?^%7:#_S]ZK_ M -_H?_B*/^%7:#_S]ZK_ -_H?_B*?,N_]?U_6XO9^?X?\$\*HKW7_A5V@_\ M/WJO_?Z'_P"(H_X5=H/_ #]ZK_W^A_\ B*.9=_Z_K^MP]GY_A_P3PJBO=?\ MA5V@_P#/WJO_ '^A_P#B*/\ A5V@_P#/WJO_ '^A_P#B*.9=_P"OZ_KJ_]_H?_B*.9=_Z_K^M MP]GY_A_P3PJBO=?^%7:#_P _>J_]_H?_ (BC_A5V@_\ /WJO_?Z'_P"(HYEW M_K^OZW#V?G^'_!/"J*]U_P"%7:#_ ,_>J_\ ?Z'_ .(H_P"%7:#_ ,_>J_\ M?Z'_ .(HYEW_ *_K^MP]GY_A_P $\*HKW7_A5V@_\_>J_P#?Z'_XBC_A5V@_ M\_>J_P#?Z'_XBCF7?^OZ_KJ_]_H?_B*/^%7: M#_S]ZK_W^A_^(HYEW_K^OZW#V?G^'_!/"J*]U_X5=H/_ #]ZK_W^A_\ B*/^ M%7:#_P _>J_]_H?_ (BCF7?^OZ_KJ_]_H?_B*. M9=_Z_K^MP]GY_A_P3PJBO=?^%7:#_P _>J_]_H?_ (BC_A5V@_\ /WJO_?Z' M_P"(HYEW_K^OZW#V?G^'_!/"J*]U_P"%7:#_ ,_>J_\ ?Z'_ .(H_P"%7:#_ M ,_>J_\ ?Z'_ .(HYEW_ *_K^MP]GY_A_P $\(;.W\LC_/O3 0JEB>=P4+W. M>_KQ[5[T?A;H747FI_3SH2?_ $$4G_"KM#_Y_-4_[^P__$TE4CJY1235WT:=UO;6_?<\",0&03+M< -&.=P( *X*_F,= M/J:X"#X9>'[3Q2_BNQ26SOI1B>*&0):R$]2RJ-I<]>1U%?7O_"KM#/\ R^:H M/?S(?_B33?\ A5NA_P#/[JW_ '\A_D$KYK->%L@SK%8#'9EEU'%8W+JZKX;$ M5(ISI233C[.2M*-FNK:UV9ZV!S7,,OIXFE0Q$H4L51]A5IQ;5.4.[B[J]K*Z M^^YX,R@8P21ZD_KQ]??';I2#.1QWXR.M>]CX7:&/^7S5#]9(/_B:&^%^AG&; MS5?PDA_^(-?2*JW%1D[OF7O-;12LHKM;17^\\WEE:W.[=5T>M]=>^IX717N@ M^%NA][W5?IYD//Y)2_\ "KM!_P"?O5?^_P!#_P#$57,N_P#7]?UN3[/S_#_@ MGA5%>Z_\*NT'_G[U7_O]#_\ $4?\*NT'_G[U7_O]#_\ $4%45[K_ ,*NT'_G[U7_ +_0_P#Q%'_"KM!_Y^]5_P"_ MT/\ \11S+O\ U_7];A[/S_#_ ()X517NO_"KM!_Y^]5_[_0__$4?\*NT'_G[ MU7_O]#_\11S+O_7]?UN'L_/\/^">%45[K_PJ[0?^?O5?^_T/_P 11_PJ[0?^ M?O5?^_T/_P 11S+O_7]?UN'L_/\ #_@GA5%>Z_\ "KM!_P"?O5?^_P!#_P#$ M4?\ "KM!_P"?O5?^_P!#_P#$4S\_P_X)X517NO\ PJ[0?^?O M5?\ O]#_ /$4?\*NT'_G[U7_ +_0_P#Q%',N_P#7]?UN'L_/\/\ @GA5%>Z_ M\*NT'_G[U7_O]#_\11_PJ[0?^?O5?^_T/_Q%',N_]?U_6X>S\_P_X)X517NO M_"KM!_Y^]5_[_0__ !%'_"KM!_Y^]5_[_0__ !%',N_]?U_6X>S\_P /^">% M45[K_P *NT'_ )^]5_[_ $/_ ,11_P *NT'_ )^]5_[_ $/_ ,11S+O_ %_7 M];A[/S_#_@GA5%>Z_P#"KM!_Y^]5_P"_T/\ \11_PJ[0?^?O5?\ O]#_ /$4 MS\_P_P"">%45[K_PJ[0?^?O5?^_T/_Q%'_"KM!_Y^]5_[_0_ M_$4Z_\*NT'_G[U7_O]#_\ $4?\*NT'_G[U7_O] M#_\ $4%45[K_ ,*NT'_G[U7_ +_0 M_P#Q%'_"KM!_Y^]5_P"_T/\ \11S+O\ U_7];A[/S_#_ ()X517NO_"KM!_Y M^]5_[_0__$4?\*NT'_G[U7_O]#_\11S+O_7]?UN'L_/\/^">%45[K_PJ[0?^ M?O5?^_T/_P 11_PJ[0?^?O5?^_T/_P 11S+O_7]?UN'L_/\ #_@GA5%>Z_\ M"KM!_P"?O5?^_P!#_P#$4?\ "KM!_P"?O5?^_P!#_P#$4S\_ MP_X)X517NO\ PJ[0?^?O5?\ O]#_ /$4?\*NT'_G[U7_ +_0_P#Q%',N_P#7 M]?UN'L_/\/\ @GA5%>Z_\*NT'_G[U7_O]#_\11_PJ[0?^?O5?^_T/_Q%',N_ M]?U_6X>S\_P_X)X517NO_"KM!_Y^]5_[_0__ !%'_"KM!_Y^]5_[_0__ !%' M,N_]?U_6X>S\_P /^">%45[K_P *NT'_ )^]5_[_ $/_ ,11_P *NT'_ )^] M5_[_ $/_ ,11S+O_ %_7];A[/S_#_@GA5%>Z_P#"KM!_Y^]5_P"_T/\ \11_ MPJ[0?^?O5?\ O]#_ /$4S\_P_P"">%45[K_PJ[0?^?O5?^_T M/_Q%'_"KM!_Y^]5_[_0__$4Z_\*NT'_G[U7_O] M#_\ $4?\*NT'_G[U7_O]#_\ $4%4 M5[K_ ,*NT'_G[U7_ +_0_P#Q%'_"KM!_Y^]5_P"_T/\ \11S+O\ U_7];A[/ MS_#_ ()X517NO_"KM!_Y^]5_[_0__$4?\*NT'_G[U7_O]#_\11S+O_7]?UN' ML_/\/^">%45[K_PJ[0?^?O5?^_T/_P 11_PJ[0?^?O5?^_T/_P 11S+O_7]? MUN'L_/\ #_@GA5%>Z_\ "KM!_P"?O5?^_P!#_P#$4?\ "KM!_P"?O5?^_P!# M_P#$4S\_P_X)X517NO\ PJ[0?^?O5?\ O]#_ /$4?\*NT'_G M[U7_ +_0_P#Q%',N_P#7]?UN'L_/\/\ @GA5%>Z_\*NT'_G[U7_O]#_\11_P MJ[0?^?O5?^_T/_Q%',N_]?U_6X>S\_P_X)X517NO_"KM!_Y^]5_[_0__ !%' M_"KM!_Y^]5_[_0__ !%',N_]?U_6X>S\_P /^">%45[K_P *NT'_ )^]5_[_ M $/_ ,11_P *NT'_ )^]5_[_ $/_ ,11S+O_ %_7];A[/S_#_@GA5%>Z_P#" MKM!_Y^]5_P"_T/\ \11_PJ[0?^?O5?\ O]#_ /$4S\_P_P"" M>%45[K_PJ[0?^?O5?^_T/_Q%'_"KM!_Y^]5_[_0__$4Z_\*NT'_G[U7_O]#_\ $4?\*NT'_G[U7_O]#_\ $4%45[K_ ,*NT'_G[U7_ +_0_P#Q%'_"KM!_Y^]5_P"_ MT/\ \14N:3VNO6WRV$X/IK^!X(>_/\1X_K7G_B[X=:)XUU31-1UDW,JZ1N2* MS63%I.S2>PGZ?P?K_\ KI?^ M%6Z'_P _NJ_]_(/_ (FO'S[),GXFRV>4YU@:6.P%2M1K3P]?WJ:J4W)* MWPR5[:J_D>CE^/Q665EB,'4E0Q$8SA&K%KFC&<5&:5NZ;7XG@%O;0VZQV]M% M%;V\$?E16T4?EK$BX&[&<'H/_K59" 9]"/Z^O?GM_A7NW_"K=#SDWNJGZRP? M_$YI?^%7:'_S^:I_W]A_^)KOPF&P>!PF$P>%PU.C0P24:-&E%0H\D;*,906Z MBEH[IW2\VN3DD8Z#OVS_ (U[M_PJ[0_^?O5/^_L/_P 32_\ "KM"[W>J_P#?V$?^RFNI MSNW)M+F=[).ROT6NR,5&:25UHDM-%I;9=O+U[Z^%45[K_P *NT'_ )^]5_[_ M $/_ ,11_P *NT'_ )^]5_[_ $/_ ,13YT^NW_ 7]??W'R-[O]?U/"J*]U_X M5=H/_/WJO_?Z'_XBC_A5V@_\_>J_]_H?_B*.9=_Z_K^MP]GY_A_P3PJBO=?^ M%7:#_P _>J_]_H?_ (BC_A5V@_\ /WJO_?Z'_P"(HYEW_K^OZW#V?G^'_!/" MJ*]U_P"%7:#_ ,_>J_\ ?Z'_ .(H_P"%7:#_ ,_>J_\ ?Z'_ .(HYEW_ *_K M^MP]GY_A_P $\*HKW7_A5V@_\_>J_P#?Z'_XBC_A5V@_\_>J_P#?Z'_XBCF7 M?^OZ_KJ_]_H?_B*/^%7:#_S]ZK_W^A_^(HYE MW_K^OZW#V?G^'_!/"J*]U_X5=H/_ #]ZK_W^A_\ B*/^%7:#_P _>J_]_H?_ M (BCF7?^OZ_KJ_]_H?_B*.9=_Z_K^MP]GY_A_P M3PJBO=?^%7:#_P _>J_]_H?_ (BC_A5V@_\ /WJO_?Z'_P"(HYEW_K^OZW#V M?G^'_!/"J*]U_P"%7:#_ ,_>J_\ ?Z'_ .(H_P"%7:#_ ,_>J_\ ?Z'_ .(H MYEW_ *_K^MP]GY_A_P $\*HKW7_A5V@_\_>J_P#?Z'_XBC_A5V@_\_>J_P#? MZ'_XBCF7?^OZ_KJ_]_H?_B*/^%7:#_S]ZK_W M^A_^(HYEW_K^OZW#V?G^'_!/"3C'/2HPVW.!GN,X//Y=Q7O)^%NA'I=ZK_W] MA/\ [+3?^%6Z'G_C]U3''_+2#MR.=M0G3BVW&4TU\,963D[6OZ63Z_+4OE37 M+))Q:Y9)KXHZ76^EUU/"&7C4; MLH[DM/!+J4,RO9I)NL0^?]8L8 5''?=WZ=Z] M!#;BO]\ *,?<95/SM[XSR>N>U>\CX5Z$ +[5!GMYL/MV$?7USUH'PLT(?\ M+]JG'820CCN/]7QFO&R#AW)>&<+6P>2X+#X##UJ\\0Z="/+&-:I/FG*,=5%2 M4FFE;5OL=F88_%YK6]MCJTJ\U&,5*3]YQC:RDU:]K63>MNIX717NO_"KM!_Y M^]5_[_0__$4?\*NT'_G[U7_O]#_\17OJ_]_H?_ (BCF7?^OZ_KJ_]_H?_B*.9=_Z_K^MP]GY_A_P3PJBO=?^%7:#_P _>J_]_H?_ (BC M_A5V@_\ /WJO_?Z'_P"(HYEW_K^OZW#V?G^'_!/"J*]U_P"%7:#_ ,_>J_\ M?Z'_ .(H_P"%7:#_ ,_>J_\ ?Z'_ .(HYEW_ *_K^MP]GY_A_P $\*HKW7_A M5V@_\_>J_P#?Z'_XBC_A5V@_\_>J_P#?Z'_XBCF7?^OZ_KJ_]_H?_B*/^%7:#_S]ZK_W^A_^(HYEW_K^OZW#V?G^'_!/"J*] MU_X5=H/_ #]ZK_W^A_\ B*/^%7:#_P _>J_]_H?_ (BCF7?^OZ_KT\OZ^X:A9IWV?;_ ()Z#$28_P 5_P#0:?2("H"\E0H +,I.0 ,D#!SZTM9E MA1110 4444 %%%% !1110 X=#_O1_P#H8HH'0_[T?_H8HH ;V'^ZO_H(HH[# M_=7_ -!%% !1110 4444 %%%% !1@9!(SBBB@!,#GJ<^[?X_SS2T44 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !112X.,]J $HHHH **** "BBB@ HHHH **** "BB MEP>#Z_TH 2B@V@!11G/YXHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHIK5VV\W^@!^'\__ M -5%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@<'. M3C'-%% "DD__ *A_A2444 %%%% !1110 4444 %%%% #AT/^]'_Z&**!T/\ MO1_^ABB@!O8?[J_^@BBCL/\ =7_T$44 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 -9L=JC\P[CZ#MQZ>O6G2_=/^ M>QKPG]HCX[>%?V;O@]XQ^,'C+,VD>%+ W7V%91%<:G<$A8M/LB>6N9B05502 M<$ 'D4TF]@/&;CP_K-Q MI.IZ'J$F;RS".?LUQ=*VUT6Y0%QE1Q].?NQ7(4@E696(!085F(^5,_Q$0&.2<<@8!W# SZ9 MS4@/HIA=0@8G]WS^\;*8!'MRV.N?6DWC*JO)SE=Q^^IY^5ARQ^H&/K0 LC;! M]?\ ZQ_E2!\KG'I^O\J)&4J 2G)Q\^5;Z< \#IU[5\F?M)?M*ZO\ M9^&.DZ M9\*O%/Q%3XA:\FBWE[X=ADFMO#2-*D(O=1*9\N !S(6(P IZ<4 ?67F<'CIG MGT_2I $M1G\1>+_ D'CB'Q)',4LK2":(RFQF M7'^N4*5!)&0,GFONA"H4B1\'>0,9RA!(PW'.?7VH FHJ-G4,2V5P=P"_,&7' MMTZ<\>N.](C@\+N.X[E'7@=>3@@<'M0!+149E0 EMR!<*Q SDYQQ]<\4C.HR M2P&,&10Q^5<94A\?+GN%SG\Z ):*8''WA\X) !3Y^OJ#P /[W4CJ.33@RYR/ MFZ_Q$8P.-R]!R3G'H.U "U$\FUAUQ_G\>XI"XVY7=\P&"?X5R<;P.48] W)/ MIZ_DO^U'_P %5_!/P"^-=M\ _!WPQ\5_&CXAVUOYWB72/"$,D\VAY"E4E6,- M^]4,&E5]I5,-GDU2BY ?K2'RP'Z?IUQZU+7YM?LU_P#!0G2?V@OCKKOP)?X: MZ[X,\2>'_#L&NZ@^J2,TEKY\:RFSN8&P8YHPP# DX(.*_1Y9."&8*0,'(R%^ M8Y;(ZYZ#T%)IIV GHJ'S54Y)^0GA@Q?<>> #]T.]A\HSCY4Z[L<#/''/-?+W[7 MW[2ND_LC? GQ%\<->T*Z\3V'AR_TVSN-*L)"D\QU28PQ-&V.-A ).#@$XH ^ MHS(,X'4C@_Y%.5LUY5\&?B1:_&'X5_#_ .*=EI\FEVWCSPY9>([?2IW)GL[> M]3?F'/\ P'H?Q- $U%1[P SC&TL MS#J 3D#'Z9Z]L>B>:N0C>V%C(+M[G.,#U[T 2TQF;D#HO]>>] ?Y@"O/S8 ; MD\\%E'!_/\<5\/?M.?MK>'?V:_B[^S[\)=8\,7^O7WQ^\0R>'M+U&SF,4.CS M1N4,MR@!WKQG&1D9HU>R ^WA)@?[V2/RSZ8)'O2>_K7Q!^U_^VUX<_9%\1_L^>'O$/A/4/$=S^T!X M_N/ NER64VR+0[BV@MIVO;@;6+PE;E=P!4_+UIV?9_,CTJ=70C*MN#+O5>K$=& 8XP5;MZ?H@'44P2+NQD;@ MN<8.!GC![%P>O/8TA<*P4GIPS 97)_O9X7D<$9P,F@"2BH1(I!^8@ABK*/G. M,_>#'!'X9'I3@^<*<#+;1M.[>/X2'ZJ22 V.GOF@"2BFY*_>Q@8/)R,DMM ; MJV=OS C')I-P^]N&S+#(&XX'\9SR ,]!Z#% #ZB9SNP#C'^/6@N".#N..5C8 MEB?X2,@ #H3S[$8KYS_:9^..I_L^?#BX^(&F_#_7_B5=0WUI8)X<\.1M)J$@ MNI4C:8JF[Y80^YG.> ?3@ ^C58D\\_E4E<-X#\42^,/!OAOQ;=:5=^'Y]=TR MUU!]%U#<+O39+F)9&MKONS1$E2#T(%=JTBKG!W%0'91T(8=58XX YVCVH DH MI@E0D*K!@.=P&20,Y# XQ]>(R/XE.?FXX*<#'MTY_&@"2BF"1=W M/'[L,RGLI_C/. 3@[0,D^U".&92#D-DCUVC^\IX7V[_B: 'T5&LJDX!1F!8C MLKC)&.1U7(!X[=:7F>>W6E+*/O,1S@-@ =1C@?>SWR>*+-;IKY -,A/ XZ'^?M3U;=GC MI7Q9^VC^V)H/[&G@OPEXS\1>&+WQ1!XL\6Z?X3MX+"0Q/;7&H3)%%<2J%(,2 M%\O[=Z^N/#FJ)K^@Z)KD<9@&NZ38:PD!<_NTOK6*Z2%3C@HLH5OI2 W:*B,B MX))!)R% .$!]"PY)]Z>$M2U#6?B/9B^L]>67%I91N#\C(.79<8&2O;.:^W M\;&5"=P?"[P>4<#<-P[%LX8=QC\0"[14>\=R.",L3M4N3C:I&>@QA>AR>]#G M;C+J5R,=B#Q0!)13-^[YN@_A7IGKNW$<_IP>!UJM=7MO96T]Y M.ZI:6L4D\DS.<)'$C/(TA(SL0 D]<$8Q5YQD*B9+@ M'/W^6SP<[>P'3/N*336X$M%,W*PQD>I(8JHXZ;ACGV[8IIECVEBQ**.?X6RO MZG/;&=W>D!+14(ERPP5/R[FW97:,9"# .6 P6(YQ3C*H9^>54%4_O>^_ZGIZ M"@"2BH#,A .X= =H+*1SR-V/F_'H1@9J42(0.ISQ@+@_@?4$=: '44S>.C?* M1C:"<O\ MSS/ *GL>HZ]Z-Q^49'\6=HSM Z<_QXZL<@#M0 ^BH1)@!5(8G..IR."J]/TIP?: #C>>-K=ASRWHQ'\)X&0,T 244P.K#/SJ,GY<#?D=SSC;^GTX MH#JW][/0G&!UQ\H!P6_*@!]%1>:!G++N7ID?(P[9(S\W]:-RY*#>25+$9RY M!.V+L2#P3UQUH EHJ)9 Q4$A25SL!RV>0H/;.>O/)'?-.#YY8[1GABH ./O* M #D\'@]C0 ^BF,^#N^0HA(P?O+_ ++>^?TQ0 ZBBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** &LVT$U$LN3Z^W3\>E3-CRV)YSA?]W)ZCWY_2O,?BU\ M3/#GP;^&7C7XG^++E+7P_P""=!OM:U"25Q'YZVD+2I;I(Q&V:YD"V\6"29)% M II7:3 ]+\SV_7_ZU/4Y -?G9^P/_P %"? /[=^C>-]2\,^'M0\&:KX*NK:" M?P_K,G_$QNM,O8C);:ND#A':UDP@68+M)K? M OXC_"#P+8?"GQ3X^@^*6HM87GB'0XI)-,\'HMRMM]HU9T5MJ-OWAVVG SFG M9]G]W]?>!]>[SG/;T_R*>K9SQC%?"_QQ_;9\._!']I7X&_LW:EX5O]7UKXWR M7":7K5O*8[72?LYPXNA@[V)^[RI/<^GW,"57>1@8'#8RV1U9NH//7'MWI\LN MWY 244PN-RJ"OSXR,D$>I5L<=\_I2[P 3Z94EAP O<#^)N""I_CP3@#GK^O%-=R QX''(7YF3GY9,'&5(P2N>A)-(":BF!]O) M(P5!9FZ#L&5,'&>I7IGK2J>,C<2 <%@ K?[6W/&!S[T #-CMFD9\?EG-02-@ M@;P-^0A/61B<' _Y9H.BG/%?E[^V#_P4Z\%_LM?$?0_@[I'P[\4?%OXE:O#' M=7'A;PM$\M[I]C<$+'*Y0.Q#98JQ&0!51CS/RZ@?J,DFXXY_S]*FK\P?@/\ M\%(-&^,7[0]O^SK=_"SQ%X,\5-X.M?%UU_:KR";3XKA/NM@L"-RQ]0.F=QQ MW[#.!3&E5>0"P!^\",98="O?:>?H,YJ0):C:0#_'T/Y4SS%;"]<[07R1'N ( MVJ>,ONY93Q^5>)_M _&&Q^ 'P9\?_%_6-,N-:L/ 6C2ZU>Z; WDRW,43*NV& M0$G'SC/!IV?9_IX[4M5N@ M'TQFQP#SW_R:/,!(ZH02=KC;QC !/\6XG([U\.?MR?ML^'/V)?"OPS\5>(?" MU_XKMOB1\3/#WPWMH=/F:*2QO?$%W#:0WLAVG=!"TREUP 0O:FDV[)78'W%O M]OU_^M1YGM^O_P!:J\4H=(7_ .>L<4F" %5GC201%NYV\6>,M'\)1VUF_EO:2:QF2JR@%O[V: MV20<@-D#[X^ZR#&1C&3G_9R<]*5G'1]- '45"7/8@C@CC;QC.X,.6P/O+CDY M%/W'(_B=1N4+PCJ<\MZ?TZ4 /HJ,2 GY>4*DEL85<'#[6/+,I^ZI &#UH,@* MA@WT7;AL#C<<=3G&5/'7TH DHIN0H._(8X) ^;:3R"#_ ,\R!R.@Z#K3=^ " M3QCI'\\8_R:9YJY^8[1@X?)9-HSC _BM>'?M&?&+4/@9\+]9^(NF>!]8^(-UI!@$?AK08WFU*]\Y@!Y*H"VX=67&, M=>* /=@^3C]:=7E_PI\=7/Q)^'WA7QS>:#J'A6Z\2Z?!?SZ!JBM'>:4\T:/] MDN58;DF1FVMVR"*]-+@X (RH'3D_]\]&'N?KUH ?14>[YMN01]TX!]G<[U(XZ97TH 9YHZ=^G?K^5/0DYS^=?(O[97[56@_L=_!Q_C)K_AZ[\3 MZ>OBC1O#?]FV4GERK-K<[01SAB"#'&5+'C !&*^AOAWXOA^('@7P?XYL[=[& M#Q7H6GZ[%:2DN((=0A6=(G8_QHK8S_\ 6- ';T4A8*",J0<8% #ZC=]N>WO^7UI^]00H.YCR"0 !V//4XP./O=^ M:B<@EC@D+T'!'S]FR1@K^.!BFDWL@$67)[GVZ?RJ4,#P,U\*_M"?MK^'OV?/ MVB/VLZO^T1J5]IND:S!.5L]&:P=U=KI-I#-)LW+T.#BON0$ 1L MGS_K^D!8HIA? +$9)^50H!#^Z]P<=_P#Z MU(&))=>4&OA/^TK\*?C M=XL^(G@_XAZJ, M^82,>XQ\O\7/'I2U6Z FHJ)GV$Y8;@NXY/RGD Y SL&/N[<_XAD7Y1N/S[MI M R"H ^Z1P1GC<<8ZT 2T5&S[3M9@2Q;9M^5< X9Q_%]>O-+O!QU3CG=P&)] M&&?PZ?G0 ^BF[AE4QR>^[AN>BM_>Z\'C H9P,\,$7@\#?N'X\\]>WX4 .HJ$ M2H>"Q5LD?-P0<]2/N[3_ \^E/\ -7&2 %'RDYRR[ONEE[DCZ\^M #Z*A,R+ MP3G>=J'D%B.I_P"F8]3GTH,@P^#GW'WPXZ(J=&R>.N#0!-13-XVC<-IX8DL0 MJ_[)(Y)]5Q@>]-WY&X,!GCC)R@ZCTH ?146]=Z@,"#C;EB-QP20!C!/JO04&4 M#@$,",C)(X.<$MC.X^G:@"6BHO,11U8YSP"7;&.V[&&ST-/+KGEMF1\H^\?H MRG(5NW7K0 ZBF^8NXYR"#P&&U>F?FQGJ.1GVH+AAD*0F-S$_+W'W,')YXP>* M '45&9!@D!L#&[(&0N>#C/?NPI=Z$]2!ZT4?AGV/?VH C? M)&TX!8_)SG*XY8^F,]._ZU^!G_!67QG=_&KXS?LW_L/^"IY-0U/Q;XQTKQ/X M[L[<.Z6.B65TERDEY'&6W0RV\;*5? +/@^I_=[Q#KFG>'-$U3Q%JTZ6VF:'I M]YJU]([A%2"QMWD==QX&X1X7/4D"OY/?@W\'/VI?^"@O[7'QQ_:O^ GQI7X$ MV/AC7KGPEX2\7WFB/K4FHV-F\D36VGGE84MV"QNRC)/0XJX;_+]4!](_#G23 M_P $YO\ @J%I?PPL)7TKX)?M0>&]/2VM7!CTUO&J6PCWP%MD47D2*\90?QL, MX-?J#_P4I_:H\:_L;_LP:I\;? &FZ3JFN:;XS\)>'?LFMQM<:>NEZU<2"^?8 MK1G[4MO$6A)8Y88QCBOPW_X*!?L ?MX^&OA?;_M+_%[]KF'XZWGP!N;?Q)I6 MFP^&YM&U'3+:"^M[NYN+*]3:1$TB*D@YR'(R :^A/^"A?Q^LOVF/^"+O@WXL MP7$,U[KWC'X6:=XCCM75UL_$5A=36FI6DOWLS1X0R@\YFY'S5IZV\_73^ON MZW6?^"EG[>?Q ^'9^.W[//[-^EZE\$?#6D6VH^)==\1PR)K?B4I"CZGJ'AO3 MBR,]FD@F$;J6 1!Q@&NI\/?\%4/V@_VH_"&@67[$WP.M_$GQ"T_1FU'XCW?C M$M:^%_#=_$#'=:5'=/A9KMIHW6&($-N^3@"OTK_9AT;3-._89^%>E6MA;QZ> MGP+B067D(ELRR:+/)*98\;"9&-,GRT!VJ3D"J_=ZVAULO.WY?",LVV/:NZ-\G*/#^JKHWPRTS2[!UN)YG8I]J\07 M:NRQ6T)P7RBEE!R1UJ]^R=#&G_!8+]I4QH%_XDD[,00IES&V'D48RP[''' / MOYW^Q=J7P\L_^"OW[5EIXE&GIXRN[R3_ (1.2\:*-RN'\TP&;.^8C[BQXO^#/\ @IU^U/\ !?XN^%/AK^W9\#=.\$:+X^U"VL/#WC/P MLI.C6TE](L<$4]QO=3-&[(DB-R,GG(X^IOV^OVS_ !E^S5K_ .S-8> -$\,^ M(=+^,7C"UT?4[W6[-+V2WTZZN+=8Y]/D=AY4QCFSNP<,!Z&OG#_@NY=Z ?@I M\'M!\VTE\>ZC\6?#4GAZ$&,:G):1:G:?:#:E2TJJ&'S$?*<'G@X\A_X*BQ75 MO;?\$X4OPRW:>*O#B7!DR&$@_LTE&!_B7=R3C/6E)4VE:-OR_#\ .Y^)4QNO M^"Z7P6N)4;?5BFWN%8GC/(/M7T?^W%_P %*]9^!7Q6TG]F MC]G[X=WGQ;_:&\26MK=0Z7"C3:1H4%X2()-2"<83K=%BOE+@L*^;_'X/_#\[ MX&'' _9YTH$^A-L^,_7%<-\!IM,TC_@NU^T-;>.3;0:MK'AS6;KP!_:H7=/9 MFSM?*%A-/\L1<^8+<1Y8L"$ )Q4ZT6SDO658X+VZA656N8]V+B%M@BY/2OIO M]N#_ (*0:=^S9K?AOX3_ J\&W?Q;^/'C>T@N/#7A;2XWE%I8W:+):ZCJ"(, MB)C(F58C"DL?2O>?VP/C[^R[\!-/\%:K^TG9VVHRZ]X@BTWP;IZ:'#XEUK^U MYBBB;3[-/])A125$DZ,%51D#(-?D+X/U[PM8?\%IDU+Q^D.F6GBGX;65Y\.3 MXE5+)?LE[;0RZ9' +L;$GVR1!(D(9'PG\-:)4[+W>FO57TN]_N [V\_X*1?M M]_LZ:CH?B3]L7]G#0K'X4:_+:A]=\#B2>3P_;W4B -K,@9Q!-#&^7C('S*1G M%?9_[;G[=]]\$/V/-#_:A^"L>D^)+/7M5T1;6+6HA<62Z3J*^9=+)$&0K<11 M@@#=G<0P,%UX7 M.-HC^89!/WA7X?\ QTM-6C_X(;?"-=<9YYIO%^@B"&X#*\EC.\:1HX;EOD5P MO0=P>10E3M\*6NJU>EN^G7?9W ^H(O\ @I#_ ,%%OB_\.HOBY^SM^S+HES\. M]&TR.\UO4/$$+B_UQ8$$U_<^';!G1I;?8'*,I*J/7 K](?\ @GS^W!I_[;?P MQU;Q3<^&Y_"'C7P=J1T#QEH4Q+0VNI0,4=X5.,+,X;]W@;,#DUZ9^R+IUEIO M['GPML+&TBM;/_A5Z#R(XHPC$Z0X;*HJ@EN=V[.[&#UK\K?^")2^3\0_VT;: M+$<"_$ZXV(!^[#&YG/SHN%!&2%[&5+:.Z?P[=29P[ M6JJ=D>"7R,G+9_LQ1LE>?P(N.MNU^O\ E^5_R I?LDO5'=>:D9 P%"X]:]Z_:,_X*-?&4_'/4/V8_V, M_A##\3/B7X?1'\2Z[K,<\/AC297VCR+J=T6-"#\P82'(^;IQ7B7[,LD4/_!8 M[]J*=FV0P>&YI)VVD9BCME=MQZ$J,D\ G! YK*OOVN?VI/C9^T-\7/"'_!/? MX&_"^*+P-J!TKQOX_P#%HL-+U#5[I9/(:=;F7;.51U9$#,Q/!%79-[+5]O\ M@ =G\/O^"DO[6OPF^.?@_P"#7[U^/VH_LO:#I_[//F07%[;70:3QC::+E?,O;N'<&M87C.]'=6 & M.*]._P""B_QY\._M,_\ !(O5/C-X9L[BPTOQE=>#[Q-/E/F3V-RMZZW%I(W] MY),X)Y&5[@5^@/[:_!R\=W_ ." ,@0[F7Q5IT<:.Q_=E=4_=88\+A]I&!@!>G-9VCVOJEN^ MZ\_,#]$[C]N7PY^R3^PQ^S+H.@:?)X^^//CKX8Z#IGPZ^&VEQ_VCJ-WJ$MN/ M)U#4[> F2TLD=DP9@HE(=#@+D_;?PE^+OQC\&?LX7OQH_;"7POX7US3='E\3 M7^B:#;K;6^BZ<;3[1'87#[W\Z^'W)%.&23(YQBOYD?A7\//C5^PAXC_9+_;P M^,%TOQB^$WC_ ,/Z7HWB2:6U?4A\*=-U54M;2&W@FWQHT"*'M;N!8E,F[&"" M:_=G_@JIXCG^*'_!.KQQXP^%5^^N:'XATG1_$$&I:8^^.;P])_I%T[+$6/EP MV^5N%R<2*R-R*?(NWXO^O^& ^7K'_@H;_P %$/VBY-9\=?LB_LQZ-$K7PFDI\, <-I-\44GS(<%@).7!#G@UZ1^ MQQ^SAXL\"?MP^//%?C[]M#P_\>_B_;>!]RV-R+8WNH0 M2BT5TD*@*\1=F&T$$TWXL#V_]H'_@I3\;]:^.NK_LV?L1?">R^(_C[PQ, M$\4^(M'=,DW'=%+("(X5(5OWA,UJ_P#! M5+5?!LO[<'_!.K3;6739O&]I\48Y=5AM9(6U&'2YG/V!KQ(QYFPA9GC$C'*$ M < 4))/16\[]_7Y?>!_0 HVHK8!0P1E !CS%V+N#]2/4?E7\['_!>_Q58>!- M>_8!\:ZC%-+9>%/CCXCUV]CMT9Y9+.RTG2IG@CB7+%Y.$&,\U_1.I^6( @KY M<0+YP518U_AR>>>/0\5_/+_P7?N_#>E^,/\ @GE?>,O+D\*67Q^UZ?Q)YX4V M\NAKIND&\BGW?+L,>T-D8&.10FM-;M_G;Y?=OK]P3>(?^"BO_!1/PUH<'QX_ MX99TK_AFB)K6XBLW21O'J>'%C0+JTMKNWQ036P,_F%?E1UQQQ7WGKG[:FO\ MQ0_8FU7]J7]F32M-U37-*TR?5KWPQX@@^T&T>PC,NHZ>\*LK"Z10WE\AB,<5 M]8?$[7? %K^SOXKUS4;G1X?AR?AM/=12>9:OIKZ,=$4VR0<^4R $L:C(*\ M=Q7Y.?\ !$'PT/$G['_QBTS4+9O^$8\7_%KQJF@+.I:W?P_?":.UDAC;Y1;! M&4J%RN![6ZC<%&3C!(Z5^3'A#XXWO[!7A?] MN[]G'7+Z;2-2EOK_ %;X6).Y0:L_B,O$CRQ[+B>XU9QFWK6]O+Y:5D&7(* MC/:OT:UW:WA[Q"%)9DT/5AQS@'3KD#/U["OPB_X(7WMJVC?M0:8+FW74+;XS M>)I)[-Y56YCBGU.4Q2-"2'"2#.QL8./I3@N9V\M^VJ ^N/'?[:?Q)\+_ /!3 M7X;_ +&=EI6B2_#SQ;\*KOQKJ6KS6Y;7(=3@C,D<,5QOQY!/5?+YSU%?/_[< MG_!3CXJ_LI_ME^"/V?\ PG\.K?X@>&_%GP\37(M.L;5IO$]WXJOKJ6WTVWM) MD8$67FJBSIY9VKGD9.?(/B+XCTK7_P#@OU\([#2;VVN9?#7P-U32M:6WF226 MVU".V\UHKC;D1RJDB[HS\R@\@'HG[3FGVFI?\%V?V8[>_M8+J*/X,O>0Q3QJ MX\^WO9C'*N\,NZ)EW(2"<\#UK5TU'EZW5_RZ;=?\P*WC#_@IO^WK^SAXF\(^ M*/VI/V=/#F@_!GQIJ-M;6=[H89M2TF*]E58X]8N [?9KJ-' 9&'S,#BOT7_; MC_:UUWX#?LFV'Q_^'&BZ-K5SK3>&KO3]/U^U2\T\66O&U;$B,P!GC2%OLY*@&,?VI "PD/*/MRI"D;EYKQK]OMF MG_X)*_"]V+RG^R? )8MD,P0V*#).>< #^[ST%2HQ:3MOZ_Y@>\_&_\ ;T^, MGP7M/V3_ !E-X<\,/\-/C.FA6?C2\6RV2Z'>ZLL.X64PD$<,8:7:B%2,5][_ M +2'Q\T/X#_L]>,_CA'[>[((U'5;F%9-.M,9^9;AY%"H"P;I M7P[\:?@/;?'W_@F-X9T"*W\SQ#X7^&VC>+?"LL:'[5;ZSHMC'>V_D2+\^]FB M#$*./VE_$'[9?P#_9+_8ZTV[GOOB7JWBNQTKXKI$Q:33=(\,7L M4/GW8'/EO%"%>-P2H."MH)1\01H+$RI,U@&\U9$MOWC,1V)(]/#_P#@L=\/ M]6\#Z]^PQX(\.>*8?AUHVC:A8^'-%\<74'GZ/X7UR 00C5[BV(,*I#+M=_-! MR74 @YKZ.F_8S_X*@3^%)-:F_P""G>E-X/?P^MY/??\ "(1G2#H?V+S)F8@& M P?8R0SYPZC'!ZG+%=%\V!]^^!_VUO"7QI_8W\L7GAG M6$,ESX=\8^'K"6Y?0]5C)5B()X@'5L8&[TK\K_@#_P %/_V]_P!K;PGX=OOV M>/@-X3UN_P!!=4^+/B76$:R\.I<&Z*)8Z 'D.Z^2UVRE SYSGWK=_8J^#GAO MX/\ [!7[<=GX7^/VD?'RSUK3?B5J>JZUH&B7&B:=IVO/HM^=0MU2:22.>ZEF M\QC+#M1B5^7I7M/_ 0/TRTL/V'X+FRA2.ZU7QMJ-Q?2;0KR7"1HH+O_ ,M& M2, *6R 2W'6G[BB_=6Z2?2SY=_O;^X"Y^T/_ ,%'/CMI'Q:\,?LN_LU_"S2/ M'?[0ESX>TW5?%[ZW.D&@:'?7-I%)=V)61XU6*&5I 75CG8< U!\$_P!OW]K? MPE\:?#_P,_;1_9_B\*WOC"X2/P_XQ\!PSW/AV.5VV1I<7$6^)ANQN)*@ Y). M*\E_:X_8]\"?M(_M;>)?$'[,?[2A^#W[6OAW286\1:%(DT<>I)&OF0/"4ECS M*R*H:0$J%.2M>)VG[0W_ 47_8C^+7PG\$_M@0>!OBYX)\;^(++PUH'BF[?3 M]:UZW1YEMEN+.2-!/:R ,'QG<& !8]Z7L]/=UM^7]+T _4W]N7]O[_AE_4?" MOPQ^'7@K4/BE\YBLDG(6"^O'B3RQ:AVR[-("%!XKX-\9_\ M%"O^"EO[-46C?$3]IO\ 9I\(Q_!V]N[*+4[SPBQN+[1;:_E5(I-1EC8?9I41 M\NC*0,$'O7K7[8W[9'C*S_:.\#_ _P#9<^"/A'QY^T)>^&[/7$\6^-8+&"/1 M[&\B$D4%M-=)YD)A4G>0YSQ@ BO@_P#X*$VG_!3B7]FWQ+X@_:C^(_PL^'WP M_NI+.VN_!?AJ[LKFZUB^60&VM;5%+2RB7<1*Z8$!'/WJ)*+M9;;W_P M>O3\ MP/K+_@L-\0M&^*_[)'[-GQ(\.2%]$\9?$KPAK&G$G$/#GS+P?\ D#V1/&.,_6L)1Y M7Y/8#SC]H[X]^#/V8O@]XM^,/CPS2:+X5M//&GVDW]PQ2PM88XD=WDN M)ML> ORY/3 K\9K+]N[_ (*I?$_PE-\;/A#^R]X3@^#[I+J&EV'B;S(_&.H: M1&3*;FVL6:.1TDMEWI(0/F94*YYK]$O^"C7[2O@K]F7]GV\\6^,_ UI\2+[7 M=3L]#\)^#=3@AN-,U+7YIA]CN+XSJT*0V3-'+L<$RXV*0>:_.RUU;_@LE\2O MAX-7@M/@M\!?AK/X;36=*NK#4-,2\L_#\UF)XX9;%&VV< M'#E",D$@]:<$G MNM=_D!^A7[!O[<^G_MB_#GQ!KVL>&9? WC7P!=W&F>-M"O"8UM+JS5GN[A0W M^KC3RI!M)X]<5\4>.?\ @IA^TY\9OC#XK^%W[!WP8TCQ]IW@*\N++Q+XS\4E MD\/37=D["ZMK>\)5%G 0JB*3EL=:^6_^"2EOXMU'X:?MUV8\01>*_&=U_P ) M,D^NZ.NR/4-9^RW8EN-.V'&R2;(5DR&##I7UK_P0PUGPL/@S\6?"\=Q90_$; M2OB;K)\5Z7*\*:W'+]IFW2W*.!.\3M\Q)RN>OK6WN)?#M^MKMN_DGMI8#X(' M[0_C_P"/G_!3K]G*V^*OPVOOAK\2/"5F='\3:/-$Z6MQ>6YV?VEI5PYPUA(< MM&ZY!3!.:_5#]KC_ (*+>./ 7QGM?V8OV7/A=/\ %KXVW-I%/J\US;W!\.: MQ4'?J-SL6%4B!4S/O.,_=X%?,7[7&H^#+W_@KE^S/I^B2Z6_B>ST;.N&Q\G[ M0F0SQI>&(Y\R-%;>'))X'6MGXK_M?_'WQ_\ M9_$3X-_L&_ WX=ZGX]\!0I; M^.OB'XT_LZRNKRX 98KV55FB@; 18V9]Y5CW&"U-V]U^GW?Y6VT]0,R3_@I M5^VU^S/\2/ VB?MT_ ;PWX=^'7Q!UNST33O&'@MRUII5W?2HD4]U.I=?,MRP M=XF/SCC<._UM_P %//V\O%W[%/PX^"7Q'\ Z9I&M:9\2/&L>EZ[/J]H;I(O# MATJWU-+NR19(RMS+%.",;L$C(/?\,_\ @J98?MY6?P^\!7O[7OQ3^'\.G:OX M[TBZ\.?"?PG-:3WLE^;B!;NZA:(M-#9Z;$HD$S-MF.57&./N+_@MQ-H]M^S% M^PC+XA!;0H/'/A&76F(#*=+C\&Z&;W>A^^&A#!AZ&E:#Z!Y$EQA5((&*^TM'_;,\4_M3_L8^,OBQ^S%X;T^[^)UEIUYI.L>"O% M,@CBTC45M7_M%+DO_'''YK1Y P0%K[7\.:OX&D_9UT75M)N]&;X?+\+;"X@N MK:6SCTB/1H_#D98,0?(14B!6X4Y<2AE(\S*C\3?^"/)%QX(_;9US10Q\$7_C MGQB^ASVQ)L)H_*OR/L9 "%&3.QDXVG ]DO*W;3R[[:^70#QC_@AYXK_:LB\1 M?%+29?"?@X? B^^)7B34_BCXE-TJ:]HOC16NGN;6P0G+6$3;]KG*HBY %?:_ MQF_X*0?'CQU\6M:^!_[!OP=M_BGKOA*[EL?$WCK6XY&\*6-U V)+5KD;8PX( M^;DD-GV%>9_\$?(]0NOV?P6_:Y^+&L_'6Q_9X_;,TWX!ZKI?Q$UX^*? MUH"ZAKMY(; MUMEZ[R#[083G<&'RC&>Q(-'>Z6G^2_X8#];/@!_P47^,VD_&G0?V<_VXOA'' M\*_'OBV01>$/$VC+)_PBFN79*A+6"X8F-GDX"G?G(QCGCSK]J;_@J+\;_@A^ MV'KG[,O@3X9:=\1;S4M#MHOA_IUC:,VJ2^(;U1Y=WJ$J,2NF61=7N6("^7\Q M(S7S!\:?V-_V@-,^-_[/$O[6_P#P43\/^+-9TKQUI&K>"?#5UX.D_M?5;B&Z MRUI;26\D=Q;),056:0M&M1VOAFV\,$2V6I::T"3_:YGW-OD3=Y<@&U5*M@"OH;XV_%OPQ\"OA7XO\ MBOXSE,?A[P=I-YJMW&@+374L,3O!;Q*!D-/(JHB]RPKUXDOF0,NS&$++P,$Y M)'?..#WZ8KYI_:S3X1S_ +/_ ,1K+X[7@TWX7ZCHT]CXBU0POWAOO M)C^?$,DFY/[FT$],UDOBM;2^W]=OQ _'7PU_P4(_X*9?&SPM/\# M]0^!:SW5S8PZI<))XNU/2+.1A)):VB2[VDDC7@E1L=@IW=:_3K]D']L>P_:1 M^$/B'XA>*_"&K_##7_ KW=MXZT/Q!;2VJV$]C \UU-;/,%#1A8I,[,JK8'-? MBEX _8;_ &[_ (*^"],\??\ !/C]K"Q^(GP8UBVN=2\.>&+W4(K*P.DB9Y6L MG:],\+[3'L=%5&#C/&03[[^SQ^V#\5_VAOVWXO_.P'6Z__ ,%' M_P!KW]H#QUXB\/\ [!'P L/%O@SPG>W6GZGX_P#&L6;E;B+3KABJR M-E65<9Y('O7T)^Q__P %#/%OQ-^)U]^SG^T_\.IO@W\=;*UDN=/LIHY(-&\5 MP6XS<3Z1(_RR1*/F5E)W#M7Y$_\ !-W]G?\ ;A^+'P,O;_\ 9Z_;LL/A'H>G M>(M3M=5^'L7AM+W4-*U-KJ3S9KR8#S=YP=WF+@GY%?VXO@ M[X@_:/\ V^/#7Q-^,.B6=TVA^#4\)21Z[J&EFUD40+=6LB?94[JM[.^W:W3;?\ /N__@H+^VM\2OV4_$O[,^C^!-(T'4[; MXR^/M-\+>(#JUN96L[&Z\A6EL<.NR9!(=I.X'C*GI7VC^T!\1]9^%7P&^('Q M0T6""ZUSPMX+O_$EI:7:@V<]W9Z?)=JMRO\ '&[QA2,C@U^,G_!:Z>*U\;_L M%W5TX@@A^,NB,\DI"1+M>U9B[GY%QGG)&*_3#]O;QCX?\)_L2_=8U*RMK M"]^&M]964\]S%''+-J&D2Q6R1ON(E,DDB>6$W9)49Z5GR/34#F_V1_VP[OXK M?L0^&_VK_C(FE^'YI]+U_5-?ATN/[/I\-MI-U<0Q10(S-\TD<07=N.688':O M@2U_X*'_ /!03]HF^USQ5^QW^S5HUS\(M!DN&@\0>.5DMW\26]HQ\V319&V_ M:)9E7]TJC#,P QQ7C/@NQU^]_P""!=A!H<=XU\NC:Q+*;0LLL=M#K=QYSE5& M7A$:EI%. 0.>#61^Q'^S'_P4 ^)G[.?@/Q)\#/\ @HAI?@_P%-:O':>$=/\ M"LQ^(OB+0]3_LGX?KI-HR"SD5@KW_B2YWE([0 @LS* RY]Z MH_LC?LV>-? 7_!0>Y\3_ !0_;8\/_'+XOZ9X?O;+QCX6TKPS+8ZA/');XA-[ MJ%O(+6)HPIRLT;,>1G-+^P18V,__ 53_;*U":&.:\AE$<+R(C"!3.P?RY2O M#$<,B$-QG/I<8P3UC?\ '6Z[@=7\/_\ @IQ^U9\)_P!HWP'\ ?VY/@IH?@H? M%75K/2/"'B#PH&.FK>:G*D-E&;D.R74OF2!95RI7&X@CBOLW_@H#_P %#-*_ M8UG\%?#_ ,*>#+WXF?&[XFI(G@GP9IQ+RK'YK6R:G=0H&I^T1I"QW"IB?9'+:R)"L@&]2')?:S$$GBN"^. M,MGX=_X+S?L[:Y\69(H/"VK?#/58_!%UKCHVCQ7EWIGV6P6!YQ]G2X;6CA4Z MI/\ .2.:=H77NVT=TM>JMKIM^H'H-U_P4I_;G_9K\4^"=2_;6_9ZT71_A9X] M>T2RUSP/%-"M*MY)-2U1]2@22U-Q;+^]1$>1$RO? -EJ-K!%;3Z5#K]S+J4TBQP?8M-8F2XG+$ M']P/D!&0,@5_/;_P4CN]2^*7[5G[&'B7X/>/G^"_AWQ=X=C?X=^/-9TTPV'A MZ2[N(S82-H\X*03,KH(XSRF?041C2E;3\79_>[K\/F!]77G[>W_!3GX5Z39_ M%OXX?LIZ/_PI6\E2YO+/PY#+)XNT#26D4R7&JVBEI(OLT)+29&3@]LU^EGB+ M]NKX0Z1^RE)^UGI\TVK^#/[(2ZM]*B.V\7564J-)F'WX;@7'[MPPRN#TQQ^: M?Q(_8K_X*51?#[Q3>_$3_@I]I7_" /H5S)XBFO\ PA&-.;0Y+?&']H&R^)/PF\0:Y>2?\+)T?1[K M2+33M5N9RL9M;*:21B\=R2?,1A'_ ! <8I-_"=Q\>OA[^S/X(O?@4&-_::8UPL_C.?0@[-YT5I%(9&E>!=PR, D<=J_6_ M]CO]IB/]J;X/Z=\2)O!^K^ ]56X?3->\-:U%-%=Z?JEN"+E5$RJSQ;@61L8Y MP#Q7X4^'/V+_ /@H[^S[X4TWQA^Q1^U%I?Q:^#,^GMJ.A>%->O8-/LG\/JC7 M TZ^>_,\=VJ0 IE!'G.W@5^E?_!*[]K_ ,2_M6?"_P <+X]\':'X1\??#CQC M?^#O$T/AJVAMM)U&_P!.S'C?0GBEJ %EVKU(;!..=NS.W\#^53BL@"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH C? 5^HXR2!QNZ*/J<=>V*^>5(L_V=M2?P=X.\;7.E/KUC:7EL6L;FTTR,;H4FO$5KL2@-E6W>]5'X ME_7]>0'N?C3PQ#_P36_X*1?L\>)M,B_L'X,?&SX8^%_A+XIEM@4T9M7\.P0: M-!)>, ($U&]O!%8'S#Q7[3_ +:WQQ\1?LX_LP?$_P"-G@VVT_4]9\&Z M&FJZ7!>QB?3IM\D)0S*& :-XY"0X.W&..;7X2R_\+!TKP='X4?3]5%YH^V;S[*^ #0F.&-IF4'#!"^.,U]">+/V MC;3]IG_@B/X[\9?VC'>>(O#W@)/"?BNV$PFNH-0T>YM;$M?IDNIN44,CM@MM M)Y.?0#*T3_ (*9_M\_&_X6:1\4?VT*#4/B M)KWB")[:+4;RW0R:K;^&+8N/.C@4?NF!8,6Z5UO@C_@K-\=?VD_"6C^$_P!E MKX"/KWQXM1-%XZ@\2;[3PEX;NK3=',LMPPV+))*K".,D8QUK[9_X)W:386/_ M 3N^&UM:6\-M'<_#W4KBZCCB3;++-92EW(0+OWD $ON(YKXP_X(G:5I]MK? M[6U[!:QQWG_"U]6BE91&'\O[=)B(.$W"(@;@%('%+ECKIV77K;[M6@/;?V$/ M^"AGQ6^-OQ<\:?LV_M(_#W3_ #\:?!8>28:3N32]0A1]KFW4E@R$8*.&P_8 M=J\<_:5_X*I_&/X'_MF>.OV9?"WPQM/'\4&@Z8OP_P!)TZRDEUW5-?U&&%W: M^F1\+IUJ9A([NH!4$&N:^%D87_@M;\4B NV7P7'OP%V%LKM5< %73U/)[^_- M:7?^";'_ (+N^.8/%S6$=[J'@31HO"?VWRE7^UQ9VSRO&TW'F-%A<*5/UQ19 M)JRZ-_=:WY@=19_\%.?VQ/V>/B'X0TC]N;X!Z3X6^'GQ"U&PTO0?%?@_<;/1 MKC4;B)(8M7N0SH)X8I0T\)V* K,2 ,5]4_ML?MO>,/@/\:OV0?!7P_T;POK_ M (5_:!U2.'4]5U*TBNKVUTZYNK=;>?2+AR?++6\ZOE(M*TWX:P*4.HR>(7N$"262K^^C81#;YB?Q[%X8XKX<_ M;1L]3TWQA_P1RL-;64:Q9>%/ MKJ#3!DF%_#8:#'7_ 4> MC_9B\4>'/@U\+/ E[\5OCYXX55T+PQI\33P6/F[5@DOT3UR&VL5R@)[I_P)K@5N-)T?\ X+CR?\+!FMH3J7@O3QX- M?6=B0?;Q;-]G_LYYQY7G @[F0\9 /.*I.-HMIMVU\WI?5/\ (#N=-_X*9?MD M_L]^/?!>B?MR_ /2/#'@;XBW=G8Z/XJ\%1SW=MHT^H,H@BUF6W\P0S+O"NA4 M;75LGH*^T?VV?^"C/A7]EW0_!6E>#O#EW\4/BG\4K*WG\!>#]'+2RS1W,*2V MUS<1*I=HOWBED8)QU->^?M>_&W]F_P"!?@73?%G[25MIM]X:?6[2STBRGTF# M7]0N-:N)0L1T[2R6G+JVTK(AQSD8.:_$'QMXN\%W?_!6WX#>//%4+Z5\,O&/ M@FSN/A8_BFR.GVML)[>$P+#;W1,5E,Z$"&$_,#@9XI6IO>%O)?\ ?\ 6H'J MFL_\%%?^"C?[/\6D_$W]I[]F7PV?@GJT<,]Y>>#%DGUSP]8W95HVU?RV)AD@ MB<&2,K_K%93R,U^B/Q]_;2C\._L$^,_VP/@>=+UV73_">G>(/#MOJR^?8B:Y MO+*TEMK^,.A:2U%RZNF]2K)CJ*]G_;6U[X?Z%^RU\9]0^(SZ4?"LG@/78(([ MXV[03:EC/;AF*O(+IH)(_+Y8 X&":_ #X=VFNV7_!OE\6I=8DGEM[G3 M=8N='@N&9##IY\96[Q(I]O39JX'NW M@?\ X*5_\%#_ -HSX96/Q!_9M_9K\/WVDZ'HL%_XLU_Q)%)!9Z]=V]L)-6B\ M*6I<&<)*KK&JNW) Y)S7Z ?\$XOV^)?VV/"7CFV\4^#)? OQ1^&&KQZ#XW\/ MR J!?,K9>&$G,*!D*NO.TD9.3SVO_!+W3K/3?V&_@!!8V\%O#<^$;>[F1(E0 M337,222M@ 8)9BK%\E^O2OS/_P""1P$'[<'_ 44M8U$4/NG ZU$N57LEOIJWUUOV^\#^@3Q3<:[;>&];G\*V\%YXBBTZX?1 M;2\^2WGU98BUI!.>JVKS;5<9P!WK^0;3_%G[?>J?\%1]:UV3X3?#/4/V@8/# MEM;W?AC4I89?#5IX7CF=;;4+*23=S-_"& 0D9)' M&[)[*2/E;IQFOP$\*M_QO.\:$Y 'PAL-Q.3SY;X"^W8MT(IPMT5G;7?^K?,# MB/A'+XAN/^"T.M3>+K.ST_Q7+\&M)E\0:?IY46=KJ;1K]IM[/:,,B."%?JP. M?<_6G[6W_!1?XC^"?C6/V7OV6/A7)\4OC*T*7NHWE_'/_8&AAR $O92BP\$C M)\PE,$@>OSGX94'_ (+I>/E!*3-\+K%BVPMB-8LHP[=N<^M+\4OVOOVA/B3^ MUI\0_A)^P?\ !+X<:AXV\#,UOXS^(/C:*PL+V>9'V311WTRK,8]P)4%B.!5V M4[.5MMG=+III;I^3 GT[_@I-^VG^S[\7O ?@+]N/X%>'/#?A/XE:YI_AW0/% MG@]G.G6^IZC/%!!"]WN999!)(OF)@%1GDU]4_P#!4+]N;QW^P[\./A3X]\!Z M+HFOIXN\O6>J6S7#_V/<1K-)_9X#H5O74^7#C=N=ERI(%?A_P#\%#]) M_;ITWQ!^S5<_M=?%'P5?QZC\;5XK .LJVDT9,JS9(1>2I%?2/QD_:;T#]KS_@DS\7/C?X>T]]+ MAU[P1K.GWNF.3(;36M+GMH-2M W&(HYF^5B#C'3CG]!OB19VJ?LK^++".UMX MK%?@KJD*6BPH;:(1^%K@A4C*E P*C P",BOYYOV,997_P""%G[0RAGD2+5/ MB5]E$L@VH7UJ+*(,8"G&3Z\<<<'>UEKT]>NVH'V)^SU^VCX&_9(_X)N?!#4; MW;XH^(_B'21IG@7X?:=(VU50G!.:^_?V']+LEM;G1M#"-=0P:E*9&+7CP;%VG!#D MGZ?RT?!SX2?'']EOP)^S7^WMXKGM_BS\*[74+?3-2\(W\+7T7@SP]+.(X;Z. MWD#Q($!=VE5%*8!).:_I3_;-^(>E?&K_ ()V_$;X@?"Z^_M32_%7@2'4=*?3 MY 3'!-;K)/;L(B?)^SY>-D/W0@SUHTW\]_N7X[ ?&,?_ 44_;L_:0\0ZWJ/ M[%7[..DZQ\+/#]U=0CQ7XYCDM[?7Q92M'(VCSL5$TLGEOL55QSP>*^O?V(_V M_+_]HCQ/XC^"GQH^']]\)?C[X.0RZQX4OT>W@U&WC8Q&_P!-63'G6\D@.UD+ M?*0:_)?]@+]FG]O?XI?LX^$==^ ?_!0+3O '@R/S;=_!=EX56YN-!NHI&,MK M60+YN& )P:]H_9X_9E\?\ @K_@HMX8\3?&G]N7PS\9OC1HFE2Q MZQX+L/"LMOJ]YIDD6(8[_4+62."!(R0?*N(BR-P>12LF]E^O3>W]?>!]-_M4 M?\%)_B?H_P <+G]EG]CGX6#XJ_&+38XY==U75(V?PQH#,<;+V96"11#E6E8@ MJPV@+K*_T17D\* M>)="37M.AN7TZ[RT1EMIF2-X]V[)SMZFOO#_ ()GZAINB?\ !1+]N;0/%3P6 MGC_4_$U[?Z'9ZDR1:G!?V7/#] M[-I(^+-S^T7\-=3T6)?*;6D\(6GB&SBUEFE7]\;,W;VH8G",X/R\4X\L9)I* MZ=UJ]]^_;7[NX']!UNK>1"3]YK:T &/E.($RJKV;))#=AQ@XK\'O^"_&HQZ/ M^SI\*-:EC>>/3/C%X3O&MHH]\UPEM>>:T.P'EVQM09RS$XK]XX?]3;9+!&M8 M K]0K&%,-]3TK\*?^"]4EM%^S_\ "%KX+'8+\:_!D]\'P(OLZ:B"[N&R!E=V M\=,=Z49+357TZ=>VNGR \RMO^"@G_!0ZW\ :)\7/ '[+=@?V=?#.C:/#/_:T M;_\ "9ZCH]E9P0S:E9VI/F?99%B=U<*< 9S7Z)^!_P!M2]_:(_8^\7?'[]GW M2["'X@^']'N[B7PGKZB7^S=7TZ-GO;6^MRRNP.UTA!(.5QU&:^E_#&N^ XOV M:-%UU+S1T^'J_"NWF:9'METU=-70XUN$RQ\DAG61>A(<'/S&OQY_X(FZ9;:^ M/VO]3TVUD?X3^+/B1J\'A$LC-9W-A+Y-?F!^P!^VK\2?VJ_B?^U1X+\<: M3HFE:=\$OB')X5\-S:/;^3/=Z?&T@#:@=[F24A0-WR@=0*_4&Z(-E?8PN;6[ MR!T!$#@GCMFOY[?^",EW;O\ M%?\%#=--Q FH?\ "Y)Y_LC2*ETT/FRCS5A8 MAS'D@,P!QGG HY8>72^NWX_\.!]P_M.?MF?$7X,_MJ?LF?LY:!I.B77@WX[Z MQ=Z;XHOKRW,NJ:?#"IV&PD\Q=A!BJ_[?5A M:7W_ 50_9!AO((YXQ)OQ(@??PC",(X*[D.3YF" ,9I\D+[I:?WNED^W?Y[Z M 5OB#_P4Q_X*!_ &30/BK\>/V:?#FB? /Q!?Q"!]-#2>(M(TRZ96@FU<[B;6 M1874LK*-S97K7Z/?M0_M@7W@#]BN/]J/X9:7IVK3:KHNF:WHVEZY$MWI\D&I M*I9;B-B!E!NYSGKQS7+?\%?;:VG_ &"OC'YD,3-::;:F"-XT/ELK$*48KA0N M!@IMQ@#C KX5^+\MQ+_P1#\&2-N+#P5X>"RLV\A0J8* ]4R",>@]Q2Y(]OS_ M ,P/H#XV?\% OC?\(O@?^RM\=X/"WAB?P)\5=0\/Z7\2R+$^7H+:T;9?M.G- M&ZK:VL8F)WR!U7::CJ?P?AU#0]Z MJ9[;6=-TQ+NUDM&(+0R/)&4C9,,6D ':OQW\7_M-^,/C)^P%\$/V)=.DOM0^ M.7C;XGV_PDU[PYYCMJWY_P"8 M'ZP?!#_@I/XFM?V)?$7[8W[3WAW3O#NE7_C#5-&^%GA+0K=K/5/$]JMT;?0[ M>"$O))5%*D*YV\UX1%^W-_P52\2Z2_QQ\,?LE^'[/X%O/)?P>'M4 M25?B)+X9A_>/)#:L1*[R08>-RN#DX2O&?^"TOPIU3X2_LM?L8^!?#UZWA[P) M\/O&G@SPMJ'B6*(MIF@:U_HL6FZI>V:@QS&*9)KIFE'*Q29.6->]:+^QY_P4 M[UOP=IGB'1/^"H>CWW@N^T.WOK+4[+PC"VCSZ%+8(RB)T_<+!%;9B(Z#:V_: MP(!RQ[?BP/T1_9F_;+\(_M2_ KQ-\4O"5CRM19NTA$NH2B'YPK94GIC%>P?\$TO@KI?PF\'_ M +9-S:?M'Z)^T+K/B2/5KCQ-?Z!H4VB66C:Y!9:B+]#*\DEO>274C'][ J!3 M&PQZ97_!!'2[2'X4_'#4XHD34;GXH^)()9DC5Y@J:W?% T@ +KD_,O3 ]N"R MUT3L^R[(#U#X_?\ !1[XY^ _$7P^_9U^%/PKTWQA^U'XIT2UU/Q!IUU*D/AC M0KR4)Y]NY9T!C1V^^&X XSWQ/AW^WY^VQ\+OC)X2^%7[:'[/&G:38^/;R&TT MCQ=\/(IK[1K!KAU2)+NXB\Q&<,R[@S YYXS7/\ [;7[*'PL_:6_:EM9?@O^ MT-+\$_VNM"THW/DI',8=4MHD7RV!66/YMZ@\9PQY4FOE3Q-\;/\ @IE_P3Z\ M1_#MOVK;WP=\=OA!X@\:Z3X3T[Q'J\FG:WK<$E]?06T=QIMLL:W5E*B2"4,6 M8J O)Q3LNR^X#]A?V[OV[=*_8_\ #W@W3]$\':G\0OBE\3IA:?#_ ,&:=:SR M2W,CLL0N;E8D8*D4TBAT=DR Q[5^=7CS]OS_ (*E?L_Z!9_&3XY?LS^"F^"\ M9AU+7D\.NTWB'2] G92)=3"N38R112 N6#;7&WO7NO[=W[9&I>%_BG\#O@[\ M"/@_X:^)O[1_C[3K?6O"]WXQM;7['X3MKV!)HH[>[NUVQLRL9_-C($03:06K MX:_;BMO^"JU]^RQ\5?$7[2/CGX6?##X9#PW=V>M^%O#E]87MYXCA9VLOG_5P/J#_@JM\8?#?[0'_!+_P+\8?"L4MOH?CK MQM\-M9LK.=MT]HMW>R&2UE.!F2%E(?(!%?L+^S1\W[/7P:(^53\//#YV#[I_ MXE\&,COMZCWK^;_XS[E_X(/_ 5'#[O%GP\9FR)"Z_VE.6PPQMZ\CT'2OZ0 M/V9N?V>?@T 1D?#KPZ2.X!T^'!QZ9!YK"5HMWV7]= -CXV?%OPQ\#?AEXK^* M7B]Y/[#\)Z7<7T]O;!VGO&AB9T@C2-7:73#XO,L.OZM80NQ%Q80R%'G,L*;ER@^8@8[U^HW[=7 MQ\\#_LY_L[>+/B'X[\,V_C&Q2,:?IGAN[@2YL]9UBY)2QM;I9 8UA,I7>S@Y M!Q7Y3?#SQA_P5[^,?PZTKQ#\/?#WP5^ _P )=7TE]7T&ZLKG2X[O1]%D0RHY ML5*J%BM\.XP#E2:T48M)VO?UM^;_ ."!]_\ _!/[]NZ7]L;P_P"+]*\7^"Y/ M 'Q1^&E^=*\:Z)*Q2&&ZBR)9USS%&'5MH;(VC\_ECXS_ /!2WX^>.OCIKG[/ M7["_P@L?B+X@\$7TEEXR\8>*=S>';6\4N'MFG#+';@,C*LF6W9SC'%?+7_!& MB'QA+\1OV\;/7O$UIXT\;--J]M?>*M**I;:YK[6%P@DM@GRB-;D_(5 &X#O7 ML/\ P1#U'1+#Q)^U7X3UV2*T^+=A\3-2N?$5KJ 2'5Y[5IIUBG F_?7%I$3\ MSH< C)XJK6V7RUW^=_\ @ ?&7Q;_ &C/BQ\;O^"C?_!/;PQ\=OA?-\-/BQ\, MO'VHZ7XEL(U=M#U47WVF>UU#193\MQ;2(K$,C8/R\# %?L-^W)_P4-UOX ?$ MOPA^SG\"OAMJ'Q<_:%\=6D-[8Z+';SR:;X+_ (]^$?"L6H>-/B1X MUBL;1K"Q\L8T_3-2NE\V*+3EQ'-,I*RF7Y H!IKIU75+MIUM\E^0'!^(O^"C MO_!07]ESQ#X9UG]LK]GGPI:_"[Q)J5CI3ZWX%[YH MVR-P(K[E_P""@G[;'B7]E[]E7PY^T9\,[#2=9'B#6/"H6'5;$-6\4Z$EM\,O M#=W:7=Q>ZO'>(%BLWB)EG6+Y6EE4A0".:^R/^"HC?YI 6Q_P %(?\ @H=\2O"< M?QE^!W[-.C:G\%]&T^TO-=O=:MWAUK646-'O[C0[-G#R09$B1E2V"!UQ7V_\ M(/VX_%/[6G[+/CCQY\ _"-G9_&GPU8W>F:CX"\32;+:PU=(GCNOM#/@J@*N$ MB;H3Z<5]/_LOZI\.I?V3_AEJ7A6;2D\!1_#JS=W62V%A#;PZ?G41<8P@D\U9 MF*2_,"1D8*BOR2_X)&-87WQ?_;[UWPRA'@6_\9ZH/#? M,#G]WC'TIKDUM'KT?Y]G]_J!\??\$C/%_P"VC'^TS\8['P]X'\$W/A'7_B6? M^&@[Z[N4^W>&;L1S%1H0R#)"). H.WID8%?IY^T9_P %'?BQ/\9=4_9I_8E^ M$J?%WXHZ!'M0M1\0-!U3P'H^J>#9'U*\UW3]5M9 NG?9Y(KH2 M3 >075S&#)R#L('I/[2VD6-__P %O?V6+6]CCU!-.^'7@J>!Y(A(5N+:*X$5 MPBL"(U8Y?YLE6+'OBIM3=O=>SVVOI9[W_&WY@?JW^Q=\1_VS_B#_ ,):W[67 MPY\)_#R".&RU+P=#X=EW;PE1*N!\V00*^N_B3X\T7X7> M!O%'Q!\1B2+0O"VD76JWB1$L\JVL32F-5]"!P0>QS7H$BL>,#H!7CWQ_B\!S?"#Q_;?$ZZ6R\ W&@7T7BB^$;,UEI M(;I?[:U:"RD?S#IT(D\V2:6*,E%,>"S <<5^C/[$'[9U]^U#X/\ $UU\0/AW MJ_PI\<> 9I;+QAI.M6LUK9[K>)GN;NWEF54,$:)(^5+ *.HQS^-'@']A/]K; MP'H@^*G_ 32_:VM?%WPLUB_O]0TOP=J5^FG6XC>1Y9+"[FNVDM]R@F)1Y*$ M=,YKZ1_9$_;#^.'QJ\&_M3_ +XS^"_#>D?&3X<^"_$$-WJ_A"VMHWU62+3+O M[4;N[LU47%WN1W67>]]TG^73?S3 [;XA_\%(OVF/C+\3? M$/PO_8#^"5E\1;7P1J%Y8>)?B'XJ1QX1N;FUD9/LFGW7$;3Q;",!CR,UZ9^R MY_P42^)FL_&BQ_9A_;&^%I^#WQGU>!I_"^IVZ.OACQ1<1_=M].E;]V2W16#, M6XX%?D'_ ,$T/@1^V3\7/AMXT/[.'[;FG_!*WTSQOKJ^(/ARWA]+_6[.\:]< M_;;]V'VB1;L R12,2H4$9&:^C_%?[('QJ\/_ +8O[+VK_M4?\%"/#GQ ^(/A M[QG8WW@CPC/X.FBUG5K61I6?33-;21/:Q7)7*2W 9 %W#((-#Y-HQL[=]=^V MOWWO=+Y!]L_MB_\ !2SQ]X#^-M0\3Z#:Z# MJ5M:O?>!->T&^NHTU5;.X\Q8A?Z?;NLG#Y#,1CK6_P#L"SZ;H'_!6[]O/2/& M\MO:>-=EXK;5 M^?ROO_2 ^L/VXOVW?B9^S3\-OV?/&/@S2="U'4OBSJ'A.V\00ZI;"2"V77+. MRGN39KO'E;'N'VC+8 'I7Z">)_&6J:/\'=2^(,,=LVK6G@5/$ODNF;5KLZ4+ MY8@A(Q$)2%*YY'.>:_"G_@KE/%;? ']BNYN9HX;:+5OAT\D\AV0Q(=-TO#22 M'A1CN3S7Z^_&;QEX>\)_L?>(_$^LZG86NB0_"" K>2W<*VTKS>'D2(1S;BKE MF9 %7)+=N#C-Q7;KY_/\+@?/W[ W[:WB+]HO]FSQO\=?C)'H?A@>"_%?BG3+ MUM-C%K8PZ)H,EP%E&[H/^_@OW0>:]R2 MNY_XOH:I*"3O&^O71:VZ_P!:Z ?K)^Q5_P % M3^//C7Q)\!OCM\/[WX/?M" M^$;62ZN/#-XCV]IK]G;QDS:GHQD^] 6&4V;MZ\\#I\*P_P#!6G]J?Q'^T1\? M?VRK"N]#O;9M&2%/ M-9WP5_9;^(/@;_@HOX%\5_';]NCP[\8OCCH'A^=+GP?9>%98-=N_#\MNX2"] MO;:1(($08S'/$60#DYK;_P""4]C9#_@H7_P4HV[;*RXV8)(K[<_;R_;Y\,_L7^ M'M"L[;PU=^./B7XXO6TSP;X0L,M-?7I^5971^S)(+-A!T KF?^"B+V6E_P#!4O\ M8YUKQT(X_ TCZ;;VLUZP?31JZS1[ISYG[D3[<;U(!V@&HY5V_._Y@=#J7_!2 MK]O_ . A\)?$G]JC]F[0M+^"'C&[MDBNO"\+-1^)-I;O\ #SP79)(=9U^\ MNX4:&VAM0OFR*LLB(S[0<@CBO=?VG?B=\$OA+\)-:\=_'9=+N?AOIR1RW-I= MV-MK*7I8%K?^S]/.?M4CKCRDA/<%>",_SH_\%.?%-I\6/''[$_C?X+^*+CX1 M?#_Q1-$GP]\8ZYHYL]+\-SW$B"WN9]&F#1VZAG3RT;IQZ9JDJ32]U_Y[;_=^ MGJ'U>_[=_P#P5(\)Z*GQK\=?LFZ,_P $F']IW&CZ9!,?'%AH)(D%Q=VRL75D MM\.V5_ASCBOTJ\,?MU_!WQ/^R;K'[6MK/=)X/\.Z+>:EK^B@?\3&RU:S4)-H M<\1^9;F.X98^1R,GMBOSCUW]C'_@IJ? NJ:MKW_!3S33X)G\/SRZC/)X1B;2 MUT"6S83R&8CR9;=[4LH"L,CY5/:J/['7P7^ 'PZ_8/\ CWX.^+?[0>E?%_X0 M^)]8UV+Q?X[T+0[K1[71+N\F_P!(ECCDDD7S[>XPPFC C(R,#.0>[]F*5GTU MVL_OO_G>^P5/#_[?W_!3?XX:'=_&K]G[]FSP9?? V,7%[IUGK-VDGB[6-,LB M[32:=;I(9)&FA3=#N"D\^PK]//V%?VN?^&O_ (2S^.-2\$:S\.O%N@ZS>>'? M%/A76K:>VG@U&Q<12W-NLR*6M9)@XC*Y'!P<5^)W@K]A#]O+X-^"]&\=?\$\ M_P!K.V\>?!W6(&UCPWX6U.^AT^SN-&=S*EE--?-/%,'1=FV-(BF.V>?O_P#X M)<_ME_$#]H/7OCW\%OC)X$\->#/C#\!=5TRT\87/A"VM8-&UA]1=X5=VM$6. M>^22,R33ACYIDS@;34M*ST6W9=OZ_ #]C0AJ:L0" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@!PZ'_>C_ /0Q10.A_P!Z/_T,44 -[#_=7_T$44=A_NK_ .@BB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CZ M\#O].]%% '@_[2'PK\1_&WX+^.?A9X;\51>"=3\9:3<:2GB%[::Y2RM9U*2% M8X764LZ$_,&'X]_-_P!B[]EC2/V/O@9HOPBL-5B\0S:=<3WNI:W;V[VSZMJ- MZQEGN9(Y,R?/)EOG)//UKZ^==P(_O8SR1P!VQT_#%1[,C9QA2"/J,8R>IX]? M2B[6P'(^.O".A?$'P5XH\%^)[.WU'0/%.@WNAZII]P@D@EM[VW> [XCG<\4C MI*HX(= <'&*_$#2O^"-7BW2/V6/BM^RBGQ^M9O!'C;XHZ+\2_"AN=&U"5O!T MUCJ$E]>:?%&9?W_]H*\<>Z$*L8ASMQ@5^]@1MS#C:>3D<$^O3W)IK1,00.YR M'X$4[ONP/(/AI\-)/A]\#_"WPDDU--1E\,^!$\&R:M&C0K/(MB]FU MX(I,N$;>KB,_,HR">1GYN_8$_8WN?V(OAIXR^'UQXPA\;2>*?B'X@\<#4[:S MGLX[)-?O)[E=-$4Q)9[<38,OW6/3'2OO'RF4C;C&23T)R>IRP)S]>*?M8'C_ M .MU[@\$^Y%/F?\ P_\ 74#\\?A#^PO/\,OVQ_B5^U.WCN+4[;X@V#V53F2>Y& M-(DAD#6E]_9]W*ZG45!"B10$8Y)0M@U].?MH_L.M^UEK_P "-8MO&UOX,A^# M'BF'Q&;-K":[&JI%<0RQ6$ @9!"(EB$>\@A05^7@U^A 1QGDY;!;.W!([[3D M#GIZ4!'&<$\DG^'J>3CCC/?'6CFEW_KY ?GGXC_8=N=:_;K\!_MEGQS#;P># M/AO;> F\%?8YFN+PV\+QKJ"7RGR%+EMRQNNX?7IS7[;7_!-7X;_M?:[HGQ-T M?Q1KGP?^.WAB.$:#\2O"LL]G>3Q6[$P6>L);O'+]*[[L#\1_@[_P2 NK3XK>'/B] M^U3^T)XH_:.UWP.T9\&Z-J@N(?#UC$OB'X4X//3U_VNOO33$V2< ;B-VTD9^N#C\?UI\TN MX'X,^'O^",?C'Q=XAT2Y_:D_:R\>_&[P1X=NH+K3O ZRW]CIMV+5E,-MJRW$ MIBN(MJJK,Z[R9=A4XRH/\NG4?Y]Z_/#X&_L.77P;_;(_:*_:P/CNWU>#XZW M,4[>$([&>"70W2*&,(]W*QCE),>24"CGN!Q^AIC?H.!C!&1_].;?5(/B1IAT^X\("QFCFLX)8UB M82WC'[/,@'!:)5R,C/%?*'QA_P""06O:A\9/$GQB_9B_:1\5?L^ZCXWG>Y\3 MZ+IZ7LVEW^:MR=]'H[?+^O(#^?#4/\ @AFVHZSX1^(^L?M. M^,_%?QDT#Q+8:W>>)_%DM[J^ESP6D\:^!7_ ."95[/_ ,$^C^P\?B;:M&M(U/3[J/4-"\/WC.@T2:>Z=DG@BMV4$QX^?<^ K8K]$1$XR>-VXL#GH6P M&([#(Z@8%.*-G/7&<9/'(YXSWZ'CFCW[;2WVNN_KW^8M=K,_ W5/^",?C?P) MK^N/^RW^UYX\^"_@#Q+]U"SL?MXN?&/Q$\3M]NU35)68NXLIFW36U MH6Y6-W+?-@G Y^]]I7=E0-P ( !4@=!C&!] !3DQPN.!RO4$?CGIQTZ4>]W: M\G)7_,&FMT_N_5:'Y$?M6_\ !*7P_P#&CXH#X[? [XJ^(?V>_C'.=^K:WX>D MN#I>K;3\L^I6-I+')-<2*QW;R4!'W>U>.Z!_P1BNK3XD_!/XR>)OV@M;\=_% M+X;^.5\7^,_$'B>.]U >)HHF)LM*TU#*'TNWMT=D 8;<$\8&*_=G85;*@ [B MV>,Y/N['4?7\*3=OBE9>M_P5_45_*7JT[=/\T4 MT4B.,D)&8U&\*"\:N@5?D(Z] <$X'>OSD_X*"_\ !/VT_;OF^ L6L^,;7PUH MGP<\;ZGXKUS3;FQGO4\46.JV=O;2:;&]O(GV21!;ES(^X9=1M.,5^DHB'/ 7 M*E2.Q'TR1D]SUI3$",9_BW8YP6QCD9Y],$$>U*\?YE^/^5OQ"Z\_N?\ D?@/ MKG_!%?QKXBU-/!NH?MA?$R;]G2WOA,OPO:[U!K_[ 9!,=*AU'SA"+$([6\,3 MJZ"(*I&!7[)?##X9?"[]G#X6Z%X \%6FE^"O ?@ZQBAMY+BXBM+=1&JK+?:A M<2LJR7$Y5GGE=]GF,V-HXKV4HS8)'0%1@XP#GC@CU./3M7 _$_X;^'/BSX#\ M1_#GQ;%,WA[Q1IT^F:B+61[>Z6"X1D+6]S&RF*4%LJ0P(//I3C**=W*/X_Y! M?U^Y_P"1_-[^W/X&^%G[7G_!2SX">"/AG?Z?XQNM/AM-3^(UYX>O;?4])&DV M5XEPMO>3V320K.#$&'F,?E!YQ@U_35HFC6&A:/I>AZ=&EGIFD6%GI=A;P@*L M4-G D0! XVE4 .._/-?'_P"RC^P%^SO^QNVO7?PE\.W+>(?$NQ=4\3:]-_:6 MN-;QC:ENE]V,<#KC&<\G@<<]:_ M9?GU\Q_?\DW^14DACD26.1 \$T\5?%']F/]IGQC\!K7Q_<3W7C308?M,\3R7CEKV/2S;&*&V@=3 MF$SH\L32,!*<;F_=P\]?3'X>F:B:/<3NY!&WG)R/0C/./4Y-*,E%Z25^EK]U MY?\ ![!OLF_D_P!=#\;O@;_P23T#X#?M/_##]H[0?BAJWB.[\'>#]4T;Q@/$ M[76J>(_&7B/6(ME[XAFU5Y'1(7PGE6LGS(@ &,5[Q\2/V$[GX@_MY?#3]M% M?'MK8P?#SP2_@\>"6L+B26_WS/,;D:@KB&/(;&TJ>>O3-?HQL^7D?=5@H!]1 MCMP>/[V2*14(&%Z=,>N_!JW\70^"WOM:TO5O[8GM9;Q(_[+NX[HPF"$B3=(L80-D*< M\UQ/Q_\ V')_C?\ LC>%?V7H?'5OH4OABUT"V/B:6SGFCO/[$,!\P6L;"6-9 MA"P 8G!89K]#"I^_D@X"\ <#ZD9Z_C@^G%- /.<'/'(&<9XRW7'MTS0W_+*_ M9)O;I^:&TUT>O]=;'F/PN^'J?#GX6>%/AA?7@UJ+PUXH:?XFFN;CPYX- M%C,L?AV2_8O,5N&=HY,N<_NPN3R0*_6C81DGNW'(/TZ>U,QC=R0&(+ M+QC(Z84C _#%'O=VNJWUVV^_^MQ'SG^T[^S!\*?VM?AGJ7PQ^+>C27ND7@-Q M8:K9&./6]!OTY@U+1;IT8VT]N^'88PW&X="/R"@_X(P_&]M,_P"%XIZA5 4C 'W<=!S[=O:E=^=OP ^._"/[&GPO^%/[+'B?]EWX26,'A30? M$'@O6?#%QKCQ&>\O]5UO3Y+.Y\1:OL)FNKYWD:9VSECPO/-87[!'[(L_[$_P M)M?@O-XPM_&SV^M7NL?VS;V4UE&!<*/W+0S.SE\J ,-USQ7W( I.0<<$?*!G M!]1_+/([5&85(VGD;]_?[P[YSG\.E";VO;7_ "_*PK]TUZIKL?E'^V'_ ,$O MO#W[1OQ'T[XX_"SXG^(_@1\:M/@6!_%?AV:2.VU:-2"%U2UMF6XN/+ PH)QC MY3Q7FGP=_P""26I6?Q1\-_%G]J7]HSQE^T3KG@FZBO/">D:@;FU\/V5U P>. MYNK2Z9@\T;J ABVD\9R:_:H1KO$AY<9P<8QGT'Y_2F&/YMPY^IS[]#QUZ=Z? M-):)-]$TEY=_U77T!.^UWMT?78_*C]L[_@F+H7[3/COP_P#&/X:_$O7O@9\9 M?#UM#8P>+-">X\BYL(% @M[JWMI$E#(@Z%BK<<'FOD[Q#_P1!\3_ !?T'6!^ MT3^U[\1/BCXK73Y;;P6[W%W!X6TF\7;Y=]J6CSR'[;)&1UB56Z'/>OZ"!'ZC M W;SSR6YP3USC/0\<\"CRNG3"D[*_5WPWI/]B>'- T(R^=+H^BZ9I)EQY:S)I]G#:M* M(VY02F(NJ,2P#8SQ6V(Y/FW$$''4#DCN#C(.,>E/6/;NR.6.3GD\=.>HZ] < M8J'*4E\+?W+>W_ Z;O[E?U^Y^7^9\K?M=?LH?#K]L;X0:K\)/B&U_9P7?^EZ M1KNFR^1JF@:E;?/:WMH3RA655!/WBJC!Q7Y2:/\ \$:OCI>Z;9^ ?B!^W;\3 M-;^$-J@LSX7TBYU*QU2;2XP%@TPZC-,0Z&U"Q2$OL/.$"\5_0.P)'&/0Y R5 M]"<$D>QINP%=I ZY^A'3'''X41;33Y9?AY>?FK?(+^OW/_(_+W]@O_@G':?L M+^*OB9-X9\?R^*_ OC=85TOP[J-M,NIZ8R >Q!/\L8SZG&?>CRVP06R&Z\G],#(_.J:_JY^(_PH_X(\V'PM^./PS^/:?&O6O&/B_PL99_&NJ>*DO= M3U/Q/?2XWM9W#R,+&U!R$B<#"DC.:W?VDO\ @D]=_$;XV:E^T'^SM\>_%/[. M_P 0O%$9/BA=+^TRZ9J%P ;N.VM67=YF T@G5U[H5/7]G3'V'&0 >@Z=.@Y M]\]>^:0JV,DEG/!..0#V!QD?RI<\NS^:7EO]Z\]06OEZW_R/YX?'?_!"6;XI M>&+K6?BE^U'XZ^(7QRDOK&?3?&/B1KZ\\+:/'9SB:1JL4CH1' MA1QR:Q_^"VO@=]'_ &>?V'/AMXFNX?$']G_%72/">KWNV2%=1BM- T[3I9U1 MCN5)XHQ^[;Y^0,\5_1GM;D98%N-V.>_MCUY/X\5\O_M._LC?"G]K+3? 6E_% M.+5)K7X:^+8_&?AR33YUA>/5TC2(?:<@EX@(EX(Q@<$4^?57E%6?6_;T[,/D MV?DR?^",GC+7-,TGPMX?_:_^)GA_]GK7+#2]6N/A8M]J!O+9+ZSBNKNQL=12 M81PV*M*Z0V[AH_+ C8=J_8GX%?LZ?"[]G;X4:?\ !SX9:$FE^%[6Q>TO)V") MJ&N7,]NT%YJ5]*P_>WEQN:4LP*Y)V@#K[GIUE#I]AI^G6Z?NM,L;:PMB3D^1 M:PI;Q[B3\Q,:+G.>?CE\ M ?\ @F#XZ_9L_:1\0?%GX:_M&ZM;?"_Q3XBU'Q+XA^$MU8W,MOJ%WJDDDDT< MTB,;38/,*!O+4@#&[FC]I+_@DGX?^(_Q2N_CA^SS\7O$_P"SC\5=7<-KUWX< M,R^'-6E_Y:W>/V/V?)COG.1QU.>O?Z'CVIN2"">H! M'/3GJ<# )]\4US/;F];V2^_7\!'X_P#[-7_!*+0_AI\5;/X[?M#?%[Q+^T?\ M4]#"GPUJ'B9[DZ+H,PQY=W8Z?,@STZGIS[ MTIW,<]U P<#OQR<9(XQC^E'/%22YTWVO?Y?\/;Y[ 2GG<4 RR+@YX922=J?P MY7.",9X-<%\1O 7A?XI>"_$?P_\ &>G1:MX9\4:7-3-+X\\6>)I1?:O MXCFN4*7D=S))ND:&3S'!5SD*WKS7VYL(QC' Q_B>G7/?K[TGED<@#)].#_3K MW]>^:;D^CT _#SXJ?\$'M,EO+CP^; MB8DS3Z;8VSB)6EW$N)$9P<89:][_ &-_^"9'@S]FCQGJGQB^(?CG6_CK\<=: M'D/X]\5237*Z3;-PT6DPW;R/9*X'[U5VGG"8K]2?+/R]/E.1['\!^=)@DDXY M(.>, ANO' .?_P!5'/+N!^37[7__ 2X\+?M _$BV^-_PB^)&O?L_P#QUAE' MVOQ9X;DN(K'6%0#<^J6=JZ27\R84JP_= _?! K\;?V]/V'[S]ESQ3^PMX[\< M_%OQ3\;?C%\1/VI-+T?Q3XW\07((8XHE>\# JT48@C.W;AAGGU.:7<#BOVTOV)?AM^W!\* M--\">.]0U?P[JFC36FK^$?%>@RA-7T#6([:,)*C\L(Y&55G*88QEMI##/"DS:E#H>DW$EI+;Z=1E2!G M).2!T!Y!R*.=_P!?+_+\?0#XZ_9A_9+TGX$_LL^'_P!F'Q;J5I\1=&TZRUK3 M=8O#:/9P:I:ZQ<2S-']EG9G58TE*YSR0I4]:_-S6_P#@C'XR\$^)_$%W^RS^ MUIX[^"7@CQ/>7-WJ?@MI+V^L+)KMF-S;Z/#;R".UB()",?G7@@U^]&QMV<<8 MXP3D?CG/X9_"I64D <<#T&?SQG/OFJ4]-;W]/^#_ %^ 'Y[_ +%7_!/OX;?L M;VVN:S9:[JOQ&^*?C-S)XP^(GBAFO=6U&1\F1;2:4R3V]KGJ-^-K8SCKD?L_ M_L(7'P2_:E^-O[2'_"?6^M0?%IHVB\-P:?/#+HLD;EV\VX>O- M?HV8R<\=?0X_ $$$#V'%.*$A@< , & XR!]!^HZ]S0YZ*U[]7I_P0/SN_;E_ M86N_VQ_$W[//B"W\>0>#S\#/B1:^/)K::SFO&UY;?R !]3ZGZU/,] M-=O) ?@UX1_X(R>+O$_CCPKKG[5?[5?C/X\^$/!$UK<^'_!4POK33':QDC:S MAU2*XE:WO %B0,[H93\Q)(Y/Z(_M4?L,?!']K'X::;\,?&.DR>'_ /A%K2"' MP%XD\.D66L^$9K*/R[673KJ,H$2!E3=&O. Q'.*^UF3/&,Y.XG)'S=,XX_ET M]Z14(>F.<>_.,]2,YH4FMMO/Y?Y?[N],@=62QN+Z2<_:1(B^5)YA>/:Q &*_66X_9#^ M!T_[/DO[,:^%+:#X62:.-+BL+>&,75O(L0C74S9\E>K!=NXEB:^JRC90XY3.W&,<^HQ@^V[IVQ4B@X(8G!QQD]C MGD__ %_:E*5U;7^OO_3_ # 4 8 R3C<<]0WW?Y4^CN6[GJ?\_2BH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@#RWXT^#?$'Q$^%OCGP'X9\2+X1UKQ9H%_H=IX MBDADN%TQ=1@>VFG6.$K*7$4C*-K!EY;( S7S1^P'^Q=HG[$'P7F^&%GK,/&*VLMK-XAU2\D9H9)A.SS2FW@D\L,6/''7-?=!&1^.1]<8_EP M?:HA'\ZL?X,[>>.NU &9K>F6FM:3JNC7\<5SINK:9?:7J4$B[EGM MKV"2UE0C^(>5*P([@X[U^*W@O_@D5JG@'X:?M3_!_P ,?&.TLOA_^T5-=76F MZ&^E7TD?@QY;I+F!K= XCF2,(RF.(!@6&X]J_;XKE@<<*2PZ=3U/OSZY]J:L M948&!\S/W^\_WNW0^G3VIW?=@?-_[/OP(?X&?L[>%O@7)X@BU^70/#4V@OKO MDO;QW#2V[0&=+=CY@V[@?+)R,'H:\5_8H_8NNOV0)OBW-<^-K;Q>OQ*\7WGB MJ)8K26Q.GBZG,T=D[SD^8P+%0V2.^,5]\>40V\?>QU&/Y,,9]P*7R\\$=23\ MP#C)ZG!R,^GIVHN^[ _/'PM^PS=>&_VV_%?[8#>.X+FW\3:/'I/_ AZ6,XN M+9_E&\WNXV[X_P!E!]:_'?XW?LV:+^U)_P %??C;\/M2\2ZSX+UBQ^'/A_5_ M"7B_P[.1@@E4-AURM?U+-$_!1R&&,= .#QP/E_2 MOES3/V/OA3HW[2GB']JNR@U/_A:7B71K?0]3:2Y1].DL;9$2%4@V[U*! 00_ M4=*J,K/5MZ>H'YP?"O\ X(YSGXG^'/B5^U9^T3XN_:-/@.\@O_!GA/5I+N/P M]#1$E1XU'[Q0'+#@_5O[7/[!\G[3OQA_9O^*&G^-K/P M=!^S_J27RZ0;":[.K0_;8+M+2/R&2&W00Q+&C,HV]O2OT45&QR/FR2W.&!.? ME/.2 .,'@]3S3U5AG "YZD8&< @9(YX!('IFGS]M^[2\O\MM?N _/?\ :"_8 MAN/CA^U=^S[^TO%XYMM#@^!XO$;PW)93SW.MO=-E1%=(WDP-M X92P/XU%^V MS_P3O^&'[95KHVNW.K:U\-OBUX0/G>$_B-X6N/LFLVC94B"[GA*S7%DY +QH MWF8&(RH.#^A8C8,I_N$E>F <8SC')]SDT\HQ(;(R#N!Z<_@.1QT/ ["IYGIY M?\#_ " _"SXZ>2.Y\G;RX^=CR['-?<'[8?[ ?P=_;&\$Z%X;\2F_\(^(/!D4:>!_& MGA;;I^K>&WM8ECBMUF0+(L 58QA",*N01G)^\C&6ZD'J.IZ-P1TZ'TZ4C1E@ M M,?V2/ M[8_#GPWK?AC3_ YH]_'9^=;Z/;VEU:3K*UO;E#(TT6.QGLY-!6YE,PMII9RRS%.! M^[P.*_1[R3N.,!>< ''/7)QR2.@R3@<# IQ1P!M*C!ST'<$9)(_#\:D"#S'3 MYRGRJ1(456# #. 7/R$=\ =/KFOS^TO]B*YL/V[=:_;-_P"$ZMI(]9\)6WA= M?!L=C<"6-8E*BYDNRQA<Y/%?H.$9>@/7.,Y'Y$D8]NE C(?>%^;D9 MX[]<#H/P H _//2_V'KG3_V[O$7[9:>.K=XM9\,0>&_^$+-E,)XGB556Y>^+ M&$P,/X%4<=&SQ7S=^T5_P29U'Q[\:-7^/G[.GQ]\2?L_>.?%#.?%#:=]JNM/ MU&X?#&6*"R>,!BV6_?!Z_9XJV,/C=IOB#3= MQ73YHKB.VMM+,ADAS>1"8&)4V@^V:^Y/VQ?V"==_:T^%/P&^'VH_$RTT/6_@ MWXG\->)M4U^?3KFYA\27.@+;+,L$<;"2W>Z> L#*6*[@"#@U^F!7YBQSNX&> MXV],$<]L=>1P9YYXG\%3>(/A9J MWPX-\MNVK>"KKPBVI["_D-=:5)IGV[RE^<[-WFE 0V 1G.:_.3X*_P#!-FZ^ M$?["GQ'_ &,Y/B=9ZO-X_OO$ES'XRATVYC6T/B&]2\&ZR+-(4@V^6S*=IYQP M17ZPB/ .,'(V^N1TZGIQWZ]::(MJ[%0 ;1C&0,YP&^\!]#4W7]?+_-?>+7L M_P"K?/JCXX^#?[(?AKP!^RCI?[*_CJZLO'F@P>'KK0-5O9K1EM[R&XC98[F" M.XR89XV8.K$Y!7@COY9^QI^PGK7[*WA3X@_"O7OB2GQ+^"_BV\U!]!\%ZM:7 M#'PUIU^\C2::D\Y9'B\IQ"%CP %^0"OT<\LE2I^Z<'!(_AZ=.?S/UIRCDANO MIVR1V'3/3''':A3>RYK/KK;R_0=GV?W?UW1^$'B__@C1XC\->.O$/B7]D_\ M:C\=? 70?%-Q<76J>#Q+>WVE68@/)KZ^_8I_X) MS_#_ /9!N]>\;ZCXEUOXK_&;Q9E?$7Q(\32->:@1N,ABL#<%[FWA\PEP P_N MGBOT?*G!^8?-SPV,\]CQCGT]Z;AMPZ#C'4YZYQG///KS3NVKZNWZ^H+7JEZW M/RH_;'_X)>^#OVD?'=C\:/AAX^USX"_'>Q2.-_&_A:6XM[7Q (F&%\0V]JZ3 M7$BKDQA"(SD;E9C7ROXK_P""(MY\0O#'AW4_B/\ M&ZWX_\ CIHWQ-\(^,'^ M)?B>*^OK6T\*>%[R"ZF\'Z-I9E#6,>I2VZ237!&PR@,VX]?Z F3M/\ >WGU MW8Z_6E"#I&,GM@GK]?<4D[ZI-6UU_0+>:?DKWZ>7G_5BG"KH@!4$Q)#" M,G>5DBC5%;:, !L%MIY#9_'X*_X*#_L1#]NKX:>&/AS<>,X_!=OH7BO3/$=W M=36<]VUW:V,N^6QVP,NPSJ2J3'A#SR>#^@+ Y( V+D9(P"V.03X&T']L/XBZ+\ M!I7M3JGPV%WJ$K_9D2-;G3],O5F$5O;2E)#'"VY5$F&4BOU[^!/P+^%7[*GP MJTCX;_#^TM_#W@_PW;JUWJE_)%#->7 7;-J&KW#;46>1LO+*VU#OSZFOH J2 M7^7X^@6E_++IV_5_CL?S4_\%3?!GPP_:X_ M;7_9E^%/PTUG2_$GBJXN;:;QY?>&]2MM0M++0K*_2X:+4)+-G#>?$I@,PK^D_P7X0TSP+X6\,^#M#MX['2?#VCV.EVD,0"+$+.W2+[HX (CQC S]:^ M/_V8?^"=7[,W[)WBC7?'/PT\.75YXV\0>9%<>)O$MXVLZG!;RRM+]ELY9C(; M=%9OE*D, ,]:^[U5ADE02V"V2.2 %!Z<<#T_P :4I.22=]/._8+/;E?X>7G MYB-M^7"[UR"%4CYN/GW@]%(R6)&TCC'.:_$3XZ_\$>Y/$7QQ\1?'O]F3]H/Q M5^SUXH\=7T]]X[L].-Q8@DVF-4'!_;S ) M&Y0N.F. <8/4=N^.G8TUX\_+]T,^[Y0 "*A=ZMKWQ#N)0/LUE#- MYC)I]GI[EQ:1N,1B1@/4(K:%(#+Y$I,B MI\O(8D8S7P+X#_X)9^#/ G[=6M?MCVGBB&ZL;]KO4](\!M8R[=(\3Z@TCWNK MVDZL+:..0RO\L:*0#AB2:_64H<$\$X(X49P1@@9[>W3OUXI OJ0"!MYP#M]. MV!P..,]?J> _VY_B5HGP M,N;E[>'P7?2:C+K<6BRO^]L$U..811R>6?*C$*)$%Z#K7]!A50#D*V>WUZM[ M$=B.?0C-"J2<@<9ZGG!]0#G!Z&?5=7N5^::8NS.5!PJ\ 9)SYY M^P+^Q5"_&?A.X\+-7\3"[MK&>Q%HFHWUQ=K;*9V8R&'SC&3 MDYVY'!Q7W_A6R60EN ,NO;VZ9]#U]\&A4++M8?+D$#Y< CH05_EZ_G1=]V%I M?RO\/\_-'YA_MJ_\$T?!W[5/BC1?BIX1\=:]\&?C3H"K%9>-O#$TT)NH8\,% MU9+5DFG12JE4!"D_>!'%?._P[_X) >)=2^(?A7QY^U;^U'XV_:!M?!%[;ZCX M7\+W)N;705O;1Q-;OJ5I<.T,R0E$*.JB0N "QK]R=OR[>,GC. ..XZ9/'K_^ MJ(Q8# #(8@D9Q]T +C/08 .!@$]?6JC.V]W_ $@M+^67X?YGYD_MP?\ !-OP MG^UQJ/@WQQX7\:ZO\'OC!\/[6"T\*^.?#\DL9^Q0[?)M;^.T:.=O)4 0B,CY M?E8,"17QIJ/_ 10\;?%K3=2L?VF_P!L3XD?%,0:1=6_A>PLI[^PT.QU(H4L MK_6+">0QZBL&29D">:QSMQ7] )4AM_.=NW. !@G.,#O[]1T!Q2NH4J4X8 \\ M$%NYP<]>_P#7%6JB3NK_ (?\&P[2_E?X?YV/QWU'_@E[KNM?L!^&?V)M2^+> MGSW?A?QQ8^*[#QNNDWK01:3IMZ;JPTD6&\3QN8F9"[-Y>=Q4=!7ZE_"WP:?A M]\.?!G@62Z&HGPAX;T[0#J(BDA-^;"!83/'"YWHK["P#Y(SSQ7=JO4C&[/7@ M,QXXR.<>QSCH!4B[U[9POJ?Y>YK)N[N_R_X/ZA:6GNO7T_'4\"_: M6_9V\"?M1?";Q)\)/B'%<'1-A2;:_M6)PKPOM8-C(QQS7XZ MZ'_P1F^-]AIL/P]O/VZ/B0WP4MIEBMO"&CSZG::HFCJVW[!]O\XABT0\I]KK M&5X*X%?T%,<\Y ;KDXS]#ZCM@\8YQVJ+;G)X']TC !]N,=3V''>B+LU_6@K2 M_EE^'^9^3_[$7_!,F#]B#XM^-_&?@KXHWWB+P'XSLXX9O"NJPRR:I'>1G)O; MN_W&*ZF;&&X#%B>>U&QC MU4?7(_7CGZ'ZU;GM;YW"TOY9?A_F?AKX)_X(VS>%?C+^SY\?-9^/VN>-OB3\ M*_%MUXL\>^(/%$=[>S^-9&,BV-CIQ>4C2[6QBE>**%QM(Q@"O4?VOO\ @E=! M\=?C/;_M'_ SXR^(?V??C-/:Q:=K^O:,]PVG:Q91#:DUQ;6CJ[W#< I*3$YY M8' Q^O)4?Q+DYR1N7&3R20>OY'VQ1M&.G(]2I'X@=?4<<9[5/-+3^K[!:7\K M_#_/>^A_/?XN_P""&FN_%;0-3U'XW?M8^/\ XD?%"-;8>$M=U62\D\)Z-+%) MO>>309)"QG; \J2## Y.XU<_X*T_#*\^%_\ P30^%GPGU_6(_%%QX7\9> /" M]_K$,4D-MJJ1ZCY37,D4Q:5%*'@;A@C':OZ 0&W$Y^\<]?3[N,C (]J^>/VE M?V8_AQ^U9X!M?AU\4XM1D\/V&O:;XBB32[A;=Q?Z7,)[4%VW!HU< L"#G.*7 MM'=)W6NCLO3I?^GZ!MOY>>_I<_&'PG_P2 \<>*_ O@Z/X?\ [6_Q!^'?P9\< M>&=$U'Q#\-+.YU%@#=6,$EY;:-=),([*WD)D.W[K;\$5^R?[,O[*_P *_P!E M'X8VOPN^&.ELNG>06UW6+P^;JOB.\D0QW-YJ4^26GD#,6)(SN)QGFO=?"OAS M3_"'AO0_"NDB1=+\/Z=:Z9IZS'=,MK9Q+##O?HS;$4DK\N<\O@U\3O$G[/OQQ=%34/$WA222/0M=8_Z^ZU6QMBD]Q?._*NS ME&&2R$XS^MJQ;>F!QC&3@@^HZ'\J0QJA#CK[9 !(YP,X^G'ZT.;_ )E;NO1; MW_K\@>F^E]O/^KH_%[X#_P#!(V#P]\6_#_QP_:J^.GB;]ICQCX)G6;P3IFM& MX3PSHU[%@P7S:;=NXEOH",H55=S']_$_P#8(N?B'^W=\-OVSXO'MOI- MO\/?#.G>'_\ A"&T^=I[]+$2DRK=JRPHK>;\F5.,$' K])=H^7H3Z8Z'L?3= M_M=?>G[#P#R. "QZU]]_L8_L#?#C] MCO1]=DTW7-<^(OCSQO-)-XW\=>*Y5NM0UN>9#]JC7.7BMGS(ICD+#8Q4\5][ M[#C&> +OV:O&_B.=YO$UKH;W$_A6^EERYEM])LVC59Y2S-* M\GF*I'R!E>*_%+SW%AX: M*#:[:)874DAMKF3)(8*"GS;0*_6?81T. !M')''X=_?K[T%#D$#D#KP.3U.. M.?\ :(W>]+FEW _+_P#;5_X)F^ OVK/%FB?%_P '^+M<^"/Q[\/1106/Q(\) M33V;:K:1\QP:[';21O>1P9PJ @MPLI88Q^+W_!1__@GQJ'[/'[-=K\:?B_\ M&KQ9\??C._Q6^'7A_3/$^M2W$>E:!H=WK"PS6^F6$\CB&ZNH@(KIP/WB ?4_ MUOE&(5=N54],C !ZEL]O7OZ$5\Z?M._LO?#;]K3X';7Q'HWB M=3ILWV:5M5T&Z%U898C!C63&3CYNYXIJ;6^H'CGQI_9%^&_[9?[*G@7X6_$+ M[9:1OX+\(WVB:Y9NJ:EH6I1:'8-#?VTJXV-"^UMG< <]/@;P'_P1B\6PQ1> M%OC/^UCXZ^*7PIT>UN;?PQ\/II]2MM/21X&BM3K'FW#?;XX%VR"')0D810,5 M^ZFBZ+;Z!H>C^'K',EIHVG6.EV>\C9]W]X'P=^Q/^Q1HW[(_P-\2_ S5=:L/'OAWQ'X@UO5# M;BPEMK--)U:20+I$EM,6>1(8I!&S CA*[N:]USPA;R7E_HT5W.Y>9-+M[21(K6W))*AP900 6.*_=C80> > M_O\ >ZX)Z9]B*/+)4+C !SA3MY]3M()_&FI/O_6G^0'YL?L5_P#!-_P!^R=K M?B+XDZ_XHUOXP?''Q7%);Z_\2_%;R7-ZEI<*=]IHYNFDEL[<\&9E7 M_P!DS]A*Z_9E_: _:2^-LGCRW\3Q_'W7H];BT6*RFMGT"-'+-%/HKT7]L;]B'X2?MH>!K3PY\0H]1T;Q#H\@N/"'C307-KK_AS4E7:EW;S* M0YCW!&D12&VC.1D5]GI'(#N9LL.G P@ZYI2C]03D9P<^HYZ\^WTXZ M4KONP/P%T/\ X(K^./$FK^&M-_:)_:\\<_%OX4>$;RVN=&\!N]];PR1V+?#O]F>&/#]C#;>"] M3T0+;:MX6EM(EB@O-+G*DV\PV)N)PK$$C:QW5]@K'\@&.Y8@],G@G!'_ -;T M%!AW;L_Q;<\L!\N,<#H/IC)ZYI\TN_Y ?SZ1?\$7?C/=V,?P]\0?MR_$F^^" M*S",>!A/J4>H2Z1Y@)T^;5FGQ)NA7RG0'R]I(Q@U^LW@3]D+X%> /V?YOV;- M)\&6EU\+]2T>XT#7-.N8D:;5S=1;)[^[?EY;EW N$N"Q82*"21D'ZF"$GYCD M;BV#@@$Y&5&,#KTIQ3!W+P<;?PQ@ #H#C//7WHYI=W_7H!^ ,?\ P1F^,?P_ MNM7\/?L__ML_$'X"[S5O%7B[QA>_VQ\0/B%XBG:]UWQ1JKL9' MDFOI-TK6D"61VCW$Y&<#[:V-A1DX7[JYX]C_ /0Q10 W ML/\ =7_T$44=A_NK_P"@BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ _#_/^?SZ'B@<;N_& M$)[>O X'L1S110 #H/\ ZY_GS^=%%% !1110 4444 %%%% !1110 4444 %( M>!D<$ D'GT]O6EIK' )()QS@'&3V&>.]-:WUV5_^!^($;M@ -W 8-T!SQM'N M,\YQ4F>.5XQTR/\ $=#C'/\ A7SI\3/VI_@7\'/$$?A7XB^/-(\/:]/ +T:; M>3#S1"XRKA#\VTG!#?=)/6O/!^W]^R<0,_%C0\^@D[_]\Y//_P"OO7EXO-)HTYN]NDIJ6GFM+[HWIX3%UES4<-5JK^:-*_(_#//'?_&IL''8'''(_P :^,%_;[_9-_B^+6B9/3Y\=/P_"GG] MOO\ 9-./^+MZ)QZ2#_"L89_D&ELYP.EGKBZ-]UI_$_K7R-%EV8]G_ M )3O??K_ ,#[,VG(Q]W@$#!Y/Y\?7T]ZB+$,06!(/3O_ $&<5\<#]OW]DY1G!)Z?3U MS^'K3<%?N]>^!T].WY?X5\1:?_P48_8[U")[BV^,OASRA(8V7[2B_O%)R001 MGHV?0UH#_@H5^R$?^:R>&Q_V^+_C7T-'!8FM"-2A@\1B*X..GX MT[#]#G';!&<^_P#^LU\:C_@H3^R'T_X7)X9&!WN8NP]CU_K1_P /"/V0S_S6 M7PV/83PG_)K7^SL?:_\ 9V(7FZ,VOL_W/Q^?4R6?90]/[8R^^CO]:H>7]]^K M^9]E?/WZ]L8Q^/3^OUH_>?YQ7QM_P\'_ &0_^BS>'/\ O_#WZ4?\/!_V0_\ MHLWAS_O_ ]^E+^S\?\ ]"^MT_YAZGE_=T_K3>S_ +_G]D_O/\ .*0B0]OO7QO_P /!_V0_P#HLWAS_O\ PT?\/!_V M0_\ HLWAS_O_ _3^?%"R_'_ /0OK;_] ]3R_N;_ '?@[']N91_T.,OZ?\Q= M#^[_ '_7[W\_L<(PQU)!)Y(XSSZY/..O Q3QO[C/Y"OC3_AX1^R'_P!%F\-_ M]_X?I_.E_P"'@_[(?_19O#G_ '_AIK+\?I_PGU]_^?%3RV]S?7Y:>=A9YE/_ M $.,!_X5T/+^_P"OX[]?LG]Y_G%'[S_.*^-O^'@_[(?_ $6;PY_W_A[=:3_A MX1^R'D ?&7PUUYS/$/Y'^E)9?F"U6 K)_P#7BHNW]W^OO23SS*;?\C? /9:8 MNA?[/]_R??=]-_LIMV.2%'UZTHYRBC/!.[(Q^..^*^,9?^"@_P"R+R!\8_#+ M$ \"YBYXSC\?I^?:$_\ !0C]D-1D_&+PX@5#(V;F+[N.<$']?R]*R2^ M39]H#+' /4?WACC\?;TIRX'7KDKR1CCG^G^>WQ%:?\%$OV/[Z%;JV^,'AUHL MLHQ/&1\I*MZY((SWXYZ4W4?^"B?[(&G6[WL_QA\.K&FW.^X55'.,L0,#KU/& M ?K7B1S' ^U=&.(PZQ$9VI*JY:7CRWCA<3*AR M^T57V53DY=/>Y^7ELK[WMZ'W!\O!VD9/!X 'OUQ^G/H::1CJ&S^&,U\-1_\ M!2/]BR90X^.?@P*Z*VTZK;K@GL074Y!.".OTJQ_P\>_8O8?-\=O!/'.!JUJ/ MU\WT].^*]/ZIBZEFZ-1VLTE"2O>VNWFM=-]]#R98F$)R_>1TM9.ZZ M:V/MQ#G.<$ GIVZ@'MU4>_IG\Z^&[?_@H]^QO=736-E\: M?"]Q(J*[O!>0S( _8NC, 1QG)XS]!6I_P\#_ &2 ,?\ "X/#HQAC^^4$@=<= M=W;H.W-<.)QV%PE3ZO6KT*55VO3JU:=.I=M6O"MJE*C4J0TW?-"+B[=5<^TEP",Y)P2<8X'H>O/7GIFER_P"/7^'\Z^&K7_@H MY^QS=O="/XT>'(WMW,,X:YB7##J"&;[V,G&,]..:L?\ #PO]CKM\;/"W/_3^ MO_ZJ]&AAYUZ:G"$YQDKQE&+::=M4T[-:W35]#P,5G65X.M*CC,VP="I!\LZ5 M6O2IRBU:ZE"4U*+WT:6_W_;O[SKUY/I_GKFC]Y_G%?$?_#PO]CGI_P +L\*Y M_P"P@I/\\?\ U\"E_P"'A7['7_1:_"WXWZC^OXGT/%5]3Q*T5*IKM[LEO;R] M#'_6/(K^[G6 M=?\Q5!?R_\ 3SS?RUZ6/MO]Y_G%)M;GCKGN._XU\2_\/"OV M.O\ HM?A;\;]1_7\3Z'BC_AX5^QU_P!%K\+?^!Z_AGGC/?TX]:/JF*_Y]U/_ M &?EY>:#_6/(_\ H=8'_P *J']W^_YO^D?;0#CIW^E+A\8_PKXD_P"'A7[' M7_1:_"W_ ('K^&>>,]_3CUH_X>%?L=?]%K\+?C?J/Z_@?0%?L<_\ M1;/"WXWZ_P"/KQ].:7_AX5^QU_T6OPM_X'KC\\^O'TYI?5,5_P ^JO\ X#/_ M "\U]X+B/(]/^%K VT_YBJ']W^_YO[C[;_>?YQ2;7Z\_F/\ &OB7_AX5^QU_ MT6OPM^%^I_K^ ]1S2?\ #PK]CK_HM?A;\-07_'\!ZC)I_5,5_P ^ZG?:77Y> M8?ZQY'_T.L#T_P"8JC_=O]OS?](^W/WG^<4A,@Q[G'\-?$P_X*&_L=G_ )K5 MX5&,=;]/TY[=J%Q*5Y4JG+ MW<96\EL.'$.23:BLVP-1MI1C&UAP&&.YR>HKXATW_@HC^R)J<1O M52.,9QDG\JU1^WU^R<>/^%N:)D=?G'^ KP:^;Y1AJLJ>)Q^#IU(.TJ=3%4(3 MB]%9PE44DUV:1]#2PF)Q-.-3#4*TX3BG&4*4YQE%V:E%Q34E;JG;Y[?9:CYN MA"CME>N.P!/;IW_"I,$YP#C/I_A7Q>/V^_V31_S5S0_?YSUS] ?S^E/'[??[ M)^,CXMZ'C/7S"/Z=:S7$>0?]#S+]_P#H+H:*ZTTJ>OX^1M_9V8;?5L2WY4:O MEO[C_IGV:1@$G( [X_+WZ\<=*K2$JP!!R3S_ +(/3)Z#/U^M?'?_ WY^R>, MY^+>B=,_ZS/;CKQ[C_)J*+]OG]E*:XMX%^+.AN;N2&UB22=4\VZG<)#'N; & M7.!SU.<<8JX9[DN(FJ-'.,'5J2<5&G3Q5%SDW:R48SYG?R7II8SE@,8KSGAL M0E%7;E2J)+1;W@NG5Z6>NEC[*/T(/<'']*VVI6 M-IJ-G*EQ:7UO%=6L\9S'-!.H>*1#W5E((/\ 2KRMCCU./I^'XUZ=/E2LHI[^ M_I?I\]?ZT.9Z77]=&2*, "EHHJQ!1110 4444 )C.0V,$\CU7^A7J"/<'BDP MIP6?..V<=/N]#@X[YZTCM@8[G_/^/2J\Y(Z^O7I55Y8HEWRRQ0H.LDLB1H M,G R[D+R>!SR>*DB?=D@@KU# @J03P01P01T()!'(- $W0V/QS0<_P_K].?UI]'OV]: "BJG MGH'V--&DC E(FE196"_>98R0Q !&2 0*L1YVDGGYB<^@XQG_ .O0 _..M)D= M.1)8V&5>)UDC;C/#H2K? M@30!OKQ4^?YX_'T^M !111U_#K[4 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!SVHHH !TY^]Z_A_C M[4444 %+]<^WUI** "D(!7!^]TR/ER/3(Y'X?CWI:* $ P/Z=0/3!/)XZYI: M** "BBB@ HHHH **** "BBB@ HYS[?KFBB@ HHHH @ZL1G!VEV!XV]< D\9/ M'Y\T;6QP 3QQD<9]3G'ZFFL;_ &_D M73/,M?\ W-8?R_O^OX'6\OS!13^K8F[V_=55V_N^?R[GV93".I(!SC';]:^- MQ^WY^R=_T5O1N..9>OO3#^W]^R:,D_%K1?\ 9!?/U[&D^(GG\I6 S#_H&Q/G^YJ?W?[OF_Q[(^R"5XZ#GE7ZZWA^?X/;ITN;HTN?E5[WT_R/N<8'N>YR/RY(.1T MZ4AV^G/J"/\ XJOB1/\ @HW^QD%Q_P +R\']3_S$+<_KO/ZFG_\ #QS]C,=? MCCX._P#!C:#_ -J5W_4<;_SYK:_W)>7EY_=\SB_M' ?]!F'7_<>GIM_>WU^7 MD?;&01ALYSV(_P ?S[>M&1Q^'\*>_P#GG\<\5\2?\/&_V,?^BY>#^H_YB5GV MZ?\ +2E_X>-_L8\?\7R\'<8_YB5IVZ?\M*/J&-_Y\UO_ &7EY>?Y=Q_VC@? M^@^ATWKTO+^]Y^7GUM]LX7W_ VCKP>,]QU].]&1CJV<]>/7I@GVY_PKXF_X M>.?L8_\ 1HQC MWP/RXIQ(('+9'<8^F<9Z_P">E?$O_#QO]C'.?^%Y>#O_ 96GKG_ )Z>M(?^ M"C?[&)_YKEX/_P#!E9^N?^>GK1]0QO\ SYK?^ R\O+S_ "[@LPP&G^WT+:?\ MOZ7E_>_JVVCM]M_(.Q_,?X_Y^E*2IZC]1_C_ /KKXD/_ 4;_8Q(_P"2Y>#O M_!E:=SD_\M/6C_AXY^QC_P!%Q\'=_P#F)6G?K_RTH^H8W_GS6_\ )>7^?Y= MP_M# 62^OT-_^@BGY6^U_P -]Y]M?+Z#N_\ S$K3N,?\]/2@_P#!1S]C$_\ -7NS\O+S0O[0P.G^WT/_!]/RV]_\/\ )GVWN7K@\>X_EG_/ M3VI<@\[?Q.W_ !KXC_X>-_L8XQ_PO+P=_P"#*T],?\]/2@?\%&_V,1_S7+P= MV_YB5IV&/^>GI0\!C7M1K+_MR3[?Y_EWT?\ :&!_Z#Z&O_413\O[W_#??;[< MX_N_^@]NO>DSC[H'OT_'H?I7Q'_P\;_8Q_Z+EX/ZC_F)6?;I_P M*7_AXW^Q MCQ_Q?+P=QC_F)6G;I_RTI?V?C_\ GW6_\%R\O\_R[Z']H8&Z_P"%"A_X/I^7 M]_\ /Y[,^V_R_P"^8^W7_/YYZ4=.#TY_NCW/?TY]?PQ7Q)_P\<_8Q_Z+EX.[ M?\Q*T[__ #^I_P!WKS77]=F?;6%'\)].O_V7^>M+O'O^8^G7/^>O M2OB,?\%&_P!C$?\ --_L8YS_PO+P=_X,K3US_S MT]:I8#'=:-9Z_P DMM/\_P 4']H8'_H84?\ P?37;^_IO_5F?;98>G\C_7_/ M6@X8CJ<=LC_'V_'Z5\2'_@HW^QB1_P ER\'?^#*T[G)_Y:>M!_X*-_L8D?\ M)W MR9]M$-_L8\_\ %\O!W.?^8E:= M^O\ RTH_X>-_L8\_\7R\'U3_9^/\ ^?=;_P %R\O\_P N MXO[0P.G^WX?2UOW]/^Z_YOZ^3/MGY/0_F/\ '_\ 72_)Z'\Q_P#%?Y^M?$I_ MX*-_L8D_\ER\'=_^8E:=QC_GIZ4'_@HY^QB?^:Y>#O\ P96GIC_GIZ4U@,;_ M ,^:VW\D]=O+3.M)A?[I_,? M_%5\2?\ #QO]C'&/^%Y>#O\ P96GIC_GIZ4#_@HW^QB/^:Y>#NW_ #$K3L,? M\]/2AX#'/:E67_;DGV_S^=T']H8%_P#,?0^=>F^J_O:?UV9]M\#M@>X0^QY. M>_\ GIA#C'/TSM7K_P !YS]?Q[5\2C_@HW^QB#_R7+P=V_YB5IV&/^>GI1_P M\:_8Q;C_ (7CX.[?\Q*UZ#Z2$]_\G%)9?C]+4ZU]+?NY>7^?Y=P_M' VL\?0 MY=+_ +^FGT_O?U\F?:_TS_\ 7H <+]W=MW!6!7 !SC(Y!(R1D\_6OB-_^"CG M[&"=?CAX//?C4H,GZ?.?RS^=3V'_ 4-_9%U"W^TVOQ5*7M MI+3=JGS6[ZI?A<^V$!X+'G' ST'0CCWS^?2I<'_)&?RZU\8+^WY^R81_R5G1 M!DC'S\8X]!CGDT__ (;[_9/[?%K0Q[AP3USZ>G^<5Y:X@R!I7SG+HM[1>+P^ MFW_3S56_#7LCO>7YC>SPN)B]%R^PJI)Z)KX?7TU\C[,P?0_E367(Y]>Q&<^^ M3Q7QH/V^_P!D\C(^+VBX_P!^FO\ M^_LG@?\E9T,C^]OQS^1R>^/TH?$&1Z) M9OE\[VO_ +7AU966KO4MJ]KO]!/+,?+X\-BM/^G-2][*ZMR_/_@'V80% .W) M[8*]>O^0:^0M&_;K_ &6O$.LZ3X?TSXJ:)-JN MM7\.GZ9;B2-?M5Y/Q# F_&^1SG;&I+MU XKZU5LH&+1$,!+\G&]6"F-\$<$@ MY'Y]Z[\/B,+BH*KAZU.M3;TG2G&K!O164J]I)/6_YERBFH])QD%6P2 I&=PP/0- MGGTI'/'X_P!#4.0.20,I)Z#WH G^4%CG (P-I&?Q_^M^5 88Z_GU_I M52*:*8$Q2PR[25;R98Y=K#DJVQCM8=U/(I6EAC&Z6:*% MP% %O(/0BEJNK?, IY/3'(P>^>1CWJQ0 F1ZBESGIS5+SHC*T?GP^:U M!11GI[]/?Z>M'].M !1D>H^O^>:BDW8!4X'U].?ZCFH1/!N\HSPB9@"L)E03 M%<\GRMP<@^NT@]J +?7_ !I,CU'YU""1C!XY[^G7BH9)X8E+RRQ1(.KS2)$@ MZXR\A51D\=>O% %W.>E''8@GT';ZU5CD5P&1PR'D-&X=&'JKKE6S[$T]E)4D M'W')SU[X[^OO0!/FBJ:2)YGD^?#YV,^3YJ>=M_O&//F;>G.WW]ZMCH.<]L^I M_P : %HHZ''<]!W-'MW]* "CCU&?3O3')"G'4=<=?_K9J/YN"0P/49SGCZ_G M0!/135/RC\?YTZ@ HH]^PZT4 %%%% !1110 4444 %%%% !1110 4444 %%% M% #AT/\ O1_^ABB@=#_O1_\ H8HH ;V'^ZO_ *"**.P_W5_]!%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#*I()&>W MY/8>G-34A&0??^F/\ ZU%GI%\LJL?MF@_\ #PGD''_"M;'CM_RS M.?KGO663Z$@@\C.1WZ9_R*_P;^GCQAQ-E/C9B<)E.>YAA\)# 4FL/0Q%2C&$ MO:.]U&=GT7DEL?WSX"Y1E6+X*I5\1A,/B)RQ%FJM-2M[D-FT[M^NS//A\(OA MKW\$>'CC_IR'3N.O3IFG_P#"I/AD1M'@C0.P_P"/)*]#!; Y/0>F/?MW/?MV MI'^P ^Q+D_ACI]E>S!NX89_#\?_ *]<[XM+'PSX@4NVUM(OF.,9 M($#X&?3J?QQ]/IN"./N-*W%_#U*7%>Z9 MY7$7#V3K*,SJ+*<%^ZRW$RHRC"'M*35"5I*T>GEMZ/3\"OA?X9T.?2-9,VG6 MDOE^)-9CC;R\".-;V<"-07R-O].:],_X1+PYC']D61_[98'7/0&N1^%6#I.M MG S_ ,)/K?0<<7T_S?7U->GX YZ'M]?4_XO?I%<8\48#QGX_PN'XAS*E1I<08^ M-.G2Q-6$(06(J*,(QC*RY59*W2Q@CPIX>/71=-'T1A_7\O7K2_\ "+>&U_Y@ M5@W3^$_U/YUO"0G^]^&3CWI0S>IZ]_\ /Z<^]?J,<@R/D:>58*UUHZ,-M-_< MT_KS/Q/_ %]XM_Z*3-?_ LK=;?WNNA@GPOX<_Z 5@?^ G^IH_X1CPYC_D!6 M'TVM^77%=!N;U/\ G_/^-&YO7_/^?_KTO]7\A_Z%. Z?\NH>7_3O^ODP?'O% MW_129KNO^8ROW7][S_%'/CPQX<_Z 5@/^ M_0T?\(QX_K0Y[_A&/#G_0!L#[[3_4TO_"+^',?\@*P/MM/'ZXK?W-ZG_/\ G_(I=S>I MI_ZOY#I_PDX'?_GS#3;^YO\ =^#'_K]Q;I_QDF:ZO_H-KZ[?W_/\3G_^$7\. M?] *P^FUN_XTG_"*>'G^[HEB@'! CSG/_ ACT_.NAW-Z_P"?\_\ UJ0DGKDT MX\/Y!=?\)>!@NLE1BWT_NK?Y_@P7'G%TK)<3YI#5>\\;6LK-?WNNUM]3G3X1 M\/;6SH]F!R>(L,,<\$MZ>W-8VK>%-"&F:DRZ3;QE-/F*2A,X^4]/F_SCUKN" M1]TY^;/8_KZ9_P \5F:M@Z-J8*@YL;IS=FK/5/_P#A9I]W?Z+IUU9)"&=\7,JJ6)8]!QGD\? M6I?VD?!?A>P^$7B:\L]#L+:Z2R=UG@B\MU(C)'(_3'.:Z+]F#:GPGT\@#_D( M:@,$9X^U3'I[<=>E2?M-G=\&_%8YRME,0#T7Y&)'\Q7_ "IYCQ'G?_$T-?!4 M\SQM#"T^-)450=6?L.2.(FE&,.;E4+?"G9;=C_M^R'),GJ?1:PF;5\OP<\=_ MJ32J/$^S@\14G+"T6ZDYN/,YRDVVWJWUOO\ RIZEJVKC5-2":GJ&$OKD+$MS M,JHHE8 @>9SM';^553K.K\?\3;4.>,FYFXXZ?ZP>G\NM0:D,ZKJA(S_Q,+H< M_P#75O\ ']*IM@8)XQ_7_/UK_H:RC!8.>48"K+#X:(O$>NQZ_#_ &S$J7!\F_+2H.%VX9W)!'4#'6OVQ/@#P8S,P\-Z2%56=1]G M *;4.-IS^F>1Q7XL_P#!++#>)?$&>?W-P<'M@+SU_/\ +GO^Z>0RG_=D !SC M 4XP/_UXQ^%?X/\ TU,^S;+/'>M0RK&8K"4']1C.-&K.G!)U7S>ZG%/3?3KZ M'^Y_T,,ERO,_ N.*S7"87$UVL4X5*]*,Y\RHQ:]^2;WZO3JMKGY16N@Z-+XV M^(T#V,+0P^)KD01>4=B8"C& XP !CCUQFNB_P"$6T/'.FVY;OM4\?\ CY_E M_A56S_Y'GXE#H/\ A)[G&.V57./\Y_"NG"#!8@]_WO:S/^1SZ:_$O$&6_21\3,%A,YQ^$ MPM#B'%+#X;"UZE*E!1FDDHQFDU;R,#_A%M$S_P @N#IZ?3OOQ_G\*#X6T0_\ MPNW_ !&?_:E=#][A0!W_ ,XHV'V_S^%?JGU3"PM&6$H2:M=I*VO*^WK?Y^A_ M*CXXXNO>7$.:)Z:?6JW96^UVL<\?"VB'_F%V_P"(S_[4H_X1;1/^@7;]^W_V MS\_7VKH=A]O\_A1L/M_G\*/JV#T_V.ETZ+^[Y>O],/\ 7?BS_HH\T_\ "JMY M?WO(Y[_A%M$_Z!=OW[>O_;3\_6C_ (1;1/\ H%V_Y?\ VRNAV'V_S^%&P^W^ M?PI?5<'I_L='IT7]V_3R8?Z[\6?]%'FO_A56_P#DCGO^$6T3_H%V_P"7M_UT M_P CCWH_X1;1,8_LNW_+CIZ>9_D<>]=#L/M_G\*-A]O\_A0L+@]/]CH].B_N M^7D_Z8?Z[\6?]%'FO_A56_\ DO)?<<\/"VB?] NW[=!C_P!J?EZ=*/\ A%M$ M_P"@7;_E_P#;*Z'8?;_/X4;#[?Y_"G]6P>G^QTNG1?W?+U_IA_KOQ9_T46:= MO]ZK?_)>1SW_ BVB?\ 0+M^W;_[9^7I[T-X6T0*3_9]NK%'P F2I5&PW#_S M..O?-=#L/M_G\*8PV!SN(8JQP.F C9_7&?YURXS#8+ZIB&\%0;5"KRMV7++V M>DD^5ZII^OSN>ED_&G%=3-LMIOB/-N66.PJDEB:UG%UH)QDN?X6M'Y'WG^P% MX \%^(/@_JEYK7AK2-4N4\5:A;K-=6ZN\:JW P2>PP<],'H8?.*_+AZ6-K4Z,(J2M&,4TK)=D?]K?T=LIRK M%^#'A_C,9@<-B,34X;P+GB*L(3J3O1C>4FXMMMW;V:WZL\Y7X2?#-F<9KT=PP7[QQNP1W MXY/KV.1_2OD[]JSXB_%[X=^$M'U'X1>%Y?$^HW6JQPZG"D7GM:VQX641C&.> M#_2OQCA+B#CSBK.<#DF%XMQ^$K8N4Z3J8S-:U+#0LE)-S"-%\ :9J6C^&-'TZ^C\7>'5^TVEL(Y,?VA!T(*XX]^#QP>* M]!\)^/?C?J7A70[[5/AK:IJ%S8P37Z?;O)<2R*I"R1;28V;D^6#Q@UXW^TYX ME^)-U\/;.+5_!%I8VI\4Z!(9X=0\R19Q?0M' \87C>P W]1SP*_??!=<@CTP>>!GNS7,]+]F[Z:6;6I_G3-0;;?NM59;RVY5H[7?5;7L?92[E[?J!]:=E MO[OZBOC4?%K]JL]?@!I0_P"YA./S\JG?\+9_:K_Z(#I/_A0__:ZU$?9&6_N_ MJ*,M_=_45\;_ /"V?VJ_^B Z3_X4/_VNC_A;/[5?_1 =)_\ "A_^UT ?9&6_ MN_J*:']>:^.?^%L_M5_]$!TG_P *'_[771>$_B/^T9JOB&RL_%'P8TW0M#E9 M1>:G%KOG-:*3@MY9C!?N<9]?2@#ZD4YZY!PQW\$* I[=B+ M+3XUZAKDFCSR+'J#:9>%1!*_$W@C M]AOXB^(O"&NWOAS6[7Q-X AM-7TJ9X;RW@N?%6GPW,4-++P_?^,O!'A66QDU&14.I7)T&SFN9WED.20PD>1N2 MQR><\_&O_!:SQ+IFF_L/^)?"]Q=Q0:UXS\;> M/T'32Z?:KV:W\2V-Y+%%!N M,GW(\LR@XR>]?(/_ 4<\#Z5X^\8?\$SO!/B:&4:;J3^"++5+9)7B:6%-*LU MN;&5EV[0RAXF!'(R.]7R>?IIOMY^H'ZZ>#_V[/V6O'GC"/P-X;^*6D76OW4K M6UG#<&2TM[V8D@+8RS(D<[,0?+,6LZI\7=2\-Z]9Z) M>3:7\-[>Z;^S_$UK$K22W5Q /EEVJ"P]<=37P3_P53^!'PJ^%7@CX ^*_AQX M/TCP;XA\.?%'PUI^G:IH4(L[U;(W=NGEW)C(-S$5)5VD.2S9/'3H_C9*;S_@ MI-^Q)<7),YNOAP/M@D8^6_GV:B4GL1(I8%<'ECDTN!H_PI^-?A;4/'VGLS&*RT_6;"VDGN8D+'R_,GF*!47YLG'5A7R7 M+?\ CC1?V/OVQ_VYK"2]A\9_&OQF/#WA2\C,GG6?@"ZU-[!+G(YM?W2Y,B@A M58-N%')UYM[=.^W4#]O-8_X*%?LDZ'XF?PKJ?QZ^Q75Q%YKV$-R)3 M$T,UW%&UJI1P5<-+A0.N,@>^^./CA\-/AYX @^)WBKQ3IMEX#O9M,BLO$JSQ M-87"ZK+%#92+.I,?DRRN$#DC!SD9%?A_\&_A1X\E_9RT'PG:_L'>!?&6@^+? M"EI>W7C*Z\6+/K&M7>JV2S2ZW_:)A:2"7S9GN,AQY3<'.TU\W_'+P5\:/"G_ M 1Z^*'PU^--SIOFZ#\=O#6C>#1HNOC7'TSP7=>(HY;73KC4XN3<6$LIL_+S MN01@]1BCD\_P_P"#_7YA_0-X"_;*_9V^)OB;6_"?@KXB:9J^J>'=,NM6U=DS M'96^GVI?[1%OA]'X=^%7B;Q% M\'/#VG1_$'*V5XUUJ6BVEU.FI:J[!RE_>RE)6(]0U.U^='(19E;< ? ?A-O'/B_Q3HFB^$EM1>'6[N^C%K)$Z[XOL4@)%QY@ M(VB/+-_+YR\&?M^?LK?$'Q3:^#O#WQ1TI]V:_.C]ICXB?L=_$7]G#]G36]5USQYK'@J/4K"3P'\,O#,US#?V1M0^ 0\+>- M/#XT+QMJ$']A:PL,=Y#''#%;1JC71DCY+NS-RVYFI0CU\[6]+._]?H!^MWQN M\<>++'_@J+^S-X0L/$>IP>%-:^&WB2]U+08)V&F:G-'&?*N+B!6V,R@ H<'M MCI7ZSR%HI"O#"0L1'GY<+\Q9L< 8X [8![5^&/B*_N=2_P""C?[!FK7KRSW- MY^SW<7%_=R ,\US+HUNY:1C_ !2.26..I)-?N5(OG,>=A!=&4#+?,QSG)&0% M&XG@ '\:EQUMOL_Z^8'Y1?\ !5?XU>)O#W@?X4_LZ_#;5[W1_B9^TQ\1M#\& MV.KZ3*RZEX=\/07EMK_ !9_9W\?:MHD]QJ\[3:OK?A"6ZD_L;6I#(V]ED3RX]XR.5YK\N_V M@_VK_''C#_@I]<_%3P/\"?&/QX\!_LNV-QX$\.:9X2M9+JRA\4W2;K_5K\H6 M19H69XHN=R>6,' K)^%_[6'CWP=_P4U\-?M#?$CX&^-/V?\ P%\?(K3X<>)S MXELI;6RU?7)"D>FW'G,Q0LDS1-(6!)&235+WHM=K;_U_PP']+7QA_:,^#OP# MT^QO?BIXTTSPS_: /V&UN]\ 1DVMO#ON)-G &M6;S=):;6(H9[O4K:R9C%=A M-[ RA6"MC.0*\U_:!^!GPS^$O_!5/]D_6/AWI%EX:E\5V^H7.K:%I^V#3?M- MOY@745M@=L;1)N8@!0/6GRQ[/;_+Y_\ #^@'["_&+]J[X!? 74(-+^)GC_3- M"U6:)9UT="][J&U^?M#VD"22)$@S\Q7^+D'I6W\&_P!I+X-?'ZROK[X5^-], M\3#3,R:C!;.!>V*XYBFM9-DT8(4_>3@?B*_&GQSX]_9Y\'_M7?%/6_"WPG\> M_M=_%.]N8=.U@K;3:YX4\$ORATJU9@;:V/59%VL4(Y%>2_L&>*-2M?\ @I[\ M7K&S^&K?!RR\3>#I[V^^'DR_\ M!+S]NW_AJ:S^*^D>-?%,&J>-[#XB>))O"^D0VDEM%:^ K.[G@TNX68J(E:6) M%=O,=9 Q&5 S7USXQ_;Z_92\">*;OP;KWQ5T6/5].N!:WZ67F7UK970.R6VO M;J&.2&"X@DRDP+Y4@\U^-O[$5]#\*/V ?VYOBAX,\-6"^-M ^(_QBL-)U;3[ M%1JEC8"_O;6WBAN$'FB#24D,T<:';'LRM>(/B'K/BA+G6_$5YJRF2?4GF>)Y+*9)'9EA5QM;Z8HY8]MG;?T_ MK_@V _?S6OC9\-M"^'/_ MN^\4:>WP]^RPWA\26]S'/8+9S%0LOG(Y'5U$B MDAH^AQ7F/@']LS]GCXG^,8/ G@3Q[9>(_$D]N+F&UTY998'B*Y4_:M@BD*CA MQO)!XQCI^$>I^!OC9\-O^">O[8O@;XEQZ-I?AB#Q-#=^ =!TKQ&->G\)Z9?W M<*WF@W5PN&M75F 2W8Y^7@BOV(_8/_9R^$WPU_9S^">K:!X1TI/$UWX*TG6K MCQ(]L#K,UUJELMQ.'NB3(8UWA0A....]9M6;0'WLI;=MRK;2@9L_\M ?]7]/ M7TP?2I:KHC<]LC' [_WO]_WJQ2 **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** (MGS@^K@CD]>.?PZ?_KK^6OXS^$?#?B?_@H= M^TVOB'1M/U80VGAM8A?0^<4SIX8+$6^XA/)QCD5_4LW5?K_45_,=\2AM_P"" MA_[3YZ_Z%X;Y;G!_L\#\./2OY<^E]F&.RWP0XNQ>7XJM@\3"&%4*]&HZ=2*E M4CS)3CJKKL?J_@S1H8CCG*J6)HPKTG.;E2J1YH2M'2Z:>V^P]/A'\-&^=_!& M@!AM4XLDPRXZ9]^N/4U-_P *E^&?;P1X?'_;BGZ<_P"/TKO5)PG)*YR 3W P M,\'U_P ]:DRW]W]?_K5_SSR\0^-(64>)4X+J[>QAO?I[O;?]=#S[_A4GPSS_P B1X?YZ_Z$G/&/_P!?K33\(_AF MV,^"?#_!_P"?*,?IW]_;]?11GN,?K3 MZEI[V^VB*_U=R&-VLIP:O*-_W,+;Q5K.5+-RC(W42*1E2#D-BOX\/$,LX\0Z\@N9A'%K%[%;HLDG^CJ M)W^48?' _EQ7]JGQ%Y^'WCCDY_X1?6N<],V4G;'8^]?Q5^(,?\)+KX[#6M18 MX_B87$O+=,^XXX_"O]U?V0F;YMQ-3XT6>8NKFTJ2HQI3QM6=9THRY'*-/VE^ M52>KVOY,_P I?VE#AD>"X2K91?+I/$S4XX3]TJC49?%RI7:VOKH_0R?/N!Q] MINQZGSY>3W. YQDTGG7&?^/BY^OGR?\ Q>?TI#U)Y.3NY]^:2O\ _0=YT_\ S\77 M;_EM)W_X%V[T>=/Q_I%USC_EO)W]?F[=Z;15_P!E97_T"832W_+N/EY:[(G_ M %ASW_H:YA_X.J>7][^OFQWG3_\ /Q==O^6\G?\ X%V[T>=/_P _%U_W_D[G M'][\?I3:*7]DY9_T"8/I_P NX_W?+R7])A_K#GO_ $-LPZ?\OZGE_>_X?YL= MYT__ #\77_?^3UQ_>_'Z=/_S\77_?Z3UQ_>_'Z4VBC^RLK_Z!,)_X+CY> M7D@_UAS[_H:YA_X/J>7][_A_FQWG3_\ /Q=?]_Y.QQ_>_'Z4>=/_ ,_%UW_Y M;R=O^!=^U-HI_P!DY7_T"8/_ ,%Q\O+R7W>H_P#6#/?^AMF/_@ZI_P#)?U\V M.\Z?G_2+KC/_ "WD[>GS=^U'G3_\_%UW_P"6TG;_ (%W[4VBE_965Z?[)A/_ M 7'I;R\EN+_ %AS[_H:YA_X/J>7][^OFQWG3_\ /Q=?]_Y.PS_>_#ZT>=/_ M ,_%U_W_ )/3/][\/K3:*/[*RO\ Z!,'HO\ GW'R\O)::O\ $/\ 6'/?^AMF M'_@^IY?WOZ^;'>=/_P _%U_W_D],_P![\/KQ1YT__/Q=?]_Y.XS_ 'OP^M-H MI_V3E?\ T"8/_P %Q\O+R7W>H?ZPY[_T-_\ 0US#_P '5/+^]_7S8[SI_P#GXNNW_+>3O_P+MWH\Z?\ Y^+K_O\ R=SC M^]^/TIM%+^R7][^OFQWG3_P#/ MQ=?]_I/7'][\?I1YT_\ S\77_?\ D]2 M#_6'/O\ H:YA_P"#ZGE_>_X?YL=YT_\ S\77_?\ D[''][\?I1YT_P#S\77_ M '_D[''][\?I3:*?]DY7_P! F#_\ CY>7DON]1_ZP9[_ -#;,?\ P=4_^2_K MYL=YT_/^D77&?^6\G;T^;OVH\Z?G_2+KC/\ RWD[>GS=^U-HI?V5E>G^R83_ M ,%QZ6\O);B_UAS[_H:YA_X/J>7][^OFQWG3_P#/Q=?]_P"3L,_WOP^M'G3_ M //Q=?\ ?^3TS_>_#ZTVBC^RLK_Z!,'_ ."X_P!WR\E_28?ZPY[_ -#;,/\ MP?4\O[W]?-CO.G_Y^+K_ +_R>F?[WX?7BCSI_P#GXNO^_P#)W&?[WX?6FT4_ M[)RO_H$P?_@N/EY>2#_6'/?^AKF'_@ZIY?WOZ^;'>=/_ ,_%U_W_ ).XS_>_ M#ZTY9[C/%Q<\C/,\F/\ T/K4=*#@@XSBI>5Y;!.4,'A'*-K)4XWZ;*W;\O4' MQ#GUM,US!^M:I_\ )?U\V.\ZY$D!-U.O!Q7]27["GPW M\$:W^SEX5U36?"^EZE?R.XDO;NW$D\XQR"22<=NO;KS7\M1V[X@ /]:#R,]2 M,=^HZ].Q-?UF?L!$C]F7P:HP2'D 8]1\@Q@CIC/IP17^2/[63&XSAOPKR3$< M/8RMEE2ICH.L\&Y47JX7]Z#CTNTK[ONS_3;]G'B:F=<6<00S)O%J.%5EBFZJ MT3V4V[7^[\SZ+_X5)\,\ CP1X> '3-DF1WP>GS=:4?";X:*,?\(/X?Y&?^/% M,Y&><]"1R>G;Z5_SF1\ M1..93:AQ-GE6E&,FV\97TC9<]OWFB_"_SM_LY4X=R1TW)Y7@V[_NY0PL+N:C M&SNDK]-UOHKW/.O^%5?#0G:/ WA]G4Y81V"!47^\?7'< +WP-'\)_"\GB.'5+Y(M:>.V\U8H6G1# MO88V_(6SGZX[5Z9:>-/C"UE9S2_#BU$TMO"\H?4=AWLH+AD"':?5:6+P_LW**56GJU\.EVM4>!%\./&8O!O( M93Q.'FG4FL%!Q;=.%FG?[[>GIQOQ?\ ^"_#WB/\ 9NU/0?#FF:3?G]I;X=1? M;;.V$$JVCM=F:/Y#\VX[>"<5_69"@6.!PP(D@MQL(PQ"P1[#GU!)///UK^0+ MXT^+/B;/J?P$^W^!+:S>W_:%\ W>G!+[?]LU&$W7V:Q)VC8)R3D^V<$5_1U' M\6OVJ?+B'_"@=,QY$.V0>(=P.88\ GRAABUK'\1>.\<''C&E'#X9X:*PJ]WV?L]=+> MZK*ZU2VV>^Q]H*6P/EZYZ'^?'\\4[+?W?U%?&J_%G]JO;Q\ M*Q_V,/O_P!< MZ=_PMG]JO_H@.D_^%#_]KK^TS\6/LC+?W?U%&6_N_J*^-_\ A;/[5?\ T0'2 M?_"A_P#M='_"V?VJ_P#H@.D_^%#_ /:Z /LC+?W?U%,9F&>V.W![5\=?\+9_ M:K_Z(#I/_A0__:Z8WQ9_:K/'_"@-+//;Q#_]J- 'V,DF]E3&1#(0?T!]L5X'\-O'WQUU[Q1!I_C[X36?A#P^]K<2-K5 MMJPO9EO4 ^S6P@\M+? OP$\$:IX0U_4- U&;XF>&+2>;2IWMKB:TGO[5) M('D3:3#(APP)ZDX%>8?\$E]7LK;Q]^V+X1N+F*+Q%I_Q=U"^FTR1T6XCM+B= M_+=8F(=E6K?M,_!KX/Z!\-=(^*7CFQ\.:U MXB\':)>VW]HS@279;38&F=G?!D+T\">"_B7I-_ MXHD=XK72Y2]I+?/$2O\ HGVI(EN,@'B+=G./>OR&_;C^'6A_$O\ ;"_8*\%> M+;9KK0[CPUHBZK9L7B69K>RA(CDC!!>(%=KJ?O=Q7:?\%//@U\.?A!XJ_9*\ M>?#'PSI?@OQ)8_%70]%^WZ#%_9LESITL\2R+.T)_?EU.&#@YR#ZT^3I?\.UO M/S ^[-33P3HW[=E]XLO_ (Q:K'XBTOX/7\]W\&4N7?3$T6VC227Q.MB#C[1# M$I?S ,XR03W^N_A7\6? ?QE\*Q^-/AMK]KXA\./>WVF#4+=Q(#?V4GEW5LYS M\DD,@*NK<@]:_'2QA34/^"W-FE^&F&J?LA7%O=B0%T>&[LK:*1903M83+(V> M.">]<-^SI\37_84^*?[?_P _%%Q_9'A#PEH?B'X]_"FRN9-L;:;J\$LU]'I MWF,/.C^TRP-&L?S \8&:.3S_ _X('[7>&_CY\+/%6N?$;P]HWBO3KG4/A1* ML'CPR7$:6F@3%69H[JZ)$22JH)D!?(P!U(!\.L/^"@_[)6J^*#X/L_BQH[:H MUX;%9V\V#37N@_E^1!J1C^SN7?*H ^"W.:_ GQEX=^(OP=_X)4WOQ:N9[^W^ M)'[7?QGTGQ1XMO\ SIK;4[KPIXJUR9+'3-1NCA[1&LHXA@_\LI$(&.OUAXE^ M"'Q.US]F^#X>:-^POX!T6SC\':?*-/\/^'M4EBCL=4N7C-I=& MX1'A59P2IWJZLKY^;(YQ7F/@_P#;3_9Q\=P^)KOPU\1M.NM/\'VQN_$%]*K6 MUC86N,EQ/,B1RY(PK1&0D' '(K\+?VNO"_Q)M_\ @G#\!?!/QGU.RUCQ/:?$ M/0-$N+[2]9.JPW.F-J4,4,)U2/'GS0V^V)CU.TKFOT%_:?\ V-/"7B+]B[1? M /PF?PM\-_%M]HOA*ZAU:?B?\:/AG\&_#T?BCXD^,=)\,:/*/]'FO+A#]ORNX)9Q@F2Y M?LGZK\1OV>?&/B6/Q]\:=:3PO::E M\/\ X)>$_M&HZ7J5LJ*T.J:SIT3*&.=I+R9#8'Z3?"W]MO]F?XR>*( MO!O@;XE:3>^);F.62TT6\>33[V]0;83U54+9'K7PSXE\=^,X?^"S MO@_P!%XCU1/!5S\ #JT_A9KF0:4VI".3%X+;/E/*" 0_)4_6ORU_:M^(-SK_ M .TO^Q/XVT#]FN]_9SNW^)^F:>ET8AI.H>(],:Y"1VUU91>4#%$GRS*RD/P& M8D9K]%_$LK'_ (+B> %9MSO^S/&9,G CS;R%G Q\A8[L*,Y(ZC.*EQ5MOLM_ M-6^7_#@?N4\8!9EX"?,0.A/7\QQ[9ZU^,?\ P5D^)GQ OM.^%/[-GP8\0:AH MWQ+^+6ODFXT.=H]5TK2+!%N9+N5(F#QVKG*;FPI.?4U^S$T\4$<\DS*L4,"/@%XU_: \+_#>UNOA[X: MF\-VDMYI-A=Q,WVN2*Z4F+SE;='M !!7&>!13Z_+]0/UQ_X)9_'#Q3\1/@]X MC^&'Q'U&XU'XD_ _Q)?^%==N+Z5SJE]!;SR1V]]5<6A=A&7 M;@;>IZ'FOLO]AWP)X/\ C_\ M9_M:^.?C!IMAXZUOP_XH/AW0--\1)]OCTK1 MT,J*(+&;YMK1)C;M@9;>5V]^*_'WX4?"+P+\&_^"R7B71O -E;: M#H][\+;O59M,M)=UIISRQ&2>6-"2+81K^\1.-@7I@5G:#\1?V;O!O[07QPU' MX8?!'XD_M>?$'Q!XLN;#Q+XGU737U;PUX;U'S&2XTBPN)Q+;6=E'S&KQH3_N MFJC23OOHK_BEY?FM_D!^X/PK_:+^$'QL\-ZMXJ^&?C+2?$^DZ"LK:R;2X!N] M,$*L[FY@/[V E%8J'1M>'WO\ P45_9&T[3%U2?XL:4\$FIWFD[;??ZZ7WLEI?ON_/TN'Z\^/?VF?AEIGP%\2?'/PWXNT[5_"=IHMU=:?K6FR? M;+?^TOL[M;0RB$,Z$2 &2)U7:0P/?/QI_P $R?VX+/\ :6^'?BMO'7C.#4/' M>G>(]9NY+:2)[2VTWP]!+*+5QA^&+]#>Z3H^J7<4A9+5)&9(E!?X M5?\ !*CXF^+? .BV>D^+M5^*.K^&[G7-,M_LNH'2[G4YK=[1KZ/+Q6^QVCQG M"@[NU3RKLON _>>?_@H)^R99^*!X.G^*^CQ:NMY_9CR[)6T[[:LGD^4U^J&U M&9<(7\P8)^IKWKX@_&WX:_##P9!\0O&?B:PTOP==36J0:X\\9L)&O,?9\3HS M*R2!ACJ .O&:_"CP3\)OB9KW[*VE^"-/_8=\#:EIOB+P:M]%\0[GQ5&-9DU" M]L?,_P"$A_M%HC*)EGS<8\P*F#G)%>4_M!>$?BOX<_X)0Z?X(^,=YIMWJVG? M%+2=,M)M'UG^VEM]#;4K>""UFOT(\R:&)C&1G(QGZ2X7>CM\O^"!^]/PO_:_ M^ ?QG\97?@+X;>.;3Q)XCL+9KNXMK.*5X/LJ*&:19VC6&95##;M=NOTKZ;7[ MH]?X@>QSR,=%[?*. .E?(/[)'P*^%'PY^$GPKUGPMX-T/2=>_P"$'TJ&76[6 MV U.]-S:1O.;VX/SRN[8)+GC'M7V!C:2!D\Y)(Y)^O?Z\5+C9;_A_7< HHHJ M "BBB@ HHHH **** "BBB@ HHHH **** '#H?]Z/_P!#%% Z'_>C_P#0Q10 MWL/]U?\ T$44=A_NK_Z"** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@!,\X[XS36D"@D_)XZU*Y8W;C#VCG>$8R2/P/X5DBXM6/-W;9/0BYA M&>Y/^LK]*?VDO^"='P0_:A^(EO\ $[QQJOC#2?$UMI<>E&;P[J4FG*UK'CR\ M[?OO"D_X(S?LW#!/C;XLLV!DMXGG!)(Y)&>#[?RK_ #L^D5]"C'>- MW'E3C#"<34,IA4P\*+PM3"NI-.,E+F-N#X'R&&25,HK MUYPFJLJT:BC&3:2]WW'II\K[O6WR@9;0@#[7:\9Z7,/?_@?6HC/:9/\ I=MG M)_Y>X?\ XK'ZX%?6R_\ !&;]F[G_ (K7XL'D?\S/.!W_ E^S%SC1?Z\X9+K?!2T7NW_Y?KY]'J???\3.X M"W_(CQ/E^^5KVCO^ZTO;5^;['R+]HM>/]+M<^@N8.^>/]9]/Q^E<[XJN+8^& M?$!^U6@*Z/?C:;F$GBW?G_69YZ'CV[U]N#_@C1^S=C_D)=F^5*^OWG#F?TDL!CL#C<-'(:M-X MC!5L-=57*7/4IN"FWR)-)O;33L]OY6?A5.IT?6LR1X_X2?6R&$B=[ZX(Y)'. M.V,8Q^/JGFQ%1^^A![YE3W']ZOZ(]&_X(1_LA:/;R6T.O?$JXWSR3M)+K:HY M>8EVY1%1AD]=O7'S5KG_ ((;_LC'[VL?$7/_ &'R./IY?]:_Z'. /'K!\&\' M397A,OG7A4]G&I+#T:=-R4>27*GRW2OU['^$/B;]"+,^/^.N M(N+H<3T>DJ?_%?KU':OZ-O^''G[)'/_ !./B-S_ -1W_P"U^U._X<>? MLC]]8^(W_@[!_797U?\ Q,_@(_\ ,DQ+6Z7MTGT:_P"75O73TZH^&7[._-7_ M ,U?A^EO]C:6G+U=?5=>^_G?^?LC?]!CXC?^#L?_$4 M?\.//V1O^@Q\1O\ P=C_ .(H_P")H_SUZT>9%_SUB_[^IZ?[W^>O6OZ M./\ AQY^R-_T&/B-_P"#L?\ Q%'_ X\_9&_Z#'Q&_\ !V/_ (BC_B:' ?\ M0BQ7_A1'R_Z=>2#_ (IVYII_QF&'Z?\ ,(O[O_3[[_F?SC^9%_SUC[?\M4_^ M*_\ U]Z3S8\@>9%Z']ZG'&>N>>/_ *^*_HY_X<>?LC?]!CXC?^#L?_$4A_X( M>?LC]/[8^(W_ (.Q_P#$Y_S]<+_B:' :?\(.)>L59XA/3FC=V]ET2OIU)E^S MLS5I)<8X=:Q?^Y]$X-Z*OKHMN]S^VHT*D*G M)']^WS^[:[MY[G\]_P"S',@^$VFAI8!G4-0P?.C!/^E2CH6SU_/^;_VF)X3\ M'/%:B6-F:RG "R(Q.V-MV,-G.!Q_0U_0-H__ 0R_9(T73Q8V7B+XFQQ"1YM MHU_8?G( 0X)RP990Z M%2/O#&3V/-?X^8GZ,F-K^+M3Q'J9]2C0GGKS99>Z'[WWJSJJ"J*I9I7Y;J.O M2VA_OUEGTD<%@_""AX:O(ZU>O1R.ED_UYU>6G:-&%*=25/V>C;BI6YGR]7W_ M ,T74F8:MJ8 ?_C_ +DL &RH:4X+#'RCUY_Q%4C(P5;_ +Y;\^G^?SK_ $CH M_P#@WE_X)_D*'T;Q7*Y4+(\UY 6F<ON37^F^#\4J&$RW"X66#GS8:C"A.HY-1E"$8QNH\BLW: M]^9_(_S=Q_A?5Q>/QM:.+C2IXJO.M!-HQR2"W;DC/4&O\Z?'_ .C_ %O%WQ&7&N#SNE@<-4=! M+#RHMMRHS4E%OFBDM==-K'^A?@1X_P" \)/#>/!&,RFIF6)A[3_:(3Y(3C4A MR-+W79WL]^FMT?R2V3QCQS\22TT7S^);AE/F+@@ Z?4+AIIO/UM,F1N#AT1>3_M<] MCS6B/^"$'[&8P/MGQ"^AUOC\]O/U!Z5_<' G%.%X3X7R7AJO2>)_LW!4<-/$ MQORRG3A&-X0LVM5HE>R^1_BAX]_0US?QA\4>*?$#!\1X7+J?$&8UL=' 5<.Z MDJ*JRYE'VBJQNE&R^'[F[G\LGFQ?\]8O7_6)SSW^;K^M'FQ?\](O^_J?_%5_ M4W_PX@_8TQQ=_$'\=:/_ ,0:3_AQ!^QK_P _?Q!_\'1_^-U];'Q,P$5RSPCY MD[.Z=W\-MU=:;KS=]=_QS_BG7Q%TXPP;7EAU;I_T^]?ZV_EE\V+_ )Z1?]_4 M_P#BJ/-B_P">D7_?Q/\ XJOZFO\ AQ!^QK_S]_$'_P '1_\ C='_ X@_8U_ MY^_B#_X.C_\ &Z?_ !$[+O=_V1_=O\-[Z>N^O;I<_P"*=G$?_17X3_PG7E_T M]]?^!]G^67S8O^>D7_?Q/_BJ/-B_YZ1?]_$_^*K^IK_AQ!^QK_S]_$'_ ,'1 M_P#C='_#B#]C7_G[^(/_ (.C_P#&Z2\3D7_?U/_BZ3S8O^>D7_?Q/_BJ_J:_X<0?L M:_\ /W\0?_!T?_C='_#B#]C7_G[^(/\ X.C_ /&Z/^(G9=_T"/9=.GNZ[;_C M^I_Q3LXC_P"BOP?3_F'7E_T]]?\ @?9_EE\V+_GI%_W\3_XJCS8O^>D7_?Q/ M_BJ_J:_X<0?L:_\ /W\0?_!T?_C='_#B#]C7_G[^(/\ X.C_ /&Z?_$3LN_Z M!'TZ?X/Z^;^;_P"*=G$?_17X3_PG7E_T]]?^!]G^67S8O^>D7_?Q/_BJC>XM MPLFZ6,84\EU ^XW0Y]^\^((_[C1/_M.@_P#!"#]C,G;] MJ^(. #R=<(^\, C* ;LY[$'H1Q45/$O U(3A#!MN<'![*W-&UTK:[O1?C8ZL M#^STXAPF,PN*EQ;@Y^PQ%&LH?5U>;IU(2Y;>VZVUOMIZ+\@_^">-Q#'\%]9S M/;@#Q?J+#,\*X#$ ;BS \]N.<>E?? N+4GF[MN@&/M,'?_@?;//Y5](^&_\ M@B#^RQX6M9[#2?%_Q8L[*2=[C[/'X@:"-9'SO8"$(I^I7//6NB3_ ((S_LV/ MG_BM_BX1G'/BJ8=!QW_G^M?XN>,_T!,S\2_$CB;C6EQ?AL)2XBQT\2L+4PCJ M.@ZC3UDJT.]M?GT/]]O"[QNP_ / W#'"-3)JN*ED>4T,#B,7"KR1J5:-)0YH MPY)M1=OQWZGR<9K;!_TNV)_Z^8/Q_P"6G^?>H&:U8-OO;0G M_(S7'K]?Z?X5^9T/V9F?X:I[6AQ[AZW]6/NI?2:RN M:2>05[>533IKK2MWUMU\CY'6>)-H%Y9; =S;;B%&+\A7)\S: B\;0,ZT^XOO$WQ,U--.OK/4K6ROO$4UQ9_:K.19HS)$Y M*L-ZC<#ZYYK[7PV_9Z9MP3QQD/%N(XQI8_\ LK,*>-KTGAIJK7A"2FX\SKOW MG)6O9OIK:QX/$_TA,OSW),9E%+(ZU&>+HRH.NZB:A3E&UM()IZZ?I9GZ>_"= MC_PJ_P"'N26W>#]!]4!)TZW'W3T [?Y(] RR@#+_ (.?_KUC^']*LM T?2M! ML-_V+1;&VTVSWL'<06L:PQ!V&-S;4 +8Z_6MRO\ 5*E'V4(TU[L5&"C3<;22 MC",;OK9M7^9_*4DXRFOL2ES0N[N*TLGYVW8*2.[<]F//X>E.W?[W_?7_ -:F MT5H2.W?[W_?7_P!:C=_O?]]?_6IM% #MW^]_WU_]:FMR,9W;NN_)"CT*\;O3 MV_&BB@"N4(4\#((*D<%&RU*T66?1]9:-45+F[TZ(K'-=Y0;Y9-P(X S7[!<9]S_G_&FE%+;C MG/;G^E"=M0/PS\%_\$K?C5\0?B9X6^(O[;'[3FK_ !Z'@?5;75O#F@65M+I6 MC/;3FN3K-G;86.RMF1E^R[$&Q<@CCCI7Z#;%]/\_A36C!'?KT_S MBKYY>7X_Y@?#_P"W#^RSK?[6'A#P3X8T+Q18>%7\*>,]+\3W%Q?V;7J7UMIU MQ'*;.-$9#$\HCP')(4D9&:Y_QM^Q_P")/%7[4'P ^/\ ;>,K"QTOX.>$E\.7 M_AUK-GGU=_(6-[B&ZSMBW$?+D$@>]??ODCCMUS_3O^-*T*L,$_\ ZA^-"FUI MH!^:7_!1G]@0?MQ^$?"FG^'_ !;;^ /&/A74S+;>(9;22X$ND7$L;7VG2B)H MY)5G1"HR^U2?ND5]&>'_ -ECP#9?LQ6?[,6MP1ZKX3'@R/POJ4ODB/[3<"W* M27R1GE&%P6GC/+ D'=FOJ$1YQG(VGCW_ ,XZU)@-R1@GZ_3_ #Q1SOR_X8#\ M;/#?[#7[:_PR\&7OP8^&7[6UMIWP@DBN]/T>/5=%GOO%_A[0KPR(^E:;K#29 MB5+>5HH) IV#;Z#'H/Q=_P"""030_:(0#\A(!SBOSI3]A?]M1?AW<_ .?]J?2=0^"$T!T6%=4\ M/F^\<1>&&^1]-.MREBS^1F*.3R\KDFOV6\E?\Y_QI?*&,9X^G_UZ2DTK: ?D M-\3O^"6^EW'P]^"NA? WQW+X%\;? ZX2]\->(-9MCJUI>W+2":[&HV9PLRW$ MHW$]AP*\Z_:#_P"";'[3?[57@S3M,^-?[2MC/K_AO4-.O?"]EX?T,Z=X5@>Q MFCD>:^TV(@W,D@C'5^"FR*^N7:V*6BWUC)OQ:(S+N*N'(&!GC MG[W\66FKZKX9\1Z?H-W'IVOZCHFJV>C:C<*9;?3]2N[26"SNI(E(,D=O*R2. MH.7"%01FND\G!&,GISZ?A3S'R",\\$_3\O6CF=[Z?B!\(_L&?L=K^R%\-_$V MC^(M>M/&_P 2_B%XMU7QGX_\7068MK?4M4O[F:2&"TAF\R6&UAMY$0QE]K2# M/I@_;Y_8_/[8OP9MO >B:Y8^#/&_AWQ)IOBCP7XKEL1/#HFIV-Q%*TOD1[)' M,D<>SAQ]XM7WAL"\$K/QUXA\'K;QQJ'B#PW>VOCZSUNU>6\U'6)K64+)I% MQE4MK6)^%@VL%3C/%?KN8^A4$L,XR0,<=>1BH1&,%0!MD#)P"0V_Y79A][#> MJX[>O)SOR_KY@?S'?L$? 7X\>+O'_P"UA\5/V>OC3!\-?$:?'+Q9X8UC1_$% MC)K'AN]M8;N2:*9M/1T5+]7D.)MV2 N1BOV!_9(_8VD^ WB#XA?%?XE>,[CX MI?&_XNE%\=>,KF)HH&M()"T&F:3"Y)L;*$X"P(0-H'-?2?PH^ _PI^!R^+A\ M+_"=KX6C\;^);SQ;XI6U:1_[6\07@S<:A/YKR%&D;YL K["O7Q&&9LXYPQV_ M'_%'[-/Q?\ $7C/ MQ'J'@"70G7Q!;3^,C>?:[8:J\C(;>/[63M\ODHN.U<-X/_8(_:V^!.DZU\+O MV<_VHK;PW\$=0N[Z?1=!\3:3/J^N>%;?4V8WEIHVH&13!"H+OB#XD-QJDFIZX;J*ZEGDBDDWK"C(RPQQE @?!Z5]\?!?P-=?#/X4?#WX>W MM]'J5WX+\)Z/X=N+^)"D=]-IUJEO)=1HP].<\U_3:^0'"LJ-\C8ES(D9##!POS#)Y'(P?:OS8^-?_!+ M7]G[XY_%3Q!\7?$6L>-M(\5>)TMDU5_#VM-86]P+2'RXSY:?/\G( ;)"^O;\ MB\;/#:OXI\ 9UP=3QJR^>:*ERXITW45-TIJ7*X M!(XR"#CC ]/>I/\ AS+^S;C_ )'7XL_^%/<__%=?QK_,Q_LR$IR ME4;E&6 ;2@VFML1O;R]5J?U!_P 3/8""IP628BUM?WK=F[2>]/7K9JY\B_:+ M8]+JU_&Z@Y/_ 'WCTJ02VK?\O%J.>GVJ Y[Y_P!9V_#\:^MO^',W[-N./&GQ M9S_V,]Q_C_(\>],/_!&7]FX\GQI\6>AX_P"$IN!GUXW<\>G3\L*7[,?.K3G2 MX[P[][_H!;5M(Z+ZQ^K6_8'])[ /FYP/?%?Z$.K_ /!%/]F[6+*2T'Q"^,EA','BG6S\3R*9HWRKI*)=X9&7 M@@]0>AKSV'_@WW_86BA1+J+QI>W"_,]Y=:C!+=7#N^2SND8#$D\G!/)K_1+Z M$G@K4^BJ\]GF67+R.+5[+=ZWT5T?P'*ZMCD'H/Q QV_SFEW# MN?S$7^>*/^(?C]@_\ Y\O%W_@PC_\ MC5?Z#0\9\"WSRRRHI2@W*\OM.UE&R=K+J[V??4_B;_B5S'<\FL_PTHV?)%4& MK6:M>]39^7S['\ >Y?7^?^%+N7U_G_A_];TK^_O_ (A^/V#_ /GR\7?^!\?_ M ,:H_P"(?C]@_P#Y\O%W_@?'_P#&J?\ Q&C!_P#0LJ=/^7K_ +M_^77^(7_$ MKV8?]#S#_P#@GT_Z>^GW^9_ )N7^\/U_P_\ U]LT;E]1^O\ A_GMDU_?W_Q# M\?L'_P#/EXN_\#X__C5'_$/Q^P?_ ,^7B[_P/C_^-4?\1HP7_0LJ=/\ EZ_[ MM_\ EU_B_JP?\2O9A_T/,/\ ^"?3_I[Z??YG\ >Y?7^?^%&Y?7^?^%?W^?\ M$/Q^P?\ \^7B[_P/C_\ C5'_ !#\?L'_ //EXN_\#X__ (U1_P 1HP>G_"94 M\_WK_N_].O\ $'_$KV8?]#S#_P#@GT_Z>^GW^9_ )N7U_G_A_GO1N7^\/U_P M_P#U=\5_?W_Q#\?L'_\ /EXN_P# ^/\ ^-4?\0_'[!__ #Y>+O\ P/C_ /C5 M'_$:,'I_PF5//]Z_[O\ TZ_Q!_Q*]F'_ $/,/_X)]/\ I[Z??YG\ FY?7^?^ M'_UO6DW+Z_SK^_S_ (A^/V#_ /GR\7?^!\?_ ,:H_P"(?C]@_P#Y\O%W_@?' M_P#&J/\ B-&#T_X3*GG^]?\ =_Z=?X@_XE>S#_H>8?\ \$^G_3WT^_S/X ]R M^O\ /_"EW+_>'Z_X?_7_ YK^_O_ (A^/V#_ /GR\7?^!\?_ ,:H_P"(?C]@ M_P#Y\O%W_@?'_P#&J/\ B-&#_P"A94Z?\O7_ ';_ /+K_$'_ !*]F'_0\P__ M ()]/^GOI]_F?P";E]1^O^'^>O3FDW+Z_P _\*_O\_XA^/V#_P#GR\7?^!\? M_P :H_XA^/V#_P#GR\7?^!\?_P :H_XC1@_^A94Z?\O7_=O_ ,NO\0?\2O9A M_P!#S#_^"?3_ *>^GW^9_ 'N7U_G_A2[E]?Y_P"'_P!;TK^_O_B'X_8/_P"? M+Q=_X'Q__&J/^(?C]@__ )\O%W_@?'_\:H_XC1@_^A94Z?\ +U_W;_\ +K_$ M'_$KV8?]#S#_ /@GT_Z>^GW^9_ )N7^\/U_P_P#K>F:-R^O\_P##_/:O[^_^ M(?C]@_\ Y\O%W_@?'_\ &J/^(?C]@_\ Y\O%W_@?'_\ &J/^(T8/_H65.G_+ MU_W;_P#+K_%_5@_XE>S#_H>8?_P3Z?\ 3WT^_P S^ /+O_ ^/_XU1_Q&C!Z? M\)E3S_>O^[_TZ_Q!_P 2O9A_T/,/_P""?3_I[Z??YG\ FY?4?K_A_GO@T;E] M1^O^'^>_-?W]_P#$/Q^P?_SY>+O_ /C_P#C5'_$/Q^P?_SY>+O_ /C_P#C M5'_$:,'I_P )E3S_ 'K_ +O_ $Z_Q!_Q*]F'_0\P_P#X)]/^GOI]_F?P";E] M?Y_X?_6]:3?[U_W?\ IU_B#_B5[,/^AYA__!/I_P!/?3[_ M #/X!-R^O\_ZC^=&Y?[P_(_X?Y^E?W]_\0_'[!__ #Y>+O\ P/C_ /C5'_$/ MQ^P?_P ^7B[_ ,#X_P#XU1_Q&C!_]"RIT_Y>O^[?_EU_B_JP?\2O9A_T/,/_ M ."?3_I[Z??YG\ FY?7^?^'_ -?\*-R^OZ'_ _S^=?W]_\ $/Q^P?\ \^7B M[_P/C_\ C5'_ !#\?L'_ //EXN_\#X__ (U1_P 1HP?_ $+*G3_EZ_[M_P#E MU_B#_B5[,/\ H>8?_P $^G_3WT^_S/X!-R^O\_Z#^5&Y?4''/^/^1UYP:_O[ M_P"(?C]@_P#Y\O%W_@?'_P#&J:W_ ;\?L'X_P"/'Q>WL-0B'_M*A>-&!^W@ M*E)=:CJ-J#TL[>R[W''Z+^.BTY9YA^56O^YN^FW[W?;[_,_@"5U9XSG[L@S[ M#(]O\XS7]97[ ,L*_LU>$/,N((V69PR23Q(01&K,%!Y'^GQ<<<8S&.G!'^<=OX<_X(B_LM^&M-32M)\7?%:"RMY7D@C_X2.2) M$W_PI'#Y:A5& IV] 37\5_3,X$J_2?X,P7#6#QRR.KA,1&K'$U:;KPJK3>% MZ;=TKI7ZH_K#Z+.25? #.,QS;%S6=?7X*E*-!>QY8-M67QI.S];JZV/FE9;4 M 9NK7(["YAY.3_M],=C^9H-Q;$Y6ZM0,$Y^TPCOT^_GZ\YQ[U]:C_@C-^S<" M1_PF?Q9R#S_Q5$[#)YX&XE?H<'OBG#_@C/\ LW9Y\9_%@C_L9[C_ !]:_P N MI_LR,XJ6MQSAXQVTP$D]HI_\OWI=.W3S/[RC])_ J+2R/$J^W[Y/ENDKQ?L[ M7ZW_ $1\@EK)\A[BRE4M\L;3VY,?/&?Q8 _[&>X_P :8W_!&;]FW/\ R.GQ7_\ "HN> M.^/O#IZ5L_V:'$?LX4O^(A4H487M%X*HX03BHJ,8^WM&-];?S-^A,?I-94JK MG/ARI4=65ZM253WOA45*ZIW^_J_4_,KXZSPC5_V;@ES#*6_:9^' V)<1.Z_- M>$2;49FPO_V:?#7BOP?XQ_X2+XC:I?\ @OQ#8^)M&M]7UV6\L?[4T]BUL9H)"5M'$.K3QL:;C#EETY.>=OB?VNNMS^=O$CC.AQKGG]JT<$L-%4^2,7*ZM[M MM.57:_'KIJ758X^\QSZDFE!P,98^^[_ZU,3[H_'^9IU?T&?G([=_O?\ ?7_U MJ-W^]_WU_P#6IM% #MW^]_WU_P#6IO).=S@9'&XT44 (0<\.W![DD8^GKCIW MJ-HU.<@$#(/'WT8$,&'T)SZU+10!^,/[0G_!+SQQJ_QGUC]H']D[X[:I\!_B M)XEG%SXC1(YKK0]0N 06GDL$94=V"\%LX:LOX0?\$NOB?J/QA\._&G]L?]HC M5/C_ .(_!EVE_P"%].\B:RT&VND<.DEQIKL8I'B8;E?;G@ 5^V)4'M_G_/M3 M/+]_TJ^=^7]?,#\^_CS^QSKWQ>_:@^!OQYTOQ?IVCZ-\)6P>6YU-.= MD5M.C*MO&H 4JV!Q6K^VS^R;KW[5,7PD30O%EEX6;X<>/\ 3?&%Z+VT:[;4 M;:QF21[*V92OD,VT@-SU%?=_E^_Z?_7IK1D]LX[]/ZT<[\OZ_P"& _/FR_8Z MU^Q_;YL/VQ/^$QLY_#]K\&!\+CX.:R?^T_MPB@C.J#4-WE^0WE%O(\O(R!GC M->5_M_?\$XY_VQ_'_P +/'OAGQS;^ -3\+Q3:#\09_L*_5OR@0,]AT_R108@<9/3_/K1SOR^X#Y@^.O[+GP\^/GP M#;]G_P 3P&T\,PZ/H^G:1+8J('TB]T.WCBTW4[0(!Y<]M+&)8]H&#DGFO@^V M_8A_;.6\,6RB*'2GUSS2YW6V(BY0$ M=N*_8[R0.1U'3K_C2^7G!/4=!_DT<[\OQ_S _,O]HG_@G]%\3?V?/A7\!_AS MXMB\,Z;\./$&B:R=0UJ&;4KC5%TV>&XN6FDDD,HNKEXV)E9B S9QVKZ0_:!_ M9JTSX_? JT^#^IZ]J.A7>FZ=HRZ5XBTBXEM+NQUC1;6&*WO$>)PY3SH4EV9P M0,$M(^#/QH_:>T3 MQ-\%[*[L8]1M;'PV;?Q7JVCV$D30V-]JSEWEW)#&CLH5B">+_ SX/UR#0/$F MN:)J&F:/KMU UQ#I<]W"\:SR6ZLK2[68$888QQ7SG^P[^RM'^R3\&$^'>H:M M9^*?%.IZYJ/B3Q7XHBLA"FL:MJ4\LTLWE2[Y%$9$51@#\^:2;7X?@!\ ?MT?L9/\ M9^&?!;>%?$-EX#^(WP^\46'B'PQ MXP>R$_V3[+<12S6[QP^6[K.B,I!; #;2.E>#ZI^P!\:_ OQ ;XN_LX?&W3_A MY\0/$NDV-C\2XM1TF2_\,^*;^WA$,NJPZ7O'V:[;YFW%R23GU-?KLR!O;Z=* MC\@>I^G^>:KG?9?>(IM/F^T7J7Q98TL5?/EVZQ@*@50>.?@[_@EO\ ;]J/Q'\ M"?B-XU_9W^/]E\.M.\3?&'Q_I.N^&?$&DOK.GV\MKJ=R&U;3%5T%G?D3*JMN M.>,CC%?T\ZGIUIJ5A>:=?Q_:+*_@EL[JWR%\Z&Y4Q2*S#&T,C$8R.IKS'X+? M ?X5?L^>%[[P3\(/"EGX0\-7^N:AXDOM/LI)FCFUK5I/-O[QVFDD)EN9/F=5 M8#CY0*.>7E^/^8'SK^S9^Q-X=^!/PZ^(FB:KXCO/&/Q%^+XO9_B-\0;[<=0U M:^O870F$M\\-I!(Y:.W'"A5 QBOEOX-_\$VOB)X,\&_$GX#_ !#^*NC^+?V> M?&VI:SJVF^'+?1WA\2:1J&HRSRPW2ZHTA!>!Y 5VH"NT>E?L=Y0QC/'T_P#K MT@A ;=DC''U'YFES2[O^OZ_K4#\;-._89_;4\.^![CX(>'?VLK:W^"11M)L8 MIM%G?QMIOAMSMDTJVUP2J5!AW(L@3Y0'!_#GPQ<>"_ OA3PE M0._;TST_Q_"@C((/?KBEQR#Z=L?UI:5KWNHWOI)+WEMUOOI8/>2UDI7>BM9Q M6G7[R)DQSU[<]?;\*D'(&1V[C_/UI:*$INS<]-%RM7:VN[JU_GY[LIMM13DY M6[[[+_*WG\PZ X'7Z<_C3"6Q]W]<_E[T^FX;U&/UQ^&.:=G_ #+TY7_G]_ZD M6OIWTU;_ !U_K7NQ@9C@8!(Z=?3ZT\?,/F4=>X_QIH3'\1/3VZ?3_(IX&!BI MC%0YFDYREK>;NEKLEO;K\K=KTND9-.UN64$XVVT=V[^=ET[ZB_T__5_*HY%S MSC)Z?AU^O6I**:6BT2?7ENE?2_7R^?S%>5]NO33MKZ]7Z>A$"!P5Y[\#\/TI M>#TV#ZCG^?\ GUIQ4'GFC8OI2Y;;)?._^87E:UVO1["9 Z[3]!SFDW+_ '?T M%.V+]/\ /OFDV#W_ ,_A2L_Y(?U;_@_CY![W\TOO_P" ''^Q^7_U_2C_ +X_ M+_Z_I_A[TNQ?3^?^-&Q?3^?^-/\ []+_ -\?E_\ 7I=B^G\_\:-B^G\_\:-=/?W_ M / _KYL3C_8_+\N_^?>C('7!]-H''ZTNQ?3^?^-&P>X_S[YI6E]GE@_YM[;= M%;S_ *M=6;TJY.2HP?8'OZ>W-2'IV_'I_G%*/\XIIM6;O.5I7;M9: MII+;Y>FKU+;E+XG%*Z3MS9-)R?(DURV5[Z=;=/UN0E>,MP< M\=?YCF@8&0"1DC/J1V.>OKC\NE3?K_GVI",D'T]O\_AZ=:I.5]6HQMI#EO&[ M:U>S]2.25G%2BDW=-Q;:^YV]-"'9DY!X[+QR>IS[CKT].:3.#CC/;!_S_7V- M3;<'//\ GZ4N!Z#\JAQ3M&:YU9/F5HI-6V7]=4UJ:ZN493E*\8V2@U&+>E[W M3;O;6_RT(@_*J4II*\8MZ:_=V[?IZ72;LO^!OI_ MD0Y/O1D^_P#^OK4V!Z#\J,#T'Y4<\_Y8?U;^NNWDKN[_ *^7^2(/Y49/O_GC^7%3 M8'H/RHP/0?E1SS_EA]VST\_ZM]Y=_P!?+_)?<0Y/O1D^]38'H/RHP/0?E3YY M_P L?ZM_7R\E:2&A!QG\0>1R*<0" M,=!GL/\ /-+122^)RA%WALKWE+31MMI+TV^1'+JDY3<;6:;T>JULOGW"D)/8 M9_'%+3<$]21Z8/;W]Z%):>\EKM9Z+3S_ $Z%6MM?3S?E_E_5V&7'(7!^H-,. M",-^2C'7KG/?H.*?M/9CGW/'\J49[\T:.[4I2327+'W=;Q;=WU^>RMNP5EHU M+Y.W5>=^[?\ FQBHHZ=,YQC ]1]<'D5)113WESV:?(H.[NVDTUMI>]]?*RM< M.MU=*VJ>M]M+^6__ X4444P"BBB@ HHHH /?'-%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 =>3R?6BBB@ HHHH *.G(X/2BB@!I0'.<\]1V/;G MCG\: H7IGTIU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1113OIIO=_I;\06^NW?\ KR(A'G))'/7'.?Q/ MH?K3M@R#T(XR,9_EUI=OH2/Y?E3J%.=M;7T>NJZ?=_3*:@]=7;9-==-_+NNO MW785 R0/FXY[Y]:3]X>OK[5)3<'N?IP/\*CEO:I.TYZ+EV2VOY?/_A@B[_$D MK/2U_)=^WY?>T;QV!^IQC_'\>OM33NXW<>AXX]>E2%2?XCP?\]._O^E!!XP M?KCC^5/G479-)6U7*_=[I:VO^'?8'R]+/Y2_S$* GO\ _7]>VWW$N]I*+Y&XV MNM_B6S=[:77XVT$7[Q YXZX[GW]R#WIVWD'L.W^?;^0H48 &*=1:6E];ZN[T M3TTLMUO_ , =TGI&UHJ*?W7?_#A^'^3UHQ[?IZ]:**JS[0Z6]W^OU'S2[_D) M@>@_+UZTN/;]***7*^T-UT?EY_Y>FX@_+TZ4M%%GVA_P" ^GG_ %\]#FEW_(,>WZ>G2C\/ M\CI112L^T/N#FEW_ 7^08]OTI,#T'Y?C_.EHH47VAMV?^?^;#FEW_(,>WZ? MC_/FC'M^E%%.S[0_\!VVVU#FEW_(/P_R>M&/;]/7K1119]H=/LAS2[_D)@>@ M_+UZTN/;]***7*^T-^S\O/\ KMN'-+O^0?A_GI_*C'M^GX?RXHHHL^T/N_K^ MNHWZ48]OTHHIV\H;_R^F^O]?/0YY=PQ[?IZ=*,>WZ>G2BBE9]H M>>G]?H'-+O\ E_D&/;]*3 ]!^7X_SI:*.5]H;=GY?UU8?4 M?/):]NF@SRP>I)QTS_3@_P#ZJ4 X&SVOMUTN']>33"7SP!CTSU],]Q_D^U/IN&)Z\ M?K_+U_2AM7W2UU5GHM.M_,I66T5]\NWJ)E_[H_/_ #]/U]J^*3;_M-^ M?_UJ4# QR:$US*TDUK?1[6CK;?=O3Y,;;MRV5GOO_GU&[%/!Y .1GL?4>]-V M*#CY@6)YX.3Z^M2T?YQ_GFFDX)I2Y[M/6Z25UHE>RT\O\B$I)@ M_K11SG@\ MZG_"JC%RU ])HKSR2GW X_E1_PLS1?^>M@](HKS?_ (69HO\ SSF_+_ZU'_"S-%_Y MYS?E_P#6H]F^Z_JW^?X>M@](HKS?_A9FB_\ /.;\O_K4?\+,T7_GG-^7_P!: MCV;[K^K?Y_AZV#TBBO-_^%F:+_SSF_+_ .M1_P +,T7_ )YS?E_]:CV;[K^K M?Y_AZV#TBBO-_P#A9FB_\\YOR_\ K4?\+,T7_GG-^7_UJ/9ONOZM_G^'K8/2 M**\W_P"%F:+_ ,\YOR_^M1_PLS1?^>M@](HKS?_A9FB_\\YOR M_P#K4?\ "S-%_P">M@](HKS?\ X69HO_/.;\O_ *U' M_"S-%_YYS?E_]:CV;[K^K?Y_AZV#TBBO-_\ A9FB_P#/.;\O_K4?\+,T7_GG M-^7_ -:CV;[K^K?Y_AZV#TBBO-_^%F:+_P \YOR_^M1_PLS1?^>M@](H MKS?_ (69HO\ SSF_+_ZU'_"S-%_YYS?E_P#6I>SEY?>O+_/\'V ](HKS?_A9 MFB_\\YOR_P#K4?\ "S-%_P">7^?X?,#TBBO-_^%F:+_P \ MYOR_^M1_PLS1?^>D45YO_P +,T7_ )YS?E_]:C_A9FB_ M\\YOR_\ K4>S?=?U;_/\/6P>D45YO_PLS1?^>D45YO_ ,+,T7_GG-^7_P!:C_A9FB_\\YOR_P#K4>S?=?U;_/\ M#UL'I%%>;_\ "S-%_P">;_\+,T7_GG-^7_UJ/\ A9FB_P#/.;\O_K4>S?=?U;_/\/6P>D45YO\ \+,T M7_GG-^7_ -:C_A9FB_\ /.;\O_K4>S?=?U;_ #_#UL'I%%>;_P#"S-%_YYS? ME_\ 6H_X69HO_/.;\O\ ZU'LWW7]6_S_ ];!Z117F__ LS1?\ GG-^7_UJ M/^%F:+_SSF_+_P"M1[-^7WKR_P _P^0'I%%>;_\ "S-%_P">?G^#[ >D45YO_P +,T7_ )YS?E_]:C_A9FB_\\YO MR_\ K4_9ONOZM_G^'K8/2**\W_X69HO_ #SF_+_ZU'_"S-%_YYS?E_\ 6H]F M^Z_JW^?X>M@](HKS?_A9FB_\\YOR_P#K4?\ "S-%_P">M@](HKS?\ X69HO_/.;\O_ *U'_"S-%_YYS?E_]:CV;[K^K?Y_AZV#TBBO M-_\ A9FB_P#/.;\O_K4?\+,T7_GG-^7_ -:CV;[K^K?Y_AZV#TBBO-_^%F:+ M_P \YOR_^M1_PLS1?^>MBYZ117F__"S-%_YYS?E_]:C_ (69HO\ SSF_ M+_ZU+V;_P#"S-%_YYS?E_\ 6H_X69HO_/.;\O\ ZU-4 MWW2^:\O/S_#YH/2**\W_ .%F:+_SSF_+_P"M1_PLS1?^>M@](HKS?_ (69HO\ SSF_+_ZU'_"S-%_YYS?E_P#6H]F^Z_JW^?X>M@]( MHKS?_A9FB_\ /.;\O_K4?\+,T7_GG-^7_P!:CV;[K^K?Y_AZV#TBBO-_^%F: M+_SSF_+_ .M1_P +,T7_ )YS?E_]:CV;[K^K?Y_AZV#TBBO-_P#A9FB_\\YO MR_\ K4?\+,T7_GG-^7_UJ/9ONOZM_G^'K8/2**\W_P"%F:+_ ,\YOR_^M1_P MLS1?^>M@](HKS?_A9FB_\\YOR_P#K4?\ "S-%_P">M@](HKS?\ X69HO_/.;\O_ *U'_"S-%_YYS?E_]:CV;[K^K?Y_ MAZV#TBBO-_\ A9FB_P#/.;\O_K4?\+,T7_GG-^7_ -:CV;[K^K?Y_AZV#TBB MO-_^%F:+_P \YOR_^M1_PLS1?^>M@](HKS?_ (69HO\ SSF_+_ZU'_"S M-%_YYS?E_P#6H]F^Z_JW^?X>M@](HKS?_A9FB_\ /.;\O_K4?\+,T7_GG-^7 M_P!:CV;[K^K?Y_AZV#TBBO-_^%F:+_SSF_+_ .M1_P +,T7_ )YS?E_]:CV; M[K^K?Y_AZV#TBBO-_P#A9FB_\\YOR_\ K4?\+,T7_GG-^7_UJ/9ONOZM_G^' MK8/2**\W_P"%F:+_ ,\YOR_^M1_PLS1?^>M@](HKS?_A9FB_\ M\YOR_P#K4?\ "S-%_P">M@](HKS?\ X69HO_/.;\O_ M *U'_"S-%_YYS?E_]:CV;[K^K?Y_AZV#TBBO-_\ A9FB_P#/.;\O_K4?\+,T M7_GG-^7_ -:CV;[K^K?Y_AZV#TBBO-_^%F:+_P \YOR_^M1_PLS1?^>M M@](HKS?_ (69HO\ SSF_+_ZU'_"S-%_YYS?E_P#6H]F^Z_JW^?X>M@](HKS? M_A9FB_\ /.;\O_K4?\+,T7_GG-^7_P!:CV;[K^K?Y_AZV#TBBO-_^%F:+_SS MF_+_ .M1_P +,T7_ )YS?E_]:CV;[K^K?Y_AZV#TBBO-_P#A9FB_\\YOR_\ MK4?\+,T7_GG-^7_UJ/9ONOZM_G^'K8/2**\W_P"%F:+_ ,\YOR_^M1_PLS1? M^>M@](HKS?_A9FB_\\YOR_P#K4?\ "S-%_P">M@](HKS?\ X69HO_/.;\O_ *U'_"S-%_YYS?E_]:CV;[K^K?Y_AZV# MTBBO-_\ A9FB_P#/.;\O_K4?\+,T7_GG-^7_ -:CV;[K^K?Y_AZV#TBBO-_^ M%F:+_P \YOR_^M1_PLS1?^>M@](HKS?_ (69HO\ SSF_+_ZU'_"S-%_Y MYS?E_P#6H]F^Z_JW^?X>M@](HKS?_A9FB_\ /.;\O_K4?\+,T7_GG-^7_P!: MCV;[K^K?Y_AZV#TBBO-_^%F:+_SSF_+_ .M1_P +,T7_ )YS?E_]:CV;[K^K M?Y_AZV#TBBO-_P#A9FB_\\YOR_\ K4?\+-T0=4F'^?I1[.6FSOY^G^?]; >D M45YO_P +,T7_ )YS?E_]:C_A9FB_\\YOR_\ K4E3EY+YKR_S_!]@/2**\W_X M6;HO_/.;\O\ ZU'_ LS1?\ GG-^7_UJ?LWW7]6_S_#UL'I%%>;_ /"S-%_Y MYS?E_P#6H_X69HO_ #SF_+_ZU+V;_\ "S=%_P">D45YO_ ,+,T7_GG-^7_P!:C_A9 MFB_\\YOR_P#K4>S?=?U;_/\ #UL'I%%>;_\ "S-%_P">;_\+,T7_GG-^7_UJ/\ A9FB_P#/.;\O_K4> MS?=?U;_/\/6P>D45YO\ \+,T7_GG-^7_ -:C_A9FB_\ /.;\O_K4>S?=?U;_ M #_#UL'I%%>;_P#"S-%_YYS?E_\ 6H_X69HO_/.;\O\ ZU'LWW7]6_S_ ]; M!Z117F__ LS1?\ GG-^7_UJ/^%F:+_SSF_+_P"M1[-]U_5O\_P];!Z117F_ M_"S-%_YYS?E_]:C_ (69HO\ SSF_+_ZU'LWW7]6_S_#UL'I%%>;_ /"S-%_Y MYS?E_P#6H_X69HO_ #SF_+_ZU'LWW7]6_P _P];!Z117F_\ PLS1?^>D45YO_P +,T7_ )YS?E_]:C_A M9FB_\\YOR_\ K4>S?=?U;_/\/6P>D45YO_PLS1?^>D45YO_ ,+,T7_GG-^7_P!:C_A9FB_\\YOR_P#K4>S?=?U; M_/\ #UL'I%%>;_\ "S-%_P">;_\+,T7_GG-^7_UJ/\ A9FB_P#/.;\O_K4>S?=?U;_/\/6P>D45YO\ M\+,T7_GG-^7_ -:C_A9FB_\ /.;\O_K4>S?=?U;_ #_#UL'I%%>;_P#"S-%_ MYYS?E_\ 6H_X69HO_/.;\O\ ZU'LWW7]6_S_ ];%STBBO-_^%F:+_SSF_+_ M .M1_P +,T7_ )YS?E_]:E[.7E]Z\O\ /\'V ](HKS?_ (6;HO\ SSF_+_ZU M'_"S-%_YYS?E_P#6H]G+R^]>7^?X/L!Z117F_P#PLS1?^>;_ /"S-%_YYS?E_P#6H_X69HO_ #SF_+_ZU'LWW7]6_P _ MP];!Z117F_\ PLS1?^>D M45YO_P +,T7_ )YS?E_]:C_A9FB_\\YOR_\ K4>S?=?U;_/\/6P>D45YO_PL MS1?^>D45YO_ ,+,T7_GG-^7_P!: MC_A9FB_\\YOR_P#K4>S?=?U;_/\ #UL'I%%>;_\ "S-%_P">;_\+,T7_GG-^7_UJ/\ A9FB_P#/.;\O M_K4>S?=?U;_/\/6P>D45YO\ \+,T7_GG-^7_ -:C_A9FB_\ /.;\O_K4>S?= M?U;_ #_#UL'I%%>;_P#"S-%_YYS?E_\ 6H_X69HO_/.;\O\ ZU'LWW7]6_S_ M ];!Z117F__ LS1?\ GG-^7_UJ/^%F:+_SSF_+_P"M1[-]U_5O\_P];!Z1 M17F__"S-%_YYS?E_]:C_ (69HO\ SSF_+_ZU'LWW7]6_S_#UL'I%%>;_ /"S M-%_YYS?E_P#6H_X69HO_ #SF_+_ZU'LWW7]6_P _P];!Z117F_\ PLS1?^>< MWY?_ %J/^%F:+_SSF_+_ .M1[-]U_5O\_P /6P>D45YO_P +,T7_ )YS?E_] M:C_A9FB_\\YOR_\ K4>S?=?U;_/\/6P>D45YO_PLS1?^>D4N#@GL.IKS/](O;B"UA$A> M>14';K^'/]*S [[!QG'!&?P_R:2A3E0RY / '?'O10 4444 %%%% !1110 4 M444 .'0_[T?_ *&**!T/^]'_ .ABB@!O8?[J_P#H(HH[#_=7_P!!%% !1110 M 4444 %%%% !03@?B.?;."/QS103QCW7^?\ ]>@#@_B(-WAZ0>DJ8]OI7SLH M.[!YQ_+'3]_'6@+OS_K_AE] MPN!Z#\J,#T'Y4W>N"O;\Z!(IQS@G/#_+T&>.N: N_/^O\ AE]P M[ ]!^5&!Z#\J%*MP&&?0')_ =Z6@+OS_ *_X9?<)@>@_*C ]!^5+10%WY_U_ MPR^X3 ]!^5&!Z#\J6B@+OS_K_AE]PF!Z#\J,#T'Y4M% 7?G_ %_PR^X3 ]!^ M5&!Z#\J6B@+OS_K_ (9?<)@>@_*C ]!^5+10%WY_U_PR^X3 ]!^5&!Z#\J6B M@+OS_K_AE]PF!Z#\J,#T'Y4M% 7?G_7_ R^X3 ]!^5&!Z#\J6B@+OS_ *_X M9?<)@>@_*C ]!^5+10%WY_U_PR^X3 ]!^5&!Z#\J6B@+OS_K_AE]PF!Z#\J, M#T'Y4M% 7?G_ %_PR^X3 ]!^5&!Z#\J6B@+OS_K_ (9?<)@>@_*C ]!^5+10 M%WY_U_PR^X3 ]!^5&WCA03V^4=,_ATH) '/_ -?M4[[F<'&$(XW#HPZ^F>?QZ]J;N7+9&#R ".,?PMSZ]??/ M2OFCQO\ M V_A_4Y]-\/V<5[):N8YKB5@4W#.<*3S@CD?AWKH_AO\9['QM,V MEZA&NGZF4,HW,#&Y'4KR BD@[5R<#/.*_GG ?2D\(LQXQJ<$X?B'#+.:59X9 MJO-4\/.O&?(XQJ>[%.+5I:VT=]=#]&J^%W&-+**6;PRV?U*<.;GUE44=)\W) MJVFGIIM;T/=%Z@,>N>0#@?7^?Z4[<,GA< <' .355;FWX#75LK<;PLJ'/]WG M(_R:BN;R&&WGE22*=XHWDCC65%+,O(7.XY.!],^M?MN(XLX;PT:E;$9[E,X4 MJ3JSG3QF'<84U#VCBDJGO2Y5IH[Z=3XJCE.9U*GLZ6 Q3J-O ^GT.<>E.50<]QZ]#_GGUKRC0?B]X2UFZ?3IKK^S M-3@N&@FMKO 3,CGI7C< M/>(_!?$]-+).(\OS"%*M4A74:]&-6G)2:]E.+<9W6]X]K;&^8<,YWELX?7,# MBH*I9JU&IR6T^TD[?>DEJ3X Q\N?PS^>>:3(_N'_ +YI0V[T]\'([]\#]!Q^ ME.YSTX]?_K5]I&49P3@TX/6+A+F7*[62EK?3KYGCU%*$W%QE"22NG>^RUU[V M$P/0?E1@>@_*EHJEHK67K;4B[[O^O^&0F!Z#\J,#T'Y4M% 7?G_7_#+[A,#T M'Y48'H/RI:* N_/^O^&7W"8'H/RHP/0?E2T4!=^?]?\ #+[A,#T'Y48'H/RI M:* N_/\ K_AE]PF!Z#\J,#T'Y4M% 7?G_7_#+[A,#T'Y48'H/RI:* N_/^O^ M&7W"8'H/RHP/0?E2T4!=^?\ 7_#+[A,#T'Y48'H/RI:* N_/^O\ AE]PF!Z# M\J,#T'Y4M% 7?G_7_#+[A,#T'Y48'H/RI:* N_/^O^&7W"8'H/RHP/0?E2T4 M!=^?]?\ #+[A,#T'Y48'H/RI:* N_/\ K_AE]PF!Z#\J,#T'Y4M% 7?G_7_# M+[A,#T'Y4AVCD@?D*=1G'6@$VOZ_KL-;:!]T>G2D!4@\*#R.W_UJ:P(QDD]: M,JN >2>< 9/;\:-;Q?NI*2PF .^ M<8XQU_'I2%AN''X?3U^M#;5R694&"3O*I@#.>&/8=,?I7GGB7XG>#O"^X7VI MQ7%T 0EI9L)I=PX_>A2/*&3U)-?(<0^('!?#5%5LYXARW+J"JJ-2M5Q="Z=T MN54^=RWZ6V>NA[67<.YUF4E_9^75L0VOL4ZCT]W5W7+T_*_9^C*03C:,GIQ] M?\YH;@]%_*N9\.^(+?7=*AU/:MDDXWQP32J90C#*.1D$*PY_$&MUKJV!(>Z@ M'RAE/FH0VX9P,-QCI_A75@N->&L?A85)PN.>< M'G YKQ/0?VE[JZODCU[388M.FG6.![$FHP4W>$W>ZM_+MZ.WUXHS@E0 1T(&1]?VLA>VN8A+%*>05<;@#_M#D9]O>K>[)7/!SG&.@SQD].+IXFE6G M1KT[OW94WU[-6U?ROL28'H/RHP/0?E2T5N8W?G_7_#+[A,#T'Y48'H/RI:* MN_/^O^&7W"8'H/RHP/0?E2T4!=^?]?\ #+[A,#T'Y48'H/RI:* N_/\ K_AE M]PF!Z#\J,#T'Y4M% 7?G_7_#+[A,#T'Y48'H/RI:* N_/^O^&7W"8'H/RHP/ M0?E2T4!=^?\ 7_#+[A,#T'Y48'H/RI:* N_/^O\ AE]PF!Z#\J,#T'Y4M% 7 M?G_7_#+[A,#T'Y48'H/RI:* N_/^O^&7W"8'H/RHP/0?E2T4!=^?]?\ #+[A M,#T'Y48'H/RI:* N_/\ K_AE]PF!Z#\J,#T'Y4M% 7?G_7_#+[A,#T'Y48'H M/RI:* N_/^O^&7W"8'H/RHP/0?E2T4!=^?\ 7_#+[A,#T'Y48'H/RI:* N_/ M^O\ AE]PF!Z#\J,#T'Y4M% 7?G_7_#+[A,#T'Y48'H/RI:* N_/^O^&7W"8' MH/RHP/0?E2T4!=^?]?\ #+[A,#T'Y48'H/RI:* N_/\ K_AE]PF!Z#\J,#T' MY4M% 7?G_7_#+[A,#T'Y48'H/RI:* N_/^O^&7W"8'H/RHP/0?E2T4!=^?\ M7_#+[A,#T'Y48'H/RI:* N_/^O\ AE]PF!Z#\J,#T'Y4M% 7?G_7_#+[A,#T M'Y48'H/RI:* N_/^O^&7W"8'H/RHP/0?E2T4!=^?]?\ #+[A,#T'Y48'H/RI M:* N_/\ K_AE]PF!Z#\J,#T'Y4M% 7?G_7_#+[A,#T'Y48'H/RI:* N_/^O^ M&7W"8'H/RHP/0?E2T4!=^?\ 7_#+[A,#T'Y48'H/RI:* N_/^O\ AE]PF!Z# M\J,#T'Y4M% 7?G_7_#+[A,#T'Y48'H/RI:* N_/^O^&7W"8'H/RHP/0?E2T4 M!=^?]?\ #+[A,#T'Y48'H/RI:* N_/\ K_AE]PF!Z#\J,#T'Y4M% 7?G_7_# M+[A,#T'Y48'H/RI:* N_/^O^&7W"8'H/RHP/0?E2T4!=^?\ 7_#+[A,#T'Y4 MFT>@_ 8IU%.\H\DG9THR?M$E[VMDI)Z.T=6_QT0O>DU%U5"'\OVF].MM%I_E MJ0D\GA?R_P _Y% ;(/RJ%&"TF =OMCW!R3VXJO/.EO'/<3ND4$ 9YIGX2-54 MN) M_C/P'X1X3#8OB[.*>!AB*BE1I.5ZLXIIS<8:N46EV=GWT/L^%.">).,JLJ.3 M8-UH4>9SF[07NJ+MS.RUM97NY79]6[D&&"LZO\N[;\BGKDC)('OCOS3@%;M_ M3^5>-_#;XLZ5X\66UD5-/U:WC\Z6V=@B31#AI803@KG SWR#BO71<6HY%W;= M.GFI^OS<>G->GPGXJ\"<TCHKQE[KV]QP3NMFKMWWZV). W.< _GZ?G3 M@02QQQC(X';_ !K&U35XK"RN;V/R;MX$,AMXYXPQ11S\Q/#<9VX]>PKAO#7Q M6\)>(I/LXOUTZ\60Q26UZ1&X=20%0M][)!Y&.M;X[Q.X"R3,,/E>9<1Y90JX MMVPLIXRE)5)W34(N,VGJFES:>8L-POG>(P=3&X/*<;7I4KJ?+2J\RY6HMV:N M[>ENO2YZD,$$[0, GV_I_G]4W#^Z/\_A34GCE&8Y8BIZ.'5@R_WU*D^G&/?M M3U R"K*P(YP>?IC]:^VP>8X;,Z:JX/%X*O1E%3]I3K4YU(Q7+RVC"5FI+5Z/ M7LSQJV$Q6':G4H5*$OMPJQE&2:LK.,^OHK7O?L.&",[0/PI<#T'Y4IX/^(P? MRHK9-SBII@_*EHH"[\_Z_P"&7W"8'H/RHP/0?E2T4!=^?]?\ M,ON$P/0?E1@>@_*EHH"[\_Z_X9?<)@>@_*C ]!^5+10%WY_U_P ,ON$P/0?E M1@>@_*EHH"[\_P"O^&7W"8'H/RHP/0?E2T4!=^?]?\,ON$P/0?E1@>@_*EHH M"[\_Z_X9?<)@>@_*C ]!^5+10%WY_P!?\,ON$P/0?E1@>@_*EHH"[\_Z_P"& M7W"8'H/RHP/0?E2T4!=^?]?\,ON$P/0?E1@>@_*EHH"[\_Z_X9?<)@>@_*C M]!^5+10%WY_U_P ,ON$P/0?E1@>@_*EHH"[\_P"O^&7W"8'H/RHP/0?E2T?E M[YXP*+VUMS:K3:XT[-7;MUMO;^DA,#T'J>*BW>R_3'^>E/<9/#JW&<*<]![# M&>?K^%12.BAFDECCVJ2!(RHY [[&(QCZ]JY,;CLOP$74QF/PF'4(\\E6Q%*E MRLPC6UM"'8R,VT(Y!(4YZ],#/-=CI MFJ0:A86MZS06OVE%<0R7"&1%(R-P)';KQG-?%Y?XH\"9OF6)RW!<39;7Q^#D MU6C3Q-!0@HI-TFW+DJ[K<]^OPGQ#A<+#%8C XBGAJU12A)49OVL6HZQ] MURBG]_X)[VY1_"./?^?K]?UI6 *8PP;.054#Y2..<\_H/IVJB[M%!_TBW('0 M^>G;''7_ /7TKR;XC_%G2O L8MX!'J6J3)NBBCD#(@/(W,/3N#]/6LN+O%3@ M?@C)L1G^><08&C@<+#G<:6)H5JW,URQM3A.3E>3U]UVWUT)R+A+/\\Q7]GY= MEN)]M5J6HNI3JI-Z7YW)+EC\_3L>P!@P("XVD!CQGO\ _K_+UJ12A] ."1R MQ^O_ -;ZU\F>$_VC6O=1BL?$6GI:6]S,D,=U;* M198XYE9)(9=K0RQG=&P8 Y# \D!@<=R<=J\KPO\ &O@;Q>P^(Q_".:4L>Z$O M9XNE).G4IJ,4HOV45&T9-+WE&UWO<[>*>!L[X-G2AGF'J4J]=)QY;NGHEKS; M;?*_=V+V!Z#\J,#T'Y4B]..<=\?C_6G5^LGQ]WY_U_PR^X3 ]!^5&!Z#\J6B M@+OS_K_AE]PF!Z#\J,#T'Y4M% 7?G_7_ R^X3 ]!^5&!Z#\J6B@+OS_ *_X M9?<)@>@_*C ]!^5+10%WY_U_PR^X3 ]!^5&!Z#\J6B@+OS_K_AE]PF!Z#\J, M#T'Y4M% 7?G_ %_PR^X3 ]!^5&!Z#\J6B@+OS_K_ (9?<)@>@_*C ]!^5+10 M%WY_U_PR^X3 ]!^5&!Z#\J6B@+OS_K_AE]PF!Z#\J,#T'Y4M% 7?G_7_ R^ MX3 ]!^5&!Z#\J6B@+OS_ *_X9?<)@>@_*C ]!^5+10%WY_U_PR^X3 ]!^5&! MZ#\J6B@+OS_K_AE]PF!Z#\J,#T'Y4M% 7?G_ %_PR^X3 ]!^5&!Z#\J6B@+O MS_K_ (9?<)@>@_*C ]!^5+10%WY_U_PR^X3 ]!^5&!Z#\J6B@+OS_K_AE]PF M!Z#\J,#T'Y4M% 7?G_7_ R^X3 ]!^5;/A\#^V=.;'*W"8_.L>MGP_\ \AG3 M_P#KYC_G2?5V\_Z^Y#3::W>JT[K33\+'U(OIV&T@>AQU^M/IJC'/J%_04ZL# M8**** "BBB@ HHHH **** '#H?\ >C_]#%% Z'_>C_\ 0Q10 WL/]U?_ $$4 M4=A_NK_Z"** "BBB@ HHHH **** "D/3\1_,4M(>GXC^8H X;XA?\B_+_P!= M%KYV'WS]/\*^B?B%_P B_+_UT6OG8??/T_PK6&WS_1&=3I\_T'T44QB3NPI( M4%B,X'3^(]@,Y]F?3->#^/_P!HGX1_#75?^$DAP 22,<5Y?\;_B+\0O% MWCBR_9R^!5U%9>*M0L8-8^)'Q%DD22'X>>$I^9H[2WC!DD\2:E%_R"D;(C42 M%U.W(].^&?P'^%/P-TZYN]+L[6;6KT)+XA\=^*I8;S6=2U'K=7<^L7_FR0&5 M\E;>*5($&%" #@+Y%W[?I^?3U1XO<_M=>-99S)X=_9D^).N:26;R]2NIH]'N M)8!@^8ME+/A9J5Q,L83QEHMU8Z4L M_&8?[;D"VK-N^5.!YAX'6OHD>-O!FQ8SXS\-*H0*R+KEAYG[LD[642?(#Q\P M SD#/I7USP]X,^(&C7%EK&EZ!XKT2_B>%EEAL]2@,;C:3%+LD\F4#I(K!U/* MD&@.1=_Z_K_ASJ+&^L]5M+75-/N[34M.O8$GLKZSD62&6.0!D<.A*D$$8.>> M*N\X9CT7ECV&?4U^=VN:5XF_8R\06_B;PSJ%YKO[.&JWT5EXH\.WDESJ%UX! MOKUP(+_2I'>1UTH.X26(M^Y"EAA%%?>NCZGIVMZ;I^L:;6-U;R M!X;FWGC$D9&"PQ@@X/(& ?8)DDK6_K;_ #-O_ '\#T/T/:B@;P-KX)7IC^Z? MNC/L.**"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH ,XZT4Q^GX_T-(&.WMD?7H*<4Y-12NV[("2C/Z]*B#L>./UH9F!8C'R#*_[ M1[C^E&D6U-/HHN-M7=7W[;?\-<:]Y7BI:;\RLNFM^VOF+(<;<^IQGUQG^7Z5 MS7B[6M'\.>&M8UG7]7L]"TNSL;B6XU*_N([6WMU$;8+2R84;N@]OJ*P/B?\ M%'P)\'_!NL>/?'_B33M!T#1+.:\O'O;A(9YF5"1:V$;L//NGV[8X(P7.>F>* M_GV\1^/?VB?^"M7Q$O?!/POCU?X:?LI>&K]$U[Q#,9K:3Q#;)(/,\IDV/=W$ MT:EEAC"*\W-L/]?R[&Y;*MR+%X2M"-1:.DJD'&U_5]=?D=>%KQH8K M"8J2]I'#5:<^6$4^;V2XOIE0>=<73R2,!(Y! M;RH\!>3CI7O7AGP5X>\)1-%H=E';&9?FEV@LRD#'[[J#Q_>Y]J_R7P?[/;B; M$^*,\\S7B!T>&Z^/Q&,A7PU3V./E"O6E5]V<.62DN:RL^VJ9_7-7Z1&24>%J M6%IY=)9I&C##TJ55-X:4H0BDVM5J[-W7E?2Q\E+\'/B[@*;YW*@ /_:; OGD MY&X"3VJK<0I.DMO+DQ2(RR;(E[E[7LKV5['YE2\:\WC4I^TR;)4W., MY*%&+J]9+E>][6MH?F+9>&/$FLZE=6NGV-WJ%S'.\+W=NK20I<* MQ5MUR@ R&Z]>!WQFOH?PE\)OBG!%;RS>*'T7(SY1EDN3& ?NH < XZ[L\^U? M5=AI=AIL0MK&PM[)(W\Q?L\2QO.Q_BFVJ-S$Y))Y]#T%;&<\XZG/3_/^>:\/ MPM^A'E/!>-J9MC>,,\QF)C7=:E0H8[$T*-6\HO\ >0A5C&H^EYINV_8Z>*O' M;&YYAZ6#PV38/#1I0]GS2P]-RDK))N3CH^NZ_*W)^'-*UO3(%AU;6)M6F5%_ M>RH%Y'<8 QGL"/\ &NI!;.#TQUQW]./QI]%?W3E> IY7@<-@J4ZM6G0I0A&5 M>3G45HI6/6N7&X)8_#5,,ZDJ4:D7S2BW%\MK M-)K6^O\ F=&'J^QG&?)&HXM22D[)M6M?OKT]3Y=\5?"WXFZEY]Q;^.);X@%D MM9F>!FSD;1*NU%Z]P<^@KY=\2>#O&.AS32^(-.O7VL1+<[6EME7N_G@$-GV/ M^%?I^R<<;NOH#_2JEQ;P7,3PW$$%W 1\T5S&'4\<@A@0>,B7QQBF]UUZ]#X3T;X7?$[5-,L[_2]12?3YH%,4L6I,A5'7*0M$&& MPJI"D'ICG%:O_"GOBVV3WK[3TW3[32[2.&Q@%O M;O(S&%0 B$MD[57HH/W>,8&*OANN3\ISAAD8&/89S]/J*G)/H2<+X;+\!A\; MQCQ:I4*,*6,G1S7$QI248I-4X/$)*]K#?&7A:2%O%;R3QS'$+F1RHB@C0;G=F/"!%&23T'/05^JFO^'])\1VALM9M8 M;RW8%5+(&=0>F">0?IC'7UQY-J7[.WPMUC3-9T;4M":XT[6K&:PU)?/DC!BG M0H6\Q7##:#F,1LKYZFOYIX]_9Y9_F/'6%S7A?B*KB\ACBJ%>I6S"LZF+IT:- M6$Y)3DY2YFHMWYF]=]V_TOASZ1F6QX>J87,,NC2S&-*I"4,'!4L/4;AR\LHP M45YWM=VN6_@%XS\*>-?ASI-YX9\2Z;XDM[,"TN9]+OHKY;6:,E7AN6B+;)4( MPR-@BO:AEE!("KD@'U YW'_Z_K7\W_Q,^"?[1?\ P2R^(MS\9?@+<:Q\1OV; M-83D8_:/\ 9B_:K^%7 M[5_@"T\<_#76H9)2L<>M^&+F5(=>T>[5?])6XL6;S3$DNZ-)401OM!7K7^I_ M!F1T^%.%LDR*-:I7_L_+\/@IU:DI3YITH0C)J]W>\>E^Q_*.<8M9KF&/QV'I M*G]:Q-3$2I2;]Q2;=H]79/J]-3ZCSQGL,<]N>G/OVHJ,%,$_-P!L+<;U/ R. M/F#9_$B<=7>ZWZ6_ MR):*0$XZ8I:IVN[7MY_\#0$[ZA1112 **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH */7VZ^WUHICGK0>.O'3KQUZ?GVK/O]5T[3X$GU'4M.TZ#<%CN-0NHK.(2#KAY67> MN.H!(!XINGZIINK0-<:7J-AJ\,9;?-I]Y#/P M)P#[$T 2X/ P>>G'7OQ^%)67M!7'3D#MG.0.V>,D^] $E'3@\'K6;J&IZ;IT0GU34;/3+ M4,,SWMU%:0MCHOF2LHR3[UC'QMX+ 8?\)AX9\MR'4?VU8[UQ_#GS>A/]?6@# MK,'GC[H!;V!Z$^@/:D[9[=<]L>N:RK'5](U1#+IFL:=K(ML-*NG74<\9'8.\ M;G++QD=./05<+=.06KRP@<&(S.J'O\F">AQBGV6HZ M=J<+W&DZG8:K;*=KW5G=0W48+?-\[PLRAAT],GD4 :60>A'7'X^GU]NM+[=Q MP?:JOM6#_PF?@OJ/&/AAA@ M?,=:LSN/.3Q+GJ,&@#JP"2 !DDX ]32=!GMNVY_VO[OU]NOY5SEMXG\,7DZ6 MUEXFT"\N9>([>UU6UFG?/'[M$DSGWYQW%= I9?[IFW;6V] IQAI-V5#$'[XZ M^W- #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBD)('2C5W?+*$8*]24U?T<.2]TWU?_#$E*,;M+[_ $O_ M %J+R:0$'/(XZ^WIGTSVJ/?D DXVE7!4XR5.0,GCGGZ^AKQ'X\_M ?#3]F_P M%JWQ'^*VO0Z3HUE'*]K;.-][J4^PM'::?:1$2W,KMA=[ #-.\8TFW*/ MM)Q^!WLXZ-_GK^G4]G#G4JBT4;Q:>O-IHUM;:S_ ZCXL>)="\'_#_P 3:_XG MUK3?#ND1V4XEU'4;N*WMD)U.5 )R#D<]?B2QTS]I'_@KY\2QJFJKJ/PS_9'T/4U M*V?^F:>WB.SB;]UY$8,9NY[B$ SR_/ I8KC=7[B>$?V7/@_X(\)Z#X,T#0IX MM+T"RBTVU1;F2222*W5(_/=Y9&?>^T%@6."?E %?P?\ 2]^C%G'CU2R3%Y'C MXX?'Y9SI8:#WBA@. H8S#YO2E5H8J2FI4E> M=-QY7"SLK)M>]=[7LCY3\#^%O$_BG4I+?PN)H[J&W+SWB2&*,09P86G'"DGD M1DYP,UZU_P *?^+HX.H2].VI-VQSG)Q]3ZU]>^&O"F@^$K;^SM"T];*#'[R0 M@>=+Q]V1QR?Q_,=NGP,8QP/K7S'AE] _*LAX4PN#XJXKXBHYS-JI6PV5YA7H MX:E:S2ITZ=:"V2NG#JSV>*/'K$YAFG4JRT6\Y0DUK;K MY^9\&WOPF^*EK;SW-W>E+2&-GG=M39*];O771= M.N=0DCF,9O85>*/>&QQ=#Y,@CD]\^]?IO>V%M?P/:W:&6WD;F($[W/&01G[A M;J/;IZEAIMGIT:PVEM;6L,8&R*WB$0R>K2;0,L?Q.>>IS5<1_0.RC-L_RS$4 M>,N(:>6X7EE)XS&5YUD]WR2=2?LVNC337?72\L^D#C,NP%:-?)LN]K.+4'1H M144K+>*@E+YK7\3Y<\)?"GXI6BPSW'C&32!A,6<4KS2)P#AYG+(<#' '3([5 M])>']/U>QM4@U35'U.9<@W$H"[L=\J!WY_D"*Z+J.@ZYY_7VR1_]:E]NW2OZ MZ\./"#*/#7!T,'@7D%%%% @HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *.>>G(/4$@^U%%&^EKW MTMM?Y] UZ:/HSGM=LM5O[)H=+U&;2[G! EB5<=.#RI/!KYQ\7?"SXH78>>W\ M72ZLOS$0RN\4O.>!(A5>O '<>M?5]-48!SWSD?\ ZOZ5^2>)/A%E7B+AZ]+, M<=F6!]K2=)/+\54I2BI*SE[LX*ZNS['A7B_&\-55.E0P>*M)2MB:$)W::TUC M+TZO[C\NM8\(^+=$NU&M:=>6\DDP1+N96: R;@1-]IY4#W.3COVKU.Q^%'Q6 MO[2&YLM2+6LT2F*1=2RC# *A6#84CN/;O7W%>Z?9:C"]O?6T-S 0-R7,8D5. M.'&X'##VQQVY-)9V-OI\$5M9Q[+5"QC&<8R,8$>< =..AK^1.'OH#Y+DV=!8?,*]+&*:>JTYM4D?KV8^/.*QN#PU&GDV5O% M8=)34J:]BI*VD(;.@E1CFF9UZM"=7F^ M&K3E6J*UK)MK3R>AIPQX^XG+LSIU\WRG+*6&3]^6#HPA4BI))^]&$=M+:W\U M8_*^^U&RTNRNM0U"[CLK"SA:ZNKJ9UAALX(R&EGEF;Y55!R22.GK7Z3?!KQ1 MX>\9_#;P=X@\+>(+'Q9I1'JUA.TG3:[12K(&6:,@/'@@;E&1MS MG\,=8\/?M&_\$@/B.VO>%IM<^+/[&OBC62VHZ;.TUW?>'-/N)22EQ$N\6.H0 M(/ 6KG.9<0YHL;C\UHT\++#4*DGAZ-*G4A-5 M(K1.HU%&=&AAM76FOWE1RU<97UMK;1W]%<_I4 M7)P.,GH!WI:\&^ '[0?PN_:3\ :;\1/A;X@MM8TV_CC:\TN5\:GH%ZP^:RU6 MV1O-@>,X192JQN><?3@C.>1U&#SFO[TBTXNI[2FX14G.$& MW53YER*WPZP=WKH_(_GZ,HRDE[T;?%S+T?N]UN2T4P%F.3T'(XP,G_ZWI[4^ MJNFHM)I2C%^]OJNR;M]X].E[>84444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6QH M'_(8T_\ Z^$_G6/6QX?S_;.GX_Y^$_G05'XH_P");^I]3CH/H/Y4M(.@^@_E M2USFP4444 %%%% !1110 4444 .'0_[T?_H8HH'0_P"]'_Z&** &]A_NK_Z" M**.P_P!U?_0110 4444 %%%% !1110 4AZ?B/YBEI#T_$?S% '#?$+_D7Y?^ MNBU\[#[Y^G^%?1/Q"_Y%^7_KHM?.P^^?I_A6L-OG^B,ZG3Y_H2 D=*P_$&K1 M:%X?\0Z[)/';+HVAZKJB32LBH)K&PGN(%/FGRV\R:-$"L#NR!C)P=NO%?V@K M"^U7X*?$JPTL$ZB_AJ\D@7;OWK !-.,=>($D;@9X]*LA;KU1Y1^QSX)CTWX= M7_Q-U"26^\8?&G6;OQQXDU.Y.^\^SW\[G2M*BE)+16FF0H4M;9"%1'8!0*\V M_P""H$][8_L:_%.XL+R]TVY%A"BS6-S);3H'E56\N>%T,3$?\M%8/D=>M?3W M[/5S8W7P2^%\]EAK1O"&GB-AB-6D 99S'LX)#C !^9>0O>OEK_@J9M/[%/Q5 M7:R*UE;IDLP.XRJ-Q4\F(GD<9X]Z#7D7F?%'[.7_ 2@^#GQ2^!'PJ^(NN_% MSXU0Z[XR\':?KNIV]GXFE\B&ZN=ZNLW0("S$[L9]JQ_@QX7\>?L4_M MYZ!\ ?!WQ'\4_$[X6^/='-S>:5XAU&XU2_T*17!%S*))9EM[6($GS$V;R",U M4_9X_8C_ &R/%7P&^$_B?PS^UJ_AGP[K'@_3KW1-!6"4'2M.E#A=.&TA6\L! MB/4$9KB/AWI7Q8_X)]?MB>%S\>KVU^+(;D:#XQ^%^I;X=1^&?BK M4-(M8V9G;^RVDE-KC<3A!"JJO0*,!0!@5]=0R"4P/$ZD7 AG$@'RNDFTQ8[* MQ7;\R^N:^+_V=Y;>[^/G[1E[9+Y5DNJ6-I),F&4W4<.)AE*;M. 47YN,CV[]3_\ 7HWD\9P.HXS] M>/SZ>E-$G!&3GIG&,=L=NO\ 6E.<:%IU)>SBM>9NRLK-N^R2OJ[V\R7'GO"] MKVU6ZZ_U^8$C)V_>[J.B_P \_I^-4+Z\MK*$27+[/+5Y$3>HE7 ^0*N-S"D_:Y5D=.3C&I.M6UC[6* MN[13LUKK8^KR[)_]D6.S6HL/A(?PX37+*O:UDE9N5U;=+\+GY"_'7]ACX^_M MB?M*V]W\9O'@L?V8- $.HZ)H&DS-:_VA.'0G39X"T?G7I4%YIIE9!$<1MN%? MK?\ #KX;^#?A-X4T?P/\/]#L?#_A[1;5+6WL=/MT@WK$JJ+N=T56FFEQ^]EE M+.6)P2#7;" A B*$C.-R.H'A+,,5M&O7;YIQAI=*-^1*RO;8\+'U*%7 M$R6$IO#T.;W5U4+1U>ZN]7WL^X*HW,2H&>HVC&>.=O8GG) R><]32D;5 'W= MQ.,# /.,#''?V]J=\^/X<^N#Z?E_GO006 !/3'Z5]6YJF_8Y'RJ48ZU>KG-)QC\.L>TM-6,4;CSR,@D=OP]._3OUJ3 R3CDC!]Q MTH Z#'3U[4O\ZTE*\>:Z<_AY'\%M+M)Z>>N]MET2Y'&4E[2%9-6EIJE9:;] M-4^Z[C=HQC' Y&3\P/\ O=?RZ?6E'' Z4M&:C6/:<%)=.KV^[\BY3K.* MC"5..MKR7=K5Z?U9[#""#OW<\@9X&#V Z?I^5-4$@@''7C []3^??FI#SU&> M_P#GD4U0!DC/IS_]:IES6C"4:56BFK)ODDMGLDU9??\ B1*"E#DG)NHFG[2' MPO;3OWZ6=MP( 3![=,>O(&,8]:0+&=A/_+/D#^'/'5F>AZ4\_3(/7Z?X M_P"%-*#MQ0H4TYN"Y:?*U*G\-V[:1L_A\W;7;N5&226DX2A#:-K3EI\6NK[; M]>AG:AIUEK-E?:3JUC;ZGINI0-:WUA>Q)-97EM.K(T-Q&X99(F!82I@D<$8. M*_$GXF?\$X/BI\$_V@?#?QW_ &%_$8\(V6M^(XE\?^!KJ=UT>TT^XN ^I7,% MLS;;C22I8M&%:ZC!_<;3BOW&,8P!EAC<"5)!VM][:O0-TP>_?UJ+R7+[@Y R M 0QP=@[@C+!O[RCY37E9S@\;CLGQ>'RRO#!8Z="K'!U)_#1K\C]G5G9._+)J M3TNWKW1OA).%6A5E>5YOVM*Z3Y/-:)77XO=/;!T'4YKNQLUOY(?[5BMX4OU7 M>D,ET(U6Z:&.3$BPM?<8[=O:N_M^OO4E1IL.!WR0,],9P# MZ8Q_^JGE@/\ 5_7M&O2Q,(U:$Z=2G-)PG2?-3DI)-.$M$XM/1GRL[P;YTX- M.TDT[J756WOY"T4U6#=,TZM91<79KHG\FKH72_1_U^H4444@"BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ..,G:.,GT]ZS] M1NELK"\O7CE)M[.ZN!%$OF2;;97*%$C!:5IL "- 7.[@=*OL-P*GH>#G(&._ M(Z<5#PN[DJ5PK$9/IMC3/0L #N7G'.#OV?_CC_P %$?C9\7?%?QT\ M9_%#X4?"/P'X@E\/>#?">F1:EX:;5+.WD=(;^TBN1:"YM[F-?,FGVNP<+AL9 MKC/CY\#/B#_P3*\>_#;XQ_!KXQ>,/%?PY\0^)-/\.^(O"'C'5KV^+PW%PL+- MY+3RVNZ0-\I1=RXY[5_1+XD\3Z/X7T74/$GBG5K;2]%TJWDN+V^OYTAAMH($ M,DB;Y64LVU>F3Z')XK\$O'_B3Q;_ ,%/?VC_ SX*\ 6EU:?LX?"/7TUC5_$ M30,FG>(-3T^<2%+:Y955\NI 525/;.* /V.U7]H[X4^$=$^'NJ>/O$UCX6N_ MB-::==:+97_R"XN[Z!7"PL^ BK(3G& ?2N(\2?MU_LI>$]?/AO7/C-X4@U7 MSEA>**]AGAAG?&VVFN8Y6BC*^QI_P#@F'^RE9_L_P"IZ%JG M@"WU;Q/_ ,(/=7]WXSN[J5M5N==&G^>=19B#SYIR1NPP7!XQ512>[MM^?]?T MBHI/=VV_/^OZ1^E_A_Q-H7BO1[#Q!X:U:RUG1]5B6>QU"QN8+JRN(6&X-;SP M.ZR8'#88C/ ^;BO$?BC^UM^SO\&=8'ASXB_%'PYH.O2Q@_V4UY!<7MKYAVJ; MVWBD,ML&4@KYJJ0<$G&*_(+_ ()Q?%OQ-\(OV.?VF;QM2N-6MO@UJ?BBR\#K M?N9TTZ6UAN4LX!YA;_1A(BL$'0G@5H?\$W/V+?AE^T-\,-1_:M_:+TI_B7X\ M^,NN:IJT-KK-W,\.AZ;#=2P201,Y=G5I?]3&WR1Q[44 C%.T;7YOZTZ?U^&K MM&U^;^M.G]?@S!_;B^*N@_$']N?]A3Q%\,?'O]M^#M7TB\5I/#VM2MIM[-'X MDBCDBO(K.?[.\J\AXYP6 &",5_0U( &YP0%3GC'W%Z?7ZU_,-^TY^RKX2_9J M_P""@7[+[?#.&YTSP#XPU1+[3/#K7#S6/AV[354CN[?38Y2%BCNV+3RJH!W9 M(!K^GF7;O*@<;4QCD8V+T/>H(/R+_P""QESJ%O\ LT::EAJ6HZ6UUXITZUGN M=,O)[*Y6WGN5CD(FMWC<$;@0"P_*O)?A)_P2.^"7CCX9^!O%VL?%[XWKJ_B7 MP]I^J7PM_$TXM5FN(1)LA+7@8 'Y03Z?GZA_P6;D\C]F'3;F.,RO;^*M-E$ M+9G*72,(\+DDL0%4<\FO"OA)_P %(OC'X8^&/@CP]9?LC_$_5[32/#NFV5EJ M=EI=S/9ZE'!$%2:!A$1Y,@^8'T/YZQ<;+:__ 0/%_VI/V>_&?\ P34\4?#3 MXW? [XT_$/6O">J>)+/2/$/ACQ;JEWJ$$\+2HMQ"L+32VA69#M20KO4YYK]+ M?VR_VY'_ &=_V;O"/C_P];6=[\3?BGINFVW@_1I\N(]3U>RBD^UI H+2>0\P M:(,IB>12OM7P!\0M"_:__P""E7CCP)HOBOX57GP=^!_A77+75;U==^TVU[?> M5(C3AXI-CB9U4!<*44\BL[_@IIH%KH'[67[#O@34&W^#M%;PAI]O#*!)8S2V M6I6]M')-OS'EEC&4)^8G##%*3C96MOT]/^&_I >J_![_ ()E_$?]H+PYI_Q= M_:V_:!^)DGB[QC;1ZVGAGPOK%W9Z9HEO>@7<%J\'VF."WNT@D0*D")$4&&&[ M('#_ !R_9;^/'_!.B_\ #_QY_9>^)_Q%^)G@JSU:RM/&OPS\037NOW4^F7EP MB2R1VB/,N1L<#:,_'IL-1\+ZEK7PV_M632[B.YTW4]$OKBR#O9S!A#<1R1 M,QP,!QCL:_*/]A;_ ()M?"[]H[]GSPY\4_&WQ3^,UIK^L76HI>0:7XGN4LH_ M)N-JF(3W8?!! V]1CFOV'_;:FCNOV5/C#<+=)>12>$+^2)HY5DC.8V<8R:"N67;\CV;X_\ _!)C0OAS\-?$GQ'^#7QX^+NF>+/! M>DW7B"VCUCQ%>?99UTY?.<.T5WOP< ;1P?0C&?KW_@E?^T;XJ_:(_9V2?QO. M^H^*O FH2>&=1UEB2=86UD:W65W8;I'&P%W8DGN^(M5C 4ZEJMS^\F=-HP4,C$A\DD'J:"=5H?6'3@ M=!THINX9Q@C)_+G%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBBDVE:[M=V7FP"BD# DCGC--WCWJTGII=/\EN)R2DH]6KV M\M]>P^HW9055B5R>PSG/&#G]/_U4>8O&01D?EZYY]ZQ=4UB.T!CA GN6P%B7 MYF&>C?3GZY'2OSWQ#\3.'?#3)*F>Y[F%.C2E^[PV"YE/$XVJK"/!>D75S M'97]I'*C0P26LSB&)_+ %S+(@+C<%)&*_9*PTF6YD%]J+$R,,QJ03L[@$-@ MC Z#Z5T^ 59"PVMM PO^K48SA<;7)Q_%V.,^GY1X/YSXH\?<0YCQQQ+260<' MXRE[/A_(ZD+8MTG>V)Q$)1]WVL7%VN]CU\XHY;A,-'!T)*IC(/FJU8ZJ/PKV M3:V::N[7U>^YS_A;PKX<\%:#IGA?PEH]EH.@:1;Q6NG:;81);P011(L:_+"% M4N54%F&=[Y8Y)S71["/[H&]+G M^OZ\444URQCS./-751>^M5RG^ST]O7_ ":***F]^EDME:UEZ+1> MB"S6ET]MMMD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%%"^X'?HK_@%%%%.\EHY7^_M_7W MV!K1ZZZI;W C(YY&>G_UORIH"KD #YNH_P /3\,4ZBILX\K7+I4YWRJTGMI) MOT^?Y5RN,7;71IO:]_-^?F^@>WIP*8Y[8QZG:,GT&1R?H?:GT4TM92<:; M7/S24FW.2M&RBK6O=?<.*I\MN67-]N]K3^&W5WL[O]>T2HPY7=D='/$^E66M:#J]O+:ZEIFI6\5Y:W$$J,C!HIE=-P!RK;0 M5/(Z"MT9[X_"CG(P0/P#?H>*4N2ZG3I1I)6;BM7*UOBZ:]=UIKU!3A3]V4:D MXOX8PT2EI9RL]EOUTN?AK8_\$]/C/^RO^TSH?Q,_9$\6/I_PE\3ZM-I Q_,]*_FCQ@SGQ,\/\]R_COAC"0SS@^E0=#B+AZE&52O2C.HI2QV M&BHR;E"";LK'U&5TWU?&25H1:2M!V6[T7;3S276@EB.<$# MYEQ[]<_AQ4E<_I>L)<*T4X*7* 9#8W-SC^G3'H*W=ZX!YY[=_P##\B:_5_#G MQ'X:\2_%QG=6L]FEHCQ\QRW$9;6E M2K0DHIVA4=N6JK*TXM;J2L_F/HIF\>YIX.0#_D=J_0+IQE-?#"_,]=+;Z;]M MEYGGN+6K37_!U"BBBG%J7);_ )>.T-_>_P"&OU"S[;A1110(**** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ K9\/G&LZ>?^GF/^=8U;'A_G6=/'K<)_.AZZ=QQU:3V;5_2^I]3CH/H/Y4 MM(.@^@_E2USFX4444 %%%% !1110 4444 .'0_[T?_H8HH'0_P"]'_Z&** & M]A_NK_Z"**.P_P!U?_0110 4444 %%%% !1110 4AZ?B/YBEI#T_$?S% '#? M$+_D7Y?^NBU\[#[Y^G^%?1/Q"_Y%^7_KHM?.P^^?I_A6L-OG^B,ZG3Y_H/K- MU&PBU&QU'3YQF&_T^_L)@!\WEZA:2V3,ON@N-V.X!'3-:5,2O/HU[ M9;BOFW$$3,+T1;O*7P_K &/M%A>_<=9-P7C&*XOP9^U(VD3S>'/CSX:O/A[XKTO$1U22 MT>;PWKBK\K7EI6OCWPA/:N/-D=+BS0E&Y4O$\2LFTCD[%87O7O)CQ%!N@B55;=\LC2B, (&89!QW/F'[*G@E_ M#'P^F\0ZE!)!X@^(NK7'BK5S>VA<,-ZB-)%7##\NE>8>$?AS\0_V M@O%^D?$SXT6ZLG0W$:JK;7![5]U1I'"BI& MBHL2B.-$ 54C0!51 . JC@ #H*"7?K?YW)^1U]2<]B3UQ]/PHH!R ?6B@044 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110"OT"FE0?0'Z5&1E MB/4G\/>F,VT=MJ]7)[#/] 365?&X3+L/7Q>.Q-+"X6E2DZTZTE"*@K2;4I-* MZM>S:5EWL:051SBHTY59-I**3;U:U^7;_@CV(& 3P._>0=QSG&,C'.!U[U?T M[28K1?-E_?7#X:5^I#'DJ.IX/0>U?Q9QCXF\8^,>;8GPZ\)9U\+D.'K_ %3/ M^.%&2I4H2DHU,/E\_P#EXU%24I*4=E:Y]=@\KPV3THYEFKA6K.T\+A$U=SLG M%3777?IMT=ROIVCEF%[J/[VX?E4)R!GZCCM]/K72(FWG&W_97[O Q_GZ4;0$ MP@&..![?Y_SFI*_H3PP\*.&?#3):&"RK!O$9E4:EF6;U_?Q^/QWPJR MV[?GYW/'3BTG&_*]5S7O^/F%%%%(84444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %(<]O?\^U+133BG>>D=I/LGI==;J^ENHI6 M:]Z+DM+Q3LWJNI7YYP2#SS_=[>G;\:R-4TF*\194S%<1@E94X+L/7OSWSU'T MK=/S#CG'3TS_ "IAW\$CISQ_];_/?UKX+Q \..&?$O(L1D.?X*E7HTDJF#Q; MBJ>)P=:W[JO0K6YU5A+56:=ST2#\P]NG?VK/OK"WO599AB1 MAB-\=^WY$>_Y<5@07=WI$HMKQ3+;=$?L#GCU[$\]/0U_+&2\7<39P+:"UB=YF;.,LBJ0/?H"]9EAOI+-;J&_P#%HL9BDT4CQQ_/%=8QL&593STK]5_@ M]^VE_P $_?@QX-T;X<_#?QA8:1I5HT-M%';6$TS+;AY9)'.?G. M%.>N:^IV_8I_9AF+2R?"+PO(\K&1Y#9Q%I'<[B[G .YB0#T8 _A0!^77_!4G6['Q+\1_V-M&X_$'A'2=53P<\,_AOSH59M'-KCRA;9'!7:-I&,8]Z](>UMVLS920 MI-92V[6TEI("T;6DJ")XS_LB,$8]!0!^ ?\ P3?^'!^+7[.W[8WPW<30S^+? M&'B[3+!G1HT74)!="SD^<+E!,RB1AT7DRN39ZQH\MS)-N#^44)WD21%6*LI7D&OW(\#_"[P'\,H MM4MO OAZPT"#5[QM2OUL8PANKB9BTDQP!NF9F;+=<8ZBN>\>_L__ 6^*%[' MJ/CWX=^'?$NJ(Q.3GUH _GH_:/\ VG]*_:=_;L_9 MAU+P'I^J/\./"FOQ:7H_B&]LIX8M>O%?T^R?Z MT\8&Q./3Y$XXS]>":\0B_9V^"MJ?#,MM\/?#=G)X,9G\,R6MC#&=/,TOGF2$ MJ =ZN,COGKZ5[0N>F2<@;">/E[=.G'&!0!^1_P#P6/+?\,U:*R+*Q3QEI.1$ MC.Y7[;&#\J@MQ]*_07]G":5/@-\)D5@BCP5H^Q0 C%#;)N+@IG<#P<\]:[/Q MU\._!?Q)TM=#\0VI$IMXV!W9@> M/S8E!Y<\5^II (QCZ<=*01X&%*Y88RP#KM(^9"C?+ALD$=.WK0!^-/[-G_!5 M/X2-X&T3PG^T"=9^'?Q(\*:?!HOB.WU73KI8+NZLD6V:X0O"2[321;V89'/T M->._MF?MY?\ #3/AQ/V:OV/K/Q+XD\6^/+^SLM7\7:7;WMK::)IGGQF3;>)& MJQ,"IF,FX;4'':OU_P#&'[,OP&^(&HR:OXK^%OAG4M3E8^=A'ODUTGP^^!WPE^%CO)X!\!^'?#-PX*27%E80QWC#H09]N[IGD$<>] M'Q3\2?AAJWP>_P"":YJVJ>(?$6B?#Z^_MO4]7NY=2OI]1O+=9;M!=2 M%II8HI01; _=48X/%-_X)-AU_8N\"C9(ICU/6 4E1DN-@NAEVB; !4XSQR # M7Z'>(/#VC^(]%U#0-?L(=4TG4XGM[[3[A1)'/;3=0000PP>?;BJ7@OP3X7^' MFB0^&_!VC6>@Z):"1K:QL4$<"-(2TC!0 [MRQ_IS0/FEW9^6W_!3_\ 9 NO MB9X-M_CO\*8;C2?B_P#"]AKD>H:6#!"HDT/Q;87T+P7/VBRQ UR!(H8DE,Y^O/(K]"I8 MH;FUGAF2.XMIHV@N()E#13Q2C:\;JYZJKA]N#G#>G7GK^GOZY MJP>/?Z5708('IG^1J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHI#R"/44 +4;/U _/\ S^5)L/M_G\*4Y"].5)_7/3].W]:J"YIP MC[J4I).4MHK>_P"%EZBV1^8_P */?T_+\:&.P%Y M' &W.[IY8ZDYX[<5R][J-U?2&QTO(B)Q)<<_-C@X.,<^N<=Z_$/%SQHR'PSP MKPW++->)<<_8Y/P_@/WV.Q=65HPG.,;SIT^9J[:^&_8]_*LHK9A4O2C[##I> M_6J*RM:+=F[:V]5YDVHZM(S&TT]/,NCE77J%SD'!Z?AV]ZETW18[0H]ES_+UJ[INDPV*$LWF7#'DYZYYP/KW]>XXK6VAOX=I'!&>_J? MKU'3WXK\J\/_ >XAX[SVCXD>,;6-QDW'$Y%PI&4GEF103C.E*M0E[DZT4U[ M[@G=,]7,,THX.@\LR=*G%*U?%[2EHKJ#T;OKUZV&#)YD/'15'3 Z'CVZ?XTO M[O\ SF@G:-H/(_Q_S_\ KIH!8CK]3FOZ^HT:6'I4Z5'^'&$5"*BHQ@DDE""6 MG+%)6/C92YG\3DUHY/5M]6R8=!CIVHI!TQCIQ]<=Z6M!!1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4&BBE)J*;:YDM6GL_) M^H._3?I?N1GCZ=.A4).<5*+ M=-QER36MTTU^\AMI=7TZ/YG/:EI"SN;BS_GN:JZ;JTB.;341 MYI^G;/ MH,U_(/B'X+\3<%9W/Q.\%ZJP&9T9RQ.>\*PG)8#.*47SU>2BO=5=I-74&^9V MUT/K,#FN#QM*EEF<^\O@P^+7Q4'IR2DWT?=_J:@P?XACL>N?I4PZ<< $CG_/ MK_AUKC;74)M.G6SU+/V<$*EQURQZ'/OR1S_C76I(#LEX=&Y7/=3T_P"!>O\ M0]/U/PD\;,C\2+<#>AG'#N8)4:]"O1M"K[.G*SG3J3NXS27,EM8\ M_-LGK8"=N95J3LZ6(IW<*D+)KF:^UMIU)Z*7D9.0=_S >@]AVZX_G25^URJ3 MDN>RC65K*VB6EG;M_P %,\%;V>ZM?I_7_!04444U>ROOU]>H!1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %;'A_G6=/'K<)_.L>MCP^<:SIY_Z>$_G0[]!QOS*V]U;UOH?4XZ#Z#^5+ M2#H/H/Y4MM^%O#GB6 VOB' M1-.UJW*E/+U"UBGX(P<,5W _C6]10/FEW9\UZA^R+\!-2NWO9?!RP/(Y9XK2 MYFM[=LG.PQ(X4I_LUZ3X1^#GPQ\"1QIX6\':/ILL9RMVMJDMWN_O&:7S#N'4 M'L:]+HH#FEW9&(P 5!;:6#A,@*K#NH &WW X]J>%PV[DG.>>G-+10#;>^HI. M>WY4E%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C_)__7VH MI"<#'."#NP,\#^OIZU-:I"C15;DG4A24W54-91:3:[^TNE[L&E9NU^XN9RBH M)2ES+W?+O_7_ 2O)*$9RSI'& 3EN]NM6G:ULU9(8SB27! 8 M="5;/ Q]?3FI[FWO]3NS;R9ALU.=VX E<\C;UY]#]>G%=#;6T5K$L<*A2G 8 M#E^WS=_?\>1Q7\4\34?$;Q^XJQ?"U'"9IP?X:Y3BY4%3!X_B"I3FDZ. M$O9_5I)23LYJ5T?:49Y?DF%I8Y\N)QM6-HTII2A2=E>Z[W[_ *6*^GV-O8QF M-$)D?)DD)RWS8) ;V)P.F,5J*@4;1R/?DD^I/_UJ:HP?NX)Y(ZX)ZX/0 '@U M+7]6<'\%<-K[A1112$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 @&.!2T44VVTHO9.Z79[^H+1IK=;?G^A&ZKMZ=.A M[]<\?X52N;2*[1DD .5(!Z8/8C@\_7H*OO\ =/X4F1CY1N/<=.V">?Y?UKQ, M]X[>NMGIJM/+_(XHK=Z'*&*22VC$%ADLRC/8\].I_F.,]59WD-U%O@8/QG M;D9'&??GH*=-$)HVC;#@GA2O;OC\/ZUS#:?+O#'-,7"GB\IC.>(S'A_P!K-)8C#+E;EAX\ MVM-).T8WD?53Q."X@P[5>,3R!Z_R_S_\ JJ" N0K/]]AEL#H2!Z>X^E3-@-GG(X]B.>1^?IS7]LX* MM4Q6!H8ODBUBHPK1@ER5:%*<82BJL'JIQNXSB[.Z[Z+XZ5->TJ)RY/9-P3WC M4LU\*[OIOZ[CZ***W("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "CTZ\?YYHHH 0C/YY__72! IR,@]">Y'H?;VIU% " 8&*0J#US3J* M$"@>^"",\XQV'L>] ( P"2?SZCZ>U+10 PH" "6P/?MZ?3OBE"J"I ^9<@ M-WP>H/J"..1TIU% #-B8QM!&=PSSM/3*^E*%P,#/U[_G3J* &[?=O7K_ /6I M0H'.,]QGL?4>AI:* "C\*** &,FXY).?J>GI3L9&&^8>C=L>F,&EHH ,< #C M&<$=<'MGT]/3 INT<#G"]!V_'USWIU% #=J@G ![ <9]<>M(44]CN_O9.[\ M_P#ZU/HH 3'.[G/\_<^]+110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444G)*]T^91YHKI*S5[]>MOD-?:\O\U_F-W':QQ@@X^G^/ M]/QJG<72PIF4A(UR6)X+=#\OH.QZGJ>>*M%SAFP. <#OD<#(SWKD9+.\U.\Q M<-LM8V)0!P-_L1V^GT]:_$?&?C[B?A/*<'EO!605\_XAS^HL+A9Q4EAL#*I' M_>*]1*7)3HVYG?=I*^I[.383#UIRGBZRIX>E%SK-Z2J037[N&OQ/3S>NY#)< M7FNS&*VS!:J2K,2JY9_O?4^G\OY5\GX2^!T,@Q<>/?$#&K MBSC[,X^UE6KP=2&72G:7U?!4Y.:ITJ-W&\;MV3TT1V9KGSJ16&P470R^%HTZ M-/2==?#S3:UET?\ PQ,5!(;'S#H1P?\ /_UZ3;SG)S]?QQ]*=17]-Q]U6LM4 MEII;2W1'S5[Q49>\E9J_1K[_ ,Q,#.>__P!;%+111K\NB["[A1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>01ZBEH MH C">OZ?Y_I3P,# I:*.J?5;!LT^J5D_+L%0YVEE49!ZYYY]!Z=?PQ4C D8' MK2A3MV^N1GMS_AFHJ1C*TJG-)O2#CO%JV[VU\]]0A&,G4C+W%9.,T[:Z?E^? M0S;NRBNH6AD16XRI. RG'&#_ $_+&*YJ&>\T24QW0>:T9ODDQN\E2>C'I@=O M\:[()D,I(R>GS9Z=_P 1V_.HKBWCE@:*51*CC#*P& ,=<]L>OTK^:/%WP+?$ M6*AQOP%B*G"_'^70]K2Q&%C[*AFOL^63H8[DLITZMES7UO9ZWL?0Y3GL:-)Y M=F-&>)P4I:.W-*$M%&4>J>NMM+:]T+!=0SP)*A#*V,-_O#Z]/7]*L!N01AE/ MIV_S@X]ZXU+*]TJ4">0H/'_ZNGKU2*=B.#MR!O_'T_P#K M>M?5^#/B!Q!Q=@<1EG&_#^.R'B/(:L<#F,I4I/ YA4A[JKX2NU%3IU+.5DFE MZ[99M@:6&FL3AZM&OAYVE3A3_B4KV;5:S=[76]E]VEJBBBOW![NVU]/0\,** M**0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 5L>'_\ D,:?_P!?"?SK'K9\/\ZSIX];F/\ G0W;4<79IO9- M;>I]3#H/H/Y4M(.@^@_E2USFX4444 %%%% !1110 4444 .'0_[T?_H8HH'0 M_P"]'_Z&** &]A_NK_Z"**.P_P!U?_0110 4444 %%%% !1110 4AZ?B/YBE MI..A!(.?\G\: .&^(7_(OR_]=%KYV'WS]/\ "OJO6-)@UJS^R79(BST4XXQ[ M'KZ9KD%^&OA__GI=#ZLIY_$YJXRLK6Z_Y$RCS6Z6O^AX-17O1^&WAT<&:Y_- M:3_A6_AW_GM<_FM5S^3_ *_I_P!/2?9^?X?\$\&HKWG_ (5OX=_Y[7/YK1_P MK?P[_P ]KG\UHY_)_P!?T_Z>A[/S_#_@G@U%>\_\*W\._P#/:Y_-:/\ A6_A MW_GM<_FM'/Y/^OZ?]/0]GY_A_P $\&HKWG_A6_AW_GM<_FM'_"M_#O\ SVN? MS6CG\G_7]/\ IZ'L_/\ #_@G@U%>\_\ "M_#O_/:Y_-:/^%;^'?^>US^:T<_ MD_Z_I_T]#V?G^'_!/!J*]Y_X5OX=_P">US^:T?\ "M_#O_/:Y_-:.?R?]?T_ MZ>A[/S_#_@G@U%>\_P#"M_#O_/:Y_-:/^%;^'?\ GM<_FM'/Y/\ K^G_ $]# MV?G^'_!/!J*]Y_X5OX=_Y[7/YK1_PK?P[_SVN?S6CG\G_7]/^GH>S\_P_P"" M>#45[S_PK?P[_P ]KG\UH_X5OX=_Y[7/YK1S^3_K^G_3T/9^?X?\$\&HKWG_ M (5OX=_Y[7/YK1_PK?P[_P ]KG\UHY_)_P!?T_Z>A[/S_#_@G@U%>\_\*W\. M_P#/:Y_-:/\ A6_AW_GM<_FM'/Y/^OZ?]/0]GY_A_P $\&HKWG_A6_AW_GM< M_FM'_"M_#O\ SVN?S6CG\G_7]/\ IZ'L_/\ #_@G@U%>\_\ "M_#O_/:Y_-: M/^%;^'?^>US^:T<_D_Z_I_T]#V?G^'_!/!J0]#Z@<'T[D>G->]?\*W\._P#/ M:Y_-:4?#7PXW'FW1]@RBES0+E'E<97>KOU[.VRO?3[F*#BFXM*H]IVVVM MIIM;[_O?@! (R,;NK8QD@<=/\_G3\_*"1^'\L5[Y_P *R\.#I)= _P"^M+_P MK3P]_P ];G_OI/\ &LHQA348THQA"#3222;[\S25V^^X^64DO:3;1 M)\N^F^^YX&IR >,\CC_/^?RI:]Z/PW\.C@S7/TRO^-)_PK?PY_SVN?S6M_;2 MYI2VYDHZ;VTW?7;LM?O!0]U>#45[S_PK?P[_ ,]KG\UH M_P"%;^'?^>US^:TN?R?]?T_Z>B]GY_A_P3P:BO>?^%;^'?\ GM<_FM'_ K? MP[_SVN?S6CG\G_7]/^GH>S\_P_X)X-17O/\ PK?P[_SVN?S6C_A6_AW_ )[7 M/YK1S^3_ *_I_P!/0]GY_A_P3P:BO>?^%;^'?^>US^:T?\*W\._\]KG\UHY_ M)_U_3_IZ'L_/\/\ @G@U%>\_\*W\._\ /:Y_-:/^%;^'?^>US^:T<_D_Z_I_ MT]#V?G^'_!/!J*]Y_P"%;^'?^>US^:T?\*W\._\ /:Y_-:.?R?\ 7]/^GH>S M\_P_X)X-17O/_"M_#O\ SVN?S6C_ (5OX=_Y[7/YK1S^3_K^G_3T/9^?X?\ M!/!J*]Y_X5OX=_Y[7/YK1_PK?P[_ ,]KG\UHY_)_U_3_ *>A[/S_ _X)X-1 M7O/_ K?P[_SVN?S6C_A6_AW_GM<_FM'/Y/^OZ?]/0]GY_A_P3P:BO>?^%;^ M'?\ GM<_FM'_ K?P[_SVN?S6CG\G_7]/^GH>S\_P_X)X-17O/\ PK?P[_SV MN?S6C_A6_AW_ )[7/YK1S^3_ *_I_P!/0]GY_A_P3P:BO>?^%;^'?^>US^:T M?\*W\._\]KG\UHY_)_U_3_IZ'L_/\/\ @G@U%>\_\*W\._\ /:Y_-:/^%;^' M?^>US^:T<_D_Z_I_T]#V?G^'_!/!J*]Y_P"%;^'?^>US^:T?\*W\._\ /:Y_ M-:.?R?\ 7]/^GH>S\_P_X)X-17O/_"M_#O\ SVN?S6C_ (5OX=_Y[7/YK1S^ M3_K^G_3T/9^?X?\ !/!J*]Y_X5OX=_Y[7/YK1_PK?P[_ ,]KG\UHY_)_U_3_ M *>A[/S_ _X)X-17O/_ K?P[_SVN?S6C_A6_AW_GM<_FM'/Y/^OZ?]/0]G MY_A_P3P:BO>?^%;^'?\ GM<_FM'_ K?P[_SVN?S6CG\G_7]/^GH>S\_P_X) MX-17O/\ PK?P[_SVN?S6C_A6_AW_ )[7/YK1S^3_ *_I_P!/0]GY_A_P3P:B MO>?^%;^'?^>US^:T?\*W\._\]KG\UHY_)_U_3_IZ'L_/\/\ @G@U%>\_\*W\ M._\ /:Y_-:/^%;^'?^>US^:T<_D_Z_I_T]#V?G^'_!/!J*]Y_P"%;^'?^>US M^:T?\*W\._\ /:Y_-:.?R?\ 7]/^GH>S\_P_X)X-17O/_"M_#O\ SVN?S6C_ M (5OX=_Y[7/YK1S^3_K^G_3T/9^?X?\ !/!J*]Y_X5OX=_Y[7/YK1_PK?P[_ M ,]KG\UHY_)_U_3_ *>A[/S_ _X)X-17O/_ K?P[_SVN?S6C_A6_AW_GM< M_FM'/Y/^OZ?]/0]GY_A_P3P:BO>?^%;^'?\ GM<_FM'_ K?P[_SVN?S6CG\ MG_7]/^GH>S\_P_X)X-17O/\ PK?P[_SVN?S6C_A6_AW_ )[7/YK1S^3_ *_I M_P!/0]GY_A_P3P8]#4(.T\C_ .M_G^M>_P#_ K?P[_SVN?S6C_A6_AS_GM< M_FM/VJNI*"4TN6_1K2W,K;*VW7J"IM34KJ:5O=FFTM5LEHO+YWN>!J>OJ3GZ M^WX4P#G:5#-TP1^?'/I_]>O?_P#A6_AW_GM<_FM+_P *X\.YR)KK/KN7/Y\5 MG4<:U/DJQ4G)WGHG!I;*,9*5K>>@.$KSG&3U6YX-17O/_ K?P[_SVN?S M6C_A6_AW_GM<_FM5S^3_ *_I_P!/1>S\_P /^">#45[S_P *W\._\]KG\UH_ MX5OX=_Y[7/YK1S^3_K^G_3T/9^?X?\$\&HKWG_A6_AW_ )[7/YK1_P *W\._ M\]KG\UHY_)_U_3_IZ'L_/\/^">#45[S_ ,*W\._\]KG\UH_X5OX=_P">US^: MT<_D_P"OZ?\ 3T/9^?X?\$\&HKWG_A6_AW_GM<_FM'_"M_#O_/:Y_-:.?R?] M?T_Z>A[/S_#_ ()X-17O/_"M_#O_ #VN?S6C_A6_AW_GM<_FM'/Y/^OZ?]/0 M]GY_A_P3P:BO>?\ A6_AW_GM<_FM'_"M_#O_ #VN?S6CG\G_ %_3_IZ'L_/\ M/^">#45[S_PK?P[_ ,]KG\UH_P"%;^'?^>US^:T<_D_Z_I_T]#V?G^'_ 3P M:BO>?^%;^'?^>US^:T?\*W\._P#/:Y_-:.?R?]?T_P"GH>S\_P /^">#45[S M_P *W\._\]KG\UH_X5OX=_Y[7/YK1S^3_K^G_3T/9^?X?\$\&HKWG_A6_AW_ M )[7/YK1_P *W\._\]KG\UHY_)_U_3_IZ'L_/\/^">#45[S_ ,*W\._\]KG\ MUH_X5OX=_P">US^:T<_D_P"OZ?\ 3T/9^?X?\$\&HKWG_A6_AW_GM<_FM'_" MM_#O_/:Y_-:.?R?]?T_Z>A[/S_#_ ()X-17O/_"M_#O_ #VN?S6C_A6_AW_G MM<_FM'/Y/^OZ?]/0]GY_A_P3P:BO>?\ A6_AW_GM<_FM'_"M_#O_ #VN?S6C MG\G_ %_3_IZ'L_/\/^">#45[S_PK?P[_ ,]KG\UH_P"%;^'?^>US^:T<_D_Z M_I_T]#V?G^'_ 3P:BO>?^%;^'?^>US^:T?\*W\._P#/:Y_-:.?R?]?T_P"G MH>S\_P /^">#45[S_P *W\._\]KG\UH_X5OX=_Y[7/YK1S^3_K^G_3T/9^?X M?\$\&HKWG_A6_AW_ )[7/YK1_P *W\._\]KG\UHY_)_U_3_IZ'L_/\/^">#4 M5[S_ ,*W\._\]KG\UH_X5OX=_P">US^:T<_D_P"OZ?\ 3T/9^?X?\$\&HKWG M_A6_AW_GM<_FM'_"M_#O_/:Y_-:.?R?]?T_Z>A[/S_#_ ()X-17O/_"M_#O_ M #VN?S6C_A6_AW_GM<_FM'/Y/^OZ?]/0]GY_A_P3P:BO>?\ A6_AW_GM<_FM M'_"M_#O_ #VN?S6CG\G_ %_3_IZ'L_/\/^">#45[S_PK?P[_ ,]KG\UH_P"% M;^'?^>US^:T<_D_Z_I_T]#V?G^'_ 3P:BO>?^%;^'?^>US^:T?\*W\._P#/ M:Y_-:.?R?]?T_P"GH>S\_P /^">#45[S_P *W\._\]KG\UH_X5OX=_Y[7/YK M1S^3_K^G_3T/9^?X?\$\&HKWG_A6_AW_ )[7/YK1_P *W\._\]KG\UHY_)_U M_3_IZ'L_/\/^">#45[S_ ,*W\._\]KG\UH_X5OX=_P">US^:T<_D_P"OZ?\ M3T/9^?X?\$\&HKWG_A6_AW_GM<_FM'_"M_#O_/:Y_-:.?R?]?T_Z>A[/S_#_ M ()X-17O/_"M_#O_ #VN?S6C_A6_AW_GM<_FM'/Y/^OZ?]/0]GY_A_P3P:BO M>?\ A6_AW_GM<_FM'_"M_#O_ #VN?S6CG\G_ %_3_IZ'L_/\/^">#45[S_PK MCP[_ ,]KG\UI?^%;^'>GG77/;HBA?! "[B<]C[CCG_ "*^@_\ A6?AP=)+H?\ ;1:3_A6OAL=9 M;K/^^/K[_P ZQG&G*=.]&BZ=-7A*4%*O"::=X5'=);].OJ+DO",)2DTFI:.U MVNC[KU1X'Q&H &3D\GT[_0D^G;BG#H./_K<5[U_PK;PYVFNOQ=31_P *X\.] M/.N#45[S_ ,*W\._\]KG\UH_X5OX=_P">US^:T<_D_P"OZ?\ 3T7L M_/\ #_@G@U%>\_\ "M_#O_/:Y_-:/^%;^'?^>US^:T<_D_Z_I_T]#V?G^'_! M/!J*]Y_X5OX=_P">US^:T?\ "M_#O_/:Y_-:.?R?]?T_Z>A[/S_#_@G@U%>\ M_P#"M_#O_/:Y_-:/^%;^'?\ GM<_FM'/Y/\ K^G_ $]#V?G^'_!/!J*]Y_X5 MOX=_Y[7/YK1_PK?P[_SVN?S6CG\G_7]/^GH>S\_P_P"">#45[S_PK?P[_P ] MKG\UH_X5OX=_Y[7/YK1S^3_K^G_3T/9^?X?\$\&HKWG_ (5OX=_Y[7/YK1_P MK?P[_P ]KG\UHY_)_P!?T_Z>A[/S_#_@G@U%>\_\*W\._P#/:Y_-:/\ A6_A MW_GM<_FM'/Y/^OZ?]/0]GY_A_P $\&HKWG_A6_AW_GM<_FM'_"M_#O\ SVN? MS6CG\G_7]/\ IZ'L_/\ #_@G@U%>\_\ "M_#O_/:Y_-:/^%;^'?^>US^:T<_ MD_Z_I_T]#V?G^'_!/!J*]Y_X5OX=_P">US^:T?\ "M_#O_/:Y_-:.?R?]?T_ MZ>A[/S_#_@G@U%>\_P#"M_#O_/:Y_-:/^%;^'?\ GM<_FM'/Y/\ K^G_ $]# MV?G^'_!/!J*]Y_X5OX=_Y[7/YK1_PK?P[_SVN?S6CG\G_7]/^GH>S\_P_P"" M>#45[S_PK?P[_P ]KG\UH_X5OX=_Y[7/YK1S^3_K^G_3T/9^?X?\$\&HKWG_ M (5OX=_Y[7/YK1_PK?P[_P ]KG\UHY_)_P!?T_Z>A[/S_#_@G@U%>\_\*W\. M_P#/:Y_-:/\ A6_AW_GM<_FM'/Y/^OZ?]/0]GY_A_P $\&HKWG_A6_AW_GM< M_FM'_"M_#O\ SVN?S6CG\G_7]/\ IZ'L_/\ #_@G@U%>\_\ "M_#O_/:Y_-: M/^%;^'?^>US^:T<_D_Z_I_T]#V?G^'_!/!J*]Y_X5OX=_P">US^:T?\ "M_# MO_/:Y_-:.?R?]?T_Z>A[/S_#_@G@U%>\_P#"M_#O_/:Y_-:/^%;^'?\ GM<_ MFM'/Y/\ K^G_ $]#V?G^'_!/!J*]Y_X5OX=_Y[7/YK1_PK?P[_SVN?S6CG\G M_7]/^GH>S\_P_P"">#45[S_PK?P[_P ]KG\UH_X5OX=_Y[7/YK1S^3_K^G_3 MT/9^?X?\$\&HKWG_ (5OX=_Y[7/YK1_PK?P[_P ]KG\UHY_)_P!?T_Z>A[/S M_#_@G@U%>\_\*W\._P#/:Y_-:/\ A6_AW_GM<_FM'/Y/^OZ?]/0]GY_A_P $ M\&HKWG_A6_AW_GM<_FM'_"M_#O\ SVN?S6CG\G_7]/\ IZ'L_/\ #_@G@U)S MSD_3MC_/]*]Z_P"%;^'?^>US^:TO_"N/#IZSW1_%?\:ARE*,X-^[-K;XHI6O M9[:V[>J[ODTM?3T[V_R/ =JC[QS_ )_/\:&)S\N<'CIU_2O??^%;^'?^>US^ M:TX?#;P^1Q-=8_WE_P :KVLUS*$YIMS_P!])_C1 M_P *U\/?\];G_OI/\:7[J+ER0Y8SMSV5-3>UWS1@G=Z[O\R/9RYG^\DH2^** MWEHM^G3Y]>YX(.@HKWG_ (5OX=_Y[7/YK1_PK?P[_P ]KG\UJN==G;^OZ_X? M1^S\_P /^">#45[S_P *W\._\]KG\UH_X5OX=_Y[7/YK1S^3_K^G_3T/9^?X M?\$\&HKWG_A6_AW_ )[7/YK1_P *W\._\]KG\UHY_)_U_3_IZ'L_/\/^">#4 M5[S_ ,*W\._\]KG\UH_X5OX=_P">US^:T<_D_P"OZ?\ 3T/9^?X?\$\&HKWG M_A6_AW_GM<_FM'_"M_#O_/:Y_-:.?R?]?T_Z>A[/S_#_ ()X-17O/_"M_#O_ M #VN?S6C_A6_AW_GM<_FM'/Y/^OZ?]/0]GY_A_P3P:BO>?\ A6_AW_GM<_FM M'_"M_#O_ #VN?S6CG\G_ %_3_IZ'L_/\/^">#45[S_PK?P[_ ,]KG\UH_P"% M;^'?^>US^:T<_D_Z_I_T]#V?G^'_ 3P:BO>?^%;^'?^>US^:T?\*W\._P#/ M:Y_-:.?R?]?T_P"GH>S\_P /^">#45[S_P *W\._\]KG\UH_X5OX=_Y[7/YK M1S^3_K^G_3T/9^?X?\$\&HKWG_A6_AW_ )[7/YK1_P *W\._\]KG\UHY_)_U M_3_IZ'L_/\/^">#45[S_ ,*W\._\]KG\UH_X5OX=_P">US^:T<_D_P"OZ?\ M3T/9^?X?\$\&HKWG_A6_AW_GM<_FM'_"M_#O_/:Y_-:.?R?]?T_Z>A[/S_#_ M ()X-17O/_"M_#O_ #VN?S6C_A6_AW_GM<_FM'/Y/^OZ?]/0]GY_A_P3P:BO M>?\ A6_AW_GM<_FM'_"M_#O_ #VN?S6CG\G_ %_3_IZ'L_/\/^">#5L:!_R& M-/\ ^OA/YU[ ?AOX>&/WERU\ :-93QW<#REXB"HD;/(R]FG:V]CT =!]!_*EJ.,G:H) 55 7.>>W!/)Z=ZDK,L**** " MBBB@ HHHH **** '#H?]Z/\ ]#%% Z'_ 'H__0Q10 WL/]U?_0111V'^ZO\ MZ"** "BBB@ HHHH **** "BBB@ (!.2..PSQGL?KFF;?@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@> M@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 MF!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0? ME2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C M]!^5+1F@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T' MY48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P M/0?E1@>@_*EI @_*EHH 3 ]!^5&! MZ#\J6B@!,#T'Y48'H/RI<_YYH[D>G^>O0^V.M "8'H/RHP/0?E2T4 )@>@_* MC ]!^5+W [GI0>,9[G'7/\LT )@>@_*C ]!^5+WQWQG'MUS2 @]#USCMG'7& M>M !@>@_*C ]!^5+_G_/8?2B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ] M!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@! M,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI: M* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_ M*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&! MZ#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y M48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/ M0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH M3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6 MB@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/ MRI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@ M>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^ M5&!Z#\J=CG'X^WY]/UIN?K^1_P * # ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* M$P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:*=F]DW\@$P/0?E1 M@>@_*EHI )@>@_*C ]!^5+10 F!Z#\J,#T'Y4N>OMU_'I]?PHH 3 ]!^5&!Z M#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y4 M8'H/RI:* $P/0?E1@>@_*EH]3Z4 )@>@_*C ]!^5.QQGMW]L^OI2#G&.YP/< MT )@>@_*C ]!^5+10 F!Z#\J,#T'Y4O^??\ +KCWQBC/3/@ M_*C ]!^5+CK[#/MCZ]/UH'/(H 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/ M0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH M3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6 MB@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/ MRI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@ M>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^ M5&!Z#\J6B@!,#T'Y48'H/RI:* &EC_ /0Q10.A_P!Z/_T,44 -[#_= M7_T$44=A_NK_ .@BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@!/F[$*,R\]^U&M!U36FB4%_-%C:23K$$ )+/(B M8!X)K^;C]G/X<_M%_P#!5^[\=?&KQW^T5XG^%OPITGQGXD\+^&?!7P]U-M/U M:SFTFY^SPR7:PMYA0I\P\S8')8 DC%5&-^ME^H']-T5Q!/GR)XI<=?LTL4OX MML /%S^,O 'A/QCJ%C<>'Y]=\ M.Z=JVI:9?K]EN-*N[FUCEO;6Z20CR#;2F0?,QP!S3Y//\'Y=/Z_R#NZ*\#U3 M]I[]GG1=6ET'5_C7\/+#5XI1:OITWB2Q6\CFW;1&T>\EI2W!'KS7M%AJECK% MG:ZEI%[:ZAIUXB/9WUE$=1DD"BRUS6[2UN2S8P@ADDW1 ^G./;FK-K\:_A)J M&I:)I%A\2/!][JOB1%E\/Z?;:U:W%SJT3]6LX8W8S'&=F,'U'HN62Z/[@/5: M*X#3_B5\/]3\6W_@+3O&6B7?C+3H7N-0\+Q7\?\ ;EE"@!>66RYE55!!+$8 M/7GB?QK\1O WPYTVVU;Q[XKT;PAI5S=QV%MJ.OWL>G6UU>SD+#;1RRD*978@ M#OD\ T6?9_Z*Q+_7='TS1I_$5[JUG:Z#;6S7MQJTMPAL8;)5W/=_: 2C0!>1( M"0HP>W/D]]^TM\ --TJVUR_^,?P^M-&NV,=IJ$OB*R^SSX)!_>;^) >H(XQS M0DWLF![G17!>"_B3X$^(EE)J7@+QEH'C#3HU*R7>AZA;WR0MD;#*T+L1N!X^ M49//2J?CCXL_#7X9QP/\0_'WACP6DT/G*HW1"6-YAD$',6[>J9Z9&>" M2!S7!>!OBS\-?B4DL_P^\=^&/&,-L%-P=!U>VOWA#9 :>.)C(@=OE&5X^E?+ M'@;X4> M)_;&^(OQ.T[X]ZUK_C?6]+CM-0^"W3/?' [Y[4M>/WWQZ^#%A?>(M,O\ XI^"[#4? M"Y3_ (2"RN=;M(9]'+G ^VI(Z-%N/"C!YZ]:/!OQZ^#'Q$O3IO@/XI>"_%>H M<8LM%UVSOKH[#AP(HW+@D@CH>>/J:J+;7[*9;"U3)DGF82914QR,9'.<<5$J$_&' MACQOH]OK_@[Q#IOB;1+G=Y>KZ3=)>6,IS@^5-&=A*G@J"2O%=#O;9U8D9"D? MQD9.&/90 2Q[ &J5]MK]/7U M45XE=_M&_ 33K+4-2U'XP> [.QTC4Y=%U*Y MG\16,45GJT#8EL+AGD4K(_C1\/]&U:!FBFT^^\ M1V,,Z.K $-$9-P=<$'@\Y]Z],\*^-O"7CG3EUGP=XFT?Q/I+X6&]T6_AO(6D MZ%6>$MGDC&#?"-[*WEBTU[7+2TNB>"\:QR M.&5R"!R ?K7XL?M"_%_5]:_X*Y_L@:9X"^(MY?\ PZ\1?#V^O;G3O#^M"[\/ M:W(&<13W%M YAFD5>A8AAU(!HY7V_KUV _H"HK@+;XF^ +_QGJ7P]T_QGH-W MXYTZ%I[SPG%?Q/K=K$/GDDDL#B151#NWC(5>O'-7O%?C?PGX%TG^WO&OB;2? M"VAPO&CZIK-[%96QEDVJD1EE(5BS'&.H) %2!V!SP ,DD 9.!GW]>,\5&TL4 M0+R2Q0J2$'FLD:;@2" SL,D]L GV[5E:9J^FZ]IUKJVC7L.HZ=>1^?9:A:RB M6UN8) #'+"X #!T.48=0>M?D!_P6:\8^+O!OP1^&][X2\2:UX:N[GXBZ':7= MSH]Y)9SW%K+J-NLD$KQX+1.#\RG (XH7O;:^GZ]@/V2DGAC ,DT,/F,$1Y)8 ML/\ 7>ZB0\\!2333<0K*(S/;[QN98FDC,S)C.Z*(L&(;T VC@"OSK^,?PV\& M_%?X2?LYW'C_ ./.N_!V?2O^$=U2RO-/UP:7<>+;T06S#3;UG=/M2W++B1"2 M7\P]SBOB+]HWX@^)_"?_ 5K_9@\)V_CW6+'P"/@W'=ZA9RZLUIX>OUM(W3^ MUM24GR9I)(U60R,>VN[ZK?:X'[[J3D@X!'S$+G;M;[N1 MC&[(Y _I3Z\/T/\ :,^ WB77I/#?AWXP> =6UU[@VZZ-9>(K&2^-V&VM$$63 M).[Y0H&TL>#7H/B_QMX4\!:'=>)_''B32O"WARSDMX;O6M8NX]/L+6:[<0VT M;W,A,8::5E2,$@$D$&IY9=OTW]?N]0.OHKQEOV@_@BGB&R\(-\5_!!\57\5M M)9:%'KMI+J-XMZBR636ULCEY1<))&Z;_%'*].C?37R[7[]; >@T5\ M]C]JC]G.:X-I#\;OAT]VMR+3RD\16C$73/L6V8*S R,^$5&0YPM2!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !28W9'7C)4\+CU^M+4$S"-7 MF8L$AC>67'7RD!=\ N*_FCT'7?VB/^"JO[3OQ\\&Z9\9]5^!GP M.^!'B^7P9_8_A6]-EXHUB:T:1!>Q;2)S]I\O?+\H"GJ1D5VOQK_X)^_M3_LB M>$;OXS?LO_M)_%7XE:UX63^U-8\">,K^XU>;7[>&5&>UTVUD)!9X]X5 =Q.? M:M(Q[Z/I^&O_ &!_18#D @8!Z#&*6OFW]E;XK>*_C+\!/ 'C_QSX8U?P?XO MU'2HX/$^@ZI;-8WMMJUNBI=R^0^2D+-\Z9X +'/%='XF_:-^!'@O57T3Q;\7 M_ 'A_58@%;3M1\2V4%XLAZ;HV?))/!7JI&.M2XN[TV?]:;]4![?17->'_%'A M[Q;I<6M^%M?T[7]&N%_-OCA\'_AO=Q6 M/C_XF>$/!]_(BE;'7-*])\"ZMXRT+3_&FMQF;1?"][J,4&M:HFW(:WL&S+*@')*C!/ M4CL6?9_9J.KZO9._R MQIN.,GC.!5W2==$U5M$U7XT_#NPU2*;R)+"X\36(O1* M#M$?D[R?,W@JR@GG\J]6B\2Z!MD%WM.9XV M=!'&@WL<\#J.*:YELFOE_P #HZ*\(N/VE_V?[32EUVZ^,_P^@TF1G@BU!_$ M5BEF6C?8Z9,O^O5@RG^+C&.*[;P9\3OA[\1[26^\!>-] \76,87SKC0=1@OC M!CH3Y+%@&[[@,_2ER2WL]?NT_#_ANX'H-'/].N.O'6N(\7^/_!7P^L/[6\;^ M+]"\)Z:R@I=:]J=O80N.Y!F92/\ @(/)]JYOP1\O8'/!&13Y9=F!ZJ9H5<0-<0F4\Q1R21*9,8R M%BW^82/79W]ZF_/\23^IKX6\=_"CP%K'[77@#XDW_P >M;\-^,]*TR.'3O@O M'K8ATKQ%$%(:[N-(+AIWD^]N5"".X[?3>M?&+X6^&_$5WX7\0?$/PIHOB6UL MO[2GT+4]7MK6_M[$[MMY-!*X9;=MI.[[N!U]#EEV_+^NH'IU%>(>'_VC?@1X MMU=- \,_&#P'K>N-(8_[,T_Q!93W$DJG#1QQJ_J-HVDY;(!%>H:WK^C^'--N M=9U[5[+1=*M%$MQJ.I7,=O8PJ000\\A"'"_O!SZ=::@VK[>33_K^ON#?HKPW M1OVD_@'XCEO[;0/C)\/M4FTF&2[U&.T\0V,\EK:P@F>6<++E-FUC@9( )P>: M]$\(^-_"7CW2H=?\$^(=,\4Z%.TD4>JZ-=I>6+/&2KA9X\H6B8;9$ZHQP>:3 MC97\^S_5(#KJ*K>>.%&6()7>!\A]FP>#Q][MR*\KUCX[?!OP]J.LZ5KGQ.\' MZ1JGA^$7&N6&H:W;03Z7!SMFNXY&4PJW4D\%<5('KM%>?>$?BE\._'VC7'B/ MP7XX\-^)M!LS_IFKZ/J5O=:;;A>HDNT;RE9?XP2#S@X.,\).O"?CO3%UGP5XHT7Q5I4C 1W^AWT-];JH'.7B M9LN>V<''S 'I63XZ^+?PT^&4<$GQ"\?^&/!<=RN^V_X2#5+:SDD7IOCCE=6? M/9@/E([T^1]U^/ETM?KKIH!Z')/!& 99HH5D)VK/)' 6(X RS!G#$] #U'K4 MGWE&6==QVEL_=/\ #M[D-C )ZBOY^_\ @JU\=FU/7/V.-6^"WQ76?0M;^+5E MI^JWO@KQ!'+;ZK"M];QFUOQ;,=\8^9=D@&[<>N,U^W;_ !-\!:+K/A[P5K'C M'0]/\::QI^GRZ;XN>(M3M=&T73U::]U&_E M2WLK.)/F>6ZG8[88@.[<#G)Q5;PMXP\,^-]'M]?\'Z]IGB/1+K/V?5-(NEO; M*XZY,5PGRNH&1\N1GO4 ='+)'$N^65(Q"6V>6/YC%(!\R'@UZ_P#&#X=>$?BS\!OV?A\0 MOCOKGP=EL!X6U>#6-.US^R+GQ+?*EI(NF78?4TTF]D!^C; MW$*[4DE@1I#A%>6)48C&1&&<,YSUV@CG%2 @X;KNSMP=R@#&PQCD>U?S M[?\ !5#QKXS\#_M)?\$Y]$\(^/->TW0]6\47EGK7]F:F]G:>(;.WNM/6*XU4 M*=EQ%Y6]W9SM;>S=Z_9&+]I3X +K4?A9_C+\/QXC@6"VN-(_X22Q%\+C8BF/ MR?,XD+D93=N);#;2,%\LM^5_=?[^WS ]ZHKG]9\2:'X?T.]\2ZWK&GZ7H&GV MQOKS6;NZ1--@TY0&-[+:\MN_VD/@1I_]BK?_ !?\ V\G MB1(Y_#JR^(;./^V+>9MD4]FH=FF5VRJ87#,#SS1RR[/^O^'^0'N5%>7^,OC+ M\*_A[%;2^./B+X1\))>Q1S6K:]K=I8">"15D6>+SG4L)$8-'P,J5]:K^"OC? M\(OB1<26WP_^)G@[Q?=0KB2UT;6[2\FQ_>\N-RX.>-R@C ZBGR/^D_+K\_ZU ML'K%%>>>)_BA\/?!&IZ3I'C#QMH/A?5=;\XZ1IVMW\-K<:DL"L9_LJS%?,$0 M4OO4\*#]:X>W_:<_9\N5U26U^,WP_GCT;/\ :[PZ_:S)IK*VP&]=&(@4L0") M"HR>"0:3BU_3 ][HK#T?6-.U[3K'6M%U"#5=)U*W2[LK[3W%Q:WMO,-T4UM, MI*R12#)1UXV]*YS2?B;X U[Q3J_@;1O&GA_5/&6@Y_MOPYI]]'<:MIF,'_3; M-"7M& (+I)@@5('?T4B$[>><^O..W%+0 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 X=#_O1_^ABB@=#_ +T? M_H8HH ;V'^ZO_H(HH[#_ '5_]!%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% ',>,=2\-:1X;UF^\8ZAINE> M&4TV[BUK4-8FCM],AT^XB,%P+R><^2D+1R,&W@=1S7X)WG_!-;XN> ?$FO\ MQM_X)R?M-VOA?PUXON-1\0Q>$DO?[6\)7UU=N9I8=*,+O9(UQ*&'F?,4[GM7 M[??&OX8:7\:?A3X^^%.N,\6F>.?#FI:'+XE$<5Y/M39#@;G^9>1QZU](?\%2?VSY/! M7[#_ (<^(7PBU=[.Q^-;:19V'B:SR;G2- U-$?4'L_)VE;NWBE>,[>?,0XKX MW_:D_;;^-G_!1+P/_P ,O_L\?LP?$/PS9^.]3T^S\0>,/B!ITMM8Z5IJ3 W- MP;IH$AA"HY/S?.0 %;@5]E?M;?\ !/7Q)XP_X)Z_#[X">![N+4OB-\$M(T76 M-'-R/,M-9U'2 ES?Z<$.1*EU(C6L:X.5(9LCKI_6_P#7_ V _(;P1J?_ 1K M3X=6EM\0];^*/BKXI7NEQ7FK>.KW3_$,VJ1ZW-:A[B:.59E7;'=.QAPO( /0 M5]D?\$I?VK[[3/!7[5/@_1_$/B'QE\.?A!I>I>)OASJOB>.\34?[.%I.]I"W MVP;\0,(QY>3P*Y3P#_P4)\%>"/ NG^!?C%_P3AUR;XP>&M+@T":31?AOIS:3 MJM_IUNME'?,TFE/)(DTL0>1]_P Y)8'O7W3_ ,$_OAW\>/BQX#^-'BKX\^"M M$^&/A7XN6NH:3X)\ Z=H>EZ-J.C:#):65M,LN9(RT=P7/%5&26CM M97TTOT=^_;<#XI_8)_8H\#?\% [/XC?M1?M4ZCK/CR\\1^,M:TS0/#QU2]@T MS1K"WGECM9H8HID5) F&&!\I R/3R?5_V7(/V4_^"L/[-_@?PUXEUW6/ -_- M:7OA;3-7U"ZNO[$M[@N\EE;%Y=LD41 5 P8*.M>G_ ?]H#XV_P#!*;Q/\1?@ M'\5/@/XZ^)OPHOO%&J>(/ WBWP+IL]X_E:E.\D5G<3+%)""@81E N0,=\5XJ MW[0'Q3_:._X*H_LV_$?QU\--9^%WAFX^SP>"-!UV(VVKRZ3#O_TN>"1%9)I0 M02V#QGU%)R;=M+=%97TLNWZ[6MU ^T?@-)N_X+B?M!_Z3,X/@C4HQ$;B0PN% MM(!B.(GRU<=]J#Z\UU?_ < R.O[+GPU*RO&TGQ@\,0GRY986?\ TV %1Y;J M5Y'+DD'TXKP7]I?5?B]^PC_P4XU;]J[_ (5'XE^*OPE^)GAB32[JX\*6,M]> M6,MY;K')'LAC803V13*O(,3,YZXKYM_X*3_M+?';]O'X6^"M6\!?LZ?$'P3\ M%OAW\1-$N-5N/$>FW$WB?Q#K.KWD%K:"RTZ&%)6L]+>(SW$JKLB1MS'FEV_K M2P'VC_P5Y_:3USX7?!3]F#X067B35/!WA7XJ:;X5M?B'XCT9Y1K5KX;L]"T] MI8;/RCYQDD7>'V'+9Y-? 6I:A_P1AB^'%-?D\$:A;K.?$.FQZ)8/?:(=:U3Q##\-=!\1:1X5U[4UN(-3O?#JVUP; M)[EIPLVXQ*@+$D@LPS7A?_!)_P#X)O\ PA_:7^!5]\2/CU<>(?&5I/KFIZ=H MWAB;6+Z+2=)"S.JSPQK,,R]P./'OA M37K_ $7P/X:T.PTV;0-*FMY7L=)>VTRUMC/*J21J%=6DW+C.B_+L!\(?L9^#C^R!_P5"^)_P"SYX%UO6;WX4W7@G5?$-IH=Y?7%U;Z M>]E:2W$$,2S.P B";,CD<=ZY?]F+X$6'_!3G]K3]HWXC?M%Z]KOB'X>_#/Q= M-X?\,>!1J=U;Z8T,$\D$:RP021*HCVY=^.HQ7T-I7A'Q%-_P6G\2ZU/X:US_ M (1F\^'5]IL.NMIUPNB))=VDD$T37JJ(7+ARR@L3E17B7A7Q'\;/^"4'[4WQ MQN==^"OBSXJ_ 7XS>(/^$BTC6_!-G)?W>F^9))*5D2.*00SEG^9),YP,C%4J MB>W+?IIVMW7X/] /MOX:?\$N=?\ V:_VO/"WQH_9C^(H\'?!,VXMO'/PJUF> M]U&"_BN2%O/[-DEG,4;*JJ;5V#>4Y.,DUXQ^SVTA_P""X7[3P,TX3_A#"ODK M-(T8QIL#*PB+&-=V><*#G-8?P]_:"_:R_P""A'[9?PRU;X=^$/B'\!?V8/A5 M?VNN^*W\16D^EW7B][=]TNE70>*..\CU#_5&*,#R@,G&:[7X!>&O$UI_P6M_ M:6\2W/AO6[;P_>^#UM;/79].N(]'NY/L$*$6]\R^1+)N!&%;.[/L*GF=^FW9 M=.7>WW^70#X5^#_[)GAC]K/_ (*E?M:^&?B!K6N1>!?#NIV^I:MH&GZI=VD6 ML,RJ(K:X$.U=E^UI^R[\/OV ?VQ/V2O%G[/DVK>$]!\>^.K M'0_$7A^#5+N2VN(6FC,LL@EE97$F2K @9W'(]?I_]@7PKXGTG_@J'^V[K.I^ M'=;L-&U*2S72-8O]-N;;3;\HR-(+:[=5BN&7YN$)( ],5H_\%??"WB7Q%\?? MV'[C0O#NM:U:Z;\4K*XU6YTO3KB[@L(5D1]][+$A6W@VC(>3 YZTW)WW6U]E MY:[/\]_30.<_X*C>*?%?QW_:K_9Z_8TTCQ#J_AGPCXTBM-?\7OID\MM)?:9< M,KO$S0LC$[#L)S@CL.:I_MI?\$E/@?\ "+]ECXC^.?@%=Z_X)\;^"O"-YJFN M:G!K5\7\46<42&\AU -.RXE+$@;1M7(]Z]!_X*=_ OXQ>&OBE\$?VVO@IX2O M?&VK_"B+3K7Q9X:T]3<:G=:'&BM)'#:QYEDPG. #@CG%?+'[7_\ P58^(WQ^ M_9D^(7PV^&/[,_Q6\):SJGA.YA^(GB+Q)I(/C7J6K6UGXJNM3 MM=.ETRQN]6DDGM9]EP)S&7>/#'(=SACT%?>W[.G_ 4W_9<_:D^(Z?"?X4:U MX@O/%5WI.JZM;Q7^A7EA;&UTZU,MV1=SCRUDC7E0?O9XZ5X'_P $B?A]X1\9 M_L#_ GM?'/A'1/$]K&MU=6%OXBTJTU&."228EI+1;R&50'?.]T'..37ZA^' M?A%\+?!^I-K?A;X=>#O#.L?9+B"+4-$\/Z9I][ DL+I<1I<6EM%)Y2ZE-X>^UE6TY'B=KJ4CY]C;R"3@]*]R_ MX(Q>%?%.@?'G]O&XU_PWK>AVFJ?$2>;3&U?3+FQMM1A_MW46>XM))E5)U9&4 MAD)X8-R*[3_@KC^S+\3?$'B_X+_M5?"/P3;_ !&UOX,ZB@\2>");1-2_MWPL MLBW,UHEA/'.LTC,'#*R-N4C;UJN=WW2MHE9=%'7;?^N@'Y:_$C6/^"/*?#6\ MM/A)K7Q.\*_%G2K1Y- \=167B&/4+W5H4,UO)<2&5@3),JA_EQRV>N*_77]A M#XV?%#]K3_@GAXMT_3/&<5\@>*O^"B_@OQ=X(NO#'PO_P""<\5]8>+O@?\ M21_\$Q/&?AZXDMH_C=XKM)/ M$>K:/X5TZVT5X+*5-[Z+#%I4%J'9;8M"5V&1L[=Q.:;DWV6W1=+?Y ?"/ASX M'_\ !*OX9>%=3T[]J?XT)\;?C*TEZ?$'BK1;_5-1$.H3%BQTG[- MQ ZYXZC_ ()'?&3PYX%\2?MWV_PS\0:_XE^#'PK\/MXL^'L.NS7+W$5O]FFF M3$=TSO"GF!%V'DJ#SWKP3]GSXY?LY?"GX7Z+X+UW_@G;\2/%?QRT^&2PU/5- M1\-SWEAJFML=BW1:[@ED*R7&UY"SS_ /!*SP]XRU;]I?\ ;"\&_&#X M.ZS\)H_C_P"$/LUIHL>B366AV.E-9SQI:6]R(H[2WFA$D6V/&6(;K1=_TEY= MEY =9_P3\_8R\#_\%![/XG_M5_M7WFL>/[[Q%X[\0:/X>\,R:G>0Z1I&G6=R M8[62&"*552X5-N-HZKTS7GU]^RAI7[)G_!8#]E[PIX4UO5]4^'VN:!J^K^$] M.U>^ENSX=C<&&72K=IF:1;>'RRR(&("D-WKJ_P!GCX]_&G_@DYXD^)?[//Q6 M^!7COXF_"6?Q?K'B?X>^+_!&F7%].\&IW#2P027"120I$H"QK"P\Q3N))R,< M]H_Q3^.G[47_ 52_9;^.GBGX+>+_AQ\.H]"UK3_ 5:ZOIMRS0Z48A(=3UV M58Q%:373%E$O:7XQ\8RV,SJ$\*13P21^8865HLJ!+ECAD^M?H%_ MP4F^!%C\?OV4?B5X:-NK:WX?T]_&'AN[7 NM.U;03)?Q3VLWWH6G>,(Q4@[. M.E?D+_P1NT'X@_M._';Q=^UK\6+8RR?#/PMIGPG\+3RN7 U'1[=+&ZF4/G), M4#%I%(R^#]*4I8^&-$L-& MM^O[R.PMX[=7*G)9GV;BY/))S7X]?\%P%Q\!_AJI[_$SP^-WI_Q,;4_IGFOV MVSD\DDGH#U'T./NMU ZGKGCG\8/^"U&@>(/$/P/^'-KX=T+5]?N8OB/H4\]K MH]C-?SQ01ZA;%YI(X%9DB4 [G/"]ZSC*,59)K7I_7YW]0/G+_@JJ67X)?L*> M7)+&Q\8>#$#QRRQL<1:=]XQN@="UGX\?\ !2+]DOX7:1KU M[X>'B+X'>'!KNJV$[V]XOAZ&V;^UK>"93N1KF+:NX'*YR3R*^D/^"H?A;Q1K M7P8_8>M]$\,Z[J]QIOC#PA)J4&F:;))+Q(E+6Z1D-O:0 +@YZ5 MX1^W]_PO/P=_P4*_99^*7P?\!:]XLU'P-\$- U&^MK;3KEK*]L+&U9]7T5[Q M4,,=Y,/C-^SY)XB\ M#_%?X0Z(/%LOB6SUN_\ /UZ'21]JOGOM\["6>4H7)&/O$$# SA_M()Y6U_QAX=^'=UJ-VCR)-+_\).FI:DEK% K-)%;S7-T/, (:-=W1@:IRE9:K1JVB7\J? M]=/Q [;_ ()]?\$Y_@L_P:^"'[0WC33M2\3?'*\T73O$-IXIU?5+R7[(T403 M3+;R'EV&WMXHH@JD'Y=HP0":^=?BY^SO^S#8?M'_ !+^(/\ P4/_ &DM$\>W M.MWYE\*_#'2+^^@B\.:<&9;:VOK*UN3L=82H^Z-[*#QG(_9+]DK3-9MOV./@ M_I BN])UY?AC86,4%U$T-U:7TFG;(H[A) '@D60J26 *$9/2OYF_ >L>%?V< M/CS\=Q^VK^R#\4/C?XQUGQKJ%]X9\7VNGW6L6KZ2US+_ &?!:7$J26[V_DE# MNC7", O7BE?S_K;^O,"G;>/?V6/A!^W7^S[*_$5MH7B3Q7::!XNT&=] M2CT^"/P9T+X@:4;%[;PM)!J]_(+D#^T-5>"W0K HZNV%(YS7Z;_MZ^'?$NN_ M\%(?V-_$6F>&O$.HZ1;6VDW-_J=GIEQ-IVG[P7 OKE$,=N1N 8.PP>*I!OV4/B=-\&/#6H:5X_T31]/\70:ZNH7USJ- MYJGAH"^>5&,[/YMY)N:9$ W+@$<5T_@C]O6+3O\ @E)=?'K6[HKXZ\/>"Y_A MT\0E#7'_ G+0R:'IZE3E]Z.DSO+!K. MYMF3S(S%=6_DS)*C9WA@V.<\8!'%?QL_$KX)?$NS_;)D_P"";/A=9)?A%XN^ M.;?&._MWE8*OAB6X@OM52-ON1I$C,8(SQG( !J)/W7\OS0'[M_\ !('X W_P M;_9*T3Q5XH:8_$'XX:K=?$WQE)=O*TL5QK,\D\%I&)F9HXA$Z2A!A?G_ K] M7T& <'/)/3UKG_#_ (>L_"V@Z+X9TJ)$T[P]I.GZ1IT8CV"*UTZUAM(@V/U_^M6($E% XHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK M>7$-I#)=W,D<-M;12SW,TY"6\%O$ADFFF ME7(W6VJ:;>Z7=*,AQ9W\$MK<,G."WE2MMXSNQCM0!^%GQ/\ ^"=<7Q ^*_C# M]IS_ ()\_M)V/P\\7:]JL][XJL?#FIQZMX2O/$D:R/=/>06,I@6^FFR&CER\ M7(9>,UY9K'[1?_!6W]DJQ7Q%\:_A_P"'OC/\/]*7[3XBU[23%<7TFE6D@6[N MI+>)5,16$F10-NT@'J#7F_@G6OVFO^"/OQK^+'A8_"/Q+\=OV7_BGXJF\8>& M-;\(VUU] ME=[::^6F_G?7;HM@/M#XZ?MXZ'K'_!/3Q+^U'\%'6WGU30)["&*6,177A_69 M(Q!J%LT:!1YEI(6"R8RV..AK\%O@+XP_X)7ZWX#@\4_M6>(/B5\0?C'XG2?4 M/$&IW5IKMS!HNHWC/,8-.\F5$=(6DQ%(OR' Q7[1_#W_@G+XATG_@FGK'[ M+VN:M%'\2?$UAJ'B:[93OMK#Q%J&;Y-,0CY#%'*?++@;&_ .FZA:^([6T=X[6[N+V?2YSQ:;86=M=7"I\DT_ MX\?M*?$3XJ?$WQ3\*-&^ /P U[P[J'AGPCX.;PII6E>(+M-1C>%;J>2#3X+N M,*C;B#)M/IUS\Q?!+XR_&O\ X)/>.?B?\'?B5\!/''Q*^$OB;Q5?^(_!?B?P M-9O?HMKJ%S(ZV[M'"Z),XD&Y#GN2.])ONU^'E_P/P[@>5_%#]E:[_9._X*K? ML4^#M \3:WJ_PJUG4M6U#X>^ M&1'@;@Q85]B_\%4/#/QH^"_[:7[,W[;/@/X;:S\3_ _P[M7L?$VEZ!$UYJ-H MRMY31I:PJTB^="YD%PX,:,H4Y)I=D][/]+@?<_\ P6)+#_@GS\?VAD<;?#WR MM!(T;B3[9:YW2*597/)!4C'3O7P_^T1^T)XK^ /_ 1Z_9NU#P?JUWH^K>+O MAWX"\,3:[#(YN[#3]1M%CO)X9 3(UQ%%NVX)<]N6E[/Y] /RF^'6J_P#!'-_AO90_ M%/6OBAXI^*VJZ3'()HS)<26CK,JA$G*/$7C3X6>%O!GB34_ASK/B:"]BU>WTI[2=5MIWN@)"JQ_( MN'ZJ#P:A^&G[?G@CX:?#VP^'7QD_X)S:[>?%OP?IT>@/=:3\.],N-,UJ_LT^ MRK>33-I+R3?:G17+K(,J<\9KZY_9/\/?M%>,?@E^TE\9OBOX$TCX9:#XV\)> M(H/AO\+='\,Z;I6L:7I#VM_L.^ ;;]DO\ X*S?%_\ 9I\$:SK4WPPN? =KJ^F:+=WUQ,^7.[A5AB(B..H&>F:^P?^"'OA[7O#7[,.NV7B70M8\.WO_"=Z]*EK MK5E/I]R\4FH7#)((+A58HZE2K8P001P:\8\(^%O%$7_!='XC>)V\-:]'XH%/(:4MEBBMG%/G?PW7W+RT6G_#>H'B7CKP=>?\ M%'_^"JGQ&^"/Q!\1Z[8_ [X&^&Q/+X4T_4+BV@UBZL[E;:\MKA(9$#?:9\?/ MCY$R,]J^K_&G_!("P^'WQD^%GQ=_8J\;2_!:;PGK5A<>,?#EW>7^H:/X@TRW MF7[5 8VN61I9H-ZMD$;R.*^>?VB/#'QI_P""?'_!0WQ#^V7X#^%6O_%+X,_% MW1%T7QG8>&(I+_4=*N)IA->RFWA5S'*\X$R3N-HP,TWXC_MG?M1_\%!/BO\ M";X4_LL_"SXJ_!7P1I'BG3=;^(OC;Q/;2:6LFDV5W'+>VOVD01QO%)$&B^S@ MAI,Y%#EMRZ*RM=7UNOOZ6?D!Z1^T$\P_X+2?LSQR2NV/"-C#(4EE$ M8PAQ&RM+N894\'O7S9^UW\"(?VB_^"RVF_#34_$&LZ)X=O\ X;:/<:ZNCWUS M;27UC&TADLY/*D 43 [6; P#S7U/\;_"'B6+_@L+^S1J]GH.MZAX?TCP9IMG MJ'B*/3[B;1X+RVLTCN&NKX*8HIY)07^=ADGI3==\,^)V_P""X5CXF3PUK9\- MCX365J^O_P!GW']C^>GF;H_M^WR!(N>06R!C-',[JUOA\GMRM?,#Y7_X*8?L M(?!K]BOP]\)/C7^SW%K7@SQ):_$#0=)U#[/K%\PU6.>[A666Y+SN&D=B9'XP M2Q YKU/]NKXC>/?VD?BC^R+^Q[I_BG4?#'@WXD>&=&USX@W^FSRVU_J!%G; M&6-9HB)")%9LKNY.>E?3'_!<+P]X@\3?L^?#ZV\-:!K'B"XM_BAH,\D&CV,V MH7$<27L;&8Q0JS"(=W(P "/>O"_VR_V?/C3X3L_V5/VU_@GX5NO%_B;X.>%= M$MO&7@-+>1M2N].:PM_M'EVBCSC<1HKY7:2C$9ZBE>^^]ETMT71; ;?[7/\ MP2'^ OPQ_9L\<^,O@7-XB\#?$;P-X4N]1GUNUUN^!\2I;VK"\75 T["?[3'Y MC!,##,V<$<['_!,?]H+P!^S+_P $S_#?Q2^+&H:K;^&[#Q-KFGW=U:V]QJ-T M;A[T%V$2[Y2"<$\\?2OG_P#:F_X*U?$7XV_LZ^._AM\-OV6_BGX:\4Z[X9GL M/%_B#Q+I4]OH7ART,.^]G20PH4#,KHI=B0IQGDY^UO\ @C)X3T;Q9^P!X1TC MQEX?TOQ%83Z]KT\^DZWI\%]I\UT;WYY6ANHY(CM8X4[>1CO0XOEO*UG;NM[6 M^]^NE@/5/A9_P5^_8X^,'Q$\*?#/P;K_ (EN/$GC#5X-)T.&?P[?6MM<7UP& M,:SSR+LB4;22S<$\5^15_P#LUZ#^U+_P61^-OPU\=:KK*?#^#0#X@U_1K+4+ MJU36OL4*L-.FABE7-FV\ H-N0.O%?TS:1\#?@OX?U6PUC1OA7X"TG5;&=;G3 MM3LO"^CVMY87*9S);30VB21.I)575EQGKBOQ/_9U\+^*+3_@M'\?_$-]X;UR MST"]\#7<<&MW=A-'I$\YCC"+;7Y012-(!PJOSTQUJ>6/;:WX[=?D!QG_ 4P M3P#_ ,$]/V:?#'P(^ BZA\.O#'Q?\:1GQ%JNGW5S_\ !%]?AR-)O=8^)]W\2FTJ.;_A8*_AGIT>L?$KX3>(+3Q5HFBS1 MI/!JVFVDGG7^FK"ZR*\UY&NS#JP(Z8S7Y\:+_P %&O &G^ 8/"OB7_@F]KR_ M&RRTF/1VBLOAMI1T2?7+.W6TCO&\S26FV2SQ"5OGR22W0U7X@>E?\$P?C3\5 M/CM^RO\ M&?!OP%\1)[74?A_/?:3\/?B9XRM[H?8O#]W'+&EQ=M"^'?@+_P2N^&V@:O:_M7?&^'XU_&.:XN'\5>*--U+4[V*WOI9 M2TT6F+;W(0>7*6^7MM &>H^BM'^$G[:GB[_@G]\<=>U#1;3PA\2?B*)-7\-> M _#.F6'AO4M-\/#S)!IC'2[2SD,QM=L31RAY&Y /-?"G[/GQS_9P^$OPUT;P M;XM_X)U_$KQA\<-+M_L.L:I>>'9M0LM=\0 XDEN?M<,LDT,MQEFE1A\K9S2_ MK3Y?UZ ?17_!&[XB^%-*_:K_ &EOAQ\'?%'B#Q#\![;1IO$OA6QUJ6Y)M5L% M<(EO%=L[P!HE W @$]0,O^$+ M\'_#NVU&YM=&73HA,L)GAMWC DB$8#-G<^1CYP5YYKJ['6?C=_ MP26_:O\ C=J,_P (O$WQ@_9M^/7B%O&EGJ_@W3Y[O4O#=\ID LFV1NL,L D\ MN?SLBX9@T0 6G_7^8'B7_!1+]A/P5^R9\9/V7/$GPOB%X ^"7@WXL:(EJVN:5<2:YK&IW-]&TNH3QPPHL%E8[ M/F8JJJ&R>22?Z7_C]\(]#^.7[/WC7X7^(8?,LO$?@DVP4+^]BNETU6MY8V/2 M6*5!@KAE-1)OIO;Y[Q^5P/RK_P""G_[3%UXT_9?^#7@#X;7I77OVI+CPU8-] MED/VE=#U)(#J[1B-MX;,DJ#9@@+[YK]5OV8?@]I'P%^!7PY^%VCHS0^&_#6E M03W,C.\UW=2VL$ >1_PM[P@/J#>(V? MTQ7SE_P579E_9;_8M"NZ*?&G@$'RY)8F*F33<*3$Z$KTRK9''3FOJ+_@M=H6 MO>(_V7/"5CX=T/5=>O8_BOX2N)+/1[*:_N8[:*Y0RW#PPJSK#'GYY#\J]S7S MI_P5%\+>*=;_ &8_V-K+1?#6N:O>:;XQ\"2ZE::;IMQ=W.GQQOIOF27D42LT M")@[V< +@YZ44]GZ[?*_Z?@!X7_P6>\*^(?'7Q _X)T>#/">H/I/B7Q/Y^D: M3J2.8WLGN9-(2YN(Y1@K-'9F;R2"&WX.3BOKCXG?\$8OV:[;X%:[J'AV?Q1: M?&/0_"=YKJ_$A];OO[8OM>M+ WSO>L9O]7+-&P3"\+CITKYJ_P""P_A7XMZI MX[_X)]:E\)O#.LZKXL\.1W-[:S6VGW-Q96-[:'2[E;749H4/V-[I();9&=ER M9&'.*[KXG?\ !6[XM>(_AAK/P8\.?L@_%NQ_: U_0G\'71FTR=O"FFZK?0#3 MFO8YUAWM;$2-(CF0A%;)^5.-.=JR5M'Y>6^FOY[+;8,#X ?''QO\9O\ @BW^ MTBOC?5+K5]:^&?A_Q]\/H-9GED-_=V6A3+:VWG3%O,DE3:?WQ;)!SDX%87_! M)C_@GG\'_C?^S;X$^./QOBU/QGXU@O3!X)GO=7OGMO#>F:9MGLHXH/.",#*S M$J1U4YR#7NW@;]DCQU^S'_P2%^/?P\\5V;ZG\3?''@KQ9XU\1Z%IJ/?366L^ M)BETVCV@M^;JYB)V$Q@_,Q7&0:^E/^"1NA>)-&_X)^^!-%O],U3PWXB2SU:* M*SU6SDL[V"YDM]MLSP3*LB R$JG'>DY/HTM5T7]W6VOE\]>P'P3\9_P!G M']F71?VC_'7C7]OO]H[0O%F@3)!#X#^$NE:A>QRZ#I%JB0VT-];6USS,L,:Y M8*N>%Y-?%.E>*_V4/AW_ ,% ?V(]>?3?&FCR3:C%I+1,P. MR..[E=)59&Y/)QTP:N>&]0T+]G3]I'XZW'[;/[)GQ&^/WB7Q'XJO;KPIXMT_ M3[O4]._LY[MWLHK,S+)#Y2Q%$98@%!!!'%8'B[QCX@^(?[7O[,WQ6\$_L?>) M?@K\'/"_BZ"S@>W\*RV]_>M<2I$+G4OL]M'E K?ZQ\@#)[4-@? M/OVH?V*_!MIJU]I$GBB_FTU[C3;J:UF%O=7RQW)B:)EP7MVDCR03M/6OO6\_ MX)._LS^'O@3\7?!O@7P_=Z1XA^)?P[GTW4]=.H7ES>'O$GB/\ ;._8#UW0?#>N:IIMCJHN+V\L=+N;FWTJ M*XN0Z_VA-&I2UPF.9",9-?OQ!A+6Q 8USO3KEL8YQUZ5G.]HW MWM^B _$3_@F)^U6_AO\ 8C^)_A_XH7#1>+?V/#XK\/:]]LE)G_L31A<#PXTQ MD.\EE1(Y'_$KX ?M8_$#X+_ >62#PG M_P % W\-V=];1.4SJDES''XDBAB3B,!-S #=]*_J,_9[^#V@? /X+?#;X.> M%[?9I'@/PCI6CH64++/=0VT;W=Y*>LDLUQ)*7SE@,9/HQ''/6I$?=DF&!')8XP!GV]J6@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH ,XZT4Q^G\O\_2F@N>AZ>O?_P"O2;45>327G?[O5A\F_0EI-P]1 M^=)@[3N.3@]OY5$/IGGW_+BFG%I-NR:NK_Y?,5U=>?76ROW_ *_0FW#U'YT; MAZC\Z9A?[C?J?ZT87^ZWZ_XT!=;?Y^7^:^\?N'J/SHW#U'YTS"_W6_7_ !HP MO]UOU_QH"Z_KY?YK[Q^X>H_.C?05DW^EZ?JJ+#J&GV=_#&0T M0U*UCN K?WHED1D#>F?4<8K3P05..0>._P"E2GJ#@DYSW(^O/%%U:_3>]GM_ M7]:,##M-(TS2AG3=*L--+@AWLK*"W,@]3Y$:C![Y_P#K5=$1)1MVWR\XSE.O M.?FX/7T_"KQSC&#C/(R.GL,]\<8QTQ4;W;/X=#0VE\3LK)J3V=[ M:+K?5:6$W:,6DY9AW/A[0[Z;[5>Z'I5U=D[C=SV%K+. M,$,LWE>86# =6ZC-:J($V"!0/*'EHGR(@'0#& 0![=JL ;@ .,<]2![=/J:? ML!'S 'D\_P#U^.:-6DTG[R33:T_SZC>F_P!ZV,2^TG3M4_=ZEIUAJ"Q@-Y5] M:QW$:L".4:9&"D=F]:_(#]J3]FCXR^-_^"B7[-OQD\&>!S??"_P+IL$'B3Q! M#>VD%OIA0./*2RXFDV#'^I ST/ K]FBN1M+?+C&,#ITY/4_C3-F!M$FU1@JH M &.!W_/IFJM**UTV5];=.VNK\M_0/O^Y_U_7DS+OK*QU.$V][9VM];@(6BN M[:*Z3RR,,R).C[6!Z;0#5;^P=%:T2Q;1]*:SBE$D=C'80I;[ARDOV=X_)\]> MI8)G-;H3G)<'C' "G\P>H_.I.O5\\$9XSCKP>H(SR>OTHYG_ #;-=9>7EY_A M]Q]_W/R\BF P0H0ZQJJHBL$0^6 !M5 !A0,C:/H!TK*'A[0%G-VF@Z/]H+B1 M;D:=:B[##?F170[1P7EY_P!6%?\ JS\O\RC)!%-&TG^STX'Y-_>'MZ48QZ8YR-H _3I1;L[_?Z=5;J%_P"K/_+^OO,NRL;' M3D\JPLK:QM"Y,EO:0PVT?F$?*VV!47@G.2.!UIB:;8Q7]:C'& #D?F'?G/Y=/: MD[IMP*]HMQ:4DFF[6U2\[Z7UT,Z#3;*VN;BXM=-LK:]GPT M]W#;0I"XDM77@%696 M9<'JR8( SG%:6YN,Y(SG_'GZ<8Z>U.4C/"@$YSC@=".@XZ<=/6DFW;W6DUJW M9*+LG:79ZDN<>DK]K7U7=:;:[Z?R^ M+?AW*3"D\5\7?$4?\ !8/] MJWP?>? GQ%^R[\)?@'X7\7Q1:/XV\>:-J<<][J6DNT:7_FHCY0R1AFVQ;5+8 MXX%?TK,H VHI11G&WC'J1C[ON1C(ZTT%L*UA.*@W=/5-6W6W^:T M^>O2XQ5GP3DD=:]_=2VT$\M@#MNS_ Y'3/?M35/R!1PJ\!0.G)P!CM^E M/R>AR1@C&/7KSCC':HJ32LEWT M;VZE&VTW3]-:22QL+&R>?(N9;2VMX))'!W;I6B1'N)"6R68L23UZU<,;,3E( MW#+B7>/OH0<@I_%QU&/7O4NT!5"KQC&#U''7)Z'KSUSCK@4GEL !D8'KR?S( MSZ_G2>CBM^97NKZ;;_?^!4?>M;X?YNB,"+PWH4%PU[:Z%I,5T90_VB+3[:*X M#'K^\,0=B3R2&QVK9<'+$[0"H4[E#8&#\H094@@XQ@_X3[6/?ITY/'Z4;6SG M(S[\_P Q57;^VD_-N_3_ #0;>9SX\.:&)Q=QZ#HQO-V_SAI=L)PYY,JS>4&W M]\ELYS[5:CTC3X[LZ@FGV2WK EKZ.UA%Y-CCRWFV;U0=-N[@8XZUJ[&SG//^ M\U'EL>_8C ) P>N0.*'K;WT_5OK;_- 8^H:5I>J>6FIZ?8:C)& \!N[."[C6 M122$(=' "YP3U[\=Y#I&EAX9VT[3EN+)=EK.EI ILXF CLI/+S$@8'**0!S MQCIJ!",8VKCIM^7\\ 9_'KWH,9(P=I'. 1ED-[;),B-R1M#(PRI&1Q[]*O;&R3GKCN>W3C&*38V",\ M%MW)/7ZXSWZ=*B*T^*-WJ]>KMY>: S+C3+"[@CCN["SG2"026RW%M#.L)!R/ MLR,A$>!T(QC [U'/H^G3S+>OIML;V-!%%=26]N]Q;PKPJ12LA=4<9#1A@@'& MT"M@*RG((SC [X'3 R./PII4C )]>_\ GGT/7TIVT;33LKZ=M^ME^(:]$V^R MW_'0QK?1=&L[E[ZRTC3;>^E&VXNK6RMK>>7."51TC5F)Y+-G/4FIKVPM[VV- MEJ-K;ZE:NR^=;WL,5S;RIG<)'B8,#)&2%0X)##BM#G/U!&>X_P!W^Z>VXVJNTG9O57V3\ M_O*D$,-NB0P1K;V\6(8H88@D'E 8 1%7"D# XZ=AC%9][H&BZG+Y^I:-I=VP M7:KWUA%=S[%../-C,_*,G'UYX[]>?\BGDG/ )(QDY(/MR><> MV )]T1S%"8T48Q@KCCW MK4()Y*]NIP0?7..O/&3FHSD$\ 9]._U/7\*2D]6^:$4KN3TCTTWO?RMY;@E= MVNEI>[O;\KM^B/F3]JSQK^T/X ^%&I>*OV9OAQH'Q7^)=KJ-K;P>"_$E]-IV MGWUA,6$\Z7EK)%(K68"LB[\MN*MQQ7YW_P#!/G]E#]H>Z^._Q*_;8_;+TC2= M ^+OC:(Z/X6\!Z;-]NM?!NF%AYKVEWN9?)N(ML*Q [QMW..:_:G!#;QE>"." M0H!Z\#@4WYBX9N<H_.FX! ++RN0, CK_/\:3"_P!U MOU_QJ1W7]?+_ #7WC]P]1^=&X>H_.F87^ZWZ_P"-&%_NM^O^- 77]?+_ #7W MC]P]1^=&X>H_.F87^ZWZ_P"-&%_NM^O^- 77]?+_ #7WC]P]1^=&1ZBF87^X MWZ_XTX;M TT^O\ 6G^:'4F1ZBF,Q#$=@>G\Z;@GG(&2<9/O]*4G MR#[#MC^>:L47T;L]$FK+>[ MMIYE+7R]= HHHJK/^MU=)Z_UT8@HHHI %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%/^O4 S1GMW]*:V<9 M!Q[?_7J+G.<\^O\ G\J6[2MNQ-V5[-^BNR>DR/45&-QQSCZD\GU'^%-SDGC/ MMS_^LT7C=^\M%=^NUN][_P!:A=6C)NREM?\ 7[R;?E/'U M_7GBEPO]UOU_QH[>:3^]7'==[^GR_P T/W#U'YT;AZC\Z9A?[K?K_C1A?[K? MK_C0*Z_KY?YK[Q^X>H_.C!N M!R-S>GMGIFCOT[]/Z4@//T/ID=/0\'BI3O'GLU>]HM>\[=E^6HG.-TE*\G]E M)M_/3IU*5UI]M>QS6U]:07MO*5F-M<0QW%OO49)C657C5\9&2.G'%4['0=&L MIA[AB'M;"TMID"CG,L,:GD9_B]ZVE)&1S@G)&3@Y]N@YJ7.0<+P> MHZ?EWQ].OO5N3DETT3L^[M^.NURKJ[UM9)MV=M>E[;E-5:0J47 +DMO;#!1Z M-U89[Y(]ZR[S0]$OYFN-0T?2KVX!PLE]80W#@+PN'EC8CGT/!KH3E@1L.TC' M\.0.P[8_#'/:FD@GG/3;R,@J.H[].8:::[^4O\C-B M@2&)(K>!;:% N(K9$CMP!_=C4#' X 'TJ&]TC3-2A"ZKI]A?JC!HC=VT=T5Y M&,1S*XC(ZY 'M6J[+@8XP1CC@<<''4$=!^E,(SG/?J>A_/K4\Z]I*FU*+CKS M->Z]$]&KZZ_U<:5W9-7M>SNM--=5YK<_'K]M/]FWXP_$?]OK]@[XK^ / S:Q M\,/A-!XB7Q]KMK>65G;^&1=W*Z MMY@HDAE@6:V<8&UGBE5@21U &W/7GKH]C3P"B;?X2> M06/?DX/8>PX'TZ7>/\T=K]?\M_+] L__ ";E]7Y>1A+H.CV]O/:6^C:5#8S@ M"XBALK>**9O2[A2-5D7.,$J3Z5>C@2WAAAMHTM[:%3!';P1"*)8QQF%5 SS MC QTQ6AN/7"YQCJO([ ^O;KZ4FX]P.F!\PX'MSP?<8-%X_S1_'_(?)+M^*_S M,"X\/Z#=S_:;K0-(GN XW>CG&"H'MN].?;/J1C_ .N7C_-' M\?\ (7++:WY>7^9G66GV%A"8M.MK6QC=MS+:016Z;NI;RT10S^IQ].:8=*L! M=?;QI]L;Z48?4EMH5OW1#PKW 3>%P!QN]!BM3GKL3ZY!'X#MQSP?\: 6!RJ@ M<8^]D'\.G3G/7^=%X_S1^]_Y!RR[/^K?Y_GV*$]K#?0-#?6\%Q:,V&M;F))X MB4R!E&4QN&!^8L"<\]^8=/TK3--+G3=,T_3C(,3"RLH;0.GJ1;1QAB.,;N]: MN3_=!]MPQ^ YQZ\#_&E#,#D!<\6]M\K%?S6]N9P#P0DFSS0%QZY/MQ2?V7IS79OQI]J^HJI, M5^]O!]J5#U0SE/.$.!]POCDUK L,#:H"_=Y!P&Y_,GG\.*,MTV+M/!Y&2#[] M3D_Y-.\?YH_C_D+E?;^M/\_ZLS+N=.T^^C"ZC:6^HQ*P95NK6.<),3]^**5& M4*GWD8 '.<&OR4_X*/?LP_M5^.?$?PX^.O[(_C2\LO&'PSE87?PU?6;JQ\/> M*X.#Y=Y917"6$_F@>4Z7,4GEJW 7BOV!5L9. #C"G=GCOZ\=AZ=JCQAE8*JD M9R%( )/!+#^(D<9-"DNDDNV_^7X,?++L_P"O^'_JQ_-EX]U#_@L=^TOX-U+X M':O^RQ\)?@CH?C.SBT3Q?\2=+U*WEOS8RLJ7=V\08AA)'O;9 Q+< YS7[9? MLC?LZZ;^RU\ / ?P8TW46U6?P[8QMJ^J$%1=ZM=!9=2F13DB%KD,8@WS!3AJ M^G2Q(P>GIYF/SP1D=,#M0,4(Z+NXYXY&=5CD '80. ,_D#G@@=P<@]:3/&W QG.-P(S].F/\ M9^[[5-X_S1_'_(.27;\O\R-"[$[ FQEPN=R..S#YNO.>Q&/UQ'\.>'Y)Q=R: M'I1NM_F-=+IUH]V9.S>:8C)U&=V[GUS70%F)R0I/U';\>,=3_3K0&8?PJ.,' M!&<=<;N#[T7C_-'\?\A=XF\K=G/)^;K[YKHLM@C:H!&&^8'([C MMSCG/4?K2@L,8 X& 2P/'4@^N1SR?PXHYK;37WM?H'++L_ZM_G_5F9']G6/V MP:@-/L5U"9-C:A'! +U(P,JGG!-^P#CEOND9I;K3[#4;8V^I65K?VXR)_XZ#S[C)_#TXZ4H)_V!]B?L<_!+P?\5+3Q58:EI?BO6-;U MB32]2\$2R6XAM;W3HC+';W2RAVV).KE2@( ;!K](R,_W">V.OY^OMWIH0C. M<]SW..1D]\?P]CK+*3YKVLC,I>-MI 7' X_2P$9 M;)*8X) ..1G=SZ_=)&!GFF8P>0I.<_-@G) !()Y!([C^=/SA5 ./5L_@<]< M\\= :)3BW\2\M_+R\_EKV8:79:BGD:A96E[ I#)#=0I<1%QRKX=6 M 8$9!['D^H@GTRPO(;:*[TZSNH('"6T,]K#/'$ZXVN@*,$,1&%(QC';'&QN) M[#V 8#Z=/Z#_ I 6&?E !Z[6QGUQC&.>I')[]:5X_S1_'_(.678QY](L+IX M7N-,M+J:R;-H\\$%Q)$ZGF2W=TQ )Y'4COGJRM[**.UL;>VM;6,_):6UNL$,!YY58%5<>G'ISWJT0IZXZ8]L- MW^I_O=?>G_/@X[@9RV#CZ]>?Y@=\T1U5W[MUS)/=^G_!\NFHI)PE",OMOE4D MFTGIN[;.^YC7VAZ5J-PLVH:1IFHS(-D]K"P:VA>SMI([>=>=Z)Y9$9R/E*@8/ITK5Q]1@]1D>_7KSSW]:L? MP],D@9 &>0?;)SSSUHVW37R]/\ /^K,2L^JT=NO^1D3Z7IUS+#->:;9WTTG7]3$D:&SN;FV>.:#Y"Y$H=55E&#BO:3NS]TY//4#GI_GWX[ M9J-L @C@XP<'G'!QU_/UYSFA:_\ !T[=_4'IY^B>GKIYI+S/P0_9F_9J_:__ M &F_VPM%_; _;R^'NA?#*W^$VGC3?A3\+]&U-=6LH=>QM77$B]VSM=[I+=KRZ6V$TTGM?OI]Y*K 9/\_6G;AZBHN, M/K^OIVQQ2Y7^Z?S/^>M9\\>52N[-V3L[>M^PN9H_.C MH_.C*=F_Z7I^I2U5TUZ==;6T\R;..M%1#).&YQ_GMUIZ[N MEO/73IZ]AU%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 .'0_P"]'_Z&**!T/^]'_P"ABB@!O8?[J_\ H(HH[#_=7_T$ M44 %%%% !1110 4444 %%%% !1110 4QF/S8[ GMDXZ@ XR:?4##=(H^79NR M^>. I8D'C!&#SF@#/U+6M-T;3KO5]8O[;3=)L+>2YO=0O98[>UMX8E+2&268 MHJ[0.YY) &2:^%9/VNO&_P 6;O6])_97^&%YX[M=#OY-)N_'OB03:'X&^W1E ME?R;EA%=7T:$,1-:130MM)5B*Y+Q-)>?MJ?&?5_AYI>L7MI^SC\%]9MX_'ES MILDENWQ#\=V[%Y/"K7R[6?2-+D_S\)?#OPQY-K!H_A+ MPEH-F=L4$5O8:5I]A:H"2[91$1$&6=F+%BQR2: /AH>"/^"B6K;]1O/B;\'_ M ],Y\R+1=.M-0O;)5!M M=N-!U'XE#5;JVG>VGETBRNM2LXY('*LZ7-M#)&T8?<-V[&03T'/U3^S_ /M: M_ O]I[3KN]^$/CG3?$LMI$3?Z<'6*]AC*D(7LI LI*]&S'QWQQ0!V'P;^/WP M\^.?A\:WX(U7?=1N;;4=!O$>VU;3;R/(F@O-/G$=Q$86# NT00[?E8]:]HC< MD'=@;>IZ#CC"@>IZ9Z@U^?W[2'P8U3P+J2?M+? NQDT_QWX4Q=>,O#&FDVVG M^,M!0K)J'VNRBQ#)?00"2=9@-[8 YYKZY^%'Q#TOXK> O#OCS2@8H=;LX);F MS8_/:7@C7[1;,.N^&7*,#SD>N: /3L' /8C(_+/]:2CG R*_#7A"S34 MO%6NZ7X=TZ2=+:._U>\AL;5[EP62W6>=XT\UP"57=EL&NFD!"CWQ_+_]5?EO M_P %2M(M/$'@7]GWPWJL;S:1KW[0OA+3]5M5=E2ZLI+/4WD@E"$;D8HN03VK MY?C3B>CP9PMG?$^(HRKT?#7!XS$8-\'9G7Q&'Q%:E*<:CY M/W$I0;MK;X7TMKWW_3J?A9CI4:4WC::E649)--?%RVT?K^)^KX^.OP7(!_X6 MEX&^G_"1:;_\DT?\+U^"_P#T5+P/_P"%%IA_E"/\ PH=-_P#DBORC_P"&3O@!_P!"';_^!4__ ,51_P ,G? # M_H0[?_P*G_\ BJ?_ !6'\,O^B0S;_P '/_Y+3U#_ (A/C_\ H,C_ %\S]7/^ M%[?!?_HJ7@C_ ,*'3?\ Y(H_X7M\%_\ HJ7@C_PH=-_^2.__ .NORC_X9.^ M'_0AV_\ X%3_ /Q5'_#)WP _Z$.W_P# J?\ ^*H_XK#^&3_YI#-K_P#7Y_\ MR7_#A_Q"?'+5XR-KK]//_/S/U<_X7M\%_P#HJ7@C_P *'3?_ )([_P#ZZ:?C MM\&",?\ "TO! _[F'33_ .W-?E+_ ,,G? #_ *$.W_\ J?_ .*I_P#PR;\ M?^A!M/\ OY-_\73_ .*POAF_^:0S7_P:O*VG-;M]_F/_ (A5CO\ H-I_->G9 M>;_I7/U2;XZ_!=>?^%I^!^O_ $,.F\>A(^T]*JS?M"? R%O+G^+?@&*3/"OX MGTE3W&XJ;L$+[G'MG%?EM_PR9^S^6&? 5EU&%-Q.C-Z# ;IGOG.>E?GO;?LR M?!;6?VEOBGX>U3PBDNE:3H-E=6-@E]<[(6:Y56*J&X;&PIN;DM=K+?UMY>!G_ F,R/#4\7/%TW# MVBB]&U=*+M^.WRMLG_2='^T-\"9I1#!\7?A_-*0S+''XHTAF*KU;:+O.T=R/ MPS6BOQX^"I5P&[ K[ MWQV^F%PSX(\74N%.WEZGUO '@UF?'.35, MXH9C2HKZS*C[U/FNE%.R3EINGOM^']'7_"]?@NW3XI>!3CU\1Z5QG_MZ_P ^ MHH/QU^#/_14O O/_ %,>E_S^U?KW]!7\XZ_L^_"DY_XII5[\WEP,Y^CT']G_ M .% X_X1I.O'^ESGGU^]S]>OOS7X@_VE'!"7_)-YA9:_Q7V6O7?KU]-#[G_B M6;.WHLXP[;T2]BEO;KS:;VOK;7L?T;GXZ?!G_HJ7@8YQU\1Z4/4]KKKW]OQJ M)_CM\%P?^2I^!V..0/$6EG&.O_+R!@>O&3TK^R1.+N?(*0L>S<'=TR>G/>NW*OVC_ V/ MS# X%\/8]3S+%8? T9^U;A2G7J0IQ;3OWYNG?KO@E*I>'XL> I%#%"4\2Z2P!'5 M,#C_ (272_\ Y)]\>W2OX(?AIH5E-8>( M/.^T$P^*]>MX1]MN?EBBU&Y2-1E^,(H'IQV%>C'PWIN,$7 _[?+CTQ_>Z_TX M]Z_VGX+\",UXOX4R'B:AF2I4LZRW"9C1IMWE"&)I0JQ3OV4K/Y>I_D5Q_P#3 M5X5X#XOSWA'%9%C<3B,CQU? UJT*G+"=2C4]G*R6VL=_+MH?W,_\+Q^"W_15 M? O_ (4FE?\ R50/CC\%O^BJ>!?P\2:7_P#))K^&=/#.F'_GOQC_ )?+CGC_ M '^/\]>M*?#&F\?Z_DCI>7/'O_K/S'2OIU]&;.T],VI)V^U'39:=?R?;H?'K M]H)P:M^&\PV6U5]$O7S_ *3/[E_^%X_!7_HJG@7_ ,*72O\ Y)H_X7C\%?\ MHJG@7_PI=*_^2:_AG/AG3>.)ST.!=W ]?]OM_6C_ (1K3?[EQ_X&7'_Q55_Q M+/GO_0XP_3[/IY?K^;*_XJ"\&VTX;S%_]Q/3O;:_S/[F/^%Y?!7_ **KX%_\ M*72O_DFC_A>/P5_Z*KX%_P#"DTK_ .2:_AG'AK3?[MQ_X&7']6-)_P (UIN? MNW'_ (&7'K_O8_3].*G_ (EFSQ_\SBAOV?EKV?X>EV3_ ,5 ^#?^B;S'=?\ M+S?X-=_3^KW_ +F?^%X_!;_HJO@7_P *32O_ )*H_P"%X_!7_HJO@7_PI-*_ M^2:_AF/AK3?[MQ_X&7/]''^>]*?#6F_W;C_P,N/Z,*:^C+G?_0XH:O\ ^1[[ M?EIH'_%0/@W3_C&\PTM_R\?]W;7SZ^7FS^YC_A>7P5_Z*KX%_P#"ETK_ .2: M!\.5_YZK4 M=5%O5O=]-'\M3^Y<_'+X+_\ 14_ O7''B72N!ZG-UG\.U,7XY_!)-*[#PO+G!QQC&_U)SS44GAO342; N( MRJS'B\N.\>X;?G^F,?0USXOZ-N5 M\5? CJ79=R>)-)8!AU!/VKJ/_K4C_'KX+0*SR?%;P(JIPS'Q+I(')!'6ZZX_ MK7\/W[.7@O0=>\ RW>JQW5U=#7]33>U[<\HEU,$4;G[*-O;@8/:NA^./@+PY MI?PR\67]A;7-M=0Z?/-!.EU.S(Z(1Q^\X.>6U M\3CZ6=K*I8F#M!U/;>QE4UU5VF]]'WZ?[+9#]'7-<:-2C&O"G>RN^5\KO:^EMS^V2/X]_!1PK#XK^ 61QE6'BC1BO3/)%Y MZ=L]C3S\>?@H1S\5O /(_P"AFTC\^;OGZ8'UK_(\USXH?$:VUC4+6'QKXCA@ M@NYEBBAU2\141'( _P!=QTQQG'2LP_%OXG#Y?^$Z\2?7^V+WUSP?,Z_E7]Y8 M/PPQ.-PE"O#%QA3Q%"E5]BU:454C&7+=+=7MTZ?+^',3XF8' XRMA*N$J3J8 M:O4H^UB_=ER2<>9*W5+5]+'^N;_POKX)*VP_%;P%O.3M7Q-I!? ]5%YGZ9QQ M[U*WQV^"Z+O/Q3\"@MH[*Y98KO4;J4KY8&W.Z4],Y&>_3TK]J1\-?""R%/[.G*LP*@W=PVU6)! MZN /S^E?Q;XT>/.2^#?'%3@O'Y?BL9B:=.A4YH2]U^VDUZ)7CVWU\G_97@SX M%YMXP<#TN-<#FL,)AY3K*5*2NK4XQE:2N[Z63OH?V$0_'[X)REU7XK^ F:,[ M74>)M(W1MQA6_P!+)W8/.1QQZU8'QV^# &/^%I^!2>N?^$ETLC'_ (%?I7^> M_/HUM'\1/B59QSZC';67B>2"WC35;N)4C,,>U0 _ !SV^E;']BP@\WFK=^!J MMV /;[_(^O3WK^J.#.&9\6\-93Q!AJBPD,WP]/$T\-4UDHU(Q=O+1_+YH_RT M\:?IB9-X/>(O%?AYCN',1CL3P[F5; RQ=.M[*-=TE&[BDOM7T>E]KL_T"1\= MO@LWP6_Z*EX&_P#"ETH]_P#KY_\ U]>E M?Y^O]BQ?\_FK9_["MV><\_Q=Z3^Q8N][JWX:K=^ONQKZ>/AIB].?&4X/K&6Z M7GZK7N?E;_:)\,?]$?C8;>[+$2D]E=WY5?77;8_T"_\ A>WP6_Z*EX&_\*72 MCW_Z^?\ ]?7I1_PO;X+<_P#%TO W?_F9=*_^2>?PZ]J_S]/[%B_Y_=6QS_S% M;O/_ *$10=%A[7NK=^NJW?X?Q?X_C3_XAIB;?[]2O?MZ6Z>O](/^*B?#'_1( MXO\ \'2_R/\ 0+_X7M\%N?\ BZ7@;O\ \S+I7_R3S^'7M1_PO;X+?]%2\#?^ M%+I1[?\ 7S_^OIUK_/T.BP]KW5N_75;O_P"*_P ^_8_L6'_G]U;//35;O'3C MJWK_ )-+_B&F)_Z#J73]/+K^'R%_Q43X8_Z)+&?^#GY>7K_5C_0+_P"%[?!; M_HJ7@;_PI=)]/^OG_/3K1_PO;X+?]%2\#?\ A2Z5Z?\ 7S_GIUK_ #]/[%B[ MWNK?AJMW_5C_ )_*C^Q8?^?W5L?]A6[ST_WL=?;_ H_XAIB?^@ZEOVWV\OQ M_P @7[1/AC_HD<9_X.?EY?UKY'^@7_PO;X+?]%2\#?\ A2Z4.W_7S_\ JZ=: M/^%[?!;_ **EX&_\*72AV_Z^?_U=.M?Y^G]BP]KW5NW75;OTYZ,/\^G2C^Q8 M?^?W5L\==5N\=.>C>O\ D4_^(:8C7_;Z6R^_2_3U#_BHGPQ_T2.,_P#!S_K_ M (;TO_H%_P#"]O@MQ_Q=+P-V_P"9ETK_ .2>/QZ=Z:?CO\%._P 4_ OL#XDT MK/U'^E=./\:_S]AHL/>]U;MTU6[_ !_B_P /PIIT6+G%WJ;,J2?>U:\R"4.# MMW 8X]R>V.*SJ>&]:G3E*>-C**BVU!:RLK\NVE[6]7Y'1A?VAO#.(Q%&BN$L M8G5JPI\WMW://*,>9W6ROK_D?Z :?'GX)S;_ "_BMX$)1S$2OB322-RX8C*W M1' /Y4X?'7X+YQ_PM/P-_P"%'I?''M=?YS7\<7[ _P ,O!?C/X8^(]1\4:7/ MJ]_!XMO[:.XN+VY?9$F,+N9R>@& /3TK[I_X4'\*/^A53_P+G]/][\/_ *W- M?Y>^*WTZN$O"GCKB'@7'\.8O$XCA_,)9=/$J=XRJ0LW-V>WO?+\_]?\ PR\( M$H9_@&G%U)1A4M+EO>SMM\S^CD?'7X+*./BEX&_\ M*/2_I_S\D]?KZ^U+_P +T^"^21\5? O(!P/$6F'IQU^T?IC/?O7\Y(_9_P#A M/P?^$73_ ,"[@?\ LQH/[/WPH/\ S+07T"W<_KG)^;D_IWK\X7[2C@:+N^&\ M6]7>U>7E?3?77IY'Z"OHR9[H_P"UZ">CUCWY;Z;?\-ZG]' ^.GP8'7XJ>!?Q M\1:8/U^TX_\ UU2N?C]\#[96DN/BSX!A12H)E\2Z3'DO]U5+78!/XY./I7\Z M;?L^_"8C'_"-'G@XN[@GKV&__/M7SG^T1\$/AG:6WPVM+70!'%J?Q#T6QOB+ MF=)+BTE=P\!(<$C'&,D]_K]IX?\ T^.#O$'BO*>%,)P_B:-;-,32P\)SGSI2 MG4CJW?STLNW1V?B\0_1[SC(E8Y[9 M6YP2.OX\5_,S^T-^RC\"/#'P5\;:YH/@M['4[#089;.Z^VW(-ON>PK[>^'/[*_P !KSP!X)O+KP)9SSW?A;1+BXD:>8M+<2Z? \LS'=RS MMGKSW^OZ+]*OZ7/#/T7,%PUC\_R7%YE#B*52CAU0FDZ7)>6ZM:RA;IUZ'Y+P MUPGB>(JN)H0Q-*E+#14Y12^*\HJRMVO?=WU\C]CQ\=/@QC)^*7@8?]S)I?\ M\D_T^F:3_A>WP7_Z*EX(_P#"ATW_ .2/Q_\ K\5^4O\ PR?^S]_T3ZQ'TGF_ M^*IO_#)WP _Z$.W_ / J?_XJOXL7[8;PRT2X0S;_ ,'/RM]K3^ET/K/^(3X_ M_H,C^/;S:]/D?JW_ ,+V^"__ $5+P1_X4.F__)'X_P#UZ7_A>WP7_P"BI>"/ M_"ATW_Y(K\H_^&3O@!_T(=O_ .!4_P#\51_PR=\ /^A#M_\ P*G_ /BJ/^*P M_AE_T2&;?^#GY?WM/7_@A_Q"?'_]!D?Z^9^KG_"]O@O_ -%2\#_^%#IO_P D M=_\ ]>*7_A>OP7_Z*EX&_P#"BTS_ .2:_*+_ (9.^ '_ $(=O_X%3_\ Q5'_ M R9\ ?^A!M_^_LO_P !L_]C'IG_P DG^=?E(/V M3?@!W\ 6Q[C]]+GZ<.?UIC?LH_L_C&/ %H.?XI9>1W_C_P \4?\ %83PRW7! MV:M[I>U?EV;?ZZ^@O^(3X_6^-@K;[]D^K2Z_@?JRWQS^"Y8_\73\#<8S_P 5 M'I?IQ_R\\Y^M(?CI\%@NX_%'P.O;GQ%IO/\ Y,_0\>M?E1_PR?\ # /_" 6 M0],RS#GV^;OS_P#7I#^R=\ ,9_X5]9R+D$_Z7/P0V!QGL../?TJG^V \-XQK M1GP=FB;E345*J[KF<5?6[TOVLM+Z7*?A5C81YGC(/:R^2=[VWW_X<_6K1/BK M\,O$FIP:1X>\?>%-;U:Z!^SZ;IFM6%W>2A068I!%.\C $G"GO\ AZ0&#F[L3Z<\Y[4I:^\]$^EDEMTO:YY$7=7^\****!A1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11119O:^FK .O!I MF%(( ]CU_GUI6^Z:B&>@.,_Y%%[;64FK11C#8ST[]:YA/CM\%VR3\4O YP0 MWP7Z#XI>!B<9_Y&/3/Y_::_*3_AD[X _] M"';'V:YG8?ENJ2']DWX M)'GP#8_? QYTWT/5LXS_DUK0_:_>&6+KT**X.S) MN5:G3C*5=^Y*M*,8R:UT3:>_W6%+PJQU*$ZKQD&H1;Y6KMM>K:M\K]C]1)/V MAO@1&TB/\7OA^LB,%93XGTD'. 3UNAC&><@>@I;?]H3X%73M';?%SP!<.B[R MD7B?27(7.TDJ+O(QWR.W3T_EZ^"/[-?P<\7?$SX^6OB#PN]_;Z%XZGL=-@6Z MN1'9V@1V2.,!\8)&,#G\>1Y5>? OX8:%^VWKW@O3/#S6?AF/X?VM\NFK>W.P M7;R)ND*;^&9LG) Z?G_IIF/BUE>7^%,?%&K@ZN(P,LIIYS#!PFU5A2GAXUDI M-QULK[>=G>Q\;E/#F*S+B/"Y!&I1I5,365%5W%.S;4;;7NV^G=^1_72/CM\% MCD#XH^!LJ=H/_"1Z7R>F>;D=_P#/2G?\+S^#7_15/ WOGQ)I7'3I_I/.>U?S MC#X _"2.?\*_B. M?[23@:"2J<-XQMS3TKRVE-02MK=?\.K:'[T_HRYW[U/^V*',I0;M%VY9?P9YS\5O O/3_BI-*Y]SFY_SZTQ_CM\%T&?^%I^!FWI2^C'GB5_[8P]EV6^W5>:L] M/^#_ $6R?'[X(PQ[YOBOX$BZ@!O$>EC.._\ Q\@ 9]_?/-+'\>_@E)&)$^+' M@)U*Y#+XFTE@><8!6Z(R.^2/6OYH_'GP"^%$?@WQ1=)X7C2>VT#59H)!=7!, MOY-O%GBKQ98^)M?M+'Q/KMI9V>JWD-M9VNIW<421).X M50BR=, 8YZ#%?VE]%+QFRGZ4E?.:62X6>4_V/2A4K1K2YW6_7_2_RQ3A\>/@J?^:J^ >O_0T:/G\OM?Z\5_E9'QEXR;+?\)7X MB ;!Q_:MWWYQS*/<\TW_ (3+QD!D>*_$>>G&J76>W_3;_/XU_:R\%\9*'/'' M4[\\&EY275Z62=[]+]+L_DZ/TG >Q_Y&?2.F,G_ )>_RH_X7U\$^/\ BZ_@+M_S,VD__)G'X].]?Y6' M_":>,_\ H:O$O_@TNO\ X_3O^$T\:?\ 0V>(O_!E=?\ Q_\ _5WJ_P#B"^8? M]!U/IT]/+U^_Y*O^)G,E_P"A16Z=?3_+]--+?ZIG_"^O@D?^:K> CT'/B72? MQ_Y>_P#]7>D'QY^"1&?^%J^ .W3Q-I'K@_\ +WZ?_7XK_*U_X3/QGC_D;?$/ M\/74KOOU'^OXQ],XH'C3QGW\6^(>W_,2N_7G_EN/_P!7I1_Q!C,/^@V&ZZ>G MEZW^>W1?\3/9(M/['KZ67\9Q[=%%I=?ZW_U2O^%\_!+./^%J^ /_ IM(_O8 M_P"?OT_7VH/QZ^"0S_Q=;P!TS_R,VD>N/^?OT_7VK_*U_P"$T\9Y_P"1L\0X M_P"PE=_WL?\ /?\ KTYZ\TA\:>-.?^*L\0_^#*[]?^N_7^G-/_B#&8?]!M/= M?IK_ %V%_P 3/9)I_P (];_P?+_Y$_U2S\>?@D!G_A:O@#OU\3:1ZX'_ "]^ MG_UN*7_A?/P2_P"BJ^ >_P#S,VD=NG_+W_\ K[5_E:'QIXSQ_P C9XA[_P#, M2N_7_KO^7M1_PF?C/_H;?$/1O^8E=]CQ_P M_P OZT?\08S#_H-I_P!6_K^M M#_B9[)-/^$>OO_S_ 'Y>7F_NT/\ 5*_X7S\$N?\ BZO@#C/_ #,VD=L8_P"7 MO\\?A1_POKX)?]%6\ =6'_(S:1V''_+W^?Z5_E:_\)IXSY_XJSQ#W_YB5W[= M/W_Y?C2?\)IXT_Z&SQ#W_P"8E=__ !_\O7O1_P 08S#_ *#:?W;>0?\ $SV2 M?]">M_X/E_\ (G^J9_POGX)@D#XK> 1_W,VD>G&3]KQU_P YI?\ A?/P4[?% M;P#^/B?2/3_K[]?TK_*R/C3QF/\ F;/$1Y[:G=CH,]YSU/\ +TH/C3QECGQ7 MXCQ_V$[K_P".U/\ Q!C,/^@VGM?;TT>FG_#_ "E_2?R6_P#R)Z__ (&Y?R]? MOM_P-/\ 5._X7Q\%?^BK^ /_ J-']/^OSU_2@?'CX*Y_P"2K> >?3Q1H_IS M_P OGKT]17^5=_PF?C#_ *&OQ%_X-+O_ ./4X>,O%Y QXL\1YS_T%+KCK_TU M]O6G_P 07S'_ *#J?GIZ>7K_ %LX_2>R5Z?V16V[OR]>W]61_JG?\+Z^"F<' MXK> 1ZG_ (2C2/R ^U^OK1_POKX)_P#15_ 7;_F9M)_^3/\ ]7?K7^5B/&GC M3)QXL\1CTSJ=V1TYZS=?3I2_\)IXT_Z&SQ#_ .#*Z[_]MO\ ]5'_ !!?,/\ MH.I].B?9]EYK]"_^)G,E_P"A17MIU]+]/+3_ (:W^J9_POGX)?\ 15? /;_F M9M([GG_E[_\ U=Z0?'GX)$9_X6KX [=/$VD>N#_R]^G_ -?BO\K;_A,_&?\ MT-OB'M_S$KSN>?\ EX[=_P"E(/&GC/'_ "-GB'M_S$KOU_Z[_G[4?\08S#_H M-ANNGI?IZ_\ Z3_ ,3/9)_T)Z_3_E_+R_N_UY]?]4H?'KX)''_%UO '3/\ MR,VD>N/^?OT_7VH_X7S\$LX_X6KX _\ "FTC/WL?\_?I^O/2O\K0>-/&G'_% M6>(?_!E=^O\ UWZ_TYI?^$T\9Y_Y&SQ#C_L)7?\ >Q_SW_KTYZ\T_P#B#&8? M]!M/?M^/]=@_XF>R3_H3UO\ P?+_ .1/]4H_'GX) 9_X6KX []?$VD>N!_R] M^G_UN*#\>?@IV^*G@$\\_P#%3:1QDX'_ "]C\:_RM3XT\9]O%OB'O_S$KOUX M_P"6Y_\ U>M(?&GC,?\ ,U^(C]-3NL#D^LQ__5CBC_B#&8?]!M/[O3I_7^1_ MQ,]DFG_"/7WUM7>VGEYORTW/]4P?'CX*?]%5^'_ S_R,^D#'O_Q]TH^//P6. M?^+K> .!G_D9](_^2Z_RLCXS\8');Q7XBST'_$TN_P"DWY?CU[-_X33Q?_T- M?B+_ ,&EW_\ 'NW_ .NC_B#&8?\ 0;3^XG_B9_)-/^$?$^?[YZWM_=_J_D?Z MIY^//P4SQ\5O /?_ )F?2.>PZ7?KQ2GX\?!0=?BMX"Z_]#/I![9[7G^>G6O\ MK#_A,_&7&/%?B,#T&J7?U_Y[?SSZ4O\ PF?C,=/%GB/\=4NC_P"UO\].M+_B M#&/ZXZFN^VFWE_5].EK7TGUG'KUT]/EI;_5-_X7U\$\?\E6 M\!?^%-I/IZ?;/\].M-'QY^"6W_,2N_0_]-Q^/O0O!C,/^@ZFU M;?3RZ?C\P_XF=R1+7**__@QP[+HM?ZTZ'^J4/CS\$LX_X6KX [?\S-I'<9_Y M^_7_ .OS1_POCX*'@?%7P#T'_,S:0.<^]WCVY]>:_P K4>-/&>>?%GB'M_S$ MKOT_Z[C\?>D;QGXS.!_PEGB$]#_R$[P>N>?./^>@I2\&,R46XXVES;QOJKZ> MG];]A?\ $SV2?]";$/;15FV]KV5M>OW:^?\ JE-\=O@IG!^*G@+\/$^CM?TD?L#?"KP1XU_9WTC7O$VF2ZKJE7Q"P[C1:2@FXW:ZMK7YZ6 MV/Z&^C[G]/QYSC&9)EL?[-JX*DJ]ZRF#&#[7/O_P#JIP^.GP8/W?BKX%QVQXBTOI]3<]?_ -=?SC_\*!^% M.,?\(Q]2;J?)[9.6]#^/?IPI_9_^%(P/^$9!R,X^U38Q[X?]*_S_ )_M*^!% M-K_5O':..GM6ND7MII?MV\V?V&OHRYXO^9SAY:WNHM7V=U?_ ("T/Z./^%Y? M!G_HJO@7_P *+2__ ))J)_CK\%0N_P#X6EX'X^]CQ'IA)//7Z[!P0NZZ&XYXXX^G6HQ^T3\!N_Q@^'JMN M/BG1R<]NEYTR1_D&OY+/C=\$OAI'\=?V6?#BZ ?[&\3^,[NQUVT-YZ_-,_J.3X[_!ALC_ (6EX'R# MT_X2+2\X(!!'^E8(.<@C.:D_X7I\&.O_ M/P-]/^$CTS/\ Z4\5^0/A+]E3 MX#7/A3PO=W/@2VEN)O#FBW,\YFF)FEETVV>1BV_DLQ)/7KGJ#71#]D[X ?P^ M ++G'6:;/X_-ZFO\[,]_:W>'>0YUFV28GA+,'/+,9B,"VJFO-AIN$F[=^73; MIJ?1TO"W&U<-3K+&T_?2>UM-.NOR[Z]#]6_^%Z_!?K_PM'P/UQ_R,6F'^5R3 M2?\ "]O@O_T5+P1_X4.F_P#R1^/_ ->ORE/[)WP!S@^ K0?[MQ,I_,-2?\,G M? #_ *$.W_\ J?_ .*KQH_MAO#)*/\ QB.:N\8MVK-6;2NG[VC]?^ M?^(3 MX_3_ &V#T6JVV]?^'/U<_P"%[?!?_HJ7@C_PH=-_^2*/^%[?!?\ Z*EX'_\ M"ATW_P"2._\ ^O%?E'_PR=\ /^A#M_\ P*G_ /BJ/^&3O@!_T(=O_P"!4_\ M\53_ .*P_AE_T2&;?^#7Y?WM/7K]X?\ $)\?_P!!D?Z^?]?G^KG_ O;X+_] M%2\$?^%#IO\ \D=__P!=)_PO;X+_ /14O!'_ (4.F_\ R1W_ /UXK\I/^&3O M@!_T(=O_ .!4_P#\51_PR=\ /^A#M_\ P*G_ /BJ7_%8;PR_Z)#-M_\ GZ__ M )(/^(3X_P#Z#(_U\S]7O^%Y_!C_ **EX&QZ_P#"2:7^O^DYI/\ A>GP7_Z* MGX&_\*/3#_*Y_P _2ORD_P"&3_V??^B?6/U,\WYGYJ:?V4/V?@?X?=^K M3_'7X+!6S\4_ W_A1:9_\D_GT[_6MCPY\3_A]XMO6TSPQXT\.Z[J*1&9K'2] M6LKVY2$' D:*":1@IZCCI7Y&_P##)_[/Y&?^$"M>G.V67OQUW]N^*\K_ &9O M ?AGX-FVJ3Z#I7] _1R_:#\$ M?2'XZAP/DW#V-RW%U,-.M'$5IMV:3LKI[>[?\+GB9YP+B<]Q_GO4H__5[BH67'(]N.H'/7. ?:IJ_T023<%)/VD(.7 M,GHUS?O3V5GLK?HE_P0HHHJP"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH <.A_WH__ $,44#H?]Z/_ -#%% #>P_W5_P#0111V'^ZO_H(H MH **** "BBB@ HHHH **** "BBB@ KS?XL^*8/!GPU\?>*;F3R(]%\+:Q.LV M<&.XDLI8+1P?47,D0Z]R>,5Z17C7Q\\*_P#"<_!KXF^%A-]G?4_"FJ-'-@G# MV,#:@H(ZG?\ 9M@],YH \T_8R\'6G@_]GCP&\5JD.K>++>X\8^(9<#=J'B#7 MYGN+W4IGQDF;:A8L3SC%?F%_P6D^+GC>=_V<_P!D;X=Z[T,D,UM(>TX**73AE[\XK\8?^"OEA/\)?VN/V#OVIY[:2;PMX*^($>G>) M7:,O:V1:9(;"65VS'$)S*Y9S@809/&:TI]?E^H'Z=? O_@GI^RK\&?A]HWA" M'X2>$_$6H6^DV46MZKXCTV'5=1OK\V\;7DGVBY5W0/.TC<'<..>17S#JW_!- MW5OA;^UIX*^/_P"RKK5E\.?#CNP^)7@J-F&CZI92."T=K;Y$2/@-PH[^U?K? MHFN:=XIT72/$>ASV^H:7K5C::G8W=I-'-!+%=P1SJ?-C+!VPX3!QC;@X/3Y% M_:,_;A^%_P"S=\0?AC\,/$5O=>(O&?Q.U1=-TO1=!G2>]TYI'6-9;ZVC#NL+ M$C+/@ <]#@ISE=JUEIK>^MNVRL!]F36L%W:RV=PH>"]MWM;A!@PF.YB,=Q#@ MYR'5F'/K7P5^Q5<:AX7\4_';X07\LD]CX,\:W6J:(6&(X-,U:66YAA0=A'YB MJ!QP*^]K:5)(K>X:.6$3PPW3A_D, DC$Q\S.?]62$%Y(NS#=$ILUT _0D @P[4ZD 4444 %%%% !1110 4444 %%%% !1110 Q\X]L\ M_P"?\]J_,K_@I>&7P_\ LT$8P?VC_!QY[?Z#JM?IJ_3\?Z&OS%_X*7D_\(_^ MS5SM _:0\(98CY JV.J9#$D8)."#FOR'Q[A*IX/\?0BI.4^'*Q-*^MOMKK9V\]#6,>]_F;'"?,3T&%^GO["OS6^(/[2GQ[T M/]NGP5\"=$\%"7X8Z[8VEQ<:EY1,K6VTF_U5;CH$LEVNPZ#//)K]*2K'8_R M$?,K2QAMNU>,9]L_3CWKY3\3E5_;&^%3&.-A_P *Y\:D-MB)9&LX-PR3N&,9 M/S IU&,U_P E7A;EV&H\3>)$L_X4GGM"&2\03PJQ^$K_ .RXN$\1[/$8=I)2 MKKE3I+6+DU>+O<_I_,FYTLOE#$M4E.CSJ-5=X:/=;;]++U/JV15WNJYVAV"G MN0&X/_ NOXTBC)X XYP>GZ40H4 ^>*0<[76=""OMSS@<=\8J3:Y;C9C&#B2, M_F"P^E?SO6RO,JE6I*GE.+C3G4E*$?JN(7+&4KQ5G3TLI+^KGLPK)V2FK)63 M=17>VK^7R\]6(00.B?K]I#$?09_WXP/\ T(TGE'T' M_?V/_&L?[)S:ZME6,Z?\PM;^[;['I]_9&BG"VM5?*JO[OGY_U?5F[_97\O\ MZ]*#GLOY?YYIWE'T'_?V/_&CRCZ#_O['_C1_9.;VM_96,UM_S"UO[O\ =]/O M\A\]/_GZNG_+Y?W?/S^?S$Y]$_ST_/M36;/;' '^?2G^4?0?]_8_\:-C#ILY M[F2,_E\PI?V3FU[_ -E8S6W_ #"5K=/[FE[K[[!SP_Y^+I_R^7E_7GKWUC4< MJV#RX'L0/X?7/.:_$[]I'XB_$?X7_%GX^>*?A=X??Q%XC@T'342RBB,K1PFY MC:5F &=JKNSZ^U?MBQD+)@Q[0P/WX^O8 EN#G&#5/F4FM4]=?NZ;GQ;X M4\?:U\2_BI\ O&7B2W@M/$&I>#=475K.)?\ CTNH[@JT+KR4?AN#@]_2ON;K MG&1W^@_SZU\+:WX%F^%W[:?AN$:K"/"'B#1M0OM'LIKF/9:ZG<3.\MM:MPJ1 M+O)6)1AB 1FONL;@6W.N1DERR88'D9 ;Y6/U.,5_2'[1/+,96\9\+B]V+'U(]>:E/(YR?3V]ATJ-<\L6C&X [3(@Q_X]_%R>:DR/[\? M_?R/_P"*K_/W^SK8*X&G M7K'YUZ&!@"IW9P?<9]*^@X6RS'QXCX=O@\;&E//,KI*V M>K+^8_GG'X?C7_?%X#5F1QV],^OH*;A">&0CCNHZ^V<\^_/IBOUIXF@Y7A*DY)?:G&UO=\[ MW6GS^=_PUX#&VUIXFVG_ ##U6]XK\FWOVWOJF4]/T_ST_P#U493T'Y?YZ?\ MZLTNU?5?^^E_J3^G/O1M7U7_ +['^-/ZQ#_J'MI]N'EY^6GHB?J&*_Y]XGI? M_9ZOE?\ 7S_1,IZ?I1E/3]/\_7_Z_%+M7U7_ +Z4?R(%&U?5?^^E_P <_K[] M>:/K$=/]WZ7]^/EMKY?@@6 Q7_/O$[_] ]7R_P"#O;_)NY/3]!_GW_\ KTN4 M]/TI=J^J_P#?2G^9/^'MFC:OJO\ WTI_F2*:Q$/^H??_ )^1VT\_+RZ?)K+\ M4[?N\3KI_NU7^[_F_/\ $3*>@_+_ #U__7BFDIZ'\,4_:O\ L_\ ?8_^*I< M="O/^T/PZ'CZ_G2]LIV494(M.,KJ<6URRB]-5T33\AQR_%MV5'$R?\OU:IK9 M+36^OX_.Y'\F00#D>_'X\U',X(_$U7F M93!-DQJ C-N+ _+LQP!SU''3\*\W-<7AY99F48N#A# 8UM*47S5)8>I97OO= MJWJK(]_AC!8NGQ'D:HXRES/+Z2LH.7,KM;?AH?R=>)!_P 3W5<$ BZN#[\2G@X[X^N: MP@_!#?\ UN>./3UZ_P"%:_B0XUW5W(8 WLZA ISQ(V.<!H74VI\\W3@UJ[6LOUL?\^G$%*NL\ MQ]"$>1T\974*WLG!33J.^NO-\GI:W4_5G_@EN?\ BXNIX'!L[T<]?NKT_P#K M?RK]\01R#TYQ_O9;^H]NV#D<_@?_ ,$M6'_"Q-48$9%A>'9_$"0G8X]P/;GG MBOWN/S;BI"A6!)8A6XR2,;ADGU_3GG_!7Z>>%K5_'M2HPK2M0P4G5HIRA.*J M+FBM&G;LGUT9_NM]!?$4Z?@+!3KQPTHU,=S\[47/]U3V3:MMO_P#\S;H*?B= M\60!D?\ "5/W_P"F$7?_ #Q@=JV5. Q^G%8$[L/B?\5\@[9?$SLO'W'$4>2Q MSR !VQD'/%;@8#@,O(R>1T_S_AUK_8GP+E)>&7"D*LH>SIY/A+N;49P:IPT: MTL_)OKKW7_(K]/##5JOTG_%25*G4FL1Q%7E3FJ4W&I&Z]Z,TFK7^?1L4]2?< MTE&X' )48'J/U/M_GFC(_O+^?^?_ *W?!K];C6A)7YJITY?+II]SW"BDR/4?G2Y'J/S_Q_K1[6'>G]Z_S#ZEC M-/\ 9L;_ .$]3^[;IZ:=?S**,C^\OY_Y_P ^U&1UR/IG_/\ CWZ4>UAWI_>O M\P6"QFG^S8WI_P P]3^[Y>GW?>44F1ZC\Z7(]1^?^']*/:Q[T_P_S&L#C?\ MH%QO3_F'J?W?+R7W/RN4C8VL>^R3 Z?P'GW_ ,]J7('G]?K7YX_\ !. %OA#XK&4#_P#"<:F4#.J$J0#DJ3STX]..M?H>(V[E/PEC MX^G//Y5_R(_3(P>.G](?Q%GA\OK5X5N)*LI3Y*CC.G-4XR<9*+32L]8O[K'_ M &V_1,K4J?@'X94:U6$?9\-X*T>9*4)\B34DVMMM>GWC=WS9.?P!_3^>*FS] M?R/^%-"D'_EF?^VD?Y_>_IFI NX9WQCL1YJ?T;_/2OY9>59@F_\ 8\:O>LDL M/5M:Z=M8]$_3Y']).M1;_P!YPVKZU(=UO[WI]_F-)^H]P#QS_C^?TKYC_:4D M C^%CZ'?0VGB/6/&^D6NBDR+YJ74DIC,NW=EL([[FX]>V*_?/HQ M95F3\:N!Y/!XMT:6<8.I7E["I'V=+VL%*;O%Z):N]M5W/SWQ1Q%&/ ^?\N+I M.H\!4Y*=.I&\FE?9-N^W_#GF/BW]H;XU_$:Y_:"\#ZUX5CB^&NB:%+%I_B)+ M=A 6ADM%$4<_W7)XY!.2>W;]Y/AF1_PKGP&!D#_A$=!VJ>FP:;; ,,=-W?Z" MOSD^+'@:/X?_ +)?C'P^HC?4(O"T;ZK>H(#/=W4DEI)+))(/WC@LY^4G...U M?HU\+T)^&W@ @QX_X0_P^H_>1[L#3;+Q4FXTIS<;PK))J$796:ZZ=3^*O"J5&%;'RJ-QE.G"W-)+FE>%^NO?I M:W8[BES]/R'^%2+$3G)7CTDC_P#BJ/+XSV_WX_\ XJO\!_[*S9?\RS&?^$E7 M2[7]Q7?3[OE^T^UH?S1^4U_\E_2]1F[V4_A_ABC=_LK^7_UZ?Y1]!_W\C_QH M\H^@_P"_L?\ C3_LK-W;_A*QG3_F%K:_"_Y/3[_(KFI]*JL[?\O5M[OGY_U< M9G/\(_ 4VI?*/H/^_L?^-)Y9_P E/_BZ%E.;>#7W7AQE-6/&G#']J9%6QV _M3"?6\ M'B,-65+$T/:P]I1J?NW[DXJS\F['#BZB>'JQA5A&4J:;TW/G; M]AKXN_$OXY_L_P"C>/OBIH7]A>(;^[D2VCV[/M]HK,PNH5ZI&"-FWDG^?V*/ MNALX.1QZV66U''!4(UL1>3;5_:1NWI=]=>Z\K'Q_K /_#Q M/]E8$]8=:Y'8?9+O /\ +G\J_>0=6_WV_G7X,:N[?\/%/V51@'-OK1&UE<9% MK=;AE21CT_+DU^\Y(W=<9)PI&#G.3SDYSGC^G?\ ZCOV=U.O2^C#P33J4IT\ M3"%:WM(.$I0=1:N,M=N:Z[VMI8_G'CJ:?$6.4'S14X+FOS7TBWK\_D+1117] MTIWY^;XE**OTUA%Z=+;_ *GQ]];>OX6_S"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :WW3_GO3 M4'4_H/Z_6GMT/T-0'." 2"1Q@9[\\<9X]^.O-&_7E_O=O/Y!]Z\UO\O,_%3_ M (*A,?\ AHW]AUO^J@7!XYZ^=TKH?VCO&?C'P!\&_'?C#X?Z,NO>+M$TB:\T MW27&Y;@QID,B]WQSQGI7,_\ !3TE_P!HO]AZ,X#_ /"P;@+(2-A4"<,'Z!"> M,HB%XV,A\C@@[N0N3N!'OBO^?C]J%A_:_2+\+:F M)RK^V,'3R[#?6Z^)7\C]R\.7)9!C:4*U.G*I M7E).4DJGP1V3U\^OFMV?+W[#_P 8/BK\:O@[!XO^+/AMO#NO37LR6Z/'Y;7E MLC;%D"G&47& >,[?PK[) RN-QR#TP>3D5Y+\"5\OX4>"T40^6--+1[&B7&^Y MG)!1"-ISWYS^E>O 8^YM&[G&]#D^@RU?Y%>)]&IF/''$&*RCA:KDF7RQLZ>$ MRS#82NJ&&ITG[.*@G!NS45JVWK=ZZGZE@:CAA*,:M?VLU!7J.HE?1?DM%^-M M!=K#LOX\]_4C)]_;IS322."J_E^/^?UJ3;GJN?<%1_[/_D4GED] ,?\ 71!^ MA)K\Z_LG.'?_ (2L99[?[)5ZV_N>:_I'7&I3;^-+S]JO[J_KO;S&;O\ 97\O M_KT;O]E?R_\ KT_RCZ#_ +^Q_P"-'E'T'_?V/_&A93F^G_"5C.G_ #"UO[G] MST^_R*YZ?_/U=/\ E\O[OGY_/YC-W^ROY?\ UZ-W^ROY?_7I_E'T'_?V/_&C MRCZ#_O['_C1_9.;N_P#PE8S6W_,)6\O[OFOZ0<]/_GZNG_+U?W?/S^?_ &\- M&6X 49_#^?T[?XU-"K++& %)#+R/<_G[=*B,;#L/^_B'''7K_DU)!'F:)O1U M_B3'7DCY_P _I79E>49J\RP2_LW'*4<5A9*$<+7]YNK#E=N1]=W\NC,ZM2@H M^_7A&\79.<7=VT6^NMOS/YU/B5\9_BQ\$KW]H3Q+\*_#8UZ[F^+4D.JR;#)' M9V<=NS_:0HR40N/+DOVL5EK>O_!30M1U"WC.X M1W%Q#;R$@C(*DLVSH,5]'?!SPQ9^,_%W[7'A.^2!X?$/B_5-);SFC86[WEC- M"DL.\X)0R"0%,,K#KFOC#X&W-]'^UOK'AK4/.:\\#^!F\*[I0&DEM-)NEL[- M\$CB6",.K%N!SZU_UL<48?%KZ'%*DHUG67 N"=2')*ZA]2C>%EKS-WB[K7[T M?AG D_\ C9F$JU91E&&.G;FVY74WOY+?RM;H?IVN/,3''[OCWYP>/_U_7FI\ M'.<\'MCZ=_\ /6HEC&X,7BP%4+LG0CD?,"VX988P5QP?TE^51]^/'_71.IX_ MO=>GZ5_@!7RO,E6YJ6&Q=*,N9J^%JV2YNFFC;V7?;K?_ $>H5Z=E-8C#NC4@ MD_?C>W(NO-?_ (;86D;M_O#^=+\O]^/_ +^)_P#%4TY;^)#MYPK(W3GG##_Z M^?:L?[,S:$%!8;%OF<6W]5J.[ MVNYR7CT_\4+XS)XSX_::3] MKDW"CA"&)@L;4W'_P!:AD7.>N3^/ Z= MN.<^_':D5N.7"Y/W"O3W/0Y/7^>.M(",_P"L7VRIP?\ /UZ_G7^^:J4))/VM M%.25USK^)%)=?6RZ;]KG^-'U;$QE9TJD%&%^51DVX2MMIJ[>OKK<-B^G\_\ M&C8OI_/_ !I?^VB=NWI^'?O1GI^\3C'\/IZ\=^]+GI?\_J7_ (&O+_-!["?\ ME?\ \$S\O\OR[:IL7T_G_C1L7T_G_C2Y_P"FB=OX?3_'O1G_ *:)_P!\^ASZ M?A]*/:4O^?M+I]M=;?YH/85/Y*^Z_P"74_+7Y6_!=A-B^G\_\:-B^G\_\:7/ M_31/^^??/I^'TXH_[:)^7OGT_#Z4<]+_ )_4O_ UY?YH/83_ )*__@F?E_E^ M7;5-B^G\_P#&C8OI_/\ QI<_]-$_[Y]3GT_#Z49_Z:)W_A]?\.U'/2_Y_4O_ M ->7^:#V%3^2O\ ^"9]+:_AI\NVJ;%]/Y_XT;%]/Y_XTN>O[Q.<_P /KZ<= MNU'_ &T3OV]?P[=J.>E_S^I?^!KR_P T'L)_R5__ 3/R_R_+MJFQ?3^?^-& MQ?3^?^-+G_IHG_?/J,>GX_6C/_31/^^?;'_U_K1[2E_S]I:_WUY?YH/85-/< MK_\ @J>FVGX?@NPFQ?3^?^-&Q?3^?^-+G_IHG_?/MCT_'Z\T9_Z:)_WSZ#'I M^/UHYZ7_ #^I?^!KR_S0>PG_ "5__!,_+;[OR[:IL7T_G_C1L7T_G_C2_P#; M1.W;T_#OWHST_>)QC^'T]>._>CGI?\_J7_@:\O\ -!["?\E?_P $S\O\OR[: MIL7T_G_C1L7T_G_C2Y_Z:)V_A]/\>]&?^FB?]\^ASZ?A]*/:4O\ G[2Z?;76 MW^:#V%3^2ONO^74_+7Y6_!=A-B^G\_\ &C8OI_/_ !I?^VB?E[Y]/P^E&?\ MIHG_ 'S[Y]/P^G%'/2_Y_4O_ ->7^:#V$_Y*_\ X)GY?Y?EVU38OI_/_&C8 MOI_/_&ES_P!-$_[Y]3GT_#Z49_Z:)_WSZG/I^'THYZ7_ #^I?^!KR_S0>PGI M[E??_GS/3;7\-+7>VFFJ;%]/Y_XT;%]/Y_XTN>O[Q.<_P^OIQV[49Z_O$YS_ M ^OIQV[4<]+_G]2_P# UY?YH/83_DK_ /@F?E_E^7;5-B^G\_\ &C8OI_/_ M !I<_P"VGY&C/^VGY'_&I]K0ZU8?G_+YV?3H_+I=>PJ:>YB%I_SZGIMIMMI^ M8;%]#^O7/U]/UI-B^G\_\:7_ (&GY&C/_31/^^?08]/Q^M4JE%[5::VWDEV\ MWW7_ P_83U?)B._\*?EHON_JVJ;%]/Y_P"-&Q?2ES_TT3_OGT&/3\?K1G_; M4X'0#'3N:.>BU9U8-=5&2I M5J\F/BHT*=.4I*34-;0U2U& 00?EZ<;I(U)/L-W3'XY[4_G/.P#U\U,?ENK_F M7_LW-%H\+C)-;R6&JV:T::LK;:6_$_W#5:A;W,1AU'HI3I\UM-'[V^HM1.3G M&./Y_P#ZJE^7^^G_ ']3_P"*I' *@[DZCGS%[Y]_IGFG' 9A!JUX[VO?^D3+$T(J+=:A-N2LX2BW'5:NSMZ7[^A\??',L/VC?V0&1%DE M'C;4VCA?[LLB07+Q(/1WE5$![!A7S_XL_: ^.'Q6T'X[^&OB)X,_L#POX3\7 M6^F:?>*F([2\M-458[ /C$DS1['E8$[=PSBO;/VC]3M=#^.G[*^LWDJ1Q:3X MCUZ_+[U^4V]C=2Q[CD_*95C7'')'(I_BM+N\_8HN?&.HPK'JWQ#\6CQC?@&/ MSQ-J>M-$RS='_P!5;1D!NS#'K7^]7T7E5H_1'="='$TJU3*,[G&FXRYX66*= MW%QYDN779;G^?7C(G7\3L0Z?-;VF&O.-N5JU.ZYD^W;[W;7]L?!!(\%^#L\G M_A&= //?_B56O7\Q73%?FZXSTX_SSW_6N5\#ASX+\'G*_P#(KZ %'F1EBW]E M6F#C>,#@Y'8=:ZS9@X!W8'4,@R>,D#=QSQUK_EO\2*JUFK6W7SM^GX.='ZMAH-I/\ S*L:^U\+6[I_R>?W^AV\]-J-JD4K)*U5+LN_]:]]4P?1/\\_KU'M MZ4TGV7\!3_*/H/\ O['_ (T>4?0?]_8_\:?]DYO:W]E8S6W_ #"5NT?[OI_2 M#GI_\_5T_P"7R\O/S^?SU9N_V5_+_P"O1N]E_*G^4?0?]_8_\:/+/H/^_D?^ M-']DYO>_]E8S6VGU6M_=_N^GI?R#GIZ?O%T_Y>K^[Y_U_P!O%IM"?GM<_)=>8!P"3@ M@]R.O?\ 2YDZ#Y-NX9_>H"S,<8!W=L?UR.WR9H2[?VO?&B?N3*G@NTVS1B%V M -PORHP.3@9W$'/0COC]Y\'U,TX26<57P[5IY?+&8>LJF78B4:EL M1AER7E4V^+W;7TNKKQLTFWB,%RXR5!*NFX4ZEXR5HZ2_7\WU^LF 5MN\X5CL M*_=8G)(]..?J1ZU\H?!Y?^-I,V"<_P#"J+7G)R,!/SSTXKZS4%N,1MM7(/G1 MC<1_=C+<-GKR??'6ODGX/L!_P5&G##+GX3P,=C@KN7: "5R ?7WYK^P?V6^7 MXO#_ $C*=3$X6KAZ?U"LOW]*K2:FU4?)&4XI6M;MN?+>(52-3(9TU5ASKDE; MGBW)CTLNNWYG\WMMV4EK&;M;_ *W^5K^>NH^BBBF M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@!PZ'_ 'H__0Q10.A_WH__ $,44 -[ M#_=7_P!!%%'8?[J_^@BB@ HHHH **** "BBB@ HHHH **** "JMS%!+#-#<( MLT-U%);S02#*S0S*8Y8B/1D=@?5#5 M-(NO]?9:A;2JDB2P.CY4@':Q!^1]#A_:_P#V<[YO#ZZ3#^TS\'X(POA^]74H M-$^*6B6\8_X]-5O=0*Z3?6=O$JQQE(VNY N Y_A/_@GM_P % M,O@1:77@SX ?MEV5A\/;=F@TNQ\5:?=:O>6MBK.+:)9I1)L>.-M@:+:5"GFO MH?\ 9*_X)AZQ\.OBPW[0?[3WQ+N/C?\ &"$,VFW5^DLFD:5IPP *\5+J/[1/[1OQ4T7R?@)\!=3\.C56-M;^-_B=>V]AIVF!AM>Y; MPX@BU@2(AW1AEVEU&>U7[65K6CZVU_,#U']J+XX_\*M\)IX;\)PV^O\ Q9\< MK)HG@_PQ!)OO3]N3[+/J4T:,6M[2R64SB9U"_)@5V'[.'PN/PG^%NB>&[U(Q MK]Z3K/B>9"K&;6=0_P!)NRTJCY]DTCJ&)/'%<'\#OV8D\#:W+\3OBCXCN/B= M\9M8MU74_%.IQ?Z!I.3NDT[PW9,,V5C"QV!]BR.J(O^"4,#2BZBGK.,O=U4G=ROO<]"6<9E*/*\76 MY>92MSRLK;):[+[_ #/D1/\ @E!\0@H _:]^*BJ/N@7J\#//_+(?@/\ ]=2? M\.HOB'_T=[\53_V_ =.F,1#KWK]H40@ ,#^&/4^O/Z5)L7T_G_C7(_ ;PC;; M_P!0^'=7>RR[#I+7RA_5^VA7]MYK:RQV(7I-][_+Y'XM?\.HOB'C_D[WXJ?3 M[=[>OE^O'ZT#_@E%\0O^CO?BH/\ M_\ _M=?M+L7T_G_ (T;%]/Y_P"-'_$! M?"+_ *(3A[_PWT/+^YY?CUU%_;>;?]!^)_\ !LO+S\OZTM^+0_X)1?$+_H[W MXJ#_ +?_ /[71_PZB^(7_1WOQ4[?\O\ T]?^6?:OVEV+Z?S_ ,:-B^G\_P#& MC_B WA%_T0?#W_AOH>7]WR_'UN?VUFO_ $'XG_P;+R\_+^K*WXM?\.HOB%_T M=[\5.W_+_P!/7_EGVH_X=1?$,CG]K_XK<=/].7_XU_.OVEV+Z?S_ ,:-B^G\ M_P#&C_B WA&O^:$X=^>78=]O[GD']M9K_P!!^)_\&R\O/R_JRM^*S_\ !*/X MA@#_ (R[^*C[3NRUZ,#KGI%G@>_^%>97/_!&'Q2/$&H^)+']JCXC)JVJQ+#? MW[7/[RYC4[E23$>YE4C)&><<8K]]&4] ..OX_C[4FP^NWM[\_ISTKZ+AKPRX M%X0QLLPX>X:RK*\7*+@ZV$PE*C/D>CAS0BGR^5SGKYAC<33E2Q&)JU82:;4Y M6A[X'-;?P'_P""9EQ\;OAKHWCG3?VG/BEIU[<[K77='EN%$MAJ M=LWEWMJZF$E'BE!55/WATXK^C!E!$A503MV,DN#'+$&VR(RGY6!7=G/!SZ5^ M?'AHZK^S;^U)JOA*>6./X0_'+.M>$4.(X=&\:*?^)G99(" WTK&:&($$KSMZ M8]'/.!^%.):E.MGN1Y?F=:G?DJXK#TZM1)_9YI1;LNB[G9@<_P WRZFZ6#Q^ M(H4W)2<(5)1CHDM$FEJDKZ'QT/\ @C9K+>[C).?X<^5P5Z$=L MBI/^'-.LGK^U-\2S_P!O*?\ QJOW-C&2^5!YW;@>6W<_,N?E;U]:DV+Z?S_Q MKY__ (@]X:[?ZH9*U_V!4?S45OK_ %OW?ZX<1_\ 0UQ?3_E[/=6U^+R7]7/P MM_X?V@O'V/^NT?IQTBH'_!!+PM M_P!'!>/_ ,)XA_[1-?T)[%]/Y_XT;%]/Y_XUTOC/B=[YSCGM_P OZG3TE_5_ M0Y'X6>'[7_)+92O-82E?_P!)9_/;_P .$_"W_1P7Q _\"(O_ (S1_P .$_"W M_1P7Q _\"(O_ (S7]"6Q?3^?^-&Q?3^?^-+_ %RXF_Z'.._\'U/_ )+^K^EI M_P"(5< ?]$QE?_A+1_\ E9_/;_PX3\+?]'!?$#_P(B_^,T?\.$_"W_1P7Q _ M\"(O_C-?T);%]/Y_XT;%]/Y_XT?ZY<3?]#G'?^#ZG_R7]7]+'_$*N /^B8RO M_P ):/\ \K/Y[?\ APGX5_Z."^('_?\ B_\ C-'_ X3\+?]'!?$#_P(B_\ MC-?T);%]/Y_XT;%]/Y_XT?ZY<3?]#G'?^#ZG_P E_5_2Q_Q"K@#_ *)C*_\ MPEH__*S^>W_APGX6_P"C@OB!_P"!$7_QFFG_ (()^%< M8WEJ:37MI>\G'E:>NS7Z=5&7 E&I2JT^&LK52C)3IR^JTKQDI/K7]"GE#[VT;CU!(Y_ ? M04I#8 P!C&,>WXFOS6IPEP[6QT\SJY5@ZF85*WMWC)T*;K^UNI.:J*-^9RNV M_,_7Z/%_$F'RZ&44SZZ['\TO@?\ X-S/A7\.=1-_ MX(^-7C'0I9$>.XN+8HDI#@94$18(./R].E>M'_@AO9#YC^TA\02X)PS3J=Q/ M .!'CWQBOW]*<\#/'M[T;"/0^W^%N'^(<93Q^=Y3@\RQM./*L3BJ M2J5FKIKFG=-VMI:Q]CDW$V>52]V+72-EV M/YQX?^#?'P8]]JFHS?'GQP;K5+K[79&6FD(VMNS%G.T9R<_SJ_P#\0^W@ M0E/_ ;[>!?^B\^.3U_Y M:IZ_]YJM%C*J2V]YZ;;:^1Y?_$)O#MV M;X3RAO\ [!:>MN_N[^EON/YU3_P;[>!?^B\^.3U_Y:IZ_P#7+OUH_P"(?;P+ MS_Q?GQSW_P"6J<]/^F7?^G-?T5;%]/Y_XT;%]/Y_XT_[=S7_ *#*VG]Y_?OO MH+_B$WAU_P!$GE'_ (2T_P#(_G5_XA]O O/_ !?GQSW_ .6J<]/^F7?^G-!_ MX-]O O\ T7GQR>O_ "U3T_ZY=^E?T5;%]/Y_XT;%]/Y_XT?V]FW_ $&UO_ G MY:[^0?\ $)O#J]_]4\H_\):=NGE_6I_.J?\ @WV\"_\ 1>?')_[:IZ?]!?'(Z?\M4]/^N7;I7]%6Q?3^?\ C1L7T_G_ (T?V[FW M_0;6_P# GY?Y?UI8_P"(3>'7_1)Y1_X2T_\ +^OF[_SJ_P#$/MX%X_XOSXY[ M?\M4XZ_],NW]>*:?^#?CP(.!\=_'70EB)(\=.!_J>G7/Y\BOZ+-B^G\_\:4* M!VI2SS-91E%XVM:2L[2>UK6W[%1\)_#N$H3CPIE"E"2E%_5:>Z=T]M^W8_GS M\$?\$-;;P'97&E>&?VDOB#I.GW%U+>R0V\\8WW$WWF.(O0=_SKN!_P $:M8( MX_:G^)A'3_C[7_XU[^G]*_=$Q_W0 /QS_A_]:E">O/Y__6K\QS/PWX'SC'5L MRS+AK*L7CL0Y2KXFMA:_ZYE_$.! MPM.%+#X:A4=.E2IPTC&$8V25M/0_"[_AS1K/0?M3_$P?2[7_ .-4A_X(TZR M3_PU/\3>,GB[3Z_\\J_=(J@ZC^=(-GWAQM/ /\1/&!W[]J\W_B$'AM_T1^2? M^$5+R_N^3^_R.O\ UNXC_P"AOC=_^?T[_>VS\([C_@CKJ-C#-=WO[5OQ*MK2 MUB>XN9Y+M L5M$C22S$F+!6.-68GU&/:OCWX>_\ !*&Y_:7\0^)]?M/VAO'= MWX2^'WB;^S_!/B749'QJ=]9.4N+ZS"H,^7(2HDR021CBOW-_;$^)&O:/X;T7 MX0^!K=M2^('QZ9?Q)#?6C74F)H$*GR3YB MD88J.O'')KTZP_X)*>.M.L;*PM?VM_BA#;6=M#:V\"7FU8((46.*%?W?W410 M!V&.*_:[:QY(Z^AS^N:G/_P"JN_BK@CA3C6GAJ/$^1Y=G%/"?[M#& MX:G75%Z)N'.G9O6]NYY6&QF)PG^[U9TG>]X2:>UN^Q^+8_X)1?$(?\W=?%+W M/V[DYX/_ "SZXZ?KFE_X=1?$+_H[WXJ_^!W_ -K_ ,_K7[1JH(Y!S[Y%.V+Z M?S_QKXM> WA&O^:$X>^>78?_ .0U.S^V\U_Z#L1I_P!/)?Y^1^+0_P""4/Q" M_P"COOBIU_Y_NWX1_A0/^"47Q"_Z.]^*@_[?_P#[77[2[%]/Y_XT;%]/Y_XT M?\0&\(O^B#X>_P##?AUVZ*%NC^_UNO[:S7_H/Q/_ (-EY>?E_5E;\6?^'47Q M#_Z.]^*G_@?[?]<_7BC_ (=0_$(CG]KSXJ?^!P/_ +3K]IMB^G\_\:-B^G\_ M\:%X"^$:ES+@3AZ]K?\ (NP[6MK_ &/(J.>YO';'XC_P8V?BU_PZA^(.&S^U MY\5<]A]N4^OGS7!M9P(@6@E6,I(!R02H/(-?O%L7T_G_C7E'QV4#X*_%O /_).?%_; MC_D!WGZU=#P)\)\/5IUZ7 ^01J4M8267X=-/I*ZA?F\_UU)>=9K)-/'XAIZ- M>T>O34_#K]F;_@F=XY\=? KX<>++3]J?XEZ!;ZOHK72Z3IMT(["P5II$V6\; M1EAYA4[LL<9SWQ7NH_X)0_$/*[?VO?BHB]\7JDX*_P#7+H#V&/I7WW^Q!Q^R MM\' !C/AKCT_X^KCK7U<,]ZJOX&^%.)JU:U7@C(95:S4JM1Y?AW*;M:[;@]T MK;;!#.)?CMXV^( MVI^"8KF'3=+U^9);8?:HI(Y''[L$',C'AN>M?K2,[3@ $L3@G. W) /KT[_2 MDP,Y[_Y%+7Z)DN1Y3P[@:&69+@,-EV!PZY:.&PM*-*C!:-J,())7:Z'GUJU3 M$3=2K)SFW=R;;;?F[Z_\,%%%%>JM$EO;J]6_5F?G_6MO\@HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** $(R,&HF3KP2,>V3Q_C4U% 'Y^?MJ_L/:?^U[ZS\--3; M5=&U+P^ZQSFXD)+;F8.01N(STQVZU\9>-?\ @EIX^TGP?XJU*3]K3XHW45IH MNH7;V\EV'BG9(2WE2*8B<2@%25( [#FOW+*MD\=_:N#^*&1\-_'/_8MZD/S@ M:OBN(?#K@KBO$X7&\1<.99FV+P:MA\3C,-3K5Z24_:)1J2BVDI;)6.W#9AB\ M'&4#=>MOVJOB;I$.HZ7YR MZ?:7@6&WS*]8?_@E'\0B!M_:]^*PQ_P!/R#]1%T[_ /UZ M_2S]F50_P(^&^<_\@/([?\OEU7O&Q?3^?^-?,U? KPGKU95JO ^03J3?-.4L MOP[O M_+/M1_PZB^(7_1WOQ4[?\O\ T]?^6?:OVEV+Z?S_ ,:-B^G\_P#&C_B OA'_ M -$)P]T_YE]#R_N];?CN']M9K_T'XG_P;+R\_+^K*WXL_P##J+XA<9_:\^*O M_@?W[?\ +/Z?F:!_P2A^(2G(_:]^*N><'[IW-WIVI+:7. MDW,K)M:63+3QH5+.@SVK^ILH3GL.<>_MUSS7P1^W:VI> =$^%7[0^B6!N[CX M(_$31M2\11Q9\^X\)^(;F/P_>1,%R\]O;7.I17^NY\1G_@C5J[%=W[4OQ,&UG50UT@R7;(8@0CG'0D\^XQ4G_#FC6.G_#4 MWQ+_ / I/_C5?N#IU_;:M96.IVDB7-IJ%K!>P31GGO::)+T/PM_P"'-.LCI^U+\2_3BYC_ /C7^?2F?\.:M:4D_P## M4OQ-Q@XVW:CU.3^[_#'N<5^ZNQ?3^?\ C05('RC@]3Z>G?ZT+P?\-T[_ .J. M2^GU*E9:IZ>[Y?KN/_6_B*\;YKB_<>G[ZIT_[>_KYL_!?4_^",.NZA97%D/V MH?B))#=Q26\\<]P"&AE4I(K8CY4@_,.XX%?,5S_P;5_#2]N);JX^,'B&6[N) M&DFG*@>8S$LQ(V9Y/K7]06UATP<]?\G% 5@VE@::H.IS24O?<+7M9)=D?-\02EQ0HQSV4LQIP?-&GB7[6$7M=*=[-W? MWG\O@_X-HOA8!_R5S7R<#.47L,8'[O\ _7WQW7_B&B^%??XMZ\/^V:X_] _I M7]0F7]!_G\:,OZ#_ #^-?:_ZSYXK_P#"C7LW?6;LF[:ZOR1\LN#.&$U)Y-@I M245!.5&#=E;7X=]%_EJ?R\_\0TGPJ_Z*WKW;_EFO<9_N?Y]:4_\ !M)\*N/^ M+MZ^?E^? MO= ?\ 5+W_ . 4@_X- MI/A41_R5O7NW_+->YQ_O^(:3X59Q_PMO7O^_:^N/[E(?^#:3X5# M/_%V]>_[]KZX_N?Y]*_J&R_H/\_C1E_0?Y_&C_6G._\ H8UO_ WY>?E^?GY?W?+\S^7H_\&TGPJ S_P +;U_O_P LU['']S_&E_XAH_A5 M_P!%W_ #_ #[U_4-E_0?Y_&C+^@_S^-'^M.=_]#&M_P"!OR\_ M+\^X?ZG<,_\ 0FP'_A/3\O[OE^=]S^7H_P#!M)\*@E?U"9?T'^?QHR_H/\_C1_K3G?\ T,:W M_@;\O/R_,/\ 4[AG_H38#_PGI_\ R/\ 7S9_+U_Q#2?"K&?^%MZ]_P!^U],_ MW/2@?\&TGPJ)Q_PMO7NW_+->XS_<_P ^U?U"Y?T'^?QHR_H/\_C1_K3G?_0Q MK?\ @;\O/RZ^?GY?W?+\6?R\_\0TGPJS_ ,E;U[J/^6:] M_P#@'^?:E/\ P;2?"KC_ (NWKYSC_EFO?_@'7_.:_J%R_H/\_C1E_0?Y_&C_ M %ISO_H8UO\ P-^7GY?GW#_4[AG_ *$N _\ ">GY?W?+\6?R]_\ $-'\*O\ MHK>O=O\ EDO<_P"Y2#_@VD^%1&?^%MZ_V_Y9KW./[G^%?U"Y?T'^?QHR_H/\ M_C1_K3G?_0QK?^!OR\_+\^X?ZG<,_P#0FP'_ (3T_P#Y'^OFS^7D?\&TGPJ. M/^+MZ]_W[7UQ_<_SZ4O_ !#2?"K./^%MZ_\ 7RU]W_ .O^&,_P#+->V/]CWK^H7+ M^@_S^-&7]!_G\:/]:<[_ .AC6_\ WY>?E^?F?^>7I7]0 MV7]!_G\:,OZ#_/XTO]:,Z_Z&-;_P8_+^]Y!_J=PS_P!"7 ?^$]/_ .1_KYL_ MEY_XAH_A7C/_ MS7_\ OVGIG_GEZ?X8I1_P;2?"H_\ -6]>'3_EFO<$_P!S MVK^H7+^@_P _C1E_0?Y_&G_K1G:VS&LO^XC_ %;[?<'^IW#/_0EP'_A/3\M? MA\OS[G\O0_X-I/A43C_A;>O]O^6:^F?[E'_$-'\*CC_B[>OD<$XC4<'/^Q^G M2OZAA\. M>'_VDO'^CZ;!<--'96$ZQQ?,,9_U>.<5_0.0YZC^5.5<%XQPM M/!<2T*><86G-U(T,;%5J?,[:\L[ZJQ[F0X3#\,U*E7(J<RDXZ M:7C9^9^%@_X(U:RW)_:F^)8[ ?:U.T#H,^7V]1]>M./_ 1IUG_HZ;XF'_M[ M7T]/+_SUK]TRH/4?SI-B^G\_\:_/O^(0>&SU?!^2/_N2H^7:/K]_D?72XOXD MD[O-\9TVK3Z)+^;R]#\+/^'-&L?]'3?$O_P*3_XU2M_P1LUD#8?VIOB7L/.1 M_^>W[I;%]/Y_XU%('&"FP,6P,\G'TS]/YU4?"'PWC?EX0R5-Z- MK!4?+^[Z_?;4/]<.)5%Q6<8V/,U=QK33T=U9WTU[;G\PO[6W_!(B;P7\.(O' MLO[0_CCQ'KV@WUI8>%;+4YT(GU?5[R&W6VML1AO-D@>=U13EO+; XKV!_P#@ MB)K>L^$-(\,W_P"TUX\?P['IVER)HGG[+>WD\N.ZV0)L&QK:=WP3D$$''I^B M/[9+W?CGXK?LE?!#3S)(-;^+MC\2/$@MSDCPSX$2<7IE49!B%Q>Q!@PVD]>@ MK]!?+8>6NQ0BL%95QN01@)"1[,BC>,<#;TK[/+LCRG*:K.3E/W$DFFV[/1/ MU/Q7L_\ @D[X^MK:WM+?]K?XHPV\$4$$,:7FT6\<$:111IB/! 50HP/ZU;/_ M 2@^(.>/VO/BKC.>;\9]3_RR[]?;-?M,% Y[TI4'DC^=?G>*\"_"?&5JF(Q M' W#]2M6G*=6;R^AS5)3DI.4GRZN_7L^^ITPSO-(**CC:]HQY%[\GHK>>^FI M^+'_ ZA^(7_ $=Y\5._/V_G_P!%_P"?>E_X=0_$+_H[WXJ#_M^/I_US]>*_ M:78OI_/_ !HV+Z?S_P :R_X@-X1:?\8'P]9)*RRZATM_<\OQZB_MK-?^@_$_ M^#9>7GY?UI;\6A_P2B^(7_1WOQ4'_;__ /:Z/^'47Q#_ .CO?BIV_P"7_P#/ M_EGV_6OVEV+Z?S_QHV+Z?S_QH_X@-X1?]$'P]_X;Z'E_=\OQ];G]M9K_ -!^ M)_\ !LO+S\OZLK?BU_PZB^(7_1WOQ4[?\O\ T]?^6?:C_AU#\0O^CO?BIVX^ MW'OU'^K[?K7[2[%]/Y_XT;%]/Y_XT?\ $!?"/_HA.'NG_,OH>7]WK;\=P_MK M-?\ H/Q/_@V7EY^7]65OQ6_X=1?$#<@/[7OQ7 "[QF]1BLI., >4/E&,CFOE M/1O^".C'M7P7X77/[?/CW< 0?AIIO_I6@Q^5=.'\$?"S"QJ1H<%Y M%2]MI5<,!0BZD-/@!6(YW?N@3SG[IZ\$=Z]B_9@_X)R?\ #/GQGN_C1K?QB\8? M$CQ!<:)_8BIKTJ2QI "-HW>6KXP,G#=?3I7ZC$-\RXXP,=O3UIA4@9KU^'_" M[@'A;'QS/(.%LHRO'Q4E]:PF#I4JKYURN\XQN]+V72YC6S+&XBG*E5Q%6<92 MNTYM^=E>]@V'L..,8X[>_/MSS_1Z@C.>^*<.@^@_E2U]\]7?KW^27Y(XD[*W MG>_7HOT04444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH <.A_WH__ $,44#H? M]Z/_ -#%% #>P_W5_P#0111V'^ZO_H(HH **** "BBB@ HHHH **** "BBB@ M HHHH 0]"/Q_'U^OOUINP;2#R,9([9^G0\^M/HH 8&D/1C]:;C]X"P&3_%@9 M/'KCK_\ 6]JEZ=!1^% !WSW]>]%%% !1110 4444 %%%% !1110 44ASZ?7U MQ[>ISCCTS4+.1\I.6'W_ "\D(3C;GNW&2=N30!/17(W?CCP9IUZVG:EXN\.V M&H( 'L;K6M/@O Q(QF"6Y60 Y^Z5# ]1710SI<0QW%K-%,MH_X*$_!<$$ MC^\?3IT_VNG%>/]'^)=QI8G\8:!I6I:'I^K*^&M=/U156[B,?39 M*J@97G@<4 =\I)4$J5/<$Y((X//OU'L:=4*-M(4MN!Q@C)()&><]NW7MP*E) M [@ $#=U4DG QSU]>* %HH/ X(SG'.=I;K@''I^N:0')P&4D?>'/''O@=: M%S14;')VYP,G..?IC'7W]^E95EKFC:C<7=E8:O87EWI\WE7UK:W4,\]D^#^Z MNHHG9X92,8615'% &S12 ]=QQ@8(ZD-VSCC'TYHW 9).X=,IC[W]WD]?\: % MHI >0&&&;A5'+ XS\W;&.]+T&21][;QG&: $(!X(S7S)^U9\'7^,?PNU"QTB MYETWQIX0N8O&/@;6(VU[1!]J$$97#F*Z@BEMF4?>=ETY5:7@YZMP-Q M[<<8'3!&0XZ/WH ^?OV:/B_:_&3X5Z)X@CN87\0Z<'T/Q?IX?;=:7XATP_9K MZUO$)\R.<.@9E<#[PQ7T*K+G*Y4Y^8$D\'COD?RZUY'X8^&_PY^%%WXR\3:# M8V?AF/Q?JDWB/Q7<27:VNGS:I*09KT)(T=O;/*2&EP1O(R2:WT^)OPY/R+X_ M\(%RRX0^(-)#.6[9-V!],X_"@#T+.>E%9UI?6E[;0W=E=17EI<8:WNK.5+BV MN%)(+0RQ,Z.%QRP8J1G!.,5;1N&R?NGYCRP/.!L(SG_:ST(QVH FHHR, YX[ MMGY5STW=\YX_*D)P3W &2 ,$<<$YP,&@!:*0LHX)VG;O)()4+Z9'4\C\* P8 M9!&"NX'G!!&?3MWH 6BD)Z ##')()&#CTYZ_6@G&<8)"[@ >_P#M>G% "T5E MW^IV&E6TE[JFH6FFV,6Q7NKVYCMX8Y)#A5DEE=$4-_"2>35RUN(;J!)H)HYH MY@'AE1@T4B,H975QD,CJ=R,I*D$'- %BBD)QR2-O3/(^;OUHSP,]2<<=,'IU MYH 6B@\<>E% !1110 4444 &:*** "BBB@ HHHH **** "BBB@ HI#GL,^H[ MX]?H._U%8^L:WI.AVS7FLZG9:39*VQKS4+F&SM8V;A$DGG>.,22'Y47=\QZ4 M ;.:,]N_I7 0?$OX=32".'Q[X3D=V"1JNOZ9DN<9C(%UN9\D !<@Y!Z\5V4< MZ2F-XI4ECF0212QNCQNG7>LBDJRLO*D'OSQ3::W7]?Y@7:*;N''5@WW,8SP/ MF+=NO0#J/SHW*" 6![$ $G?Z<9&/\*0#J*:64=QAL;"<@#UW\:KJ5U%9Z?IUK/>W<\[A(HX+:,RNTDC$+&@53ELK M]:U'YP$*E^"5.0V.N 2,=#GKS7$>/]+\+>(/">L:!XRN[>T\.:M;M8ZM]IO1 MIZ3VD_[J2W-V63RWDW[0@;+9& =H5E/<^# M?A39!,VHTRTD>&\U>VSQF651Y<^W?MZUR/@GPIX M;\%>%=$\+^#[.*R\-Z/91VNCVT)#1PV2+^[(88\UG!+&X..?_U4NX$%A\RJ-W&KL3@G<,$@+MR>6Z!L9QCOBL77 M-*T_7](U/1-6A6XTC6K"ZTJ_MMVT75I=Q-!=PEAR@DB9T]P3Q0!\W?L09_X9 M6^#0 VM_PC &T8(8->3DL"<_=4\=Z^KOHY^G:@'<.&7/49R 5]1QG.?\ .: '44#OGC'7/'3KC^F: MJ7-W!:0O=75Q%:6T89Y9KEECBBB0;I))96Q'&BC^)V X.?8 MYHK+L-4T_5; M:&]TR^M=2LY06AOK&>*YLY@K$,(;B!I(Y#QCY6/S9%:>X'H1\PRJG.[IGYAC MCU^E "T4#G[O.1PASWZ@C\J3('!(! )(/7CJ0.N!WS0 M%)G/3D'!4CT M[Y]^F,>]+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&&'Q!XCT/1[F8%H MK?4-4M+*611U8)=31ML'0G;UXK6L=6T[5[9;W2]0LM2LVQMN+"YBNX1D##>; M;N\;+UY5CC-5R2 U0#V(Y7Z'&3FG \;C\HQT/WCGH1[$Y]\4 %%(,]^F,D\\<=QU MZ^W0@T;AGH2,*V!C.TXRQST S]?6@!:\_P#BIM_X5QXY#?*6\,ZEN&>N+=]C MCTQWQSZCI7?Y'3<-QY'#8*_4#J.KV%[I5Y&;FUO[66UN8!D!K>9= MLBEB!]X<$9XH \;_ &8B?^%#?#!R#7O&:Y?PS MX?TOPMHFG>'M!MOL.C:5#]FL;0-O$$89W=1U.-S,WS8'/K738VH>>3G9R#], MXZ4 +D=,C-&1ZBJV=Q)5^"<1@@Y++]Y6...G!]Q6>FLZ5+J4FBQZG82:U%&) MY=,6ZA:\A@R 9I;<.9DC[*Y0*3@9H VIY) W(.K)]>V34XZ$ ML1QV&21_O>G;^E !12;@"<@[00,Y R?8'!QFD!)X*G/. ,$Y'KZ+TP?K0 ZB MF@^N,\],XR.M.H *\^^*O@VW^(7PW\<^"[FUCND\1>%]9TVWBF561M1FL9UT MU\/E0T-\;>:-S]V2-2"" 1Z#36)7#;2VXA0 >A7Y\D=#C&1[B@#XV_83^*-K M\2OV??#MH4FMM<^%^IZS\(O%EKM?96X>HKR+0/!WPP^#,GB_6M*&D^$8O'?B-O$/B2XO+V&QL=1\0W(8R7*FY M>*&.]N"SO*J$F8Y=LD5OP?$GX>321Q1^//"4TLKA$CAU_3&9F/"HJBY)WY[8 M&<\9/6E%M70'?T9JHDZR!61_,1D$BRQ,&BD5AE6C8'# CN./3BIT;&0YRP&7 M"Y/E]<;O;UQDU($E%)D8R&7D94YX('4>N[VQ^M+R<8'49#G[GT/?- !130ZM MT/TSWQQD?CT[TI. 3SZ8(Z'CD]MOH0>XHWWV]+@+12$@ D?-@@$+G//ID#G_ M .OWI1@GY2#M&7&"&'TSQ^=')#R^Y^7]?\.P$R/44M8U_K&DZ5)#'J>J6&GR MW;K'91WEW#;R7$K$X2,3.GF-TXCW,?3I6JK<=1@GY6R"&& Q((]CD9_E1R0[ MK[GY?Y?U=@244@8< @Y.W>] MU?4;/3+*,8:YO[F&UB!.,9EF=(AGW;=[5RR_$_X<,%">/?";Y(4HFOZ69"[8 M"HBBZR3SD]B.15*E%I-6^[^NWS^; [^C-4K>XCNHDGMYXKF"3#K+!()8GB8; ME9)5)C?<#_ Q%6E8,!L( (P,@GYO3C(_6E[.*T;5].C\OZ\_FP'T9(Z4W))V MY4-SUSCCJ,^NG^SGUY(]^*7+%:JU_1^7?\ K[V ZBDR M =I(#-]TAZ '!& W^![=\4 %%'((#8&>IS@ ]ASSD^W'O3 M2P!88.5ZM_#[>] #LXZU"X R20I.",]47&&(QG[Y/ /0'(]L[4-6T_2[?[5J MM]::;;!PCW=[<16UI&S.$1&EF9%#.6 0$C)X[U;AFBGBCEMW26*3$D;H5E69 M#@B1'!*M&>>'/ASX4\,^,/&7CK2] M.:V\4^.3IL.OZG//)/)>0:3&T5A$@.1%';I(^Q%(4Y'%>A'&H_.L;5]/5RA/_ K/321_$B"Y0].Y8XYY(R?P^Z\- MM(#\DYX'SC'(//7&!P:X6W^'WA2R\@XR<'IG&,TM0QG)"@;L9'R_= )XQGG /7T M%2YP.H)SM(!YSG (S_#ZF@!:*9OY*\$CG(^[CTSW)Z@#/')%#,%91E3GC /. M>.?3:,\Y(('7% #Z*;N (!Y.TDA?Y@GYSDM^&T$<\8YI"1@L 2.,#'+#O@>H.>#^= "T4UV"ACZ $ D9.<<<&L MJ[UC2M/FLK;4=3L]/N-1E$&GP7EU#!->3X.8K:.1U:9\CA8PQZ\4 :]%,3/ M9@,L5))SD_PE/56ZC/Y4H;)Q@Y[#N>H/3CMQS0 ZBD)&1A6.>B\!OU/X_2C= M]X?W<#J/F)/1?IGD\T +11GDC!P,#/8GOCZ&B@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!PZ'_>C_\ 0Q10.A_W MH_\ T,44 -[#_=7_ -!%%'8?[J_^@BB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :^<<8!SP3@[3Z@'@GL M![U\9_M_?%'QY\&_V1?C3\0_AA8S7GC'0_"=V-,G@C:2716N2MO"_$.F6EI]K2WL?$$SVS:CJT05@=+MP-UT[#:JLI)!P:%]P'XL?LS_\ M$W?@A^T?\'_"/Q%\3?MB^/O%GQ9\::$OB'6[JU\8H9]%UO4"\]Q9^1)>)3WO_!-W]D'XN^&H_B3^SY\0M?^#UWX MDM5\1+K_ ,/?& 2QMWU*%+K$VF"=(+:.)CMDB)4?*RXXKYK_ &9_C9\:_"%_ M^V1^RYJWQ,N?C+8_"SP+J>H>"_B#'*;N[AE%O(ALI[R(L)+P)C,0.58<$]]? M>_FV\O3R_K3OH'Z/_$3_ (*1_LV_#[Q;JG@Z35-7\3ZGH4\D.M2>&=)N]7M= M&9.95O)[*":&/9@EMS\ 'N*^F/A-\>_A?\:? K_$7X?^)['5O#4$=+Q&VO;M"%8R"4*5VMD<5^&/\ P34T_P#:=U#]GR^UKX6^!/@=XCMO M$GB/7AXKUCQ;J-L?%.H7!O;H7$&M_:(995C0.P\F1@H XR5R*VA?#'XF_!?X M&_MXZSI?BWP#KV6.1=16"W@ 2 R!I2_EL-N2<#&* M.6^[N_+_ (8#])M5_P""H?[+6E>(M5T1/$&J:E9:%=7%EJWB33=+O;K0-/NX M2PG6748K=K;(*MAO,P!G)XKN?#_[?W[/'B3X)^*OVA='\427?PU\&:I+I.K: M@D;EUO8YEMSSLR49W7.,@=!Q7@?[#7PU^#VI?\$[])L[K1?#.H:7X@\"Z_?^ M,;RY@M);J;6&TV:2ZGU"YES,;J.;+)O=&5OE!.[!_'[X86&E:?\ \$G?VL]. MT5H3I%A\5-=CLO+QY4=I!KT"Q,,;AM5.A/"CC/!H4(^;_KR _J%M_B_X0N?A M#_PNZ*[*^!1X5?QB+\AC(^B" W#2,N P58U)Z9(&<9KBOA_^T]\(/B/\#X?V MB-'\26MK\,?(OKLZ[J+K;6T=KITDD=VCO-M+OO0B-<;F. O.*^7K/5--M?\ M@E9_:%Q?VT>G1_LTW*R733Q&)9!I,J!?,+;3EV"A.ISMQD@'\4/%^J^(;+_@ MBE^SM:Z-(\5AKOQ5T>Q\1+%8'[:Z7_ ,%3OV6K_5K2R_M;Q!8:)J=_]AL?%VI:/J%MX>GE9_+# M+J$EL+;RV8_(QE"E<')&37O?QW_;%^"'[.^B^#?$/Q#\4V]CX>\>S1Q>']7M M\2VMZDT"7"2I)%O5D:.1"ASG=@8SD5^>_P 0?AA^TWXP_9B?P%K'@#]F?0/A M/<^!=.^Q:TFI6$-KI-L^E0FVUBUG$*[;Y$Q*\X?S&ESU&*^&_P!ISX:7&E_ M3]@#X;>.?$NF?$:SMOB/::>^K6EQ]LTS5-.^T1F*WAN&_P!=!"I$:L1@HN*. M2+V;^\#]A=%_X*?_ +,&J^+M%\)7&L:WH9\0W,=AH6L:UI=[8Z1JLLS!8C9W MUS!'!)O9E"E9#G=P.E?1'QU_:B^#_P"SIX=TOQ#\3/$UMI=OK[1C0K* ?:=2 MU5I@#"+&WC#S7'F C;Y:$'/!K\Z?^"O'@SPAI'[&O@Q])\.Z18S^'/%O@>+P MY=6-E#;W&DHMU8*ZVDD:)(JNJ_.2X[L1DG/S[XNM-'\>_P#!13]DGPY\7IS< M>"-,^"?AS6O",6KMYND7GBI;6 I %G(ADF+\C<"W?/%')%[7_K?H!^IOP2_; MW_9_^.?C;_A77AG7+_1/&SP+=6?A_P 2V$^DZA?6Y'RS6EK>QP&9&!W Q[BW M)["O%OV>?%/[.?@KXP?ME^,/!_CWQ+K?B'PKJ\VL_-7FFFTWPY-:1-+*N MCPR96"(*"2L.>^.M>F_';P_^QUX4_:&^!7C#XHV]EHGQOU#51HWPLDT=_L5Q MJ4R@HL%]:V2J+BUBY5//7RQG S@FORG_ &>E;_A9O_!8YRP1D37B$:,,462Q MD;<6SSQC P>N>N:.1>?WK\- /T0M?^"LW[*>IZ/%K_A_5]>\1V,,,MQJT^A: M1J&H0Z3%!(\4TVH2V]M(L"H4);>5*CJ,X2\:0J89(@,R1RA67C(K\ZO^"._P ,/ =G^P-H M]XGA317O?&\_C-O%ES=:?!+<:S)++!; M_7O#7_!.#]N+2O!YN[338OVC]1TVZL;$R"WLM"N-/ '[17@6'XB?#+4O[5\,3W4UI#>9;;*T M1(9TW#)Y!&#_ +PZBOCV7X5_ R;_ ()P6FA1:!X4N? "_!6TU4S+;V3QOJ)T M".:XO1=$!SJ"79D)D\PRDKM(XK@?^",45I;_ +&NE0:?M-A#XLUV&RVMD?9( M[F9;9@V/G/DA!CIP32<4DVG>W_ \@/UN!R ?6FLH88/^?PI1T'T'\J6LP/SS M_P""I5W>Z9^PY\;;K3KRZT^ZCT1 EW92/!<1!YXE8I.I#QD(2?E/./:OR"^ M_P"P'^Q9XX^!GP^\;^-_VN]XD *&K]=?^"K!W?L)?'5/E!;04B!;H!)J3^)/%/@+3-4UJ_7QG=6\*ZC:5][::^5ON^8'1_P#!'O5?'ECK/[47PTM_B#KGQ5^ OP[\ M8'FOM;XG?\ !1']G7X6 M>--4\!3:KJ?BCQ+X>+)X@T[PC87>LOHK*NY_M_V*&9("2.#7YG?\$S MG_X9^_;:_:C_ &._A]XGG\:_ /PUI4GB+2;PSK='POJ&UI9;1M0C+HS2(S6V M2[8>/()Q70_!#XV/=^/?CAJ/[#G[*#>/=.OO'FHZ/X\^)GBZ_CGM=3UZTGDB MU)3>W8W1V,,JRC[.%V$)SP*7(O/\/\@/U3^#'[8WP0^//@KQ7XZ^'OB1=1LO M!,=Q<^)M-F1X=1TI+5&EF^V6LJI/$RQQM@,G7@9->1>$O^"EO[-OC[Q-HOAG MP?JNK^(+O6M3DTI+C3M-N[BSTV]CE,,D6I7$<+0P*'!&)G3CGI7Y ?L4ZOXI ME_:B_P""A*>(M&T'PO?WW@*]GU_POX3GC?PW8:HEO,0MI% ?(\YB-TIC&"V< MX-?8W_!*WP;HF@?L3?%7Q-H&@Z;<>*]0\0?$'47O9[*&YOGOXDOS;A9G0R(( M2 T2QL,$9ZXI\J72^O7S:_K[P/LOXH_\%'?V;_A;XOU+P)?:[J?B/7]%B\[6 MK3PQIUWJRZ,C#>5OY+.&9(0B9+[F&T* ])M[B;5]1GNTB_LM[4'[1!=Q2%6@EC;"['4.3G K\S?^"-_A7P7XB^#WQC M\4>(].TK6_B#KOQ/\76/C6^UJ"WNM5:P>YN%%A,UT#+;6:1DJJX"*@P#BOE_ M]N;_ (99\*?LP_%_P1^R]JM_I\0^/W@G3?C9;:=>7,NEZ>=2U,_VO:V\JXB@ MM)#M%PL)\KDAC1RQV_X?^OZWN!^E<'_!5C]E6:^AB?5_$$'A^ZU :;;^,9M$ MU"/PVUP9?)#C56MA!Y.[@N9 A!^]7V1\0/CW\*?AG\+&^,GBWQ?I5G\/FL[: M[M==AN(9(=22\4FUCM'1F\^2&)?#7A( M?#>U^#,]W T4%C]GM[A- \]=2M[P+NCO&N<2K.LGF>7WP?UC]J_P 5Z'XD_M:25M-U'PKI%XK>$8=3FE(5M/\ M/9UB,K&-^5XQPN1:[Z/]$^WF!]Z_\%!O^"@_P4^+O[*_C+P=X%UGQ+X8\4ZW M)HEUX"]\R1]*NIH85F7RL.3&^60^E?J;H/QS^'WP._95^%/C MWXJ>)8M%TR'X>>$ ]W>.7O+Z]DT2RQ% OS37-Q,Q((1&9F;D<\_$?_!:+X>_ M">3]B74+Z_T3PWINH>&==\*Q^!KNR@L[:\L4^VQQQVVDO $;[-<6ZQI(B;TV M(H/#^GFUM M]5E<>0ZAPA$*&3SEJVY0PZ$ _G2T@((! P" 0!T M&>:6I **** "BBB@ HHHH **** "BBB@ HHHH **** $(R" ,MVYQQW&1R"> M,>N*_'+_ (+D7NHV7[#6I-8:Q?:&;KXF_#VTN]0L+N2RN(;6YUGRIPEQ$0X5 M8SF0$[2HY]:_8ZOQG_X+IV\5W^PO=VESDVMU\5/AS;70#F-C!-KBI-A_X"48 MC?VIK=>J_,#X]?\ X)Y_L,P?#>S\3S?MG>(-#UL^#].UJ26+XB64TMEJL^CP M7DRB!=1:82"Y O&.O.9KO7/!EE+<"WU&6^G;=/'B-,2,P"@X'RXSQMA_P $;?\ @G[K M7POT?4KSPMJ6C:EJ?@C2-4N=:?QO7FB6UU/J#0R2B-T2:1Y-I^7C"?+ M@5XK_P $K_B*OA'P+^U[\$?%GB*Y\3? KX%ZAK(T'QE;R$8T"-+C[7I]M>1C M!N%MT+AUW-D#K6ZCS76Z32=].WIZ^?H!]^>,_P#@IS^S-X.U[7?#\6IZUXI? MPQ<367B#4/#&D7VK:9I<]L2LJ7%W:V\L,;Q;&#_/A2.37T-X!_:I^#?Q,^#F ML?'+P9XEAU;P'X\ M;WGP[\6#]D']C_2G^"OB&_\ $MS>>/\ QW>V[KXC7;/O^"EO[,O@+Q1K?A1 MM=U3Q)?>%[CR?$MUX9TVZU2ST78<3?;KBS@EAA2 @^<2^$QSBOE7]AGP=8># MO^"5=]XK\#Z#:1^-]2\!>-?$$%[:6<3ZA+K4:7(2ZM9-C3I)@E@$<$GCO6Q_ MP1_\#?"W6_V0-3UN\T_1M<\4^-M7\41_%FXU&"VGU&*]N9[A=2TS4Y;D/,(E MB&=CA50@MD;01+C'M:S2_+^O^"!^BFB_M2? [Q'\')OCYIOC[1&^%]M:275W MXB-U#'!:M&I+VDNX@K<[E9/)*B4L" A-?+>F_P#!5#]ER_OM)CN]6U_1] UR M\2TTKQ=JVCZA9^'+QFE\J*2#4IK:.W>.0XVN7VD<@D5^2_[9UQ^RSIOP ^&G MPQ_9?U2^7X&W?[7-AHWQRBBN[J?2K:;2=1BE6X;5A>1K-:Q6/E[VN9)D=-B0ASD@8YK\9?^"@'[??P:^,/[/%QX M/\!^(/$?AOQA>>*_"UUIEEJ5G?Z!=ZI9-JUEF6QDFAA-RC(%OC?>WUW\)I-9U62*?7MYM-3U:QF:+1K:_>X*K/"B) L*3 M?+MVA'M+\:Z'XW\,P>![NSAM+:^:-M2L_, ML[>.!8VF@:(EE^4HHZ=*.1>?WK_(#] =<_:(^%_[//P*^&WB_P"+/B5=*BN_ M!_AR"T0EIM1U2[;3K8".WM$#RW,C.^#A6+$]STX?X6_\%#/V>/BEXNL_ EAJ MVI^'/$FK.%T6P\2Z?>:+)K&[[ILOML$,%]>T9/A%H.H:%HGC^\6T\*W/B6.SB:-[EIE-N]W$_,:L"20,9XKU3] MKKX/_M0?$FS^'-[\28/V>OA1J?AWQ?HU[X3\8:1J]M;:VDEOZ@]<]<$'/<8/;UJ8G R%5CE>&..IP<> M_IZ?K7,>$(KZ+PKX:AU.Z2]U&'0],BO;V-M\=U<1VL2R3QOP7$K#>&XSGM72 MOT'S!.<$GNIX*J/[S#H<\5('XH?\%D?BQ\4/!_AS]G[X3>$O%U]\,O GQL^) M(\+?$OXHZ?O2?PYH7EQ.88KF/"Z>9C(^Z9F574X)[5XXO_!(?X4ZQX*N/$/P M,_:V^(6I^/\ 3[)KW0_$EKXTBG@O]>BA,UA'<^1?2".*>98RZ_>(?! '-?>_ M[9WQV_9O\/>./A=^S3^TIX'76_"_QLDNK;1?$FK6J?V'I6I0C&V;4W_X\+_D M>5(KJV,$YX-?+GQ:_P""9?PI\%^$]4\?_L]?M%^,?@EIVB:?<:_965GXP&H> M%+JYLH6NH?.$ER%D23RUC"+G@XX'36&WS^_;^NFC^X/O+]EG6OC)\/\ ]G/3 M9/VN+ZPTOQIX'M[RSUGQ+/-%'!J6DZ:I%MJDLN_87FMXPTTC,&=R3C)KR)?^ M"I_[+;:F;9=:(-XU3[+]F,6X@;_,V<@YP:_*/ MXA?M0?&/XZ_\$K?B%J/BS46U#Q-X2^(,'@*^\66_F6UKXIT.WU&*VCO9F0D" MRDA4I&_AW^TSXA_9)T+P99_#G]F>S^$^H?#JT0ZG-JEBD4,, MVG MJ\MUY):.^C!\UY2?-\P;<]J'%/5_Y+^F!^L'C?X]_"GX??#)OC!XB\7: M3;> 6LX;VUUL3Q/!?+.NZ-;9T+&61\X"1@MN(&,YKXON/^"LW[)MAH\^N:YK MNM>'K&)H6L)]9TJ_L(-9BGD6)7TZ6XMHUN$RRD&,MG(QUK\J/B9\/M8\"_ + M]BGX7^.?'>E^./AW=_'-8/$6I:1>O>^'AISZGNMM)N;KA'LH&41 R90KZ U] M\?\ !8?X;_!]OV#]3N[C0/#-E<>&[OPA%X%O+2*RM[BT1KF#9%I$\(1WMV0) MY@ <,.3U&3D7G_7R ^[O'_[7WP=^&>G_ 4U/Q-K,MK8_'K7-,T+X?.(V#7M M[K"HUC&X53EGWJ07V]03BNW_ &@/CS\/OV9_AW=?$_XGWS:9X8M-8T;0YKM4 M:5?MNMW@M-.&P D,\[A6*C'7GL/PW_;=>"+P#_P24GN&40Q_%;X?-)*2 (UC MM;+?-YC850@PQ!(QD'O7UE_P7$U[1[3]B&?2KJ_LUU'Q#\3_ (:+H5J]P@GU M+[%K\-W<26PY:016Y$DC*I55.XG%+D5TKO6_X6\@/O/XS?M4?!_X#>"/#GCG MXB^)$TW3?%\%C+X5L$5YM6UDZA!'>0)8V$*R3SN\4R\+&>N#Z5YM\'/V^O@% M\9/&D'PXTC5=2\.>,KJV^T:=HWBS3[K1KK4 3UM([Z*$3$CHJ$GV]?R5^.-S M\4O$?_!1O]EGPKI&D>#-=MM _9G\,ZM\,] ^(]RL/A.^UMM.LS?:G DRO;W6 ML6^6CMP5\P;5 ![^R?M1?"']IKX@>-/@GXB^)\\.>)]$U M2UB\2:SY5U"9?#P\F..:Z@N$# 1$,HW;02,4FKJ=OI,-M++=7D?"A;>WA1VG,K%0BKDY[5)\$_P!O?X"? M'?QU/\-/#&K:CI7CA83=P>'_ !%8W.DZA2-E^8-&&SQ7YO:W MX%\/>-_^"QG@R?QMI5AK5YH/PQBOXX[N%+BQ_M:)$W2PV\@,9"38="ZD9 X[ M5V_[7>DZ;H7_ 4Q_92UK0]/M--U>]T;4;:YN;*&.TEO(EBVO7\+>7F!]^?'3]N/X#_ +Q-!X+\7Z_<:EXODC\X^&M!M9M7U>* M$ DO)9V<J\9KG=,_:J_9X_:<^!_Q@GT#QGVJ*UA MXF\.6?V9ENKAK*01W,$L*9,;!.ISGH*^ /\ @G9I?A_QC^VG^V!XJ\>PVFL_ M$O3/%4UCI46O1I<7FFZ%NV1RV$=V&,44D9(_=1\C)R,9'L?QFTG]COPCJW[8 M^C?#-Q8?M":Y\&O$VH>/](TV=O[,6T:Q=A/]FA7[);7,+W2+^W\.7U MU<,L<9AU&2W6U,0=@F\2;3M."UK;75GJ$SK_ *=]MC2:T6S$>]KAKJ-T:)8@Q(<< M=*^+V_X*O_LGVNG2W^O:YK7A='\@Z"KOQ(^H3LNGZMXCM] LUTZSU&=O MW<5]-_\%G_ (;?!M_V1VUK5M&\/:9XI\,:[X:B^'EW9QVM MC>6K#4+)/LUG'"%:ZM_(# (!M4,"*.1;:_\ #6_S _8+POXAT_Q9X?T+Q-I$ MAETGQ!I-GJ^FR'(+V=]"D]N2N.&\MP3D]_7IT->+_L]N?^%'?" CXM80!D_O)XXT.!G!X!(KK6'RDY']?7_ZWUKAOB+XLA\!>!/%WC>ZL+G5+ M+PGX?U37KW3K-3)=7MIIUI+=3VT$8!,DLL4;(%]^]-;KU0'\Q'[(O[.WA?\ MX*&/\1?B]^TU^U!XQTGXGWGC[Q%HD/PLM?$:Z*W@_3M/O98+2VL]+N+JWE>, MQ@'#?B3KWQ>_98\8Z0XO&\2:F-0OO! MVJ6Z[4%NIFEV1L3PL197'SGISS_PU_9]_8+_ ."@_@U/V@?A=%>_"WQ_K\][ M]ON/"7B'_A'/$F@ZI;SM%=_VOI431[YI),R2,ZCS6(/&#CR/X=^(OB?^P_\ MMO?"#]G.Q^.>J_'[X;_&1-4M+O2]9O%U+6_!$L:2/;S7$L,LQBPR#:6XVY&> M:V^_T:TZ?UO^0'ZD?'']MWX$_L_^)[;P5XJUN]U3QI=1BXC\,>';:YUC58;8 MY;SY[>SBF=!MY)E"@<5UGP _:S^#/[20UF#X<^(O.U?0O^0UH6I0/9ZO9D=3 M-9W213*J="0A7WQ7XH_LK2?M!^(?VNOVQ==\$^&OA;XG\>Z/X_GT:RN_B+J$ M4>O:;XO4[SX2_'KP_^U)XA^+&I:K\)?A] MXQ;X9^)(=4\!_#S5(9=3\0SBP9K>^N=.M8U D$C%D=@"#[BH4$TM7JK_ -: M??OQ&_X*,_LW_#GQSJ/P_N]:U/7M?T+?_P )!_PCVGW>J6VC"')D.H26D,L4 M 3!W;W! !%=?\+/VY_@%\8M*^)FN> _$O]KZ?\*-)N-7\63)&QCMK6ULVO9E MB9E!\Z.)6+1XRN".U?&G_!(KPIX'USX!^//$?B72=&U?XA^(_&OB>W^(]UK4 M%O 88%\- M1Z3XU-G:V#B:TMICI5\TZP%>-D;EP(QPJ@*/=\B\_P /WT^"_QX\"_'KX7: M;\8/A_?M>^#=5M=0N;._D0HSC3"XO%=& )$9C< D<$<>M/85\4?\$H; M^QA_X)K^";R6[M5L[;0O'INKAITC2 1SW^\3YP(6&#PV#T/>ORD^"OBOQ3H? M_!*;]OCQ%\/M0N;?4)OC#XKB-]IK.+JWT.\UKRKEX)(7EOV _9_4_^"I7[+VFZGJ=M::IK^K:/HNIOI6I>)]*T>_N_#EC M<1R^3,TNIPV[6WEQ,/F=960#G<>M>]?$;]K_ .!_PU^#>G?'?6?%MM=?#35Y M+-+77K&031%KGA=[IN*[6X9."O(('?\ ,G]F'PE^TY-^Q[X#T'P9\-OV<+WX M5>(OA]%+?W6H7]BW]HP7MB_VZ^U]GC=AJD6YI9&E-/#ES\<+:XT>#PO=#5-'T&UO]6C-YHL=R"!)#;MF- H MP@XQBGR+S^__ ( 'ZXR?\%5_V4()M.NIM;UN+0M4N;>V@\5OH]_%X:5[S:L4 M1B^_=N#'!.%%?F)^T+?W6H_L1_L#>'=;OKT^# M-4\:^';3Q$MQ/*;.?2Q"_\ @IW^ MR_XO\5Z1X637-8\/OXBO$L= U?7M,O+#1M7N)6"P_8KZ[@BMYO.+ H%D^;(( MSWU_#-S\#T_;T^(]UIGC+7KOXUP?".PN]=\(B=Y?#=KX3%U&]OJEK 3Y!NYG M"B21,N5))XJ3]I7P'^QUI_[/_@:^^/NF:/HOPS\('PS=^&-6T@0:;>V&J"*V M&GMIES9_Z2_F,$WA-VX\MRQ+6_DR.\BB3,D>U]SC=SG&>IR+S_KY ?5+?\ !4S]EEY_$6G:9KFL M>(=?\,ZWJ&B:MX?T#2KW5=2MIM+D>"\N'MK:WD:&UCEC96=L#(XR.GTM^S[^ MU9\'OVF_#6L^)/A9XF@O(/#4[6OB6SN-UM?:).J,[QZE!,J26[HJLQ#J ,<\ M5^5O_!%?P!X1-W^V'XXGT'2KKQ?=_M!>(-)FUFXMHKF]@TGSKPOI\-Q*K;;> M? >:- -S9W$C(/@/@/[?X"^,7_!733OAI VCM;^')-5T_3=)5HH8-0N=,N/M M5Q:Q1#$4S1-([>6JD1JRYN1C"895!#\A2">G;%?%W_!-/X??"J[_ ."= MWAV1]#\/:A#XL\/>);WQ[>W<%I=W.HZE(+DWK:M=3 S&:%P"%E8&,@8P&A"OA_3?B_JEII(@P85LDNI?+2)QP\:DD*1QC [4I12 M3TLT_P [;_H!^[$1.", *0&0-]\,?O@]>?7V_&I*B7J/JW\A4M9@%(5SM/OC MDX ]"#USVZ=*6@_=SG^(#'XCF@#\1O\ @NBTK?LU?!W3?^$@U#PS9:W^TG\/ M-&UG6+"^DT^>VTS4#>P7KM/&R_N%A8NVY@HV*Q^[7S!\0/\ @GE^PQX6\">( M_$6C_MH^(M-U?2=#FU&QEM?B)9WD_P#:,-H)[<*D6HO.\DUSA5"QEE#C*Y!Q M].?\%T]%L?$?[.GP.T#5$:33-;_:E^&6E:C$K^4TMC?SWEM=(),CRRT,C@29 M^0G=VK?\;_\ !&7_ ()\Q>!_$MQ:>'M4\*7BZ%/*_^"G_ .S'X5U76;"W MU/7_ !%:^'KB6UUS7M TF^U+1["YMVVRI-?6MO+;*(VR'S)A<$?BQXDO=9^#OP/U_7O"^D>(;=S!<7_A2$R0F&TNHP=I8*D4;K MN.)&;/'-/X5_%CXA7OP \6Z;^S+^Q[HVB_ 35M.\23'Q7XVO+:0Z];3)<"XU M34+FZR]U,P9IXFDY!P5 (I\B;;UW]/T_K8#]9'_;,^ Z_ BZ_:1M/%-O>_"V MR-NEWJT'SFUEN'V,LX +QNI)4AER&'.,5P7P<_X*$_L__';Q;8>$_A_?:W?G M5+66\L]=ETV\30GA@4R2LU]+"MKB-%RS&7: #DY%?SY_!^YO-1_X)0?M8:7> M&*WMH?'ZP_8[63?I^GF75IQ)#9G)4QJ24CV +CH0*_9GP[X:L? 7_!+B*^^' M7AVRT?7;'X"M17)Y_LP>#O$>L>'6UO4O$1\,WEZA>7$OA63Q_::BQLM-NIY]EL(WG5O*@W&)EV* ,TB>&KC6M9\*R^*;U++PWJ7B?2;[2=,U:>5MD*6=W>6\4$G MF,1L.\ EAC.,5]'?';]I[X1_LX^'+'Q%\3?$<%C;:M)'!HEG:G[7J.LS3*&B MCL;6 23W+.&!4Q(ZD'K7R!_P56\!?"C_ (8=^)NH:QHWAW3-5\%:!;W_ ,+K MZU@M+*\TC7[6YL_[-AT*2#9-O?;Q##NWYW8[G\XOA+>:A\2/VQ/V#+#XX*VK MVD7[-VA:]H>G^(P39W7BR2T?S'"76(;B_58XR"X+H2.*%!/O]Z_0#I?VUOVS M?AY\>OB!^S/I7PTUOQ#HNLV/Q/TAM4T+4K>^T*_EL99X_GEMIXX6N+>1>5)# M KUQQ7[._&_]J;X1?LWZ%XQA@@N[C35FC M"K>Q1!"\2#B)V7ITX''EWQ(O?C)XJ_X*G3Z9H.B^"O$VH^&?A]IEQX)T+XEW M:6_A^V_T> 27FDQW*-#)= ?W4+#C@TE!.SUU7]= /UO^"G[=7P'^.7BZ;P+X M=U>^T+QIY"7%OX:\1V=SH^I7=NI!,]O;WL,)E3'_ #SR<=17VCO)) &>3T/^ M(_G7X0?&SX/?M$^,/VAO@#XX^)%[\#_A9XR\->(HI+6\\.:Q!_PD'BK32RK- MHYMXHHY+B+R^%WJ1R.U?NI%OV1>;CS1!&)"HPIDVKO*CT+9Q4R25K=?G^.@% MT$GMC\#4?V-]:L;E3);7_BC M1+&Y7.T_9Y;D)(H(QM)4_>S\O7TKQ[X5_P#!'O\ 8&\5_!KP5XBUWP=JUMJV MN^"--O=2U7_A-KB*.WNKO3HVENEB,WE1")CO"9 X(8CMO&W*KMK3HKW;Z6\[ M_?V6P;/_ 1V\4_%"\^'OQ3\*^*O%FM^._AGX.\8WNG_ W\<^()GNKO6-'@ M>15D%[*V7MQ&HZ$K@#MS7U'X^_X*2_LW^ O%.O\ @X:IK7BC4O#3O'K3>$=+ MO-9M-+GCW"9+NXL8)HXS%AB^6.T*=W-KV&7^WYY7G_M*:^U&\!=K4YE8Q,-GE$@J0 M!2<4]?R _6KX/?M5?!WXZ_#;7?BE\.O$D6K^&_#4-_/KRQKNO--?2[>6YO([ MN*0++ Z)$YVNH8X)7-?.W@K_ (*A?LQ?$/7?"^B>"=6UOQ%/XIU2UTW6GZ7J4\LD$5I>W<=NT$#L\3Y6612 /FP*_,;_@E/>:K)X=_P""H$.HV>G: M;-%KWB*X_L317670=+GE\+ZT\]IIC(3&UOYG$90*-HX![?2W_!'_ ,$>'M"_ MX)O7_B+1/#6E3>)]1UWXK:VU\UG#<7\^L63W9T^5IY$,GFV3,QM=A&S=\O7- M3RK7?1I=.MO+S ^ROBE_P49_9Q^%/C35_A[>ZYJGB7Q/X> F\1V'A?3KG6$T M5&0.1J4MC#/';-&IS(C-E<'1R,DMO-%@@HZ*VX%0,@9_+#_@B5H'A+Q+\!?C#XT\36.F M:W\2?$GQ<\=67CW4M8@@N=>EM?[0FC2*^-WNG2V$0V1(512J^U?.?[;LO[+' MA+X&?%/P/^RMJ%]:2S?'7PAI_P >-/TN[NFT>SCOM85=5@7;^XMK61F=9UA( MCVD@XP01-JVNQZ)<:@=,@\6W&C7Z^&Y)/-\L M2+J;VPM_+9OX]X0@9W8KZ^\>_'[X4_#?X9)\6_$WB[3[;P++:0W5GK"3QRQW MHN4#P16BH6%P\@92%CW'D#&>*\'^(7PM^!*?L4:IX?'ASP>GPYMOA1#<6;QP M6*V:2C0XWBO;:]7YA=_:#O+"3>9"W?('\\/@/Q%XH\2?#?\ 8=\&?$6[U"^^ M#ES\8]=TNZ367E.DW.G6=_,FBVL\\I"&W,2P"$N2C#:!P::C'MMZW_0#[P_X M*!?\% /@[\8_V2V MT86&UBPTUQ/(Q "Q([9(XYKX*_X+-?#_ .%"_LD^&-0N-(\/:9J7A_QOX.@\ M%7%G':6UU%;F_M4%I93P*KRP,BQM@;EW;3P6.?ES]LR[\>:Q\;?^"FDEL!^I M_P .O^"D7[-OQ!\9:!X';5-9\)ZKXF98?"\GBG2[W1;779SQ'%97%[!!%,\A M^YA\MG@5]^*SD*VY/G(^M>8+F[6RA22XAD/WTNB@DZ#[V>] M92?O/Y?D!VP.1FEI%&!QS[^M+4@%%%% !4,GWX\XVEO+?<>1OZ>7W!SC=T'K M4U5;@%F4*,NH9D4=7<*653Z)QSZG%5&]]-/\@/YE_BGI-_\ MI_\%$?C5\%? MVA/CUX@^"/PV^$-G86GP]\':;J8\-VGC1;@'S+Z2>6>""_*@YW^9N)/RY->^ MQ_\ !.?XN_LP?$#X>_%[]C'XV>+?'VCV/B"T@\;_ V\1^(%U#3=5\.W;HM] M>0 7,J2SQ)ET9B#'D$?>!/LUVG["G_!0'XR_%_X:_$/P9_PC'QC^"/B >%]3 MU*>^7PKXFU0IN%IJ.F7RE)+ZU4X,0^?)ZG%?)7[4?PN\<_\ !-4^%OC1\'_V MF?%?BW3;CQAX>T6X^#WC#61JLNJ:5?7HADATV,322L@A(C+!!PH)!%7[W\VO MIZ7_ #_K6P?MM\;OVF/A5^SIX8TSQ+\6=>BT.36EMX++1XRUQJ=YJ/O5Y/\'?V^_V?_C#XQMO .C:QJ6@>++Z'S=/TCQ3IEQHM MQ?H?NM:_;8H?.W<;0A+'/ K\MOVD-=^)?Q&_X*/? .'3/#OA#4X;SX+Z?XM\ M*^'?B7?"S\,Q^);VRAO+F*TCN%:"6_@$NV.%ANR 2><5Z7^T]\&_VFOB%XI^ M#WB'XECX#?"/Q!X:\:Z/<^'O$NA:I:Q>(=1BBNH#/HT,<4:2SQ/""BHQ**WR MC ?+'MT_*W]-_Y@?I+\?OVSO@G^SIK6E^&/'FM7,_BO5E,UCX9T*VFU/6I MH>\@MK6.:=%;U95![$BN0^%W_!0O]G/XN?$3PY\+?">OSMXW\302S66A7=K/ M!J5H(6\N6.\MIHD>%E?Y<2!<\XSUKX._8_TN/Q=_P45_:+U/XP066M^._#>F M:19>"3K(5V@TA(%6:\TRWN048RRC>KQ*>O2L[XA>#_A[X:_X+-_"/4/"%GI6 MFZUK'@?SO$UGI:PP@W(G4K=WD,/R"XE7)SM4YYQWI*O@W>V>G^,K$QD?8+G48FFMB,C#O(D;?*"0.YY MJ&/]I'X8S_M&S?LMIJ;CXK1^!8?B++I;1$1CPU<,T8EW8VJS.N& )8#M7YR? ML(W=K#_P4%_X*-6+S01ZA=^+?"-Y! =L=U<6Z6-PAEMU8AIXTSAW P C?L4WD,)M'28QZ[:VD\T-H61CBXC8Q Q'!5B0V M":7(O/9_I8#[Z^+'_!03]G[X1^-[WX;:GJ>J>)?%VBQ!]>T;PGIMSK,VBH1N M\N_%C#,L4B#ED=@0I.[!KUKX2_M2?![XV> =:^(/@'Q/%JNB^&XKJ7Q#:(2F MJ:,+1&::*_L9A'+ \8C8,KH,D;1FOP@_X)9O^U!XB\'?&;QM\._#'PC\6^,- M9^+?C&T\;>)O'E[#_P )R)$U.X1+"^2Y1YUL$B58XH\".1 !V%?1?P(^#OC[ MP+\:/VJ/&.OZ[\,M(C\6_#K5D\7_ L^'^I1WUEINLQ0RS1ZG-;PJL=K//(? MWJA1UVT^1=W^ 'U59?\ !6+]E#5+&\O]!UW7/$CZ5?7MGJ=KH&D7NH36)L99 M+:9[Q+:WD6%(WB;XM':5'/V?!(PI&1G/2OAWP#>/?V._%WB'XBZM:W'B+QPEW\'_\ A';PG1_$^KSJQ%IJQA8I M-:D JL!]?\$SZA\1KF>"T:XFD M^SB6_N[NZ?=*MY$%=M[.LBMT'WL_"'QFO?@!=>.O^":-C^S7?WFH?"[2/V@K MW3]'EU"6:Z2&X@EF6Y@MYKCYG@$P81*HV%,;<#BCD7G^'^0'ZO\ Q3_X*$?L MX_!SXGZW\(/&_B2>S\>Z-I=CJ:Z';67@O$)L[:SAAC>2:655.T1JW.E?G!X7\">$O&?_!<7XCZAXHT&QUN?PS\%-.O]'34X8[F#3[^. MW'E7EO#(&1+F _ZN0A_+W<9KH?VF-)T[0?\ @K[^R5J^@V5KI>L:_P##_P 4 M6FMW5C EM)J4<%LQMXKMH@@D8?*/.(9O+"+_ FER*]M=K]/+R\P/T.^/O[< M/P+_ &>?%%AX)\9ZU=:EXTU.W^U1^&?#UG/JVL0VW(,[VEI'-)'&O.2X7'\L M+X/_ /!07]G3XW_$G2OA3X%\1SW7C;4=/N;^/1KJTEM;RS2V#?:$NX)8T>*1 M IW"0*01QVKX%_X)\Z=I?C?]O/\ ;O\ %7Q&M;/6?B1X;\71:-X:77HTN;K0 M?#9F5(X-%M[L?)%,H.Z2%<'=G(K#_P"$2^'WAC_@MMX<_P"$&T_3=+N=7^$V MH:AXGM-)CA11J_F2![B=(#LMY)0-LB ]6Q3Y%Y_@!^_*Y Z8&3CG//&XX[9 M.< 4ZFKGH3DCC .0!VX[''7WYIU9R5FT 4444@"BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH <.A_P!Z/_T,44#H?]Z/_P!# M%% #>P_W5_\ 0111V'^ZO_H(HH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** $; 4L3@*"3QG/;&/QKSGXH?# MCPE\7/ ?B?X<>/-%AUOPQXHTR33=5TZY1)HS;SH5,]NK*=LT1(974AT8 @]< M^C_GQ^OL?;UIFS&.AQGDYW;6^^H/8' QD'&* /PQE_X(H>&M)N;VW^'O[3GQ ML^'?A&XE:5/".AZ_=C3+>V=C_HRJ\G^K4$JJ(,D9?%GBCQ [7FI>(!/D2_:Y9LN0P)8J3C)-?:VQ<;>=N> > M=@_V3GKR<9R*4@;1NRQ7H2?XNF3C\,= ,5?._P"M.W^3^\#\M#_P33LO"7B7 MQ7J_P.^.7CWX0Z%XRO+J\UKPCH,KR:,+B]9GNY+6 N!;22-(YW(, L2.V/HS MX _L>?#'X"> ?%'@FQ2Z\5R^.?M8\::]KTKW=]XA;4 Z7#W F+Y($KX X';M M7UJX5W^<;\<\D\G'10I&21T!R2>_>OQA_;I_X*2_$']F[XY>'OAC\,?".E>+ M-*TFRM-:^(US=*7N-$T.XN8X;B1'!Q%+$C%OF'1<=:.:3=UMIIO^G4#N]:_X M)F67A?P]X[\/_#_X\?$/P=\--=MM:U:_^'VGW+G3D!M;B9[6UE#[[:UD;AXD M RO"Y[_-?_!*;X(>"?B7^R+\??@CXJM)=1\(:Y\0O%_AN\\U)/M#VJWVR.4, MX#?: ZK()AR,$5^WGP[\::#\4OAUX:\;Z/,+C1_%^@6FI1F'#+.EY;#SH/X@ M47>T;CH<]QW+S\_N_KT _,>'_@EA!)\-;WX(ZI^T1\2=2^#KVMU8Z?X-^UR M0)8VTF3!9-*I9I;2W)_U+<-MQCT^A? G[!/PD\-?LC6?[(.ORW?C7X?VD%RL M6HZD!'J45R\KR6MW"X)-O<63MF*13GOBN3_8^_:T\:?M!?&C]J;X;>)=(TS3 M],^!_C*#0-$N+($S7MK*6S+>.KE?HIM9=FUHC(0"HRH0 ]U&_ M)X]0<\],47GY_=Z?U\_0#\H(/^"8>HR^$K?X8:W^TM\3]7^$-I=Q,/!$]]*T M36$+#RM*>^W"9K,1 1,G0I^->Y_&+]@CX9_%32?@;X>L[[4/!_A_X#:K8ZMX M9TS2=QAN_L0B$<=Q*2S.7DB\Q\DDLV3D=/NQ-P<*NXR$-N#XVMQR2.A..A'& M.@XY#%(N#\I":&,@ ;1*T0#CC@GO7G7QU_81^''QR\.? M#>RO]:UCPUXR^$MAIUGX1\>Z(Y@U:V>R2..%\HP:0?(-X)*G<>*]2_:S_:)M M/V8/A#JWQ4OM';74T^^M+"*Q65(F>YO94A5SN(W1Q;^<9( SQUKUOX:^+&^( M'@#P;XX^RQV4WBG1++5Q;!PRVXO(4F*1L&*_+NVC/UI*OC3XY\*PI;^$V\5$&RT(Q*52:R@8LD(/VJM?M?%>L74_[5<=]%XAM[A2%T)KZ$P3&P]%4'(;L1P*^_ M0LA^0JF#R 7!<@'U#A(XSFF$')VG"HS"4,P15W$<@L01NXQV)_1J4KK7K MV0'SA^RY^S?HG[+OP1\/_ _PYK=]KFCZ$FJ"/4KY=]Y*=0>623'88#+JT']L22RW?\ M9B*IU5=0T^SU6RN=/U* MV@OK&]MWM[NTNHDFMYXY%VM&\3@JT; D,I'.:KF\I?_LV6>K_VY!\)/"D>H+(5TZ(0BX#[S)Y!'E9+Y883 M/TKZ.M+:"TB2VMX8[>VBCCAMX($6**&*,!4C2.,! BK@ !1T%$I)IZ_@!>7[ MH^G^?RIV>,8'Y1VQU]Z*R \"_:8^!>D_M'_!CQE\&M>U6]T32/&5B M;*^U/3US=6T6Y6\R)NJR!E7!_6OR>TS_ ((K7.C:7:Z+IG[9_P ?]-T2QMH] M/L=+LM=G2UM;->(X+>%778C*2I501COQ7[ND ]0#V./'V>,/&.O2O M=:]JQVD".:YES((RSF3;D@,<\]!XGH/_ 30_P"%=ZMX[/P=^/OC_P"''@OX M@:Y>:_X@\%Z1(ZZ:=0U&=Y[^:VD0AXI9S*X9UW'GH*_5?:/EZ<#&,#!&,9YR M=W'4D_C1M')Y4GG*X&3[@Y'3C^E/FEW_ "_R _,#X(_\$QOAI\"/&_Q)\9>% M/&_B>]N?BAX7N?#_ (CAU:XDNVN);Q76?4C*^6:?=*Q&2=H],&OIW]EO]FGP M]^R]\-+CX8:!J]]X@TB\U?4]7>[U)-[L^IR.]Q;,<G'6EVC SU'.!P@;U"_SY]?I1S2[W^2 _,#Q#_P $WM*L?'7C/QM\ M%_C#XT^#,?Q&,Q\5:#X9FT7"03S*S!I5P>2,_@7J.FS>*-.^(-S/>^+]>U0^;K6KZK@Q@C_ &BV*:FUOK_7H!^2S M?\$P+B?PDOPKU/\ :3^*%Y\'8W,0\!F]E\I],$@<:1/?AO,:R9 (WB;JG'2O MJ'XD_L0_ WXA?L^Z%^S=-X?70/!'A.&QE\(3Z2/)OO#FKV&7M]3TZY3$BW;2 MDRR2*P9FSN)Z5]D]!QCJQ&1TSV^G ]_<4@50NW'RYR1SAB>N0#G'UQ\:?V*OAK\=/@WX%^$OBRZU&)_AO8Z9;^$?&-DYMM;TB M]TFT@LX-0MIU*O'.P@0D X/XU]H! /XN>_IU%3S/N_O _+FT_P"";JZ]J_@V?XR?'KXA?%CPSX$N[:[T3PCK M,\L&F/):,IMVOXXY/],,>Q2'DX+ -GI7Z;V=G#IMG:V%A"EK9:?##!:0)@JM MK%&(XU(]%48 SZ$]!5_:-VX 9*[&SDY0#[HY&/U_I2;%P> O(P5ST&/E./2G4?YXHH **** "BBB@ HHHH **** "BBB@ HH MHH **** #CN6&.WKTKY'_;3_ &3_ ]^VA\$;_X)^*_$.J>%],OM M>T77!K&BN%O(;K1[DW4"Q=OF.".F3WKZW89'U!4YZ;6^]^/H>U(%4 #'"C&/ MX2.>H_O<\'/Y4 ?A4G_!%Z]DBBL;S]M#]H"[TI(8[)M+DUZXCMY=/A18DLF' MF B$1)Y051C8 >*_0/X"?L0_!O]G[X'>*/@=X5L[B_T#QM%>Q>+-4OF9]4U MM]0ADM[BXNIFS)-(/-?JW(/?-?:9'7'']T=@??.2??I2!0&) "Y !91\V1SQ MG@<\\?3WJ^>7<#\HO"?_ 30N? WAS4?AMX7_:-^)&D?!Z\N[F5_ 5I,/$$_ACXV:=> M6.JQ7[O-+I'V^%HI[JSE;!EFE+[V_V_MKTOYT=QG8,0SIMZDBOU2VGIP-WWR!@^VWL/Z MT! ,X)R<#)"\@= 1CTZX/M[T*3_JW^0'P#X>_P""=?[/&B?LU:G^S'-H#ZCX M3UN_EUG5=8N#NUF]\3EWG/B)[O'FB_,[&4N&RW '3->,WG_!,2Z\3>$]!^%O MCS]H_P")7B[X0^'I8D3P3=7,D,5Y86S[[;3]0O%9GNK>&,+$J.1\B@9/2OUE M*CC&1@DC'8D8('LW .<\#K1@9SVSE5XVKQ].3GGFGSO^OE_P?O ^-/C7^Q)\ M&?C5\)/"'P>NM*;PSI'P]CM9_ .I:$?L-_X8OM/1([:^L)(L.)CY*O,P;YVR M2.:^2?B!_P $I-.^,%EHMM\7?V@/B)XYF\,7&G3^&)K^=Q#I9TV2&2-2@8QR MRNL>QI7&_:3E^''[0?@GP!X=US4M5T#Q%\-+32[?PCXXT2X:UU MS3I=+B2.*5)H\2'.OC!!X"D M@N?#/AW7KB1-,AN;7_CVN;B"-PMS-$0#O;.<1@ @C(/&"<<=> M<\_CQ2!0H4+D!#E0WS8Z<9X../7ZTFV]]0*T,:1110Q(L<44<<44:KM6..-0 MB(J]@J@ "K73;PS8.F,_7G@X[9QZ@T+? M:X'RI^U/^R1\(_VO/ D/@OXI::\_]EWDFH^'?$5@&BUC0-1=/+^TV-RA66)P M N=K8.T=#7YKV_\ P12T7%MIFK?M5_'+6/!:^1+3_@F+>:=X4NOAA8_M)_$R'X/75RKR>"#>R@1V*,#_ &3;W6[S M8[,QCRC&"#M[>GZT%0J'YB3R%[%!T 3C'3)[_A4$\D$437-RX2&V@EEFD; 6 M.*&-I))I,8X5$8D\8ZT^>^BO=]O^&OTUM;2^X'R#XR_8G^"7C#X"Z9\ 'T>3 M2_"6A00MHNH6SN=5T[4XBKIJL5R6,HO3,HD,@8'=^-?D5_P4<_84U#P-^R/X M@\1^+?CI\0?B-IWP]N=#B\+>&]8FG%A;(]_$L0N0K,UT]NB@*7' ZG/%>Z:/ M_P %1?%=_P#M8Q> 9O#VD)^SW?>-IOAWH_CE1B[D\50R-"\(ESY9A:4;59LX MK]D_&'@WPS\1/#UQX8\6:19>(_#VI/#)+8ZA&L]M,[V]T6\\+^&_"_B'PMXETF0KJ>A: MO!80-'E<)X0_P"">]@WQ-\)?%3XR_%WQG\;-5\#^7)X5TSQ%/)'I6G7 MMNP,-\+1'\M[F,* 99%)8@DCK7Z/;6^[Y:JQP5!D3>%'5P=W0'/8^^>*:I)Q M@X)++O9E0@<[L*V-Q8YY I3[_=Z>7H!YQ\ M7/V!?#'C/XO7/QW^&OQ!\1_!GXCZM;):^(-4\+.4@UJ)8S&&O;50(VD .=S MX/X5#\+?^"=WPZ^'?AWXR6VI^)M;\9>/?CAH.HZ%XR^(FL2;]<%EJ4;1E;.1 M]S!4+!D2,CIC'(K]#@9'P3RRA&8 HJL656\L$\$#/)!../44N6C5<$-_>9,% M..??RRNGWZ;@?F7K'_!,WP#K'[+?P8_9;G\;ZZGA[X+ M^*K3Q3I.MJ,7E_<6FJRZHEK>C. @>4KNSD].#T^IOVB?V=M$_:'_ &?/$G[/ MNO:WJ&CZ'XCT33-#N-:TQW2FLN6.YF+ C:-P551P=AYYZE<<&ES2]=5T[->7H M!^.__!0#0O@9\(/V;/@!\(OB]HGBS5_!ND:QX;\%>'_B1X?BF;5? 5]I5G;6 MMAXMO)8$,L"HD,;28P _#>E?G/\ MK_#7X7>+OAWX$\&:!^T[XL_::^).N:[ MX?T_X9>&[>XFOK71X%O[-VU#6$ARBO';APQN0)%P=R+QG^G/Q?X$\)?$#19O M#OC70-,\2Z).P>33]5M8[J$R <2A90P60'D,N,=L#BO,/!7[+OP%^'NL1:_X M1^&7AK2=;MV+6NI0V$3W-NS,\Y!^A%-.S3[,#\6/'7_!&+X6ZAXRUSQ=\&_C+\3/@:/$M_/J&K:1 MX%U:>STZ2YG=I9&@M4<1PJS,2P50"/PKZ"_91_X)J_"K]F/QC)/B MO\3+B'[/!XU\;WTFHZA9"0'S'M#.7$+'')CQUZCFOTEVCOD],C@ X&,\ '\L M>E+CI_#@'A>!DG))!SWZ>F?PJN=_U_6_]6 _.OXK_P#!/[PUXU^,+_'GX;?$ M3Q3\'/B-?0?9M)_%,\EV]M8R+B2VMHY&,4,3J2NP)C'%?<+DH0 M51,\E 3@%>C9)/4:<;M[NWX>G;]0':[_P3HTFV\=^+?%_P M@^,7C7X0Q^/[B>X\6^'/#4S-I%[)=Y-S+##D);7,Q8[G7'7BOC'_ ()B?"+P M_P"!OV@/VW?A.KWVN:)_:]QHNI7&J&26XU2#4K9H+^:^ED'S-=B63=R<;]O: MOU%_8L_:-/[4/P&\-?$^\L8=,\0W0>R\2Z=%A?LNL6K-'\,_P#!,.U\#Z?XJ\%> OCY\0?"WP<\7W]U=WOPYL97 M73[-+YV>^L-/FW V]K,9) R+CAKW#]EW]@[X8?LQ_!CXB? NQN[KQQX)^ M)&M:MJ&KVGB%1/\ Z-JT2,YCR"FT;N@SCH$OA/K\UVLO@6SN998++3KF3,MAIMPS^99V[(3'M085&P&ZBO7/& M/_!.WX4>(/V%M"UZR\0OJEM,]SJ>I:E!.+F>:YDD)9VNI M6D))Y/05^@Q_U@3+9P7 & !SC8P#$?/P4^;E]>3WW["GPFU_P#9H\/?LS^+7O-<\.>%(8DT3Q!+^ZU: MPO8LM!>VTF/,26-B&5E.,@8X%?2/QD^)5I\(?A?XS^(VI6#ZK;^$M*N=3FTZ M"6.-[E84W")6/1R!UYYZ"N5_9G^-*?M!_!_PQ\5X=,&C1^)UEE@TYG1I;>"* M1U1)7RRM)A*?AG9?#;_A%8(P-)T_1K-D,-Q:1K@).@14( P /PK[!(92<;?,&Y MLNZ9R1R&PW3&>=N!WXJ/<7R$(SMW%68+)O/5@QP BC)VG[PPPXI-R[O\OZW7 MX ?(O[)O[(_AC]DJP^)MEX7U_4O$2_$WQ]J'C_43J./,M+V_EEE:T@;M&AE( M53@[1@CI7 Z/^RMX,^ /CK]J']I&-]<\U@05*MG(9<@@Y!!&1BJ4]-5KY=@/YFO@Y#^S%XJ^$'Q/\ %/P^_:8\ M>?L^^!-1O/$+^*_V?]9NY[35-%N%,OF:9I-G*%G7^T9@4"6R-G<-VT'=7U;_ M ,$3/AIJ/A+X4_%_Q-'8ZK8^%/%WQ!U&7P>^M0RP:E?:/:S,T%]*LP$C?:@Y M?S&SN)'TK])]6_9"_9OUS7;GQ)JOPC\*7&JW=WGW$46R.1 M]V2D^'M,L](T6PM=,TVPB$%I8V,$5M:P1J,*J10HB[0, <9] M2:3FW^&^NUO^#]X&HKW()J2F[>=W?H?0CMQV_.G5+=^B^0! M44N?9?1ZGI$=PEM' PYX:G:C P >@YQQUSGG()_7\:=VMFP/BWX8?L-_!7X5?L^:]^SEH& ME3S>#O%-G/#XFO;MB][K4UTN);BZE/SM+N^?)).[GFOG;PY_P30N_#/A-OA? M;_M&?$?_ (4\K720^!HKM[>""RN&=CIT=U'@FU ?9Y>,A1U.<5^K6W."V"P8 MOGG[QZ]\8/'&,<4C(#G !S_>&*?SE@M9&/*O(6)+9.3DX[_? MWP_^%6C> _A7H'P@K;< M'CN "3R3@YQCIC]:4JI&,8'J"=V,Y(!SWZ?3CWHYW_7Y_P!=P/R?D_X)A:;X M:3Q?X>^$?QU\>_#'X>>.Y[N77? VD73C3(X[Z1Y;R'3.0+5)P[H^P@ ,1[5Z M5J7_ 33_9RO/V<='_9UM]+FTW2O#VM#Q3HWBZVRGB6V\7M*+@Z]%J2!;C[0 M9OG==V&;GU)_138..YZ9(&0N,87C@GC)Y^E*5R1S@* $ QQQR2<=<],#C)HY MW_7R\OZOZ ?E5>_\$T(O&=QX.L_C5\>_B#\5?!'@O4;/4=-\&ZW/(FFWAL9 M]K_:6UB+HQE5XE!5@.17T!^TA^Q)\-?V@[+P1,MYJ'P_\7_#-(5\ >,/"K_V M?J.A6T"(D=O&\6"T&Q%!B)"D=LYK[5"*""!T&#T);W)(_D*4#'?CL,9VC_9_ M^OFCG?\ 7R_X/W@?D9K7_!*W2O'7CGP%\2_B=\=O'WCKQ7\.]6LM0T:\U&1T M@6*Q8-';F/<5+2$8DDV_/Z5]%?M)_L/> _VA->\)^.8?$&M_#GXG^#T@BT;Q MQX6F:#56MX8TC6VO&BV^?"=@+1R>]?=)53C(R!CCIG;DKTQ@Y//J,#C&:0*! M[$G)P.-WJ,\@>V?7IFIYI=V!^='P^_X)_P"F:5\5]'^,WQ9^*7BSXQ>,O"\0 MA\//X@GE2RTH@ "2WLPPB:7: "V.>:_1 =N,< =,$#TQVQZ=JF9%WITR#D9' 'TZYZ\YZ]J=@8(P "<] M!P>^.,<^^:M3:M;2VFFG;_+\0/B']FC]A;X-_LR?#/Q5\.O#4-]K">$/\ @F;*,'9ST0C. M.17U#L'S9QR,# &0#R1TQQT4XX&1S2[1AD C8$!!R.>I.>3[ $#K2YI=P/S M US_ ()N:/I?Q!\=^//@E\7?&'P67XF2RW/B_P .^')6_L74+N\R+B\M[0;8 M[:>3)(:, [CDD<5Z-\/?^">GP%\"_!;QC\&+K3)/%%M\1Y9+WQCXHU8B77=7 MU>1VE74I[AAYAN(YF:2-]P*G QP*^^=H)R>_!4#"%>W')!'J,?XFT=.H_B! M(/Z C\*7,^[^\#\EU_X)?7$OA.W^%NI?M'_$S4/A):3(8_ >]!4$8QW MZ8^4<@Y YY&!CG@CWXI3:7?U _'OQ_\ \$H+/XM>&M%\'_%;]H7XC>--%\*7 M-A<^%++4991#ICV%S#W. G)OO_5O^'^8'Y:Q_P#! M-J#Q3K/@:X^-?QU^(/Q=\,_#NZM=0T'P=K-S-#I22#@#';-6*0C//!/0;AD =\#U/7/K1=K8#\M/VG?\ @EK\'OVB M/B+=_%O1O$WBOX/?$R]CC76/$_@>YEL+O4"@/E377D,B3.W/F2R9*X%>??"C M_@C[\-/!WCOP]X]^*?Q<^)'QUO\ PS=17^C:9X^U6XU+3H+F%@\,_P!GEIX.5<_P 2\]/PI<'D<;3U&.?H#U"XXQ]>>:?, M^[^\#XM_:C_8J^'?[3+>%-6O]2U/P3XY\!RQS^$/&OAF8V.IZ6L2A5M_,CP7 MMU1$0Q9"[%QCK7E_A'_@GU9'XD^%?B5\8_C#XS^,U]X,V-X.FT+SC\<\_K\S?M:?'FT_9J^" M'C'XHL+>[U72;98_#VGW3J%U+6+G,=I:[?XB\S*A4=,YJN:3LOEZ@>5_'K]A M[PM\7?B)I/QB\(^-/$7PD^*&E6R:?_PDWA1S"VH6<; QPWUNFT2H@&T-)NZ9 MXK\N;?\ 9_\ ^%$_\%5?@P]]XS\1?$/Q1XI\(7FIZWXGU]Y;FYGD6;$,(',< M(C!.U5( &:^VO^";?[=/CO\ :UMO'&@?%SPS9^#O'WA.2"X32;5?(#Z;>)YU MM.JL(5UVX>YBU-K[RS=:M,9!E+AVB4F( *JY '-:?[7'[5GC/X M _'O]D_X6>&]'TW4='^.?BV_T+Q)=7X_TFQMK,PB.6S96^69O-R>H;:<#C _ M0E0VXNA.U4!V'"*Q8 ABS?Q$MP<[<@&E>7=@?FGK_P#P3ET;3?BEXM^*?P.^ M+/C'X(7GCR6>_P#&&A>&)670-2U"Y!\R_2Q&(8IY&.\LN&9F)Y.:]5^!'[#_ M (!^!OAWXCV]MK^O>+/&/Q7M;NV\8^.=;N9+C6KL7B.':)I&81QJ7)5$5<8 MK[9.Y""?N$ &7BL 3\R=FV[K?#'PSKU_KFFZQX@UK7WO]1'^DBYU>2:62((>5\LR MX')S@'O7$?!S]A?X^+=+^.U_=7OBC3-6B#6]JMYY@FA@W<*- MTI"X&1@&ON)M^4\Q"-NYBI(,:XXW&53M5@,8#=<&OC/]GS]KC3/C]\7_ (V? M"_2_#TVCQ?!K5(M(O=0GGCE%]>398RIL(*18&X!MQ.>M%Y?TEY>7I^ 'S++_ M ,$LK'3]!UGX=^$/V@/B+X5^$/B&]EN=1^'UG>2-8_8[F3?/86LY8-!:RQDQ M&-0%VGWKVG7/^">7PEO'_9B@\-7MWX4TG]F'Q$GB/P[IVGQ*(]=O?F,DNIN- MIEFF9B[N"[?P= M<^'I#G38+2V18Q=1/VE8!2RD<>M/^)?[(/ACXE?M.?"3]IF^\0:I9>(OA#I> MH:9I6AP+_H&H0ZBFUGN'&-S*0<* <]"0,5]?%&*J> V#L!=,,0<]C@JQ]!Z9 MXIJG?@<^8C$G.0%;@G;R-P'0#HN<]Z?O7N_1O3:^O];@?@3\6-5_9^\;_MP_ M$33Y/'GC']D7XS^%[2.TNO'PD?3?"WQ6L2%8W*2LJVD\\08@/*X;%? EY;^,OBCJ_VB>TU+Q%=S.A@M;J4! M710WR+'A=@7CH:_>KXC?L]?!OXK7L&I^/_ &@>(M2MP$BO[VQA:[2'',2W"J MLFTG)^9F^M=#X ^%'P\^%FG3Z7\/O"6B^%K6YQ]I&EV45O)<#CJ33JR>^FW0 H MHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 X=#_O1_\ H8HH'0_[T?\ Z&** &]A_NK_ .@BBCL/]U?_ $$44 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4UL[3Q_G(IU-8G! !)(^;!P0OKSZ\\CGBKYO[J_K^G_ $M0Y7Q? MX@LO"'A?Q!XKU"6*&TT'2KS5));A@D(^R0M*NYS@ $IUS7\F/P;_ &R?V*_% M6J?MH>(?VF_BPFB>,OBY>ZSX9T&WGT#4=8FT?3;8745B=.O((IECCFN%B(56 MC0AL[TXS^]W_ 4EM/C3XA_9QUKX?? _PQJ'B3Q+\0;VU\-ZHVG2+%_9>@7C M(NH7;-)B12L+%MT9&".2!FNA^ ?[#W[/OP^^#7PW\'^)_@O\.-<\2Z+X8T^+ M6-1UOPGHFH:C=Z@\4M]:CUW4?V?8?$TNF.Z21O?^';:WN;K0I8HYB74/#' M$94/*_,..:I_LH? 7QM^W7\/O%W[1WQ=^,WQ&T7Q#XC\0Z\GP]T[PGKUWI6D M^$K6PFD33KB"SMYHH+F0L$\]+B.1&4L,>FMXC_9 \:? _P#;JU'6OA'\-\?L M[_M!^";WP?XU3PU'9V6F>#=4OK.:V75I],C5(S!&'W#9%N"# Z51^ 6K?MD? ML"Z/XV_9W'[-'B#X]>&'UW6]0^$WQ"\':K86>D+%K$YDMX?%,.H2+/!:VA"O%__ 4:T*RU^V\0?%+0O$$M MEIGB+6\I#>:[;PSK::EJDF0OE#*RR.2-OEL7XJ+5O /P1T'X2ZOXA_:K_;HU M2_\ VBM837K^^O/AGXYN]0A\-:A;---8Z/8:#H]\8XX;5O)A5KB%0Y+@,2"! M9_9/_9F_;'N/AQ_P4$Y_AC\6/CS;W%SX$U&VO3Y+ZC=Q2/]GTVYC<-$ M%3_1FFD<,6DZXS6/\!/"OQ=^''[/FC? +2/^":'VS]H#3='OM!UOXO>-G\+Z MCX6U;5IC[_>Z=%?I?K;OMZ[@/\ M@9^U!\6OB[_P2;_:"U[7O&^K:EXP^&^M^)/"7AKQJ)I[/7;C0;(,NA3W4R,E MPMY)$%:5]P?+D$Y%=_\ L\?L2?$7XH_L;^%/C/XU_:$^*Q^+]]X'_P"$C\-: MG9>)M0@LM#%G&]Q;6TEI]I"7C3&)4F>XCD.SOS7@_P (?@7\9OV?/^"8?[9/ M@KXT^#Y?"GB:_P#%?B;Q!:Q"2,V=['?>9(DVFM'\WDQR-MB1_ECB5<8KUW]E M_P#:9_;6TO\ 8K\ ?"/1OV2O$OC7Q!K?@J+1O ?Q1L]7TV#P6FA7\9AAOM=@ M:1=16YMO,/RP *X0YS@4.W2^ZOHO*]M?7_A]P\+^.GCG5_VK_P#@G _BCXKZ MOJ\WQ$^"WCX>";O4+*^GM;7Q!%;:@+,7M_#%)'%D_8N_8Y_9R^%7P_\ &'B;PDWQN_LJX\3>.)9;_P 0:UX;TJ[A@%^VB0O) M/<#?&S>1!!CRB0 JXKUWQ-^P'\4?!'_!.CQ'\*=#LH?%OQG\3>(T^(/BG2K* M4)#<:K-TTM(ENH8IK?=;JEWL=8%N#P"-PW4_<_O>6B?\ MPP'R7\4OC+\ /A)X)TGXB_LO?M+_ !_UWXX^%[S2[RZT;7_#GCF[T?Q\LES# M_:EIJ4.H(]E8B2-GV- 2@_V<#/NW[:/Q(^*GQR^,/_!/;1?"7C;Q9\,XOCGH ML$'C*#1KV[TR86M\J-?Q3VQD17N,1LL3LADC#MAEQQ[/K_Q9_;"^*_AKPS\- M?A)^PQ'\$?BC,?BOXNTOP=J/@_0K.WEB34K[1+**![JZ>6-9#&MTC' M++C.*[?]HS]GSXU:W^UY^P)XHL="N?%VB_"UDC^)/C'38+.PL--E>(_:KPV2 M*D5O')+_ *J*%$V+PH%2^5)[WZ726UNWX?+J@/TD_9Z_9Y\/_LZ>%]4\*>'O M$7BGQ);ZKK4NLS7?BK5KS6+RVFN4C#6]O/?3W$JVH=7<0JX5=QP *^@@@'?/ M.?09_GUIQ^\[#DG@#^%L<*!NYR>Y7T'UI1GO67._Z_KU_I:@UEW'.?\]_6GT5+=W< HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 -;&.>_YGGMFOBW]O[XZ:7^SY^RI\4_' MU]J L+@Z#>:/ID?&>&7 M]HW1/&,7Q*2V3PWJJSKXD?41>7%FVI&()_JU(,XFY9]NP!23^R7Q)_;OUF?_ M ()U?"+XA_#+6H3\2?BX?#OP\TO4]XE?2=2NV^PWMS-L)9+B)5$D>?FW'YLU M^C\O['G[+DND2Z3%\"/A'?AKXBU3P[IUCKOCWQ->1Z;8>%?#TNJ72ZQ= MQ74KQQQ71@8QV[L>9,;3DBN(^*_QI_X*"?%S]F#Q)^SGHW[(WB+PC\4)O!%_ MX8\8^/M1UC3)_!NJZ/967V*[7PVD6%&" M_-*T9=BPD 4;@!2TU_RZ6ZZ][_(#YZ_;(O\ ]G[]G;X.#Q?\#_VS?&OBG]I/ MP+-H-XUSI/B_5/%6A>*]5=[9]7M=2:UNY])M[)T\]X%P/+(57&20/9?VZ/BC M\;?BSI'_ 3LNOAEXZU[P)XE^+)\.Q:]>:9?RV\4T][IULFIWD\4+K'-(SR3 M3QB56C!QQ6'^TKX$^-G[2_[.NN?![]G#_@G99_ /_B464OB;Q/XOM?"UOJO_ M !)XU==*\*S:6/M=W+="%K;[7>MYTBL'E ;<3YI^V!;?&CP7X"_X)FV'AKPG M/IGQ?\)ZA868\&:M+&MQ_:.D111G3IY(_D"7PB,:OD%=X/0<))6V_!?IH!]@ M_M3_ +._C_\ 8=\%^&/VF/A5\:O'^NZUX.UO1C\2=%\3Z[?W^F^,(-0O8$U. M6.VN;B6TM2S2LR(D2*J_* .@\Q_;V^%?A/XQ?'[]B7Q[>ZCXEMYOC#-X>O\ M4K:TUB]MDL([G9(5TQ8KA$LVW#YWA$9?L2,U[%\=?$W[9'[=^C>%/V>Y/V7O M$?P/\(7FJZ1>?&;QCXPU;3+RPG@TVYM[BYM?#*V,C2F">2$M";C,K*PW$FN^ M_;U^"OQ8\/:E^R-X[^#?PXU7XK:7\"-4TBUU;P[H<]O:ZO-I6EE(U:W-T1%D M@ECG)PN.M4K65[];I;>7+_P=K=0/E;]IG]HKP;=?M42_LQ?$CXQ_$/X6? SX M-^'=-AU&'P9IWB#6/$'C>^DM0R0WVIZ5YEU:VX;'FS22&5Q]TDC!R?@]^U!X M!^#G[6'PH\+_ +.GQ7^+OQ;^$'Q/O'\/^+/"7C;0/$Z1^%]0F98K"]M-4UR( M,UJ&^>0-M89*Y(&X^X?$;X9_'[X:_M'VW[:'PU_9S/Q4\'?&+0=/MOBO\'M; M72)_&'A>ZMH5CV?"K4_VH/CQ\>_#.OV7P L?V4? M@!X/07.KVGB/0O"6I^-_&NI#;LMC+96\L6FVT$BL1/:LLGEE079@32;BK:OL M[VM?3SOW^6K ^77^&_Q!_:=_X*E?M.?![6OBMXWT'X0>"/#.@>(]4\.>']K7,M]J-U%YC,OVJYG:2:65%8+N=V8J,DU^<'[.GP>^)GAC_@I MS^V9\7/$/A._TKX=^./ ?@?2O"/B69XVL->O--O(Y+R.T13YBR01 M(7X('R M]*_6#@,<'!#94#C@KU_*HYE^'X]N]_\ @W ;L7_Z_P#GBD"8.)O# M'PE\>:MX-\/ZAXG\5IX=U"WT#1-,,:7E]J5Q"T5M'%)+^Z0*[AW+GH#CW_.? M]@']@WPGX3^#U_XJ_:1^%/A+Q)\7_B3XDU/Q9XG_ .$JT+2-9GTP7UT\UM91 M3WEO/)'Y$959A&P&?NBM8N*6]O\ .RO_ %_P0/BO_@EU^UI\(5_:N_:-^$/P MI\:MXI^$GBC4=0\?^"YY;673?*N'=KFZLK*RNL&$1ID!%'.<8[5ZI\$/#OB_ M_@I%\7?CKXW^(_Q)\<^#/AG\.O%^H>"O!G@GP;K5YI5LK6E>,-!\%:?8:! M;7_A#4F6+4)KR.UAMXKJ98781^8&D^7KDUQGPIT']J'_ ()]_$[XB7/ACX ^ M(?CU\%?C-?/XXL;?PIJ%C8^+/"OBC4X_/FTF^6_9;-[*.YF>.0X+@*2!DYI\ MT=[Z_P!?Y_U8#SK]A7X<>+OA#_P5D_:3\">+_%.K>.+K0_A5HRZ/K^L3&?4; M[19FBFTJTFG;+NT%H8HR\A;D;2?7U'QCX(\.ZM\0OC!XQ_;I_:WT_P ,@^(I M[7X;_"CP!XYETJZ\->&=LL=AQZG/JP5D=PL3PAE8LNX#.;^Q[\*OV MM/$'_!0#]H[X_P#QK^&%[\,(OB=\)XM'\(WKW:7EIHET8O*TC3IFA9T:[L83 M#)=/ ?OQN$.<5X]^SW\._C'^S)K_ ,8M!^,_[!&L_M*?%+Q9\1-9\0>$OC#+ M=^'=:TS5[2>2X_LX:C-XA>XO-,L(O,C86]GC]R/+9%D(93F6FNNFWR[_ /#@ M-_80_:%\1ZL/VY?@IH'Q7\2_$OX:_#WPCXBUKX5^,/$$E['KUC91:;<.L1N; MIS=O\^PQ2F0GCQTSQ/ MJ5N-(>VN9=E]/EXKD?^ M"8O[3/[5?P;_ &8+_P .:)^RUXI^-'A#4?$'B5?AYXH\(:OI<$=AJ%S>S(Z^ M)HKY]XL[>5D9S; 2E1UZU3OT[K\]?P [K2/$GCWXJ?LJ?M@_L^?&CQ/K?B34 M_P!G74M0M/#7BR/4)K;5M7TJ*0K81:K/#)&;K$7RN'+AP.#[6820:&DH,MCI1N" MQ0S!6\LD'APV*\<\ _L^?&K]H+]B)/V7/&GP8\3?!_XB?!RZ&N>$?%/BFXTW M4?#?BS7--O)IK:*SBMM\T<5X!&K&[&W:3GI3TZW^[_@@?,MW\0OV8U^%?_"; MZ/\ M>?M#2?M(V^F#Q/;:O-X9\=R:1=^+%MOM8T-],"?V:=+GNO]%CDP4$6" MRXS7M'[5/[2_QB^*_P#P3&^ WQ7TGQ!XC\"?$KQ+\4-#\*76L1?:]%U*;4#> M+I<=[+"##*L-S.3X=L--T>QL[>/4K:\U26.RLXXK6*'3$#I&8 MD#.(PQR:F345=7>O6RZ+:U[ZW\P/L']DC]D!?@JVB_$O5_B5\0/&'C7Q+X(M M++QI:^)->O-3T>YUR_:&_N-2LK*6>2"R>*3?#$(8XP(CSS7WZO&X]69< #E? MTZ'&.IKG_#D+6VAZ':S*ZRP:5:0R(W)#0P1HP9U^4NI!!R=W7&170=!T_ "L MI2OTL 'D$Y_#'UI H'(S3J*D HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M(?,RS!.9%VOM[+EMISVX SST%?ST_P#!87]IGX5Z?\5/@)^SU\1_%Y\(> F\ M36GC+XBZM%:S:A+!8Z?<12V\0M;;,KB5X]A7H=QP*_H,N7-ND]R(_/:&.>=4 M0[3))&A*PIC'^L(VCS#MR3ZYK\9OVU^OW/]= /S]M_ MVX/V4M%_X*(_!;QQ^R[\1[?6O"_CG1+'X>>.=(_LF_T>QMS&4M;2^<74<"2S M3 +\[Q @OCH,G[Q_:#\<^.?VKOVW=)_9!\.>--?^'WPG\)>$[+Q5XUU;PM?2 M6&K^)9+D+,FF_;(721+8@[0T4B-MR00:]C_;O_8)^&GQ&_9S\2VGP4^$O@[P M[\5/#4UIXH\%WOA;P_I&A:U+K.EW"7%K:B^L;6"0Q.\2;E:382,$'?A+>^./'/_"%Z?X ^.'PFGO8;77WBTR..!-;T.4,MI-< MRQ@L!+N16(+8S6]XO>.MK:?GT5_D!YE^T[^S;K7[.G[>?[!FEZ;X]\5^,?AS MKOC^]N= T?Q1JEUJLOA[4(7!U(0WEY+/<.MP9$E422E4'R@"OT,_:U\*>)?' M'[0>E)\9_P!HW0_@=^RMH/A);JR\.6/BN'PWXJ\;>)7C#3&XE:ZMIY-,R/D2 M!Q-A,(D:LBR)%_95[JDLS2HK*LF8FW8?;E@,G;^!?PD^*W[5'[>'[8/@SQ5\; M/B'H?P=\&^+=S>&=&UZ]M9+MPZ);VMO+%<(;"RC89,5NT;%>NF?!CX0:5J,NC6_AC0H](MKWPWI]M""NN>*DTM([>2:\1] MK&W7".F>,BN'_9Z^,?Q]^#/_ 4-_;5\0?#/X+ZO\]YI6\MOQT] /L3X-OX_\ V9OV MX+[]D'4?'OB7QK\&OBCX0O=8\,MX@U6ZU#6?#LX#12V]M>SRRW&W;D(S2,Z] M'?#\WAKX< M_#W5KN&\\1/;SELZGJDEL[6R3 8#+'A2>0"<5XE\//@Y\9_AY^T?^UG\-?&G MP0\8>(?AQ^U!>75OI'Q/\/7NE'1M#LKF":)+K6+:Y)O R2NK,(0"8\@#D5?N M^?39+LKK?[OEH!\D_#+]H+]GK]H#2/$/Q+_:?_:;^..C>/\ Q#J>I)X?\/\ M@K0/&9CFG_!"']I#]BK0_$'P0\;?L2?\-#:'IVH:A-\,O'_ (-B\,K)=V<[.;*W M\2KJT;31Q1-Y7FF+$I3>0?&3P_HNC>-?BOX7U^ MW\!?"'PQH^C:>?"UE-;O'IND37FFP1M?7$BNHEDN7OB2_73&\. M6-Q.NGZ-?VC7(@N8[E2XNS/'(YV+SQ7[S*JL VW:2,%>@).=S'.&8=<# MTKXD_P""=?P_\7?"[]CSX->!/B!HL_A_Q=X?\/QVNLZ-=,LDUC<_:)F,+/'\ MIX(().<$9K[>3)+Y[-Q^0_E[U#E)]?Z_K_@ &P>_^?PHV#U-/HJ0$ P,4M%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% #AT/^]'_P"ABB@=#_O1_P#H8HH ;V'^ZO\ Z"**.P_W5_\ 0110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !36Z9[C(]OFP#GU_'BG44 0#=DE3AB,9//&G'2D' MF %0<+G.T<*?; '3VX%6@ .@HP/0?E1=]V!7 HS^%(#YQ_:E^"=]^T/\#?'/PBL] M7@T"Z\8Z;+81:K<1M,MKO4@S!$#$YR 5/!"]*VOV=/A/>? WX&_#7X17>KIK M%SX$\.6VA3ZG$I1;X6[NPG56 *9W8 QQ^E>Z<_0849 P0 >1GW_7C-)M4 #& M<9&2/FQG@>_UH KA<,&!._(^<\G/3)['CCI3F4YRQSG(P>F"P.! MG)%6@!]/H/\ ]5!Y]_J* #_$GZ9QT].G;'M1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #' M7<]^>/P'\\T87' MW1GU_P#K4 4RKG^+;Z;25P/1<#@>PIP3 !( )/U)_B)[L/X&ZIVJS@>@_*C M ]!^5 %4[]H0R'<"2#['J/\ /]:3:3\OR;NJ_*!C'.Y>.'ZG=UX'I5O:/0?E M2%5/8:^#/VIOV.=5_:'^+OP!^)ECXM MMO#T'P:\5Q>(;VQFB>2XU2% &^SI)&I5"S-V/N[FX/7D_E0!%+O!SZ5&H96SD@9)(4D8W=2! MP!^'TJWSU/4\D>A],]3[$TF!Z#\J (/F# H<'E>>X/8^O;K3=C YF.OTI ,< M 4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 1R $#+$>._-&XJIY)&0>2>.>QZCU..2>:L=.@I#R.WXC/^?;WH \^ M^*'@^3Q]\/?&G@>*[73I/%>@:EI"WK ^5 ;^UD@6=POSL$WAV !R17SM^PW^ MS)?_ +(_P-T_X/ZCXDM_%%Q9ZSK6L'5+.$P1NFIW1F6,1,H'R [22,_6OLG' M.<#(RJEB22IZ\_PGN,9YR:0(!D_>Q]P'@\_>#,.3G'4]>].[[L"KY9&5W'<. M"')9_7?N.2 <\ <#'%2D2L!N8LH!!&XX(/!R.Y S@GD=>M3X!Y(!.,9QD_B3 MR?\ ZU+2N!7 ."J]^A;YF4#G )Y XZ=*15$9X&#G)Z?,3W;'WN#@9Z U9Z=! M28'H/RH A4*,C&%))VC(&3WQG'K4])@>@_*EH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH K[-V>,^H[?B.AI2C2'YB,+@ 8 X4Y ./0_@:GZ=!10 M!'@KN;C+$YP.QXP/0GIVJSCV_2CCGCD^WUSF@"N%>3 M())_=O$,GC#@CY@.O;GVY[5\"?LR?L;:I^S_ /'_ /:'^--YXLM=9M?C7JT- M_9:+9PO'-IJ12!V29Y $5)(/%?H)P!QD'V&/3N#Q]<4S:,+NY(R?F&_: M2/X2>?T]:=W:W0"N0&&23)D<%QDC(Z]6< ]0#^%&!TQP.:0%9=Z;MK8W#!/?ZYQG/OUI0OW<9!!&"#ACVY;J<]\GG MO5FC [ "@"- WS;@OS$$X Y([GU[YSUXIX &2!UY-+]/Y?\ US10 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% #AT/^]'_Z&**!T/\ O1_^ABB@!O8?[J_^@BBCL/\ =7_T$44 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M #AT/^]'_P"ABB@=#_O1_P#H8HH ;V'^ZO\ Z"**.P_W5_\ 0110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .' M0_[T?_H8HH'0_P"]'_Z&** &]A_NK_Z"**.P_P!U?_0110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .'0_[T?_ M *&**!T/^]'_ .ABB@!O8?[J_P#H(HH[#_=7_P!!%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 X=#_O1_^ABB M@=#_ +T?_H8HH ;V'^ZO_H(HH[#_ '5_]!%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 X=#_O1_\ H8HH'0_[ MT?\ Z&** &]A_NK_ .@BBCL/]U?_ $$44 %%%% !1110 4444 %%%% !1GMW M]*CDS@8Z\\?EVZG\*YC7_%WA;PG!#=^+/$WA[PO:7$Z6UO<^(=7L='@GN'.$ M@@FOYX(Y)V/"Q*Q=B0 #0!U=%9\5U%=0Q7-I<0W-M.BR6]Q;2++%-$PRLD4B M$I)&P^974D$8.:Q8O&/A9]?;PJOBKP])XH6#[2WAI=8L&U]+?K]H;2!/]N$. M 3YI@\O'\5 '5\=FR>X]*2H$&[:X(*L1M.00?92.I_PJ8G )Z8&>>WH3[4 + M16;_ &C8QWB:>U[:)?S*SQ6#7$8O)4C&7>.W+>:Z(I#.RJ0@.6XK05C@@GGC M([XSP3^/% #J*.G!Z^E(GO0 X?452D2Q/H!C))X!H?C#P?XCN=1M/#?BOP]XBN]'F%OJ]KH>LZ?JMQI5R M>D.I0V4\\EC-_P!,KI8I/]B@#K**J&X"[B[JBJ"S,Q50J@9+.3P%"@DD\ #/ M2L+1O&/A?Q*UXOAKQ/X>\1'39VMM2&A:OI^K&PN%.TP7GV&>86LX((,4VQPP M((S0!U%%(#E0>YSQ[#'-8FN:[H_ARQFU;Q!K.DZ!I=OC[3J>LW]MIFGP \?O MKR\DBMX@?5Y%Y[T ;E%>-_\ "_\ X$$ K\;?A&5/ /\ PL3PHIV>JV9.,X%S9RS0G@]G- '1T4@.0#V M(R".A^E+0 449_GC\?3Z^W6CU]NOM]?2@ HHSV[C!Q]>GY]J,XZ\4 %&:9(< M#GC) Y[YZ?G7.Z]XH\-^%+,:CXK\0Z'X9TYYX[6._P!?U2RT>R>YF;9%;K=7 M\T$+3RL0L<0?>[$*JDD"@#I:*@AGCGB6:&6.>&5%EAFB97BEC<;DDC=25=&& M"K*2"#D&AF)ZX_\ KT 3\=S@]AZT9KE]1\5^%](U73M#U7Q/X?TO6]69ETK1 MM0U>PL]5U0C&5T[3[B9+J]89Y%M'(1D9QFN@#?,#DDDE>G&X=0>^>V* +%%) MG@$\9_+WI?\ ]= !11GC/;IGM^='.<8Y'48Y'X4 %%'H.YY ]0.XHS_+/X>O MT]Z "BDR..1SP.>OTI>F?;@^WUH **,TF1C.1@M'_Z_P]: "BCW[?X=?RJ)VVL.0"!T/XT 2T51FO[6!HTGN[:! MY?\ 51RS1QO+SC]VKL"_/'RYJ=9"QP#R!G!QT/0_3WH GHHH]^W7/MZT %%& M?Y9_#U^GO1GK['!]CZ'W]NM !11_0X/U]/K1_G\NOY4 %%')QQUZ>_TH_H<' MZ^GUH ***,_XT %%'I[]/?Z4>GOG'OCKCZ=Z "BC/0]CG'OCKCZ=Z.O3TS^' MK]* "BC^O3WHZ\CD=* "CZ\49XSV]>U12YR.#@XSP?NDG./PH FQQGC\Q_C0 M.V3@'H>O3_\ 57*ZYXL\)^&6L5\2>*-!\._VGPTIM1NVQMM; 7T MT!N[ALC$,&^0Y&%YKH%EC 0A]R=4(Z$.,C'8[NH]1R.* +7N.1G&:/3]1Z5S M>N>*O#/AJ*&7Q)XCT/P]!=W"V]K)KFJV6E1W-R_W((&O9H5FF;("QQEG;( ! MK;MYDGC22)TEBD17BDC(>.16Y5XW7*NCCYE8$@CD4 6**/;O_AU_*C/]?TZ_ MEW]* "E]/U'I2>_;U^G7\J:S #D\D<>] #J*P-?\1Z#X7T]]4\3:[HWAS2XF MC234M>U&TTFPC:0[(U>[OI8($:1B%0-(-S<#)K0L[RWOK>&ZL;JWO+6YC6>V MN;26.XM[B"10T<\$L99)8G4ADD0E67!!P@ HHS_+('VA>>XGAMH8UWR37$B11(@ZL MTCD*H]R<=: ++$ 9ZGCC_P"O]>*., @\D9QZ=/SKEM8\6^%O#T-G=>(/$WA_ M0K7494@T^YUG5['38;^>0@1Q64MW/%'HI!P /0?Y-+G^>/Q]/K0 4@RX-(Q M&WOSG&.A_P \Y_2L#7O$OAWPGIKZUXHU_1?#6D1210RZKK^IV>D:;'-._EP0 MR7U]-!;)),_RQ(T@9V^506XH Z&BH;>>&Z@AN;>6*>WN(HYH+B%UE@GAE0/% M-#*I*212HRO%(I*NC!E)!J;V[]?PZ9H **!STY^E'_U_TZ_EW]* "BDR..1R M<#W/H/4T9'J._P"G7\N] "T4>_;C]>GY]J <].?I^7\^* "B@'/3GG''KZ?7 MVH_QQ^/I]: #K_G'\Z*8^,K6.C61<]$%UJ$UO#O/9?,SZ T =-FBO&O^&@?@.#E?C=\(^!G_DH?A7@' MC)_XFGUQ6QH7Q?\ A3XKU&/1_#'Q0^'?B36)E9H=*T'QCH.K:E,D8W.T5E8W M\UPX13N8K&0HY)Q5I7B]-;Z?A\NH'IM *D @Y!)R?3W]ZY[6?$&B>&[%]3\1 MZWH_A[3HS^\U#6]1M=+L4Q]X-=7DL,*G'JXXS7-:!\5OA?XJOO[+\+?$OP!X MCU!EW+IV@^+M!U:^8=BMM8WT\QRW PN,\=:7++M_7]/^K,#T;Z?J>N7]MI=A . /.O+R6&WBSQ]]U^N:\^;X__ +X M(^-OPDZD<_$/PGC/X:KUZ_K4Z]@/8:*Y#P[X[\&>,H99O!WC+PKXLB@.V>3P MWK^E:VD7J)'TVYN%0^S$&LGQ%\5/AIX-O4T_Q?\ $;P)X4U"2/S4L/$?BK1= M%O7A)XD2VU&]MY6C..'52OO3L^S^[^NZ^\#T6BO+-+^-'P?UZ]BT_1/BS\,] M8U"X?RX+'2_&_AV_NYGX^2*WM=1EFD;IPJ$\BO2HW)8="&&01R&!/!![@]CW MI 6:7M[YZ?UK%\0>(=!\*Z5=:[XFUS2/#FBV(C:]UC7=1M-*TNS65UCC:ZO[ MZ6&U@$DCI&AED4,[*JY8@5;M;V"_MX+VQNK>]LKJ"*ZM;NTECN+:YMIU#P7$ M%Q$6BF@F0AXI8V9)$(920OTH 6BC/3WZ>_TH!STY[\>GK0 44>GOR/?Z44 %%%5;JYAM89;FXGAM MK6"-I;BXG=8H((4!,DLLKD+&B#EG8A5')Q1\OS M45RGA_QAX5\60SW/A+Q1 MX>\3V]I,]M=S^']8L-8BM;A.'@N)+&>>.&93PT'[47_B M#6M(T.Q::.V%]K&H6VG6;7,SA(8%N;J6*$S2L0L<>[>[?*H)P* .@I1[\>]4 M8IDE1)(I$DCE17BEB8/')&P#))&X)#*PPRL/E88(/-)<7,5K!)<7,\=M;6\; MSW%U.Z106\,89I9IIG*I''&H9I'P&B,\\8Q[CG\**Y#PYXS M\'^,(;BY\'^+O#?BR"VE,-S+XG3GKQZ?UH DI.<]./7_ZU5[NXBMH9KFYFBM[>")IKBXG=8H(88P6DEFE M8A8XHT4N[L0JJ"2<"L'1/%/AWQ-9#4O#7B#1/$.E^9(AU30M3L]5T])8F*RQ MM>V4TT"RQ%2'0OE""& ((H Z?-%^(-2U M6RLM%LP)!$3=:G&(H+GQ/XBT3P[;7-PMI:W&N:I9Z7!/=L0$M8);V:&.6=CP ML2,9"< *: .FHJ"*XAFB2>&1)H)$5XYXF5X9$< K(DBDJR,""K D$$$5/GI[ M]/?Z4 %% YZ<]N/S_E29!'7KDF3[]O6N$U_P"* MGPS\(7G]F^+OB-X%\*ZF4$G]G^(_%FAZ+?&,YVR?9=2O;>8JPY#!"#V--)L# MT.BO*+'XX_!?4;B.RT[XP_"Z^NYI!'#:67COPQ=7,KMPJ1P0ZD\KNQX"HA). M M)K('!O/#^KV.L6H)&1F?3Y[B+D%2[LQ"JJK_:G)+< #YB>,4N679@>Q M45EV6H6.IVT-]IE[9ZEI]PN^WOK"XBN[2=>/FBN8'>&1>?O(Q'3FK;EE(Z9^ M]SU]BS1HQ:,GL& )[5HT %%'] M>GOCK1UQ[\#W^E !11SZ4>W?./Q]/K0 449Z^QP?8^A]Z/7VX/M]?2@ HI&. M ?48/X$CG]:AWL&"\Y/J /YT 3T5GV]_:7@E-I>VEXL4C12FUGBG6.13AHY# M&3LD4@AE."""".*N1[N<],Y'T[__ %_>@"2BC/3WZ>_TH]?;K[?7TH **,]N MYY ]O6C/\L_@._TH **:YP#P>0>WH,G]#5$7MH+@6@N[;[:8C.MEYT?VPP@[ M3,+?/F^5N^7S-NS/&: -#-%+/#&JZKJ&BZ7XG\/ZEK.EX&IZ/8:O87>J M::3@#[?803/ M1)GC>\*K[T =9]>!ZT?3D>M4P[KA.YY ;J0?3..*Q8_%WAB379O"L7B309?% M-K;1W=SX:BU6QDU^WM9,>7=3Z2LQOHK=\C9,\(C8$;6.: .FHS2*=RY'X_AU MSZ8__72')*K_ 'L].I ':@!W.>G'K_\ 6HXXP<_YZ5RVF>+/#6LZEJ6C:1XH M\/ZMK&C2K%K&D:9J]C>ZGI,C?=CU.PMYI+FQD/\ =N8XR>P-=-(PC!'3 )]@ M ,DGV [GCUH ?17+:9XP\*Z]?:AI>A^*/#^L:KI#^7JFFZ7J]A?7^F2'CR[^ MTMII)[23/ 6=$;..*Z2(L=P/4'D8]LG/O_G% $M%']>!1TZ\4 %%'.<8Y'48 MY'X49_S]* "BCT]^GO\ 3UI,CU% "TO&.O/IC^M9FH:I8:7;37^IWUIINFVJ M&:[O[^XAM+.VB7DRW%U.Z0PH,'+R.JC'7K4.C:]HWB&T74]!U?3-^MM1L9R!@B*\M))K>0KC!V2-B@#8HJ-SQ[=2.^#@@FN* .GH.!C MGD]NG_ZZJ0745Q%%/!+'/;S(DD$\3K)%-$XW))%(A*R(ZX9'4D,#D'%9WB#7 M]"\,V)U3Q'KFD>'M,1D1]1US4+72[%'N#CKG%)Z>_3WQUQZXH **JM/@_?0#:6))& JY+,3V51 MRQ/"CDFN&T_XH_#75M;D\-:7\1O FI^(HI&BDT#3_%>BWFLQR)]^-M,@O'O4 MD4\,K0@J>"!0!Z'13%+9 /.<]O3/I^M/]/?I[XZX^E !12$@=2!QGGC@]#]* M4\=>/K]W7/;'K0 44#GIS].:/?MG'X^GUH **,XZ\=_P # MT-'_ .O^O\N: "BDR,9R,>O;\^E+_P#J_K_*@ HHSGIS_P#6ZT#GIS]* "D! MSTY'K_\ 6ZTUVVKD8RYV. JD\4 =!13(WWQJ^0=R[P0005/1@1P5(Q@] M#3\]^WK0 44#G@/Q]/K[4 %%9ES?6MI+##<7MK;SW186T,L\<4U MT5Y<6\;LK3%>-P0';WQ5R(L3SZ\\=GK0!/11Z^W7V^OI1[]NN?;UH M**,_IUH]/?I[_2@ HH_S^?3\Z,]?;K[?7TH **#QUXY YXY/0?4]J.G7UQ^/ MI]?:@ HH/'7CMS3&8@[1UQGIVZ9'X\9Z9H ?F@YUF?P[:>)_# M]UXCMD#W.@0:O83:S;QGG?-ID*- \0FPN&M;]=$U>QU0V5RAP]O=BSFE M^SS*00T4NV12,,HKJ>V?;.>W_P"K- !11GDCN "1W /0D>A['I4E<[K?B+0_#EB^J>(]\O98;=68 MD!0SC<3@P_W5_\ 0111V'^ZO_H(HH **** "BBB@ HHHH * M*** &NJLI#@XP^+_@)\+/"VD7*_,V0JW=JVX[>,KU57Z:'' M_!<;Q!&KNN_X1V:L2[*AD(7"QJA *?>) !/'.:[+_@H]^S1XMTFT^%_[=?[ M/5BEM\7/@IIFAZIXQM]-5H;KQ?X1MX+9KN.[BMP#?O';^8B12;@H*OMX)KX[ M_9*_:+\.?M1_\%2HOB[X/:2*35O@,4U2RF!^T:9XCLK/9?6,D?WQ)%=C R/D M/0Y J^6+Z?G_ )@?JQ^UA_P54_9K_9/\7V_PUNK;Q=\6_BJ\G^E?#;X5:9_; M_B338D&#+<6D9\L,#DO;Q%IXQC>@)(KI/V2/^"F'[/'[7TNN^'/")\2>"/B7 MX>@O+O5?A3X]T\Z1XXB@LXS-(PL)?D=W50J0@F5"1NC&0*_/?_@D=X;^'.N_ MM)?MO>-_&.GZ)JWQRTOXRW\.GZAKGV:[\2:7I&VB@FU+PTR)]EN?$ MZ6F&A:;]ZLD\RAYUC0R;CEBN6.UOG??;_/\ /;0#Y_TK_@I79_\ #U?4O$,_ MPI_:!F\*+X1?X8V/@8Z'//=V6MM=/9W7C+^R NV'P_(!O_M .8\$RL% /ZZ M_M6?\%/_ -GC]DN_T?PIX@@\6_$7XF:W;6U[;_#/X=::NM^+UMKRW2:%KNS5 M@(63S5C:(D2+("2G%?-.@E$_X+A^+%C\KSO^&:8V2/8%)P+@EOE'+'@;AEFR M=_0X^#_V>K[XZ2?\%!OVM/$_PP^$/P9^+7Q%TSQ']GTJ?XP^([[1-<\/:?YR MA&\+I;0SF=>,/+A7B0[D*L P=HOIT7K_ %^?R _:']D?_@I1^S]^UU>W7A;P MQ_PDWP]^).G!VO?AG\2-+DT7Q=:HG5VMG)4]"-F[DZ[^V!H.A?M/Z5^ MR]+\,OB=>:WJVBQ:R/B%8Z \WP^M$D4$6UQK*@K%6#MG%WI]\+>6[FA& M=DGER%L#:VTQX<.6 ".YR"$WJ-^.S<]CG'-1-6M96W_3^NH" MX8[#O5AEB05^4IM*LA!YPQ.#D=#[5^!'AVW3]A__ (*UWWARS:XL_A#^V3HQ MU2*WN'*6\?Q&5&\U;/.(Q;QN7!7@\\#/-?OV S,[\$X S@;2V1D>A"XP2>O7 MKT_([_@L)\(-1U[X$^&_VA/ ]LR?%/\ 9D\7:-\0]#U&-&>X7P]9WL;>(K!( ME^_'=0$8.-(_9L_9@^*OQ/U*YC34[;P]=:/X9@X MWZOXGUB-K+1]-M>I\VYEF(CV_P!TG-> ?\$IOV?=1^!O[*GA_6/%44A^('Q? MN;CXF>+5GWO>VD_B*:2^M]+N7GRQ-I#(A 4D 2#%?!G[2OQ9T[_@HS\4/V$_ MV;/A](-,\-_M!?&^UM666/0/#6F0Q7%E;W."8VOA=PW!6WD.2K8901 MS_0MIUE;Z=:6&EV:*MGIMG!8VD0&$AM;.WCM[=P%X $<2C:.A[57N=G_ %;M M]X&JA&T!3T4@$]2<9*Y/.1T],8[U^:/_ 5NB$G[$_Q*0L\7FK:1RA"5WJ[$ M.,Y 4GL1C'/I7Z6;MN/E!;G / ( ^9D/J>< X]:_-?\ X*TL/^&*/B-DF0,; M-MARK.!(>%QW /XYYXII1=M-'?>^MEY:>>ORT ^,OV7O^"-G[ GQ+_9Z^&'C M;Q9\*M6O?$_B3PE97^KZG#XS\0P,]_=6ZO)=1VT=TL".KL'"(A4'^]G;7A<' MP]\9?\$EOVS?@_X<\'>./$'BK]F+X_:A_P (U;>&_$&H37DGA.]:01M*BS2O M&0C-$D+E0S(V3ST_;[]B(,/V3O@DS841^!-*W@8W!#:(>'!QN4?>Y[8/05^2 M/_!4OQ+H?QG_ &N_V-/@!\/KZW\1^-M)\8V^M>(H=+E2]7P]81W4=RDM^]NT MBP[XH6WERN#M!PSW]?Z_7=!_0O#+'/'!V.?7&>U2S$@DJ%+$* M%7+8#.>"&'4^HS@4ER=4_O\ ^&_0#XQ_:V_;W^ 7['-GID'Q(U34M;\9^(5/ M_",?#?PA8OJWC+Q X&[_ $+3HSN&Y)82QP7].6_: M<^)_@E_VX_"_@/X*_LU>'/CI^U]I7@X:ROB3Q]J]QIO@_P '^&K=0[7#-$KO M]M@'*-$AV9^3YN:_-[_@H5=_M/W/QR_9=U[]I>/X(>&]2;XD:='HFC_#:=KS MQ186PN(3Y.H:G.B:@]G#TC$^%W'(]K5-.^VBZMW^71@?MQ^TQ_P4P^ ?[)OQ M6T?X7?%FR\3:?+J^@RZW:^)K.WMKK10B M'8NHD^W27$M?\ B/X<;1-&\3RRR^7;OI4D MY$DD5VK*\4A4+Y;K\P;@?*7[7/@'PG\2?^"H_P"RGH7C72K;7M('@S2=3?3] M0C2:QN9HH+:2"2>-]R3@L Q5@3SD\UZG_P %J/!WA>P\.?LX>(=/T+2[+6=# M^*'AW3-*O[*SAM[JPT_^T+1?LL#1(A2 *-JJGW%&%':CEBK:?TK?Y_F!^E_[ M5O[97P1_9 \%6?C'XNZW,AUG,?A7PYH\)O=>\3W2A66TTR!3LE=B0(W+ %G4 M;LMBOY_O^"AG_!2SX(_MB_LKVG@[PYH7Q$^%OCZQ^+G@"]M_!?Q+T*30->U3 M1UU:V8ZQ81R?+/9$%=CJ2< B"(E###DJK8(%'+ M%M*RZ^7Y:_@P/W#^%N1\-? )9RQ_X1#0?,SEG8MIUN5?=D_*?XNGZUW3 !L= M3C//_P"JN'^&9_XMOX# 5<-X3T#9R0"O]G6QR2H)#,#E4SM&.M>':_\ M@_! M[PW^TYX?_92UB^O[;XJ>)/#3^*=/@FCB@TK^S"N85>[D=0US,01#"FYW(Z'F MI2C=K5_TO/I_GY ?FM^W6'7_ (*5?L,E3*2VJW14*WR@;(N2,Y />OW2>,>8 MV/EWELXY&5!.1C)5FSSTSS7X1?MQWUM_L+ZXN+JV@=9VM MH'6/][=(I:2(#&4WJH?@>M?O&#^\.2 0QR .H!.UF./0 ?7GIU+15K[6\]=O M\P/SY_; _P""D/P!_8UO-,\-^,8/%'CCX@ZXHDTSX<^ -,DUCQ7=Q9XDCLB5 M 5FX7D9SCK7S?\/_ /@MS^S'\1?%WPX^'VF^"_BAI?C[XA:[_P (]+X0U[2; M;2=8\)W!8K%-XBM[NXB>**7'R^0LK+O\ @J7^UMK/QACT M[5/B%X5:PMOA'%XED2:YL]&'=(\-:7X_P!:\9VR>*)=&CLX=2OHAO6A&Y;G3(YB%G251NBCW&5U!,:D#%?EEXND^+>I?\%8?'^H>%/A;\+/B MUXU\.^%=,C\'Z'\9=;GT?3M.T\6Z^5J'A\1I*MU>Q':48J2IY /2O7OVI/@O M^V3\=_BU^S_X\^(/PI_9D^"7C7X<>.M)U?2/%_A[Q_=GQ9KVFPW"K/H*1:B+ M6348EC#K;(OFLA9EC&S"@Y4GMY[]K= /OO\ :+_X*I_LY_LL_'K4/@'\6[+Q M9I6M6?@&V\>V_B6SM+>[T/4S?*QL/#FG1I.=1EUF^>/R8XA;^27ZOCFO//V> M?^"RW[.7QZ^+&F_!S4/!?Q3^#/BK7F,7A23XJ^'&T.T\2S2,/LD>E MYTZ7Z M,IM93'Y+EP"PP:^/OB7\-?!_Q-_X+R_#O2/B+H&F>*K/0OV;-$\0+I>I6\=Y M8+K^F66^VU"2VF5XKN*&'/#^F_&__@GWXIT[2]/TOQ G MQGCT>+5+.VBM[S^SH8[3[-8O-;HI^QP$DV\6=L1X0* #E6FG]*UEY_UW _4 M/]K']M;X&?L;>$;;Q-\7]=N(KK4I#;:!X2T>*.^\2:]>-]VVTZQ5A(S-G*.= MJY( 8D5\K?LW_P#!8+]F[X_^/=/^&6H>&_B3\$?%VM[5\.:?\7-!;P\OB .X M$)T^28[9?.^4HV<$,,$YK\\_VLYOB;KO_!63P%I^G_#OX)KN"^UNQ\+Z5;:E?0RB6"^N8;**/[5"XSY\2 MSME/V:ZT;3+B;[0\\B#;DQ!?FP6P34\L;M6U^?\ 7_#@?1G[*_\ P5A_9Y_: M?\>)\*7\/?$7X+_%#4(VET'P+\7?#\OA[6?$=I&,F72E8%&7IM#LCOZ-@5VW M[7__ 4M_9[_ &.=6TSP?XL7Q)\0/BEK2))I_P +OAS8#7/%UQ:L"4E>S4[5 M8 <1#]ZXQM0\U^97PN_;(_:=^%W[37P>^'7_ 40_90^'/\ PE_CO6/^$>^& M_P >].T71/\ A)I+N+=#";*2V6=[6Q5AB4AXI%8@*#V\>^"MY\;;C_@IE^V/ MXI^&_P )?A#\7_B/H7B&RM_#C?&;Q%?Z-K7A>P8!HKCP;#;Q2M+'(AVS3JJR M6J\Q%20P.2/;3\_QV_K8#]C_ -DC_@IG^S[^UUK=[X'T2V\4_"_XK::LL\OP ML^)^F/H?BYK.,!GNTLSD2 #EH682J",I@U<_;&_X*3_ 3]C._P!%\+^,X/$W MCKXC:\@GT[X;_#FQ36O%=S:9P+@6 ;*H7X,;;9 #T(P#^=OC_P""/[5_Q2_; M,_9J^-WQ"^''[./P"\8>"/%ZW'B2]\$^/;BY\6?$;PY=K&ESIU_97RVLU])$ MB;HG47$LP8+*Q &)OV-](\*>,_\ @JW^V/KGQ3T[2M5\>^'+R*'X?1>)$AEO M-*L'F7=)H$-\.%$6"QM02N21@\T^1;V\[7_+;?S ^D?AO_P6E_9K^)?B[X:? M#S1_!GQ0TKX@_$+Q(OAN?P;KVCP:3KO@V650\-[XAM+Z6-H[29V$0-NLL@)^ MX%Y/NW[0'_!2KX"_LT?&*Z^#?Q+L/$]KKT7_ (*,?L8^(_"5IHUI\5M9\:Q1 M>-TTWR(Y;K34,7V6[U.*W_>+/_P#@M1X%'B[1 M;+7H= ^#HU/3K748(KF"#4861X;E8G#*6B95;W?!W_@LY^R?\48?&R^)K3QU\&]4\%VMQJ0T+XGZ0-%UO7[>,'RFT.P#F M:=[HE5MHG17D+* #DU-^S[_P6,_9P^/7QCMO@K_PB'Q1^&/B/6'EB\)7_P 1 MO#_]B:?XN8MB$Z/N;SVCN@N^!G1 RY('>OE#]L_X._#;QI_P54_9HM]?\(Z5 M=VLNDVUY?V?V*WAM=3N+)Q]EEO(D54NTBP#LF!!('&>:[K_@I]X4\-:1^UU_ MP3AU?2M&TS2]0D^+#Z1)=Z?:0VDLFG0>0+:UE\A$\RW@#NJ!MWEJ<# Q1R0= MDKZ[M[+1/=/U\NUP/T)_; _;X^ G[%FB:;'_ +*__!6?]G+]I[QZ/A3-H?C_ ."7 MQ+OC%_PC'@KXNZ*_AW6?%UO*6Q+H:,3%)@D,L4CK),&(A#N-M?F)\3)OBUK7 M_!7SX@7&@_#+X8_%GQGX,\&Z/_A#^RS\"OB)\/\ Q[H?B/P=\3=# M^(EZGBV*#0 M-.MX9C?R:O<2KY<:>0(\D9>N)_9G_P""P'[._P"TA\4+/X02^$?B5\&O'&KJ M3XH4DX%?(OB7X;^%_B)_P6X^&%G\ M1-%T[Q.V@_LY0:R;;4K:*[L#XDL;".22^\F9621UOTDF@EP=V02>:Z[_ (*V M>$?#.E?'_P#80\8Z7H.F:9XGE^,5GI\VO:=:0VM]/I\0@:.QN9X%5Y((7&Z. M-CL&!1RT[K?O>V]FNE[:Z]/*P'S1^W)_P4';P-_P45^'NC)\//CI=^&_A)>P MZ9KWAS0;&X2V\;7=[('2^\/V:KY6IV<"GYR%E(8 '&<#]1?CS_P59^ 'P%T+ MP5=:IX3^)GC#QYXWTJWUVU^$W@[P\^J>.],L;B-71M7TR//V5D# &$\J0?E] M?FW]K\QG_@J)^R6Q$!E_LL2!957YV:0$.PVD,&.%.WD!]M_LD_P#!4#]G_P#:W\2W7@+1M,\9_#'XH6<+7)^''Q.TE_#W MB>6S89%U!;3A!+"P^88RW;':OT965@ @1B#\I*C*JS' (W\G;CGMZ&OYY/V< MOVQ_C?X8_:K\$_![]O/]E+X>>%OC-XPMW@\)?&S0M%T8^)=8 ^2)+F:S$S6] MC)M)B:.51M)W!L #^A@,V4DC0_$5_:6T7FS7%M;[V$;!2&"7!CF88V*V1CYH7?_!2KX#>&?V< M]'_:/^)MIXL^%.A^(#/!HG@?QMI@T_QWJMW$OR6EOH9(N/M$SXC164# M!M4UM9PZR75U K 3Q_=4*I9^ ?]?J!]J_ G_@M'^S-\8_'FE?# MWQ!X/^*OP2O?$EQ]G\)ZM\5/#>%/'UG\1=0L]2\,/8W,,T,>CR75O9P""8JBI:Q/L8;=B M+DAOVT^!FE^*=*^$7P\T[QK=65]XDTSPOIEAJM]IDYGL;J2UMTB\RSDSFX60 M+Q*QY'.:B22MI:^_EM\_ZT ^>/VLOV__ (/?L;^(_!&A?%;3?$GV?QS'>O:Z M[I<5K)IU@UD%)CO5FF2Z'//M.HQRI'YL<=MOE='7"MFOA MG_@J_P"&-$\8?M;QW"UYIEW!'<6]]$DX=+:Y@E'E3HSJ"R M/D9"G&0*[S_@N>VHZ5^QAX7\/:!#%I_AN[^(O@C3]7LH]]CI)L%N(X[.QU!K M1=L&GR'='*JY41Y!Z9(H/1Z6WZZK3R ?'_P7E_95F\5FRC^'OQJD^&:ZS_8\ M_P X_:"^#EO\ ")OCS)X[ MT>]Z[BX@N M7*>8% %?F_\ 'KX6?%?X'?\ !,G2?A;\1?$7AS5/!UW^T5:22V_@/Q&^N>'/ M#G@>[OQ

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�!I44U3N.!M.,=&!+J?XD'H/?K3FPH7<<%CCIP2,$$=1C*_Q$<]NO;O3@H7H*%8,..W!/52>^T^QX-+0 4444 ,* ^ MWZC_ #^-*JXYZFG44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %(5W4M% $9CRNT>HR>.W^> ME*(P!CG_ #^%/HH *3'(/C_]#%% #>P_W5_]!%%'8?[J_P#H(HH **** "BBB@ HHHH **** (W[ M>G.2ZL-"^+&C7YTFRB$UW?FUDM MY1%:Q;6+O)M**N&SD#%?N/)D@J.X_4_X5^'G_!;WQ%H_A3X4_ _Q/X@O$LM$ MT3XMZ)?ZA>R M'%:6DUM+"+_X*?$7QGHOB&TO?&'C?QQJ.O>-_"D$Q6,Z?"DEN M8'>:1#$OFX0L_.1U\"_X(]>$?%_C+XT?M2?M1V7@O5?AA\(_BGXG>;P'X4U. MQGTMK^VE+N-3%A)'#'MB4[!+#'Y,9//YU^$7_!12SO?B)_P4,_X)Z?#?PW$=0UOP MWXEU+QCJ\<'SSZ?HT<@>34;L+EH+0*OWGVJ,U^[X"Y*9X50N1URJJN,_45B! M_-G\?OVH?A_^RG_P6"U_Q[\1M.UK5M%N?@!I^E)#H6GMJ-XMS=R3I'(UNJ.S M("H!8#"]6F MA:=;W"GEO,5XK=0I&1CD$XQWK52C9:O9=_Z_KJ!_-K^T=X ^)O[,?_!)GX3? M"CQ5=W.GZUXY\<^'=.\065M*ZG3=-UR:VWZ?YF<+L6Y(>,\ @J0.E?OK^RS\ M)_!7PE^ WPU\,>$-!TJQM(?"FDW-P\5E LEW_9CU[PCX+BCG\:>'+NW\5>&+!R(TNM5TEA-'"I! #.8E MVJN3NP.:_/[]F?\ X+#_ C^%7@#2?@[^V/HWBOX*_%'X=Z>-#O)]7TF\.G: MXVFQ^3%)IVZ%BR[3BGI)/Y777\>P'ZJ>,/V-O@GXU^.?@3]HF MY\,QZ?\ $WP*LJV&L:2/L2WJN6W1ZJL'EK<;26\O<&7&..!7X@_MZ?'A/V;O M^"N7@+XGS>!/$WQ*6R^$&F6@\,>$;%]2UAS-;L1)%:QQ2NPX.6*$#R_9OTWQQ\.OV8_AM>'5/&OCS4;:[TR#QZD#V-%"T6].DOSC;_)?KJ!YA\1_P#@N3I%_82?#KP]^RA\0=,^(WCBWET; MPIX=\>Z3'IMO?76I1R6V'BFMHIY.9 X*CRQQN'%?9'_!(O\ 9A^*?[._P6\; M:O\ &+3[?PWXM^*_C2_\7_\ ")02+)#H5GJ,S7D=NOE!49RDP!V*" JYZ&O6 M_P#@HG^Q3H?[5'P@U*Y\,PP^&/C5X"CD\4?#CQ=I,,-MJJ:MI&ZZ@TV6Y@"3 M?9+EDV.J-YC' 4$<5YE_P2P_;1U']HWX8:C\*OBK=)8_M$? ^:3PAXXT>Z*0 MZMJ=MI+FSM]::RN=MPDDJ*&G(C!\O8['DFCGBTE9+SUZ66KZ[)_F!]0?MU>% M_B3XL_9G^).F?"SQ)9^$O$BZ-=7#ZC#4\47$O@E(9([N3Q!8RW7GZ@LA C\N6= M2=OW@&]C7]#'QPM;J]^#GQ+M[2&66\F\)ZW%#';(]Q--(;&4!%B :0N_W0$! M/<=Z_G:_8'\=?#[XV?L=_M#?L/:?KLVD_'75IO&LUOX5OK6ZM;M0;FZ=3YDJ MIR[+M"=_,P*:=UIW_77_ #_X('H?PZU7_@JM^VUI>L_&_P"&WQ*T'X0?#J_O M[IO /A[4;::2;5=*CD9K>Y5XE"8G4(N6_O@DU]C_ /!.S]L#XS_$+QQ\1_V8 MOVF;"VC^,WPHE'_$XM@4BU_3APE[&A"EE4+@Y'.<@U\@_L=?\%3?A'^RA\%K M;]G;]J[1?%'PO^(_P;2?0-)L+C1;Q8?'%O8.R6:=D7YR?)8N"&(% M=O\ \$VK;Q]^T/\ M>?'C]M34_ >N^!OAOXHM1H_@7^WK>:SU#6K%#E;A+>9 M(R5;(_>*A1P-_$7QM^''[+>EIKFI M0>'/ 7B#5[.2ZMM+AE863WEW&Z0QBXC4-%YF#ACN)Q7[>_'#5/&^C?!_XEZU M\-;-+[X@Z5X.UJ_\(V+*=DFL)92/;*%'WYL!F7 ),BJ!UY_E@^!WQS_X)_#P M->^*/VRO%OQ>\,++P_I.A(XL)!<-B.S5X" MWEY+*W ,J"\UMI\@/T[_ .":?[:/Q9\;7?[4OPH_:,\4>'O&.O\ [-LHO)?' MNAW$=UI.MV)CF:>6":W+)+;#;%Y%?\$JY M+3XI?M%?M]^##X)NOA(GQF\#B;PG\/\ 4(6LM:T703%(EI ;:Y6*59&CV2RR M2(O,IYQ7J_[#O[?7PZ_8%\(>-_V3OVJ]"\2^ O&G@CQAXAN?"%U_8]XUKX[L M+N[DDL8M*D6#;/>SQF)$>(R0NY(!R*TYK7]U/;?ITOOUM=]W<#)_8!^(WQ(\ M/_MM?M1>,OVA-.M=+\<>!O UQ-XK:U.;;4YM-C=A?6VW&%NEBZ_P[CFNZ^&W MCG_@IS^W!>>+?CA\%?B/X=^%_P ,-#\17UEX+\-ZE;RS-XAM=-GD"QAHAC=. M(U D;(&\9.#SX_\ L@^)-4_:Z_:\_;(OQX7UKP2/B1\/-1LO#&BZS&+77(=. MFBF2QN+Z"01F(W>4E4NJGRW!->C_ +$G_!1#X;?L->"/%/[+_P"T_P"'?%/@ M7Q]X$\1:K'X3@_L6\D3QQ!)/+]BBTD^05N+BZ81*DT/F1EI!R<9I._1=M%_7 M]=FP-/\ X)/:O\3M8_;:_:>N/C!86UC\0X%MK/Q EH28+BXM4=)+F+.%597! M<#'3\:_HN\2;1X<\0G(R-$UA@1PP']GW(YS_ '0<'U.#SS7\ZW_!*;XG77Q@ M_;G_ &I?'UWXL,[+@D Z=VGY_.^VW^>@?R/?\$^?"'[= MGQ4\/_&'P3^R_P"--#^%?@70_B_XXUC6/&>K0RW$FN:Q>:F\BZ5;)'\VVV*[ M"X.U<]*_4[]@K]K']H;3?CU\2OV*OVN'LM<^*O@_1'\4^"/%E@#%%XKTE$:1 MTE5@K1YPGV=1R27WYXK\]/\ @F3_ ,%!_A5^R-X/^,7A;X]6NL^&?A_K'QA\ M?ZIX/^(D&G2WNB:EK*:HS:EX:88[.-W6,Y8,!U'T?^Q]JWC#]L MG]OCXN_MV^$_ NO^&/@]X6^'>H^!O &I>(;5K.X\7ZM!9RK:7EG$RJTD(E42 M&6$/&ZL%#$@T_P"ORM_7<#M/B/!_P5*^,WQ&\?ZA%\2? /[*?P\T#5;FS\%: M?XBU2R>[UK1H698[^9HV3R/,5?,/FG&?BEJ'A/1+K5=%\;^&+B*XMIOLRNY,5Q 3&Y(&<%F K\XOA+\-=Y_P34\;^$?$/_!1_XA7O@[X?ZS\*?">O?#_5I/!7ACQ3;RV. MNW&A0Q2B/4Y[>X2.9O.VY1]I#(PYYYJZ_ECT[^7G;IVZL#USX8_%3_@HO^UQ M\:OC3\,OA#\5M*\#>%/A=X\GCG\1:M;R23W.G&X>--.01*"&C4 H22I8"O:? MC]^TC^V'XN^-'A']AS]FGQ1IH^)&@>&+:]^*7Q1OXLVXN JI<3)'M+X#AFXQ MCTKM_P#@DE)&WQ?_ &SFC9#Y?Q(N"Z_*9"!K?M&_$/PKKVL? KXK:$FGZAXST?3YKN#PW>S/E_MTB1LEO##NW2;V0' M!V]>9;UV2]+_ -=OQ\P/HWX!6'_!4'X$?'/1O#OQROM)^.7P3URRE?Q#XPTJ M6.PD\)I!#)-+(;CPJOB:]CDN+C7[VQ9DGED$0+^<\O$@4[5P-@ R![;IW_ 5#N/VJ M?CYX*^"O[&OAJ?QQ\.]4LK^#XK?$C5M,U"'2=#L[ZTFACCTNX2(PI>QF1 5N M)%+; ^F/V6_P!J3]J[X#_M^&GQ!T^,Q0WLMJC2M9AB SRR@,'B=F:(K\X&>>.\6? M';]N#]N+]HCXP> OV0_&6D_"SX1_!+61X9U#Q3J4#32:[KULYCGEA55+D&16 M1T!RJHS8 ZZE5>)#YIBCBB9I% M9&WQ[6HUMMKII^8',_!>[_:0MO\ @J[\&_!7[48T[4O'OA#X?ZY:V7BG2U<6 M?B;0FC(;F*'[3?SD(+>!797F"_,N(R2H!.*\*^'7[36F?M6?\ !77X2>/? M"_AW5M#^'8^'^N:+X/U;6+66PNO%%FL3/+K5O!.D#OBEX1UCQ!I&C6&7/FQZO+I,D43 M[0^ KMN &0,BJ3MT7SU_7^N@'WE\"/VGOVJ/V9_VDO!O[/7[67CKPK\5_"OQ M286?@_QMX:N(YGL-3!(6"9%+,/-(Y\P[@#D5X%\6OVM_VH/CU^U[\5_@I\.? MVC?!7[-.D?#F^;3=(LO&0%DFNB,MB\2^E:*%Q,RH"%8GYNYK"^ ]E^Q!\;OV MI?A[I_[)OP'^(OQ3LO"5Z=7N_B_XP\7^,)?#>@2QD_9[O3CWP:U3X&^,O#EP+7PE\6O"D6K6^G^+=.B5 ME@NVDACC6YE]4HQG?F5DMK.VKLNM^GWVUUL!^PO[!52;O[0T3M@JVS9@X 8CK7Z#7$D MD4,TXADGDBAD:**-@!.T:.RQ^H$C!5SSC=DX%?S1_P#!(N/6H?VK/B-;?L]^ M+?B=XT_8RM_"\D(U_P"(<5S':7'BA4 M(?#1E_=-8H20SI^\?C?S7])/BFXU M:Q\,^(;SP_"+K6[/0]2N-*A;)6;4%M)GM(<8R3YJH .YP/:L))*24=5=;O7\ M-K@?A)XXA_X*E?&WQYX_UV;XE_#[]D?P/H>K75EX*\.^)]6LY+O4-"BD:&VU M:YEC=%C2Z1/.!E^Z' )XKH?^"<7[67[0?B/XU?'/]F+X[>-O#_Q'UOX=:++J MNA>/?#MS!?6-XR C%O<0%HGC(&=S,PS\OM7YJ?!?X[?L?WC_ !2UW_@HUXQ^ M+.I_M,6WQ"\2I:?#B\O_ !181R:1;7TJZ-IFD:/ Z64UO=QK''!'+#Y;##*I MWUZ;_P $N/&N@:W_ ,%#OCA<^&OA[JOPE\+^-?ASJNH^ /!_B6VFLM7&@6=O M($OYK:Z2*X99BGF[BF#N!!QBM .J^!WQF_X*7?M??$KXX_##X2_$O2/"7A7P M)XXU>*?QCK$#R206T5]-;6NE0")<$J563*G&.".M?5W[#O[5?[2?@;]HGXH_ MLN_M=^(K+Q;J/@;P[>^*=*\66"&)+BPL8999%:.3#@LL1QGU[]I/^"+\D."?Q#\& M=6TR)T*[H+FYM)X(F<9# %G4,3P.?2B]VUZ?_C M7QUXZ_9M^(FA_"3X+>#O$NH>'_##:G;233:_>:3<.CK((0#'%*\8C\Q_EPQ( MX%<7^P5KWQHUK_@J=\1+/]H#2K73OB7X=^'']AZM=6)/V;5S90B,:K%N'W;P M?.!SUQ4G[&_[;O@?_@G-/\2OV7OVL-!\0^ ]0TOQAKFO>$/$L>EW4^F>++6[ MNI9;.VL"L>V>[G/EI&(G8,[8;))J3]A_XW7W[07_ 5=^)/Q+NO"NJ>#]'U[ MX=FX\+6&MP_9-9N]#2,#3M0OK8JC1RWD9,A38 !CBCO<#^EU]QVI@'D?,WWL M'<6RH_W0 ,/M$^'OB[P?^S#\%/"$Z6_@[Q'XJU6 MTDN/&T,?$NK")&66U0G)9)SL" ;0"37[>S.S(YB!:X6*21(^FZ9$;RE/H"V! MSQQSVK^3B'XU_L[:M^T'^T+)_P %1O'?Q*\)^/=%^(.I6OPW^'D-_P"(='\* M+X-@EV:9_9$>DO';ZC]IC53(7#0MOP&)S65-^\[[+[^C_4#[ _8V_:I_:>^' M?[:]K^R)^T'\5/!GQLTKQ7X+U;Q9HWC/PE?P7]KI TF)YG@E:V>0Q74P0AH) MFW!,$#%96H_&K]O/]N[XX_%;2_V3_'6E_"[X)?"?79O#2>)-6M9)X]=UNPF> M&\@Q"N]7#Q2@*& V\D9YKX<_9Q^)GPT\6?\ !5/X/^(/A7\+M<^#OPDU#P-X MD\%^ Y?%EG*_B+K?Q$\"_$^WTVZGT+63K%Q-.^F^1@FM6U]G==[7MI?;KZ^0' ? 34OVB_^'MOPS\,?M-VNG7'Q \+ M>!=0L(?$6EAEL_$>C[I#!?A)/F1RJA#NY&<]!7W%^T0__!2CXM_&GQ+X7^'? MBGPG^S/\(?#J@Z!XL\3ZI9R-XIC4$-.D$96:%" #ND. *^+OA/\ M*Q_M0_\ M%>_ 'Q&\/>%=9\,^%!X!U:R\%-X@MOL>H^)K&(3E=7$$H5ELYI@JP8!^1ER< MUPVO_&?]G^7]J#X[C_@I#XX^)N@3:%KD]O\ #/PE!?>)])T*_P!(B9S;Q:?' MILD,%VTP 491LX)YII_W4V^]W_P /J7]D#]J3]JGX+;.QT[0/$*K!XJUF%FLO ^CVRAMD05-I!'/'RS^S)\1OA-X MC_X*E_"S6?@]\-O$7PP^%VJZ)+IW@^[\8P7%K=^*&CPHU*VEO0KW$-UPZ-ND MR#RS'D^K_#G]L7PU^Q__ ,%-/VR_$'Q)\-:_?_#/Q/XHAM?$?B[1-/EOX?!5 M[&H%C=ZLL2.4T^XRYDD)&W'&>A&]]%KV_P"'MT ^J_A!^T%^VI^R!^UM\,/V M>OVR/$^E_$CP!\?99M#\ >.M/B> 0^+$C#6]C%Y@!1M[J+A'/S)@( :^1?&W MP8_;)G_X+"Z)X;M?C9HUO\0=2^'NJ>+?#GB=K29K72_A;!J-Q))X5FB4>8]P M]LK)O'RY/->Y>,?CA8_\%2?VY?V3K+]G_P /Z[=_!']EKQQ-\5-?^+NH:=>6 M^D:WK$2PB+1M+N_+6UD4QQQQ^0TIG60.945"*[']J3XZ?#W]F3_@LY\)?BA\ M8+^\\,> =<_9XOO"5GXHDLYI=.DU_4;FYAMM/$@0F1P[J72 ED4[G 0YI:Z: M=.WI;[[@:?[0'[5/[5WQ[_:8U3]DS]ECQGX:^&T/PMT33/\ A9/Q$\03QPB[ MUDPQ).(UD(+P33;V54.]<@OQFI_A!^TE^UY^RI^TI\._@=^U+\0?"/Q?\!_% MK48](\,^,/#\\#/B'<_ ;X[:?I?B?P/\3O!.L:_H^E:,EQ!!,L^KW.D21!UGMW&;65]ZJ2 MRIOYKU?X-M^PA\8_VJ/A/H_[)'P3^(WQD@\+:]:ZYJ'Q4\2^+/&,_A7P;Y4B M%)K'[;.T,UXI42".[.,#&.M 'MG[0OQX_;9\8_MX>,OV4_V=_&&G^'+6[T&* M^M=7U:-Y[3PS&%(GF3R\EI9,%\,2%[>E?L?^S'X(^,?P^^%^EZ'\=O','Q!^ M(4,C&^U^VB>.W9<@@JCX)SV&.*_+?X9S1O\ \%D/B;&TPEE3P)$I!\L. (R5 M)V<[@1@D=3UZFOW7=1@Y4=^PX//^>]9U.GS_ $ _#[_@JW^V5\7O@?XT^#_P M8^%?BS3/A9_PLF8_VQ\3=6.>U4EE1N, MDJPKI_\ @JG\4/A/X1O_ (?^$?VF?V=W^)G[/GB4LNL_$K2H+]]<\$7YRI9[ MNSB9;*R0MO8M)&TNW'SUBB8Q@2YB;:2>];Q47&]WHM-NEM;;VL!^Q?[ M8W[6G[2'Q._:M_X8L_9#\3>'?!&H^%=%BU3XH?$+Q#+'!!H;W #+9,)N MHFN]$U*XDCCAN6CW%T4B11@XR1CN<_.'[8OPV^'?[//_ 4,\7_&#]K7P)X^ MU[X _'WPWX^*[2SMK;4(M6O-%>-38-+ _FQWDBJZ?\ M'KF0YJ#2&_X)Z?&;XW_"CP-^R5\$OB9^T5=Q>*K+5M3\7:OXT\92>#O!MO:3 MQ2?VDTEW1L)R1\W7'>O2_CW MXLU+_@G[_P %"X?VD_'7@[7=2^ WQ*\)6GAS6?%>BVLU[;>%[VS1((?M+JC^ M1;P1 -(]PT8D12"VXFOF_P#;3_;N^'7[7O[0G[*^G?!;3=9U;X?>&?B)I=S/ MX_OM.N+/1=5U1[E";'399(4\UX%)\P1LP9QQQD4P/U!\>?M#?%?1_P#@IW\( M_@=:^(I;7X<>)?A9;Z]J6AQA1:S:BT*L9I"ZDAV+'H?>MS_@IE\>?BA\$M4_ M9BM?AOXAFT)?&OQ9T_0?$;Q!6%]ID\\2/:DR!OO;F [?A7Q3^WC\1IOV5/\ M@H3^S]^U5X^\+:]>_!<_#NP\+ZMXFTNU^TQ:==F&-'FNAL=+>*+[Q\S:[!3M M!R*\!_;W_;H\"?M=?$_]D1/@IIVNZE\,_#WQAT6XU/QWJ=A+I^E:EJ=W=1;= M/TLW"(;A[&+'Q7\0OB%X@N8;>UT>WDMXIC:KYNT-(,[C''@R-]W=@5X?-\>_VY?V"? MB)\,]>_:1^+W@CXZ? SXB>+=.\(^*M1T"YADOO!]UJ4R10:B8 6E,:.Q4D8" M[?FXKQK]O#X6>#/@G^VUH7Q^_:*^'_CWQC^SE\3?"&C:7>^+/A[J6L:3/X*U MP6D<8_M.\TMXF2RB"B67SG42*P6++9K@O$ES_P $V?C=XW^'GPC_ &4_@]\4 M_P!I;Q%XJ\3Z;_:<^I^,_''_ A/A"VAECEGO]6N'N6,-Q9DY!DV E#@GL?+ MU ^VO^"B?[5'[4_@C]LK]G7X2_LQZY!+:_%?X^U.Y:*U\03_ M "EREC:R1W @7EMA)!!KR/XB?$K_ (*2?L&?$?X0^,?CI\5M ^+'PW^(/BVP M\.ZQI5C;R6[:7+J4\0G WJ-WEB9]FWHRBO7OVD]/@T7_ (*\?L)Z%"D%BFF? M!VZT^"W$GGBU33V:TCMX6D+3R"%(E1)GR64!G.2QKT'_ (+=2Q1_#KX"+,P1 M6^,.BE"2 0_VFV.03S\Q/0'GICM1S?#91>G6_3EOM_E^J8;G_!07]LWXW>&_ M&GP=_9R_99@L[7XG?&2QM=5;5-07S/['TB]5";E1@L'CW98C&X XX.*\[\#^ M%/\ @KK\ ?B=X"O?$_B#0_VB/A[X@U"VB\::992KIT^@65TX6XE#W8"N;-&+ M$(?X1@5Y?^W>GC']GG]I?]D[]M)?!^L^+OASX7\"Z)H'BV30K.:_N=(MY;:& M66\DCCCE2-8X29#)* HQU]/8O%W_ 6&T#XO>-/AK\,?V'O#NI?%OQ5XIU2R M/C"\N],OX-,\'6%S(JWW]J3+%M2YM$9R1O$)=1@GC"5]-%Y_AZW??>_<#G?V MA?VJ/VJOVC/VD/$'[-'[)OBOPU\*K'X:6EK_ ,+!\9^(KJ!8X-2N8C(UI%E@ M9O*8,K-&2%(Y'-9OPD_:9_:S_9%_:,^''P5_:U^(/A+XR> ?C-=KH7A3QGX7 MNH6DT?7IF46JS+N)6+S"1.6/( V8R:^)OC+\./A7^S5^VM\0O$7[;'@7XB3_ M N^,,%EKFD_$?P/K6O:-H_AW4)HM][%K4^D21"6)924$4C%\#&WK7?_ PM MOV#?CM^TW\)_#/[)7P-^(_QHB\+^)+77=6^*GBOQ=XPD\*>"H[1D=+_3OM-R M\+W$1))@N3B4CA3UI@>P_M@?MA_M%^+OVX?$W[*7PU^.'A7]F_0_".FZ=)8> M)/%\,D=GXJU&]5&$B7A*1Q0L)%1Y6?R1MW+@Y-?>?["CZ#XQ\':A;WT]IJ@D+N)F@D<_9I4/E@$FO@+_@H%X^_8VU[] MI#Q-\*/V\/@1J?@CPSI6F6O_ K']HWP\-4A?5HE@CW0ZQ>VR*EQ/'RMM;+* M^UD!=5'->!_\$[M/MM._;Z\,:9^PMXY^*?CW]EC3O"VI#XE^(/&2W0\'N9D8 M64&DO-^[EG64F*+>3,YZ G\ M37X>_LG*;W_@J7^W]9!E62X\#^&[4(I7?F:&%%W<[EQG(X[4E)/8#R*^^./[ M??[=7QL^)/A7]ESQ=HOPC^$OPGUFZ\-7/BF^A>X;5]8L6:*:-A"I(W2(<*", M9QBO1/V7OVHOVMO@E^U#:?LB_MBWNG>,Y?%^G7&H^"_'.GHT*SK$A=,*P5PI M/!SD\$>"_'?Q$UCX@>$OB9_9-] M/H%X-0GEFCLFO5A9))OW@01I*?F()&,YZ'P1\3]0_P""BW_!1#X?_&3X3>"O M$L'P,^#^C75K-X[UBRFTZRUV=(RP;39RD8G1V'"*SY! .>*J*3>NW_#6_7[E M\@QU^,?_ 4&_:/_ &K_ -H#]GWX&_$[3/!FB> ?$3RGQ!JUNURFGZ:[K]GL M+985.Y2H<%FRH"@BOQX_X)RR0O^WU^W-@*'_X2"".3(7>JJX"C"Y*9 '48 M/7-?O(0C8RN5#!<'[WL3W[_TQ42E9I+;K??_ "_K[P_F;_X*7:I\6-(_X*G_ M ++5Q\#;6UO/BA?_ JUS2/"IOVQ:6DNHO-;3:K./^H>C?:,$9<+A>:L?$3X MK?\ !2']@WXK?!CQ+\=?B=X<^+?PW^*'B_3O"^LZ5IUM-;?V9=ZG*?!K]HCPW_P $Q_VK_P!HCP;^T[H?B'PQX ^+7B6X\5>$OB3'IMS/ MH9K629(_+E-;?5]%GTR6?SK"$QVGB&V1E"7<@9%*AP-P;/4@Y[UY=_\%<_@WXU\%:%K6F^!]%\-SZ9X;U;6K&2P?Q+:JR#[?9"6.,2V MS\%"V[@@YR*^U/V.Y(C_ ,%6_P!O9$908DT/=AD:1,1?-N'+-^1Z<= *&[K9 M+TO_ %TZ(#SG]G'XX?ML?L[?MS>%OV4?VJO&VE?$C0OB=X4U#7O#GB?3HGAB M@EM$WJJ^8,^;OW1N,Y&S'6OVMU'XW?!?0KZYTO5OBY\.=,U*PD:WN['4_&&A M6=[:3HQ+B>WN+V.6.4?W)$4YQR37Y'?M7S1Q_P#!7#]C@$G5&1D)/B!XY^'6NZEXH\5ZA/JFM7\' MC#7K6.ZO)W+-Y5M!=+%",]%C50.0,=:G=+Y/3_@_\.!^5W_!:7PA\:_%7QJ_ M9L\8>$/B=HD_PW\8>.-'TGX5V^F,MY'H_C!S:M_;[WD)DANK1LC*V[MQT.," MJG[>%G^T7\)O&W[!6C>(=8T_XG?M$:9>ZA:IK\:/#I>I:E?WQ&D3&)_FV:?& M\:NIY^2O OV(5T/1]3T_X2?!WXM::TTY-Q??V'H>GK;RR MC4+P[Y5 BB+)-.P>0C8I)X-?]J+XW_#+]H?]J#_@G=\5/A9K\'B3P1XAU^9= M,OTC:#S9[*Z^SSP/''_'/@#7?%&EVWBGPAIMM(JZ)'JEU%%+;+(ZE7\KS@FU3U[5]6_\%)?V MK_C;\+_"W[+&M_ NY6Q\0?&;6=*L#82J9()Y]>MX7ACGV XCMVG)^BX[$5Z! M_P %I9$'[(-RYE1"/&OAI(Q( H\X:K9?Q-_L@X]$D7V/_@F2,QJ MLGC/P,V&8/B!\8_VD/B7I/Q M2\;^+#9Z5\-?!UC;M#%I6L:QM6U@5& :XDM7D3S-H8#/(KP^S\"?\%D=9^'C M?M!)\9/#=I<3:9_PF%G\-)+25KE=-\D7\=HC*GD^8UKA-A! QR*^Y?\ @K3\ M$?&GQ:_9EMM=^'FEW/B#Q;\+M^)Y/V,E M^)AOY/\ A-)/@0/%W]I%1O76?^$6&H?:77_5%_M?SX QQS7\^NG_ ++?QNLO M^"2'Q^UK5_ VK6OC3XG_ !%7XMQ>"Q8SR:S;:%)J4U^RFR2,SB:*!A(\0B$F MW^'(KWS3?^"M/P+\0_L.V_P<^'^B>,_%7QY/P?N/!.J?#FST>Y^V>'+G3]"- MAJ&J:S=M#Y%KI]M%')/(DA214&UL$,*7IT:T^[M;H!ZS\%O^"@?Q"\!?\$R; MG]I+XD79\:?$B?7=:\/>'_/4#[;JMQ?2VNFQ.L8"_N"\>,@@A>.*\3DT?_@L M-'\)[G]IMOBYX>:SN?#\GB^'X:BTD%W;:--9M>PPQG9M,L-L1\NW)P,8S7CG MPG^#'CWXU?\ !%K38/A_I4VO>+O"'CB_\:1Z#8@W5QJ4NCZO]JO+6UBCWLS1 MI#)A2#YBC" DBOI>7_@LU^S]/^RG=_#X:#XR7X_V/@/_ (0>X^%+:+=#6X]9 MM](_LZ>\DB\G?;Z>LBM*?,C241C'0 U7-_=COK^'1NWW=_,#CO#/Q\^*?[0W M_!)GXY^.OBSJTFK^*8-5O+9O-C*&!K>X7?:J,!L*R&,K_#GD9K@O@9X:_P"" MH'Q#_98\*_$WX1?$+P[\,_ O@WPI)+X7\%3P2RZAKUCI2/(\DDB+L5[E%)&[ M.!UK#_9ZO;J]_P""/?[0.H:I UI=W?BB_O9K4X06\T]]')/$,X96C+;75\$G MJ/3]M_V+6A'[!G@$P[?)'PROV0KLP,Z?<9+ '!Y[X.1WS3[A M!78H=TSM(W ]0*^5/@7J/_!6+]K?X+>&?C-X ^*VC^"-"L]-DET+3-5M96U# MQC+:O)FXE9$VAI60JH((/&<@U2_9L*2?\$TOVZPLBR(/'GC>1ECV@N_VR7Y> M/NY( .,=*V_V$_\ @KE\!_@!^R1X+^'_ ,;=)\4>&?'O@W1I+;PUH=MI,\T7 MCV-YI_LDGAJ=8_*E:?_&K]BGX9_$OXB:S-KGB_6;'69]2U295$EP]K=2Q0X;:%8*@& M!U/:OS;_ &)/@A\8O&W[,_[>OQM\0>"M1\+ZE^T['XQU3X=>#=3M9;?5[G1Y M;"]FL'GM)8UGANKIF2/RVC5I'?* J0:\Q_X)\?\ !3CX)?LZ?LC67[.'Q%T+ MQI8?M _#J?6O#]K\,8M$O7UKQ/JU]<3BU.F0F#?;VT$S(DS7*J" TB;DJ+R_ MEANF^RT3[OR>G6_<#O?"OQ<_:7_:;_9N_P""AV@V_P 1_LFJ_#_Q7XOTOP]> M7L&8K;PKIL5Z]YI<:PJ'D::SADA7)/WQGV[W_@A?X!^/VF? K1/&WB7X@6&I M?!G4UU6'PUX*C@9+S3K^*X\NXEDDP(\/+\Z*/F RIY->'?\ !,2\U_QW^S]_ MP4:OI-(O;3Q-XGU7QQ=-X?V>9?Z??:AI.I.-/:"(%S?(T@B,87=O[9KZ<_X( MD?M'_"W6_P!GS2OV:H-7NK7XQ?#Z]UZ7Q+X6OK*>WN[*.2^9R9A-&H25%'S! MANSC&*IV6WX][+]?^'8'ZK?M,_%/4_@A\"_B/\3=&TM]:U3PKX?N[^PT]$G7=F\5PWDZ68[F1)&;;B/"+U7FM_$%FD;&YM2B!VEE:/.U"K GH"<5_)3X_UG_@E'\1]"\1>-+^Q^ M)7[+_P"TK_Q,&N_AWX=354O;WQ6C.J66E6#*D,$2#4DW)V MUZ?TP/WS^.?[7GQ<_91_8QTCXD?%S3=#UGXYZN;;PMHEMI,Z/H.HZ_?8A@OH MY%XDC3*3D@L"6^M?G]<6?_!6&U\ W/[1 _:0^&DEQ8:._C0_"@7]L+AM-^R_ MV@^CY+;&F^SD*BX)+G;UKPO4?@=^TY\$^ M-=IHR:7<_!:3QAXW?Q)K/B-;412V$5JMR5$4]Z'C6()O6!D"IGI?NK5:OLUI M\]@/UCO_ /@J'$O_ 3AT_\ :UM-!AD^).K2'P-:^%(&$FWXC?:/[*DA(Y&U M9\WB@KM*_*HZ5\JQZ=_P5^\'?#6?]I;6_B7X:\1Z7-X;?Q9??"Z.VDBN[+1+ MK3FO]\]74;JPC-TUH!DN64)O.#V6J_P#!9CX& M^(_V7=6\ Z3X3\;R?M$CX=W'@S4OA)W \K;'I<[O=M:75K:7\_QV=]P/HW]F+]N;QYH/[''[0WQ_\ BSJ\GBC4OA[XO\0: M?H,4R(L32IR7=SI"["6>X,9\L=3OSW%>(?!GXH?\ M$M/"WPJL] _:'\/?&KX>?'3P?8'1-:^'TGB_QO9W^NZM8JT!/AZS6ZCAC2_E M7;#$$"KN_=TTHKX?GK?HK?J!^BEK_P %"_BG\2O^"=?QW^(S36GA7X[?!748 M_!_B2^TK#6+:I:W3P2W]HV#Q,(F9O[VX;0:\"^&@_P""NW[0O[/MA^T+I'QH M\-^#=&A\*S:]HGA=K60WNO6FD6S22W4DJKB.>\6!W <[26)Y&:Y]_"7@C1O^ M"6'[5OC?P-\!-=^ OA?QMJL&IZ-:>*=6UC4-<\2Z>URZVVNWT>LN9XKF==K2 M)@*0V]>,&OV0_8Q,1_X)W?#=HMH3_A1^I$LH^5G.@W674,.O^Z,;@>],#YE_ M93_X**^(M?\ ^"?GC_\ :2^-%I;S>./A#)K?A[Q";7"1ZKK&FF2VL6:,@*KR MW 19RB@L"S#UKY,^'<'_ 5W_:;^'Z?M(^$?BMX>\#Z'KR7>M>"?AT;=FNKW M3%(/VB/^"7O[8'PU\&'S_$^I_% M3Q7>Z1"K[OMMWIE]/=K8D1G'F7"V[1"/J6<<'.*]C_9G_P""OOP/^ G[-.B? M"'XSZ%XL\"_'GX6:%/X2M?A[)-3TU3;6:Z/F ,\/](\-:\]O/:W\&N:=) M?10&_C,2&*,7$19V0 .-V.O7C_V]?VJ?VK_ ?Q-_94\#_ +7XXM<^*W@_2_M M=E2_M9_'/XU_'_P#8E\%_%+XV^#8/ M #:]\9= E\$:&8)[:_;P\VJ1"WGU*&Z1'2=XMASMR_ M89HBTO@W1BA$B?\%._V(]>^%GQ7^,'Q<\/_$+P M)XN\6:9H_B/P]9V\D?\ 9ZZG+&)+==ZX9HTD"_+]WCUK[:_;N_;2^+&B7?P0 M_9]_9B@BA^.WQVTNTUV/5+H*;?P]H-Q:Q3RR ,IS*&E M./\ 9Y^&&XJ%_P"%K>&MH=U0@FXM^C,1DG@8'7%?-'[:&G>,OV>?C'^Q[^W; M:>$-<\:_"_P=X T7PQ\08= M9+_4-#-YIULOVX1QK*([81@DS,%3Y&P^5- ' MC7[77C#_ (*Q?L.?!N_\;>,?B]H_CSPWXJDTZQO]?TBP=;GP#?&Y2;,KSQE! M'>+FS60X4LV!S7])WP0UW4?$_P &_A-XCUF9[C5_$7PV\$ZUJ=PV!Y^I:GX> ML;V\FD(Y!FGFD?@A<\"OYJ?^"J'_ 5(^"W[37[*'B#X0_L[6^N>-['Q8^@W MGQ,\3?V5=KI/P]M+?5+6[M;"_N6B9(M2GU&**)OG1"-R@G>17[E6G[1_PC_9 MC_93_9Z\:_&GQ,OA?P[JGP]^%_AVQO?LT]P;C6;OPMI,=K!Y<*L4$N]7!880 M@AN,@J^GGT_J_P"%_F!]N2'(P#@[L,_B;^RG\ K MJYGM_"/C7XA:7<>(HHG:.._M[>]7=:7 R%EBE!P5.01VXK]Z=#UBR\0:1I>N MZ1(-&ZGH,YK\F_^"M?[-WQ"^+7PW\$? M%WX1:*_B#XB_ WQ+8^++#1;-7^VZG86$XN;BUM'0>;+(\8Y09!P0HYK%.W1? M.X'ZB^"/ ?A+P'X3T+PCX:T+2M,T+1])L-.M+2VL+:*(1);QJTL@6,>8TG)< MMD9Y.:\#\._L;?!WPI\?]<_:1\-:'_87CS7;7[%K/]FR/;6%[$ /WLMI$RVT MCD9=*5HE8).\8"_:=C%B M!--N=-\/:+X@ANM.?QS=NQ$5W=6C+"D\9SOBF1'#JR@-@<6G)[) >B_\%=K* MZ\">"?@U^TEX8"V/C3X3?$G1V?58!MN+WP[J=Q#;WFE2LF'^SRINW+]P%R<= M:_5?P#XD_P"$S\#>#O%J!8SXA\.Z3K/EHZM$K:A8P3E=PSN"/*>.SCG Z_E? M_P %HM523]EOPUX,C65M6^(?Q.\-^'M#MH%+7%Q>&^C9H8U W;0CAL#G%?IA M\%/#]QX4^$/PU\.7\36]]HW@SP_97<))\RWF@TRWB92&/+!U)9<9SQ1K;5)+ MR>VJ]?N_(#\T?^"E_P"R_P#&KXA?$+]GO]J#X&:%I?C[QG^SSJ%Y))\-]=V' M2?%.EW\"OH]_\ #?\ :L_90^)' MP[74=/N-&\57'_"./J?A6SM;F%[6Y>UO/LC^8D*EC&4E^50",8KJ/^"B?C'] MI?\ 9;_:0^#W[7OP[L/&7Q+^ 6D:1<>&OBQ\+/#SZC=&&6=V":]#H]EY@D2" MT8R&:2W8QW2 LPC!(QO'_P#P6>_X)]^,OAG>/+I.I?$#QKJ6GW$$'P@D\+IJ M'BF75YX6@329UE@DA603R!)?+)DX;"EL*:222M^>VV^N_P#PVX'N/@/XG?LS M?L:?L*>)_C%^SWJI\4?"J%-0\1>'[*6\:3R-=U:1=NF&!I&:U9;N:(20D#&W M!7@BO@SPLW_!5GXQ^#_^&@;#]H?X9>"+'6K>7Q3X:^&5S?VS7$FCG=<6%E(R MN DK6Z[?*8;@Q_+COA#^QW\X4-A>@/;(KY/^'@_X*Y_%GP1_PT_I?Q)\.:-X>U*"X\4: M-\+;JUG$M]X=C#W-O!$X4(LUQ:A0O'S9[U-\(/V9=&^+W[ _[2$?P:_9]UKX M*1_$F8ZKX3T[Q'K&M:MXB\:P:5,UU:WM]#JSN;>YNE&X&(!),XR:W/@;_P % M=O@_\,/V<;/X*_%3PMXXT7]HCP!X:E\!VWPOBT&];4_$=_96KZ?:7>FCR,K: M;EC>:1UP(R2&P00GY)+;:_EW8&S^QQ^UY^T%\3_V//VQ?B9\0M?E7X@_#>\\ M10^'MR'_ (I^XL+*Y<6D0"@LL<\6P, ;G4_#]A\,8=#NGUGQ3K.H7SQZ=;:1&(MT, F>)+ MB>[50@WRH67&!^EP/K;]A']L;QQK?AK_ (*!>/\ XT^(KC7/#WP$^,_BS3?# M<$X3.G:#HR7[6VGQL@!599888AN)^\!DX-?*_P /O'G_ 4K_;3TK6/CU\./ MCOX!^"7P]U?4]0;P/X,U>[MA>WNEZ?*4M4N8U*R1O( H+D /NSD\UR'_ 3/ M\%>(_P!H?]F3_@IYX+^Q_P!B^,OB)\5/$AET:Y9A-HWB&ZM+^_&AWC)RTZW" M+:LQX+MG %?,7[-WBC_@GA\*_ DOPF_;9\+?&;X/_'/X>SWUAJMJ?%/B^PTG MQ<\V9X-.+:'( )^8_6OBC M]F?Q)_P5C_;/^#W_ L/P5\7=!\$:%H^IZQ8Z5>:A:3'4/%4EA C& NN^*P2&#[&%Y+E MF?D-U&-A(!/ID4;+[E^@' ?\$^OVUOB?XT^#?Q]M_P!H5;6\^(/[--_K5AX@ MU2!Q%!K?]CQ2MD%]NTS,BC:>><]*^.OA9XR_X*B_MXV'B7XX_"'XH>'OA5\- M8M;U.T\#Z#>VD[OJ-K97,L4;9C4;PYBVDN63G/0UK_L2>!)OBM=_\%/_ #I MS,=1\2^,_%5CIR),%9[\B00^8%;*K(Y P<9Z=^>6_83_ ."D'PB_8=^"^H?L MT?M3Z9XI^'?C_P"&&K:U%I-O/H]T/^$RMC>W+VW]C^;"OGRW#,L:."8G###$ MYIZ@?2'Q-_:#_;F^%_\ P3=_:3\8?'7PY;_#[XV?"9M'L?"?CBPN;2]M?&>G MW6N65K+K2VJJPMU6)WC\N1-_[T$5S?\ P4*_:X_:#^"?[)G[#GQ"^%>O$>/O MBEK'PXTO7MZAHO$-SXD\/V4S03(JDJDVH7".=@&U6/\ =->3?M&_M1_'']JW M_@F+^V[\3_B+\.S\.OA;G0K;X2'4K>>UUWQ!X<_X26PSJ=S;7*1F)?F))SB/+;@>V, M'?U_1 -^.M__ ,%9OV:OA]/^U3XX^+?AO6/"NARZ?KOBOXX)%?9G[6'_ 4(\:>#OV4O@7XR^$6DVD?QA_:2L?#UMX3T MJ4,ZZ7=ZXHBFNHQSE;>0,V<< #GI7NO_ 5JDV_\$^_VC-Q4Y\'QB3<0JL?M MED=T9;A0.O'_OHX+=)7F\B(;D*J2!DY !I+5 ,^/ _X*\_LQ?!S5/C/KWQCT+Q M7I3Z?#?:SH.GVC_;- 2\597*R2(5D:$.481\@CD5^Q7['7Q_M->_95^%/Q"^ M-7Q \-:1KWBC2([N[U3Q1K%AHOVRX9=VU7OI[96P>"BDG .>U?DA^VQ_P6 ^ M 7QH_92U_P"'OP:TSQ3XM\>^+-$L]/\ $.C1Z1-CP.0BI?#6I?)/ER6[ @L- MBC')SP/L#]FG]C?X$?M>?L,_ '1OCKX9O?$6GZ#H\5UIT-KK%_I)2=E.[=+8 M2QO( 20$"_@3X=AO=3\1>%DM97UG7= \.6SRZG/')MV^=>&UE90^5V M2 #DU]3_ !9_81_9K_8\_9._:4U3X%>$[[PM<>(_ U\NJ7%_KVIZQ]H2.%VV M!-2FD2!3NR" O X(P*[3_@G7X77QQ_P36\*>#;65+:;Q5X&\5:):R*RE4N-2 MM+JWAD=U)Q'YSH220-N<'/17[:NZT[;)_P!=P/@GPW\WEO7A9A)&;AHP[&4' )V]*^L_V" M?VL_CF_QI^(O[&_[4M]H?BGXJ>#=!7QAX3\::%=0RZ?XK\.2 %8%D0[?M9)# M1+DLJ@YR>*_%_P#9_P!,_8T_9FO_ ![\"/\ @H-X5^+/PQ\?>'/%.K3:)XTL M?$GBG2O"'BW1I[B66R-@FFSQ6;32H$PT&XLC?.0V2?T._P""?NB_L^?$?]H; MXD_&/]ES]GCQWI7A3P)\/]5LO"GQP\?>(_$M_>>+_$(M)?LFA:/9:I-)97>F M-.(VCE =HHP51:1M+) \ULSQ&0(O[Q2Q*$@D#%?G]\._CE^R3J M'BKXL:W_ ,%)?&OQ2/[15CX^U^*P^&;7WB;3]&CTBWNF72++0;&QDCM[N&>, M(BAD,;LPV[AD&Q^P)XQ\+>-_^"D?C2;PA\-M8^#?@CQM\+-9\.>"/#_B"VEL M-8U6QDM&ACU:5+U(I)9K]65S)@H5P0QY- 'ULGQB_P""@/[>'QB^*L/[+_Q MT7X3?";X3Z_#="USQKJOB;P3XW&E7W4D\%E!/%$89KI MMX5!"YP3SZ52_9C_ &A8OVD?^"M>J?$K3O#&L^%?"^I>"S:^%[?7;9K74M6T M^$CRM5,$B).+>Z10ZMLQALT ??\ ^P_^T!\7KW]J+]I3]F?XZ>('U/7_ 9K M,GB'P6UP!"[^#;F1UM6C)"B14#+@C/3)ZTO[-/Q^^+G[0_[?G[0]OI/B&63] MGCX-06O@N'38UQ%-XR1#)<2"51LE&V-]S;CCIQFOEK_@KY-XP_93^*OP]_;8 M^&UG<+<7GA_7OAMXP3349?MUQ?Z;.NDR7S1XDD^SRM')!N#?O4PN"#7W)_P2 M<^#MY\+OV3/#/B+Q%"X\;_%V[O/B+XNO9X2E]?S:X[75FUTSJ)BT4%QY:B3G M;C!QFIEMKY7^] ??/Q3 /PN^)OSDH?A]XSR@ +/X;]D M7XD>+_A)_P $,/'7Q$\!ZC_9/BKPOKWQ)OM!OC'O%E./%EO$,H0=ZJKN.G)( M["OZ'/BJ/6_P""M?P3\$0? MM+^(/B)X:USPEHMCI>JZY\++6VE%S:>&TMK=?M MXZ_?^'/V#_\ @G;XBTJR.HZAIES\-+ZWTY,/)>_9(H95@M@?E-Q* VS@EB<" MO9OVD/\ @K;\'?BE\ [_ .!7PS\(>./$?[0OCW0K3P=/\-TT:ZCU#PWJMS;Q M6\MWJ@,.TV*29D21%P4*[CQFK^0'?_ME?MX_$A_V,?@+^T!\#-3;P[XA\=^( MM*T[4+4(C0F_G\N.736W!CC[0)%8GCGI7K'[/WAK_@H=X,\*^,_CA\3/&>E_ M%F]\1>"$U+X>?![30UD;?6KV(3VHO+RX B!C$B,Q0[<#TKX#_:U^#_B#X$_L M _L@^!/&WE6WB9/B?X5U'5[0$+#87=_>07#VKQOR94$WEL ,YSP#FOV$_:^\ M4_%/P=^P9XLU[X*PZ@?'EE\.-,.ER:1"]S?PVSZ?&EXUDD(:;ST@)=&B!:/ M)(QP ?F#KGAO_@JMKWAS6/B;XP_:@^%?P8U)8-2U=?A=JNKV:7%A%:1RW$>E M27GF)#]J94 C7/S8&0'98=;\#27WBK5-4/C:\M"CI+I,SRPB*RU)\.5A8^2C+C&*B_8VUI; MS_@D[_P4XT][!=$U+2-0O&U'P_.OD3Z$]W.LXTZY@D"-;R01J4\N95D4C&.U M)_K'\T!]T_L;M_P4B_:/\,_#+]I+Q;\9](\*_"-]&>\N_!D5H\FJZ_I6F65S MG45EV^6DVH2>7(0_.%([5Z5^R'^W!XMTGX!_M@?&GXTZRVO:?\&_'.NZ?H<4 M42"E?C[^RY\'->_:#_8S_ ."@GPQ\)2B;Q1J_Q0\2R:1!&5V7 M%Q9WDEPMO(T?):=$=3M).=O>F!U_@O6?^"HG[3WAR7X\^%/C]\-OA;X[ MSXA:3!J?Q\_9PM[[3O$%OI++!OVJO#/QK^&/QR\!6\VAZSX7_ .$K\9V2>);VP+PFX\/V ML5Q'#%%LZ_J^N?%71HE_"GPC)\9WTN7XA+9A-?N-%='TRXD1 J312KE3]H(WG8>C=Z_DM\? M:S_P2D^)&DZ_XTUBP^)/[,?[1T:Z@UY\-_"\.JQW5SXDA\QDATBR*1B&*:]7 M*@HKE6 -?M#_P $T_BOXX^#/[!.K_%?]JC6]?T?P+X1N=0UC1]:\76]S)XD MMO!)NUBL+G5H)U,[N5EM_+4*2(VXQ@5G4^S\_P! /VC3.P$J$']T<*#GG&>< M\C/KU&:=_3CUZ\UY=\*OBQX)^-G@'0OB9\-]977?!WB:S6]T?54CDB2ZB8*? M,$R?2LP'T444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 .'0_[T?\ Z&**!T/^]'_Z&** &]A_NK_Z"**.P_W5_P#0110 4444 %%% M% !1110 4444 -*[B/7/Y\^M<+XW^&O@'XCV*:1\0O!/AGQII,$OG0Z=XHT6 MQUNQCFZ>;%;7\4F.,=0/K33LTP/G&']DK]E^WDCGB_9W^# M<,J-O22/X>^&HY49#E6#"Q!# X((.1P0>E>Z0:?9Z%IT=II.EVUIIVGV;1VF ME:9#%;C9;PL8;*S@C"11;RBQQ*-J@L 2%-;F?89[D@$G\Q4+H3@C&/J.>]#=_3_ (" _,O]E;X"?%'Q%^TS\:?VQ?VA/"[>&/&.OS3?#GX0>$[^ M:UGO_"GPSTF010WLWV*2XM4NM=15FDD63S@ 5< DU^FGEG!P?F/ZD_S_ "YI M45E &>G'JQ49^7=V^HR3WI_/KSW;')]*0'&)\/O!">+&\?1^$_#R>.Y+,:7+ MXMCTFT7Q')IJDXL7U@1_;&M,G'D&7R^3@#)KLE5EZ%2A^]QSD<#\NE/SCH,9 M'/O28Q^- $3*2<@ XZ=..YZ^_->5>-/@3\&?B/?+J?C_ .$_P^\9ZB@"K?>) M?"VCZQ=!0.!Y][;2R?ANQ7K5 Q_=4_49IW8'+^&_"'AWP;H\.@>$/#FB>&=& MM2/LVDZ%I]KIUA JC&(K2UCCB3L,*N,9Q6=<_#CP#>>++?X@W?@WPY<^.K2U M%C:>+YM(LY?$EI: %1:V^L-$;R*V3) B20(%_AKN> <@8/MQ2Y/.. <\?Y]* M5VMK_("EY8!W#&[).<U9Y [:AJEM"EW>%P!O\Z1R0!Q7H^ >H'Y4 =.] %7RBX(8;PP M*E5'56!#!^FY6&01SP>:\[T7X.?"KPSXFNO&?AWX9^"-%\7WGF&Z\2:7X:TN MRURX,K%I&N-2@@2ZEW,2S[Y#N/)KU#/H,'U'4_4TG&<\[CU.?Z4 >3>,/@?\ M'?B%JEOK?Q ^%?@'QGK=KM6WU3Q#X5TC5[Z +@H(KJ]MI98PN 1M(VX_&O0] M,TC3]'LK;3=)T^TTO3;.)(+.PLH([:UM88P%2.&"(*D:(H"HJ* !T K6H_SZ MT[OS_K_AE]P$>QVW#Y3E=OSG((.!C\J\=O?V=_@1J7B8>-M0^#/PUO\ QB+Q M-0'B6Z\'Z)/K8OH^8[S^TI+-KK[2C?=F\P2 \@BO9O\ /2CZX/T&./PHN_,# MAK'X;^ ].\67GCNR\%>&+#QE>VGV&[\5VFBV5MXBNK, +]EGU6*);J:V" (( MGD*X&,5E>+O@W\*O'NJ:=K?CCX:^!_%^L:48VTW5/$GAO2M7U"Q\IM\36EU> MV\LL!C;E#&RE2.*]/SSSS^--ZXS@X/< \?W?I_C1=^8'#:9\-_ FAZ_>>*]# M\%^&-&\3W\$=K=Z_IVCV5IJUW;1*$2VN;Z&)9YH410J1NQ15 %9GBGX.?" MKQQJVG^(O&OPV\$>+/$&DNCZ9J^N^&M*U34K%XV5HVL[R[MY)K=D905:-E*D M BO3?[W"C.,84#;]/KWH'3!SG^\#@C\!1=^8'":'\./ 7AS6;[Q%X?\ !/AG M0_$&I*L>HZSI>C6-CJEZB<+'=WMO$D]PJ ;0LKL . .*[)X3-')#-"KQ2QO M&ZD K)&XVR(Z]&1P2&4Y!4D&K/Y_7G/YT=,8+#U^8\__ %O:E<#QFZ_9Z^!= MYH+^&;[X/?#>X\//J4VLG0IO!^BRZ0=7NG\VYU0V#6WD?;YY!OENQ&)I& 9G M+\->'_ KI-KH7AC1=.T#1K&,16>DZ/:0:?IUI'V2WM;=4BC3V50/: MNASZ\\>M)3N^[ \>\0_ #X)>*_$0\6^)?A!\.=>\4"2.5O$.L>$M&OM9,L1! MCD.H3VKW)D0@,C&0E2,@UT"?"[X

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end GRAPHIC 12 g4bdklltl5z5000012.jpg GRAPHIC begin 644 g4bdklltl5z5000012.jpg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n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Þ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g4bdklltl5z5000016.jpg GRAPHIC begin 644 g4bdklltl5z5000016.jpg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

?!7Q_H-K-+8/INH:A&L\^B7^G1I'<:>F8%D9KD*9:^?OB1 M^W)\)/V]OVEOVB]=_:__ ."NOB__ ()I^"?@G\2M;^$?P$^"GP9O-;LIO%?A MC0[RYM=1^(GB/4[.$2:I=:K>VRS)]I)-D)?LD&81S^B'[!NN:9^V5^VWX:^) M?[+W_!,WX0?LP_L#?#GP[J\?BKXI_%'X$Z+X+^+OC;Q9J$#Q']JOX/AU!9W%O-?+;:>95;5)V6!8;M9% M'G )@YGW?WA966BZ=%_7X_>?3?\ P2K_ &\Y;OXH?MG_ +!'@?\ ;+O?V]?@ M_P##G]FSQS\&O$%]<[-1O[^PUN>VN;&ZE!^P M>2([=@AKY]_X)H_L:_MF?\%4?V)-&_:!^*G_ 4K_:<^"^B^&-=^)W@GX8>& M?AEKDIU;6KOPQ?72ZMK'C[Q#/FN_"6JS MSZI=ZK8Q1:K>Z#J,BJ]_HUS:VZV6J&"WMHY1\U>T_P#!MMH>N>'/^"2/A#2/ M$NB:SH&KK\6/VA9&TC7-*O-)U,1SZU.;9FLM0AMKE8I@08)3%ME7!C+=:I0; MUTU_KL'-'37H;O\ P09_:'^.'Q?_ &9_BG\(?VB_%]]\0_B/^R]\8_%7PH'Q M%U0F;5O$OA?2+[R-"BU6[=GDU#5;"W#&?5+AC=7KR_OC\BBOJ#_@KM^V5XI_ M81_80^)7QX\!62W'Q$U#5O#GPM^'-Z;:*\A\/>,_B'=/HVB>*+VPN2(;^#2I MR;B:WF^1L _3XC_X(+>'_$&A_P##P9=>T/6M%%Y^U=XPN[-=8TJ]TUKZVDU# M,=W9_;8(/MD+@;EN+OIRK? /Q'XS^)GP9\57CZ MW\$/$6D^+- 76/%7@[1;*^NV>TWZ9=Q0Z)=+;J]G<[TAQ$B$^;>"?VLOV@/@ M-_P0^_X)-_L\?LQW5KX-^.7[;>MZW\"=,^(-T@NV^%^DS>*=2?Q'JT,3G:ET M]K=O:0Z@A^TZ:T0NK;]Z*]9\31K[XDV/B9 \>JSVVGP0ZG%I-DTS7"-&$ M#,SQUYEX=_8V_:7^+'_!&'_@DM\9?@!X/U7Q9^T3^P[XUU'XN'X.WEM-HFK_ M !-CD\6ZC#JNB+#J"VEQ8&XAMCV"7&P3C;7)?MJ_M0?M8?M9_M M=?\ !(#3_P!CSXW>(?@;J7[7/[.WB/4O%%G9W_: M&\%_M-?%&*Q\$_'77?'?AJXT+P/\$M-U/44L/%6I:?K5X8K;Q'I*;[VSU.42 ML\&G"2Y@CF<(*[GQ?^S5J_[-_P#P5B_X(-_!_2=)U/5]%^#?[.'Q%\,>+/$V MD6&H7_AJS\1Q:5>+JS3:VEL;2TLKO4$DFTY+V6"2:!DVJ6.*TO+^7\?T_KL. M_P#7?S1Y'^T!^SO^T_\ \$;/V@?V-?C9X2_;^_:'_:J^&WQB^.&C?!7XC?#G MX[:S)>V=RWB,JL=[IMDEY^[NDL(+A[:R1L%[BX6.!3]YQ7%_MS^%_VEOV!_\ @I]J M7_!4[X4?!3Q1^TK\!?BM\#_#_P )/VBO!_@F$W'BGX5:-X7M[.V@\6Z9I\+B MXU:>XA4R):1I(>?+VX)HO+^5]MU_EYD\R[_UZ['BFK^"OVJO^")?[5'[+^OW MO[7'QC_;$_8^_:>^(VD?"7XQ6OQVNQJOB'X=>(M5F-MX?U+PE=-=70AN;I\F M6VW1PW #LYRJ9\A\*? W]L+_ (*(_P#!3C_@I;\!M,_;H^.O[//[-/PE^(7A MG5=1;X=ZW/-XGT[5;VWCNO!.A^#WN+N)=!\/W"M:XCV**^KO\ @EAX?US2?^"HO_!; M>]O="UK2]%U3XF?"F+P[J6H:9>V5GJ]M:V=Y;!M-N;F"*TOUB1(Q-+933HA) M+E3C,MN\;JVOKV!RT;3V_4_;/X&?#*;X,?"KX=_"FY\;^)_B1<> ?#UCX>N/ M'WC.Y>^\6^*'MI)'?7=0W.HW._\ ?2&1R%4#) K^1+X#)@]0 /O$\'D?7^.7X>_M M6_&S]@[_ (*Y?\%8_C-/^R_\5OC3^S)XH\=^%K7XI>(_AWX?U*\\0> K:TL; M!]*\3:%ILL,,7BN'6;TR:?-%827'V40>8V 6!*G3Y_H3![_+_@GV9^PUKW[2 MW_!./_@JEHG_ 3*^,/[1_C7]KGX+?M(_"?5OC9\#_'/Q.N9+SXC^"K_ ,+> M=_;D6NZL\LTSP7T-N]G!HD-+!K'Q=\4='\3S74>JZ_K^FW++<:3#9V\[S1[T20W(-OL\M0Q^!/V5O MV*/BC^U]_P $_?\ @M+\"/"^GZGX2^)'B/\ ;N\5>-_A5<^(]/OM&&JZWX9E MGU?37TP7\%N-0&JQVTEAI\T6ZV>XN;?,P R,RWMKW7YH^A=$_P"".O[=/CC] MG.T_:HU;_@J[^U'8?M3>)_ X^/4'PVL=5>V^#EMXKO=//C&T\'MI4-_L@TQG M T^72(839QR$6:_Z-S6CXW_X+%_M/M_P1O\ AK\;+#1=,\._MD?%SX[G]BR3 MQ(MA!=:9X4^)+:F/#UWX[DT>8BW5I[8RS2VPS!8S2M-;$R0QY3PY_P %H/VF MO!OP T7]B_4_^"P[ESX ME?\ !'C]N_\ 9W^!.I?M-?#;_@J7^U!\0_VI/A9X37XHW'PM\3:U)J/P;\2> M(+"U36==\)I;37S2W?AY[?[3%;)<0;A$H;:-JUR_QW_X*8?M$_MU?L_?\$W/ MV=_V=?%FJZGX2^/GQ3\-EEU/X7GP))'9>-/^$4FS'):IJ5R&:UU M)&2ZM\($'S,:ZWXO_P#!9_\ :A_:$^!7BS]D3X._\$_OVCM#_P""AGC'PO)\ M./&7A[4/"UQ9_#7X>RW<,>B:SXLTOQ?-(MCJR65O))--:^>(UM3,\;N0JURO MQB_X)B?M,_L4_L^?\$ROC]^SKX 3XY?'7]A;Q#J/B_X\?!_PEJCR1_$F7QTP MU/QR^AW[^3,FDZ$0_"*))98PJ(P:A\VE[]]29.SCZOT^9\T?\%8/^";_ .TK M^PQ^R]X/UI/V^OC'^U+\ _&'[1WP/TSXP^"?V@3#J^OZ7XRT[7Q_PK[5_ASJ MAN;NXT^R34GU ^)("85N[3[-N#$$#^T?PHI_X0_P66^_%X'\&+P<#F%R MK?QJ>,>_'2OXSO\ @J%_P4I^*G_!2']E_P $>&_@C^QA\=/"/P3T#]H;X-:A M\;?B'\1O".K:7J^C?$K3?$"?!Z/ P.X.GAW3%8*2/W;1.I\R-MI!!!&>!<=H^DOS M0IO:W5/]&;5%%%69!1110 5!=*#9:@,,S&PO?+"]=_V2;:!_O' X'.<5/3E( M!7)R"PW@\84.<>] 'XO,LZ/,+F)H)S=W@E@8$-'(+F7.Y3C!*[ M3_\ 6I*].^->A7'AOXK^+;*ZN[:=]5GB\26=K;1B);#2=4!^Q6\BK\OFJ8Y- MYX)SSTKS&L).[>EO(UAM\_T0V%XH8;C3TA0R27[ZK<7/E".9A-&L26YN,9E5 M2N[;G@'\*Y[^T+;2[6:]>!Y9KZ\=Y_LH4S!HAMEN)@Y"A;:W"O+N.X("4!;B MNL=#Y%O+DM&I\LJ3D>8@R<=P<$8_PKSOQ-H.H3P:O_9LEP;75HGGNH;95DO[ M;4%0HESIJNRK*DZ!8;BR=EBV9DW$MBD'-+^5_P!?+^OD>N_"CP[%XP^(7AK1 M7N?(BU'7['4-/1<,9(]+":DS+D_*)1%N!7DYYQUJ;XQWB^)?BQJ^JR^=)/:Z M[\2$SM<0Q0OO\XW-G;MY2TMJCS\?,VUMQ M9F#.F275/NQXSS\^=Q]<5PGA>XDU?Q+XNUV"X@N=*^TV>AZ:B8W6]UI*M#K$ M4AY._P XIL_6N_B/[Q&+!V=EVRH24=2ZG<"F.U?.6B>,;/X>>!O$ M>O75L;F&7XK^);%((LI-,U[JL,*R1@\>86<-'TRH8]L4%S^%_+\T>A>&XUTG M5/B!X?B+R6T32>(_/E&9);G7K>5IX@?[MN8@/4;NAK2^'*&/P)X5CXR+!QQZ M-=7+8_49Y_6JFA$7,/C34'YN9+F[LC)G,D<%G ##;OV)59<.V<^WIJ> /\ MA"_#G^SI[$?7SYO\:!0V^?Z(ZRBC'.,]0&!Z]"2X^O/']*R9M52/4X=+6VN) M7DB%S=7<2JUIIEO(QCMVOV+!XUN908H2BN3("#QU"S6J2+F2,'C+I[\Y'^"(M,T9F:X\/6MA+ MH\SY\X+9-&93(>N_[)YW^-_#77X+A-\*^)O$N<^'<,T5J5<,+2/0/#BPE^&Q#%,)]W] MT,2#GKZBGZ;/._BO>86>VNY]81KK_EFEO;"+[%GM\^7"G^+'L*".:7\K^_\ MX']?(]!&<#(&?;OCC)]S03@9].1]>U+ZD'()X_E_2C!(/L"?RH+1DZ]>S:;H MFJZA;IYES!87-Q91#[SW"1MY<( Y+2. !RQ/>J%WOU+PQ:SW0V3RV6G:G,I MZQ311QW$L; ]"DN5(XP1[5TUO9IJ6L^%+*3 AO/&'AF":,G*R13:E%'-&01] MQT)!4=TR+Q%H/Q/T>2>XL;>]DL[! MKRU=HYX?M-FX\V-EY^7<2R9Q(@*-PQKXOT=A_9.G1DL1%:Q0LW^U&NQB?4@\ M8Z?2OT2_90TRV@\ ZEK=ON MW?\ X!ZS\./A7X8^&&FBST* W6H7$:QZIK-PBK<7S [@XC^Y:PJ>L4;;6SR, MUZ422225//5<[?PSVIES*(H9YB3(;:":ZD4\EXH(7ED#*1@R;4.Q/^"PWP(/3P)\0?\ P A_^/T]?^"P MWP)!!_X0/XA?\!L(2>>.!Y_)]JKG7G_7]?AZ ?JUINM:1K4M];Z+JNGZC/IS M^7J5C8W4%W>Z?,GWH[NVB=KFS$K857N8XD;.$).:U/P ]@2<9[9/)([^]?R" M^,_VG/&MO^T%\0OC7\&?%?B?P-%XQ\0V^JG3HYY(!=P6JQM;67B'3 _V>]MA M,A<6CGRR6.3\U?I[^S]_P5UL;DV/A_\ :/\ #QL+EY8+4^//#<*BVEDE<1F[ MU?2\B'3K. $-,]NTA"@D GJ1DG**5_B3_!E1^)?U_7Z'[AVW_'Q!_P!=4_\ M0A7\/_[1N?\ AH#XT\?\U+\6_C_Q-KBO[5O /CGPA\1]#T7QCX#U^Q\4>%=8 M9WTW7-.$_P!CO1!.(I?)\^.)R(W^1B4 )Y7(YK^*G]HT_P#&0'QI]OB7XMS_ M .#:XK^>?I,?\D+@/^QU0_\ 3=4_OC]G7_R>G-/^R1S+_P!3<">,4].I^G]1 M3*>G7\/ZBOX)I_Q:/^)_A*E8_P!ML5_N]7_KW4_](D?TI_\ !%C_ )-U\<_] ME&U;^<5?L57XZ_\ !%C_ )-U\<_]E&U;^<5?L57^J' 7_)&<-?\ 8IPO_I!_ MS/>-7_)V/$#_ +*7'_G$****^N/S **** $/0_0_RKU:P_X\++_KVB_E7E)Z M'Z'^5>K6'_'A9?\ 7M%_*IG\+^7YH"W1116(!1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ;LG('&Y&/T!/TY MX[U\>_&V P^,PY&/M&GQS+_N^9M_I_.OL+_#'X?Y[]?>ODSX\@#Q9I9QR=#7 M/OBZG_UJ^!_ \#77C#0;11F22]3:N<'" M9D)'L0.IZ*/^P5-_-:^#D^ MXO\ NK_(5]X_$/\ Y$;Q1_V"IOYK7P1B:UN(&P%FMYHR3GJR'' [<=3TK\[YP1!<*]U+!DGKL0'&.F5//J1BJ.2,_4#\P ?YF@ ML^C/@ F9_$$V,!HX5_(@U]*U\[?L_H1::_)_"+F.)3CMY8;'OR1_6OHF@QG\ M3^7Y(****"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHI#C'.<9'3J>>V>]-7N@TZMI=6MT+1408MC!X;.#C(XSD8QP.V><'/45EZCX M@T'1U1M9UW1M'!5B?[1U2RL5P"<$?:IX<],>@^N:45*46H0J5))OW>1M-IJ[ M:@I:>=O)OJ3*I&DDISII='4J1C/ET_F_#SVU:-CG/;'?USZ?YYI?\_Y]:Y*R M\=^"=1E$&G^-O"6H3%MJPV?B/1KF:1CQL$=O>R-GN 3QC!KJ1(#@_P\$NN& MC8'D;'Z'(],X/6J<:_)^_HRI)M[2_#H]PA5IU)Q5"=&HE'7V

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end GRAPHIC 18 g4bdklltl5z5000018.jpg GRAPHIC begin 644 g4bdklltl5z5000018.jpg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�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�O' MH2]UJ_@:6[F MDF,WEQR7=_X6N9Y]4TV$236MQJ]A;7-];_IO7^=A8^)_$6C:C9ZGIFI7.E:M MI5[;WVGZA8K'8ZCINHV,Z7%I>6=W;QQ7-G>V=S%'/;W$$D<]O/ⅅ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�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end GRAPHIC 19 g4bdklltl5z5000001.jpg GRAPHIC begin 644 g4bdklltl5z5000001.jpg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

4>M:DFJZ9%J$>E3:E"MU,K&&W:4!W ZD#J<>W2L?X MJ>'?$7BWX=:QH'A#6$T_5[BPD72=1<9%K<[A?\ "0_$[QW9:3;(=2;XG?M,^-+[QUXC:9A<0WEP_V:%EFV$,92&TL;=8HXP>3A5 Y)/'>/[GX;:+<_%/[%_PD$EBC:H=-8F#S M".JD@=L9QQG..,4?$W1M/OM'AU>[L+>X;2;M+N'[3'N"[3R0/7!(J;P3-/:1 M3^&KN3=)I\Q2-B>6B/*GGKQQGVK.ZA"[9(PR\8R#S3KVW2ZM)+=P0LD95L>XQ6-X%O2 M-+;1II?WMA,T#*S9.!]TD]^,5N'&S%$HRA)KS-Z4HU*.G8Q_A[-*?#L=E/"T M;6;/ WF-ECM8C/XBMO@XQ7R]\=/VEOC]\.?B_KGPK^ ?[/EWXAN6L4O&U*1F M$22/& '4='"MC(W#G(XZUO\ [.4'[>NI_$AO$?[0]_X=LM 6P,?]CZ;&"SR] M5D4@L5(Z'+8(Z#/-$Y1E4;774\?#YQ1EB%A8TY-K1M+W5;NSW^=EMU9WDVKW M9NGUKS?Q;^UW^S/X+@O)=>^.OA=9+%BMU:V^M13W",#@KY,;-(6!_A"D^U=9 M\2/ VC?%#P#JWPZ\1R72V&M:?+:7C6DVR01R*5;:<=<'OD'N",@^#^"?^"=/ M[(V@ZZ_AF^^'<<;<5'+4EJNUS;,ZV;4Y1CA M(QUW)O\ @JC^R'H6F?;-'\8:EKQ37DA>/5(%CE#(Z[CA688^8<@UT^C?LX_L_ MZ).XYKA)?B9XH M\">'M'L-$^&FI:TLUCO>:S5RL9W$;3M1N>]>EZR =+N21_R[M_Z#5/PA;?9? M"]C"4^[;K_+_ .O7+C:5;$825.E-TVW>ZU^6IM0<:6+C*HN:R]/R/+_^&KDT MN^^R^-OAUJFF[EW(IY<_\!=4X]\TOA+]J+X<)=R6UY8ZA;-=7KNUP]NK(@8\ M9VMN/X UZ]>);06TEW+&/W:EF)7T%8/@W1M!O_#=CV\]C?,A*@9[5'+ M=1Q-MEF5?5=U3N$7H!T]*X;XG? [PA\3;M-8UN>[AN+>W,44EO(,!1NR/TKIL9KQSX6_"WQWHNI6/B;2OB;=76EM*_VBTNF8^9&"57 )(!( ], 8 MKU>>X>&![A49MJD[.YXJ<+C,17A)XBBZ;CI9N_35JQ/L*5.WLIJ:>MTK;OS) M[GE00:Y[P$JWXU'Q*VU_[0OG\N0+@^4G[M ?IM)_&N!OOVI?"UQ876EZAH^I M:7=O&5A2ZCQ][C=D?=Q7>>!O$_A/5-#MK/PQX@M[Q8K<+E)AN.WY22.O7OBI MPNHZV#Q5*LG.#44KWMNWY^AT/D6Y99#$N5^Z<4RX:0 M1L(_E[;L=*D@_> L34VU<8*UW144M"-#S^>[^*WA&XDD:-=8L_,W?*NZ0*3T MP.<_3:_5;'G2P^+H^]1G==I?HS:A M8NBL6[5G>(=:BT73)M0)7>JXC7'&\+:4-,34I;B.-F,9E M'W0>BCV_S[54OKNVU7Q0L4URL=IIC*TC,V \[#Y5Z]AS^(K",(^TNMMSHG4D MJ2O\3_K&M&_L_2%MK]!)+-NDNF9?ONWWNO7_"KFC:)HWAW3(](\/Z1:V5 MK""(;6S@6../)).%4 #DD\=ZM*$9 ZA:&V@&IE*4K^9M",8Q2730^*_VE_\ M@JQXJ_8M_:PG^%7[2WP.N;'X^7S"$ N6F7D.$D= R)MDC7G9 M+O0GZ@^ _C'P5\3/A]8_$_P)XNL==L?$4*WT.I6,PDC=6'W1W&WE2IY!4@@$ M$"CX]^'/@?\ :'LM0\$?$GPQ9ZWX5$;V]UIFH0B2*ZE_O8/]S@JPPRN RD$ MU\,_$K]@/]J?_@F[XQO_ -H/_@FYXKO-7\)R3"\\4?##4I/.^T1(Q)2+(RX" M,0K#$J@#)<9!^HHX?)\SPD/PI&4*N5'_?->+?L(?M;K^V9\"HOBG<^ =3\,:I9ZE/I6O: M+J5NZ_9[Z#;YHC9E!D3YP V 0=RD!D8#VM1@:?= M'J0G&I%26S.2\=P^-;*]C\2>%[YI(X8PLNF["?,'.6P.OTZ\<<\'0\!^-[/Q M=;N C0W4*C[1;L#\ASC\L_CZUN[5' 457AT[3K6ZDN[:RACEF_UTL<8#/]3C MFJ=:#H\LHZK9_HSG5&I'$<\9>Z]U^IKITYU9J$5=LSJU:=&FYS=DC(8]9U35&>UB4;;':=N1WSGIZC'/K3OAS/XMU"";6O$LH6 M.Z939VQ7!C09Y_'(Z^E=1R#S5N=3"5':6VEU^)CRTL;13G'3>S(+2%+>-8X8 M]JJ,*J]A4^,<&E=E*9##%5+/6]*O[JXTZQU6WFGM&"W4,#W\=>*M9C\3ZI< M/8V2\1V"AL2C!YP<=SU(YQQQ76ZCIMGJ<2QWMK',L<@91(@;!'?FIXAMX%;Q MK1A2Y4O>?5]O(Y:F'J5JRDY-171:7?F*@YY'%.8BE9E)R&KP_P#;2_;[_9Y_ M8>\&/X@^+?B=7U:XLI)]$\,63!KW4V4A0J#HBEB!O; #'G:16=&G5KU%"$6 MVSLC&4I66Y[;@'D#\:\#_;7^(OQ[^'IT*#]G?X57VN:YK N+635K>W:2'3EP M@4R@*4Y+[E:1E12A)W#('=_LK_'2]_:0^"&D_&"^^&NM>$7U8S?\2/Q!#Y=U M#LE9,LN!PVW(X'!_&N_N8UE.UTRM.494JCB]&M&<.98.>,PLJ,9N#?5;KT/E M_P#9L_8O\:2>.]-_:2_:&^,]]XD\41[IK.SLYV6SM-V[Y,G!< -PH"*.1M; M-?49^[@+]:YC3BO@[Q#_ &+,<66H,7L_[L4G4QCT!ZCM73*V1DFI=/V>VWF8 MY9@\/@:'LZ>]]6W=M]VWW.<8MX<\8_<*VVK#_OF=1[#N/<#BNCW97!'->*?M M3_M;? CX+:)<:=XN\6K-K4?SV>EZ=B6X65>5+ <(,X!W8X;.#6O^R?\ '+QC M\?\ X?W?CCQ=\.Y_#6W5Y;:PMKECYD\"JN)64@%3DE3Q@[>.,&G*4:EM=>J_ M4RHYE@_K[P<9WE:]ET[I]%J2?'+XV_"S]GS4K#QI\1_&%OI<-XK6\D+*\DLV M.0RQQ*SO@\$@$#/->#WO_!0']H?X_P!RV@?L=_LXZI-&TAC_ .$DUY5$Z:CC3;JZC),.?; M(#+GG:V1GM6U\.9+#_A$[6PL=,AL_P"SU^QO:6T:HD#1_)L51PJX P!T&!1) M2G3YK[:'%B<'FN*QDJ<:WLZ3VY5[WGJ]%\D?,OPU_9._:3G^,/A_XF_M'_M' M7DE]#?->6VC^'Y"L/FKL)B)*JHC>,,KHJ#@D!NY^MCDC(_&L;Q];3?V$VKV: M_O\ 3Y%NEPY7.S[P^A7/UK7T^[AO+6.]MI?,ADC5XV_O*1G-'+&,4T]]'=]5 M_P [LKR^CEO/2A=W=[MMM^;;]#"\2 :;XHT?6_,15DF:SN&\LEGWC*#V^8? MK70Q\]OSK'\?6D]YX6NGM)&6>W43V[*NY@Z'>,>_&/QKF_%_[2GP-^'>E?VC MXX^)NDZ;M6,RVLUXK31[U!4-&I+]".U5+WJ<9=M#>5>CA*DO:244]==#OI&4 M=ORK O96MOB#9B.W7;=6,@DDP?X2"!7S[XP_X*K_ +.VD2SZ3X'LM;\2:HMT ML-E:Z?8D+=L6 _=L>O'3C)Z"KGP6_:O^*7QX^*]K:S? #6_#/AZUX;5=64QM MYS _NRK*,@CH5SSUJ:4H\S5]TSSIY_E=:M&E2JB7D.H:1: MW41^62%67Z8JV& '7UKSWX&^ -;\'Z+_ &CK'C"[U)K^"(K;RR,8[<*#@+DG M^][=/ICLM9T^75M(NM,CNFMVN;>2)9X3\T992-P]QUJ\/6Q%;#>TJ4G&3UY; MIV\K[$RA3IU%",N9=TG9^9-K,L/]DW69/^6#?RHT)XO[#LQG_EUC_P#017DF MO_L_ZWI.AW6I-\8-=<6\#-L:9L-@=#\]3Z;^SGKMWIUO=1_&37$\R%6VB9L+ MD=/OUY?]I9YR7^INU_YXG3]6P'M?XZO;^5GJ'B":.+0[R61U51;O\WI\M0^# M[&/3_#MC9QMN\NW3^54:ZCM<0;ONF0+QGVS7O8:M4K8.+J1Y6WL^C_IGG58QIXJ M7*[V6_=&@PP>.:S?%>HOI7AR^U".55DCMG,9?&-^.!^>*Y5?$GQ;TQWBOO"T M=YW62%MH''3KS5K6=3O_ !'X8TVUU#1&ADU'488Y[=FY5%;>S#\$_*NSZK*$ MES-->33.1XR-2E)133L[737D=#X:TY]*T&RL)559(;=5D5>F['/ZU>8[?G[? MSJEJ>NZ/H4:2ZSJ=O:J[;8S<2A,GTY-266J:;JMNMSIM]#<0MG;)#('4X]QU MK@GB*4JO(Y*_57/0A3E"FK)V6GW'.>.-#T'Q+K>G^'-0TZUN(Y&::ZCFMP=\ M:C&,X]3TKFO$?[+?@N_D:\\*7]UHET=Q5K:4M&23D?*>@!_A!7^5=EX?9M1\ M5:IJX+>7%MMH_P!YE3CEB/Q/-= 2/O;:Y,PR?+<=:-6FFUUV??=:_B7@\;BJ M#,/&#:PS3[K>9XRK(F.A)))R?RKH[Z\MK*) MKFZN%CC5U.!);K577-&LM>L7TK4[?S(9,;ADBNC"X>CA:,:4; M\JTU=W^(J]2I4DYZ7?R18MKBVN(Q-;RK(K! MM>;R]V?LERW'7D>G\C7:Z>UU]AA-^%6;RU\Y4;(#8YQ[9KNJTZ<;.$KI_>O5 M''0K5:DG&I#E:^:?S*WB;5O[#TJ;4"IDD5=MO$N=TDAX51CJ2<5D#X?66I>& M5T?679IGD,]Q<1L-WGGDL#C\!D= *?,R^)_&*PKS:Z2VYN.R_4X2PL/B%X%U.&TC$FK:7)(L:@#YX\]^ M3E<>N=N.N">-_P 7:K,KNV3SYE*Z9&^<)%_#]"W4UHZGMGSR2OY:7]3.-'Z MO^ZA)N_1]%U-?1],MM(L(=-M1B.-?O>I[G\35T*"M<7IGQ+O]*U%M$\>V*VD MGS&.Z13Y;CL/_KC^M=C;S1SHLL15D89# YS6-6C5IM.77J=&'K4:D;0Z=.PV M"RL=/A=+*TCA5Y&=EBC"[F8DLQQW)))/<\FO._CU^UG^SY^RY)H*?'SXEVOA MJ/Q+?-9Z/<7UO,T,DJ@%@\B(R0J P)>5D4>O%>D2.&4K'U]J\<_;%_9I^"W[ M6/P_A^$/Q<\'IJSW$YDTJXC;R[C3I,8,R2 $IQP1R&X!!XQM@(X:IBHQQ+ER M7UM:Z7=7TT*Q$I4Z+<-^G]>9Z]8WD%]:I>6=PLLM%1G)7(IR'* MU)H.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH *0LJ]32UP_QY^./P]_9S^%>L?%[XH:_#I^DZ1:M+))-(%,K M\[(D_O.YX"C))-5&,IR48J[8TN9V.V:6/D;Q^=8.J>"-(UO6X->U,2R/;KB. M%F_=D^NWU_''KFOF_P#X)=_M1?M3?M=^!_$_QC^/'PXL= \*ZAK(D^',D,;1 M3W-B=V[>I^\BX3;+QO+/Q@*Q^K#RN&%:58U,'6<).S6CM_P":U&$O=FDQD*> M6!\G%/=T9#@CTH=UVE0:^=?^"BWB7]M#2_A3I_@[]B7X??VIXA\2:A]AO=<- MQ%&NA6Y 'VD^8PSU/(#%<$X/ J*-/VU90;2OU>R+C'FDH['FO_!1+_@HEXQ\ M&>*(/V+?V']%?Q9\:?$B>7(NGJ)HO#-N5RT\QSM$^SYE1OEC7][)A=B2]1_P M3!_X)[ZS^QCX0U;QK\6/B#>^)OB-XT*3^*KZ2^DEMX<$LL,>X_.P+,6E(RS' MC"@5>_89_P""<7A']C'P#-K,6M/KGQ,UQS=^+O&UX2\M],QW- -Q)$&[G&=S M-\[$G 7Z(\.^((]65[>>'[/>0?+TN?7->U:WL;.UC,MU=7TJ:1TBU'2KM9X696VLNY21D$$$ M5Y?*[72T)Y6UMH?'W[=W_!4SQ!X#\=G]DW]AKP(_Q!^+TUPT&H6]O8R3VNA+ MM!+2;2HDE&X?+NV1[6,A& C8_P"QM_P2JT[X6?$J+]H?]NSQ&GQ*^(VM30WM MI>ZH6FLM$O0WF&- Q*RRA^5D*JHV 1JIR6^PO!?[/GP8^''Q%\1?%OP-\-=+ MTOQ)XLD63Q%K%K;[9KYE'!8]L]6V@;F^9LMS72ZWH=GK^F2:5J,6^.08.TX* MG/!'N*]2..IT:/LJ,>5/XG]I_/HEV^\JM4E[/EI:/^M/0NP^6D>W*^V*<&7N MU<_X:UB_AGD\-^()O],@SY,K+C[1%V?Z^HKXZ_; _P""O6E>'_&4G[,_[#/A M*3XG?$_4EDM+632D,UCI-T)5BS*1Q+MR[$@B-<*6?!..:C@ZV(J\D%?SZ6[W M[$4)?6(WC\_(^Q/'%QX6FAC\/ZWXAM+*YO9,:=YUPJR-*.04!(+'Z5/X2UBX MU.P>SU2+R[VT?RKJ+T..&^C#D.OBK9?M??\%#OB MI?\ B;QQ'J"ZEI'AJQOW6QT63=N$8YQM "?(@5>.2Q!)^U/%5I+H.IQ^,]/B M_P!6NS5(_P#GI;]WQW9>H]B16M:G1IM4H3YO/I?LN_J98B$:,_:1=^_I_P MX'P9^PW^S]X+^)6J?%F/PM)J>L:IJ#W8FUB;[0MH[DEO*#?=!))R6Z\@Y[<_I7)2M&5GHGH_\ ,X_J6%PU-SH12M[VG7Y^ M9K,*]8TW6;SXG?"G2?'QT&[T>\NK MH=.OD"SVDA0/Y;Y'!&2IX!]A3IRCSN%_(QIYE@<=)JA-2E"S=O\]OD0_' M#]H'X1_L_:';ZW\7/%4>FV^H3-#:K]GDF>9@,G:D:LQ XR<8&1GJ*^=_A9_P M4!^(WQ(U[3?!?P%_9E\0:YH\=Y#%=:UJUQY)@A=VQO"*\:80<,9,'!^45],: M]X ^&?QATW2=3\:^$=/UA;)C<6*W]NL@A=DVL0&'/!(((P< XR :=%I^F>#/ M%&GQ:590VMA=6HLUMK>,1Q1%!F,*H&!Q\H[ 8%*,:DHN"=NOW'-C<-F6(QD: ML*RA35EHKR:?F]-SI-N4VR#[R\\=*^?] _8(_9C\3^,-1\>^*_A])J&JKK$C M3?;M1F>*0YR"T6X(001\I!%?0F0W?/TKGM/ TGQY=6P1(UU&U25?FY:1#@\? M0BB-I0E%^OW'?C<'AL34INO!22=M5U9#X2^#WPO\!V<6F>"_AYI.EV\4C211 M6>GQQJKYSD8'!SS4_P 0+8/X?6Y>7REMKJ*5V_V0X_*NB#J3@-FLOQI9V^H> M%[^VG/RFU<\>PS_2E1]VHC>6&P].@XPBEITT+T;"2(2*?E905([TX@!,$53\ M-W<>H:#:7L(PLENC*/PJX64#ANU3)2C-KS-XR4J:?=&#\,1,?!UNEPS;EDF7 M#]1B5AC],5T "L*P? M^+FSO[4KM^RZM<1CW!??_ .S5O;TVY#CWJZU_;2=N MOYF>%<5AX)=C'^(/'@K5.?\ ES>K^@9.AV8_Z=8__016=X_V2>#=22.12?LC M]_:M#075-%LP[=+:,'_OD5E' M)1?^+=8OTGWI&T5LBE>5*+EOPRU%/X9/LOST"MRN48]W_P ']!_C3X>^&?B! M8KI?BK3?M$<,F^/#LK(WJ"I!'OSS7G6N_LUVGAA)/$/@?XAZKHOV=9)&W?O% M1,'Y5VE6'XELU[("&XS7/_$!S=Z=:^'K>1M^I7B1$QM\RH,L[>X"KS]:\C%9 M'EN95N:M#WOYD[/3S1WQS'%82B_9RT[/57]#RS0M4_:/^'%E"9/#5KXBL;G9 M.S6V3+EQD\@*V<]2RL/>O;;4S/;QRRIL9E!9/0XZ4^WC"?*PX' J1BO^%& R M^6 YOWLIQ=K*3O;T>^OF56Q'MTGR*+ZVTO\ +_(9OVG+';0L@SD&OE#_ (*) M?LW?M;_%3QEX;^(_[(G[2MYX-U[3=-NK)M&9F^R7X8^8&;AD5\@+N93@=.]8 M'['?[8G[=C?'6T_97_;3_9=O+74IXKB2U^('A^W8Z7-'&;AO,D8!HUW^6B(- MRN?O,HW 5]6LHE5R_P"LT:L&TFY0O:2MUL[)KT;?D>9];C&M[.2>^^Z^_H?9 MP.?F!K+\4:N-!TB:_P"6DQMA7/WG/ 'YUIH0!ACBN;D+>)_&GE+\UEH_+'L] MP1P,_P"R/U/->53CS2N]EJ76J"^\3_#CQ==F1;QS)&S)&\K^7*#\^=SPRQQ@B.5F8 =O^QU_P %DOA3 M\9=6C^"_[3^@R?"OXF6L@M+W1]:CDAL[RX4%9#%)* 83O5AY,IW D*KRD$U] MI1[EXS^E>"_MR?L/?LW_ +7/@66V^,'@U/[4AVKI>O::BQW\<@W!$\T#+QY8 M_NVRO)Z'FOIJ.<8',XQP^:4[]%4@DIQ73F6BFEYV?F>6/S'I\HX-=-'&(D"1KM &,+7D/[ M$O[,&J_LF?!:W^%VL?%/6/&$RW4DYU37)-TJ*V,1 DD[5Q@9/'; XKU[<#G! MYS7@8R-*G6=.E+FBF[.UK^=O,ZL/&7+SS6KW_1%#6O#>E^);/[#J]HLJ9RN[ M@I[@CH:XLP^+?A1<'RT?4](D;YOE.Z(?T./P/M7H@;)V9IEY=6UK:/=W+Z/^M&9XC"TZC52+Y9+JOU,_5]?MM#T=M9O(V*A5VQ MC[SDXPH]R3]/YU7\)Z'=VKS:[K+J]]=MN?:V1"O:,'T _6JND6DOBC4E\5ZE M_P ><:@Z5;MV_P"FI'J>WH/K65\._P!I7X#?%#QYKWPQ^'_Q4T?5M?\ #=QY M&M:5:W(\VVD'48.-X!X++D \$@\4>SJ>SE[--VU;71>95.TY*4GZ+OY_Y'>; M0QWUS_C[Q-J?A:*UU&VTPW%KYV+[;]Y%[$#TXSFM_/RY%,N;>.YC\B6- M71UPRE<@CT-84Y14DVKHVK1G4IM1=GW(M$UC3]8L8]2TVY62&1_YUVN@ZY8:]IZ:EITP:.3 MG'<'T^M:UJ"C%3IN\7U_1^9SX?%>TDZ=16FMUW\UY%UL-SG;7@WCS_@H7\"_ MAC^UKIO[(7Q-L]<\/ZQKEG%+H7B+5K!(M'U&1\;8(K@R9,A)*#*!3(I3=N*J MWMNMZQ8:/:->:A.%5?S)[ #N3Z5X-^V?^Q5X6_;P^"NH>#?B';QV.J)#)-X- MU#R\R:1=8^60DEUO%])6ZI=5V\[%8BI4B MK4M9;V_S/H-7#( 'S4L?W!BOF7_@F%I/[;7A3X)7GP\_;5TN$ZEX;U#[!X?U M8WPGN-2LT7_62,/O ' 5SAV'W@",GZ9C("\FN?&8>.#Q4Z*FII/>+NFNZ-J< M_:4U*UO(?11FBN,?#/@7POJ/C3Q?K=MINE:39R7> MI:A>3".&V@C4L\CL> JJ"2?:OS$L?#GQ"_X+B?M;?\)]<:EJ&G_LW_#O5ECT MVVNH?*_X2"Z3!8^2%OVIO@3XD^ GC+5;^Q MTWQ+:+!<7>F7'ES1%9%D1@>XWHN5/#+N4\$U?^ OP#^&?[-OPNTOX0?"'PS# MI.AZ3#M@ACY>1OXI9&ZN['EF/)/H !7?A<53PE.4X?Q'HGT2ZOU[=C2$HQC= M;DEOX9N/AW#&/!5I'_8\$81M#BC"K"@XS!Z8'\'3@XY(QTFF:[INN60O-.NE MDC8?P]O8CM]*L^5N3&*\R_:*\)?%JQ^$_BC5_P!FA+./QI-I4RZ3;WTVR":< MC 8GD*XR2IQ@L!GC-AY_\ %K_@H_\ "/X= M_M=^"?V,O"FA:AXN\7>)=26#7XM!*NGARW:-F6>X/=L[6:,$%(0\C$8C27Z, M^;&"*^,_^"5G_!/#P[^RQINI?&'XL:J?$'Q@\1,S>)M4O&+MIPD;>UO"7Y.X M_,\IYD(XP!BOLP3;1UK3&4\-3JJ%'6RU;ZONEV.F4H/X-08.P*BL'Q9X;O;Q MX]<\.RB'4K7_ %9SA9E[QMTR#[]#Z=1I>(?$_A[PEH=UXF\6:Y9Z7IMC"TU] MJ&HW*PPV\2C+.[N0J*!R6) HT+7]"\5Z/;^(?#&MVNHV-Y&);.^L;A9H9XS MT9'0E6!]0<5STY2IRYEM^!G4IQJ1LS\T?VE%_;&_X*Y?M%:G^R]X!T74_AS\ M&/ ?B!].\::Y>+MEU:]@;$IQQYRJPQ#"/EY664Y95B_0;]GSX ?"_P#9E^$^ MD_!CX0>'5TW0](AVPQ[MTDTAY>:1OXY';+,W';F.^_X27066.^0 M8D1C\MRO]UO?T/;Z5>T'7+77+/SH0T@_ MSBN7\*VGC+QEK4/BG7KB:SLX'W6MJA*^9]1W'UZUS4\.Y4G-NR7Y]D<]3%*% M14HIMO\ !=V01@_/ RK+ M$6CD'RL-X&/6LG]AC]B[]G3]C[X=MX<^#G@\0:Q<1PKXFUJ^8R7]_<1J5W2, MWW1DL1&@6-=[;5^8D^[",@8"\"N=\1:?>:#J/_"6Z!:M))\JZA;(N?.B'\0_ MVE'3U%:4\14EA_8_S\S2I4JTOAVZK]3I,M44\0E5E==W;;ZUS/Q&^.'P ME^#WP\F^*OQ.\?Z;HGA^W0&35+^X"1DGHJCJ[G'"*"Q(P!FODG]G/_@IY\=/ MVW/VE;;1_P!E?]G!I_A!I6I+:>*O'7B"Z+81_* MURRH6^S @'!+84?+_%T-?,EU\./V[_VW[QA\3M4_X5;X%>1A_8MJK?;+A-TH MVNN0[MC:K>88XR-CI&37U]XH\/MKFG;8)-EU"PEM9/[L@Z?@>AI/"NLIKFFK M,Z;)XG:*ZA_YYR+PP_S[5%2,:D>;[_T/G\9ED<;4C1K5)*&ONIVYO)M:V\KG ME'P2_90^"W[,OB.UM?"7A>.>2^M_+&M:F%FNS*.2#(1\H88.U0JY'3/->SLF M5'<8[^E4/%FA/KFD-;Q2;;B/$EJ_]V1>5/\ 3\:=X8UQ==T6&\",LA7;-&PP M8Y <,I],&B48RIIKYG;@\+A\O_<48I1Z6_$S?"SQ:+K]]X7^ZNXW5HN,!D8_ M,!D\X;^=6_'%C+?:!)+9JWVBU99X=K;3N4YZ]L]*I>/+V+0_LGBL21AK.?9, MNX O&W#*/4CAL>U9/B#XUZ-;J]MHMDUXVTAI)/E3H/Q(Y]JZJ6'Q&(E&=.+? M?U7F9UL5A,-3E2JR2[>CVL=EI&I0ZGI\.HP,K+-&&7#9QD5@^.=5TW2-4TO6 MI+^WC,-T8Y]QRWEL,$ ?7!KS&3QMXF:S_LZ+4Y(;<9"QQ<87.0,BLN226:0R MS,SNWWF=LDU[&'R"<9-SEIKHM3P\1Q)3E3481UTU?='K&H_&GPG9OMLXKBZ] MXH]H'_?6/TKGM6^..K7L'D6&@6\.Y2'^T2-(&'T&W^M<.G2EKT:.1X&ENKOS M9Y5?B#,:VBE9>2-R#XD^-+6SCT^SUS=,?ZU1HKOC@\+':"^Y'GRQN+EO-_>P:6<[CYK[F8DMN/)]>O6CS[@G_7 M/_WT?\:*0=:V=.G;8P52:EH]S>\=M*%T=5D;YM!M\Y;_ 'JPA)-C'FO_ -]5 MO>.^NC_]@&V_]FK!KDP,8_5HZ=_S.O'2:QDGZ?DB6VU+5+*036E]-&R_=9)2 MK#CU!K2LO'_C73V9[;Q%<$MVF?S /^^LUD45TSPV'J?%%/Y(QIXK$4_AFU\S MK+'XT>-+1 ETUM<\\M+%M;Z?*0/TJ]X2^+UGI44Z:OH[F2>X:5IK7!W,QSR# MC&!]E<53*,#4BTHVOV.RGG.8TI*7/>W?4]KTSXF^#-48+#K"(W MV3 H<_CU_"HX9K;7O'_GPRQ21:59_+MSQ-*?7H?D7]:\7V<<58TO6=6T6;S= M)U"6!N1\C?Y%>9/A^,$W2ETZGJT^)92:52&B=W8^A$<=C0T@Z UY3HOQLUJT M7RM9LDN4Z;U^5_\ "NFF^*7AV_T::329&:\*;8;22,[BQ(4=.O)['..:\.ME MF,HRM*.E]UJCZ*AG&!Q$;J5GV>A6.>_-7_,4''-K]3F_BOK7BGP]\/-6O/ JZ>_B!K"5/#\6J*[6SWQ0B 2A"':/S-NX*0 MVT''.*^!?@[_ ,%2?V@OV//$%C\$O^"H'[/-]H,UU<[8/B1HL2R6MXS+"3). M$)CD(\PEY8'(!(00KM8U]\2O_P )3XVV[MUGH_\ ">CW!_\ B1^IH^*?PA^& MOQM\'W?@+XK>#-/U[1[U=MQ8ZA '0^X[J?<$$>M>SEN,R["Q=#&4.>,[-M-J M<=';E>W6[333.:5.MB*GM*<[_$WX?\ Q8\+6OC;X:^,=/US M2KR)9+:_TVZ6:-U(R#E2>U5K3_BK/%#:INWV.F.T5ONZ23_Q-@YR%' /'.>H MK\_/B[_P3H_:;_87\;7'Q._X)??$B\DM]2E$FH_"_4)EDCG!#JTB-*P3"!EV MABK9Z,=H4_H#\%V\577PE\,7WCGPQ%H>N7'A^SFUK1X9-ZV-X\*M/ &!.[9( M67.3G&_-'\FKIZBIU*V(J^:.6T;>;7^&<>GO]#P?K72&5,@&E,@V< ]*\6G4] MG4NE?\3LJTHU:?*W;T.2\&?$Y/[)U>$6>IQY5K=LC?CDXS[=CR.>W)=>" M3QMJ_P#9EN^_2;5L7C#@7$H_Y9Y[J._YHO- MK 01G/\ >(X4=>_053\;_%[X)_L\6>AZ;\2O'^E^'(M;U 6.CMJET(Q=7)!; M;N/?'4D@9(YY%=G*IU$Z$7S/HM7_ )G%352473JRNH[O:_Z>IVB0+&BPK&JH MJX5:^!/^"D7_ 3G\8>+_BS:_M:?L':G-X?^+6CR+=ZK;Z=,L,>IA1@2'/R" M?'RE6!69/E8>OW+XB\2%(H]*T)Q/J%Y'FV5.0B_\]&]%'Z]!5CPYH,>A:<+; MS?.F=M]Q<-]Z5SU)_P ]*WRO,L5DV(6)I[ZIQ>TD]U)=4S7$4XXK]TM+=5T[ M)>9Y_P#L9?%3XT?&7]G;P_X[_:%^$EUX*\731R0:UHEQ&8P98I&C\]$8EXXY M-OF*C_,H;&7&V1_4\C;DTSB+<6/R]L5Y!\#OVZ?V?/CY\7?%GP(\%Z_>6WBK MP=>-!J6CZU8M:33*I ::%'^9XPQ +8!&0<892>.5.KBYU*U*G9+5I7:BF_OM MTU.E2C3C&,GKY]3UVYC2XB:*=59&&&5ESFL4V_ASP!ILC:=:,@N)OW=M$Q=I M)#T503U]N /:K/B?Q1:>'8%)C::XF;;:VL7+R-Z?_7J#0M!OI[L>(/$3*]X5 M(CA_AMU/\*^_J:S@I1C>3M'MW,:DHRJVI_%W[?UV*VC^'-1U'4AXG\7.C7 R M;6QC.Z.U'U_B;U;IZ=L=&J2;>#^/K7*^+_%6N>$_$,%Q?6RR:/,H1WC7+1OZ MGVKJ-/OK2\LTNK2421R+E'4Y!%55C4:4WL]NWH*A.AS2IQW3U[OS),D#+-6+ MH7CG1=7D=T'YIP.> M:Q?!_BNQ\5:/'>VDJF0*!<1C^!L=/IZ>U;0Z5G*,H2Y9;HZ:=2-2*E'9A111 M4E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1129;=TH M1GQVKDOB-XTN-#BBTG1=S:E>-B#Y =G;//'YYKK)(V<\-7-V7@(0^,;KQ7J% M\+EY#_HT;1X\KC_/_P"NMJ$J,:EZBNET[LY<5&O.GRTM&WJ^R-G1UU-=-MQJ M[(USY0\]H_NELG*-8BDCT^QDV MV4.WB0@^_7WXY/'8BO2%&U<5M7HQHR4;Z]?+R]>YS86O+$)SM[O3^OR,+Q+X M6N+]EU;1[W['J$"XAN%Y#KW1Q_$IZ^QY'O4M_'.EZ3IUW/XSO(=-ET^W>:_D MN)-L:QJI9I03_!@9]N]=-+_JSQ7P7_P4X\+?ME?M0_'3PG^Q5\(_A[JFB_#[ M7(%N_&'Q&M8\QM;!OWMMYO2+ X$1^:5F! *AL;86G'$U%3J222UN^B7Y^AO' M#_O>:&E]_P"NYY'XU^+?Q6_X+@_M,M^SU\*!JV@_L[^#M06;QAK=OF*37Y$; M*!V(X#$?N8.2!F:0%A&L/Z9?#OX<^#OA-X)TOX<_#SP_;Z7H>BV:6NF:=:)M M2")1P!ZGN2FD?JT[D9;<?]Y^;_#8U^L4ZT?E2IJ']M>&YXUU*.,&:U9L+(-4+P>$_"MN_P#I&J7. , #)6)"REWQ@;E RS*#Y9_P M39_9M_:/U#QGJW[=?[7_ (XU)O&GC;3O)TWPC'%J1P[KR=H[*_VGY"J4%.G>7R]3ZSTK4=%\8:?ODME?RW FMKF,%H MI!V93T(/_P!:M2-<=NG KG/%'A_4--OO^$N\,J6N%&+JU'2Y0=L?WO2M?0/$ M%CKVEIJ%BWRL/F5NJMW!]"*QG#W>>&WY?UT.6G4]]QGO^:+Q<*<;<_2F2&)B M26]J^+/^"B7_ 4P\2_#/Q#%^RA^Q1X; MCG:Q C7YWVC;GUC_ ()W?LX?&G]GWX+W7_#1'Q5OO%7C;Q9K4FN>(IKBX,L- MC/+&BFVA)_@4(,X !8L0 ,"MI825+#*K-VOLNK\[=$=TJ?+3YI:>15_:V_8; M^!W[4=WX:\/?':UU:\\*Z1K4FI1Z?8ZD;:.2Y>,QF.9T'F^4Q[XY%(D7UK%\.7UUH^HMX0UF;YE^;3KA_^7B(#G_@2\ CJ1@X[U$JE M2K2Y;[=/7KZG&I2HR4'\+V[)G1!"3N#5S6OJWA375\5VJ?Z)<[8M615ZXXCD M'?C.#[=N,UTN:\_\ 'GQ=TU;>;1?#\8N)'4I):I*SZ=[]D=MJ_B71M%L?M^I7 MT<<>W*LS=?IZUY?JOQ/EL-6OV\&IY,-Y)O8S1CB3&&= /[WRG+9.<\5R=S>W MUWY9N[N23RUVKN8G ]!4:KQQZU]/@\DIT;NH^;\CY''Y_B,194ERV^\L:AJ6 MIZM[&G",4HJQX$JDZDG*3NV-( M;-+@]Z6BKL0'TH (ZT44 %%%% !2#K2T@ZT!]I&_X[ZZ/_V ;;_V:L&M[QWU MT<_]0&W_ /9JP:XL!_NT?G^9V8[_ 'J7R_)!1117:<84444 !'I30K4ZB@/0 M3:0<@T@0XVYIU%3RHKF9N>'OB-XI\..J0W[7$ (!AN&+#'L>J_AQ[&NT@^,F MC7NBRM#$T.H>7A+>3H[< 8;&,9/?TY%>6MM[T9PV0>GZ5YF*RG"XCWDK/NCU M,)G.,PJY>:ZVU/=O">B1:-H<-F7W2M^\FD4_>D;ECU]?PJ]>7D5A:R7<\BI' M&A:1O3CFO'_"?Q/U[PY(L%S*UU:CCR9&^8HW/X>K/L,)FV%KT5&&DM%;U-7PE97.HSR^ M+-5MMEQ=96V5L_NH/X5&3QG[QX'Z"NC\K:N*9&@CCQ&BA>@XXJ6/.RO-G+GE M<]:G35.-CY'_ &A_^"G]A^R7^U?!\&_V@/@QJFB?#V_MHQI/Q.21Y;::Z:)' M,;0B(;45BR%E=B" 2H7M6VM6Z2Z+/9S>9'=* MXRKJR]5QUK,_:)^#WP?^//PGU3X=_''PK:ZMX?NH\W$%PGS(Z_$=!U+:>Z:ZK:VUGH<'[*?P<_:[^"4_PN^* M>G-]J:0OX9U2T0?:M-O<866(GJO9T/RNO!P<$>R:KJEEI&GS:A?2[(HEW,S< M9] /J>*R?#6F7VJW*^*?$MN5N),_9;5_^7>/Z?WCW[_3I7!A<17PN(CB82:E M%W36CNNQI6C&5/V"6ZZ]%W/SA_8U_:6^-G_!,/XO0?L M_B4\CRPV\0.([=I6ZVQ_ASAX#\K9C"B'].K.\M=1@CN[*X6:*6,/')&P974C M(((X(([UPG[2?[-'PH_:L^%FH?";XO>'([[3;R,^5)@"6TE_AFB?JCJ>A'TZ M9KS+_@G9^SK^TQ^RMX0USX/_ !H^*=CXK\+:7J 3X?W:[VO(K''W)RP 7'0* M"V,<$ A1[&;XS 9U1>.5J=?13C]F?3FCT3_FCMU78C#T:F%G[+>'1]5Y/_,^ MC) =H/'N*^+_ /@J)^Q3>?$)]/\ VJ_V6KV\T+XX>#RMSHEUH:CSM9BCZP2I M]V0A-P4L&#*6B8.K@#Z[\1^(7M95T71;?S]1G7,47:-?^>C>BC]3P*9X7\)) MI>^_O[MKF^FYGN)!_P".KZ+[5YF68RME>)6)@_\ MU[275276+V:*Q$?K'[J M*]7V]/,^7_\ @E__ ,% O!W[;7AF_A\:Z?\ V1\4M!_=^)M#E1E15#;1+:JQ MW+%GAD;+HY(8L-KM]=1KYO.:^2?VC_\ @F[J^L?M1>&_VQ/V3?'%MX%\:1ZM M&/&;&W+6NLV3$"9GB7AIMN1S@/\ Q$$!A];6@*QX/K6^=2RVO7CB,%I&:NX/ M>#ZQ3ZQ_EZVT8\'&I3@X3W3W[^?KW*NO>'['Q#ITFF:C LD<@P<_P^X]Q5+P MCX:?PEI0TF34I+I49MAD4#:I_A'M]2?;'2MVLWQ(-6&DWO\ 8+1+??97^QFX M0M&)=OR;@""5W8S@@X[UY/M)>SY>F]CHC1IRK*5M=KEQ;A0< _A226_GC.!A MAWKY&_X)T_MV>/OC1KOB']G3]J:RM=#^*'A:\9)K%XA;OJ$(R6=(\;?D&WE" M0R,K@;3N/U[!GRQFLJ=2-2/-%_UV/2S++L1EF*>'KI75GIJFFKII]4UL<;I/ M@K6?#/C1KS0#%'I5PN;B$M]UO0#&>O3MU'I79F0+QBFM%WW57NM3L;:XBMKB MZC62;/DQM( SXZX'?'?TK>I4J5I)OIH>72HTL-%I:)NY:W\9Q3JB5MW+"I:S M-O0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CEN#&VT+ M4E&M&9(&S>70\NUC7[V>[8]OYX]:NG3E5J*,>IG6JQHTW.70U-+\ M5Z7K5[<6&G3[Y+.3;<+CI[^XK0$G\5<[\.?"YIT9SP\E.WI?\PQ&']O3Y&[)[^:*^ MF:39Z3I\6FV*;888PD:]< 5;,C#M2 *.]8_C'Q%'X7\/S:NZAF4;8UY^9CTZ M"HCS5)6W;_,J4HT:=[:+]"X_B/2O[5706O(_MZM6D\7>( S:A?'=MD7F)3V^IX]/2NT;*+G%76C&G/EB[_EL:/9:I826.H1^9'(OS*?YCW]^U>;?&KXQZM^S7\)O$'Q&\3:! MJ'B*UT739+BSCTFU,MS<.!\D)50>22!NQ@#)/2NR^*7Q3\ _!GX?:M\3_BAX MDATG0M%LVN=3U"96988UZG:@9G/HJ@L3P 34/PZ^(/P[^.GPXTWXC?#S6X=: M\-Z]9^?IM]'&ZK<0DD9VN PY!&" 1Z55&7*N:<;PO_5F:5*/O*HM'^#\F?G_ M /\ !/O]AGXT_M=?'!?^"F'_ 4',T^H7C+/X \%W496.TM02UN[1-_J8(PV MZ*'[SLS32$LY,GZ2JA48S7+I]L^'0S!%-=:1CYHURTEJ?4?WD]1_#]*Z.RU. M#4;6.]L9$DAD7/Z0^'O[7W[.GQ6^-?B;]GCX=_$NTU;QAX/C+^(]+M+:=EL]KHC S^ M7Y+.KNJ,BNS(VY6"LK >D;?-.<5GAZL\'74YP3ZV>S[?+J:-M>C5_%GBR2,^9-+G<;:+=\T<*-V.&=OG?^%4 M^GH]NS:*YW6=,O= O6\1Z!&S[N;ZS7I,/[P_VQ^O>M72-=L=8L(]1TZ3?'(N M5..1[$=CUX]:G$U*F(DZTFW?^K&*K2G4Y9_%^:\B[NV\YKFOB3A [CU'3'X4SQ[\1[#PBBVRQK<7DBY6%7^X/[S>W\Z\CU M?6M2UV];4=2NFE=VSUX'T]..*]'+*XUM[J<0P!0&AA)"N?5N>?IT'ZU@>7MP0>G^=+1M0U)).4@MBQ>2%D/#@?*1A]K'8/IH%MV"*WE&479F7*X[CJ** M*!!02/6C--);^$=Z3#7H+D]10"34^F:1JVM2^3I.FS7## ;RXRP3/]XCA?J> M*Z32?@SXNOMLE]Y-HNXAQ))N8#UPO'ZUR5L=A#;>02Q>&[967 M[K>75P:!I 3":9;_ /?I?\*Y)\1P6U-_>=E/A:J_BJ+Y7/&_'A(&B^^@V_\ M[-6#O_&O>+/2GG,W]LZ?9_).RVGEIG]R/N@YZ'KD#BIKKPCX:U&'RKO1+=T/ M8PBL(Q'08 M4RN-T8VD?C61?_!#PE.B_9);BW*\EHY=V?SS7;#B+"RW37XG%4X9QD=8R3_ M\F!I-WD',VAS2)NV^9;C MS ?!K;3_0\NOE.88=7E!_F8OS4M-1B<<'ZXI02U=T91EU// ME&4=T+1115"$*Y/6@+CO2T4!<;L/3=4ME=7NFW"W>GWDD,B_=DC8@C_/Y4RB MIE&,XVDBHRE%WB['IW@7XOVU^4TOQ(5AN&8)',!A'SQSZ'/X93,R_P"L5,\J/4'N#^%?,9ADL;\] M#YK_ "/K,MX@DH^SQ"]'_G_F>CV2GQOK,>N3C;I]A,WV*%A_KY.GFG/8?P]\ M\Y['>N9[:U@>YNY%CCC4EV;HH]34>G3:;+ITV*PY3_PL M&]6. [=)M9OWDH/_ !]R#^$?[ ]>_;BOGK7J?3QDJ=/363_'_ (!\ M@_\ !2[X[?MU?L_^+O!_[4/P6\-6FN_"?P[(Q\5^&&LU:XG)8C[3*2I>./81 MYOC!_ MP27^,TW[;_[&VFS7OPZU"Y4?$#P.)#Y%NC/]\ [(R3\LF#Y3$ Y4XKZ; PR M_/L''!(C\$ME/^Y+^]_++KL^AS253 S=5^]%_%W7FO+R/T]8[D^8\5@Z M_P"*;B/4%\/^'+<7&H/]XM_JX!_>8_TZFN&^ /[4W@W]K;X.Z%\5?@@]P]GK MUJ9))+RU,;:>5=HY$D!X,BR(Z *2&*[@2N"?1]"T*PT2W:WMHF+,I7LCZ MAJ/[V>^F7_7-T += !C 4< 8]>>F@ ((#=:P_'/@Z#Q;I!M&D\N=6W6\V/N- M_@:C^&]$HPE1YT]>J_5$TY5*>(]E)>[N MFOR?G^9T36X?JU4]527-L=53G]F^3?H&F:Q;:O8PZC8N&BFC#HWL:E91*V[VXK MB/!%AK_@WQ1-X5-K/<:?*IEM[HJVV/V)Q@'MCCU[XK?U?QA!877]C:9:R7VH M%=PM8/X!ZNQX0?4]QPT\:^"0AU95EW)>6"$G!B/#%=S9 P2K'J0"/I']D+]I[PA^ MU;\#M'^+OA.1E^U1^5J%K( KVUTGRR1L,G'S#(YY!!Y!S75GP;/X@W7/CF2* M\$B8_L]5)MUXQT/WCUZUYE^RC^PYX"_9%\:^.?$WP]\2:E)8^--1BNAHD^W[ M/IVPR';$% ZF4@DY.U4'\.3Q2I^RK+>L7Z;Q[:H]T$I*Y(KD?BCX5EUBPCUO2E_XF%@V^%X^&91R5R#^(Z]/:S[#3-/TI&@TZR6%68NPC3 R>]6EFD; 4K1.4)5&X[=/\BJ,:D::4VF_+ M\R42'=C%/J,*6;Z5)4F@4444 %%%% !1110 4444 %%%% !1110 4444 %-= MF'2G4R3[W- #&F9<"N%L[*\\9_$JXU75K5UL]);RK:.13AV!Z_B1G([!0:[B M0KU)I1''C;@5I3K>SO9:M'/6H*OR\ST3NUW%7"+@#%5-:UK3O#^E7>NZS=I; MV=C;O/=3R?=CC12S,?8 $_A5S8Q QV]ZCNK>VNH6M[F%9$D4K)&ZY5E/4$=Q M6>YT=C\R/V3;3Q)_P4?_ &_-4_X*(?$'PRUU\.?AQ>2:1\.K PQLQGB):.Y* ME#YJ1[Y)MP.5F,>TCRRM?I=IFNV6LP"YTZZ61?XL?>4],$=CUIN@^&O#GA;3 M4T;PYH=KI]I&Q,=K9VZQ1KDY)"J !S5+5/!]E7K^;9-:=9SO#5=NOWFSYS;?NTHBC8 L,XKX _P""H?[9 M_P =K7Q]X*_8!_9B\6QZ7\2_&&N6TFM:]I-Y)G2-.R&0R;(F:!6YFE;.Y(+= MR5*2@U]V>$(]7L_"VFV>O^(5U6^BL(8[S5([=8ENY@@#S;%^5-[9;:.!G K& MO@ZV'HPJ2^UJO3O\RHVE!-Z7Z/222222:VH](T^TFGN[:QACFNF4W$J1 -*0H4%C_ !84 <] *Q=1\.7V MEW;:YX1E"2=9K!CB&X]?]UL=&]>M>A5Q4<11A1BN516U]WU;\W^1-6I4C9KX M5T-YXT/&/O?>%?*O_!27XG?M/_!?X>Z7X._8X^'5[JWB+XA:H^C0ZA!#NM] MD=?^/D_W&(+%6/R*4+-G 5OI30_&6G:S<-I5R5M=1C'^D:?,X\Q/&&$-[C]Y"6Q'<#^ZP[$_P![K5GPYXJL]>CDA16AN;?BZM9E_>(?IW'H M1UIXB4\1)U6[WW\O^!V)^L2E4Y:F[V[/T-60#H]>9^-_$\/@;Q#<1>$+Q UU M&S7UOMS'')V<#IN]1],]L;'Q0^))\/Q_V+H[*UW(O[R;_GBOK]?3_P#57E+R M/,YDD9F9FRQ;N?6O8RC+95/WM7X7T[^OD?,YUFT(25*C\2W?;T)+JYN+^XDO M;V=I)I&W2.S9)-1Y(.,]Z;D= :YWXE3:UK/@37/#_P /_'^GZ%XBN=,G@T?5 MKJ)+A+&[*,(Y6B+#S KD,5SSC%?61CRV25D?&MRJ2N]6<#^W!^V#X6_8J^"% MQ\4]9T*XUK4KJ\CT[PWX?LS^^U/4)>(HAW"Y^\P!('8D@5X_\//A/^WA^V#X M'\5?##_@H?X,\ Z7\/\ QEX8NX;+2?#,9EU+2[LRP&VD:25WC+*AE8,$#+)$ MI^4XKYO^*NI_M&?M@?"N']FKXKV5G#^U7\!?%EOXD\.Z;<21PVWB^SBE5ENK M5F:.&9654)^Z0%Y4,S8]$^,'[EZY#\%?BM>? 3_@IO\??'^J6WP7N+7_A5OPUT&65&\3D,W]GW2S0 M/YC3 @!ZM=7ES'%X=U*\6 M:86J2D03-MY0O'@E6Y!R1E2I.-\"/V+/@U\(/"G@F'6/"6GZ]XI\&^&X])M_ M%NJ6HGO&7<))")),L 98IS4M!2V!FA5E MED"11LS%L*JC)-=#X2^&'B'Q2%N'7[+:'K<2CEA_LKW_ !P/KTKT_P +> ?# MOA= MG9>9-C#W$HRQ_P'':OG\9G&'PUXQ]Z7E^IZV!R+%8RTI+ECW?Z'FGAK MX5>)-?99;J,6EN3\SS?>(]A7>>'/@]X4TO#WT!O91SNF^[G_ '?3ZYKK/*C1 M,(M.C4 Y%?-XC-L9B-.:R[(^LPF1X'"I>[S/NR.VT^SLH5M[2!8XU&%5% % M2>1'V%.HKS=SUTE%60T1@# )H$8'IYK010!D>E9>B0:5$UX-*N/,W7DC7.)M^ MV4XW+U^7MQVK67[HJI?$R:?\-"%0W6C8N,8I:*"AHB49P3S[TA@C(((ZT^B@ M#(UWP9X9UR,G4])BD8X'F;<.,=/F'-<1X@^!X"M<>&]1.YFN M,CI33&K=5]NM=5#'8G#2]R5CAQ&6X/%?Q(?=H?/NL^'ME4MQZ-FOHC4+"TO83:W=LDD;J0RNNQ MYV_3![=*^APF?TY/EKZ>?0^5QW#=:G[U!\R[=3S3)QP: 3GDU+J6EZAH]VVG MZI:M#,GWE=?U^GOS4*V$EQ:R0.\,J+(A:.5 M5DC)5AE7564\$ @BCE]V]M!^]HV=-H'C'5=$M'TD7TRV,S 31QM\RJ3\VPG[ MI(_SGFO8O"\VAWFA6S>'#&+54"QJG\/L??Z\UX.%&,FMKP3XXU#P=J'G0[I+ M9V_TBWW<'W'H?_U5X&:Y:L1'GI*TM[=_^"?0Y/F_U6IR5M8[7[?\ ]R==M_;KZ;NDTO2K+1[*/3[" 1Q1\ #^9]Z^5Y98=W? MQ=NQ]GSK%1M'X>_?T,7X:?"SP!\'O!MOX$^&?A'3]#TJTW&&QTVS2"(,S%G; M8@"Y9B23CD]:Z"(KGN1_*G2-MZ?GZ5^?/B']L;X]_L)_\%%]4\)?M6>/9+[X M-_$:\$GA?Q!?$/;Z%-M55B9E ^S(&X=67: RR9QO>NW Y?C,ZJU/9RO-1<[- MZRMNEWE:[MN[%5*U'"J*:LF[:=#]!BF[@G@TV5EM$\W/J33;.\COH([BVE62 M.1 TU>2[IV.E:GF?[-'[7WP6_:STG5]<^#/B5KZ+1 M-1-G?)-;M$X;&5<*W)1AG:W0[6]*]$U36;+2;-M0U:[C@B3[S.V*_.G]K/PM MJG_!.K]KVU_;3^!%HEQX-\17:VGQ"\-V4!?-1JK1NWNR7Q1EYI[;76I=-YXD\7?+IPDTNQ;'^ MD2#]]*/]E3]T>YYJ30=8^'FC:Y)\/M(UW3_[6AC^T7&FK>(UT%./WC)G?@[E M^8C'S#VKHO+'0"O@#_@IKX&\>_LE?M#>&?\ @I3\&Q=3+!=6^E_$#38Y'*W- MF=B*&RCK%&Z((BYP%D\AE!8Y%8G$>SIWBM/T.7(\IIYGC/82G:I)/E;6CETC MY7VOWL??H&[I2A$'S$"/$4DGB#P?<>3K%C<6KQ,.<;DW ;USQD=_SKT[:Q7I7Y\_\ !1GX=^(? MV0/VE_"G_!0[X0Z?:;9*,74;?+O*B13(S("H'3TJ2E&5M'\K='?8]/ M.,'@\)AJ&)P\[PJ1VW<9+XHM?.<+D*&;A"V-F_JN_<.0*\6_P""5'[8>K_M+?!2;P7\4=09O'W@ MFZ_L[Q$EPFR6Y0$B*Y93SD@%'X'[R-S@!E%?1MMX/:ZG74/%%VU]<*P98SQ# M&?14[X]3S7P/^UIH5S_P3O\ ^"@_AC]L#P=:26W@GXAW!T[QM;VZGRH[IS^\ MR[H_1B/%251TC4K;5[*WU33[N.:WN(UD@FB<,DB$9# C@@CH>]7JV/FI1 ME%V84444""BBB@ HHHH **** "BBB@ HHHH **** "H;N01+YC/M ')]*FSC MK5?4(EN(6MW9@LBD-MH]0=^AQ/AG4M0\7>/;O68+J5=/L08H463Y7;U(_7\J M[A 6XQ6;X5\-:=X6TM=+T[>R!BQ>3&YCZG@5J#/0<5MB*D*E3W%HK)?UW9RX M.E.E2]]^\VV_4AO[J'3K62[N)-D<2%Y&]% R37/?#SQ/J_BRRNM1O[=8X?M) M%JPX)7T/TXY[G/I6?\7-5NKQK7P/I'S7.H2+YG4[4SWXZ9&21R O0YKJ=#T> MTT32H-(LE_=V\84$XRWJ3CN3R?>J]G&&%3EO+;R2_P S.-6I6QS4?ACOYM_Y M%Q&+8##/O7#?M&_'SP-^S+\&_$'QJ^(5XL.FZ#8M.T88*]Q)T2%,D99FP *[ MH97@?C[5XE^V_P#L6>$?VY_ >D?#/QYX\UW1]&T[7H=1O[+1YE5-45,_N)@1 MG;W#*05/(Z5%#V7M8^TTCUMV/0CRW5SYI_X(Z? KQ-\7_$'C7_@I1^T)I"W' MB;XE:A-'X6CO$+_8=)S@F(.QV"3B,#D"*%=IVR,*^X)/#&I:)*;[PC>^2O); M3YB3"Q]NZ?AQ6KX9\-:'X/\ #MCX5\-V,=K8Z=:I;V=M&ORQQHNU5'T J[A5 MR4_M ?M6>!?V;?@IXC^,GQ.CFT^/ MP[I[3M9S*=UW*2$BBC(&"SR-&H]"XS@9(\?_ ."1OBS]J_XL_"#Q!^T#^TWX M@OFC\:^(I;_PEH=_;A3ING\[ GRKF-L@*2,D)D]STV-0DEI"B[5CC_A9%4 !3SC %=U:C2P^%5. MR52=F[](]$NS>_I8OD=>BJ/XF8D*H[LP%:NA^)M'U]&DTV\W,G^LA8%9(^W*GD=.]? MG1^W9JOCG_@IM^W%IO\ P3I^'5WJ5AX!\"W27_Q3\06$# K+MR(CYA5">D:< M/\TC. X0K7#A,+[>M:II%:M]DO\ /IYET.6L[IZ%O_@G5X%^,W[?7[3VM?\ M!4'XTZC?:3X=@CO-(^$&F6\R1F*S$LL+EE7.X(-Z,Q.9)3(1A45:^^;3Q-J& M@7*Z9XQ2.,,=MOJ"?ZN7M\W]UCU]*T/!'@[PM\/?".G^!O!FAVNF:3I-HEKI MVGV,"QQ6\2*%5%50 .U7KZVM;RU:UNK9)(V4AUD7((_P#U56*Q4<15NU[J MT2[)?UJ9XCFG+FAI^7S'(?-&YC^1KC?BQK.G^'1;:E8/Y>J[OW$D>/\ 5_Q! M_53Z>O(Z5)JL^H_#&V^U6LS76EDX^RS3$R0$\ (3U7V/3UYKR_5]8O==U*35 M+^;?)(V?O9P/3Z"N_*\N>(J<[?N+\?(^=SC-(X>C[-+W_P O-$-S$O@MJFO?L@_#_ ,-^+/&MG<0F M'1_$6I/!"800TH4)CS)BG"HTD*_-O+MM$4GV=..T4?"RE*I*\NIY9^U!^W%X MTT_XWZ/^R+^QUX9L?%GQ)NKJ&X\1M>%CI_AS3@P,DMVZ?=9EX51\W(.#P#\1 M_P#!1S]@7]FGQMXRU+_@H?\ !/4&\9>#M)\330?'#PQX/UC;-:W*'_2KVRG9 M6"E&99'C(*\AE(4D+J?&+3=(_;^TSQA^TE^P)J?B+X;_ !\TW26TWXR?"5KH MV.HZO:CY)HT)7YYDVF-90H+@!'1&VJ>J_8%^(?QT_:O\>>"_A?\ L=_"2;X/ M_L\_"ME'Q#3Q!81W%SXJU)X2EUIT@;/GEO,=2224W?:)3YOV>$>E"/L8\\'M MO_7GT.A+EU1H^ /^"1OP1_:AU+PE^V+^S)_P4#^)/V6UMX9?#>IZE?#5+VPD MCZQ>;,ZM&5)VM"5QC((*MS^E-G \%I'!-/YTD<:JTK*!O('WB!QS63\//AO\ M/_A/X2M/ 7PS\&:;X?T6Q4K9Z7I-FEO;PY))VH@ &22>E==X5\(ZKXNO_L>F MC:B?ZZ=U^6,?U/8#J?H,UYN*QBC#FJRT7R*.F:9?:Q?1Z?I MMNTDSM\JJ/U/M7IW@;X1Z=I/DZAXA5;JX^5O+/W(VS_X]_*N@\(^#])\)6:V MEK$KR8_>7#*-SFMP*@X KXO,,YJXB\*7NQ_%GVN5Y#2PMJE;67X(%AB3[J4N MQ?[M+17BGT>VP;1C&* .E%% !1110 4444 %,.0_2GTQCE^E*6P&=HUS8W+ M77V*P,'EWKK-F'9YD@QE_P#:SQ\W>M1?NBLW3;G4+J2X&H:=]GV7+)#^\#^; M'QA^/NYYX[5I+P,4W\3)I_ @HHHH*"BBB@ HHHS0 V0GC%-,8)V"FWUS%:0- M//*L<:*6DD9L!5'))YKY8^ W_!9/]@C]I3]J?6OV0/A5\8/M?B?25(L[Z:W$ M>G:W*C.)H;&&='\26_V35+)9%7[K]&0GN#7E'C3X9ZOX4+7EJQNK,8/G!<,OU']:]F7 M+J59<\TD]O%+%Y;HK*PY4BNG!9AB,')XJMKFH MW>EZ+=ZG8Z;)?36]K))#90$![AE4D1KG@%CP,\9->G?$#X2ONDUOPPJ]"TED MJ_>/^S[_ .S^7I7G>"O7K[BOM<'CJ.-I\\'ZH^ QV Q& J\LU\^C/PR_X*>^ M ?VQ?VE/A3:?MN_M97C>!])O?'UMX:\ _#[4&98](LIDN&DO+CKM8F!-S8+, M,GA505]O^*O^"_W[(:>(;7P'\#O!OC#X@ZY>:P-.L=/T;2?)%TV[:'A>0_.I MX(X&0<\5]@?&WPK8^(_ 5WJB?"C2_&FL:!%-JWA;0=6:*-)]4B@D6!1+*"MN MSES'YQ!VB0D@C.?S7^#GQW_9#_8=^(6I?M,?MG^+H?'G[2'BB\,-SX&^'.FQ M7W_"&JT@B&EP .L$$J9"N7E#GE$\S#/+[D9TZ]*SCMLEY_UN9Q<9QU1^IVCW MEQJ6DVVH7=A):23VZ226LV-\+%02C8XR#P<=Q5@JN,A:^$_V;/\ @I)^VO\ M'S]OW1OV;O%'[*>A^!O"?7_$-GJ>M"\US3+'R6%M+-LEC6WDEN'M1]FD M@,JI*6Y4>8/NTXQBN.I3E3E:757.>4>4Z/X>>/[KPG>BSO"TEC(V67J8\_Q# M_#^O7V);R$0B[>X41;<[MW&/6OGD^G]*ZSX>:O;:M>P>%_$U_/):;LVL.[Y2 M_HV.<8Z#IFOE\XRR,_W\/FD?39'F\J?^SSUOLWT.ZGUO6?%TC6OA=FM;53B: M_EB/S]L1COQSNZ=/?'!_M1_L5?!C]K#X':A\$?'^FR0PW$GGV.JVYS<65V 0 MMPI/WB,_,IX8$CC@CUY$@M[?9&%C55P-O&!6%?>+KF^NFTSP=;)=SIQ-=/G[ M/!ZAB.2?]D?I7@8?$8BA5C4P[Y7%IIIV::ZW/K)0IJ/[U\S?]:&=\,_">B_ M+X0^&_AI)XAN+Z+P[H=GI<-]>-NN+P01+$)&')9VVY/7DU<*>)?&+9NI)--T MW_GFC8GD]\_PC]>*X?\ :4\0_$'X&_ OQ%\8?AWX)_X3;Q5I5GY]O8W4A4%0 M?G**N3M4%W$:_,WW0>A$W[&7[4OA?]K[X&:7\7?#\2V\UPIBU33LDFTND.'3 M) R,\@]"#U-85,1#VSUO-ZMOK?>QWPRS&5L#];:M234='JG:ZOY/H=5\1?@U MX ^)OPQU7X2>)]"BFT;6+)[:[MU)7(9<;LCG<..%_#-\)_!_B2\SY+6SL0(8R1RN!N SP2PP!@5]G>6N,T!06Y M4?E7/*FIU%.^J.["YE4P^75<$XIPG9I/[,D])1\[:/NGJ" LO)_&L7XB^!O" M_P 3?!&K?#WQII<=[I>L:?+9W]K)G;)%(A5AD8(R">001V(K:W#.Y6^[6/K? MB_2=*E%F!/=7;_W^K34[V:U7?Y'PO_P3 M,\;^.OV4_P!H/Q/_ ,$X/BPUQ<16DT^I^"=0D)836>=Q_B(164;@HX5_,'.< MU]R7GC.T69M-T*!KZZ7&Z.!OD3..6?H!SG\#7.W/P@T'QMXRLOB?XS\+:;;Z MQ8VKV]G=6\"FZBA?&^(W&-VTXY52 >*[;3-%TS2;06>F6:0QK_#&H&?>IHTH MX>GR-WMLO+M?K8[LZS)9UC%B*JZU)]I\7ZEY MB[MPT^WRL0]F/5OY<5NVR65NR65L(X\+A(X\# 'MZ^'M M=T_QY9,Q6W(ANH^P4DX/"G&QXM:2PM'GM>V_ MIW.XV[03BO,?VLOV9_!O[6WP5U+X,>-;R2SBOMLEKJ%O&&DLYT.4E4'K@CD9 M&02.]>D6%Y'?VT=Y;R[HY%#(W/(-2LH8L:Y904H\LO2QZ&%Q5;"U8UZ$K233 M371]SEO@E\-U^#_PNT'X91^([S6%T/3H[1-2U!AYTRH, MCCIQCL !76;B3P M:SM1U[3-'>&/4;M(FGD\N%6_C;T_^O[U>B??R*KEY8I]":E9UJTI2=Y-W?JR M4;@V":=30I+*PIU!(4444 %%%% !1110 4444 %%%% !39=W 'K3J;*2,$4 M0S9QN)(_&O/_ A^T[\$/'OQCUKX!^$OB!:ZAXJ\-VHGUC3;<,WD+N56!?&T MLK.BLH.5+ 'D$#6^.OQ2T+X*_"'Q!\5_$KJ+/0=+FNI(VF$?FLJG;&&/ +MA M1[L*^/?^",'AV:R^'WC#]IOXFZC(->^*GB.6]6:X5%26VBFD42 !%".]Q)5LUP'[0'[3WP8_9GLM'O_C!XJ;35U[5$T[2 MQ'9RW#2SL"0-L2LP''WC@#(YYJY2Y;N6AX]&E5Q,E"BFV^B5WYZ&OI7A#5#X M]O/%6L^6R[=MCMY(7ISZ' _4UU<:@9IL4@DB62,\-S3LG=R:UG5E4:O;30YZ M=&.'NEWU.(_:'^-_A;]G/X-^(?C/XTD;[!H.GM<-"C;6GDX6.%3@X:21D0$\ M L,\9JE^S#\>+;]I7X':#\;;/PE>:+#KT$DL.FWS RQ*LKH"2 ,A@NX$=F'6 MOFO_ (*O^#OCK^TGXP^'O['/PO\ ">J1Z%XCU9-0\6>*H[!GM;.WC;;AF\U% M;RP7F:)L%V$ 1@3@_5'ACX/Z)\/?#NF^&_AK=R:+:Z38PVEI:QYEA\F-%1%9 M'/.%4#.<]R23FL*3E.LT]$OS/>QF%P>%R.C47O5JDF[)_#!:;=V[OT.P4XZ4 MURI! KG7\5ZUH,WE^+-$98^AO['+Q=N2OWDY( '.3WP,UX/\-OVZ?$?QA_;V MUO\ 9B^'_A"QNO"7A71W?7O$8E9IA>?+M5,-L\O+;3D%MP/W<8.D_P!SRWZN MR//P.&KYA&K.DOX<>:5]++;KWZ+J=A^QS^PU\'?V+XO%O/J. MM:MJ]R9;B50\AA@SW2(2N >K%V8]0![9(F5I4"]^])-M6-F+8QSFG4JSJRYY MN[\^ISRES:LR=9\)6&K/]L@9K6\Q\MY;_*XZ=?[PX'!KFM$\/>'_ (;^(]0\ M37/P_P!+AOM6*_VIXDTK2HX[B[QT-RRKO?'J20*M>#O%6N>+?&=Y)8R*NDVJ ME0K1\LQZ'.<\X)[@# QD@UV,V/+Y'U[UO+VE&7LYZ[?+R.*CRUXNI1?+JU?H M[>1#9WUKJ-NMU97"21-RKHV0:?<20V\333R!45269C@ 8ZU@7_@V2PN9-7\' M7'V*ZD.9(6R;>. MQQT;OG!P,'(-50PGUJLHT]?S1GBL=]3HRG55K;=F8'Q$\8/XMUIO(<_8[=BM MNH8X;G[_ ./\OQKG]J^E(A Z_2JVLZSI&@63:IKNIV]G:HR+)<74PC1=S!1E MCP,LRCW) K[[#4(8>DJ<.A^;XBO4Q59U)[L\^_:-_:__ &;?V2]+M-7_ &@O MBQIOAM=0WC3H+K>\UT4&6V1QJS$#@;L;02 2,U\%Z=\;/%'A/]HWQ5^W5_P3 MB^-#?&3P/KTGVWXM?"&2^D_M2SVJFZZLH90&^1&7;L4C"^5\^%"]-I]OX&O? M^"[_ (ROOVNX-+VV'@FR/P9;Q L:0JH6/S&AZ(\@=KOYI-SCL1A<.;7K?P]K?_ MS1? ]DTW]IVM2IJ+M9MM7\O3^NHX1CM8D^$'C+3_V]?^"J_@/]J;]E MCX-^)?"&A^%]!NH_B3XKU;0VM$U>?'E_86/W7D0X4GEL ;@ !7Z::7I&E:/; MO;Z3IEO:QR7$D\D=M"J*\LCEY)"% RS,S,S=222>37GG[)?C#XV>/_@=IOC; M]H'X1Z9X&\1:I-/T2 9&1G"$F-/7_"/A2^\7 M:HMA9G9&OS7$S?P+Z_7L!W^F37#B\1&G'FGHHK\OS"%.IB*RIP6KT2'>#_"& MH^+M0^RVRE(4/[Z?'W/;ZU[+XI]32^'O#VF^&M/ MCTW3H-BKU/\ $Y]2>YK30?)TKX',?2HU*M^1-V3;MKIU/5G4C3^)V/I M:ALD8%('4C.ZFS;3'R:DH3:3P#WIR_>YKR7]I#]K3P)^SC<^'?"MWH&L>*/& M'C#5%LO"?@7PK#%-JFJ,"/.F599(XHK>!,R2SS21Q1JO+995/7_ KXJ:%\=? M@WX3^-_A:RO+;2_&/ABPUS3;;4%59XK>[MTGC20(S*'"R , S#.<$CFGR24> M9Z$J47*QUM%%%(H**** "F/CD#K3ZC;/-*6P%/38M2B>7_@O/)\5Y-7_ &+?V,/& M#+X85GM/&?C33I\'52#A[2V=?^6'4/(#^\Y ^7D_D3X=\2^(/!^OV?BOPKK5 MUIVIZ;=)[?6Z/BLPJ8EXI^TW6W:WD?T6?\ !#C_ (+G:'^V9HUC^S)^TOK5 MOI_Q0LK<1Z;J4C".+Q'&H^\O87 RR#[W)'<#].8^F#VK^>C_@A[_P $B_[1 MN=&_X*2_MDW&H>&_ /AC48-0\"Z+&)4O?$>H)(#;R*D8\UHA*%$<48+W$FU0 M"FX/^\'[.OQSTW]HCX9+\1]+\(:MH.W7=7TB^T;7A!]JM+O3M1N=/N$?[/++ M&1YUM(5*.P*E3P<@?F?$5' 4\PE]4?N]>REV1]-EM6O/#KVN_3S1W2JK_+7 M_$_X8KJ;2>(/#\.+C[UQ"G_+7_:'^U_.N]7*C(I/A\36PM93AO^9T8K M"T<91=.HM/R/G$HR':Z_,.H(Z&O)OVDOV9/@7\4_ACXV/B3X"^']?U36]!G6 MZ8:7"EYJ$D<1,*&X51)N#(@5MV5P,=*^IOBE\-%U!)?$>@0!;A5+74"_\M0. MK#_:]N_UZ^9 9Y)S7W> S".+IJ<'9]5V9^'_$'A_P"/&EBY\,PZ#- W]A7H MC,B0((V^:)H]K-("Z9;AN!GZ[7]B3]E ?$?QE\6Y_@9H5QX@\?::VG^+;ZZM MO.%_:LNV2(HY*()!CS-BKYA52^X@&O)_V;O^"//[)7[,WQLM_CIX6O/%NO:E MI4V?AV-W9@MFODJZ[0S*ID>1@"3DL2Q]EUJ,HMM:O?3\NR1S M^TIN]^O]?(^K\ CI0'=&#HS*RG*E3R*!QQ0D>"M3O?B);B MRUK6ML5HJK-9PG:UR,#YV/7&<<#WSUKNM/LK/3[9+.RMECC5<)&JXQ7A7A;Q M!=^&-;@U2U+85MLR*<"2//*G@_\ ZZ]TTK4+/5[2/4K"<21RIN1A7PN;866% MK7C\+V\C[_(\93QE%J7QKJ]V27]K:WEF]E=P+)%*I62-URK*>H([BOSHLYC_ M ,$KO^"@TMA+ ;/X3?%J9%MV#A8--O2X&<$A41&?#'LC*3@)BOT1YV@B,ABKKOC/#8W[@K, MJBO#K49U$G3^):K_ "^9]]D&98? UY4,7_ JKEG?IVDO.+U^]'N4$BW$0E0[ ME;D-FJ&O>)-*T-%6\N?WC [((UW22=>BCGL?:O*OV4])_:(@_9S\(^%OC)J- MO'XBL=)2WUC5XYI)GN N5C;,G+RF(1F21CAI#(5!J&B^$](T)FGAC::XD M_P!9=7#%Y6/N3_3 KHC&,8WF]>Q\_B5..(E3I--)M^A MZ)I6E6N-/M0C/R\CUTQ[Z:?[+;)$US=2[I)-J@;G;C M+'&2<=:QI^TCS1Z-W6OX'LYKB,#CJ-"M%6JQCRSLK)\NTEYM;^:+I50.G3M7 MS?X-_;NU&Y_;TU[]B_XC> DT/;IJW?@_5OM+/_:N(Q(Z8V@9*;W&#A?)D4G= M@5[EJ'C?2XI#:Z3'-J%SN(\FS7=@]/F;H #Z]O6OD/\ X*.?LO\ [0'C?XC? M#3]K#X"^#K:\\9>$?$5I:S:3;LS-/9/*&1YI/,0&*.4LKJHYCN78NJQDT5XU M:<%)=UIU:ZBR'^R\9BYX?%.RE&2C+I&5KQOZO1^I]M?P_,:H^(M(BUW1;G2I MAD31$#CH>Q^N:M6_G/!&TZ[7*C<,]#4N"RX)YK2,N22:Z'CU(*47![;'&?"+ M59FTR7PQ?_)JY^GKGGO79OD_=],5G6/AK2;#5YM:M;0QW%R/WTFX_ M-^&<"M(E PYK7$5(U*KE%6OK\^OXF.%IU*-%0F[VT^1ROQ5T#^V?"DT\:_O+ M3]\IQV'+#/T_E6AX$UUO$?ABUU:0KYC+LG5>SKP?IGK]"*V9D#)CKGVJKIUA M8Z7"MKI]K'#$N=L<2A5&?84W5YJ"IM;._P NJ%["4<4ZL7HUJOR9)F!,;$<$K@D5M1J54Y0UC&#C6<[[V7 MHD>MBLRIULHHX&,;*#E*7]Z4K:_))+[S!?P/;V4OG>']1N-/)(+)"VY#CMM/ M'/M7P;\=K?7_ -JK_@K-X3^#^I6$FK:+\(='74]>6&SC56GD"3\AV^>-@UFG M R&W8]:_0]QN(R?_ *U9&E^ ?!>@^)=3\:Z+X0TVTUC6O+_MC5+:QC2XOO+7 M9'YT@&Z38GRKN)VC@8'%:5N:O%*6R:;\[=+F.3XR&3U*E:G%\TH.,7TBY:-V M]+[=PTWQIX?O7%B+HVMQ\O\ HUXAB?D\##=?PS6PCJZ\56O-'TS4U$6H:=!. MHY59H@P!]>17S!_P4L^//BC]CO\ 9Y;7?@SXJN=/\2ZWJ4.F>'K.2);I1(YR MS(DJ.N\*"0#\I/&.:JI*C"FYO2VO -: ME^&UA:W/B :7<-HUO?2F.&2Z\L^4KL 2J[]N2.0,U\R_\$S?V*_&7P.^$FH> M-_C$UU9_$3QAJLNH:]-O0S6^7;$;%258DEI#@X)<=Q7USYB/)A7^M+N4< 5G M;]XI]5^IWT\PK4N+ M-<2@/45M&I3YE=6:V M^7D>5+#UO9RY-8]?*_F;7@SPS#X4T>'2XF$CI_D/H*UF_O;OUKG8 MK?QKX>7$5PFL6R_=6?\ =W"+QQNZ/@#J<$D]>U6-(\9Z/J\QLY6:UNA]ZUNE MV./P[_AFBI&=1N=^;O;S)IU*=&*IM3.6/M["NW^-?BKS[J+PO92';%B6Z*MU8_=7@_B1C MN*X ')X%?59'@_94?;2WEMZ'QO$6/]MB%1B](_B_^ ##T'_UJ_-[_@L5\<-% MUC]IWX5_LG_M*2:GX1^!5[>+KGC+Q=]BE:+5Y[>.9XK /#OS%O$2.NW<&E5\ M81'K[#_;S^.7B[]F[]D+Q[\:_ =JDVLZ!H$UQIOG6WFQQ3?=61UR,JN<\\<< M@C(KX9TK]OW3+S]E[1OV;+_PI)^V?\0O$\4VK>.M-L;?.G:=!*WVCR6D$$BJ MT+A1&B1KL,)8"/:@/U>&I^]SM7Z?AOV/!I)_%83XK_'OX+?MD?LP^*OVI/V[ M?@XNH?#W4/'$6F? '3=%5;?Q'=6^\PRLA4EG9V7=L&[!5EQ@!C]H_L8_L&?L MK?L=>'/[2^ 'PPDTR]UBQ3[=J^L%I=2EA9C*(9'?E0I;!08^ZH.2H-?)O_!- MS_@G3\"?B'XB\ _MN?"'QCXL3X5&._UKPW\*?%6K/.-"UTW#VYDC,;['B5$( M4OND(CC\QI"25_28'Y?F%+$5>7W(MV[?H.I+7E1-I>EWNLWT>FZ; SRR-A5' M0?7T%>V^#O"-GX2TA+6SC'F-@W$G=VQ_*L#X1^!CI.G_ /"0ZE:C[3<+^YW* M0T:>GX]?I7>(-J 8KX'.

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q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end GRAPHIC 20 g4bdklltl5z5000010.jpg GRAPHIC begin 644 g4bdklltl5z5000010.jpg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�RYH XGX%W%Q=^'+Z6UO;RXT4:K*/#MS MJ#,TLMIA<'>]% .G%!.*!Z44 -//44X=**",T M 0WUY;Z?:27UU,(XH8R\CMT50,D_E7'^$_B_9_%3P')XT^$=B-44SR06PNIE MA1V SO)!/R\K_M8/2NJU^""YT2\M[F-6CDM9%D5NC*5.17R[_P $]]"O?"_[ M/7BY_@A/)*+R+3]%UZ\)M-.FCC50L9502C?(QP0#U&W)% 'J/A&T\>ZG M\-_&EMX'N[*SUY_%FH&S:\0R0B3>A*MC!P>1D,KEED_XF_VA-L5O++)*1Y<3-\I8'!Y4(6;/J'P 2]DTCQ$ MVJ>6+C_A,+\S"'.T-N7.,]LY_"NRUOP]H?B/39-%U_2;:]LYQB:UNX5DCDP0 M1E6!!Y /3J*JG[.-:-1Q5U=7M=VDDGOIMMV>J%6GB9X&KA8S:A4<).-VDY4V MY0;MKHV[I/5:.Y_,_P#\%P/V%_'?B_\ :0\7_M'_ !FUB>.QUZ>;_A"[!52- MKJ2-]FR*%/F*9)RVT%F#$]:^%?&OP8^#/A#X<6WAS28K[5-2NM22\75+BSEM M[>!439+ JL_[QM^ S8P,#!!R*_JN_;/_ ."6?PH_;)75_$'BK7KC3/$TD+#P M[X@L8$\W3'\DHAY^^%8[^"#GOQ7YE^./^#93XJ67@6X^&NC_ !PTG7/'H:XU MNR:[AO$5K%'E1H(IBOV=9)G:V8K(0RMOY*C=7]?>$?$G@7ALECA\ZHPC5NHS M3IR:E%IW?.U)J,79R?,FVW[MK'A<04 M^O-)-6L?*/\ P2(_8KG^-'QDLYOV>_B]I7PZ\4ZC;N]MJZV8OEMYTR_V=[>9 M2,-\A!7/!/0BOZ0/V4_ WQK\ ?!W3_#WQ^\"/V+] TOQ9XPUA=8\90QQLUU#;B&&S7[. M8S HW-OQO6+>Q@?%-?^+>ZP/^G% MZA\;_#W2_B-H>GZ7JFI:A:QV>I6>H(VFWC0M));R+(L;D?>C8C#H>&4D&I_B MGG_A7NL?]>+_ ,JV[)0;.$G_ )YK_*OEY1C.-F=5&M4P]15*;M).Z?9G'^*+ M_5OA[X(\0:SBSCM--M6ET:WLM)EG\E%C&T-#%\TIW_PI@D<#FOQ#_P""M/[- MWQ'_ &F?VCOB!^T/X"T1_&EUH^FZ)#XC\#W&FW-N=(0P+!/'+-=#9 \DYB*P M6TKX^9^#O+?O;)&I.<5XEXI_9QTKQ3J'C;QZGPOTRXU[Q'=1Z<;?7O(\B;3T M>!9'#6ZASO6+S%\TNZNH *KQ7W/!.?99D6/>(Q>&A5M9)347'644]&M/=4GS M)IIZWW3564:M"46O>[W].EG?KMU=S^:K]A+_ ()@^+/CY^UGX7N?BAXHU'PM MX;G\66^CW&J6-U'-?V1K3]EN]7P1 M\%VM=,\!W$,T4>AZ*!;):3O'&9=0FW^8US=RS1D;E,:(K'*,V6/*7_\ P2X^ M#7AO2M6C^%_@KPRD^K^=%>6NKZ8WEW,$ES', \T+"99(BKO'(C*PD*MGY:^A M?AQI/A+PWIUYX+\&^%9])L]*OG3RFLWBBEDD_?/)$S?ZT,\C$N"?GW#J#6OB M!F7#.?YE]?R:E[%/XH1CRQ5K>]:[LVW:R336NCNC# RQ&'OS)/??S_5/5>?= M71T6FVC65E%://)-Y<:KYLK L^!C)]S6/XSP-:\-C_J,''_@/+6^G P*Y[QL M?^)YX;_[#!_])Y:^#-&[N[.BHHHH **** "BBB@ HHHH **** "BBHKNZCM( M'N9GVI&I9V] !F@-M62T5Y[X;_:;^$GB.X:V7Q)]CD#%56_C\M7YZAN5_7-= MU9:G9:E"+JPO(IHV^[)#(&4_B*UJT:U%VJ1:]4<^'Q>%Q4;T9J7HTRQ0>::C M;AG-#OMYS61T#9&9#PU?./[4WQO_ +:NY/AMX6NLVL+?\3.XC/$CC_EF/4#O MZGZ5VG[3'QR7P-I#>#_#MW_Q-KR+]Y(I_P"/:(\;O]X]OSKY?5BV7 MIKZ3):PNI%2^L<\.,XW+_MC]>AK[,MY!+"L@!^90<-U%?)GPUT'PG\-O!]U^T5 M\7F\G1]*7?IMO)]Z[FZ+@'J2W"CN>>@KVS]F[]I?P)^TEX-_X23PC,UO=6[" M/4M)N&'G6K=LXZJ1R&'!^H(J<[HNL_;TH.T7:4NE^B^7?S2[&O"F(CAHK"UZ MJ4YKFA!O7E6[^?1=E='I5%"G*YHKYT^W"BBB@ )QUI&8!L8]=N+5VTVRN)@&DDVG;QG."151C*?8J^, M/C+\/? FL0:%XE\10V]Q<8*QX+;!V+X'R#ZUT\%S'<(LL4BLK+E67N#T-?"7 MBI_$4GB.\?Q@)_[2^T-]L^U#YP_?/].V.G%>I_L]?M&S>#Y(?!?C>Z>32V(6 MUNW;+6A[*?5/_0?IT][%9'*GAU.D^:5M5W]/ZU/CL!Q;&MCI4L1'DBW9/MY2 M_P ^GXGT_G'6@'-0P7*7"++$ZR(ZAE93D,".H/I4V,=*^?/M HH)/84G^]0 MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44''0T# X% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&:,T %%%% M !1110 4444 %%%% !3)I/+QS^E/)XKPO]JN:_N_'G@?0H_$&KV5G=1ZK)=1 MZ5K-S9&5HXX=FYH)$9@-QX)QSTKHPU#ZQ5Y+VT;OO\*;_0Y\5B'AJ/.E?6*M M>VLI**UU[GMWVC/3ZEI$.I?/ MI\.K>--?FFFAWE5FD,5T%@1B#C.X]ST./6;7XE:#+\-;KQS=WGC-+VSU :=- MI*?$#56+7A90J*_VD HVX,&P/ESD9&*]*IDLJ<8MR>NBT_\ MCE^N8S?V2M_ MB?\ \B?;@N >:;IOC; M7HYEC3/F>5+)=&.9D&:RMM:6? $K*ER76G@\+6CS4ZRE'575FDX[IOFTMU.C%?VM@ M9J&)P_(VD[2;3L]G9QV?<^[//XSM;\J/M _N-^1K\Z?V;/VHO"_QSFM1;^-] M$->UOQ=J?BZSOO#,:G4K6U\?:O(L@924:(FY!PY!4 \@@@YQD^/P_ML:+ M-\8F^$D?CF];6E29@O;;C/'7FNVCDWUB[IR;2ZV MT[Z>]VL_F7'$XZ7PTD[*[]YZ+N_=/T\^T#^XWY4?:1_=;\C7PWXY^)ND:3X- MT77?"FO>*9KK7[62YM!J'CW6%CM88U!E>4+B=2 MS=[)K5VWLN;6QS2S2K3K*E*$>9[+GU?_ )*?H5]H&,[6H^TC^ZWY&OSU_:!^ M/EK\*=2N=/L?%GB"SM["Y2UN+Z^\9:U*M1TY;H));:?>^--/+N\V;+:X#*T4UPZL!(JD-M_N]#Q65/ M+(5N=4:G.X74DE>S2;L[-V>AA4S&M1Y?:P44VMY=VEI>*ON?9WVA/[K?]\T? M:$_NM_WS7"77[2'PJ-FTVC:MJ.K;6VE=!T"\OW4_[L$3G\<8KQ*;]I3]K[QQ M:Z;XZ^%;_"O3_#VMPV\]C8^(IKEM0MHI=A'G_OX5#[7'R!1A_ER1ACS1P.(Y M7*:Y4K*\KK5WLMO)G5+'4.;DI^^][1L].^Z74^J/M"?W6_[YH^T)_=;_ +YK MY1M_CQ^W2ZJ\_CKX"QJTC!&WW9^4,B<_Z;][>O7:W_?-'VA/[K?]\U\IW/QQ_;N@B4'Q?\#5N&N9H5@DCNAO*,X M#?;CEB%&5QE<]QS3K/X\_MIZA]KCL_B)\#?.MBO[HQW)X8J%+D7YV99@O(P> MU'U6/_/V/WO_ "#ZU4_Y]2_\E_\ DCZJ\]?[K?\ ?-'GK_=;_OFOE&7X[_MU MP7ZV8QD9;D,(U"'?M^W9XW-D=MHYYX=;?'?]N&83&;QS\"H5AD* MK,PNF63"%Q]V^)!*@$#'9CT )/JL?^?D?O?^0?6JG_/J7_DO_P D?5GVA/[K M?]\T>>O]UO\ OFOEE_C9^V_]J:UL?B1\!KMA&K+'##>AWW%@.#>="%!!Z'< M.0:?I/QF_;HEOX8]8\9_ V*U:\"221K>9DC_ '>=G^EYW@.6P1P #_$!1]47 M_/R/X_Y!]:J?\^I?A_\ )'U$UW"A^KR_"[P?XX2 MSCM+C5M>NK&\@M[CS(Q);M+#(4? +(7B8J2 2I!(!XKV+X;ZU+KGAV"^F^\\ M8- MD_\ %3:A;1VL#7,DIC2."=$ ,CLQ.,DL>:DH_1G]KFZA'[*OQ),+'&&D=FPJ@9/2M[]I_\ X)9?L.>'?V:_B!K^E?""\CNK/P3JDUO( MWC+5F"R+:2%3AKH@\@<$$&O=/V&(TB_8M^$L<8PJ_#?1 /I]AAH \_;_ ()5 M_LR8Q_PFGQ@'_==_$_\ \GUV6B? _P =>$OA>/V<_#\UK-X76W:SM=-/'W@CX;Z%)XI^(/B_3=#TR)U274- M7OH[>!&8X4%Y"%!).!SR:\$_X4U_P5&/'_#!]+^*7AF\\3>&?#OP1N3<36D>HQ-)(0E[_$7X ?LO\ PT@\ M/Z==/:QKXH^&0M+K4+A%#2(8IH8Y+:,;E :(XS&!,H^7S,E64#*G P >A:1XHTOQW MX'.O:;)-!#=6\R2+,NV6W==R2(PYPZ,K*1S@J>M>(_L8>#O%'AS]G+6- ^&W MQ/L]8NI/$-\VE:O?1W$BP;E7Y661VRP?+$ *N6.5SN)]IT_PC:>"_ $OAK19 MIF$-I,?M$\F9)97W.\KMC[S.S,2!U8\5\^?\$](M0\6_LX^)K+P1XR.FZ@WC M"^AEU142\\BX\F$,51B!\K'C8X![-^SVE_%HWB*/4YXY;A?%]^) MI(TVJS[ER0.PSFO0#ZXKQ70/%'Q!^$WAKQ5K4^BZ?>:7I^L7MY?:M?:EY+,% M ,CE%0XZ$X!-<_I?[>FBZE#(Q'@RSEM[S[)<6FL>.A8W,,WRG8\,EON3(92# MR"I!!(- 'T40&ZBN6^+/Q3\!_!KPG)XU^(&IR6UC&P11;V4UU/,QR=L<,*O) M*V 6(520JL3P":\@TO\ ;V\':M*MO9^)/!;22K&T,?\ PE!/F+(0$=3Y?S(2 MPPPX.1ZUEZA^WG\.]1\;VW@_6[#P+_;%CJ5XEBNJ^+&A:"ZMI4M9MCRV>U) M;@( &RRNQ4LNXU=/V/M$ZJ;CU2=F_1M.WK9^@.]M#T;X+_'WQ5\4M2OH-3^# M>OZ+IZM)-HFK7<(6#4+3:C1/AB)(Y&#_ .K905*D'%=1\)_B)KWQ'T.;5=?^ M&&O>$YXKCRQI_B!8!+(NQ6\Q?)DD7;\V.2""K BO%+K_ (*(_#ZVO;+3X-8\ M*W7VRX>WCFM-=9XXY%=(RKMY?R_/(BYZ9;V-+MWJ:4Y M0A0E"4>:3:M*[35KW22=G?S3:MIU/=OBE@?#O6/^O&3^5;MD?]#A_P"N2_RK MQS7/B?\ %SQM\(]2UW3_ (9V,-O):2*T=YJ3Q2QD<$,C1Y4UTUEXN^/S6\,? M_"F]%5=BCS!XN+8&.NW[,,_3-8F9Z"1DYI/+3TKSW7?B+\6_#6G2:QKO@GP_ M:6L9 :XO/$@AC!)P 79,+DD#\:YJT_:FU:\U,:-'8^"1<-?R61BB^($&&NKRUDN;*V; MQ4J&XBC*AW4^6?E!9-/AYI^DVJZHQ6XM?$'VIF?R)<+M\E,#KSG\/ M0 ])HHHH **** "BBB@ HHHH **** "N=^+.I2Z1\-]8J&QZCH?Q%=_\ $GQ[^Q%;_%#5/A=XBUJZ M\+ZMIMQY,UXD+"U:0@-C/S*,9P#BI*ZYD[-/SV9^._V;7C6DL+4C4E!M/DDN9-;JVC5O M0N>$_P!K_P").A;8/$,%KJL?3=(GE2?7&]0U+1HI(; M[3[-II["+?!=R+?Q7H%S9LS$(TT?RMCT;H?PK8 M^!OBE/!WQ0TO4IW_ -'N)?LEVK=#')\O/T)!_"N'&97@J]%U*45?=6V=NG8] M;+<_S3"XJ-#$R;BW9\VZOL[[Z'.Z]KNI^)]:N/$&KW+37%U*TDC,3W/0>P[> MU=1\&OAE%XZU6;6O$,ZVN@:2AGU:\D;:H4#.W)]1U]!6-\1?##>#O'.J>&V^ M[:WCB+WC)RI_(BO._P!H;XN^/O#GP=7X8Z%=>1H^KZDTFI21\2281<1$C^$X M)([X]*]BG1J8J$*=!IR[KSML?-UL11RZM4KXR+ER7;7\TNB;[-[OL<<7<2K$<[C)-2E-:#M0U?P_I_P!KO;>U M9[>WZ[V^@ZXZX[XKXHUSQ#KNNZ[-XBU?4)I+Z6;S&G9B&# \8],=L=.U?>!C M4J3MKPG]HK]FUM5:;QWX LO](&7O]-C7'F^KH/[WJO?J.>#[F2XS#X>HX5%; MFVE^A\CQ5EN,QE&-6BVU#>/ZKNUV.'L-7T3X_:5'X?\ %%U%9^+[6/9INJR8 M5-24=(9?]OT/?\Q7G.L:/J>@:E-H^M64EO=6[E9H91@J1_GZ&J^2DBNI9&5L M^A4_XUZ=HVKZ+\>M*C\)>+)X;7Q5:Q;-(UAOE6]4#B&4_P![T;O]NKT/V>_VB[KP5/#X-\:W32Z M2S!;:Z9LM:'T/JG_ *#]*^G+6ZBNHXYH)EDCD4,C*V0P(Z@U\'ZWHNJ>'=5F MT77;*2VNK=]DT4BX*G^H]#T(KT[]GW]HBX\ SQ>$O&%TTFBR-MAN&Y:R)_\ M:?J.W4=Q7DYIE<:R]OA]]VEU\UY_F?1A6 M_623_OE,G]*^9IT:]:5J<&WY)O\ (^[KXS!X6/-6J1BN[:7YL[[I1FOFWQ=_ MP5#_ &9O#I9=&OM8UJ1> MCIQ13_ ,"D*T?L[_\ !1+PC^T'\6D^&-KX'O-' M^TVLDEA=W5ZC^=(@R8RH'!VY(Y/0UZ4LCS:-"5:5%J,5=MZ:>CU/%CQ=PY4Q M<,-#$QE.3225WJ]M4K?B?25%-B+')/K3J\D^C"BBB@ HHHH **** "BBD+ < M$T +12!LTM !1FD/)H'M0 N/:CIS12/RM <[NE+FJ.L:[I.@:?)J6LZE#:V M\:YDFGE"JH^IK&\"_%OP%\29[F#P9XACO6LR/M"K&RX!R ?F R.#R*I1DX\R M6AG*M1C44')<'D?A482GL M8UJ]*A9U':YZ#),B$AF P,DGM2JX*[@:^>?&OQNT3Q-K?V[2=#G6.14BO%DO M&VW<"Y(C9%.!\QSD'.,@\$BM*\_:*U/5M(ET>X\*>7'+%L62SO7C9/0@X[5T M?5*MEH>>LXPG,U?TWU_ ]VS17FOPL^+.C:KNM_$/B^3[?E<9XM^)'@T^!%US5KR[MX; MI3]FBC*H/M=AX9U![6&XNGEDD7 D1W0N&$BS%5"P X% MQG/S(QX '.3--L,Z+E(N"I-:UG#?S1*8-5FV\'9YI*D@YY!X.*Z'@XIK4\RGGDY1 M?NW[:_I8^HM#UW3?$FG1ZMHUT)K>3.R15(S@X/6KE>%Z-\#[ M9$T3*MY;@)-&Q4X/8'!(],>]>E?"_6=;UKPU:W&K2V\ZK;1K'>0W/F-.0N&9 M@ -K9ZCUKEJ494]6>SA%?M/JQ^*OP_ ;!^SZT!_WQ!7=EO\ O3_PS_\ M2)'GYE_NJ_QT_P#TY$^._B[^SK\"[GQM#;ZOXM\-W3:7)BUAU;3;BXFTY-V[ MR7:!MK*I/"R8([^_M>E_"3P+/\'IM /BE;FUOI/[2G\21S)AK@887*D':%7: M,#.-JX.>37S?X\\ ?%G2=;L=(MO%=]H,NG,1J,(M9V6\E,A+7"M&I$P<>ISV M/>O8K#X=>.+C]G_5+D6^UY=2M] D7;(UF)$9X2I^ZS[6?9ZM@\DUZGUK M%8BK*E44HQA**C*7+:=]>:-M?=\^YT5L/3IT*&X9M3=H[B]T_3)X9KU7/SI&\K>4I?H2A8G/RUZI^T MC\)OAQXC\(0?\))KFGZ3;PV+:8(-2A,MO>6I _T9HP0[8P"I0[@1WKYC\&?" M[XZS_%#5[O6/B'J7B#3=6CN(;'P[]BN 59S^ZW(Z".W$7!+ \;>.":]T_:E\ M!?$>Y\.Z;?:5J]RMS#X9;3EUJUA>8V%\=FZY*J"P5PI7> 2M=M? X?"8BG2H MU(\KNVDDE=K6ZY4FY;/1_,*M:MC*T?;U>;1+FDY.R[:W=HKHODBO^RC\ _@[ MX,U&.+P9KVBL--N&O(=$TFUEAQ.R[/M$GGGS'(7@<;1GUK8^(.E:3\-_%UY# MX6^*^EZ6-1E:ZN-%O+&6X:V=SN9U\G)56)+8<=S@XKSG]C_X:?%S3M>TF/Q5 MXKN];FTO5I+NXUB6*;9!:F(J;822J&D+L<[>0,9K2^(/A[QAX9\3:EI^J7=Y M9W$^K7-U]N6UD9+^.1]T;AT4\JN$V'D;?I7G9CA<.Z:FVI?8[<""!GVJRI*4V ':N,[B2U?/>H?!;X>Z'\;KCQ3>^./A+%KD M-TUM>>*H]8OF:&3&P[[A;(V:3 94N6&#G(!S7K'PY^&_Q'\4ZTNE>';V?1[S MQ5I^LVWA^:X5H66Y.C3QF[V_>C#LRI_!G]H_1OVA-)O8?$7BC M1]#TF*WL[KX9P^';V1F\N());1I'&;>=)6!82[L$/G/ KUZ=26#I1=.G*HY. M*<8M)Q3&=6T&TLOAW+H_AC19/#/A^ROM.UZ3Q4]Q;O:WC7$2 MQX%H&G\PVCLRC&?D().0.5^%'PQU/7_%=C%IWQ1\)64MK.+Q=(A\-WBM<2)R MDF)Y8S*$/S87@$ D<4:E\&/BG\.M5\+Z?XLTNYFF\-_#?3CJ6DVI-Q)IRW&I MZW);@ 9W_9XF$)"YVC..%K4\$:/KOC3Q?I%OH%I>.UAJT-Y<:E-:211V<<;9 M<;G RSKF,*,YW'/ -<..QE7!9E2PU##\\)*3=9NMO% MPV#ABJ;KUIOGBVDMG:[3LXI;==2C^T-^SYI6MZBS>/?C[#_:&I3+2K!ESU.[EL^G7D?VI_AQ\0+KQ/JTVF:E>:?'JU[#<0:K;P2R1R0I"$^ MS.T0+(58%@,8.?K73?LZ_#_Q]+HFK7EW?WD+7'ALZ;'JUY T3WMR=Q6<*V&* MQ@[0Q )R?2N^IB,1_9D6JZ6VB2CV[)/3UZ%1IQE4]E*+<5JKMR5_1MI?+]+\3R6D'C70[R*UGV+?:OH=QJ4EESC8TQ=HB5Z#=C&.>]?2'P6^'O M@3P%XC^'&@^"+.T:QCUJ1X;J&.,^?OLKIC)E!@[B<\<=,< 5\K:YX ^(VG^, MM-4:GJVDKI<<<,FAPZ=/)N*<-Y6Q3'*LGJ3SGFOI_P#9R\,ZYX2O_AWI>OV_ MV>9O$]U.EENW?9(Y+6[=8<^J@\XX!XKAEB<56_P"X_>5OUNSG MI1CS27L>2THI/35XVX);@\?=?O\L;<'H?#IU*=/+ZDI1;]Z&SMTG_= ME^1]!0P\L5G%*ESNH:Y;0W$,UR\G+_P "7ZTSTLTRW$9>X\M5-.^\$MDOY:TN M_P"&][VP;CXM;[B&'3_&FK1^7&SE3\!;F1(F+3%&#?8AC]T!C_=)R1FIKKXB MIXA988]8N;MYF\O-U\ +R:,H[1[491: LC('S\PS'DC.S)+Z/X%>);^SU[4/ MV0_B9/J'A_4WLK6::.ZMVF:%YMMV%.P7$16[F.\J5$^.=;5&21I%7X!S^6RDQH_6Q_B M/F+[EN^,4ZS^)=I-!)>S^*M0E,+2-;S1_ .Y61%,3Q\?Z$00'P">,!@O\7&M MX%O/@O?V#ZM%^RMX\L_M,-NEU#XBL[B-T5-0+QDHT9V)&51_E &UP K#YJEU M.;X-VGQ&7PY=?LI>,+>:Z:ZNFU:TLY6L(9H=2N%5I)/+*JSAIYU7!!C=/E+% M<'-A-/7_P @'^U:_O(Z?W7_ /)F9??$'21*S3>.M9"5MQ&^5-LV" MRY7>NPJKE?F& .C\-^ /@]/8Z]9Z-^RYXRA=FU#4[R36-3G:9KA98[DB)I=^ MV2:6VC<1C"C--8?S)+$VS-F\O.3"P4Q'UC(!7I@8Q7UE\%O\ D3+3_KBO\J^3 M_&/_ ":_\-L?]#]KO_I??5]8?!;_ )$NT_ZY#^0HS"/+F%9+I*7YLK 2PVMUX@\-WVG6MQ<*3' M%)- \:NP')4%@3CG%?.OP:\"_P#!5WX._"/PO\)=/L_V?[N#PSX>L]*ANIM0 MUL/,MO"D0<@18!.W.!ZU]:'W%(3CM0!\C?L#/\;W_;3_ &CG_:"MO"T7B,KX M1\U?!\MR]EY/V"YV8-P ^_KGC'3%?76.U?)/B#PG^W1\%_VQOBE\7/@;^SGX M3\;>'?'UGH/V:ZU7XAG2IK:2RMIH9$,7V27.3("&W 8[5O?\+Q_X*B_]&#^ M?_#U'_Y6T >Q?M'?&?2?V/7@NH%EA8_$'PP,HP!!P=0 MR."*\6_X*+?&+_@HSJG[ /QMT[QU^Q+X)TK1;CX3^(8]6U.T^+WVF2TMSILX MDE6'^SU\UE7+!-R[B,9&//\ PXGA?_Y84ZS_ &F/VH/%_B/2/!OC[]D/Q1\*='U?4!;7GC;5 MO%6A7T=GF-V2-8[:YF99)75(E=D*!I!U)4'\K?VU_BG_ ,%3OVI_'WAGXWZ1 MH?BB'P_JTEU!X'M/AF]]]CMVMK^:W82[&)^TEX0S%^"I7;\H-?LY^S]I'Q#U M3]G/PGHG[0]K#?>)9O#-K'XHAN8UD66Y\H>:)%P58Y^]Q@G->9A7'EM+9R2%A]G=T"A\JH<9&X#.205KN=HZD M&?#OA6P_LOPUH-GI]OO+_9[&V2)"QZMM4 9/K5\G KTSXD/NBD ![55U;5]. MT;3I]7U>_AM;6VB,EQ(/A1\0]'\1 MV,4QAFN]&U%+B-) /NDH3@^QJ>:/-RWU+5.I*FZBB^5:-VT5]KL9XJ^#WA+Q M9K$VMWDNHVTMU$L>H)I^J2V\=ZBC 6548!P!E>><'&<5TNGV%II5C#INGVZP MP6\:QPQ1KA44# 'H!4V :09SS5$%77EA;1KI;DKY9MWW[VPN-IZGL*^>_V% M_!_B=?V=?$WAR'7K/3Y-0\2ZD=(U+1+RWN8[>.14V2)Y+8W DL58AMW/"E:] MN^*WV1_AIKRWX;R3I%QYFUB#CRV[CD5XE_P3H\,:@/V1(?#^NZ['(+J^OD^T M:3K1G\I&;'R2AR4;.YOX2"0#TCX4Z):^+?!?BKPEXO5=4M)O$6H6-TER M@_?Q9"D-CU&<_6L+4/V!?V2M61?[4^"NEW$WF(\EW(TGG2LLCN"[A@6YD<'/ M56*GY>*Z/X"1+9:7XDMU=GV>,M04,[98_.O)/K7>12H_^K.?I0!\U_'W]C_] MD[X6>$9OC='\%;6:X\+:="MO:0WCP120Q;42.5OFQ$N%).#PF3FO%[WQ?^P= MXU\67'BJ^_8AU3Q!XF%VNJZA?>&7CN(Y)EQF>-I;B%F5BZ*N8T\]7.P2(K,/ MOV01R*4D164\,K#K7&>(OCY\%/"1NDUOXCZ1;G3=?M="U"'[4K-;:A<+&\%J MZKDK(R31N%(^ZX;@=*N[;-+P#YCAGR ;]GWP-JE]-J/AWQ%IM]KEUI\86 MWLQ;W$5T \I#+AO+*8QR0PR",UZ]X!U*_P!7\)V6I:IJVF7\UQ'O:\T=B;:5 M??_ACC_CQ\!O '[1O@&;X8?%&TN+K1+J9 M'N[.WN6B\[;RH+*00 <'@]0*\LTC_@FW\(-!O+_4=)\;>+(YM5CN8-3?^T(< M75K.8VD@8"$#YI(DE:5<2NR_.[ D'Z'))/%.'3I02?/?C'_@F]\#?'/AO0] MUS5M>+^'=/@L]+O(]0#21PQ2F4(5D5XW5G*EE=65@B@@@8J&V_X)H? B'QSX M?^(=QKGB6YU'PS>K-I/G:HJI'&N=EN1&B;HU!.T')&XGDX(^B&E ;;_DU2?7 MM(;6/^$?&I0_;EMO/:T\P>9Y6[;OV]=N[C/3- U&4MD757"[<5@>,@&USPW_ M -AAO_2>:N@0Y45SWC7 UWPT/^HT?_2>:@1T5%%% !1110 449YQ1F@ HHHH M **** "HYU##)J2HY3DXH _'W]H#Q WBOXY^+O$;ON^U>(KQE;_9$K*/T%<] MH'BCQ-X0OUU7PIX@O--N$;*S6-T\3 _52*_3_P"*W["7[.'Q8GN-2U3P.NGW M]PS/)J&CR?9W9SU8J/E8D\\C-?.OQ-_X)*>);#S+OX3_ !&M[U N5L=8B,3G MV$BY4_B!7ZME_%.2UJ,:51N%DE:2TT5MU=??8_G;.?#_ (HPN*GB:*52[+?AMJ,,4+[EOK6/SH>.<[X\@?C MBO9O">LQ>(O#5EK,7_+Q;J[9ZAL<@^X.16^+I8+EC4PO+RO?EM:_?30YLMKY MHZDZ./Y^>-KW;76R?YGJGQW\OQ)8>&_BC;I_R&M+$5X5_P"?B'Y6_P ^ MU>)?&/P[_P )%\/;ZVCBW2P1_:(=O4E.2!]1D5[7X14>,O@1X@\*L2UUX?ND MU2S]?*8;90/;J?KSVKSJ55>-HV4;6&&4]P:\C+YRHRY%O"5OENOP:/HLXHQQ M24WM5C=^OPR_\F3?S'_\$X/V/_\ A,M3A^/?Q$TTG2K*;.@6<\?%W,#_ *X@ M_P "GIZGZ5]])"H !4=*YOX/ZCHNJ_#/1+SP_90V]K_9T:1V]O&%6+:-I4 = M,$$5U%?'YSF6(S+'2J5-+:)=EV_S/T[A?(\'D.4PHT->9*4I?S-K?TZ)=$'3 M@"@C/:BBO)/H@&0.:#110 F,]!2.BE,%:=10!X5^T9^S@NMI-XZ\!6&V]7+W MVGPKQ<#NZC^_Z@?>^O7YT G@EW+NCDC;Y>JLK _H:^_G52OW:\._:+_9Q'B' MSO'7@2Q5;X+NOK&-<"X]74?W_4=_KU^CRG-N6U&N].C_ $?D?"\1<.<]\5A% MKO**Z^:\^Z."T77-&^/&BQ^#O&=U':^*;6,)HVM3#:MX.T,I_O>A_+G@^=Z_ MH&L>%]6FT#7["2VN[=]LT,G4>_N#V/0U397AEVL&5U;GL5;_ !KTWP_XCT;X MXZ3!X"\>7D=MXAMTV:'KTO\ R\>D$Q]^S?U^][EI8-\T=8=5_+YKR[KINCY- M2CF45"II56B;VGY/M+L^NSULSP#XS>!O$/C71(Y=%UZ^^T6<>V.Q-X_DRI_= M"YVJ?3'XU\^W%M<6MR]K=P-')&VV1'&&5AU!]Z^P/$GAG6O!^MS^'_$-@UO= MV[;9$;OZ,#W!Z@]ZQ-/^%GP1\4>-8=;^+&@WTUKMV3?V7=>4S'C!8?Q=,=0< M'K7T&!S.&'H^\N:-KJUF^^FU_O/C\TR&IC,0G"7+.]GS72[7>]CY8<#\ZZKX M*ZGXU\+?$W0_&O@;0+Z^O-+U**X6*QM7D9P&&Y<*.ZDCTYK[$TL_L>^ V4^" M/V:3[_.7K8;]JOQ;IUO]A\%>$]#T6W'W8[.R''X# _2HK9]5 MK4W"GAFT]/>DDK/R7,:87A'#X6K&I6QR4HM->SC*6JUW?*OS/J;2[K[99PWG MDO'YT*OY<45PGK!1110 49HJKJ5_9Z5:3:CJ%PL,%O&TDTTC85% R2?:@& M[:LM$CO7S#_P4-_;7'[.?AE? 'P]OU;QEK$.Z%P PTVWSCSF!R-QY"*1ZD]. M>DL/VXO"4WBR;3+_ ,.W46D^85M]223Z_K M'[0?P9\;MX\L]6NGN[NT\P&]@SSL4#AU484*,$ 8->M@,)36(7UG1>>S\K] M#XOB3.,54RJ:RGWY[-KXHKJTMWVNMM^AM?LT_P#!7#6M+:W\*_M'Z6UY;\*O MB+3HL3(/66(##?5<'V-?<7P_^)O@?XH^'8?%?P^\46>K:?,N5N+28-@^C#JI M]B :_$6]L;W2[J33M1M)+>XA?;-;S1E71AU!!Y!KIOA-\:OBE\#/$*^)?AAX MPN=+N./.C1MT4Z_W9(S\KCZBO9QF1T*WO4?=?X/_ "_K0^#R+Q S#+[4<>G4 M@M+_ &U]]K_/7S/VT]LTO('%?(?[*G_!43PQ\5)X_!_Q>T"31]76/_D)6,+R MV_X>9[WX@\3:%X9T]M3\0:Q;V-NOWI MKJ8(OTY->&_$S]M[1].:33/ACI?V^7D?VC> I"/=5^\WXX_&OGSQAX[\8>/= M0_M;QAK]Q?2[OE$C_+'[*O11]*A\->%/$7C+45T?PQHEQ?7$G_+.WCW8]R>@ M'N>*[J.7TJ:YJCO^1X.,XEQF)E[/"QY;]=Y/]%]S+?C?XB^-?B'??VEXO\07 M%XP_U<;-B./V5!P*ZC]EO7O$VA_&33?^$=L)KA;J3[/?0Q*2/);[SL1T"X#< M_P!WWJQ#\)/ /PY_TKXU^,U:Z5=R^'=!<2W#'TDD^['_ )YXYK:]^T'K5O8- MX=^%>BV_A32_[NG\W,WO)-]XGZ'\371*U2FZ=-:/KLO^">334\-B(XC$U&I) MWLM9/UZ+YN_D?:R%NM25Y'^R5\6K_P"(_@N32O$%_)<:II,@2::5MS31-]QR M>YZ@_0'O7KE>#4IRIU'%]#]*PN)IXS#QK0V?]6^04445F= 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A8 M 9S0 M!..M?.O[6?_!5?]AC]C&UF@^,GQRTUM8B4E?#6AO\ ;M0'WMX]=URSLVN[A8+475TL?G2L<+&NXC!R,U_([\0 M?VTOVJ/BO\5M+^-7Q/\ CAX@U[Q!HNJ0ZAI=UJ&H,R6L\4@=#'&,)& RCA5% M?U+?L=_M%>'OVL?V8_!7[0OAIE\GQ1H,-U<0JW_'O<[=L\7_ "4.OX4 >F4 M444 %%%% !1110 4444 %%&X>M&>U !1110 4444 %%%% !5?4))H87DM8O, ME$9,<9;&YNPSVS4Y;%<=\0/&NH>'-9@>QM+BXM[6SEN=2ACM?E,>,*?,8A5( M/.W)8@< U48N4K(RK5(T:?-+;^ORW/._B/\ %WQ3X EU*TF5(=0U)899$COC M.MD=FPHHV@ D*&].2:\*U'Q7=ZMJ+3WDS32,Q+;F)R>N23R3]:E^(WBF]U?5 M;K5+^;?-)(S.WJQ/-<_H7[U_,8]:]^C1C3A?J?FV88^IB,1RINR;LOG^9UFE M3WCD>4%&?;I76:1%>LB@Q*W_ &L'PW%&\B_E7HGAVP@DB4;?QK*I*QU8.FY ME'^P[>_BV31;6'KU_.NB^$OBZT\%Z_'HGB2PMVBN)6%GJCPKYL3MU5GZE3CK M].W1]_I\,4.]1R*Y_7(H=1L9(R1N&1^-8NU10QW!5E') M3.T@\D<#O6#\&-3\,3^%+/7I[&VL[[Y=.DFX4S,O*J/4G/UZUR_[1=C<>'M% MN=:N-3'$(T$**65&QRY!Y!)ZD_2N&-.]?E/EWZ=/ MQL>)_$KQL^K:C<21)Y5OYSF.W$A98PS9V+D\ ']]ES(W&>!5#Q-< MN;A(W<^IK0\-R)\O->^HJ-.R/SF5:5;$>\==H&EI,RYKMM%\-[D#(&]>*Y?P MS.FY2YKT3P_?6OE ,U<=5NY[F#IPEN57TUHX_*N$[8W4SPOXEUKP)?S:+IDO M^BZL#"B^;L%O,PVK(#VQGGBK^MW]NT64/\/6N9UFZ2_TPL/O*;E>F[KCK6Q7 _"GX MAS>*?L.DBW>-8])5II;R)XWN)AA28MP D0=V&<$@<5WU>94BXRLSZK"U(U** M<7=>84445!T!1110 'I7A?[3YV_%'X?O@G;;ZT<#O^[@KW2O"_VG>/BM\/S_ M -.^L_\ H$%=V6_[R_\ #/\ ](D<&9?[JO\ '3_].1/B7XC?M8>/],UW3KBZ MN_$#+K*^=;0:',L,-I&7*K&@*$RR#'S;CU/0=![%9?&OQI!\&M0U>X>&;6+' M75T=-4:$")V=D N&0<94/R.A8=@<#GO$1^&FN^(+[4O _@GQ--9K=.;BXT;5 M(K:VNI,_.\2R$G!.?F78&Y(/>N_TCQ!\%1\"YKJ+2EA\,Q1O!>:7-"6F6;=A MH64DLTQUK][.ST;6U_43<>6RT:ZWW_P O MD>!^'?VGOB+-XUU'1;+6O$2W&DI--)-JTB26]P(N626+8/+5@"%*D$9%>M_& M_P",7BFSM-)L_#DUWI<=YX?&K7DEJJFY925 @0L"$(+99@,X].:XS1?$GP1A M\0;/$7AWQ%)96\BFXL[S7X;I+-01AIX8VWE%[@E\#J#7I_Q[U;X:G3]-M/$6 ME7>HZC-NET9='G$<\4>!NE$A(5(^1G.0>!@UYM#"8W#Q5+$3=2I)S:ER1C9- M>ZN5-I\F]WJT=F;XC!XJ5\'1]@N5*W,Y^\EK.\DM]--M-SA/@A\:O&M[XITF MUO\ 5-1O-/U74#8RV>I2+,\3["XFC?:&VC&&4Y'/:N=^,G[27CC2]>X4 %<2Y#R+P"RJ.>"217;@82HU(PKKVDE'67*E=][)V7;?IZG!EMZ M<8>V_>][:I):?VLOQ%U[[=M\SS&UF?[+NZX\G?MV>W7'>O7?A M=KOPDB^&.J3:;IC:?I]GYA\16NK'S)0Q3+-,OV ZLA00^OD;O,VXYV;LXXQVKFQDLRJ5(1P==T%&I%R7+&7/&VM M-*32BY/6\;OR(GAZ%23DX)_UNWV2TU(_B!#HUSX6\)^*O#FC:IHNJ>(-+DGO MM4TS6;M9F2W&X6Z,92&W-*[)N#87>0,DFN?^'?CKXHW6K68T'XI>++&*?6+> MTN+74+B'45F65]N4^U1.RLN0Q (&T'IU'M_Q8\1?"EOA_I,6H:&VKVNH>6_A M^STMO+DX3(DC?*^4JIU;(P#C!SBN0^$VM?#?3?'%B=;\*:C#?3S-#I.J7VM" M^AAE88$>0%\IV&0&*\_=WM)X+ZE##THN-9-MSYW+FCTCR232MW M3U/'+7X]^)=82#6O$_BOQEI]U:KXWT>34[;Q)7G*!ACC Y/%>::EK_PD MO=8:;P]X#UE--NI'=;.W\1BT%XI).^*W)R%;J!NC^E>T_#ZR^&'Q!U+X=Q:9 MX9T^ZT.35Y(X=/O;!&2(+970,;1N#AE8$$'N._6N*C3C3JUYU)RES.3C'W$J M2Y'[FBN^_O.YQXGV_LJ:CRJW+=M2O+WEK>]EVT1]5_:K>[LS-;7"2QLF5:-L M@\>M?"GPS\"_ F]^%_AFYOM(^&#W7]DV$NH0:AX7N+B\;."[.\4@R[Y8!MI" MLO.[D#ZRG_9G^#<%7T>:0Y,WA_4KC3VY&, V\B8&.W2O-;S]D7X]:! M'I_AWX2_M97F@:'I$,=MI]C/X?%U(+>,J8XY)#. Y4*%WA59AG>6))KAHU,/ M##RA3K.+;B]4UHE)?9YN_6QK5A6EB(U*M)2236C3U;B]I.YF\!ZC\\N^1T+*DFWR]B1DG)),;D?*X ]1M?V5/VIX0HG_;.FFV MR,XW>'YUX+*VWY;P?*-NT9R<'DDY)D?]EC]J9M/BL?\ ALB7=%&5%Q_8-SO; M(/)Q>@'&1C(_A'ODYI_]!*^^?_R)I^[_ .@9_=#_ .2/(Y? WP(AU&.Q72O@ MS;>;IMQ+#;?\(C?R3;_,=>GF A%",K?Q!F0@+P'V-*^%WP.6*2Y?PW\'Y+B& M\<&.U\&W3*%W*\88&0G><9(Q@_='7GT6Z_9:_:DN(DC7]L%H?+W@21^'[G<= MV_K_ *=@X+ \CJH'W<*$A_9:_:JCN5GD_;+DF7S"S0MX=F52"1QE;P'C'KGG MTXHYI?\ 04OOG_\ (BM3_P"@9_=#_P"2/*E\)?!F;080="^#*W4(5;Y(_!=^ MT:Y2'+J2V]1@AAN!'S8+=6,*> ?AA_:($>E?!.2$R,L9C\!WX;RO(ESM82E6 M?>IX[(K'J!CU=?V4/VJDC6,_MH7!VKMW-X?F.[A!S_IGJI/L6/;.72_LK_M6 MA5CMOVTI80LA9L>&96W@HRE#NO#@?-NXPP*@AASDYI?]!*^^I_\ (CM3_P"@ M9_=#_P"2/*[GPU\&[77K&.71O@;'8R2)ON;KPA?1R$E)RWEJ6V9))PC-\H1P MZ65C_PBSJ9E"[=C!;L#!Z].OXY.:7_04OOG_P#(B_=_] S^Z'_R M1Y;XHTZ/2?V5?A=I<,=A&EOXTU>-5TJ%H[9<7=X,1(Q)6/\ N@DD+CDU]9?! M;_D3+0_],A_*O!?VM? EE\-?AC\/O!UEJ-Q>"W\37$LUY=8\RXFE66:65@H M!:1W; S@<"O>O@N<^#+3_KD/Y"N/%5(UL5.:=TY-_>SLPT'3P\(M6LE^1U MB$!GS_>K\[_^"!I:+QM^UY9SQ212Q?M0:]YD4T;(PS(2#A@."""#T(.1P:_1 M"/):0?[5?.?[("A?VQ/VHPJ@#_A8&@GC_L6M.KG-CZ/YZT#![4I.*!S0 8IH M!7O3J* /,_VS/@SX@_:*_9&^)WP \):G:66J^-OA_K&A:;>7^[R()[NSE@C> M38"VP,X)P"<= :\HT63_ (*Y:#H-GH:^ _V>WCL[..!9&\3:U\RH@7/_ !Z\ M=*^HZCG!,>%':@#YG_X(^#5W_P""?/@EO$L5HNH_;M:-^MBS-"LW]KWF_P L MN Q3=G!(!(QGFOII]D4;.5^Z,U\9?LS>!_\ @I_^RU\(K7X'^'?V>/@]X@T_ M2=4U*2RUB\^+&H6DMS%<7]QO\2O^"JWEL7_9'^"N MW;R?^%U:C_\ *.@#Q']HO_@HWX[_ &A/ W@/PY^S3X/^,'PZL?&WQ9T[P_\ M\+2;PO8K:_9?MDMO/Y+3O*,NT3*I:+MVKV _L._M(A'_\ MY7UR/[!/[.GPS_:M_P""6OP\^'7[1_@B'4+5=2OM0N-/L=6N(EMKZ'5[QU:* M>%HI/D?.UAMR.2!G%=P?^"27[#"J6'P[\1_^'(UW_P"3: /B?]KW5O#/QAE\ M2?L,^%/^"N_CSQ1XXOI4L;?PWXHTW3;;1=4OEE4_V;+>6ME&5D8C:,.%W[5; M/(KTW_@AC_P3Q_:B_9 \3>,OB%\?+== M=;LH;&Q\,QWRS-/)'(6^U2!"57: M/E7G)#MG QGFO#'_ ;NVGA/]KZQ^+&C_&Z&/X>Z=XDCUFUT5K>9]2&R83+: MF5F*E=P ,Q8N5[;N:_3^ ;6%?,X+ XK&9B\=CZ?).FW&'++1Q?5K777\=C]M MXEXMR/AW@J/"W"F,>(PN,A2JXKVE)*=.O&S<(3:B^7W8W7O6MI-\S)P6 M]E_HX\MU(?!3&TX/45T&<=:Q_'.E>$-5\.S#QS';-IMNK37+7DFR-%4'+,<@ M 9SGC'6@#@?@[J^@^"M)U+1G$RI=>/+ZRL1%"\OS9XW$9P,+]X\5-I]_!X- MOY+WP[H?B;3]'T_6)=/NM"M]#69=3N;J6%AJ"O\ -)Y49:3+*57#.6'R"KW[ M/:V!T?Q$=-,;0?\ "8ZAY+1MN4KN7!![\5U7C;_A+4T"=O D&GR:IM'V1=4> M1;?.X9WF,%ONYQ@=<=LUI'ET7ZZ'+6C4C>HGLG9)7>WKJ[^G8^M33:/H^D>6SW,<=P(TL-WD.,MM.["-(H8_6OR,_:S_ M &E-<_;3^(,W[+$_PJA^'NDZG=1>,_''BJW\87=];W^GPW4JWEQ=33-;3>XO-4FU3POKMGHZ"[T^[FC* M2/R,!]OR^8N&(8GK7Q#^SA^P9\(?'O[1_P 2O@_^UMIT=O\ V/X>TUM)TG7_ M !)Y]Y*MU<6=S&7,=O!;S N7R6190 M617!8 FOUP\">%-*\$>%;+PCH8F^QZ?"(+87$S2/M'JSL:($AC1\;F5(PJJQY( KU>(*!\M?$5XT_;WCK9 M6OZ?E?3;LCZ#!_6*&%E1DURRG*=EY[7T3=DWOLW*VC,#XL'_ (MSK7_8/D_E M5S4=,N-7T%],M]1FLVGM=B75N1OBRN-RY!&1]#5/XLC/PYUK_L'R?RK=L?\ MCRA_ZY+_ "K/?0WC)QDI+IJ+!&8XU4N6(7&X]Z\M^/OQ?^*'PW\7^'-,^'WP MVNO$%G>6NHW.OM%9G;:0P1*8V\]I$C5C*ZKY6&>0;BH 1C7JU<'\=?A/>_%G MP_;:=8>*+RQET^[-W#9PW30VU]*(V6..Y*#S#$&(?",IW(O)&0=*,:6MUKMN]YI6BZ9J>LZE8ZH+J*UGB@ MA9H8XXQ'73WGVAC<*\UP2YQ*6P =@QA0!BLOX6?LH_![X27N@ZUX-\'6NF7NA:7< M6<7V/E7\]Q),S%\NY,@9@2V1O;U->G1A57A<5V9I_97UI_V?S^S_ +]N;=]M M-K/U;70FFZG+[PJA5X KG_&G_(=\-'_J,M_Z3RUT//I7.^-?^0YX;_[###_R M7EKSRCHJ*** "D;[O6EIDY(C./PS0!XK\>_VI+KX6^.+3PGX?TJUO?)C$NK> M; ?<=Q[C@U M\/=1?Q]92QWUS=R2M*Z_+,"QPR'H5QTQTK(T#Q%K?A758==\.Z MI-:74+9CFA;!^A]1['BO9>!ISHKE>MM^Y\%'B/&8?'S=6-X7^%Z-+R\S]#,B MBO#?@?\ M<:)XO,/ASXAO'I^IMA([O[L%P>G7^!C^7\J]NCD5P) R[<9&.]> M54I5*,K21]G@\;A\=2]I1E=?BO5$E1SN$0L6QCK6'X[^)'A+X=:0VN>+-7CM M8>1&IY>1O[JKU)KY;^,_[5GBWXCO-H?AQY-*T=\KY:-B:=?]MAT'^R/QS6E# M#5*[TV[G+F.;X3+8^^[RZ16__ /8OBY^UQX/\ W']B^&X%UK4%;$RPS!88N> M07&ZGW!R/PK\_CUR:^H/V&IO%: M^#]4L=3LIETE;I)--FE4@,S ^8JYZC(4\<9)KLQ6#IT-K/7]'L(K>UU2U.Z.",*HF0_,< #DJRGWYKZDKS']JSPB/$WPLNKV*+=/I M,JWD?'.T?*X_[Y8G\*]+*<0\/C8ZZ/1_/_@GA<18..+RJIIK%H8'(/YUWW[0$,>KZKH_P 1K6$+%XBT M>*>9EZ"=5VR#Z\"OL)?N\8GTDK?-:K[TW]Q^8Q_?98X]:1B@<#% !CG--E4&,\4ZJ/B758-#\/7VM M7+[8[.TDGD;T"*6/\J:BY.R)E)1BY/H?G3\6?C_8O^TSXNT75HHH]+;7)(;. MYC0*(63"'=CJI()SU!)[=.BBE!"SPR J<%65OUS7ROXFUB;Q!XCU#7;B0M)> MWLDS$]RSEOZU]!?LC>%/%_CSX5^*/$4NI*UEX8:'R4FZLK!BZJ?8 $ ^M?K^ M.P-'!8.,[VLHQ?F]%^9_-.59KBWW'O'ASQ)HGQL MT*'P!\1-16WURV79H.NR?\M/2&4]\]CZ^_7S_P 2^%-<\&Z[-X?\26#6]Q"V M&5NC#LP/<'UK.!VL&!*L.00>E?4_P&&F_%_X56<_Q T6VU.:RN)+=9[R$.SJ MI&TY(ZX./PKY?$U?[+C[1*\&]NS[KR?5'WV!P_\ K!+V,I6JQ5U+=22MI+S5 M]'VT?0^6PK2;4BC9F]%7-;6B_#'X@>(F T?P9J4P;H_V=@OYG K[*TGP-X.T M%<:+X8L;;'*^3:(N/QQFM@*J#:!7F5.(G_R[I_>_\CWJ'!,;?OJWW+_/_(^2 M]%_9+^+NJ[7O+*SL%8?\O5T,C\%R:^H/ NC7WA[PEI^AZG>BXN+2SCBFG4<. MRKC-:W'K2;E]:\C&9AB,4R@ KR3]K?PW\3/% M7@:/3/ <#7%L9BVJVUNW[Z5!@J .ZYY('/ ZUZWD>M(R@CI6E.I[.HI+H<^* MP\<5AY46VN96NMS\Z9K6>TF:TO+=HY(VP\]>U1Q='$>[+1]F?GN.R7'Y9+V MD-8K:2W7KV_(D\>#]F3]JK2G@^.OA8>'?$:1XA\4:+%M9F /WL [O]U@WL17 MS/8_LI^&]+\170U'Q?+JNGQ7!^QF&V-N9TSPSY)*Y]!^=>H ]B:VO!OP]\:_ M$*]^P^#_ [<7C+]^2-<1I_O.<*/Q-=U.CFE:,JE)2J M=TM9>J6C];7.:T3P]HGARQ_L[0=+@M85_@AC"Y/J3U8^YKH/"?@CQ7XZU(:5 MX2\/W%]-T;R4.U/=FZ*/J17?S?#?X/?"=?-^*OBIM?\ A']!DRB'^[+- MV]P,'TS61XK_ &@O%^L:7_PC'A"TM_#.B@$+I^CKY9&_ &F6OA726^7[+I*;99!_TTE^\Q M]2,5P;9Y8G))_B[UZ)\,OV8/B=\2(X]0;3_[)TY@"MYJ"E2X]43&YOKP/>IE M&G'WZLOOV^2-J53%8B7L<'"WIJ_G+_@I>1YV^Z5M[R;F9LLS')8UWGPS_9O^ M)GQ-\NZL]+^PZ>W_ #$+]2BE?]E?O/\ @,>XKZ/^&'[+7PV^'7EWTMC_ &IJ M*X)O+Y0=I_V$^ZOZGWKTN*-$7:%'3@#M7#6S+I27S9]!@>%F[3Q4ODOU?^7W MG ? _P" 'ASX,6UQ)I^H3WM]>*HNKJ90HP.0J*.@^I)]\<5Z'GM117ESG*I) MRD[L^NP^'HX6DJ=)6BMD%%%%2;!1110 4444 %%%% !1110 4444 %%%% !1 M1N'K1F@ HHR/6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \__ &J/BGXV^"'[.WC/ MXO\ P\\#+XEUCPSX?N-2L]"DN#"+PPH79-P!(^4,>!SC'&:_G,_:V_X+C?\ M!03]K;[5HNI?%:3P?X>N-RGP_P"#-UFK(?X9)@?-D_%@/:OZ;KVVM[RTDM+N M%9(I8RDD;C(92,$'VQ7\JG_!47]E"?\ 8Q_;D\=?!2WLFAT==3;4O#65^5M. MN?WL(7U"9,9]XS0!X#<33W=P]W=SM+-(VZ261BS.?4D\DTVC(KI/A;\'/BQ\ M'6? M_C+]C'Q/JNZ;19O[?\+QR/S]FE(2YC7/99-CX_Z:-7@7[)?_ ;'_M5?%8VO MB+]I[QKI_P .=)DVO)IEOMOM4=?[NU6\J(_[SL1_=-?JE^PU_P $E/V,/V K M^/Q;\&_ ]U>>*_LK6\_B_7KQKB]:-@-ZH!B.)6QR$4$]R<4 ?50.>:*:DD> MJFG4 %%%% !1FACQR:Y/XN?&/X;_ -\!:C\3?BMXQL-"T+2[V2>I)X"CDG@ FE*48Q;>Q=.G4K5%3IIN3=DDKMM[)+JSJFD55R361XG\>^ M#O!VGOJ7BKQ-8:=;QKEY[^[2%!^+D"OPG_X*G_\ !TE\;8A>>#/^"=WA:RTC M15+03?$#Q#8F:^8GCS+:U;]W"OHT@=L_PBOD[4?BO\7_ (PZ5I_B;XT_%37O M%VK3V<#]C"$Y:351M127,EK:5W?1JS5[I?TA']N_P#8 MW^W_ -FM^TUX%%QY@3R_^$GML[O3[^*[[PW\3_ 'BU]WAOQ?IVH?]>E]')_Z M"37\VO[+GAS2_$?QJTNVU.!9(K<27*QNN0SHA*_D<'\*^S;6[NM/NEO=.NY; M>X0Y2:&0HR_0C!%<&%XDJUH\TJ:MZGWG%GT=,IR/$QP^&S"W>OLK]EK]NK]GC]J[4-:\+_#3Q]8R^)?#+(GBCPO+.!?:8SJ& M4O'U*,",2+E2>,@@BO?P>.HXS2&C6Z9^#<6<"YUPCRSQ-I4I.RG%Z7M>S3LT M[+M;S/;**0,K=#2UVGQ84444 (W]XUYU\7M4O6Y\0M"N[*Y MGM;B#9)'(Q:,]5(/(_.N0M+EH9,J?8U]-'WHGY-6YJ=?4]+T'4$B96W]:[;0 M?$:P+_K,5Y#H^O; "6'Y]*WK#Q%M7B;CZUSU*7,>GAL7RH]2O?%D4D7W]U8< M6MB:YDC63AEKD7\2,RD"7]:DT;46FD9PYY7&?QK-4K(ZWC'4DD>S? CPI+K4 M$^OP:E)')8ZHK1PR?/ PV_,=G9L' ;J*I?'_ $KQ;-X:D;4)&EL+/4)8K:>\ M7;<.6!.> %*#HIX)Q6]\&?#GC#0[?3+.662WL=0WWTC6]N"<@!1%(S9P&!5A M@ \$9KH?C&E[JFA7'AZ;0FFM[J-5M[I;F-66YW#8@5B,Y/?/3->?[3EQ-]SZ M*.'4\K<=4[>>KM==]-CXK\4!A=(W^S_6GZ'J*(5!(XZ^U;?Q$\'ZAI=_-8W= MFT4\,C#RV_A(/*UQT4YMI3D8;/S"OD:/K C <']:Z?3 M_%311\25Y/8ZZT8^_6M;^)"%QN K&=*YW4,9R]3T*^\6-+%S+5>RU8RVDCL= MV6XQ7$_V])<-Y4?S,>E=]\)?!U_XVUVVT1(_W6[?=29X6,'YC]>P]S6I[U\&M0\/MX7T;1$N8)-0M]-\XJOS-$C,>_;GC&<\&NZ'M6' MX6\(V'A:^O)M+8QV]XZ.MHJJ(X2%VG;@=^I]_K6Y7AU'&4VT?H.%A*G149;K M3[M HHHK,Z HHHH *\*_:@56^*7P_1NC6^M _P#?N"O=3TKPO]I\,/BG\/V4 M?,+?6L?]^[>N[+?]Z_[=G_Z1(X,R_P!V7^.G_P"G(GS[9>!OBQ\-(%\':+H5 MCJUBKE;&]&I10,(\_*)$D(.X#KMW9QGJ<5M6GP#U?_A4][X:O-:MUUR^U==6 M\Y%8V\=PA4I'V+)M0*6X)))QT%<#X2T7X?>+].O-:^*\D=UX@:9QJG]IX,D, M@/,8#?<53P%&!@ CUK8TKQ#XZC_9PU.XL-1OC8PZU]FLM2WLTZZ7YB"5U<_, MP7,BA^2%&0> :Z,+E^#PN.KUL-25.K4G!U)\MO:22:C*[;YK)O:VX2YO9QN[ MJSLK[=].APWA/]C7Q!9>.[_5].T$6%W>K-'<7=SKL-Q;P++D2-'&@\US@G ? M &><5Z_\5O@SJUV-*U?P5Y5P=)T<:;/8W=QY;36ZX*,KD8#@C^+ (/48KRS6 M-'\$^']%_M_PLEO9ZA F_2[S3V N&G_@VLIW.6;@@YW9.REIRN[LM M4EN[K;74UJTZF,K*E6FIB3T5WT2OKV1M?#'X.^+KKQ1IGB/Q)80Z;8 MZ3>?:H[=;Y)YKB<*57)BRBH,D]23Z"N>^*/[-7B)M8E&GZ6-2T^34)[BQ:'5 M(K>:'SG,CQR"8A6&XG#*22#R.*Y#]C_4_BO:^*]+7Q%X>M=+U*\U)TU"PTU% MCCFT\1Y,TL2$JK*^-K<$].G7OM+T?P+XU\9^(KCXWO')JUKJ4T,5O?$%;>W# MGRQ&I'"E-K9 ^8DDDFN7!XBIB:<:R3C%Q3Y7%J25]G&]T[W>YI[.KPWC72PT MTI4FTI4Y)K;7EELTT['3>#?V?[R/X=>(/#_B2_CM[SQ%:PP 6KF1;..),0C< M<>8P)+,>ASCH,GG1\.OC ]XVACPWI@NMNW^TO[6C^SYQ]_R_];_P';UXSCFI MO!&L^+-+^&'CR#X<3W%QI^F\>&IN9&C?83,D77<$^4JO0,2!TQ7DHM(QXC:^ M.GV(TD#S5UY9O]*SMSYOG;O,\W=VZYXQ2K970S*I?%1C/V\>,/@'=#P9X=L?"U_!)?^&[.2V_TZ0I' M=Q2A3*"0#L)90RG!QC'2N=^'?P9\2:WKEI>:FEC9Z98:A'>6OV9;C&,* MPW,5.!OP#Z5Q/P6?QM8>.]*ECTZSM-6DU6&../3513-9EC]H$JQG:8Q'DAFY M# _2YK3RN&(PE3&<\%[ M-Q7*Y)3ES:>['=I=>QZ1\9_@/K^K>(-0\2:/'#?6.H7"W,UL]\MM-!.(Q&2K M.-C*RJ."00(/C@^B_%25CI<&G12:':W/_'NY.?,< \,X88).2HQC&:K> M %70?B!K^B_!-M]C_P (]<326L9S;1WPV^00.B,Q+@XQN R>@KT'F&(G_L7O M)**GS?VVL"2J@^1I(B-X.,9";AQ7N'P7\#O\//$W@'P]L M@(.U8U[# /0?7'[/WCWXLZ_-X#BT?X>7L\D?B"Y_LK5/%5W]BCN+?[+="$L MLDY/E\Y,8)P,D9S58;!1C*O.E2]G=OGDX\BG+D?O)M^\O3O>Q.,QRE&G"<^: MW+9)\SBN9:-+X?F?=#M^[YQ7)ZU\;O@UX8U630_$?Q7\-:?>P$">SO-_#OP4?$FD?"VXU233=.G>?Q#XAG@U"=I FYWVON:8L"P8EM M[L6.UBQ/E+#T8T74<^:S2M'S3>[7E;;YG5]8Q$JRIJ/+=-W?DTMEZ]_D?67_ M T;^SYNR/CCX0ZX_P"1DM>O_?RE_P"&C?V?C_S6[PCZ?\C):_\ Q=?.UEX< M^%L%RL0T/X+JDUQ<;)?[8N"T\JR(L@92_+;8CN;+%64C# L3)_PC_P *()X[ MC0+/X07ES:J]I#(=5N8&C4XX)6:0[E81DKR21GO\C:V*[Q^Y_Y MGT(?VCOV?0>?CAX1_'Q):_\ Q=!_:,_9_!S_ ,+O\)?^%);?_'*^>[WPK\$C M:#P]+#\)8[6YNKBYFL9M2N&#"220/*O^D#+%VVLO"D\[AP%?$?_ I+7_XN@_M&_L_8W#XV^$/W/_,^C!^T?^SXS M;5^.'@\_]S):_P#QRB/]HW]G^614A^-_A%F=MJJOB2U)8^GW^OM7S_JNF_"^ M]NUCU&T^#;1R+%]LVW4\/EVC$5AI'P5T75+?5]*LO M@V&FU2-;N?\ MN4"*9EB>+:OF,KR,4"X)0[0I&[YD*Y<+VE]Z"V*[Q^Y_P"9 MV'[?L\5SH?@>X@E61'\2,R.K9!'D-R,5ZY\%_P#D3+0_],U_E7RS\1)()/V: MOAI]CD@:WC\;:M%:_9&S"D*7=VD:1\G$:HJJ@R0%50.E?4_P7)_X0NS_ .N0 M_E6=>G[&M*FG>S:^YFE&HZE&,VK72?WHZR,GS'X_BKYS_9 S_P -B?M28_Z* M!H/_ *C6G5]&1???_>KYS_9!R?VQ/VH_^R@:#_ZC6G5D:'TA\U .>E'4<4$D M"@!#D#BC=ZFOG[]H7]L+XP_#C]H?3?V;_@;^RU<_$/5[KP<_B.^N%\76NEQV MEN+K[,J_OP?,8MD\=!4>B>.?&_B3X::E\6_'_BG4O"/C:QN)HSX)CU>.XM]/ MF5R(;-HD&VZ,B[3Y@&7\S*$87 !]#9]J0G;Q5;3K^.YB6.26/[0L:F:%7&Z, MD=".U6B,T %-E7?$R?WEQ3NG6B@#Y&^$W[!W[:7P+\#P?##X5?\ !11=/\/6 M%Y>2Z78W7PGL+B2!)[J6X*&1ILOAI2-QZX[=*Z,_LT_\%%0<#_@I7:_^&;T[ M_P"/5]+G?_'J^E >.*,$CF@#YK_X9K_X**'C_AY5:_\ AF]._P#CU+_PS5_P44[_ M /!2JU_\,YIW_P >KZ4H.>U 'AWPD^!_[9W@_P"(-CXA^+'[;MOXPT&W\S[= MX>C^&MEIYN=T;*G[^*0LFUBK< YVX/!KU'XE/\/H/!]W-\3H]/;1HX6:Z74H MP\94*<_*0=QQG@ FM_)/2L3XA>*/!7A+PK=:U\0KRV@TJ.-A=&\CWHR[22NW M!W9 /RX.: .9_9VN-/NM"\0W&CO&UJWBZ_-N8ON[-RXQ[8Q7H )[UY[^SI>6 M]WX7UK4H5\N&Z\7:E);[HS'F/SR$(![%0.U>@&>+',JX_P!Z@!91D<"N4O?@ M?\'=1\8:A\0-1^%GAZXU[5M/73]4UF;1X6NKJU"LH@DE*[GCVNR[22,,1TKJ MA<0YQYJ_]]4OVB G'G+_ -]55.I6HR;IR<;JSL[76]G;=72=NZ#1[D6FV-II MME'8V-LL,,*!(8HU"JB@8 '0 58[]*89X1_RV7_ +ZI/M$/_/5?SJ0,#XL9 M_P"%=:U_V#Y/Y5O6)_T*'_KDO\JY;XYZD;#X.>)K^V>,R0:+<21[N1N"$C-= M-:31+91*95_U:_Q>PH G!'K2U&)[<#_6K_WT*//B_P">R_\ ?0H >32BF"># M_GLO_?5)Y\(Z2K_WT* )*YWQK_R'O#6?^@RW_I/-6^;B''^M7_OH5S?C&X67 MQ=X5M%D7;)JD[-_P&TF(_6@#IZ*** "L?QWXPT'P#X0U+QKXFO5M]/TNRDNK MR9C]V-%+'\>.!W-:[=*^<_\ @ICX.^-/CG]G27P[\(M(DO(6OEE\06]LY\^2 MU0%MJ+_&-^TL.N%Z'FML/3C6KQ@W9-[G#F>*J8++ZM>G!RE&+:2W;Z?\'R/! MOAU_P4O\$_%_6[[P-^U'X/MK;1;Z]D.CZQ8Q'?IR%OD63J>!C+K^(-=5\2_@ M5J/A33X_&G@[4H]>\,W2"6UU:Q82!4/3?MX_$&[J3_B8>';YLPN#PS1YSY;D=QP> MX-?75LMY%S8;[NC].S_ _$,#Q5]9E[+-;OM42]Z/^)+XHW^:Z7V/:&*[5G^6I]7E-:6'S!.C.ZUU6S5FT_3JKG%^-O'?B7XA^()O$/BC4GN)I M&.Q2QVQ+G[JCL!5+2-$U7Q#J,>D:)8375S,VV.&%"S,:IX ''I4WCC]O3PM\ M O!2_#_X#>%8Y/%TL.W6_$>H0Y6UD/58P?OD?@H/K71[.II"E&[_ 7FSSIX MC"QE*MC*O*MV]Y2?9=W^"1Z;JWAKX*_LMZ%'XZ_:8\20RZ@T?F:?X4M)!)-, MWH5!^;ZG"CN37=?L.?MNZ1^U%?>(/#3^%+?0;C1Y$ETRPAEW>98L-H)X WJP MYP ,.N.]?E_XO\:^+/B!XBN/%7C;Q#=:IJ-V^Z>\O)"SL?Z#T P!7JG[ >J_ M$K0_VH?#>J_#7P_=:DWVG[/J\-NA*BSD^64N>BA1ALGNHK7$97%X23J2O.U[ M[)6Z)>9R97QA5CG5&GAJ?+1)NANK=HI%]FVFNFZB[6J%**E&S/A'Q)HMSX8\ M07WAV]7$EE=/"W'7!QG\N:["PE/C#]GR\TTC?=>%=46XA[D6TW#?@&YK4_:Y M\'GP_P#$_P#MR&-EAU:V63/;S%^5A^6T_C6+^S]JMI'XW?PGJCXL_$5A-IUQ MN/&YU^0]?[PQ^-?>2K>WP,:\=6K2^[=?FC\@CA_J>;U,'+12;A]_POY/E?R. M+LKZ?3;V'4+0[9K>998F Z,IR/UK[G\'>(K3Q3X7T_Q#:,/+O+2.9>>F0"1^ M!KX:U;3+K1-6N=&O5VS6MP\4RGJ&4X/\J^G/V0O$EQJWPP;2KA&_XEEZ\4;D M<,C?.!^!)_2N'/Z,:F&C5CT?X,]C@W$2HXZ>'E]I?BO^ SURBD7.T9I:^1/T M@**** "BBB@!I;'6O,?VQO%W_"&?LT^,-:CDVR-H[V\3?[4N(Q_Z%7I[?=KS M3]J;X'ZC^T+\(;[X:Z7XB72YKJ:*5+B2$R(Q1MVU@"#@^HZ>]=> E1CCJ3JN MT5)-O?2ZN>;G$<54RJO##J\W"2BN[::6Y^2A '45]I_LN:;_ ,(9^PCJ6L$; M)O$OB)E7_:12J?R1J\3^*O[ G[2OPJ,EU-X(;6K&/G[=H3&X&/4I@./^^<5] M*^+=#F^'/[,'PW^'-S;-;W T_P"U7L#H5992NX@YZ'RM][_X!K=13'*G&:4R*#RP MJL-2LKIMMM>Q2;6(8)(&P1U''I7R9^D'S=^WS_P4A^''[%BZ?X5O+==0\2ZQ M:RS:?IX?Y45,8:3'.#SC'I7#_LU?\%F/V=OB-\.CXB^-^OV_A'4UOIHEMY$= MEFB0@"08!(SNQ@\\5XU_P6J\%?#_ %[XC1R^&?@1K&M>-6\/K]H\26MTT<5E M$21$4!^5WR""!SBOS'\]>!B,;BZ>+DJ;NE9-=%?57ZW/U?)^'>',9P_3>)3A4DG)2NE*5M++5KE MN^W34_1G_@JA_P %$OVL?A+\>/#?A#P1XJT_1_AKXNTV.\\,:]IWS3:HC)AP MQ/*@%NG&>.:^;?V>OC5\?_'7[3%GX.^"/Q7FTWQ=>:;?*M]J5XY@D0(6)(.< MO@$@="_#][I>@:3;>"?"\=O<^%;RQA8S:9;X,*UCV^'8XJ.1U\!A,/"52[BW[KNHK[3;V>BOLVWT.H M_8K_ &TOVTKWX[3Z3HWQ7U_QAKW]MBWDTNXD+1W)C9@PV'HN-W/'J:_%]/OO$NGK9ZA-:QO?6JMD12E067/?!K\0/%_PO\ $_PM_:$A_:$_8YGU MBVOIG\ZXFOVC;['/(Y,@Q@;D^8CFOMSX@?\ !9_PK^SMJ/@KP+\4? >HZUIA5+"RG.K)V=NMTOU/C^()X?/HX;#Y?2C M[2*DG:/+)OS?PM::6;U3L?>V[G=D4!\]Z_'_ /;P_P""RWQ=\:)X5N?V?O[> M\&:=+.XU"X"Q-]I;<-@)(.T8'3OFOMK_ ();_MC:U^U3\'[D>/;_ '^(M%N/ M*N?-0+++#_#(RC Y]A6U',L/6KJG#6^SZ,\O,."\XRS*Y8W$)+E:YHZ\T4]F M^EMNO7UM]4#&.*CGA692C*I4C# CK3E*D8S3ACL*] ^1/)_BQ\*_V?O"6D7O MQ)\6>![=A;KN>.W9D$[DX5=JD#)/'ZFOG?QQ^T#XT\5VC>']#2'P_HH&U-+T M=?+4KZ,PP6]^@]J]J_;KUS[+\/M+T-'.Z\U3>P ZK&A_JRU\N#&<+7M8&GS4 ME.>NNE^A^?\ $&*='&.A02BK*]E9MO75K41BJAF=QZEC_.N%\;?'SP1X1,EI M:3G4KQ>/(M2"BGT9^@_#)_IT'_!1OPYI?PFT?P/X)\.W5Q'>:GH\E_KDGVAL MS%B@52,XV@[\#'US7S'X1T67Q-XJTOPY I:34-0AMD4Q^?9QCL1@<:\'32YE:[WU:3LO2Y^M7[-'P)\#:+\/=!\=:KX:CFUK4M+@NY MY+S]Y]G>1 VU 1@8SC.,\=:]C4*J]*IZ)91:3I5II-O%MCM;>.*-0.@50H'Z M5?Z"OC:M256HY,_=\'A:>#P\:<$E9*]N]@XZXH.>U HYK,Z@HHYILIQ&QS0 M;N::TLFXJJK^+56.I6&[G4(<_P 0\P'VTS&/$OB\:>?"_CQ[:.'4K5Y+.*&W91MF#&?=(,Y4<[=_!WPSXE\(6]Y_PE'CM[I)= M0NVCLIHK=%&ZX9A-NC&\/ZIXV;6[T>*YO#Z:>K-_9S:?=R- M,5W';Y@X MC(7=SBB2Y,,9EF:-57EF9L 5Y?K_ (+\:W_Q9L_$EC\4YX;)-/NE#+9VA%L& MEA(@&5RP8*?F.2-G49YO?'_P[KWC;X::IHWA+Q-LGEL94_L^,0M]M)'$99_N M?4$52P\/:0CSKWMWKIKUT,98ZI&E5E[-WALKKWM+Z:_UTUT/0Q+-C[J_]]4B MW+.S(AC)3A@&Z5@^'[>_TSP^VFZKXX_M"Z.[;?S1PHRYZ?*@"\?3GO7'_"_P M?XM\.>-O$6K^(?B!)<6MSJJR+%)!;*-07[)"GFL4&4*LI7 P#Y><[I?77^O6R/3FN74JK>6"S87Y^M.,DPY*K_W MU7F/Q/\ !_B[Q+XPT+5?#_Q&DMK6WU;S&ACM[5Q8C[-*AE!=GS+"JV1&-I&NAX\G\/Q#BI1Y)R47=)[]_0*&*]K3A*<7%R5[::>O8IZO\ '#X= MZ)K$VD7^N8:UF6*\N([65X+:0D +)*JE(SDCAB*Z#7_%&C>%]%F\0^(-2@M; M.! TEQ+)\H';'J3Q@#D]J\?\)?$'PI\.OA]J'PU\8Z3)>:Y'>7B-I7V-Y/[8 M,LKLCJVTJRR!ADD\^#O#VLC2U^SZ-K5E>ZEI5JPD*0IPP55^_Y M9(; '.RNF6#BJL8V:3=KZ:[:KU^:/-IYG4EAIU+Q,2R6=Y:26\OEDX$@615)4G^(<5T;RS1(7=5 MVJ,GDUP'AKXH>"?'GCR&3PKI,=XMKIL@N/$4D)C%ON=,6ZEU!8MC<0#@;!GK M7::QJ%L^B7SVMU&YCM9#\CAL?*:Y:U/V*='275+MG)':_-__ (+N?\$C_BE_P4%U[X>_$;]G6VTB/Q1I4TND^(+C M6+X6T(TUP9(YF;!9O+D##:JLQ$W X-?I!3)0C*5:@#\J?V2?^#8']G+X8DGUKPK]KW_@L+^PY^QI>WWA7QU\3UUSQ1 M8,T79:O_)?-H_3^$_!_COC! M1J83#.%)_P#+RI[D;=U=XO\ 7-3>9P#D MX! M#OHR<+Y=4A6S^M+$R_EC>G3_ ?/+7K>-^J/Z3/^"4G[PTO2[&6[U"_NI L=O#&A=Y&)X "@FOYG_P#@ MK7_P50^(?_!1+XQW%GHFH76F_#30KN2/POH&\K]H4''VRX4?>E?&0#G8I"CG M)/WY_P '6O\ P47?]G+X$>%?V//!KF35OB5=->>)/)EVO!HMLZ_)QWFN"@]" ML+CO7XMV_@?QA>6T%S'X9N\7$*R)NC^8!AG!]#]:^,XMQ6*IQA1BK0EJWW?; MY;^9_3WT=>',HS"KBUKR=XIK5*+_F.?US2EUK1;K2 M) ,7$#1_-V)!P?P-?0G[+'P1_:W^,7A*R\-_"_\ 9X\2>+WTG07N9]0TRQ=8 M[BW@(1G0N KD95=JDL6Z"OJ[_@B#_P $=;?]K+7+O]H/]I30+ZW\$Z#J$::! M!!=0A=5U"":-Y(ID969H ORMTW$D9X-?NI-IW[/VI6'Q2R#26>H6[;+_ $C4 M(S#=VOGW]K M[]A+]FK]NWP=KE_I&B1:;XWMV>>Q\2::L=M=75PL!2)9G(S)"<(#GIM'3%>M M4X<>&IMX>?-UL_T:_P CYO!?2&I<39A2AQ%A8T5\/M:-VDFU;GA*6J6K;C*Z MOLT?G+\;OVA/AE\!O#$VO^,->@^T>2QL-+AD#3WD@'"*HZ#. 6. ,\FORW^' MGQQ_:S^#_P"ULW[;GPB^*T>A^.)-:?4&6W:3[/+&6S]CF' E@* 1E&&"!G@X M(]._;)\">*OA+\5KSX1_$*T6'Q%X=O)[75XEG$H216 P&!.X'J#W!KR'//!Y MKY:&=8S!U'[))/9W5]NFI^T<1>'/#/$E.%+&U)5J:2E%PDXQ?-%-27*]='HV MVK/;4_JL_P""9'[?'A'_ (*'?LLZ+\=M(TM-(U@[K+Q5X=%R)6TO48\>9'N' MWHV&)(V[HZYY!KZ*!STK^:S_ (($?MKS_LH?MSZ+X(\2ZXUKX3^),D>@:E#) M)^Z2]D?%E,1T!$Q$>>RS'TQ7])UO)OZ>F:^^R?,O[2P:JM6=VGZJVWWH_BOQ M(X-CP-Q-++Z,O!5GXK@??))'&)$=[&S+)(W0?NU&>3Z5 MZF%QWLTHR/E:O:6>GW3PB6!;6YVLT4P.!O1@0#CG!/&X5)8?!_68?$*^']3L?"]K.^W; MYEG;X+$GY!A>6P"<=<"NZ6+I7:1\Y'),8DGT?E_2/#]/BU*^9048!FZ$1D\\%PNU<*<]LGIVS7H5[\!-+T>ZT^[$=L MU[/<1QM'#;*EJ-H))<9!(; &!W/3&:] U+6_^$+\.V=QK&B1M!&-M^VGJ!%: M* 3O"M@E<@#C)&U@5K?UK^J[&QX<_MA]+A.NZ=; MVMSMPT%K*9(U&> "0,\8[5:N;.SNPGVJW63RW$D>Y0=C#HP]"/6L_P />)4U MC3(KZY2.UDER5MS<*[!<_*3@]2,'VS4&B^/]%UG4!H\<<\-X6D$EM)"_!G7/#NI2VFI:;)#,K$+\OWO<>H^E?;UQ; M6ESM^TPI)L<,NY<[6'<>AK#\>^"[GQGIG]DK>PPPLK>=YEJ)&;*\;2?N<]P, M^F*[,/C)4K1>QX>99'2QG-47Q>G]?>?$.G?"KQ7JEK)>VS6D<,4BQO)=WB0_ M,P) &\C/ /3/2M#3O@QXKG<)_:6EGYL!8]7@_P#BJ^MK7X->#Y/#$=GJ_AF$ M7&T/<0V=PX1Y0I&02>^3^?M6-X>^%UII%C<:FWA_0XU:-I8Y+RY:86KAO]6Q MP 5"C[VM=7]H7;U[I7A M?[3^#\5?A_QG_1]:_P#0+>N[+?\ >7?^6?\ Z1(X,R_W5?XZ?_IR)\XZMKNM M_%N^;QGH/PP\(26/2TF\0:5]HNKJ,=&8AEV CD+\V ?PKL[/X[Z4OPNNO%TW MAHQWEC>KIDFBQ2*5-V2JHBO@#RV#*V['"YXR,5YWXE-G\.-:N/"'@+XE[["& M4K/:KX?GO3IG.3&98B =N?NGY@.#7?:#\._A?J'P3GL(/%WVK3KR0ZA>>(A( M$87*L#Y_/$>PH!L(X"[3WKUJD*<4G->[=V_2W_! M/'/!/[2'@ZU^(EPNG>#/!,2,G5V)(PG'?D8Y\8\*?#7X4 MOX[FN]0\4VME;ZE(8YM;A\,W%M]L5SAE661C'#OZ%@ #GC&17LGQ^\'>![71 M=/URZ\2QZ)=6=M]@T^-K5KA;N'C%OY*G<^, @J05ZGC-;8B-%8B"MKK_ #6\ MO/?>QC3]IR/F9A_ [XIV6EZ];>'+OPCH-K!K%UY-O?\ A_3S:C[1M+".6,EL MY .'#'G@CO3O&7B*_P#BQXBNG\,?#_PO=V>E7$EHNH^(M,^TR7#HY5]@#+L3 M<"!DDG&<"J/P!\.^$-3\76\^L>*E;4]/W7%AH;:5+9X;!7SCYI+2D \8/RYR M11\34T[X;^,KRS\!>._*EOICZ?I: M?N65@3$81@8#$$;3R"#U&"?-D^(\Z^-#KJ?##P0U[YQE^Q+IC"ZSUQ]J^[YN M.^S&>/>O1OAEX&^'?B'X;:PK>)O[:77P4U[4-IMV5E7 CV'F'9G(#<@G)SFO M)VL/"2>)6C?XJQ_V8K>6WB2/PS.?EZ']]GRL]O-QM[UQXJGF4JD5@%!6G'VG M.IO]W;WN3E::G?;FTL=>%E@U&7UGF^%\O*XKWNG-?[/>VIZMX^^.%A-X*T6; MPQH]K>7'BBUDFM[?54W0P0H!YK2J/O;2P7:.K'J!S7)?#_XD3^!M0^SWGA7P M[;V.I2+;27?A_1_L*X;X::1X3\3>*;>Q\4>++AKF-F MFTG2YM!DL([NX525)9W?>5^\$R.>>0*VITZCJ1E3M[)W]HN5JUMNOR/,OVDOVA?A)\.O@IX;;Q1I_VR>S\-Z5>^*O$/BS5]2OHY M+Z[@\R.WMK2"=-TI7+LY950$#!Y(T/@G\#]>U2UM+NTBU&WM[N.2VEF+V\R^< 1N8,&)!!&*D^/WPC^%/BKX?>&?!WBC MPWK-IXH7PEI]CXHT'4/#*:I8WIM(]D=Q^YN4DMW4Y42@X9>-IQQJ?!/X6?"O M1_@_X@T'PGX2U[7->^PVVEQZ1:^'(-+L=*L3>PW,\:6\EPSL91#DRN3O* #' M(KZSF]Y2O^[NK?%SWG?J9]Q\ M7/A_X4\;6MEHGPS\"Z3=W,D62JQ79O+JLNP\!@KCCJU?4GP:T;PKX?U_XVN2RQ7GF;C<,]E=LTC'U9B2>F#Q@8Q7SE6GC(3G+$K?FY-))\O(_BZY>>[BUS;=L?W:^0?AMX ^,MC\!_ O MB3P-XFU35H;OPJL]Q;-9:9FR\I$,4<>ZPD>0$,XY8MA<#(-7U^ZEM[_ %+4[U[&7XU62VFZ]!BE&TV08QJD?[I<_NO*.#G(J8RQ5[OD M^ZGY>0\+#EBU5Y_OF^_:WD:FLG]M'[=I$-GX*\6:E8WEG#)->)_8T/\ 9RR& MY#-+%+IP_ME6,%JMS\+?&VK2M<67]HV>GG01%;0 M2Q,TS[[BQC$Q1EB7RXP6*L1PRE1G_P#"K]8@2:RU#Q/*JR7MQ=O'=?&2TS9^ M;)^\@CQ9?NXPRX(&3ARN[' G@\!^,[R2"*QUA]/:WURUU*&ZL_C!9?//:A5C MB(%DV8.C&# 4_,#G<1V4 M2FZ +&R"LKM+R.C!@3P :CN/ ;77C2+6[/Q!9VL:V]V)M-A^,EL;-_.NI+YE MDA^QDR'?M53_ QQ*OW07D+EH:OW_ +Y_YFDNN_ML75AJ^HMX M.\9Z=':S3K:1ZI)HTEU_ M$*Q\->*/^$ET[1[G49O^)I:V^C3&-$3*M*O]G*B]LX8Y+80OM;&9I_P[F$(OA[X[L/% M-GK=OJ N/$DMTD.J?&"UDMH7E3.V-#9 B-CM 1/FX'09-$98B._)]T/('&@] MN?[Y_=N9/BY[Q_V7?AJ=1O6N)QX\UL37#QHK2L+Z]&XA %!/7 'H!7UA\%C M_P 49:?]<5_D*^3?%2SG]ECX8M=FW\R3QQK3O]DN!-%\U[>GY' =>>&P,CF MOK+X+#_BC+,_],1_*L\Q_P"1A6M_-+\V7@/]QI7_ )8_DCK(R0[X_O5\AZ?J M7[7O[.'[6'QL\5^#_P!AGQ'\0/#OC[Q'I.IZ'KFA^--#LTV0:-:61???_>J2N,ZSYM_X:__ &U/^D4GQ _\.-X5_P#EC1_PU]^V MIU/_ 2E^('_ (<;PK_\L:^DLC.** /B_P" WQ4^+_Q1_P""J=U?_%O]F;7/ MAK<6_P !?+M;+6_$&F:@UVAUG/F*UA<3*H!^7#$'/;&,^D_\%&?B-XW^!_P4 ML_B;\&-%\,#QI?>,-$\/Z;JWB/234_:"U M?XW_ :_X* :=\>O!?[*WC/XB>'[OX1/H,\_@^;3PUI>#4_/"R"[N8>#&<@K MG\*\K_;W_:O^+7Q.^&/@_P (>*/V%OBAX-L[CXQ>#C)X@\12:2;2WQK=J1O^ MSWLDG.,#"'D\XZT ?2?@S3/#HO?"MGX1\*:E:^+K.\A/BB]ET^:-P@C87)N9 MF4+.'.=OS-EBI7@5[3J>K:?HNGR:IJ]_#:VUO&7N+BXD")&HZEB> *^4?C9X M1^*?QY_X*&3?!+2_VI/B+X!\/:3\(;76H[/P+J%I;_:+R74YX&>7[1;39^1% M QC%="O["/Q#\,W]CXI@_;2^+_C1M+U""\_X17QGKNGOINI^7('\F816,;\X MX.X -M)R,@@'OWA/Q_X/\<),_A?7[>\-N0)HXR0\>>A*G# $<@XPPY&16SSB MN"\*Z9XQ\1?$A?'VO^"/^$?AM-)>RCAFO(IKB[+R*^6,3,HC3;\HSN+,W0#G ML=>UW2_#>E7&N:U?);VMI"TMQ-)T55&2??@=!R: +G-&!C%\*^$XKR\O$EOKO6-!6X\PAE M.< @%CCJP.?8X(RO''[(_P +M2FTV'P+\+?!.GI;W\,NI->>'$D9X ZEDCXV M@LF]WK5P)98M@F*M_"WEGBJ/ MBWPMH/CGPIJ'@?Q38B[TO5K&6SU"U96 EAD0HZ9!R,J2,CF@#P>XT;_@G]'X MQAO96^&<-G%8RPSZ?+:VZR-,6C=7YY4(@;>"/E#*3@==N7X(?LK:;X^OK_6/ M#WPYATA=/2VBTV2TMEECN4=C+(Q/0;7C&WMU.,C,^L_L"?LS>(KR34?$W@Z^ MUB>9IFDDUG6KNZ^>:%8)9 ))"!(T:1C<.1Y:D8(%5?&G_!.?]D/X@^*=8\9^ M+OAC)=ZEKQ)U.X;5+I?-)D63( D 4[U!X SSG.: )- ^'/[+6E>-]?T]U^&O M]ES65K$V@PPVOFP3@S*[2\X*N,*JD?\ +-O0+(=K(&7*-R 5S3_VA?V.?V<)O",WB^^_9\N/%ES86 M=G8VNAV-U<+O@CE54"JA/^K#%\[20$'(Q0 7/PK_ &2] \6W?B_Q*GPFMO#2 MZ?Y:6C6]K'(DV4<.\C.1@(Q/RXR)%.. 3U?AK]EKX%7]_=^*#\,/ VH:/J%O M#)I2Z=H<>-GSGS#)E@^Y"F"N%^7..!V]* //_"G[(OP6T[4]6F\0_"7P?=Q7VJ&?2UM]!C4 MV]KY:*$;CELJ>>^?RL:'^R1\#-+%\=>^$'A.Z6?4Y);4QZ#&GDP-C8AXY(Y& M>^1[UZ9;QO S-YN=S?+^[/"^G\Z<[LZ[&<[3Q_JZ /*_!/[(OP7TC2I+/Q5\ M(_"-Y>M?74RS6^AQ(L<+S.T4?W>2J%5)QR036_\ "/X+^'OAKHMA]N\-:#_: MMGYL:ZAI6E+ $1F;:JX&1A"%/3)ST!Q79VRRVZ_/-N8]6\OKZ4Z4M+&5,F=R M_P#/,T 6LYZ457BN(H(56:8DXQN88R:L*P894T %-D4,F,4ZB@#YK_:\_P"" M=7PY_:%@G\7>$(X?#_BO;N^VPQ8AO6])E'?_ &QR.^:_-GXN?!GXD? KQ;-X M*^)GAN;3[V/F-F&8KA,\/&W1U/J/QK]N&RPX%<7\:O@+\-?C[X0D\'_$KPW' M>0')MY^DUJ^,;XWZJ?T/<&O:R_.*V%M"I[T?Q7I_D?!\2\#X/-[U\+:G6_\ M)9>JZ/S7S3Z?G+^SU@?"K3\C^.;_ -#-?0/[/\JQ>%_B"[G_ )E9A_X\17G_ M (A^#=K\ =]?4S9!SZ5[9^RW_P3\^%6FWL?QT^($0\0:IJS_;;&SNHO]&L@ M_P R_)_&X]3P.PK:.,I8&\Y]=D>=4R/&<03A0H65G=M[);7\]]CY<_9-_P"" M+_2;Q?^F2'H#_?;CT!K]&_@O\!/AA\!/"D? MA+X9^%H;& )($"(@55'RJHZ"IMPKP,9F.(QLO M>=H]E^O<_2LAX7RW(:=Z:YJG6;W^79>GS&Q@CC!IU .:*X#Z0***"2.U 'F/ M[4'POUCXC^#86\.6:S:AI]UYL<6<-)&5(90?7[I_"O+_ (;?LG_$E]QZT$XZUZ-'-,5A\-[&%K:ZVU5SP\7P M_E^-QWUJK>^FB=D[?C^)PNJ_L^?"[7?%$WB_5?#GG75PVZ:-YF\MF_O;1W_3 M]:ZS1]#TK0K-;#1]-AM8$^[#;PA%'X 5=!I:XJE:M4BE.3:6UVSU*>%PU&;G M3@DWNTE=@.G2BBBLSH"BBB@ HHHH **** &RKE>!WKQ']J7X->//'^I67B+P ME;+>1VUJT4MF) K@[L[ESUSTZYX[U[A37 QTKHPN)J82LJL-T<>88&CF.%=" MK>SMMOIJ?%O@7X?^)?\ A9^C^'-;\.W=M(VH1F6.XMV7Y5;+'D=, U]G95%! MI#" ^XJ/]ZN:^,_Q1\/_ 9^%VM?$_Q/?0P66BZ?)ZQX0_;*FTN/X> MZAIDEM8Z;J6DB6WLIV(VOYC#(!7(+#U&<5YO^U1\#_V._%GQ2\0>)M%T'[9I M]K8FUT]],O-MN 5^5X0.%4#'KU-?'UO:8RM&<)/EUZVM;_,_=,OJ8?AG!RP. M)H*51V6BYU-MN_SBO=LM.O77O/ O_!1OXD?M8_LVV?B6ZU:WO/$%UK%TFV.' MY8&5B$;8>G&.,XS7RS\8/V5?B!XG^+-O\0OVG?B1_;&C94NP58SL+$K;JA.3 MD\<<8-=]^S!\/?AE\$_A#>ZO%8W4,UKJ4C-):;C)< D>7&3RHP:\I M^,%WXV\3^.QXAOO%AU***9OL-A?*P:)Y7 ' )7A 0. .]..(G0P\H4Z33B]6 M]M]&G]K]#S\)EN!S'.J>LO-W/J#QK\=] U+X;Z M7K7B:RTK1_#>AZ0+:QT^QT\*S6X7;APHRS8 Z?E7QO\ !/XX_#[0?$T\,NM+ M<6-OK\UUI=Y- ?-91\J97&2VUR/8=J]R^#5C>_%"^L_"2ZHD.FQN4FNO+\Q8 M<9^7' P#Q[D@$=Z\9\:?LIS_ Z^,.A_$?0?#MU)X'UF\3CANPJZ-/ SH4J,O=E92MZMM[]VF[>1Q/$YEP]F6-6!CS4I.=/O:VW=W2 M:UON?8-E%M;D5;BW$]J(052Y!!VLP88XP2,_X5\Y>-+;XI?$W MXQZ5X:\57VH3PZ7)Y%Y'?2"-9]Q:3SAD\A=Z@\X., <8KH)?V@M=T/XDV]I ML?\ 8MU9_8[6&:;;]B2%5);;@J5((Z!QD*M2*L]6VE=M=UZV_!'JT:.?\(XK"*JO:1DE M&,6^6,*C=^5O6Z5[N^C3:N>A>$OV5?A5I_B31-0^._C9[;POILCZM=*;8&.Y M9-TBPJ1PG3:,]1[UXCX-_:OUR#]I+6/VEO@W#?Z"!KZI;Z+HK$V:01]/-0'! M38,\CK7T!\&;^T^(_@1O@YXTU"^\0^'[N&?3[S7+JS6$VXW,L31X8Y( &6SR M>F!7GOQ(_9BU;P_X?U;]F?X&:#=?;BB7$-QIK(9M;F\S$;MN/"A=V0.]8XZC M1P^#C6I)PCITUNVDCU.'>(\1F.;5*&9S5:H[I+3DY4G*5MEHE;KLDM+L_8K] MG3XRZ/\ '3X/Z'\2-)OHYFO[-&N1'C]W-M^92/X>>U=Z#E]!]+/6U]GRWL[=CYC_ &\-6$_BO0]# M5_\ CVL9)F7'=WQ_[)7B7A;3'UOQ-INC!=WVJ^AAPJ\G@_MA:P=3^-U[ M;JWRV-K# /\ OG>_'9%+?S KZVC^[P:?E<_ M#'XY,QZ'H-I:JN>C,#*?IQ(*\Y_8I\* MCQG^U7X%T-H=R#7([B12/X8093_Z!7MG[7'[#G[6?Q>_:0\5?$#P]\-_M>GZ MAJ'_ !+[@ZI;KNA5%1."X(X7H175_P#!/K]ACX\_"']H.W^)'Q9\&QZ;8:=I MEPMN_P!NBD9YY $ 0G^%G.3BO1CBL/1ROE4U=1VOU:/EYY/FF/XN=6=":@Z MM[N+MRJ7?:UD?>ZK@9IWX4#I17QI^[!WZ4444 %-F&8SSBG4V7[E 'G/P\\$ M:#X@T5K[4[=F99$5=I"_\LD/IZDGWS6A=>$/AM9%H[J;R]K;69I. ?3..M3_ M B)_P"$9D'_ $V3_P!$Q5QWQ*.J#69@A?R?/DV[?][G]S4F_(ZH>$?AH\7GI,S1GG>KG:1]<4D'A/X97.?)N#)_USD) MQ^0K&^&7VAK-8M;9_L378V>=G:9<' .?^ ]>-V.^*Z[Q>(TCC-F/]*VM_J?] M9Y./WF/PZ?[6VHJ.5.IR2*\K&6OA;X7^;]G2[S(/^6?F?-^ M6*)O"GPQ@;9<7/ELW17FVD_I6UJ$?AX>&FVB(6JP_N3%_>_AVX_BSC&.,_AC'MBE2YJGVF.O&G1M[D7?R-9O"7PSA7?+.R+TW M.Y _44)X2^&DT1FBG9D_OK)D?GMJ7P1Y,DBB^VY$9_LTOC[F?GV^V[T[;>U6 M=7&GIKP2('R6:/\ M(1CY.IV;O?.,_[/7BIE*?-R\S^\N-.DZ:GR1U\OZ_X8 MSX?"?PON,B"Z,A'WO+FW8_(4'PE\+_-^SBY_>?W/-^;\L5J>*T*VT,FF ?VA MYG^A[?O$?QCZ;<^V<>U2QIX>_P"$65IF7[+Y&YF;J#W.>N_=^.?>I]I/E3YG M]Y3HT^9Q<8Z*^W]?U;N8TOA/X96P_?7/EYZ>9)C/YBA_!_PU1/.DD95_O,QQ M_*M3PF$DCD.I _;_ )?M(E_U@7:-H^GTXSGOFJVE)I[:_L('V-6?^R^\9?C> M%[<<[<=M^.E5SR3?O/3S)]C2LGR1U\MO7^M]"M#X0^&LR;X9V=?[ROD?RIL7 MA/X7SR,EO<[RO+!)-V/TXI?'XD1;L:&%$C6>;[9TQO386]\!_P !SQBN$\'? MV^/$MNUIYWF>;C#9_$?EU]LUM1A.K31'SSG&T8S^N?]K=6WU>IS17M'KYG/]D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %1RH[MP./K4E% '\__ /P<@_LFM\%O MVQ[7X\Z!IGE:-\2M/^TW+QQX5=3@"QS@^[IY4GN2Y]:_.TDYQTK^D[_@N'^R M8G[5O[!GB:'1]-^T>(O!B_\ "0Z#M35EU>_XZ_,_T(\$^/LMS#PYIO,\3"D\)^ZG*I)17*E>F[R:^Q:/=N+/G$,Z M'AL;NOS8S2PR/!,EQ$V&1@5([&OU5^)/_!M_XQ\#?LM^+OBIKGQ-M;CQKH6A M3:CI7AOP[9E[>8PCS'A>60AG8H&"[5 W8Z]_RIYZFO%QV6XS+I15>-KJZ_KN M?J7#7&G#/&'MGDV)5949*,FE))-JZMS)73UM)73:=GH>T> O&6I:-J&D^._# M=ZT%]8W4-Y:S1MS%-&X8'\&6OZ8/V3/CSI/[3'[.WA+XWZ0R[=>T>*6ZC5O] M5<@;9H_^ R*X_"OY;?A5JOFP7&CRODQMYD2_[)Z_Y]Z_8S_@W+_:<>\TGQ7^ MR?XBU3+6;?V[X24F?J@.E(YVH3CM2K]T4RX!,# M@?W37Z,?Y\G\L7_!P]\78OC3_P %T=5\*^(+E9-)\&G0_#UO#(P9$"PIG2OT7_ &W?V1?V;K_]M3X@?$/Q!\$O#]_KVI>(/M=UJE]I MZS2R/Y<>ULOG& %Z8Z5X'\?/V6/"5QX9O/%GPZT[^SKZSC:>6UA8^5.BC+8& M?E8 9&, X_&O@^(I_7L0G!/W+JW?7H?WC]'FE2X)R6I#&RC_ +6Z=2,X_93A M91FW;17O=72;=[+4_9/]F/POI7[//[%?@KPWX?U"/4(-*\)VC6]S/8?8S6?LB?M MJZ7^V9^QYX%\:Z!?&98=/6RUBZ^W1S-@:GJ MNI:S<+>:K?27$BQJBR2-DA0, 5]OAW'ZO!1VLOR/XDX@6*_M[%O$24JCJSYF MFI)RYFVU*/NN[UNM'NA^MW>F7^IR76CZ7]CMV"^7;^9NV\8//N:FM?$]YIVE MPV.G0QV\UO=&:.^ARLQR,;2PZK[5GBFMCO6IY)^6_P#P51_9&M?VDO\ @H7> M3^%K[2?#S3>#-/U'Q1/!I;(US=/-/&9@JX661U1"S @ XSDYKQ/Q;_P2?NK; M26G\#?%H7%\BY6WU+3Q$DA]-ZLVW\0:^POB/\5=1^+'[:'Q(33?$5U=^'O"- MIIVA6L,D41ABOE5Y;H1.HW$!G4$,3R>V !XW^V9^U_;_ +.&E6NA>'-.AOO$ MFIPM):Q3M^ZM8NGG.!R^#GI7Y_G6%P=/&U)M6_S:/[<\*\TSK%<%X*# MDVTI)72^&,Y*-]]$DE?L?EO^T/K?CCX&?$2#P/=6=UI/B3P[JEO>S,V5:&6) MEEA9#WY"L&!],&O[*/V>/B+:_%_X&^#?BQ9[O+\3>%=/U6/=UVW%O'-_[/7\ MAOQW\3ZI^TEXK_X3;XPF#4M36U%O'=0VZP%(@68(/+"Y +'&WPWBL'4PKP]"+3CJ[VU;_X;\#\5 M\<.'N(L)GJS?,JL)PK/DIJ-TXQ@KJ+35NK;:;NVWI>Q[#1117TI^&A1110 4 MTH&/(IU% $,5G;6SO-%"JM(V9"J@;CC&3Z\5@W5WX7T77DTU]&C5KP2WLMUY M*[%:/;EG;LV#Q]#6OKFMZ5H%BVHZO=K#"K*&D8' R<#I[D5X)^TKXF\/Z'JL MFA^&],MX;IY#-J%TH.^25EQM)]-O4=#D5O0IRK3Y3S\PQ4,)1Y]-.G]=P^+7 MQET&W\3K<^!S(TT%UYK7$TIDC>0*4W)$V57@_>&,G\ZX/5/'OBCQ1<;]?U^: M;^ZLDQ8#Z#H/P%<#/JD]Y?LLY;:+GYNBX.*ZKPMXD\;^#)?M'A[5B8WDWRV]P-TYS^'->LB12OWJ^<]7TO(2^LY3#A?"7Q1XM\6W/_ D%U''*JA;*]A^V,OE;03YVS&"S' [8'TKBK4H\O-'0 M^@P&,ES>RJ7;;T?D=WXACU6XTJ2+0=0AMKHC]W<3PEU3GDE]?,/Q3^* M%[;V\W@O1=45M-ANYI5:&,H)B\AM=&!H\WO,\OB',' M#W(W3UOOM_P?Q+EIJMS=SDIG)/S.QR371Z-;7#CTKN_"R1 MLRY/O7?4:BM#YS"IU'=LW=%TZ^$0S)E?]JM*XT6WOK8PW$/S?K^%:_A^"W>) M05[?G4FL1P0#?$<,.V>E<3D[GT,*$53NR_\ #KXN:AX8L[CPQXDF:X:&%FTF M>3),A XA/4DD]/\ ]5>I^$_$=KXETI+R&XA>5?DNE@?CM(+-5^T7.FI>3>0GR*6P""?[V>W7BN M3$4XIZ5X7^T]_P E5^'V1_R[ZU_Z!;UWY;_O3_PS_P#2)'!F7^ZK_'3_ /3D3X9^ M+O[/WQ/?6-+TEM4URQ;29GVW&G6,UQ%>DREA<(T1XE.>0^"#WKVC1_A!XZO/ M@MKVERV7V>_UC6(M1M=)N95!V1F(^5(1\JO)Y1)'0%AGO7E?CWXP?$?5-0L= M:N8=6O)+V>3=;V-_/;QV.)-H@182OSJ.K/DDUZGI?Q<\>VOP4\0ZPVI_:+O2 M=8CL+36)XE8K#(8@TC\;7:+S"I;H2H)[Y]NIGE;,/]AC)=F_+0QCPK#)KYKRV^N7=^=2O[/W?AYGR6]%<\^@\%^-]8U^\M;+PQKDUS M?1RPFQO=-DCCBW#'[V1OD"+D<@GIQ7H'QM^&7C&/1M!U'2X[G4%TOPZVEWAT M^,O-"Y5/])1.K E,''S8P>><>2Z5\5_B/9_$#5+>"XURS-BD\JZQ=:E-*K; M2&E1R8F1\=%4?>&*]4^/GQ4\=6OAG18M,BNK;^T/#$FJ7=OI[F.:ZF"(?LJ/ M@L@^8D[?F(Q[Y\_!Y7A:$7A\+&T*DI\R;EK*6DM9.Z3V5FK'KYAE^89!B(?6 M$E/EA45G&2L]8OW6UTU3U[JS.9^!7PO\:W'B726\C4/LNEZLM]<:EJ%H\"(% M4CRHA)AV9MPSQM ZUN^(='\0?#WQ7K*:OX7U"ZM]2U:>]M=2L;-YUF61MP1] M@)5U^[@C!"C!KC_V9?C+\1]3UC2S>V>H6L&H:TMC/IM[=2SI-&R%C-'YQ+HR M8YP=I_EH_%CXA>-=8\2:DUY>:BT5GK5Q9V^GV5]+;I:I&<*6\HAG=_O;F)&" M,#%;PR.C@**RQ)*E"*5N:3=N:_Q7;;OYG+C,XQ&*QY?V MG7GFO?OA_P#%7QWI MWP[\8W#33:E+X>TN*YTY[S,DL321.QAD8. M]::\:,2'58]4<)TSN$6?*V?[.W&*ZZ>,JY?.2;2YFHK1O5I6[NUK7;U.C+98 MV7M7AK:PES7Y?@=N:W-UVVU.J\6?!WQMIOPE\)Z9:1R7U[X>CG^V6EDV9%69 M6&8^"WCFXUN&RBT_5DA76+:ZNK[5+)K>.V6"42?* M'.7E;&W@8P:Q\(O"&HO<36,VO+-_:-S9_NI+@Q*^Q(V_Y9^;M M#@CG' /-<+\)?B!X[T?Q!:7=K'J%KYVLVMI)8W5[/-'>K)($=-LS,0ZJ2^Y< M8QSQFN">9QPV*IX*H_WM7GY;1DU[M^:\DN5=;7_R.&.0RQU&69I*U"R;YDG[ M[LK1;3EYV3L5?V\OV8_B!\6;?5K;0M6U6TM=6O[>\COM)MGGVM%%Y9MYXXSO M\O\ C5ER,GD5UO[)'P!\<>!/"L.G^(=7U58[+PS+I,%]JBF.YNWDDW^:8\DH MD>,)N.<$]*U?BCK6N>*OB5K'A?5M7OK:PTGR5L]/L[IX/.#1AC.Q0JSY8E1S M@;#W)JY\'_%OB?1?$VI^#K.]O-6L;?09+Z&"[N&F>UF5@%CWMEL2 G"L3@H2 M.IJ_[<]HWE*?OP@JC]V5N5M)6G;E;\K_ (IVZ9+$?48MM>SYG;57YK:^=K?( M\C\9? /QA=ZUINB>(O">KS+I\4<'V.STLW5K<;/XXG'RC<.N_!'>O9/@-^SY MJ_P_U?P78Z)XOU3PW?WGBBZG73[&Y6YL[#?:W3K&D$P>)<#@B,*N6;V-?/?C MKXU?&*7XAZ##;^']8UB/5X899M5M=3N85C=F^=(EB81Q"/T8'IS7U9^S?XKU M_P 7ZMX%U'Q#=?:9H?%]Y;1WQ4+]KCCM+M5EXXR1P2."03712A+!RK2I:<[; MGNTYAY6*X;I9;&&+E!7Q#C--23=N9+HVXORT_,]WCUC]HOPBK0^) M?"&C^++95/\ IWAVY-C=,,=[:X8QY[<3X/7Y>E?)GAGQM\)_ W@;P[X1^*?Q M#\$>'-8M=-LXIM/UKP?'->65S&RH\,S-"P9E<<8*D$[@[+@U]]$;U.!5>32+ M*:4RS6D3,W5FC!S7BQQ5%TW"I3W:=XNVJNMFFNO1(['A:T:RJ4Y[)JTE?=I[ MZ/IU;/A?PM\2_P!G"">&/2_B[\*_W-Y>1M'9_#>*(A1<'Y!^ZZ!E)+# EP& M7>"MYOB'^S5=6\.H6'Q9\"!VM9MLDO@6T9D&Z3NGV_P#W MY'^%)_8VG=!I\'_?H?X4>TP/\DO_ )?_(BY<=_-'_P%_P#R1\.6?Q._9]BL MULA\:?AM"5F+6[1_#^%=KN(RP93!@EBK,"NWA@"&QFI+OXB_LZV30W6I_&GX M9I(\VS:? 5OQ*T$W*_N"R94@9)88WC.6Q7W -'TS&T:?;_\ ?E:/[&TX];&# M_OR*/:8'^27_ ($O_D1\N._FC_X"_P#Y(^%;OXF?LVIJUKJ(^-'PCDG+QS1M M??#R//SQRD.K)&"C[57.2<#*G!934*?$_P#9PNYM+L=0^,?PEO-/?6'2TMV^ M&Z%HV-NW (BVQX"L!(4PP0'^]4F><5F:" 'J:6COG% .: $V ]J^6?^"O?B+0?!_[+.B^ M)_%&KV^GZ;I_Q;\'7%]?7D@2*"%-;M69W8\*H ))/ KZG)QR:IZUH.A^)M/ M;2O$.C6M]:R$%[:\MUEC8@Y&58$'!YH ^2_@7^T#\$?V@/\ @J?XE\0? _XK M:!XLL;/X$Z?!=76@:G'=1PR_VQ'U\9?#7]B' MXW:_HDUY%O^"KVOV?AC MP[8Z;%)\ ]/>2.QLTA5F_MFY&2% R>*M_P#!)(#_ (8#\$Y_Y_-:_P#3Q>T M.'_!0/QU_P!(\?CY_P"$S9?_ "97A/[:/QVU/]JOQW\ ?@SXR_90^+'@K3=0 M^.VGR3:MXITN"VM6>+3-3DB7,5RY9EE5)0C*5/E"_&5OXDT'7]"L[6XFBNHK>XMPK1W4AL\UE%I-E)$9KAHVB\R0N[8 1W^1>[9SP!3 M?BW^T)\.?A+KFA^!=8\3:;_PE7BNX:W\)^&Y]02&XU65<;_+#%]-M;;PA?SSV+PW+R6,,)4L(G"[\@L O1F! /M7PEX[\4 MS>)_^$)\?>&+73=0FLVN]/>PU W$%Q$C*L@#,B,'1G3(*XPZD$\@=?@XYKRO MX=>'O$G@OXQ2:3XU\>7/BZ^O]!,UMJMW:Q02V,4?[ M-/C"36%O/+P,;_LV4W9SG Z4TKBD^4\WUKQN+>VT_XQ>-_BQ\5(]6O/B9#I MTUKX/U1&L-*4:G';PZ;;RI&5D >W\I3A_E(HYFG76K[3=9%U',1@RQL@;:Y&07&&.<$\FM_=MK8RO M+I<]"T#XT_M?^//C?\0O _AB[^&ECX?^'_B&&V-Y?07DUYJD,ME;W7EA$E5; M=HEFYE)D$C#;Y:#+UQ?[/'[9'[5?Q!\6Z;/\0O\ A7T>A-I_A^]OH-)L;LW4 MRZO)=1111R/,$C\EK;'/VB?B M5H>BZW=R6MQ'I5ZMG/]"_9Z_9#TW5KKS!<:QI.CZO'?3B3=O\ -DVKNW!FW?,< MD]^M3RQUNPYI=F>E?"C]H[]HQ7\.^)OC'-X)O])\7>']1OM-TGPGI]REU:O: MH)%!FFG9;CS$SE5CC\ML -(/FK+_ &5OVO/VB_C'XP\,W_C7P/I\GACQEI[W M5M)I?AVYM4TC]T98Q]MFN'34%*_(62& ACG:5Y'-^&_@A_P4>\*S:6^A_"/] ME>Q_X1_[1_PC[:;8:PLEEYYS-@' 0OU;:3N.-= ^/_ (UA\2PZMK4.G^))?%4MQ=:=]EUJYMK9HO,8J L:("I!63;\ MP;FO,OV*='_X*9^)(/CWX?TK0O@'>6]Y\>->B\36FJ#5Y(9;QK6Q$R1C@FW* M[0-PW?>SVKT;2_V5OV^-$\":G\-]+_9W_9#M=%UD@ZKH-IHNK+IMX0Q8&6+ MWNS M06L&IQ%S#J%FC';"ES$D,RL <"5E))5JV/B[XT^,,/A'XW:GK6H>*_"VJ>'O M!V@W&AZ9IOQ"-PZR$R@R12!E5&E$:!BP7)))ZYK2USX#_P#!2CQ-X=N_#'B7 MX*_LCWUK?:9;Z;>6-UI>LR6D]C )O@#^R1J$FI65O::C#>Z3J\EK\R30O MBO\ %C2?"7C[PEJ/CSQ-X)A7Q?X>TF!/%.M0:AK'A^RO+E(KG4!$_&7P_3XL?$+PW<^'];L M;W5K#5?&!OI[2U^SN_V>WU&.0R&.4C<2S;UQ@@9KMOV%O!GBW2? 4OCG6_C! MKGBBS\16MK):6VN:O+?/8S1>8DI621F.'RIVC &WWKRO1_@7_P %)?#7@F[^ M''ACX1_LLVN@ZD3_ &MI_M'_##1-3\ M)_&7P9\*]"TB-HY-!L?AI!>1*LC%_/,JW!*@']WMV\YW9[5,OA>J*C\2T+W[ M67Q,U#X;VWAF2P=E_M#5)(7V^@CS7>?#76Y]=\.PW\_WGCS7BO\ P4'_ .// MP,?^I@E_]%5ZU\$\_P#"&6N?^>*UB:'94444 &.]-D^[3J1\[>* /BC]J?C MX[ZZ?]N'_P!$I5KX$D)X ^(DY[>&T7\W-4_VIB&^.NO$#_EI$/\ R"E6O@D3 M'\-/B--CC^P8AC_MJ:^@_P"86/\ V[^A^9_\SJKZU/RD>:/GJ:^\/@BI'PD\ M.A@0?['M_P#T 5\(,GP:!7X5^'5(_P"8+;_^BQ6.:?PX^K/2X2_W MJI_A7YG39 X-<=\8_C#X<^$'ALZWJ[>=<2_+8V*-AYW_ **.Y[5ULY ()_/T MKXT_:NL/&UK\6;RY\6/(]O/SI,G_ "S%OV5>P(/7OFO/PE&-:K:3T_,^CSK' MUPPK::A;-B]T_S=QCST8' RI]<= M>*[P'/2O@'X=?$'Q!\,?$\/BKPY<;9(OEFA;.R>/NC#T/Z=17VY\-OB'H'Q) M\*VWBG0)MT MGN*_6B3[M?#_ ,7/^"%W[*_QS_:#\2_'7XE:YK-Q_P )%>1W:Z1:3>3'!.I! M9PPY.<=/>N3&4ZU:"C3=M=3Z#AW'9;E^(G6Q4.9\ONZ7M*^_K;9]#\Y_BM^R M!_P3G^,_PE;XZ?"3]I?Q5I\UNRVR>&]:1&N(I C%6X .&VX]#TKS?QIJ'A_P MI\!=-T[X?:_+=V=O#Y=Y/<0E9)F,G[XG'*[0.,#'2OHW_@I'_P $^O#W[-OB MZXB_9IGN+K0H-.^U7^FPR-/-9R@E6>=B"#'DKA3R.:^/M,^$OQ^5=)AO=$M( M;2X3SKDLRA'AR2&CBQN7HLGSG6S2,EY&]XS2$?-( !\X] W'3M7O'P!T+X= M:+J4GBCQA0H4?0@^U2Q>!= ^+VO:M\19/##:; M=:O*9=1CL)"L,#D'$D2D@,0.*[*,L534L-%QQ7P2\8Z3H6AOHVB: MY:R_O&,ENQR1," P;H"00>G?! !%=QJEEK/C^^FLIO$4D.@MHI;3-+CW1+:S MNP1WPP.6QGM@D8[UX/KJ:+X2U9?!$WF3Z;97$*V>WYO+^8_O"& ,@W -@CDX M'6O2+_XVS:5X6L]'N+"'[&^I"+4KZ,2;DCF"?.D2\/F0*Q4KQM)'+5W=N-[-[=.W8]3'9;2SW-*<<@:5-4X^T:O&,7=W]80 -RAR.^!ZG@CM7(ZUX:O[[4+C5_#MS+-&MYMA:/;L99 M(U)8#I894U.G%+F5_OZ'RN?X[.*F-J8;&5I5/9R<7J^6 M\6U=+;OK:^I\Z>'_ -O3Q7X T^S\#)J$=A*MPRW2MIXD^8 EE/7J#M ZYKV+ MP'HW[1?CO]F]OBQ\$_$=[:^.M+O+B*2XN)O]*_LV?@XS]QE"JX]#G'>N9^ W MPK^%_P ;_CSJ6OV]GHD.@7VEW1U"V-D6N)[A]Y5X9!S&.=W7Y0,\=*Y'Q5XN M_:S_ &7]>\3?#+X5>"-6ET[2XR+L:58FZDDM3G+Y /!R26 '2O$K>WCC9.;; MBM+]+R6B2TV[_KH?>97BLIQF1PP^'IPA5]V3TLW&$ES.4E=N]GIH]>J.#@\0 M_%C6?CYI^K?%?Q5?ZO>PNL-KKUU?[I5PIW9)YQV'3VK]\/V*?B_I_P :/V<_ M#OB>QFFDDM[-+.Y:?[S21*%W>^1@Y[U^+/["G[.%W^W1XNLOA%XKU"*."XEN M';7;0D362*"PCV8&U@[JGZK5?/4[/$6MDU/):>$4OWMU4IJVJC*\6GI9)6TU=] M.FIM>+?V;/A/XWUZ;Q-X@\.R27ER09Y([IT#G&,X!QG JUX ^ 'PR^&VL-KO MA;P^8[MHRGVB:X:1D4]0NX\9]J[5,E.:4#'>OJ?;5>7EYG8_"U@<'&I[14US M;WLKW&A<=J7;ZFEHK,Z@HHH)QS0 449XH!S0 4V7E*=39?N4 ="K;\MGN#Q_45U7PA!_X1B53_ ,]D M_P#1$=PDTWS+I;J0M-Z*7/RX[GOGMGWKU*5GC):7/G\0Y?V;" MTK:?TC0^'6OZEXATL:#=%(TW',BPKDIAOE Z9X'..GYUO7]A!X.MOMFBA4$S MB-HV4; 3G#D@ @ \GGH#6'X#O](U;0(]*TW3O+O%FW[UD*[6Y_>Y'3@$;1P> MGY_M*.1&C1M@7:Q&-FP?*2W(W=1TZ$UC6TK-;>7[M\7;R)9_"MA8+)K%M.5O(U:3SY$3!.#P0%Z?3!'K7,:Q?2ZY>?:;V),HQ M$(:%3Y>&(R,@Y-;TVB^(([/?>7WG6BKEM+W?P?W?,QN?'H>#T-86NW-MJ.I2 M76DI]G1I")#M#>:>[8/W>_3KUZU6'^+77S[>08KX;)6\N_G_ %KW1MZ-GQ=; M-IVL*K0VNW*K&!YF1D9XZ8XXZD'Z5-):-I%Q#X=LI46WO.!NC7=$.2W;!! V MC/0XZU!IJ_VO;0P>&Q_9\UJA6:?>7V%CG;M/$F[.[)QC/J:G-I/:,^FZK']J MO;HKY%YNQYA&2./^6>W!.!Z9ZFL9?$_R_4VA\"?_ )-W\N_EV\[A?:=:^"K- MM8TF+^)5FA*K^]R<9!P#GN?8=*FA\,VL\:ZYYJ"]=1)]J$:8W8^GW<_C[U7E M@U+0W35/$^H?;H(V^63:$\AB, [5&&SG&3R,^YH71-=EM=ZW'^@LN?['9L?) M_=\SK_P'I_#G%%]/B^??R*TO;D^7;S[?=VTN[I.L+"W\:6:ZGK 7^[#'&H_= MG ^;)&2<\CH,'IWHBCDU:_F\+7*T M^VR3096?=M\Y0P&W _U>"R].O7J*Y/P'KOANV\1B2XTKJW^CM@?N^O.._;KT MZ]:[*%O82;C?S[GFXIR6+II3Y?+M_7]::E'5O&>M?\)*VH.MLTL,V%;[*AZ< M<$C.#CW/2KOCGQQJ>J2PV\EO L:Q@['MU;)*J2?F'J>/;!JOJ^M^&#XI:XCT M'_1TF*O#N()P3QN'*]N!P.@XJ]\0_$GAB]NXDL-+_>+&NZ0J.F/N[>G' SUX MQT%="C'VD/6AQRE+V57][U7S.@^$>M7FMO=2WH7?#:V\898PN0&FQP/K6 MMJ/_ !^>)/\ L%1?^@35G?"R^TV[:X72K/R4CL;973.= C&.U?5R_=XKY M0_8!/_$BCQUVBOJY?NC'I7*>B+1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#HJC#8V^G0K96=LD,42[8XHHPJJOH . *U*IZG+%"C3RN%5!EF M9@ !ZG-'F&NQ5DC62-H98PR,N&4KP0>U?S'_ /!53]E)_P!D3]NCQG\*=-LO MLVAWVH?VMX9S\J?8;HF1%!Z81B\?MY=?NE^U/_P6(_8-_9.%QI_C#XR6NNZY M;@_\4]X3Q?7&X#[K,A\N,_[["OQ7_P""LW_!2WPS_P %(OB-H'BGP[\$QX7A M\-6L]G;7UU?^==WT#N&590H"*%() &<;SS7P_%U?+<1A5#VB=2+NDM7KHT[; M?\ _JKZ.&3<:93Q%/%2PDXX*M!J*?Q,^:K6&U\&:[97 M4>L0W!D8BX6$Y"J>.O\ GI7TO^Q'^T1>_LK_ +4G@WXVVLK_ &72]61=52-O M];92CRYU]_W;,0/4"ODE^!]6_MCP_$7?,D/[J4>N.A_*OB,'7E3JJ4 M-&G=?(_MNM@\)FV!KY?B8WI58RC)=XR3BU\TS^KS2-8T[6],M]8TJ[2XM;NW M2>WN(SE9(W4,K ]P001]:MG[M?&O_!$?]IP_M ?L6:7X9UK4/.USP)+_ &)? M[GRSP*-ULY[_ .K(3/(\5E&(^ M*A.4;]TG[LO24;27DS\[/^"FOP[G\*_':#QE#!MM?$.FHY<#@S0XCX9_NA "6)]L9K]./VZ?@5-\:O@C?1:/8M-K&BYU# M28T7+RNBG="/=TRH'][;7X2_'?\ :CUWQO977@30M!N-'M?,:'45O.+ERIPT M;#_EF,C!7KV/<5\CGD5@L2YO:6J]>I_6G@C+$<:\/4\)2:YL/:G4;:]V/V)6 MO=WCHK)ZQ:/"_P#@F+^V-XE_X)\_%;Q)/8:B+SPGXNU2.75-+^S!_*C29V0Q M$L"C>7(RD_[N0<5^T?P4_;E_9G^.>D->>&_BKHME?0V[3WVCZIJL,-S:Q@XW ML"V-O?<#C!YQ7\__ ,1-.M]*\9WUI:+MC\S>J^FX!B/S-8F.>3STKS\!Q-C* M-=O$OGB_O7H1QIX Y'C8S\0>*/M5U9:GKEY$XL]/"#;YL# A;ALYPP)4;<\\ _DIJ7BOQ7K$* M=2NDDBCCE6XOI)%=(Q^[5@2W1EC8C[[D8 M_("O6Q/%N']FU0@W+SLDOQ/CN%/HW9QC,YI0S;$05'F7,J;;DXK>S<4HZ=7> MW9GW%^QM\1/AMH/@%? -U?QV&LM>RW5_/?3\ZE<2MN:?S&/S.>A!YX%?+G_! M1QKZ3]I[4+FXN%DMY-,M#8M&V5\OR\$ _P"^'_.M(X'W_P :Y_Q]X%@\96:, MLPANH1B&4C@CT/M_*OD<1BJV*A:>K;O?OZG]@0X!R_*?>RQIQ?[/'P@U[]H#X[>$/@GX9MWDO?%'B&TT^,1KG8LDJAG^BKN8^RU_7=X M,T&Q\*^&=/\ #.EQ".UT^QBMK9%'W8T0*H_("OQE_P"#;/\ X)KZ_%X]OOVX M_BOI")::5'-IW@6.1=WVB=QLN+P9_A1=T2GNS/\ W:_:N-&0Y-?;<*X*6'P< MJTU9SM;T6WWG\-_2 XEIYIQ1#*J3O'")J7_7R5N9?]NI13[2NN@^BBBOJ#\% M"BBB@ HHHH Q?&&@IXDLUL+J_FAMUF62XCA*CSE'.PD@X&>>,'CM7QW\3=3^ MU:Q>7*22,JLQ7S)"S8SQDGD\8_*OKGQ[I/B"_DLYO#5U)#=+,R&1GW0HA0[F M>/(W^@[@G.>M?(GQ1TBXTC6;_3;G#21,\,UU>A:L @&^O4J1;/C\+4Y M9'K7A>^@4*K?CSUKK#JEK]FX;/RUY'I7B(1 O\ B*U&\7';CS_;K7#*F[GT M5#&1A"QU%[JL27WE;OO<<^M6OAIXLU/PMX@U,:/837+W-@S*(U++$RG_ %C* M.2H[XY]*X!]=>>_0!^K5W?P4\2:/H?C.XUK6+K8D>GR".-06>5L@[54X#27=GE[=U:/*_ M-_"Y!SL/(%?-7B=F%W%Q_#7V7\74\,W?@JZT.6:&SNKZW-Y"LJ^7O= "=QZ M[1CGG\J^0_&VD30,WEC/EM^:UI@)1Y;'-Q%1G&JI.7-=?U^%B#0;T1E5)Q7: MZ'JHA(PWZUYC9W9ADRI&.O-=!INO;%QOXKLJ0N>#AJ_LSU[2?%(MX5/FKZ?> MIVI^+O-0X>O.;;Q$NW;YGX4LWB)2N-YY[5S>Q/6^O?N[7.RBU47%C*I?Y=WR M_E7NOP4\):5IWA;2]>L8/LUQ<6/^E+%\JW&6R'? ^F7OB:_MM M#L(V:6ZF"K[9[_0>%M1NA?3R7$<$4=OI<\MR6/V< ':4P%4AL MC(&2 /2N+&6C'EN>[D:E4J^T<;K:_9[_ *?B==1117FGU8$XYKPO]I[!^*OP M^)_YX:U_Z+MZ]T/(Q7A?[3N?^%J?#['_ #[ZS_Z!;UW9;_O+_P ,_P#TB1PY ME_NR_P =/_TY$^2?B_\ &+X&Q^,/MTFB:=9C4KEHUNKOQ))I_P#:S*VUG6.( M$%<\;WQNZUZYX>^(_P ,+;X.WFJ0^&OL.EZ7FSOM!\A6996( AQ]V0N77#9P MV\$\YQX7\=/V1/AYJ/BFRL_%/B'P_-'8Y724U#Q#]BGC@+;A#,N&\Q 3PRX8 M@U[=H?P'LC\*+[PI=>(HVO-6N([^34K11Y,,R;#%Y:]XT$:#KEAGIGCZ#%_V M?]6I^GI_2)]WE7+O;73[K=3R/P[\2/@U:^-I+6?P%9SKILAEET:'Q M1)=2V04Y+?9W C22K=7%IK_GLADR) M6AMR 1(03PS$ GVKV/XT?!ZPO?#NGZEI6M6-C_8NE_V>ZZQ/LAN+3 ^1I!]Q MAM!# =<@CGCCG*?.G4:YM;6 MF-K8P37(_MG?&'X"?"?Q7(_B+XSZO%<6=Y'IFJ>)=6UK3=%MY[P(K/:1%+)Y M+EH]P#,5"H?EW<5OCX)Q^(?ACXGN=)UO2[V*RT.^FM]-T'4/MUQ=7?V:18PQ M4# !;A5!+$C\?*?^"B?['?[+G[0GB:&\\6^,&N]+N-4FU?3[6\_M'2+_ $ZY MN0ANH@S6]=I72O=)/LCVWPC\0?!]C\'-.UWX=?%C7M$2V\46 MUIXFTN^L=+NE2UN;2XN$NXIH[?%RLHA^63)SAE(!''G$_B:[L?&W]E66G^%M M3#XFA\+ZK,9+B/4?$ M&E6UV=+TF_73]&T>SLKN"W"W-Q"N\JT^6E; +.!C Y9%^S]X:O/BA#XBL?&_ M@^XUQI%:'4H_$'R2/MP)C; !A%Q<[2=1.+Y/M-- M*[DNB;V[E913RK$5JT<35FK1O#DE?WK+E33E9)ZWWLST;QO\:+X_#739O$OP MAT/6]+UJ(_V?#8Z]Y:A40L69)H5\D1X()WY4C KS3]GC]JWX,W'BEKY?A#=* MT.E>S_ ! ^ GA__A4NG>&8M=M;5=!M MY5%UJO%O<)-N\]9L$;5\N+DPOOB3+A?+B#_ #< D],]ZQHU\O>%GS1TUVFN-+-OO&1"IV"1FQR5Z# M-=G^SA\3_A;J>E7&D>&](TS2YA:_;I)['4!=17T(.#,)3\[%3P589&1CK6)^ MTU\%?#.M:C-X@U7Q-HMM!JDR2W%GK=^UN?/1-@EA=03DH K*01QFG_!/]EKX M1W6DR:]K^E>&=;62S:QM5TJ-9H[:,MN;]\?G>4G&6.,=!ZU$GEKP*5Y+;K?7 M\%_7<[''EPJDI7JW=U:T>6VFMVV[^5CB_'/Q<^#-UXYB9_ FBVK:I()(;/4- M?FM)=05CA9&BC'EKO[;^3GGK7T1\&?%/AWQ;XE^'^I>&-.^QVL/B&:W.GF,* M;5X[*Z5HL#@8QVX/7O7RIX\_8R^%.G>-8;#_ (3GP_#<6;*EG-=>)I[>>-0? MD$T665F7LO6JL=L=Q8W6GS.N.\BO,@ M/TCQ7@>E?M.?'_Q5IFC^,+?XX^!M(AUR.VFDT.ZT&Z,VG+,5Q&)-C"7!;RP[ M!5UK]'NCT%C+U%3]G*[3=M-E;K>W5;-GV"" M#U%"\#DU\DP_'SX[2&0-^U!X+W>6.0Y=2XP!QQUPZ M3X^?'6TEB2__ &D_"5NC0EI#=>$;J%E?L@#0C<2,X/!8[0%^85G]7A_S\C_Y M-_\ (FOMJG_/M_\ DO\ \D?6I/I1GCK7R7=?'+]HVW@5?^&B_!@NGNYH857P MA>20RA6?8"RQ9#D*,@9!'*Y!&5/[0OQEQ<0S?M*^$[.:## W7A.[2,*2@W.S MPJ%4,P^;D;>WA:\!6-%0LQ'DXW#+'&0,>N"0V'X_?'ES);W7[3 M'@F$^$I_,\LQ+)X$NX?,#-(!AMK# M!"?*<'+$=WX)X' MIN*GU>/_ #\C_P"3?_(B]M4_Y]O_ ,E_^2.K_P""@;J^D^"0_E7SG^T1X]U/XF?!3X<>,-:-NUY)XJO+>YEM8V2.9[=I[%.2H;'.*^C/@O_ ,B9:?\ 7%?Y5E4IRI5'"6Z;7W&M.:J4U-=53_ 'JDQGJ*@L0Y)X%!XZFES1D'B@ ZCD4G/I2G/84 8H ^ M7_C3X'_:Y\"?MOO^TC\!/@AX=\;:/J7PQ@\.7D&K>-_[(FM+B+4)KC< ;:82 M*5D Z@@CO3O^".=SJUW_ ,$ZO %UX@TR.RO9)=8:ZLXKGSEAD_M>]RH?:-P! M[X&:^G& "\"ORB_X(G_LD>"/VHO@)\0/%OQ2^)GQ,6?1_C!K.EZ7:Z#\3]6T MVUM;55@E$<<%M.D:C?+(QPO)8DT ?JZ2-F">U?$'Q!_;2_X*(_$7X:_%GQ/^ MS'^RYX-N+#P?KFN:#I6JW/CB=]4EFL6,;7$=@+$I(^?F2(S#<0 3V/IG_#J_ M]G?M\2/C)_X>W7__ )+KY(_X)G^%/VV)/C-^T5^RO\(_CVWP_P##/PT^*<\N MBP^+O!$FLZAJ,.HO+.+A[NZN%DF#;!M<[L@]34U(\T'%.U]+]C;#U8T,1"K* M*DHM.SV=G>S\GLSEO^"%/[4_[=?QD_:B\0^%/BKXQ\2^*/"']DSW.OW'B)69 M-,OMZ>4$=E'ER,=RF$8& 3M&WG]8?$\?A2_TI]&\7&R>TOOW+6]\RA)L]%PW M4^G>OF_7/@W^WSX(TF?7M:_X*$^$K&UC(::7_A3< W,3@# N\LQ/ R2>!4W MP9/B"/4M;N/VA/$'_"WKV:WC@T_5M+\"_9!90[27M6LV9C$6.&\W@2# S\F* M\_*L#4R[!JA.JZC3;YI;Z]/D?6<><4X/C+B2IF>%P-/!PDHI4J2M!$O XF;PWI1BDN-OVBYFN))II0/NAI)&9R!DX!.!GC%;9! MS7-?!_1];T#X<:7I'B&&2*ZAA8-#)-YC0H7)2,MW*H57\._6NFZ5Z1\:1S_= M_'^M.&0.139\;>?7^M2#DG?$WX;Z7X M>D\>2Z)?>$=:M94U!+>.9X2L=S]H ^V,5#"$PD') / )^CV7)KDT^!?P7C^( M7_"U_P#A4_AS_A)^2OB$Z- ;Q,C!VS%=ZDC@X(SWJHM=1,\^\!S>$_"O[7OQ M"M_#NIH1>^!=!OI[-=4:02WAO-961E1F(5RL<8(4#A%XX%<=\-OVH/C1K^I> M!?'FN^-_ TNA_$#6)M/C\$PVKZ41'*X*S>>1<21"+]_&8DV*68-\F&]BT MCX#?LU-X^D^(NC?!_P $R>*;.X+R:]%H=H^H02G//G[#*C-;SXE:)\+/#]GXBU",QWNN0:/"MW,I.65I@N_!(!(S@GD\U7-'L+E?1 MG@GP:_:7_:*O?$'AK6?B9XG\&:KHOBO7/$6E66E^']%FM[BW;3C<&*;SWN9% ME:1;3+%]FC;<6.%",I^EM*^ OP2T.739M(^$7AFWDT6\F MO-'FBT. /97$HQ+-$VS='(XX9E(+#@DBC2?V?_@9X=\>7'Q4T+X-^%;/Q-2WOA;XQ\$_% M*^U+Q=X\\-^)KGXT6,WBB:[Q+;RQ O/ \C+:FVN"UO& J;5+(,@5-^Q%X9\. M?"7_ (*-:_J7@3XC>%_%7A/XG>&9KKP/8^$?B)?ZL=!TVTE3-Q=17$LD;-=2 MR,3,I78T:Q*" QK[8\'_ U^ OASQKKOB?P#X \)Z?XBU1E_X2;4='TNUBO; MMCDC[2\:B1R3US4/PR^$O[/'PSUW69O@W\,_!OA_5+R<-X@;PSHUI:SS M2'+ W'DJK,3DGY^>2>]-U-_07)L>._\ !.')U;]HG_LY;Q#_ .DFGU]$^'?% MGAGQ=8R:GX5\0V6I6T=U-;27&GW23(DT4ACEC+*2 Z.K*R]592" 1BOGC_@F M^ =7_:)'_5RWB'_TDTZOHK1M!\/^&[5[#PWH5GI\,EQ)/)#96J1*TLCEY)"% M !9G8LS=222&_%EDVI^%M?LM2M8[F:W>XT^Z29%FBD M,FVOG2S_9;"U2&/S)9&DD?:@ W/(S. MQZEF).22:DH;X9\6^&O&>C1^(O"6OV>I:?*\B17MC<++$[(Y1P&4D'#*RGG@ M@T>&/%_A?QKHD7B;PAXALM4TV=G$%_I]TDT,FQBC;70E3AE93@\$$=J=H.@Z M#X;TU=%\.:/:V-I&[O':V=NL<:,S%F(50 ,L23ZDFG:!X:\/^%=)CT#PSH=G MIUC"6,-G8VRPQ)N8LV$4!1EB2<#DDF@!ND>*/#NOZ*OB;0];M;S3I(V>.^MY MU>)E4D,0P., @Y^E.T'Q!HOBG28==\.:O;WUE<+NM[NSF$D<@SC*L.#S2Z9X M?T71]+70M)TBVM;%$94M+>%5C4$DD!0,8.3^=/T;1M)\/:=%H^AZ;#:6L*XA MM[:,)'&,] !P* /GW_@H0,V?@;_L/R_^BJ];^"G_ ")MK_UQ6O)?^"@Y_P!" M\#C_ *C\O_HJO6O@GQX-M?\ KB* .QHHHH 09QS0^<4M-D)"\4 ?$_[4#A_C MOX@V]IHQ_P"0DJS\&WV?"GXCN1G_ (DL _\ (M4OVFR?^%Z>(#_T\1_^BDJ[ M\(&$?P@^(S;W(@7I]HE'9 >@_B/'0$CP MO]DS]INS_:Y\'S?L_?'?7(_^$OA:2X\-:Y,H4W?5C&< #>O/ ^\O3D5P/_!4 MW]FCQEX*^*EU\>HKNZU+0_$,RB::5BQL)@NT0GTC('R]NH],_*VC:UJWAW5K M;7]"U":TO;*=9K6YMWVO%(IR&!'0@BO4P66X6MEZ<'[SUOV?;T/CN(.*,VP? M$G<^S?$OAO5_!_B"Z\-Z_9M!=6LA22-OYCU!'( M-=9\ _C/J/P?\5B[E,DVEWA5-0M5/1<\.H_O#]1D4G@GXR>$_P!LCX#3>,M5 MNK>Q\>>#[11KD/"_;H1P)5'<'_QUCCH17#9R?TK'E=2+IU59K1K]3T%4CAJL M,3A9WB_>B^MNS\U9IGZ(:7JUEJVG0:I87"S6]Q$LD,L9R&4C(-1:QXFT+P]: MM?:]J]O9PK]Z6ZF6-?S)KYRN?B]XG^$/[,WA?2-,G\O5M7CF:VG;!:WM_,)# M >N& 'I7ANM^(O$'B6\-_P"(=:NKR9LDR7,Q<_KTKRJ67RJ-MO2Y]EB^)88> M$5&%YN*;6R5U>Q]8>,?VR/A-X<>2'19KG6)AT^QQ[8_^^VQ^@->4>,/VU?B7 MKA:W\,Z?:Z3&?XU'G2?FW'Z5XT>#NQ6QX8\">,O&4=_\ ,^S/@#XYU'X@?"G2O$NKW*S7CQM' M=R*,;G1RI/XX!KMA7F_[,GP_\4?#GX:)H/BM5CNGO)9_)1@WE*V,+D=^"?QK MT@<#%>)6Y55ER[7/T# NM+!TW53YK*]][VZA11169U!1110 4444 %%%% !1 M110 V8D+Q7Y7_P#!6+_@H[\(-22TN;^WU P/';Q*23 MCD$G@9(Z5PYC[3ZO>,K6=^Q]5P;+"_VQ[.M2]ISQ<4K7LWUM==+KYGC_ ,&/ M^"OUA^T/JWBNP\*-#THC;;V<-M_:,=PD=S!YF[#*ASA2 P+ 8'XU\OM#=:EHP/A3PXNGS MV\K7-G''. "@)X&.U>;3Q53'8=X:&DK[[JU[]&OS/J,YX=HY!BH9E-\U*R]UMI\UK&=993#=_96A:,J ( MR>^,$'K^/'I63+\-;73;%M*TK6O)N)%9I/*A 0*5^<)@+M!8;CDGDG&!Q7;B MH8^6(C[%VTU;VW[=_P"KGC9#B>%Z63U8YG'F;G[JBO?^'2TM$EWON];'SW\' M/'NM?%3XR6=I:6$EU>7UZD_V,QR$^6FYRV,?, P]0&QUY-?1'Q1T#P[83:9K M -O+(H4K)$YB%F=A'FE#GG'(!Y&/>N$\->.?%WP^\4V>L^&;.T2YTZQ72K:_ MCL8HY!;R#D9"\8.0"<]:V?C-XIF;PK:3^&]"C:-K-5N)HF8%)'D4A7P3R=K, M,#H#P.]T6YO?%5_;Q6MY;KK(C8>8\ =6E7!S]]=QSTP.N>GM?B+X-_# M'Q]I>M_#[PGX6A_X1_6M6.I:)?7UNL,ENK<, PW9&0FT<]:]^_9Q^.%E:ZLVE^*_%JW% MQ P-C8R7!$@P"L94 ?/D:2M;S25G=61R'B_X2>(_V;/$,GA=[5M0CF+26CZ/<%7B MMW&/,(7YB%5@2H!X&.O&:^6+[_@HG'\.?VE[,Z]H&E-I6GZGY&M7EYH?GJ8>1)&AQO7*M MQ@]..>:_2#]E'Q'^QSXX_9;\1ZG\"9K>U\-V.FWMQK>G?O8I$C9&+MB0[P/X M0>GI6,<++^U7-OW5JM;WW^YIK;HCU_[?J?ZG?552?.UR\T8I65TM6MU):)]7 MIH<;\ /^"F__ 3$_9NT+^V/ 6A7'_"6Z]'YNO1Z7II^:Z.<@LQPNYCU'&37 MV_\ LF_M-:!^U5\+E^(NC>'[O1Y%NFM[S2[[!EMW'(R1P05((^M?SH1^+/A1 MXG^,7_"&?#7X>7L N[IDCFFG$N]]QP$X&"",\YZ5_0-_P3O^!6L? []G;3;' MQ/J'_P#BJ U-;S5]:-Z]S6#-\,/!,WW]%S_V M]2__ !559?@Q\.Y^9?#P/K_ID_\ \703[W]?\,9O[2?QOLOV=?@MK?QFU'0I MM3M]#ACEN+&WE"22(TBH=I/&1NSSUQ7+_LT?MW_LU_M56BP_##X@6_\ :ZIN MN/#NI8M[Z+CG]VQ_> ?WD++[UC?M@?LDZ5\3OV>O$G@7X6>%HO\ A(-2MXXM M/:XU*58U;SD))+,0 %!/0UXC^RM_P1%^$OPQUBQ^(WQX\23^*-?LYEGM;#3Y MI+6QM95.0Y*J?[IHZG'4J8U8A*$4XVU/NI6##(I)?N4D,0A18U'W1 MBEFSY=!W'(_")O\ BFI2#_RVC_\ 1$=/:UU)&RLP!#!B M._\ 2O3I66,E=V/!Q%_[-A:-]#6\&66BZ=X?74M#U%GNOM.V-?+W;FP?DVCJ M""3D'CUXK"0"HRP'7OVK!^'VAW?A[1E\0 M/)'(N_YXQ(N/+P<>];-(OL6D?*L>)9))L?> ^5=N2N21NP?3ITK?G\76^HQMH]M;?Z;*&C M,@R3Z5SFN6@T+439W4ZD.Q,;>8.A;//(P><'/'OS58>_,[Z M>7<,4XRBFG==^WD;FDJNF1VT_AYVNI+A2;J/R\;@#]XY(V%3\N">0,=1FI9I MY+F6>_U2=X+ZV9!;VXC/RY/&!GY]_*D@^W'-0Z6Q\&VO]H:L T=Y@MY;*?+8 M# &1NR/3/.>QJ=KU];E3Q+9(@M[,YC61EW2==^><+@'@$]>N*QE?FOT[_H; M1_AI;/MV\_U'W,MUJMS#I_B*T^S6[V*B.JZO#I6R M,2?8U^4:EY(+"+^_MSGI_%C&/FQBBYU2Q\+([>-=#^RAM01?*\O:,C+\<@C/'/0],>E"S MRZ+++U(_)NEQ-&)%)C7 V$$G!S@Y /IC.*.67;?;S"ZMOMNOY?Z_+RT*^ MLP6VM6E]_P )1*UJT<.V.'R_N(2IW#D^82P X/'3@URG@71_"LGB6%9=7:1@ MW[N-HP%<]AD$_P#U^GKGJM;BN:6*IN, M%*[W?4CU/1/"*>(F@'B"3RFGSN\G=QGDYR"?J!SUYK2^(?A_PE;W\,EMJ[1[ MH5W+&H?C: &SD: M5-!(EW'(K1J!F3G<% /'ID<<<# XQ71>//#W^AR.-3V52]);KY'4?"NUTBT- MP=(O&F5K.W,C%<8;?-QC\OKU[UI7Y_TSQ%_V"8__ $"6LKX2Z%<:*UU%;B'^^GK?1?H>Y@[_5Z5U;5Z?^ M!'SM^P#\NAQD_P!T5]7+]T8KY2_8!'_$AC_W:^KE^Z*Y3T0HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH *X7]I3X.Z;^T%\"/%WP5U>[DMX?$V@W-A]HAD*O"[H0D@((Y M5L-^%=U3)(W?CBIG&-2+C+9Z,VP^(K8/$0KT7:<&I1?9IW3^31_(7\2? GB3 MX6_$'6_AKXQL6M]6T#59]/U"%\Y6:*0HW7W'ZBL,<55<;C^..E?B..P$\9[2C/#M[:KT>_X_F?QC]*SA%83.<+Q'0C[E=>SJ/^_#6+?G*%UZ0/ M1YY))Y/L\70?>;/3VK\QO^"PG_!(37O']SK'[5W[*/A=[_Q UO)=^)/!=EM5 M]5D5"QFM&C)PYY'.0?U M+98(-F ,I4C/&*^DQF#P^.H^SJ MJZ_%>A_.?!O&G$/ ><+,LHJ\E2SBTU>,HOI*/57LUV:31_&CK/B.\USQ?JEC MKNFWFF:U9W;)JNC:E:O!.2-P&4CIR.U-@MI+Z9+**8QM,X19%QE23C/ M-?U ?MX?\$:_V./V]6N/%GCWP;_8/C22W6)/&WAU$AO7"_=6;C;<*/\ ;!(' M 85^77QW_P"#7+]LGP+J-'$Z\]TXPEKO&5VE=;W:L[V MZ'Q-9?"3P1:",MIK3,J@,TLS'><=2.F:Z*WM;>R@6VM8$CC5<*B+@"OII/\ M@C?_ ,%*;.*?V<9FN,*LK6VMV3IN[G/F]*[SX8?\ !!?]O7QW=QIXOT30 M?"=KN'F7&K:LLSJOLD&_)]LCZUYT&&5X7VRS/#QC: M^E2#D_DFY-_*Y^6O[4GQ?^(OP=\>Z%J7AO7 VFW=JSS:7/$IC=HW ;)QNY## MH>"*_0'_ ((V_P#!/SXE_P#!31+7XO>.O!&L>#OAK9W2B^U6\78^M$?>AL2< M%ESPTV-JY.-S<#[_ /@-_P &U7[%GAOQGI/Q/_::EO/B=K6DP@6.FZDOD:1" M^[<6^S*%_#_A'1[7P[X7T6UT_3[*%8;.QL;=8H8(P. M$1% 50/0#%?;X7(<++"4OK,%SQWMUUZVWT/XLXL\>N*<'Q=FDN&L=)X.NUR< MZ#]-\ ^!M#M]-T?1[..UTZQM M5PD,2 !5'Y=3R3R>:W***^B2459'\[U*E2M4E4J-N4FVVW=MO5MM[MO5A111 M00%%%% !1110!3UE=4_L^9M'2)KK83;K,2$+=@Q'.*^;_COX/U;6I[KQM_9$ M,<;7'D71MY69?M"J ^,J" 2"!ZE?>OILKGO6+XTM;BYT*6PM?#D.J><0DEI- M<")64]3N(/(Z^M=&'K.C.Z1YV98*.-HN,FU_F? .NZ7+IEVS;/D9CCVIECJD MD!#5[WXR_9TU?6--N/$'ARR^T0K>31-:1[FEC".R\[@-_3J/P!KRB?X2:Q+J M\>E6T30S33+&JR X5F.!D=1^5>]3Q%.I'<_.,1EN*P]3X=]BG8^)&7^*KA\2 M\<,/IBIC\'?)N&MYO&MGN1BIVV\_7_OBMW3/@;JCPQWFE3KJ2[F\S[+%(3'A M0V2"HP,'KFB4Z7<*=#&2T2,[P_+S74%[-]EN,21;2'C4D'...AXY/IFL?X%_ _PI#8C7[Z^M=0G\O MX\,MN67 M.'SU< ]"!BO3O!O@W3_"&DQV-K%'YVQ1<7"PA6F(& 3CVKRL7B(R]V/0^PR; M*ZE&U2JD[K[O^"RUKN@P:W:?9+B:2-1,CLT;8+;6#;?H<8/J#7AO[17PFT>? M49M>\/WEMYSN/M>GK(/-1VQ@A1R0WICKR,]OH)@2N!67JOA33-4E6\DB\FX2 M>.4W$ "NY0Y )QRO8BN2C6E2E<]G'8&GC*+@TKGP7K_@G4+"YD=(2O/S*U9, M=IJL9VI:2Y'94)K[8^+?PFT'Q';?:-.\)-+J%QN_TBUD6-4;:2&DS]X9QT!- M>'_ !1<:>;SRYIFDMFAD3:&!4@,.,M^E>M',*?LTV?&5N&J M\<0XP>F_]7L?+-G:>(9OD6PD^K1D?TKH/#'@_6-7OHX8[:221FPL:J6)/L.Y MKZ$\!?#"XUB^,5WXZUIHV5I+.X2.41W$8P-VYC\O.?E/)'/0BNQM_A'%I_BY MM7\/2G35\ABUW"P>6:1Y-S A@0%P!C'//;O-3'0CHC3"\.U9Q4V]+^7]?>SD M/AQ\'_%_@NXL;FSOEM;Z^@E2:1K)9ELP,-DDG&XXQZ<]\5[-!$\:*';<=OS- MZFA(2M25Y-2I*I*[/M,+A:>%I\L-@HHHK,Z@KPO]IT'_ (6M\/O^O?6?_1=O M7NA.!FO"_P!IX_\ %U/A\?\ IAK/_H%O7=EO^\O_ S_ /2)'!F7^ZK_ !T_ M_3D3X>\8P?$#2-7^PMK5EIVIQW,K^(/[2VJ]Q*9"?-RX/F1%<;=O&./IZGX< MT#QK-^SEXAMM(L+Q;&ZU19]+LXU99'T_,1G$2YRJOB4JO4JW'WA7G/QO_;[M M? OB+3AKMY)8V^I,9]+AL]"CNFCM@Y02SO(W4D$[8QD=.:]KT7X^ZD_PGU/Q M3J.CP2:QI-]'8F.#*P7$TOE^3(,Y**1*K,#DK@CGBOJL94QOU:BG22LU9KKJ MM_ZT.6GD]7 U)8R;GRU]5S.\;1T?+V\['SQ91^+[[Q/=6LVK6-]H]QYL>CZ5 MI\:F?S#GR5B15#I(K8R3C&#^'KG[3.F>/HO"_A^[O[A=UOX?>+[5<+OM[?5R MB@33<$8^\ Q!4$GUIW_"TOBAH=S-XA&KZ;>31*7N+%M)CBCD5>65'4[U)'1F M+#VK8_:'_:7C^&7@2#Q18HMO:R>'9-;U"ZN+,SM;V2H#A8@?WDI+8 )P,$FO MGR M^V[ZR]#RG]E[3_BQ<^--)_X2/6+?4-4MM3\RXN]/VL(=/V$2)-)& I#';M7D MY_3JO$TL.@_$3Q /'$D<&J7&IR31W%[PL]IG]SY3'@HJ87:#P0<\UC?L=?MU M:;\?)H7T)IKG39-573;I+[28[6YM;B12T3?NB8Y(V PMGX[?M47WAG6 MYKRN_*U M^AN_#'3O&&H?#OQUW0CN!036_CA<:=_PG9UK18[ MCR]ZZ?\ V6K1 9^[YF?,/INW>^.U>Q@L56H7<'H^6SYOBT5KNWO75F[[W\RJ M7-1G5A*A&;Y91:E!2Y-=7&_PRB]FM4<3X\TS]H7PS\'_ K/X^T>'Q%INEQL M]X+.,I?0$J1 US"[>7*4!&6#*-QR5&,GE/@SXVD\=>--)TS2_$B3:ZFKP36T M,D1AGLXD?,[/N5<(T>5P,@[@*]J\?_M&7>G?"71_&V@6:6#C(?J#\P'(([Z0P=3&6Q4X->SYO@DU%\UT^:'PRMK:W+L<4:6 M,IX>?LK2AI?F5VNR4]U?S3/0OC?#J.A?%+5-5\1R+;K?+"-'U"X7]T+=8P&A M5B,(PDW,1U(8'FM#X!67B+5/$6K:]X5E5+.70W@N+U8BL-S?;@863@;BB[MS M#CY@,\<<'^TO\:/$_P"SW/J6G_#[QUJ5EI>GW4-K'8:E:KJ?F7+1^:5C:<[H M8PA Y=AG[H&,'H/V>_VT=6UKP\M[\7O#5U!:3:7)?6&KZ=9F=/+C;;()A"N8 MQNQB0HB\\\#<>'^RW]8EBJ-1RE*$8N'.^51334E3=ES/JTV+ZIBJ-%8^M3E& MG)N*D_@ +;7+::W5_%5W+IMK<*0\%JUI=F-"#R,#G:>@(':O /$?[ M;.J-XMTZW/BH0R:@L'<82Y4D[\R?O/[3\SZQN.8&Q_=-?"G@3XB?\ M"$^ / UMXB\3>/-$CU#PO!)IL-OHND36UU'; /*T3R.9 /F'WMK$-A1EL5]U MW'^I8'^Z:^1_#'BXO^SQ\.;"R\.^$O$6GP^"O*U*UU*\1;NVE;R454S.G!!W ME<;CY& REE(^?R^-.>'G&<;KFCUM]F?7^KGHU(\V84US.?'ES'HM\T&JL8-"C6.1PKQQLTDZ\ *P7&2=K!B<-FC_ ,+HTJTU MZY\,ZMXO^(*:AIEQ+;W5K<:7H\36AC"N8V)FP0JF,[PQ!ROS%F45>L?%.BCP M]J.D:O\ LY>"8_[0\2PQVME;ZQ!(+^W6"X+RMB;_ %JJ'3=(4+>;M95 R9/B M/\3+[Q/X@OH(OV:?"UY)'>:I%9:OJ7BBTD66W\J.*V=T2=7I (4"D?%FG:7:Z9;I^Q1X2NY=+EFM+*6 MWURP*);K(9H)XF:X+1 N[LR_,Y^^'NLRKJNN_L4>$+BX:^TN&\M MY-6L3+'9Q(?,N$W3LGF1EF6. $-NZO\ /N'-?_IU^?\ F3;_ *>_^D_Y#;_X M[>$='T?^T-4\??$G[.(A-))'I^D$!6G2!2460E2TJE!D G.1TS4F@_'[PEK- MC<7]GX_^(EXJNX7=IND))']Z Q@>:K$^:"=I&XD-CY5;%KPMXEL/"L$T^E_L ME>%M#EDM5:X$6O6\R.S:@9MQV3 2-&NR5@V&+EMIVCYIM5\6ZD?$MQ%X@_9L M\%Z@+B2Z2/6M+UZ)/+VZC(\$C0FXWR;HQ)<&12K*TZH%P7-.\=/W6_K_ )BY M9:_O/R_R*.J?'?P)9ZM=:/E_Z5Y>8-2Z5?R.5\8W9O?V7/AG=EKEC)XZUDL;R-%FS]MO< M[PA*AO4*2 >A-?5OP7/_ !1EJ/2,?RKY.\4SPW'[+GPTFMY5DCD\>:XR.AR& M'V^^P0?I7UE\%QCP9:E%!.* #H]Z%\D1DQ2HQ)QG@\\4 ?2?@#_@M7^Q3\2_VEX_V9/#>N:P;^YU)M.TW MQ!)IX&FWEV&VB*.3>6^9@55BH5CC!Y%=W\3O^">?PN^)OQHU[X[6?Q=^*/A/ M7/$MK90:VO@OQ[<:=;W2VJ,D+-%&,;E5V&?>OSD_:N_8Q_89_P""4_QWTWX_ M:S\6=0UK4!2UQ)', /,O &5;2%V4X*AR%V@L>:^VO^"5_P#P M5)M?^"AND^(M%\0_#E/#/B3PUY,MQ;V=TTUK/B?XJU+1KL3P: M%X^^(5S?Z;=95D(:-U(#@,61\':P!QQ7JG@[P_XLU+X@7WQ(\5:/#I?F:3%I MUGIT=T)W9%D:0RR, %!RV HW8 )SS@=HWRJ2XIOG#&0G%?0'Y . [@4X YS4 M<?"F^T:U>2:RCE=/(08^U"X*A7\X,8L9)7:0P^ MK6QCD503P[H4>K-KT>B6:WTB[7O1;KYK#T+XSC\:J+M<3/ ?!'Q8_9^T/]N/ MQYX;\+>/?"<6M:KX'T%6TFTU2W6YOM0CO-:,B>6&W/*$V;A@L%VYXQ7)_"?] MI?XB^(/&W@K4M1_:.TN_UCQ5JUQ:^(_A%_8]OYVB0JDA9T>,"XA>W9%#R3EH MI 2 JNRFOJ#2[7P/=ZK<-I-OI,E]:R9NFMTB:6)S_>V\J3SUZ\U;M?#FA6>H M3:O::-9Q7=T +BZCMU624>C,!EOQI\T>PN5]SY'^!G[2OQ9'B;P;K_C']IO2 M_%MMXV\3>)]&M?#4>FV%K%'_ &?]H:V,#Q#SWF*PIYFYV4B;(1.#6+^R_P#M M9XB\9Z@]W&UUJU^I8O]G@DB*6[2DNWF2L-J;%KD?\ @F]\*?&O MP^_;LTGX;^$=(\":Q'X!\-ZU9_%'XK>"=2NKJ?Q5=37BM;C59'B6-;[.YVA\ MV>2,J_S(A53^D>A7_P -;[59%\,W6ARWR*WF"PDA:55S\V=GS8SC/O5O1M3\ M)27EYH^@7VGM<6LN;ZULY(]\,C<_.J\J3UYY-4ZF^A/*M-3Y\_X)OMC6/VB> M/^;EO$/_ *2:=7J/CZT^"/[4_P #?$WA;5?$4%]X7O$OM,UC4+2\:#[)+;N\ M,["4%3&\,D;?-GY63->7_P#!-X#^V/VB@?\ HY;Q#_Z2:?7TH+.U6)H%MXUC M?.Y HP<]M^ M%=26WMM,TW3F>"WN$*2,(9G\K[8TA/#.JC,:+7)_#KQQX!\:?L:?$#]I'XH? MM&:3I>L:]=MX,F\8^&S)-:Z;:V=^^EVKND#@I'=-%]HE="FU+C"N%C5Z^\[7 M0]'L8I+>RTFUACE_UD<,"JK\8Y '-11^'="L[=[:WT>TCAD.9(8[=0KGU( P M:?M!EO>7'@O7Y+[09\Q2[3:JX'D/CF1 M03G*'->^> ?B-X+^)_A.V\=> O$-OJFD79D%K?6N?+D\N1HWQD#HZ,OU%6]! MTOP]I%N;+PWIMG:V_F,6AL841=Q/)PHQFKL-K#;((;:%(T&?E1<#KGM4R=Y7 M'%%(O&_AW6([K2IHGDCO(\[65"P8\C/!4_E4O@_P 8>'/' MGAVU\6>$=4COM.O(]]K=0YVR+DC(S[@U?CM8((Q##"JQ@8\M5 'Y4000V\0B MMXE15^ZJK@#\*DH^=_\ @H,#]B\#Y_Z&"7_T57K?P4_Y$VU_ZXBO)/\ @H,, MV?@;_L/R_P#HJO7/@KQX-M1_TR% '84444 %(Z[EQ2T 8H ^?_C#^R#XC^(' MC_4/&.B>*+.&._=7:&YC?*,$"G!&]T_ MS/EE/V$/'I91)XQTO;GYBJOP/RKZ:\.:,F@Z%9Z)')O6SM8X%8]2%4#/Z5>P M/2D()/6IK8BK7MSLVP.5X/+Y2=%6OOK!?&6EQWFF:E;M M#=6\G\0/<>A'4'L17Y&?M;?LQ>)_V7?BA<>%-162XT>Z8S:#J97Y;B'/W3Z. MO1A^/0BOV.*YZUYM^U%^SGX2_:5^&%UX!\1Q+%<8,NE:@J@O:7 'RL/8]".X M/TKLRO,)8.M:7PO?R\SP>+N&J>?8/FIJU:'POO\ W7Y/IV?JS\M?V6=.O9_& M=YK$5Q)'#:Z>8Y%5R!(7;A3ZCY2<'T%?0OA[1;SQ+KUCX>L%_?7UU'!']6;& M?PKC/A?\'M?^"T.J^$O%]JL6JQ:M+'=+&VX;4.U2#W! +#V85[9^S3IUM!X\ MN/'&HQJUGX:TJ?4)MS8!=5(09]R>/<5[>,KQDY37;0_/LAR^<84\/45FW[R? M17U^Y(/VFM;M;_XD_P#",:6,67AVQBTVW Z?NU^;]3C\*YOX?Z#X#UB^N+KX MD_$6Q\-:39PAYKR\F56D). B GD]3T.,5CZIJMUK6IW6LWS[IKNX>:9O5F8D M_P Z^=?VF?$7]J^/ET>-]T>G6JIM[>8WS-^/*_E4X?#RJ)4T[:;FN:9K'#U) M8N45*[T3=EY)^21]1^(OVQ_V'O@\&@^'W@K4O'6I0_5;DYZY<#CZ(:\ MP\>_\%5_VA_$$L=OX%T[1_">GPR*XM]+LQ)(R@Y*EY 0,CCY5%?,HV@]?H*[ MCX8?LT_'CXRS+'\._AAJM]$S8-TUN8X!]9'POZUW?4<%17-5U\Y/]-OP/ EQ M)Q#CI^QPON+^6E&S^]>]][/V8\(:Q#XB\+:;X@MW5DOK&&=67H0Z!L_K6E7& M_L^>&/%7@GX)>%?!WC81_P!K:7H-K:7XADWJ)(XPIPW?IUKLJ^'G93:1_0>' ME.>'A*:LVE=/H[:A1114FP4444 %%%% !1110 4444 ##(Q7R/\ \%G/@EHG MQ:_8OUG6=1CD-UX;FCO['R,/#UYX6\062 M7%E?6[07$+@$,C @_P ZSK4_;4G#NCNRW&RR_,*6)7V))V[KJOFM#^8CXA_& M)_ VFMX*\&A[5F5S?7\)+33MC*C<>BCT%?1'[._C#4_B)\'['6=5:-KRWC5+ MI4Q\V.A_$5]>?M(?\$2/V9/V??!WQ6_:&D\6ZO-ILWAICI>ER6RSMID_F*=Z M,3D@GY?8$FORQTC7OCWH.L:9\)/AC$;VWU#4_P#CRTZ(^?[5_6Q^A9S_QE^&>)PUU&G*UM;)2L_\ A['WG\4/@_HL'PRTWXN_ M#S49Y)DAM[._TV2/.^5V<^9P>H#%2?3:*^:/B7XF\5^!;N6ZATJWNYK=HWFL MKRYVI)&\@4*0,\GT/7'OBO4=(^*.H_#[PYJ4WQ5TZX\-W$VK&WM-#FF\SR(X MU :5F.#@GD#%>8Z;X+\:_$[5]0\8)\1='N;74;@SQM9PEY HSL5-WW".A)4X M/(K:MF%6M03P\6I7LTUM;?U[76E[ZGD9+P[EU/,I+-*B]BHWBT[@W#;N;C[V!GTKH=*^#WP4^,7@N;4/@UX^C-O96:6=E;E96N%N@S M$EP<L? -O&OC#XHZ3I+:YJ[::^C'4%COO M)CD8B63<<*I!.%..&Z\U:TKX%?LV?#2;3_$-E82337\XMM'>\DW ^<%=8HFC MR&!P.A(Z5X+X]_8R\2_!_P"$^H?%CQ/Y=Y<-,((8)IFC/F.N=H!SAN!^&?2O M8OV(?VC_ SX>TK2_@#XMT22^N!"EQX9O/L)G:WF+9<.P&4 =@J'OSVI5/9Q MQ3I5[3D[\K:LDGM%I=MK[LY\EPN=4^'7C<#B)1@IWE"&DM&DY1?\VE[;)(=^ MUG^S#^R7:_ S4/%/BO5FT_Q3=9NM%2.X'FWMQ@H(6C[Y?J.HKHO^"3'[%7B# MQ]\3]!.N^)9K71?#J_;;ZS%XWG7R.L@^S2Q[L-"2_.00<#I77?M(_P#!&CXS M?M2?L_ZE\1M1UC^Q/%&D23W?A73;J0Q+%#YC32/+LSEWYQZ9%?$O[-%]\8_@ M5H^F?$;P'\1/$%GKUCJ+2:M-'.Q:6-&P8UW'# KGJ#TK#'QE2=*>(LG?51V> MOGMI_D>WPC4J9E@L;A3K[_ ((Z_!74/VI6 M^+EGINGZ?X4C2&YMO#^GPF-H[Q<@MD?PGJ17V=IUC;Z?90V-I"J10QK'&OHH M& /RKR7]AGXA?$GXJ_LO^%O'_P 5IXYM9U2Q$TTD:A=RD_*2!QG'7'>O8(R2 M.17N8:G1C'VE-6YM6?F^=8[-*E98/&5.;V%X*VVCU?FWW>MDELAU%%%=1X@4 M444 %%%% 0#R11CG@444 %-E^Y3J;-]R@#D?A'_ ,BQ+S_RV3_T3'7'_$FT MUE]8>6"*1H6N)!&(QWW'('XY/Y>E==\( 1X8D!_Y[)_Z(BKE?B1X@U>WO9M( M@D:.W^T2$XZ,2Q/_ -;\#7J4>;ZY*UCY_$\O]FPYF_D7?AQ#>VNG)7^,K+Q GB*Z^V+(TGF9RN>!G@GMCWZ8X[5Z M=<^'M/L;.34K:Y>.ZBB+_;FD)9L#/S=B..1C&.E>:^+/&&NWGB&5YI-GV>9A M'&R\+@_Y_'\*VP-^=\FOJ<^:6]E'VFCZ6_7^OO.V^'HETZRMSKZJLDD6+%I% MZ+U8#/0D\^XQCIQ>U*XT^?53>6\>ZUB*#4I(S\C8)P#CJ5."WH.OI5/PA-)X MPTZ./7-\B0Q*?++;?.SW;N=N-OU!)YQB]=0KI5_'H5C>^7;W!4,A8YA'/W3G M@-C:/0GBN>?\5WW_ .RE_N\;?#T;W_K^O,D\231WRPP:++&VH;@UNRL#L7^ M)B>P(R.>IQ3DO?#J^&EM;B)?+\ORVMF7]YOQ]W'7=G\<\U!JUA:^%+8:GH=N MRMY@#6ZL2)\\8QZCKD)T\'V3 MW(D,6YMFT$=3S^?&/^!8SD9=XZ\7:W?:G&DK^6L<:NL87Y0<9Z'ZYYYY'M4V ML>-O$D_A*VAE=E#%EDD8',@^OH/?KN7TY]:/M>2GHCY^7U?VE7WI;%?PWIOB MB3P_JGV*&81^6!(ISR0R\8]<;OZ]JB\#6.NR^(83:)(&!!5FSP,_>^G7)Z8R M.I JWX8\:^(;/P]?PQ.TBQPCRCM_U9W*N1^#?^.]CG,/@3Q7K4.O[D9IA,V9 M(_[Y) Y]^>/?VSD?M?WFB)B\/S4?>?\ 3,W6+;6QK4D^#NSSUR>XKS;4_%NOOXA:^^W M,9H9,1NHQD>H]CU Z8/?G/HVAP1^,;5KO7H]P1E5;7D*OR*V_'ONX]L=\USX MR_LX\RLO([,MY?;SY'=WV>B_XR&+>6*W,./NMS+EE]BV?KU[ MTZ__ ./WQ'_V"X__ $":CPVIA\4ZI8K,9([>WMDC+-D@9E;:?IG'TQ1?'_3? M$@ _YA4?_H$M>?/XI>B_0]BC\,?\4O\ VX^=?V C_P 2&,?[(_E7U@O2OE#] M@ 8T*,D?PBOJ\=*Q.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XZ_X+B?LE_\ M-6?L$^*+?1M.\[Q#X,4>(M!VKEF:W4^?$/\ ?@,@ _O!:_FR4YK^PJ^M(;R& M2WNHEDCD0I)&ZY#J1@@CN"*_EQ_X*=?LK3?L<_ML^-O@W:V,D.CKJ1U#PWN7 M@Z?=L _E7;>%_@#=?$[Q+I MOP[^'>C27&O:U?0V6E6ZS?ZZXD<(BDG@ DC)/ ZUY[H'B[5O#D;PV9C:-VSY MFM\L=QY4@9HR>Q95'+*LL-!3K*,N5/9RM[J;Z)NR^9]N?LX_ M\$P?V5!\;])_90^*'_!0#09OB-;WA'B'P1H>D2NHD7YI;&WO&(C><(&!&,AM MV <8K[V_X)4_M_>&?C;\:?&_[*/A[X;6/@[PWX/L8U^'^B1Q[9TM+>1H+D3D M_>E+&.0^A+Y)/-?GQHOQ2_X)&^!_VMD_X*1>'/C%XXOM?DUB7Q#8_".;P[L- MKKE?88?'X7*ZM/V/*ES:\KYKPT2;=W;=NVFNZ/YGS'A M+B'Q(X;S!9NZTYT:$71]M!453Q%W*I&G",8J2:C&"G)2M%M1G).5OZ5%Z<45 M';3K<0+-$?E905_&I*_0S^%0/(Q3#"&ZM3Z* &"(8ZTCP!FR*DHH 8(R"IST MI]%% !1110 4444 %%%% !1110 4UDW'FG44 1/ [*5#[<^G:N6TWX76MEX@ M?6+^]74O.MU6=M0MU>0R*V5=6XV@ D8 ]*ZZBJC*4=C.5*G4DG);;'#Z[\(] M-O=2CFT72]+LHX5,GG-:>8[S<@!AD ISG'Z5X7^T]G_A:_P^Q_SPUK_T7;UW9;_O+_PU/_2)'GYE M_NJ_QT__ $Y$^5_B;\/_ ("7'C*2&TU*ZN/[/U!YI[>'PW'J,6G3$[G$+LO[ MLYYVJ6P>PKU'PUX3^#LWP8NK*#5UNO#]ZDEQJ6J74VV1Y0Z=K!&GRNMO=Z78M<1W:F0L)04/R2$'G=W[XKTC2? M@UXWN?@SKVE7%JEOJFKZQ'J5OI#HU*=;GG)2YHABW28$_=DG R%/3=M3(_B]?1 M/CUX<^%4OAK3SXPU!].: -:Z6+&W$TDJ,F&MQ#M82QE0,J1@8SD=:XO5%\9^ M*='D\$Z?\+-66^GA,#?;;3RX(\C:6:0_)M&?X2BZ'_ &;?6]N!Y@XC_?QJ3\V=F"!SC'7!KGRG$X[%)SQ5!X:2G-*//"?- M%?#4O!)+G[25UU;Z<%2%.C%^R?-I?:VO;7MW,/\ 9R^'_P #O#/B&VTO0Y7M M]0L_,N=/T=M#338 Q&&FCC0;9) #R=Q(ZX%'QN\)_"&7QC>6Z:U=#4)IUN=2 MTRUT--0@BE(&92& $4C#!.&YZ[>+/&7C;1=3A\+WVG6&D:@MYL[.3CIO:.KN]-^I[A\)/#?PGN? .I#0M2.J6NI;XM>N-141RG";3% M(F%\H*IX7 !R.N3YNUS\-;<_P!C0?%SQ0/#:Y3SH]'+(%SVN-N2F.-^P\<[ MN];WPO\ @GXR/PN\4:/JTT]C<:[H]O8V1OF_?/Y,3KYTVTG!G%S; ME%27-%^#]C\ M+M-M=6U!K/3+/R_[!N=,;?-O*X7R0 WF%E)R""&!)/K7!_!GPG\#;/QI9P(^ MJ6UU]L,^FV.HZ3#907-R 2'_ '(Q)(!RJL0VNK MR^U2W\A8$@E$F$4DL\C$!2GR-\Z;M+WD[1Y5KJG?9'H?[0FB?"*Y\1G^V;O4/[8NK53>:?I5C'=+ M-$I(1YHY!L4CH&)4D<#(K8_9\TGX60Q:A/X4U"\NM26-(=0CU6W$,UO#R4C6 M)0%6,\\J""1R217GW[4/P&\9>+=:U:^L(M0FL=4N(+I;G3(?.>*1(A&8I(LA MF3@,"N<$G.*W?V=_@AXL\/V\MQKC7]C;Q^'Y=+M'O7 N+@RN&,K*"=@3 " G M(R:Y_:5'%T_L**:ES)W=U>/+NK=[V/%C7Q3Q3HN'[NUU*_7KIW\SA?%WP@_9 MFG\8-KOA*_\ $UF]G<.5U7PWI<;+;$$[E25ES(@.>-L@'\/:O6_A+;>,/A]X MA^'O_"!FQ\8^'1K$DMBUNPM=1E+6=T69F8^3,YRQ.?*.X8/J/.G^&WQ!\/SV M>A7_ ((U66>SC6&&3385DMYU3HZON C!QD[L8]Z]C_9[\$ZOX&UWP-IFOLJW MEWXNO+N>WB?^.Y'&'?%^ER:)XKT.SU*SF7;+:WUJDT;#T*L"*\ MEZ7&L.EZ/H>K6L<%I;JP9(!NMV=XTP%4.S$+\N M<<5\_"IA98>4(OD;:>MVM%+9I-]=FMNK/0E#%0Q$:DUSI)K2R>KB]4W;ING\ MCS/PW\2'E6SMYO%&L.[S3(LS?!6. NZS#$A^; R. 0,/NW#DBM"Y\0ZK]GCO MCJ-XR^2[^9;_ JLW8Y,DBMS.>B@<#J44GYFY[FW_8;N+6.,GC"XQM%9^RI_\ /Z/_ )/_ /('1[:I_P ^9?\ DG_R9YU=?$R*'58] M,35=65VL;EFCMO@XC)%(LK@YD#E%*%0OEDDMYJ*X^R:K=/=1W M102-\+88UY9,*6 9= MRD'YOLF3UR,G@\]>:AA_8>NX;P7A_:P^*DGS2'RIM5LGC.]0&&TVF,8'3'!Y M&#S1[.G_ ,_H_P#D_P#\@+VU3_GS+_R3_P"3.!3XEW=Q9+%+JVK%K=3Y\?\ MPJ&-"\92':X#2X;A_F*9&[<"%P14,'CV^EGCOXM?UID8E8R?A#;Y4>3,2I_> M;D(V9.<= /XQ7HD'[#D\&TQ_M5?%(;<@9U6R/!&".;3H?YTZ?]B&[F6-(_VK M?BE"L0ZI^\N+CX*AHY3Y60 X?RTW<_/NS\K+PQ7/H\W[#FHRR12+^ MUW\6HS#&B+Y>LV2[@JLHW8M/F/SDDG)+8)R0,$/[#5[']E_XRW^+#?8[S[3$ M9-9LCN?8R8;_ $3YUVL?E;*YP<9 -'L:?_/Z/_D__P @/V]3_GS+[X?_ "9X M_P"/3_QC3\-LSF7_ (KO6OWC6ZQ%_P#3;SDHO"$_W1P.E?57P6_Y$RT/_3(? MRKPO]L;P-I'PW^'?P^\&:#),]M:>(Y2)KJ4R32R/'(\DLC?Q.[LSL>,ECP.E M>Z?!8Y\&6G_7(?RK#%5(UL3.<=FVU\V:X>,J="$9;I)/[CK(Q\[@_P!ZI#ZU M'&?G:3!S^-.QCI2 YZT +GFDXZ8I:,@]* &]6Q7D7[=OP M&\;?M+_LN>)O@S\-]:TO3]>:]?I MIX'2@#\I/VN_$WQ+A_;S\)_!/_@H!\ =&^)7_"QOA+J&C^%_#?P=65;AI8]0 MANFE:34)HA&Z+"S*RN#U'.<5['^R!+H'[#_AC4/#'P$_X)2_'2T_M:Y6;5-1 MO[G1KBZNBN0@>1M1^ZH)PH R3U)->L_MS_L@_$7XJ?'GX._M8_L^>$/!][X M^^%NL7N)O%FI7-JD^F75I+%);J\$99?*C=Y@<#RV7 7;C.2:\C-L1 MAA^A3_ +>'QL9=G_#L[XW3#+)&(?X1L;=E6R01@?IA^R'JO MQBUS]F'P)J_[0%HUOXTN/#=J_B*.2()(+@IR74?=8X?&9A@>7#572DV MG>VJ6[1S\%9QP[PCQ4\1GF CF%""G!T^>T7)KE4U*S32W5U9WNK-(@_9J^)N MM?&CX$>#_BOXE\.2:/?>(= M;Z[TR12#!))&&*X/..XSS@BN^P,5#;6<-LBQ M0HJK& $55P .@':IJ]**E&*3=WW/B:TJ=2M*<(\J;;2O>RZ*[U=MKLCE&.1 M_>%/Y*\"F3'C_@7]:-?&'Q'L)=<_:YTWP]KTGCR M;3[SX4W6BV[R36$//!=Q??M&VNH> M)/$VJ3P>*?A'_8L'FZ) L5)P>N">:O0Z-I%M=37UMIMM'-C6T:16VF6L:QN6C5+ M=0$8]2,=":D71])CO&U&+3[=;AQAYUA7>WU;&:?/'L+EEW/SC_81T/X%:!_P M4W\:>/OV=?''@/Q?9_$3P_>-XBLO!?A)].F\#6]I)&+:WN75R//N7EG:42HD MK21 CY5 $O\ P30OOV-_B'^W5XJ\6_LJ:WX9T/3_ AI6J>'/[+BU(W'B+QG M_T+PUK>CS7]FP_M*ST M^ZB:: GIYJ(=RD_[0%2VUUX+@\1-H=E=:7'JRP^4'S;<\9QB MG*I>_H+DV/G_ /X)P-C5_P!HD_\ 5RWB'_TDTZO?? OQ$\'_ !)TB;Q!X)UJ M/4+.WU&ZL)IXE8!;BWF>&:/D#E9$93VR*\!_X)P#.L?M% 'K^TOXA_\ 233J M^EHX(HEVQ*%YSPOZU%3XF5#X49/@CX@^$/B3HLGB#P3K4>H6<6H75E)-"I % MQ;S/#-'\P'*R(ZGMD<9%>._M3?&OX->,?V.O$WC"'XRRZ'X=U"ZDT*3Q9I]E M-*ME="^-C()$7:_E+.KQR,I7";B& ^:O>$MXXUV1@+R3\HQS461E&T^^*2WN4?-_[!3^!['Q9XZTOP1H7AV*.*+2VFU+P+K$UUH-WF.7:;57 M&V%P.9%0L#N0DDU[U\/OB1X-^*O@^U\>> M:CU'2;UI1:WD:,JR>7(T;8# ' MAT8=.U7-"L_#MI:_9O#=M9PV_F,S)8JBINS\QPG&<]>]7!!#:IMB"QJ.<*H M%.4N9W%%61F^&_'?AGQ=X3B\;^'M1^T:7-$\D=T(V7?@?_L/2_P#HJO6_@I_R)MK_ -<1 M7DG_ 4&XL_ _/\ S'Y?_15>M_!3_D3;7_KBM '8T444 %%%% !1110 44$9 MHZ4 %5=:O[;2M,GU6\=5AMX6EE9NRJ,G]!5KG->8_M8>,?\ A$_@[J$4_\<#5=.'M*BCW.?%5XX;#3JO[*;/D+Q3X@N/$_B74/$UZS&2^ MO))VR<_>8D#\!Q^%=YI#MX,_9GU/5.4NO%>KI:0MG!^SP_,WX$Y!]0:\TB21 MW6*)2S,V%4=R>E>E?M&2KH:2PT.'>_S-G!D< #CT4UO_ ++'A!O%?QET MYY82T&F[KR;Y>!L^[_X\17VE$F%Y%<^*QU?"RY*3M=:GJ9-P[E^;4?;8R',D M_=5VEYMVW[?>>-?"C]@?]F#X1B*XT/X:VM]>1_\ ,0UG_2I,^HW_ "C\ *]A MM;&"R@6WM8DCC7A(XT"JH] !4XSW-!('6O'J5JM:5YR;]3[G"X'!X&GR8>G& M"\DE^0B+L&,TM SWHK,Z@HHHH **** "BBB@ HHHH **** "FM@_PBG4Q0O2 M@#&^('@/PW\3?!FI> /&&GK=:7JUF]M?6^<;XV&",CI7P[X2_P""(_A'X"?M M,Z/^TS\"/B+>>9H-K<-%H>L?OA<2%&V(7_NY*CD9 %??97MBF.N>3652C3J2 M3DM4=^$S3&X&G*E2E[LMXO5/I]_FM3\"OVHKSXM?&_XI:];?M(>&[/39+"ZN M+?4(+6R,:^=YAY1SP1M('!KB_@+\./@QJ'C>UNM#^,JZ"N@QK_:EI>2;([S9 M( J)_>W'KWQS7WW_ ,%N_P!CO]IKXA^+=)^.?P1L9/$&FV.FM!=>'8[56^S2 M#),V.K;L^YR*^8_A+_P3T\$Z#_P3Z^(GQX_:T^&_B'P_XFT_6%DT.XAM',S@ MHO'E]U+'!)Z=:^:^J8BA6J4U)V:=GLTNK6]F?L5;-LES;(<+45-*2E&Z2NG+ M:,6M&TGK;RWMO5_:,\:?!W1_ _BBVLKS1]2NM0FDL]">&0M)$Q/RLY4Y"@9. M<\_C7 _L?>*M,^#OC.S\*>'/#MQ=WFJ6L*M]FC.Q9R^-\A'W?OX49R06)&*P M_P#@G1'X>\=_M:>%? /B;3HKZPNM96"^M+BW$D4T,@VX?(Z[?Q!KV+_@H+^T M+X<^%7[>%CX,^ NB:;IGA?P/'!$VI:?;J4>0 +*\K<;]H&P#D9%9XBMC)N-2 MG;W-%=[Z*U]-;ZW.G+\MRC T:F7U(.7UA2S[&]_P4GM M?'7@+X8:;K?C?P4MSHXO$_LZ2XFECS)+V.%'NF92ZAXR1DG(XR<8K[B_;:\(^*?\ @I)^P?X; M;]E9-'U^WO9DDU"XOK<+/&$C&Y8MW^KP M:;4KZ1=T$\;C(!(^XVQ@"*]#B_X),_LHVNJPWNFZ+?V]G',)&TU+O,+L">N> M>_/-7/\ @FS^P_IG['OP3L[#7+:&;Q=J=NDGB&^51_K.OE@CL.E?2(4@8Q7M M8?"1JX6$<3%-K:^MO^#W/SO,L]EEFFV]Y)I4^EK-(EU(S.W##+<#/(Z8/(/6NC^$/\ R+$A_P"F\>?^_$=< MS\2;?PV;EIKB:1+UKF087[I7><9[Y^@/OVQZ5/E^N2NCP<0Y++8.+6W4T_!N MJ6>NZ"NA6.FQPRF?=N;.$')\S((.X8P,$=N@XK# 9(' [Y) QG62]L[;?C\C?#\WU>/-\5E M9K;YCI?#=_86 N#<"<0_.=/W$0X'.U)S98U)&CL-I\ZX51]H\OU90<#CJ1DCT';B/'=M MX2A\1N+663_6$S+CY0V><>O.>N._-:X7^)[^NG0Y\PO&BO9Z:K?]/Z]#?C\3 MVFHZ78_V;9_99(8R&>'(9 >RGL#PW.?Q/-6;36PNEW<$ED)IIONW#DEF/)RQ MSGY0-PP1GM@U2NH/#D&C6+^'IF:0QG<& PPR =_<'TQG@=, $6=-71#HET=1 MGE6Z 7:JXX).!LYYST.3TZX%*4:?+>W7Y[EPE5Y[-K;Y;!IWB..PU)+W5&DF MC7Y?,G8LT1/&5[<\#IGW[5$VIO+)B.W_ '32;OL/F'R3SG;@>O\ WSGL:;X< MBTZ?4E&OH G_ "SCX,9;'\1[8_+/]LU7+ M#F>AG[2IR)WZ_/\ X8I^//&&CWNL*/[%5ML:EF;AB<9^;^6.ON.!5C6O&FC2 M^$+.UBT6%CNQM .U?<<\%N>N>0W4GF>7^]SU5<4W&G^\T9,98CFH^]'\.Y'JO MBG2#XC:Y?PW#NCF^9#]T$'D'U.Z^&UOJ-ZVNV4-PVGLV\G<#*Z]:_*'_ (.?OV3F\4?" MKPG^UWX:TS=>>&+S^Q_$4D2\FRG.87;V2;*_]MJ_6"N"_:4^!'A']IGX&^*/ M@+X\1O[+\3Z/+97$B*&:%F'R2KG^)'"N/=:\_-<$LPP$Z'5K3U6J_$^PX!XH MJ<&\783-4WRPE::76$O=FO\ P%MKS2/Y*L ]30 ><5]6?M:?\$:/VZ_V4_$N MH0W'P=U3Q5X>@N'^P^)O"MJU[#/#N^5G2,&2%L8RKJ #W(YKP_PU^RW^TMXQ MU./1O"OP \:7]U+($CAM?#-TS;B>APG%?C=7!XJC4]G.#3[6?],_TRR_BCAO M-L"L9A,73G2:OS*<;+UU]UKJG9KJ<%R.HKZ=_P""7O[(7Q _;N_;$\*^%K;3 MYI/#^@7MKJ/BW4E3]U:6,+AMI)XWRLOEJ.I+$] <>X?LB?\ !N9^V)\;[^WU MOX^F'X;>'RP,RWNV?4I5[A(%.$/N[#'H:_:K]C[]BSX#?L2?"JW^%/P*\)I8 MVXVR:EJ4WSW>HSXYEFD/+'T'11P !7TF2<-XO$UHU,1%QIIWL]&[=+=O4_$_ M%+QUX?R/*:V7Y)75?%33CS0=X4[Z.3DM)272,6]?BML_688Q'$L:# 48%/H MQT%%?J!_!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 !Y&*\7_:F\)W/B&WTW6;;29)[ MS2//_L^6"^F@9?- #@F-AD$*.OI7M%5[[3+34$V7,0;ZUI3J5*,^:#L_\U9_ M@9U*=.M'EFKK_)W7XGPO//\ &2.1D7PC-M!Z_P!O7_\ \=IGVCXT$8'@^;'_ M &'K_P#^.U]NGP9H+=;"/_OFC_A#-!_Y\(_^^:V^O8K^;\C'ZGA?Y3XC%S\: MNI\(3?\ @^U#_P".T&Y^,YY'@Z;_ ,'VH?\ QVOMS_A#-!_Z!\?_ 'S1_P ( M7H/7[!'_ -\T?7L5_-^0?4\+_*?$?VCXTC_F3YO_ >ZA_\ ':/M/QG'_,G3 M?^#Z_P#_ ([7VY_PAF@_\^$?_?-'_"%Z#_SX1_\ ?-'UW%?S?D/ZGA?Y3XB% MU\:&''@Z;_P?7_\ \=H^T?&H<#P=-_X/;_\ ^.U]NCP7H(_Y<(_^^:/^$,T M]=/C_P"^:/KV*_G%]3PO\I\1_:?C1_T)TW_@^O\ _P".T?:/C1T'@^;_ ,'U M_P#_ !VOMP^"] _Z!\?_ 'S1_P (9H/_ #X1_P#?-'U[%?S?D/ZGAOY3XB%S M\:<\>#YO_!]?_P#QVE-Q\:._@Z;_ ,'M_P#_ !VOMP^#- /73X_^^:#X+T$_ M\N$?_?-'U[%?S?D+ZGA?Y3XC^T_&CMX/F_\ !]?_ /QVK7A[Q!\;?#/B2Q\5 MVOP^M[BZTV9I;1;_ %.^FC1S&R%MK2X)VNP_&OM+_A#-!_Z!\?\ WS1_PAF@ M_P#0/C_[YH>-Q4DTYOM]XU@\*FGRK0^;/^&LOVKNI^&'AO\ [\W/_P =I/\ MAK']JXGCX8>&_P#OQ<__ !VOI3_A"]!SG[!'_P!\T?\ "&:#WL(_^^:Y3I/F MW_AK#]JX#_DF'AO_ +\7/_QVFK^UC^U<.#\,/#?_ (#W/_QVOI3_ (0S0?\ MGPC_ .^:!X+T$?\ +A'_ -\T ?-I_:Q_:NQ_R2_PW_X#W/\ \$= M$B;4JP_*OG;5_@Y M^TC/?226WQ@\3(F[Y576)@/_ $*OK!D5QM84P6T'>)?RH ^2?^%+_M,#_FLO MBC_P=3_XT#X+?M,=?^%R>*/_ =3?XU];&VMSUA7\J7[- .D*_\ ?- 'R3_P MI;]IG_HLOBC_ ,'4W^-(?@O^TQGGXR^*/_!S-_C7UO\ 9X/^>*_]\TAMK<]8 M5_*@#Y)'P6_:8ZCXR>*/_!U-_C2_\*6_:9[_ !E\4?\ @ZF_QKZV^SP?\\5_ M[YI&M8&_Y9K^5 'R2WP6_:8/_-9/%'_@ZG_QII^"7[2S<-\8O$_KSK$W^-?7 M'V6W/6%?RI?L\'_/%?\ OF@#Y''P2_:8_P"BR>*/_!S-_C2_\*7_ &F#_GBO_?-'V>#_GBO_?- 'RMX8^$'[1MC MXITN]U+XN>))K>'4H'N(9M8F97C$BEE()Y!&>*^JU( P34,]M;A=PB7.X=J^ M=?BE\0_VZ[+XO:EX/^$_C'X!_8C(K:5I7BC4K^/5!"<8,D<+'))/88Z8ZU48 M\PF['T=+@+E>M?*'@+XQ>*_%GQ'L[OQ'^URWA_Q-_P )]-I][\+9-&MIEDL$ ME=5MUA\O[2C,@5_M8?R^IQ@XK85O^"NB$_\ ) 7W?WEUA=OTP3G\<5##8?\ M!6*&\;4%T[]GF2Y9=K7+QZNDFWTRN*?#J:MJG@?0X/LMG+&DE[J$-YK32QG;@O*JLFX'+ ,OJ*XSX2_'WQWK?C MKP9=WO[1L^H>*O$.L7%OXR^$SZ1 R:+;K'*7(V1B:S\AE3]],[)-G:!N=2-^ M/3/^"KUN_FQ:5^SP)"Q;[1Y6K+(">^!D9_'FB/3O^"L5O-)>0V7[/:S3?ZZZ M6'5ED8>A /S#ZFGIW7WBN_,Y?X%?'3XHP:]X+\4Z_P#M)W'B^/QIXF\4:.-$ MNK&SBM4CLC<-9^288ED$N(HPS,[!Q+T'RXY;]F7]J']J#XC?%/PY9^*_B)I: M7VN27T/BSP;?^(K!I=.D6&5EBM[&*T2ZM9(951-TTC)(FYB22AKU&+3O^"L4 M$*PP:=^SS&JMF.18]7#*2>2%^Z#^-*--_P""KR7+7T6G?L\QW#J!)>1QZN99 M /[V<'(+?XGZ+X7\4I\<);?37ANE MO'EC.-1>"P_9[ADD8&62$:P6E_P!XG'Y\TW*\ M6M/O#JGJ._X)OD?VO^T4?^KEO$/_ *2:=7OO@7XA^$_B/H\VO>#M3^U6MOJ- MU8S2-#)'MN+>9H95PZ@G;(C#.,'&02"#7P-^PK_P\U?5OCH? A^"L;?\- :Y M_;2Z@NJ,/MWV:P\SR2I'[G;LV[OFSNSVKWS9_P %<-^Y(?@"@Z^4O]L;3]6X M//TJ:D?>>J*A+W5H>_\ @?Q_X5^(^C2>(/!VHF[M(M0NK*25K=X\3V\SPRIA MU!^61&7.,'&02"#7CW[4_P 9?A%XY_8\\3>*?^%E:II'A[4;J30IO$6F:-<3 M26=P+XV,A>'Y)&A69660@KF,.P8##5@_\;3)_P!@H^";/Q?X M\LO!FC^%V2)-+^T:]X!N9CH=^?*EVB"*1W6"1!]]4=Q\RY)(YU_VK_BO\(?B M5^Q[=^*C\39])\->(-4LM/A\0#1;B:!'_M!(MMW &BD^QM(ACG^:/]RTAW*/ MF''^"O$__!3+Q'9R2_#O7?V:=2M8Y")$TFZU-XHV/O$6Y^H&:UO*_P""M6QH M6LOV?)(VZPR?VPJCV& =WX@537O7N@O[MK,O_L+WO@C3U\?'PMHOAZ&UM=1M MI+K6?!=Y/+HM^WD$DVRR%O+9 ,.B%ER1@FO>?!GC'P]X]\-6OBWPM?\ VG3[ MV/?:W'ELN]02,X8 CD'J*^=;"Q_X*T:;;_9+*T_9]CBQQ&L.K1JGN I.?TKT MO]G6+]KV'^U$_:B'P_\ +VP_V(/ \=VI!^?S?.%P2,?ZO;M_VL]JF4>MT.+Z M'#?\%!P39^!C_P!3!+_Z*KUSX*G/@VU_ZXBO(_\ @H,AE]/FK@CB&_GVR /QK%\?^*+CQGXVU3Q3$O M@YXP^(N[9<7D<>BZ>W&$9;3P_JWC6XAP;ZX6VM6(_@CY8_3#1X%^%VB^&Y(?+FALU>Y7CB5_GWWKY;89?0BJ'B/PAX>\7:'<>&O$VD6U]I]W&8[BSN(0T< MBGJ"#6G119/$K)E5 MDSG/X=A5#XO?\$J/V.OC1XFF\5^+/A]Y=QYZ^M?2-%< M_P!4PUKV]CFOA=\)/ /P9\'VO@+X:>'+?2=)L M_P#4V=LN%'O]?>N@^S#V_*I:*WC&,59(\NI4J5JCG-MMZMO5OU&JC+WHV'&- MWZ4ZBF9C=K 8#4Y00,444 %%%% !1110 4444 %%%% !393\E.J.X)6/- ') M_"++>&IL_P#/9/\ T1'7,_$#P9K>IZM+?:?IMU(S7#_*L.1M)X()..F.XYJY MX8\0:_X-TUM/E\/QNK%&+7$TL;*1&BD8$3#JO4$YK0/Q0U4CGPY9_P#@PE_^ M,5Z,?;4ZSG"VOFCQ+8:O@XTJC::[)O7[C.\"Z'JWA6W%^^C7DEQN.ZW^RD?) M\W?INYSZ=JW=4U.^U^);=O#6I6JQL)%>>W#9<L M?_!A+_\ &*#\3M5!Y\/V7_@PE_\ C%*7MISYW%7]?^"73^KTJ7LXR=O\+_R- M.X\4:I=VTED/".H1R.K)YK0@QKD8W<'<1[8'X5P/B#P!KT^JRW&G:5>RQRR% MMWV?!&>QR1^F:ZP?%#5O^A>L_P#P82__ !BD_P"%FZIGY?#]D/\ N(2__&** M/MJ+O"*^\G$1P^*BE4F]/[K_ ,C*@\,ZCI6FV\4&DWT[XQ,JVN,'&!C)'8#J M1S^56K32]4>T>5]'O(I/^6<+6IRW!!!(.!P3CD\]:N?\+0U;_H7[/_P8R_\ MQBC_ (6;JW7_ (1VR_\ !A+_ /&*KFQ#Z+[T*-/"+:3[?"_\C.MM%U&^;R;_ M $34((NK.;?+'G( "D]_7L/>D&F:\D_EIX?OFPWS3?9\*??KG\,5H#XG:MU' MA^S_ /!A+_\ &*SPO\ -+_P%_Y',^*? M FMW%XDNF:9>S)Y:JS&UVD$=3@D?IFG7_@+5/^$?@MK6QO'N$;,D?V1L'GC! M/U/Y^W/1_P#"SM5Q_P B]9_3^T)O_C%'_"T-6_Z%ZS_\&$O_ ,8JO;8JR5EI MYHS>%P#E)WEK_=?^1S6B^ =532+R&^T^\BEFCQ'']E)YW*>2"1_"/7]*9X8\ M!ZW;:HMSJFE7T42_>*VNXD9[ $_KC&<]L5T__"S]6[^';/\ \&$O_P 8IP^* M.J'Y1X?L_P#P8R__ "/3]MBM;):^:#ZK@$XN\M/[K_R-"W\2:S:6JV#>$[^2 M15"+,L($;(W;A],&J^C7E[X9@:UC\.ZE>1R-YFZ&U"LK;0",,PXR,CG@< M=A5<_$_5NO\ PCUG_P"#"7_XQ1_PL_5?^A>L_P#P82__ !BN?V=2UN7\?^"= MOM:=T^=Z;>Z_\C4\+K?W&OZEK%UITUL+F"W54FCVD%?,R/%_L!9.@QC;V_ MI7U@.E?*7[ 2,NA1Y_NU]6K]T5S'>%%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4UHPW4TZB@"/R$]:%@1!A34E% #?)3&*.+.QDZ M;9E?^BFJC*PFKGS9?>._BPGQ:MX]'\>^/)/B*?B5':R>#9=/D_L(^'S=A9I& M/D^6(EL]TJS^8'\T*!DL4.?\-?%OQ0T/QQX6\??\+:^(FJMK7QPU?P]?:3K5 MK,;%-$_TLV_[CR%"*NRW9;@\Y.W>0Q6OHD?M<_LT@[A\6M,W>N)/_B:!^UU^ MS2/^:M:9^"R#_P!DJO:>1/+YGSMX&^(_Q;O/VP;.SLO'WBS6H;KQ9JT5UHXN M+VU^PV:V]UY(NK">V:U^R)(L02YAGCED=HB0X9E&3^S3\0?VHM7^.7AF'XF_ M$>\L]!M)DW #Z>/[7G[-/ M;XM:;_WS)_\ $T#]KG]FD<_\+;TSWXDY_P#':/:>0N3S/ _V>O%OCK0?%W@' MQCK/Q=^(FO-XK\6^)M+UBP\0V\[6T5G UP]D!!Y"+;E52#;,0IDWD,S9 7$^ M!WCGXQ>(_P!I"VTV;XH^--V4FEVQ\YK5;S3KFU-M;)%\D4< MUO.K3$H[)(&8I],#]KO]FG&/^%M:;_Y$_P#B:/\ AKS]FK.3\6]-_*3_ .)H M]IY#Y#R#X7?'+4-4^*7P[\%+XP\:7VK6'A_4;#QO;S:3^> _'NF_$/19 MM;TC3M2M8X-2NK)H]4T^2VD,D$SPLP5P"4+(2K]&4@C@UY;\/?C)^Q7\*YO$ M$_@+QUI.G/XH\17&O:Z8WG;[5J$RQI+.=P."RQ(,# ^7I71_\->?LU?]%G?$'19-%9M&AUDI'*-AMG.S?$" 7 MC 4^8!C*U[?\.OB'IGQ-\&VOCC1=-U*SM;MI5CM]6TU[6X7RY&C.Z)P&7)0D M9'((/>N2'[77[-*]/BSIG7LLG_Q-._X:\_9KZ_\ "W-,_*3_ .)IR?,[BBN5 M6.Q\+>.-/\6^#X?&MA87\-M-#)(MO>V317 ",P(,;?,"=O ZD$>M2^"?%]AX MY\+VOBO3K&]MH;Q"T<.H6C03+R1AD;E3QWKB?^&N_P!FH?\ -7-,_*3_ .)H M7]K[]FM.GQE%%!H R?&]IK6H>%-2L/#\BI?36,R6CMT60 MH0I_.OAOQ/\ "KXC>#[DV_B'PC?0E6QYHMV=&/LPX-??1 88-1O;QNNUQD>] M=6&Q4L/>RO<\?-#?AE-$T-PT$NK:E$PY$L MI(0'W"[A7/\ P/\ "$GC?XJZ+H/E[HS>+-?$U M8W\7Z MQ-"FV&XCD9)$&2I() P!G.!S79''4XT&OM:_B>)6X=Q$\PA)M.FN5>=DNWR[GHL(Q'@4_G% M-"C'-.KR3[,09SS2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4CKN7::6B M@#R/XW?L^V/Q0&+I ?JM>4G]@'1"23"O_?(_PKZRZ]11M'I0!\FC_@G_ *$1 M_J%_[Y%'_#O_ $+.1 O_ 'R*^LL#THP/2@#Y-_X8!T4<>4OY4#_@G_HG:%?^ M^17UE@>E&!Z4 ?)I_8 T3/,*_P#?(H_X8 T//,"_]\BOK+ ]*,#TH ^3?^'? M^AYSY"_]\T?\, Z)VA7_ +Y%?66!Z48'I0!\F_\ # &AG@Q+G_='^%'_ [_ M -$SGR5_[Y%?66!Z48'I0!\FC]@'1.HA7\A0?V =$QQ O_?(KZRP/2C ]* / MDW_A@#1,E&T>E 'R;_P ._P#1?^>*?]\C M_"E3]@+18V#+"O'^R*^L<#THP/2@#S/X)_!:#X9VOV>W'%>F#@8HQ[44 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%13W"P#<[X'O0!+17@_[2/_!2 M+]C']DZY_L[XZ_M!^']#U#:#_9+77G7A!Z'R(@T@'N0 >U>,^'/^#A'_ (): M^(M6724_:+^QLTWE^?J7A^]@BZXW;VBQCWZ5UT\OQU:GSPI2:[I-G'4S# T9 M\E2K%/LY)?J?;U%]O;S]K&_;F5_S/KBBJ>EZSI^KP1WEA>1S1R*&CDC8 M%64]"".HJYFN,[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHILDBQ+N<]!F@!V:,UY1^T+^VK^S'^ROI*ZQ\??C;X?\+QR*6@AU*_59 MIP.OEQ#,DG4?=4]:^=$_X.'/^"63:NVE?\-"S#;Q]H;PW?"$_1_*P:ZJ.!QN M(CS4Z*+)-OG2:3?K(T)/02)]Z,GT8"O2(Y$D7*M7/*$Z:I)17=M)?B:@_8S\$C_F'K_WS1_PQGX)[6"_]\5X MWX,_X. O^"7/C35X]'MOVD8[!Y9?+676-%O+6//N[Q!0/<\5]:?#SXJ> /BG MX;M?&/P\\9:;KFDWL>^UU'2[Q+B&5?570D'\ZTKX3%87^-!Q]4T9T,7A<5_" MFI>C3_(\O_X8S\%=K!?^^*/^&,_!7_0/7_OBO"@,?V>O_ 'S1 M_P ,9^"LY_L]?^^*]THH \+/[&?@GJ-/7_OFC_AC3P5CBP7_ +YKW2B@#PL? ML:>"A_S#U_[YH_X8S\%?] ]?^^*]THH \6T;]DCP?I%ZMY!8JK( MM>']%BT.P6R@7"JN*OT4 %%%% !1110 4444 %%%-EE6)=S&@!U%>6?M!?MF M?LT_LM:,NN_'WXT:!X7AD5C FJ7RI+/CKY<0R\G4?=4]><5\X?\ $0Y_P2R_ MM=M)/[0DV5_Y>/\ A&[[R3]'\K!KJHX'&XB/-2IRDNZ39RUL=@\/+EJU(Q?F MTC[BZT@7;TKS+X ?M??LY?M1:"WB7X#?&30?%%JFWSCI-^KR09Z"2/[\9Z\, M!^->F1R+(NY37/.$Z]% !1110 4 M444 %%%% !1110 4444 %%%% !1110 44UVVCDUQOQ@_:!^#OP%\+R>,_C%\ M2-'\-:7#P]]K.H1V\9;&=H+$;F]%&2?2JC&4IO98>N,[UBQ7M_P"S3_P4/_8__:Y!B^ 7 MQZT'7[I4WR:7%=>5>1KGJ8) LF/?:1[UT5,!CJ-/GJ4I)=VFOT.:GCL%6GR0 MJQ;[*2?ZGM]%1P7"3#I-"]YV0-V5V;5%?&7Q(_X+V?\ !,'X:ZS)H>I?M+V>I30R^7*=!TVY MOD#9P?GBC*D#U!(KL_V?/^"N_P#P3]_:9UZ/PI\+/VD]!FU:=PEOI>I2-8W$ M['H$2X5-Y]ER:[)9?CJ=/GE2DEWY7_D<<Q72 M^9'("O:IJXSL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"B@^QJ&ZNX+6%IYYECC5A\O.#]:Z?X=_M _!?XNQL_PS^*&AZWM&7CTW48Y'0>I4 M'(K^QI5X2G_*I1;^Y.YV=%1P2K(N5?=4E:'H! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110!'=7*6L+2NV,5^1O_!>3_@M-XN^ VI7'[(/[+GB,6?BJXL\^+?$< M*YDTF"5/D@MVS\EPRG<7P3&NW'S-E?T\^/\ XZA^'WPYU3Q3(?C-\6O$GQ8\5WC7&H>(M;N;^ZD9B?FDD9MH_V0"% [ M 5]7PGE=+'8R56JKQA9V[M[7]+'R?%F:5LOP<:5)VE.^O9*U_ON8>LZWK/B M/5KC7O$.KW5]?74ADNKR\N&EEF+X=^!;'3;C4=:UQ MMOF2I"%/V6+=G]Y)G PKG@X5CQ7Z%?\ !7S7?V6/$/\ P1@^#=]^Q;X-N-&^ M'4/Q.N;70([Z QW%UY,=Y#)=2;B6+2NC2;G.\AAN"GY1]_BLRCA\72PT8/WF MDWLE>]M>KTV['Y]A+.&R.C##+U!%?TR?\ !/+]NKX>?MY_ ML\Z/\;/ [?9Y+E3!J^ER2;I-/O$P)(&]<$@JV/F5E/?%?R@CBONK_@AY_P % M,O"?[ /Q(\4:1\5[;7;SPKXDM(95M=#MXYI(KV)L!]LDL8 :-F!(.3M7@XX\ M;BO*J.(P+Q45:<.O==GZ'M\)9M6P^-6$D[PGLNSZ6]=F?TK Y&:*_/N#_@Y! M_84\E<^!/B5T_P"@#9__ "93_P#B) _83'7P)\2O_!#9_P#R97YARR/U*Y^@ M-%?G[_Q$@_L)_P#0A_$K_P $-G_\F4?\1(/["?\ T(GQ*_\ !%9__)E'+(+G MZ!45^?O_ !$@_L)_]")\2O\ P16?_P F4?\ $2#^PG_T(?Q*_P#!%9__ "91 MRR"Y^@5%?G[_ ,1(7["?_0B?$K_P16?_ ,F4?\1(7["?_0B?$K_P16?_ ,F4 MNW\5M:6=N\]S<3.%6.-5+,Q)Z M$D]A7\W_ /P5N_X+*_%K]N;XA:C\.?A7XJOM#^%>GW;1Z=8V)KW^S/#>A7NH7&,_9[&U>9\>NU 34>JZ/ MJ^B7K:=KFDW-G<1_?MKJ%HY%^JL 17Z"> _^"I7PF_80_P"">W@/X5_\$^3I M]O\ +R:\^+'BO5?"I>XM6ZI%#).FR1>0B[2541L0 7)KTC]M'QAJ/[<__ M 0VT7]N7]J+X>Z/IOQ0T7X@1Z3X>\5V&EI:2^(+%I=CEE0 ,IS)P/E#6Y9< M9(KZB698BG6C[2E:$I\B;?O7Z/EML[=[VU/EHY9AZE&7LZMYQCSM6]VVEUS7 MW5^V^AY#_P $@O\ @LY\5?V*/'^E_"7XQ^*[W6OA7J%PL$UO?2O-+H.X@">W M)R1$#]Z+[NW)4 CG^C7P?XJTSQ;HEMKNCWT=Q;74*2PS0L&21& *L".H(((- M?QK$<&8'T];O1].MYXI+5'/ MV?YI+A&W+&40C'\'7FOEN,,II4XQQ=)6;=I6Z]GZGU7!V;5JTI8.J[V5XW^5 MUZ=3]I**_/W_ (B0?V$_^A#^)7_@AL__ ),H_P"(D']A/_H1/B5_X(K/_P"3 M*^$Y9'WUS] J*_/W_B)"_83_ .A$^)7_ ((K/_Y,H_XB0OV$_P#H1/B5_P"" M*S_^3*.607/T"HK\_?\ B)"_83_Z$3XE?^"*S_\ DRG?\1('["G_ $(?Q*_\ M$5G_ /)E'+(+GZ 45^?O_$2#^PG_ -")\2O_ 16?_R91_Q$@_L)G_F0_B5_ MX(K/_P"3*.607/T"HK\_?^(D']A/_H0_B5_X(K/_ .3*/^(D']A/&?\ A _B M7_X(K/\ ^3*.607/T"HK\_?^(D']A/\ Z$/XE?\ @BL__DRC_B)!_83_ .A$ M^)7_ ((K/_Y,HY9!<_0*BOS]_P"(D+]A/_H1/B5_X(K/_P"3*/\ B)!_82_Z M$3XE?^"*S_\ DRCED%S] J*_/X_\'(/["8_YD3XE?^"*S_\ DRD_XB0OV$_^ MA$^)7_@BL_\ Y,HY9!<_0*BOS]_XB0OV$_\ H1/B5_X(K/\ ^3*/^(D']A/_ M *$/XE?^"*S_ /DRCED%S] )'$:%B:_/G_@MI_P5U7]@?X.ZB\R'3K96"O=2KN&3U5%[L,GA3F'7_\ @Y _89_LV40>!OB4K;3M M)T&RQ_Z65^'/_!1+]JF;]LW]KSQ9\=(3>KIM]=+;Z#:ZA@26]E$H2-"JLP4D MY8@$C+$\DDU]!PUE=/,J\8J[7?LOZ['SO$V:5,MR^])VE)V3[=W_ %W/ M+_B1\3_B)\8O%]Y\0/BKXUU+Q!K6H2F6[U+5;MII7).<98_*H[*,*!T Z55U M'P3XTTC2H]?U?PAJMK8S$"&^NM/ECADS_==E"G\#7M/_ 33^*W[)GP-_:RT M/XL_ME>#M3\0>$M"AFN;72=.TV*[$NH #R&FCDD16B4Y8CG+!>",U^E__!,S M]O;]MC_@I1^U%KWP_P#VA/@AI.J_L\:[H^I-J5G?>$HXM+T.S"/]G6.Z9 )' MR%C.68G+/A=OR_HF.Q];+TW"DN2"NVW;Y1T=WIUMT6[/SC X&CF$E[2J^>;L MDE?MK+567W]7T/R!^"'QW^+W[.'Q!L?BK\$O'VH>'M:T^0-'>:?<%?,7/,(!J:X>(LLHYAE\JR5IQ5T^NBNT_E]S._AO-*V7YC'#N5X2 M?*UTNW9-?/[T?U6*!OB46QS_P 2&S_^3*F_XB0? MV$_^A#^)7_@BL_\ Y,K\IY9'ZU<_0*BOS^_XB0?V$_\ H0_B5_X(K/\ ^3*0 M?\'(/["?_0A_$O\ \$5G_P#)E'+(+GZ!45^?O_$2%^PG_P!")\2O_!%9_P#R M91_Q$@_L)_\ 0B?$K_P16?\ \F4?L/E[R+MB%W8SA3QVIQISJ244M7H3*I&$7*6RU/! M?^"[W_!:[QWHWC+5/V,OV4?%LFF-8@V_CCQ18L5N$E(4_8[:0']V0.)' SD[ M5(P37XZWEU=:A>27VH74EQ/-(7FGFD+O(QZL6/))]3S4WB+Q!J_BK7[[Q3K] M^]S?:C=R7-[<2,6:65V+,Q)ZDDD_C7HW[&G[)OQ,_;:_:)\/_L[?"VSS?:Q< M;KZ^:,F'3;).9[J4]D1>?]H[5'+"OV7 8'"Y+@;*RLKREW[O_(_%$O!GQDA\/+JRHO_ !,[RUAO$NKK;IVMV@D$GH]5 M^9^M93CO[1R^GB'NUKZIV?XH_0*BOS^_XB0?V$_^A#^)7_@BL_\ Y,I/^(D' M]A/_ *$/XE?^"*S_ /DRO/Y9'I7/T"HK\_C_ ,'(/["8_P"9$^)7_@AL_P#Y M,I/^(D']A/\ Z$3XE?\ @BL__DRCED%S] J*_/W_ (B0?V$_^A$^)7_@BL__ M ),H_P"(D+]A/_H1/B5_X(K/_P"3*.607/T"HK\_O^(D']A/_H1/B5_X(K/_ M .3*3_B)"_83_P"A$^)7_@BL_P#Y,HY9!<_0*BOS]_XB0OV$_P#H1/B5_P"" M*S_^3*/^(D+]A/\ Z$3XE?\ @BL__DRCED%S] J*_/W_ (B0?V$_^A$^)7_@ MBL__ ),I?^(D#]A3_H0_B7_X(;/_ .3*.607/T!HK\_?^(D+]A/_ *$3XE?^ M"*S_ /DRC_B)"_83_P"A$^)7_@BL_P#Y,HY9!<_0*BOS^_XB0?V$ST\!_$K_ M ,$5G_\ )E'_ !$@_L)_]"'\2O\ P16?_P F4?$;Q1&PT&WN(_,AL858"2[F7<"0,[47^)_8-6 M=KG_ <@?L,?V=(8?!'Q)5MIQNT&S_\ DROQ"_X*2_M9M^VG^U_XG^.%D;Z/ M1YY([3P_:Z@ LMO9PH%565695);>Q )&6KZ#AO*Z>99A:JO=BKM=]4DCYWB; M-)Y;EW-3?O2=EY::O_(\J^)GQ3^*/QS\=7GQ ^*GC/5?$FNZE<%[B_U*Z::5 MV8_=&?NC)P$4 #L!5 >"_&!Y_P"$0U3_ ,%\O_Q-?0G_ 1Y^$,?QM_X*7_" M'P9=68FMK?Q4FJWBLNY?*LD:ZPP[@M$JG_>K]-OVNOVH/^"\?@3XH^/O%7P, M_8RTN3X::-XAOH?#MQ)X-M;J[FTZ"1D2Y\L2^8#LY## K]"QF8O!XF. M&I1C\*?O245O9):,_.\'EOU["RQ-64OBM[L7)O2[;U7<_%WX0_&;XO\ [./Q M&L_B5\(/&NJ>&?$&FS9CN[*9HG&#S'(O1T.,%&!![BOZ-/\ @C7_ ,%5M*_X M*$_!R2U\8QVNG^/?#0C@\3Z?#\L/6O$6L3W^J1VEI]GC2>1MSJL?\ !_A[5[)_P $M/VRT_8; M_:^T7XP:P-0E\/S6\VG^)+/355I9[>1>:Y>(,KIX_+95 M7%*I!737DKM7ZHZN'!OB4QVC+?V#9__ "95G_B)!_83_P"A$^)7_@BL_P#Y,K\GY9'ZY<_0 M&BOS^_XB0/V$\X_X0/XE?^"*S_\ DRD_XB0OV$^_@/XE_P#@AL__ ),HY9!< M_0*BOS]_XB0?V$_^A#^)7_@BL_\ Y,H_XB0?V$_^A#^)7_@BL_\ Y,HY9!<_ M0*BOS]_XB0OV$_\ H1/B5_X(K/\ ^3*/^(D+]A/_ *$3XE?^"*S_ /DRCED% MS] J*_/X?\'('["A_P"9#^)7_@AL_P#Y,I/^(D']A/\ Z$3XE?\ @BL__DRC MED%S] J*_/W_ (B0?V$_^A$^)7_@BL__ ),I3_P<@?L*#KX#^)?_ ((;/_Y, MHY9!<_0&BOS]_P"(D+]A/_H1/B5_X(K/_P"3*/\ B)!_83_Z$/XE?^"*S_\ MDRCED%S] J*_/W_B)!_83_Z$/XE?^"*S_P#DRC_B)!_83_Z$/XE?^"*S_P#D MRCED%S] J:[8&:^ !_P<@_L)G_F1/B5_X(;/_P"3*BO/^#D#]A7R&V^!OB4/ ME_Z -G_\F4N60KGM7_!3?_@H=X&_X)]_L[ZC\5M>C%]JTS&R\,Z*K?-?WS(Q M1#CD1KC<[=0H.,D@'^:/]J7]KKX^?ME?$Z\^*GQ\\>76KWUQ*6MK,2,MG8)V MBMXXK]/X;RW#Y?EJQE1>])7=_/0\]TGP=XN\064NJ:%X4U2^MK?_ %]S9Z?++'%_O,JD#\33?"_B MGQ/X(\06GBSP;XAO-)U2QG$MEJ.GW30S02#HRNI!4_0U^UWQQ_:$_P""GOPC M_:!NOA?_ ,$Q/V(I(O@/\*]071&T_3?!L3P>(S;D"\)DD DD&_S$#1Y.5+$L MQ-?F/_P5!^+7P$^-_P"V+XA^)7[/GP7UKP!I^H1Q?VYX8URPCM9K;5EW+/M(LS-I>L;0G]N6BX#, MXZ>>F1NQPR_-@8:OU(MY1-$)%;.:_C^_9@^-^N?LW?M">#_CAX?GF2;PWKEO M=RK;MAI8 X$T74#YXRZ\\<\U^]O@W_@Y _8=&B0_:_!'Q(:38-VW0K/'_I97 MP/%654\OQRG15HS3=NS6]O+K\S] X5S6IF.!<:KO*#2OW3VOY]/D?HQ17Y^_ M\1(/["?_ $(?Q*_\$5G_ /)E*/\ @Y _83(S_P ()\2O_!%9_P#R97S/+(^H MN?H#17Y_?\1(/[">,_\ "!_$K_P16?\ \F4G_$2#^PG_ -"'\2O_ 16?_R9 M1RR"Y^@5%?G[_P 1(/["?_0B?$K_ ,$5G_\ )E'_ !$@_L)_]"'\2_\ P16? M_P F4 ?V9_A#KWQE^)&K_ &/1_#VFR7E],!EM MJCA5'\3,<*J]V(%?S,?\%%O^"GW[0O\ P4.^*%UJ/BC7KS3?!UO=.GAOP;93 M,L$,.\E'F56(FN",;F.0#PH Z_4O_!*M/LY-< M6^\0-KMG#;B:.)#Y48\J:30<#**>PQ^:G@WQ5JO@3Q?I/C?0Q%]NT;4 MK>^L_/C#IYT,BR)N4_>&Y1D=Q7Z)PEE-*.%>,G&\W?EOT2T\]WU/SCB[-JDL M5]2A*T5;FMU;U\MD*W@GQJ3SX/U;_P %TO\ \35>_P!(U[06CFU+2KRS8MF% MKBW>,DCNN0.GM7ZK?L!_\%>/^"I7[>G[4?AS]G/P7:_#NVCU"8W&O:LO@6)E MTS38\&>X/S8R%^50>KNH[UX[_P '!/[??A+]K7]IJV^"_P *-.T\^%/A;-=6 M$.M6<*AM5U!RBW4H*\>4K1"- ,YVLV<, /?HX_'3QRPU6DEHVVI7LME?W5N] ME?OV/GZV P,<"\52JMV:23C:[ZV]Y[+=^A[!_P $./\ @ME\1/!OQ"T;]D7] MJCQG<:QX?U>9++PEXDU2)SA59CE&P,[3Q^[&DW\6H6JW M$3[E9<\5_&7!]MK?+]3]5**_/W_B)!_83'7P'\ M2O\ P0V?_P F4O\ Q$@_L)_]"'\2O_!%9_\ R97QO+(^VN?H#17Y^_\ $2#^ MPG_T(GQ*_P#!%9__ "91_P 1(/["?_0A_$K_ ,$5G_\ )E'+(+GZ!45^?O\ MQ$@_L)_]")\2O_!%9_\ R91_Q$@_L)_]"'\2O_!%9_\ R91RR"Y^@5%?G[_Q M$@_L)_\ 0A_$K_P16?\ \F4'_@Y!_83'_,A_$K_P16?_ ,F4$]0\;^+M5CL=+TFSDNKZZF/RQ1HI+'\ATZDU^-G[;_ M /P4=^+7[5_B6ZT+0M8O-"\#PS,FGZ':S&-KM!QYMR0?WC'KL^ZO0 G+'T3] MN3_@L3\%_P!LWX%2_!OX!:-XMTZ2XU*";79->L(($DM$#,(U,4\A),@0D$ 8 M6OBG'/RBOE<[QE7VOL(NR2U\[Z_D?ROXY\15SP_XBU_PEK%OX@\+:Y=:=?6LF^WN[&X:.6,CNK*01^= M4R>X%!"FOG]MC^;Z=2=*:G!V:U36C3/TR_X)Q?\ !3O7_B5=0_!OXXZE')KD M)=2 M\&^*].\5Z-<-%=:?>1SPR*W=6SCZ'I]#7[9?L>?%H^._"-J\L^XM"K<]LC-? M79+C*F(HRA4=W'KY/_*Q_9_@KQICN*,EJX7'2YZN'<5S/>4))\M^[3BTWU5K MZW;]WHH!R,T5[1^TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% 'C?[:6AS>)/@MKNA1_\ +[I=Q;M]'C*_UK^3'Q3X M>U'PCXHU+PEJ]JT-UI=]-:7,+=4DC#Q M]AP?F%'"8J="H[<]K/S5[+YW/CN, M'_!N1^SV2/\ FJ6J?^C-1K\YP<\U[9X\_;M^*/Q"_8F\&?L)ZOX:T&+PKX'\ M07&KZ;J5O#,+Z::5IV99&,AC*CSVQM0'@<]<_?X[#U<14H.'V)J3]+-?JC\^ MR_$4\/3KQG]J#BO7FB_T/$STQ7T%_P $\?V%_BM^W%\2[_PO\,]:TK3/[)M8 MY+J]UAI1#ND;"H/*1CNPK'IT!KP[P=X.\4>/_$EKX2\&:)<:AJ5[)LMK2V3< MS'U]@!U)X%?T!_\ !$;]@F7]F7X60/KD*R:OJ4PN]7NA'@-*5&(QZJ@^4>O) M[UX_%68T\+E[HW]^>B7E?5_I\SV>$\MJXK,8UVOI?^(:_]K_M\:OAW_P!_[W_Y'K]JK6(0P+&! MT6I*_*N>1^L61^*7_$-A^U^.#\:?AW_W_O?_ )'I#_P;7_M?D_\ ):?AY_W_ M +W_ .1Z_:[IT%%/VD@Y4?BB/^#:[]K[//QI^'?_ '^OO_C%+_Q#8?M??]%I M^'G_ '_O?_D>OVMHI<\@Y4?BC_Q#7_M?Y_Y+5\//^_\ >_\ R/0/^#:_]K_/ M_):OAW_X$7W_ ,CU^UU&,]13YY!RH_%+_B&P_:^_Z+3\._\ O_>__(])_P 0 MV'[7_P#T6GX>?^!%[_\ (]?M=11SR#E1^*(_X-K_ -K_ !_R6KX=_P#@1??_ M "/0/^#;#]K[_HM/P\_[_P![_P#&*_:[ /444N>0OVMHHYY!RH_%'_B&P_:_/_-:? MAY_X$7W_ ,CT?\0U_P"U_GCXU?#O_O\ WW_QBOVNHI\\@Y4?BC_Q#8?M?YY^ M-'P[_P"_][_\CT'_ (-K_P!K\Y)^-7P[_&>^_P#D>OVNH/(QBCGD'*C^;'_@ MHK_P1L_:,_9"^%MW\6/&?CKPMK-CICQM=6^BR7+3*C,$W?O(E&!NR>>E?!HZ M8K^K[]NOX :3\#-K2\FGI]]SZ1_X)N_\$Q?AKXX^%=U_P4!_X* ^,U\&_ GP M[<'R(YI#'=^*IT8C[/ !\WEEU,>5^>1MRIC!9>&_X*??\%0=7_;P\1Z/\-_A MMX7A\&_"'P.OV?P+X)LU5%C15\M;F8)\OF[!A5'$:D@$DLQ]3^%7_!Q'^TY\ M*O@3X5_9XL?V;_A#JOA[P?HUIIVFQ:QH-W,9!!$(Q,Z_:=GFMRS,%&69NF:X M7]KO_@L]\7OVP_@7J7P'\6_LT?"/PY8ZE<6\TFK>$_#4MM>Q&&59 $=IF !* MX/'0FO7HT5HQ[I6UDUN_DCQZU?+(9;[##U6FU>7NN\GV; MZ13V7S9\QU;S);6UUI[H M3>6'*!SY<++AMNX<]"*^7_V.OV1/'O[6OQ1LO"7A_3[B/1TN%_MC5EB)2WCZ ME >[L. .VE>%M+TY;6WL;*."WA16U?:RQDU:-K1\]5?\ (_,A?^#:_P#:_P 9_P"% MU_#O_P "+[_Y'I/^(;#]K_'_ "6GX>?]_P"]_P#D>OVN"@=J*_/N>1^A\J/Q M1_XAK_VO\?\ ):?AY_W_ +[_ .,4O_$-?^U_C_DM7P[_ / B]_\ D>OVMHQW MQ1SR#E1^*/\ Q#8?M?8_Y+3\//\ O_>__(]'_$-?^U\?^:T_#O\ [_7W_P 8 MK]KJ*?/(.5'XI?\ $-A^U_C_ )+3\._^_P#>_P#R/2?\0V'[7_\ T6CX>?\ M@1??_(]?M=12YY!RH_%'_B&O_:_/3XU?#O\ [_WO_P 8H_XAL/VOO^BT?#O_ M +_WO_R/7[78SU%%/GD'*C\4?^(;#]K_ !C_ (71\//_ (OO_D>@?\ !M?^ MV!W^-7P[_P# B]_^1Z_:ZC /44N>0OVNHI^TD'*C\4O^(:_P#:^Q_R6KX>?]_[[_Y' MI#_P;8?M?$?\EI^'G_?^]_\ D>OVNHI<\@Y4?BC_ ,0V'[7_ %_X73\._P#O M]??_ !BE_P"(;#]K\#_DM/P[_P# B]_^1Z_:VC ZXI\\@Y4?AWXU_P"#<+]K MG2]#FOI_C1\/6"1Y*K-?9/\ Y+U^6_[1'P4\6_L[?&;7O@_XXDMY-1T>\V23 MVI;RIE8!E=-P!VD'N :_K[\3:9'JNERVCK]]2*_#K_@NW_P3G\3^(/$S?'[X M;:&\^I6!S#EJNT9JU^SOI?\ M+YGS'%66U,=EZE25Y0=[=U;6WYGYV_L<_L5_'']NSXGW7P@^ %GI=QK=GI$V MI26^J:DML'MXV56V%@=S9=?E'KVK[,_X(Y?\%&_VS]-_:/\ '_!.OQ?9V_B M;X;WEQ/X8U;P+J'A^ -96K&4SN76,29C);1/$N@W#&WF\L%6!&UX98VX=&!*LAZCWP1]FZU_P '#O[0,?\ M;'C'X8_LK?!OP;\0/$%JT.L_$;0?"O\ Q,YMW60,['+=_P!X7&><=*^ZS3#X MO%*5-4XS@U[K;LXRLU?6]_)K4^#RO$X/".-1U)0DG[R2NI1T=M+6ZW3T/F__ M (*;_!SX;?L__M\_%+X/?"!$C\.:)XIEBTRUC(((XUR6KWUYJ^MZUJ#S75Q*S2W%YD&+7-:CC'V>6/YK*W!R(L_WB<,V.F .U<^=8Z.6Y/[.5=V[ M6;_K]3?(\#/,\Z56$;0C+F?9*]TCG_#O_!MS^UW?:5#_P#R/1_Q#7_M??\ 1:?AY_W_ +[_ .,5 M^UU%/GD'*C\4?^(:_P#:_'/_ NGX=_^!%[_ /&*#_P;8?M?$?\ ):?AY_W_ M +W_ .1Z_:[ ZXHHYY!RH_%'_B&O_:_[_&KX>?\ ?Z^_^,4O_$-A^U\.GQI^ M'?\ W_OO_D>OVMHI<\@Y4?BB?^#;#]K[_HM/P\_[_P![_P#(]'_$-?\ M?8Q M_P +I^'?_?Z^_P#C%?M=13YY!RH_%(_\&V'[7X_YK3\._P#P(O?_ )'I#_P; M8?M?Y_Y+3\//_ B]_P#D>OVNQCH**.>00#\: M?AY_X$7W_P CT?\ $-?^U_\ ]%I^'G_@1??_ !BOVNHI\\@Y4?BB/^#:_P#: M_'_-:OAY_P!_[W_XQ0?^#:_]KX\#XU?#S_O]>_\ QBOVNP!T%%+GD'*C\4?^ M(:_]K_\ Z+3\//\ O_??_&*/^(:_]KX?\UI^'?\ W_O?_C%?M=1C'04<\@Y4 M?BC_ ,0V'[7W_1:OAY_W^O?_ )'H'_!MA^U_T_X75\._^_\ ??\ R/7[744< M\@Y4?BD?^#;#]K_I_P +I^'?_@1??_(]>(;OXK>! M;T6]J\GV6SFO/,DPI.T;H ,G&!D]:_?3'M7%_&GP;'XQ\(W6F^7NW1$=,]JN MG6G3J*2Z.Y,Z<:D'%[/0_CUGMY;2X:UN(=DD(-6M6N+S1]*29D%M;H&39YD8+[] MV*_V=/C/J_Q-\):!,_AG6+Q[BZ6&$XL)V.6R .$8_,# MV)(/:OC; /4?2OU_FH9]E\94YV5TW:S=UKRM/3?IUMV/QOEK\/YA.-6";LTK MWV?5-6Z?,_;KXA?L8?L?I_P0\T?X)I_P4.\.R>#=-^)ESJVG_$C^QV^S7]^% MNC_9ZQ>;D.2S?-N/W3Q7XCG:K?*^>>*]KU;]NSXI:Q^PEIG_ 3\N/#6A+X1 MTKQ@_B*WU2.&;^T&N6\W*,WF>7Y?[UN @/ YKS+X8_"_QO\ &'QC9^ OA]H4 M]_J%Y(%6.%2ZUQIE2:1 MP6*IY4;Y*@*3G'WUK[LM_P#@VQ_:^:)67XU?#OI_SVOO_D>OKW_@CO\ L26G M[+WP5TWPXT0DNN9]0O/+VFXN'Y=_IT4>@45]YQ((XPJBOR_.,P6.S*I6A\+T M7HE9?D?J>2X&67Y;3H3^):OU;O\ J?BH/^#;#]K['/QJ^'?_ '^O?_D>D_XA MK_VO_P#HM/P\_P# B^_^1Z_:ZBO+YY'J_P#R/2'_ (-L/VOSP/C3\._^_P#>_P#R/7[744^>0_QH^'?_?\ OO\ Y'K]K:*.>0_\ QBC_ (AK_P!K_P#Z+5\//_ B^_\ D>OVNHHY MY!RH_%+_ (AK_P!KW'_):OAY_P!_[[_Y'I/^(:_]K[_HM/P\_P"_][_\CU^U MU%'/(.5'XHC_ (-L/VO^G_"Z?AW_ .!%[_\ (]+_ ,0U_P"U\#_R6GX>?^!% M[_\ (]?M;1TZ"CGD'*C\4C_P;8?M??\ 1:?AY_W_ +W_ .1Z3_B&O_:_[?&K MX=_]_P"^_P#D>OVNHHYY!RH_#WQA_P &WW[7&F:+-=S_ !H^'K!$SM6:^R?_ M "7K\N_VE?@5XP_9L^-FN?![QW-;RZAI-P ]Q9[C#,KJ'5TW '!![@'BOZ]O M$>G1ZEILEM(F=RD5^(__ 7=_P""L_ M\$^_V[O^"COB+_@JEX1TWQ'\9/&6N:WKGCK^S/%_AJ_OI7M&M_.9;J(VO^KA M6)0[#:J[/+[8KX_^ GQZ^+_[*7QETGXU_!OQ-<:%XH\/71:UN/+![%7BEC;A MT9259&&"#ZU]J:G_ ,'$WQ]BDU;QUX"_90^#?A?XCZY:-;ZI\2=)\+D:E*", M%\LY);@'YRZYZJ:^YS##8BM6FX48S4X\J;LFGKOO=:W5M?O/@26T4ERH X'[]I,CUS7CW[*/[.WC?]J?XYZ/\'/ %S:V]_?&25KN^W^3;QQJ M6+OL5FQG"\ \L*XO7=;\6?$;QA=^(]=OKS5M:US4'GO+J7,DUWX_Y+3\._P#O_??_ "/2'_@VP_:_ M/_-:/AY_X$7O_P CU^UU%+GD'*C\4?\ B&O_ &OO^BU?#S_O_??_ !BE_P"( M:_\ :]'_ #6KX>?]_P"^_P#D>OVMHHYY!RH_%$_\&V'[7V./C3\//^_][_\ M(]'_ !#8?M?GC_A=/P[_ ._]]_\ (]?M=11SR#E1^*9_X-L/VO?^BT_#O_O] M>_\ R/33_P &V'[7W_1:?AY_W_O?_D>OVNHHYY!RH_%(?\&V'[7P_P":U?#S M_O\ WW_QB@_\&V'[7V/^2T_#S_O_ 'O_ ,8K]K:*.>0O MVVP.N*AOK=;FW:)EZBCVD@L?R:_MZ_L8_$[]BGXP0^ OB3J^F:A+J%G]IM;[ M2'D,+@,59?WB*VX8!/'1A75?\$;?&6B> O\ @I]\&?$'B&X2*U/BT6GF28"B M2X@EMX\D]/GD6OU6_P""Y7_!/J\_:(\!?\)'X5LE77M%D>YTJ8I_K./GA8XX M#X'/8A37X1:II7B_X;>+&L-3MKS2=9TJ[!V-F*:WF1@0P(Y!! ((]B*_4,AQ ME'-,E^JWM)1<6O*UD_2WY'Y7Q!@ZV5YVL6E[LI*2];W:^\_27_@KA_P42_X* M*?!__@J]KG@WP%\5_$WAZP\,:Q8Q^"_#.FETL[ZV>.)E=H<;;GSG9@Q(;/*C M&W Y+_@Y0\+^&-(_;I\.^*K#2+;3?$'B7X:Z;J/B^QMU V7Q:6/<_P#M%$5< MGJ$%4/!__!PI^T7:Z=H6J?%_]F_X3?$3QIX5LQ;^&_B)XI\,[]6M<9^7D\G))-?'/[1G[1?Q9_:M^,>L?';XX>)WU;Q%KDV^[N/+")&B@*D4:#A M(T4!54= .YR3T9;E^(HXBE*5.,%3BXMIWYF[?K&-24W4 MDI)-?#:_?KK;32QA_#GP+KOQ0\?Z+\.?#$:MJ&N:G#96>_.T/(X4,< G SDX M!X!K]5/A?_P;F_M;>(?#-OJ5K\9?A^BR("%DFO<]/^O>O-_^"'__ 3O\8>) MOBG9_M#?$7P_-:PVO'A^RNH"&.X#-R0>GRDJHZ\D^E?T >!-#CT'0(+!$QY< M8'Z5\EQ9F5/%XV-*D[J":;\WO]UD?8<(Y;4P>!E5JJSFT[>2V^^[/QL'_!MC M^U^3D_&KX=_]_P"^_P#D>@_\&V'[7W_1:?AW_P!_[W_Y'K]K:*^3YY'UO*C\ M4?\ B&P_:_/_ #6GX>?^!%]_\CT#_@VP_:_'_-:OAW_W^OO_ )'K]KJ*.>0< MJ/Q1/_!M?^U]C ^-7P\_[_7O_P CT?\ $-?^U]_T6GX>_P#@1??_ "/7[744 M^>0D/_ ;8?M?D8_X73\//_ B]_P#D M>OVNP!T%%'/(.5'XH_\ $-A^U_\ ]%I^'?\ W_O?_D>@_P#!M=^U_GGXU?#O M_O\ WO\ \8K]KJ,8Z"CGD'*C\4O^(;']K_M\:?AY_P"!%]_\CTB_\&V'[8 Z M_&GX=_\ ?^^_^1Z_:ZBCGD'*C\4O^(;#]KX=/C1\._\ O_??_(])_P 0V'[7 MY_YK3\//_ B]_P#D>OVNHI<\@Y4?BE_Q#7_M?9Y^-GP\_P"_U]_\CTV7_@VP M_:]"'/QJ^'?_ '_O?_D>OVOIKKN4C%/VD@Y4?R]?\%+O^"8?QO\ V%[/3?%G MQ'\5^']8L[V_^Q^;H;SMY$A4LN[S8TX.UL8STKY&XSG-?TX?\%7/V.])_:?^ M!^L>#-1M#BZM]T-PD89H)E.Z.5?=6P?<9'0FOYN_C7\$_B!\!/'MY\/_ (BZ M-):W5M(PBD\L^7<1@X$B$]5/YCO7Z7PCF5*M@OJLG:4;V7=-WT]+ZGYAQAEM M:ECOK<5[LK7?9I6U];:'Z&?\$S;Q?V'_ /@CW\>O^"@MB@A\8>+KQ?!G@F^" MXDME.Q&D0]CYLSR'_KU7O7YCO))+(TDDC.S-N9FZDGO7N?B/]O\ ^+OB;]@[ MP_\ \$]YO#>@V_@_P_XD?6X]2MH)A?W5PSS/ME8R&,J#.V,(#A5Y]?"P?05[ M^!PM2C6K5:BUG)O_ +=22BCY_,,53K4:-*E\,(V_[>;O)@Q ')]Z_3?]D?\ MX(%_M6?&'X6Z3XVT_P")/@O2EU*QBNO[/U.6[$\&]0WEN%@(W+G!P2,@U\T_ M\$S/V$/&'[5'QDTKQ%K.BS)X3TN^CGN)I83LOY$<$0KZKD?,>F!CJ>/Z7OV? M/ $7@?P39Z8(E4QPJ/N^U?&<8YE2J5(86F[\KO+UV2_._P C[7@S+:M&G/%5 M%;F5H^F[?Y6/R3'_ ;7?M?_ /1:OAY_W^O?_C%+_P 0V'[7XX_X73\//_ B M]_\ C%?M;[8HP!T%?$<\C[KE1^*/_$-A^U_G/_"Z?AY_W_O?_D>@?\&U_P"U M_C'_ NGX=_]_P"]_P#D>OVNHZ]11SR#E1^*/_$-A^U^#_R6KX>?]_[[_P", M4'_@VP_; SQ\:OAY_P!_[W_Y'K]KJ*.>0_]%J^'?_?^^_\ D>OVNHHYY!RH_%+_ (AL/VOO^BT_ M#S_O]>__ "/2?\0V'[7_ /T6CX=_^!%[_P#(]?M=11SR#E1^*0_X-L/VO@/^ M2U_#O_O_ 'W_ ,CTG_$-A^U__P!%H^'G_@1>_P#R/7[744<\@Y4?BB/^#;#] MK_I_PNGX=_\ @1??_(]*/^#;#]KX?\UJ^'G_ '_OO_D>OVMHHYY!RH_%'_B& MP_:_S_R6KX>?]_[W_P"1Z#_P;7_M?=?^%U?#S_O_ 'O_ ,8K]KJ" >HI^TD% MC\)?C)_P2-_:&_80\"2_%7XA^-/#.MZ9=WT%G(N@R7#26[L'*N_FQ(-I/R\$ M\D<5X\/3'XU_0+^T)\'O"_QV^$NM?"SQ?:>98:Q9M#(5'S1MU21?1E8!A[BO MP[_:0_9M^(O[,GQ NO!/CK2Y/)69O[/U2.,^3>19X93V..JGD&ODL]P]18CV MZV>_DS^2/'CA''8?.O[=HPY-86DVH7\-A!&3)-*L:JO<-S9:;#9Y;9%"B#\! MBOSS_9J^!VL:WXAM_$NKZ]1G* TZ@<#%%>X?NP4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 V2-94V,*\C_: _9I\+_%K2)K6_P!. MCD:1"/FC!S^E>O4, PP10!^,?[4'_!!7X=^*];N=9\,>'IM)GEDW--H[>4K' MW3!3\@#7B_AS_@WRGEU98]6\1Z]/;F09C_=)QZ9"9K]^;K1=/O.)[9&^JU!' MX4T:)MZ6,>?]T5ZE+.LVHT^2%:27K_F>75R7*:U3GG1BWZ?Y'Y[?L2_\$@/A MA\"7AOM/\'6]O-P9;B1?,FD_WG;+$>V<>@K[]\$^"-,\'Z9%IVGVRQK&H'RK MBMF"RM[<8BB4?05+7GU*M2M-SJ2;;ZO4]"G3IT8*%-))=%H@HHHK,T"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH JZIIEOJ5JUO<(&5AC!%?*/[ M87_!/+X>?'O1[JSUCPO9WB3*=T-Q;JRGWY[^_6OKBFR0QRC#KFJC*49)IV)E M&,HN+5TS\'?B]_P;Z:,-9DF\(S:MIL;,=L-M-YB#Z"0,?UJ3X/\ _!OGHG]L MQ3^+Y-6U*-6&8;F;RXS]1& 3^=?NA<^&M(NCF6TC)]U%%MX;TJU.8K2-?^ U MZ7]N9O[/D]O*WKK]^_XGF_V'D_M.?V$;^FGW;?@?+_[(7_!/KX?? 71[6STC MPS9VD<"@I%;VZHH_ 5]4:;IT&G6RV\,855& !VJ9(DC&$7%.KS)2E)W9Z<8J M*L@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1E#KM-<#\ M8?@MH'Q*T6:PU&SC?&_M*_LG>$?C-H]Q::CI4,OG(599 M(@58$=#V-?E_^T=_P0'\#:UK=QJGA/1KK1Y))2Q_LF3;&?\ MFP*C\ *_;%D M5QAA52ZT'3;O_7VR-_O+73AL9BL'+FHS<7Y/\^C.;$X/"XR/+7@I+S7Y=4?@ M;X*_X-\C)JR#7]>URZ@$F3&S)&"/3*IG^5?H!^Q1_P $G?A?\ [>%M(\'VMJ MW!DD$>Z20^K.V6;\2:^[(?"NC0'='91_]\U>AM88%VQ1@?05KBLSS#&1Y:]5 MR7:^GW;&6%RS+\'+FH4E%][:_?N9OA7PKI_AG3H[&Q@551< *HK6HHKA.X** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** !AN!_% M[X-Z!\2M&DL-2LXY-R\;EZ5WE! /!% 'Y,_MA_\ !#OX9_%+6+G7[/PF+:]D M+'[=IO[F0^[;>&/NP-?+:?\ !OK?C5-C>)M>\C./+VQ?SV5_0%<:99W(VS0J MV>N5JI_PB6B;_,^Q1_\ ?(KTL/G&:86GR4JTDNU[_=>]CS<1D^5XJISU:,6^ M]K7];6N?EU^QI_P1&^&/PDU:#7Y?":S7D;*WVZ_/G3#Z%N%_X"!7Z1?"KX2Z M'\.]'BT_3;*./8N/E7%=?;:=:6@VPPJO_ :G X KCK8BMB*G/5DY/NW<[:- M"CAZ?)2BHKLE9 %&!1116)J%%%% !1110 4444 %%%% !1110 4444 %%%% M !01D8-%% '-^/\ X?Z1XUTB33M1MUD5U(^9_P"VM_P1P^%OQNNY=4O/ M"$,EQR8[R!3',OMO7!Q['(]J_2RH9[*WN!B6-6^HK2E6JT*G/3DT^Z;3_ SJ MT:5:')4BI+LU=?B?S_ZW_P &^5W'JV-/\2:]% '_ -5^[;C/3)3->\_LG_\ M!!WX=>"-=M==\0>')-2NHV#"XU<^;MZ%-&=][64?_ 'QU MJQ;:/869_<6ZK]%KOK9SFN(I\E2M)KM>WY6."CDN4X>I[2G1BGWM?[KW/-_@ M3^SWX;^%6C0VFG6,:,B@<(*]0CC6-=JBG!0.@HKS#TPHHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** ,WQ%X?LM>L9+.\B5E<8(917Q3^VI_P2W^&? MQ_L+A-9\(6EXK9*>9"-R'U5A\RGW!%?=%,EMX9AB6,-50J3IR4HNS75$SA&I M%QDKI]&?@9\1/^#?.!-8E_X1K5M9O*GR.O*WK^NYYL_8V\&?!/1K: MSTS1;:W$$86..&$*J@8X '2OH"UMTMH5B1<8&*K/4VT04444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C+NF7Q[_9V\%? M&;0)M(\3Z!:7T2([>Z;;^1S69X)_X)PQZ)?K)!X7S(K9$UQF1 MA]-W3\*_3J?3K2X'[R%?^^144>AZ;$VY;5?^^:YXX+!QES*FK^B/GL/P=PGA M,5]9HX"C&=[W5.":?=::?*Q\U_ 7]C>Q\,2QW^JVJM(N#]VOI31=&M=<M; M:,*%7' JU'%'$-L:XIU=)](%%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 45R_Q0^-?PD^">G6VL?%[XCZ+X:L[RX\BUN=:U M".W263:6V*7(!. 3CT%9_P -/VEOV??C-J4NC_"7XU>%_$EW#'YDUIHVM0W$ MJIQ\Q1&)VY(YQCF@#N**P/!/Q1^'GQ(FU.#P%XVTO6&T74&L=773;Q)C9W*_ M>ADVD[''=3S6]N7UH 6BC6]G;27=Q.L<<:%Y)';"JH&23[8H EHK$ M^'WQ'\!_%;PO!XV^&OB_3]>T>Z9UM]2TJZ6:"0JQ5@KJ2#A@0?0BN6^(W[6W M[,OP@\3Q^"_BC\>O">@ZM)MVZ;JFN0PS#<,J65FRH(Z$X!% 'HE%0:=J>G:O M8PZII5_#.1&&0RL."".01UJ?(]: "BDW+ZT%U'5J %HJCXD M\3>'_!^@7GBKQ5K5MI^FZ?;/<7U]>3".*")1EG=CPJ@$_%OAKQSX;LO M&'@_7;74]+U*W6>PU"QF$D-Q$PRKHRY#*1T(H T:*3H:A\+?BWX>\00:2JMJDND: MI%.MJI#$&0JQV@A6//\ =/I5#0OVK_V:_%'A/6/'GAOXZ^%;[1?#XC.N:I:Z MU"\%@'SL\UPV$W8.,]<4 >A45QX^/WP6;6X_#:_%/03J$V@_VW#9KJ49D?3= MI;[6%SDPX!._I@=:AL?VC?@5J=AX=U2P^+OAV:W\77+6_A>>/58V359E;:4M MSG]ZP;C"YYH [:BFJP(Y-+N7UH 6BC34-'O5GB650"R%E. P!!QZ$5QL/[=_[&4]X+!/VI? ?G,^T1 MGQ/;#YLXQR] 'K5%0V-]::C9QW]A=1SP31B2&:%PR2*1D,"."".]2[E]: %H MI-Z_WJP-?^*?PZ\*^,-)^'_B/QOI=CK>O>8=%TFZO42XOO+&7\I"?%72)M?^&WC73-\DM)[O2KQ9HXYTQOB)4D!ER,CJ,UO M9STH **** "BBB@ HHHH **** "BBAC@9H **\OU[]M?]D?PMX@N_"GB7]I/ MP38:G873V][8WGB*".6"93AD92V58$$$'I7>:5XT\(Z]X8C\:Z'XHTZ\T>:W M,\6JVMZDEL\0&2XD!VE>#SG% &I17GOP\_:O_9J^+'BF7P1\-/CQX3U[5X02 M^FZ7KD,TQ ZD*K98#N1G%5?%O[97[*?@+Q->>#/&O[1/@W2=6L)O*O=-U#7X M(IH'P#M968%3@@\^M%F!Z9163X+\=^#/B+H$/BOP%XKTW6M+N<_9]0TJ]2XA MDP<'#H2#@\'G@UJ;U]: '44!@>AK)\:^.O"'PX\,W?C3QYXFL='TBQC\R\U+ M4;A8H8%R!EG8@ 9(H UJ*JZ-K>E>(=(M=?T34H;NQOK=+BSNK>0-'-$ZAD=6 M'!4J001U!KB?BA^U5^S=\%-@45QOC3]H7X'?#CPKIOCGQ[\7/#FDZ+J[ :7JM]J\4=O=DJ6'ER%M MKY49X/2LSP#^UQ^S%\4_$T/@SX;_ !\\)Z[JUPK-!INE:Y#--(JC+$*K$G Y M/M0!Z+17G7CW]K?]F+X6^*T\"_$;X_\ A#1=98@?V;J6O013(2,CXC$D,\$@=)$(R&4C@@CN* )J*** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBN?\4_%7X<>"?$VC>#?%WCG2M-U7Q%,T.A:=?7 MB1S7\BXW+$I.7(W+D#/44 =!17.ZE\6?AMI'CRT^%VJ>.M*M_$E_9O=6.AS7 MJ+=3PH#ND6/.XJ-IR0,#!J3X??$_X>_%;19/$?PV\:Z9KMA#>26LMYI5XDT: M31G#QEE)&Y21D=10!O455UK6](\.Z/=>(-XO+NXD"1P1(I9W9C MP%"@DD] *I^"_'/@_P"(OAFT\9^!/$]CK&DWT9>SU+3KA989U!(RKJ2",@CC MTH UJ*0NJC<3Q7,>)_C9\(_!FF6.M^*OB5H>GV>IZI_9FGW5UJ4:QW-YEA]G M1LX:3*.-HYRI]* .HHIH<8Y-&]>H:@!U%('4]Z7<.YH **3@#IZ*;O7J3095 R3^M #J*Y?Q+\: M_A'X/TVQUGQ/\2]#L+/4]4_LW3[JZU2)8[F\W,OV=&W8:3+M8\ ^&O&NEWVM^'VC&N:3:WB/<6!D7<@E0'*;AR,]10!T%%)O7UI M>"?$.C^%/%WC;2]-U+Q!<-!H=A>WB1S7\B@%DB4G+D C M@9ZUN;U_O4 .HHS10 4444 %%%% !1110 444CNL:%W. HR: %HKR6X_;S_8 MMM9Y+6?]J;P&DDU\;?#WQ58:UI%\ M&-GJ6FW2S0S!6*G:ZD@X8$?44 ;%%(6 ZFC5(U+NP"CDDG MI0 ZBJNDZSI.OZ?'JVAZG;WEK-DPW%K,LD;X)!PRD@\@CZBN%^(?[6O[,OPD M\4Q^"/B=\>O">A:Q)MQINJ:Y##,-PR-RLV5R.F<4 >B45#8:C8:I90ZEIM[% M<6]Q&LD$\$@=)$(R&5AP01R"*F!![T %%)N7UI"X ZT .HKCX?C[\%;BR\1Z MG#\5?#[6_@^9H?%5Q_:D6S29%SE+@[L1$8/#8Z5F^"OVKOV;?B/=:18^!/CC MX7U:;7I)X]%AL=8BD>]:$9E6-0X@D#I*A&0RL."".01UJ8,#T- !1110 4444 %%%% !1110 45A0 M_$WX>7'C^7X5P>-]);Q)#9?;)M!6^0WB6^0/-,6=P3+#YL8Y%-\:_%'X>?#F M[TJQ\>>-=+T>77-02PT:/4;Q8FO;IONPQ!B-[GLHYH WZ*:'!')I=Z^M "T5 M7U/5+#1]/GU74[R.WMK6%IKB:5MJQQJ,LQ/8 DFL?P)\5/AS\3_ DOCWX= M^.-*UO16:0+JNEWJ36Y,9(<;U)'RD$'GC% '045P/A?]J+]GCQO>:/I_@_XU M^&-3F\033PZ'%8ZQ%(U_)"NZ58<-^\*#EL9P.M=YO3^]0 ZBFAUQ]ZEW#N: M%HHSGI10 4444 %%%% !1110 4444 %%&<=:\_\ B-^U5^S=\(?$9\(?%'XY M>%O#^J"%9O[/U?6H8)O+;.U]KL#@X.#[&@#T"BL?P-\0O WQ,\/0^+?AYXPT MS7-+N,B'4-)ODN(7(." Z$C(/49XK8W#UH **3?$ M&X^%%IXUTR3Q-::>M]=:"EXANXK8L%$S1YW!"2!NQC)%;VY?6@!:*;O7&TZ' M5]#U.WO+6X3?;W5K,LD^#G_!4SX+^+?CS^R9HOP!M-2M[[3O#T'@ M>:*[M_$-^ZB-8;EX7 C4>-?'_B3P MXWA;7AJ^EZAX7N(HKA+@(44[I(WQC.X%<$$ YK@?@_\ \$DOA-\._C;H7Q\^ M(GQS^)7Q*UWPNS2>'O\ A/O$8O(K&4C_ %B*$7D=0"<9 .,@&KYO=$?'_P ) MOVNO'O[(?PC_ &@M:^$>CV-UXL\7?M2W/AWP_/J?_'K93W"?\?$H_B"A>%Z9 M()R 0??O!G[5?[8O[('[6^G_ +-/[8OQ*T7XE:7XG\":AXATG7=#T)-/NK&: MRADFE@:)/E="(F56(R+)-&;2+'6OB!JRWDEA8$$-!$ J@ J2I)R2&;&-S9?-$9\DI^WG_P % M(K?]E2'_ (*EW'Q&\'-\/[CQ,T0^$W]AKYB::+UK/=]MR)#-YBD8/&!OZ'97 M?>*OVI?VU?VMOVA?BSX(_9K^)OAWP3X3^%?A.VNI-+USP\MW+X@GN;/S_*F= MBK6Z$;EWIC;@'#9..^@_X(D_LW0:U'I ^)WQ!;X>Q>(/[83X3MX@SH0NMV[_ M %6W=LS_ [LD<$G-=5\;/\ @E3\&OB[\;=2^-NB?$SQQX)N/$FEQZ;XTTGP M7K0L[7Q!:(@013@(2 4 0[2,CT/-%X@"ROW?[2U;'_ ('S M5\D?&7]F;XA:5\9_CE\:?AQ\#OAO^TYX"\6^(KV?7K[3]>ADUWPLWS2R6D;J MY:"6%9 $60XCC.W(*U^EO['O[*_@S]C3X#Z7^S_ . M>U34M+TF>YE@O-8: M,SN9IFE8,8T1< N0,*.!7AOQ3_X(W?![QO\ %+Q/\2_AS\=OB1\.X_&TTDWC M#0_!6O+;66J/(6,I="A^^68E02?J_Q?_P $A_V?;[P=\-?#?PI\9>+/ %_\*VN3X9\0>&=207A^TG=<-(TJ M.K,[;F+ #&XC[IVUB2?\$6?@-+\'O&_P3G^,'CZXTSQYXHLM?U6ZO-0MI[I+ MRWWY=97A);S2Y+E]Q.!@BG>(:GE%[\9?^"JEA^V)>?L4S?M->"SJ.N?#U?%\ M?B:/P.NS0XP9 UI;PE_WH,D>P/*6.T[\ Y6N9O?^"GO[9WB#]AKX.?%#PKK^ M@6GCGQ-\:)/!NLWESI:-:7\:)+M=TQ^[!;R]Q3'W3C&<#[DOOV,_ 5_^UO'^ MV))XDU@:]'X#/A0::LD7V0VOFO)YN-F_S,N1][;P.*^0_P!L/_@EA?>$/V>/ MA#^S/\!-/\5>*=#L_CBNM^);XW$2WEA9W$4JSS;XU0(J;AM8#<#@\T7B!E_& M;]H3]K7P)>?'[]A3]JKXC:+XZ\[X#ZEXH\/^)])T-=/:%?+*/;O$A("Y9L$D MGY!R=^!Q[?MX_&/X)?LX?LO_ ++WP=\"SXC^%=MJVO>,O^$2DURXMH51E MCBALXU.\EHVW'!QN'*X)/UQX!_X).?"'PI8_$2\\7?%WQUXQ\2?$?PO+X=U+ MQ?XHU2.YU"STUT"^3 QCVC[J'+*,?^"4WP?\1?#[X9^'/#'Q.\9> M%_$GPFT4:7X3\=:!?Q0ZF+7;M:.4^7Y;ALG("C[S8P&(HYH@?,.K_P#!2G_@ MH-K7[%5OXST?P%J5KK>B_$>30O&7CC3/ -KB& M7Q)XJ\472275R(@VQ (U554;FZ#)R,G &);C8-3W2BBBI **** "JVL_\@>Z M_P"O:3_T$U9J.[MUN[62T(K:[N%@ M^,WPKU33=#$*DXU:"]-LA&!U6.5V&?4^H%>S?LK^%]4_9@_8B_;(\%SZ9INI M7WA23P_:W5KK.GQW5M).HE$BO$X*NH7!K[@@_X)L_":#XHV/Q67 MQKXC-]8_"$?#V.W:6#RFL!$T?GG]UGS\.3D'9G^&L_PK_P $M?@UX3\(_!;P M=9>//$\EO\#]=FU3PY)++;[[Z628RE;G$0!4$X&P(<=Z.:('S5<_ML?\%#OC MO\//BW^VQ\"OBCX3\,> OA9XDO+#3_ .J: ES-K$%F$>:2>X)#1.R.K *<$D MJ,;=QZ'Q?^W5^U]^T!^T9\"_A;^S1XTT7P78_%WX0_\ "0:BVM:"M^-+N,W# M2RH"5:0J(=B*6"$D$\5ZA\2O^"-'P#\>^-?$FL:)\5OB%X6\->--5_M'QEX" M\.:^(=)U>XW[V9XRA*[FR2 >IXQ@8]13]@WX/V/[2?@']I'P]>:EI=U\.?!K M>&?#WA^Q,0L%LBLBC<"A?:+2E\P27Z62D)(ZO&% P%"R@L!M+5[)_P2A_;0 M\:_M'>(?&'@GQU^TOI7CR32X8+G3+>]\(R:%KMI&<++]IM@I@:,.0H:.1R#@ MMC> .LU3_@DG\#-4\(^.?#)^(WC6UN/&OQ";QF-8T_5DMKK2=2)+/'7CCQ+8QV.H>)O%U['),+ M5""(D6-$4#*J22"?E'.*/=Y1'G'[:7[3'[3FN_MH>"?^"?\ ^RIXSTGP9J^O M^&9?$>N>-=7TM;[[/:*\Z+## _RNY-NY.?[R\J Q'RW^U9^TW^U1\:_V"_VA M/@'\7_'.C#Q)\&?%.GV/B[6=(TC;#XGTV:Z$<<:C(%M*)E21BHY5=N!N)K[R M_:W_ & OAA^U=XI\/_$VY\9>)O!GC;PO&\6A^-/!NHBUOX87W;H2Q#!TRS'! M&1N;!PQ!Y;3O^"4GP!TK]E+QI^RQ;^*/$TB?$*]BO/&'C*[OHYM8U&X2XCG$ MKR.A3.Z,#&W&&8]3FCFCH,Z3_@G%\*M=^$'[%WA'0O$6JZ+>W5[HD.H+<:'X M?CTV,130(T:.D9/F2JF%:4_,Y&37Y+_LR?"CXP^/OV$O'ESX _X)Y^#OB!:G M5-8C;XC:CJ,*:EIC"&(L(8B5D8PC]XN#RS'@X(/[E^ /!&G_ ]^'FC_ XT MNZFFM-%T>WTZWFN"/,DCBB6-6; W$+S@ 9KXO\ #W_!"CX8^%?"U]X#\,?M MB_&S3?#VI7$TNH>']/\ $T$%G<-* )-\20!6W* #D9( S0I=Q'K_ /P2A\3> M!O$__!/SX;M\/O%^H:W8V&A_8I;S5+7R9A<1NRRQ%-S85&RJX8C8%YKY]TK] MHW_@H]^UO\1OBUXT_9?^,7@KPAX?^%?CB3P[IOA/Q%HR2+K302E)9;F[<[H M=I8;0,YV_*1D_;'[/7P!^&_[,/P>T?X(?";27L]#T.W,=K'-*9))&9BSRNY^ M\[,2Q/J>, 5\Z_&3_@C;\"_BW\2?%'C.P^+?Q \+:/XZU".]\<^#?#>MK#I MFMSJVXO(A0D%FRQP>I)&":7NZC/GK]J?_@IQ^UN_[3/C#X,?"_XAZ?X)_P"% M=>'+.6:TTSP//XA'B+5Y+:&:2W\Q$)M[?=(424AY2,))A7&X*64L >@(ZU]#_&#_@DA\%? MB#XYG\??#+XI>./AI=:EX;MM \00^!]66"/5M/@B2&.*8.C(K:3X-:?=6?AVS:^69+Q9T"NUR\J-([<9R& M7D^G%5S1$?GO^S_^T'^U!^SM_P $\[[Q)^SEI5]%:WO[0.N0>,O$NE^&UU:Z MT2QQ"?.CM68*Y+9&6(48 )&X$?9__!)_]KGQ7^TWX/\ %>G>-_VA]"^(%YH> MIQBSN+?PW-H^JP6K@X%[:,@C5MRG#0LZ]03G%+!_P2"^"FE_!^W^%OAGXM^/ M-)O--\=7GBO1?%.EZM';WUC>7)C,B+LC$;Q_NDP&4D$=:]$_9!_8/^'?[(VM M^*O'.F>-?$7BSQ9XTN(I?$GBKQ3=))=7/E@A$ C1%51GL,GC)X%*3BQGNE%% M%0 4444 %%%% !1110 4CKNT'..* /QE^&WP]^)GCK]J7]IY?AW^P)X+^ M-'E_$F\CGNO%6I00/I;--=;4C$A#.'QD[2.4'/2L%OB&_A+_ ((M67P9\*>, M-:M[B;XSKH'Q,L[F$VYT99'>22SC.YLP[HTRP(RQ?('2ONSQ%_P1J\#:A\3_ M !E\4/!W[7'QB\(S^.M&O$%P]WKEYJMX7OKN\)4BY,J@;9%*KMV@ M8Z')SIS(FQP?Q)_X)[?\$TOA;KWPM\:7-QI?PRU+0]:MT\)ZQHVL1:=+K5RJ MAHX)96!^T%B-W7-WD5\'=Y8^41Y/'-?:WPB_P""-_P5^'GQ/\-_$CQ[\:OB M+\0H_!<@?P;H/C77A//!H,6-AM&+ %9%P 5[!5ZDU#\>_CK^ MW#X^_P""E&I?L6_LX?&O0/!^D_\ "N8M:_M+5_#<=]):.'PS1*2I=V8HN&)5 M5+-@D 5[I^Q_^PA\.OV*=6\7?\*A\9^(&T'Q9JK:@/"NH30M9:7,2?\ CVVQ MAU&TA<,S<(OI7SO\>_V"_BE^T-_P54U3XCR:WXV\%^&8_A;#!I/Q \'ZDMK+ M%J"RJK0!N=P:)Y 5*X(YSD"BZYFP.*TO_@I=^TIXC_8SNKKQ3\V^GOHNJ>*/ <>GR7L%Q*O%WIT@VKP%9589^;//!KZEU+_@C M7^SE)\$?"7PE\)>-?%V@:GX-\52>(],\;Z?J$9U634Y-OF7$CNA1B2D9X4;3 M&N,H:MJ-O<7330R;_ +2D MC09\QCG(;@^( M[FXO?#,,T5E(8CYGE(%^4-M2,)]U5/ &*\_^.7[,7Q:3]J#XO?&;X9?"/X9? MM0:+KDD-MXOTUM8@;6_#-RD)26W10X-M("C[0H9L(@VAE(/WG\-?V!?AK\,? MV@= _:)T;Q?KLVK>'OAG9^";6SN9(3;R6=M]R9PL8;S3W(8+Z**X#XS?\$AO MA-\2?C+KWQN^'?QS^(WPUU3Q;_R-EOX$UY;6#5&(^9Y%*'EN:?9?&PV'_"%^,]56Z<7V&9[!Y]J@ MPNT@ .U<))R!C%?67[.GPQ^-_P -/$^N?$'Q'_P3 ^&/POET?P=JEUI'BKPM MJMOG&.]=_X[_P"".W[-WBG]G?P;^SAX5\5>*O"NF^"_ M$+:Y8ZMH=]%]ON-09"K7$LLD;?/D@@J%P54# %;?P'_ .";]]\#_BIIGQ/N MOVV/C5XO33?.W>'_ !=XN%UI]WYD31XEB\L;MN[<.>&53VHYE8H^6?\ @E_^ MS3^PS\9_V(?^%R?M7:=X9UKQA\2?%&JVNM:]XLOH_M?VT2R[;>!Y&#)*(T\[ M"?,=V[IC'KW_ 04\5^(]7_9.\1>#=0UJ?4M%\*?$+4M*\*WUQ+OWV*E&55; M^Z"Q([?-QQBCXN_\$&_V6OB9XDU.^T+XC^.?"F@ZSJ_]IZEX.T'5HQI;W7/[ MU(I8W\MN3C'"@D# XKV[]@G]C*Y_8;^%M_\ !JQ^+%UXGT$:Q+=^'X[S28;: M73X9.6B=X_\ 7L7R3(V#T I2:L)7/=****@84444 %%%% !1110 4444 M%%%% !1110 5^=O_ 6,UKXA>'?VT/V6==^$_@VW\0^);7Q'J4FBZ+=W@MX[ MRXW6FV-I3P@/][M7Z)5X]\>_V-/ '[0/QP^&?QW\4>(]8M-2^%NJ37^BVFGO M$(+J20Q$B8.C,0/*&-I4\FJB[,#X@\+^/OVE_'W_ 6?^&>L?M0? [2_ NM0 M_#C5H['3=.UI+])[?R;@^:SKD [LKM]LUR_P._;:^._@_P#9'\'?#7X!V?A/ MPOXN^*'Q^U;PY9ZU;^'88;/385>'=/Y"*$>4F12_LL?M ?ML_LG?LJ_LW_ !,A^*7A^\^'?B[Q9'X: M7P&OAU5FCMI;B7_2'NRQ,+OP MW\(+KQAX=\0:?X;CL/L=PL!=8O*!8/&&/\98G:,GDBO+/!O[?W_!1#P#^PS9 M_MQ_%/XD^&=>A\;)%H/@GPQ'X?2W%EJ#W31#4+F5 -PV12MY8(4DKTY%?;/B M_P#8+^&WC']H3QE^T;?>+-=CU;QK\/9?"&HV4,D/V>"T=-AEC!C+>;CIEBO^ MS573?^"-559$=B00N,# M!!!.5>('B?PV_:'_ &XOV8_VR_A_^S%^UI\5?#OQ$TOXJ:#=W.EZMH^@K8SZ M/>01M(T16/B6+C:&(RV=WR[2#YQ:_P#!2#]JJ7_@D?XF_:MD\;V7_";:;\1Q MI%GJ/]CP>6MK]MABV&+;M)V.PSC/>OIG]G#_ ()@_"WX"?%^W^.WB;XL>./B M)XGTO26TSPYJ'CS6!=?V/:$,IC@"JN"58KN.2 S8QN->=^)O^"&7P \1Z/XA M\$Q?'7XF:?X4US76UFW\(6>N1+I]A?,X8RI$T1#G *C?NP#Z@$%X@9WC7]IC M]M+]H']M3_AE3]FSXL^'_ L'A'X1;%8K2-XHD,*$ M1XW1B1^3G)7O7O?_ 4-_9E^(,'[4/A_XB>#/V7OB9KFEV_@Z'29O&'PA\9K M8ZE?HBE#97L)3_5$#'F(5RKXYVX&M^PS_P $J-4U']CWPAX+_:2BU?PGJVB_ M%I_'6G:+IMW#)+;LNQ8+:X9E<$%(P6 (89QD'-4G%*X%[X>_M4_MH_"?X_\ MQP_9C^.7Q9T7QA>^$?A+/XO\-^(K'PW'8FVG$8(A,2EE9 S_ ,18G8,GYB!Y M7X?_ &\O^"C?@#]F#X6?M^?$KXO^%-=\'^)O$D&D:QX'M?#*0SR6[S2QFY^T M*<^?P_<'5[[X4: MEK"MI$&II<2;)3#@E[8#J_!_[;_P"T!K%[^V4E[XIM2GPA MCN7\!K_9L0^Q;;6XD7?Q^]^:-?O9Z8KYP^-_CO\ :L_:3\7?L5_$W_A=MAIN MN>,%EDTZYD\/QR16&K+( ]X\095E#(T:B/ V[&(/S5]B_&+_ ()$_!GXM?%G MQM\3[;XP_$#PS;?$2W5/&GAOPWK26]CJDBIM620&,L<'YMF=I.>,$@S_ ! _ MX)-_"7QK\(/A9\+=)^+OC?P_=?")I/\ A%?%.BW\,6H /C?N;R]H)*J0RJI! M'X4)Q0CZIL4GCM(X[J422*@$DBK@,V.3CM4M0:9:/8:?!9274DS0PJAFF.7D MP,;F]SU-3UF,**** "BBB@ HHHH **** "BBB@!'.%S7XZ96C1E3#+, S%_[/ M_P"RG\*YOA=H6B#Q-]LU2YO]0UOQ39V]Q>7+O$FEZ7JD=]9I-$MRWF17-NZD' M://C(R,';R.HKFO%?QP_;\\-?&GXO?L5_%KX^^']8NKSX%WWBS0?$FF^%5M? M[+D78)+98U?+*4,R!F8L#L<8.5KV/3?^".?P,TCX(/\ L]V'Q/\ &2^&T^)$ M/C'3K8W%J387,?\ R[Q_N/\ 4'C((+ZUZEXI_8<^&/C#]J'4OVI==US6) M=3U;X=S^#KS1UEC6S:QE;+O]SS!)VSNQ@]*=X@?FK\*?$/Q4^&O_ 3-_9]U M_P 3:OX<\2:5X@^.%G%X=TW5O"\,S:/;F>[67YY-V^9I5>190%90VT>I]*T? M1/VM-:_X*5_M93_LK_&30_!5QI=OIFH:E=ZIH*7TEZT5A&8K= YVQ(WS[I,, M1\N!UKZ&\*?\$;/A%X:^$^@_!:X^/7Q"U+0_#'CRU\4^'[;4-0MW6QEA$F+: M,>3M2%S*S. 6;G(YJY\7/\ @D+\,OB?\9?'7QVT?]H3XE>$]>^(1CCUQO#. MM16\+6JP+"]KL\KYXW"*3O+$$<8!(I\T;@>$>&/^"H/[5W[4'@?X#_!7X+7> M@^$?B!\5/[3_ .$A\8WFGBYMK&/3YI8I'M[=_E=Y/*+[22!]T8R6&G=?\%-O MVHOV9_ /[0GPM^/$NA^,/'7P=L]/FT/Q1I^GFVMM22^EBAA>>!3A60SQN54C M(#+V#'W[QM_P2<_9H\1?![P'\*_!]YXA\(WGPU9W\'>,/#6I>3JMG([%YG,I M4AS)(2[9'WCQC)S:^&7_ 2T_9R\#?"'QY\+?%EWK_C*X^)B_P#%;>*?%.I> M?J6H,#F-O-"@(8V^9<#[P!.2*5XAJ?&WQ#T_]L,_M:?L?^(_VI?C9H7B\>)= M:?5=)?2?#\=E+I,TUO&[VY*';/&JM'MDVJ/O@N?("A7'EPRC./^6D9/45[I\,O^ M".7PK^'GQ#\ _$W5OVA_B9XFU#X:WPD\+P^(M:AGM[:U5=J6BIY6$B7K\FUC M@#. /+_ (=?LM?$W]J;_@KC_P -D_$C]F#6/A_X5\%Z>$A?Q!-&9->U2 /# M;W**AY4*P<-_TRCRI7RPK&+BX M" 22;5^5=S9.!P,\5J4*,"BLP"BBB@ HHHH **** "FR(DJ-'(NY6&&![TZB M@#\T?VV_V2?V8_#'_!37]F[P)X?^!7A>ST?Q1=:LWB/38-)C6'466)F4S*!A M\-SSWKM/V\OC%XX_93\:^%?V<$"OIKXR_L<> OC3^T;\.?VEM?\1ZQ:ZQ\-9+I](L M;-XA;7)G0JWG!D+' /&UEKC_ -H[_@FQ\/OV@OC[;?M'V'Q?\<>"?$G]@'1- M6N/!^J1V_P#:6GDY,+ED9DR."4(. O< U?-M<#Y"N_\ @IS^VWX[_8Z^ OC? MX=^(]#L?''C_ .)MUX3U*ZN='1K:[99!##(T9'[K+.I;9CD'&.E>E>*/B[_P M44E_:9\"_P#!//0_VE?#=AXN7P?=^)/&7Q&D\(13+=H+AUAMH;4[5P$\L-C# M$LYR-O/IO@W_ ()"_ WP3X'^'?P^T[XD^+YM/^&?Q(/C+P_]HN+9G>X,D4B$;H=T>>,/\S?-TKSW_@JK\!_B1XM^/W@7XO\ @;]F[Q]KJ:5I-/A M'XL73]>L\M)FU:)U(DA8-PX*D!Y!GH"_=Z >-:E_P5G_ &R?AM^SW\3+GQQK MOA_4/&VF_&E/ ^BZG9:-FRTU5CF,TZ1*-TPS"=BMN;YAG=@BK=O^V%^U_P#& M+X#_ !\^ ?BKXFW&M0Z3\.9M:\/_ !/F^&]QHWVJ% OVW3W@D5 LC1LRI(.5 MY;YN .V_87_X)3V_CO\ 94^('@#]J+X>:UX/@\8_$9O$'A/36U82:OH20J5M MYFG^8>?AG!W9W#)(&[ ^BOA+_P $UOA[\/=$\>6GCKXR>//'VI_$307T;7-: M\6ZYYTT=F8S'Y<2JH1#C'S;2QVCG'%'-$#'_ ."-.B?$?1_^"?O@:X\?>-[; M6+>^T\7'AZ&WTT0-IU@0 ELY!/G,'$C>8<$[P,<5\3_&+]F?XA:%\4OC9\7_ M +\"/AS^TS\/_%7B"]N->UG3-?A?7O#9PSRVZ.&+02Q \!%*/%.F0WAETUO%%U'*UA%M51;PA$4)$,;MH'WF8] MZ\9^*/\ P1H^#OC/XE>)OB!\.OCQ\2OA[;^-KAYO%OAWP;X@6WL=2=\^860H MN!X+I_P"V)X\\+? /]E7X=?\ !/7Q6^A:+\0-4U#0&A\? M0QZE)9/%(B>7)( I<0N\FW;MW (.!P.@O_\ @H_^U9^R';_M"?"+]H77-%^( M'BCX6^']/U;PKXDL])%C%=B^F@@1+B&,[5"-(+/P'X.\1WQ\0:UH=]LNM)CE$3_ &UIR=PE,JE]P!^8=,<5 M[9\+O^"5'[/W@SP)\1/"GQ%\0>)OB%J'Q2@C@\8>)/&&I":_N8H^8421%79Y M;A74@9W*IZ*H#]T6I\U_L5?\%(OVJ[[XW>'?#WQD\6W'Q"\+>*_"5SJFK7MI M\-[G2/\ A&;V*V:Y%NLK1JEU$0A02?Q%@1CC=T?[+OQW_P""HG[47@GPW^VC MX0^,7P]M_"/B#QA<6C?#'5M-2VC@TR*XD@9OMV&E,^8V 7'/ROR#L'N?[-W_ M 3$\"?L^_$73OB'J?QV^(?C9] T-M'\+Z7XLUP2V>E614IY211HBOA"5&_( M Z#@$<;IO_!$K]G/2_&5I-#\3_B _@;3_$W]OV7PMDUT'1(;[.0PCV;]OMNS MC(S@D47B,^,OVM_%?Q'\;_LV?MC#P_>^']!TKPW\:K.#7K72_#,,-QKEJ^HB M*-)9TVMYBS&.0R-N+!64_>)'L_@VW\1_LU?M%?LF?#3Q-8>"]8DNO!NMZG>: MOIO@>ULIHT^SM-&D)4%HG$>Q'=3F4J6;DU]&>+/^"47P6\7?#SXR?#>]\?\ MBF.T^-?BJWU[Q#-#+;>98SPW:W2I;YA("%UVG>'.WH0>:[CQ1^PS\-_%7QJ^ M%_QPU+Q)K(U#X4Z'-I>BV*M#]GO898?)8W ,98G:/X2HSVHYD!\L_LQ?M#?\ M%/?VK_!NE_MF_#WXO_#VQ\(ZEXVEL5^&>MZ6EO$FF1R[&?P0% Y/S= M/DKQW]L7QC\1_%=A^V]H7A.YT#P_#X>U/07U:YT_P_"EWJ]@^]9+>6X7:[,7 M:,B1B2%1EZ.:^JH?^")7[.5OXRCG@^*/Q 7P-%XH_P"$@C^%JZZ/[$6^!SO$ M>S=MSVW9QQG'%=UK_P#P3&^"7B>Z^-4^L>)_$+Q_'*"VC\16ZS0JNGFW_P!4 MUMB/(PV#\^\'&.F:.:*8'SQ\*?VD/VG?V--3_9IT_P"/_P 8--UKX6_$#PI_ M9U[=)H,5HNDW7V<26:M(,L<1F)"Q;#;7; Q7O?\ P2U^/_QW_:L^$_BC]HCX MNZI#_8?B#QI?)\/=+BL8XC9Z/#(40LZ@&1F;'E21H_L\C +M18N%4# 1N,D M 5][_L]_!SP]^SY\$/"OP4\*Q[;'PSH=O81-CF5D0!Y3_M.^YR>Y8U,K =E1 M114@%%%% !1110 449%% 'PCX0 _XB"_%!V_\T/C[?\ 3:UKJ/\ @JOXXNO! M?Q"_9QMK;P]HE\-5^-NG6LKZQH\5TUNK,O[R R ^3*.SKAA70?M&_P#!+3P3 M^T#^T9=?M.6'[17Q*\#^)+S1X=,FD\$:S#9@V\>/EW>47PQ"DC=@E1QQ4=G_ M ,$K_!DVD^#].\=_M*?%#Q=-X)^(D'B_2=0\4ZY%>7!N(DC46I9XN(/W>XJN M#EF^:J]VZ \#^+G_ 4\_:$_9?M_V@_@9\5==MM3^(GA_7+&/X.RQZ7$C:A: MZBVVW_=*H65H5^<\'<$?C5-^S)9?&BU\-ZWX!\!6-[ MXDU>U^'(M=P ^S?CS_ ,$Y/@+^T3^U M#X'_ &L/'/\ :4>O^!_+\BSM7B%KJ7E2F6#[0K(6;RW)(VLN> <@ 5D_M)_\ M$R?AO^T!\7;SX[>&OB]XW^'OB?6-$_L?Q)J'@G5$M_[7LL >7,'1LG:JKN&# MA5ZX%/FB!V?[#?QT\6_M4_LG^&?BI\5? LFAZYJEG-;^(-&N+-XE6>*1X7(C MD&X)(%W@'. ^,G&3^:VH?';4/^"XN)>2S/ M)(Q)9F8DGL,X \>_:(_X)E? #]I;]J+P;^U=X[N]5AUSP$6NH M_9YS-#]H5HRS;7;^%ER, Y I1DK@?-?A#X:-^Q[^T7^Q;^S#!X5T.28Z'K+Z MW?7FCPS7D-\]I)-.T,[ O#F5F!VD948Z5A?LN?M:?\%*/C-^R_\ $']LGQ-\ M>O#L'AKP5IVOVEGHWD%OOAN&?;M54=U7;_$(SD'.3]R?%7]D/P/\ M7?VD_AS^TYKOB+5K?6/AJ+T:186CQ"VN?M,1C?S@R%C@'(VLO/7-8G[.G[ ? MPA_9U_9H\0?LL:;J^L:YX<\37&H2ZHVL31^>RWB;)45HD0 #@XR#SFGS+J! M\[^)OV[_ -HO3O@3^QSXULO%]F-4^+WBO2;+QQ)_9<)^V03>5YH1=N(L[SRN M",UY3^TW_P %'/VUOA-^U3XP\)>/_B\OPHTG1_%"V_@VQUSX9O?:'K&FB3 N M+C4(M\Z%X_G_ '2,,G;\ISM^@_!'_!%3X.>#M7\!:I?_ +07Q,UJ/X9^)K?5 MO!FG:OK4,EIIT<4PF^RI%Y6U8W=4+,,.0@ ('%:?Q:_X(^?"GXJ^*?%%PG[0 M'Q*T3POXUU8:CXI\#Z;KJ-IM[-NW$@2QNT0)[*V!T& [Q ^K/!GB"S\6>$ M=+\4Z?J%G=P:EI\-U#=:?,9+>99$#AXV(&Y"#E3@9!!K2K+\$^#O#WP]\'Z7 MX#\)::MGI>BZ?#8Z;:HQ(A@B0(B9/)PJ@9/)[UJ5F 4444 %%%% !1110 44 M44 !&1BOSK^(7P:^%7QR_P""\VI>"_C#\/M+\2:2OP/CN5T[6+-9XA,MQ&%? M:PQN 9@#_M&OT4)P,XKY9_:5_P""7'@?]HO]HE_VF[?]H;XD>"/$DN@PZ1)+ MX)UB&SS;(2=N_P HO\Q(R-V#M'%5%@?)?@SXM:1_P33_ &KOVM-$^!&C+)X+ M\*^";#7-,\+K.QLK+5YFM8HTQG*)ONCN (P@Q_",:/[*'_!07]N7XD_$SPCX M"UCXFMXLM_BAX9N2=0@^&$^GQ>"M4>V:2TVS.@BO(=VT%CE6&<'HS?8/P7_X M)C_LQ?!OX/\ C3X/+I.J>(HOB)&Z>-M<\2:B;C4-5W @%IL J5+%EVXPWS=> M:QOV;_\ @EUX#_9Y^)6@_$.?X^?$?Q='X0TR33_!VA^)=>$ECH]NPQL2.-$W MX7A0V0 %X^52*YHBU/FKP)_P4_\ VH?C!\.OA/\ LV>$]8M+'X[:]\4KWP[X M\N#I43I86%@VZYN3"1M3,4B$'&"8)L= *Y'XR?\ !5[]L36/C+\3-3^#'C>' M3]/^'/BEM(T'X?I\.KG5#XE6"8QS27%[$A^RL=C,%RN0<<8W'[B^'G_!./X" M_#7]M3Q)^W#X?_M#_A)O$EI)%-ILC1_8K2:58Q-<1*$#B238=V6(S*^ ,C'% M_%+_ ()"?!SX@?$KQ/XX\,_&GXB>#=+\<:I%J'C;PIX3UQ;:QUBX1]_F.-A= M&9B6)5AR21BA2B,\%\-?M%IX:_X*6_$?]J[5?!]S#]C_ &2[;Q-<:#-E)HRJ MVUPULVX95@?D)(XQG%9__#<__!13X2_ 3P#_ ,%$?BE\3_".N> ?'7B:"UO? MAG8^'UBETZQG>41M#= [Y)0L1.ULX.T'=D[?LO2OV /@OIO[0NM?M S3ZE>- MKGPYC\%7OAN^E22Q;3$"#!ROFLY6,*2SG()XSS7EG@W_ ((M_L]^%O%6AOJ? MQ4^(6N>"_"^M'5O#GPSUGQ!YVBV-UO+AA'M#,H8\ MSEMV=QRN:(CRF]_:,_ MX*0?'?X[?M%>"/@5\?/"_AC1?A#J'VG2H]2\+Q7$]VGE.\=GO/$<;")]TK!F M!*@#&<9K_P#!2#]L+X_Z1^RW!\$?$FA^$]8^,5OK=EXF?4-$%W;1W-I(D)N8 MU8AL "258PP!)56) R;_ (1_X)>^/_CE^UQ^T;XL^(_C#XB?#G1?%'B2.+1] M2\*ZLEM#XBTN5'$\,B$,)(^%Z@$;CV)!^F=/_P"";'P'\/\ BGX+^(O!]YJ^ MD6_P.M[R'POI=I-&8;O[2JB5[DLA=V+ N65ERSL3G-.\1GQ->_MJ_P#!4.U^ M$WQM\3K^T'X3;_AG?Q0;'5+QO!!Y_$$US>W4"RI:) BL8X? MF ,F.,GDG"GZ=N?^"8'P>N_ GQL^'\GCKQ,+7XYZU_:?B2836_F6,GF&3;;? MNL!%?"$7AA?%/A/4HX+K4 M=-CC""*X!C*L<#.5"X)'H,'-$6I\WS_\%'OV[/B7X&_9WTWP?!IG@WQE\0_% MFJ>'?$T>N>''^SRO!Y0CNUBDQ(J[)/,VJP#,-N<=,WXA?'_]M#QA\!_VOOV5 MOBY\;-+U36/A3I%K<0^+;+P[':MJ.G7$,TD]L8D8")FC555AED+-RV :^M-) M_P""8OP6T%_@_)I?C+Q5N^#>K7&I:-)=ZDMQ)J5Q/CS&NGD1F8$C("% .@P! M6E/_ ,$Z_A!>^-?C;XSU3Q%KURWQVTB#3O%%FTT2QV<<4#PAK8B,,K8?.7+< M@?2CFB!F_P#!)+1/B/HO[ _P[/Q$\;6VM"[T"VN=#^S::+?[!I[0IY-J^"?- M=,',AP6STKZ4KRG]CK]EBR_8]^#\/P:T?XI>)O%5A9W+/I]QXHNDEDLX-B*M MM%L552)0O"@<%C]*]6K-C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH *0H&Y-+10 8X%%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 !SBFQ>9C$@Y_G3J* (W M:7=A0*!]H/7%244 1DS8Z+03<9X J2B@"/=-CA:3_2#V'Y5+10!'FX/512)Y MWFYD'&.U2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>E 'SU^ MWK^T'XX^$#_#KX?_ J^*'A_PSXF\=>-K?3K-M>T:XO5N[?_ ):QQK"C;9,O M'\S[5 SDBN>\;?\ !8O]@OP!K.M^'O$'Q3OWO/#FM/I>M1V?AV[F6VF1]C.S M)&5\K>"H?.">F:X_]KCX9?&3XG?\%,_A3XUL/A;K=]X-^&7@W5=<_M:WL6>V MFU1XY!%;J>C2Y2/"]?F%?-=I^QQ^TQI7_!)?5? ?[!OP8_:G^'W[4?@^S^$/P M6^+7@_X7:=!.F*]*\4?L;?M+_ !KOOVS/&^F?#C5-'UKQ99V/AWX= MQZE";4ZEIMFR,ZPLV 4EC@C0"<$D5[M@/JGX0?\ !5;]B;XX_%FT^#'P M^^*TTVKZE+)%HTUUH]Q;VNIR)G"/#_[/ M)_8$M_AWX>\$_#.YTN+QGX\L!'J%IKCVC0K+I^!G#2[9&DQG[Q)!P#X7X;_9 M[_;#\8_L3:'_ ,$LK/\ 8>USP[K \8?:/%WQ(U)8AI/V=;MIC>1S@DRR%=JC M&253"]0 N6('Z@?M&:7^T+XE^%AKXG_9!^/O_ 5C_:.^.?C7X>7/QJ^&,-C\+_&5OI7BQ6\+R*U_%O)D M^S,H.W*(P!8 @D5^@WA;15\*>&--\-I/),NGV,-LLS#EQ&@3=^]B)^^O(Y'K27P ML#KKG_@K?^Q!#\0]0^%B?$34IMT1WF+,$VA0(WPV<' M::["[_;\_9EL?A5X#^-$_C2Z7P_\2M8ATOPC=?V7,6NKF5V1%9-NZ,%E/+ M5\U_L6?LF_%"S^'/[5FA^,?A3>:+K/CGQMK2^%KS6+$0M?6TMO(L,D;M_P L MR\C -G'S'WKY_P!*^'W[9_C']G3]G']F6]_8A\?:4WPF^)VGS^)M>O+5/L\D M:W;L)(54[WC",S/)C8N%Y.X57+$#ZB_X*X_M^_';]ERZ\)?"K]E/3[*^\;:S M:7^M:I%=:<+H6^DV<#R2/L)'4JQSG.(F Y85L?M&_P#!0/Q99_\ !*1?VY_@ M+6HGBMKB2YB@N8F0D9*,9%Z]@>:\8E_8L_;+_;*_;E^*7[ M3,OQ+UOX,V>FM_PB_@V?4_!L=[)J>D[&25HXYW4)&^-Q8 [O-(X KS1_V4/V MR?A7^P7\?O\ @GY)\(O%'B:UTKQ'8:A\.]>L-$<0:S;O>0-.L !(! 42E 3M M)D&3C)+1T%K<[JV_X**_MY?"77_A?XA\7_'#X-_%"Q\?:Y86-UX)\&6[#6;6 M.Y0.6VHWRF,$@DY ; (YR/TZC8LN37XV^)?V9_B=\3?#?P_\$_LO?\$K/&GP MF^(NCZGIKWGQ4OIOL$/_LD_\$HOAK\;?C!\;O&G[9/P%UZ-KGXG MWKTS]K;]D>XC_ &M_V5=%^#WP-DD\ >!- M:O!JD>EZ;OL=)A$:&(R]0H+KGI?$'_@JQ^QC\,? _A/QUXK M^(6H+'XVTS^T=!TNUT"YFOY+/)'GO;JA>*/(.&8 '!(R :Z'7_\ @HG^R%X= M_9TL_P!JB]^,=G)X-U"Z%I87MK!))-<77/\ HRP!?,\T;6RFW( ).!S7SG\> M_ /QU_9/_P""DNJ?MG^%OV7]:^*WA'Q3X BT."R\)PQRWNA7,6P;1$W2-PGW MEXQ(_I@^!#_@G]^UYX&_9O\ "?Q]F^!$M]JNE?'Z?Q]??"&PE22:WTR40A84 M094RKY(S&,E5$/"GBJ.;X4^'?A4WB& M;[1X?EM[^UNXG3SUD$@$G"'.S;W&,U[I/_P4$_9CMO@WX*^/ =&_;[\)?LJZ$+>\\,:WHD4USXDMK*>=Y[Z[5&LXX=@V^2 MR.CM-\R_-@E<&O%=0\._M5?L;_&O]H/PMIO["FI?%ZW^,'B2/5?"6M1V4=UI M,O W[1WPN_X*,_!/X_:G^RW?:EILWPKA\- M^(+?P#9B73] OI9CO!)^Y!"&!R>JJ=N<$4K1 ]>_9A_;CTH_ ?XD?&[]I;X] M>%[W1_"'Q U#2_[6TG2;BSCLX(A%Y=HR2HK33@OC*!@Q8 $X-=5\ /\ @I5^ MR'^TG+K5E\,?B+<-?Z#IHKX3B_8) M_:I\:?L,^/?#NG_"*^CU[1_VF+OQC8^$]:C^SMXBTU(U7;'OPKA]Q9<\-L(' M.*](M_AY^T=^V;^V;;_M2R?LF^)/A7H/@?X3ZMHDEKXB@CBO-=OI[6YC2WBC M3F2-3,,,1@>6._>%/\ @LA^P'XS\1^'O#.A_%^X,GB:ZCM=/NIM M!NH[9+AWVI#+,T82-R2."> P)Q7U(IR,U^3NJ?L>_M!K_P $A/@W\*=._9^\ M0+XPTCXM6^J:UHD6DM]LM8?/N]UQ(N-P7:T>6/8K7ZP1<1J,=JF5N@QU%%%2 M 4444 %%%% !1110 4444 %)M'7%+10 @4#FEHHH **** $* TM%% !1110 M4444 %%%% ";1Z4M%% !1110 4444 %!HHSCK0!^?_[:7_!53XB_L=?\%*/# M?P6\5K8R_"V\\.V-QXB9=/S=6+7,TT7VOS0^$=+UG2[_R4C\B*:UBGFFDGS\Z8=F!Z 5P/QS_ M &--6_:-_P""I7BK_A97PQU*X^'/B3]GIM!F\1_8S]FCOOM\@>#_ !9J"[+/6ULID^SQ M1S'C8\$,<9R?E#?-T-:>Z+4_0']GO_@IK^QY^T]\0S\+?A+\2YKC6I())]/M M]0TFXM!J,4>=[VS2HHF ).TYP"<<'%N#_@HI^RO=? #Q)^T[!XWNF\'^$]> MDT;7-0_LF;?#>(T:L@CV[F&9H_F (Y]C7PO^PS^S#\<->_:!^# ^(W[/_P : M--E^%NDNFHZYXUURTM=(TF18O+,%C$EJSW,,N!\@D! ()8@%CQGBKX-?MJ>" M/V*/C3^P9I'[%?C?6-0UGXF76O6GBFQ@C;3Y[!IK'/\ @KU^PEXI\77G@S3/BS<"ZT^&^EU.:XT.YCM[ M)+16:9I9&3:O"-MYRV,#D@'QC1O 'QR^#/\ P5.\&_%Z;]G;Q1KGAGQ+\'M* M\+SZUI%D)(='N]\ EDNB3^[6(1,6[X(QGG&)^R%\ /VG_@Q_P3M^.H\&? N2 MR^)VJ>/-8N_#-AX@T6(S7MJPMPDB),-LHV>>8PWRLXQ@YP5:(SZ6_9__ ."H M/[(7[3GQ"C^%/PL\>:A_;EY8R7FDVNK:#<68U"% 2SP-*@$H !;@] 3V-?-G MP1_X*1?M'?$+]G?X?_$CQE\6O"6@ZIK_ .T ?"=XUYX;F=-1T\,@%K"L"OY4 MS!CB5MJCN17F7[*7P6_:CU7]NKX$_''QU\$OC1_9^CZ'?:=XHU[Q_#&8K2\: MPG0I;6\ LK(/*BIE5#9/78QK+^'/[('[4NG?LM?!SPKJ'P"\40ZEHW[6*:[ MJUE)I;B2TTSS(_\ 3)%_AAX/S=.*=H@?;'Q/_P""Q?["GP;\8ZMX$^(7Q UF MQU#1-2FL+Y3X5O&C$\;%657$>U^0>02"*TOC7_P5;_8O^ ?C(^ ?'OQ"U!M3 MAT^WO-2ATKP_-KAHT(A)5E.&.0",U\8_'K6?VJ/C+^WG+\6OVA? M^">?Q0\8?#WP#J$R?#_P?H&EJMG=3I)A;^Y9QB8OM#@8QC8/N@[H_P!LOPI^ MW5\<_BK\4-%U?]GKXKQZ+XF\)V;> ='\#V]I9Z?(&M5DDCUBX $D[QL67R2V M2Z[ N"IHY8@?2?Q+_P""O?PV\,?ML?#_ /9V\,&'4/"?B;18;W4?$T%A<3O) M)=Q;[&.!47!1@\3-)\P7)!VD&NK^!'[;5G:77QV\7_M!?'KPM-X9^&_C::PA MDL=)N+5M'MU>15MIS)&OVB(OA+X=^&?A"]LM2D\31QPW&JW,T4D: MVL*I@R1(6X; /3(4^1G]CC]H6/_@BGXN^$"_L^>(/^$WO_ (J2:E!H']CM M]NFA^W1[9PF-Q'E X;^Z/2E:('ZRV\R3PK-'(K*RY5EZ$=C3ZS?!T%Q:^$]+ MM;N)HYH]/A25''*L$&0??-:50 4444 %%%% !1110 4444 %%%% !1110 44 M44 (% .0*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!KR)$I>1PJJ,DGM7*V' MQZ^"&JW\>EZ9\8/"]Q:@VE2;[22SLYU^T6?FG?;-*$ 93D[6*G'8Y6!]W45\M_\$YOC-^V+^TO MX8_X7Q\:-?\ !\7@_4)-1LM'T/1]'FCOO-MKYX!<22M(5VL(Y/D XPISR:^I M!4[ %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ";5 M]*-JGM2T4 )L&,8HV+TQ2T4 (44\$4FQ?2G44 -V+Z4NQ K^UTKQS\1M#T M:ZOFVV=OJNK0V\DY]$61@6_"M]ONU^??Q/\ @AXB\&_M$_%#XM^-/V)O#W[1 MWA/QAJRLFM:9?6=YK'AV&*%8GTS[-,M4UFTL]8^)5K)// MX7M-/)ENK::W4HTLL+2)!'&6 VA26(P:U?C+\?\ _@HU\&M'\(_"[6$\ S>+ MO%7Q27PUHGBI;&7[%?Z?+:/*MY):B0M;R1NI!3(]7\*W^I M6]E'8W MPUK9(%ED\]R'7S"H1<@DG%'+(#]#,YZ45\ VO_!2O]I'7?@5YW@W M2O#]]XRL_C)I?@V#7KS0KVSTK7+2]SY-ZD,Q66+T=06VE#@\C'M_[-/QI_:2 MLOVJ?%_[*'[1VO\ AOQ#2%I9.5=1M8-DC M.>H .5@>[>+?B)X!\ QVTOCKQKI.BI>7 @LVU74([<3RDX")O8;F)(X&3S6S MD5\'_MM>&?$5Y_P4G\ ^+/&VL^&]0\*^%OAKKGB6'1]6\)_;6AM[.2U:Z"[I M=IN''^KFVCRO[K'FM#3OVP/VV/"'P8\$_MM?$VZ\$W'@'QEJVFK?>!=-TF:. M^T?3M0F6.WF2],I$\R^9&70QJIR0#W!RZ ?<%%?+/[,7QG_;&^/?[1OCZ74/ M$'@^P^&O@'XB:EX:?3UTF8ZGJ/E0I(CB7S-B!#+$"=IW?/TP*R?V^_VOOC3\ M /C#H/@K2?&>E_#WP;>^')KV3XB:]X*N]:LY=2$P1+"0P.HM%V?.97SP>!2M MT ^O*,CUKXRO/VJ?VP_B3XP^"?PL^$WBOX:VNH?$7P/J^K>)O$VGQR:OIUJ; M.6V47%GB2(RAO-V^6Q&#)R?DYYOX@_\ !3/XR?![X5ZUX!\?6WAW_A96B?%R M'P'-XDBTZY?22DUL;Q-5:UB+3<6P.8$+$R .:AU+4].T;3YM6U> M_AM;6UA:6YN;B0)'%&HRSLQP%4 $DG@"O@[P?_P5*\=^ _"_Q6D^(%[I_P 0 M(? _@N/7_#?BO1O"M[H=OJ4TDRV_V":&YW;)!-)%\R,048G@BNS^+NO_ +?7 MP[^"7CS7/C_!\-?&WA2Z^$>N:AJ5K:Z/);1Z5?16+R+9R123/]OMI/F1C\C8 MZX'4Y0/J3Q)\6/AAX-@L;KQ=\1-#TN+5/^07)J&JPPK=\ _NB[#?P0?ESP16 MQI>J:;K>G0ZOH]_#=6MS&LEO.5",AE89!!'0BOS3\9^$O&'Q#_:U\,^ M./$EOX&OM'T7]E-/$6E>%]4\%BXM;*W"XDMH@TVU)&E4D3 #;$1'M.WK7>@/(="M]9A\.SZQ:QZA<0M-;V+W"B:6-2 SJF=Q49&2! M@9%68+B&Y3S;>574YPRL"#@XKXF\3_$+]I&_^,OA/P/\7/ W@70_B-=?!OQ< M\GB:QT\WAM9()H4BD@;S%=(95VR/"6R&P-W%1Z2T%QI=^$\^RCEE,C";S-ERI;"Y)7C@Y.4#] \]J*\9_ M8F^.?C[]I+X?Z[\9/$L%G#X?U/Q=J$/@..VMRKR:/!+Y$4\A).YI7CD<' &T MKCK7LU2 4444 %%%% ";%_NT;%QC;2T4 -V+W%+L7^[2T4 )M4]J-BXQBEHH M 38N<[:-B?W:6B@!NP=:/+3TIU% #3&IZBCRUZ8IU% "!%'1:7:#VHHH ,# M %%%% !1110 4444 %8/BOXJ?#3P)=Q6'C?X@Z+H\TT>^&'5-5AMVD7.-P#L M"1GC-;U?!/[<<'AV?_@IKX/'B;]E.7XP6Z_!N_*^%X;"RN&B;^T8_P#2=MXR MI\O*Y!W?/QWIQ5P/N+PSXW\'^-;%M3\&^*=.U:W5MK7&FWLQ^ M)GP\U+Q?,O!C20PW_$#5/#KC6_&]O?.8 MULKB6%G;"+-YJQ,"SQ^7A0,9?*P/UE\3_%WX5>"M371?&/Q)T'2;QHQ(MKJ6 ML0P2%#T;:[ X.#S6QI.M:1KUA#JNAZI;WEK.NZ&YM9EDC=?4,I((^E?&ES\& M?@C^T-_P5;\90?%[X3Z#XJL(O@IHMU86OB;0X[D0,]Y-\P2="4;:<'@'L:U? MV7_!OAG]FC_@I#\0/V9/@M9?V;X#U;X\-7&G^"O\ A)_$ M_BKQ%I$FH;(I+@V\%K!;K)&"6979G9L #CD<^1ZA^W]^UGJWA_PM\-?#6C>$ M+/XC?\+ONOASXJNKFUFDTN1X[0SK?0H'$BJ8VBEV$DY!7(!R!1N!]V45\\_L MB?&SX_:U\&5\"^%['5/$/B#Q-H\NH-=W5Z9#; M6<422QB--D3,\I+$;AA>.5R@?3&:,U\7_'7]KK]J'X=V7@KPO\2_B;\,/A+K M>I>%Y+S7FNH)O$%U=ZDLIC%O9V,#K(8"HWF4[L;MHR5.>6\%?\%#_P!JOXO? M!+X-ZA\.['PG;>+/'GQ,U;PAK%[J&EW(LMEK#<-]M2!F66,XC60Q,(KQVRG#3$$Y$8/!8\ ] MZ^*]6_;N_:I^$K_$3]G_ ,=IX4\1?$30?'GAGPQX/\16FGRV>GW;ZW#YL,US M;^8Y7R45V95?YMN,]SRGCAOV@O '[9'Q$N/VBM9\(^,+[3?V3M8GTN\L=!>U MM=1MQ>%VBN;9Y9!_K-Z$!L,A'0DT17%O<1++;SP2!T MD1AE64C@@@@@C@BH=%U_0_$=E_:7A_5[6^M_->/S[.X61-Z,5==RDC*L"I'4 M$$'FOCGX6?M ?M,?&J]\&_ ;]F"\\$^"X_#OP8\.^(_$5YJ7A^2ZMWFOK8&W MTZUMTEC\F%5C.7W,54J #CGRO]G#]HKXM_ []B3P3:0_$SX>_#^XU[XB>,E\ M4>(/$RR7IM+A-9NV\BPL4=9+QFD9AG=A%4$Y+ T9C@ M"E5PPS7YB_%K]JG]H/\ :E_8A\56]W\0M#6_\$_'7PYH=SK]GX5NK2/7+:34 M=-DM9_LT\B26Y669&=#D2(FT8#[J[[XO_P#!13XUZ-\8?&/P>\._&7PCX;N/ MAM9VMG>76J?#_4=2_P"$IU8VRRS!1:L5L;?TN58QS1X8!MHD1]I(!*X/>O1J MD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH;.WBOB'PW^U7_P % M /B/I7Q-^*7@+7?@[8^&_ /C;7-'BTOQ1!>PW%Q'8-]YIDDV(64@9X&<]J:5 MP/M[(]:*^2_$/_!0SQUXK^#'P:N/@=\*+>;XC_'"W,GA_0]=NG6STJ&*+S+N M\G=0&>&-?F4* 9 RD8Z'K/ACXZ_;M^'_ ,;M$^&G[1/A+PYXN\-^)K2Y:'QG MX$TRYMUT.ZB0.(KV.5G CD&520$$MP12LP/HC-%?%/P$^/7_ 4D_:/^$-]\ M<_!/BGX/Z7I<.L:I:VNFZYI%^K!+2YDAS),DNU0?+SNQ@5[Y^Q)^TE'8=*NM6%S#?6-M<&6%+BWN9;:5HG(^>)GB+*?[I'4U7+8#UJBODK MX-?\%5/@0VO^*O _[1?Q2T/P[KFD_$S5_#^GVT=K<>5':P7;06SW,H5HX&DV MG#2,@8CBO8?CA^VK^S)^SEKEKX7^,/Q4M=+U*\LS=QZ?#:SW4T=L#@W$B6\; MF&$'(\QPJ<'GBERR ]4HKRWXH?MJ?LP_!WPMH/C/QU\7=/CL/%%M]H\-MIL< MM_+J<.T,98(K9)))$"LI+JI R,D9J3P7^V3^S3\1+?PC=^"_BUIVH1>.KNZM M/"TD*R8O;BV3?/!RH\N5%R3')M;@\<4@/2-1LAJ-A-8M)M$T3)N Z9&,UY_^ MRA^SSIO[*W[/_A[X":5XEGUFW\/PS1QZE=6ZQ23>9/)+DJI(&#)C@]J9KG[7 M/[/7AOXI+\%M:^)=I#XF;5+/33IK0RG;>74;RV\#2!/+621(W95+ G ]1GI; M#XN?#W5/B=J/P:T[Q+#-XFTG2X-2U+2XT8M;6TSLL3NV-H+%&PN=V!G&.: / M'OC!^P_XM\8?M'7?[2WP?_:-U+P-K.L>&8-"\01Q>';/41/:PR.\;0&X!^S2 M NWS*"#P<<NZ;)J%C$9KS^T8I( MVAF=2 2GF%MX4;CU KV;X\_'CPC^SSX*M_'GC6TO9K.XURQTM4L(@[B:[N$@ MC)!(^4.XR<\#UKM0P8<4[L#SK]E3]GK3OV6O@CIGP4TKQ-/K$&F7=[.FH7-N ML3O]HNY;D@JI(&TRE1SR!FO1J^6/A1^V=\1/'S6;:[K_ (2T5I/V@-6\%+;W MUMWAN ,FV^T)$86G ZPAS(.?EX-/E8'N=%?*NI?\ !3?X1_"7 M]IGXG?"']H?QYI>@Z5X7?2&\-R16%S-<3PW-BD\\TPB5RL2.X'F%5101DUT. MI_\ !0;X9Q_MB^#_ -F70[^UOK'Q9X1_MBVUZUCN)EFDE=/LD43)&8RDD;,Y MDW%1P"5/5%]6^*%GX<\::CJD,T# M:1;NDCS>9'*$D@E4*"!(HX/0Y%):[ ?55%>3_#S]N7]E+XH^!?$7Q)\(?&C2 MVT?PD,^)KG4%ELFTQ<9#31W")(@8?=)7#=LUG_#O]N[]F;X[+KV@?!?XNV-U MKFCZ'-J366J:==VCK %XN?+GB1Y8 =N7C##!Z\B@#VBBOGW0_P#@H)^S]X ^ M$W@O7/C[\?8])U"TAFGDO+K+ V\<$:-,TH*MF,)N&TY MQ3LP/6J*X_X)?'WX1?M%^#V\>?!GQM:ZYID=Y):7$L"O');W"8WPRQ2*LD4@ MR,HZJP!''-=A2 **** "BBB@ HHHH **** "BBB@ HHHH **S?&6K7.@>$=4 MUVR16FLM/FGB60?*61"PS[9%?(7[./Q8_P""H?[2?P,\,_'3P_X[^">FV?B; M2TO;:QOM%U%IH%8GY7*RXSQVIVZ@?9]%<9X%^,O@O7]5UKX>7?C'3[CQ1X-L M[0^,K.WCDB6SDFA\Q9 ) ,QL S*P)&!@G-<-XJ_X*)?L=>#?"6@^-M<^,]K] MA\3VLEUH*V>FW=S<7MO&Y1[A((8FE\D,"/,*A/>D![917S]XO_;0TC6/'GP- M_P"%'>(=%\0>$_BIKVI6EUJT6Y\0V]C+./+.1L<21[6##(P00#7?1_M5? )_ MA%%\=U^(MK_PB4VH_88M9\F7RVN/M)M?+QLW9\X%.F,^W- 'H=%>+_%3_@H5 M^QW\%/'%Q\.?B7\;+'3]6L6B74XH[*YN(M.:0 H+F:&)X[8D$'$K*<'/2N0\ M?_\ !0?P;H'[5=]^R_I.HZ;#)'\.YMNK>ZEA-YM\R*-O*C*^0(096D#$ M'A00W!+ ?2]%>%0?MT? [X8_!/P'XX^/GQCT(:EXPT&"\LV\.6-Y<+J1,2M) M/:VR1M<>0-V=S(-H(W8K=U_]N7]D_P ,?#/0/C)K7QQT.'POXHF>'0=:69I( M;N549FC!53AP$8;#AMPVXW<4:@>L45P/P%_:>^!G[3FBWVO_ 1\?6^M0Z9> M?9=2B%O+;SVDV,A)89D22,DJ&?2UT M^-HX[S26EFA2?YV.2);>96(XX'3-+^Q1_P %%;W]H+7/C1XL^*JZ-X;\#^ = M4AD\/:Q.QA\S2768K=3N[;<.L8<$ <-C%5RL#ZVHKP/2?^"B/[-/Q4\-^+K7 MX%?%&UU3Q)X?\(WNM6^DWVFW5H]Q%#"SB:-;B.,SQ;MH+1EAR.>:N_LY_MC> M"OB/\/?A7:?$#Q-86_CWXB>"[?7(O#NFP2R,4:%7EEVJ'\F$$D!Y"%)XR34@ M>WT5X[IW[?O[(>J_%=?@I8?&[2Y/$#:HVFQQK%-]EDOAUM%N]GV=YP>/*$A? M/&,UZ9XX\=^#_AIX0O\ Q]X_\26>CZ+I=JUQJ6IZA.(X;>)>K,QZ#^9XZT : MU%>,_#?_ (*"?LB?%J36K?P/\8K::;P]H\FK:I:WFFW5I,E@@R]RD<\2-+$! M_'&&'(]13?AQ_P %"OV.?BYX[M?AK\//CEINI:Q?6KSZ=!';7"1WJHF]U@E> M,1S.JYW1HS,N"" 00 #VBBOD+X3?\%*=.^/FE/?>#O$GASP_-9_&JW\+20:[ M8Z@POM-EF:.+RF$0 NY_+,/&?P\_:&^)NB>'M M:T/XFZIX?TV%;2X$,=G#<^3;274P5HK=I"" TC(&(^6JY6!]845Y+\:OVYOV M5_V>/%$7@KXO?%VRTO59+07(GI)+M4^M7?BQ^V+ M^S;\$_"V@^,_B)\5+&WT_P 4<^')-/BEOI-238)/,@CMDD>1 A#%U4JH()(S M4@>FT5\D_!C]O?Q!\:M#A\7Z+XZ\%VND77Q\D\(Z1>SP7+IK.EB R1I;F/=_ MI3]0S[8\*V<'%>J:A^WS^R)I'Q6/P5U'XX:7'X@34UTV6,Q3?9HKYNEH]T$^ MSI.2<>4T@?/&,\4^5@>Q45X]\3OV^OV1_@W\0Y/A9\2/C-8Z;K5LT(U"%K6X MDAL#-_JA?LM_M;>(_AG:^--2;4O$WA^WT.SU.SEO MG $MU MR";>1P 25)&1G'8?2]% 'S.__ 33\'^'?AOX.T/X3?%SQ!X<\9>! M]=O=:TOX@21Q7EW=WU[G[<]U%(/+G2?/S)@ ;4P1MY=X9_X)V-:>(?#_ ,0_ M'_[0&O>)_%FF_$2/Q=K6N7UC%&NHS1VC6L=K' A$=K D;/I:BG= M@>"_&C]C#Q5XN^--Q^T)\!?VA-4^''BC5M#BTCQ)+;:':ZE:ZI;1,S0,\-P, M)-'O<+(IS@X(QG.!?_\ !.5M)T/P3J_PQ_:.\6:/X^\$6][#;^/=46/5)]3B MO'$ES#=07&4DC:0*RH-HCVC;TKZ9HHN!\VVG_!/.2\\%Z7H_CS]H;Q-XDUVV M^)UCXVU7Q!JL:$75S;/N6UAMPPCM+?'RA8QQUY[>E:5^SIIVE_M5ZM^U,OB> M=[O5O!5OX<;1S;J(XXXKEIQ,'SDL2V-N,<5Z0:\#_:-_;E\(_L^_M,?#']GW M7+=?^*ZENSJ%\UK'/A[>:7:Q[# YDMH+B]0":XAA;!5#C.U020 M*]'N/^"@/['UG\5C\%+KXY:6OB!=5&EO&89OLJWQX%H;O9]G$^>/*,F_/&,U MZ!\5/BY\//@GX2;QW\4/$D>DZ0MW!;27\\;M'')-(L48;8IVAG95W' !(R12 MU YW]G[]GO3O@%<^.+C3_$LVI?\ ";^/+SQ-.)[=8_LDEQ'$A@7!.Y5\H$,< M$YZ5RO[07[*7Q,^)WQ+M/BO\(?VGM<\":@-%;2=6T_\ LF#5M-OK8R;U?[)= M9CCF4DXE49(P",==W]HW]I'P5\(= OO#J_$31-(\67'A34M9T&/6H)Y;98+1 M%,MS.($9A"A=,D8)W +D\5A7_P"WW^S)\.]2\,?#OXK?&O1[?Q;K^F:7/!I] ME9W3K=->J1%+$!&2(G=6PS8VY4-@L 34#YYUW_@G_P"._A-\?_@/\+_V;Q\NC0WL8O;BYM)&CN8G7R=DQ:8B+Y<; 5Y3->N3?\ !-'P M???!^;PIJ7Q<\02>.KCQTOC63XF)#"M\-?4;$N5@P8EB6+]R+<#;Y>1G))KU MB/\ :H^ =Q\(K/X\0?$6U;PGJ&I16%IK7D2B.2XDNQ:)&%V;LF\>:5^U%^T'XB^(T_C[P^NB7@:WBTRSTZS4EE- MK:09B2;?AS,0S$J.V0<:Y_X)R^._'.E:EIGQX_;!\3^,\>!-4\+^&/M&BVUF MFF17UJ;:6ZE2$C[9<>7@!I"!P3C)R/J6.19$WHA'>G4N9@>"Q?L*:'%XM MM_%G_"Q+PO;_ 1/PX$/V%,-!N+?;,[OO\_<^[[USI_X)V:UX.L/ NM_ 7]I M#5_!?C#P7X!A\'W'B2/0;6]CUC3(\,J3VLWR!UD!=^LPY!KZUJ[T/PSK>EZI-JP22;5Y]4G2:YNW?/[LAE(6- M5V@$#MSX7^TO^R=XO^%O[%&D?L >&-1\:?$36M6\10M\-?$5GX96WA\)10SP MD-=7'_A3X3@$>F^ M'='M]/LU"X^2*,)D^YQD^YKI***0!1110 44,<#-?+'QK_:C_:"\0?MKW>K>/A-++JS7+NJP6<$;IO5!&=[Y)!8 #@Y /J> MBO$_A+^TCXV\,?!7Q%X\_;;\.:;\/;SP=K4^GZOJWVAUTO4H4V>5?VC2?.8I M?,"A#EMZLO/%.T?_ (*(_L;:U\/]8^)]O\<=/AT;P]?6]GKTVH6EQ:RZ?+.V MV'SH9HUEC5S]UV4*<$@X!P >U45X?-_P4?\ V,(?AYI7Q2_X77;2:/KE]<6F MC>1I=Y)=7LL'^N$5JD)G=4XW,$*@$'."#737_P"V!^S5IOP2M_VCKKXQZ-_P MA=X52SUV.1:-^W?^R=KWPKU3XU6 M/QFT]/#>A:C;V.NWMY!-;R:9<3S1PQ)<0RHLL!9Y4 +HHP?A3XCT/2?$7C;4)3?:OXBT&]O;?3K1(V*%8 M[=1YCR2#R\!OD'S, #NKT-/^"@/[(EE\3D^"FI?';2?^$D74ETJ95AF%H-0/ M'V3[5L^SK.6X\HR;\\8S3LP/:**\FU;]N/\ 99T3XY1?LUZE\7+-/'$VI1V" M^'5M9WF6=X4F16*QE4#)(A#,0I)(SD$#9^.O[4/P)_9IATNX^-_Q$M/#Z:U+ M+%I/VJ*5S=21IO:-!&K%GP1A0,L2 H)(%(#T"BO*_#_[:W[+WB7X.:I\?=/^ M,>EQ^$]#N&MM9U2^\RU:PN%(!@FBF598Y!_CG\4OB!:Z/-XQTV-H=+M]-O)9Y;Q8U-S%!;K$T\ MJ1.2"ZH5Q@YP03U^L?MP?LI:!\+-%^-NK?&_18?"?B&\-KI&N>$2Q+LWN&955@F V2*^B?AWXZ\/?$OP1I?CWPG? M-I?LWZ; MJ/[6&F_M5-XHN$N]-\$7/AM='%LICDCFN8Y_.WYW!@8]NW&,'K4>F?MG_LPZ MO\#)OVE+/XS:./!-O(T4VN32-&LXTYIG5(O.MI8UF0.SKM)3#9R"0" M:-0,?QO^P=X&\6_M$:U\=K+Q3=:?:^-/!LWASXB^%H+93:^(H2A2*=VR&BGC M4[1(N25&..2?)?%G_!'^Z^*'@#1_@U\8/VQ/&FO>"_!L+?\ "O\ 1H]+L[6? M1YUC,=M/+=(GF730(=JAMH( SZ5]-?$K]H?X2_"G4[?0/&WBR.TU"]T*_P!8 ML;(6\TDD]G9K&UQ(HC1L[/-CX^\=W /->%_!/_@K1^S'XE_9N\,_'3XX>.[' MP?<^(9+R+^S9+.\D5;BWVL\$3>3F=A'+"-O&$T+^)O&/B1H_M%S'"I6&"-(U5(84!.$4 M=3R3P!E^.?\ @I9^Q+\.9;.#Q9\=+6%KS3+741]GTN\N/LUK<('AFN/)A;[* MKH0P,VS@YK%^*/[87B/1?CSJ/P_\%Z[X:7PW_P *#OO'.F^)+Y9)K=9HY@L4 MSM"27M?+(D.Q2Q'W2>!1[P'1?'G]D'7OB+\9-,_:*^#/QQU+X>>-K'0Y-$O- M4L])M]0MM2TUI?-$$]M.-I9)/F1P05).=W&.=\)?\$X?!'@^W\#W%G\2-8N] M6\+?$BX\;Z[K>H0QR7'B/5)X9(I7FQM6($.,!!A5C5<'K6O=?\%!/V_P##-EJMU<:3X?U&6SE2:$/YT;K VV,\D!B&"XW &DT+]M+X M:>+_ !W8>*O"OQ@\,W/P]NOACJ7BEF:SO%U"2&TNECDO$S&$^S(HD5@?WA;! M4$4>\!V7@+]G73? G[1OCS]HF#Q-<7%UXZTW2;.XTM[=5CM!8I*JLK Y8OYO M.0,8&*XWXU_L8^*_&'QHNOV@?@+^T/JWPW\4:SH$>B^)IK/1;74;?4[6)F:% MS#<#$<\>]@LJG[N!CKG4^&'_ 4&_8\^,OQ L?A=\-?CCINJ:UJENTVDV\=O M/''?*J[W6":2-8YG5>61&++@[@,&J>O?\%)_V)/#/C.^\ ZW\?--AU+3]2&G MW'^B7+0->&18S;1W"Q&&6968!HT=F7DL 2%[P' Z;_P3!OOAMXPT/QY^SY^ MT]X@\+:M8>#4\-ZSJ&J:+::S-J4 N9+DSAKH'R)S++(Q905Y VX'.E\'O^"9 M_ASX/67@/3+/XR:UJT/@'XE:KXNL)M4LHFN+M[VWFA:"9U(!VF9G\P*"Q_A% M?1'C3QQX2^'7A+4/'GCKQ'9Z3HNEVC76HZGJ%PL4-O"HR7=FX KS/X0_M[_ M +)_QVU_4/"OPQ^+4-]J6FZ8VI7%C=:;=6N(EN(D,T8R/GCW#D<\T[ MR Y?XG_\$[O!?Q3\8?$_QOJ_Q$U:SOOB%?>']2TZYT^%(YO#NH:1"$M;J!R3 MYC;E#%6 &"5Z'-8NC?\ !.KQIJOCKQ9\4?C/^U;K7C#7O%GPPO/!,UQ-X;M; M.&SM9VW"6&*$A0R\DJ<[F8DD=*[/P-_P4@_8I^)GC+2_ '@CX]Z7?ZEK@QI* MQVUPL-W)LW^2DS1B,S!>L.[S >"H/%>8>$?^"F&E?&'P!XVU[P/XF\.>';OP MK\4K?0()_$EAJ#6UQITEY';QRDK$")Y_WH1 /W;;-^!R3W@.KOO^"?GB#PW= M^%/$_P !/VDM8\#^)-#\ V'@_7-8M]#MKV/6]/M(PL+R03Y2.=#O99%R1O(. M1BN4\.?\$I+GX;Z'X!N/A+^TYK6E^*/A_^FDM/^?DI;1R,L'_ $U8!.O/!H]X#R6W_P""6ULOPC^)7PSU/]I' MQ+J%]\1?%VF>*9?$U]IMLUW8:O9RV\PF55"QR(TEM'B,JH5!M!/!K1U__@G[ M\4XO$^L>.?A3^V1KWA'6/&>EVMM\1+FT\+V,\>LW4, @_M"&-^+*X9!@F,D= M" ",UZC\0?VQOV:?AE\+]%^,GBSXN::OAWQ))&GAW4-/\R].J,X+*MO';J\D MQP"2$4X .<5X;\,_^"ANH_&77M>O?!/Q \%P>'+/XU:1X6T+4KZWNC_:EC ^G/A%\--+^#OPUT7X8Z+K&J:A;:)IZ6L>H M:UJ#W5W<[1S++*Y)=V;+$].< =)7CWC?]OC]D7X;?$R3X0^-/C=I=EKEO M=16U]&T4SV]C/+CRXKBY1##;.V1A974\BI?C)^W9^RG\ /&"^ _BU\7;32]4 M^RQW5S;QV5SN457TG5M-UW3+?6=&OX; MJTNX4FM;FWD#QRQLH975AP00<@C@BK% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 #?=K\I_#'PB_9#36OB]I/[5?[#?Q0\4>*]5^*GB"XTK4=#\"ZO(MU M8239@,5Q'MAP3N(8G'())%?JQUZT8YS5*5@/SO\ "_PM_:X^#GPU_9M_:V^) MW@'Q%XJU[X8QZUIWC#PQ:JMSK$.AZ@K1P/L4_OYK>-(-R*=YQWPU>^^!OVQ? MB=^T5\>O#/A/]GSX->(;'P+9QW%S\0/%GCKPG=Z9M7RR(+2R2?RW>8RX+MM9 M%4'O7TF0#30B@8 I7 _,OX'_ /!)?P+^T#^Q/K6I>(O!6K^%_B?<>)M;N-,O MM4EN[='D2_F:W2>UD(1X)$"@_)RK;@:^S/V"_B'JGCS]FG0[;Q'\$Y_A[K/A M]6T?6O"AT5[*WM;FW^5FM5*A7MW^^CIE2&QDD&O:L"C IN5P/SYU3X(^+#_P M3I_:NT2/X4:HVN>)/B#XON]-L?[#E-UJ(-U_H\L2;-TH*@%&4$$WD$ MF64':C"0DG.:_2; ]*0J#U%',P/S"\,>'_C#^SQI/P?\$MX/^('PZ\.+X#U* M3_A+=.^'\'B;Q+;W%QJ4LPT=Y8+9ELT,;+*%$>-S["+K/X@> /CI>>._!=IXHTOR=2OVA,$V"L:*DC7%NT\3"(%2[LHY%?I MAL4]12E0>U',!\%VG[+WQ"^)G_!//QU\9_%6A7&B_%/QAXDF^)EA#J"M'<:5 M>6L@ETZU?=@ILMH4A((!42.*]2_X)?6OB#XG_#SQ/^VIXZTF2SUOXRZ^=4M[ M68Y>ST>W3[-86^?3RT:3C@F;TQ7LW[1'[/7A#]ICX?-\,_'7B'Q%I^ES7*R7 MB^&]:DL)+J, AK>1X^6A=6(9.,CN#@UUGA7POH/@GPWI_A#PKI4-CIFEV45I MI]C;IMCMX(T")&H[ * !]*.;0#YG_P""@7_!.#P3^UA:P^,-!T0-XN;6M)^U M7EYK]W! =/@N%:=!&C% YBW@':#DCD'FO>/@E\#?AS^SYX)'P^^%VDW%GI:W M4EPL-UJ$UTWF.06.^9V;'MG KL,C.*,=L5-P/SK\#_"?XHV^J>"VF^'>OP^1 M^VEK^K3R/HTX\FP>SNPEXV4X@)( E/R$D8/->;_&SQ9?_!W_ ()D>-/V/_B! M^SWXHN/%%CXGN)9O$D.@M)H]VDNL">/5A?C]T6*NBA,^;OPNW&2/U:9-P(KY MY@_X)A_LRQ>+)-9>7Q9)H3^(?[='@&7Q5<-X>74/-\XS_8L[3^]^?824W?PX MP*KF Y7X*_"S46_:J_:6\5Z_X NO(UW1?#]IIE]=:6_EZA$NC!9(XG9<2@/\ MK!2<-P>:\=_8VT3Q[\'/'?[+.N?$+X6^+H+:?X$R>&+J:/PU=2?V=J3W4+K% M=@)FU&T'YI JC')%?HDL:JNP"G;1Z4 =6\3> M%_ 'BZ]N/%6FZ'I[WMU;I<69AAODMT!>40OR0@+ /D#K7COQ8\S]ISQ[X+^( M/@C]D75M#\.7'[1GANZNM:O_ S-;WGB*"""02W]Y;-$'A@B.V-9)&_CK\>/''PU^ S^)$U'X?^$XX?MGA,ZC: MS-'?R>?/' 5V7<]O%^\$8).57CH#R?@#3?B?XZ_;,TOXB"_^+'C;29/A#XDT MQO%WC#X?G2+87C0AUM;>!+>-XU(Q@R9#L=J$[6K]+RH)S0$4=%HY@/@G]AOX M0>,])^-G[/6M^,?AGJUHF@_LORV-Q=:EH\L:Z??->6V8'+J!%.4W_( -/D_M+PS'*F(]0CM#"[ M7=K+N9&V*1@Y![U^EV!Z4A4$8(HY@/ES_@F-J?QDU;P[X]O/B;HLTVFR>+E? MPSXPU;P0OA_5/$T)MHQ)=7=J%5BZN/+65U#.J\\ 5]24BJ%'%+4@%%%% !11 M10 4444 %%%% !1110 4444 8WQ&@N+KX?:Y:VD#2RR:/M2+\:O :> _$T8TN:.;2( MIF22TU"YC*[H3#%)$K#Q9X(\%:/\*[ M+2]%\8_#GX7KK6K:Y)'*0^G/=>1+]E5 JN RA69V8GBOOX@'@TTHIZTE8NKZ[\2="_867]A]?V>/B)-XVT7XI&;5/(\'73V$=A_;[78O$N@ MOERQM&RX"%FR3D D?J2% [484=J.8#\NOVF;OX]>,HOCY\+)O#OQ"T#4-5U MC4H_#_@#X=_"R/[%XGMS"%BU&\U1H'6;S57,GSJX"[%^8@5W3:?XT\*?$KPE M>ZO\+O%TEOXJ_9)'AJQN;7PS=3)!JJ1^8;:YVH3;/@8_>;?FP.IK]"]@SFE( M'7%',!^=G[.,/BG]DWQI\*/CK\9_@]XPO?#^H?LZZ1X;BNM(\*W-_<^']2@8 M22V\UM$C30^:I W;<;EVG%4OAY\ _B9>^(?AGXVU_P"">L:;HGB3]JC5O%^G M^';K26+Z+I4UBRPRW4:@BU+RQF7:V-K2@'FOT>* C%.Q1S ?./[/?@OQ!H/_ M 4$^/7BBY\*7UGI>L:9X9:QU"2Q>.WO94MIUD,;D!9&7Y0VTDCC-?1U&**D M HHHH **** "BBB@ HHHH **** "H[H%K:11WC(_2I*"0!DT ?E3H?P;_:>^ M$G[.OPX^(_P;^%GB"/Q1XKM?%/P^\367]DS)/86U_K%U-9:A*A4,L<+,[[F M&V13D#!KTCQE\'OB3\ /"O[2?ACX._ :3Q':V7A_P3IWANPU/PVU]:WT%M81 MQ33Q0LNV]>':9"@SEU&1GBOT$TS6=&UN-Y]'U2VNDCD*2/;3K(%8=5.TG!'I M5@JAJN8#\OK33?BK\1/VF=%\2V M>.SMK=+>-XP=F,ON5G*JA)!!Z;_@GE\$?B_^QWJOA*W\5>%_$6MZ?\:OAM8V M\_B2^T21[_P?K%O:X33[@A-UO9%& 3> $=,-US7Z-[5' XI0%/2CF _)'X=_ M!+XCVGP)\*_L>>/8_CM>>*M+\66\=YX'T_PO:V^BPR17_G'5(]6>S9/(_P"6 MV\RF0DE3S7WK_P %'+GXBZ;^QMXDD^&?PQMO&&K*UB/[+O-#&J!8?M47G70M M",7,D*;I5CQRR#@]*]RO]1TS2XOM.IWT-O&6V^9/*J+GTR319ZGINI1>=IM_ M#<1]-T$H<#\J&P/R[U#1?BQ\2/VB9_'5E=_%OQWI]Q\#/%6E)XG\5_#PZ3;_ M &U[8,EG;6\=M&Z \8\S(=CM0G!KVN?X/^)=+^"_[%>F:-\-=2@F\,:YH;:U M#!H\@DTM?[(=9VN %S#^\XI>(?#FBRQ6^KZW9VLD[;8([FZ1# M(?102,_A4E]J^D:7&LVIZC;VZ.<*UQ,J!CZ9)HY@/SATKPQ\0=J_".7X3>+H M]5T']L^Q\1WDC>&;K[*^EW%[(Z7<'/@U^T MM^S)J'[*?CK4/%GQ)^)/B4>%6A\%W+66N+=3&."=KLIY44<1^;?(RC: RDYK M])+#6-'U;=_9>J6]SM^]]GF5\?D35@A?6CF ^!OA%-X@_85^(_Q.\.?M ?"# MQCXNN?&GA_0_^$?\1>&_"MQJ\>L?9M(CLY;!WB1O)831L0)=J,'W9ZUSG[.W MPS^)W[#/BCX-_&#]H+X4Z_?Z+;?"G4O#MQ'X=T>75I_"U]<:K)?PQ/#;J\@4 MV[I;[T! :+:2!BOT /B+K_ACPSX@TWX&>*/ M#=O>?MJOX@ATJ^\/30S6.FR6>V/P.^)OA_X&:O M^QW\1Y?CM>>)[KQI=+)X-\.>%;4:/J?FZF;B/4TU62S=(TVE)&=Y=ZLNW &! M7ZV6US;7D"W%K<1RQN,I)&P96'L13B%SDFCF _-']J[0?&O@'XO?$P?"KPO\ M5-!\5:ZMFT?AI?!*^*/"OQ%=;6.-))@8#':O\OER;W4*%W 5^B?PQ/B$_#C0 M#XNT.UTO5CHMJ=3TVQ4"&TN/*7S(HP.B*V5'L!6V1&#N)Z%?VJ_P!G M_P"+:^#O$&HZ'H^K:]8:M>^']#FOFL)+VP$%O)(D*LRQF3@N1M7&3BOJ2@@' MJ* /S).D>-+;_@GMJ_\ P3:E_9L\83?%2YUB>QCN%\+S'2YYGU+SUUG^TMGD M"/8=Y8N) 1C%?>GQI^!^G?'']G'7/@)XTN1<+KGAE]-N+QAR)C%A9QZ,L@5P M>H(%>@;%SG%.IW _-CXD>/_!/Q>^*5O\$O!'Q-T7Q3X@\31W%V@,=ENV_O-\@,90'@]/TWVKZ4;1G.*.8"AX4.IMX8T]M:L(;6\^PP_:[6 MW_U<,NP;D7_9!R!["M"@#'2BI **** "BBB@ HHHH **** !ONU\3_MEW'P_ MUOXXZMX1_;E_8OO/&7@$6-O+\.O'7@WPG=ZC>V9*8NK:Z>U8SPOYN&0J%0@C M.2,U]L4A4&A ?F=HOP?_ &@H?V<8/%5A\-/'FJ?#/P7^T!I?B7P=X%\61/<> M(#X9MX62=?(D)D95N)!-% _[S;$>,E172?MA>((_VP? OBS5_A5^R'X@CTR7 M7/"-I=>,-4\)W-GJ6NB/5HWEMA:R0B9K:"/&.,5X_?_LU_%BQ^!O@OXT>&_#OQ*/ VLV__!3_ ,"^-=*\'72Z3#\&]7L;S5K?3W%LDGV^T:*! MY0NP-M#%4)S@$@<5]($QCJ:7Y>M',!\X_M2^#_%FO_MH_L]:WH>@:A-9:;>^ M)?[2U*ULWDAL?,TIDC:5P"L>YN%W$ G@9-?+']E>-8?^">-__P $V)/V:O&$ MOQ5EU:2P6;_A%YSI%+I9]0U[P_#8 MZY>:>T:ZA'#HELKO#(R@2*)3)DJ2 Q(/.:YO_@I-XVT7X,OVT?!?P)\3S^!_^%P>"]<_X1&\T1[?4-?L-(M[B*]OEL90LC$M/$R(X M#2"U!QVKN/'UAXJ_:Y^-OQ&^-_P9^$7BBP\/P_LXZYX5-YKWAV?2[C7]5N29 M+>"&"X5))!$$9=Y4#=+M!K[LN;RRLH?-N[J.%-P7=(X49)X'-2*% ZTXU+1-7M6B,R36D]M+*()@ MI"SQQX)0?-@D5N_#S]G[Q1<^#/A;K*_#+X@7&GZU^U=_PD]TOC;2XC=FT:W< M'4)[:W@1;**21/,\N11M+\D;@*_2D[.AQ0%&*.9@?GI^V]\&/B;XF\2?M9/X M+^&&M7W]O?#OP>VEFQTF5AJC:7J=G:ZG8I-#:ZUIDMG=1#IMDAE57C8$=& -=%@>E &.@I7 **** M0!7S5\8O 6L>(/\ @IM\'?&Q\'7EWI6C^ O$8EU7[ [V]G<.UL(PTF-J2,N_ M:"02-V*^E:,#&,4 ?F+\9/V=OC3?^&?&7BOPWX*\6VNF>&OVOKCQ1?6OA[10 M^H2Z6;.%/[1LK>:,I=>7(Q< *X;Y\ D5G^/?@G\0OCWX.^.7Q'^&&G?&#QK> M7'P]TS3+?7/'>AP:2VN26VJ0WIMK:R^RP2RO%''*!*W!,A0 \8_4K:/2D" # M@57,!\2:#\6M8_:?_;V^%?CGP1\%_'FF^&_#_P -_$EC?:WXF\(W6G1"_N!9 M9MOWR*05$0&X@*Q9@I;8V/+_ -E'P3XK\2:G^R'X,\3?!7Q9:3_##4/%MCXN M76_"MS!#877V-6AD\R2/8T;%@$D!*LP(!R,5^E:J%&,4N!UQ1S ?FQ^TQJ?Q MMUCXK?'/X<3:!X]\+?VMNMO"WAOX9_"^*=?&D)L%CCNKS57@D3!/[ME9DV(N MT?-BJWA#X8?%6Y\ Z/N^%WB2.2+]@V^T*2.;0;E634QA!989 ?/)4XB^\1C M(-?IAM&^+OQ7\:^(?!WPO_ &*_'?PQ^)F@_#NQ^'^CW'Q. MUSP_X!U2\N-9(M(2-%@:V@;R4/\ R\.2#@-'P=P/3?%W2S\4/B)JWB_X*?![ MQ1I_A9OV0_%FA:+9W/@Z[L&AN!.D<-F()(E9)&"?)'C+[[X;_P#!.#P[^QYXU_9W\46_BSPW\0-(34?$3:"3I(;^WXW7 M4H;\?NIC.'$85&,F9F# *#7ZL21+(NQAP1@@]Z^>?#7_ 3$_9F\+^*['6;6 M;Q9=:+I.OG6]%\"ZAXJN)M!T^_WF03Q6;':"'8N Q95;D <4!+>-HE( M0\R$JS%50DAA7Z7A<#!H" #&*%*P'Y]:)\%?&6F?\$Y_V6_"MK\+-6BU?0_B M=X7OM6T]=%E6ZL!]LD:XFF39NB #DNS !N2*YOQ]X:^(4_PC^,'P2C^$OB_ M^W(_VHK/Q+;[/#-TUO>:7<:S;.ES!,$*3*$1F?:3L49; Z?I5@>E&!Z4$[K2_!-S=6OB /I%O;I;>>L>Q$ M21BQ=R$ =R"2K /_ &;-(\8_\$]_BI<:A^TC\+?%OB*+Q'\'O".DZ3K_ (7\ M,W&L_9KK3;)K>[TMQ;HS1%Y2)%) 1RW+9 K]!2F:4H#UHY@/S<^"'PM^)W[* MEQ\$?VC?C%\$]?;PSIEUXT%YX?T?27U"[\'KK-VEQ8RM;0*S_+"CPOL!\OS< M''(.9H/A+QY\0_&>K?$+PW\ /%VAZ7K'[87AG7;*SU+PS<6TK:>L">9?/&4! M2,D%V8\(6PV#D5^FY4'C%&!Z4:MXN\ M=:O=67A7P9X0MKG2O%EO?7&^*Y&HO:2K"2I'F&613$4X XKM/VE?!'B7X2_$ M/7D\+:;\7O"?BB^^'.CZ?]JTGPFOBS0OB"UOI_D"UOH%MVCBF0@P.SE%=27Q MBOTNVC.<4THI.<4$56R HX &!TKN***D HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** /C[]N#_@H'XM^"7Q7\$_#WP3\) M_B0JK\1[&RU[4+/P:)[36[%X)'>ULY6;][,3MP%"GY&&1CGZ>^$_Q%A^*_@* MQ\>V_A'7=!2^5BNE>)=.-I>P;7*XDBR=I.,CGD$&HOB/\&_ /Q8N_#M[XXTJ M2ZD\*^(8=;T1DN7C\F]B5U20[2-X =OE;(.>E=0!C@4 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5 M\>?MD?\ !0;Q9\'?C=X%^'?A'X0_$Q;9?B$MCXBN;7P8)K?7K/[%0>%=;T--1B+KI?B/3S:WMO MABN)8B3L/&<9/!![UT%(JA>E+0 4444 %%%% !1110 4444 %%%% !1110 4 M444 %>-_\%!=2^(NB_L6_$[6OAAJEG8ZI9^"=2G^U7@D_=P);2-*8S&P*S; MVQLX#[201Q7LE*O"]_I"Z@T'FBV-Q;O#YFS* M[MN_.,C.,9% 'PS^RYXS_:K^!L?PU_9%_9O^&'PHM[KQ'\,X?&FM:U>KJ$4 MC,J1%I KL\MPZ;06X7>2?NC![V__ &]?VL]2^$GB;]LSP5\-/!<_PG\*ZU=V M\VBW=Q=+KFIZ?9W!@N;^*53Y,7S+(R0LC$JG+ D5[+\,/V0;SX=?&OPG\7)? M'4=XGAKX16_@F33UTXH;AHYDD^U;]YV@[<>7@]?O5YKK/_!-WXI2>$_$?[.7 MA;]I1--^#?BK7KC4=2\,_P#"-"35+>&YG\^YL(+WS0J02.7Y:)G4.P!.>+O% M@9?C_P#;A_:Z\3?$;XI:)^S=X%\!S>'_ (9^%=-\12:CXHDNQ-J%O#]/\#_&^SN'\.6.D MWES+JFD,MI]JB:XD?$4HDCZA%7:3U..?1]!_8MB\-^(_C%JND^,HX[/XH>%[ M'1;&R_L\_P#$HCMM/ELU8MO_ 'V1(&QA<;<9.%M"T'PA'I-K'>31&)KB4^ M;*\A5#PNX#//U-.4#RC]A#]ECX+?MS_ N]_:R_:N\,_\)IXI\?ZYJCLVK74I M70[2*[EMX;*U56 @$:1CE0&W$\US'[;?P>T7X#?"W]GGX.?$35O$WQ?T'2_B MQ<6TFGQ6HN=1O['[/<&.QVB4>>T2[4RS@D)SC&*]NL_V(?VF/@OK'B32?V/_ M -JG3O"?@_Q-JUQJ;>'/$/@T:F=%NKAB\[V,@FCV*SDL(W5U4G\[7AW_ ()N M>'_ _AWX2>'O"7Q%O';X<^/I_%FN:EJMKY]UXBOIXY!/([!E$3N\F[.& "@8 M[T7U ^=_V>;+X7?$K]OKP?%^Q!^S7XJ^%#> )+B7XP1^*)!IK7FG7%NPM[7[ M#]HD:?=+L=9-H5=H.3D5]:?MX?M%?%3]F_X?>%=:^#?@O2M>U[Q-\0-,\.6N MGZQ<210G[7YHW;TY4AD'.#QG@G%/^._[(=S\0?VA/ 7[47PM\^9'R=C"O'GQ ^&'PT\/_#K4;[3] M6/QJT![?5]/L#<-IN//_ -)9,8*(<%MV!C@D9H^)H"30/VL?VEOAWX]\;? G MXW^ _">N>,-'\!-XN\(7'A.^;3['5K59##);S&]D/V9XI2FZ0N5*-NX/RUYI M\-?^"D7Q+U_X^Z'\ _B-XJ^#_C*W\9^'=6F:/X:ZI,J ,$]YXI_X)T^/_ (VZ%\1-5_:0^/L>K>+_ !QX0C\,Z?JOAW0/ ML-GHNGQS"<)';M+(TC23 -*6?YA\HP *SO#/_!.7XU2?$KX>_$?X@?'_ ,,- M'\/;74+/3?#OA7X?KIEC+!>6$EI)*P$[-]H),;;L[ $VA 6+4>Z!P?P?_:W_ M &DYO ?P%^!_[)7PA\ Z?<>.OAWJ6LF/Q!=7WV'1UM+I%(!5WE=6#E0"2=TB MG. 09OB]_P %6_'OA[Q_X[\/^#_%/PCT>'X9WC:=J&B^,=4NH]0\3WT$0:Z2 MR\LA;:,/NCC>02%V'(4=/9OV>?V"+[X%^+/A3XEF^)D6ICX:_#S4O#,D*:28 MOM[7=S#/YX/F-Y>WRMNW#9W9R,8K$\<_L!?&73?'OCS6/V#/"<5CH_@+2_$7B2\\=27&Z:?483-!IL MF'EN$5M\S;E5N C8R>F_ MX)#76J7O[!'@^\UJ!H;R2\U4W,+R%C$_]HW.Y,GK@\?A4>N?L-?%_P %>/Q\ M1?V8_P!I ^'=0UCPA8^'O&4OBC0?[6.J+9QF.WOU_>Q;+M59P6.Y&R,KQSZ1 M^QC^SG??LH?L[Z'\"M0\:MXBET>2Z9]8>T\AKDS7,DV63>2,\=*-+ M >J4445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 -?[E?!Z_\%#OVT8/@GJ7[6]]\,/A^OP]\-_$" M;P_K&F+<7?\ :M_;+JW]G_:X&R8HBK.@V,&W%6;*C K[Q;.WBOF*_P#^">=_ M>_L/>(OV/O\ A:<*R:]XLFUE=>_L.T$1 M"6Z@GRD=Q)OD!& ,X]H^ ?[:US\?OCUH'@CP]X>M[?PUXB^"EEXXM)I]WVN. M:>\\@P-@[2JK[9)'7'%ZL)_-3R7D5%.'5PK_,/2M;QO^Q'\7](^)7A7XN?LY_M'?V#K MVB^ %\'ZS=^*M &K_P!J62S"99S^]B*W D!;=DJK7=HNZ%A),PMX(A MNC$CNPXWE?NA2WP=_P $S_B)\-/A_P##72O ?[1<'_"3?#?X@:OXCM=>U;PS MY\5_'J(F2>&6%9EP_ES,-ZL!NY"C@#KM0_X)]_VY^S-\7?V=-3^*NKJUEI^QM/^U20R+"4+D2JIA ;E0ZL1@4VX@>;_ S_ (*+_$WQ3^U#X5_9 MW\?^-?A'XNA\::/J$WF_#'4KB:30+FW@\[R;AY'>.=64.H="O*G@#!/G_P"Q M=XSU>U\'?LN^$O#7A'0[SQ-K'@?QH^@^(-+>5!6.10\;L5#Y!;:/ ME*GFO9/A[_P3Y^-.F_&;X;? _'CPO*GPW6^M]/\,^$_ "Z783075FUO)( M0L[-YY/EMN^X FT("2QA\/\ _!-3XA>!_!OPQTOP!^T+#INN?#/PCXCTC3M; M_P"$<+[Y]34A+H1F;"F'.=I+;B!R*/= F^#G[3?[:/C3]L*7]GK4;/X:^(M" M\,69G^(GB#PK9WT::1,RMY-BDDTI62Z8[6* 81,EB#Q7G?C#_@J+\=?AQX[T M6?QW?_!R.UU3QQ;Z'??#'2?$>$S=33>(DM/AY-!JNK23;C-.]ZU^Y^T, MQSYA1L8 \_TO_@DE\8]-^#VE_ "U_:8\.VGAGP[XBMM7TJ33_AVD6H:E M)!>BZC74;@7&;@ Y'R!"6"DG VD]VX'GNK?$KXQ:%HG[1&N_&?3?"_B_0['X M[:/I\.DW3WZM%;PK\*-6N-+O8?%%Q=?;O$=[:PK+=16S0D):JN[RU=P^Y^H Z,^(W M_!-[X@>,]>^)FGZ;\>+&U\+?$3QAIGBAM*G\,F2YL=2M9[1WQ.)U#Q.ELRA2 M@*F0')VX;5\:?L+?'#3O%GQ"'[._[3%MX1\+_%2\DO?%.D7WA47UQ97 M%[71]>L]:U#1M@'J5%%%2 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<-^TW\5M2 M^!7[.WCCXTZ/I4-]=>$_">H:M;V5PY6.=[>W>548CD E<$CG%=S7D'_!0.TN M]0_88^,%C86DMQ/-\-=:2&"",N\C&RE 55'))/0#DT+<"?\ X; ^#'@GX,^" M_BG\>/B1H/@]O&&BVEW:V^I:@(P\LL"2LD>[YF"[NN.!C.,URO[/G[>_PY^( MGP2\2?'CXL^+/#?AGP_H_CW4]!L=6;55^RWD-O*%AE5V/SM(IW87.>U>":'X MB\)?LY_';X6_'/\ :2\,Z@/!NH?L[Z9H&AZR= GOH=*U12)+BWDCAC=XGFB9 M &*C=Y94GC%?/_AGP?XGLOAS\/?C+HNF>)/ ?P_\/_'CQI=WUTO@6[ M6$:?=S:=+&W[M0)4W["8C(,8)J^5 ?I_I7[4O[.>N?#)OC/I/QI\.3^%([R. MTFU^/5(_LL5Q)*D21.^<(YDD1=K8.6'K7)Z_^W_^RK%\+?&?Q.\$_&GPWXBB M\$Z3+>ZK::7K$;., B-.^!(^(U;!4LPYKX/\6?#VT^(7[-GQQ\:^&];\9^-= M(\8_$+P/!=:UJW@>'1[#7)(M8M%GGM+6(+(RB-MLLCQH&VYR<''O7[6WPJQ^ MUQJ&F_#_ , ;5U+]EOQ-I_EZ9INU+B59HA;P'8N"PS\J]?04N5 >K> OV]/" M/Q \.?#WXG6OBGP98>%O$W@W4M9\2F\\0'[9ITUK#;.\4*; LR1&9UF8[=F$ MX^:L/_@GY_P4(3]K];J]\7>(_ >F7&K233>$O">C:Q+-JJ6L+LLC7:N N_;Y M;XC& 'YKR']F_P 1:%\2?B%^R;JWA+2KZ2ST7X/>)M'US[1HT]N+2^AM-*CE MAD$J+SO5ESRK$':6YKE?#GAC6?@Q_P $T?@?^V5HWAFXAU_X+ZQ)JNJV1MS% M<76C7-U+;:A;D-@Y,4BR#/>(=B:?+T _13PY\0_ _C#5]9\/^%_%-G?WGAZ\ M6TURWM9@[65P8UD$4F/NML96VGG!%?,?P@_X*7Z#\6/VD/'WAH>-/A_I?PV\ M!SI9R:O=:U(VI:A*RP@7$:@");?SIA#DY);BN\_X)R_"_7_ ?[,]AXL\>P;? M%?C^_N/%OBIF^\+J_?SA$?\ KG$8X_\ @!Z9KY=^,GPY\7:Q\#/VPE\,^ K^ M\N4^,5CJ%K:V>G,9KFU@MM+FE,*@9D 6-SA?$A=U&W( (RX SS71_ M /X)VGQ?^*EA\+?'V@7:Z/X@_8QT#1]0DDM654=YYE906&!(F0V#R" <4:6 M^XM8^)7@/0/$&B^%-9\66-OJ7B-I%T&QDN )+\QIO?RE_BVK\Q(X (]:\G_: M(_;4\*_LV_M&> _A=\2=5T31O#'BKPWK>I:EXBUB^\G[)+9-9K%$F>&\S[2W M'7Y1@=:^??\ @F-8?%3XV_&9_&OQRTR1+GX!>%?^%;V$DN2EUJR3,+V]3_>M MXK10>N)&SU%>J?M&> M-\9?\%,_@%?:_X574;'2?!OC"X22XL_-AM[C_ (EJ MQL2055L,^W/.U:#^TI\ _%'@_1_'_A[XNZ!>Z+X@U:/2]%U*VU%' MAN[UV*I;(0?]82"-G7VJ]XG^./PA\%ZAK.E>*_B+I.GW/A[11J^N0W5T%:QL M22! ]2C\-^"?VS--\1:E;Z3H\LGV M?2XX[;S[F*&-'=?N_#]U^S;'8:-J MEUX?N[5=5E2>8OY"31J[@%MOW>2K8XHY0/MJ+]O+]C.9-8DB_:<\%LN@H'U8 MKKT)\A2X0'K\P+$+\N>3CK6Y/^U3^S?;?">W^.MS\;?#.*^9I_@1X#TK]M/]EM+#X6V:66C_#'68RZZ0/+MW2TM MO*#G;@,&9RN[G<6(YR:\/U36M7^$'@B&R_X0?2]"T?\ X:B\5R+X\U[P+<:S M;^$$$9,%Q#91%^& MM-N$M]2UB'5$\FTD9@JI*21Y9)8 ;L9S5CX5?M2?LZ_''7M0\+_!_P"-'AWQ M'J&EKNU"STG4TFDB7.W?@'E<\;AD9/7FOS!U[3M;\9?"K]JM%O?$GB>'Q)_P MB-U8:WJ7@*_A_I/A3_@IO\'KW MP;X-CT^QC^%>O65U-IVG^7"L:/;>3$Y0!0!SM4].U#C8#ZJHHHJ0"BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ KPS]L3]JGQE\!]>\"_"[X6>#M)U;Q= M\1-9GL-#?Q)JS66FVGDP^;))-(JLS'& L:C'+P*/LMPL<'[Q8VRZM)&"R_CRUN!V/[/ M_P 9%,$ZD;C M&Q.5.0<5U7P__:Y_9D^+'C:X^&WPS^.WA?7->MA(9-+T[5HY)2$^^5 /S[>^ MW..]?"?@#PMXB\9WWQ0^&?\ P3K\9?$;6/A?JGPCU.&5?&!O19VNOOA;6#39 M;]5GW-%YBN,E1\I)/&,/]GK3--^('C/]G_X=Z3\6?'^K^(/ ^N6EU<>#['X/ MVND?\(D((&2Z2^O&CB_<,"T;!7=I2P;:6Q3Y0/M;X#_MN>#O%W[/^I?'KX[: MSH7@O3]/\7:IHS7%UJ'EP$6MV\$9W28)=PF=HSSG%>A>%OVDO@%XV^&MU\8_ M"GQ@\.WWA:Q#_;M>AU2/[-;;?O"1R0(R..&P>1ZBOS5OO OQ'T?X7?"WXI:C MJ>M^'?"GA7XV>,YO$.LV?A#^UFT:2>YF6TOI+*1&WQ!LCS-AV;PR\XS8NO & MH^./#/C_ ./'A"_\=_$;P@WQ0\)ZIXVO+GX?PZ7:>(K*P M:6B'F>5QNY-'*@/MKXL?\%'/V9O!G[-_C#]HGX>?$[0/%]KX3ML2:?I>L('F MNV!\FW)P2C2$':2N#@XSBMSX4_M2Z5\5O'Q70O%?@ZX\)R> ;37X;RTUPO?( M\DTR2M)&5"K;+Y>!+GEE<$#%?,/[1OCWX+_M3?"#X_:[^RY^SQJ&H2-\(#9W MGQ$@T&XLQJEPKLT>F16\L*/.\:#S#(H.W(7TSQ/QBTWQ'^TU<_$[4/VUDO&AU2Y^TVBK(J'S&1)$V8RVX=F!+458#[N^&G[7W[+ M_P 9-8OO#_PL^._AC7K[38'FO+73=5CDDCB3[TF ?F0=V7('K5?PI^VO^R3X MZ\:6/PZ\'_M$>$M2US4T#:?IEGK43RW&1D!0#RV.=OWO:OD?QCX]^$_[3OQ& M^"EC^R+\.-6M;OX?V]_<>+;D^$[C3E\/Z5_9349!-*^%WC*G#,>V, M\8I60'Z2 YHIJ$8XIU2 4444 %%%% !1110 4444 %%%% !1110 4=.@HHH MY7XM_'#X0_ ;PVOB_P",GQ%TGPWILEP(([K5KQ8EDD()"+GEFP"< $X%4+3] MIC]GR_\ A4_QSL_C+X;D\'QY$GB-=6B^RHP;;L+YP&W<;3\V3C&:\"_X*C6_ M@^QF^&?CCQ-XC\:>#[C0_$MU-H_Q+\+>'X]5M?#=P]HZ9OK1E=I(9@3&"J'! MZLHZ_*?B&S^,_P 0_@!HOQ%G\/0VOA#PK\?FU/6?'G@_X7-;_P#"0V9M-BZ_ M)HTZMYGES$*YVD'&X#*9JE'0#]+?AO\ M'? ?XO^#[[Q_P##+XM:#K6BZ;N& MI:E8ZDC1V>U=Q\TY_=X7YOFQQSTK*^'G[8_[+'Q9UZ/PO\-/CYX7UO4IC-Y- MCIVK1R3.(DWR,%!R5"@G=T('!K\^-8^&/BOX^^$_V@/'GP/\;>.?B3)J?@_1 MK+5-7D\"P:#IWB+[-?1W$MK;1*(Y;FY6U6>(L8L,)0FXY&?3+/XW?L[_ +0' M_!0[X&S? #PK=PSZ?X!\1V6H76]KH>L+>+]GOIIWV0QQMT9G;Y5 ZFL?Q1 M^UY^S#X*^),?P>\6_'CPOI_BB62.-=%NM8C297?&Q&!/R,V1A6P3D8'-?GKX M/^-.CW7[&_P _9"C\&>*O^$Z\%_%;PW#XTTF3PK>QIHRVNID-)-,T0BV,2NT MJQSNSQ@UR_BCPCJ_@_P7\7OV=?CC\5/&]AXH\3?$'5)V\!Z%\)(-2NO%*W-T M7M+RSU"2(@Y0H59I5\DH0,8HY0/TO^)W[8/[+WP7UBX\/?%;X[^&= U"U\G[ M18ZEJB1S()5+(2F=V" 3G& .N*N^/_VF?V>OA?X)TWXD?$+XR>'=*T+6%5M' MU2ZU2,0WRLNX&$@GS!M.?ESQS7S7^SO\';*3]M#XQ77Q \'3:C&_LG:OHG[.D_P,^.'[2/A'5(? MMK\)]8T+2]6F\/W-[%H>J_VQ/(5DCCC=X3+;!$5]O(3;G%'*!^@VL?M/?L\> M'?A9:_&[6OC-X;M_"-]M^P^('U2/[+<,<@*C@_.W!^49/!XX-11?M6_LV3_" M>3XZ0_&_PRW@^*;R9/$*ZM']E27./*+9X?/&S[WM7P+\8[&/4IOA!^T7\./A MAKWP?^%>F^-/$T_]H0>#1JS6DUV5^S:W+ITL1,$=RPD*Y0M%O5A@L*QCX+\ MZU\+O'_QHU7Q5\8=4T#4OBYH&I67Q*TCX?VEA#I^HVL$B/K<.FA=\UH-T<?#S>+/@W\1M)\2:?',89KK2;Q95BDQG8^.4 M;'." <5U5?'O_!+OQIXP\8^,OBA>:A%H_B;1_P"TK!K'XM:;X!D\.R^*IO(( MD6>W<#S)(>%,J@*=WN*^PJD HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M_"BBB@!LK%>:Y7X+?&7P1\>_ %O\2_AY=SSZ7=75S;PR7-N8G+P3O#)\IYP' MC;![CFJOQW^!OA?]H#P='X*\6ZYX@T^VBO%NEF\-Z]/ITY=0P"F6!E8K\QRN M<'CTKPW_ ()O_L$2_LK^"+/7_&^K^)%\4B34X+G39O&$]YIJV\MZ\D3K 6,0 MD,8C)<#=N9\G)-/2P'U11112 **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **\,_:V_:-^,GP9U;1M ^%W@?PGY&H6=Q2V\69)U$4,;[%!4_/YVU9">,X%'*!]^>7&ZX(R*/*C_NU\>_##]MCX M[_!ZR^&MA^UC\&M&\.^$_&_A_9H.M:3X@DO+NPG@L?M BOXWB4!Y(HV;,98* MWRG/)I-'_P""A_[0MCX$\+_M0?$C]G?1=+^#_B[6+2ULKRU\222ZWIMI=RB* MUOKF Q"(QN60E$ ?"?B7P/\8]'ATV/X>_"'1/%>E:E]L9WUK2Y-/4R2$-TD6X0Q$# M.2R_WA1RL#ZP$:#C%>6_M)_LL>&/VH8-&T'Q[XV\26OA_3KP3ZMX9TC4%ALM M>4/&ZPW@V%GB#1@[59 VTW6KOPJ-9O_#> MFR-,\),)F%LI8 M)MVJ>/OYQQ7@?[(?_ 47^*G[2'B/2=3O_ G@*;PKK%C= M7-_)X4\<+<:KX4,2%UBU.TF2-MS8VGR@=IZ\:YXDBTRWTZW\?))XIM;>6X\B._F ML=FT(6(8Q!MZHV3T-=]\4OV\_P!H6"#XJ?$#X!? /0_$7@GX0WEUI^O7FK>( MY+:^U.\MH%EN?LD21,GEP[QN+L"V&"\C%/E8'UHL2*,*N,5B_$+PC=>.?!>I M^$+#Q7JFA2ZC9O!'K.BS+'=V;,.)8F=64..HRI'L:\A_9Q_; UOXY_%C4/AS M?^#K6PBL?ACX<\5+=0W3.SR:FLY:#!'W4\D8;J=W(KR.^_X*MZIZ\Z\U.]GXH6-%& *^7?^&ROV MG_@YI.I>/_VMOV:M.T?P?!X+N_$"ZYX/UYKXZ<\$8<:?=K*D?[^3(5&CW(7X MZ9(Y'X+?\%2]>\3?%+P'X2^*^D?#B+3?B9,-7QO^SG_ ,%)_B[^T'\3['3] M ^%_@J;0KSQ-<:5J7AZU\;!?%/AZ*-Y$%W>V4RHI0E 2D99@&&-V,UZC^WUX MQT'P;X(^']WXA\*2ZM'>?&#PY96\4.L3V?D32W6U)RT)!D"'DQ-E'Z,"*7*! M[P(D':@JB\$5\7^,_P#@HE^U)9:?\5_B%X$_9O\ #=]X-^#OBZ\TOQ%>7_BB M6&\U&&W",YM8UB90ZQN&.]MI)P,X-?17Q8\>>,=7_9@U;XE?!NVLVU2\\)-J M.C+K%T\$:J\ DRS1JS*RH21@'Y@!P.06 ]&22-R51QE>"/2G5^=/[%WQ ^-G M[-G['G@'Q!X.^%/@M=4^)&GMKOB#X@^-?B%<0Z;M$,9CEO))PTANY6=L0PJ4 M54SNKM;;_@K=K4W[+S?%V7P%X7CURW^)_P#PA-]J2^)VD\-6LNT/_:3WL<;, M+0J0 0I.X@9'6GR]@/N!G5>II58,,BO@?]J']K#]K7QI^Q3JOC#0_#OA;1M0 MLOB!H>G+XH\(>.6NM-UBRFO+8++9SPKYBJTCB&6.4(P1G(W9 K[F\(2>)9O" M]A-XRM+.WU9K6,ZE#ILS26Z3;1O$;.%9D!S@D D=A2M8#2HHHI %%%% !111 M0 4444 %%%% !1110 4FP9R:6B@!H@B485,#I@4"&,$G;U^][TZB@!IC0C!6 M@1(%VA<#& !VIU% #5A1>%7 ZX%'EKT IU% #1#&.BT>6NU<+XP^ '@_QG\;O!_P >=4N[Z/5_!-KJ,&E0PRJ()%O(UCE,BEN:[RB@!ODIG=MYH\F/.[9R.].HH :8T/5:&BC9=K+D>AIU% #?*3&-H_* M@11A=NS@<4ZB@!JHJ !5QCI3J** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H) ZT4 M'D8H :9X@<&1>N.M*'5NAK\H=.\;_L.>'OB!\=O%?[9/@OXEZM=:;\9-:BM] M:T'^W#96=F'C\N'SK29(8F#EC@D$;AS@BOH?]E3XB_M2? +]AP^);[X;ZMKT MVI^.IT^'MCXZ\3QQS:1X:G=3:3ZG=NS%4C7>Q'SOM9%^E,_#G@3XP3>+O!'@C7-?\ A7HNG:M'<> ?%S:AI>IP7-R(3%YI0/%,A/*D M&V\:>!-4UKPG>>'?$4EZ]O]FC!DM;O M=$@$H5P=\>5R,#.<@Y6!]3*ZO]TTX *, 5\*?\$J_P!L7Q!\8OA1\,?V?_A! MH]OK\/@_P)I[?%7Q=JFI/C3KB2,^59PKRUQ ;?Q)XZ^(FKSV/AS3]1OC:V<$<$/G7-U<2JK,(XTQ\JJ68M@ M=#1RN]@/:*"<'?V?U_9^\$P?%#7K&\ MUVXLI_%D[:5I6A0M%''--,D)D:>260QA$4@;"V<*OVEM4\/Z7X>UKQ,L5AIU[+%&[++>2#;':PK'( MY8*,C !:NKO_P#@KEK7@[X>_$YO$_A7P3KWBOX=Z%8:W;GP'XN.H:3J]C<7 M:6[!)M@DBEC9L%&4YRI'!I\L@/N:BO/_ -G/Q3^T%XP\#OK/[1WPVT7PKK4E MXQM=+T/6&OD%J45D,CE%Q*"65@,C*9!P:] J0"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "@\\444 ?+_ .UQ^Q5\4OC!^T?X8_:)^'%]\/M7 M?0_#=QI#>&/BCX?GU#3[9I)EE%];K#(A6X&W82>J\ C.:Y'X7?\ !-'XM^"= M!T72/$WQ@T'5+C2_C\OQ$N;ZUT62T6XB:/$ELL(9EB;>3MP2H4 5]G8!ZBBG M=@?+?[1?_!/[Q7\=/%OQHUZS^(>GZ=#\4/AUI7A[35DLWD:PN+.::7S9!D!D M8NHPI!&#[5E^/_V#OCO\8;'QKK/Q&^(_A./Q!XS^ $_AQ8S MQ:'8^%]"N+2ZUBXDM&M%N;YY9752D3OA8@ S')P.*R])_P""?7[3FL?#GPO^ MR9\4/CQX7U#X0^$=6M)[9]/\/SQ:_JMG:2^;:V5Q*TI@15*QJTB)N8(.A))^ MRJ\C^.W[8?PJ^ 7QB\ _!GQIJ]E;ZAX]O;B*":ZU:"W2QBBA9Q+('8,0[@1) M@89SC.1@O4#Q/XK?L$?M7/X=^*7P2_9^^.G@_1_A]\4]0O\ 4[Y/$&@W%QJ> MD7-Z,W<-L\4BQF&5\G+J60.V,\5Y[^U;\"O!OQM_:.^!O[*7A'Q9<7/BKPKH M]OIGQ9ATVSE$#^&8H;>X*3R$;566>WB$:YR3(W]W%?=1^*GPRB\*7'CB7XA: M(-%M)V@NM8;5(?LL,JR>6R/+NV*P?Y""&?%R^#O$7Q<\* M:?KT\ZV\>EWFO6T5W)(4$BQB-G#EBA#A<9*D'I1S,#?\0Z'?#[_@FY\==5^//@KXI?M!> M.?AQ=-X%>Z9_$G@[PC+8:[XK66!X FI3>9Y93:Y9@BG6NCZ?XDM9KJ:W9=ZRK$DA=D*D,& P0<]*3Q-^T5 M\ /!?C6W^&_C#XV>$=*\17C*MKH6I>([6"\F+?="PNX=L]L#FEJ!\J_#S_@F MG^T'\.K#0_@CX>^)WPWM?A[X?UQ+FU\10^ UD\53: M5 /7(+/VK_V5OVF_@U\*?CU??L]_%CPO:> O'NFZMXDU_2=9T&>?5+"[DLB+ MN.RDCE6,K.(Q_K%)C+$J#W^MM8^.GP6\.>+(? 7B#XM^&;'7+JZCM;;1KS7+ M>.ZEG==R1K$SAV=EY"@9(Y%,@^/7P-U#X@R?""U^+_A6?Q5$#YWAB/7K9K]. M,G-N'\P<>J]*=Y ?+'PP_98_:@@C\(?M!_LS?%;PKH;^+/@OX?\ #OBK3_%V M@W%TUJMM"7BN[7R98_WRB:0;)/D)QG/:'2?^"7'Q+\"_";X4KX.^(?@_5/'7 MPOBU6T9_%OAU[K1M_VE%Y.G21#,J3ONQ$4'+!B-HZXK)\8_M%? +X>Q--X]^-OA+1 M%6."1FU;Q';6X"39\EOWCCA\':>C8.,TZ?X<\+BPTNQL[/M>W>+_C7\ M'_A]X0M_'_COXJ>'-#T&\\L6>M:MK=O;VDY<939+(X1MPY&"6=\+B/48HHH9%N5( #"7@ D8&<\T>]N!Y+ M?_L9?M9_M!:3?> /VQ?VB-#F\*?\(;>Z%#I'P]TRYL_[4FN(EC&H7WGR.K21 M;0Z1H @?G@9!J_ _]A[]IKPOX\\&O\3_ (B_#*W\.^!U_=W'@?P"MIJOB)TC M\N%KR6X[;4OV^_ >L>)OBY\.?AJ^@W_ (C^%ME#*MKJWBZT MLX-3D:(/*!(S$0Q0L5CDD?A7.T@8&?1M0_:5^!GA&RM5^(_QD\'Z#J$RVR3V M6H>*+6,QW$T0D2(%G&XL#E7D9!H]X#YCG_P"";/[0_CGXK^$]:^,GQ4^' MVK6/@WQG%KEG\0+'P:]MXQU&&&9I8[*XN4=8?+.0CE5^90.*^@?VM_V>-=_: M,\+^$- T+Q%:Z:_AOXCZ+XDN)+J)G$T-E/YKPKMZ,PX!/ [UV.B?&SX.>)/' M-Y\,?#OQ4\.7_B33X?-OO#]EK<$M[;I_>>!6+J.1R0.M1R_'GX(P?$1?A#/\ M8/"\?BR093PP^OVXU!AC/%OO\P\<_=Z4KL#Q<_L/>,?^%!_'KX1#QSIOVKXN M>)M8U32[S[/)Y>GI>011JDHZN5,9)*\$'BO8=.^&>HV/P#M_A ^IPM=0^$%T M:'\1?#]Q?:/)*?+/]H6T<;JR3@IMRW53C(K1\"?\ !/G]JGX8?"GQ M1X<\)_M"^$Y->USXE'Q5(MUX1_XD^JP2P+'/IEW:;F*097*^4^X!5YZU]F44 M^9@?#ND?\$K?B6GP3^*&A?\ "<>!_#OBCXA>(M$UBQTGPCX=GM_#>CS:9/'- M&$MVE,A,S(?-<$$D@@'%?9G@2+QK!X.TV'XCW&F3:\MG&-7FT6*2.T>XV_.8 MED+.J$YP&)('4UK 8X HI %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%5=WMY,L<4$2#%?CU\$?'7BVZ\ M^"/C!X7UC7+&$2WFCZ7K]M<74"'&&>)'+J.1R1CF@#K:*Y.T^//P2U#XA2?" M/3_B_P"%YO%<*EIO#,6O6[:@@ R2;5K27XC> 6M-8U!?&NDFW\/R/ M'KTXU*+9IKHH=UG.[$152&(?& U '#?L[?LEO\+='^*_A MGXCWNF>(-+^)7Q#U;7GL?LS>6MG>I&AMI0_WB IR1P'? _Q+C\0?#O1?&6EW%W:3:2!+C1]356!FBC:3=&RDXV@$8" M[??/C3^VI\+_ 9^RUXR_:9^#?BGP[X^L_"6FM&60,H\IIH2X0X M;/0UH:#^TYH5EX@\7/\ %S6/"7A;P_X>FTN/3]8O?&-KNF:[LTG*7$;,IM'# MLRHLG,B@.O!JKR ^9]=_X)8_'SQI9_%&Y\2_$[X?Z?"?C5I_B:RM;3PK MX3US2+BQFA=I)Y+Z&.-'4C@*A0D@\G/%:7B_]K7X4W?PS\4>*_@7\3? OC+6 M/#VAS:@NEP^-[**$[>GGS[V6WC+8!D?Y1GFMK6/VF/@/X)LX5^)GQK\&^'[S M_1XKJUU+Q3:0^5<31+(D67D&2RL&7^\I!&0:/> \ ^ '_!-WQ=^S/<_!WQE\ M)?&^AZ?XA\'^&4\-_$R.&QD2S\5Z=DN7VK@KH?M;?LR^ M.OC+KO@7XN_!CQWI_A_QY\.-8N+WP_<:U8/0W,/D7-I$?'G@GQ]8S:GX&\7Z9K%M;W!@GN-+OX[A(Y0H8H6C) ;#*<'G# ]Q2U M ^3_ !O_ ,$ZOC1\9/!?Q)\4_%[XM>';CXB?$1M MO.T?2YH=(T?3=,OXKM+ M:%'=II& !SZ5^T-^S5\9-8^-'AG]IO]F?QMX=TGQIHN@W&@:E9 M>+=/FN--U33)I%EVMY#I*DD.?V@_@5\,99H/B3\9O"OA^2W$) MN$UKQ!;6IC$N?*)$CC&_:VW/WMIQG%&H'RS;_P#!,#XLZI\&]2T[QM\9O#NH M_$%?C/-\1=%UV3PVTFF/=R0B)[6YM'[CN'F9FW7,TLFS!R^U> M, ]O;/C'^VU\%O@]\5/AO\+==\3Z7)+\2)[C^S]1;7+:.WM;>.!I$N'+-\RR MOMBCQP[$@'(P>2U;]O"?P1K/P^LOB;X=\-Z79^,_&.O:1?:M;^,(+BTTNWT^ M&:5;B29?W89A& \;%3$203D8I^\!]'PHR( QYQBG5S_A3XK_ Q\=^#?^%B^ M"?B'H>L>'S&[_P!N:7JT-Q9[5^\?.1BF!WYX[U7^''QM^#OQBM+K4/A)\5?# MGBBWL9?+O)O#VN6]XMN_]US$[!3QT.*D#J*,]Z\)\8?MV?">W^,WP_\ A'\* MO%OAOQA)XP\47>C:Q-HOB2"X?19(;.2X_>)$7^8F/;M8KZ^U=5\//VA]&N/@ MU)\8/C9K7A7PG9P:E>6]U=KXNMKG3XDBN9(48W881AF" LF$SC=]HW^7C/&=W6KGP^^)OPZ^+ M'AZ/Q;\+_'>C^(M)E8K'J6AZG%=V[L.H$D3,I/XT ;E%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !7R%_P4,O/AGX,_:N_9Q^)7Q7@TRT MT6V\5:M97VLZI:JT,4DM@?LT;NRG&Z7[H/\ %R.:^O:ANK&UO%"75O'(JL&5 M9(PV".AYIH#\H_B/^T-\*O W_!-[XH?LG>(/$'D_$9?BEJ"3>$6MY/MD<+:^ MES]J9=ORP>3\_FD[#D#.2 ?H+X=?!WX8>,?VV/VHOB3XN\"Z5JFM:'IV@KHN MH:A81S26!_L-7WPE@3&VX [EP?E'I7VNVD::T[7;6$)E=0KR>2-S+Z$]Q4HM M80S,L2@O]["_>^M/F _,KX>_!KX6^!OV _V/_B+X2\!Z7I_B"X^)'A:>XUVU MLT6\E>Z\TS[Y@-[!N%P21A5'0 5Y3^UG\2?!'C3X:?'S3K:#X<^$-6_X3+4_ M.\%W'A:ZU?QEJL\$J?Z2N]E]">I'M3Y@/A/]E/X3^!_BO^UE\8OB M7?\ A32M:\3:;X#\&R>$]8U*TCN)+"Y?2FD6>)W!V.9$C;>,'Y!S7A^GW_[/ M]]^P%X4^ ?@7PU;K^TQ9^+K4OI$>F,OB.U\1+J7F7%[.^WS%CV;F:5FV&,@9 M((%?K%%:V\+%H8%7=C.U<=.E1KI6GK>-J"V4(N&7:TPB&\CTSC-+F _,GXK_ M +1/PK^#G[-W[87[/'Q"U\V/CKQ!XS\37.B^%WM9/M5_:WMJGE742!?GAVAW M:0?*JHQ)&*]4^ GP=^&'Q2_;SUZZ^)'@'2=>^P?L]^%H[*/6-/CN$A$RRK(0 ML@(!95"DXSC([U]PR:3ITUS]MEL86FV%/-:$%MIZC/7'M4JVL"2>:D2*VW&Y M5 ./2CF _*O]E+5?A;\.K3X ^._VI!:)\,=+\+^+M'T'4/$4/G:7IFLKKVVEZ?XGU;P;8:EHEFUFL=Q=6(TV(7$T1V MCLZKI=T=0U2UM52XO6N-#\Z0 MS2 !I=TA+'<3UKYWM=(A/P,U/X/_ !-^-_AS1_B;-\2));OPK:_"U[SQLVL_ MVH9(;J"X-U&\JE-C"8800Y7/'/[-"TMAL'D)^[_U?RCY?IZ5"VCZ8]\NIMI] MN;A5VK<&$;P/3=UHY@':2EQ'I=NEY(SS"!!,S+@LVT9)&3SGW-6* ,# HJ0" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \@_P""@3 ?L,_&#U_X5GK9 M'_@#+7RQXF^"?@7X5']CG5/@KX)TK0_$%Q]LL8M2L;-(IK@S^&KF0K,X :0- M,JNVXG+9/4YK]!)(DF4I(H96&&4C@TTVD!VYB7Y/N?+]WCMZ52E8#\9_AII% MM>?!;P)\)=1^./A[2_B=9_$*UF;PCH_PJ>;QM9ZXE]ODGEN6NHW9#RTEPV$: M(^F*]T^(_P"T%\+/@/X9_;*^#'Q,U\Z=XN\4>(=1OO"_AV2UD-SK%O=Z3"D4 MMNH4^8FX-N8<(%); !K]'AI&FB^_M,:?;_:"NTW'DCS"OINZXITNDZ=/=+>S M6,+3*I596B!8 ]1GKBFY7 _-CP->?#'P7\<(X?%L&EV&J>*OV+=%3PK)=6:K M)J%[%!?^>(7V_-*( N[!W;-H/&*HZMX6^!GP$_X)I_L^ZSI_P.\#K-XNU+P^ M^N^+?%5G*NEV%UY$UPE_JGV8JUV@D=PD^0$XP!7Z;-IUD[QR26D3-&,1 MLT8^0>@]*2XTRPN[0V%S9PR0,N&ADC#*1Z8/%+F _'[5?$&CZCHW[73:+X\\ M-:];ZG\'])NTU3P;X7.CZ5?LER\;R6T6]A.J,3&9P2&8$=C7MOB#]HWX0?LO M>/OVHOB;\8?"EAK]NVJ>";71M!U"WCDBOM1?PY;^0C&0%44;69I#]U58]< _ MHHNF:?''Y4=E"J[=FWRQC;_=^E+)IMC+N\VSB?<03NC!SBCF _,"R/[*4/[ M?[0?B'PG\:_ OC#XO^,/AOJ&J>-O^$2DC$.GVRH!'96L: ".U@+JN0,NWS-D MXQZ?\$/@=\(OBE^TG^TAK'Q'^'>D:Y/#X(\,64$FK:?'<>3"_A^-G5-X.PDA M[R[&%=R[6VQ+R/3I4BVL*LS+&H+8W$+U^M',!^87[.OB M?X;^"!^S9\6_VPK>*X^'?_#.4.F^&]9\06;7>FV&N>&IOCAK;Z%826;6YAM3%:[ (V :-<= M%(!48&!C ]B_:"_9:\7?%CQCH_Q%^%G[1_BCX=ZSI6GR6$G]CP6]Y8WML[A\ M2V=TKPF16SME"AE#$&-9U+59KS5+G5-!O%VL?M(>%YK7X<>$-6;4 MKZRD\/ZYX4NM<\7>*9([4+%8"-S!0"W7@CN:_05M'TU[S^ MT'L(&N-NSSS"N_;Z9ZXJ2.RMH>8H44[0N54=!T'THY@/RT^"]W\,_ _PV_8T M\??%:/3K;P_I/C#Q?I$^L:O;AX+9=]W'96[2,#M&]5$8)P&7CI69:ZE\&=%\ M,? ?6OVA;.UF\(V?[1_CJ?5OMUKYUO%MEN3'+,N"/*278[L1M55)/ -?JY+I MEA-"MO+90M&K;E1HP5!ZYQ]:5M-LG3RY+2)EY^5HQCGK^=/F _+;XM:?X>^( M&F?'OXE?LZ^&[B^^!M]XZ\&3>((_#-DZV6L0VT@.N2VL<8 EB\OR5E* AC&_ M6MS]H^Y\ _'GXLZGJO\ P2^MK&ZDM?@'XEL?&NK>!+'R;.;S4@_LNS+1!4:[ M!2XV+]]5.#V _2ZVT^SL[5;*TM8XH57"Q1H%4#TP.,4VTTRPL(VBL;.&%68L M5AC"@DG)/'O2Y@/S;\/^.OV&_&/[3/[)-A^RYI>BQZYH]Q=VNLQZ1IHAFTZ# M^R91]EO2%!$_G*Y".2^5D;N2?,TM-?L_A)\ ?&>N^*]'T'P+I7Q(\>?VMKOB MKPZVJ:-IVJ/JDXLI;N .BCCSU25SMC=LGJ*_6ZWT;2[1VEMM/@C9GWNT<(4L MWJ<=_>G2:98S6S64UG"T+YW0M&"K9]1THY@/R;_X1KX4:M\)_'WCK4/CO>-X M3N/C5H.HZ;XT\+?"](_".GZU#;3+)=M:R7+I<6#%D6>0*%$PB;GM]/\ _!*+ MQS!XK\8?%JRL/#O@?4(8-6TV:X^(WPVM;FUT?Q-@KY=LOCOX[_8W^$FD_%C]K?X\:Y\2 MH_&E[I]CX8]?)G[)-#NO&-Q#?:>D[+H-G:B>2)D M8$)).\D4*MU#%L$$ UE_M=?MH>(7\!_ ;QS\'?VB]-^''AWXI:L_]K>+]3TF MUO8[.U_LZ2Y166YPBGS5"'E3DX]J?*!]CEN,@T>8G]ZOEC]@_P#:3^)/Q5^+ MGCKX5:M\=M"^+7AOPWI^GW.G_$?0=$CL$^U3F42:?(L+-#(Z*BN&CZ"0!N:/ MB_XG_:J^)/[==Y^SG\&?VDH_ &BZ7\,[;Q!(P\&66J-<7#WKP$$W&"HVA3PW M;IWI6 ^I]XZ@TH.>17QQ+^UO\:_AQX>^(_P8^/WQ,L[+Q=\/-:\/&W\=>&_" M\G7G_!07X0V?Q0O/AM!X*\;7EG MI?B=/#NJ>,K'PV9M'L]58JHMI)56%%F![T2<<"@9[UX'=_\ M%%/@;:>/_P#A$5T'Q=/HR>*?^$:N/'MOX?9M"AU;?Y?V1KG=NR)?W9<(8P_R MEP:@L_\ @I'\![WQ5!IR:!XOC\-W7B0^'[/XB2>'ROA^?4O,,7V=;G=NP908 MQ*4$1<8#FBS ^@^$K?1_[/'] MH#5OM9M3;M%OP"K*SL=W$:EO:L:/_@HY\"9/&*Z,NA>+/^$=?Q,?#T?Q$_L M_P#"/MJ@E\G[,+G=N_UV8O,V>5O&W?FBS ]_YHY[U\T7_P#P5*^!%AK'B2V? MX??$*32_".O2:/XD\41^%O\ B56-VEW':LCW!D .'E1B0#A"2<8('L.F_'?P M3K'QOO/@#I)NKK6M-\.P:UJ,T, -M;6\TK1PJTF?]8Y1V"X/RJ22.,JP';$G MH!03V%>(_&W]O3X!?!+XL>$_A-KWQ%\+M>:]KD^GZV\_BRU@;P^$LY;@2W,; M-E58HL8W;>9%Y.0#Z1XJ\=2I\*-2^(WPQ@M_$LBZ#-?Z'#I]P)(]3<0L\21N MA(82$ @X.>* .EW#'WJ"3U-?!'[-/[5W[1?Q9U3PCXL\*_MF^"?&?B'4-5M MT\=?!/5/#]KHEWI%LY(N5M6=QC[P^TYZBO>O&7_ 44^!O@SQ=JVA7W MA_Q==Z'X=UE-(\4>/-/\/F70]'O695,,]QN#95G579$9(R<.RX.'R@>^%\\" MEY'2OE[P9^W!'X(U'XM:C\:-6N]2MM!^+B^%_ VBZ#I*S7UZ9+.WEBM(8XP# M-(6>1MS'A02S!5R.JM?^"AOP)B\ ^(/&/BS3_$WAW4O#&J6NF:MX,UK0V76E MO;K_ (](([>-G$S3_P#+-HV96PWS#:V"S ]XS@9:D5E;H:^0?C;_ ,%/SH7A MO38OAQ\&?&EKXDC^(FC:'XH\,^(/# 2^L;6[D5MP03^6SS1Y6%E=E+9#8(KI M]%_;K\&^"1XH3Q=KOB;Q9K$GQ-NO#WAGP?H_A&-=2\Z.WBF:RA2.3;.L2,S- M<2L@&2"1@9.4#Z8.>PH&>]?/>I?\%*OV>M$^&#?$O6]-\66CV_C"'PMJGAF7 MPZYUC3M6E4M';2VJDL2X VE"ZON7:3SCM/V>/VJO W[1U_X@\/:-X5\2^'-= M\*W$,6O>&_%VD_8[VU$R;X9-H=U9'4$AE8]"" 1BE8#U 9[T4 ]L4BDF@!>: M!GO10>E !DYXHHHH *.@ YS11FB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HIID0-L+<]:4,&Z4 +1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 URP^Z*K_:]3_Z!)_[_ "U:HH J_;-2_P"@.W_? M]:/MFI?] =O^_P"M6J* *;7VJ _+HC-_V\+2?;]6_P"@$W_@0E7:* *7V_5O M^@$W_@0E'V_5O^@$W_@0E7:* *1O]6'_ # 6_P# A*/M^K?] )O_ (2KM% M&>VHZX#\OAUO_ I*/[1UW_H7&_\ I*T** ,_P#M'7?^A<;_ ,"DH_M'7._A MUO\ P*2M"B@#/&HZY_T+K?\ @4E!U'7!T\.M_P"!25H44 9IU37P<#PPW_@4 ME']JZ_V\,-_X%)6E10!F_P!JZ_\ ]"PW_@4E']JZ]_T*[_\ @4E:5% &;_:N MO_\ 0L/_ .!24?VKK_\ T+#?^!25I44 9?\ ;'B/_H47_P# V.C^U_$?_0I- M_P"!L=:E% &4=8\2 <>$6_\ V.E_MCQ'_T*3?\ @;'6I10!E_VOXC_Z%)O_ M -CIO\ ;'B7'_(HO_X&1_XUK44 8YUSQ/V\%2?^!T7^-']N>*<_\B3)_P"! M\5;%% &.=<\3]O!4G_@=%_C1_;GBCMX*D_\ Z+_ !K8HH Q_P"V_%'_ $)D MG_@='_C0=<\4CIX*D/\ V_1?XUL44 8O]O>+/^A%D_\ !A%1_;WBS_H19/\ MP815M44 8O\ ;WBS_H19/_!A%1_;_BW_ *$23_P81?XUM44 8O\ ;WBS_H19 M/_!A%2-K_BT#*^ Y&]O[1B_QK;HH PO^$B\8_P#1/I?_ 90_P"-'_"1>,?^ MB?2_^#*'_&MVB@#"_P"$B\8_]$^E_P#!E#_C1_PD7C'_ *)]+_X,H?\ &MVB M@#"_X2+QCW^'TO\ X,H?\:1O$?C,-O^B;S? M^#2#_&C_ (23QM_T3>;_ ,&D'^-=!10!S_\ PDGC;_HF\W_@T@_QH_X23QM_ MT3>;_P &D'^-=!10!S__ DGC;_HF\W_ (-(/\:1O$_C=?N_#28_]Q2#_&NA MHH YS_A*/'?_ $3&;_P;0?XT?\)1X[_Z)C-_X-H/\:Z.BF!SI\4>.NWPQF_\ M&T'^-)_PE'CO_HF,W_@V@_QKHZ* .=/BCQUV^&,W_@V@_P ::?%7CT'CX73M M_P!Q:W_QKI**0'-?\)7X^_Z)7/\ ^#>W_P :0^+/'_\ T2J?_P &]O\ XUTU M% %;2;F^O+".YU'3S:3,N9+9I%%[JPTU;R8Q1&:1"%W/@[1GJ<&O4^<<5'(TP/R1YH \'^.WP"\?\ MQ#\*?!31]"MK-Y/ WC[1-7UY;BX*A;>UMY4D,?RG>P9EP.,]>,5YA^T5^SG^ MV'-XG^.7AKX'>!_"NKZ-\:-(MA'KFL>)'LY-%GCL/LC^(?$QA^T:)>6,J+;2O)!+M>&>9\95MP /!Z?H!NGSRGZT9F/ M&Q:7,!\O_LP?LY_&O3OVI]<_:?\ B;\+_!OPYM+KPA'H4/@_P7J1O%OI!<>= M]LNI!!"C.H^1-J9PS9-.^+GPZ_:V\%?MNWG[2?P'^#OAOQ=I6I?#>W\.S6^L M^,CI4EO.EZ]P7XMIMZX(';KUXKZ>WW&[ 04J-(3S'C\:=^H'Q7XM_8;_ &E/ MB;\/OB1\1OB/-X;;XC_$;Q)X._AM\/_ ]X7U2^\9VVH6OQ4\,>-KK3F?3%DC9X M+_251H[V!=-\50W#?$:'7F:ZFTF&_P#MJ1+8^2"MT=JQES)LZMSG%?<. M,CI2TVO[>]Q\6[G4[$_"V.^F\6:=HJRGSD\436JV%_%6F^,_&]WK%CXSUSXA:I;0Z?:WEP)IH;K2H'5+EXR75"K*'&TM@@ MY_0O&>HHQSFJYF!\*?%K_@G'\7O&%IXHUFQTC1]0FM?C='XP\/:#-XBN;*/5 M].&F1V4EN]S /,M92-[*PW8*C)(8YK:)_P $]_C>NC:E\5?#'PG\)^#O%6F^ M/M!\1>%_#$WC&_U9K^+3?-!@O]0G9QF03R>64CQ$0,[@3C[T.3U%'.W&*.9@ M?(/QF^%7[>_QZ\%3>+/$G@+P?IU]HGQ \/ZYX0^'\?B+?F&PF$EQY^HB #S) M3]T",J@7N36%8_L=?M3>!/BW)^T]X0\+>'=0\06'Q4US7+;PG>:\8HK[2M3L M;:"1!-X 5RI! (.-U?;@&!2$_%3XT:Q#:+HOB[2-!MM':*YW2M):1W"S;TQ\HS(F.3GFO8CDCBBE< SSBB MFG.M*B@ SSC%(#SBEI, M)=0UG2M'FO] T!M4NX\>58QW"0F7) /SO\HP,GGTKE!\0_C)C_ )-] MNO\ PI+/_P"*KNUSCFB@#@_^%B_&3_HWFZ_\*:S_ /BJ=_PL3XR?]&]77_A2 MV?\ \57=44[KL!P+?$;XT*?E_9VNF_[F:S_^*H_X61\:O^C?\ A467_P 51_PLGXU_]&X7G_A467_Q5=_11\@//_\ A9/QK_Z-PO/_ J+ M+_XJE/Q)^-?;]G&[_P#"HLO_ (JN_HH \_'Q*^->/^3<+S_PJ+'_ .*H'Q*^ M-G?]F^\_\*BR_P#BJ] HHT[ ?^%38_\ Q5'_ LKXV_]&VWG_A4V/_Q5>@44 >?_ /"R MOC;_ -&VWG_A4V/_ ,51_P ++^-O_1MMY_X5-C_\57H%% 'GO_"S/C?_ -&U MWG_A56/_ ,51_P +,^-__1M=Y_X55C_\57H5% 'GO_"S/C?_ -&UWG_A56/_ M ,51_P +,^-__1M=Y_X55C_\57H5% 'GO_"R_CA_T;9>?^%38_\ Q5+_ ,+, M^-^/^3;+S_PJ;'_XJO0:* //1\3/CAW_ &:KS_PJK'_XJC_A9GQO_P"C:[S_ M ,*JQ_\ BJ]"HH \]_X67\<.O_#-=Y_X55C_ /%4#XF?'#O^S5>?^%58_P#Q M5>A44 >>_P#"S?CC_P!&TWG_ (55C_\ %4'XF?'#M^S5>?\ A56/_P 57H5% M'R \]_X6;\>_ M\+-^./\ T;3>?^%58_\ Q5'_ LWXX_]&TWG_A56/_Q5>A44:=@//?\ A9OQ MQ_Z-IO/_ JK'_XJC_A9OQQ_Z-IO/_"JL?\ XJO0J*-.P'GG_"S/CCG/_#-- MY_X55C_\50?B;\<3T_9IO/\ PJK'_P"*KT.B@#SP?$SXY=_V:;S_ ,*JQ_\ MBJ!\3/CB.O[-5Y_X55C_ /%5Z'10!YX?B;\<3T_9IO/_ JK'_XJD/Q-^.?; M]FB[_P#"JL?_ (JO1** /._^%F_'3_HV>[_\*JQ_^*H_X6;\=/\ HV>[_P#" MJL?_ (JO1**0'G?_ LWXZ?]&SW?_A56/_Q5'_"S?CI_T;/=_P#A56/_ ,57 MHE%,#SO_ (6;\=/^C9[O_P *JQ_^*H/Q.^.O_1L]Y_X5=C_\57HE% 'G?_"S M_CK_ -&RWG_A66/_ ,50/B=\=/\ HV6\_P#"LL?_ (JO1**0'G?_ L[XZG_ M )MFO/\ PK+'_P"*H/Q/^.@_YMEO/_"LL?\ XJO1** /RH_X+Q?M7?M+?!#5 M?A'X]\&P:W\.-4M[K5?)N[/Q##,+H;;8E'6(E64=UD!4YZ=:]W_X)+?MQ_MR M_M6^'%;]HO\ 9EEL]!2VW6?Q(7%A'?L!P/LDOS2[O^>L.(_8&OJ;XH_LU_ O MXU>,/#?CKXL_#'2O$6H^$9)I/#LFL6XGCLI)=F^18VRA?]VF&*DKC(P:[B." M*)%CBC"JO"JHX ]*KF]VP#ATHHHJ0"BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / "BBB@ HHHH **** /_9 end GRAPHIC 21 g4bdklltl5z5000014.jpg GRAPHIC begin 644 g4bdklltl5z5000014.jpg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end GRAPHIC 22 g4bdklltl5z5000009.jpg GRAPHIC begin 644 g4bdklltl5z5000009.jpg M_]C_X 02D9)1@ ! 0$!+ $L #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" *=",H# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_#L/]U?_ M $$44=A_NK_Z"** "BBB@ HHI#V&<$DCH3CC.>*&TE=Z+N M%-&<#UZ'/.=O M!Z>O8G ]>>*4D^Y] .U)M*,9*\E+:R_KYA]I1ZO\-+ZW\A:*/\_X?Y[>]+QZ MG\O_ *]._P#7]>J$W%-IR6F^_EY?U9B44O'J?R_^O1QZG\O_ *]%_P"OZ]5] MXI_+_ .O1?^OZ]5]X7C_,OQ\O+S_,2BEX M]3^7_P!>CCU/Y?\ UZ+_ -?UZK[PO'^9?CY>7G^#$HI>/4_E_P#7HX]3^7_U MZ+_U_7JOO#FC_,ON?EY?U9B44O'J?R_^O1QZG\O_ *]%_P"OZ]5]XI_+_ .O1?^OZ]5]X77=:^OEY>?YB44O'J?R_^O1Q MZG\O_KT7_K^O5?>'-'^9?CY>7]68E%+QZG\O_KT<>I_+_P"O1?\ K^O5?>'- M'^9?<_\ +^K>ETHI>/4_E_\ 7HX]3^7_ ->B_P#7]>J^\.:/\R_'R\O/\&)1 M2\>I_+_Z]''J?R_^O1?^OZ]5]X77==._6WEY_F)12\>I_+_Z]''J?R_^O1?^ MOZ]5]XCCU/Y?_7HO_7]>J^\.:/\R^Y^7E_5 MF)12\>I_+_Z]''J?R_\ KT7_ *_KU7WA==UKZ^7EY_F)12\>I_+_ .O1QZG\ MO_KT7_K^O5?>'-'^9?CY>7G^#$HI>/4_E_\ 7HX]3^7_ ->B_P#7]>J^\.:/ M\R^Y^7E_5F)12\>I_+_Z]''J?R_^O1?^OZ]5]XI_+_Z]''J?R_\ KT7_ *_K MU7WAS1_F7X^7E_5F)12\>I_+_P"O1QZG\O\ Z]%_Z_KU7WAS1_F_!_Y?U;TN ME%+QZG\O_KT<>I_+_P"O1?\ K^O5?>%X_P RZ=^MO+S_ 8E%+QZG\O_ *]( M3@9'..<'"_KFB_\ 7]>J^\+KNM?7R\O/\PHIFXXX]\X&25/W3QP>_3C'7-!< M '.0S3WMYWZCZ*0%CC.0I&0,/4_E_\ 7HX]3^7_ ->B M_P#7]>J^\+Q_F7X^7EY_F)12\>I_+_Z]''J?R_\ KT7_ *_KU7WA>/\ ,OQ\ MO+S_ 8E%+QZG\O_ *]''J?R_P#KT7_K^O5?>'-'^9?<_+R_JS$HI>/4_E_] M>CCU/Y?_ %Z+_P!?UZK[PYH_S+\?+R_JS$HI>/4_E_\ 7HX]3^7_ ->B_P#7 M]>J^\+KNM?7R\O/\Q**7CU/Y?_7HX]3^7_UZ+_U_7JOO#FC_ #+\?+R_JS$H MI>/4_E_]>CCU/Y?_ %Z+_P!?UZK[PYH_S+[G_E_5O2Z44O'J?R_^O1QZG\O_ M *]%_P"OZ]5]XI_+_ .O1?^OZ]5]X77== M._6WEY_F)12\>I_+_P"O1QZG\O\ Z]%_Z_KU7WAS1_F7W/R\OZLQ**7CU/Y? M_7HX]3^7_P!>B_\ 7]>J^\.:/\R^Y^7E_5F)12\>I_+_ .O1QZG\O_KT7_K^ MO5?>%X_S+\?+R\_P8E%+QZG\O_KT<>I_+_Z]%_Z_KU7WAS1_F7X^7EY_@Q** M7CU/Y?\ UZ./4_E_]>B_]?UZK[PYH_S+[GY>7]68E%+QZG\O_KT<>I_+_P"O M1?\ K^O5?>'-'^9?CY>7]68E%+QZG\O_ *]''J?R_P#KT7_K^O5?>%UW73OU MMY>?YB44O'J?R_\ KT<>I_+_ .O1?^OZ]5]XI_+_Z]%_Z_KU7WAS1_F_!_P"7]6]+I12\>I_+_P"O1QZG\O\ Z]%_Z_KU M7WA>/\RZ=^MO+S_!B44O'J?R_P#KT<>_Y?EW_P ^]%_Z_KU7WA>/\R_'R\O/ M\Q**7CU/Y?\ UZ./4_E_]>B_]?UZK[PYH_S+\?+R_JS$HI>/4_E_]>CCU/Y? M_7HO_7]>J^\.:/\ ,OQ\O+^K,2BEX]3^7_UZ./4_E_\ 7HO_ %_7JOO"\?YE M^/EY>?YB44O'J?R_^O1QZG\O_KT7_K^O5?>%X_S+\?+R\_P8E%+QZG\O_KT< M>I_+_P"O1?\ K^O5?>'-'^9?<_+R_JS$HI>/4_E_]>CCU/Y?_7HO_7]>J^\. M:/\ ,OQ\O+^K,2BEX]3^7_UZ./4_E_\ 7HO_ %_7JOO"Z[K7U\O+S_,2BEX] M3^7_ ->CCU/Y?_7HO_7]>J^\.:/\R_'R\OZLQ**7CU/Y?_7HX]3^7_UZ+_U_ M7JOO#FC_ #+[G_E_5O2Z44O'J?R_^O1QZG\O_KT7_K^O5?>'-'^9?CY>7]68 ME%+QZG\O_KT<>I_+_P"O1?\ K^O5?>%UW73OUMY>?YB44O'J?R_^O1QZG\O_ M *]%_P"OZ]5]XB_]?UZK[PYH_P R M^Y^7E_5F)12_AGKQT^G.::2,#).6!/';&,?,.,GW/?MQ32P8CH#_ 'L8/7I3U.=W)P#MZ?Q#KGI^?Y#O2UUT M=EUZ=/\ ,2=TY--)2M=K\?2^FEQ:*7CU/Y?_ %Z./4_E_P#7HO\ U_7JOO#F MC_,ON?EY?U9B44O'J?R_^O1QZG\O_KT7_K^O5?>'-'^9?CY>7]68E%+QZG\O M_KT<>I_+_P"O1?\ K^O5?>%UW73OUMY>?YB44O'J?R_^O1QZG\O_ *]%_P"O MZ]5]X?X,2BEX]3^7_UZ./4_E_]>B_]?UZK[PYH_P WX/\ R_JW MI=**7CU/Y?\ UZ./4_E_]>B_]?UZK[PO'^9=._6WEY_@Q**7CU/Y?_7HX]_R M_+O_ )]Z+_U_7JOO"\?YE^/EY>?YB44O'J?R_P#KT<>I_+_Z]%_Z_KU7WAS1 M_F7X^7E_5F)12\>I_+_Z]''J?R_^O1?^OZ]5]XB_\ M7]>J^\+Q_F7X^7EY_@Q**7CU/Y?_ %Z./4_E_P#7HO\ U_7JOO#FC_,ON?EY M?U9B44O'J?R_^O1QZG\O_KT7_K^O5?>'-'^9?CY>7]68E%+QZG\O_KT<>I_+ M_P"O1?\ K^O5?>%UW6OKY>7G^8E%+QZG\O\ Z]''J?R_^O1?^OZ]5]X'-'^9?CY>7]68E%+QZG\O_KT< M>I_+_P"O1?\ K^O5?>'-'^9?CY>7]68E%+QZG\O_ *]''J?R_P#KT7_K^O5? M>%UW73OUMY>?YB44O'J?R_\ KT<>_P"7Y]_\^U%_Z_KU7WAS1_F7W/R\OZLQ M**7CU/Y?_7HX]3^7_P!>B_\ 7]>J^\.:/\R^Y^7E_5F)12\>I_+_ .O1QZG\ MO_KT7_K^O5?>%X_S+\?+R\_P8E%+QZG\O_KT<>I_+_Z]%_Z_KU7WA>/\R_'R M\O/\Q**7CU/Y?_7HX]3^7_UZ+_U_7JOO#FC_ #+[GY>7]68E%+QZG\O_ *]' M'J?R_P#KT7_K^O5?>'-'^9?CY>7]68E%+QZG\O\ Z]''J?R_^O1?^OZ]5]X7 M7==._6WEY_F)12\>I_+_ .O1QZG\O_KT7_K^O5?>'-'^9?CY>7G^#$HI>/4_ ME_\ 7HX]3^7_ ->B_P#7]>J^\.:/\WX/_+^K>ETHI>/4_E_]>CCU/Y?_ %Z+ M_P!?UZK[PO'^9=._6WEY_@Q**7CU/Y?_ %Z./?\ +\N_^?>B_P#7]>J^\+Q_ MF7X^7EY_F)12\>I_+_Z]''J?R_\ KT7_ *_KU7WAS1_F7X^7E_5F)12\>I_+ M_P"O1QZG\O\ Z]%_Z_KU7WAS1_F7W/\ R_JWI=**7CU/Y?\ UZ./4_E_]>B_ M]?UZK[PO'^9?CY>7G^8E%+QZG\O_ *]''J?R_P#KT7_K^O5?>%X_S+\?+R\_ MP8E%+QZG\O\ Z]''J?R_^O1?^OZ]5]XCCU/ MY?\ UZ+_ -?UZK[PYH_S+\?+R_JS$HI>/4_E_P#7HX]3^7_UZ+_U_7JOO"Z[ MK7U\O+S_ #$HI>/4_E_]>CCU/Y?_ %Z+_P!?UZK[PYH_S+\?+R_JS$HI>/4_ ME_\ 7HX]3^7_ ->B_P#7]>J^\.:/\R_'R\OZLQ**7CU/Y?\ UZ./4_E_]>B_ M]?UZK[PYH_S+\?+R_JS$HI>/4_E_]>CCU/Y?_7HO_7]>J^\+KNNG?K;R\_S$ MHI>/4_E_]>CCW_+\^_\ GVHO_7]>J^\.:/\ ,ON?EY?U9B44O'J?R_\ KT<> MI_+_ .O1?^OZ]5]X7G^#$HI>/4_E_\ 7HX]3^7_ ->B_P#7]>J^\+Q_F7X^7EY_F)12 M\>I_+_Z]''J?R_\ KT7_ *_KU7WAS1_F7W/R\OZLQ**7CU/Y?_7HX]3^7_UZ M+_U_7JOO#FC_ #+\?+R_JS$HI>/4_E_]>CCU/Y?_ %Z+_P!?UZK[PO'^9?CY M>7G^8E%+QZG\O_KT<>I_+_Z]%_Z_KU7WAS1_F7X^7EY_@Q**7CU/Y?\ UZ./ M4_E_]>B_]?UZK[PYH_S?@_\ +^K>ETHI>/4_E_\ 7HX]3^7_ ->B_P#7]>J^ M\+Q_F73OUMY>?X,2BEX]3^7_ ->CCW_+\N_^?>B_]?UZK[PO'^9?CY>7G^8E M%+QZG\O_ *]''J?R_P#KT7_K^O5?>'-'^9?CY>7]68E%+QZG\O\ Z]''J?R_ M^O1?^OZ]5]X?YB44O'J?R_P#KT<>I_+_Z]%_Z_KU7WA>/\R_'R\O/\&)12\>I_+_Z]''J M?R_^O1?^OZ]5]XCCU/Y?_7HO_7]>J^\.:/\ MR_'R\OZLQ**7CU/Y?_7HX]3^7_UZ+_U_7JOO"Z[K7U\O+S_,2BEX]3^7_P!> MCCU/Y?\ UZ+_ -?UZK[PYH_S+\?+R_JS$HI>/4_E_P#7HX]3^7_UZ+_U_7JO MO#FC_,OQ\O+^K,2BEX]3^7_UZ./4_E_]>B_]?UZK[PYH_P R_'R\OZLQ**7C MU/Y?_7HX]3^7_P!>B_\ 7]>J^\+KNNG?K;R\_P Q**7CU/Y?_7HX]_R_/O\ MY]J+_P!?UZK[PYH_S+[GY>7]68E%+QZG\O\ Z]''J?R_^O1?^OZ]5]XCCU/Y?\ UZ+_ -?UZK[PO'^9=._6WEY_@Q**7CU/ MY?\ UZ./4_E_]>B_]?UZK[PO'^9?CY>7G^8E%+QZG\O_ *]''J?R_P#KT7_K M^O5?>'-'^9?<_+R_JS$HI>/4_E_]>CCU/Y?_ %Z+_P!?UZK[PYH_S+\?+R_J MS$HI>/4_E_\ 7HX]3^7_ ->B_P#7]>J^\+Q_F7X^7EY_F)12\>I_+_Z]''J? MR_\ KT7_ *_KU7WA>/\ ,OQ\O+S_ 8E%+QZG\O_ *]''J?R_P#KT7_K^O5? M>'-'^;\'_E_5O2Z44O'J?R_^O1QZG\O_ *]%_P"OZ]5]X7C_ #+IWZV\O/\ M!B44O'J?R_\ KT<>I_+_ .O1?^OZ]5]X7C_,OQ\O+S_,2BEX]3^7_P!>CCU/ MY?\ UZ+_ -?UZK[PYH_S+\?+R_JS$HI>/4_E_P#7IK9P2". >#\I/'8] 0>F M>#0M7:ZU_K]5]XZ_']5;^O2ZT5%EBF3\HXZ$,P'KQU!/4_6I:%JF^W??M MIY>8WI;K?M^NUOF%%%%"=]0%'4?4?SH/4_4_SH'4?4?SH/4_4_SH 3L/]U?_ M $$44=A_NK_Z"** "BBB@ HP3[>I] 2<>I[8/'?K12$9^H!QU[BDW9-\O-Y M=_\ AMP][[._K:RZN_I_70_G#_X+F_MS_M3?LA_$3]GC1/V=OB7'X"TOQOX4 M\::GXHM)/#.B>(!J5YI>I:?;V$RRZM;S26OD0S2+L@*I)NRX) Q^&7_#Z7_@ MI?V_:(M/Q^'/@P^OK8_YQ7Z-?\'+G_)6/V3>N?\ A _B%_Z>-*Q^-?S/YKZC M 8:C4PF'E+#PD^;WI.*N_>OJ[:I;6_X!^=9WC\73S7$T88R="%-*2C&K-)WI M0ELKK?7SU[GZB_\ #Z3_ (*7_P#1Q%M_X;GP9_\ (%'_ ^D_P""E_\ T<1; M?^&Z\&?_ "!7Y=45Z?U3"?\ 0)&__7JGY=?Z_.WE1S3,>6/^VXAZ+7VDM=%K MKZ(_47_A])_P4O\ ^CB+;_PW7@S_ .0*/^'TG_!2_P#Z.(MO_#=>#/\ Y K\ MNJ*7U3"_] L?_!-/R^[^NS'_ &IF/_09B/\ P9+R_P D?J+_ ,/I/^"E_P#T M<1;?^&Z\&?\ R!1_P^D_X*7_ /1Q%M_X;KP9_P#(%?EU13^J83_H%7_@FGY? MU_3L?VIF/_09B/\ P9+R_P D?J+_ ,/I/^"E_P#T<1;?^&Z\&?\ R!1_P^D_ MX*7_ /1Q%M_X;KP9_P#(%?EU11]4PG_0*O\ P33\OZ_IV/[4S'_H,Q'_ (,E MY?Y(_47_ (?2?\%+_P#HXBV_\-UX,_\ D"C_ (?2?\%+_P#HXBV_\-UX,_\ MD"ORZHI?5,+_ - L>G_+FGY?U^FC#^U,Q_Z#,1_X,EY?Y(_47_A])_P4O_Z. M(MO_ W7@S_Y H_X?2?\%+_^CB+;_P -UX,_^0*_+JBG]4PG_0(O_!-/R_K^ MG8_M3,?^@S$?^#)>7^2/U%_X?2?\%+_^CB+;_P -UX,_^0*/^'TG_!2__HXB MV_\ #=>#/_D"ORZHH^J83_H%7_@FGY?Y_P!:V/[4S'_H-Q'_ (,ETM_DC]1? M^'TG_!2__HXBV_\ #=>#/_D"C_A])_P4O_Z.(MO_ W7@S_Y K\NLT4?5,)_ MT"+_ ,$T_+^OZ=C^U,Q_Z#,1_P"#)=+?Y(_47_A])_P4O_Z.(MO_ W7@S_Y M H_X?2?\%+_^CB+;_P -UX,_^0*_+K..O%'3K2^JX33_ &6.O_3JGKM_7_#, M/[4S'_H,Q'_@R72W^2/U%_X?2?\ !2__ *.(MO\ PW7@S_Y H_X?2?\ !2__ M *.(MO\ PW7@S_Y K\NO4=QU]OKZ44_JF$_Z!5_X)I^7]?Y:V%FF8O;&8AVT MTJ2=MM_N1^HO_#Z3_@I?_P!'$6W_ (;KP9_\@4?\/I/^"E__ $<1;?\ ANO! MG_R!7Y=?Y_H?R/!]#UH_PS^'K]/>E]5P?_0+&[V7LJ>NW^?]:V/[4S'_ *#, M1_X,EY?Y(_47_A])_P %+_\ HXBV_P##=>#/_D"C_A])_P %+_\ HXBV_P## M=>#/_D"ORZY]*.?2G]4PFK6%6F[]C3TVW[?UIO8_M3,?^@S$?^#)>7^2/U%_ MX?2?\%+_ /HXBV_\-UX,_P#D"C_A])_P4O\ ^CB+;_PW7@S_ .0*_+KW[=@[GI[_2E]4PG_0+'_P33VT_KI^#L?VIF'_0;B-/^GDNEO/R1^HO_#Z3_@I? M_P!'$6W_ (;KP9_\@4?\/I/^"E__ $<1;?\ ANO!G_R!7Y=#)Z#/TYH]N_\ MAUIK"8-_\PJ^5*F^W^?]:V/[4S%?\QF(_P#!DO+_ "1^HO\ P^D_X*7_ /1Q M%M_X;KP9_P#(%'_#Z3_@I?\ ]'$6W_ANO!G_ ,@5^773KQWHS1]4PBWPJ2\Z M--=O\_ZUL?VIF/\ T&8C_P &2Z6_R1^HO_#Z3_@I?_T<1;?^&Z\&?_(%'_#Z M3_@I?_T<1;?^&Z\&?_(%?EU12^J83_H%C_X)I^5M?Z_!A_:F8_\ 09B/_!DO M+_)'ZB_\/I/^"E__ $<1;?\ ANO!G_R!1_P^D_X*7_\ 1Q%M_P"&Z\&?_(%? MEU13^J83_H%7_@FGY?U_3L?VIF/_ $&8C_P9+R_R1^HO_#Z3_@I?_P!'$6W_ M (;KP9_\@4?\/I/^"E__ $<1;?\ ANO!G_R!7Y=44?5,)_T"K_P33\OZ_IV/ M[4S'_H,Q'_@R7E_DC]1?^'TG_!2__HXBV_\ #=>#/_D"C_A])_P4O_Z.(MO_ M W7@S_Y K\NJ*/JF$_Z!%_X)I^7]?T[']J9C_T&8C_P9+R_R1^HO_#Z3_@I M?_T<1;?^&Z\&?_(%'_#Z3_@I?_T<1;?^&Z\&?_(%?EU12^J87_H%C_X)I^7] M?\,P_M3,?^@S$?\ @R7E_DC]1?\ A])_P4O_ .CB+;_PW7@S_P"0*/\ A])_ MP4O_ .CB+;_PW7@S_P"0*_+JBG]4PG_0(O\ P33\OZ_IV/[4S'_H,Q'_ (,E MY?Y(_47_ (?2?\%+_P#HXBV_\-UX,_\ D"E'_!:7_@I>.?\ AH>U/!X/PZ\& MX^O_ !X=NM?ES12EA,)RO_94M-_906NG;7K_ %K8_M3,?^@VO\ZDK=-]=M$? MJ/!_P6B_X*7F\TZ)_P!HFV9)=5TBTDS\.?!J[X+C4[6"?@6.-TL4KIG^'.5P MPK^^CPOI:!HEW>3!1&9KBZTZVN+EPJX">9+(S;5PJYP, M 5_EJ09_M#2_^P]H>/I_;%C7^I-X'S_PA?@OT_X1;P]D?]PFSKY[-Z-.A[%0 MBH\V_*DOY+;+=7:=_-:'U_#6)Q&*^M.KB93Y73Y;MNWNIOUOUVZ==_Y.O^"K M?_!3#]MO]G+]L7Q=\+O@U\8;?PCX%TS2-.N;+1G\'>'-9>*>>*(RN;W4K66Y M.XL3MW[1V%?F_P#\/I/^"E__ $<1;?\ ANO!G_R!7:_\%R/^4@GCW_L Z1_Z M)@K\A:]C!87#/#4I3P\9RE!2!FF98V&/Q$*>*K0A"HXJ M,)M)6MT76Z7W>M_U%_X?2?\ !2__ *.(MO\ PW7@S_Y H_X?2?\ !2__ *.( MMO\ PW7@S_Y K\NJ*ZOJF$_Z!5_X)I^7]?T[>?\ VIF/_09B/_!DO+_)'ZB_ M\/I/^"E__1Q%M_X;KP9_\@4?\/I/^"E__1Q%M_X;KP9_\@5^75%'U3"?] J_ M\$T_+^OZ=C^U,Q_Z#,1_X,EY?Y(_47_A])_P4O\ ^CB+;_PW7@S_ .0*/^'T MG_!2_P#Z.(MO_#=>#/\ Y K\NJ*7U3"_] L>G_+FGY?U^FC#^U,Q_P"@S$?^ M#)>7^2/U%_X?2?\ !2__ *.(MO\ PW7@S_Y H_X?2?\ !2__ *.(MO\ PW7@ MS_Y K\NJ*?U3"?\ 0(O_ 33\OZ_IV/[4S'_ *#,1_X,EY?Y(_47_A])_P % M+_\ HXBV_P##=>#/_D"C_A])_P %+_\ HXBV_P##=>#/_D"ORZHZ=>/\X_GQ M1]4PG_0*O_!-/R_S_K6Q_:F8_P#09B/_ 9+I;_)?#/\ Y H_X?2?\%+_ /HX MBV_\-UX,_P#D"ORZS13^J83_ *!%_P"":?E_7^6MC^U,Q_Z#,1T_Y>2\K?DO MN/U%_P"'TG_!2_\ Z.(MO_#=>#/_ ) H_P"'TG_!2_\ Z.(MO_#=>#/_ ) K M\N\'T//3CK24OJN#O;ZK&^]O94[]/\_ZUL?VIF/_ $&XC_P9+RM^2/U%_P"' MTG_!2_\ Z.(MO_#=>#/_ ) H_P"'TG_!2_\ Z.(MO_#=>#/_ ) K\NOISVXY MY]/K[49_S].OY4?5<)M]5C?3_EU3\O\ /?\ X-C^U,Q7_,9B/_!DO+_)'ZB_ M\/I/^"E__1Q%M_X;KP9_\@4?\/I/^"E__1Q%M_X;KP9_\@5^75%'U7"=<+'? M_GU3TV_'7R_,/[4S'_H,Q&G_ $\ETM_DC]1?^'TG_!2__HXBV_\ #=>#/_D" MC_A])_P4O_Z.(MO_ W7@S_Y K\NO;O_ )%'_P"K\^E'U7!V3^JQL[?\NJ=M M;6^^_P#6MC^U,Q_Z#,1_X,EY?Y(_47_A])_P4O\ ^CB+;_PW7@S_ .0*/^'T MG_!2_P#Z.(MO_#=>#/\ Y K\NO;OTH]?;K[?7TI_5,)_T"KI_P N:?6WZNW] M.Q_:F8_]!F(_\&2\O\D?J+_P^D_X*7_]'$6W_ANO!G_R!1_P^D_X*7_]'$6W M_ANO!G_R!7Y=X.,X./7'%)GI[G ]SZ#WI?5<)_T"Q\_W5/RM_7^3#^U_: MCGTI_5<':_U56[^QIVZ?U_3L?VIF/_09B/\ P9+I;\K(_47_ (?2?\%+_P#H MXBV_\-UX,_\ D"C_ (?2?\%+_P#HXBV_\-UX,_\ D"ORZS1[]NGY=?RI?5<& M]L+%_P#<*GY?U_3L?VIF*_YC,1_X,EY?Y(_47_A])_P4O_Z.(MO_ W7@S_Y M H_X?2?\%+_^CB+;_P -UX,_^0*_+K_]5'^?SZ?G1]5PG_0+'?\ Y\T]-K_/ M[K?)A_:F8?\ 0;B/_!DO+S\E]WJ?J+_P^D_X*7_]'$6W_ANO!G_R!1_P^D_X M*7_]'$6W_ANO!G_R!7Y=4?XX_'T^M-83"/585-=U2IO337\?ZUL?VIF/3&8C MI_R\EY6_)'ZB_P##Z3_@I?\ ]'$6W_ANO!G_ ,@4?\/I/^"E_P#T<1;?^&Z\ M&?\ R!7Y=9I,CU%'U3"?] J_\$T_+_/^M;']J9CM]I]J/JF$_P"@1?\ @FGY6_/^M;+^UM&>_;I1 M]4P>_P!55O\ KS3\O\_ZUL?VIF/_ $&8CO\ Q)>7^2/U%_X?2?\ !2__ *.( MMO\ PW7@S_Y H_X?2?\ !2__ *.(MO\ PW7@S_Y K\NO\#/_D"C_A])_P %+_\ HXBV_P##=>#/_D"ORZS_ (4?Y_+K^5/ZIA/^ M@1?^":?E_7].Q_:F8[_7,1;;^)+RM^2/U%_X?2?\%+_^CB+;_P -UX,_^0*/ M^'TG_!2__HXBV_\ #=>#/_D"ORZST]^GO]*/7V.#[$\X/OCFCZI@_P#H%7_@ MFGY?U_3L?VIF/_09B/\ P9+R_P D?J+_ ,/I/^"E_P#T<1;?^&Z\&?\ R!1_ MP^D_X*7_ /1Q%M_X;KP9_P#(%?EU1G^>/Q]/K1]4PG_0*O\ P33\OZ_IV/[4 MS'_H,Q'_ (,EY6_)'ZB_\/I/^"E__1Q%M_X;KP9_\@4?\/I/^"E__1Q%M_X; MKP9_\@5^75%+ZIA?^@2/_@FGY?U_PS#^U,Q_Z#,1_P"#)>7^2/U%_P"'TG_! M2_\ Z.(MO_#=>#/_ ) H_P"'TG_!2_\ Z.(MO_#=>#/_ ) K\NJ*?U3"?] J M_P#!-/R_K_+6Q_:F8_\ 09B/_!DO+_)'ZB_\/I/^"E__ $<1;?\ ANO!G_R! M1_P^D_X*7_\ 1Q%M_P"&Z\&?_(%?EU11]4PG_0*O_!-/R_K^G8_M3,?^@S$? M^#)>7^2/U%_X?2?\%+_^CB+;_P -UX,_^0*/^'TG_!2__HXBV_\ #=>#/_D" MORZHH^J83_H%73_ES3\OZ_3>Q_:F8_\ 09B/_!DO+_)'ZB_\/I/^"E__ $<1 M;?\ ANO!G_R!1_P^D_X*7_\ 1Q%M_P"&Z\&?_(%?EU11]4PG_0*O_!-/R_KI M^##^U,Q_Z#,1_P"#)>7^2/U&'_!:3_@I /C[\5HO&_A#1O@Y/XGTS2(_"F@:&+37H_$VGZ M>MZ+O2K>&XG'V6>2/R)F,62'"[AD?R=5^_7_ ;D?\GH_%G_ +(#<_E_PF6E M?_7_ ,FN#,,+0AAJDZ=&-.26CY(Q?2S5K:ZZ[=%T/3R?'XRKF.&C5Q=6<93Y M72G)R36FNK_3IW/[._$5Q<66@:_?6TGE7-IHNIW4#@9V3VMA/+"Q!ZA9$1L' MTQT)%?P7^+?^"R__ 4FTWQ=XKTZR_:$MH;'3_$>L65E!_PKSP0)&BKOWAW6S_Y3;G^F:_R^/'G_ "/GCC_L M;O$'_ISN*\W):5.I*HJM-5$K:.*GNWLI:7>A[?$V)Q.%AAG2Q$Z,ISE=0DXN M5E&VRZ::-_B?HW_P^D_X*7_]'$6W_ANO!G_R!1_P^D_X*7_]'$6W_ANO!G_R M!7Y=45]#]4PG_0(O_!-/R_K_ (9GR/\ :F8_]!F(_P#!DO+_ "1^HO\ P^D_ MX*7_ /1Q%M_X;KP9_P#(%'_#Z3_@I?\ ]'$6W_ANO!G_ ,@5^75%'U3"?] J M_P#!-/R_K^G8_M3,?^@S$?\ @R7E_DC]1?\ A])_P4O_ .CB+;_PW7@S_P"0 M*/\ A])_P4O_ .CB+;_PW7@S_P"0*_+JBCZIA/\ H%7_ ()I^7]?T[']J9C_ M -!F(_\ !DO+_)'ZB_\ #Z3_ (*7_P#1Q%M_X;KP9_\ (%'_ ^D_P""E_\ MT<1;?^&Z\&?_ "!7Y=44?5,)_P! B_\ !-/R_K^G8_M3,?\ H,Q'_@R7E_DC M]1?^'TG_ 4O_P"CB+;_ ,-UX,_^0*/^'TG_ 4O_P"CB+;_ ,-UX,_^0*_+ MJBCZIA/^@5=/^7-/RO\ UI^##^U,Q_Z#,1_X,EY?Y(_47_A])_P4O_Z.(MO_ M W7@S_Y H_X?2?\%+_^CB+;_P -UX,_^0*_+JBCZIA/^@1?^":?E_7].Q_: MF8_]!F(_\&2\O\D?J+_P^D_X*7_]'$6W_ANO!G_R!1_P^D_X*7_]'$6W_ANO M!G_R!7Y=44?5,)_T"K_P33\OZ_IV/[4S'_H,Q'_@R7E_DC]1?^'TG_!2_P#Z M.(MO_#=>#/\ Y H_X?2?\%+_ /HXBV_\-UX,_P#D"ORZHH^J83_H$7_@FGY? MU_3L?VIF/_09B/\ P9+R_P D?J+_ ,/I/^"E_P#T<1;?^&Z\&?\ R!1_P^D_ MX*7_ /1Q%M_X;KP9_P#(%?EU12^J87_H%C_X)I^7W?UV8?VIF/\ T&8C_P & M2\O\D?J+_P /I/\ @I?_ -'$6W_ANO!G_P @4?\ #Z3_ (*7_P#1Q%M_X;KP M9_\ (%?EU13^J83_ *!5_P"":?E_7].Q_:F8_P#09B/_ 9+R_R1^HO_ ^D M_P""E_\ T<1;?^&Z\&?_ "!1_P /I/\ @I?_ -'$6W_ANO!G_P @5^75%'U3 M"?\ 0*O_ 33\OZ_IV/[4S'_ *#,1_X,EY?Y(_47_A])_P %+_\ HXBV_P## M=>#/_D"C_A])_P %+_\ HXBV_P##=>#/_D"ORZHH^J83_H$73_ES3\OZ_P"& M8?VIF/\ T&8C_P &2\O\D?J+_P /I/\ @I?_ -'$6W_ANO!G_P @4?\ #Z3_ M (*7_P#1Q%M_X;KP9_\ (%?EU11]4PG_ $"+_P $T_+^OZ=C^U,Q_P"@S$?^ M#)>7^2/U%_X?2?\ !2__ *.(MO\ PW7@S_Y H_X?2?\ !2__ *.(MO\ PW7@ MS_Y K\NJ*/JF$_Z!5_X)I^7]?T[']J9C_P!!F(_\&2\O\D?J+_P^D_X*7_\ M1Q%M_P"&Z\&?_(%'_#Z3_@I?_P!'$6W_ (;KP9_\@5^75%'U3"?] J_\$T_+ M^OZ=C^U,Q_Z#,1_X,EY?Y(_47_A])_P4O_Z.(MO_ W7@S_Y H_X?2?\%+_^ MCB+;_P -UX,_^0*_+JBE]4PO_0)'_P $T_+^O^&8?VIF/_09B/\ P9+R_P D M?J+_ ,/I/^"E_P#T<1;?^&Z\&?\ R!1_P^D_X*7_ /1Q%M_X;KP9_P#(%?EU M13^J83_H%7_@FGY?U_EK8_M3,?\ H,Q'_@R7E_DC]1?^'TG_ 4O_P"CB+;_ M ,-UX,_^0*/^'TG_ 4O_P"CB+;_ ,-UX,_^0*_+JBCZIA/^@5?^":?E_7]. MQ_:F8_\ 09B/_!DO+_)'ZB_\/I/^"E__ $<1;?\ ANO!G_R!1_P^D_X*7_\ M1Q%M_P"&Z\&?_(%?EU11]4PG_0*NG_+FGY?U^F]C^U,Q_P"@S$?^#)>7^2/U M%_X?2?\ !2__ *.(MO\ PW7@S_Y H_X?2?\ !2__ *.(MO\ PW7@S_Y K\NJ M*/JF$_Z!5_X)I^7]=/P8?VIF/_09B/\ P9+R_P D?J+_ ,/I/^"E_P#T<1;? M^&Z\&?\ R!1_P^D_X*7_ /1Q%M_X;KP9_P#(%?EU11]4PG_0*O\ P33\OZ_I MV/[4S'_H,Q'_ (,EY?Y(_47_ (?2?\%+_P#HXBV_\-UX,_\ D"C_ (?2?\%+ M_P#HXBV_\-UX,_\ D"ORZHH^J83_ *!5_P"":?E_7].Q_:F8_P#09B/_ 9+ MR_R1^HO_ ^D_P""E_\ T<1;?^&Z\&?_ "!1_P /I/\ @I?_ -'$6W_ANO!G M_P @5^75%'U3"?\ 0(O_ 33\OZ_X9A_:F8_]!F(_P#!DO+_ "1^HO\ P^D_ MX*7_ /1Q%M_X;KP9_P#(%'_#Z3_@I?\ ]'$6W_ANO!G_ ,@5^71..O'UXI<' MT/KT[>M+ZK@_^@6/3_EU3WTT\OZ\[']J9C_T&8CI_P O)>5OR7],_43_ (?2 M?\%+_P#HXBV_\-UX,_\ D"C_ (?2?\%+_P#HXBV_\-UX,_\ D"ORZ_KT]Z/7 MV.#['T/O1]5P?_0+'M_"I^7^?]:V/[4S'_H,Q'_@R72W^2/U%_X?2?\ !2__ M *.(MO\ PW7@S_Y H_X?2?\ !2__ *.(MO\ PW7@S_Y K\NN>!CD]/?Z>M&> MGOT]_I3^J83_ *!5Y?NJ?E_7].Q_:F8V3^N8BSV?M)6>VW?9'ZB_\/I/^"E_ M_1Q%M_X;KP9_\@4?\/I/^"E__1Q%M_X;KP9_\@5^77K[=?;Z^E'I[\CW^GK2 M^JX3_H%C:Z_Y5OR1^HG_#Z3_@I?_P!'$6W_ (;KP9_\@4?\/I/^"E__ M $<1;?\ ANO!G_R!7Y= YX')]N:,TEA<)_T"QTW_ '-/?3[M'_5F']J9C_T& M8C_P9+R_R7],_47_ (?2?\%+_P#HXBV_\-UX,_\ D"C_ (?2?\%+_P#HXBV_ M\-UX,_\ D"ORZHH^JX/_ *!8Z:/]U3TV_P _ZUL?VIF/_09B/_!DO+_)'ZB_ M\/I/^"E__1Q%M_X;KP9_\@4?\/I/^"E__1Q%M_X;KP9_\@5^75'I[]/?Z>M/ MZIA/^@1?^":?E_G_ %K86:9ATQN(=NU27EY^2/U%_P"'TG_!2_\ Z.(MO_#= M>#/_ ) H_P"'TG_!2_\ Z.(MO_#=>#/_ ) K\NO\_GT_.CV[GH/6E]5PEK_5 M8V?5TJ=NFGX_UJ']J9C_ -!F(_\ !DO+_)'ZB_\ #Z3_ (*7_P#1Q%M_X;KP M9_\ (%'_ ^D_P""E_\ T<1;?^&Z\&?_ "!7Y=?_ *_\_3OZ49[]O\_X&A87 M"/7ZK%I]J-/;3[_P_!A_:F8_]!F(_P#!DNEO\D?J+_P^D_X*7_\ 1Q%M_P"& MZ\&?_(%'_#Z3_@I?_P!'$6W_ (;KP9_\@5^77;/;CD\#GIST%'/I3^J83_H% M7_@FGY?U_3L?VIF/_09B/_!DNEO\D?J+_P /I/\ @I?_ -'$6W_ANO!G_P @ M4?\ #Z3_ (*7_P#1Q%M_X;KP9_\ (%?EUZ^W7V^OI^-'I[]/?MQZ_A1]4PFG M^RK_ ,$T_+^OZ=C^U,Q_Z#,1_P"#)>7^2^[U/U%_X?2?\%+_ /HXBV_\-UX, M_P#D"C_A])_P4O\ ^CB+;_PW7@S_ .0*_+K_ !Q^(ZCZT=,^W7V^M)83"/\ MYA8_^"J?E_7_ S#^U,Q_P"@S$?^#)>7^2/U%_X?2?\ !2__ *.(MO\ PW7@ MS_Y H_X?2?\ !2__ *.(MO\ PW7@S_Y K\NO_P!5%/ZIA/\ H%7_ ()I^7^? M_#:V/[4S&]OKF(NM;>TE>VFOX(_47_A])_P4O_Z.(MO_ W7@S_Y H_X?2?\ M%+_^CB+;_P -UX,_^0*_+KOCOZ=Z/4=QU]OKZ4?5,)_T"K_P33\O\_ZUL?VK MF'_0;B-+?\O7IM;KY(_47_A])_P4O_Z.(MO_ W7@S_Y H_X?2?\%+_^CB+; M_P -UX,_^0*_+K..O'_U^E+@CJ#^5'U3"?\ 0*O_ 33\K_\/_P;']J9BK?[ M9B%?;]Y+6UMN]K+^F?J)_P /I/\ @I?_ -'$6W_ANO!G_P @4?\ #Z3_ (*7 M_P#1Q%M_X;KP9_\ (%?EUUZ?6C.?PZ^U+ZKA.N%C_P""J>W]>GX,/[4S#_H- MQ'E^\ETMY^2/U%_X?2?\%+_^CB+;_P -UX,_^0*/^'TG_!2__HXBV_\ #=># M/_D"ORZ]3Z8!]B>@/H3V!ZT=.3Q_G'\Z?U3!]<*E?_IU3\O\_P"M;']J9BO^ M8S$+;_EY+RM^2/U%_P"'TG_!2_\ Z.(MO_#=>#/_ ) H_P"'TG_!2_\ Z.(M MO_#=>#/_ ) K\NLXZ\=Z.G7Z4?5,)_T"K_P33\OZ_IV/[4S'IC,1_P"#)=+? MY(_47_A])_P4O_Z.(MO_ W7@S_Y H_X?2?\%+_^CB+;_P -UX,_^0*_+KIU M[=?:C-+ZKA'MA8_^"J?EU_K\&']J9C_T&8C_ ,&2\O\ )'ZB_P##Z3_@I?\ M]'$6W_ANO!G_ ,@4?\/I/^"E_P#T<1;?^&Z\&?\ R!7Y=4P[ MT_JF$_Z!5_X)I^7]?T[']J9C_P!!F(_\&2\O\D?J+_P^D_X*7_\ 1Q%M_P"& MZ\&?_(%'_#Z3_@I?_P!'$6W_ (;KP9_\@5^770X/!]._Y44?5,'I_LJU_P"G M-/R_S_K6S_M/,M_KF)M_U\EY6_)'ZB_\/I/^"E__ $<1;?\ ANO!G_R!1_P^ MD_X*7_\ 1Q%M_P"&Z\&?_(%?ETE'U3"?] B_\$T_+^OZ=E_:F M8[_7,1;_ *^2\O\ )?TS]1?^'TG_ 4O_P"CB+;_ ,-UX,_^0*/^'TG_ 4O M_P"CB+;_ ,-UX,_^0*_+KGTH_P ,_AZ_3WI?5,)_T"Q_\$T_*_Y^7X,/[4S' M_H-Q'_@R7E;\D?J+_P /I/\ @I?_ -'$6W_ANO!G_P @4?\ #Z3_ (*7_P#1 MQ%M_X;KP9_\ (%?ET>,9XSP,]^_'X4>OMU]L],^F:?U3"?\ 0(O_ 33\O\ M/^M;']J9C_T&8C_P9+R_R1^HO_#Z3_@I?_T<1;?^&Z\&?_(%'_#Z3_@I?_T< M1;?^&Z\&?_(%?EU1TZ]C@^Q]/K1]4PG_ $"K_P $T_+^OEZV/[4S'98W$7T_ MY>2\K?DC]1?^'TG_ 4O_P"CB+;_ ,-UX,_^0*/^'TG_ 4O_P"CB+;_ ,-U MX,_^0*_+K^O3W^GK1VSVZ9[4?5,)_P! J_\ !5/^OZ\G8_M3,/\ H-Q&G_3R M6EK>?DON/U%_X?2?\%+_ /HXBV_\-UX,_P#D"C_A])_P4O\ ^CB+;_PW7@S_ M .0*_+JBE]4PO_0+'_P33\ON_KLP_M3,?^@S$?\ @R7E_DC]1?\ A])_P4O_ M .CB+;_PW7@S_P"0*/\ A])_P4O_ .CB+;_PW7@S_P"0*_+JBG]4PG_0*O\ MP33\OZ_RUL?VIF/_ $&8C_P9+R_R1^HO_#Z3_@I?_P!'$6W_ (;KP9_\@4?\ M/I/^"E__ $<1;?\ ANO!G_R!7Y=44?5,)_T"K_P33\OZ_IV/[4S'_H,Q'_@R M7E_DC]1?^'TG_!2__HXBV_\ #=>#/_D"C_A])_P4O_Z.(MO_ W7@S_Y K\N MJ*/JF$_Z!%T_Y7^2/U%_X?2?\%+_ /HX MBV_\-UX,_P#D"C_A])_P4O\ ^CB+;_PW7@S_ .0*_+JBCZIA/^@5?^":?E_7 M].Q_:F8_]!F(_P#!DO+_ "1^HO\ P^D_X*7_ /1Q%M_X;KP9_P#(%'_#Z3_@ MI?\ ]'$6W_ANO!G_ ,@5^75%'U3"?] B_P#!-/R_K_AF']J9C_T&8C_P9+R_ MR1^HO_#Z3_@I?_T<1;?^&Z\&?_(%'_#Z3_@I?_T<1;?^&Z\&?_(%?EU11]4P MG_0*O_!-/R_K^G8_M3,?^@S$?^#)>7^2/U%_X?2?\%+_ /HXBV_\-UX,_P#D M"C_A])_P4O\ ^CB+;_PW7@S_ .0*_+JBCZIA/^@5?^":?E_7].Q_:F8_]!F( M_P#!DO+_ "1^HO\ P^D_X*7_ /1Q%M_X;KP9_P#(%'_#Z3_@I?\ ]'$6W_AN MO!G_ ,@5^75%'U3"?] B_P#!-/R_K^G8_M3,?^@S$?\ @R7E_DC]1?\ A])_ MP4O_ .CB+;_PW7@S_P"0*/\ A])_P4O_ .CB+;_PW7@S_P"0*_+JBCZIA/\ MH%73_ES3\K_UI^##^U,Q_P"@S$?^#)>7^2/U%_X?2?\ !2__ *.(MO\ PW7@ MS_Y H_X?2?\ !2__ *.(MO\ PW7@S_Y K\NJ*/JF$_Z!%_X)I^7]?T[']J9C M_P!!F(_\&2\O\D?J+_P^D_X*7_\ 1Q%M_P"&Z\&?_(%'_#Z3_@I?_P!'$6W_ M (;KP9_\@5^75%'U3"?] J_\$T_+^OZ=C^U,Q_Z#,1_X,EY?Y(_47_A])_P4 MO_Z.(MO_ W7@S_Y H_X?2?\%+_^CB+;_P -UX,_^0*_+JBCZIA/^@1?^":? ME_7].Q_:F8_]!F(_\&2\O\D?J+_P^D_X*7_]'$6W_ANO!G_R!7Z"?\$LO^"G M7[@+X+\,Z2UY-H_AJ>_TUQJ&G6D M5Y!]GNT64K$X67&R3*\5_-M7ZK_\$2?^4F'P'_[ 7Q0_]0ZZKEQF&PT<+6E' M#J$E!M2]E!6:LT[K5?TNZ._+,QQU3'8:%3%5IPE42E"51N+3LK-=5HC^_4QD M[2&VG=C([+U.%Z9/3]>M24'HO^\?_0:*^1L^::T2LK/ING^!^D\W[N#;N^57 M[] HHHJ1WOKWU^\4=1]1_.@]3]3_ #H'4?4?SH/4_4_SH 3L/]U?_0111V'^ MZO\ Z"** "BBB@ I1].Q_E_3K24H_H?Y&@:VETTW^:/Y#?\ @Y=_Y*S^R;_V M(7Q#_P#3SI5?S05_2_\ \'+O_)6?V3?^Q"^(?_IYTJOYH*^RRQOZA2TNGN^W M[W^E\S\OS_\ Y&N(]*7_ *:@%%%%=QXP4444 %%%% !1110 4444 %%%% !2 M$X!-+2$9BVI1:Z-?F%E+1JZ>C2T_$]?\ @'\$O%W[1WQ?\#?!#P+>:+I_ MB[XA:LFB:'>>(9I[72(+R2.23?J$]K%-<)!MC8.88W?)551LXKW/]L_]A+XQ M_L*>*O!O@[XOZUX(UK5?'%NMSH\O@:_U"_@@C:Y2T!NUU.UM)8I?-<,&4# 8#E2<[6PR\\9R*_P!/_3KOPE!\)_!6G>-Y MM)7P_P"(_"7A+PQ/:ZYY)L-8N-=T6TL+?0Y(YODN7U1I#;QVI5OM#,R!23BO MX(/^"K?[&$G[%O[4'B7PSH-@;;X3_$87?COX6_Z7-J3V.F7M]*FI:'J-W+## M'%J5EJGVI[73D+&'1OLL@RF".;+\PG57P-NF]$FHQ2DEYJZ>O?37?NSC M)*>#HX?%8?F=!SI*M3T^,WPJ\5?"K2/"=]J=]I4-GXOU36;36XKBQD"3,U MMIEA=PK"S',+2.ID&<#(;'[4_P#!;$?\:S_V5AS_ ,>WPR!]Q_PK?3L@_7C_ M #R/7/\ @BW?7>F?\$M/'.I:;4# M]W/:W$:30R#_ %;HK=J3Q]=8#VL7'VCKRIW:]WE?[8?_ 3X_:5_8?U'3HOC+X>T^Z\+:P;>VTOXC^%9 M;J_\%:EJERN]=!M[RZCBNX-0@'$T-U;PY./++@$CF_#?_!1S]O32KJTU?2OV ML_C=KVJ6%P;JTTN_\47?B"RU">RG>6*WN=*AA:2_M9GC2*> +B:-C&O\ @B_XN^)GQAT'2=0\-96-R^LZ7ID MH,FDW=M-_;2SW1G M1P.58^CC%A:>(P]7#4IS4JE5RBW3LW]E;:=;:[KK_,!^R-_P2:_:6_;4^#D_ MQP^%/BCX5:/X1@\1^(?"SV7C+5M8L];74/#2PG4)3%86%S;);2>>GV>265=Z MAF?"J2/S,O[>2QO]3TJ5E:YTC5-3TBZ:-F,4ESI5_<:?M5Q..H.5Z<9IQLONU_X:[\CAQ^$P^&P67XB,7SXN MC*I4;>CDE!II6T^+M^1^BO['W_!*7]I']M_X7:M\7/A'XI^%FC>&-&\3:EX7 MN+/QGJ>K6>I-J6EVMK=W4J1:?8W,*64D=W$J2S/'N=9.-L;$3?LF?\$GOVE? MVR]!^)'B+X6^)OA=HMC\+/B;K_PLU]/%>HZQ#/<^)/#NQ=0N-*;3["Z#:6WF M(8))C%(X;[G! _H6_P"#>(?\8._$7MN^,/C$8 X'_$CTH#CISG],'BOY7)OV ME?VBO@?\1/C;H'P8^-_Q)^%>A:M\9/B#JNJ:1X)\0S:/I^HZL?$>HP'4KJWC MC<27I@CCA,Q()C15P,9K"EB<95K8JG2G0C]7:Y74A=J-U?UV=KVMZG1/!Y9A MZ&5UZ].K_M5&M.LZ=5P3:BN72S2=]][VMM='Z>G_ (-UOVYN_C_X )GUUOQ2 M,CH5&-&SENN[MT^C)O\ @W:_;EABFF_X3KX!$0PR2%%UKQ0&E6-2_E!GT@!& M8 C>6 +8W$+DC];O^#?;XW?&;XX_!#]H#6/C1\4O&WQ4U;1/BYI.E:-J7C?6 M9-9N]+TR3PQ!3:R7#-.\8R&E)8FOYT?VH?VXOVT="_:7_:-\-:) M^U7\<-)\.Z/\9?B'H>DZ%8>,[F#3-+T:TUNYM[72[&V$)$%G;VW[B*($A(OE M%84J^85:U;#PG03IN,FU3WNXOW7>^^_Y;LZ,1A\CH8+"8^=+$..)4H04JZEI M%M*Z<.6236FD>FMFS\__ !CX7U#P-XN\4>"=9DMY=9\(Z_J/AS4I;*1Y+22\ MTN9H+AK:1U5GMRX_=LP#,O)%\N-3U34[N6_U+4;V0S7 M=]?7#%Y[NYF.#)<3.2TK\%FY(JE7N)U%3Y:S;VZ^EM;7TV^\^8JI*7M*?\%] M+K7:U_/7\]M@HHHH6R]$9A1113 **** "BBB@ HHHH **** "BBB@":W_P"0 MAI7_ &'-$_\ 3Q95_J2^!_\ D2?!?_8K>'O_ $TV5?Y;5O\ \A#2O^PYHG_I MXLJ_U)? _P#R)/@O_L5O#W_IILJ\#.]L'UTJ?/6)]MPGMB_^X?\ Z2C^$_\ MX+D_\I!/'O\ V -'_P#1$&?UK\A*_7K_ (+D?\I!/'O_ & =(_\ 1,%?D+7K M8/\ W6A_UZA\O=1\WF__ ",<3_U\84445TGFA1110 4444 %%%% "X.!P.>$ M(;DL/XW0X5@OW=N<'J3FOU2_9/\ ^"/G[47[97P8T3X\_"KQ5\*-,\'^(=3U MS2+2T\8:EK=IK2W.@7[Z;?O/;:?IUU:I ]U$YM]LWF;0&91D$_E7@?-D Y& M3U0]=R?W6)ZGO^5>_P#P^_:Q_:D^$/A>V\%?"C]H7XK_ X\&V-Q<>9^FM_F?K1_Q#K?MR\?\5]^S^K$@ M$-K?BIB1T!'_ !)N-O3 Y;\*X_XB?\$#?VT/AIX%\8?$/7?&?P/O=%\&^'M4 M\1ZI9Z;K'B,:A+8Z1:R7EVMAYVEQP-J>/\ XH?$/Q;\0?'FK27=:K=;>9]!C, M+D>#PV'Q/LL0_K-%NFE7>EXJR?NVENKVY>M]3PSX=?#+XA_&#QGI7P\^%OA' M6_''CC7;IK+2_#N@6C7ES/-"_ERRG.V&"$=3-<21I@,2V*_:70_^#>+]N/5M M(L-3OO%WP5T*?4+*UO9-%OM6UZ34-.EG19&LM0^SZ9+:B[MPWEW!@FD19%9% M8XK]+_\ @A9\!/!GP _9*\>?MF_$WPU+IOB;Q9_PD>MVGBNZ=;L'X1>'[875 ME=Z-9N +"6[N$U,7T\I'&C[53G\#?V@_^"I_[;/QA^*WBWQCHG[0_P 1 M?A[X;DU?4]/\->'/AQK3^&M!M/#EMJ,\&C74EC LJR:E/8);SW%QO+222.3U MS6LL3B<36E0PG)3A#2I.:YE*HK7Y5HHQNM%TVZ'*L'EV!P5&OCJ>)KU<9K2H M4&XM4K^XY/[3Y=;M7=MA?VOO^"5_[6O[%VA6_C#XCZ%HOC3X>O:K-JOCKX<- M?ZCHOAJZDNS;0:?KWVNWM[ZWNK@_O87BMGMC#\QF#*P'D/[&/[$_Q;_;L^(7 MBKX:?!W6?!6B>(/!WA&+QKJEQXWO;ZSTR;1YM5AT=(+%]/MKJ>6^%S<1NR^7 MM$(:1B "1^V7[.W_ 7)^%6M?LH>)/@=^W3X>\;^//&USI&K>#(=>\->'8M; MMO&_AF_TUK2WUK7[V6XB&D^)+66:3$RP3N\MO%>(T49<*>*^Y?\ @@W\=?VY M?BQXC^)UI\<-:\>_$#X,6]A#>V'C;XGF^;7K'Q4S(+/2M$N-0M[:XGTVZMC< MR747E!8I(X^N\;,ZU@,HJ8IY?'#X ME3C.=&-;G

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g4bdklltl5z5000006.jpg GRAPHIC begin 644 g4bdklltl5z5000006.jpg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

XML 32 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 139,065,000 $ 123,436,000
Short-term marketable securities (amortized cost of $214,115 and $564,036, respectively) 213,996,000 564,833,000
Accounts receivable, net 17,409,000 10,047,000
Inventory 19,263,000 14,063,000
Prepaid expenses and other current assets 13,015,000 14,535,000
Total current assets 402,748,000 726,914,000
Long-term assets    
Property and equipment, net 85,262,000 39,692,000
Operating lease right-of-use assets 87,678,000 99,350,000
Long-term marketable securities (amortized cost of $218,163 and $118,429, respectively) 217,145,000 118,525,000
Restricted cash 2,138,000 2,138,000
Intangible assets, net 8,526,000 10,225,000
Goodwill 118,972,000 118,972,000
Other assets 875,000 598,000
Total assets 923,344,000 1,116,414,000
Current liabilities    
Accounts payable 3,307,000 3,237,000
Accrued liabilities 9,343,000 13,162,000
Accrued compensation and benefits 15,642,000 11,950,000
Current portion of operating lease liabilities 5,055,000 3,529,000
Current portion of deferred revenue 80,460,000 73,319,000
Total current liabilities 113,807,000 105,197,000
Long-term liabilities    
Operating lease liabilities, less current portion 106,685,000 104,333,000
Deferred revenue, less current portion 98,750,000 163,618,000
Total liabilities 319,242,000 373,148,000
Commitments and contingencies (Note 11)
Shareholders’ equity    
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020
Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2021 and 2020; 141,393,865 and 137,646,896 shares issued and outstanding at December 31, 2021 and 2020, respectively 14,000 14,000
Additional paid-in capital 1,324,006,000 1,253,971,000
Accumulated other comprehensive (loss) gain (1,137,000) 893,000
Accumulated deficit (718,891,000) (511,612,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity 603,992,000 743,266,000
Noncontrolling interest 110,000  
Total shareholders’ equity 604,102,000 743,266,000
Total liabilities and shareholders’ equity $ 923,344,000 $ 1,116,414,000
XML 33 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Statement Of Financial Position [Abstract]    
Amortized cost of short-term marketable securities $ 214,115 $ 564,036
Amortized cost of long-term marketable securities $ 218,163 $ 118,429
Preferred stock par value $ 0.0001 $ 0.0001
Preferred stock authorized 10,000,000 10,000,000
Preferred stock issued 0 0
Preferred stock outstanding 0 0
Common stock par value $ 0.0001 $ 0.0001
Common stock authorized 340,000,000 340,000,000
Common stock issued 141,393,865 137,646,896
Common stock outstanding 141,393,865 137,646,896
XML 34 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue      
Total revenue $ 154,344 $ 98,382 $ 85,071
Operating expenses      
Cost of revenue 49,301 22,530 22,274
Research and development 142,343 116,072 70,705
Sales and marketing 95,465 61,358 38,453
General and administrative 74,502 49,536 30,332
Amortization of intangible assets 1,699 1,703 1,698
Total operating expenses 363,310 251,199 163,462
Loss from operations (208,966) (152,817) (78,391)
Interest and other income, net 1,668 6,590 9,785
Net loss (207,298) (146,227) (68,606)
Add: Net loss attributable to noncontrolling interest 19    
Net loss attributable to Adaptive Biotechnologies Corporation (207,279) (146,227) (68,606)
Fair value adjustment to Series E-1 convertible preferred stock options     (964)
Net loss attributable to Adaptive Biotechnologies Corporation common shareholders $ (207,279) $ (146,227) $ (69,570)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ (1.48) $ (1.11) $ (1.01)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 140,354,915 131,216,468 69,165,315
Sequencing Revenue      
Revenue      
Total revenue $ 78,896 $ 41,439 $ 43,519
Development Revenue      
Revenue      
Total revenue $ 75,448 $ 56,943 $ 41,552
XML 35 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement Of Financial Position [Abstract]      
Net loss $ (207,298) $ (146,227) $ (68,606)
Other comprehensive (loss) income:      
Change in unrealized gains and losses on investments (2,030) 222 778
Comprehensive loss (209,328) (146,005) (67,828)
Add: Comprehensive loss attributable to noncontrolling interest 19    
Comprehensive loss attributable to Adaptive Biotechnologies Corporation $ (209,309) $ (146,005) $ (67,828)
XML 36 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity - USD ($)
$ in Thousands
Total
Revision of Prior Period, Accounting Standards Update, Adjustment
Convertible Preferred Stock
Common Stock
Additional Paid In Capital
Accumulated Other Comprehensive (Loss) Gain
Accumulated Deficit
Accumulated Deficit
Revision of Prior Period, Accounting Standards Update, Adjustment
Noncontrolling Interest
Beginning Balance at Dec. 31, 2018 $ (258,112)     $ 1 $ 37,902 $ (107) $ (295,908)    
Beginning Balance, Shares at Dec. 31, 2018       12,841,536          
Convertible preferred stock, Beginning Balance at Dec. 31, 2018     $ 560,858            
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2018     92,790,094            
Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us 320,850     $ 2 320,848        
Proceeds from initial public offering, net of underwriters' discounts and commissions, Shares       17,250,000          
Initial public offering costs (4,986)       (4,986)        
Conversion of convertible preferred stock to common stock 561,931   $ (561,931) $ 9 561,922        
Conversion of convertible preferred stock to common stock, Shares     (93,039,737) 93,039,737          
Conversion of convertible preferred stock warrant to common stock warrant 2,602       2,602        
Issuance of common stock upon exercise of common stock warrants 9       9        
Issuance of common stock upon exercise of common stock warrants, Shares       54,792          
Issuance of common stock for cash upon exercise of stock options 4,413       4,413        
Issuance of common stock for cash upon exercise of stock options, Shares       2,043,767          
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value     $ 109            
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares     249,643            
Vesting of restricted stock units       8,310          
Change in redemption value for vested Series E-1 convertible preferred stock options (964)           (964)    
Change in redemption value for vested Series E-1 convertible preferred stock options     $ 964            
Common stock option and restricted stock unit share-based compensation 13,124       13,124        
Other comprehensive income (loss) 778         778      
Net loss (68,606)           (68,606)    
Ending Balance at Dec. 31, 2019 571,039 $ 93   $ 12 935,834 671 (365,478) $ 93  
Ending Balance, Shares at Dec. 31, 2019       125,238,142          
Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us $ 271,839     $ 1 271,838        
Proceeds from initial public offering, net of underwriters' discounts and commissions, Shares       7,200,000          
Accounting Standards Update Extensible List ASC 842                
Issuance of common stock for cash upon exercise of stock options $ 21,539     $ 1 21,538        
Issuance of common stock for cash upon exercise of stock options, Shares       5,204,254          
Vesting of restricted stock units       4,500          
Common stock option and restricted stock unit share-based compensation 24,761       24,761        
Other comprehensive income (loss) 222         222      
Net loss (146,227)           (146,227)    
Ending Balance at Dec. 31, 2020 743,266     $ 14 1,253,971 893 (511,612)    
Ending Balance, Shares at Dec. 31, 2020       137,646,896          
Issuance of common stock upon exercise of common stock warrants, Shares       54,162          
Issuance of common stock for cash upon exercise of stock options $ 26,484       26,484        
Issuance of common stock for cash upon exercise of stock options, Shares 3,674,057     3,674,057          
Vesting of restricted stock units       18,750          
Common stock option and restricted stock unit share-based compensation $ 43,251       43,251        
Capital contributions for Digital Biotechnologies, Inc. 429       300       $ 129
Other comprehensive income (loss) (2,030)         (2,030)      
Net loss (207,298)           (207,279)   (19)
Ending Balance at Dec. 31, 2021 $ 604,102     $ 14 $ 1,324,006 $ (1,137) $ (718,891)   $ 110
Ending Balance, Shares at Dec. 31, 2021       141,393,865          
XML 37 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating activities      
Net loss $ (207,298) $ (146,227) $ (68,606)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Depreciation expense 12,254 6,769 6,093
Noncash lease expense 7,028 3,266  
Share-based compensation expense 43,251 24,761 13,124
Intangible assets amortization 1,699 1,703 1,698
Investment amortization 7,233 773 (4,463)
Fair value adjustment of convertible preferred stock warrant     2,266
Other (78) 71 359
Changes in operating assets and liabilities:      
Accounts receivable, net (7,362) 2,613 (7,817)
Inventory (5,200) (4,994) (1,231)
Prepaid expenses and other current assets 1,286 (1,362) (8,576)
Accounts payable and accrued liabilities 3,940 7,495 6,149
Deferred rent     78
Operating lease right-of-use assets and liabilities 8,522 (886)  
Deferred revenue (57,727) (43,389) 266,927
Other (275) (276) (597)
Net cash (used in) provided by operating activities (192,727) (149,683) 205,404
Investing activities      
Purchases of property and equipment (61,746) (18,803) (11,200)
Purchases of marketable securities (316,544) (694,965) (884,217)
Proceeds from sales and maturities of marketable securities 559,500 596,724 413,720
Net cash provided by (used in) investing activities 181,210 (117,044) (481,697)
Financing activities      
Proceeds from exercise of stock options 26,717 21,748 4,055
Proceeds from public offering of common stock, net of underwriting discounts and commissions   272,160 320,850
Payment of public offering costs, net   (321) (4,986)
Proceeds from issuance of common stock upon the exercise of a common stock warrant     9
Proceeds from initial capital contributions for Digital Biotechnologies, Inc. 429    
Other     (12)
Net cash provided by financing activities 27,146 293,587 319,916
Net increase in cash, cash equivalents and restricted cash 15,629 26,860 43,623
Cash, cash equivalents and restricted cash at beginning of year 125,574 98,714 55,091
Cash, cash equivalents and restricted cash at end of year 141,203 125,574 98,714
Noncash investing and financing activities      
Purchases of equipment included in accounts payable and accrued liabilities $ 682 4,679 773
Noncash additions to property through lease financing arrangements     36,607
Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases   $ 36,607  
Conversion of convertible preferred stock to common stock upon closing of initial public offering     561,931
Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering     $ 2,602
XML 38 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Organization and Description of Business
 12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Organization and Description of Business

1.

Organization and Description of Business

Adaptive Biotechnologies Corporation (“we,” “us” or “our”) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune disorders and infectious diseases.

We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.

Digital Biotechnologies, Inc.

In 2021, we formed a subsidiary, Spin Technologies, Inc., to facilitate the development of a potential new early-stage sequencing technology that is ancillary to our core business. In February 2022, the subsidiary’s name was changed to Digital Biotechnologies, Inc. We have a 70% ownership interest in Digital Biotechnologies, Inc. All intercompany transactions and balances between us and Digital Biotechnologies, Inc. have been eliminated in consolidation. The remaining interest, held by certain of our related parties and related family trusts, was reported as noncontrolling interest in our consolidated financial statements.
XML 39 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies

2.

Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, its wholly-owned subsidiary and Digital Biotechnologies, Inc. Other shareholders’ interests in Digital Biotechnologies, Inc. are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.

Cash and Cash Equivalents

Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.

Restricted Cash

We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of $2.1 million as of December 31, 2021 and 2020.

Investments in Marketable Securities

Marketable securities are classified as available-for-sale, consist of U.S. government debt securities and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders’ equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.

Concentrations of Risk

We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.

Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions.

Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.

For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:

 

 

 

Revenue

 

Accounts Receivable, Net

 

 

 

Year Ended December 31,

 

December 31,

 

 

 

2021

 

2020

 

2019

 

2021

 

2020

 

Customer A

 

*%

 

*%

 

13.9%

 

*%

 

 

19.1

%

Customer B

 

*

 

*

 

*

 

11.3

 

12.2

 

Genentech, Inc. and Roche Group

 

41.9

 

55.8

 

42.1

 

*

 

*

 

* less than 10%

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts Receivable

Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.

Additionally, we had $0.2 million and $0.9 million of unbilled receivables as of December 31, 2021 and 2020, respectively. These contract assets are amounts that will become due for which we have an unconditional right to consideration.

Inventory

Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.

Property and Equipment

Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.

Useful lives assigned to property and equipment are as follows:

Laboratory equipment

 

3 years to 7 years

Leasehold improvements

 

Shorter of estimated useful life or remaining lease term

Computer equipment and software

 

3 years to 5 years

Furniture and office equipment

 

3 years to 10 years

 

 

We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our consolidated statements of operations in accordance with the use of the asset.

Goodwill

Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our consolidated statements of operations. To date, we have not recognized any impairment of goodwill.

Intangible Assets

Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.

Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have not recognized any impairment losses on intangible assets.

Leases

We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy, as well as server space. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of Accounting Standards Update No. 2016-02, Leases (Topic 842) (“ASC 842”).

Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.

We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on our consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.

Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.

Fair Value of Financial Instruments

The Financial Accounting Standards Board (“FASB”) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:

 

•

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

•

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

•

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level 3 within the valuation hierarchy.

Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2021 and 2020.

Convertible Preferred Stock Warrant

We had issued a freestanding warrant to a venture capital firm to purchase 56,875 shares of Series C convertible preferred stock with an exercise price of $2.64 in connection with a $5.0 million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant.

Prior to the conversion, the fair value of this warrant was classified as a non-current liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders’ deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $2.3 million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our consolidated statements of operations.

When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $2.6 million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.

Revenue Recognition

We recognize revenue in accordance with ASC Topic 606 (“ASC 606”), Revenue from Contracts with Customers. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications.

Overview

Our revenue is generated from immunosequencing (“sequencing”) products and services (“sequencing revenue”) and from regulatory or development support services leveraging our immune medicine platform (“development revenue”). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price.

Sequencing Revenue

Sequencing revenue reflects the amounts generated from providing testing services through clonoSEQ to clinical and research customers, from providing our T-Detect COVID test to clinical customers and from providing sequencing services through immunoSEQ to research customers.

For clinical customers, we primarily derive revenue from providing our clonoSEQ report to ordering physicians. In these transactions, we have identified one performance obligation, the delivery of a clonoSEQ report, and we bill and receive payments from medical institutions and commercial and government third-party payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience.

For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient’s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.

For research customers, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered.

Development Revenue

We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers’ initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements include single or multiple performance obligations, depending on the contract. For certain contracts, we perform services to support the biopharmaceutical customers’ regulatory submissions as part of their registrational trials. These services may include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. If agreements include sequencing activities, we separately classify those activities as sequencing revenue.

When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers’ control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.

The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.

During the year ended December 31, 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as development revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).

Contract Balances

In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer’s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.

Share-Based Compensation

Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model.

Advertising

Advertising costs are expensed as incurred. Advertising expenses were $22.4 million, $14.5 million and $6.6 million for the year ended December 31, 2021, 2020 and 2019, respectively.

Cost of Revenue

Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs and allocated facility costs associated with processing samples and professional support for our sequencing revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.

Research and Development Expenses

Research and development expenses consist of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our Genentech Agreement are also a component of our research and development expenses.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.

Income Taxes

Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

We calculate basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders by dividing net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect is anti-dilutive.

Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders in conformity with the two-class method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is calculated by dividing the net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to Adaptive Biotechnologies Corporation common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to Adaptive Biotechnologies Corporation common shareholders was not allocated to the convertible preferred stock under the two-class method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect was anti-dilutive.

Segment Information

We have determined that our chief executive officer is the chief operating decision maker (“CODM”). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning at levels or components below the consolidated entity. As such, the consolidated entity operates as one operating segment and represents one reportable segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3, Revenue.
XML 40 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue
 12 Months Ended
Dec. 31, 2021
Revenue From Contract With Customer [Abstract]  
Revenue

3.

Revenue

We disaggregate our revenue from contracts with customers by type of service, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Sequencing revenue

 

$

78,896

 

 

$

41,439

 

 

$

43,519

 

Development revenue

 

 

 

 

 

 

 

 

 

 

 

 

Development support

 

 

65,448

 

 

 

54,443

 

 

 

39,552

 

Regulatory milestones

 

 

10,000

 

 

 

2,500

 

 

 

2,000

 

Total development revenue

 

 

75,448

 

 

 

56,943

 

 

 

41,552

 

Total revenue

 

$

154,344

 

 

$

98,382

 

 

$

85,071

 

 

 

MRD Development Agreements

We have entered into agreements with biopharmaceutical customers to further develop and commercialize our MRD product and the biopharmaceutical customers’ therapeutics. Under each of the agreements, we received or will receive non-refundable upfront payments and could receive substantial additional payments upon reaching certain progress-based milestones or achieving certain regulatory milestones pertaining to the customers’ therapeutics and our MRD product.

 

Under the contracts, we identify performance obligations, which may include: (1) obligations to provide services supporting the customer’s regulatory submission activities as they relate to our MRD product; and (2) sequencing services related to customer-provided samples for their regulatory submissions. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated immunosequencing services. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers’ own submission decision-making. We recognize revenue related to the sequencing services as sequencing revenue over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed.

We recognized $3.2 million in revenue during the year ended December 31, 2021 due to changes in estimates of total samples to be provided under certain of our MRD development agreements for which we had previously received upfront consideration, of which $0.3 million was recognized as development revenue in the respective period.

We earned $10.0 million, $2.5 million and $2.0 million during the year ended December 31, 2021, 2020 and 2019, respectively, upon the achievement of certain regulatory milestones by us and our respective customers’ therapeutics. We recognized these earnings as development revenue within the respective periods, as we determined that the amounts were consistent with our estimated standalone selling prices and the respective performance obligations were complete.

In total, we recognized $11.8 million, $3.4 million and $3.7 million in development revenue related to our MRD development agreements during the year ended December 31, 2021, 2020 and 2019, respectively.

As of December 31, 2021, in future periods we could receive up to an additional $333.5 million in milestone payments if certain regulatory approvals are obtained by our customers’ therapeutics in connection with MRD data generated from our MRD product.

Genentech Collaboration Agreement

In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (“Genentech Agreement”) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $300.0 million in February 2019 and may be eligible to receive more than $1.8 billion over time, including payments of up to $75.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones and up to $1,430.0 million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines:

 

•

Shared Products. The shared products will use “off-the-shelf” TCRs identified against cancer antigens shared among patients (“Shared Products”).

 

•

Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (“Personalized Product”).

Under the terms of the agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in ASC Topic 808, Collaborative Arrangements (“ASC 808”), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity’s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC 606 to account for the activities related to the Genentech Agreement.

In applying ASC 606, we identified the following performance obligations at the inception of the agreement:

 

1.

License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology.

 

2.

License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology.

 

3.

License to utilize all private antigen TCR product data in connection with research and development activities in the field of use.

 

4.

License to existing shared antigen data packages.

 

5.

Research and development services for shared product development, including expansion of shared antigen data packages.

 

6.

Research and development services for private product development.

 

7.

Obligations to participate on various joint research, development and project committees.

 

We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech’s control of product commercialization. Specifically, under the agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other, as opposed to both. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.

Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.

We determined the initial transaction price shall be made up of only the $300.0 million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the transaction price as of December 31, 2021. We excluded the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.

As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize the revenue over a period of approximately seven to eight years from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and the Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.

We recognized revenue of $62.0 million, $52.8 million and $35.1 million during the year ended December 31, 2021, 2020 and 2019, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.
XML 41 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

4.

Fair Value Measurements

The following tables set forth the fair value of financial assets as of December 31, 2021 and 2020 that were measured at fair value on a recurring basis (in thousands):

 

 

December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

131,946

 

 

$

—

 

 

$

—

 

 

$

131,946

 

U.S. government debt securities

 

 

—

 

 

 

391,145

 

 

 

—

 

 

 

391,145

 

Corporate bonds

 

 

—

 

 

 

39,996

 

 

 

—

 

 

 

39,996

 

Total financial assets

 

$

131,946

 

 

$

431,141

 

 

$

—

 

 

$

563,087

 

 

 

 

December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

103,283

 

 

$

—

 

 

$

—

 

 

$

103,283

 

U.S. government debt securities

 

 

—

 

 

 

671,777

 

 

 

—

 

 

 

671,777

 

Corporate bonds

 

 

—

 

 

 

11,581

 

 

 

—

 

 

 

11,581

 

Total financial assets

 

$

103,283

 

 

$

683,358

 

 

$

—

 

 

$

786,641

 

 

Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government debt securities and corporate bonds, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.
XML 42 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments
 12 Months Ended
Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]  
Investments

5.

Investments

Available-for-sale investments consisted of the following as of December 31, 2021 and 2020 (in thousands):

 

 

 

December 31, 2021

 

 

 

Amortized Cost

 

 

Unrealized Gain

 

 

Unrealized Loss

 

 

Estimated Fair Value

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

186,752

 

 

$

4

 

 

$

(109

)

 

$

186,647

 

Corporate bonds

 

 

27,363

 

 

 

—

 

 

 

(14

)

 

 

27,349

 

Total short-term marketable securities

 

$

214,115

 

 

$

4

 

 

$

(123

)

 

$

213,996

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

205,472

 

 

$

—

 

 

$

(974

)

 

$

204,498

 

Corporate bonds

 

 

12,691

 

 

 

—

 

 

 

(44

)

 

 

12,647

 

Total long-term marketable securities

 

$

218,163

 

 

$

—

 

 

$

(1,018

)

 

$

217,145

 

 

 

 

December 31, 2020

 

 

 

Amortized Cost

 

 

Unrealized Gain

 

 

Unrealized Loss

 

 

Estimated Fair Value

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

552,539

 

 

$

723

 

 

$

(10

)

 

$

553,252

 

Corporate bonds

 

 

11,497

 

 

 

86

 

 

 

(2

)

 

 

11,581

 

Total short-term marketable securities

 

$

564,036

 

 

$

809

 

 

$

(12

)

 

$

564,833

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

118,429

 

 

$

98

 

 

$

(2

)

 

$

118,525

 

Total long-term marketable securities

 

$

118,429

 

 

$

98

 

 

$

(2

)

 

$

118,525

 

 

All the U.S. government debt securities and corporate bonds designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective consolidated balance sheet date.

Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of $1.4 million and $2.5 million were presented separately within the prepaid expenses and other current assets line item on our consolidated balance sheet as of December 31, 2021 and 2020, respectively.

The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2021 (in thousands):

 

 

 

Less Than 12 Months

 

 

12 Months Or Greater

 

 

 

Fair Value

 

 

Unrealized Loss

 

 

Fair Value

 

 

Unrealized Loss

 

U.S. government debt securities

 

$

345,014

 

 

$

(1,083

)

 

$

—

 

 

$

—

 

Corporate bonds

 

 

32,886

 

 

 

(58

)

 

 

—

 

 

 

—

 

Total available-for-sale securities

 

$

377,900

 

 

$

(1,141

)

 

$

—

 

 

$

—

 

 

We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.

As of December 31, 2021, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2021 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.
XML 43 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment, Net
 12 Months Ended
Dec. 31, 2021
Property Plant And Equipment [Abstract]  
Property and Equipment, Net

6.

Property and Equipment, Net

Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Laboratory equipment

 

$

36,312

 

 

$

27,767

 

Computer equipment

 

 

6,988

 

 

 

3,600

 

Furniture and office equipment

 

 

5,579

 

 

 

2,717

 

Computer software

 

 

992

 

 

 

860

 

Construction in progress

 

 

5,658

 

 

 

7,185

 

Leasehold improvements

 

 

65,959

 

 

 

21,945

 

Property and equipment, at cost

 

 

121,488

 

 

 

64,074

 

Less: Accumulated depreciation

 

 

(36,226

)

 

 

(24,382

)

Property and equipment, net

 

$

85,262

 

 

$

39,692

 

 

Depreciation expense was $12.3 million, $6.8 million and $6.1 million for the year ended December 31, 2021, 2020 and 2019, respectively.
XML 44 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets

7.

Goodwill and Intangible Assets

There have been no changes in the carrying amount of goodwill since its recognition in 2015.

Intangible assets subject to amortization as of December 31, 2021 and 2020 consisted of the following (in thousands):

 

 

 

December 31, 2021

 

 

 

Gross Carrying Amount

 

 

Accumulated Amortization

 

 

Net Carrying Amount

 

Acquired developed technology

 

$

20,000

 

 

$

(11,638

)

 

$

8,362

 

Purchased intellectual property

 

 

325

 

 

 

(161

)

 

 

164

 

Balance at December 31, 2021

 

$

20,325

 

 

$

(11,799

)

 

$

8,526

 

 

 

 

December 31, 2020

 

 

 

Gross Carrying Amount

 

 

Accumulated Amortization

 

 

Net Carrying Amount

 

Acquired developed technology

 

$

20,000

 

 

$

(9,972

)

 

$

10,028

 

Purchased intellectual property

 

 

325

 

 

 

(128

)

 

 

197

 

Balance at December 31, 2020

 

$

20,325

 

 

$

(10,100

)

 

$

10,225

 

 

The developed technology was acquired in connection with our acquisition of Sequenta in 2015. The remaining balance of the acquired technology and the purchased intellectual property is expected to be amortized over the next 5.0 years.

 

As of December 31, 2021, expected future amortization expense for intangible assets was as follows (in thousands):

 

 

2022

 

$

1,699

 

2023

 

 

1,699

 

2024

 

 

1,703

 

2025

 

 

1,699

 

2026

 

 

1,699

 

Thereafter

 

 

27

 

Total future amortization expense

 

$

8,526

 
XML 45 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Liabilities
 12 Months Ended
Dec. 31, 2021
Payables And Accruals [Abstract]  
Accrued Liabilities

8.

Accrued Liabilities

Accrued liabilities as of December 31, 2021 and 2020 consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Professional fees

 

$

3,687

 

 

$

3,219

 

Clinical and contract research organization costs

 

 

1,646

 

 

 

1,781

 

Travel and entertainment

 

 

184

 

 

 

91

 

Tax liabilities

 

 

391

 

 

 

1,767

 

Purchases of property and equipment

 

 

615

 

 

 

4,423

 

Other

 

 

2,820

 

 

 

1,881

 

Total accrued liabilities

 

$

9,343

 

 

$

13,162

 

The accrued tax liabilities balance as of December 31, 2020 includes a $1.4 million tax withholding liability related to unsettled option exercises as of December 31, 2020.
XML 46 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Deferred Revenue
 12 Months Ended
Dec. 31, 2021
Revenue From Contract With Customer [Abstract]  
Deferred Revenue

9.

Deferred Revenue

Deferred revenue by revenue classification as of December 31, 2021 and 2020 was as follows (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Current deferred revenue

 

 

 

 

 

 

 

 

Sequencing

 

$

21,915

 

 

$

15,463

 

Development

 

 

58,545

 

 

 

57,856

 

Total current deferred revenue

 

 

80,460

 

 

 

73,319

 

Non-current deferred revenue

 

 

 

 

 

 

 

 

Sequencing

 

 

174

 

 

 

724

 

Development

 

 

98,576

 

 

 

162,894

 

Total non-current deferred revenue

 

 

98,750

 

 

 

163,618

 

Total current and non-current deferred revenue

 

$

179,210

 

 

$

236,937

 

Deferred revenue from our Genentech Agreement represents $56.1 million and $94.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2021 and $55.1 million and $157.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2020. In general, we expect that the current amounts will be recognized as revenue within 12 months and the non-current amounts will be recognized as revenue over a period of approximately five to six years from December 31, 2021. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various development activities.

During the year ended December 31, 2021, we recognized $3.6 million in revenue as a result of changes in estimates of total samples to be provided under certain of our agreements and cancelled biopharmaceutical customer sequencing contracts for which we had received upfront consideration. Additionally, we recognized $2.5 million of sequencing revenue during the year ended December 31, 2021 related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and a change in our estimate of expected cumulative tests per patient for one of our covered indications.

Changes in deferred revenue during the year ended December 31, 2021 were as follows (in thousands):

 

Deferred revenue balance at December 31, 2020

 

$

236,937

 

Additions to deferred revenue during the period

 

 

38,062

 

Revenue recognized during the period

 

 

(95,789

)

Deferred revenue balance at December 31, 2021

 

$

179,210

 

As of December 31, 2021, $75.7 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2020.
XML 47 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases
 12 Months Ended
Dec. 31, 2021
Lessee Disclosure [Abstract]  
Leases

10.

Leases

We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy in various locations, as well as server space.

In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately 65,500 square feet. Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years. The amended lease also requires us to pay additional amounts for operating and maintenance expenses.

In August 2019, we entered into an agreement to rent approximately 100,000 square feet in what was a to-be-constructed, new headquarters building in Seattle, Washington. In connection with the lease, we entered into a $2.1 million letter of credit with one of our existing financial institutions. Due to our significant involvement during the construction process of the leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance that proceeded ASC 842. The resulting asset and long-term financing obligation recorded on our balance sheet as of December 31, 2019 for the cost of the building was derecognized effective January 1, 2020 upon adoption of ASC 842. The lease commenced in December 2020, when the landlord delivered the premises to us for construction of certain tenant improvements. We occupied the new building in 2021, cash payment for rent began in October 2021 and the lease term ends in August 2033, subject to our option to twice extend the lease for five years. In connection with this lease, the landlord agreed to fund $20.0 million in improvements, which was subsequently reduced to $14.8 million as a result of our change requests made during landlord construction of the building, net of an administration fee. As of December 31, 2021, we have incurred $14.9 million in certain tenant improvement costs, of which $10.9 million has been reimbursed by the landlord. The remaining $4.0 million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on our consolidated balance sheet as of December 31, 2021 and will be reimbursed by the landlord. As of December 31, 2020, we incurred $5.2 million in certain tenant improvement costs, of which $0.7 million had been reimbursed by the landlord. The remaining $4.5 million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on our consolidated balance sheet as of December 31, 2020. The lease also requires us to pay additional amounts for operating and maintenance expenses.

In October 2019, we entered into an agreement to lease approximately 14,750 square feet in a separate Seattle, Washington location, pursuant to a lease expiring in October 2029, which is subject to our ability to exercise an early termination right after the third year. In connection with the lease, the landlord agreed to provide a tenant improvement allowance in the maximum amount of $0.7 million. The lease also requires us to pay additional amounts for operating expenses.

In April 2018, we entered into a lease agreement to lease approximately 13,400 square feet in South San Francisco, California. The lease term is through March 2026 and provides for one five-year extension option. We are responsible for our share of allocable operating expenses, tax expenses and utilities cost during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $2.4 million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately 19,900 additional square feet and provides for a $0.6 million tenant improvement allowance.

In December 2019, we entered into an agreement to lease approximately 3,100 square feet of office space in New York City, New York, pursuant to a lease that expires November 2025, subject to our ability to exercise an early termination right in 2023. The lease requires us to pay certain operating expenses.

In March 2021, we executed a lease to rent approximately 27,000 square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the year ended December 31, 2021. Rent obligations commenced in October 2021 and the lease expires October 2031, subject to an early termination option after the seventh year and an option to twice extend the lease for five years. The lease requires us to pay certain operating expenses. Furthermore, the landlord agreed to fund $1.2 million in improvements in connection with this lease.

As of December 31, 2021, we were not party to any finance leases. Our leases have remaining terms of 0.3 years to 11.7 years and include options to extend certain of the leases up to 10.0 years and terminate certain of the leases after 3.0 years. We adjust lease terms for these options only when it is reasonably certain we will exercise these options. As of December 31, 2021, it was reasonably certain that we would exercise our option to terminate two of our leases after 3.0 years.

Other information related to our operating leases as of December 31, 2021 and 2020 was as follows:

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Weighted-average remaining lease term (in years)

 

 

10.55

 

 

 

11.33

 

Weighted-average discount rate

 

 

4.6

%

 

 

4.6

%

 

The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of December 31, 2021 (in thousands):

 

2022

 

$

14,184

 

2023

 

 

13,964

 

2024

 

 

13,692

 

2025

 

 

14,098

 

2026

 

 

12,330

 

Thereafter

 

 

81,188

 

Total undiscounted lease payments

 

 

149,456

 

Less:

 

 

 

 

   Imputed interest rate

 

 

(32,410

)

   Tenant improvement receivables

 

 

(5,306

)

Total operating lease liabilities

 

$

111,740

 

Less: Current portion

 

 

(5,055

)

Operating lease liabilities, less current portion

 

$

106,685

 

 

Operating lease expense was $12.4 million and $5.5 million for the year ended December 31, 2021 and 2020, respectively. Variable lease expense for operating leases was $3.5 million and $2.6 million for the year ended December 31, 2021 and 2020, respectively. Rent expense recognized under ASC 840, Leases, inclusive of operating and maintenance costs, was $5.3 million for the year ended December 31, 2019.

Cash paid for amounts included in the measurement of lease liabilities was $8.3 million and cash received for tenant improvement allowances was $11.5 million during the year ended December 31, 2021. Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2020 was $3.2 million, net of $2.5 million of cash received for tenant improvement allowances. For the year ended December 31, 2021, ROU assets obtained in exchange for operating lease liabilities was $5.4 million. For the year ended December 31, 2020, ROU assets obtained in exchange for operating lease liabilities was $109.1 million, inclusive of the $33.0 million recognized from the adoption of ASC 842.
XML 48 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

11.

Commitments and Contingencies

Legal Proceedings

We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2021.

Indemnification Agreements

In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.

 
XML 49 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Shareholders' Equity

12.

Shareholders’ Equity

Common Stock

Our common stock has no preferences or privileges and is not redeemable. Holders of our common stock are entitled to one vote for each share of common stock held. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time.

As of December 31, 2021, we have reserved shares of common stock for the following:

 

Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted

 

 

13,990,175

 

Shares available for future grant under the 2019 Equity Incentive Plan

 

 

22,299,923

 

Shares available for future grant under the Employee Stock Purchase Plan

 

 

2,804,298

 

Total shares of common stock reserved for future issuance

 

 

39,094,396

 

Our 2019 Equity Incentive Plan (“2019 Plan”) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.

Furthermore, our Employee Stock Purchase Plan (“ESPP”) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.

Effective January 1, 2021, our 2019 Plan reserve increased by 6,882,344 shares. Our board of directors determined not to increase the ESPP reserve in 2021. Furthermore, our board of directors determined not to increase the 2019 Plan and ESPP reserves in 2022.

Common Stock Warrant

In 2014, we issued a warrant to purchase 56,875 shares of Series C convertible preferred stock at an exercise price of $2.64. The warrant was exercisable for a period of seven years from the date of issuance. Immediately prior to and in connection with the completion of our initial public offering on July 1, 2019, this convertible preferred stock warrant was converted to a warrant to purchase the same number of shares of common stock. The warrant was exercised on February 25, 2021 through a cashless exercise, resulting in the issuance of 54,162 shares of our common stock. The impact of this cashless exercise was immaterial to our consolidated financial statements. As of December 31, 2021, there were no outstanding warrants to purchase common stock.
XML 50 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans
 12 Months Ended
Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Equity Incentive Plans

13.

Equity Incentive Plans

Sequenta 2008 Stock Plan, as amended

In connection with our acquisition of Sequenta in January 2015, we assumed Sequenta’s Equity Incentive Plan (“2008 Plan”), including all outstanding options and shares available for future issuance under the 2008 Plan, which, prior to the completion of our initial public offering, were all exercisable for Series E-1 convertible preferred stock. Upon completion of our initial public offering in July 2019, the outstanding options were exercisable for common stock. No shares are available for future issuance under this plan and no equity awards are outstanding under this plan as of December 31, 2021.

Adaptive 2009 Equity Incentive Plan

We adopted an equity incentive plan in 2009 (“2009 Plan”) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the option exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Options granted under this plan expire no later than ten years from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While no shares are available for future issuance under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.

2019 Equity Incentive Plan

The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, options granted under this plan expire no later than ten years from the grant date and vesting is established at the time of grant. Except for certain option and restricted stock unit grants made to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a four-year period, subject to continuous service through each applicable vesting date. As of December 31, 2021, we have authorized 29,131,628 shares of common stock for issuance under the 2019 Plan.

Changes in shares available for grant during the year ended December 31, 2021 were as follows:

 

 

 

Shares Available for Grant

 

Shares available for grant at December 31, 2020

 

 

18,617,001

 

2019 Equity Incentive Plan reserve increase effective January 1, 2021

 

 

6,882,344

 

Options and restricted stock units granted

 

 

(4,306,265

)

Options and restricted stock units forfeited, cancelled or expired

 

 

1,106,843

 

Shares available for grant at December 31, 2021

 

 

22,299,923

 

 

Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2021 was as follows:

 

 

 

Shares Subject to

Outstanding Options

 

 

Weighted-Average Exercise

Price per Share

 

 

Aggregate Intrinsic Value

(in thousands)

 

Options outstanding at December 31, 2020

 

 

14,433,560

 

 

$

12.82

 

 

 

 

 

Options granted

 

 

3,052,025

 

 

 

39.39

 

 

 

 

 

Options forfeited or cancelled

 

 

(992,428

)

 

 

25.90

 

 

 

 

 

Options expired

 

 

(40,116

)

 

 

26.56

 

 

 

 

 

Options exercised

 

 

(3,674,057

)

 

 

7.21

 

 

 

 

 

Options outstanding at December 31, 2021

 

 

12,778,984

 

 

$

19.72

 

 

$

156,105

 

Options vested and exercisable at December 31, 2021

 

7,281,600

 

 

$

10.99

 

 

$

132,537

 

 

The weighted-average remaining contractual life for options outstanding as of December 31, 2021 was 7.0 years. The weighted-average remaining contractual life for vested and exercisable options as of December 31, 2021 was 5.7 years.

The weighted-average grant date fair value per share of options granted during the year ended December 31, 2021, 2020 and 2019 was $24.22, $21.11 and $6.87, respectively. The total intrinsic value of options exercised during the year ended December 31, 2021, 2020 and 2019 was $156.5 million, $190.4 million and $39.1 million, respectively.

Of the $26.7 million proceeds from exercise of stock options included on our consolidated statements of cash flows for the year ended December 31, 2021, $0.3 million related to options exercised during the year ended December 31, 2020 but settled during the year ended December 31, 2021. Of the $21.7 million proceeds from exercise of stock options included on our consolidated statements of cash flows for the year ended December 31, 2020, $0.5 million related to options exercised during the year ended December 31, 2019 but settled during the year ended December 31, 2020.

Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2021 was as follows:

 

 

 

Restricted Stock Units

Outstanding

 

 

Weighted-Average Grant Date

Fair Value per Share

 

Nonvested outstanding restricted stock units at December 31, 2020

 

 

50,000

 

 

$

28.10

 

Restricted stock units granted

 

 

1,254,240

 

 

 

37.98

 

Restricted stock units forfeited or cancelled

 

 

(74,299

)

 

 

43.20

 

Restricted stock units vested

 

 

(18,750

)

 

 

28.10

 

Nonvested outstanding restricted stock units at December 31, 2021

 

 

1,211,191

 

 

$

37.41

 

 

The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2020 and 2019 was $28.10 and $41.63, respectively.

Grant Date Fair Value of Options and Restricted Stock Units Granted

The estimated grant date fair values of options granted during the years ended December 31, 2021, 2020 and 2019 were estimated using the Black-Scholes option-pricing model with the following assumptions:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Fair value of common stock

 

$30.86 - $66.50

 

 

$17.68 - $55.23

 

 

$7.80 - $47.81

 

Expected term (in years)

 

5.27 - 6.08

 

 

5.27 - 6.08

 

 

5.27 - 6.08

 

Risk-free interest rate

 

0.5% - 1.4%

 

 

0.4% - 1.7%

 

 

1.4% - 2.5%

 

Expected volatility

 

67.1% - 70.0%

 

 

70.5% - 73.3%

 

 

64.3% - 72.9%

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 

The determination of the grant date fair value of stock options using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:

Fair value of common stock—Prior to the closing of our initial public offering, the fair value of our common stock was determined with input from management using valuation methodologies which utilized certain assumptions, including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of our common stock, the methodologies, approaches and assumptions used to estimate the enterprise value were consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. For option grants made after the closing of our initial public offering, the fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.

Expected term—The expected term of options granted to employees and non-employee directors is determined using the “simplified” method, as illustrated in ASC Topic 718, Compensation—Stock Compensation, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is based on the midpoint between the vesting date and the end of the contractual term of the option.

Risk-free interest rate—We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the options.

Expected volatility—As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term.

Expected dividend yield—We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of zero in the option valuation model.

The grant date fair value of restricted stock units granted is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.

The compensation costs related to stock options and restricted stock units for the years ended December 31, 2021, 2020 and 2019 are included on our consolidated statements of operations as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of revenue

 

$

2,100

 

 

$

817

 

 

$

555

 

Research and development

 

 

14,061

 

 

 

8,519

 

 

 

3,934

 

Sales and marketing

 

 

12,312

 

 

 

6,627

 

 

 

3,480

 

General and administrative

 

 

14,778

 

 

 

8,798

 

 

 

5,155

 

Total share-based compensation expense

 

$

43,251

 

 

$

24,761

 

 

$

13,124

 

 

As of December 31, 2021, unrecognized share-based compensation expense related to unvested stock options was $96.8 million, which is expected to be recognized over a remaining weighted-average period of 2.9 years. Additionally, as of December 31, 2021, unrecognized share-based compensation expense related to unvested restricted stock units was $38.3 million, which is expected to be recognized over a remaining weighted-average period of 3.4 years.
XML 51 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Microsoft Collaboration Agreement
 12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Microsoft Collaboration Agreement

14.

Microsoft Collaboration Agreement

Summary of Agreement

In December 2017, we entered into a collaboration agreement with Microsoft (“Microsoft Agreement”) to computationally derive a comprehensive TCR antigen map for purposes of developing a universal diagnostic based on a single blood test.

Contemporaneously with the Microsoft Agreement, we entered into a separate agreement to use Microsoft’s Azure cloud services at standard volume pricing with a minimum Azure purchase requirement of $12.0 million over the seven-year term of the Microsoft Agreement, which we expect to meet in the ordinary course of business.

In addition, contemporaneously with entering into the Microsoft Agreement, Microsoft made a preferred stock investment of $45.0 million as a part of our Series F-1 convertible preferred stock issuance.

Summary of Accounting

The terms of the Microsoft Agreement meet the criteria under ASC Topic 808, Collaborative Arrangements (“ASC 808”), as both parties are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity. ASC 808 does not provide guidance on how to account for the activities under the collaboration and we determined that Microsoft did not meet the definition of a customer under ASC 606. Accordingly, we looked to other guidance to determine the accounting for the respective elements.

We determined that the preferred stock issuance and commitment to use Microsoft’s Azure cloud services were made at terms consistent with market rates. All consideration received as part of the Series F-1 convertible preferred stock issuance was accounted for as part of the Series F-1 preferred stock issuance. Since the commitment to purchase Microsoft’s Azure cloud services was at market terms and we expect to meet the commitment in the ordinary course of business during the seven-year term, we record the expenses in the period in which the services are consumed. These costs are recorded in our consolidated statements of operations based on the underlying activities for which they support.

The remaining elements of the agreement were highly interrelated, so we evaluated them in the aggregate to determine the appropriate accounting application. Specifically, we determined that the transfer of license rights between the parties, our commitment to provide data and immunomics, diagnostic and bioinformatics expertise to Microsoft and Microsoft’s commitment to provide machine learning software and related development services to us were highly interrelated because they were necessary for the parties to perform the activities under the Microsoft Agreement and, therefore, should be evaluated as one unit of account.

We accounted for these collaboration activities by analogy to ASC Topic 845, Nonmonetary Transactions, and determined that major uncertainties exist about the realizability of the value that would be assigned to an asset received from or provided to Microsoft under the collaboration and, therefore, fair value could not be reliably measured. As a result, we did not recognize any non-monetary assets or corresponding non-monetary income or expenses pertaining to the rights provided to us or to be received by us under the Microsoft Agreement.
XML 52 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

15.

Income Taxes

The components of loss before provision for income taxes for the periods presented are as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Domestic

 

$

(207,314

)

 

$

(146,227

)

 

$

(68,606

)

Foreign

 

 

16

 

 

 

—

 

 

 

—

 

Total loss before provision for income taxes

 

$

(207,298

)

 

$

(146,227

)

 

$

(68,606

)

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of our deferred tax assets and liabilities as of the dates presented are as follows (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets

 

 

 

 

 

 

 

 

Net operating losses

 

$

200,363

 

 

$

105,433

 

Tax credit carryforward

 

 

31,200

 

 

 

18,981

 

Nonqualifying stock options

 

 

18,072

 

 

 

12,096

 

Deferred rent

 

 

—

 

 

 

—

 

Operating lease liabilities

 

 

30,401

 

 

 

31,052

 

Deferred revenue

 

 

42,481

 

 

 

59,713

 

Other

 

 

4,345

 

 

 

2,983

 

Total deferred tax assets

 

 

326,862

 

 

 

230,258

 

Less: Valuation allowance

 

 

(297,020

)

 

 

(197,527

)

Deferred tax assets, net of valuation allowance

 

 

29,842

 

 

 

32,731

 

Deferred tax liabilities

 

 

 

 

 

 

 

 

Tangible and intangible assets

 

 

(7,310

)

 

 

(5,760

)

ROU assets

 

 

(22,532

)

 

 

(26,971

)

Net deferred taxes

 

$

—

 

 

$

—

 

 

ASC Topic 740, Income Taxes, requires that the tax benefit of NOLs, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $99.5 million and $96.6 million during the year ended December 31, 2021 and 2020, respectively.

Federal tax laws impose substantial restrictions on the utilization of NOL and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through December 31, 2020 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the TCJA federal income tax law, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years. As of December 31, 2021, we had U.S. federal NOLs of $192.5 million and U.S. federal tax credits of $33.6 million that will begin to expire in 2028. We also had $576.2 million of NOLs as of December 31, 2021 that do not expire.

The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:

 

 

 

Year Ended December 31,

 

 

2021

 

2020

 

2019

Statutory rate

 

21.0%

 

21.0%

 

21.0%

State tax, net of federal tax benefit

 

8.3

 

13.8

 

8.1

Stock compensation

 

14.1

 

25.2

 

9.8

Permanent items

 

(0.1)

 

(0.1)

 

(1.0)

Credits

 

4.7

 

5.7

 

6.1

Other

 

(0.3)

 

0.5

 

0.3

Change in valuation allowance

 

(47.7)

 

(66.1)

 

(44.3)

Total

 

0.0%

 

0.0%

 

0.0%

 

 

We account for Global Intangible Low-Taxed Income as period costs when incurred.

We recognize, in our consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $6.9 million as of December 31, 2021. A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):

 

Balance at December 31, 2018

 

$

1,260

 

Additions in 2019

 

 

792

 

Balance at December 31, 2019

 

 

2,052

 

Additions in 2020

 

 

1,437

 

Balance at December 31, 2020

 

 

3,489

 

Additions in 2021

 

 

3,426

 

Balance at December 31, 2021

 

$

6,915

 

 

During the year ended December 31, 2021, 2020 and 2019, we recognized uncertain tax positions of $3.4 million, $1.4 million and $0.8 million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.

We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had no accrued interest or penalties related to uncertain tax positions as of December 31, 2021 and 2020.

We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.
XML 53 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

16.

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019 (in thousands, except share and per share amounts):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

$

(207,279

)

 

$

(146,227

)

 

$

(68,606

)

Fair value adjustment to redemption value for Series E-1 convertible preferred stock options

 

 

—

 

 

 

—

 

 

 

(964

)

Net loss attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(207,279

)

 

$

(146,227

)

 

$

(69,570

)

Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

 

140,354,915

 

 

 

131,216,468

 

 

 

69,165,315

 

Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(1.48

)

 

$

(1.11

)

 

$

(1.01

)

 

 

Since we were in a loss position for all periods presented, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is the same as diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019, as they had an anti-dilutive effect:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock (on as if converted basis)

 

 

—

 

 

 

—

 

 

 

46,104,469

 

Stock options issued and outstanding

 

 

13,097,374

 

 

 

16,125,548

 

 

 

17,183,546

 

Nonvested restricted stock units

 

 

693,173

 

 

 

38,125

 

 

 

4,952

 

Common stock warrants

 

 

8,570

 

 

 

56,875

 

 

 

55,961

 

Convertible preferred stock warrant

 

 

—

 

 

 

—

 

 

 

28,204

 

Total

 

 

13,799,117

 

 

 

16,220,548

 

 

 

63,377,132

 

 

 
XML 54 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Retirement Plan
 12 Months Ended
Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]  
Retirement Plan

17.

Retirement Plan

We maintain a salary deferral 401(k) plan (“401(k) Plan”) covering employees who have met certain eligibility requirements. Employees may defer up to 100% of their compensation to the 401(k) Plan, subject to federal limits. We made $2.5 million and $1.6 million in discretionary contributions during the year ended December 31, 2021 and 2020, respectively, which are fully vested after one year of employee service. We did not make any discretionary contributions during the year ended December 31, 2019.

 
XML 55 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, its wholly-owned subsidiary and Digital Biotechnologies, Inc. Other shareholders’ interests in Digital Biotechnologies, Inc. are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.
Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.
Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.
Restricted Cash

Restricted Cash

We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of $2.1 million as of December 31, 2021 and 2020.
Investments in Marketable Securities

Marketable securities are classified as available-for-sale, consist of U.S. government debt securities and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders’ equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.
Concentrations of Risk

Concentrations of Risk

We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.

Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions.

Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.

For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:

 

 

 

Revenue

 

Accounts Receivable, Net

 

 

 

Year Ended December 31,

 

December 31,

 

 

 

2021

 

2020

 

2019

 

2021

 

2020

 

Customer A

 

*%

 

*%

 

13.9%

 

*%

 

 

19.1

%

Customer B

 

*

 

*

 

*

 

11.3

 

12.2

 

Genentech, Inc. and Roche Group

 

41.9

 

55.8

 

42.1

 

*

 

*

 

* less than 10%

 

 

 

 

 

 

 

 

 

 

 

 

 
Accounts Receivable

Accounts Receivable

Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.

Additionally, we had $0.2 million and $0.9 million of unbilled receivables as of December 31, 2021 and 2020, respectively. These contract assets are amounts that will become due for which we have an unconditional right to consideration.
Inventory

Inventory

Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.
Property and Equipment

Property and Equipment

Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.

Useful lives assigned to property and equipment are as follows:

Laboratory equipment

 

3 years to 7 years

Leasehold improvements

 

Shorter of estimated useful life or remaining lease term

Computer equipment and software

 

3 years to 5 years

Furniture and office equipment

 

3 years to 10 years

 

 

We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our consolidated statements of operations in accordance with the use of the asset.
Goodwill

Goodwill

Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our consolidated statements of operations. To date, we have not recognized any impairment of goodwill.
Intangible Assets

Intangible Assets

Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.

Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have not recognized any impairment losses on intangible assets.
Leases

Leases

We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy, as well as server space. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of Accounting Standards Update No. 2016-02, Leases (Topic 842) (“ASC 842”).

Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.

We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on our consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.

Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Financial Accounting Standards Board (“FASB”) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:

 

•

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

•

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

•

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level 3 within the valuation hierarchy.

Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2021 and 2020.
Convertible Preferred Stock Warrant

Convertible Preferred Stock Warrant

We had issued a freestanding warrant to a venture capital firm to purchase 56,875 shares of Series C convertible preferred stock with an exercise price of $2.64 in connection with a $5.0 million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant.

Prior to the conversion, the fair value of this warrant was classified as a non-current liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders’ deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $2.3 million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our consolidated statements of operations.

When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $2.6 million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.
Revenue Recognition

Revenue Recognition

We recognize revenue in accordance with ASC Topic 606 (“ASC 606”), Revenue from Contracts with Customers. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications.

Overview

Our revenue is generated from immunosequencing (“sequencing”) products and services (“sequencing revenue”) and from regulatory or development support services leveraging our immune medicine platform (“development revenue”). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price.

Sequencing Revenue

Sequencing revenue reflects the amounts generated from providing testing services through clonoSEQ to clinical and research customers, from providing our T-Detect COVID test to clinical customers and from providing sequencing services through immunoSEQ to research customers.

For clinical customers, we primarily derive revenue from providing our clonoSEQ report to ordering physicians. In these transactions, we have identified one performance obligation, the delivery of a clonoSEQ report, and we bill and receive payments from medical institutions and commercial and government third-party payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience.

For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient’s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.

For research customers, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered.

Development Revenue

We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers’ initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements include single or multiple performance obligations, depending on the contract. For certain contracts, we perform services to support the biopharmaceutical customers’ regulatory submissions as part of their registrational trials. These services may include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. If agreements include sequencing activities, we separately classify those activities as sequencing revenue.

When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers’ control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.

The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.

During the year ended December 31, 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as development revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).
Contract Balances

Contract Balances

In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer’s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.
Share-Based Compensation

Share-Based Compensation

Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model.

Advertising

Advertising

Advertising costs are expensed as incurred. Advertising expenses were $22.4 million, $14.5 million and $6.6 million for the year ended December 31, 2021, 2020 and 2019, respectively.
Cost of Revenue

Cost of Revenue

Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs and allocated facility costs associated with processing samples and professional support for our sequencing revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.
Research and Development Expenses

Research and Development Expenses

Research and development expenses consist of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our Genentech Agreement are also a component of our research and development expenses.
Sales and Marketing Expenses

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.
Income Taxes

Income Taxes

Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

We calculate basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders by dividing net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect is anti-dilutive.

Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders in conformity with the two-class method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is calculated by dividing the net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to Adaptive Biotechnologies Corporation common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to Adaptive Biotechnologies Corporation common shareholders was not allocated to the convertible preferred stock under the two-class method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect was anti-dilutive.
Segment Information

Segment Information

We have determined that our chief executive officer is the chief operating decision maker (“CODM”). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning at levels or components below the consolidated entity. As such, the consolidated entity operates as one operating segment and represents one reportable segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3, Revenue.
XML 56 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of Concentrations of Risk Percentage

For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:

 

 

 

Revenue

 

Accounts Receivable, Net

 

 

 

Year Ended December 31,

 

December 31,

 

 

 

2021

 

2020

 

2019

 

2021

 

2020

 

Customer A

 

*%

 

*%

 

13.9%

 

*%

 

 

19.1

%

Customer B

 

*

 

*

 

*

 

11.3

 

12.2

 

Genentech, Inc. and Roche Group

 

41.9

 

55.8

 

42.1

 

*

 

*

 

* less than 10%

 

 

 

 

 

 

 

 

 

 

 

 
Summary of Useful Lives Assigned to Property and Equipment

Useful lives assigned to property and equipment are as follows:

Laboratory equipment

 

3 years to 7 years

Leasehold improvements

 

Shorter of estimated useful life or remaining lease term

Computer equipment and software

 

3 years to 5 years

Furniture and office equipment

 

3 years to 10 years
XML 57 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue From Contract With Customer [Abstract]  
Schedule of Revenue Disaggregated by Type of Products and Services The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Sequencing revenue

 

$

78,896

 

 

$

41,439

 

 

$

43,519

 

Development revenue

 

 

 

 

 

 

 

 

 

 

 

 

Development support

 

 

65,448

 

 

 

54,443

 

 

 

39,552

 

Regulatory milestones

 

 

10,000

 

 

 

2,500

 

 

 

2,000

 

Total development revenue

 

 

75,448

 

 

 

56,943

 

 

 

41,552

 

Total revenue

 

$

154,344

 

 

$

98,382

 

 

$

85,071

 

 

 
XML 58 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables set forth the fair value of financial assets as of December 31, 2021 and 2020 that were measured at fair value on a recurring basis (in thousands):

 

 

December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

131,946

 

 

$

—

 

 

$

—

 

 

$

131,946

 

U.S. government debt securities

 

 

—

 

 

 

391,145

 

 

 

—

 

 

 

391,145

 

Corporate bonds

 

 

—

 

 

 

39,996

 

 

 

—

 

 

 

39,996

 

Total financial assets

 

$

131,946

 

 

$

431,141

 

 

$

—

 

 

$

563,087

 

 

 

 

December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

103,283

 

 

$

—

 

 

$

—

 

 

$

103,283

 

U.S. government debt securities

 

 

—

 

 

 

671,777

 

 

 

—

 

 

 

671,777

 

Corporate bonds

 

 

—

 

 

 

11,581

 

 

 

—

 

 

 

11,581

 

Total financial assets

 

$

103,283

 

 

$

683,358

 

 

$

—

 

 

$

786,641

 

 
XML 59 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments (Tables)
 12 Months Ended
Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]  
Schedule of Available-for-sale Investments

Available-for-sale investments consisted of the following as of December 31, 2021 and 2020 (in thousands):

 

 

 

December 31, 2021

 

 

 

Amortized Cost

 

 

Unrealized Gain

 

 

Unrealized Loss

 

 

Estimated Fair Value

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

186,752

 

 

$

4

 

 

$

(109

)

 

$

186,647

 

Corporate bonds

 

 

27,363

 

 

 

—

 

 

 

(14

)

 

 

27,349

 

Total short-term marketable securities

 

$

214,115

 

 

$

4

 

 

$

(123

)

 

$

213,996

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

205,472

 

 

$

—

 

 

$

(974

)

 

$

204,498

 

Corporate bonds

 

 

12,691

 

 

 

—

 

 

 

(44

)

 

 

12,647

 

Total long-term marketable securities

 

$

218,163

 

 

$

—

 

 

$

(1,018

)

 

$

217,145

 

 

 

 

December 31, 2020

 

 

 

Amortized Cost

 

 

Unrealized Gain

 

 

Unrealized Loss

 

 

Estimated Fair Value

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

552,539

 

 

$

723

 

 

$

(10

)

 

$

553,252

 

Corporate bonds

 

 

11,497

 

 

 

86

 

 

 

(2

)

 

 

11,581

 

Total short-term marketable securities

 

$

564,036

 

 

$

809

 

 

$

(12

)

 

$

564,833

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt securities

 

$

118,429

 

 

$

98

 

 

$

(2

)

 

$

118,525

 

Total long-term marketable securities

 

$

118,429

 

 

$

98

 

 

$

(2

)

 

$

118,525

 
Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position

The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2021 (in thousands):

 

 

 

Less Than 12 Months

 

 

12 Months Or Greater

 

 

 

Fair Value

 

 

Unrealized Loss

 

 

Fair Value

 

 

Unrealized Loss

 

U.S. government debt securities

 

$

345,014

 

 

$

(1,083

)

 

$

—

 

 

$

—

 

Corporate bonds

 

 

32,886

 

 

 

(58

)

 

 

—

 

 

 

—

 

Total available-for-sale securities

 

$

377,900

 

 

$

(1,141

)

 

$

—

 

 

$

—

 
XML 60 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2021
Property Plant And Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Laboratory equipment

 

$

36,312

 

 

$

27,767

 

Computer equipment

 

 

6,988

 

 

 

3,600

 

Furniture and office equipment

 

 

5,579

 

 

 

2,717

 

Computer software

 

 

992

 

 

 

860

 

Construction in progress

 

 

5,658

 

 

 

7,185

 

Leasehold improvements

 

 

65,959

 

 

 

21,945

 

Property and equipment, at cost

 

 

121,488

 

 

 

64,074

 

Less: Accumulated depreciation

 

 

(36,226

)

 

 

(24,382

)

Property and equipment, net

 

$

85,262

 

 

$

39,692

 
XML 61 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]  
Summary of Intangible Assets Subject to Amortization

Intangible assets subject to amortization as of December 31, 2021 and 2020 consisted of the following (in thousands):

 

 

 

December 31, 2021

 

 

 

Gross Carrying Amount

 

 

Accumulated Amortization

 

 

Net Carrying Amount

 

Acquired developed technology

 

$

20,000

 

 

$

(11,638

)

 

$

8,362

 

Purchased intellectual property

 

 

325

 

 

 

(161

)

 

 

164

 

Balance at December 31, 2021

 

$

20,325

 

 

$

(11,799

)

 

$

8,526

 

 

 

 

December 31, 2020

 

 

 

Gross Carrying Amount

 

 

Accumulated Amortization

 

 

Net Carrying Amount

 

Acquired developed technology

 

$

20,000

 

 

$

(9,972

)

 

$

10,028

 

Purchased intellectual property

 

 

325

 

 

 

(128

)

 

 

197

 

Balance at December 31, 2020

 

$

20,325

 

 

$

(10,100

)

 

$

10,225

 
Schedule of Future Amortization Expense for Intangible Assets

As of December 31, 2021, expected future amortization expense for intangible assets was as follows (in thousands):

 

 

2022

 

$

1,699

 

2023

 

 

1,699

 

2024

 

 

1,703

 

2025

 

 

1,699

 

2026

 

 

1,699

 

Thereafter

 

 

27

 

Total future amortization expense

 

$

8,526

 
XML 62 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Liabilities (Tables)
 12 Months Ended
Dec. 31, 2021
Payables And Accruals [Abstract]  
Schedule of Accrued Liabilities

Accrued liabilities as of December 31, 2021 and 2020 consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Professional fees

 

$

3,687

 

 

$

3,219

 

Clinical and contract research organization costs

 

 

1,646

 

 

 

1,781

 

Travel and entertainment

 

 

184

 

 

 

91

 

Tax liabilities

 

 

391

 

 

 

1,767

 

Purchases of property and equipment

 

 

615

 

 

 

4,423

 

Other

 

 

2,820

 

 

 

1,881

 

Total accrued liabilities

 

$

9,343

 

 

$

13,162

 
XML 63 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Deferred Revenue (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue From Contract With Customer [Abstract]  
Schedule of Deferred Revenue by Revenue Classification

Deferred revenue by revenue classification as of December 31, 2021 and 2020 was as follows (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Current deferred revenue

 

 

 

 

 

 

 

 

Sequencing

 

$

21,915

 

 

$

15,463

 

Development

 

 

58,545

 

 

 

57,856

 

Total current deferred revenue

 

 

80,460

 

 

 

73,319

 

Non-current deferred revenue

 

 

 

 

 

 

 

 

Sequencing

 

 

174

 

 

 

724

 

Development

 

 

98,576

 

 

 

162,894

 

Total non-current deferred revenue

 

 

98,750

 

 

 

163,618

 

Total current and non-current deferred revenue

 

$

179,210

 

 

$

236,937

 
Schedule of Changes in Deferred Revenue

Changes in deferred revenue during the year ended December 31, 2021 were as follows (in thousands):

 

Deferred revenue balance at December 31, 2020

 

$

236,937

 

Additions to deferred revenue during the period

 

 

38,062

 

Revenue recognized during the period

 

 

(95,789

)

Deferred revenue balance at December 31, 2021

 

$

179,210

 
XML 64 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2021
Lessee Disclosure [Abstract]  
Summary of Other Information Related to Operating Lease

Other information related to our operating leases as of December 31, 2021 and 2020 was as follows:

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Weighted-average remaining lease term (in years)

 

 

10.55

 

 

 

11.33

 

Weighted-average discount rate

 

 

4.6

%

 

 

4.6

%
Summary of Reconciles Undiscounted Operating Lease Cash Flows

The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of December 31, 2021 (in thousands):

 

2022

 

$

14,184

 

2023

 

 

13,964

 

2024

 

 

13,692

 

2025

 

 

14,098

 

2026

 

 

12,330

 

Thereafter

 

 

81,188

 

Total undiscounted lease payments

 

 

149,456

 

Less:

 

 

 

 

   Imputed interest rate

 

 

(32,410

)

   Tenant improvement receivables

 

 

(5,306

)

Total operating lease liabilities

 

$

111,740

 

Less: Current portion

 

 

(5,055

)

Operating lease liabilities, less current portion

 

$

106,685

 
XML 65 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Summary of Reserved Shares of Common Stock

As of December 31, 2021, we have reserved shares of common stock for the following:

 

Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted

 

 

13,990,175

 

Shares available for future grant under the 2019 Equity Incentive Plan

 

 

22,299,923

 

Shares available for future grant under the Employee Stock Purchase Plan

 

 

2,804,298

 

Total shares of common stock reserved for future issuance

 

 

39,094,396

 
XML 66 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans (Tables)
 12 Months Ended
Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Changes in Shares Available for Grant

Changes in shares available for grant during the year ended December 31, 2021 were as follows:

 

 

 

Shares Available for Grant

 

Shares available for grant at December 31, 2020

 

 

18,617,001

 

2019 Equity Incentive Plan reserve increase effective January 1, 2021

 

 

6,882,344

 

Options and restricted stock units granted

 

 

(4,306,265

)

Options and restricted stock units forfeited, cancelled or expired

 

 

1,106,843

 

Shares available for grant at December 31, 2021

 

 

22,299,923

 
Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan

Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2021 was as follows:

 

 

 

Shares Subject to

Outstanding Options

 

 

Weighted-Average Exercise

Price per Share

 

 

Aggregate Intrinsic Value

(in thousands)

 

Options outstanding at December 31, 2020

 

 

14,433,560

 

 

$

12.82

 

 

 

 

 

Options granted

 

 

3,052,025

 

 

 

39.39

 

 

 

 

 

Options forfeited or cancelled

 

 

(992,428

)

 

 

25.90

 

 

 

 

 

Options expired

 

 

(40,116

)

 

 

26.56

 

 

 

 

 

Options exercised

 

 

(3,674,057

)

 

 

7.21

 

 

 

 

 

Options outstanding at December 31, 2021

 

 

12,778,984

 

 

$

19.72

 

 

$

156,105

 

Options vested and exercisable at December 31, 2021

 

7,281,600

 

 

$

10.99

 

 

$

132,537

 
Summary of Restricted Stock Unit Activity

Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2021 was as follows:

 

 

 

Restricted Stock Units

Outstanding

 

 

Weighted-Average Grant Date

Fair Value per Share

 

Nonvested outstanding restricted stock units at December 31, 2020

 

 

50,000

 

 

$

28.10

 

Restricted stock units granted

 

 

1,254,240

 

 

 

37.98

 

Restricted stock units forfeited or cancelled

 

 

(74,299

)

 

 

43.20

 

Restricted stock units vested

 

 

(18,750

)

 

 

28.10

 

Nonvested outstanding restricted stock units at December 31, 2021

 

 

1,211,191

 

 

$

37.41

 
Summary of Estimated Grant Date Fair Values of Options Granted

The estimated grant date fair values of options granted during the years ended December 31, 2021, 2020 and 2019 were estimated using the Black-Scholes option-pricing model with the following assumptions:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Fair value of common stock

 

$30.86 - $66.50

 

 

$17.68 - $55.23

 

 

$7.80 - $47.81

 

Expected term (in years)

 

5.27 - 6.08

 

 

5.27 - 6.08

 

 

5.27 - 6.08

 

Risk-free interest rate

 

0.5% - 1.4%

 

 

0.4% - 1.7%

 

 

1.4% - 2.5%

 

Expected volatility

 

67.1% - 70.0%

 

 

70.5% - 73.3%

 

 

64.3% - 72.9%

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 
Summary of Compensation Costs Related to Stock Options and RSUs Included on Statements of Operations The compensation costs related to stock options and restricted stock units for the years ended December 31, 2021, 2020 and 2019 are included on our consolidated statements of operations as follows (in thousands):

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of revenue

 

$

2,100

 

 

$

817

 

 

$

555

 

Research and development

 

 

14,061

 

 

 

8,519

 

 

 

3,934

 

Sales and marketing

 

 

12,312

 

 

 

6,627

 

 

 

3,480

 

General and administrative

 

 

14,778

 

 

 

8,798

 

 

 

5,155

 

Total share-based compensation expense

 

$

43,251

 

 

$

24,761

 

 

$

13,124

 

 
XML 67 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Components of Loss Before Provision for Income Taxes

The components of loss before provision for income taxes for the periods presented are as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Domestic

 

$

(207,314

)

 

$

(146,227

)

 

$

(68,606

)

Foreign

 

 

16

 

 

 

—

 

 

 

—

 

Total loss before provision for income taxes

 

$

(207,298

)

 

$

(146,227

)

 

$

(68,606

)
Schedule of Components of Deferred Tax Assets and Liabilities The significant components of our deferred tax assets and liabilities as of the dates presented are as follows (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets

 

 

 

 

 

 

 

 

Net operating losses

 

$

200,363

 

 

$

105,433

 

Tax credit carryforward

 

 

31,200

 

 

 

18,981

 

Nonqualifying stock options

 

 

18,072

 

 

 

12,096

 

Deferred rent

 

 

—

 

 

 

—

 

Operating lease liabilities

 

 

30,401

 

 

 

31,052

 

Deferred revenue

 

 

42,481

 

 

 

59,713

 

Other

 

 

4,345

 

 

 

2,983

 

Total deferred tax assets

 

 

326,862

 

 

 

230,258

 

Less: Valuation allowance

 

 

(297,020

)

 

 

(197,527

)

Deferred tax assets, net of valuation allowance

 

 

29,842

 

 

 

32,731

 

Deferred tax liabilities

 

 

 

 

 

 

 

 

Tangible and intangible assets

 

 

(7,310

)

 

 

(5,760

)

ROU assets

 

 

(22,532

)

 

 

(26,971

)

Net deferred taxes

 

$

—

 

 

$

—

 

 
Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate

The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:

 

 

 

Year Ended December 31,

 

 

2021

 

2020

 

2019

Statutory rate

 

21.0%

 

21.0%

 

21.0%

State tax, net of federal tax benefit

 

8.3

 

13.8

 

8.1

Stock compensation

 

14.1

 

25.2

 

9.8

Permanent items

 

(0.1)

 

(0.1)

 

(1.0)

Credits

 

4.7

 

5.7

 

6.1

Other

 

(0.3)

 

0.5

 

0.3

Change in valuation allowance

 

(47.7)

 

(66.1)

 

(44.3)

Total

 

0.0%

 

0.0%

 

0.0%
Schedule of Change in Unrecognized Tax Benefits A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):

Balance at December 31, 2018

 

$

1,260

 

Additions in 2019

 

 

792

 

Balance at December 31, 2019

 

 

2,052

 

Additions in 2020

 

 

1,437

 

Balance at December 31, 2020

 

 

3,489

 

Additions in 2021

 

 

3,426

 

Balance at December 31, 2021

 

$

6,915

 

 
XML 68 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019 (in thousands, except share and per share amounts):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

$

(207,279

)

 

$

(146,227

)

 

$

(68,606

)

Fair value adjustment to redemption value for Series E-1 convertible preferred stock options

 

 

—

 

 

 

—

 

 

 

(964

)

Net loss attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(207,279

)

 

$

(146,227

)

 

$

(69,570

)

Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

 

140,354,915

 

 

 

131,216,468

 

 

 

69,165,315

 

Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(1.48

)

 

$

(1.11

)

 

$

(1.01

)
Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019, as they had an anti-dilutive effect:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock (on as if converted basis)

 

 

—

 

 

 

—

 

 

 

46,104,469

 

Stock options issued and outstanding

 

 

13,097,374

 

 

 

16,125,548

 

 

 

17,183,546

 

Nonvested restricted stock units

 

 

693,173

 

 

 

38,125

 

 

 

4,952

 

Common stock warrants

 

 

8,570

 

 

 

56,875

 

 

 

55,961

 

Convertible preferred stock warrant

 

 

—

 

 

 

—

 

 

 

28,204

 

Total

 

 

13,799,117

 

 

 

16,220,548

 

 

 

63,377,132

 

 

 
XML 69 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Organization and Description of Business - Additional Information (Details)
Dec. 31, 2021
Digital Biotechnologies, Inc.  
Subsidiary Or Equity Method Investee [Line Items]  
Ownership interest percentage 70.00%
XML 70 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Dec. 31, 2021
USD ($)
Performance_Obligation
Segment
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2014
USD ($)
$ / shares
shares
Significant Accounting Policies [Line Items]        
Restricted cash $ 2,138,000 $ 2,138,000    
Unbilled receivables 200,000 900,000    
Impairment of goodwill 0      
Impairment losses on intangible assets $ 0      
Warrants issued to purchase stock | shares 0      
Fair value adjustment of warrants     $ 2,266,000  
Advertising expenses $ 22,400,000 $ 14,500,000 6,600,000  
Number of operating segment | Segment 1      
Number of reportable segments | Segment 1      
Sequencing Revenue        
Significant Accounting Policies [Line Items]        
Number of revenue performance obligations | Performance_Obligation 2      
Series C Convertible Preferred Stock        
Significant Accounting Policies [Line Items]        
Warrants issued to purchase stock | shares       56,875
Weighted-average exercise price of warrants | $ / shares       $ 2.64
Line of credit facility       $ 5,000,000.0
Fair value adjustment of warrants     $ 2,300,000  
Financial liabilities $ 2,600,000      
XML 71 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) - Customer Concentration Risk
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Customer A | Revenue      
Significant Accounting Policies [Line Items]      
Concentration risk, percentage     13.90%
Customer A | Accounts Receivable, Net      
Significant Accounting Policies [Line Items]      
Concentration risk, percentage   19.10%  
Customer B | Accounts Receivable, Net      
Significant Accounting Policies [Line Items]      
Concentration risk, percentage 11.30% 12.20%  
Genentech, Inc. and Roche Group | Revenue      
Significant Accounting Policies [Line Items]      
Concentration risk, percentage 41.90% 55.80% 42.10%
XML 72 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)
 12 Months Ended
Dec. 31, 2021
Laboratory Equipment | Minimum  
Property Plant And Equipment [Line Items]  
Property and equipment, useful lives 3 years
Laboratory Equipment | Maximum  
Property Plant And Equipment [Line Items]  
Property and equipment, useful lives 7 years
Leasehold Improvements  
Property Plant And Equipment [Line Items]  
Property and equipment, useful lives Shorter of estimated useful life or remaining lease term
Computer Equipment and Software | Minimum  
Property Plant And Equipment [Line Items]  
Property and equipment, useful lives 3 years
Computer Equipment and Software | Maximum  
Property Plant And Equipment [Line Items]  
Property and equipment, useful lives 5 years
Furniture and Office Equipment | Minimum  
Property Plant And Equipment [Line Items]  
Property and equipment, useful lives 3 years
Furniture and Office Equipment | Maximum  
Property Plant And Equipment [Line Items]  
Property and equipment, useful lives 10 years
XML 73 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]      
Total revenue $ 154,344 $ 98,382 $ 85,071
Sequencing Revenue      
Disaggregation Of Revenue [Line Items]      
Total revenue 78,896 41,439 43,519
Development Support Revenue      
Disaggregation Of Revenue [Line Items]      
Total revenue 65,448 54,443 39,552
Development Revenue Regulatory Milestones      
Disaggregation Of Revenue [Line Items]      
Total revenue 10,000 2,500 2,000
Development Revenue      
Disaggregation Of Revenue [Line Items]      
Total revenue $ 75,448 $ 56,943 $ 41,552
XML 74 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 31, 2021
Feb. 28, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     $ 154,344,000 $ 98,382,000 $ 85,071,000
Revenue recognized $ 75,700,000   (95,789,000)    
Development Revenue          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     75,448,000 56,943,000 41,552,000
MRD Development Agreements          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     3,200,000    
Milestone revenue recognized     10,000,000.0 2,500,000 2,000,000.0
Revenue recognized     11,800,000 3,400,000 3,700,000
MRD Development Agreements | Maximum          
Disaggregation Of Revenue [Line Items]          
Additional milestone payment receivable 333,500,000   333,500,000    
MRD Development Agreements | Development Revenue          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     300,000    
Genentech Collaboration Agreement          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     62,000,000.0 $ 52,800,000 $ 35,100,000
Non-refundable upfront payments received   $ 300,000,000.0 $ 300,000,000.0    
Genentech Collaboration Agreement | Maximum          
Disaggregation Of Revenue [Line Items]          
Revenue recognition expected period     8 years    
Genentech Collaboration Agreement | Maximum | Regulatory Milestones          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments 75,000,000.0   $ 75,000,000.0    
Genentech Collaboration Agreement | Maximum | Development Milestones          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments 300,000,000.0   300,000,000.0    
Genentech Collaboration Agreement | Maximum | Commercial Milestones          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments 1,430,000,000.0   1,430,000,000.0    
Genentech Collaboration Agreement | Minimum          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments $ 1,800,000   $ 1,800,000    
Revenue recognition expected period     7 years    
XML 75 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Financial assets    
Total financial assets $ 563,087 $ 786,641
Level 1    
Financial assets    
Total financial assets 131,946 103,283
Level 2    
Financial assets    
Total financial assets 431,141 683,358
Money Market Funds    
Financial assets    
Total financial assets 131,946 103,283
Money Market Funds | Level 1    
Financial assets    
Total financial assets 131,946 103,283
U.S. Government Debt Securities    
Financial assets    
Total financial assets 391,145 671,777
U.S. Government Debt Securities | Level 2    
Financial assets    
Total financial assets 391,145 671,777
Corporate Bonds    
Financial assets    
Total financial assets 39,996 11,581
Corporate Bonds | Level 2    
Financial assets    
Total financial assets $ 39,996 $ 11,581
XML 76 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Schedule of Available-for-sale Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Short-Term Marketable Securities    
Schedule of Available-for-Sale Securities [Line Items]    
Amortized Cost $ 214,115 $ 564,036
Unrealized Gain 4 809
Unrealized Loss (123) (12)
Estimated Fair Value 213,996 564,833
Long-Term Marketable Securities    
Schedule of Available-for-Sale Securities [Line Items]    
Amortized Cost 218,163 118,429
Unrealized Gain   98
Unrealized Loss (1,018) (2)
Estimated Fair Value 217,145 118,525
U.S. Government Debt Securities | Short-Term Marketable Securities    
Schedule of Available-for-Sale Securities [Line Items]    
Amortized Cost 186,752 552,539
Unrealized Gain 4 723
Unrealized Loss (109) (10)
Estimated Fair Value 186,647 553,252
U.S. Government Debt Securities | Long-Term Marketable Securities    
Schedule of Available-for-Sale Securities [Line Items]    
Amortized Cost 205,472 118,429
Unrealized Gain   98
Unrealized Loss (974) (2)
Estimated Fair Value 204,498 118,525
Corporate Bonds | Short-Term Marketable Securities    
Schedule of Available-for-Sale Securities [Line Items]    
Amortized Cost 27,363 11,497
Unrealized Gain   86
Unrealized Loss (14) (2)
Estimated Fair Value 27,349 $ 11,581
Corporate Bonds | Long-Term Marketable Securities    
Schedule of Available-for-Sale Securities [Line Items]    
Amortized Cost 12,691  
Unrealized Loss (44)  
Estimated Fair Value $ 12,647  
XML 77 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Additional Information (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Prepaid Expenses and Other Current Assets    
Schedule of Available-for-Sale Securities [Line Items]    
Accrued interest receivable $ 1.4 $ 2.5
XML 78 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Schedule of Available-for-Sale Securities [Line Items]  
Less than 12 months, Fair value $ 377,900
Less than 12 months, Unrealized loss (1,141)
U.S. Government Debt Securities  
Schedule of Available-for-Sale Securities [Line Items]  
Less than 12 months, Fair value 345,014
Less than 12 months, Unrealized loss (1,083)
Corporate Bonds  
Schedule of Available-for-Sale Securities [Line Items]  
Less than 12 months, Fair value 32,886
Less than 12 months, Unrealized loss $ (58)
XML 79 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Property and equipment, at cost $ 121,488 $ 64,074
Less: Accumulated depreciation (36,226) (24,382)
Property and equipment, net 85,262 39,692
Laboratory Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, at cost 36,312 27,767
Computer Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, at cost 6,988 3,600
Furniture and Office Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, at cost 5,579 2,717
Computer Software    
Property Plant And Equipment [Line Items]    
Property and equipment, at cost 992 860
Construction in Progress    
Property Plant And Equipment [Line Items]    
Property and equipment, at cost 5,658 7,185
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Property and equipment, at cost $ 65,959 $ 21,945
XML 80 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Property Plant And Equipment [Abstract]      
Depreciation $ 12,254 $ 6,769 $ 6,093
XML 81 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Intangible Assets - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2015
Goodwill [Line Items]      
Goodwill $ 118,972,000 $ 118,972,000 $ 0
Purchased Intellectual Property      
Goodwill [Line Items]      
Amortization period of intangible assets 5 years    
XML 82 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 20,325 $ 20,325
Accumulated Amortization (11,799) (10,100)
Net Carrying Amount 8,526 10,225
Acquired Developed Technology    
Finite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 20,000 20,000
Accumulated Amortization (11,638) (9,972)
Net Carrying Amount 8,362 10,028
Purchased Intellectual Property    
Finite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 325 325
Accumulated Amortization (161) (128)
Net Carrying Amount $ 164 $ 197
XML 83 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]    
2022 $ 1,699  
2023 1,699  
2024 1,703  
2025 1,699  
2026 1,699  
Thereafter 27  
Net Carrying Amount $ 8,526 $ 10,225
XML 84 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Payables And Accruals [Abstract]    
Professional fees $ 3,687 $ 3,219
Clinical and contract research organization costs 1,646 1,781
Travel and entertainment 184 91
Tax liabilities 391 1,767
Purchases of property and equipment 615 4,423
Other 2,820 1,881
Total accrued liabilities $ 9,343 $ 13,162
XML 85 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Liabilities - Additional Information (Details)
$ in Millions
Dec. 31, 2020
USD ($)
Payables And Accruals [Abstract]  
Accrued tax withholding liability related to unsettled option exercises $ 1.4
XML 86 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current deferred revenue    
Total current deferred revenue $ 80,460 $ 73,319
Non-current deferred revenue    
Total non-current deferred revenue 98,750 163,618
Total current and non-current deferred revenue 179,210 236,937
Sequencing Revenue    
Current deferred revenue    
Total current deferred revenue 21,915 15,463
Non-current deferred revenue    
Total non-current deferred revenue 174 724
Development Revenue    
Current deferred revenue    
Total current deferred revenue 58,545 57,856
Non-current deferred revenue    
Total non-current deferred revenue $ 98,576 $ 162,894
XML 87 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Deferred Revenue - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Disaggregation Of Revenue [Line Items]      
Current deferred revenue $ 80,460 $ 80,460 $ 73,319
Deferred revenue, less current portion 98,750 98,750 163,618
Revenue recognized 75,700 (95,789)  
Development Revenue      
Disaggregation Of Revenue [Line Items]      
Current deferred revenue 58,545 58,545 57,856
Deferred revenue, less current portion 98,576 98,576 162,894
Development Revenue | Genentech, Inc.      
Disaggregation Of Revenue [Line Items]      
Current deferred revenue 56,100 56,100 55,100
Deferred revenue, less current portion 94,000 94,000 157,000
Sequencing Revenue      
Disaggregation Of Revenue [Line Items]      
Current deferred revenue 21,915 21,915 15,463
Deferred revenue, less current portion $ 174 174 $ 724
Revenue recognized   3,600  
Medicare | Specific Patients      
Disaggregation Of Revenue [Line Items]      
Revenue recognized   $ 2,500  
XML 88 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Deferred Revenue - Additional Information (Details1) - Genentech, Inc. - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Dec. 31, 2021
Disaggregation Of Revenue [Line Items]  
Deferred revenue, expected to be recognized 12 months
Minimum  
Disaggregation Of Revenue [Line Items]  
Deferred revenue, expected to be recognized 5 years
Maximum  
Disaggregation Of Revenue [Line Items]  
Deferred revenue, expected to be recognized 6 years
XML 89 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Revenue From Contract With Customer [Abstract]    
Deferred revenue balance at December 31, 2020   $ 236,937
Additions to deferred revenue during the period   38,062
Revenue recognized during the period $ 75,700 (95,789)
Deferred revenue balance at December 31, 2021 $ 179,210 $ 179,210
XML 90 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases- Additional Information (Details)
 1 Months Ended 12 Months Ended
Feb. 29, 2020
USD ($)
ft²
Dec. 31, 2019
ft²
Oct. 31, 2019
USD ($)
ft²
Aug. 31, 2019
USD ($)
ft²
Apr. 30, 2018
USD ($)
ft²
Dec. 31, 2021
USD ($)
Lease
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
ft²
Mar. 31, 2021
ft²
Lessee Lease Description [Line Items]                  
Number of square feet | ft² 19,900 3,100 14,750 100,000 13,400     3,100 27,000
Lessee, operating lease, option to extend       cash payment for rent began in October 2021 and the lease term ends in August 2033, The lease term is through March 2026 and provides for one five-year extension option. options to extend certain of the leases up to 10.0 years      
Lessee, operating lease, rent commencement month and year       2021-10          
Lessee, Operating Lease, Existence of Option to Extend [true false]       true true true      
Lessee, operating lease, extended term of contract       5 years 5 years        
Lease expiration month and year   2025-11 2029-10 2033-08 2026-03 2031-10      
Letter of credit       $ 2,100,000          
Lease commenced moth and year       2020-12          
Landlord contribution for leasehold improvements       $ 20,000,000.0   $ 14,800,000      
Proceeds from landlord reimbursements           10,900,000 $ 700,000    
Tenant improvement costs incurred           14,900,000 5,200,000    
Tenant improvement costs receivable           $ 4,000,000.0 4,500,000    
Tenant improvement allowance         $ 2,400,000        
Rent obligations, commencement date           2021-10      
Tenant improvement allowance and commenced $ 600,000                
Operating lease renewal term           10 years      
Operating lease termination period           3 years      
Number of operating lease terminate | Lease           2      
Lease not yet commenced, termination option description           subject to an early termination option after the seventh year      
Lease not yet commenced, option to extend description           option to twice extend the lease for five years      
Lease not yet commenced landlord agreed to fund for improvements           $ 1,200,000      
Lease not yet commenced, option to extend term           5 years      
Operating lease expense           $ 12,400,000 5,500,000    
Operating lease variable lease expense           3,500,000 2,600,000    
Rent expenses               $ 5,300,000  
Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received           8,300,000 3,200,000    
Cash received for tenant improvement allowances           11,500,000 2,500,000    
ROU assets obtained in exchange for operating lease liabilities           5,400,000 109,100,000    
Operating lease right-of-use assets           $ 87,678,000 99,350,000    
ASC 842                  
Lessee Lease Description [Line Items]                  
Operating lease right-of-use assets             $ 33,000,000.0    
Maximum                  
Lessee Lease Description [Line Items]                  
Tenant improvement allowance     $ 700,000            
Operating lease remaining lease term           11 years 8 months 12 days      
Minimum                  
Lessee Lease Description [Line Items]                  
Operating lease remaining lease term           3 months 18 days      
Seattle, Washington                  
Lessee Lease Description [Line Items]                  
Number of square feet | ft²       65,500          
Lessee, operating lease, option to extend       Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.          
Lessee, operating lease, rent commencement month and year       2020-01          
Lessee, Operating Lease, Existence of Option to Extend [true false]       true          
Lessee, operating lease, extended term of contract       5 years          
Lease expiration month and year       2032-10          
XML 91 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases- Summary of Other Information Related to Operating Lease (Details)
Dec. 31, 2021
Dec. 31, 2020
Lessee Disclosure [Abstract]    
Weighted-average remaining lease term (in years) 10 years 6 months 18 days 11 years 3 months 29 days
Weighted-average discount rate 4.60% 4.60%
XML 92 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Lessee Disclosure [Abstract]    
2022 $ 14,184  
2023 13,964  
2024 13,692  
2025 14,098  
2026 12,330  
Thereafter 81,188  
Total undiscounted lease payments 149,456  
Imputed interest rate (32,410)  
Tenant improvement receivables (5,306)  
Total operating lease liabilities 111,740  
Less: Current portion (5,055) $ (3,529)
Operating lease liabilities, less current portion $ 106,685 $ 104,333
XML 93 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity - Additional Information (Details)
 12 Months Ended
Jan. 01, 2021
shares
Jan. 01, 2020
Dec. 31, 2021
Vote
shares
Dec. 31, 2019
shares
Dec. 31, 2014
$ / shares
shares
Class Of Stock [Line Items]          
Common stock voting rights description     Holders of our common stock are entitled to one vote for each share of common stock held    
Number of vote for each share | Vote     1    
Warrant issued to purchase stock     0    
Series C Convertible Preferred Stock          
Class Of Stock [Line Items]          
Warrant issued to purchase stock         56,875
Warrant exercisable term         7 years
Weighted-average exercise price of warrants | $ / shares         $ 2.64
Common Stock          
Class Of Stock [Line Items]          
Stock issued during period, common stock     54,162 54,792  
Maximum | Employee Stock Purchase Plan          
Class Of Stock [Line Items]          
Percentage of annual increases in number of shares   1.00%      
2019 Equity Incentive Plan          
Class Of Stock [Line Items]          
Increase in share reserve 6,882,344        
2019 Equity Incentive Plan | Maximum          
Class Of Stock [Line Items]          
Percentage of annual increases in number of shares   5.00%      
XML 94 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)
Dec. 31, 2021
shares
Class Of Stock [Line Items]  
Total shares of common stock reserved for future issuance 39,094,396
Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted  
Class Of Stock [Line Items]  
Total shares of common stock reserved for future issuance 13,990,175
Grant | 2019 Equity Incentive Plan  
Class Of Stock [Line Items]  
Total shares of common stock reserved for future issuance 22,299,923
Grant | Employee Stock Purchase Plan  
Class Of Stock [Line Items]  
Total shares of common stock reserved for future issuance 2,804,298
XML 95 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Weighted-average remaining contractual life options outstanding 7 years    
Weighted-average remaining contractual life vested and exercisable options outstanding 5 years 8 months 12 days    
Weighted-average grant date fair value $ 24.22 $ 21.11 $ 6.87
Total intrinsic value of options exercised $ 156,500 $ 190,400 $ 39,100
Proceeds from exercise of stock options 26,717 21,748 $ 4,055
Proceeds from settlement of stock option exercised in prior periods 300 $ 500  
Unrecognized share-based compensation expense related to unvested stock options $ 96,800    
Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition 2 years 10 months 24 days    
Option Valuation Model      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected dividend yield 0.00%    
Restricted Stock Units (RSUs)      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition 3 years 4 months 24 days    
Unrecognized share-based compensation expense related to unvested RSUs $ 38,300    
Sequenta 2008 Stock Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Shares available for future issuance 0    
Equity awards outstanding 0    
2009 Equity Incentive Plan | Grant      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Shares available for future issuance 0    
2009 Equity Incentive Plan | Grant | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Option expiration period 10 years    
2019 Equity Incentive Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Shares available for future issuance 22,299,923 18,617,001  
2019 Equity Incentive Plan | Grant      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Number of shares authorized for issuance 29,131,628    
2019 Equity Incentive Plan | Grant | Non Employee Directors      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Vesting period 4 years    
2019 Equity Incentive Plan | Grant | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Option expiration period 10 years    
2019 Equity Incentive Plan | Restricted Stock Units (RSUs)      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Weighted-average grant date fair value $ 37.98 $ 28.10 $ 41.63
XML 96 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) - 2019 Equity Incentive Plan
 12 Months Ended
Dec. 31, 2021
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Shares Available for Grant, Outstanding, Beginning Balance 18,617,001
Shares Available for Grant, 2019 Equity Incentive Plan reserve increase 6,882,344
Shares Available for Grant, Options and restricted stock units granted (4,306,265)
Shares Available for Grant, Options and restricted stock units forfeited, cancelled or expired 1,106,843
Shares Available for Grant, Outstanding, Ending Balance 22,299,923
XML 97 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Shares Subject to Outstanding Options, Options outstanding, Beginning Balance | shares 14,433,560
Shares Subject to Outstanding Options, Options granted | shares 3,052,025
Shares Subject to Outstanding Options, Options forfeited or cancelled | shares (992,428)
Shares Subject to Outstanding Options, Options expired | shares (40,116)
Shares Subject to Outstanding Options, Options exercised | shares (3,674,057)
Shares Subject to Outstanding Options, Options outstanding, Ending Balance | shares 12,778,984
Shares Subject to Outstanding Options, Options vested and exercisable | shares 7,281,600
Weighted Average Exercise Price per Share, Options outstanding, Beginning Balance | $ / shares $ 12.82
Weighted Average Exercise Price per Share, Options granted | $ / shares 39.39
Weighted Average Exercise Price per Share, Options forfeited or cancelled | $ / shares 25.90
Weighted Average Exercise Price per Share, Options expired | $ / shares 26.56
Weighted Average Exercise Price per Share, Options exercised | $ / shares 7.21
Weighted Average Exercise Price per Share, Options outstanding, Ending Balance | $ / shares 19.72
Weighted Average Exercise Price per Share, Options vested and exercisable | $ / shares $ 10.99
Aggregate Intrinsic Value, Option outstanding | $ $ 156,105
Aggregate Intrinsic Value, Options vested and exercisable | $ $ 132,537
XML 98 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Weighted-Average Grant Date Fair Value per Share      
Weighted-average grant date fair value $ 24.22 $ 21.11 $ 6.87
Restricted Stock Units (RSUs) | 2019 Equity Incentive Plan      
Restricted Stock Units Outstanding      
Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance 50,000    
Restricted Stock Units Outstanding, Granted 1,254,240    
Restricted Stock Units Outstanding, Forfeited or cancelled (74,299)    
Restricted Stock Units Outstanding, Vested (18,750)    
Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance 1,211,191 50,000  
Weighted-Average Grant Date Fair Value per Share      
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance $ 28.10    
Weighted-average grant date fair value 37.98 $ 28.10 $ 41.63
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited or cancelled 43.20    
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested 28.10    
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance $ 37.41 $ 28.10  
XML 99 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Options Granted (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Risk-free interest rate, minimum 0.50% 0.40% 1.40%
Risk-free interest rate, maximum 1.40% 1.70% 2.50%
Expected volatility, minimum 67.10% 70.50% 64.30%
Expected volatility, maximum 70.00% 73.30% 72.90%
Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Fair value of common stock $ 30.86 $ 17.68 $ 7.80
Expected term (in years) 5 years 3 months 7 days 5 years 3 months 7 days 5 years 3 months 7 days
Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Fair value of common stock $ 66.50 $ 55.23 $ 47.81
Expected term (in years) 6 years 29 days 6 years 29 days 6 years 29 days
XML 100 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Total share-based compensation expense $ 43,251 $ 24,761 $ 13,124
Cost of Revenue      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Total share-based compensation expense 2,100 817 555
Research and Development      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Total share-based compensation expense 14,061 8,519 3,934
Sales and Marketing      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Total share-based compensation expense 12,312 6,627 3,480
General and Administrative      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Total share-based compensation expense $ 14,778 $ 8,798 $ 5,155
XML 101 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
Microsoft Collaboration Agreement - Additional Information (Details) - USD ($)
 1 Months Ended
Dec. 31, 2017
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]      
preferred stock investment  
Microsoft Collaboration Agreement      
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]      
Minimum service consumption requirement amount $ 12,000,000.0    
Minimum service consumption requirement term 7 years    
Microsoft Collaboration Agreement | Series F-1 Convertible Preferred Stock      
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]      
preferred stock investment $ 45,000,000.0    
XML 102 R72.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Domestic $ (207,314) $ (146,227) $ (68,606)
Foreign 16    
Total loss before provision for income taxes $ (207,298) $ (146,227) $ (68,606)
XML 103 R73.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets    
Net operating losses $ 200,363 $ 105,433
Tax credit carryforward 31,200 18,981
Nonqualifying stock options 18,072 12,096
Operating lease liabilities 30,401 31,052
Deferred revenue 42,481 59,713
Other 4,345 2,983
Total deferred tax assets 326,862 230,258
Less: Valuation allowance (297,020) (197,527)
Deferred tax assets, net of valuation allowance 29,842 32,731
Deferred tax liabilities    
Tangible and intangible assets (7,310) (5,760)
ROU assets (22,532) (26,971)
Net deferred taxes $ 0 $ 0
XML 104 R74.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Taxes [Line Items]        
Increase in valuation allowance $ 99,500,000 $ 96,600,000    
Maturity period for NOLs carryovers 20 years      
U.S. federal NOLs $ 576,200,000      
Unrecognized tax benefits 6,915,000 3,489,000 $ 2,052,000 $ 1,260,000
Uncertain tax positions 3,426,000 1,437,000 $ 792,000  
Accrued interest or penalties related to uncertain tax positions 0 $ 0    
Domestic Tax Authority [Member]        
Income Taxes [Line Items]        
U.S. federal NOLs 192,500,000      
U.S. federal tax credits $ 33,600,000      
Tax credit carryforwards expiration year 2028      
NOLs expiration year 2028      
XML 105 R75.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Statutory rate 21.00% 21.00% 21.00%
State tax, net of federal tax benefit 8.30% 13.80% 8.10%
Stock compensation 14.10% 25.20% 9.80%
Permanent items (0.10%) (0.10%) (1.00%)
Credits 4.70% 5.70% 6.10%
Other (0.30%) 0.50% 0.30%
Change in valuation allowance (47.70%) (66.10%) (44.30%)
Total 0.00% 0.00% 0.00%
XML 106 R76.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Balance $ 3,489 $ 2,052 $ 1,260
Additions 3,426 1,437 792
Balance $ 6,915 $ 3,489 $ 2,052
XML 107 R77.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Earnings Per Share [Abstract]      
Net loss attributable to Adaptive Biotechnologies Corporation $ (207,279) $ (146,227) $ (68,606)
Fair value adjustment to redemption value for Series E-1 convertible preferred stock options     (964)
Net loss attributable to Adaptive Biotechnologies Corporation common shareholders $ (207,279) $ (146,227) $ (69,570)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 140,354,915 131,216,468 69,165,315
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ (1.48) $ (1.11) $ (1.01)
XML 108 R78.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 13,799,117 16,220,548 63,377,132
Convertible Preferred Stock      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities     46,104,469
Grant      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 13,097,374 16,125,548 17,183,546
Nonvested Restricted Stock Units      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 693,173 38,125 4,952
Common Stock Warrants      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 8,570 56,875 55,961
Convertible Preferred Stock Warrants      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities     28,204
XML 109 R79.htm IDEA: XBRL DOCUMENT v3.22.0.1
Retirement Plan - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]      
Employees maximum annual contribution of their compensation 100.00%    
Employer discretionary contribution amount $ 2,500,000 $ 1,600,000 $ 0
Employee service period for vesting 1 year 1 year  
XML 110 adpt-10k_20211231_htm.xml IDEA: XBRL DOCUMENT 0001478320 2021-01-01 2021-12-31 0001478320 2021-06-30 0001478320 2022-02-10 0001478320 2021-12-31 0001478320 2020-12-31 0001478320 adpt:SequencingRevenueMember 2021-01-01 2021-12-31 0001478320 adpt:SequencingRevenueMember 2020-01-01 2020-12-31 0001478320 adpt:SequencingRevenueMember 2019-01-01 2019-12-31 0001478320 adpt:DevelopmentRevenueMember 2021-01-01 2021-12-31 0001478320 adpt:DevelopmentRevenueMember 2020-01-01 2020-12-31 0001478320 adpt:DevelopmentRevenueMember 2019-01-01 2019-12-31 0001478320 2020-01-01 2020-12-31 0001478320 2019-01-01 2019-12-31 0001478320 us-gaap:ConvertiblePreferredStockMember 2018-12-31 0001478320 us-gaap:CommonStockMember 2018-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001478320 us-gaap:RetainedEarningsMember 2018-12-31 0001478320 2018-12-31 0001478320 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001478320 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001478320 us-gaap:CommonStockMember 2019-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001478320 us-gaap:RetainedEarningsMember 2019-12-31 0001478320 2019-12-31 0001478320 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001478320 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001478320 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2019-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001478320 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001478320 us-gaap:CommonStockMember 2020-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001478320 us-gaap:RetainedEarningsMember 2020-12-31 0001478320 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001478320 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001478320 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001478320 us-gaap:CommonStockMember 2021-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001478320 us-gaap:RetainedEarningsMember 2021-12-31 0001478320 us-gaap:NoncontrollingInterestMember 2021-12-31 0001478320 adpt:DigitalBiotechnologiesIncMember 2021-12-31 0001478320 adpt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001478320 adpt:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001478320 adpt:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001478320 adpt:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001478320 adpt:GenentechIncAndRocheGroupMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001478320 adpt:GenentechIncAndRocheGroupMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001478320 adpt:GenentechIncAndRocheGroupMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001478320 srt:MinimumMember adpt:LaboratoryEquipmentMember 2021-01-01 2021-12-31 0001478320 srt:MaximumMember adpt:LaboratoryEquipmentMember 2021-01-01 2021-12-31 0001478320 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001478320 srt:MinimumMember adpt:ComputerEquipmentAndSoftwareMember 2021-01-01 2021-12-31 0001478320 srt:MaximumMember adpt:ComputerEquipmentAndSoftwareMember 2021-01-01 2021-12-31 0001478320 srt:MinimumMember adpt:FurnitureAndOfficeEquipmentMember 2021-01-01 2021-12-31 0001478320 srt:MaximumMember adpt:FurnitureAndOfficeEquipmentMember 2021-01-01 2021-12-31 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2014-12-31 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2021-12-31 0001478320 adpt:DevelopmentSupportRevenueMember 2021-01-01 2021-12-31 0001478320 adpt:DevelopmentSupportRevenueMember 2020-01-01 2020-12-31 0001478320 adpt:DevelopmentSupportRevenueMember 2019-01-01 2019-12-31 0001478320 adpt:DevelopmentRevenueRegulatoryMilestonesMember 2021-01-01 2021-12-31 0001478320 adpt:DevelopmentRevenueRegulatoryMilestonesMember 2020-01-01 2020-12-31 0001478320 adpt:DevelopmentRevenueRegulatoryMilestonesMember 2019-01-01 2019-12-31 0001478320 adpt:MRDDevelopmentAgreementsMember 2021-01-01 2021-12-31 0001478320 adpt:DevelopmentRevenueMember adpt:MRDDevelopmentAgreementsMember 2021-01-01 2021-12-31 0001478320 adpt:MRDDevelopmentAgreementsMember 2020-01-01 2020-12-31 0001478320 adpt:MRDDevelopmentAgreementsMember 2019-01-01 2019-12-31 0001478320 srt:MaximumMember adpt:MRDDevelopmentAgreementsMember 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember 2019-02-01 2019-02-28 0001478320 srt:MinimumMember adpt:GenentechCollaborationAgreementMember 2021-12-31 0001478320 srt:MaximumMember adpt:RegulatoryMilestonesMember adpt:GenentechCollaborationAgreementMember 2021-12-31 0001478320 srt:MaximumMember adpt:DevelopmentMilestonesMember adpt:GenentechCollaborationAgreementMember 2021-12-31 0001478320 srt:MaximumMember adpt:CommercialMilestonesMember adpt:GenentechCollaborationAgreementMember 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember 2021-01-01 2021-12-31 0001478320 srt:MinimumMember adpt:GenentechCollaborationAgreementMember 2021-01-01 2021-12-31 0001478320 srt:MaximumMember adpt:GenentechCollaborationAgreementMember 2021-01-01 2021-12-31 0001478320 adpt:GenentechCollaborationAgreementMember 2020-01-01 2020-12-31 0001478320 adpt:GenentechCollaborationAgreementMember 2019-01-01 2019-12-31 0001478320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001478320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2021-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2021-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2020-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2020-12-31 0001478320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-12-31 0001478320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001478320 us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001478320 adpt:LaboratoryEquipmentMember 2021-12-31 0001478320 adpt:LaboratoryEquipmentMember 2020-12-31 0001478320 us-gaap:ComputerEquipmentMember 2021-12-31 0001478320 us-gaap:ComputerEquipmentMember 2020-12-31 0001478320 adpt:FurnitureAndOfficeEquipmentMember 2021-12-31 0001478320 adpt:FurnitureAndOfficeEquipmentMember 2020-12-31 0001478320 adpt:ComputerSoftwareMember 2021-12-31 0001478320 adpt:ComputerSoftwareMember 2020-12-31 0001478320 us-gaap:ConstructionInProgressMember 2021-12-31 0001478320 us-gaap:ConstructionInProgressMember 2020-12-31 0001478320 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001478320 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001478320 2015-12-31 0001478320 us-gaap:IntellectualPropertyMember 2021-01-01 2021-12-31 0001478320 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0001478320 us-gaap:IntellectualPropertyMember 2021-12-31 0001478320 us-gaap:DevelopedTechnologyRightsMember 2020-12-31 0001478320 us-gaap:IntellectualPropertyMember 2020-12-31 0001478320 adpt:SequencingRevenueMember 2021-12-31 0001478320 adpt:SequencingRevenueMember 2020-12-31 0001478320 adpt:DevelopmentRevenueMember 2021-12-31 0001478320 adpt:DevelopmentRevenueMember 2020-12-31 0001478320 adpt:GenentechIncMember adpt:DevelopmentRevenueMember 2021-12-31 0001478320 adpt:GenentechIncMember adpt:DevelopmentRevenueMember 2020-12-31 0001478320 adpt:GenentechIncMember 2022-01-01 2021-12-31 0001478320 adpt:GenentechIncMember srt:MinimumMember 2022-01-01 2021-12-31 0001478320 adpt:GenentechIncMember srt:MaximumMember 2022-01-01 2021-12-31 0001478320 adpt:SpecificPatientsMember adpt:MedicareRevenueMember 2021-01-01 2021-12-31 0001478320 2021-12-30 2021-12-31 0001478320 stpr:WA 2019-08-31 0001478320 stpr:WA 2019-08-01 2019-08-31 0001478320 2019-08-31 0001478320 2019-08-01 2019-08-31 0001478320 2019-10-31 0001478320 2019-10-01 2019-10-31 0001478320 srt:MaximumMember 2019-10-31 0001478320 2018-04-30 0001478320 2021-03-31 0001478320 2018-04-01 2018-04-30 0001478320 2020-02-29 0001478320 2020-02-01 2020-02-29 0001478320 2019-12-01 2019-12-31 0001478320 srt:MinimumMember 2021-12-31 0001478320 srt:MaximumMember 2021-12-31 0001478320 us-gaap:AccountingStandardsUpdate201602Member 2020-12-31 0001478320 adpt:CommonStockOptionsAndRestrictedStockUnitsGrantedMember 2021-12-31 0001478320 us-gaap:EmployeeStockOptionMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-12-31 0001478320 us-gaap:EmployeeStockOptionMember us-gaap:EmployeeStockMember 2021-12-31 0001478320 srt:MaximumMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-01-01 2020-01-01 0001478320 srt:MaximumMember us-gaap:EmployeeStockMember 2020-01-01 2020-01-01 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-01-01 2021-01-01 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2014-01-01 2014-12-31 0001478320 adpt:SequentaTwoThousandAndEightStockPlanMember 2021-12-31 0001478320 srt:MaximumMember us-gaap:EmployeeStockOptionMember adpt:TwoThousandAndNineEquityIncentivePlanMember 2021-01-01 2021-12-31 0001478320 us-gaap:EmployeeStockOptionMember adpt:TwoThousandAndNineEquityIncentivePlanMember 2021-12-31 0001478320 srt:MaximumMember us-gaap:EmployeeStockOptionMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001478320 adpt:NonEmployeeDirectorsMember us-gaap:EmployeeStockOptionMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2021-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2019-01-01 2019-12-31 0001478320 srt:MinimumMember 2021-01-01 2021-12-31 0001478320 srt:MinimumMember 2020-01-01 2020-12-31 0001478320 srt:MinimumMember 2019-01-01 2019-12-31 0001478320 srt:MaximumMember 2021-01-01 2021-12-31 0001478320 srt:MaximumMember 2020-01-01 2020-12-31 0001478320 srt:MaximumMember 2019-01-01 2019-12-31 0001478320 us-gaap:ValuationTechniqueOptionPricingModelMember 2021-01-01 2021-12-31 0001478320 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001478320 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001478320 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001478320 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001478320 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001478320 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001478320 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001478320 adpt:MicrosoftCollaborationAgreementMember 2017-12-01 2017-12-31 0001478320 adpt:SeriesFOneConvertiblePreferredStockMember adpt:MicrosoftCollaborationAgreementMember 2017-12-31 0001478320 us-gaap:DomesticCountryMember 2021-12-31 0001478320 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001478320 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001478320 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001478320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2019-01-01 2019-12-31 0001478320 adpt:CommonStockWarrantsMember 2021-01-01 2021-12-31 0001478320 adpt:CommonStockWarrantsMember 2020-01-01 2020-12-31 0001478320 adpt:CommonStockWarrantsMember 2019-01-01 2019-12-31 0001478320 adpt:ConvertiblePreferredStockWarrantsMember 2019-01-01 2019-12-31 iso4217:USD shares iso4217:USD shares pure adpt:Performance_Obligation adpt:Segment utr:sqft adpt:Lease adpt:Vote false FY 0001478320 --12-31 true 2032-10 true 2029-10 true true P5Y P4Y P7Y http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member P10Y6M18D P11Y3M29D P5Y3M7D P5Y3M7D P5Y3M7D 0.005 0.004 0.014 0.671 0.705 0.643 30.86 17.68 7.80 66.50 55.23 47.81 P6Y29D P6Y29D P6Y29D 0.014 0.017 0.025 0.700 0.733 0.729 10-K true 2021-12-31 2021 false 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION WA 27-0907024 1165 Eastlake Avenue East Seattle WA 98109 (206) 659-0067 Common stock, par value $0.0001 per share ADPT NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 3951000000 141583720 The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the registrant’s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2022. 42 Ernst & Young LLP Seattle, Washington 139065000 123436000 214115000 564036000 213996000 564833000 17409000 10047000 19263000 14063000 13015000 14535000 402748000 726914000 85262000 39692000 87678000 99350000 218163000 118429000 217145000 118525000 2138000 2138000 8526000 10225000 118972000 118972000 875000 598000 923344000 1116414000 3307000 3237000 9343000 13162000 15642000 11950000 5055000 3529000 80460000 73319000 113807000 105197000 106685000 104333000 98750000 163618000 319242000 373148000 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 340000000 340000000 141393865 141393865 137646896 137646896 14000 14000 1324006000 1253971000 -1137000 893000 -718891000 -511612000 603992000 743266000 110000 604102000 743266000 923344000 1116414000 78896000 41439000 43519000 75448000 56943000 41552000 154344000 98382000 85071000 49301000 22530000 22274000 142343000 116072000 70705000 95465000 61358000 38453000 74502000 49536000 30332000 1699000 1703000 1698000 363310000 251199000 163462000 -208966000 -152817000 -78391000 1668000 6590000 9785000 -207298000 -146227000 -68606000 -19000 -207279000 -146227000 -68606000 964000 -207279000 -146227000 -69570000 -1.48 -1.11 -1.01 140354915 131216468 69165315 -207298000 -146227000 -68606000 -2030000 222000 778000 -209328000 -146005000 -67828000 -19000 -209309000 -146005000 -67828000 92790094 560858000 12841536 1000 37902000 -107000 -295908000 -258112000 17250000 2000 320848000 320850000 -4986000 -4986000 -93039737 -561931000 93039737 9000 561922000 561931000 2602000 2602000 54792 9000 9000 2043767 4413000 4413000 249643 109000 8310 964000 -964000 -964000 13124000 13124000 778000 778000 -68606000 -68606000 125238142 12000 935834000 671000 -365478000 571039000 7200000 1000 271838000 271839000 93000 93000 5204254 1000 21538000 21539000 4500 24761000 24761000 222000 222000 -146227000 -146227000 137646896 14000 1253971000 893000 -511612000 743266000 54162 3674057 26484000 26484000 18750 43251000 43251000 300000 129000 429000 -2030000 -2030000 -207279000 -19000 -207298000 141393865 14000 1324006000 -1137000 -718891000 110000 604102000 -207298000 -146227000 -68606000 12254000 6769000 6093000 7028000 3266000 43251000 24761000 13124000 1699000 1703000 1698000 -7233000 -773000 4463000 2266000 78000 -71000 -359000 7362000 -2613000 7817000 5200000 4994000 1231000 -1286000 1362000 8576000 3940000 7495000 6149000 78000 8522000 -886000 -57727000 -43389000 266927000 275000 276000 597000 -192727000 -149683000 205404000 61746000 18803000 11200000 316544000 694965000 884217000 559500000 596724000 413720000 181210000 -117044000 -481697000 26717000 21748000 4055000 272160000 320850000 321000 4986000 9000 429000 -12000 27146000 293587000 319916000 15629000 26860000 43623000 125574000 98714000 55091000 141203000 125574000 98714000 682000 4679000 773000 36607000 36607000 561931000 2602000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Description of Business</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Corporation (“we,” “us” or “our”) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune disorders and infectious diseases.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Digital Biotechnologies, Inc.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2021, we formed a subsidiary, Spin Technologies, Inc., to facilitate the development of a potential new early-stage sequencing technology that is ancillary to our core business. In February 2022, the subsidiary’s name was changed to Digital Biotechnologies, Inc. We have a 70% ownership interest in Digital Biotechnologies, Inc. All intercompany transactions and balances between us and Digital Biotechnologies, Inc. have been eliminated in consolidation. The remaining interest, held by certain of our related parties and related family trusts, was reported as noncontrolling interest in our consolidated financial statements.</p> 0.70 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Significant</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Accounting</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Policies</span></p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Basis<span style="letter-spacing:-0.05pt;"> </span>of Presentation and<span style="letter-spacing:-0.05pt;"> Principles of Consolidation</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, its wholly-owned subsidiary and Digital Biotechnologies, Inc. Other shareholders’ interests in Digital Biotechnologies, Inc. are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of <span>$2.1</span> million as of December 31, 2021 and 2020.</p> <p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Investments in Marketable Securities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities are classified as available-for-sale, consist of U.S. government debt securities and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders’ equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations<span style="letter-spacing:-0.05pt;"> </span>of Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, Net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech, Inc. and Roche Group</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* less than 10%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounts Receivable</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we had $0.2 million and $0.9 million of unbilled receivables as of December 31, 2021 and 2020, respectively. These contract assets are amounts that will become due for which we have an unconditional right to consideration.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Useful lives assigned to property and equipment are as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;"> <tr> <td style="width:223.55pt;"/> <td style="width:7.85pt;"/> <td style="width:223.5pt;"/> </tr> <tr> <td valign="top"> <p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 7 years</p></td> </tr> <tr> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of estimated useful life or remaining lease term</p></td> </tr> <tr> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 5 years</p></td> </tr> <tr> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 10 years</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our consolidated statements of operations in accordance with the use of the asset.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our consolidated statements of operations. To date, we have not recognized any impairment of goodwill.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have not recognized any impairment losses on intangible assets.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy, as well as server space. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of <span style="Background-color:#FFFFFF;">Accounting Standards Update No. 2016-02, </span><span style="font-style:italic;Background-color:#FFFFFF;">Leases</span><span style="Background-color:#FFFFFF;"> (Topic 842) (“ASC 842”)</span>. </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on our consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases. </p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Financial Accounting Standards Board (“FASB”) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 1: Quoted </span><span style="Background-color:#FFFFFF;color:#000000;">prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;color:#000000;">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;color:#000000;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p></td></tr></table></div> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level 3 within the valuation hierarchy. </span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2021 and 2020.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Preferred Stock Warrant</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had issued a freestanding warrant to a venture capital firm to purchase 56,875 shares of Series C convertible preferred stock with an exercise price of $2.64 in connection with a $5.0 million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant. </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the conversion, the fair value of this warrant was classified as a non-current liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders’ deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $2.3 million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our consolidated statements of operations. </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $2.6 million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Revenue<span style="letter-spacing:-0.1pt;"> </span>Recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue in accordance with ASC Topic 606 (“ASC 606”), <span style="font-style:italic;">Revenue from Contracts with Customers</span>. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue is generated from immunosequencing (“sequencing”) products and services (“sequencing revenue”) and from regulatory or development support services leveraging our immune medicine platform (“development revenue”). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sequencing Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue reflects the amounts generated from providing testing services through clonoSEQ to clinical and research customers, from providing our T-Detect COVID test to clinical customers and from providing sequencing services through immunoSEQ to research customers.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clinical customers, we primarily derive revenue from providing our clonoSEQ report to ordering physicians. In these transactions, we have identified one performance obligation, the delivery of a clonoSEQ report, and we bill and receive payments from medical institutions and commercial and government third-party payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our clonoSEQ coverag</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> under Medicare, we bill </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognition commences </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the number of tests </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we expect to deliver</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> either</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as we deliver </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our estimate of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the remaining tests in a patient’s treatment cycle</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or when </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the likelihood</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> becomes remote that a patient will receive additional testing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research customers, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Development<span style="letter-spacing:-0.05pt;"> </span>Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers’ initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements include single or multiple performance obligations, depending on the contract. For certain contracts, we perform services to support the biopharmaceutical customers’ regulatory submissions as part of their registrational trials. These services may include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. If agreements include sequencing activities, we separately classify those activities as sequencing revenue.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers’ control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as development revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer’s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advertising costs are expensed as incurred. Advertising expenses were $22.4 million, $14.5 million and $6.6 million for the year ended December 31, 2021, 2020 and 2019, respectively.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs and allocated facility costs associated with processing samples and professional support for our sequencing revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. <span style="Background-color:#FFFFFF;color:#000000;">We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. </span>Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. <span style="Background-color:#FFFFFF;color:#000000;">Costs to support our Genentech Agreement are also a component of our research and development expenses.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We calculate basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders by dividing net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect is anti-dilutive.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders in conformity with the two-class method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is calculated by dividing the net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to Adaptive Biotechnologies Corporation common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to Adaptive Biotechnologies Corporation common shareholders was not allocated to the convertible preferred stock under the two-class method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect was anti-dilutive.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have determined that our chief executive officer is the chief operating decision maker (“CODM”). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning at levels or components below the consolidated entity. As such, the consolidated entity operates as one operating segment and represents one reportable segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3, Revenue.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Basis<span style="letter-spacing:-0.05pt;"> </span>of Presentation and<span style="letter-spacing:-0.05pt;"> Principles of Consolidation</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, its wholly-owned subsidiary and Digital Biotechnologies, Inc. Other shareholders’ interests in Digital Biotechnologies, Inc. are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of <span>$2.1</span> million as of December 31, 2021 and 2020.</p> 2100000 2100000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities are classified as available-for-sale, consist of U.S. government debt securities and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders’ equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations<span style="letter-spacing:-0.05pt;"> </span>of Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, Net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech, Inc. and Roche Group</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* less than 10%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, Net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech, Inc. and Roche Group</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* less than 10%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0.139 0.191 0.113 0.122 0.419 0.558 0.421 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounts Receivable</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we had $0.2 million and $0.9 million of unbilled receivables as of December 31, 2021 and 2020, respectively. These contract assets are amounts that will become due for which we have an unconditional right to consideration.</p> 200000 900000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Useful lives assigned to property and equipment are as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;"> <tr> <td style="width:223.55pt;"/> <td style="width:7.85pt;"/> <td style="width:223.5pt;"/> </tr> <tr> <td valign="top"> <p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 7 years</p></td> </tr> <tr> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of estimated useful life or remaining lease term</p></td> </tr> <tr> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 5 years</p></td> </tr> <tr> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 10 years</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our consolidated statements of operations in accordance with the use of the asset.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Useful lives assigned to property and equipment are as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;"> <tr> <td style="width:223.55pt;"/> <td style="width:7.85pt;"/> <td style="width:223.5pt;"/> </tr> <tr> <td valign="top"> <p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 7 years</p></td> </tr> <tr> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of estimated useful life or remaining lease term</p></td> </tr> <tr> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 5 years</p></td> </tr> <tr> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td> <td valign="bottom"> <p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"> </p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 10 years</p></td> </tr> </table></div> P3Y P7Y Shorter of estimated useful life or remaining lease term P3Y P5Y P3Y P10Y <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our consolidated statements of operations. To date, we have not recognized any impairment of goodwill.</p> 0 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have not recognized any impairment losses on intangible assets.</p> 0 <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy, as well as server space. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of <span style="Background-color:#FFFFFF;">Accounting Standards Update No. 2016-02, </span><span style="font-style:italic;Background-color:#FFFFFF;">Leases</span><span style="Background-color:#FFFFFF;"> (Topic 842) (“ASC 842”)</span>. </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on our consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases. </p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Financial Accounting Standards Board (“FASB”) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 1: Quoted </span><span style="Background-color:#FFFFFF;color:#000000;">prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;color:#000000;">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;color:#000000;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p></td></tr></table></div> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level 3 within the valuation hierarchy. </span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2021 and 2020.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Preferred Stock Warrant</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had issued a freestanding warrant to a venture capital firm to purchase 56,875 shares of Series C convertible preferred stock with an exercise price of $2.64 in connection with a $5.0 million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant. </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the conversion, the fair value of this warrant was classified as a non-current liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders’ deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $2.3 million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our consolidated statements of operations. </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $2.6 million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.</p> 56875 2.64 5000000.0 2300000 2600000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Revenue<span style="letter-spacing:-0.1pt;"> </span>Recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue in accordance with ASC Topic 606 (“ASC 606”), <span style="font-style:italic;">Revenue from Contracts with Customers</span>. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue is generated from immunosequencing (“sequencing”) products and services (“sequencing revenue”) and from regulatory or development support services leveraging our immune medicine platform (“development revenue”). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sequencing Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue reflects the amounts generated from providing testing services through clonoSEQ to clinical and research customers, from providing our T-Detect COVID test to clinical customers and from providing sequencing services through immunoSEQ to research customers.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clinical customers, we primarily derive revenue from providing our clonoSEQ report to ordering physicians. In these transactions, we have identified one performance obligation, the delivery of a clonoSEQ report, and we bill and receive payments from medical institutions and commercial and government third-party payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our clonoSEQ coverag</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> under Medicare, we bill </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognition commences </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the number of tests </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we expect to deliver</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> either</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as we deliver </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our estimate of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the remaining tests in a patient’s treatment cycle</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or when </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the likelihood</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> becomes remote that a patient will receive additional testing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research customers, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Development<span style="letter-spacing:-0.05pt;"> </span>Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers’ initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements include single or multiple performance obligations, depending on the contract. For certain contracts, we perform services to support the biopharmaceutical customers’ regulatory submissions as part of their registrational trials. These services may include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. If agreements include sequencing activities, we separately classify those activities as sequencing revenue.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers’ control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as development revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).</p> 2 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer’s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advertising costs are expensed as incurred. Advertising expenses were $22.4 million, $14.5 million and $6.6 million for the year ended December 31, 2021, 2020 and 2019, respectively.</p> 22400000 14500000 6600000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs and allocated facility costs associated with processing samples and professional support for our sequencing revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. <span style="Background-color:#FFFFFF;color:#000000;">We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. </span>Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. <span style="Background-color:#FFFFFF;color:#000000;">Costs to support our Genentech Agreement are also a component of our research and development expenses.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We calculate basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders by dividing net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect is anti-dilutive.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders in conformity with the two-class method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is calculated by dividing the net loss attributable to Adaptive Biotechnologies Corporation common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to Adaptive Biotechnologies Corporation common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to Adaptive Biotechnologies Corporation common shareholders was not allocated to the convertible preferred stock under the two-class method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect was anti-dilutive.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have determined that our chief executive officer is the chief operating decision maker (“CODM”). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning at levels or components below the consolidated entity. As such, the consolidated entity operates as one operating segment and represents one reportable segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3, Revenue.</p> 1 1 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revenue</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We disaggregate our revenue from contracts with customers by type of service, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,896</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,439</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,519</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development support</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,448</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,552</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory milestones</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total development revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,448</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,943</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,552</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154,344</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,382</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,071</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;font-weight:bold;font-style:italic;;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">MRD Development<span style="letter-spacing:-0.05pt;"> </span>Agreements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into agreements with biopharmaceutical customers to further develop and commercialize our MRD product and the biopharmaceutical customers’ therapeutics. Under each of the agreements, we received or will receive non-refundable upfront payments and could receive substantial additional payments upon reaching certain progress-based milestones or achieving certain regulatory milestones pertaining to the customers’ therapeutics and our MRD product.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the contracts, we identify performance obligations, which may include: (1) obligations to provide services supporting the customer’s regulatory submission activities as they relate to our MRD product; and (2) sequencing services related to customer-provided samples for their regulatory submissions. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated immunosequencing services. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers’ own submission decision-making. We recognize revenue related to the sequencing services as sequencing revenue over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognized $3.2 million in revenue during the year ended December 31, 2021 due to changes in estimates of total samples to be provided under certain of our MRD development agreements for which we had previously received upfront consideration, of which $0.3 million was recognized as development revenue in the respective period.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We earned $10.0 million, $2.5 million and $2.0 million during the year ended December 31, 2021, 2020 and 2019, respectively, upon the achievement of certain regulatory milestones by us and our respective customers’ therapeutics. We recognized these earnings as development revenue within the respective periods, as we determined that the amounts were consistent with our estimated standalone selling prices and the respective performance obligations were complete.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In total, we recognized $11.8 million, $3.4 million and $3.7 million in development revenue related to our MRD development agreements during the year ended December 31, 2021, 2020 and 2019, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, in future periods we could receive up to an additional $333.5 million in milestone payments if certain regulatory approvals are obtained by our customers’ therapeutics in connection with MRD data generated from our MRD product.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Genentech<span style="letter-spacing:-0.05pt;"> </span>Collaboration Agreement</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (“Genentech Agreement”) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $300.0 million in February 2019 and may be eligible to receive more than $1.8 billion over time, including payments of up to $75.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones and up to $1,430.0 million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines: </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-family:Times New Roman;">Shared Products. The shared products will use “off-the-shelf” TCRs identified against cancer antigens shared among patients (“Shared Products”). </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-family:Times New Roman;">Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (“Personalized Product”). </span></p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in ASC Topic 808, <span style="font-style:italic;">Collaborative Arrangements</span> (“ASC 808”), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity’s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC 606 to account for the activities related to the Genentech Agreement.<span style="color:#000000;"> </span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In applying ASC 606, we identified the following performance obligations at the inception of the agreement: </span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">License to existing shared antigen data packages. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Research and development services for shared product development, including expansion of shared antigen data packages. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Research and development services for private product development. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.87%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.27%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Obligations to participate on various joint research, development and project committees. </span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech’s control of product commercialization. Specifically, under the agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other, as opposed to both. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined the initial transaction price shall be made up of only the $300.0 million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the transaction price as of December 31, 2021. We excluded the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize the revenue over a period of approximately seven to eight years from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and the Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognized revenue of $62.0 million, $52.8 million and $35.1 million during the year ended December 31, 2021, 2020 and 2019, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.</p> The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,896</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,439</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,519</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development support</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,448</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,552</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory milestones</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total development revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,448</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,943</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,552</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154,344</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,382</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,071</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;font-weight:bold;font-style:italic;;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> 78896000 41439000 43519000 65448000 54443000 39552000 10000000 2500000 2000000 75448000 56943000 41552000 154344000 98382000 85071000 3200000 300000 10000000.0 2500000 2000000.0 11800000 3400000 3700000 333500000 300000000.0 1800000 75000000.0 300000000.0 1430000000.0 300000000.0 P7Y P8Y 62000000.0 52800000 35100000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value<span style="letter-spacing:-0.05pt;"> </span>Measurements</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth the fair value of financial assets as of December 31, 2021 and 2020 that were measured at fair value on a recurring basis (in thousands): </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,946</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,946</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391,145</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391,145</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,946</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431,141</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563,087</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671,777</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671,777</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">683,358</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,641</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government debt securities and corporate bonds, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth the fair value of financial assets as of December 31, 2021 and 2020 that were measured at fair value on a recurring basis (in thousands): </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,946</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,946</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391,145</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391,145</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,946</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431,141</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563,087</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671,777</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671,777</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">683,358</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,641</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> 131946000 131946000 391145000 391145000 39996000 39996000 131946000 431141000 563087000 103283000 103283000 671777000 671777000 11581000 11581000 103283000 683358000 786641000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Investments</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investments consisted of the following as of December 31, 2021 and 2020 (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,752</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,647</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,363</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,349</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,115</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,472</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(974</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,691</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,647</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218,163</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,145</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">552,539</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">553,252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,497</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,036</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">809</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,429</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,429</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,525</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All the U.S. government debt securities and corporate bonds designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective consolidated balance sheet date.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of $1.4 million and $2.5 million were presented separately within the prepaid expenses and other current assets line item on our consolidated balance sheet as of December 31, 2021 and 2020, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2021 (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than 12 Months</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 Months Or Greater</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,014</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,083</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,886</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,900</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,141</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2021 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investments consisted of the following as of December 31, 2021 and 2020 (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,752</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,647</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,363</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,349</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,115</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,472</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(974</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,691</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,647</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218,163</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,145</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">552,539</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">553,252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,497</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,036</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">809</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,429</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,429</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,525</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 186752000 4000 109000 186647000 27363000 14000 27349000 214115000 4000 123000 213996000 205472000 974000 204498000 12691000 44000 12647000 218163000 1018000 217145000 552539000 723000 10000 553252000 11497000 86000 2000 11581000 564036000 809000 12000 564833000 118429000 98000 2000 118525000 118429000 98000 2000 118525000 1400000 2500000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2021 (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than 12 Months</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 Months Or Greater</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,014</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,083</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,886</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,900</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,141</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 345014000 1083000 32886000 58000 377900000 1141000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment, Net</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,312</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,767</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,988</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,600</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,579</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,717</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">992</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,658</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,959</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,945</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,488</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,074</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,226</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,382</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,262</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,692</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $12.3 million, $6.8 million and $6.1 million for the year ended December 31, 2021, 2020 and 2019, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,312</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,767</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,988</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,600</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,579</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,717</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">992</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,658</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,959</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,945</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,488</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,074</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,226</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,382</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,262</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,692</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 36312000 27767000 6988000 3600000 5579000 2717000 992000 860000 5658000 7185000 65959000 21945000 121488000 64074000 36226000 24382000 85262000 39692000 12300000 6800000 6100000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Goodwill<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Intangible Assets</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes in the carrying amount of goodwill since its recognition in 2015. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization as of December 31, 2021 and 2020 consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,638</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,362</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,325</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,799</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,972</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,028</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,325</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,100</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The developed technology was acquired in connection with our acquisition of Sequenta in 2015. The remaining balance of the acquired technology and the purchased intellectual property is expected to be amortized over the next 5.0 years. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, expected future amortization expense for intangible assets was as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future amortization expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization as of December 31, 2021 and 2020 consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,638</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,362</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,325</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,799</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,972</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,028</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,325</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,100</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 20000000 11638000 8362000 325000 161000 164000 20325000 11799000 8526000 20000000 9972000 10028000 325000 128000 197000 20325000 10100000 10225000 P5Y <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, expected future amortization expense for intangible assets was as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future amortization expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1699000 1699000 1703000 1699000 1699000 27000 8526000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. </span></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accrued Liabilities</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities as of December 31, 2021 and 2020 consisted of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,687</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,219</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical and contract research organization costs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,646</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Travel and entertainment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,767</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,423</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,820</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,881</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,162</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accrued tax liabilities balance as of December 31, 2020 includes a $1.4 million tax withholding liability related to unsettled option exercises as of December 31, 2020.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities as of December 31, 2021 and 2020 consisted of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,687</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,219</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical and contract research organization costs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,646</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Travel and entertainment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,767</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,423</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,820</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,881</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,162</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 3687000 3219000 1646000 1781000 184000 91000 391000 1767000 615000 4423000 2820000 1881000 9343000 13162000 1400000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Deferred Revenue</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue by revenue classification as of December 31, 2021 and 2020 was as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,915</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,463</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,545</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,856</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current deferred revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,319</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,576</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,894</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current deferred revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,618</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current and non-current deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,210</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,937</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue from our Genentech Agreement represents $56.1 million and $94.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2021 and $55.1 million and $157.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2020. In general, we expect that the current <span style="Background-color:#FFFFFF;">amounts</span> will be recognized as revenue within 12 months and the non-current amounts will be recognized as revenue over a period of approximately five to six years from December 31, 2021. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various development activities.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2021, we recognized $3.6 million in revenue as a result of changes in estimates of total samples to be provided under certain of our agreements and cancelled biopharmaceutical customer sequencing contracts for which we had received upfront consideration. Additionally, we recognized $2.5 million of sequencing revenue during the year ended December 31, 2021 related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and a change in our estimate of expected cumulative tests per patient for one of our covered indications.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue during the year ended December 31, 2021 were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,937</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions to deferred revenue during the period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,062</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized during the period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,789</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,210</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$75.7</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million was recognized</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as revenue</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that was included in the deferred revenue balance </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> December 31, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue by revenue classification as of December 31, 2021 and 2020 was as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,915</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,463</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,545</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,856</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current deferred revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,319</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,576</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,894</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current deferred revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,618</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current and non-current deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,210</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,937</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 21915000 15463000 58545000 57856000 80460000 73319000 174000 724000 98576000 162894000 98750000 163618000 179210000 236937000 56100000 94000000.0 55100000 157000000.0 P12M P5Y P6Y 3600000 2500000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue during the year ended December 31, 2021 were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,937</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions to deferred revenue during the period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,062</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized during the period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,789</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,210</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 236937000 38062000 -95789000 179210000 75700000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy in various locations, as well as server space. </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately 65,500 square feet. </span><span style="Background-color:#FFFFFF;">Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.</span> <span style="Background-color:#FFFFFF;">The amended lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In August 2019, we entered into an agreement to rent approximately 100,000 square feet in what was a to-be-constructed, new headquarters building in Seattle, Washington. In connection with the lease, we entered into a $2.1 million letter of credit with one of our existing financial institutions. Due to our </span>significant<span style="Background-color:#FFFFFF;"> involvement during the construction process of the leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance that proceeded ASC 842. The resulting asset and long-term financing obligation recorded on our balance sheet as of December 31, 2019 for the cost of the building was derecognized effective January 1, 2020 upon adoption of ASC 842. The lease commenced in December 2020, when the landlord delivered the premises to us for construction of certain tenant improvements. We occupied the new building in 2021, cash payment for rent began in October 2021 and the lease term ends in August 2033, </span><span style="Background-color:#FFFFFF;color:#000000;">subject to our option to twice extend the lease for five years. In connection with this lease, the landlord agreed to fund $20.0 million in improvements, which was subsequently reduced to $14.8 million as a result of our change requests made during landlord construction of the building, net of an administration fee. As of December 31, 2021, we have incurred $14.9 million in certain tenant improvement costs, of which $10.9 million has been reimbursed by the landlord. The remaining $4.0 million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on our consolidated balance sheet as of December 31, 2021 and will be reimbursed by the landlord. As of December 31, 2020, w</span><span style="Background-color:#FFFFFF;">e incurred $5.2 million in certain tenant improvement costs, of which $0.7 million had been reimbursed by the landlord. The remaining $4.5 million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on our consolidated balance sheet as of December 31, 2020. </span><span style="Background-color:#FFFFFF;color:#000000;">The lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In October 2019, we entered into an agreement to lease approximately 14,750 square feet in a separate Seattle, Washington location, pursuant to a lease expiring in October 2029, which is subject to our ability to exercise an early termination right after the third year. In connection with the lease, the landlord agreed to provide a tenant improvement allowance in the maximum amount of $0.7 million. The lease also requires us to pay additional amounts for operating expenses.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In April 2018, we entered into a lease agreement to lease approximately 13,400 square feet in South San Francisco, California. The lease term is through March 2026 and provides for one <span style="-sec-ix-hidden:F_000687">five-year</span> extension option. We are responsible for our share of allocable operating expenses, tax expenses and utilities cost during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $2.4 million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately 19,900 additional square feet and provides for a $0.6 million tenant improvement allowance.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, we entered into an agreement to lease approximately 3,100 square feet of office space in New York City, New York, pursuant to a lease that expires November 2025, subject to our ability to exercise an early termination right in 2023. The lease requires us to pay certain operating expenses.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In March 2021, we executed a lease to rent approximately 27,000 square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the year ended December 31, 2021. Rent obligations commenced in October 2021 and the lease expires October 2031, subject to an early termination option after the seventh year and an option to twice extend the lease for five years. The lease requires us to pay certain operating expenses. Furthermore, the landlord agreed to fund $1.2 million in improvements in connection with this lease.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of </span>December<span style="Background-color:#FFFFFF;"> 31, 2021, we were not party to any finance leases. Our leases have remaining terms of 0.3 years to 11.7 years and include options to extend certain of the leases up to 10.0 years and terminate certain of the leases after 3.0 years. We adjust lease terms for these options only when it is reasonably certain we will exercise these options. As of </span>December<span style="Background-color:#FFFFFF;"> 31, 2021, it was reasonably certain that we would exercise our option to terminate </span>two<span style="Background-color:#FFFFFF;"> of our leases after 3.0 </span>years<span style="Background-color:#FFFFFF;">.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Other information related to our operating leases as of </span>December <span style="Background-color:#FFFFFF;">31, 2021 and 2020 was as follows:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000705">10.55</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000706">11.33</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of </span>December<span style="Background-color:#FFFFFF;"> 31, 2021 (in thousands):</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,184</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,964</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,692</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,098</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,330</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,188</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,456</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Imputed interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,410</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Tenant improvement receivables</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,306</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,740</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,055</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, less current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,685</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Operating lease expense was $12.4 million and $5.5 million for the year ended</span> December <span style="Background-color:#FFFFFF;">31, 2021 and 2020, respectively. Variable lease expense for operating leases was $3.5 million and $2.6 million for the year ended </span>December<span style="Background-color:#FFFFFF;"> 31, 2021 and 2020, respectively.</span> <span style="Background-color:#FFFFFF;">Rent expense recognized under ASC 840, </span><span style="font-style:italic;Background-color:#FFFFFF;">Leases</span><span style="Background-color:#FFFFFF;">, inclusive of operating and maintenance costs, was $5.3 million for the year ended </span>December<span style="Background-color:#FFFFFF;"> 31, 2019.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Cash paid for amounts included in the measurement of lease liabilities was $8.3 million and cash received for tenant improvement allowances was $11.5 million during the year ended December 31, 2021. Cash paid for amounts included in the measurement of lease liabilities for the year ended </span>December<span style="Background-color:#FFFFFF;"> 31, 2020 was $3.2 million, net of $2.5 million of cash received for tenant improvement allowances. For the year ended December 31, 2021, ROU assets obtained in exchange for operating lease liabilities was $5.4 million. For the year ended December 31, 2020, ROU assets obtained in exchange for operating lease liabilities was $109.1 million, inclusive of the $33.0 million recognized from the adoption of ASC 842.</span></p> 65500 Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years. 2020-01 P5Y 100000 2100000 2020-12 cash payment for rent began in October 2021 and the lease term ends in August 2033, 2021-10 2033-08 P5Y 20000000.0 14800000 14900000 10900000 4000000.0 5200000 700000 4500000 14750 700000 13400 The lease term is through March 2026 and provides for one five-year extension option. 2026-03 2400000 19900 600000 3100 2025-11 27000 2021-10 2031-10 subject to an early termination option after the seventh year option to twice extend the lease for five years P5Y 1200000 P0Y3M18D P11Y8M12D options to extend certain of the leases up to 10.0 years P10Y P3Y 2 P3Y <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Other information related to our operating leases as of </span>December <span style="Background-color:#FFFFFF;">31, 2021 and 2020 was as follows:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000705">10.55</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000706">11.33</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> 0.046 0.046 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of </span>December<span style="Background-color:#FFFFFF;"> 31, 2021 (in thousands):</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,184</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,964</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,692</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,098</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,330</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,188</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,456</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Imputed interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,410</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Tenant improvement receivables</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,306</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,740</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,055</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, less current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,685</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 14184000 13964000 13692000 14098000 12330000 81188000 149456000 32410000 5306000 111740000 5055000 106685000 12400000 5500000 3500000 2600000 5300000 8300000 -11500000 3200000 -2500000 5400000 109100000 33000000.0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Legal Proceedings </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2021.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Indemnification Agreements </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="color:#231F20;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#231F20;letter-spacing:-0.05pt;">Shareholders’</span><span style="color:#231F20;"> Equity</span></p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has no preferences or privileges and is not redeemable. Holders of our common stock are entitled to one vote for each share of common stock held. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we <span style="color:#231F20;">have reserved shares of common stock for the following:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,990,175</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the 2019 Equity Incentive Plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,299,923</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the Employee Stock Purchase Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,804,298</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved for future issuance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,094,396</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our 2019 Equity Incentive Plan (“2019 Plan”) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our Employee Stock Purchase Plan (“ESPP”) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2021, our 2019 Plan reserve increased by 6,882,344 shares. Our board of directors determined not to increase the ESPP reserve in 2021. Furthermore, our board of directors determined not to increase the 2019 Plan and ESPP reserves in 2022.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Common<span style="letter-spacing:-0.05pt;"> </span>Stock<span style="letter-spacing:-0.05pt;"> </span>Warrant</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2014, we issued a warrant to purchase 56,875 shares of Series C convertible preferred stock at an exercise price of $2.64. The warrant was exercisable for a period of seven years from the date of issuance. Immediately prior to and in connection with the completion of our initial public offering on July 1, 2019, this convertible preferred stock warrant was converted to a warrant to purchase the same number of shares of common stock. The warrant was exercised on February 25, 2021 through a cashless exercise, resulting in the issuance of 54,162 shares of our common stock. The impact of this cashless exercise was immaterial to our consolidated financial statements. As of December 31, 2021, there were no outstanding warrants to purchase common stock.</p> Holders of our common stock are entitled to one vote for each share of common stock held 1 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we <span style="color:#231F20;">have reserved shares of common stock for the following:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,990,175</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the 2019 Equity Incentive Plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,299,923</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the Employee Stock Purchase Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,804,298</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved for future issuance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,094,396</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 13990175 22299923 2804298 39094396 0.05 0.01 6882344 56875 2.64 P7Y 54162 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Equity Incentive Plans</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Sequenta 2008 Stock Plan, as amended</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our acquisition of Sequenta in January 2015, we assumed Sequenta’s Equity Incentive Plan (“2008 Plan”), including all outstanding options and shares available for future issuance under the 2008 Plan, which, prior to the completion of our initial public offering, were all exercisable for Series E-1 convertible preferred stock. Upon completion of our initial public offering in July 2019, the outstanding options were exercisable for common stock. No shares are available for future issuance under this plan and no equity awards are outstanding under this plan as of December 31, 2021.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Adaptive 2009 Equity Incentive Plan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted an equity incentive plan in 2009 (“2009 Plan”) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the option exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Options granted under this plan expire no later than ten years from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While no shares are available for future issuance under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">2019 Equity Incentive Plan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, options granted under this plan expire no later than ten years from the grant date and vesting is established at the time of grant. Except for certain option and restricted stock unit grants made to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a <span style="-sec-ix-hidden:F_000752">four-year</span> period, subject to continuous service through each applicable vesting date. As of December 31, 2021, we have authorized 29,131,628 shares of common stock for issuance under the 2019 Plan.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in shares available for grant during the year ended December 31, 2021 were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Available for Grant</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,617,001</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 Equity Incentive Plan reserve increase effective January 1, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,882,344</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and restricted stock units granted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,306,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and restricted stock units forfeited, cancelled or expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,106,843</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,299,923</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2021 was as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic Value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,433,560</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.82</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,052,025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited or cancelled</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(992,428</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.90</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,116</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.56</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,674,057</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,778,984</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.72</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,105</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and exercisable at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,281,600</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.99</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,537</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining contractual life for options outstanding as of December 31, 2021 was 7.0 years. The weighted-average remaining contractual life for vested and exercisable options as of December 31, 2021 was 5.7 years. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of options granted during the year ended December 31, 2021, 2020 and 2019 was $24.22, $21.11 and $6.87, respectively. The total intrinsic value of options exercised during the year ended December 31, 2021, 2020 and 2019 was $156.5 million, $190.4 million and $39.1 million, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the $26.7 million proceeds from exercise of stock options included on our consolidated statements of cash flows for the year ended December 31, 2021, $0.3 million related to options exercised during the year ended December 31, 2020 but settled during the year ended December 31, 2021. Of the $21.7 million proceeds from exercise of stock options included on our consolidated statements of cash flows for the year ended December 31, 2020, $0.5 million related to options exercised during the year ended December 31, 2019 but settled during the year ended December 31, 2020.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2021 was as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-weight:bold;;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value per Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,254,240</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.98</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units forfeited or cancelled</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,299</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.20</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units vested</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,211,191</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.41</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2020 and 2019 was $28.10 and $41.63, respectively.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Grant Date Fair Value of Options and Restricted Stock Units Granted</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated grant date fair values of options granted during the years ended December 31, 2021, 2020 and 2019 were estimated using the Black-Scholes option-pricing model with the following assumptions: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.86 - $66.50</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.68 - $55.23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.80 - $47.81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000805">5.27 - 6.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000806">5.27 - 6.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000807">5.27 - 6.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000811">0.5% - 1.4%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000812">0.4% - 1.7%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000813">1.4% - 2.5%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000817">67.1% - 70.0%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000818">70.5% - 73.3%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000819">64.3% - 72.9%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The determination of the grant date fair value of stock options using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows: </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair value of common stock—<span style="font-style:normal;">Prior to the closing of our initial public offering, the fair value of our common stock was determined with input from management using valuation methodologies which utilized certain assumptions, including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of our common stock, the methodologies, approaches and assumptions used to estimate the enterprise value were consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, </span>Valuation of Privately-Held-Company Equity Securities Issued as Compensation<span style="font-style:normal;">. For option grants made after the closing of our initial public offering, the fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<span style="font-style:normal;">—The expected term of options granted to employees and non-employee directors is determined using the “simplified” method, as illustrated in ASC Topic 718, </span>Compensation—Stock Compensation<span style="font-style:normal;">, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is </span><span style="color:#000000;font-style:normal;">based on the midpoint between the vesting date and the end of the contractual term of the option.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<span style="font-style:normal;">—We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the options.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<span style="font-style:normal;">—As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield<span style="font-style:normal;">—We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of zero in the option valuation model.</span> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant date fair value of restricted stock units granted <span style="color:#000000;">is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation costs related to stock options and restricted stock units for the years ended December 31, 2021, 2020 and 2019 are included on our consolidated statements of operations as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,100</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">817</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,061</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,519</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,312</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,627</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,480</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,778</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,798</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,155</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,251</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,761</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,124</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, unrecognized share-based compensation expense related to unvested stock options was $96.8 million, which is expected to be recognized over a remaining weighted-average period of 2.9 years. Additionally, as of December 31, 2021, unrecognized share-based compensation expense related to unvested restricted stock units was $38.3 million, which is expected to be recognized over a remaining weighted-average period of 3.4 years.</p> 0 0 P10Y 0 P10Y 29131628 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in shares available for grant during the year ended December 31, 2021 were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Available for Grant</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,617,001</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 Equity Incentive Plan reserve increase effective January 1, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,882,344</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and restricted stock units granted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,306,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and restricted stock units forfeited, cancelled or expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,106,843</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,299,923</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 18617001 6882344 4306265 1106843 22299923 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2021 was as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic Value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,433,560</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.82</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,052,025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited or cancelled</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(992,428</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.90</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,116</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.56</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,674,057</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,778,984</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.72</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,105</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and exercisable at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,281,600</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.99</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,537</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 14433560 12.82 3052025 39.39 992428 25.90 40116 26.56 3674057 7.21 12778984 19.72 156105000 7281600 10.99 132537000 P7Y P5Y8M12D 24.22 21.11 6.87 156500000 190400000 39100000 26700000 300000 21700000 500000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2021 was as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-weight:bold;;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value per Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,254,240</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.98</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units forfeited or cancelled</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,299</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.20</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units vested</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,211,191</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.41</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 50000 28.10 1254240 37.98 74299 43.20 18750 28.10 1211191 37.41 28.10 41.63 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated grant date fair values of options granted during the years ended December 31, 2021, 2020 and 2019 were estimated using the Black-Scholes option-pricing model with the following assumptions: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.86 - $66.50</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.68 - $55.23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.80 - $47.81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000805">5.27 - 6.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000806">5.27 - 6.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000807">5.27 - 6.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000811">0.5% - 1.4%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000812">0.4% - 1.7%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000813">1.4% - 2.5%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000817">67.1% - 70.0%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000818">70.5% - 73.3%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000819">64.3% - 72.9%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0 The compensation costs related to stock options and restricted stock units for the years ended December 31, 2021, 2020 and 2019 are included on our consolidated statements of operations as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,100</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">817</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,061</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,519</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,312</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,627</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,480</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,778</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,798</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,155</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,251</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,761</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,124</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> 2100000 817000 555000 14061000 8519000 3934000 12312000 6627000 3480000 14778000 8798000 5155000 43251000 24761000 13124000 96800000 P2Y10M24D 38300000 P3Y4M24D <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Microsoft Collaboration Agreement</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Summary of Agreement</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we entered into a collaboration agreement with Microsoft (“Microsoft Agreement”) to computationally derive a comprehensive TCR antigen map for purposes of developing a universal diagnostic based on a single blood test.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemporaneously with the Microsoft Agreement, we entered into a separate agreement to use Microsoft’s Azure cloud services at standard volume pricing with a minimum Azure purchase requirement of $12.0 million over the <span style="-sec-ix-hidden:F_000844">seven-year</span> term of the Microsoft Agreement, which we expect to meet in the ordinary course of business.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, contemporaneously with entering into the Microsoft Agreement, Microsoft made a preferred stock investment of $45.0 million as a part of our Series F-1 convertible preferred stock issuance.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Summary of Accounting</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the Microsoft Agreement meet the criteria under ASC Topic 808, <span style="font-style:italic;">Collaborative Arrangements</span> (“ASC 808”), as both parties are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity. ASC 808 does not provide guidance on how to account for the activities under the collaboration and we determined that Microsoft did not meet the definition of a customer under ASC 606. Accordingly, we looked to other guidance to determine the accounting for the respective elements.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined that the preferred stock issuance and commitment to use Microsoft’s Azure cloud services were made at terms consistent with market rates. All consideration received as part of the Series F-1 convertible preferred stock issuance was accounted for as part of the Series F-1 preferred stock issuance. Since the commitment to purchase Microsoft’s Azure cloud services was at market terms and we expect to meet the commitment in the ordinary course of business during the seven-year term, we record the expenses in the period in which the services are consumed. These costs are recorded in our consolidated statements of operations based on the underlying activities for which they support.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The remaining elements of the agreement were highly interrelated, so we evaluated them in the aggregate to determine the appropriate accounting application. Specifically, we determined that the transfer of license rights between the parties, our commitment to provide data and immunomics, diagnostic and bioinformatics expertise to Microsoft and Microsoft’s commitment to provide machine learning software and related development services to us were highly interrelated because they were necessary for the parties to perform the activities under the Microsoft Agreement and, therefore, should be evaluated as one unit of account.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accounted for these collaboration activities by analogy to ASC Topic 845, <span style="font-style:italic;">Nonmonetary Transactions</span>, and determined that major uncertainties exist about the realizability of the value that would be assigned to an asset received from or provided to Microsoft under the collaboration and, therefore, fair value could not be reliably measured. As a result, we did not recognize any non-monetary assets or corresponding non-monetary income or expenses pertaining to the rights provided to us or to be received by us under the Microsoft Agreement.</p> 12000000.0 45000000.0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before provision for income taxes for the periods presented are as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before provision for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,298</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of our deferred tax assets and liabilities as of the dates presented are as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,363</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,433</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforward</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,981</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonqualifying stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,072</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,096</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,401</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,052</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,481</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,713</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,345</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,983</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">326,862</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,258</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(297,020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(197,527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net of valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,842</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,731</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible and intangible assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,310</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,760</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,532</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,971</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 740, <span style="font-style:italic;">Income Taxes</span>, requires that the tax benefit of NOLs, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $99.5 million and $96.6 million during the year ended December 31, 2021 and 2020, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal tax laws impose substantial restrictions on the utilization of NOL and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through December 31, 2020 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the TCJA federal income tax law, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years. As of December 31, 2021, we had U.S. federal NOLs of $192.5 million and U.S. federal tax credits of $33.6 million that will begin to expire in 2028. We also had $576.2 million of NOLs as of December 31, 2021 that do not expire.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax, net of federal tax benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47.7)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66.1)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44.3)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for Global Intangible Low-Taxed Income as period costs when incurred. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize, in our consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $6.9 million as of December 31, 2021. A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,052</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,437</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,489</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,426</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,915</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, 2020 and 2019, we recognized uncertain tax positions of $3.4 million, $1.4 million and $0.8 million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had no accrued interest or penalties related to uncertain tax positions as of December 31, 2021 and 2020.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before provision for income taxes for the periods presented are as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before provision for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,298</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> -207314000 -146227000 -68606000 16000 -207298000 -146227000 -68606000 The significant components of our deferred tax assets and liabilities as of the dates presented are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,363</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,433</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforward</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,981</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonqualifying stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,072</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,096</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,401</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,052</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,481</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,713</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,345</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,983</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">326,862</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,258</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(297,020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(197,527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net of valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,842</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,731</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible and intangible assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,310</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,760</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,532</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,971</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> 200363000 105433000 31200000 18981000 18072000 12096000 30401000 31052000 42481000 59713000 4345000 2983000 326862000 230258000 297020000 197527000 29842000 32731000 7310000 5760000 22532000 26971000 0 0 99500000 96600000 P20Y 192500000 33600000 2028 2028 576200000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax, net of federal tax benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47.7)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66.1)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44.3)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td> </tr> </table></div> 0.210 0.210 0.210 0.083 0.138 0.081 0.141 0.252 0.098 -0.001 -0.001 -0.010 0.047 0.057 0.061 -0.003 0.005 0.003 -0.477 -0.661 -0.443 0.000 0.000 0.000 6900000 A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,052</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,437</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,489</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,426</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,915</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> 1260000 792000 2052000 1437000 3489000 3426000 6915000 3400000 1400000 800000 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss<span style="letter-spacing:-0.05pt;"> </span>Per Share<span style="letter-spacing:-0.05pt;"> </span>Attributable<span style="letter-spacing:0.05pt;"> </span>to Adaptive Biotechnologies Corporation Common <span style="letter-spacing:-0.05pt;">Shareholders</span></p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019 (in thousands, except share and per share amounts): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Adaptive Biotechnologies Corporation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,279</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustment to redemption value for Series E-1 convertible preferred stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(964</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,279</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,570</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,354,915</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,216,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,165,315</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.48</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.01</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since we were in a loss position for all periods presented, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is the same as diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019, as they had an anti-dilutive effect:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (on as if converted basis)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,104,469</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,097,374</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,125,548</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,183,546</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested restricted stock units</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693,173</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,952</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,570</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,875</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,961</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock warrant</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,204</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,799,117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,220,548</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,377,132</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019 (in thousands, except share and per share amounts): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Adaptive Biotechnologies Corporation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,279</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustment to redemption value for Series E-1 convertible preferred stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(964</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,279</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,570</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,354,915</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,216,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,165,315</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.48</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.01</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> -207279000 -146227000 -68606000 964000 -207279000 -146227000 -69570000 140354915 131216468 69165315 -1.48 -1.11 -1.01 The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019, as they had an anti-dilutive effect: <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (on as if converted basis)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,104,469</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,097,374</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,125,548</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,183,546</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested restricted stock units</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693,173</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,952</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,570</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,875</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,961</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock warrant</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,204</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,799,117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,220,548</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,377,132</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> 46104469 13097374 16125548 17183546 693173 38125 4952 8570 56875 55961 28204 13799117 16220548 63377132 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Retirement Plan</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a salary deferral 401(k) plan (“401(k) Plan”) covering employees who have met certain eligibility requirements. Employees may defer up to 100% of their compensation to the 401(k) Plan, subject to federal limits. We made $2.5 million and $1.6 million in discretionary contributions during the year ended December 31, 2021 and 2020, respectively, which are fully vested after one year of employee service. We did not make any discretionary contributions during the year ended December 31, 2019.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> 1 2500000 1600000 P1Y P1Y 0 EXCEL 111 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 112 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 113 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 114 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 221 486 1 false 72 0 false 9 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity Consolidated Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity Statements 6 false false R7.htm 100060 - Statement - Consolidated Statements of Cash Flows Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Organization and Description of Business Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 8 false false R9.htm 100080 - Disclosure - Significant Accounting Policies Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Revenue Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenue Revenue Notes 10 false false R11.htm 100100 - Disclosure - Fair Value Measurements Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 100110 - Disclosure - Investments Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestments Investments Notes 12 false false R13.htm 100120 - Disclosure - Property and Equipment, Net Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 13 false false R14.htm 100130 - Disclosure - Goodwill and Intangible Assets Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 14 false false R15.htm 100140 - Disclosure - Accrued Liabilities Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilities Accrued Liabilities Notes 15 false false R16.htm 100150 - Disclosure - Deferred Revenue Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenue Deferred Revenue Notes 16 false false R17.htm 100160 - Disclosure - Leases Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeases Leases Notes 17 false false R18.htm 100170 - Disclosure - Commitments and Contingencies Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 100180 - Disclosure - Shareholders' Equity Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquity Shareholders' Equity Notes 19 false false R20.htm 100190 - Disclosure - Equity Incentive Plans Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlans Equity Incentive Plans Notes 20 false false R21.htm 100200 - Disclosure - Microsoft Collaboration Agreement Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreement Microsoft Collaboration Agreement Notes 21 false false R22.htm 100210 - Disclosure - Income Taxes Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 22 false false R23.htm 100220 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders Notes 23 false false R24.htm 100230 - Disclosure - Retirement Plan Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRetirementPlan Retirement Plan Notes 24 false false R25.htm 100240 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies 25 false false R26.htm 100250 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies 26 false false R27.htm 100260 - Disclosure - Revenue (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueTables Revenue (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenue 27 false false R28.htm 100270 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurements 28 false false R29.htm 100280 - Disclosure - Investments (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsTables Investments (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestments 29 false false R30.htm 100290 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet 30 false false R31.htm 100300 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets 31 false false R32.htm 100310 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilities 32 false false R33.htm 100320 - Disclosure - Deferred Revenue (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueTables Deferred Revenue (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenue 33 false false R34.htm 100330 - Disclosure - Leases (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeases 34 false false R35.htm 100340 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquity 35 false false R36.htm 100350 - Disclosure - Equity Incentive Plans (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansTables Equity Incentive Plans (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlans 36 false false R37.htm 100360 - Disclosure - Income Taxes (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxes 37 false false R38.htm 100370 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables) Tables http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders 38 false false R39.htm 100380 - Disclosure - Organization and Description of Business - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails Organization and Description of Business - Additional Information (Details) Details 39 false false R40.htm 100390 - Disclosure - Significant Accounting Policies - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails Significant Accounting Policies - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) Details 41 false false R42.htm 100410 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details) Details 42 false false R43.htm 100420 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details) Details 43 false false R44.htm 100430 - Disclosure - Revenue - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails Revenue - Additional Information (Details) Details 44 false false R45.htm 100440 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 45 false false R46.htm 100450 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails Investments - Schedule of Available-for-sale Investments (Details) Details 46 false false R47.htm 100460 - Disclosure - Investments - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails Investments - Additional Information (Details) Details 47 false false R48.htm 100470 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details) Details 48 false false R49.htm 100480 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails Property and Equipment, Net - Schedule of Property and Equipment (Details) Details 49 false false R50.htm 100490 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 50 false false R51.htm 100500 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails Goodwill and Intangible Assets - Additional Information (Details) Details 51 false false R52.htm 100510 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details) Details 52 false false R53.htm 100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) Details 53 false false R54.htm 100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 54 false false R55.htm 100540 - Disclosure - Accrued Liabilities - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetails Accrued Liabilities - Additional Information (Details) Details 55 false false R56.htm 100550 - Disclosure - Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details) Details 56 false false R57.htm 100560 - Disclosure - Deferred Revenue - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails Deferred Revenue - Additional Information (Details) Details 57 false false R58.htm 100570 - Disclosure - Deferred Revenue - Additional Information (Details1) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1 Deferred Revenue - Additional Information (Details1) Details 58 false false R59.htm 100580 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) Details 59 false false R60.htm 100590 - Disclosure - Leases- Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases- Additional Information (Details) Details 60 false false R61.htm 100600 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails Leases- Summary of Other Information Related to Operating Lease (Details) Details 61 false false R62.htm 100610 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) Details 62 false false R63.htm 100630 - Disclosure - Shareholders' Equity - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails Shareholders' Equity - Additional Information (Details) Details 63 false false R64.htm 100640 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details) Details 64 false false R65.htm 100650 - Disclosure - Equity Incentive Plans - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails Equity Incentive Plans - Additional Information (Details) Details 65 false false R66.htm 100660 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) Details 66 false false R67.htm 100670 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details) Details 67 false false R68.htm 100680 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details) Details 68 false false R69.htm 100690 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Options Granted (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Options Granted (Details) Details 69 false false R70.htm 100700 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details) Details 70 false false R71.htm 100710 - Disclosure - Microsoft Collaboration Agreement - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails Microsoft Collaboration Agreement - Additional Information (Details) Details 71 false false R72.htm 100720 - Disclosure - Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details) Details 72 false false R73.htm 100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) Details 73 false false R74.htm 100740 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 74 false false R75.htm 100750 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail) Details 75 false false R76.htm 100760 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail) Details 76 false false R77.htm 100770 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) Details 77 false false R78.htm 100780 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) Details 78 false false R79.htm 100790 - Disclosure - Retirement Plan - Additional Information (Details) Sheet http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails Retirement Plan - Additional Information (Details) Details 79 false false All Reports Book All Reports adpt-10k_20211231.htm adpt-20211231.xsd adpt-20211231_cal.xml adpt-20211231_def.xml adpt-20211231_lab.xml adpt-20211231_pre.xml adpt-ex211_7.htm adpt-ex231_14.htm adpt-ex311_6.htm adpt-ex312_8.htm adpt-ex321_11.htm adpt-ex322_13.htm g4bdklltl5z5000001.jpg g4bdklltl5z5000002.jpg g4bdklltl5z5000003.jpg g4bdklltl5z5000004.jpg g4bdklltl5z5000005.jpg g4bdklltl5z5000006.jpg g4bdklltl5z5000007.jpg g4bdklltl5z5000008.jpg g4bdklltl5z5000009.jpg g4bdklltl5z5000010.jpg g4bdklltl5z5000011.jpg g4bdklltl5z5000012.jpg g4bdklltl5z5000013.jpg g4bdklltl5z5000014.jpg g4bdklltl5z5000015.jpg g4bdklltl5z5000016.jpg g4bdklltl5z5000017.jpg g4bdklltl5z5000018.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 117 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adpt-10k_20211231.htm": { "axisCustom": 0, "axisStandard": 30, "contextCount": 221, "dts": { "calculationLink": { "local": [ "adpt-20211231_cal.xml" ] }, "definitionLink": { "local": [ "adpt-20211231_def.xml" ] }, "inline": { "local": [ "adpt-10k_20211231.htm" ] }, "labelLink": { "local": [ "adpt-20211231_lab.xml" ] }, "presentationLink": { "local": [ "adpt-20211231_pre.xml" ] }, "schema": { "local": [ "adpt-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 608, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 36, "http://www.adaptivebiotech.com/20211231": 4, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 44 }, "keyCustom": 73, "keyStandard": 413, "memberCustom": 33, "memberStandard": 37, "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Revenue", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Fair Value Measurements", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Investments", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Property and Equipment, Net", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Accrued Liabilities", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:DeferredRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Deferred Revenue", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenue", "shortName": "Deferred Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:DeferredRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Leases", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Commitments and Contingencies", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Shareholders' Equity", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Equity Incentive Plans", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlans", "shortName": "Equity Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Microsoft Collaboration Agreement", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreement", "shortName": "Microsoft Collaboration Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Income Taxes", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders", "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Retirement Plan", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRetirementPlan", "shortName": "Retirement Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Revenue (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Investments (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Accrued Liabilities (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "adpt:DeferredRevenueTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Deferred Revenue (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueTables", "shortName": "Deferred Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "adpt:DeferredRevenueTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Leases (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Equity Incentive Plans (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansTables", "shortName": "Equity Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Income Taxes (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables", "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtOwnershipAxis_adptDigitalBiotechnologiesIncMember_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Organization and Description of Business - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "shortName": "Organization and Description of Business - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtOwnershipAxis_adptDigitalBiotechnologiesIncMember_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Operations", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Significant Accounting Policies - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-5", "lang": null, "name": "us-gaap:UnbilledReceivablesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails", "shortName": "Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails", "shortName": "Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails", "shortName": "Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Revenue - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "shortName": "Revenue - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20210101_20211231", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails", "shortName": "Investments - Schedule of Available-for-sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Investments - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "shortName": "Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails", "shortName": "Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "shortName": "Goodwill and Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20151231", "decimals": "INF", "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails", "shortName": "Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails", "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20201231", "decimals": "-5", "first": true, "lang": null, "name": "adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Accrued Liabilities - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetails", "shortName": "Accrued Liabilities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20201231", "decimals": "-5", "first": true, "lang": null, "name": "adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails", "shortName": "Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Deferred Revenue - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "shortName": "Deferred Revenue - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "adpt:DeferredRevenueTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "adpt:DeferredRevenueTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Deferred Revenue - Additional Information (Details1)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1", "shortName": "Deferred Revenue - Additional Information (Details1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "adpt:DeferredRevenueTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "adpt:ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock", "adpt:DeferredRevenueTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails", "shortName": "Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "adpt:DeferredRevenueTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity", "shortName": "Consolidated Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20200229", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "U_utrsqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Leases- Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases- Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20200229", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "U_utrsqft", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails", "shortName": "Leases- Summary of Other Information Related to Operating Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails", "shortName": "Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommonStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Shareholders' Equity - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "shortName": "Shareholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommonStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails", "shortName": "Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Equity Incentive Plans - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "shortName": "Equity Incentive Plans - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails", "shortName": "Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20210101_20211231", "decimals": "INF", "lang": null, "name": "adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails", "shortName": "Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails", "shortName": "Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R69": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Options Granted (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails", "shortName": "Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "lang": null, "name": "adpt:NoncashLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails", "shortName": "Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231", "decimals": "INF", "first": true, "lang": null, "name": "adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Microsoft Collaboration Agreement - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails", "shortName": "Microsoft Collaboration Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231", "decimals": "INF", "first": true, "lang": null, "name": "adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails", "shortName": "Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail", "shortName": "Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail", "shortName": "Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R77": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R78": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Retirement Plan - Additional Information (Details)", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails", "shortName": "Retirement Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Organization and Description of Business", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Significant Accounting Policies", "role": "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adpt-10k_20211231.htm", "contextRef": "C_0001478320_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 72, "tag": { "adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued clinical and contract research organization costs, current.", "label": "Accrued Clinical And Contract Research Organization Costs Current", "terseLabel": "Clinical and contract research organization costs" } } }, "localname": "AccruedClinicalAndContractResearchOrganizationCostsCurrent", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued purchase of property and equipment current.", "label": "Accrued Purchase Of Property And Equipment Current", "terseLabel": "Purchases of property and equipment" } } }, "localname": "AccruedPurchaseOfPropertyAndEquipmentCurrent", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued tax withholding liability related to unsettled option exercises.", "label": "Accrued Tax Withholding Liability Related To Unsettled Option Exercises", "terseLabel": "Accrued tax withholding liability related to unsettled option exercises" } } }, "localname": "AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_AdditionalMilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional milestone payment.", "label": "Additional Milestone Payment", "terseLabel": "Additional milestone payment receivable" } } }, "localname": "AdditionalMilestonePayment", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital capital contributions.", "label": "Adjustments To Additional Paid In Capital Capital Contributions", "terseLabel": "Capital contributions for Digital Biotechnologies, Inc." } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalCapitalContributions", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital conversion of convertible preferred stock warrant to common stock warrant.", "label": "Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant", "terseLabel": "Conversion of convertible preferred stock warrant to common stock warrant" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital, initial public offering costs.", "label": "Adjustments To Additional Paid In Capital Initial Public Offering Costs", "terseLabel": "Initial public offering costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid In capital share based compensation stock option and restricted stock unit requisite service period recognition value.", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Option And Restricted Stock Unit Requisite Service Period Recognition Value", "terseLabel": "Common stock option and restricted stock unit share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for sale securities debt securities current.", "label": "Available For Sale Securities Debt Securities Current [Member]", "terseLabel": "Short-Term Marketable Securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrentMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for sale securities debt securities noncurrent.", "label": "Available For Sale Securities Debt Securities Noncurrent [Member]", "terseLabel": "Long-Term Marketable Securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of presentation and principles of consolidation policy.", "label": "Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in redemption value for vested convertible preferred stock options.", "label": "Change In Redemption Value For Vested Convertible Preferred Stock Options", "terseLabel": "Change in redemption value for vested Series E-1 convertible preferred stock options" } } }, "localname": "ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, weighted average exercise price of warrants or rights", "label": "Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights", "terseLabel": "Weighted-average exercise price of warrants" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "adpt_ClassOfWarrantOrRightsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or rights, term.", "label": "Class Of Warrant Or Rights Term", "terseLabel": "Warrant exercisable term" } } }, "localname": "ClassOfWarrantOrRightsTerm", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "adpt_CollaborationArrangementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration Arrangement Disclosure [Abstract]", "label": "Collaboration Arrangement Disclosure [Abstract]" } } }, "localname": "CollaborationArrangementDisclosureAbstract", "nsuri": "http://www.adaptivebiotech.com/20211231", "xbrltype": "stringItemType" }, "adpt_CommercialMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial milestones.", "label": "Commercial Milestones [Member]", "terseLabel": "Commercial Milestones" } } }, "localname": "CommercialMilestonesMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock options and restricted stock units granted.", "label": "Common Stock Options And Restricted Stock Units Granted [Member]", "terseLabel": "Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted" } } }, "localname": "CommonStockOptionsAndRestrictedStockUnitsGrantedMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "adpt_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrants member.", "label": "Common Stock Warrants [Member]", "terseLabel": "Common Stock Warrants" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "adpt_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer equipment and software.", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer Equipment and Software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "adpt_ComputerSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer software.", "label": "Computer Software [Member]", "terseLabel": "Computer Software" } } }, "localname": "ComputerSoftwareMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "adpt_ContractBalancesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract balances.", "label": "Contract Balances Policy [Text Block]", "terseLabel": "Contract Balances" } } }, "localname": "ContractBalancesPolicyTextBlock", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "adpt_ContractWithCustomerLiabilityCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract with customer liability current abstract.", "label": "Contract With Customer Liability Current [Abstract]", "terseLabel": "Current deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrentAbstract", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" ], "xbrltype": "stringItemType" }, "adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with customer liability milestone method revenue recognized.", "label": "Contract With Customer Liability Milestone Method Revenue Recognized", "terseLabel": "Milestone revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_ContractWithCustomerLiabilityNonCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract with customer liability non current abstract.", "label": "Contract With Customer Liability Non Current [Abstract]", "terseLabel": "Non-current deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNonCurrentAbstract", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" ], "xbrltype": "stringItemType" }, "adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion of convertible preferred stock to common stock upon closing of initial public offering.", "label": "Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering", "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering" } } }, "localname": "ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering.", "label": "Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant Upon Closing Of Initial Public Offering", "terseLabel": "Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering" } } }, "localname": "ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "adpt_ConvertiblePreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock warrants member.", "label": "Convertible Preferred Stock Warrants [Member]", "terseLabel": "Convertible Preferred Stock Warrants" } } }, "localname": "ConvertiblePreferredStockWarrantsMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "adpt_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A.", "label": "Customer A [Member]", "terseLabel": "Customer A" } } }, "localname": "CustomerAMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "domainItemType" }, "adpt_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B.", "label": "Customer B [Member]", "terseLabel": "Customer B" } } }, "localname": "CustomerBMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "domainItemType" }, "adpt_DeferredRevenueTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred revenue.", "label": "Deferred Revenue [Text Block]", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenueTextBlock", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenue" ], "xbrltype": "textBlockItemType" }, "adpt_DeferredTaxAssetsNonQualifiedStockOptions": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets, non qualified stock options.", "label": "Deferred Tax Assets Non Qualified Stock Options", "terseLabel": "Nonqualifying stock options" } } }, "localname": "DeferredTaxAssetsNonQualifiedStockOptions", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adpt_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating lease liabilities.", "label": "Deferred Tax Assets Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adpt_DeferredTaxLiabilitiesRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities right of use assets.", "label": "Deferred Tax Liabilities Right Of Use Assets", "negatedLabel": "ROU assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities, tangible and intangible assets.", "label": "Deferred Tax Liabilities Tangible And Intangible Assets", "negatedLabel": "Tangible and intangible assets" } } }, "localname": "DeferredTaxLiabilitiesTangibleAndIntangibleAssets", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adpt_DefinedContributionPlanEmployeeServicePeriodForVesting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined contribution plan employee service period for vesting.", "label": "Defined Contribution Plan Employee Service Period For Vesting", "terseLabel": "Employee service period for vesting" } } }, "localname": "DefinedContributionPlanEmployeeServicePeriodForVesting", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derecognition of lease financing arrangements upon adoption of guidance on accounting for lease.", "label": "Derecognition Of Lease Financing Arrangements Upon Adoption Of Guidance On Accounting For Lease", "terseLabel": "Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases" } } }, "localname": "DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "adpt_DevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development milestones.", "label": "Development Milestones [Member]", "terseLabel": "Development Milestones" } } }, "localname": "DevelopmentMilestonesMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_DevelopmentRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development revenue.", "label": "Development Revenue [Member]", "terseLabel": "Development Revenue" } } }, "localname": "DevelopmentRevenueMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "adpt_DevelopmentRevenueRegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development revenue regulatory milestones.", "label": "Development Revenue Regulatory Milestones [Member]", "terseLabel": "Development Revenue Regulatory Milestones" } } }, "localname": "DevelopmentRevenueRegulatoryMilestonesMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails" ], "xbrltype": "domainItemType" }, "adpt_DevelopmentSupportRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development support revenue.", "label": "Development Support Revenue [Member]", "terseLabel": "Development Support Revenue" } } }, "localname": "DevelopmentSupportRevenueMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails" ], "xbrltype": "domainItemType" }, "adpt_DigitalBiotechnologiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Digital Biotechnologies, Inc.", "label": "Digital Biotechnologies Inc [Member]", "terseLabel": "Digital Biotechnologies, Inc." } } }, "localname": "DigitalBiotechnologiesIncMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_EffectiveIncomeTaxRateReconciliationPermanentItems": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": { "order": 10040.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Permanent Items", "label": "Effective Income Tax Rate Reconciliation Permanent Items", "terseLabel": "Permanent items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" ], "xbrltype": "percentItemType" }, "adpt_FurnitureAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Furniture and office equipment.", "label": "Furniture And Office Equipment [Member]", "terseLabel": "Furniture and Office Equipment" } } }, "localname": "FurnitureAndOfficeEquipmentMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "adpt_GenentechCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genentech collaboration agreement.", "label": "Genentech Collaboration Agreement [Member]", "terseLabel": "Genentech Collaboration Agreement" } } }, "localname": "GenentechCollaborationAgreementMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_GenentechIncAndRocheGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genentech, Inc. and Roche Group.", "label": "Genentech Inc And Roche Group [Member]", "terseLabel": "Genentech, Inc. and Roche Group" } } }, "localname": "GenentechIncAndRocheGroupMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "domainItemType" }, "adpt_GenentechIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genentech Inc.", "label": "Genentech Inc [Member]", "terseLabel": "Genentech, Inc." } } }, "localname": "GenentechIncMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "adpt_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "adpt_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "adpt_IncreaseDecreaseInDeferredRent": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in deferred rent.", "label": "Increase Decrease In Deferred Rent", "terseLabel": "Deferred rent" } } }, "localname": "IncreaseDecreaseInDeferredRent", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in operating lease right-of-use assets and liabilities .", "label": "Increase Decrease In Operating Lease Right Of Use Assets And Liabilities", "terseLabel": "Operating lease right-of-use assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "adpt_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "adpt_LeaseCommencementMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease commencement month and year.", "label": "Lease Commencement Month And Year", "terseLabel": "Lease commenced moth and year" } } }, "localname": "LeaseCommencementMonthAndYear", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "adpt_LeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration month and year.", "label": "Lease Expiration Month And Year", "terseLabel": "Lease expiration month and year" } } }, "localname": "LeaseExpirationMonthAndYear", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "adpt_LesseeOperatingLeaseExtendedTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, operating lease, extended term of contract.", "label": "Lessee Operating Lease Extended Term Of Contract", "terseLabel": "Lessee, operating lease, extended term of contract" } } }, "localname": "LesseeOperatingLeaseExtendedTermOfContract", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease lease not yet commenced tenant improvement receivable.", "label": "Lessee Operating Lease Lease Not Yet Commenced Tenant Improvement Receivable", "terseLabel": "Lease not yet commenced landlord agreed to fund for improvements" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, operating lease, lease not yet commenced termination option description.", "label": "Lessee Operating Lease Lease Not Yet Commenced Termination Option Description", "terseLabel": "Lease not yet commenced, termination option description" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability tenant improvement receivable.", "label": "Lessee Operating Lease Liability Tenant Improvement Receivable", "negatedLabel": "Tenant improvement receivables" } } }, "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReceivable", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "adpt_LesseeOperatingLeaseRentCommencementMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease rent commencement month and year.", "label": "Lessee Operating Lease Rent Commencement Month And Year", "terseLabel": "Lessee, operating lease, rent commencement month and year" } } }, "localname": "LesseeOperatingLeaseRentCommencementMonthAndYear", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease rent obligations commencement month and year.", "label": "Lessee Operating Lease Rent Obligations Commencement Month And Year", "terseLabel": "Rent obligations, commencement date" } } }, "localname": "LesseeOperatingLeaseRentObligationsCommencementMonthAndYear", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "adpt_LesseeOperatingLeaseTerminationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease termination period.", "label": "Lessee Operating Lease Termination Period", "terseLabel": "Operating lease termination period" } } }, "localname": "LesseeOperatingLeaseTerminationPeriod", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "adpt_MRDDevelopmentAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MRD development agreements.", "label": "M R D Development Agreements [Member]", "terseLabel": "MRD Development Agreements" } } }, "localname": "MRDDevelopmentAgreementsMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_MedicareRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare revenue.", "label": "Medicare Revenue [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareRevenueMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_MicrosoftCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Microsoft collaboration agreement.", "label": "Microsoft Collaboration Agreement [Member]", "terseLabel": "Microsoft Collaboration Agreement" } } }, "localname": "MicrosoftCollaborationAgreementMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum service consumption requirement amount under license agreement.", "label": "Minimum Service Consumption Requirement Amount Under License Agreement", "terseLabel": "Minimum service consumption requirement amount" } } }, "localname": "MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum service consumption requirement term under license agreement.", "label": "Minimum Service Consumption Requirement Term Under License Agreement", "terseLabel": "Minimum service consumption requirement term" } } }, "localname": "MinimumServiceConsumptionRequirementTermUnderLicenseAgreement", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "adpt_NetOperatingLossCarryforwardExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Operating Loss Carryforward Expiration Period", "label": "Net Operating Loss Carryforward Expiration Period", "terseLabel": "Maturity period for NOLs carryovers" } } }, "localname": "NetOperatingLossCarryforwardExpirationPeriod", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "adpt_NonEmployeeDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-employee directors.", "label": "Non Employee Directors [Member]", "terseLabel": "Non Employee Directors" } } }, "localname": "NonEmployeeDirectorsMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_NonRefundableUpfrontPaymentsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-refundable upfront payments received.", "label": "Non Refundable Upfront Payments Received", "terseLabel": "Non-refundable upfront payments received" } } }, "localname": "NonRefundableUpfrontPaymentsReceived", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash lease expense.", "label": "Noncash Lease Expense", "terseLabel": "Noncash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "adpt_NumberOfCommonStockVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock voting rights.", "label": "Number Of Common Stock Voting Rights", "terseLabel": "Number of vote for each share" } } }, "localname": "NumberOfCommonStockVotingRights", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "adpt_NumberOfOperatingLeaseTerminate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of operating lease terminate.", "label": "Number Of Operating Lease Terminate", "terseLabel": "Number of operating lease terminate" } } }, "localname": "NumberOfOperatingLeaseTerminate", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "adpt_NumberOfRevenuePerformanceObligation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of revenue performance obligation.", "label": "Number Of Revenue Performance Obligation", "terseLabel": "Number of revenue performance obligations" } } }, "localname": "NumberOfRevenuePerformanceObligation", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "adpt_OperatingLeaseVariableLeaseExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease variable lease expense.", "label": "Operating Lease Variable Lease Expense", "terseLabel": "Operating lease variable lease expense" } } }, "localname": "OperatingLeaseVariableLeaseExpense", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_OperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Expiration Year", "label": "Operating Loss Carryforwards Expiration Year", "terseLabel": "NOLs expiration year" } } }, "localname": "OperatingLossCarryforwardsExpirationYear", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "adpt_PercentageOfAnnualIncreasesInNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of annual increases in number of shares.", "label": "Percentage Of Annual Increases In Number Of Shares", "terseLabel": "Percentage of annual increases in number of shares" } } }, "localname": "PercentageOfAnnualIncreasesInNumberOfShares", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock upon exercise of common stock warrant.", "label": "Proceeds From Issuance Of Common Stock Upon Exercise Of Common Stock Warrant", "terseLabel": "Proceeds from issuance of common stock upon the exercise of a common stock warrant" } } }, "localname": "ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "adpt_ProceedsFromLandlordReimbursements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from landlord reimbursements.", "label": "Proceeds From Landlord Reimbursements", "terseLabel": "Proceeds from landlord reimbursements" } } }, "localname": "ProceedsFromLandlordReimbursements", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from settlement of stock option exercised in prior periods.", "label": "Proceeds From Settlement Of Stock Option Exercised In Prior Periods", "terseLabel": "Proceeds from settlement of stock option exercised in prior periods" } } }, "localname": "ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_RegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory milestones.", "label": "Regulatory Milestones [Member]", "terseLabel": "Regulatory Milestones" } } }, "localname": "RegulatoryMilestonesMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_RevenueRecognitionExpectedPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue recognition expected period.", "label": "Revenue Recognition Expected Period", "terseLabel": "Revenue recognition expected period" } } }, "localname": "RevenueRecognitionExpectedPeriod", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue recognition milestone method expected milestone receivable.", "label": "Revenue Recognition Milestone Method Expected Milestone Receivable", "terseLabel": "Expected revenue through milestone payments" } } }, "localname": "RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_SalesAndMarketingExpensePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales and marketing expenses.", "label": "Sales And Marketing Expense Policy [Text Block]", "terseLabel": "Sales and Marketing Expenses" } } }, "localname": "SalesAndMarketingExpensePolicyTextBlock", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of deferred revenue by revenue classification.", "label": "Schedule Of Deferred Revenue By Revenue Classification Table [Text Block]", "terseLabel": "Schedule of Deferred Revenue by Revenue Classification" } } }, "localname": "ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueTables" ], "xbrltype": "textBlockItemType" }, "adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of estimated useful lives of property plant and equipment.", "label": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block]", "terseLabel": "Summary of Useful Lives Assigned to Property and Equipment" } } }, "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of reserved shares of common stock.", "label": "Schedule Of Reserved Shares Of Common Stock Table [Text Block]", "terseLabel": "Summary of Reserved Shares of Common Stock" } } }, "localname": "ScheduleOfReservedSharesOfCommonStockTableTextBlock", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share-based compensation, shares available for grant.", "label": "Schedule Of Share Based Compensation Shares Available For Grant Table [Text Block]", "terseLabel": "Summary of Changes in Shares Available for Grant" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "adpt_SequencingRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sequencing revenue.", "label": "Sequencing Revenue [Member]", "terseLabel": "Sequencing Revenue" } } }, "localname": "SequencingRevenueMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "adpt_SequentaTwoThousandAndEightStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sequenta two thousand and eight stock plan.", "label": "Sequenta Two Thousand And Eight Stock Plan [Member]", "terseLabel": "Sequenta 2008 Stock Plan" } } }, "localname": "SequentaTwoThousandAndEightStockPlanMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C convertible preferred stock.", "label": "Series C Convertible Preferred Stock [Member]", "terseLabel": "Series C Convertible Preferred Stock" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_SeriesFOneConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F one convertible preferred stock.", "label": "Series F One Convertible Preferred Stock [Member]", "terseLabel": "Series F-1 Convertible Preferred Stock" } } }, "localname": "SeriesFOneConvertiblePreferredStockMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award increase reserve shares available for grant,", "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase Reserve Shares Available For Grant", "terseLabel": "Shares Available for Grant, 2019 Equity Incentive Plan reserve increase" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" ], "xbrltype": "sharesItemType" }, "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable", "terseLabel": "Shares Subject to Outstanding Options, Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "sharesItemType" }, "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "monetaryItemType" }, "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "perShareItemType" }, "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award outstanding number.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number", "terseLabel": "Equity awards outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Vested And Exercisable Options Outstanding Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life vested and exercisable options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment awards forfeited, canceled or expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Awards Forfeited Canceled Or Expired", "terseLabel": "Shares Available for Grant, Options and restricted stock units forfeited, cancelled or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" ], "xbrltype": "sharesItemType" }, "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment awards granted.", "label": "Share Based Compensation Arrangement By Share Based Payment Awards Granted", "negatedLabel": "Shares Available for Grant, Options and restricted stock units granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" ], "xbrltype": "sharesItemType" }, "adpt_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "stringItemType" }, "adpt_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "stringItemType" }, "adpt_SpecificPatientsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specific patients.", "label": "Specific Patients [Member]", "terseLabel": "Specific Patients" } } }, "localname": "SpecificPatientsMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period, shares, common stock warrants exercised.", "label": "Stock Issued During Period Shares Common Stock Warrants Exercised", "terseLabel": "Issuance of common stock upon exercise of common stock warrants, Shares", "verboseLabel": "Stock issued during period, common stock" } } }, "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares restricted stock award vested.", "label": "Stock Issued During Period Shares Restricted Stock Award Vested", "terseLabel": "Vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period, value, common stock warrants exercised.", "label": "Stock Issued During Period Value Common Stock Warrants Exercised", "terseLabel": "Issuance of common stock upon exercise of common stock warrants" } } }, "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders equity convertible preferred stock policy text block.", "label": "Stockholders Equity Convertible Preferred Stock Policy [Text Block]", "terseLabel": "Convertible Preferred Stock Warrant" } } }, "localname": "StockholdersEquityConvertiblePreferredStockPolicyTextBlock", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity, stock issued during period, shares, new issues.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity value change in redemption value for vested convertible preferred stock options.", "label": "Temporary Equity Value Change In Redemption Value For Vested Convertible Preferred Stock Options", "terseLabel": "Change in redemption value for vested Series E-1 convertible preferred stock options" } } }, "localname": "TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "adpt_TenantImprovementAllowanceAndCommenced": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance and commenced.", "label": "Tenant Improvement Allowance And Commenced", "terseLabel": "Tenant improvement allowance and commenced" } } }, "localname": "TenantImprovementAllowanceAndCommenced", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_TenantImprovementCostsIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tenant improvement costs incurred.", "label": "Tenant Improvement Costs Incurred", "terseLabel": "Tenant improvement costs incurred" } } }, "localname": "TenantImprovementCostsIncurred", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_TenantImprovementCostsReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tenant improvement costs receivable.", "label": "Tenant Improvement Costs Receivable", "verboseLabel": "Tenant improvement costs receivable" } } }, "localname": "TenantImprovementCostsReceivable", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "adpt_TwoThousandAndNineEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and nine equity incentive plan.", "label": "Two Thousand And Nine Equity Incentive Plan [Member]", "terseLabel": "2009 Equity Incentive Plan" } } }, "localname": "TwoThousandAndNineEquityIncentivePlanMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "adpt_TwoThousandAndNineteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and nineteen equity incentive plan.", "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]", "terseLabel": "2019 Equity Incentive Plan" } } }, "localname": "TwoThousandAndNineteenEquityIncentivePlanMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "adpt_UnvestedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock units.", "label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Nonvested Restricted Stock Units" } } }, "localname": "UnvestedRestrictedStockUnitsMember", "nsuri": "http://www.adaptivebiotech.com/20211231", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r639" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r185", "r319", "r325", "r578" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r264", "r275", "r343", "r344", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r575", "r579", "r626", "r627" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r264", "r275", "r343", "r344", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r575", "r579", "r626", "r627" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r185", "r319", "r325", "r578" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r182", "r319", "r323", "r533", "r574", "r576" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r182", "r319", "r323", "r533", "r574", "r576" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r264", "r275", "r334", "r343", "r344", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r575", "r579", "r626", "r627" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r264", "r275", "r334", "r343", "r344", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r575", "r579", "r626", "r627" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r3", "r110", "r111", "r112", "r113", "r114", "r117", "r118", "r119", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r141", "r212", "r213", "r386", "r419", "r456", "r460", "r461", "r462", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r644", "r645" ], "lang": { "en-us": { "role": { "label": "Restatement [Axis]", "terseLabel": "Revision of Prior Period" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r3", "r110", "r111", "r112", "r113", "r114", "r117", "r118", "r119", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r141", "r212", "r213", "r386", "r419", "r456", "r460", "r461", "r462", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r644", "r645" ], "lang": { "en-us": { "role": { "label": "Restatement [Domain]", "terseLabel": "Revision of Prior Period" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": { "auth_ref": [ "r3", "r113", "r114", "r120", "r127", "r212", "r213", "r386", "r419", "r456", "r462", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r644", "r645" ], "lang": { "en-us": { "role": { "label": "Revision Of Prior Period Accounting Standards Update Adjustment [Member]", "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment" } } }, "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r183", "r184", "r319", "r324", "r577", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r183", "r184", "r319", "r324", "r577", "r610", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r186", "r516" ], "lang": { "en-us": { "role": { "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "stpr_WA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WASHINGTON", "terseLabel": "Seattle, Washington" } } }, "localname": "WA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update201602 [Member]", "terseLabel": "ASC 842" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r113", "r114", "r115", "r116", "r194", "r195", "r208", "r209", "r210", "r211", "r212", "r213", "r252", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r418", "r419", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r515", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r641", "r642", "r643", "r644", "r645" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update Extensible List", "terseLabel": "Accounting Standards Update Extensible List" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r41", "r519" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable, Net" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r27", "r187", "r188" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10290.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r92" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Investment amortization" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r14", "r15", "r45" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits Current", "terseLabel": "Travel and entertainment" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r22", "r544", "r561" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes Current", "terseLabel": "Tax liabilities" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r14", "r15", "r45" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r39", "r242" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r59", "r60", "r61", "r562", "r587", "r591" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive (loss) gain" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r58", "r61", "r69", "r70", "r71", "r110", "r111", "r112", "r444", "r582", "r583", "r645" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Gain" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r386", "r519" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r110", "r111", "r112", "r383", "r384", "r385", "r460" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r113", "r114", "r115", "r116", "r127", "r194", "r195", "r208", "r209", "r210", "r211", "r212", "r213", "r252", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r416", "r417", "r418", "r419", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r515", "r535", "r536", "r537", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r641", "r642", "r643", "r644", "r645" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Costs Policy [Text Block]", "terseLabel": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "verboseLabel": "Advertising expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r347", "r375", "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r91", "r228", "r234" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10130.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization Of Intangible Assets", "terseLabel": "Amortization of intangible assets", "verboseLabel": "Intangible assets amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area Of Land", "terseLabel": "Number of square feet" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r104", "r165", "r174", "r180", "r207", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r438", "r445", "r480", "r517", "r519", "r543", "r560" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r56", "r104", "r207", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r438", "r445", "r480", "r517", "r519" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r463" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Financial assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Noncurrent [Abstract]", "terseLabel": "Long-term assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r201" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r202" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r199", "r214" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r196", "r200", "r214", "r547" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r198", "r214" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10280.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available For Sale Securities Debt Securities Current", "terseLabel": "Short-term marketable securities (amortized cost of $214,115 and $564,036, respectively)" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r198", "r214" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Available For Sale Securities Debt Securities Noncurrent", "terseLabel": "Long-term marketable securities (amortized cost of $218,163 and $118,429, respectively)" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r348", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r6", "r109", "r161" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r95", "r96", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Purchases of equipment included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r36", "r93" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10270.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r18", "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r18", "r94", "r541" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r88", "r93", "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r88", "r489" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Noncash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r102", "r104", "r130", "r131", "r132", "r135", "r137", "r145", "r146", "r147", "r207", "r253", "r257", "r258", "r259", "r262", "r263", "r273", "r274", "r278", "r282", "r480", "r637" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Warrants issued to purchase stock", "verboseLabel": "Warrant issued to purchase stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r429", "r430", "r432" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Microsoft Collaboration Agreement" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r47", "r250", "r548", "r567" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r247", "r248", "r249", "r251", "r613" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Total shares of common stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r110", "r111", "r460" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26", "r519" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2021 and 2020; 141,393,865 and 137,646,896 shares issued and outstanding at December 31, 2021 and 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock Voting Rights", "terseLabel": "Common stock voting rights description" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r332", "r333", "r345", "r389" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation And Employee Benefit Plans [Text Block]", "terseLabel": "Retirement Plan" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRetirementPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r64", "r66", "r67", "r76", "r553", "r572" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss attributable to Adaptive Biotechnologies Corporation" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r66", "r75", "r436", "r437", "r449", "r552", "r571" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest", "negatedLabel": "Add: Comprehensive loss attributable to noncontrolling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r66", "r74", "r435", "r449", "r551", "r570" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r155", "r156", "r185", "r477", "r478", "r612" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r155", "r156", "r185", "r477", "r478", "r593", "r612" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Accounts Receivable, Net" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r155", "r156", "r185", "r477", "r478", "r593", "r612" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r150", "r559" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentrations of Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r155", "r156", "r185", "r477", "r478" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r155", "r156", "r185", "r477", "r478", "r612" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration By Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract With Customer Asset And Liability Table [Text Block]", "terseLabel": "Schedule of Changes in Deferred Revenue" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r298", "r299", "r320" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "periodEndLabel": "Deferred revenue balance at December 31, 2021", "periodStartLabel": "Deferred revenue balance at December 31, 2020", "totalLabel": "Total current and non-current deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r298", "r299", "r320" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails": { "order": 10010.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "positiveTerseLabel": "Current deferred revenue", "terseLabel": "Current portion of deferred revenue", "verboseLabel": "Total current deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.", "label": "Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination", "terseLabel": "Additions to deferred revenue during the period" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r298", "r299", "r320" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails": { "order": 10020.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract With Customer Liability Noncurrent", "terseLabel": "Deferred revenue, less current portion", "verboseLabel": "Total non-current deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "terseLabel": "Revenue recognized", "verboseLabel": "Revenue recognized during the period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r273", "r274", "r278" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r335", "r342", "r592" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r79", "r533" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10090.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost Of Goods And Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost Of Sales Policy [Text Block]", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r78" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10080.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs And Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r154", "r185" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "auth_ref": [ "r199", "r214" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities Available For Sale Amortized Cost Current", "terseLabel": "Amortized cost of short-term marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": { "auth_ref": [ "r199", "r214" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities Available For Sale Amortized Cost Noncurrent", "terseLabel": "Amortized cost of long-term marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r204", "r216", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer", "terseLabel": "12 months or greater, Fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r204", "r216" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss", "negatedLabel": "12 months or greater, Unrealized loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r204", "r216", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months", "terseLabel": "Less than 12 months, Fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r204", "r216" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss", "negatedLabel": "Less than 12 months, Unrealized loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale [Table]", "terseLabel": "Debt Securities Available For Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r203", "r215", "r217" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Unrealized Loss Position Fair Value Table [Text Block]", "terseLabel": "Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r413", "r414" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r407" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r409" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net", "totalLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Net [Abstract]", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r413", "r414" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10060.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r413", "r414" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10120.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": { "auth_ref": [ "r412", "r413", "r414" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards General Business", "terseLabel": "Tax credit carryforward" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": { "auth_ref": [ "r413", "r414" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.", "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent", "terseLabel": "Deferred rent" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r408" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Less: Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r396", "r409" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities", "totalLabel": "Net deferred taxes" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities Net [Abstract]", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan Employer Discretionary Contribution Amount", "terseLabel": "Employer discretionary contribution amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent", "terseLabel": "Employees maximum annual contribution of their compensation" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r91", "r240" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "verboseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired Developed Technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r319", "r323", "r324", "r325", "r326", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Schedule of Revenue Disaggregated by Type of Products and Services" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Equity Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r138", "r139", "r140", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r397" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r107", "r397", "r422" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": { "order": 10010.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r397", "r422" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": { "order": 10070.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r397", "r422" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": { "order": 10030.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost", "terseLabel": "Stock compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r397", "r422" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": { "order": 10060.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation Other Adjustments", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r397", "r422" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": { "order": 10020.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State tax, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r397", "r422" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": { "order": 10050.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation Tax Credits", "terseLabel": "Credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options", "terseLabel": "Unrecognized share-based compensation expense related to unvested RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Grant", "verboseLabel": "Grant" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r69", "r70", "r71", "r110", "r111", "r112", "r114", "r123", "r126", "r144", "r211", "r289", "r296", "r383", "r384", "r385", "r418", "r419", "r460", "r490", "r491", "r492", "r493", "r494", "r495", "r582", "r583", "r584", "r645" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r91", "r269" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment Of Warrants", "terseLabel": "Fair value adjustment of convertible preferred stock warrant", "verboseLabel": "Fair value adjustment of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r463", "r464", "r465", "r471" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r463", "r471" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r265", "r267", "r268", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r464", "r520", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Level 2" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r463", "r464", "r467", "r468", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r265", "r335", "r336", "r341", "r342", "r464", "r520" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r265", "r267", "r268", "r335", "r336", "r341", "r342", "r464", "r521" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r265", "r267", "r268", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r464", "r522" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r265", "r267", "r268", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r520", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r470", "r472" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Off Balance Sheet Risks Disclosure Information [Line Items]", "terseLabel": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]" } } }, "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r510", "r513" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite Lived Intangible Asset Useful Life", "terseLabel": "Amortization period of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r233" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails": { "order": 10020.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 10060.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense After Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r235" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r235" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 10050.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r235" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 10040.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r235" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r235" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r229", "r230", "r233", "r236", "r534", "r538" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r233", "r538" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails": { "order": 10010.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived Intangible Assets [Line Items]", "terseLabel": "Finite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r229", "r232" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r233", "r534" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10120.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r221", "r223", "r519", "r542" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill And Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill And Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill And Intangible Assets Goodwill Policy", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill And Intangible Assets Intangible Assets Policy", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r91", "r222", "r224", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill Impairment Loss", "terseLabel": "Impairment of goodwill" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r91", "r237" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment Of Intangible Assets Finitelived", "terseLabel": "Impairment losses on intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r106", "r421" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails": { "order": 10010.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income Loss From Continuing Operations Before Income Taxes Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r72", "r165", "r173", "r176", "r179", "r181", "r539", "r549", "r554", "r573" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Total loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r106", "r421" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails": { "order": 10020.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income Loss From Continuing Operations Before Income Taxes Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r244", "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r107", "r398", "r405", "r411", "r420", "r423", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r68", "r394", "r395", "r405", "r406", "r410", "r415" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r90" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r90" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r90", "r530" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Contract With Customer Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r90" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r90" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase Decrease In Other Operating Capital Net", "negatedLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r90" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InformationByCategoryOfDebtSecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.", "label": "Information By Category Of Debt Security [Axis]", "terseLabel": "Debt Security Category" } } }, "localname": "InformationByCategoryOfDebtSecurityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Purchased Intellectual Property" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10060.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest And Other Income", "terseLabel": "Interest and other income, net" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable Current", "terseLabel": "Accrued interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r53", "r519" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10300.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r17", "r54", "r100", "r143", "r218", "r219", "r220", "r531" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory Policy [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r206", "r540", "r557", "r609", "r638" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Summary of Other Information Related to Operating Lease" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r13", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements Gross", "terseLabel": "Landlord contribution for leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Lease Not Yet Commenced Option To Extend", "terseLabel": "Lease not yet commenced, option to extend description" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Lease Not Yet Commenced Renewal Term1", "terseLabel": "Lease not yet commenced, option to extend term" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Summary of Reconciles Undiscounted Operating Lease Cash Flows" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r512" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r512" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": 10080.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r512" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r512" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": 10070.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r512" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r512" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r512" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r512" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Imputed interest rate" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Lessee, operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Remaining Lease Term", "terseLabel": "Operating lease remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Operating lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters Of Credit Outstanding Amount", "terseLabel": "Letter of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r44", "r104", "r175", "r207", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r439", "r445", "r446", "r480", "r517", "r518" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r104", "r207", "r480", "r519", "r546", "r565" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46", "r104", "r207", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r439", "r445", "r446", "r480", "r517", "r518", "r519" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent [Abstract]", "terseLabel": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Current Borrowing Capacity", "terseLabel": "Line of credit facility" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Investments in Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r52", "r104", "r207", "r253", "r257", "r258", "r259", "r262", "r263", "r480", "r545", "r564" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Minority Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Minority Interest Ownership Percentage By Parent", "terseLabel": "Ownership interest percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r88" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r88" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r88", "r89", "r92" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r62", "r65", "r71", "r73", "r92", "r104", "r113", "r117", "r118", "r120", "r121", "r125", "r126", "r133", "r165", "r173", "r176", "r179", "r181", "r207", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r462", "r480", "r550", "r569" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "totalLabel": "Net loss attributable to Adaptive Biotechnologies Corporation", "verboseLabel": "Net loss attributable to Adaptive Biotechnologies Corporation" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r62", "r65", "r71", "r125", "r126", "r441", "r448" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income Loss Attributable To Noncontrolling Interest", "negatedLabel": "Add: Net loss attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r117", "r118", "r120", "r121", "r128", "r129", "r134", "r137", "r165", "r173", "r176", "r179", "r181" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income Loss Available To Common Stockholders Basic", "totalLabel": "Net loss attributable to Adaptive Biotechnologies Corporation common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r95", "r96", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Or Part Noncash Acquisition Fixed Assets Acquired1", "terseLabel": "Noncash additions to property through lease financing arrangements" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r110", "r111", "r112", "r296", "r433" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r165", "r173", "r176", "r179", "r181" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10050.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r499" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r499" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "negatedLabel": "Less: Current portion", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r499" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liabilities, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r501", "r507" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r498" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r509", "r513" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r496" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases Rent Expense Net", "terseLabel": "Rent expenses" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "U.S. federal NOLs" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r14", "r15", "r16", "r45" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 10060.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive (loss) income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r63", "r66", "r435", "r436", "r443" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r57", "r59" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10040.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Change in unrealized gains and losses on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r92" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income Expense", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.", "label": "Other Than Temporary Impairment Credit Losses Recognized In Earnings Categories Of Investments [Domain]", "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments" } } }, "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "auth_ref": [ "r81", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.", "label": "Payments For Proceeds From Tenant Allowance", "negatedLabel": "Cash received for tenant improvement allowances" } } }, "localname": "PaymentsForProceedsFromTenantAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r86" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "negatedLabel": "Payment of public offering costs, net" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r197" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments To Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r82" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r348", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r25", "r273" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r25", "r273" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r25", "r519" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020", "verboseLabel": "preferred stock investment" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r34", "r35" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10310.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromContributedCapital": { "auth_ref": [ "r84" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.", "label": "Proceeds From Contributed Capital", "terseLabel": "Proceeds from initial capital contributions for Digital Biotechnologies, Inc." } } }, "localname": "ProceedsFromContributedCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r84" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from public offering of common stock, net of underwriting discounts and commissions" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r85", "r86" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds From Payments For Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r84", "r378" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r62", "r65", "r71", "r87", "r104", "r113", "r125", "r126", "r165", "r173", "r176", "r179", "r181", "r207", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r435", "r440", "r442", "r448", "r449", "r462", "r480", "r554" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10030.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r39", "r243" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r245", "r614", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property Plant And Equipment Estimated Useful Lives", "terseLabel": "Property and equipment, useful lives" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r38", "r241" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r243", "r519", "r558", "r566" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r37", "r243", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r19", "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r241" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Property and equipment, useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r189", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivables Policy [Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r392", "r532", "r628" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10100.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r12", "r21", "r98", "r611" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r296", "r386", "r519", "r563", "r586", "r591" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r110", "r111", "r112", "r114", "r123", "r126", "r211", "r383", "r384", "r385", "r418", "r419", "r460", "r582", "r584" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r163", "r164", "r172", "r177", "r178", "r182", "r183", "r185", "r318", "r319", "r533" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10070.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Total revenue", "verboseLabel": "Revenue from collaboration agreement" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r101", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue From Contract With Customer Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r309", "r322", "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue From Contract With Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1", "terseLabel": "Deferred revenue, expected to be recognized" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r508", "r513" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "ROU assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r155", "r185" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]", "terseLabel": "Schedule of Available-for-sale Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r347", "r374", "r388" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Compensation Costs Related to Stock Options and RSUs Included on Statements of Operations" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": { "auth_ref": [ "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.", "label": "Schedule Of Fair Value Off Balance Sheet Risks [Table]", "terseLabel": "Schedule Of Fair Value Off Balance Sheet Risks [Table]" } } }, "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r229", "r232", "r534" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule Of Finite Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r229", "r232" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]", "terseLabel": "Summary of Intangible Assets Subject to Amortization" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r225", "r227" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule Of Goodwill [Table]", "terseLabel": "Schedule Of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]", "terseLabel": "Schedule of Components of Loss Before Provision for Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r39", "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r348", "r377" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r354", "r365", "r368" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Summary of Estimated Grant Date Fair Values of Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r48", "r102", "r145", "r146", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r282", "r287", "r290", "r291", "r292", "r293", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.", "label": "Schedule Of Subsidiary Or Equity Method Investee [Table]", "terseLabel": "Schedule Of Subsidiary Or Equity Method Investee [Table]" } } }, "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).", "label": "Schedule Of Unvested Restricted Stock Units Roll Forward Table [Text Block]", "terseLabel": "Summary of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]", "terseLabel": "Schedule of Future Amortization Expense for Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r153", "r155", "r156", "r157", "r477", "r479" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules Of Concentration Of Risk By Risk Factor [Text Block]", "terseLabel": "Schedule of Concentrations of Risk Percentage" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r166", "r167", "r168", "r169", "r170", "r171", "r183" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10110.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling And Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling And Marketing Expense [Member]", "terseLabel": "Sales and Marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r90" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Restricted Stock Units Outstanding, Forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Restricted Stock Units Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance", "periodStartLabel": "Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward", "terseLabel": "Restricted Stock Units Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward", "terseLabel": "Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Restricted Stock Units Outstanding, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized", "terseLabel": "Increase in share reserve" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Number of shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "periodEndLabel": "Shares Available for Grant, Outstanding, Ending Balance", "periodStartLabel": "Shares Available for Grant, Outstanding, Beginning Balance", "terseLabel": "Shares available for future issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period", "negatedLabel": "Shares Subject to Outstanding Options, Options expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period", "negatedLabel": "Shares Subject to Outstanding Options, Options forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Options forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Shares Subject to Outstanding Options, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Fair value of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Option outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r356", "r377" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Shares Subject to Outstanding Options, Options outstanding, Ending Balance", "periodStartLabel": "Shares Subject to Outstanding Options, Options outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price per Share, Options outstanding, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price per Share, Options outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r346", "r352" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Options expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r348", "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Option expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r371", "r387" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted-average remaining contractual life options outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r99", "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r102", "r104", "r130", "r131", "r132", "r135", "r137", "r145", "r146", "r147", "r207", "r253", "r257", "r258", "r259", "r262", "r263", "r273", "r274", "r278", "r282", "r289", "r480", "r637" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r51", "r69", "r70", "r71", "r110", "r111", "r112", "r114", "r123", "r126", "r144", "r211", "r289", "r296", "r383", "r384", "r385", "r418", "r419", "r460", "r490", "r491", "r492", "r493", "r494", "r495", "r582", "r583", "r584", "r645" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r110", "r111", "r112", "r144", "r533" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r50", "r266", "r289", "r290", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock to common stock, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r25", "r26", "r289", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Proceeds from initial public offering, net of underwriters' discounts and commissions, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r25", "r26", "r289", "r296", "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Shares Subject to Outstanding Options, Options exercised", "terseLabel": "Issuance of common stock for cash upon exercise of stock options, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r51", "r289", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock to common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r25", "r26", "r289", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r51", "r289", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock for cash upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r31", "r32", "r104", "r190", "r207", "r480", "r519" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "totalLabel": "Total Adaptive Biotechnologies Corporation shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Shareholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r70", "r104", "r110", "r111", "r112", "r114", "r123", "r207", "r211", "r296", "r383", "r384", "r385", "r418", "r419", "r433", "r434", "r447", "r460", "r480", "r490", "r491", "r495", "r583", "r584", "r645" ], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r103", "r274", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary Or Equity Method Investee [Line Items]", "terseLabel": "Subsidiary Or Equity Method Investee [Line Items]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r400", "r404", "r406" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary Of Income Tax Contingencies [Text Block]", "terseLabel": "Schedule of Change in Unrecognized Tax Benefits" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "U.S. federal tax credits" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the limitation related to use of the tax credit carryforward.", "label": "Tax Credit Carryforward Limitations On Use", "terseLabel": "Tax credit carryforwards expiration year" } } }, "localname": "TaxCreditCarryforwardLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "calculation": { "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity Accretion To Redemption Value Adjustment", "negatedLabel": "Fair value adjustment to Series E-1 convertible preferred stock options", "negatedTerseLabel": "Fair value adjustment to redemption value for Series E-1 convertible preferred stock options" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r253", "r257", "r258", "r259", "r262", "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Carrying Amount Attributable To Parent", "periodEndLabel": "Convertible preferred stock, Ending Balance", "periodStartLabel": "Convertible preferred stock, Beginning Balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Outstanding", "periodEndLabel": "Convertible preferred stock, Ending Balance, Shares", "periodStartLabel": "Convertible preferred stock, Beginning Balance, Shares" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity Stock Issued During Period Value New Issues", "terseLabel": "Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TenantImprovements": { "auth_ref": [ "r568" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.", "label": "Tenant Improvements", "terseLabel": "Tenant improvement allowance" } } }, "localname": "TenantImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r113", "r114", "r115", "r116", "r127", "r194", "r195", "r208", "r209", "r210", "r211", "r212", "r213", "r252", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r416", "r417", "r418", "r419", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r515", "r535", "r536", "r537", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r641", "r642", "r643", "r644", "r645" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type Of Adoption [Member]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r108", "r335", "r555" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Debt Securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnbilledReceivablesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.", "label": "Unbilled Receivables Current", "terseLabel": "Unbilled receivables" } } }, "localname": "UnbilledReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r393", "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued", "terseLabel": "Accrued interest or penalties related to uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Additions", "verboseLabel": "Uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r148", "r149", "r151", "r152", "r158", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance Deferred Tax Asset Change In Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Technique [Axis]", "terseLabel": "Valuation Approach and Technique" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Technique [Domain]", "terseLabel": "Valuation Approach and Technique" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueOptionPricingModelMember": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating price of option.", "label": "Valuation Technique Option Pricing Model [Member]", "terseLabel": "Option Valuation Model" } } }, "localname": "ValuationTechniqueOptionPricingModelMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted", "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.adaptivebiotech.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://www.adaptivebiotech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r389": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r426": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r432": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r514": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r557": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r609": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r629": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r630": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r631": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r632": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r633": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r634": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r635": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r636": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r637": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r638": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r639": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r640": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" } }, "version": "2.1" } ZIP 118 0001564590-22-005228-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-005228-xbrl.zip M4$L#!!0 ( .^#3U0G#^85*($$ !LX0 5 861P="TQ,&M?,C R,3$R M,S$N:'1M[+UI<^+8MB#ZN5_$^P]Z/O? M.(2T 54*B=)@)^?7]UIK#]H2 H-'":NZ[TD#&O9>>\WCS__KQ\0UC#L6A([O M_;+5:C2W#.99ONUXHU^VXFA8/]CZ7Y__[__KY_^G7C=.SKJ71L>*G#MVXH26 MZX=QP#[T+GXRNI[K>,SX[R\WY\:);\43YD5&W1A'T?3HX\?[^_N&/72\T'?C M"-X3-BQ_\M&HU^6#CP-FX@_&B1DQ@_X[,MK-=KO>;-=;N_WF]M'N]E%SK['= MW&EN[[3^WV;SJ-G4'O [WX"A_7=D[#::C59COWV@77AM6M_-$3.Z)]J%!]O# M0[O='![N[NWL#%K6P?[>#K.MUH[=;-O;+5-?J3^=!.9GN68KM&3.ZT!:*R&T7%=XP9O"XT;%K+@CMD-\=1Q!"< I^"%1S\& M@>O\LJ5!#;]I^,'H8[O9W/X($(S@!6Q+N]Y.;M OWOO(?Y27FO8T2CW9M,TI M'N3 \2-FC>E$8#NM5GN[)6^*PWHTF[)0W3@TPP&]0?Y"M]2;K7KJII%I3G/O MP1]R;@FC:9#>1+O M'7FI%0L]>/&GG86>[";N.F!'GZD7Q7.1<%"LCG\"+_*"^<>F28P_'E@ MAHK G-#?:;?VEY$DOT*M.73R5@R7MC[^]\5YSQJSB5G/TK'S8]$;6DCTR%J1 MLRK$ X833Q[ #KBH3H!U+'7?PS>E;W!^1/DW)&OZ& 6F%P[]8$('B$O>1:;= MWM,>4@\/-' M^2H4"9=?02IX($(C%AAW*'3:C7TIG :^/?O\L^W<&6$T<]DO6[833EUSAH?( M<-7_XV?GQQ$^C@7XB7]T;)MY])$^P[67_&0,Q_YEZ^RVB?\!9#QS@H]DSE$' M)*Z-4O?,-4=BCS^B&S:$W>/EK9W]@^UVD[;4A/^G]K;U>6BZ(?OY8^H]#[U[ M1W^W%/AGH!.8[C5@M(?EUS(8?Z0HZ)=PI@_,G,X-2S4:U9;RWU>JL-R+_60O9V#^1"A*P].F=A MR-C5E/BK-SIGP-Q.?S@A$(#%KH974R2VOG^*W-A>LD(0E;T(-H''_)7YH\"< MCAW87P>>=8M"^H\.++YUV#R@7> ?N(LHB-?#K+V]IMP"4N&16/#4X?+A M8W M[G@V@O7Y5]MN;H.VN=[A[^WMOQ3,GP6>^P?/ $]<0*LI5M)J&U<'> M"\+J $R#EOACN_D86!V^X/+F"'S]Y1WL9XXR;VVX$&;W63"Y&J+8"TPK6@]N MU[OK\>']W786;+VQ&; OL![[V)],0<\C9.L$(.)'1)1?9LDEU^8,O^K^=3J:N/V-@JP;,BOP@O&"3 M 0MNQ3+I9:@2T#WB2WE/+_*M[_Q\TW==NZ9W";M5+^K?^_VQ'X>F9P,E78(^ M$S'FG8+F$.%?BA/XR. M?=M_5:;(]F^V/'^TAV?(=JB/1][#E_7MUNA:7_KG6QILO=@ M.XM\@'(3)\+7AW >2 . 3$"O#GM('Q&F;^@<>8X+ZB%0Z-9GN4RYI,>N<^?9 MUME\T77N9M=Y'; A Y7&)I+XW73CAU29%UW?'(]>>WV/@-\8TN!Y' M;\XA05K,_,'0E<7L#A@]YHC=@$T+'$C\B(QF&=?6V%ZK^>?>1>O@9,W5S:' M\ZZN*5?7^G/[HGVXWNH.YF%'HF[PL#0<9*7AF>D$A,^=4#+T$'0WD&5@!IX VQ,[&\M[=JPF>5,3#?\ M96L;[/I&L[F[MOS)W__SZ;K/NO\,@L_O?^>9]C^G;A5B_UFB@+W]UC-!8,['5!0(/$ #^\_& PX+"H&'J&!O9_L) M6C@'1HC["#5P[!\^'SBXO1U^A0NCL.MQ#T!&G:,?T9^J8/>,6I &L?;6Y^UF MXV#O^2%VT&R6&&*+J0P@UMIO[!V\!,2>3^UX=8@MH4J V'[CH/D2 'L^/>7E M 6;^6(,H]_8:NR\"L>?3;%X?8DN)WT7X!QG_0G'-IE0=BRXER!ZARN;J4 M8QWFZT5O;AT^0%R?K_?^7-_'D2_R"[?7.;/_$7MMY0OKHNUUWNI_<*^K*[S/ M1^@K&WU\>T\S^I_-Z,MWZ;WY_A\R^EO[S[3_?"_?6^__0:.__4P&7_OY]/4U M#+YGH(#]YOJ:4CX$7M;M]P0(/&3T;Z^O^>1#X&4=?X^'P$-4L-\^S(4 ?:DE MFB% *)*&J0VA !+F0QZ%E+0([S8HY_((,P5_V0J=R=3%#$;Z;AS@TBAQ3B7- M_0AM^;,96(&/V6\K9UZND?RY:D[GYY\_IO>3P"&S<0Z+T(^#!!2$%4?B( @Q M'LKPH/ODC8S2T\1W\DO'QJ^'#@L,6A3+39(\[OZ6SDW+WBS?]#'G5>)-4]*H M,Z\/(S,@C?JS#"QA/9N-WB!2U]"_IQ>@OEM\)(*8 B_1'4$T% M?M.;F# 3"PX^BPN.X KY2/E3ZCWXS#5.;P^S7PI_:#QW.!)'ME??3IXM?GGR M >CV7OX)"!RA2Y[O".@4RG4$O$#EF8Y@*7J6A*>DT#/%'UX.-LWRP:;YG+#) MY9U+J)ARY;*,'1]RR0LQ?+G#M3EOFO#G'J>]ZH1Y_L3QEKWL02:3?MO\$^6O M^G[79TQ@;%\'OAU;T54@,NQ4_EN/_1UCRI8WNF%WS(O98C_+:V.G$O)LA)IG M&L@V+.''U'4L1^3H&;8SP20EK &$#1_E[7CK,R4;+MCSSQ]S'YP]J?1R2JVR M/#?&9+U5%<8\.\8TU\:89H$Q9L[G5V',C+.;*Q@*A#.E%$R+<&9S15-Q<&9PLJF K",S23& M#59F*LB.FH MHN%CUPS#JR%5%.G5@:+.'VMYTF5'">,[*!N_4_&L19O?^IR4K"W=_NNPP,2+ MUCIX%0]C%CEX:2<&_7R/JO=2"#*9^-[&H43>EG6TR&RZ0H1IQ[8=C+6:[K7I MV%WOV)PZD>F^'Z18"H *0:8=RXHGL0M7VE?1F 5X5<#&".T[UO4L?\+>$;*L M"HP*<:8W+#(=C]FG9H!5K>'[P9+\G6\H2KS=>18?-D_6R-[:BMITU:R41M^3 MU+EW@U$%T.M*B5U/<"EL$&X5W+=02LQZG+*X04A57*UQX_!I+:OUW:!8P1I9&^>]+/IJEDI4YU[/QA5 +VN%-B%;5!8*&$J MFZ'L(*R\!\V\R9;GWF M7S[E5#=4@7D1 B@C]E9H4P0;^AU)Z&(9TZ60UL\B6-\/BA4E4K41^)1OH6XX M!KUYS.!Y&UN\DI&YX4A1 -NRV BREKZSZ[Q /O")%P*)+ MC&V8^Y7:J6S8N7ROY<:L9<=^8?[E!\=Q&('<#4)U]O*;3CK[]1BH#[83T!0K M',GV9?:%>=9X8@:I?@4]TV6AZ'QZR:('']*?35G*MA*OG[MT$^J&$0?GP2X0 M,0/X!Q!O#?[ZT-$E+#;W\%YT(?+X-3MS.0*\OLNBL"72+T;#(AL6,,%BSITY M<-D+D'&)\_:*3L:+SN^]4W)A$Q)1!WX M\*)H=NV:7@1HAM%FFM.GD2*BX[DY\&DL^4Q=L0F:M,2J%< @R'(A()Y.!]2( M0YX8[\N1.K-*1UV,V^:/"K?+AMOZF56XG4U_6@5[Q:7GS S9V'?M[F0:^'>4 M-K11^?PKH;"\> DT*BQ[&>T L]/BB 7J=[BVYP^C>S/8J-*EU5GIPQ"I](6R MZ@L5MA<%VRL-XN5Y^UD<>$X4!PRNN1H.'8N]L77 M'U\8@^?6@S>Q\/CXX3%Y.V7%X0?J8PA[5P/#ZR"8UKUVISA55.LA2WDC+67% MFE($&IX?T\HK6LN&8*]0O8=[OF;!T \FIF>QVZN!ZXPH;+>@G(^ E'^'?.5J M]7V91?0XJ):]55RRWFN6Z::@:MFQ%5T%<.AWH#XEU83LCKD^:5*]>#KUJ1\] M!E8W0=%$)2YOY[*Z*XWON3"HW.E/I<*@ F?Z/ JSRE0V#"JO>K8A! M GPW;(3=3/Q@=N&X+(Q ^]F(4.3JZ/0@("KY]B*X]1Z$71%QJ^22;Q7<>A=B ML("X55B9*,Q]])9?#3M!@/YKBGM*!+NX.=% VQD%;/.R@Y57X2LE!BZKG/1V32JS>E1&3"JO5K91+\B2A M6Z%761-$WJH+ZF)T4P6"Q[[K\LH-@)>"O\[=VH*[-=OM@TU#OY7 \#9,KKTN MDX,[V@>OS>3RDD.?CG6;R>N> ]D>R?)>/__S+?JO/BQ_C^%N!R[R(O@KA//G M9Y#)Y%SBSJM0O @HKA5]+S].L:Q'NR4K#>,5R$U3 "MZVPAZ6W*B%<&]/<'A MX"$66([I5O2V$?2V^$ KG;'_M=O5G[_"D9N!-9Z=HW='?Y:ZI.M- MXRBDWUL+'WC!Z^+P),X"]G?,/&N6^S3M0FSR'P%:),L*!]Q7F0)2U O!T#SR+?9KHGG(_&*(M\?16XZ\G_K??7O6.#QM"(X M18>%)VP0]?"@G,C)>KR?+O':%7UM)GVMBDK%DH'MB@T\C0U45%M1[>83R+$? M3-&H9I5PK,CL$62V%'\JB5A^@J_H\]W2Y^:00N7$?)]447D07Y9 *K7NO1+( M>U.F*GQ^97S>'-39U !L:?-8RL&:JP#L^B3>+">)5Q3Y_BARTY%_$P.P%7V5 M.93S3BRDC6$#%=565+OY!+(Q =B*S$H7X*DD8@D(OJ+/=TN?FT,*E1/S?5)% MY4$L>P"V(I!B$LA[4Z8J?"Y] /954:?KT0A(WB_I&/2OD1_,KH::%C93M=:= M.]-QS8'+SOR@9[HL4=/22MLQ@(^IVFOUHCL61@@BU61K7=]7F?,"YK?_EH[; M%4]=%)<_ZMPW.V^A &2C+*8OOF>_&UI9NNN*0-X1@90;PROT*AQZ7?J>56DN M[U)SR1Y]13PO3SR5_E(Z_:4BDV85D142R%_2_E-8M^!ZTF+?5_]^; MV_)!_64C::74^DM%(,_K?RDQAE?H53CT>EG_2XEQ=?,UES?7^3>/>,J-\A62 M/17)OIBNZ5FL-V8L.O

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
9?8^Y8Q[L,^X."(L4U!'.[4L62'2*_ M=XX56+((G[G/P4L__ZZZ3<=&&^N% Q MKC_G$IO9LRU<[W%F6" 2,."')7;X6.=.SB7#F_T_8)FY,9G$D+CJT2)P! MP74OQ=.-.)[>T%Y+T\B],?Z;X,W;0QX +APR1J>;ZNW4V? OKQJOM"'WX82? MQE\]^3DZ5Y8_9Y[LK3D+O7?1R;+D\&G WL;_>*?%R02-J =>K@SG2/52W<9Y MZX7BMH-6?)0V3V@_R]\\[YQR]-S8L UV9 MQ)/U*G;6FS2'K8*ROPF216'[7^&W7F5,>7*>>O(ZT&/DZ]" 8?/BSC*P2H7U M!91#&8B$;YH4^,;HGC?;VR>:UIN0Q![BY,1#J0$!#5CHV;U"Z@3#",-84EQ% M3 6&D1PL5-JRK%2VR).O;N3A$PM5?'(6J!R&^>'U/(&%7!62(K/JHD*WAJ]6 M54 $R^\ZDOQK7CEG#)IZK]FCAT[-].-D)> @!EK+7C?!!S&0A.6UT1[HW3ZF MM)X:B#V,6#]8_*0^6[JH%,82J66OH_W=FU3"_.X;O(.!!!X_55ON6MDIJC" MS%_]:O0-O6F<+&H+':&M(V (2'^-80!#R/Z0/;W1/MG(!2C)_K9[.,';ZW9O MWD,#IW@EY0X$HRH. RC\U:_-GFZT3]8#$RI"6T5 $)#^&L, @N $,6CIG3Y2 M/19Q.+F*D&V*O'FS@HU7<.]5\C=)DN5%9GM6P8X@ER\EEVK6S+>C!CJB.'YE M;?PW,]!^, ;-\]Z\=Y+J?B'^,F^J98:A;S_,5 &[;,#G\BVRZ*JKNK8T>N>M MI&^+;*HA/S M][R1=%V5O0RW?-OLZEJS:%%_Z/3F2&@^$\U7Q+]$\\>XE6/?LOYHH*!([M1=R91Q?W[)VWDUN^T'M%E^^I\/VADUJM]/>2 MWBR)*(EV4,O0-%WMA_Z\;5?F*HL-OU*K)Y^Z-6]OO/RIE[5X24.P=/U4>Z14 M-[:9;%#S()[?ENK&U::IQTM@I*3>8O.'X)(F/Y_I(ZNZ@BJ!J&JOHGU9ID9D MF=J#'2T3WPDO*'7.,F4Z_ZZQ3NW&7JQ3LYV^S.;6:;"Q<4J9OZ7&:9,77F6@ MN&UM']M =>;&=I6AD;JXW(RMT<6DX]5\#?B%&BG+DE;J-19)+K-HQ"87.5AK M\0H9*\4YG05!SJS_2G.MVJIU5W8)3_MX6\PV.(6/=YWD6=7#QTL?/RS+,=O2 MS^NG')S-K"E_@"%C5M2L>V*&J>;SD]5=Z3N99IS+%"'N7?C"E5I&=T'J,U_D MC\>5,FJD/>].*[[9->;,40NVW4$^8K8U4F[MAO*Q&8S=0=J&;P.CT7^)=+,B MJCH:JN:\&PKKH+M&4DID'#\DYY/U,X[+SF:W,X[-WKSS:!';J!INBZ[ER@M3 M$T/4I*1JN_M[PB$R0LU!:^ZK; 8$Q\Z86PGE\REHN&,H>E1R-TXZ2OPAQ*08 M_YM0?S?JW3Z+.]4K7XD[L79Z HCT'?F;S0(]\JQBEU6V)HPO%S)^U]D#U^#Y M->)^I-(\_[\9?W+QFIGFS2+FT%OVY$6$JJ"MRH!_DB%5(MUB'K[[*/9NEZ;O M/_,ORD%B5>IW^8>-MJM">'QOKG,#\;V--[_S3\69!3W+FKEW.HWXW[@ MUZ)=A2M;=ZL]VZ5G22DT!OVN]OJ?_^@W^5*FOBA_8[Q[HWIU\ALYIJ^:A*M; M!?' #;;DH;.C3J+Q!;:?+-3Z17I@(]%'?#9?7#G%)I2=R(.Q[.3[(-M/+ZZ( MZM,>]U%.#;AX&9EA?%GY&LR2TQMDF^NYYIN9E37Y5YQ"S1QERL'H?[#V$BY4?O+__? MA9[YZWSNFHRL&?UT\VG5U342?X&"+2RO D(3RCT2$S>8:.W.R4#>(;+S$9C" M8,XX>V3O&&14RCA*^=TR%EW0;CR65;=LV*]LP?;]>W8D1+/.KDBF]1Q72%59Q^Q+/-EWSPS1XEXUZ<_FP_T[]\Y1O. M1R?*Z*C/K(WG?.0&\OSKXN+V7!.S7=2U$BI08SE>OF;4/S_0U%F+G'?$8C$1 MWG(PFTRC*3%<@OXSLQ[CN7MB[!;WMH?*]OERQ B3L7/IU?.'4"9'SP13U=S: M:&8FWP(X7B#G*44F5 Z-C'R@%Y\^X\W'P>UXK)(:FRN62]QIO@M2#RI^$L,< M/$M-!F3*ED9##N,%6'AG&3Y)1DL]F)R]Y9S]ZGB4&4^I";,6D&P%+E[Q/XG7ZR4;"B_6UUA*IS;8:S#D2L6 M^GS/+@:HF6YR"R9FGPK!CF18JHP]8>J4)Y#WE,<4?F;S$NU#Y/96?5/&4N2_ MA-)MY>!N$C@M+YA9"%\<" M/JOS6[$ZM5 VX=^DYT2J@4C)U.>$^7U?F#>^4Q, M+!0?4;^+'V7$(M*(Q]?*\:ZQ7Y1ZU^29LC/*XOM)7?@N4QU2#R ?V1'3UARN M7V**5_+JV_>X#R)<&.7+"M&(94SR M:Y0]H;S/>%R<2NU(^3:)FY8?QQ;)W8(!#4(V5>Y3''Q0#[3L(1[261QOM=?& M&R5?$;3/L0,M_:9HWK#RH?[YC\[@G?:Z&7UA?B_.&-(IC7RJB2WLL7"0 BT: M;)C(X0IW+NUOI:[VK#A0SH\;)A%&\4 KQ6]'@3[H=*)VB9D[@X MKE (,/^0[4KJ6B[7T?7;T?5%X&0HH%[NA4:4MO^Y$=YR+3PPG7RI7>RT&&0=OA'3$<[>9R:W.\EO70SLO5KR]B".:L8S* M;?%-0XS\&7']5$#ECF^@+!%G MO/0LZ?;)!XH#\A=WETD@_MZ;VD.MV^CJ2S9H:=2[C/4_D MAT6;_A5R&1-?BB3G^IN>)K@XR-EGCS,G&L(Z>^#+&R0)3\(L/JGQSF*(L-A# MWJ5V5[;I1JW MTM=,487M3F?2T'JS4/Q+F88)-X*>E66-=*!"';6$T;LO;J'KH>5_L41>E?HE MZ";1)+$XDTB9HSW2JD\+H4T_0"03T=>%EZ:\05N*-T?L M09V$RW!89C,H4<:2X31L&4 MZ:#6?[BQRL3#8I7S9'3)68)1+23]/N?:[6R4I#LIC*SR^-3:LW@ZNHS !D%\ M=N1[7)3.M3\"94>5>9:_5"-DXQBH-,OJ EPFXCH"Z=K(OV6X),%8^8WRD94R M).0J! MYY^?CV!?E) HN*>@BTYQ$V^.1$NQ8=H,/R2,=E)AKH2UK38+:'0F11RZ25* M>N)9S%%R&7E)%]!>N+^%8'%_F M0]5BKY4\NUC*)1@N/M$<@?1$]%3@F).6"K$_I$_3IYY8=A&%XTZ/"+NKR(I\ MF^G"@^HBG5]EH7"!Y%S_\)Q&-.5XCABS1.'K_)ADQ VBYP>2(J.R 6[OOKK> M-U>>OZ@O^[+8XCH7M:R*Y.5DV9954-TJKA0/(0=Z,S_M)N@)$8HOIY)+ MLKB(%Y?2F_<&9T'BW":^@B)Q3A##\=EL&F^(A716[+C>:#2*SKJN7) WOUD\ M_3/]*SHF6S$"NY*L'+^S\+>%*5>'WL*&"$\WH<$HE3[R?(2#FZ0"S?91GY:J_Y%FPF[6-GB98^9T3AQ'V9:1-C/%&_-'JX>KE\XT6(61S.3V@]AY M%ZO^-P=-)LCQM8[),!-1B:E+[4K79ZG-)28^6IOO*&7LBU_!D5$(\569:RFR M,*4[)24ZFS 1'](O>T:9 2C2YLRA[W'*<[V)/12\:=G1[B6UU9 A.-?B+J/_ MG-EWJ-H_3IS"M8JOK2>;R?E98-J]FQ<:)DD60N;"Y[. ^P5BCQ[+ :]2U4+JDL8!TYWK?HU6)7 M,I/SHXZJXU3(C%^9RF%87/@E^0$B19C?,4K!$ D&Y]KO:]((9 )$[CLI[U;9 MJM2S1J?25BYA1B6OS/U:VQ4(2Q]RYL;B*\V?&R5@Q.6@,L'(C&ZNB[**%0D2 M,F0[3X$0Z<_?6&:SKW)(#Z^)Z:@:*OM)K.HP.94RE3 M?$CHBOI48J=2-HJ_))?P?RWY"_MNB_V//-/(AI_RKR8.)C=^O8CC^,KF[J;, M2/:3,4'/GSY0);M*0%(/$V=]BQO.K\P5R'],99!%M=N9+(14[H5XHVFT2Q": MI *X7UY=WU_]_J7UY7_^N/AT?WU_ M<7_]YY7XX6/\[_?7=Y/7K-5])K7=QKOU/6O:$5OY/2F+?IS(&+Q[X MKI/;$$D>G^W@J[93J8I8N9W7:5^5UMQN<,71/@M.$:]6I2*K0X.TJ06<)J(DN.*W>29+2T /5"R^_ MHJK%I/I::ZXNRV1;@WGYHOS8#T8SU:I!1#>$TR$D6"3TCYF3?@/A-$==*+S MCI^8+^!SO# B1V3UXR9/&8RY)3T3E*/V%)[[J'Y:77_;;AGG1A18B!]6/AY_ MJ#_.[\ZY6>)>EAN51#R$Z>^KFIA4NY;5S]C8Y1F[_Q<+AF])S MG\Y\80"5H"8^@DR"%-Z!Q??;3]%N*MG@B,H>?S:)MRW*S9X'>>,W5'(?+J\O/GZYXS[3U>]7G^[OOEQ\ M>O_E[H_;VX_\Y\AUZI]K'Q(YN9L[ID*Z[F;3J2-_%G;OO1F:+XO$1G'5S65E M^2H.#KB(&U?C7%CF5.K9;[8G#B-<_O='P2"7$7O(--NE@<]BR]:NPJI=\R?] M+HS097I'M$P$L78YB7O![Y3_P+(M+MN'*&O[?V5M\M7RAB*I@NUFPQBL6,7# M%#P:1K[B,6HCJSS;!Q%+\']YU7BE#9GCB%:[W!5(?HZ:\\J?,P_ZUIR%WCOU M[3-Y-#X-V-OX'^^TJ(5OHQ$U%\_-*IG8EN6P4XR.&33/!\T#]#P_99DG=\=] M-OKEU3\^7]W>?+[_6"C,M[62*R),GEKIE-0/ MMC])Y-Q<60YX[&727M]>7MS\IEV_?ZO];'\7G_W$?5>?/[SP;SY\$8AZ W^'_D/OMYT+ MCWP'A%0KP[4ZV3JE=J6W]Q> M?;ZXO[[Y5%C+[C(G2C?)B1+TC92^=:%O%/3M\N;WV\]7_[[Z="?.$C_>W.U) M[RZ]R=1G8Q%Y?F*R)1[TCY3^]:!_-/3OTY]7G^^O?_MX]84KXH>KSV+;>W=_ M<_G?7_:FBNX3\T/9[^W6C_N9W/11CAI+?.;)SH5B5P3VV>J)(O_L%G"TX[KDWJG MC0M5<[DGNU>NWDQM5[;74 FWR]VD2N76J\D!XB"=6?F6HIGZE8?H3"^09WJ; MBH;V6ESU4EWSS:J&\JDD>M5U>=XZYL7Z&5UF$\\CL")'5_QN'@J:)J&@( D% M!MK MD9P3I_QKR=.*Y&A5AQ4U#%O6R#3N(';.C5\T,%(*L5K)I:U?HPIEF;DM2@QL M.1(@Z=L;%R $BY>0%0>I]C,1JJ*P>!VB\W=6E7 BP5W\3X*@*N:4Y5O[7&O5 M"UIH@9ZH4WD1I/6_TM, D]9M)LQ'9D,]S M5$7\7.#FY7XK[(:>:KSBVU)\16D WR;9W$S)XH5D-LZENH>\>?.=^/6C&AKR M0?0R^>;Y7U5[;EFA$3WM1(R+DG4-=U-ABV15^XW_:+K1()5DA>ZY"VIQSU-] M2W7">]UL&"UM%%_^3=+81KV7%FW&V8,_$ZG61D>^5%/DXHMN(S*W7YNYL@A3 M]E^-5%L5':\>@5RWLSBY98^4:9F6YH)-;1 %KC'8]-2UG+$_6A121Y[ MVHD)4=E\<5?YJ!-]7&UMI]STJ)-D$,\R2A/+"O,DK7@\*BA5Q.68W^;>K.PE M.92)M/XLGC09U;RG%?Y_2X_B2\IVJQ@JBO\),%J;-(=^<%^2* M:/>J#UORUWCP0#R<8NJ8T2S15"MC>2M9D?D@:^I3,RM$H;ZO^@/(LMUTL^&5 MBC3RE:5.W!@!7_P1/;E&-'*->UBB:X(HQN?FHQ6'TM,HK\(;,DC5D MTBL+6%0A+XJG@I6W36KDELXC6?M(>GK!%A]!K*M2_ZCGI%A_^2A1H5KJP_-& M_]]-U;E:5\5RHBQ?50;JR5@KH2&FG[1.C<>SR!9@J6KJN.7YLL;ZZ:64+L?\ M :(15/'%ESE=<4V;E>F..6_T$'<#FQO#S%R7A5O$73\BCS?3/''YP_^5'EA@ MAFFEB(;PR18/B:@^)-25\KUW+\O/$_.1J'@^%DJJY^\F=X#\X*6BB[;XCRS. MF$TS$17YP/W.C^_$><396#VOT>1O*'=G_$91O(HOS3RJQ:_RZ_K02RFMK>@L MF\RW4.9O(M=7[& G,U=VA1&]+D6;%=FU.OHSOY+L[)-,&HWZVL5;('6M-7(= M66)5>3N_DYPBD&'FS)_C;K;RZL/$&U9T:(:RD7RTDU5F,9YKSZ^;MA:JPZ?L M:!?9R.C*RVVY:)S[2W6G47?59]HQI]( MG4!G/M!MI/^Z*D5!\,DY=S<1F^QW._EB+-IFH^5ITE. MJ+N'6>=CS42).LB) <#/V<%RVY#DV;NP][^IVU+;>JH>YN(18D=5G&>H&RZ9!<$?SAVXSM0"+1TS)7.=D ME,BRXQIY R::474:\_Y4VT68NR53#N$G"_%8,Z R.7Y2 ,<-Z5?"JH"7K3[E M7/E((N.-26KP9S"??)-J&QG?+VDU&3>VDK]THH>*^Y&GMS.R>;X4B70S=;$? ML67X2$:3^&_$%Q;'XXG="/.%^L?SX9/VZ^D6[]$IC:..2!+C<%XJIMR7D!Z) M*?_M?1,QJ0O+BHZ$YEPIK+B(M4DY!G'N.S"NPM+Q(9S($Q#Q;1EUB-L9*S0X MK?*UCLZY61#_.CK?%FVP8W9SHU[@D2(%\P[@BX+U(0Q 6DT9RX5P8]%+SZZRPJF8ECN\8G MTRQ(IE<(9W/V@C OD=Y$(E:2GNJC)^<>R8>;]UR,/+;TY<1WHM$@8B"(R!.: M3>/, \L;RAYZZJ'$6&S/][T'U2@R44=Y8)%YF61Z%9<5$?Q.]^&.5I%[6>Y, MQ$X3/WA1F:+9L/D-/S+"<=0^?KQ=;.>SZQJ2H8(X1U.88S6!>9F[8*K%Y&PN]K3-AM&I MS *L%J?N$G'Z&$W(VTZD[AAWJ,5)S5]F,.:&.1092!45J%RZV1[-S1HCMJ?2 MA*2_(-G[E.1$K%WT1"S_XIFC?6/IFZ]SQ<^-P8^;EJ&DS_ /7X:2-'O-I#\X M3&R^SZ+#L+=GC?.&V@O'U2(+V?#;?;EH5479"HJ.BZ2DC<769LLZEFT'5MS> MK)J+]NMKVUVW'KGE",?>+. [H4#?;AG%D+1IN-UW9/W&=E_A3[;=%_CF62MR M'Y4T]Z;N;635BQZP7CS*!QB<=_H_OHO>,UY>J=F:^J":DRP&#KB+,+]>89@D"! M<2A#DS!.DP+C&,WS;HIQQ HOI1M04@I7$;D$%=78PA52$YA F,#*X"I:2\ $ M$O3&TQEG^:6__/"A\>'R $H4>>>G6_X#GT0$011I+B+P!UMUQ4HGJ%,H133M M<,N^ 5LQJG2S4ZK@'8?? 0,HAN*R@V+*@1,HIL3@U9YB MBNTB#Q:*.=0ND@P"EU'C&'.G_>3A0F$@^Y,L>^WM$ T8%)>#JBEB Q4A 0,( M M)?7QA $'2QJ;V*5.Y$T&B=]VB#(,NVGT_KA[_RI=W-V+B[MGP=FC:4[? M"E-WX5KB?Z[F=NXBO#1]7PPK^M-T9B]U$I#5WK+-#7^LX)=79ZU7FNP$%_[R MRO[.7W4VL;PP^CL7EJ$ID&F]^M5H#?1&MQ,7A^Y[\:>SS_+_(G&'_PK4U7VJ3%4 MK\V)Z!WW?U$?8-FC>%N38#2:BR;A/7L(Y\.J+IY,VQ%W_N#Y=UQQ+^)[7O); M1J>\A_*&FT9;-XR\-RPC$05>M77H5RUN"CO=MMY88@KU>&29'-GYAEXT$@XH M@L#UA0%>:!$O=+!HAQAKKKFLE7C4' B1),,$2&N M. SP28KX)$;.)XG,W>?$VGUBAX[V&CV]W1C@,(B:.%%5=1 =I+^^,(#HBA!= M[K"S.-'MD/;0T!OM'HB.FC@AZX$ "-?N$W\HSW^F%W>"PX%P7WUA@,-1Q.'( MI1PE]HW[&0?;20_T9A>1?'+B0U6U06R0_OK" &(K0FSMXL2VP\ZYK3= ;/3$ MA\H1]1X&Z%1L.WWKLZG)WYM]GS(W8&J O!>.F:\-]]*B;3^0[3)7I]J*1"42 MN,E0B)K;/!I09?NT[@077)Z,R]-9='DBXWJE;.N%:]T(PZI&*!SZL+RE-Y94 M1IW8BF]NPF$JP+ UQ (,6P&HP+"'8MCNWAEVIUA#IP6&+8>H43FZ/W8 HMD[ M;W5H0W/OA::SIV##(49:_?)G-' ;Z)K-D#'=+ '=@XUWKQ*%&,7K.K#XPVZ+@44D4E MC^* %0C$$?CH\=>6/1=/FQ:!9$UBRXXQM>7 "6-J2PQ>[=,F:< B@'% "=0 M3!7!JSW%H*;]!$GXWI3YX;-,OA?#\Z83_I []8]#,6#%(K.UMTLT8$ Q8)'8 M=JZA>VSQ;AU^Z0O7NHJ-W@&KWOL=O=EMDHET0]6)JSJ(#M)?7QA = 6(KI-K MWEZG< HB,G3C4XO:6_U[[AZFB&_/4UAYD!TZ35.O-&9S/^ \YT MB2@&C66OO7VB 0-V+Y/@K#)^&X&?T1,)EG=K!-=T_O]O:7[0U= MK[BN@^D@_?6% 4Q7A.ER3=MW8+KBN^[!0&]U&F Z:O*$$VX"(,S3IB<''%6? MZSFYQ?SV3YX[//3TX+YN+.E.671:?:[=U '>=H?V&/QMV\W\N"8,K*=F#FDL M>^U9B08,\$"+>*"Y+OZ;SNP]!NOT=*.]OSY%L 5MP#@/TA_?6$ _Q7AO]S& M:]_\M]L^I-,$_Y&3,F1#$ #A,PM"WQZ&(NYB!F-ZP4IX(X@1UQ<&>"-%O)%< M8'1NY2ZYD3O"GELW6LAY("=)5+4<' ?IKR\,X+@B')?KA%^,XXKOJ\%Q)"4) MV0X$0+AV0]-]M$6.@ZHH0"D_#5V@L>RU-TDT8(#C4<3QR'6-_V#S[["/]A.S MYG9/]:X]9#&_WFEV$=2G)D]4=1U,!^FO+PQ@NB),EVO(O@O3[7" W=";.+^F M)U XOR8 PK\\S_IF.PZ]N!,\#H3[Z@L#/(XB'D>N35YLW@XV)=[HZX/>_EH% M0:\KKM=@-4A_?6$ JQ5@M6ZN)]YFK+9;RC=8C:#L4#F$"-58\GIL,(>&$%39.30[P067)N/2Y'OK"?L9'07LDEZ>;IQ')^:/H:QT MU1^L20<+L&8%H )K'HHU\WWZMF?-I5&!.6MV!OO+20=KEB$6L&MP9ETLP/)F M(H>[>;Y' FWVSEL=VM#<>Z'IG+@7_AJWYA"HE$Y9J,0O7YQRN@Z\6OH]/]"# M<<.!M7N!$CY1QB?*=XZ39O=0!_Z#9DMOM=MDCD96^4@K;7RM3,5IS3XHF X6 MH&!0,"CX,!2<;UZW 07OD)V@&T97;QL@X7((%)6DA0/F^2]'(+V0#YYC[0A) MT?7_:)L/MJ/&!(A.^<&8"^&8/P_S@W_^H\\5^IW&_I[9X3.]6#+2)4]\VB(6 M%?X.59SR3@\.P*5*0=&<^9Z3 M7J@0C(]:G?K"@!H\NMA 14C (* ]-<7!A $76QJKR*5.SJD7]I\,1SRM0P# M;6H^BXET],(9:%2&WXLFY+;W9 KF1DZ,:G(R68B/MSYB%PU%2BD!C MV6MOCVC )^CB,^1&VD56;I4Y<&!]]0#O=5ND:D'@IH35W.0'*2_OC" Y(J0 M7&Z:54&2VZ'PM:4;773E)B=+.*4F $*\N1YZDRES U-JM2AW?6 N&]FGZ\H- M+X38LM?>.M& 5Y($2\D-^'J:C)UO&?&/C/'#(^YY38Z>K>]/V\$^EYQ?0?; M0?KK"P/8K@#;]7*3KW9DNUU&8NF#3@-L1TVF<+!- (2XZG?J^5*QO9'F39G/ M]^#NH^8P,V X\R:E(S26O?:FB@8,<$V*N";Y"5:QQ?LH#%[LF3P?>!?>T1N= M_7*I< MB[LCU@48+;V_QP9WAQK."0_J]+8#G$P'"W!R'; $)Y^,DW.=^8Y8O=#HZ,8 MG%P.T:*24G' F@;B"'ST^&N'S)_L(W"!DLJ*G01LP)\UMUI>W3"R'")4!= M47UA0 UAD=AWKD/\BAK"3YX[//#Q=*.K=_LHF2/WPGD[[,:[+;UK]$%Z MU$2+RMDX"LE7%)*C@)P8+%0#UBA6JPZ6*%8[F>>4:V^?*E8[5$2@90STYAY' MRJ%*K;I& V1,!PN0<1VP!!F?C(QS'?@W)N,=VNWW6KK1WE^H F1I.)'4[X@P5R[+S02KX2S!UR)=5>?_)"IAG&&WJ1/IRKH,(/.*'";R>7 MAK^X&[_I6<"&9_;WL[%M\4=]&_DPK3G$XL,X\C@U9E05#GP$/@).X*,#\U$; M?$0+,RI'\/7=PMZ-39^-/8<;EN"?_^@WC=X[C?T]L\-G>M%(> DHTJDO#,@& MI(L-5(0$#" (2']]80!!T,6F]BI2N:-)^H7.MWYR3&]R)Z]^:_HU_%YHAL_XTG1F[9;[<7&Z9.7C]Z<.& MZ1(K'S37>&@?#YK+JI /VC@7GUJ2,+'P"VUJ^D+F1;GYFI=;]4:YWA+9-Y*/ M'US,PK'GN!DN#[QTZ=<]L-'0^17$_V^ C'IZS4P> M1C-#[3T;LLD#\[66H6MBS>3YOGB6?_ZC,WA7 $,C5Y>T;$FN@V"V,WXB^"F6 MY)OG6P%SBP!HY'*!BS[MB^#MXVESR5++GO9F%@8AAY$3 H$%SLT8W^F1MU]E MUWM9-S;7'EM*@E02;_[,ZS6)7O0=^T<<>M07!NP?-SI$[ @$^TVCB5-$(J!1 M52C0":2_OC" 3C:BDR[HA!AH-4A*H1^\%*45GKN?R*71SK>$$5>G%;8T[RZ8++&(G0"D Q9(NC@6@V%HN"T"1BQH7AV+[H'^K MIW?;7;T_Z!XV;JEK_)M3QB_TQ!RD29[>/:.Q[+7WDFG @&UGD6X#Z]P?Z7 6 MZ/^3:H'8)M-2 /I+7'_!7I#^^L( ]BK"7NOVJANPU]*&.6 ORC*"!%,"(%SP M=Q?J8#K:U+0M_I#:T)S:H>G0.\. 6X&CH_K" +>BB%N1B[O.#=XMMW?7[J6R M=@<;6ZNWFFV]T5@6SZ0F85!T$C" YB#]]84!-%> Y@:Y\]-"-+?#@!R]V6GI M@]ZRE 1J$E9[14'[",W M@I]8>#.Z-[\7.:R6HG*VLZ M&>R5_EXX[>X/6B V:C)$Y;C[V*-JR[4YM]C('MKAJ:)6&(]7AACU>FS0=I\0 M5-FV^SO!56D/I\ ./]?]Z#,+3=MEUI7INQR-(&57WRNS>O!-?<_HZ_T!G5,( M3+\[R%X?-%L'VPV:+0U4H-F#T6RN\<&N-+L\>+ 5S78,0^\:^YOX#IH]&LU6 M[O"_V3MO=6@#<.^%IJ-=6.94U)MKO]E>R(9CES_>HQ@R>^GY4\\WI3T(,,N' M"FI4 _*8^%<.G##Q[R G*[D62[)$,#*95])4'BJ9O]MHZ8/!_MP>G*U4W 2 M(<&0P D,>5R&S'7MVY8AB]?D&M[];O.K<>_F.K*ANS6\,Y:U\L7Y M!CW).:WF@S#I8 '"K !4(,Q-\8M&CH"3*()#H^K^V/OMTIS&TSMHAR-1AICU M!O%J>!HEP7+#\P>X(OO?N^?:_>;/**[=H3,3R-UZOKCJ11CZ]L,L-!\<=N]E MPZ8[[/@W//EOZT:#SLD_G"^Z]@8\3@<+\'@=L 2/GXS'<_UUC\'CU1V#*(YM/MB.'8HJ!C%:;_]!E0.>SAP"N=(I%(V0__;DG0&O MEL[8#_1@+.:'%8,2?EAZ:FLCUP#ZX]PT7[C6\6HD!LV6WFKO;]S2H8ZI5EK_ M6AD1LJD3(&]"SKE>R+N1\RYC&@RCJ[?W. VQ7O1\ 9_ZUE/VWW\IEW_3'U;MUIF+GC"G4>,A&A>UF?%^X3K2B7VP_-T\8MQNQG M+CQN_&H."_G[2'GBDOGVK''>Z,B5T'[^27SN5W,H)C68[K,HSG"]D 5;?M_? M]H;N=I\7!2./ONEL]RVN3>$+WS R7_!&V]T@'+-@TS?GQDYRD>S &7U_9+NF M.[1%ID[(?S_A@A2<+PIF<7$WBHB[N*K1G"ZCL]4W.K:$&XU.]$)C/WZCJ?G( MSAY\9GX],T?\A=Z:SC?S.7BE_?3"BSNVR\[&ZN$,8^F;K[.NY\;@QZ5+$[WO M R>]'6U#T66*N[%L)]4+K5NV^W*JS\M>!'GMLL@5+"3ENQCU#61<8KX,Y8)( M2D?K[O[B_NKWJT_W=U]N;J\^7]Q?WWRZ>\57/&58[A([HGDC[6;*%!3!_A>& MB(B_MM=2R1*3[B]BYQJ+G^. M.0W8V_@?[[3(\6XTH@85N2.U([G^G=ZY\4*Z_T'#/[4-^,3!-XI92GT*2/"' M$_;@EU<&UZW3!W#:C?/F"UC%"[DR&+,IGVVH-DLHKAB417'[7V;ZVA5_+$M[ MSX9L\L!\!67+T$\>T3A&I((&#)OG:=2$5$C;-3 ,%202AFE2(!C#..]U]Y1& M61L&$F?E)V<:2LF#-&"A8?C:NZH33"-,8VEU4)Q4PC22@P6F$:81IO'4IM$8 MP#22@X5*TXZ5RA;%-4ZW_(<]L/K,GI@[8RLTXT1K+N,7U[8WS/FBH1CS=\A-G>XPP?$YDY0#EXK.[2JDOM4R[\A':," M.UV!W6PN5F!'1PT??&]RR6\BKO27'8XO9P%?'N9??8]ZUET$ >/_9]V;W]<4 M90=^>.M[UFP8WOAWS'^RA^SBNQU\,:UI.+>AT3U_EWG*LLN*J W?K=U*KZ_W M!QOWLX/-J*_=QOX5<@^N!%>^R)4MDES9B+FR>/>3MJ&W6P-P)2GY)&FWP960 M>W EN/)%KFQ3Y$IC$'&E,2C.E2V]8X K:PR% IZL/VBUP-'VI!4<# M"'!TV7$"1Q^*HWLD.7HOAP^&WNEL/&P='$W)Y)QR0NOQ3B1*,Z'UE&G[.(P@ MTW9K$S]JI]9--;=Z-+!L[*\5%YRQ[9RQ_F&=L?V<3QB==BEFL\*W.G&6'N(? M1( ;U<>2)#VR4A[<'#2WL.!Q:"OM_I["H: L"MJ7D#81( 85<>2!#VJ0B[ MU3@T8>_C]*+?T1L] X1-7P"IU%.LM#45[_<=S>!U'S7V?1TKF;7F-HH 2!NZ0 #JU$#5OD"2 9H)@ 6 4A@D?("!18Y/09@$; (0 *+ ME!>HVK,(&I@?'81++P@U;X3NY204@,"2U]X($<"@@59S!*$KE/6=6Q;(?=UQ <5X3CEVI7/S#=Z-H-_46E5:D7:6T'?*^@Z>@]S7$0/P7!&>6S*DH2C/[2.8W&OHO48'-$=*JI"%3 "$ M.ZXB@8PD\^?^RD3' V)'+(@CXU2KAAC [RCB=^0&3]PQQ^$+S-V.WV/[=JP@ M\J"CM[M[RM(?=UQ <5X3CB:^U2LFP5RD2MT;EI[>T0 _@>!7R/=JZ3?V3FN.]QD3%RQPHD M]]IZIX$D+5IR15+ALCV$$UN#_1.JPNB(R57)!4> M1 >YKR,&(+HB1)?KW;0+T>TEI-S06RWLZ&C)%95\Y$S\^ @34^G'F2\FGA_: M_V=*=?=&FNV&IOMH/SA,,X. A<5FL^UKL"WFVE(]>UT/#-KO4\&ID9F3L!-6 M\'PRGD^NHU?:E-Z,KA-#>B'MZ.$;:^C=P8#&43KFSQ*U$Q@83P0($&O9<0*Q M'HI8''#M\W>^>M#FUH[KW0=#1ORL0IF_NH,77,5BQLOQ]\$+:G M>\B]P$EE +*QV?QCN%'[=Z-R#=C$* \QQ"-*<3A\J+_5;>DM8T]3JO9D M].$Z43,>B$D0 0)T7'D@0<((?/2"0!OY MWB0^0_#T4 9 V='+J[<"\WMZ#R37(NXE/5Z_= MH3=APF3N$N(/I-2<;1I<:/3U07=/E?OHD;-^.)(U.4^\;/9 D*;$"2<+^@B1+ !)(\C DF>L"MRU)OA .WXXD M>WV]-3# D:2DZLWIL^KK&_R^YHKGLR"47=:]<,Q\S9:*J6LN"XF=:2(,CBY= M-<2@@;9\VY_"=W)M^6)3=^%:-\+0*0?D&$UINGLJ\8.:5UG-L3>'W-<1 ]!; M$7K+]5XK0F_[F-&I=P9$RK"@YI35'/0&N:\C!J"W(O26ZX!6@-[VD4D]T'O] M#NB-E#0A9?K4"'QBH>9X =*D2\)N.-RN-4@XW#[,X7:NF]RM[XWL\-C9T3V] M2:6)''P4)'[![((;RP,2N/$PW)AK$;8I-^XU*;K=U9M-)$73DB9P(\PNN+$$ M(($;#\.-N7Y=&W+C7G.ANWV]VT!1+2UA(I +C0&AN0&AEO56BT/>FAF&OOTP M"TTQ(#3T^,=[CIX:-Y&DP1K"4 Z<&1K >Y\RMC5. 3A>;-U 1],2R" ZFI8!"/6&(%U !=[=!W[]IM$\ M&8 @)!!2V8$ (0$J$!((J9;*A8SITV1,Y\+'%Y8Y#>TGIOUF>R$;CEW^Q(\V M?Y9+SY]ZJATUL3.9&J=9OVC'<&)>=YQP:'Z80_-<3^I,W/C(^=:]C0/#)[48 MM3((2"N#_05/E@8G\.1!>+*;:TN]!4^>,/<:/ F>K.1R4[6_X,ERX 2>/ Q/ MYCI3;\Z3)\S#!DTB%;NNI[D?3-L7*S]CFFG]9Q:$$_Z,(H9^QWP1,;\Z,X36 M/C$_M$5T?>JS$?-]9O'%\(9?-6]:?+8C,K/)4"V.Y0$5CN5Q+%\%<) G1A\( M$!*@ B&!D.JN7" D(D" D 5".F$H>/<:*%[-A&YFO[SU=\S.WR^& Y])JYU M[WUF%O^;^/>?(G!UD<2M=@HPS]M3=]M[BQR#6HF'DW<-[:\+)UO>3(1,F^?U MX=B=4K*Y]DXF_'^",5^FL>?PI3Q--^S5@>4:0DKU#'>#\]MUX-72K_J!'HP; M'L7O!4KX7%F?*S?O*MLVY,FT'=4SY%(:YCMQXA?9Y=_,P![6-T%\E5^VDA]J M969.DPVW)MH!VB9C[T';H&W0]DZTG9OCM5?:KG*^.F@;M$T; ]!V=; $;8.V M4[2=FVRU3]K>;_K\0._T-AY #=:FP]KTHP8V_'(;KV($R! M9KJ69MG.+&06L=3[&N)--5LA2_1+21P^V[Y\MF,EG1P62OAL[[]\?_ =6QK= M(.._Y::O79F^RR$+;IE_)SXNO;0+UWJO#'/1TY'FW%W[E6^+-YY">K)D%/AA MZZ(GQX(% 120<<6P!!F#C%>0<6[>PPG85\#367_D$&2CW(>&S'2CZ!QU9F+.&V[0G@-5[;*E#C8:Z])/?C7:#;W5:>L#HX/,DU)(X&E- M#((M=+ ==/AUOYR8B'("WUQR:K.?M[D WNAV]A1UW00$\N8&)#E1^DO%X M_EO+?EJECD/^.LQ_61\S;__CR^\G5Z([#3//M]]GB-:?R_:'9F/#)YH;AST" M<#]F/W-1<^-7-\T9'KH3V\T_B<[^:0W&:8KK/_,_;?=/U M0OYF\LC%U6R^;(^^Z6QW":XAH>:-M'#, B8,B*SU,[DYT4:V:[I#^\4K&ID+ MPI3D,NAAA8(U]H[,=O-.4, ME2Q.][X/G M6,NT=@YII&A(BO:^[ M^XO[J]^O/MW??;F\^?WV\]6_KS[=7?]Y]>7CS=W=*XYHRA;>)59-&,M+;J]] M-F9NL+60B3+>TZSJ%FQ8.$O(=M>M1FXQPK$W"[@O&[PYCLXL$>W(&5*Y"LJ= ME![QD#E.]-S)SY$K*G_./.=;_3>=S"KC$AN2],_)'[MB6SL*$^EH)Z>E-^X= M&\Y\.[19<.'; ?_3>_ZC^WC+?-NS/K'P9G1O?C]B8JS>:#7(G*J2K,@A([&G M'X\.CB9L^,'1I8$*'+USM_ 5%-VE0=$OI/;.Z;?9!/F60A1/:TK P'2P -7 M "HP\*$8N$>"@5_*/4X8N->C4Q4*!C[&<0/2C8L>*V02C7?I3H'D@,J=?+[8 M]JCFMHH&3HW-6E35V^7OPA#WWZ8R1D+ M]]XGSQ5NC>\Y#O_(M>CVQ8+PF)TR!GJK26<(*;(M=HW^@VPK9L1!MN7 "61[ M&+(=G)1L]]VUH]&@,SH49 NRA1$'V980)Y#M0ZW@TA/[V-C2T\H M]]!!!!4$>\;DPK+>:OEXOV:F-%H+/?Z%M$[+(=M"J9$F00%$JF?O2),H#51( MDSA0FD3?V,*OHG5"( 9V(&&B!$*)E$5@ 2ZN#%3@XDWQZS>-YJGM'CB)H'*! MD^A@ 4ZJ %3@)'!2!<"AD5B^)@IM>3,1<6V>UX>=-H@^7UCF-!1__>/_5\4\0F*(W[K2^85$^-MQ_7FP&OEKY(X<$>)S_\WPN4E?93 M"B0(Y.8[K@ED'SF-O;&_2/6A9DVOY():F923I=N!I<'2U<02+ V63K%T;DAE M89:N>_M>RG M5?HW9"*1\&4%S+SYCR^_FER%[C3,$-=^GR%:>R[G'YJ-#9]HCLL>U_Y^S'[F M8N;&K^:PD+^/E#PNPV_/&N>-CEP)[>>?Q.=^-8=B>*?I/O,_;_=-UPOYFW'Y MUDQ7IMT_^J:SW26X=H2:-]+",0N8,";2SILAL[21[9KNT'[QBD;F@D'(ORR' M"9PO@GP8L3*,(G(E;FDTI\O(9ME3G$:-C48O>J&Q'[_1U'QD9P\^,[^>F2/^ M0F]-YYOY'+S2?GKAQ1W;96=C]7!RS;8S>.?&X,>E2Q.][X/G6,N4<(N5*UZG MHDX MY/\A>/"[;Z\<+9(5SSF"\/\0"9\]-YM>('7T17>LY$]M,,W MVM7?,SM\WC_81-3VM>VN6YG[R^O&GP7P!PG>K3DY\AKEC]GGN6M.0N]=Y'? MS+%WS&G WL;_>*?%>\!&U&H@EP%S).^^]7)BV>I@3P$U>=G!KVW 1P&R"Q[[ M6OTE=BNWW^H=TFPM!8(_B3 "O[SJOJ(0OFF==[J;960>2VDV@:U_2-C6>02G MCF$<(S9! P4:5JR=RJV4(<>-HILG)QZ@ET-/7F0#PU9M", ^U&&[]"83SP7= M4- 6.,U$@$C,5O.(9BNJKSCO$]Q9GARF"[Y<(J9I.GN(.I7EI6]-VSJ[/G6- M"*VR+!K(P'Q3!N+DYKL^9GDXG$UFCCCGJ)%=EB.C:O2^F30?L!$Y?.BP49T6 M^.0L@TW">C9"**-FU@>^,*P4?9BR#3)/;JC@3L&@E0D(J,-U[8:W"LLL2 M*>OS]J_C+% P%\4"F\V[A=4[5Y)FMAZ\#") G,3+6)FXDG4\-BUZK7=BBV3I MDXV 1QR(@$$KI"@T+%Y-]E6P>/L,?\LZ'UB\FEF\#7/&:Z,&]%!9G0L.(@(1 M54\#B;C>E.)#-("A81HW)ZP^+1MWAP]=X :!-BCVMNC*%GJY+8(.T,8 M+ H+#(-%'+5K\3HL@,6B!PT=BX6M(2Q;Z5";-RVN_*Z0QH+O:W#UP>;#MRKM M?_UF.J8[9)H9:N_9D$T>F*^U#%UK-HS^"BTX$0X'@F&G52<3&CG8JF\R$>N4 M(2S )&%J;W8<3VJ8U;&A6S/*ZON#[]BR:7Z0F67569QE=<\F8G"&_ZS\!)7# M=#,+@]!T!3)K!EI%ET@&/5PZ9A#UO6G#^OF8/TZ:.J]04-O#-I[FX!U2(L#@W)R%,"V8-O3PU1XM"2(EB;1 MKI@9V7V!9R]-WQ?SY50&W448^O;#3$Z1N?=N913I1,0K!E%N-'^RTVWH_<[^ M!E""?BM-!+L7[%3.JI0"J4T'.@ H^%: "0[6T2(9O44/:Y?01>24>=Q'<_F/ M0=:+$J-"=@U8&$V]WS;T3JL+CXF8\!&U&PA8@%1/#Q,"%F5$;?N 13]'IX+P MHG9_BAZOW:$S$YC<>KZX:C9JD>WO&N=3'96#1>QB'J P0+3$I)*HR5]&M%4V M#D1A /.">SX"28_HRL^OXB!G8E) M;N'Y R!F$'.=% 7$7$;4"A"S09J8/[/0M%UF79F^RZ\>;,K"&^V@FX,.WT(C M!X^:%(.D3XT 2+H4,(&DRXB:G/[6)*E==5(>HC8.5$,"!E -J*;\J!78#S:/ MOA_AU$0PLYDKULKE8/V.#M7*AD#$KT$:^-]%LKONV MZ6C3V8-C#S5O-&(^7Q9=K/3T/G#["U #J-1::.!O3,)&* ,%% M@VY?F3MH;TB@?YK.C)V8/[.]+_9WB@R[4&F[ )(D 0.4@0(*(,D"))F;*'%, MDKRP7NA.L9XP-VM3T6SH_?;^BFQ@1"IM1,"H)&" ,E! 8R*(ULJ,)!4$+ % M"1B@#!10 %N +:C 0%)!P!8D8( R4$ !; &VH (#204!6Y" $$4!5(N-&1482"H(V(($#% &"BB +< 65& @J2!@ M"Q(P0!DHH "V %M0@8&D@H M2, 9:" MBBR*%/_SB'/CBJJ8%AP##QTZW] MI><^,5^, !?#PH?RI]!^<)@V]1G749]9_*V]X5&.M'* MH=(HP(%9Z\"LF@0WV&H2W-Q.WHPNYU;RC@WY1T-[J^;]EXX9!#;_L=)OD MNK>Q\=UN5MP&WM"O@Y;>: WT7JN'7C'$Q+APS@K:I57;Q-=,#XBB *+=/E+0 M;#2VZ9=&GF:WCSETNH8^:!D@6V*B3)%L4;-?#B9 S7Y)@*J932.* ARG[4?5 M<^?C9 &*(XZP1S2"K,@2-28(29" 1*3 M2J+V N1) @8H P440)X%R+-%D3Q7I!SN=>2]C.,WFV!:8B),U+B :4G &6@ M@ *8%F,IJ-)#2HNR E>WB04:_9PL+X;:/80-WOX9OK\ MBN%BTX?X]X6:/QRUG56%4"/:-ZGVQHL$"O!GT.N0"@PD%02[7Q(P0!DHH "V M %M0@8&D@J $OYQ(H02?+% P;!10 /.#^:G 0%)!L$\D 0.4@0(*8 NP!148 M2"H(V(($#% &"BB +0KDU'2V'J"R(K$FV\/T+W5 ?^^E^HE$ORM1K753[S;V M5VD-\U-I\P,N)@$#E($""N!B[-RHP$!20< 6)&" ,E! 6P!MJ " TD% 5N0 M@ '*0 $%L 78@@H,)!4$;$$"!B@#!13 %@5.A;J43H5PEE,GHU&L%OM@M?%5 MK\46W1-,=\A4)7:JQ'HVY?]DWYD_M(/\7Z,"[*!0!?916\Q4""NBO4QJ;[)( MH _!_W'J,! 4D&P*R8! Y2! @I@"[ %%1A(*@@JL,N)%"JPR0(%PT8!!3!_ MD2'HO4Q _(4)Z(NQ[> J"J-9-(>?=]IZ;X")*[*?-JTZGZ'J[]Y4*%"Q8G",XZY4NY7:VRP2*, [08LT*C"05!#L94G &6@@ +8 M FQ!!0:2"H)B\'(BA6)PLD#!L%% /M_6VT<).C)C0$C4GX%82,$ 9** ;L5.C H, M)!4$;$$"!B@#!13 %F +*C"05!"P!0D8H P44 !;@"VHP$!20< 6)&" ,E! M 6Q1X)2G>Z!WV_MSHF!' M*FU'$%8@ 0.4@0(*(-4"887V8EAA,UJ5408RK)IM8F'+] GHM(H@+716HP*#"05!'L\$C! &2B@ +8 6U"! M@:2"H.*UG$BAXI4L4#!L%% \Q=IJ=7)M-1:VT/K)H5.=V M]_66T4 W4F(R2M1Z8!-- @8H P440*781%.!@:2"@"U(P !EH( "V )L004& MD@H"MB ! Y2! @I@"[ %%1A(*@C8@@0,4 8**( MP!948""I(& +$C! &2B@ M +8 6U"!@:2"@"U(P !EH( "V )L004&3&@^*0"78]-]9)KM:CZSV$3.3E8C MD^4DYB>9Y;CEZ&4,6RX-Q:"M0:51 -&C[P<5&$@J"+:%)&" ,E! 6Q18(IP M-U-&M#!"6,X*5B[VM?LY<;#EKS]XOJHA6CG_]T:YT[1&# ^Z;8P8)B:U1.T) M"J[+B10*KLD"!<-& 04X2MA64X&!I()@6TT"!B@#!13 %F +*C"05!"P!0D8 MH P44 !;@"VHP$!20< 6)&" ,E! 6P!MJ " TD% 5N0@ '*0 $%L,6OK[?/ M\.AE,CR.F,VQKF/L9Q::MLNL*]-W.=;!QHD<4@3/D-%!6TS?D , 1$H"AIKI M 5$40*38=E&!@:2"@"U(P !EH( "V*+(MJM_K&T7]DS5D+',G@E3I8^Z]FJ M3:8,7#-=:_F(:4U.XSE[, /^ZZ$WF3(W,,57,'JZ-&2)!AB51@$N"SK$4(&! MI()@@TL"!B@#!13 %F +*C"05!!40I<3*51"DP4*AHT""F!^,#\5&$@J"/:) M)&" ,E! 6P!MJ " TD% 5N0@ '*0 $%L$6!=I2#3-;,A?6?61"*6H+@WKO@ MZRRN8CJWIFU=NY?FU Y-YTXSRKX]9.L0DEJ@M ;&2@ '*0 $%$"NV M851@(*D@8 L2,$ 9** M@!;4(&!I(* +4C &6@@ +8HD#0KGF\H!W":Z66 MK7V5.N]:>IZI:XYSJZ,%SF17R]>:2JFL+BI<)36'J^9)QE"GG9#:(T&TNXBQ M'IIXW>IMR4@@I?R7O8!591_GQ)W%-M*JM, AT7FEWHJ-IZ0]+J@9_*@A3X M"?Q4>FPH\-.&Y=N@,/KPK:[I!GJTT(,#4GJDX(# 2D]-A08#!MD>MB GTJ/ M%/@)_%1Z;,!/P ;\5$FDP$_@I])C WX"-N"G2B(%?@(_E1X;\!.P 3]5$BGP MTT;HO=Z^"J6U6(5RZWLC.Q0U)WOJ O.9A:;M,NO*]%T.;K!QRQHV8O@%+4X2%J.T'2Y<%*; T=I&EQP:[2& #?JHD4N"G0^TB MVX5VD=@"UI9G,UO TPQN7]?-P/)F#P[3FN<'KZ%/+^R#YUB[(504CM],QW2' M3#-#[3T;R@"-UC)T32CF2::YK_&$CH<-%64AVO4G9=K$FFY2BY/!#IX1&2BS MGM%AT:RRZW3BGH&K7(Z5)A.J=UQH0&@$H "A[1'*'\BA""X#EU5=ZVAP6;%N M"AO27;55BQI\&W=3@+-"A.;@K%0&2G@L!^_!_/W!=^Q@S$U5D#FXZ"P>7-S) MS]S,PB T70'7GK+@^&\GGGL7>L.OJ02XQ4./ZT\?UAUV_&HT.WJSU=>-=I-, MEV8X:F0M#H(.9* CR/H H_P!B%;H[!!<>./8>O#VP_%[3W2W'[! MY47 =(O@Q"#] $%2!^D#](_6%'A@#3KKVEK MLWLI8ZO;T=N$)C'#%3A$.QMX ? "X 7 "ZB/%X": LK88$<+*,!EX#)PV4'" MV*W&T3>T.QU"=WJ&WF@-L DM@S3F*:-85YV#-=^*&NU4%H#K()C)'CK>B.NC MR/KD+\G56YM-^3^G7$3M(?_;B/E\>73-'''EY5IIS;A2N8_<>G")_N9S@?6# M_](L.QAR5,) ,UU+@Z%<<9")-K9;<,QJ M[W01A2GO><&K(M8<=YV*08-.C@+H!?0"F$ OH)>RPT!2@S9N:5,GA2D!4JN[ MUP"HTQLV^ [T88+O<(CV,B+POB3B+T*%S'H_$_&\6^;;GJ6ZSO!'EW_:U^2U M9<7GS4;4<;_9V+;Y3$_G7];YLY!IL0]WBK116;9;K[*!( H#*+@4,(&"#W'F MWMR0@?\TG1D[,0$OM($!S1*3/J*& S1+ @;0;"E@ LT>@F9S8\2/2;,7UOI& M+"]0[D;)<,V>H?=;^ZO( B=7VLJ DTG $XN!4S@9)Q"/M<69;JHF#*SXO6C#PI9,?IM0MSXFZ*4!#2"@)R@.S7%060 \B!"@PD%02=#LJ)%#H=D 4*AHT""F!^ M,#\5&$@J"$Y22< 9:" M@";$$%!I(* K8@ 0.4@0(*8 NP!1482"H(V(($ M#% &"BB +< 65& @J2!@"Q(P0!DHH "V*)"1WSGZ0,7 Y[\,XJ94L@F5_-63 M'?"+WXQN?=OS51G 19(_?!>:KF7Z5O#'U.+?G.[+31KY28E!*U'SA?)@$#E($""B#3 N?+@VWZ=A.B4HR# MIRV)1&T$"),$#% &"BB ,+6$<8[&[H'U1.T)R)4$#% & M"BB 7'&H2P4&D@H"MB ! Y2! @I@"[ %%1A(*@C8@@0,4 8**( MP!948""I M(& +$C! &2B@ +8H<,QC'/*89X^',QAM3DW6,-K\Q #\R0(YF-P;::+5A6\/ MQ51S51@O%!]SRLM#BFCE46D4X)J@@1P5&$@J",@!LE]7%$ .( 9,K3LTI *^A94&@50.WI=48&!I(* '"#[=44!Y !RH (# M205!B7 YD4*),%F@8-@HH #F!_-3@8&D@N!\D 0,4 8**( MP!948""I(& + M$C! &2B@ +8HT#"_E>D^=&']9Q:$HDM0<.]=6$LG%&4D)&" ,E! 6P!MJ " TD% 5N0 M@ '*0 $%L 78@@H,)!4$;$$"!B@#!13 %@4R,#MQ!F;4[^*M3,6Z3&=B7$'QBX^VFX,A[/)S.&?M%8] MT*8M.%+9E\WFWE(O84LJ;4M K"1@@#)00 '$BFT8%1A(*@C8@@0,4 8**( M MP!948""I(& +$C! &2B@ +8H$+3K'B]HA_!:J66+RC3J3!ESG%L=+7 FNUJ^ MUE1*9751X2JI.5PU3S)D.NV$U!X)HLU$C/70Q.M6;TM& BGEO^P%K"K[."=N M)+:15J4-'C3KN-" C@A 3HJ/5*@(]!1Z;&A0$<;5FL78ZQJJQ8U^%:7< ,] M6NC! 2D]4G! X("4'AL*#%9\/UQMO2%I];U]TTELL.KGUO9$= MBA*3/35]^.IQ_>G#NM..7XU63^^VNWI_T"73EAF.&EF+@Z #&2C XP@Z M@,+W/S>AT\@QN.#8L>?P=0X4(U^[0V,-KB]#+(*;@<4X'9P.[C]4-QND.;V"RXOXI:FX/G-E#WH&/($R2#8\ 4 !3P"> #R!0WD"3=J>P' XF\P<_DEK MU=3&C7?__4$+I%\&(0;I PJ0/D@?I'^HNL).BS3KKVEMLWLU8\ &H*J",#7:T@ )B,.7])_A&Q+KJD,"5 :G47&F@07 7 !%=AOU'Z%5UA.ITX M3&]:TU#%Z$5PCUGO9[Z(S#/?]BS5*295X/V7"N0%5U&DSSID#;D1=\XWMNTA MTVGK1G=_B65PI2IM8;!3!_T")M O=NIEAX&D!H%>0"^ "?0">BD[#"0U"/0" M>@%,H!?02]EA(*E!H!?0"V "O8!>R@X#20T"O8!> !/H!?12=AA(:A#H!?0" MF$ OH)>RP["?PN^#]9NH;>$W_Z8V-(-QO@)<_=V;BM3+H%#I]\'0JCA8=#OK MU-MFD4!!L3Y(_70-VJ @I!4$Y #9KRL*( >0 Q482"H(RJ[+B13*KJG@ CM& M 040?9&BZ>[2WJ:KZJ;E'V]4_(MXP71+[_;:>J/3(],'%?:#M/W )AFR7U<4 MP)W8)%.!@:2"@!P@^W5% >108&9$;\-]U9^F,V.'W%9=<%3%A4WGUK2M:_?2 MG-JAZ6RRQ=IXXD2SJ[?[;6RTB$DM47L"+H7LUQ4%<"DV6E1@(*D@( ?(?EU1 M #F '*C 0%)!0 Z0_;JB '( .5"!@:2"@!P@^W5% >10X(BF?\@C&ARLU,H* M8&CW40'XDP4A?W%1D^WS?_KV,&165)XM%+]8<39ZME2J&4CMC1()%.":H.,* M%1A(*@C( ;)?5Q1 #B '*C"05! 49Y<3*11G4\$%=HP""B#Z(L79@\TG6G]. MPF#R8Q??3-\243*JY=E&7^]U&IAG34Q(B9H/[)$A^W5% =2)/3(5&$@J",@! MLE]7%$ .( 2ZR90?N\J9E/88*2"\"Z09?]2N<#@P.!@"AN,5! &!Y;]2^4"@\/V M<^C[S=*4GVOW7VF^&MX[2X]O)=&_KS%//I-(8U>&%%_';@+ X%^IV7\ ME7HQ\.9.1 ^>(^3\H"_"">\#>@Q-NC^A[G5J[U^+Q^(:I@*'&B8&99?]2 MN<# S+LV4]A@I((P.+#L7RH7&!P8'$QA@Y$*PN# LG^I7&!P8' PA0U&*@B# M \O^I7*!P6&'?$_K9/(]G*6Y*)/"AQB_* .4 NSWDX:RZP]\.#4$QA@Y$*PN# LG^I7&!P M8' PA0U&*@AW2Y\FI[A;VA2^L!TS@0L,] STIK#!2 7A72#+_J5R@<&!P<$4 M-ABI( P.+/N7R@4&AQVJ9]I;5\_H_Q33[&8T.>3ME"AN,5! &!Y;]2^4"@P.#@REL,%)!&!Q8]B^5"PP..\3:.B;% MVCZ% 77*A+X/'/X(=\13!KVC MW +GNHQSQDD4'UA]9 ;<)A,1T>'3D9B((/8>A.6'<I(UH72BK:E4FEZHQF)[?DR!'1V]T[E_;"" M.6'RP([6>M9HNEV2$3.44]+#V0NSSMD+.O(PRXVTJFCP6+->EC4,1P:P@N'H MY#G%<,1P=/*\,0&.-FR]W@VQSENU3&/?ZGYL]C?,1#'V-TZ%4^QOL+]Q\KPQ M ;!X^WMT5C -PQ'S J&HW/@%,,1P]')\X;AB%G!<'0.G&(X M8C@Z>=XP'#$K&([.@5,,1X=J(!DL-I!\CL*QEV"[R)[FM7P1B>T%PGUO1P$P M-S[0<);FH-8>F'/T'4/S(6:V,"J?OZUG5#X53C$J'PJ5AP='Y6<>JZZQN7"^ M.F/O24@C8Z\)7##4HC/VG@JG&'L/A;U7.V'O(;:S5T.&U%,0LCT,37CN_(IU M0Q/<,!WYPFHW#HZN1<*.0M]]'H=V9<=;V[<#1UAV8KT3#GFT5J=5LU SCW+@ M^QK/Y^5X8XJR&#I^J&#:D*:;] "5>,>ND3&L++M&A^7F.?M.1YY5N,KE6&DR M6?5>EC4,: :P@@%MCZS\FW%<9"QC+#MWK3,#RW:;XK AW)VW:IG&OHVG.+"S M8@C,L;-R-JQDCV4_[%V3N/@^BGPOGH"IBHN9BT%S,7-Q1]?C $/X<"%]>>S!H51 <,782^D#G6"+RQ\#Q4^3;TE,I#U>ZJTZ3 M?&K[OU6O0ZO6Z@S8-S@%6=^Y>9#= G8+V"U@MX#=@C5N0==HMV#-')_G^P"# MUK VO&JQ%W *HLU>@ E<8"_@;%C)7L"Y>@';.P$]HYV )\<&/5$-T&HRQ)^" MW'(2@%G!.,\XSSA_*)SOOSC./RN)WV]V:ZUFF]%[%VEL'1TRU%2BGTEVX%/7 M>UBEFXY 47I:.4MO_T/A;?NSI+2&_3Y'T1CD^$.[1./F"Q/YZT3\'<0IT*_F MBP3>AR0,9/5UO=EH]H@2UM]_QNM^L1T'?&H[F,/7<)M$Q%O^/MKV@<%VUWO MD/O(]K?[%>A7\L0O6J4?A./M'I!,1+SIFX/Q(P##Y*7^_=@+[,#Q;!]^KK8X M<6-1,'<7]V&CMXO XWU;[=DR%%SYJ!>7\59SJ%YH$NDWFMGWHCZ*A/VM;H_A MA5[;_J,]CU]9/S_QX@!3HCZ1BVNUEK[Y.HO;:%W]L)0T2P:.[6@==B73M6O/ M$N]A2_5\ZX$-<"8!+/G>V]88W(31+(QLQ."]B/):LA %6P MD9/DH-U]O?[Z_K?WG[[>_7ES???__?GAU]L_[EX!Q0NF)0N6Q%8XMF[L>+(= M^S[XX6-\'"J^@#[\Z*U%GB46/DQC.W#CGPY$DIVD6_E(Y#(I+_,?KYK@8 O? M5Z^2_:T\5/J[I(:O[30)WR@?%;CAV[-8O-;_>&,I/[8)*WVU=&[D"WG2O4&C M77&F-YS+O .3GO:ECXAZ)@2_6HWN,>=DKS(DNVVT]\H(6 D:C7^\:H&N&1!! M:38ZFPUB?BFE.3K;_D_8D?4>EN5F U@E)SNMVM'C!2\1!S"##2NC (PQAO.) MX<8<1F1PTS8!;5JM4E)LTX#]9>/1FL'?1XM3'W5POAEL,<_N[:1.;!C9,)XH M7\$P-MDP&L<6-HPGS2DVC"?/UW83CS-DPV@86S:/:"1K#_0YV*EL,L)Q/.H? M-JUS.Q.8<0SN+2S^>? 2S%J:=C">!*Z7*^TYK>3$(4^./&J%%;-!)1()[8VJ MQ63>L(J8Q 8&");^RV4# X2YO&$5,8(-+PL05TQU X2?N6 L/#!K6$%VC_4= M++!^H%B?,>C\2226'\8[1_@.E]'@#=R1&KXORCLUKUG;1'!^<;;L,%=ML-AJ M_3D*QU[R*QBW)]JEF_!_>YIPUFX.:NVKH3$-U*SGQYYFQ@!G&-DO3/ 9X(QD MRPX -]P5X)H:X)I[&./=[=?:;7,&>;.>,\"9$KHP@^J7%4!B>#.1*SN@V]6. MZ-:Z4NC6NGH^NO6'M;Y!)UBQDB_!MLLH!C7&K[AV_Y7&B1R"DH16)$ 7'<\7 M5J BQ_@I_MNQXXGU8QH+U_*"GZQ9%#YXV!P^FEOADI+2U^:E7GA#?H$9+V:# MN6X+\X95Q"0V,$"P]%\N&Q@@S.4-JX@1;."(Y^4)/W/!6'A@UK""G&--::O3 M&)@-T._$+!*.1Y.K+?%])H)8F!=%Y_WUU.4)HF1Z;J.",<2__ELH$1;A>$:^V.<.LK33W=H[H]L3E:8;HEOSJL/H9I@4G?_$4?,C MQGC0,5:0^L*.Q7-#QN>2X3TQ-^]<,UC,!G,]CA/84'>TRV&[L^2U,G2_HIU[ M+\WN]!QIOCSA9RX8"WC& M1YJO*G/_GH%W>XDXPQ:/6SI-DRLN9SZ^R_$Q>!#RQ+*]1)K/)=M]8J[?N:; MF WF>B'F;[NO*L,9KQTG$OCCLC_RSHL=X&,27P?NYTA,O70:YX;Q61'H[8Y4 M'=3:'9YX99SDF6H5&!-9^B^7#8R)NV!B9:3C(3!Q?8AZ2TP<,"(:)W>FV@2. M5%^>\#,7C,7#EV;-C]OC8><%\' ?(>QNK=MG(#1-X'[BF)?]X>W\!2;=F WF MNB]'X W/V3*##V;J"",$2__ELH$1@A'"'#Z8J2,< +T\X6;Y](;*%9K)@QU\?NSH.;B1W^2+FA6(G;O@SR4A>6*N MTKDF)Y@-YJ+V*1245LX4^Q@XD;!C\4[(_WX,M 7\DAG @Y\L-JAU^FU.3)HF M7UQYRM;V(@7?5#8PZ.U2B%,Y5.SYF+?/(M1VK=_B@77&R9FI-H!#M9VB3YXEG'2"VD=/1J\'6G::&>W. MS,Q>F.";R@9&NYW0KG)FV#/0;GV(><.C4*ZNNHQVI@G6Q:/=:84SSU7NF0O& M8MT)!)4KQX'M#G7[B":W:O!+ACK#Y&H/T60N9GX&_3]'8F9[KB7DG!$YRR#$ M,226DT81G@$FAQR8EW;A_?<%9KN8#>;Z),87>G6:E1']59]$6<1WZJ1#-8#I M.G!I.-,U&<-GC=+=JO0+O);A_H;XLU4X&2%_"%#< M0["ZQ3U )DK0+"Z,GO^ !BXCRCVL-8;\'[0-('C MFFA#1G+,[#FV)E 4VW:<*!6ER;SF97MXPWZ!239F@[F^R@D$L2O'!JSNUOHL M[2$X*=?2&OZ:&\.#EU)W:E==+J4V3N!,-08,A2S]E\L&AL)=H'"+856[0^$> M0M>#6O>JQU!HFL"9:@PX?GUYPL]<,!8(33])KM/<8H#5SCBXC_!UO];J[N]\ M.38%/%;Z;&+8.J]D8=&U>0D=WIU?8!Z-V6"N4W($W@S;K;:!S&$=,8(-C! L M_9?+!D8(1@AS^&"FCG!8\_*$G[E@+#X8']9L97.);7>6+(EIZIC)%WC7Y\0N M"XFZ(1?7&B8V^XI. MJMMWKLD49H.Y'HCY%4:MUA,N2&88?\6_B3NWX]]C(?N!KH,7K;@=UGKM_77( MLD4X,C2?[EL8#SKT&4PH5)T^B" 5YB4[>)-Z@3DF9H.Y M<'T*F]0-SAZX@8?A#?_PDLE-&@.91*2WIO.7&_#;&]0&;3[EUCBAN_BIAFR" M+U/P364#(^%.2+C!Q/MG(.&&(=K-SJ+KU#K#_36'LD%@)#R7P(@95+_T\)09 M7# 0!\TO)-Y@Q/WN*+B/P0CM?K]VQ?M XT3-E.+C8D3:&H61*R)-WSCT/=>2 MUUGT5C,;9PB<>>2:IFX?*X=3]$->@!V&>XBFYCK7\T83[J*<>5-9);V:O;"+ M(P!EWV>#HPW(EF:%6S?VS$ML_Y-8WU/U5!@\]VT&YHP^W,@R%*WV15F'H]5J M,9Z>@I%F/#T95C&>'@Q/-QB_OQN>/A%,+^"I.67.C*>,IZ<7PS'#1IL/I\RI MDT93\\_=:VTPP'\G,-UXX$?O:G]!]XL"TQ,\8^^Y29$7#L(;[MR "EJ.'4^L M']-8N)87_&3-HO#!<^&/T=P*LXDAJ%4/SQH)LA_&&>H.G=B>]9"91#7=86)>+O68#LM/#E"4?:K*81!@J6_ 4']6UOGM_'O,0+]]MH '/W>QWZH-NOMKRF83 M<.K%3XQ]AI']P@3?5#8P]NV$?97C+/:%?>OK@C-!VI73*_8$?/LHK6VU:H"?#'R&2=D>YH2<6OVL,3Y' M*1H-Z_XF$GOD"RL63AIQ/>WI[03/-4_&;##7+3F%#7GE/)&*7_);9OWN,N-W M\#ATI]6O];K[Z_9A]3_V9IQQ[\P,[H4)OJEL8-S;"?/N+/PV&W!JMET#-,PGA0 MM6%.R.PZZYC ]MY1Y00/;6X_@+6] V-[';B_24L[OQT?)2S>ZUW5>@:EZD]J M"-:%F1!&7G-XP=@S\NXA,-^[ZM<&;1X_>1HBR,AK3!#) M5&MN/O RITX:=XT?]]RI'-*P7]C=1VJ@V^H [/*&]R0DT)2ISYPT6'JZ9?%, MR_RD2\^@6=%&.TXGYL0>=?::Z:X5\_+,S]HP/^C1V?2PC6R8_WX.M]RP%;Y5 M@_L84Y%Q4F[7A1D7!FUS>,&@?0F\9- ^6@EEIS*\;5^HO=>#+5N#6M.@[CF& M;R-;"XQ&[N,'K\PP]F< W,S*\\9M\SL?.I6Y_3+3]X@1TX^\E8G,N(P!/;&Q_U'/"+VER8RJ<-?2&C_!QF MGA%MD,P&AAB&&.830\P9,X\AQ@@V\(P91AAFTQD!#//.!'PY/A=XGOB+,J \ MN45\%Y'CQ0*GM<1)Z'RSPAE&^GFH^&GY7>=5+L*T-[ M=RO-W7ME!]V#%S2W^[4!3Y@S3[A,57R&/9;^RV4#P]XNL%<]2N-YL+>'J25M M/,YYR+!GFG"9JO@<[KT\X6@EM,IZ#S%HVM6(!+\$"@OHD<<]@,7 MN5[L "\2.70U6S\\J['8_QG%J!XZX'=^0)TV[W\-'> ?M&HB8,0,R6?,- MUWP.\5Z>\#,7C$4]\T.\:X]%VA[T]A'BA3O5ACT&/=.$B\N,CQWDE>>Y8N1V M,<+KA'$24US7O%0([\4O, /%;##7*SFU:"WKR)GK"",$2__ELH$18J>A?]5C M!:5['-^.:9^J-Z\WZ!H_:SIO86?:XM(CTT3G: -V3<&SX\ M=9Q7%O^\XMI3PP2+:T_-"H""7GNV;SGVS$OPO_"CR!NE- P$OGGK MA8EP)@&\Q[TGXIKU,7 :YF42>&=[@0D<9H.YGHOY_:+=RF'A1>_E1EM$X=Y( M(_F<*;B%U&Q[?\X)Z_69ZS6C&DO_Y;*!48T[+\SA@YDZPO%:%OZ+90,#! .$ M.7PP8X)J,9JIS[Y3!"X=?T=O-;,CH.09<^4VF8CH6+'_(D0S*TS-^JWGC0D' M>C*KEI[H^2QVL4]P<+NWN=%CY6),ND!>,":= :L8DQB3SH YC$EG$?)D2&)6 M,20=KLV_LZYD1+?\?P@CBCM]\ ([<(!'UW#[!R_QQ+,Z_V.2JWJQF*35-J;0 ME0'VP*W_SXW4XU%I=@?2;9!\9L9N7%0K;YHSKZ!T+LO9P9U[JJ7;5XFWT2HF=* MK?M*(W/NPSPP>^$%3B3L6, _*)-1D_D,\5?J ?4Q#VG9@6M%(DXBSTF$2]^; MEZWF'NA!C IPW=):-YPT@R!X+THX3"U1(-9Q1VDAW6W>I5SHI_E;F6.U3LO MGH6Q[?\3!&0&OX"_T:_R@E2XMS,1V72PPQ/QCMV3#>U>K3?H+IDAX.-G MIC$.. ?S MEG:AG"]KV+)>:9X)&]."__9AX;=VM#W8V5'%DE6 M&J<#C:,JTG$4^NXSO:Z=AU&% 251O. !E!K;03#%8M)9&J8TW)Z8]_M2XSR- M83RN=*O,=)F:>$0VES :&&(88YA-#S!DSCR'&"#;PV"!&&&;3&0$,\\X$ M?#D^%[B,_/B@_SF-G(D=PS/",162S_"0;QR_[Z=X;K 76+;C /V3V)K9>_ZSXYUFGH4_,BWN)/+2I:68N)UO1Q6>^1W$"U6*5XXEN M[)F7V/[[[S,1N%Z21@*SPVD4"?=MFGP*D_\3R6?;CD?;XP2$S3+CY M0,O%T:>*L^;7/B\YP&8/,/O$W/L<2P<#;C@^"13M1-8"6A M-8O"F8B2N95,@/3W$\NG4W8+]O(#@Y]^H(>CILM]K'GF=Z&A[*A1E1!C1S>,& QH#&@,: =O+,84 S-OQA MAB$\ SP[F>@VPYGIK-T^_%TY/%9%U&ZCSW:4J#^NG;]2+Z8 VP?ONW"OXU@D M,7T:";=U\!-@._U:OSDP?I*ZD:!]?*#@$OCC>U+O1"2<\#X@'<8R^'4A<2N= MP46V&\[TU?>IY\*%P@JS4GG\$3Q6WHCKXHW@LOD5!B?KI)U.T.$E![2=AY=V M:D&'B\KS7Y@194 SAQ<,: QH#&@'B3OTLU/4;7>6O"YM3V['O^*>XH/>FUP7 MMB:_P\[D6FU,;L?_5-N2V^ ZVY1\""/Z^<&KX/<.W0 M^88EZDXXG<*%\F\*MSM^&&-,'7[KH1]L^]8,:.@Y\ G\&K[B.@@C=<^,##I[ M+UP'P=X+5_6= F^XJ(]9P6#&8,9@QF!V\KQA,&-6,)@QF#&8'2A3W"IEBO,H MV^WX)H^Q?=8AMCN,J'T-;RB^1G]@ROA&!M=NQQ]E:.TS1=9N56#MX/7KO7ZK M=M5I<0'[*4@H%["?=G3]D4K9DTJ477]^X&@[UPH8X]-QK8!!K.1:@;/UZ;A6 MP&3><.$;LX+!C,&,P8S![.1YPV#&K& P8S!C,#M0M+V]?;3]#QE8*P7=U6<& MQ-[;M7Z3CP7;+?$SR3$SYUO8=5NNO ZXCH:>4MO?T/I7<8A;[[ MIO#^_5E26M5^GZRH#G+]H7W4T/K7B?@["%B@7\T7";P/R1Q([^MZL]'L$26L MO_^,U_V"$V"F\(\YALFW^F40)O J(-D6_,@#LMU'MK_=+4 O$@S;)Q,1"S0> M<>A[KIT(5T^S>?*.K=(-XP1^3,VEC44F[R1,Z[@F&=S:1:[PD:WV;!D\+5O% M<42IU;Q2+S2)]!O-['M1'T7"_E:WQ_!"KVW_T9['KZR?#ZW*S].P76EP[=JS MQ'O84J?>>J :SB2 )=_C.<-;_?@FC&9A9".RF2S"SS&-&P@P\7P9EW?D)+E% MGVZ_OK_[\^OMGQ\^?KK^=//Q^M<_[[Y>?WW_V_M/7^_^?/?^YOUO;]]_^;.# M1U$DV_(M":V;H@'[H V8=9<9)8)#Z;U\2J?@,SE%=ZVS.+[O;0K.EHCC=R)V M(H_ZY*\#]ZT=>_'M&/RV&.Y)@O(5Z/#6!U=MN[-7X;;V#)DP R M\NK)E+R\N-OH=9<=0K_4BT)Y["^UL888EY)\&;*F5D.)\PJG&GER &+OM-H- MS5N3U/0VNK<#[]_2KJY1[*J#%+C;&8*"MJ)OHY4X(R@YPJO=X"<)6K2O4B&V M-+$+8K1'ET'#I;6 @%8!U*P?,2H+ZWP4-?I7ZXVE/DEC_4$8Z<_"-%(?_F1Y MX&Y2'8B(T+#",L$=L93_:MGN@YI_".XD^(_"=ZDD9#I- V%-A>O!EV#"YM;$ MCI C^E(OF CC/-+&M8?\&#A>P+NMN;6<(O QE/**' ]>!-;TS!.T!<6_MQ* MX$I7/RT![*#'P=K!B*?X-XYPI!^HQ\8U:Y0FZAWMD>=[>(Y2B#OOT(7/$J!$ MC#4W#PCM="]))P M)#-&&.;6. JGUCCU804^7!G9]T@X+XDM0 ]Y5V!QP[I- MHPJQ9[Z=$)WLV#O3[<(\&/X"4=( J\PR1\E!0I_'-FD-BY>$*,*Q7@IOJ [!QS'-?M>0,2D9X7P$=S5!L6' MV]8L@#%G@BRG9* OJ>KP6H[Z;Z56,1/7@.DA[?\%'0=BZQ/; GI!VA)6Q<9 #L M\-P4?UZ@PL1^$(7'K+@U<<2*PE$*DCGS9J & ;%RBR6Y B@,%88&@IS81@ MY7;R),TTL.X1+!Z\IZ/LLG"EF OIK"+=_K!C$+;[!%$LL.[$#-1D)"*Y31C6 MK':S>25%EWZ'GJN5V?^O-U^*-A^,0V"]$T[A#NT6WJ(%_PLL=B8X%,HEY:$; M 9CV .MC^8UZPX, MI?6U0H,:BLP87#) (Q1@@A!I#+4A .0 X@54'QK "X 1]>?*AXC%7ZE0SH.^ M]UQ:(()UN*]/%2(_G<[K<7MY&\>D!D0_2/NXT6LX^,H_R'U]^]^$],+JB76'@'>(/?2.4+>\X\ZM_. M(OOU]JM?!LU*7/\'*]0/HO@BKAEU>SW%KGU?7JW]0A(\>4MIWD>VCP@0@T>6 M/ H!I)2?K[\OL6&$EP. 3<&?4D8SCUJ20?H*G(_$U/8(K?2R:V"A?(GN(@)\ MI9T!2E(D?+H11D(]!9;Z,ZERL'X 3E@%RDTDP/3A=_!O(!4R*8(-=?%1V@E9 M'DVU%B*DFN@J'+$F.M%=%*<[1.0Q 'B0Y!/[/L,C'7B1?40DZ)=>D KW.LF7 M\:?K!,F?K_5+03_W^3\<]%F]B+?OIXD6Y^F_P MH/ISGJ3-RR)#E\145EJR87E6,N9@;!98D=!$,YE=X8>Q)/@C7LW/W55-$GJ M'U%GDVU3C:(WCQ/ K7D=?2RWX*QNX K=8M#)BB?@*L(]<-NL/-S,"8F?]M-P MVQ9/X.EZY_GT.Z]V>K9R^Y9Z4?#2ON]N^QN!V_CQ-P=Q,1'\!$ MF+YI!0*@1&8DV(.2'EDM9^!_VRJ,+3L7G]12O COC9'41R^96/^\OOX,?CP= MMQ5;L'!;CL/&O>#4_B:R'8+0=*M9_TK=>Z4"&$R+XW0ZDX)-6U1[C/$J4J)\ M@S#-3()-)WS13WTO"]CJZ'&VW7"]&#LI4UR6+>_FJEC01NI90_U\!)<9_[MJ M+11K3M73Q?>9"&+XPTTC'8R?@5Z%+D6E8XI*R]@Y!F)Q5Y,1!8-2$R].8$>+ M(42\5>0)/-8([QR2A8(W$P_8)EJAV&,A'!_"/S'N'(]N_A #"%BO,[^CG*: MWT(+%7(Q>L#O<.'W8>@^>KY?0Y' CEUD4TR;9N!O3AP,^@--8?/K!0^A+Z/, M@/_?+0\XF6V328=RY:AE5Q,H!K8_QZ0,++\@*+"@U%?: #+F>H[6YG$J0_J1 M"%RX%_C-V2/ 2L"'N$U7THDZXF@Q<2A'A*_RB0YK11+'LM/ K2$OEK2=E-2&G!0.;JWY 4*%ZJ M?<\P F-A0/6FQ %'"O4?5 <4#:@ DCW%-.9B'V$(I$0F+-))K%%I\W%&=*0 M-J%-3"/0&I4Q)?$W-.8A0 \N5!JWE:\TFF,"DJ*Z>!.P#J V M$D?IER,[^%8%!,HG ,'AW>1C'P'%)M(OII^I+V7:!%Y'S.$UHV\"J ;8$2N" M+5T16&JX%*-Z"*=@E?"=<1F6"V 9>XE.0.4K!6N^Y!G;:7VELFBYUG^!A\(O MX;76684+- 8Y88BWIVT"5,I,89LK_4[8.I'?H/R';*\DG2%YP&3I6$D$_SB4 M2JN3^O!CJ28J$3-7!TJJ- 9Y YJ.I!KP6PH!_/*W;9L;NIT*DI6E%T^[3:,G MP\>R%_<;^6\4 M8KC+?.:U%>'#2LXUOT=^BX-Y92?@RQ1H6MB'H'OC^+!/\,8>YY8I24[DHU=:I>RAJ%X(9GF_X\U%7> M.OT> )1@_9UK8:0<=R+WX%^I8%P8QVJUD1C[PE&)?1N>2F%&&?: UY<%+,L" M[NC$)1@FP21 .DUEU$6&O_#'\ ,!;PC;&GRN]2,^\R<+DW48>9!+:UA?]"(K MBPME;!Z)E3=J+9!:'??W;QD/"T2BHT*XQPMC&=^!U4@R3Y>R#.R=BZ4V,C"E MGSH#[V=,*H%U.YC+)#LT%R#PQ 2&R?">7V!G>4.[/?S7!6YQ M2M38/K.'5#N+;5$A?(>UY@6B4/@: Q 4D[.SN&Z0DC>-"II2E3.&62DTFH=C M50$JD _%7E]6V42!=4+K$D:HT;!K2/.@OXX)DC:!HM!*/)U H-*B! @L$HK M6'^E\'8J[A*GT9K=9@4=[YR)<%-=_Y(KPNT83?W;.?[O!]L!6W7<*IBC MB^('D GB?KQ$)FN9?)%?-\L*;923VTH"\T'&LVN!VK2(43@SYH"UNKOR8U_47Q)_J@QQ&1XR_+24$; 2 M=/'_\0H XOBSI#KM)QF5UXJ^C-(G15H(;^A M':4O!4?IDTA,&RNV4IU>8JR8&:S:_#B/BW;D#.030Y(YC##:IT,*+\4CQJP" M7_]/V)'UGDI2RVWUG5;-!+6[2'4RT<-C==IHO()A.K2L(?AR=(I]NM/@$_MT M%\B(E/KUR:'1FPYL3@3NGL@%:G<54]/< XH6?C8P8?+L[X,! ?GP>&ZL(+E9HQ M&]:S84 FZ4E.G+6&;.TB/3W1Y<@NDNXLRAN+#N EM9NZL;XR,G#!2[I:.C/0 M,$VX-(/TP_/CU0?+#5U,O/JM<5EQCE\,S. #J\+16<"J M8 8?6!6.S@)6!3/X<'&JL'54HO]B48FW)D9*=I9VE_7+(SM+.TGXY9&=I9VF_(+)?? C!"#9L.,J .7'V"G%T M+JB0VL]TJ#Q\BF?,ZV39IW0J(L_9CABE=]_\>/O%9_Z]]&>>"NT,*\TC>65T M_#GT/6?^%9;PU@^=;VL2H4OJJD3LV#,,:T>ID+_T@E2XUTG^Z#^=(/FS51:/ MMZND=2VIABM(59P07&"UEX"J.-LH\!92L>1TWU4L452A;&R)*&SA-NP_A!PLP\@#\I1,)UTLL;SJS/?A=D%#Y M<"3N4]^._#G\9?OS?PLKF0B@K)VDM)P8+*#4L/H7/EKT]!DO]-WX/Y3T4# M1>V$I0: !94!J5FS'H4UL5WK;VOJ.[PX[+9;@]_OWI4*/%J+5NWW8 3,$F[! MNMVD$8XK?\*J+19#U'M9-43_U2_-)?T;%A#.QV6BW.VP]O:^UEXI*EM<>[6^ M-5L[2&BJ'EM2 YNTI7)ZI86DHA?&Y];@)_$,=>!!^/.&]74B8M+^!)\#]X@% M"+(=BHT$@Y8 6D60)O!G7 F4A >X/* ]"O00F)1HA0U@TR+*V1A M2R.SMT4#NP8$*W72'X,'(&\8S?<'@:NTLC5\4BT!S3;V:S:#NBU4,B/%:5N6 M[#5**.3;HQ!D!C]&FPH_\F,2XSB=S7P/%IC&H %>@%=*Z(#?$A0!:XFV "5> M=N_'B0BL61HY$QM_)Y''"2/7$M]G(@ M2&>H77B.@C5._3&(/&%4CGG@6"/, M8:477&>EB8<&7GH( 2$?*)>PX1%T>Q$-MCV-D>O WNW5GRXY<3VWW;>';KT[[/3J73$8 MUD?M]JC>;?=']M7XJM\>."=K&S1MB;$984_;4)3>2>AW*ED-0*A9"M8B_[J6 M?Q:'X^01L*U6-"Z%"WT!IF$"G$ 7-0H?1*X:XS0"[R!%7(2_0$7 \Y_VK!6 M+ V!5%H9J>&DU-(VS.!S3QD/E,=H9Z0-'-A*O[J-G.Q7))'2M M$9DO^%7N;8(A!(-E^=Y8-*S?; ]T)2#_51HY]+8EIH/MB^[A!^C[*J,'7H,7 M..BS2)N(*R1*EDD0%:VJ*Q5_A:)WF]G&%+;\4HK\!5MS"'Q_01$_G?-V@?R\' O)/DW6RUP-N[3< \3OU;ZCK$.#$31 M9D0>%?2/5TV@J/"Q] Z!+?M;19#H[Q+)7MMI$KY1!PWA3LJ>Q>*U_L<;2]4) M];J-*XP$O2H5,*D[J6/IVYU&#Z-5KXHQLM(E@\9P_05TC](5ZSJ!5UKQYE(1 M6!OG:G?IP<>4BE^7F*_U$<>-RAE7Z\2S"?)$7'3?/&H>F4$K;6.WL[$3I(WD M6*QO<_AB@TM&'078\^ %WC2=EKL05CZBT(V ICH7J^R*U*>EZ06^D,B[+(&]D_R3JL5N2Z\V'M;$>MG"G8.$J:2.#+%PF7W#-+4G7 M,;9;FT?C7][ [9U"K>;&!NXP!4+;!!+[%-9:4S%429^N,#KEH]8IEM+>)&MQ MQ.JY5JNE8I:32+_1S+X7]5$D[&]U>PPO]-KV'^TY["%^?N+%,6Q>G\C%M5KK MS-O2 K=&Z^J')TN75"442."']O9UA[L78]@S3.'_'1NG-0%\D>B'.O0A@R?>>B+?[\4T8S4*9Q%_,(JT4N8T)W3&5T)^ M8E1A=!,&<>A[+NT6/WB87_%LW[I+X .9(_GQ1J<:?UJ19MNNEG"Y+5A=FM;O MRK2F.^Z.!W:S66\/1NUZM].^J@];O4&],^HUG>ZXU^IT6TOSHOH& WOD"K[8M!_6HHAO71L'\U&+NMT;C?>K6V2.ZY"=:]%%T61*2U0,47,>,' M\7CR0CO,Q-A#BZ0=[:PZ'-F3>TYK"/!2CK,5L*=J0; ^J?M!3))ZH=84"!K M!N4O72^>A;&NW"@L3EU*>44?\UIC#U[DT4LFJI+"*>I;G&L9K M]"!(Y? 6J MQXM<2G?BS^EETAC+&&19'ZYCVZJCJ\H4HG^&H8M%4."0? R ?O=80WA-=-=? MR:*%"RQ#T@0X[>("_1:8,,;Z7>#*K"P)(E4RV-<+L/S[/":@LI#@WKXQB+)./" M"HCV'GWL3,(PI@+BT7QFQU+DBF^0UVA1T:VNX[+Q(I Q=55&G@)IP'&!I_]S MR3?B.Y7+4$4U03K-MK5!6"D33HJE1%3&E],+"*!)O5WIWE6E:'L-'B[^?;&XF!/" MDI0X;8 LO,XBI*V&+ET IP0R%C,;%!!M+7F)F>8C*.*U'NB<;-@HBC'98C & M!8N@[#,M(:::EG5WL?HYUK:=>!=&E0GHEH.UP/Z4./432=>2 MJX*NO&(8.N&@A=0% R"35Y$1!VD)RO@1 KJAB D/"9'&:1J9L52>P:K_4X_U Q-8QOL_\S&T,7*)2@[ @<%7N: \;M>-& ?D"E$+35 M,P5)U/:-"M\7:+XELE1::GX%R1*"BZ[T3&7-0U1G8G0 [DYDT1%HKE:^7U7#8]Y%0 MGB!: FJVR,JZ:CK/1WT08#8F(0818/^@MVFR#PINZSCI#*X'4_@H$+EBZ@[! M\G+LK&Y8MPO/I=1?/1S7\88__N=_#-OMYILOM[_3OUIO?BH:Y\4UE_:)92A5 M .CJ XP742^W'E0[$6V:\'O'FS/SWHPT4'&A6C S:%,PX*WR]X*H0FXXZ>N4&TEA/"6"YZ#DZAZ\U().EZU M\)2I[1*;X05&8HP[MOR1\)93;&354F?)'-AT3'>@* MV#R+ *B. ."&A'981>31"DG>M:KX0Q78";X!R47YYRBQ_2UF,E08PZWI&PMP!9+G@ M&\;6[S/2GT]A Q;1ZM>;[9K.=Y3N6S7K:YZD;7/U-FM^9/WX-9P!- Z[[9\R M*W%]=X,?:$NA;MFPSM3NWX K:GN!YK*2 67N+M"+4(MRGB MNX@<+Q;E.X#-U\LMHHRR)GK]8"T\%YUN:2_N0?KA]860P3;0O0#^C"O[DS/A MK49E:O67&*.R3:DDW#H ZWM*UIH1.,8#;W MC0B5B?@XK$"25G7#ADN":"/;I[O$$T&8KK4+R32Q"Q\@8B L@6>$O 91F)!X M$R!3WYO>46JML O[U%F^\P2%D_Y.115)_:46GJNN_%H4HX7NP)6;Y,P1DS9/ M.0=2_'!KG+E!]V1V7.DP2F\@ESMY?4U)G6QX!J69D"C,X8M%+S16EE6:/&!. M20=V7:ZUW2:RTE3S 3:J_XMF]G:H_!K".E-;Y[)#DLO3Y54=FO?NB:7?= M8;?>[O1;]6[/%O6KH>/4QQVWU6N/^GW7&9W=?A0);OVO=H3S^H@"T<]46;^" MV.;ON]3+?!O"?S*G[L/UW=ML[X?6TQ5CV@X4HYM9[I&2<"K;*"TC>?,CD6UG M"%NR7#W\>V9[E#^1ZR>77N\CY](!#]"G3N1=4=?5=@:4WIO!2U!F$ -C[H-- M!^T .NDY!-)]LI/\<=F]*8BH)BA@,JT031P)@ 1PL-1- ,,3#Y]%NP[Y>)7D MS+8*-)O$0F*1)S#R/4 ?,#A%,DT\V/8 >J@1!9C(A%VEW"5A8W M[MCJ^U1[;ZO9_&&AM7?9B;M9$^]@V=BYE572M/[=QHSU-PVVJWM2,_/&:KY0 M';=9R5EFCC8HREYH;FZTS2;<&GO[7PO$^*]G4?G5DGWX1L;;16^60A3R@57B MT(LSQ*%"!(_XV^T8;E_I>@:T]$7/+%+(K(*MC+]>L, M$BT56JF%/NY IAP+\D-BEX MH0EV*JFS%$IJ"S_P@@R(2J%0!5*81I05E(5="UY3V!AA3-O&C9_E8$**(I\8 M29P7+U+;0=CNV7*1Z0B+3%4%D$P^^GX>5IP(AL*+4$^&0H9"AD*&0@F%G=?6 M[TN";AGLX$18G.E"\ *(D$C\"4(-,(1;GAJ6E_^L,%A_/PIO+ZMIM M<]CUQ_7NV.[5;7?8KS>;CG/E=(6X MIM[%H==Q;8TS2?6R_*F%K;KW8:0GCJM>6<0HV22''^:) MIJQFCZ::Z\GB<2)S3EG**9OMO1X,"\FYQI:^V*&IM:9>[RCK^1ADI2J.K*60 MF<6$_A=[YV G3N6,VBG1]3%T_QEX)H&#%4JH3YFK$^9,KBT5CTHOM1T70P2= M)^2E815BGJ(Y[!(;44/HIQH*%\/ER71M)%Q5HOUY/57>J$ M#NS?#_+G+'5M=?E5)/*V8[C"]6+'#^/%'F19WQ,)K(7#]Y*U/1N=1+)U3WZW M/%4\"9UO./111#$.!TKF .0/0$ML1?DI%RWMAX MZL_;N;HN5A=N,$XU\WBUKNC2T6SFUIW LTEN5FI1-GBKU7VJNPP[R]PP41>\ M^J77KPT'O>J)1I(R:"ODPZ6EN,&7R<1REHEE3&)),SZH@$E58JM!#.,-SW-: MR9-.R;PL9<@?)'_@?./LDWOQ7BWA,ZX@N]84IH"SWV[TNU6JHV,2!H$JO);T MW.$PK%YE7O>OL'&_'=_0(6\?9$GI7)V&]58WI=S8N%5-UM5>O@1QRL=M]1K- M"ID4GJHSM]3)=:I0=F[1?ID:G_'HMP";1[H-Z^-T"I?)]F802ZR4"U7/;87D MLG-G.H,=O&IDD7U LCEJEH[ ZF.5N$!<5<,3UJF%,EGJ&EDY9JMR\/(U9]L^ M\EF3/"=63/[RLL@>MA4KFCUBW7S)<58G+<'#ZHX48/E!J=01[UHNC*_AB!.G MTHZWCF\(0B.LC"PO "0?PS;J? =Z7IP(VZ7S$"?4,$">#T:U6X,W5%8HN]0J M\Y#L- '_,!L4DGKR.]T"J9_KJ'8N+'HL5&(6.Z"I*=\58DI!V#A#I8;U.^XQ MLUV/+%F5,I]$H:]GRN2>90A[&FRP4U*OKBM6G?O>7[A2N=^);1G0S0I:Z: ? M]1M%B;P;;C6QL;"27&''EF>'T2F.+M!:=HYF K0H/$5)B=/1O[!QD3HFBJ3" M3C7;F91E0@\E0$X4!NHLG;BR4%:?]W?(W;KJ/Z0V495]Q0;/<>4ET;JZ>= MO).5J?@V. D3+!AN7;2/;DGWO'5%TU *"]D!%RJ3X;-B_.NL4R!'RY<%@BOE MW;>NUB-"N]%9>P"C;F^(A&\K8XN4C42^M=Y 'K585U M#)RIW?]#SS':$T!:WK-P7#)P#8[OH%.5@>U9+/O7?.N>Z=D[N5D'P_2BVO74 MB:S@CJY6JCPLD6L#FENP13DR*C6SLZ-HJ=>A3J$VN3NKJ$;)&M=D%&Y$)TUJ MJ)'CVU0?14&#MQQD43%[7^1)D1^B<(HY!GSC/T!B;M1ARH<]X_"JIX:!#H8# MMS6RZR-'#.K=JUZO;G=;_;HC[%97# ;VU:!YL@.6%(6?R(BU2@FQ+Q+;EB7$ M3FL2T!\%G,Y.)5WB_V$/N6PM[S?[I:O2?#MRV>D0.[P&?-_9PA"_\I'= M^OUQCE[1?WEM_=CZ2?KN:B;C7".%// XC/(%R,;Q']OJ!]6!@;)+*IQZZ#SB MZ"H*GF;GH6, 7JV?R!^"[;^7V%MT;0MWDXW(K@?>8. D&OV5(2AX$+0^M;R. M6IYN"Z(>RD*K5=;45;1OZ"!@$V9 GF+62EPZFEG=OZONCZ>@9]-A*P_0IGC% M^RX[I3(68.EA/;+&4#X-0?7'GGIB59RIK>I'&AGQ$PU1A+O'P$+RLY<_6@;: M<]'!<#3X[-,I;J9T30<>(.R4W+3\5&QK&KK"IS9C?$HV]5&NJ+Q=6N)3[1;\ MW376N\2H;),4>4#1%8^G;0AO"^SQ]#07VEJAI0)?+@W"F$:^/)@1DR:% Z!5C5)^6\S#1O9]-@$& MUXDY%Q?/F0;%@MN0)=2/+]YLX?D-BUQ@381EQE7N>X6?;PR G1.K^DZ5DZO5 MYV2=E?3/LXM+8V$"FP+E>E+N4O54%5@X@4":%[=J6TY;J>YRDFK_Y*35ZZXJ M(N#^X^B(N #"%;V3,Y0(?Q "$,2UY.MAKK!'"<*[]_^/(BX #;+5B8XL5J>H M.]JOJ"W>%%7F:_T=0#3@YLWM_WY\1\\IW2K[=:Z?^0T*DE]9F+09:F75Q9SX M",D/Z/-4:"2]KPBP.O)P$A9L;QYR(%Y"_8Q[1'B>J^N/S\5;T$F1@ M59+=2U+IK(#N'3PJD(.4)U[DUK%G?8XW"T$"<(*8NF\^<+/@ M0\C+*.#X@(Y'R4XB2["C/A+>=)1&L0P?1C37$A\]@W>6EC>>H8.6=VD\YB[; M:K=L5)@5H^B 1K-JEM$LB\-HPDKJZU&PZ&)/0]CRA6I4+7:9R)'G M*&X>NO$T=DY/B(*W"00.?2]QSI834['!0\5_<%&1A_/*&LOGE9QUQ6^'*WZY MXM<80I]@Q>]&!;OK*GZ'8M 9-J]$_>JJ,ZQWKP;C^NAJ:-?%<.PV6_"EW1^M MK_C=1Y#P!#R>:FSK>)Y7R762I^CE@S+PY=Y=\(.\D.8L(U*U](QC;IT!+X0([.IKV+'. >JXFO^(9Z"R^F& Y M]Q#>.O=-\%>QGGH$NW:9XK6U ZF* ^+"4IRYXQ=GY*OJ!G#X\S@==D?E5:VA(BN=-PM X==9' M6X A(F:BYIQWE*G.,KH;Z%62*&582_36-%X=UI;[ ]4.U5-V^0)R.I$13258NG*^7I@-E\D06 M^-*(*ANLR#SV)*NJU2KH^5)6O<# 54O<6D8_!EFR0O834[FWO$79H=8G:&+9 M3'8#3-Z1FXV;?EP-*1R\(8U_ENX1]2OGF;D<73,B5,5_&1WDL39V<7L)&P!G M4D]G,K(@J^1+YPZ%=,*H5!#Y5DMVHW(AM%W5]=9ZB?HW6:)()L*R6ZS+V1I? M4O N+\?8+A=P%@4(=!I8*1L]FI<2^0O9^V+Q2N$T%A0(+YQ-;+BM(])DH43@ M<8*'BXAO6#])S?CA^K*<8H*&[(&N?]"KC/--53%Q#0L?XT'%Y)'HHB U"@"W MSS/914-.;5@<.YX7)5!3 *SMMR_O=,F2+ATLOGNULBU[6]TV)'=[="R$3-!6 MD[+Y<3DYE&-:N] V;Y=._(0/L&\J$F,PP[2%5+AMC06-*,R/ *4GN$7;*R^! MEP*^Q7%=&@D0.K!P89"9Y*S&*O]&+G\%Z[7#H0Z@QO'V8'(]-)TKZS5=,1.R M&SC,JS+Q]1L6%5#H9J=P6?5J+I-AQF-J%ULM@)HEA;<#WV;JD:@07F !@F*J MAV!V[V%J7ONVH#5^K",LV?.14_KM2W>6:RH+FPSS*K&>4Q,*-0E)4RH#+M(/ M*BREL,K:HO@17LKW!+T)XNP N@+'$5AK^8$ 4H0"ZU^A)RL@E$<93J=>0H+QO3K[0^>%4,!@KC=U4P$R MZNKQ-\N71NZHKC&B,XG RJACV&!)(QF"E-O[XH0B%.\HMFF.4<'-S L4LP@G M!0.0)7AN9X0]GO)%"^^4C\W-,W,EY[S@B89RC(R?!1M$$(6^3Q:/PD^9[)!% MENA&$LN9:39B"+) '_P!@4\MN593VPF)&0MJRB2<>,MXJNZ5OHK?8 MZF#.=ZKGHM@GL4P.\W>BI@O]4'E )AU^5CX0IB@[_TK=>QIDA7NJJ?U-BC"- MK4%+,:7<)B9N9"<8&!K'4YG,6E8X62N1).O2C+SX6UPZ&U:>:J5&;HGQF-P] M:B4$IRM1%=8J@8M=AI):*QF^MC;Z!"SZUXFN,ITK Y&=5XT<#;,\+[I&\_8HX@[2Z:L^.9]32(#?Z M;8+_TIU!D.'\73DH5'71,NZ#"5:QAQ7"+P&IF'S@2% \M5>, )2C%JT"[X#?@: ;M M-$3AW/;E0 A,-*[^#8)*=K%$Z%+7G@RU5EI0LK.%T8M#B9#M8=Y/REK*!]"* M)!"B3OSHJ>]7]*/ >J1^Q^&4MH988J-EMO)RRN9:0-MC6Z)!6CBA)@L^DHF4Q56PGMD*BX(@41 MLI!@@/' TOG6LI-]$CYB3((RNW3 D@U]?(HB'P' MEE4#I65I++0G+BQT:6:3',XXQ;/;9? '&1C(UK5PE,@8EMK\%4-4A?9T% P= MK]ARPLQ@<<+,'4Z">XLR B(;X_&(IVO7K#1.L_/"'E1%LKRRMO+\>34U;ZS;.H$P8^%AP$(B32FH ML_(]2J14+Y3'Q-_ZMO.M?N=,0MJ1TE5U#! 1AN*4D15]HRLMP'#1 ER[-),+ M'WD3QLF!7;$3T/8"0?86*3W2*1"%-W'"6#E.2I')<0)51^@&O"U>JZZ(Y:3- M'6;-K1.R]_+FV\G5RGEP[<:2\<1J(%QMEZ5?/7?I3;WTYOJEMT \5L^R0YNV M_>K[S6>N?N/IEOVU@_C48-CUX44DD1KECT-#\U2%/]_2JZGP# W9[?@.8V\7 M;\Z0%@@T>R[D.HY%TR^3#ZM3KHI,+L@O=8H>RX# ?\9IFWY=._F9;?LQ[ST$ M%]N.J%)B) (Q]O3XIA4.TD\U^,J;S2@U24=Y!*Y?M)LU&KDL-V#*[F*N-HOV M9C/ U9=Q'#J>K7>)Z-MC_5BQ)I%F>BPK^UI2#I/MU;+"#K#NJYZM*T=<=+MP M$:K^RK?IN-50C8^>R91F(2FYY&UP/S^SZ>09RD[F_5:%DB!Z;,.ZV?C-%[;Z MBL:4/ 7?C4Z]T;-(L@WR0A)_ZU&JD;(TT48GB! M+):BR]["6,>Q-J77*T95,B-2*&$L:$QF@*2TKS-#%5-16VDG:JM4*EN-G$&D M E]ZPZ._;5B[G9_Y!PY:B\/,4GA!7E.WDB[:'%=5/ ['R:,L5"\7^N4#%4LU MC^-4'IV2CU8*Z0OTA M\"DWNA*J1 -=G?,IY]BK("&EOZGY)9 5,/@;]=XK25TLVXL*D3J2 3G)&+?" M%"X+,BM:F V?[^A5B8E<)47D@ =@$F40K9@773*F%%]Z-\&2$%!@#N(8%ED& M*-O6=990I@I)%,&%>?:EAHQ5HE@^9W53\]\J'Q2%CB08_M^H]B)WI2_>MR3" M$.DSTIR)Z<_?;)J]6<7JY[/N9$_6*E=S3".",P-&-0&UK.Z>?$-9 P/"^Q[ M(9VM[,&U\LBR6C: #KMT\I&8(PP;H3M45(-L5=+D:%7+5Y,UP$M]RIH3]"!3 M"F_KBE5=^9R]F08%(*R( IIMADJM:_[L)4&%6AZ\+Z\?QR*'JBXVOU@78:F^ MJ>)MP@!L'L7.59%K9&.17 D.5X'IENY@Y;2MCW26PE?[^T%GL,.#9?;5Z8R= M86LXJHO1L%?O#MU6W>Y/>ZT1G;'[O6ZIVI$)"DMH.6I&PWU)@F^R9*Z M_KRG,#^?0!8P8M6JPF_X3"F36)T+(DO.%[K](2#]J;S5_QY',3<4K.Z]3U)RL+O/,#K(I2JUWO M$H]TPI9<["3QT2FE8:'P.X>J29OMC18=C)]=(54*@[ MUBB/6#<+8T\&]\( ![B,%#[U,QV2-)ZLG*/GP(O< YDP_B6M(FXP?#\_$5>NB$9K M%-\#LT*P R!'8?4[Y8>9%1NI<5P=[.+F^LA:%6+ TN!9"DN/19P=8*Q%AH)[ MRTZRQ-;F0HF:W#4%(;6>BA6%?WD60;7TKGPU(+><%$3-3^*[ZF3.QIX4ED=' M01R>>S65#O$BS3'J"$Z\NF;4B8<"RD=< Q55SGS-V>&XW?V?%" 9*W6RL(T. M<^0E]I!@L2CDX,54>!2!\Z M>0SKU#*@3\RC?N.LW5I%]@'J91LBUC#D&1QC$DLD7?'H:X' <>@YFQI17F\6@U>UD M&BB3OL+-)7KOG[1X/C#N,0IGR67'%JU4B'0C.;3C)V_D>BX]G70K;YS':O)R M?[$48#5K0X7Z7LR?01J=JD.SDO9KORPX/TM](ED>6'*+J%1Z4Y>'+C;3VWFT ME[D[FV=*NY4.(T%#$[[0$6O 4;F#O?A]K"(+P'A6TW7:?J4>/5O08"HY(#]G MXHFQ&B:!4AIB^QL.-5$FDK[.TX!8=$[^Y-3^!E?IX;TWM^]^R\\K1>N'GZ@I M.I%/1XIZXC$NW"F;C)J-U\F3F\5J.M5S),>)VHMI+SFO=>+YHMB&)Y\F DH%E-.1653TUU7N@B %57O2"=HHB.9VTE">13 MY72[)V8A*YTL=52T%NV9GG]\J]]&_2K>M:/ER0'&0(AJKT5.3,T7=<_M M\*Z5*I=\UC,*!S+X."\;9<_7;TN[*3VS#EQ+^_X>"\(3L7 @13YQE#9G^;!6 M%-3YK#@E'.<&"0L3.%:G5CIE:,.LZLH&E7ZO6DU.-_X 2]2M_W_ ^F[4\@Y4 M3@0+D9F:L2U:;K%COBF:K/G*[K?J5(YIV?]!K#]HM E;8V&@TDODZ M3,"]H:^4OM.!K?]XU83G"=]7Z<#L[QE6CJF_U7WD+[ VU+=GL7BM__$&..0F M$P N@&7YA(C^U\54.#P;WBN<9;>1%TO4 _.6"$I%(G ]1O9L6Z]@2;)P ]@L M. QER-U+ALF0-77*%;2)NX0ISZ?V"A=LV^4^G=?-B/*J.-J:W@O^)\+_0<&& M_X+L;YZ4[2]UQYZ7@][S .R"D52ET[O923T& X!9S1G$(\'PC!\]$6ZB %N. M;ZNITJJ:;M!!H$H#-=TAF>>EW/E)0(X=3RRLR%=U=+0WD;M/ 4L-IV!?\3P$ M.DAY]6:D,N[@74X$''.@#S'XBBP_6 WGX$^TN2TYN7 <8C4/[6QMM?.,U:8X M)T$9T HLT%6Y<@.JR_'+>^BB:_@C%2J%:0S7QS^]KF+8N@J!?.4K7HNP1'3= MONOVG'I_X-CU[F#0K-N.W:VWW);H#4>CH=-UGS&59^F^IECA(%'J.8@DG_[: M3I/PS3/02;Y/CG.K^B#4"E0M"[R-_N +J7NS,>@5/OR*-)$?R17T!HWV#V_4 M:VHBDM=KR>OD -B9C1-9WKS::^$-_%W>0.,'1S1KA3J7*C"]$#]:C>YP5W[L MB_I+ZIY4FTW.G.$ARYZ6,@)6@H[#/UZU0-=>C"OZH[%?B*NRK&G0NV9SNI"1L\-G@GRE><@<4&CPW>4RIPWAQ@ M0W;R?,7*X*,;LDV=A$LV>*LB"\7<:I5%-Q\^-#_<'$#99*1A[]1?1>R7GR-3 MF0E#90R?_F8>BYJ;>0)/LJD _'1LZ#YP MWQB^;3^EN-+E^D0YU/OO:E+K-1U@(=RO]O0W@$R/O:?)M>^2M=.<8@;QKCDS8%'F[K5JW<\7(:YJ(F@H!C+R, MO ;PB9'W-/FV/?)NVP+T(LB[[KB?C9&W4^NU&'F-$]%]A?X/EF<[]]!_\3R4 M9\;^#Y?K9#_H*&2_>%MD!ANDKW/9KHRIO&$5,8(-#! L_9?+!@8(HG2WWZMUNT-.8YHFJJ::$091EO[+90.#Z"X@6AE':12( M[J$*M]<%$.TPB)HFJJ::$091EO[+90.#Z"X@.C091/=14-NYJO5Z;091TT35 ME(+:YX_H/+.@^QY'>A:[V),J>5)71GA2ZJ&Y$?\ML^%[#?"WFC58W-[07VK4>0_B)R#)#./."(?QL6,40?B@(KYPP M;2R$[R.[T>9=^,G(LBD=!2^<\6@/&IV>V9SY&B:V#^JWMPDC^V$1^UMF5QSL MZ52+"S>"9O!RPSEM[+'MWV-KF^2Q[7> N5E=$.R>F6N9&/'-X04C_B7PDA'_ M:(A_Q!-+UB'^/EHV^K4K@UHV&/'-M4R,^.;P@A'_$GC)B'\TQ#_B22EK$'\O M ]M;1O67,.*?>-.)&Z8C7UCMQB6F8(X\V'V-2W8(MIR8=Y$N MV6,D;._#I.7OJ,.EU:YUNU_CBEI7(<%$&QMCZ5 9N8RP^ M S<#-P/W$%XS;C-N/V87#[P*,J M]Y/)&/9JS4&+<7LG&3PZ5*A$QL^)#=2!3UWO8=G++[QJ@1:E=_WAZ;>A]^[K M]U;O-@I]M_AF7@+BXKQ96#%(&,JR%Z2V$C$IQ[41]%POY6M\?P0J]M_]&>QZ^LGY]X<=\+1'TB M%]=J+7WS=0+=:%W]L)0T1=XI 0<;\J&]O9'=E4S7KCU+O ?Q=]#>0!/ %PF\ M-2DTF(;7]6:CB7;AU2_6WW_&ZWYYZX6)<"8!+/G>$_%V/[X)HUD8D?PI#CTM M>]!N26RDQ5XGBS=H=1W''H][]:MF%6_&K2E?D.PM9/6W+^^L0O'&=NI]?1\)*<@KA!?)T7^2 M'-U&K_O#M@19T.,]PLD?PIK8#\(BJP2*ZP6@RG;VJM8C^)#6R MG$QM^X8@T M\<"]LQSE5I+FC],HF8A(MSM:=N""]DSA:[0 L'0K3",+B3^3)35T!?QDW8W_ M\S^&X/:^P V7>M,(*U^[[^ M -XXJ$=B#.XDNC-6.AM'0!%K9L_EB\I%I[Z;_2).1W$"U$(KALXDJ@'\,_M% M.@.=CG M(#"6(Z+$]@)\15A1'-='-GC9A8&7N"*\5CP4+X^6S<:T9O);O!#H MBZ^YEBZT^ 4:-YYE8J64;NZQ%6W',Q]JC&I(62/BJPV5%#$/%^N-Y\@EV@8% M#DCX"-"=+"5>-/% 0*?V'-0)MUWBM?5CZR=)H<*%R%O@U@/%P4&!'3JQ3%""^ZL'D!"X09VC#^K=:W8GLY 6G$;B$_SHN7K HW]"B]!]%9; MVQFXXZ"UOA\Z^O;XGJ R,X$O(5:1U?)B"_0#]ICXLS3&Q8+YMMU_P>I0T^SH MFP#30OM;:KFV9[!>-!5JE>4U$IGSUT5ZV!8JO&O[(!7PC>_C,^2"]2WR%7C3 M:1J$2RC7L*Z33&10 L0,7X!D9YSZ_AR_C.%;4'\[D'\!4:7G6"3[4MM04PQ6 MMH1,']K".$61RTV(AZ(T^A?05)+8B]PZ;&N3>?&V1*$'M&_*(%?,3/@8%.4, M-_GXC_K4_@;OW+#^(),;W@=HYE6Q5?$=\*;+I M>HO"Q_F'X@!H':I[S-TR3 M69I84Y%,0M>21A46@O>%M9.JP)]( !))%*34!^OL"A^$"2&-5H."I9:34&&8 M/0U31;GR#\5W%$2Y^I'([X-J+8+%KVUK; -$ E_ARIGGZ-5H&" *I;&0A+#A MS=2;$'\UX9X03K@)/GHOU "Y",)DV]<@X06L(32'=7A!81F*5R#(<:)A+X0G MYNO36A/C/<5XC"\''@*L$):P"JE.U9_*V.I:?]L^L'?@\?GJKE_G,W$[OH[@ MG>[)A&3%S0 4!1C>---K-A0W> M78 (\PZ\,'RBU6G5+'P87$H2164JTU,$FQSO J)2S73A=*36T7$K5.A41KBBM*)&HW>JL5"YV_'8C4 M/A$BK)$1%,OH+O:B7PCY-#BM]\6O5U%3[ MWFI41][(P,5SC'RE@] DVFQJV#N-:CU[B32[6O=*1;]!U-G8HG<:@[5;D&4& ML!"\>&*3L ](."O#=4T;,4T *88Y%8#>XS1)HPQ-T+R50^[I#,E.4;TLWKZ# M[/9+GLEU=J_,#?DL8_CK=TI?4#!)*.&/W^SOWC2=[G%+M"BY'S]]*(ENI[/. M9P-B9@Y"GI+PEGH2.LH'\!HAAN+W(*C@5:" K\\LP)V 1H&0I"N%6L ^>;IJ H"J+X2FE#?\)[QE@7<"V]0"^;X]418"5R< Y*3QX*IFY M ]LV)(^EG$JT'L/(=Q\QQ^&4"(+V$/@B@KB0Q),2EA'<^A&%$MXQ_R2C(WW3 M>O,36@P?="VR[V6BT;%G"I7P*YV4=,#1!(6(E'A[,H(4!DC+^WG#NDM',B"= MJ-"L\&;DFB\+E\,O_\<.4AL^DR:]F'FT%W*-M<5D(]YU!ZLV*%FU3V'P)7O$ M[_(!RJS%7]12G@/"&<5+8IQ1OXC%;87%S79[N :+F^NVZ4C2#V(4930E^< 4 MV@@D"KQ^#[.VFC, %=,PPK@YZ.,.I!R62%EV7O 6"_O5]RI8GGTL"8R4WP9" MO& ;"-F4 4\BR3+OV1HILF<9EYK*5=)F3.,)"*J$Y!UH?'44&B^#:5EV!&B5 MW!0CM6_G2/R,WFLFJ[\NVQF-GH:_O@A2P@8>+)-'E3#VW MCME:N(,+F)K$.BF.7R0"G#%,U]KW0*E[O$'NO 4BL6+;E[DVY>+CAL*+2P_ MNH9$W'M.V=NK%8L1\BT*WD25S*#?ES]W*K'2&OMA&&5U7Z5ZKXPTLS2*4]J( M/X99A5E1@V9V,L%Z:,KJ!8!XOO65_$%5PU'R"&7J+O].Y!%PU@%+%L/J!A?]2_\XQ689[R-VH-D?ZO>!_I;=U/(C@=BRBP6 MK_4_WEBZEP'%PD+QXTAH-EAXNO[-BA]:^M!5LL^U^Y.RGO?3;>JRSL MUA9+HJ_A:G]QM_1$_UR5+NU&VQ"ZK*G^_J^%/>)_/8N(KWXI;8HWWV""156V M03[P;:7=QTZ3\(BO)3?QU;?;\/$H/+!![;_1-UHM1.>F-26:K>#K4AE83O5R MA]0:SJR(@;SZY6YB(T*JT@=5E!C+#S,HHVIA-/$JY!".QW5 AGH\$?Y8!1ND M^5<%H(C@]CT 69Q8#J:GT,8GWCV"J+JY/0UI.P6P3 T0ZM8+Z]&1C(:U*"O4 M@U7IP&)X,$30&1X8'A@>3AX>/HLHQO00)=F54988,2M^H[<6&5 HNUY7&SJG M@@XC+!:T_3I5-,M- ^Y38 -%5ZX"#ZQLQ+)U=?\,-I:M[@5YJ;RK9S 8LD8M\SYME9E(.)BJJ#:OP3L4H7-R],(^'3@N.]2 M::G**10CJL7'B.]>3/T=VDF0?)U*[_CR ME/J/P<*B3MM8&>#%WV3P+1*/=N1BX=1,!,38L'RKK$VG$-H9VYZ/&WX@>)PZ M#C4%O%7+5>]AN:&0=?FZ'^@^!=91R5-@3<)'2HL[#K4LZ%:40L^/+&^VBS&7 M!U%DE0R6S&;^_\_>NS>W;21[PU\%Y6?S5%P%,03O=!)7R;*=QZ<2VQ4INW7^ M2H' 4,0: AA<).O]]&_W# "!'@!"(@#HL^>VK4D$IB9OORZ>_IBB42PS?,C M,DWZDP/OV"KJ*+B1Z^W5RUD%M:^\M.T%^E,JT*<"?6D.NH4%^L?5UU]*G6F1 MUCS_JO 2 O#B&4$. $+0#U B70(;@\D28,=]XC?'.Y)UHQSAI!@R9[*]2<,# MQ3B.\=8VCE(-OMH![FICK(.?3PDMVX(XQ\MN2>O)%)QX679O.$CQ>Y3XAK>* M454M3XE+^:C@;Z*[9=O<^TQB#,G=(EY,VC8S@A";4G@N]HQXWN_&8K5YY(FF M M^[_%<*1[>4=TE5=TY5#TA5OZ"J1J7,HW6H8BU'I O%^?%Q]'9/=$\$G$ 9 M\]03Y1O(VQ4&>4S+-VP>@1(5?_#*="(*:>:VLRIIYLYIYB%IYA?6S&O/>L0< MPECS@OF\20M$+5Q0T^0QG^D>:%G4S)EROTT ?-M.#GU&BKBEG$F*N'.*>$2* M^ 44\9&7VZ0V6\E'I#8[IS;'I#:;4IM_[C(ZDRZ9F(:1S5-.?RZ=8,2^PXO\ MN/DCZ=[+8T;2O9W3O1/2O>?5O7$HH4#YDAYM*6.1'NV<'IV2'FU*CW[9&F<0 MIUD'/*$!-^.&OO)?U^(=UH3.5;,15H<;M[PX'-,5+-CO\69JPX-Q+G6V14%V M/WX\3LN+RQ74W8'Q!"GR2-%1I!N.1HUEHC7$4]14)5[ MZY$Y8L@!+WR(!C9LHO/\D2OXD_W,4V.\.%\]:BD*?\4&TCN&NNS<9D'E1/J M>)U$W/\;&Z'!BES/%PN-"C7@???\9-//C3:8ZG.:1,X*W395/&K3I"JS2*3? M$^^DM\!G_A-:7M3:'\LADH$EN#D^S $;1*Q=;,^*YQ VXJR#3BY1VS3*H@) M?W* (4TOO,?" +8.>%ZG*#80A1:1791T6(C[MW*.BYIP\4X/.XXW^:*@;W+; MG:JC YP[533B7S52D^YC;*C1*U,6-0L(G61+BHMTL?$6TBP+(&*RF-2_)8= MT;/[-+"%E;%R71$>A8\8#-XIFN(ZO"@$%\H3 7AW77>=U*#@0WO*M0%Z&4U MW%I![UV\\HJX*966N[=KKAX$GK4(@[B3""Y$-/.S=WPQGFEC96J)\)U;3(WM M, KSU=+!BBW.%HEJ(O,<'_^@?V/Q@Y(]&5&!$AZ@#T?[J%MVO/X-;3>T9!9? MXA9-+JK=YFW2$T858PJPYH>K%%1(FQ9XF>/AU0UQ;SX<-&(_;[4FX3HH:0LV,TTU$;KBH; -FVBS<7W'M MQ@<;103.2R=\0]_W_N=-W54D,*$3]:+A8W%P5$JFF0WH+#B=(OTMU+'H)9., M&8K8/]OF<*NA8=+$6X 8%R;1#J:H%Y H.N.-?9Z3KFR%6H ?8^;\\$Q1S^D* M-MW&4MRX9! _'QTHCGX1)5\(7CBA+#6Q"'2/0#+^1E[VNET?=@0#B:DYZ9Z0 M"Q8\,19-K1&E>CWED@1SF\.Q\,$24)N;A.6O4($#'1YTDS? Y1FX<*;XM0IM MO@92=HD\?FC,H=9I? OJ]CB_2#8X@O(+8P6,?\LW>0+12\R146E* =')[$.W3! @S'2%MS X;*F M1TI(C7KU9Y>U-3LL,FWYGU#.HU%S9IRG4C!T+=.>.>E/S34RSSLW(V[=K8M2 MYYJT&TO49>Z-T:PRM'VL@#W$-:0X3,=T'[ "+;"?XX+2N!=LI!GC\NT,?O$- M6T)>]&CBC5 P/!,SFH*&9,+FE881>I>E6*[]R)7A?<\26B1.S6/&'@/]S]!8 MTKUG-=?7+&JM&IM0)IC"1E (+:C[.5CH0M>G)HUMV8MBZE=FLEDL,P@8R.[% MYB5GP0>F^Z''=C\^F0F7F3Z6#!G#\6.8I054WSWV;3.$0GR<-_C=X9R(065^ MRJCD9CX^;*N##_]JH>41^P+)"+?GV/8HIZ)$,;OC*K8+.MC;H0P.Z@ U\DSC M61V1+*6&3(A#%K, '\+H",'X-E97 $[;9[Z35FABX)NP]85PDI$J7-[%Z+FB M 7BI(8!ZU"2>&W5H8'WG9(.O_Y*9[)Z&ON&!#I=Q2\NO_,DR=.[= L54W\DK MGQEOS-![ M_/9\[6..H;^-+(6&@S\VHZ'D^N1J8QNIH;FG$U&.HC-C7GX^5\ M^>JMCV<0HVET8F_QY'[56_C[ M(MVE*@O4L@(G>*].,589E(S'N +(S)^,PWS94;0"5T1% WY*1((WH4 U&2GJ M"PL8/I>07DVKQB5CYD(WOO& (_?M8W,*K9^->L%J"N>R8#\[QRG1DU6ZR,]S M>+YD[1[#9-_8KBJ#@>:3MAS1L4."QH.B%O"G#0B:3UMR2LYX8;IX4]RBS!M\>TV9 &S^6W%X=X[]?7YN*2./C/JZ$,=?:0Y:-DZ M^C1_#<\%9;N)4)'_,ISDP/NC;GG_UNV0O1?5M2&HR3M8Q#O;-;[M : "$X0! M6*R1M[R0O6I#P8P\E+QW6Q9(P_L[4I#.NJ71944VG76FYI3*'4' 4+CGE ME/(?(HX7]6W^PB\H=OK4NF;\(C_(NT[6+4\5/]>[D=:Y(_D<\:O0TEPFZZ/S@ M=UTF1)8OF,!1[-A+ KLF!@733W7XA4=$J*C?S8\\B'&*4A6T M><.3W4Y0L(*V&U6=RZ;[R/_OYV@%D24!Y(M_\28?(*'XE5C & MD0)FB?89D5\4 1VUSJ&/'[>F;I8R>Z!G[,8C;\XI_6]-U_WA2BB]0:S MJ@2IX?AW 4*4A;DASJQ)I"LD!*P$E?ZOK[31JY>C2ORK=YM#C0R>:6]R0'0V MN:N-BXT<="N>QWMF@2JR2KLC.#]%T$( (SFA"&KD(40"-0,9D$;K][04H?"$ M"V&&H"A%U]\Q**V<'WN.%:\N8]2Y55\EB2+=2+JQI705NG% NE$ZRI!N;#6E M2#>VGJY"-PY)-TI'&=*-K:84Z<;6T_4.ZQI(,TI'E^.CONF\C3R);CY^['^\ M:4#:HBAP[<>_Z[1?_.;PX]:==54A:8P" K@NEP"G&0?-'?O+7#X1&?:38<[! M_B E4M#-2T/K0&XB#4E(&\A ^$#@$M?$R7\/^E?OMJ?< MXY0EAT\',-D"QSF#_/$FNO(E"Y!11#D:G24#648G>\TD(I=SOOZ3K_-?M;XFY?7T/_C"8V>_!ZKY-C.ZZDVD&$GOGP[FF:J-Q;=XY M*;C+5G $[\3]W24#P3OY?_+004H1(8 @[N\N&0@@JOA_6DO\/W+72!\U?)DJ MP4RI"[MAC<=2XZC*,Y:92C%02AJBR)M[=DP[ZXYK-BE(-<]T)S^)6A=MC9TY MR5G*GN02$4>V@0T$29+I.8*DUI"*(*FI ,'@)0,$B<"PW:?A46F4IR03./>99$_1IG=C(DK]3=O)SAGB= MM-\JMW)I.!_Q92A)MEW&MALU8]M10^>7 JCCT:E32NZ\@$7&@SRT(..!C \$Q>'4IX)@\M M",\(SPC/&G&&)\TXP^?W7<>3H=J?37*+_AIT"'TX'?FM9CT>9Q MJY-UD1!G]OK#WMVDWP_OB%[%WQP1Z]=7?6!_9MM(#B!L\G-$:/YS9F5O]#!P M?XY(#<=LZVN?O8G_\;,2L4._'_7SR25RO%#&S4G=#%*ZU("_,J\.99KFK85K MFSN9='8,D[8S75"*+%N)"0$K@6T#);31*PF2.$?3WN2 $,6GUAD!>L\,CN*" M?D--50#.^V=/+WP)5)6# ,?G#!+42$8H@AIY")% S4 &I-'ZE5SE;D,1OV=5 M-,*>#JNT2I)".H]T7DOI*G3>@'0>Z;Q#4G#9%"!=UGJZ"ETV/+LNDZDT40[* MD,Z3D@*D\UI/5UY62AI/.KK(4HF]4]I.'^PL>8[#1TE*K7?K.YK2(FLN6*?R MO"2ETY')7MU.Y)*4=C1Y1 XR$,(0PA"="&$NCW:$,'*0@1"&$(;H1 AS>;0C MA)&##(0PA#!$)T*8RZ,=("/^!OSPJL^1L+E&5XQFF\!/F2 M'7O'U%'E_@8-#WGH-E:7;TTP?H_@_E = MS(;2S((@328YH!".$_<3CG<3Q\\\&Y"D0W(E1=A W$_80-@@$VVZ)AVR*BG" M!N)^PH9N8D/Y^-],RO@?A>M(\31\#RIQ;:#\]Z!_]6Y[RKW[R#P'10\$;!$H M?C*16;YD 3***$>CLV0@R^CL0TA(1.06$0((XO[NDH$ HHKK/'])U_FOV]\2 M<_OZ'OQA,+/?@]5]FQC==2?3-#\SL[IW/IEJZG0JS]P14G!R*SB"=^+^[I*! MX)W\/WGH(*6($$ 0]W>7# 00%?P_K=\2_X_<-=)'#5^F2C"[ZL)N6&]<;^UZ M>H##,<]89BK%X"IIB")O[MDQ;;T[KMFD(%6VX\1)U+IH:^S,2B!9D/)#Q0,9#6^KM"<_DU:&$9_+0@O",\(SP MK!%G>-R,,WQ^WW4ZFZB347T)#MW"^K/#2Y3?\%.@P^G ;TWKL=SF,WO]X?!N M^+XGZV!K-8)[/HA! KP8HI2Y!LE*J0 M*0O=9Z8":NB?T W@7VLX0OX2!67QD46/]/G#+#PGRT@R*!3XG6WI"\OF2^LI MJ34/TFL&K>1;?J"X2^5 PW=%=TSX>*9E@^X#/AG5[[H*O'!;YK+@+GWF/*!WQRTP]T'M%7/M+YL>-]A]. MO?#@[4.T)H6+8 M0JQ9"N $_>$^@9(! ,3?O0?\03-8&6JJ@H?%\0)M8N5'P)]@Y88^_,9__49! MJC=E'*7-(:%(3U&:8AUO]#!P?SY!@;Y0.O))K9Y2CB8:$LRKP]-L;0CH(NJ. M=NG[G/\T:Q+("@D!*T%P^_457F^?OZQE-.U-#DA.?&HO)35GIUNLT 7]8JU^ M]H*+EX@SR$& XZLHNHTO$A**H$8>0B10,Y !:;1^I QVAKKO-]UR2/>1[CLD#9=- =)IK:=K2J?] M[OKG;L,N5P\'.2A$ND]*"I#N:SU=/_B!]<"3(C"G3.%)9:0 I2.3+!UL=@I? M%(N]W+3?VY7KP6>9]Q E#/$KW$U2DW19P33M3MJ<^D[ERTM*IR.3YKN=$"\I M[6B"FQQD((0AA"$Z$<)<'NT(8>0@ R$,(0S1Z041IK[X)A&/(*8-9""((8@A M.I$3-:GAT M5K>!NWS#ITFNX=-6A7]V@E52*8*%(N]TW_(/]X'ZY(@.3;"@=\\W>L#N7>_Y MRS+U8-$+2C?7P>[^ MEUW(0>9LQDFR5O&A__)1K\^IXY1NZ! MFQY36O7A"K.).AT/I!FB1?RR/S_E! M0A7Q&8OV.HO/6G].""V;-+R6CP($SL3X!,[=!.?2V#SL'\+F74#8#?@].KP] M&4T)G643!UF*:6OH8GAAR0,WV>D"$@ZO>KD^7M(01=[LIF,Z.71D("2R\ U2HUT@;3-7A9"C]F*NSMD"11CZD'6E)5H$L M4$-606M(159!JZE1?JA\9 FW(,&AR3J+I MAMC!>M"KT3 83'O#L=RDN7,#W5;\AKIY-S@\L0EZM4Z,9,F7*CMD(D.\3EIZ MLF:&O@PER0K,I"W,+B%MX31S3ANIFC:6)CETESVW$W4ZI;SDFS]%1H%D:$)& M 1D%9!2+']&MK498$, 7G!APP!>6A!A@ 9 F0(-),K4K;)8GMR18Y( M]AC45XU MH"4V1YD!I 90&8 F0&=,@/*IXH<[-\HDB:U;EEDI&Y)2F=\C87V5-MH1WUDI*##(0P MA#!$)T*8RZ,=(8P<9""$(80A.A'"7![M"&'D( ,A#"$,T8D0YO)H1PA#D]EI M,COAOZ2)2YW23;+F''4;N,O7%,_;65/\V74,&:?7#/IC=32EX>S228:LL$%H M3=Q/:-U-M#ZQ13E)QX4K*<(&XG["AFYB0X7ZS[)3K62N_SR#?[=QXN93>1I+ MD)HZ=]THX;-DQ]XQQB=\EI$JY0LS#S9JDJLP4]X(ZT@=S6<$T+))A"P%G30? MG.:#MU)<9,FQH7$K[2 5C5MIJJ=FORN7X@U.7M$&ZF2NT>255H@(S6,E6I!A M<"FD(L. 1H1? '$(DH@6!$F702J"I,:N_>8=!PN'HT)5N@%:(A2V$\#0K?,2C<;J:U-(T MD<<^H!$@,M%2UB11&@%RAO0%[4+2%TZ-9,ZD/9YG6M2GTX[3I#[6ORU$B2K2!E9P,R M$\A,N$Q:DIEPL69"^;2(< MRVT^L]42.%Z((4]J%Y'2MP;\E7EU*-S.6D)2Y-NF MCW3AVN9.%3$[AC:U$@)6 ML&2FBC5Q(8-J-I;W) RFI.3O=WC.#0[>@ MWU!3%<#P_MDA]R6@5 X"')\@V&U\D9!0!#7R$"*!FH$,2*/U*_G0W8:B)+E+ MP>PN@J .:[9* D.JCU1?2^FZN=Y3?M,MAW0?Z;Y#TG#9%""=UGJZIG0:YBR< M7:?)5)XH!X5(]TE) =)]K:?K!S^P'C!Y2_FH6Y[R;]T.&2E Z<@D2Q_XG<)W M^M1RR5,D;E>N%S10?MU<]Q::I'/FICD[$:A3:6.2TNG(W+%NYX5)2CN: B,' M&0AA"&&(3H0PET<[0A@YR$ (0PA#='I!A*DOODG$(XAI QD(8@ABB$[DQ%P> M[0AASM/!N,%+,OGG(O_5N^TI]\G,\=TDZS-$[H-W.7[ M'DS:V0;XIMQ,B+]N?TLT^/4]'ZF \('2631QDJ::MH8WAA64/),/(X30<\VQ%M5+T,)2&*/*F-QW3 MRJ'CFDT*4F6S"$^B%MEIF7R$:2?R$1)8> >H4*^1IFGJ:#ZMS4:K"7GDZH$B MC7R<5[V152 /+<@J:#^IR"IH*O5AT-W4AVJFPL8>F$W(%FB%5) M0+0@6^!2 M2$6V0&-9%F5#!!>497&J,5#?W0W9 E*F6Y 9T %L(3.@-:0B,Z"IA(Z#(8%6 M)W0T>T$PGFED"+1"+F1I ;$OLV/G5.X3R#*8]H9CN4ESYP:ZK?@-M5%O<&IE M$_1JG1C)DJ=6=KI'AGB=M/1DSG_Q29 O+"#YD" M\M""3 $R!<@4:"99I&R H#W)(DDHPBWK44U+F+=PF=)3OVCC$^H;.,5"E?'7O0@9:K.E;F,/=X,": EDTB9*FJ MI1[J.WJHVW(6W5)SE';D/U%SE!>SW%XP!9&:H[S0_4G_0K(=I,I1:&HJ#O5) M.3\6D5T@#RW(+B"[@.R"1NR"\27G5;QH-@09 Y<+0&0,R$,+,@;(&"!CH)$, MCG'9*$&K,CA>,N^"C $IDS'(#B [@.P L@,Z90>4-P,.!@4DSQ61*L.C6Z; MV2$HROKXB><7P&]-Z_%M3,O/X0/S+*/<863V_L/AW?%SF*R#S.HJOW'4&X]^ MB(\;6/KCH'_D$C9ZIL;SOK9M)5@QY4!O"$5W3% %WMKU0,2!<1W3A\_X(#'H M+"BZK_@KUPOVY(,H*_V1P7,4MEPRD$#X 627*PC%Q(<&*SU0+%]A_X0Z+,I5 M7$^QF>_C'QP%]J \,]U3EI[[P)?L,7\=/0B4%,<2OI:%;NN. :]>,1;P1_>4 MNY7K1V\ F=I:^8%$EJ,7_@#>40V+%/P]X M:=H\DI^5%^]HK=^SJP6XFM^N]"5LZ(UN/^G/ #X_'=BX;3GL:B46IVF%.]^G M"7O:_(?"HXGVNW!MLTA42YQ<9;DT]35RRR^@]IWX &P6P*XY$@"FO+GJ]_IC MKI>47W["S[U]9[D!,U8.+/D>4[!*??DF$F_ QFT-MY/ECC[HH:P'_1E.S$=M M 7J!)]Y4?X2& Y(3-?GP0!&0'*[884?:^%;_ZKO!$^V3;"/T6/_C-Y1M[1R!P&F.>[#^,)MJ"L81NH)$W@)[#@ M@>WL9^7)"E:6P_ES+98#G"O6PX_0Q14ID=<#1@FN24%X4\#V?P"#@O/J'M,! M[!A@R_=P>K@19:BI"E*6/QQWI:9,$/NY%ZN:C8VQH 07?V:[Q;0\]<<%]^$^*)QF<_!H1"(3Q'#'SGWP[?@W?[K-THM"+J#>EN.&GJ,Z./S8Q8^]Z^O@,4-9MN1 M.93\'/GK_.?,RM[H8>#^''GLP$BVOO;9F_@?/RN15]_O1R5\N2J%QBM']A4J M9")MNX/9I]IYA:&%U@:T&QS3>B0]ZCK] C,[%^F9-6EE%Q("5H*.!\*J!/55 M@T%O,ME/J/C07DIHSDZVWS'\JRFMM5Z-MM$UI"0A$>R4.(!(\&,N"1UJ^4 M[=%MP,*(F<)#9@13TA%'/NU72:A(/9)Z;"E=-]<,"MXSD(Z4CD+RZ4A2@:0" M+T@%DH4H,7'DTWYD(9)Z[))Z) M1=@K)TM5QI]R=/@BR^/BEJ1YJ: HD38&^ MN*)+JI>4H%Z22AW+)1;/RJ6NWB39C,5)K)@!@PDPVD!<)1]3$%E'0^M\2O:Q MY8[#T5B%-4E3[D@:1G)%3_A*W$_XVDU\+=]2:*(U"["I%D3X,?GQ5E/[LR&A MK6R8[S$),1U7:U*0*ML.]B1J7;1U4/X* M="[O%6BBR]^!*J_YWG.@SF83:>;X2ID#)@U3RY&5 3EC=VV M#EISVUH-VC?X/:YO5FS)W;J#;BAX'3:[@"U>^GIG\09-( M92"4O/EB-(GT4I+.:!+IR]]-3TI.EJGQ;OJTR^7I5)WW^]*4^;1KAFBWT(.0 M7!Y:$)(3DA.2-W,U/93E:OK$\EUMI!&NMX))SU;32Y!.D'Z9M"1(OUA(/W-9 M&4&9O#J4\$P>6A">$9X1GA&>U4NW,..!E^:QIXM3=*-D#^/TQ9PQ&ZIF7HMOVL>.S1@G>[H;?_=EL)7$7' M"?(^GQEO>,RT L5Z6.N6ATG]/>76?6!\(#R.J->-P/5\C+SX%K \,_D(>/Y] MD([4]^#WAAV:C'\-MH&_@E>!"!BKZ%')L'K+5VQ<0(!SA?%O^H/K!;QIN^'Z M@;+0?#L(GX_>B;3WC/'N<71_Z@?>LP+;NF7L/ MX@8O5T 4=54QX%7W8O?QEQ1/#V //GX>?A=L3B/^@^Z8B@OO\?"][!$(H "# M?&.!8NJ!WMO!3L@\DW61YI68G:Y])/E[9O!B#66HJ0H&U53EB2DF8)7C(H6! MJJ:*7X)?>PS_!H1CBFU]8\""G)SX03CD!8,S^R>TX$!5<>BVO8LYK:2BQ(?O M+?&)2%R/&=B\[SGB1>">8C81+/:@/^-+'_2 $[>GO--]^*#KB+=RCL57\!T! M1W%F-160G303Z\7'$.W(!-Z%?\5"(5B#[SIB'-OU84%^".N!)\4\9SG\Z#S8 M)+(6\WO*=?P->+_[I#L&'"9\ P\/MWWO\%TB_^%)I!8(JSLLXO@H?(QG"GD5 M"S7YULI?/1>T4/#\U09V MNG;,#T#R-2[TO>4;\(K08W? A.]LU_AV('[;A_^D KG,-_0U&C1>R#AH GS$ M@B;L&P1%@:<<82)0_O55'UX$W(:P"U*<_!P!.O\Y-A$$C(,0VOK:9V_B?_RL MQ!,X^E%+IKUY6^+#0J#SD%^(^*@CM%FADDA+-I_24-;@JGR5C[-/XG6>;143 M8$I0N;DV>;D';9;Q^-'X1]]8>SX:&;$5I"+6AKMG1\M-%CAD4^.4'SB66]T>YI?&Z-2=16V M3 =4V')H7MA$AGEAPS[7NC0.+$6V6,L+\H&J/WN]! WZZB2,R*W("%3DH85D M0RB'O3G-H"Q'5O0F"&E;JZ#C3I./E%+?^F).M0&TE0*[=,XG5(HLBI^PEO" M6PGH1'C;2K*5Q]NQE'C;KXRW@ZDZG4P);V7C3%DN]CH;;KAQ']9AP+S3@PW- M14W)^#E3H]..JR(YR, -'+)?RMDODW/8+\GL"J%2:PT83-3Y3)Z9%J0T)%<: M!)G$_=TE T%F!+7UWQ]D>A6^,P7KEEKC0*,U?%T3K<8 MLC&HK+J#D).XO[MD(.2L@)QSJ9'SA 0 =:K1_;]T#$KW_[+<__ON,GC2/29? M?(RL& I+=I<,9,64MV*FN<%@+V7%Q.KT-M*F!YS^C7TRG]=7#4 ZX<)U B$B M<7]WR4"(6 $1CV_W^&*(6.C,;Q!Q-J'+>^D8CR[OS^ZO.W[@A4+L+4=9>^Z] MQ_RS31HG(T6R8^^\0I*##&2D5#!2!F=-0=PHUD_.UTBMUG-I/QG7E[I/FN/" M-0?A)G%_=\E N%D!-W/#LR7"S>I7]E-5FXT)-V5C3UFN[*D7=Z9M(--]MG)M M$R<\>>XCXS.P9.IDVUW:R!I(/V[ 0\>5FQRDRG0Y.HE:9#IE3*>S-!:,/IKH M[$\IE5U+LX"Q.A_75R=06QOE8Z& 5 XA=0=I04A] :0BI&X(J<_2DO XI#ZA M+$%3YZ/Z@AR$U&V(?%#R0T4"[!K%J@=\BK=\H4&ZRZ&VS42GXVPEZMU2)6.4D-7*3+02-;X/%VEM(94=)5R M%/E^+&_UY/HCIG3I^Y0JA7_;#/\!AM#U@^L%UO_'?[_32&HJF#"GP; MT_)S^, \RRAW&.F]CWKCT0^I[4[60681M3WXQ64U'6!4V/_O.<@-FK!Q8\KW%_')?OG&]M>LE MB6)'L=S1!SV4]: _PXGY2N JV*X+#5R>-??1MW ;P"U[5JOP('PDL M)V3FZY-0KK\/.W_)"/Y&O0WS \A^%% MS+8C/DM^CDPZ_G-L) I##NANZVN?O8G_\;,2&7O]?E3VL/>&1GQ8F YYHZ^D MS7>L*N0<6\2CE;V$M*R>;1732!?(L9I>O)IBGP.9H )U\ZNMM+S#&BDYA%=O M8U'=IY%S"AGL@W(:?*,%%*$&DH/C_D#6&R@X.#RFR4'[(66D'[?]NDV(NQ7S MF++2'T'I,.8HY2W%7,>$F#[[K<3QMG'XZ?/'C#=]Y3,#/>HGT&P^B/X"_'"CN4KF/5J/XEF,PQ0+L 3O6O8=]1C+2<_W%KK)@9VNS+$N -].3O8%_DD.,.6:0NT&@I@Z7D2.>'HOCA MXK]@H*.=H*=R3>#/2*_8RE=B S\R[<'&A^/S+1]-"O@>23_58%;K..-'@;NSR> ^ NEPHRGO7-F/;;V@J"N MG-/1C').=] "5H? _>LK#83K_%F-HWYO>%Q6X\[P?27W<+?<%/B'.5+.FG0/ MBP,X9\_M>XG@MAP$.+[.L 5P)6] M13A)7DBS0E:KI]90$:E]%22OL&RB(I<;OCVVO@GM#S>3^F1V>X:_I5DVCS+E[O-(>UR MJ2%OY0,5+9R7 GUN E#!0;E\B%ROQST) D?.D-CSA'?/?^C_=;T;6_?]]"R) M][%JO4LT*V>$6B8_#?HJ+%*:<@;2(9*K $P% M*-/QR?:!JJ:IDR$-,I".?ROW&20\)3QM,QD(3Z4D2WDXS=6A[H&^_47PDD+G M3!U*U/2&%$C-@?;SYQI>$E6^AIZQTGUF*A9(N6TS(PAU6UE';3%DNC_N+I%D M;=5+795;0ZI^Y@+_)'*1/96)\.?F&IPEPO\II;WCGD8'C*E40Z(!C8-N!WO* ME]5%J"R;JB=4;@VI")4;NS7(=?J3Y-;@)*#6)ODF6034,G+LV><1$4;+K/@) MHUM#*L+HIFXB"X#9ZK6,G+CW( M]WHZ]RR$ A.*9B%(='U*LQ N)HF#AB&8BU_;VA)N+4RL(ZKR"Z-9 A&[A M 6&S/+0@;"9L)FQNZ/XBUV.XUON+4VL3IO,YP74K6.]L!0N$U(34ETE+0NK+ M1>KR0)V;>%#Y%N/$JH?Q8$*8?#DS!9L:6)#:-VZ<7=!F(SJW@J-4V:< N:4!I MYQ*0$I10"7:) J3<6D]7FB/0!BK)4F&P4_9HCH!4-[;4M5'6? ?*96A%+@/E M*93+4YA(T:?HB,Z/?9I$<&%*1E8P( PF#): 3H3![:1;A:S^,B5WDLTRJ [+ M-)OTR5W1F'(53'7@U']7QT)KBJ8AM(\]Y&5(3*#=T[3/JRSE ^":BU&@,;!-127C401G=!\1-&MX94A-%-747( M,)?Y-#B>3PF.6\&7S0[S?G4#$M-HJ)#@FLI:QX(J0FI M+Y.6A-27B]3E@;J^F>'3TW(5$C&L\Q;L5*^Q\I#SIOJ+'O9$L!P7.84*@@S,Z]LHBN*>"C ?PA>7KJK;IC\K^M M]U=4*):OL.]K^"U^W546\#1AL\//[B/S^$,<. ;EEPS]TW-,2W0V^4IKLRF?&&S/TGIGNO7H[[O6WV5W!O_@]Y20F/7HRR+98 M[#K[D9:[M;XU5LP,;>8N]YS?QS (/9;VSCX $S@^NT.)OX,EO[-=X]N!63E; MQ\E _:\1D;V0E5264DGRM8^"53A> /X[D98E/\-87/@A\C_"*2)GH;Q%9Z[H M_-"%)O#AC[;M/OG*CR#=PG/'S4F#Z) MV8_L#UC1ZL!=]0FC@-6)1). 20U(UEV@TT;(4+KL;3)"SE7?T''M(P<9R!*I M8HF4Z1M<8(G\+].]NR>W'08(J0#)#!"*@IQ@@(RDL\/) "'WI\-D( .DB@%2 MIJ70+@-DY;%]-WXGFB#3_I!B(+(Q&L5 SDT!D*JQ=)8XF2#D '68#&2"5#%! MRM0&[C!!/KJA1T&0CNL "H*\N 4RD8/ZF^3-3>LAT\)DO<99_5T\W^EG=NH-O[*M?.6Z!= M: ]1>PZ)O#=JSW$Q%4'4GN,,QE29/EH'VW-4#Q?-U#$&YB4)%U%WCMJ[<]3> MK:.VE@7#: 8XM/1.@G9(:H5+QB87I-Q>CBPZ(/0I[5"SD=2:<-UD7J-O4VD@LE)1C)KKA>V-(* M.]N&Y-I$Q6U#OBSSLM=H4Q \YDGA*>]H"G(>J(]/WMX<"_;R2#4*B0<%:+SW M#G;/PH/R+1^;A42=>D3K#] :YVG^H6GK5O;BJ"=<,YGTIF>,MK?6GZQK!MB4 M[IYVT0)6AQ#UZZO)*PF"Z<,^U[;'!--W.GL&G#SSZO#V>7\()DN/LY;I%/S.,R*W("%3DH44"*@,90$4;]N;E@X[=!AWT)@AGSH@S MY]9HE<2D>2]&3DJ1OFL[64\9LTCZKK5Y&CME2)C:EVNV??7<)?-]RW4P*X.E M@KG2W!5S.+I<"K0XTX*R*,Y+HL%1^$X)$N42) 8%E\-X\9)6E1]!4]Z$'AJX M325(#-7)K+YT4ZJGN7!U32A)*"D!G0@E6TFV\BB9F_IR"DI6G_(U5 <:59U* MQT^RW)=UUJ^_L2W' BGAF4 H>B@:BL=\IGO&2G&]>]V)"R\,UP\J^_W-12_) MHJ$./=TE [=:R"@I9Y0D.:6ZN0YBBR16A=>.>1,IPC\C/?@EI09O4 LV[--K MZF147]$#Z8 +UP&$@,3]W24#(6 %!!R_" *>,)5;GUK;[S-@[YK"E M=8KWG3(P9B.Z#I"-96259L(RXO[NDH&PK *6Y491G8)EA7[T!LOF]7G*),R2 M>^Z:><&SN&W^)[36=-,LA5#(<>R=UTURD($LD/(6R*!?E/X6*[\O MRZ^1YKMVS ^QWJO#L9YH8XK4R\8]L@HVP1IQ?W?)0+!6 =:TAF"MNJ,]4D># M(6&>;*PER^TT]2E.4^5+L#KWG%]J4RQWO)GF_+:&5)E^,B=1BZR6A!T'H!I")H;0A:<]W:3H'64Z[G M9Q)5?Q.TMN'.?D\HH8FY[-JP-Y6;,'=N@'W=\M,@SSP\N<@,:H)"K9,;62*A M+S-N_9)HV=INMK50DFRHC V5&UC\XI&)N3HF]?@VIN7G M\(%YEE%T&+CUR;I(^-)['_$1YN<,%*Q8$B8(LE7SRD*W=<> O_.*@'BTN#+4 M5 7E0;$OAV4 J=OXT;P4)XV2TH.Z%GQQ**4 MP(7=1LM27+XNA<4+VW5X/<%BN]DHI<6S\S.1L;3!0<[JGY6M-#$1&#:T\N(= MK?5[=K7PF/[M2E_"AM[H]I/^#*3[Z<#&;8"K>DS7I@[\\LA^P8FP\0'8P$J@E5'? L.]N>KW^JBV7[U5?OD) M/_?VG>4&S%@YL.1[#.F5^O*-ZZU=C_=RC2A4V\C6GC:4]: _PXGY**DWKL,M M+RZY'RT'%)REV\IM +_ E$A?^1';WUH.**/7VP=T\#AV"N"$TR %+AG!WZC% MX32;QOF>+1G8)N:?[)'!DN[@^>]LU_AV('K0A_^DP@@,=-T:"0PJ5GR3[^\Z MV+SU;]-P@K^78WU@Z,;R:FGHPZN1.9E=+?ISD%ISLAR,-)TMEAJ'?@#!^% $ MPR '"*N XV1D6OSZJ@_O8[8=\6/RDW\:F=/:8EDLZXT> M!N[/->GH"\TE;VWTDG+<&J<%K ZQ"_U-"9*HAGVN>(_)HMH96ZSD(NR6FP(? M(4?*69,N0EJSGSW;Z"5";G(<.U4CM4:'$9[(0XL$3P8RX(DVK'*]U6V\0>>! M<.:,.'-NC59)3)IW8.2D%.F[MI,58R2D[UIG5U,[O8H$B))*%',KQ"A?;A(U M&Y(ULZ]367NRTNFXU+UNI^7)2KO.M_:1@PR$,(0P1"="F ND7><1YM)&F\E? MW'W+_@F9@WD;\G7G(*2G61$2%WC1,!BI:K-R@U(Q]QJ_CD4@-Z$/9\*\I KD M<)F6[P5?/=<,C>"+=\N\1\M@U]\M_V_,C]QHS2@;\@^>[G%B'SA-G=?8UYT4 MQ(7K:8)'XGZ"1X+'X^ Q-_+S//!X0N7S6!U-ZNM&0@I",B^^P;YM362]R._: MOP?9L]VSSEJCY,MVA!VI86U+2$4-:QLRCW*C9!LTCU**N<;PP7BFCD?RC(6C M9K?RZA>"97EH0;!\ :0B6&X&EH=]26"Y>MAB/%5GXPG!.90RF MO>%8;LJ()O1&S7GP5%PJ#SJ_Q$">DZJK.JX)Y:!EI=ZW9(K58(II-9MB)P4[ M9GUU-*&A>>W@-?G*I0FC9=/KA-&70TO"Z'-A=&ZB[>D873WR,1VJ0VU.&-T* M7I,EBZ.Y6@S)"?#9=:[J#F]0$>:%W3-0$68[Z$1%F.VE7>?3-^4@ R$,(0S1 MB1#F FG7>82A,O^7I@&5^4O$_G(<>^>UD!QDH&+&"G'N8:DX]V?7,5ZTW#]5 MM#C-CX.4CP=)%4A!!@)"XO[NDH& L (0CJ0!PL)[XM1E\(" 4#I^D^72ETKW MJ71?;H+(&TJDK+B6D(IJ!!NR@<8O:P,U4[T_GZGC*94)MH-'J7J?:$'(?#&D M(F1N")DG\B#S"7T')P-U-J\O>D'0W(:0!E7PUTT94<'O-)#F3A6"\J T50@2 M+:E"4%Z3K-R4A*-,LE/C'M,Q%?*W@]VHD)]H03#='5H23)\+ILM-:S@6ID\) M@@S5B38CG&X%O[4@K\-TPX7-E$&OBT&0. "B.V8C 9$&;YB:H%OKI$F.:XOR MT)PA7BFY#XH; M>LIOS($5,F.E7-][C&$V%'QH[3$?_N4K_RHOCG5W_O:]X _]OZX7?]5/,KB2 MM7]RC"AWJ[Y4['$BW)-7;\>3GI:3; 4H:>.98&"FPD$U4Y9^]K.:CWIY]R0Y M*W>I!"NV)Z:5O#<7WU(6NJT[!O-5^(V_9O!D^/"SJN@^/O8],_@2E:&F*KC, MJG2INRWNBQ E#UQ9!AXWP,#-E).>_:RT\50.#N[WE$^.<@\;]W1;59Z8PK[C ME^#]>I!9Q"\ VTX,3>]VW9^\>JL_P*\#_Y>?\/-OE2?8DK)@L!C#O7< ?4Q< M2;S8)Z"BY2B_9$ P3?]<*4UTTG^R!]URP![YRCQN.\&6ORS [M'Q)#_P/3 3 M(! ^\F5Y"[_UE^*4X0N6:VIU,4BTKI.7=1OH7O!>#P1[ 64&5WT-_C^E#5,V MXI7/C#=FZ#W 'E; 3H-M.T+A?_$YZR 5T^P34>@ :=Q'X!)=6?/C0M;1UVO/ M_0[L' _[2%9+L=:-I+!A__4G7MQTOA-6-5#^" %09_ D :S2&S5@@68UP'N M=3K7F#XR%E>S!>M?C4QM=K58+N%YS!@NS.%PJ"V7K]XN0=9SG!"X>XB5R[Z2 MGECZ=^F(]=:WON,11S3C;^.'?"S=E&>F>SZG7/H9.>] V-0Y*Z2GW*TL/R6J M 9C^:1,;%#?S RZZ,;;@GW0/;'+4$&E B9X"7!/]5C&8;8>V[N'WP&6SP*L MG0U0"YK_'I %O#IXSH/^+)0)@"5H$M>##QD>TWWX8<'_&PX%WXRN@QOZF9@!$_+S0-HK#-9OYBG+$3FEGRM84.42-Q)) MBE_90(.JOI81K%TVTK"7KSY-+"1@P!BH +-T9.?0#I"YC16J"\ZB,<]SRR?@ M%]V^_K"VX1? WL"L &B/%AX\D A.W6!>H%O<_$*_58^]50&C!JH3VT9VMMSU M2@>*&RP,+(/?GXMS5/QDW_S<<-T^JHY(2(":*QUM-8.!JH;WKD&B@?_ALSXL MQ.-BWU.N3=/"?^DV6FXGLT"Y:Z62++!#E=^"LK66EO$5MH1'>(0]_0%9A'7 F ^@NM$'X _G(!$_D;\&=%G,[P::?/ =T*6P05P2:F-N MQO,PU@XC8J0=555W[?LLN';,A,_N, QV!VSUSG:-;PN;;M/OO*CA:P&" M,XK]^LP-/=X=8,Q'5 MHT.*&%Y-!SWAE1C?Q(@TTCF*$/_ZJO^*VQ,8 X;=)3]'T67^&P4>%%!RN2B#='=I M@UY_%>9,501V;86A0E3U\- MU&;BU$,M8<]08P1Y8S'4]Z EI!*V$?4U.$2_'\L;4.52,(K\\?"]IG,G6P-J_,?95VWBXBA893!TDF:Z2"RBE? M\":LZ8 3U5.>(6I5KBZI+8T.FNHA1?64E>LI]]57IF32P+1S+WTXVF!=)*1% MR5'G$3IM,(CRK%9>O*.U?L^N%A[3OUWI2]C0&]U^TI_]5\I/!S9N6PZ[6HG% M\52NJM$^8[O+!?+$!S,<+>87^[+-ZZW=D4J[W;RW4Z6._J@A[(>]&IOIN%>4BRC5V2;U/Z)Z)CX V5:Y*;R6;66\:@D/ MSW(,.S1Y?1"_8M[5>4 VZ=(#R1:T'6Z6;'G2+2A3A):OD=Y1EC:^ MS]B7-:^S=.Y_QPPHOXX*M&RU?OQZX63,M)DQ'X_&5Y/Y4 M\YY2_O]@3?PX)- MIBQ!I&W>!R'"77BL883K9P3=N'$"*"M1GGQRE/\)[6< 5DWT3^"!-FZW!*ZBBU8XO):?:]4M8O&61$ 558F* MM;&7A@I6)*P#+&G%7W%BV=@O@-=/;\BXH:Z@ M+LENE!8,,#_J/[*^"- ,O[ M[U;Q:[$\W!<5O'ZX$/7I :P=8(M7^SY@1?G:%JL >C^X?L"[!_!/P?.OPWLP M]G&O?Z[]Q&_U9UN7H[[O,>3L9 MJ^-^02 U70BW/*( MCN;M#7"2LM:?'^(2?M[4*6KKDI ^H;;A/L GL27+[GTE78"P#4/AIOZ$=]Q$ M3\(7_P&;6ET[YO\RW:M]BQF"8QR9-[/"(GALMO,_.IA^WG-45YR]WE'AJZ&7 M-+_".Y!(\3HF$!D[W=B6Z')0?%H@&Z'0U]B2 XP[(1'85R1J#@)$!;VD6 _8 M/$3H=S5IL[61:OX,4*RK'4(8?R._!& :7_EB!"YZ"(/^<*"B;O@O;\KF\D8- M[EKTDW"5X F5#^.<'J2U8EYEWL)$ORSBTT"B=(5$#YR )PMB%BZ-T?<-8TK_03JD8S8 M=(ISA2&ZYSD^RS3.N'P3Z-,V$&V#KI,"V, 5&NL4#)KDREZ.PJ#R^ (>DMH_ M #"(PT]QE$2'_5TMV%6B/IBI*@X0;,5T$[\#Q^(KB]"RT5G;:2+ B<(3'"8. M@]LDB7@7&37E0XB3 O<8+S9]$'AXL!5\"0,_@/.$)5USWB]YL-N]>?8T!Q57 MJES+\E>+#:=:TR3Z*9JSX>'%,3Q_A8Q=V#-4FR?^C('FZ/9^ M4 I@1YNR%+9LI_(O?0BIZ'>B:M6D0+N=V'EKM%.,F>+;!5 MC4);=<'N=6<_.<=-6:1E*;PQQ 9:KAUC@=G'K;>]6YOD.?7#][4E$D8:VD6" MSL-AGDMWF%/':

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ⅅ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g4bdklltl5z5000017.jpg GRAPHIC begin 644 g4bdklltl5z5000017.jpg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end GRAPHIC 25 g4bdklltl5z5000002.jpg GRAPHIC begin 644 g4bdklltl5z5000002.jpg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ȓ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ⅅ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end EX-101.SCH 26 adpt-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Organization and Description of Business link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Revenue link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Investments link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Property and Equipment, Net link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Goodwill and Intangible Assets link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Accrued Liabilities link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Deferred Revenue link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Equity Incentive Plans link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Microsoft Collaboration Agreement link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Retirement Plan link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Revenue (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Property and Equipment, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Goodwill and Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Accrued Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Deferred Revenue (Tables) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Shareholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Equity Incentive Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Organization and Description of Business - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Revenue - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Investments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Accrued Liabilities - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Deferred Revenue - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Deferred Revenue - Additional Information (Details1) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Deferred Revenue - Additional Information (Details1) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Leases- Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)2 link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Shareholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100640 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details) link:calculationLink link:presentationLink link:definitionLink 100650 - Disclosure - Equity Incentive Plans - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100660 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) link:calculationLink link:presentationLink link:definitionLink 100670 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details) link:calculationLink link:presentationLink link:definitionLink 100680 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100690 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Options Granted (Details) link:calculationLink link:presentationLink link:definitionLink 100700 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details) link:calculationLink link:presentationLink link:definitionLink 100710 - Disclosure - Microsoft Collaboration Agreement - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100720 - Disclosure - Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details) link:calculationLink link:presentationLink link:definitionLink 100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100740 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100750 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail) link:calculationLink link:presentationLink link:definitionLink 100760 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail) link:calculationLink link:presentationLink link:definitionLink 100770 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) link:calculationLink link:presentationLink link:definitionLink 100780 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100790 - Disclosure - Retirement Plan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 27 adpt-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 28 adpt-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 29 adpt-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Lessee operating lease liability tenant improvement receivable. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Voluntary Filers Entity Voluntary Filers Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Public Float Entity Public Float Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Entity Interactive Data Current Entity Interactive Data Current Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Annual Report Document Annual Report Document Transition Report Document Transition Report Entity Incorporation, State or Country Code Entity Incorporation State Country Code ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Auditor Firm ID Auditor Firm Id Auditor Name Auditor Name Auditor Location Auditor Location Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term marketable securities (amortized cost of $214,115 and $564,036, respectively) Available For Sale Securities Debt Securities Current Accounts receivable, net Accounts Receivable Net Current Inventory Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Long-term assets Assets Noncurrent [Abstract] Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use assets Operating Lease Right Of Use Asset Long-term marketable securities (amortized cost of $218,163 and $118,429, respectively) Available For Sale Securities Debt Securities Noncurrent Restricted cash Restricted Cash Noncurrent Intangible assets, net Finite Lived Intangible Assets Net Goodwill Goodwill Other assets Other Assets Noncurrent Total assets Assets Liabilities and shareholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Accrued compensation and benefits Employee Related Liabilities Current Current portion of operating lease liabilities Operating Lease Liability Current Current portion of deferred revenue Contract With Customer Liability Current Total current liabilities Liabilities Current Long-term liabilities Liabilities Noncurrent [Abstract] Operating lease liabilities, less current portion Operating Lease Liability Noncurrent Deferred revenue, less current portion Contract With Customer Liability Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 11) Commitments And Contingencies Shareholders’ equity Stockholders Equity [Abstract] Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020 Preferred Stock Value Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2021 and 2020; 141,393,865 and 137,646,896 shares issued and outstanding at December 31, 2021 and 2020, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive (loss) gain Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total Adaptive Biotechnologies Corporation shareholders’ equity Stockholders Equity Noncontrolling interest Minority Interest Total shareholders’ equity Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total liabilities and shareholders’ equity Liabilities And Stockholders Equity Amortized cost of short-term marketable securities Debt Securities Available For Sale Amortized Cost Current Amortized cost of long-term marketable securities Debt Securities Available For Sale Amortized Cost Noncurrent Preferred stock par value Preferred Stock Par Or Stated Value Per Share Preferred stock authorized Preferred Stock Shares Authorized Preferred stock issued Preferred Stock Shares Issued Preferred stock outstanding Preferred Stock Shares Outstanding Common stock par value Common Stock Par Or Stated Value Per Share Common stock authorized Common Stock Shares Authorized Common stock issued Common Stock Shares Issued Common stock outstanding Common Stock Shares Outstanding Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Sequencing revenue. Sequencing Revenue Sequencing Revenue [Member] Development revenue. Development Revenue Development Revenue [Member] Statement [Line Items] Statement [Line Items] Revenue Revenues [Abstract] Total revenue Revenue From Contract With Customer Excluding Assessed Tax Operating expenses Operating Expenses [Abstract] Cost of revenue Cost Of Goods And Services Sold Research and development Research And Development Expense Sales and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Amortization of intangible assets Amortization Of Intangible Assets Total operating expenses Costs And Expenses Loss from operations Operating Income Loss Interest and other income, net Interest And Other Income Net loss Profit Loss Add: Net loss attributable to noncontrolling interest Net Income Loss Attributable To Noncontrolling Interest Net loss attributable to Adaptive Biotechnologies Corporation Net Income Loss Fair value adjustment to Series E-1 convertible preferred stock options Temporary Equity Accretion To Redemption Value Adjustment Net loss attributable to Adaptive Biotechnologies Corporation common shareholders Net Income Loss Available To Common Stockholders Basic Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted Earnings Per Share Basic And Diluted Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Net loss Other comprehensive (loss) income: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Change in unrealized gains and losses on investments Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest Add: Comprehensive loss attributable to noncontrolling interest Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest Comprehensive loss attributable to Adaptive Biotechnologies Corporation Comprehensive Income Net Of Tax Adjustments to additional paid in capital, initial public offering costs. Adjustments to additional paid in capital conversion of convertible preferred stock warrant to common stock warrant. Stock issued during period, value, common stock warrants exercised. Stock issued during period, shares, common stock warrants exercised. Temporary equity, stock issued during period, shares, new issues. Stock issued during period shares restricted stock award vested. Change in redemption value for vested convertible preferred stock options. Temporary equity value change in redemption value for vested convertible preferred stock options. Adjustments to additional paid In capital share based compensation stock option and restricted stock unit requisite service period recognition value. Adjustments to additional paid in capital capital contributions. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid In Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive (Loss) Gain Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Noncontrolling Interest Noncontrolling Interest [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Convertible Preferred Stock Convertible Preferred Stock [Member] Revision of Prior Period Restatement [Axis] Revision of Prior Period Restatement [Domain] Revision of Prior Period, Accounting Standards Update, Adjustment Revision Of Prior Period Accounting Standards Update Adjustment [Member] Beginning Balance Beginning Balance, Shares Shares Outstanding Convertible preferred stock, Beginning Balance Temporary Equity Carrying Amount Attributable To Parent Convertible preferred stock, Beginning Balance, Shares Temporary Equity Shares Outstanding Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us Stock Issued During Period Value New Issues Proceeds from initial public offering, net of underwriters' discounts and commissions, Shares Stock Issued During Period Shares New Issues Accounting Standards Update Extensible List Accounting Standards Update Extensible List Initial public offering costs Adjustments To Additional Paid In Capital Initial Public Offering Costs Conversion of convertible preferred stock to common stock Stock Issued During Period Value Conversion Of Convertible Securities Conversion of convertible preferred stock to common stock, Shares Stock Issued During Period Shares Conversion Of Convertible Securities Conversion of convertible preferred stock warrant to common stock warrant Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant Issuance of common stock upon exercise of common stock warrants Stock Issued During Period Value Common Stock Warrants Exercised Issuance of common stock upon exercise of common stock warrants, Shares Stock Issued During Period Shares Common Stock Warrants Exercised Issuance of common stock for cash upon exercise of stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock for cash upon exercise of stock options, Shares Stock Issued During Period Shares Stock Options Exercised Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value Temporary Equity Stock Issued During Period Value New Issues Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares Temporary Equity Stock Issued During Period Shares New Issues Vesting of restricted stock units Stock Issued During Period Shares Restricted Stock Award Vested Change in redemption value for vested Series E-1 convertible preferred stock options Change In Redemption Value For Vested Convertible Preferred Stock Options Change in redemption value for vested Series E-1 convertible preferred stock options Temporary Equity Value Change In Redemption Value For Vested Convertible Preferred Stock Options Common stock option and restricted stock unit share-based compensation Adjustments To Additional Paid In Capital Share Based Compensation Stock Option And Restricted Stock Unit Requisite Service Period Recognition Value Capital contributions for Digital Biotechnologies, Inc. Adjustments To Additional Paid In Capital Capital Contributions Other comprehensive income (loss) Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Ending Balance Convertible preferred stock, Ending Balance, Shares Convertible preferred stock, Ending Balance Ending Balance, Shares Noncash lease expense. Increase (decrease) in deferred rent. Increase (decrease) in operating lease right-of-use assets and liabilities . Proceeds from issuance of common stock upon exercise of common stock warrant. Derecognition of lease financing arrangements upon adoption of guidance on accounting for lease. Conversion of convertible preferred stock to common stock upon closing of initial public offering. Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering. Statement Of Cash Flows [Abstract] Operating activities Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation expense Depreciation Noncash lease expense Noncash Lease Expense Share-based compensation expense Share Based Compensation Intangible assets amortization Investment amortization Accretion Amortization Of Discounts And Premiums Investments Fair value adjustment of convertible preferred stock warrant Fair Value Adjustment Of Warrants Other Other Noncash Income Expense Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable, net Increase Decrease In Accounts Receivable Inventory Increase Decrease In Inventories Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable and accrued liabilities Increase Decrease In Accounts Payable And Accrued Liabilities Deferred rent Increase Decrease In Deferred Rent Operating lease right-of-use assets and liabilities Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Other Increase Decrease In Other Operating Capital Net Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities Investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Purchases of marketable securities Payments To Acquire Marketable Securities Proceeds from sales and maturities of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Financing activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from exercise of stock options Proceeds From Stock Options Exercised Proceeds from public offering of common stock, net of underwriting discounts and commissions Proceeds From Issuance Of Common Stock Payment of public offering costs, net Payments Of Stock Issuance Costs Proceeds from issuance of common stock upon the exercise of a common stock warrant Proceeds From Issuance Of Common Stock Upon Exercise Of Common Stock Warrant Proceeds from initial capital contributions for Digital Biotechnologies, Inc. Proceeds From Contributed Capital Other Proceeds From Payments For Other Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of year Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents and restricted cash at end of year Noncash investing and financing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Purchases of equipment included in accounts payable and accrued liabilities Capital Expenditures Incurred But Not Yet Paid Noncash additions to property through lease financing arrangements Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases Derecognition Of Lease Financing Arrangements Upon Adoption Of Guidance On Accounting For Lease Conversion of convertible preferred stock to common stock upon closing of initial public offering Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant Upon Closing Of Initial Public Offering Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Description of Business Business Description And Basis Of Presentation [Text Block] Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Revenue From Contract With Customer [Abstract] Revenue Revenue From Contract With Customer [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Investments Debt And Equity Securities [Abstract] Investments Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Property Plant And Equipment [Abstract] Property and Equipment, Net Property Plant And Equipment Disclosure [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Goodwill And Intangible Assets Disclosure [Text Block] Payables And Accruals [Abstract] Accrued Liabilities Accounts Payable And Accrued Liabilities Disclosure [Text Block] Deferred revenue. Deferred Revenue Deferred Revenue [Text Block] Lessee Disclosure [Abstract] Leases Lessee Operating Leases [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Equity [Abstract] Shareholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Equity Incentive Plans Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Microsoft Collaboration Agreement Collaborative Arrangement Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders Earnings Per Share [Text Block] Compensation And Retirement Disclosure [Abstract] Retirement Plan Compensation And Employee Benefit Plans [Text Block] Basis of presentation and principles of consolidation policy. Basis of Presentation and Principles of Consolidation Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block] Use of Estimates Use Of Estimates Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Restricted Cash Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Investments in Marketable Securities Marketable Securities Policy Concentrations of Risk Concentration Risk Credit Risk Accounts Receivable Receivables Policy [Text Block] Inventory Inventory Policy [Text Block] Property and Equipment Property Plant And Equipment Policy [Text Block] Goodwill Goodwill And Intangible Assets Goodwill Policy Intangible Assets Goodwill And Intangible Assets Intangible Assets Policy Leases Lessee Leases Policy [Text Block] Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Stockholders equity convertible preferred stock policy text block. Convertible Preferred Stock Warrant Stockholders Equity Convertible Preferred Stock Policy [Text Block] Revenue Recognition Revenue From Contract With Customer Policy [Text Block] Contract balances. Contract Balances Contract Balances Policy [Text Block] Share-Based Compensation Share Based Compensation Option And Incentive Plans Policy Advertising Advertising Costs Policy [Text Block] Cost of Revenue Cost Of Sales Policy [Text Block] Research and Development Expenses Research And Development Expense Policy Sales and marketing expenses. Sales and Marketing Expenses Sales And Marketing Expense Policy [Text Block] Income Taxes Income Tax Policy [Text Block] Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders Earnings Per Share Policy [Text Block] Segment Information Segment Reporting Policy Policy [Text Block] Schedule of Concentrations of Risk Percentage Schedules Of Concentration Of Risk By Risk Factor [Text Block] Tabular disclosure of estimated useful lives of property plant and equipment. Summary of Useful Lives Assigned to Property and Equipment Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block] Schedule of Revenue Disaggregated by Type of Products and Services Disaggregation Of Revenue Table [Text Block] Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Schedule of Available-for-sale Investments Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position Debt Securities Available For Sale Unrealized Loss Position Fair Value Table [Text Block] Schedule of Property and Equipment Property Plant And Equipment [Text Block] Summary of Intangible Assets Subject to Amortization Schedule Of Finite Lived Intangible Assets Table [Text Block] Schedule of Future Amortization Expense for Intangible Assets Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block] Schedule of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Schedule of deferred revenue by revenue classification. Schedule of Deferred Revenue by Revenue Classification Schedule Of Deferred Revenue By Revenue Classification Table [Text Block] Schedule of Changes in Deferred Revenue Contract With Customer Asset And Liability Table [Text Block] Summary of Other Information Related to Operating Lease Lease Cost Table [Text Block] Summary of Reconciles Undiscounted Operating Lease Cash Flows Lessee Operating Lease Liability Maturity Table [Text Block] Schedule of reserved shares of common stock. Summary of Reserved Shares of Common Stock Schedule Of Reserved Shares Of Common Stock Table [Text Block] Schedule of share-based compensation, shares available for grant. Summary of Changes in Shares Available for Grant Schedule Of Share Based Compensation Shares Available For Grant Table [Text Block] Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Restricted Stock Unit Activity Schedule Of Unvested Restricted Stock Units Roll Forward Table [Text Block] Summary of Estimated Grant Date Fair Values of Options Granted Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Summary of Compensation Costs Related to Stock Options and RSUs Included on Statements of Operations Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Components of Loss Before Provision for Income Taxes Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block] Schedule of Components of Deferred Tax Assets and Liabilities Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Schedule of Change in Unrecognized Tax Benefits Summary Of Income Tax Contingencies [Text Block] Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule Of Subsidiary Or Equity Method Investee [Table] Schedule Of Subsidiary Or Equity Method Investee [Table] Ownership Ownership [Axis] Ownership Ownership [Domain] Digital Biotechnologies, Inc. Digital Biotechnologies, Inc. Digital Biotechnologies Inc [Member] Subsidiary Or Equity Method Investee [Line Items] Subsidiary Or Equity Method Investee [Line Items] Ownership interest percentage Minority Interest Ownership Percentage By Parent Significant accounting policies. Significant accounting policies. Significant Accounting Policies [Table] Significant Accounting Policies [Table] Series C convertible preferred stock. Series C Convertible Preferred Stock Series C Convertible Preferred Stock [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Restricted cash Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Customer A. Customer A Customer A [Member] Customer B. Customer B Customer B [Member] Genentech, Inc. and Roche Group. Genentech, Inc. and Roche Group Genentech Inc And Roche Group [Member] Accounts Receivable, Net Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenue Sales Revenue Net [Member] Accounts Receivable, Net Accounts Receivable [Member] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration risk, percentage Concentration Risk Percentage1 Unbilled receivables Unbilled Receivables Current Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Laboratory equipment. Laboratory Equipment Laboratory Equipment [Member] Leasehold Improvements Leasehold Improvements [Member] Computer equipment and software. Computer Equipment and Software Computer Equipment And Software [Member] Furniture and office equipment. Furniture and Office Equipment Furniture And Office Equipment [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, useful lives Property Plant And Equipment Useful Life Property and equipment, useful lives Property Plant And Equipment Estimated Useful Lives Impairment of goodwill Goodwill Impairment Loss Impairment losses on intangible assets Impairment Of Intangible Assets Finitelived Class of warrant or right, weighted average exercise price of warrants or rights Warrants issued to purchase stock Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Weighted-average exercise price of warrants Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Line of credit facility Line Of Credit Facility Current Borrowing Capacity Fair value adjustment of warrants Financial liabilities Financial Liabilities Fair Value Disclosure Number of revenue performance obligation. Number of revenue performance obligations Number Of Revenue Performance Obligation Advertising expenses Advertising Expense Number of operating segment Number Of Operating Segments Number of reportable segments Number Of Reportable Segments Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Development support revenue. Development Support Revenue Development Support Revenue [Member] Development revenue regulatory milestones. Development Revenue Regulatory Milestones Development Revenue Regulatory Milestones [Member] Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] MRD development agreements. MRD Development Agreements M R D Development Agreements [Member] Genentech collaboration agreement. Genentech Collaboration Agreement Genentech Collaboration Agreement [Member] Contingent Consideration by Type Contingent Consideration By Type [Axis] Contingent Consideration Type Contingent Consideration Type [Domain] Regulatory milestones. Regulatory Milestones Regulatory Milestones [Member] Development milestones. Development Milestones Development Milestones [Member] Commercial milestones. Commercial Milestones Commercial Milestones [Member] Revenue from collaboration agreement Contract with customer liability milestone method revenue recognized. Milestone revenue recognized Contract With Customer Liability Milestone Method Revenue Recognized Revenue recognized Contract With Customer Liability Revenue Recognized Additional milestone payment. Additional milestone payment receivable Additional Milestone Payment Non-refundable upfront payments received. Revenue recognition milestone method expected milestone receivable. Non-refundable upfront payments received Non Refundable Upfront Payments Received Expected revenue through milestone payments Revenue Recognition Milestone Method Expected Milestone Receivable Revenue recognition expected period. Revenue recognition expected period Revenue Recognition Expected Period Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Recurring basis Fair Value Measurements Recurring [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Money Market Funds Money Market Funds [Member] U.S. Government Debt Securities U S Government Agencies Debt Securities [Member] Corporate Bonds Corporate Debt Securities [Member] Level 2 Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Financial assets Assets Fair Value Disclosure [Abstract] Total financial assets Assets Fair Value Disclosure Debt Securities Available For Sale [Table] Debt Securities Available For Sale [Table] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Corporate Bonds Corporate Bond Securities [Member] Debt Security Category Information By Category Of Debt Security [Axis] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments Other Than Temporary Impairment Credit Losses Recognized In Earnings Categories Of Investments [Domain] Available for sale securities debt securities current. Short-Term Marketable Securities Available For Sale Securities Debt Securities Current [Member] Available for sale securities debt securities noncurrent. Long-Term Marketable Securities Available For Sale Securities Debt Securities Noncurrent [Member] Schedule of Available-for-Sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Unrealized Gain Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Unrealized Loss Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Estimated Fair Value Available For Sale Securities Debt Securities Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Prepaid Expenses and Other Current Assets Prepaid Expenses And Other Current Assets [Member] Accrued interest receivable Interest Receivable Current Less than 12 months, Fair value Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Less than 12 months, Unrealized loss Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss 12 months or greater, Fair value Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer 12 months or greater, Unrealized loss Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss Computer Equipment Computer Equipment [Member] Computer software. Computer Software Computer Software [Member] Construction in Progress Construction In Progress [Member] Property and equipment, at cost Property Plant And Equipment Gross Less: Accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Depreciation Schedule Of Goodwill [Table] Schedule Of Goodwill [Table] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] Purchased Intellectual Property Intellectual Property [Member] Goodwill [Line Items] Goodwill [Line Items] Amortization period of intangible assets Finite Lived Intangible Asset Useful Life Schedule Of Finite Lived Intangible Assets [Table] Schedule Of Finite Lived Intangible Assets [Table] Acquired Developed Technology Developed Technology Rights [Member] Finite Lived Intangible Assets [Line Items] Finite Lived Intangible Assets [Line Items] Gross Carrying Amount Finite Lived Intangible Assets Gross Accumulated Amortization Finite Lived Intangible Assets Accumulated Amortization Net Carrying Amount 2022 Finite Lived Intangible Assets Amortization Expense Next Twelve Months 2023 Finite Lived Intangible Assets Amortization Expense Year Two 2024 Finite Lived Intangible Assets Amortization Expense Year Three 2025 Finite Lived Intangible Assets Amortization Expense Year Four 2026 Finite Lived Intangible Assets Amortization Expense Year Five Thereafter Finite Lived Intangible Assets Amortization Expense After Year Five Accrued clinical and contract research organization costs, current. Accrued purchase of property and equipment current. Professional fees Accrued Professional Fees Current Clinical and contract research organization costs Accrued Clinical And Contract Research Organization Costs Current Travel and entertainment Accrued Employee Benefits Current Tax liabilities Accrued Income Taxes Current Purchases of property and equipment Accrued Purchase Of Property And Equipment Current Other Other Accrued Liabilities Current Total accrued liabilities Accrued tax withholding liability related to unsettled option exercises. Accrued tax withholding liability related to unsettled option exercises Accrued Tax Withholding Liability Related To Unsettled Option Exercises Contract with customer liability current abstract. Contract with customer liability non current abstract. Current deferred revenue Contract With Customer Liability Current [Abstract] Total current deferred revenue Non-current deferred revenue Contract With Customer Liability Non Current [Abstract] Total non-current deferred revenue Total current and non-current deferred revenue Contract With Customer Liability Genentech Inc. Genentech, Inc. Genentech Inc [Member] Medicare revenue. Medicare Medicare Revenue [Member] Specific patients. Specific Patients Specific Patients [Member] Current deferred revenue Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis] Deferred revenue, expected to be recognized Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 Deferred revenue balance at December 31, 2020 Additions to deferred revenue during the period Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination Revenue recognized during the period Deferred revenue balance at December 31, 2021 Lease expiration month and year. Lessee operating lease rent commencement month and year. Lessee, operating lease, extended term of contract. Lessee Lease Description [Table] Lessee Lease Description [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] Seattle, Washington WASHINGTON Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] ASC 842 Accounting Standards Update201602 [Member] Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Number of square feet Area Of Land Lessee, operating lease, option to extend Lessee Operating Lease Option To Extend Lessee, operating lease, rent commencement month and year Lessee Operating Lease Rent Commencement Month And Year Lessee, Operating Lease, Existence of Option to Extend [true false] Lessee Operating Lease Existence Of Option To Extend Lessee, operating lease, extended term of contract Lessee Operating Lease Extended Term Of Contract Lease expiration month and year Lease Expiration Month And Year Lease commencement month and year. Proceeds from landlord reimbursements. Tenant improvement costs incurred. Tenant improvement costs receivable. Letter of credit Letters Of Credit Outstanding Amount Lease commenced moth and year Lease Commencement Month And Year Landlord contribution for leasehold improvements Leasehold Improvements Gross Proceeds from landlord reimbursements Proceeds From Landlord Reimbursements Tenant improvement costs incurred Tenant Improvement Costs Incurred Tenant improvement costs receivable Tenant Improvement Costs Receivable Tenant improvement allowance Tenant Improvements Lessee operating lease termination period. Number of operating lease terminate. Tenant improvement allowance and commenced. Lessee operating lease rent obligations commencement month and year. Lessee, operating lease, lease not yet commenced termination option description. Lessee operating lease lease not yet commenced tenant improvement receivable. Rent obligations, commencement date Lessee Operating Lease Rent Obligations Commencement Month And Year Tenant improvement allowance and commenced Tenant Improvement Allowance And Commenced Operating lease remaining lease term Lessee Operating Lease Remaining Lease Term Operating lease renewal term Lessee Operating Lease Renewal Term Operating lease termination period Lessee Operating Lease Termination Period Number of operating lease terminate Number Of Operating Lease Terminate Lease not yet commenced, termination option description Lessee Operating Lease Lease Not Yet Commenced Termination Option Description Lease not yet commenced, option to extend description Lessee Operating Lease Lease Not Yet Commenced Option To Extend Lease not yet commenced landlord agreed to fund for improvements Lessee Operating Lease Lease Not Yet Commenced Tenant Improvement Receivable Lease not yet commenced, option to extend term Lessee Operating Lease Lease Not Yet Commenced Renewal Term1 Weighted-average remaining lease term (in years) Operating Lease Weighted Average Remaining Lease Term1 Weighted-average discount rate Finance Lease Weighted Average Discount Rate Percent 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months 2023 Lessee Operating Lease Liability Payments Due Year Two 2024 Lessee Operating Lease Liability Payments Due Year Three 2025 Lessee Operating Lease Liability Payments Due Year Four 2026 Lessee Operating Lease Liability Payments Due Year Five Thereafter Lessee Operating Lease Liability Payments Due After Year Five Total undiscounted lease payments Lessee Operating Lease Liability Payments Due Imputed interest rate Lessee Operating Lease Liability Undiscounted Excess Amount Tenant improvement receivables Lessee Operating Lease Liability Tenant Improvement Receivable Total operating lease liabilities Operating Lease Liability Less: Current portion Operating lease variable lease expense. Operating lease expense Operating Lease Expense Operating lease variable lease expense Operating Lease Variable Lease Expense Rent expenses Operating Leases Rent Expense Net Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received Operating Lease Payments Cash received for tenant improvement allowances Payments For Proceeds From Tenant Allowance ROU assets obtained in exchange for operating lease liabilities Right Of Use Asset Obtained In Exchange For Operating Lease Liability Number of common stock voting rights. Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand and nineteen equity incentive plan. 2019 Equity Incentive Plan Two Thousand And Nineteen Equity Incentive Plan [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Employee Stock Purchase Plan Employee Stock [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Common stock voting rights description Common Stock Voting Rights Number of vote for each share Number Of Common Stock Voting Rights Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Common stock options and restricted stock units granted. Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted Common Stock Options And Restricted Stock Units Granted [Member] Grant Employee Stock Option [Member] Grant Total shares of common stock reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Percentage of annual increases in number of shares. Percentage of annual increases in number of shares Percentage Of Annual Increases In Number Of Shares Increase in share reserve Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Class of warrant or rights, term. Warrant issued to purchase stock Warrant exercisable term Class Of Warrant Or Rights Term Stock issued during period, common stock Share based compensation arrangement by share based payment award outstanding number. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Sequenta two thousand and eight stock plan. Sequenta 2008 Stock Plan Sequenta Two Thousand And Eight Stock Plan [Member] Two thousand and nine equity incentive plan. 2009 Equity Incentive Plan Two Thousand And Nine Equity Incentive Plan [Member] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Non-employee directors. Non Employee Directors Non Employee Directors [Member] Restricted Stock Units (RSUs) Restricted Stock Units R S U [Member] Valuation Approach and Technique Valuation Technique [Axis] Valuation Approach and Technique Valuation Technique [Domain] Option Valuation Model Valuation Technique Option Pricing Model [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Shares available for future issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Equity awards outstanding Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number Option expiration period Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Number of shares authorized for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Share based compensation arrangement by share based payment award increase reserve shares available for grant, Share based compensation arrangement by share based payment awards granted. Share based compensation arrangement by share based payment awards forfeited, canceled or expired. Shares Available for Grant, Outstanding, Beginning Balance Shares Available for Grant, 2019 Equity Incentive Plan reserve increase Share Based Compensation Arrangement By Share Based Payment Award Increase Reserve Shares Available For Grant Shares Available for Grant, Options and restricted stock units granted Share Based Compensation Arrangement By Share Based Payment Awards Granted Shares Available for Grant, Options and restricted stock units forfeited, cancelled or expired Share Based Compensation Arrangement By Share Based Payment Awards Forfeited Canceled Or Expired Shares Available for Grant, Outstanding, Ending Balance Share based compensation arrangement by share based payment award options vested and exercisable. Shares Subject to Outstanding Options, Options outstanding, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Shares Subject to Outstanding Options, Options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Shares Subject to Outstanding Options, Options forfeited or cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Shares Subject to Outstanding Options, Options expired Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Shares Subject to Outstanding Options, Options exercised Shares Subject to Outstanding Options, Options outstanding, Ending Balance Shares Subject to Outstanding Options, Options vested and exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price. Weighted Average Exercise Price per Share, Options outstanding, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted Average Exercise Price per Share, Options granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted Average Exercise Price per Share, Options forfeited or cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Weighted Average Exercise Price per Share, Options expired Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price Weighted Average Exercise Price per Share, Options exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted Average Exercise Price per Share, Options outstanding, Ending Balance Weighted Average Exercise Price per Share, Options vested and exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value. Aggregate Intrinsic Value, Option outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Aggregate Intrinsic Value, Options vested and exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term. Weighted-average remaining contractual life options outstanding Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Weighted-average remaining contractual life vested and exercisable options outstanding Share Based Compensation Arrangement By Share Based Payment Award Vested And Exercisable Options Outstanding Weighted Average Remaining Contractual Term Weighted-average grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Total intrinsic value of options exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Proceeds from settlement of stock option exercised in prior periods. Proceeds from settlement of stock option exercised in prior periods Proceeds From Settlement Of Stock Option Exercised In Prior Periods Restricted Stock Units Outstanding Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Restricted Stock Units Outstanding, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Restricted Stock Units Outstanding, Forfeited or cancelled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Restricted Stock Units Outstanding, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance Weighted-Average Grant Date Fair Value per Share Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited or cancelled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance Fair value of common stock Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Expected term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Risk-free interest rate, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum Risk-free interest rate, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Expected volatility, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum Expected volatility, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Cost of Revenue Cost Of Sales [Member] Research and Development Research And Development Expense [Member] Sales and Marketing Selling And Marketing Expense [Member] General and Administrative General And Administrative Expense [Member] Total share-based compensation expense Allocated Share Based Compensation Expense Unrecognized share-based compensation expense related to unvested stock options Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Unrecognized share-based compensation expense related to unvested RSUs Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Minimum service consumption requirement amount under license agreement. Minimum service consumption requirement term under license agreement. Collaboration Arrangement Disclosure [Abstract] Collaboration Arrangement Disclosure [Abstract] Schedule Of Fair Value Off Balance Sheet Risks [Table] Schedule Of Fair Value Off Balance Sheet Risks [Table] Microsoft collaboration agreement. Microsoft Collaboration Agreement Microsoft Collaboration Agreement [Member] Series F one convertible preferred stock. Series F-1 Convertible Preferred Stock Series F One Convertible Preferred Stock [Member] Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Fair Value Off Balance Sheet Risks Disclosure Information [Line Items] Minimum service consumption requirement amount Minimum Service Consumption Requirement Amount Under License Agreement Minimum service consumption requirement term Minimum Service Consumption Requirement Term Under License Agreement preferred stock investment Domestic Income Loss From Continuing Operations Before Income Taxes Domestic Foreign Income Loss From Continuing Operations Before Income Taxes Foreign Total loss before provision for income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Deferred tax assets, non qualified stock options. Deferred tax assets operating lease liabilities. Deferred tax liabilities, tangible and intangible assets. Deferred tax liabilities right of use assets. Deferred tax assets Deferred Tax Assets Net [Abstract] Net operating losses Deferred Tax Assets Operating Loss Carryforwards Tax credit carryforward Deferred Tax Assets Tax Credit Carryforwards General Business Nonqualifying stock options Deferred Tax Assets Non Qualified Stock Options Deferred rent Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent Operating lease liabilities Deferred Tax Assets Operating Lease Liabilities Deferred revenue Deferred Tax Assets Deferred Income Other Deferred Tax Assets Other Total deferred tax assets Deferred Tax Assets Gross Less: Valuation allowance Deferred Tax Assets Valuation Allowance Deferred tax assets, net of valuation allowance Deferred Tax Assets Net Deferred tax liabilities Deferred Tax Liabilities Net [Abstract] Tangible and intangible assets Deferred Tax Liabilities Tangible And Intangible Assets ROU assets Deferred Tax Liabilities Right Of Use Assets Net deferred taxes Deferred Tax Liabilities Income taxes. Income taxes. Income Taxes [Table] Income Taxes [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Domestic Tax Authority [Member] Domestic Country [Member] Income Taxes [Line Items] Income Taxes [Line Items] Increase in valuation allowance Valuation Allowance Deferred Tax Asset Change In Amount Net Operating Loss Carryforward Expiration Period Operating Loss Carryforwards, Expiration Year Maturity period for NOLs carryovers Net Operating Loss Carryforward Expiration Period U.S. federal NOLs Operating Loss Carryforwards U.S. federal tax credits Tax Credit Carryforward Amount Tax credit carryforwards expiration year Tax Credit Carryforward Limitations On Use NOLs expiration year Operating Loss Carryforwards Expiration Year Effective Income Tax Rate Reconciliation Permanent Items Statutory rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate State tax, net of federal tax benefit Effective Income Tax Rate Reconciliation State And Local Income Taxes Stock compensation Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost Permanent items Effective Income Tax Rate Reconciliation Permanent Items Credits Effective Income Tax Rate Reconciliation Tax Credits Other Effective Income Tax Rate Reconciliation Other Adjustments Change in valuation allowance Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Total Effective Income Tax Rate Continuing Operations Unrecognized tax benefits Unrecognized Tax Benefits Balance Additions Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Balance Uncertain tax positions Accrued interest or penalties related to uncertain tax positions Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Net loss attributable to Adaptive Biotechnologies Corporation Fair value adjustment to redemption value for Series E-1 convertible preferred stock options Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Unvested restricted stock units. Nonvested Restricted Stock Units Unvested Restricted Stock Units [Member] Common stock warrants member. Common Stock Warrants Common Stock Warrants [Member] Convertible preferred stock warrants member. Convertible Preferred Stock Warrants Convertible Preferred Stock Warrants [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Defined contribution plan employee service period for vesting. Employees maximum annual contribution of their compensation Defined Contribution Plan Maximum Annual Contributions Per Employee Percent Employer discretionary contribution amount Defined Contribution Plan Employer Discretionary Contribution Amount Employee service period for vesting Defined Contribution Plan Employee Service Period For Vesting EX-101.PRE 30 adpt-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 31 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2021
Feb. 10, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Trading Symbol ADPT    
Entity Registrant Name ADAPTIVE BIOTECHNOLOGIES CORPORATION    
Entity Central Index Key 0001478320    
Entity Voluntary Filers No    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Well-known Seasoned Issuer Yes    
Entity Public Float     $ 3,951,000,000
Entity Small Business false    
Entity Emerging Growth Company false    
Title of 12(b) Security Common stock, par value $0.0001 per share    
Security Exchange Name NASDAQ    
Entity Common Stock, Shares Outstanding   141,583,720  
Entity Current Reporting Status Yes    
Entity Shell Company false    
Entity Interactive Data Current Yes    
Entity File Number 001-38957    
Entity Tax Identification Number 27-0907024    
Entity Address, Address Line One 1165 Eastlake Avenue East    
Entity Address, City or Town Seattle    
Entity Address, State or Province WA    
Entity Address, Postal Zip Code 98109    
City Area Code (206)    
Local Phone Number 659-0067    
Document Annual Report true    
Document Transition Report false    
Entity Incorporation, State or Country Code WA    
ICFR Auditor Attestation Flag true    
Documents Incorporated by Reference The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the registrant’s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2022.    
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location Seattle, Washington    

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Æ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�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end GRAPHIC 17 g4bdklltl5z5000007.jpg GRAPHIC begin 644 g4bdklltl5z5000007.jpg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end GRAPHIC 13 g4bdklltl5z5000013.jpg GRAPHIC begin 644 g4bdklltl5z5000013.jpg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�!X?X7_9.F_X;,U[]KOX M@^)(=5O&T&'1/!NGK;$+HUF#OFP6+9DEDY9EV@A5&.*]N56#9.*/+6G4 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 24444 %%%% !1110 4444 ?_9 end GRAPHIC 14 g4bdklltl5z5000015.jpg GRAPHIC begin 644 g4bdklltl5z5000015.jpg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